PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Omoto, Y; Eguchi, H; Yamamoto-Yamaguchi, Y; Hayashi, S				Omoto, Y; Eguchi, H; Yamamoto-Yamaguchi, Y; Hayashi, S			Estrogen receptor (ER) beta 1 and ER beta cx/beta 2 inhibit ER alpha function differently in breast cancer cell line MCF7	ONCOGENE			English	Article						estrogen receptor alpha; estrogen receptor beta; estrogen receptor beta cx; breast cancer; cDNA microarray	FACTOR-BINDING-PROTEINS; MESSENGER-RNA; CATHEPSIN-D; EXPRESSION PATTERNS; WILD-TYPE; GROWTH; PROLIFERATION; GENE; ISOFORMS; CLONING	Estrogen receptor (ER) alpha plays an important role in the proliferation and progression of breast cancer. In order to explore the function of wild-type ERbeta (ERbeta1) and its variant form, ERbetacx/beta2, stable transformants of ERalpha-positive breast cancer MCF7 cells with ERbeta1 or ERbetacx/ beta2 expression vector were established. Constitutive expression of ERbeta1 or ERbetacx/beta2 reduced the S phase population of the cell cycle in dish culture and the number of colonies in an anchorage-independent assay. DNA-protein complexes of ERE with nuclear extracts from ERbeta1 transformants were observed in the electrophoretic mobility shift assay, while no complex was observed for ERbetacx/beta2 transformants. Reporter gene assay using estrogen-responsive element (ERE)-luciferase showed less responsiveness to estrogen in these transformants compared with parental cells. Endogenous mRNA expression of two known estrogen-responsive genes, cathepsin D and IGFBP4, was weakly induced by estrogen in ERbeta1 and ERbetacx/beta2 transformants compared with parental cells. A comprehensive gene expression analysis using our custom-made cDNA microarray showed that MCF7 and ERbeta1 transformants had a similar gene expression profile, whereas ERbetacx/beta2 showed a distinct profile from others. These results indicate that ERbeta1 and ERbetacx/beta2 inhibit ERalpha function differently in MCF7 cells.	Saitama Canc Ctr, Div Endocrinol, Res Inst, Ina, Saitama 3620806, Japan		Hayashi, S (corresponding author), Hiroshima Univ, Dept Mol Epidemiol, Grad Sch Biomed Sci, Minami Ku, 5-2 Hijiyama Pk, Hiroshima 7320815, Japan.							Berchem G, 2002, ONCOGENE, V21, P5951, DOI 10.1038/sj.onc.1205745; Bieche I, 2001, ONCOGENE, V20, P8109, DOI 10.1038/sj.onc.1204917; BTIST G, 1986, J BIOL CHEM, V261, P15544; Chu S, 2000, J CLIN ENDOCR METAB, V85, P1200, DOI 10.1210/jc.85.3.1200; Clarke M, 1998, LANCET, V351, P1451; CLEMMONS DR, 1990, ENDOCRINOLOGY, V127, P2679, DOI 10.1210/endo-127-6-2679; Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960-0760(99)00055-2; Dotzlaw H, 1997, J CLIN ENDOCR METAB, V82, P2371, DOI 10.1210/jc.82.7.2371; Eguchi H, 2000, CELL DEATH DIFFER, V7, P439, DOI 10.1038/sj.cdd.4400675; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; Ferrandina G, 1997, BRIT J CANCER, V76, P661, DOI 10.1038/bjc.1997.442; FIGUEROA JA, 1993, J CELL BIOCHEM, V52, P196, DOI 10.1002/jcb.240520211; Foekens JA, 1999, BRIT J CANCER, V79, P300, DOI 10.1038/sj.bjc.6990048; Fujimura T, 2001, BIOCHEM BIOPH RES CO, V289, P692, DOI 10.1006/bbrc.2001.6038; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Honma Y, 1999, BRIT J CANCER, V80, P96, DOI 10.1038/sj.bjc.6690327; Inoue A, 2002, J MOL ENDOCRINOL, V29, P175, DOI 10.1677/jme.0.0290175; Iwao K, 2000, INT J CANCER, V88, P733, DOI 10.1002/1097-0215(20001201)88:5<733::AID-IJC8>3.0.CO;2-M; Jarvinen TAH, 2000, AM J PATHOL, V156, P29, DOI 10.1016/S0002-9440(10)64702-5; JENSEN EV, 1980, CANCER-AM CANCER SOC, V46, P2759, DOI 10.1002/1097-0142(19801215)46:12+<2759::AID-CNCR2820461402>3.0.CO;2-7; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Leygue E, 1999, CANCER RES, V59, P1175; Leygue E, 1998, CANCER RES, V58, P3197; Locker GY, 1998, CANCER TREAT REV, V24, P221, DOI 10.1016/S0305-7372(98)90051-2; Moore JT, 1998, BIOCHEM BIOPH RES CO, V247, P75, DOI 10.1006/bbrc.1998.8738; Ogawa S, 1998, NUCLEIC ACIDS RES, V26, P3505, DOI 10.1093/nar/26.15.3505; Omoto Y, 2002, EUR J CANCER, V38, P380, DOI 10.1016/S0959-8049(01)00383-5; Omoto Y, 2000, Breast Cancer, V7, P27, DOI 10.1007/BF02967184; Omoto Y, 2001, BIOCHEM BIOPH RES CO, V285, P340, DOI 10.1006/bbrc.2001.5158; Omoto Y, 2001, CANCER LETT, V163, P207, DOI 10.1016/S0304-3835(00)00680-7; OWENS PC, 1993, BIOCHEM BIOPH RES CO, V193, P467, DOI 10.1006/bbrc.1993.1647; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Peng B, 2003, J MOL ENDOCRINOL, V30, P13, DOI 10.1677/jme.0.0300013; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; PRATT SE, 1993, CANCER RES, V53, P5193; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; ROCHEFORT H, 1992, EUR J CANCER, V28A, P1780, DOI 10.1016/0959-8049(92)90003-K; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; Saji S, 2002, CANCER RES, V62, P4849; Speirs V, 1999, CANCER RES, V59, P5421; Tanimoto K, 1999, NUCLEIC ACIDS RES, V27, P903, DOI 10.1093/nar/27.3.903; TOI M, 1992, CANCER RES, V52, P275; Tong D, 2002, BREAST CANCER RES TR, V71, P249, DOI 10.1023/A:1014465916473; VICKERS PJ, 1988, MOL ENDOCRINOL, V2, P886, DOI 10.1210/mend-2-10-886; Vladusic EA, 2000, ONCOL REP, V7, P157; Vladusic EA, 1998, CANCER RES, V58, P210	48	110	114	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 7	2003	22	32					5011	5020		10.1038/sj.onc.1206787	http://dx.doi.org/10.1038/sj.onc.1206787			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902984				2022-12-17	WOS:000184578900009
J	Kraus, AC; Ferber, I; Bachmann, SO; Specht, H; Wimmel, A; Gross, MW; Schlegel, J; Suske, G; Schuermann, M				Kraus, AC; Ferber, I; Bachmann, SO; Specht, H; Wimmel, A; Gross, MW; Schlegel, J; Suske, G; Schuermann, M			In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways	ONCOGENE			English	Article						lung cancer; Akt; chemoresistance; radioresistance; adhesion	NF-KAPPA-B; INDUCED APOPTOSIS; MULTIDRUG-RESISTANCE; TUMOR-CELLS; IN-VIVO; EXPRESSION; PROTEIN; GROWTH; CARCINOMA; LINES	Most small cell lung cancer (SCLC) patients relapse within 12 months of starting combination chemotherapy plus radio-therapy, due to the development of acquired chemo- and radio-resistance. This phenomenon relates to the induction of tumour differentiation, resulting in apoptosis-resistant, morphologically variant (v-SCLC) cells, which lack the neuroendocrine expression of classic (c-) SCLC cells. In this study spontaneously adherent SCLC sublines were shown by differential gene expression analysis to provide an in vitro model of variant differentiation in SCLC, with down-regulation of neuroendocrine markers and up-regulation of epithelial differentiation markers cyclin D1, endothelin, the cell adhesion molecules CD 44 and integrin subunits alpha2, beta3 and beta4. The sensitivity of adherent SCLC sublines to etoposide, cyclophosphamide and gamma radiation was significantly diminished relative to parent suspension cell lines. Western blot analysis using phosphorylation-specific antibodies to Akt and MAP kinase revealed markedly elevated activation in adherent SCLC sublines, paralleled by increased levels of phosphorylated Bad protein and activated NF-kappaB. Subcultivation of the adherent sublines on uncoated surfaces reversed their adherent phenotype immediately and under these conditions Akt activity reverted to low levels. These results suggest that c-SCLC cells can differentiate spontaneously to v-SCLC and that the associated cellular adhesion may trigger Akt-dependent inhibition of apoptosis in SCLC cells, thus leading to acquired chemo-and radio-resistance.	Univ Marburg, Univ Hosp, Inst Mol Biol & Tumour Res, D-35033 Marburg, Germany; Univ Marburg, Univ Hosp, Dept Neuropathol, D-35033 Marburg, Germany; Univ Marburg, Univ Hosp, Dept Radiotherapy & Radio Oncol, D-35033 Marburg, Germany; Univ Marburg, Univ Hosp, Ctr Internal Med, Dept Haematol & Oncol, D-35033 Marburg, Germany	Philipps University Marburg; Philipps University Marburg; Philipps University Marburg; Philipps University Marburg	Schuermann, M (corresponding author), Univ Marburg, Klinikum, Zentrum Innere Med, Baldingerstr, D-35033 Marburg, Germany.	schuermann@mailer.uni-marburg.de		Schlegel, Jurgen/0000-0002-5544-2717; Suske, Guntram/0000-0002-4807-0513				Abe Y, 1996, BRIT J CANCER, V74, P1929, DOI 10.1038/bjc.1996.655; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; BRAMBILLA E, 1991, J CLIN ONCOL, V9, P50, DOI 10.1200/JCO.1991.9.1.50; BRODIN O, 1995, LUNG CANCER-J IASLC, V12, P183, DOI 10.1016/0169-5002(95)00444-6; CARNEY DN, 1985, CANCER RES, V45, P2913; Cheng QW, 2000, ONCOGENE, V19, P4936, DOI 10.1038/sj.onc.1203861; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dingemans AMC, 1996, ANN ONCOL, V7, P625; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Fushimi H, 1996, CANCER, V77, P278, DOI 10.1002/(SICI)1097-0142(19960115)77:2<278::AID-CNCR9>3.0.CO;2-I; GAZDAR AF, 1985, CANCER RES, V45, P2924; Gazdar AF, 1996, J CELL BIOCHEM, P1; Grossi F, 2001, CRIT REV ONCOL HEMAT, V37, P61, DOI 10.1016/S1040-8428(00)00098-6; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; KLUG J, 1994, MOL CELL BIOL, V14, P6208, DOI 10.1128/MCB.14.9.6208; Moore SM, 1998, CANCER RES, V58, P5239; Nakashio A, 2000, CANCER RES, V60, P5303; Okada S, 2001, INT J RADIAT ONCOL, V49, P1149, DOI 10.1016/S0360-3016(00)01429-2; Ozes ON, 1999, NATURE, V401, P82; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; RADICE PA, 1982, CANCER-AM CANCER SOC, V50, P2894, DOI 10.1002/1097-0142(19821215)50:12<2894::AID-CNCR2820501232>3.0.CO;2-G; Risse-Hackl G, 1998, ONCOGENE, V16, P3057, DOI 10.1038/sj.onc.1201845; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Salge U, 2001, J CANCER RES CLIN, V127, P139, DOI 10.1007/s004320000210; Savaraj N, 1997, AM J CLIN ONCOL-CANC, V20, P398, DOI 10.1097/00000421-199708000-00016; SCHAUER IE, 1994, P NATL ACAD SCI USA, V91, P7827, DOI 10.1073/pnas.91.16.7827; Schlegel J, 2000, CANCER LETT, V158, P103, DOI 10.1016/S0304-3835(00)00515-2; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; SHTIVELMAN E, 1995, P NATL ACAD SCI USA, V92, P4661, DOI 10.1073/pnas.92.10.4661; SUPINO R, 1993, INT J CANCER, V54, P309, DOI 10.1002/ijc.2910540224; Thiede C, 2001, LEUKEMIA, V15, P293, DOI 10.1038/sj.leu.2401953; Uhm JH, 1999, CLIN CANCER RES, V5, P1587; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wimmel A, 1997, LUNG CANCER, V16, P151, DOI 10.1016/S0169-5002(96)00625-3; Wimmel A, 2001, EUR J CANCER, V37, P2264, DOI 10.1016/S0959-8049(01)00271-4; Worden FP, 2000, EXPERT OPIN INV DRUG, V9, P565, DOI 10.1517/13543784.9.3.565; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	40	110	117	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8683	8695		10.1038/sj.onc.1205939	http://dx.doi.org/10.1038/sj.onc.1205939			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483521				2022-12-17	WOS:000179734400002
J	Wilson, MB; Schreiner, SJ; Choi, HJ; Kamens, J; Smithgall, TE				Wilson, MB; Schreiner, SJ; Choi, HJ; Kamens, J; Smithgall, TE			Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis	ONCOGENE			English	Article						Bcr-Abl; Src; Hck; Stat5; pyrrolo-pyrimidine inhibitor	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE; CELL-LINE; CYTOGENETIC RESPONSES; HEMATOPOIETIC-CELLS; C-ABL; FIBROBLAST TRANSFORMATION; CLINICAL RESISTANCE; GROWTH-INHIBITION	Chronic myelogenous leukemia (CML) is defined by the presence of the Philadelphia (Ph) chromosome, which results in the expression of the 210 kDa Bcr - Abl tyrosine kinase. Bcr-Abl constitutively activates several signaling proteins important for the proliferation and survival of myeloid progenitors, including the Src family kinases Hck and Lyn, the Stat5 transcription factor and upstream components of the Ras/Erk pathway. Recently, we found that kinase-defective Hck blocks Bcr-Abl-induced transformation of DAGM myeloid leukemia cells to cytokine independence, suggesting that activation of the Src kinase family may be essential to oncogenic signaling by Bcr-Abl. To investigate the contribution of Src kinases to Bcr-Abl signaling in vivo, we used the pyrrolo-pyrimidine Src kinase inhibitors PP2 and A-419259. Treatment of the Ph+ CML cell lines K-562 and Meg-01 with either compound resulted in growth arrest and induction of apoptosis, while the Ph- leukemia cell lines TF-1 and HEL were unaffected over the same concentration ranges. Suppression of Ph+ cell growth by PP2 and A-419259 correlated with a decrease in Src kinase autophosphorylation. Both inhibitors blocked Stat5 and Erk activation, consistent with the suppressive effects of the compounds on survival and proliferation. In contrast, the phosphotyrosine content of Bcr-Abl and its endogenous substrate CrkL was unchanged at inhibitor concentrations that induced apoptosis, blocked oncogenic signaling and inhibited Src kinases. These data implicate the Src kinase family in Stat5 and Erk activation downstream of Bcr-Abl, and identify myeloid-specific Src kinases as potential drug targets in CML.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Abbott Biores Ctr, Worcester, MA 01605 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Smithgall, TE (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA.	tsmithga@pitt.edu		Kamens, Joanne/0000-0002-7000-1477	NATIONAL CANCER INSTITUTE [R01CA081398] Funding Source: NIH RePORTER; NCI NIH HHS [CA 81398] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnold LD, 2000, BIOORG MED CHEM LETT, V10, P2167, DOI 10.1016/S0960-894X(00)00441-8; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Branford S, 2002, BLOOD, V99, P3472, DOI 10.1182/blood.V99.9.3472; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chin H, 1998, BLOOD, V91, P3734; Cortez D, 1996, ONCOGENE, V13, P2589; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; de Groot Rolf P., 2000, Molecular Cell Biology Research Communications, V3, P299, DOI 10.1006/mcbr.2000.0231; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; FELLER SM, 1995, ONCOGENE, V10, P1465; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Furstoss O, 2002, EMBO J, V21, P514, DOI 10.1093/emboj/21.4.514; Gambacorti-Passerini C, 2000, JNCI-J NATL CANCER I, V92, P1641, DOI 10.1093/jnci/92.20.1641; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hoover RR, 2001, ONCOGENE, V20, P5826, DOI 10.1038/sj.onc.1204549; HUANG M, 2002, IN PRESS ONCOGENE; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KLEIN E, 1976, INT J CANCER, V18, P421, DOI 10.1002/ijc.2910180405; KLEJMAN A, 2002, IN PRESS EMBO J; Li JZ, 1998, J BIOL CHEM, V273, P13828, DOI 10.1074/jbc.273.22.13828; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; LIU JX, 1993, ONCOGENE, V8, P101; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; LOZZIO BB, 1981, P SOC EXP BIOL MED, V166, P546; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; Morgan MA, 2001, BLOOD, V97, P1823, DOI 10.1182/blood.V97.6.1823; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Nagar B, 2002, CANCER RES, V62, P4236; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; NOWELL PC, 1960, SCIENCE, V132, P1497; Oetzel C, 2000, CLIN CANCER RES, V6, P1958; OGURA M, 1985, BLOOD, V66, P1384; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Roumiantsev S, 2002, P NATL ACAD SCI USA, V99, P10700, DOI 10.1073/pnas.162140299; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Shuai K, 1996, ONCOGENE, V13, P247; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Skorski T, 1998, BLOOD, V91, P406, DOI 10.1182/blood.V91.2.406.406_406_418; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Talpaz M, 2002, BLOOD, V99, P1928, DOI 10.1182/blood.V99.6.1928; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Waller CF, 2000, ANTICANCER RES, V20, P809; Warmuth M, 1999, ANN HEMATOL, V78, P49, DOI 10.1007/s002770050473; Warmuth M, 1997, J BIOL CHEM, V272, P33260, DOI 10.1074/jbc.272.52.33260; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505; Woessmann W, 2001, EXP CELL RES, V264, P193, DOI 10.1006/excr.2000.5124	72	110	116	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2002	21	53					8075	8088		10.1038/sj.onc.1206008	http://dx.doi.org/10.1038/sj.onc.1206008			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444544				2022-12-17	WOS:000179231400002
J	Dunican, DS; McWilliam, P; Tighe, O; Pale-McDermott, A; Croke, DT				Dunican, DS; McWilliam, P; Tighe, O; Pale-McDermott, A; Croke, DT			Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by high-density cDNA array hybridization	ONCOGENE			English	Article						colorectal cancer; microsatellite instability; chromosomal instability; gene expression	NONPOLYPOSIS COLON-CANCER; DNA MISMATCH REPAIR; II RECEPTOR GENE; MUTATIONS; CELLS; PROTEIN; YEAST	Two distinct pathways of tumorigenesis exist in sporadic colorectal cancer. The microsatellite instability pathway (MIN), which is characterized by widespread microsatellite instability due to aberrant mismatch repair machinery, accounts for 15% of all sporadic colorectal cancers. The chromosomal instability (CIN) phenotype, which accounts for 85% of sporadic colorectal cancers, is characterized by gross chromosomal lesions but the underlying mechanism remains unclear. We have addressed differences in gene expression between the MIN and CIN colorectal cancer phenotypes in vitro by the use of high density cDNA filters to compare gene expression patterns between MIN and CIN colorectal cancer cell-tines yielding a panel of 73 consistently differentially expressed genes. Nine of these genes were subjected to confirmatory analysis by independent methods, of which six were confirmed as being differentially expressed; PLK, RanBP2 and CCNA2 were overexpressed in CIN tines while BTF3, H2AZ and PTPD1 were overexpressed in MIN lines. These six genes are involved in diverse processes, such as maintenance of chromatin architecture, DNA-damage checkpoint and cell cycle regulation, which may contribute to the CIN and MIN phenotypes.	Royal Coll Surgeons Ireland, Dept Biochem, Dublin 2, Ireland	Royal College of Surgeons - Ireland	Croke, DT (corresponding author), Royal Coll Surgeons Ireland, Dept Biochem, 123 St Stephens Green, Dublin 2, Ireland.		Dunican, Donncha/A-8147-2011	Croke, David/0000-0003-2718-3583; Tighe, Orna/0000-0003-0931-1254				Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Bardelli A, 2001, P NATL ACAD SCI USA, V98, P5770, DOI 10.1073/pnas.081082898; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; DRUCK T, 1995, CANCER RES, V55, P5348; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HEINEN CD, 1995, CANCER RES, V55, P4797; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lal A, 1999, CANCER RES, V59, P5403; OUSPENSKI II, 1995, J BIOL CHEM, V270, P1975, DOI 10.1074/jbc.270.5.1975; PARSONS R, 1995, CANCER RES, V55, P5548; Partanen S, 1996, ANTICANCER RES, V16, P943; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Sambrook J, 1989, MOL CLONING LAB MANU; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	20	110	114	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3253	3257		10.1038/sj.onc.1205431	http://dx.doi.org/10.1038/sj.onc.1205431			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082642				2022-12-17	WOS:000175373600018
J	Bieche, I; Parfait, B; Laurendeau, I; Girault, I; Vidaud, M; Lidereau, R				Bieche, I; Parfait, B; Laurendeau, I; Girault, I; Vidaud, M; Lidereau, R			Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer	ONCOGENE			English	Article						breast cancer; estrogen receptor alpha; estrogen receptor beta; mRNA level; quantitative RT-PCR; real-time PCR detection	MESSENGER-RNA EXPRESSION; TRANSCRIPTION-PCR ASSAY; ER-ALPHA; CLONING	The recent cloning of a second estrogen receptor (ER), designated ER beta, has prompted a reevaluation of the role of ERs in breast cancer. We have developed and validated a real-time RT - PCR assay to quantify ER alpha and ER beta gene expression at the mRNA level in a series of 131 patients with unilateral invasive primary breast cancer. Although ER beta expression showed wide variations in tumor tissues, its range (nearly three orders of magnitude) was smaller than that of ER alpha (nearly four orders of magnitude), suggesting that ER beta is more tightly controlled than ER alpha. We observed a negative correlation between ER alpha and ER beta expression. 'ER alpha -negative' tumors (containing very low ER alpha mRNA levels) were associated with SBR histopathological grade III, RB1 underexpression and ERBB2 overexpression, confirming that ER alpha negativity delineates poorly differentiated tumors. The amount of ER alpha mRNA (but not that of ER beta mRNA) increased with age and was consequently higher in postmenopausal patients' tumors. Expression of ER alpha (but not that of ER beta) also correlated strongly with progesterone receptor (PR) and PS2 expression, suggesting that ER alpha has stronger transcriptional activity than ER beta towards genes containing an ERE (estrogen response element) in their promoters. Interestingly, we found a negative correlation between the expression of ER beta (but not ER alpha) and CCND1, which contains an AP1 element but not an ERE in its promoter. Taken together, these data confirm that ER alpha and ER beta play different roles in breast cancer, partly by mediating the transcription of various genes via different types of DNA enhancer. PR and PS2 seem to be mainly ER alpha -responsive genes, whereas CCND1 may be mainly ER beta -responsive. Our findings also underline the need for a reliable method, providing full range of quantitative values, to determine ER alpha and ER beta status in the clinical setting.	Univ Paris 05, Fac Sci Pharmaceut & Biol, UPRES JE 2195, Genet Mol Lab, F-75006 Paris, France; Ctr Rene Huguenin, Lab Oncogenet, INSERM E0017, F-92211 St Cloud, France	UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Rene Huguenin Hospital	Bieche, I (corresponding author), Ctr Rene Huguenin, INSERM E0017, Lab Oncogenet, 35 Rue Dailly, F-92211 St Cloud, France.		Bièche, Ivan/O-7399-2017; Vidaud, Michel/O-7346-2017; PARFAIT, Beatrice/O-7392-2017	Bièche, Ivan/0000-0002-2430-5429; 				Bieche I, 2000, MOL CARCINOGEN, V29, P151, DOI 10.1002/1098-2744(200011)29:3<151::AID-MC4>3.3.CO;2-Y; Bieche I, 1999, CANCER RES, V59, P2759; Bieche I, 1999, CLIN CHEM, V45, P1148; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Clarke M, 1998, LANCET, V351, P1451; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; Diab SG, 2000, J NATL CANCER I, V92, P550, DOI 10.1093/jnci/92.7.550; Dotzlaw H, 1999, CANCER RES, V59, P529; Fuqua SAW, 1999, CANCER RES, V59, P5425; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Jarvinen TAH, 2000, AM J PATHOL, V156, P29, DOI 10.1016/S0002-9440(10)64702-5; Jensen E V, 1987, Prog Clin Biol Res, V249, P283; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Knowlden JM, 2000, INT J CANCER, V89, P209, DOI 10.1002/(SICI)1097-0215(20000320)89:2<209::AID-IJC17>3.0.CO;2-6; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Leygue E, 1998, CANCER RES, V58, P3197; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PERSYN JP, 1980, EUR J CANCER, V16, P1513; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Planas-Silva MD, 1999, CANCER RES, V59, P4788; Soubeyran I, 1996, BRIT J CANCER, V74, P1120, DOI 10.1038/bjc.1996.500; Speirs V, 1999, CANCER RES, V59, P525	25	110	112	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2001	20	56					8109	8115		10.1038/sj.onc.1204917	http://dx.doi.org/10.1038/sj.onc.1204917			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781824				2022-12-17	WOS:000172396800008
J	Mousses, S; Wagner, U; Chen, YD; Kim, JW; Bubendorf, L; Bittner, M; Pretlow, T; Elkahloun, AG; Trepel, JB; Kallioniemi, OP				Mousses, S; Wagner, U; Chen, YD; Kim, JW; Bubendorf, L; Bittner, M; Pretlow, T; Elkahloun, AG; Trepel, JB; Kallioniemi, OP			Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling	ONCOGENE			English	Article						microarray; prostate cancer; hormone-refractory; androgen-independent; CWR22	MAMMALIAN TARGET; GROWTH-FACTOR; RECEPTOR; XENOGRAFT; EXPRESSION; CWR22; MODEL; RHABDOMYOSARCOMA; INHIBITION; MECHANISM	Androgen deprivation therapy for advanced prostate cancer is often effective, but not curative. Molecular pathways mediating the therapeutic response and those contributing to the subsequent hormone-refractory cell growth remain poorly understood. Here, cDNA microarray analysis of human CWR22 prostate cancer xenografts during the course of androgen deprivation therapy revealed distinct global gene expression profiles in primary, regressing and recurrent tumors. Elucidation of the genes involved in the transition between these states implicated specific molecular mechanisms in therapy failure and tumor progression. First, we identified a set of androgen-responsive genes whose expression decreased during the therapy response, but was then systematically restored in the recurrent tumors. In addition, altered expression of genes that encode known targets of rapamycin or that converge on the PI3K/AKT/FRAP pathway was observed in the recurrent tumors. Further suggestion for the involvement of these genes in hormone-refractory prostate cancer came from the observation that cells established from the recurrent xenografts were strongly inhibited in vitro by rapamycin. The results of this functional genomic analysis suggest that the combined effect of re-expression of androgen-responsive genes as well as the activation of rapamycin-sensitive signaling may drive prostate cancer progression, and contribute to the failure of androgen-deprivation therapy.	NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; Univ Basel, Inst Pathol, CH-4003 Basel, Switzerland; NCI, Med Branch, NIH, Bethesda, MD 20850 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Basel; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Case Western Reserve University	Kallioniemi, OP (corresponding author), NHGRI, Canc Genet Branch, NIH, Bldg 49,Rm 4A24, Bethesda, MD 20892 USA.	okalli@nhgri.nih.gov	Kallioniemi, Olli P/H-5111-2011; Bubendorf, Lukas/G-5299-2015; Bubendorfl, Lukas/H-5880-2011	Kallioniemi, Olli P/0000-0002-3231-0332; Bubendorf, Lukas/0000-0001-5970-1803; 	NATIONAL CANCER INSTITUTE [U01CA057179, R01CA057179] Funding Source: NIH RePORTER; NCI NIH HHS [CA 57179] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Amler LC, 2000, CANCER RES, V60, P6134; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Cheng L, 1996, J NATL CANCER I, V88, P607, DOI 10.1093/jnci/88.9.607; Craft N, 1998, CANCER METAST REV, V17, P421, DOI 10.1023/A:1006141806801; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; DILLING MB, 1994, CANCER RES, V54, P903; Gregory CW, 1998, CANCER RES, V58, P5718; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Khan J, 1998, CANCER RES, V58, P5009; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Mousses S, 2000, PRACT APPROACH SER, P113; Nagabhushan M, 1996, CANCER RES, V56, P3042; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; PRETLOW TG, 1993, J NATL CANCER I, V85, P394, DOI 10.1093/jnci/85.5.394; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Sekulic A, 2000, CANCER RES, V60, P3504; WAINSTEIN MA, 1994, CANCER RES, V54, P6049	22	110	114	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2001	20	46					6718	6723		10.1038/sj.onc.1204889	http://dx.doi.org/10.1038/sj.onc.1204889			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709706				2022-12-17	WOS:000171551600008
J	Xie, SH; Wang, Y; Liu, JX; Sun, T; Wilson, MB; Smithgall, TE; Arlinghaus, RB				Xie, SH; Wang, Y; Liu, JX; Sun, T; Wilson, MB; Smithgall, TE; Arlinghaus, RB			Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation	ONCOGENE			English	Article						Jak2; Bcr-Abl; Philadelphia chromosome; chronic myelogenous leukemia	CHRONIC MYELOGENOUS LEUKEMIA; CONSTITUTIVE ACTIVATION; SIGNAL TRANSDUCER; MYELOID-LEUKEMIA; CELLS; KINASE; RECEPTOR; PATHWAY; HEMATOPOIESIS; ONCOPROTEIN	We have previously reported that the Jak2 tyrosine kinase but not Jak1 is tyrosine phosphorylated in the absence of IL-3 in Bcr-Abl positive M3.16 cells, which are rendered IL-3 independent by BCR-ABL gene expression. We have explored the involvement of Jak2 tyrosine phosphorylation in Ber-Abl oncogenic effects. Our results indicate that Jak2 became tyrosine-phosphorylated in a number of cell tines expressing Bcr-Abl, when maintained in medium lacking IL-3, whereas Bcr-Abl negative cells lacked Jak2 tyrosine phosphorylation. Jak2 was poorly tyrosine-phosphorylated in cells expressing the SH2 deletion mutant of Bcr-Abl compared to either wild-type Ber-Abl or its SH3 deletion mutant. Moreover, tyrosine phosphorylation of Jak2 by Bcr-Abl was inhibited by the Abl tyrosine kinase inhibitor, STI 571, in a dose-dependent manner. This inhibition of Bcr-Abl kinase by the drug did not interfere with the ability of Jak2 and Bcr-Abl to form a complex. Studies with deletion mutants of Ber-Abl indicated that the C-terminal domain of Abl within Bcr-Abl was involved in complex formation with Jak2. Similarly, GST-Abl pull-down assays confirmed the strong binding to Jak2 by the C-terminus of Abl. Jak2 peptide substrate studies indicated that the Bcr-Abl and Abl tyrosine kinases specifically phosphorylated Y1007 of Jak2 but only poorly phosphorylated Y1008. Phosphorylation of Y1007 of Jak2 is known to be critical for its tyrosine kinase activation. Tyrosine residue 1007 of Jak2 was phosphorylated in 32Dp210 cells as measured by Western blotting with a phosphotyrosine 1007 sequence-specific antibody. A kinase-inactive Jak2 mutant blocked the colony forming ability of K562 cells. Tumor formation of K562 cells in nude mice was similarly inhibited by this kinase-inactive Jak2 mutant. This inhibition was independent of Stat5 tyrosine phosphorylation. Furthermore, tyrosine-phosphorylated Jak2 was detected in blood cells from CML patients in blast crisis but not in a normal marrow sample. In summary, these findings provide strong evidence that the Jak2 tyrosine kinase is a critical factor in Bcr-Abl malignant transformation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Arlinghaus, RB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P30CA016672, R01CA081398, P01CA049639] Funding Source: NIH RePORTER; NCI NIH HHS [CA 49639, CA 16672, CA 81398] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barge RMY, 1996, BLOOD, V87, P2148, DOI 10.1182/blood.V87.6.2148.bloodjournal8762148; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chai SK, 1997, J IMMUNOL, V159, P4720; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; GUO JQ, 1993, HEMATOL PATHOL, V7, P91; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; Liu JX, 1996, CANCER RES, V56, P5120; LIU JX, 1993, ONCOGENE, V8, P101; Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Shuai K, 1996, ONCOGENE, V13, P247; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; SIRARD C, 1994, BLOOD, V83, P1575; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TENHOEVE J, 1994, BLOOD, V84, P1731; Ward AC, 2000, BLOOD, V95, P19; Watanabe Sumiko, 1997, Leukemia (Basingstoke), V11, P76; WilsonRawls J, 1996, CANCER RES, V56, P3426; Wu Y, 1999, ONCOGENE, V18, P4416, DOI 10.1038/sj.onc.1202828	29	110	113	0	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6188	6195		10.1038/sj.onc.1204834	http://dx.doi.org/10.1038/sj.onc.1204834			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593427				2022-12-17	WOS:000171206300010
J	Macaulay, VM; Salisbury, AJ; Bohula, EA; Playford, MP; Smorodinsky, NI; Shiloh, Y				Macaulay, VM; Salisbury, AJ; Bohula, EA; Playford, MP; Smorodinsky, NI; Shiloh, Y			Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase	ONCOGENE			English	Article						insulin-like growth factors; IGF receptor; Atm; melanoma; radiosensitivity	FACTOR-I RECEPTOR; BREAST-CANCER CELLS; HUMAN SQUAMOUS CARCINOMA; IONIZING-RADIATION; ATAXIA-TELANGIECTASIA; ANTISENSE RNA; MONOCLONAL-ANTIBODY; GAMMA-IRRADIATION; DNA-DAMAGE; P53	The type 1 insulin-like growth factor receptor (IGF1R) is required for growth, tumorigenicity and protection from apoptosis, IGF1R overexpression is associated with radioresistance in breast cancer. We used antisense (AS) RNA to downregulate IGF1R expression in mouse melanoma cells. Cells expressing AS-IGF1R transcripts were more radiosensitive in vitro and in vivo than controls. Also they showed reduced radiation-induced p53 accumulation and p53 serine 18 phosphorylation, and radioresistant DNA synthesis. These changes were reminiscent of the cellular phenotype of the human genetic disorder ataxia-telangiectasia (A-T), caused by mutations in the A TM gene. Cellular Atm protein levels mere lower in AS-IGF1R-transfected cells than in control cells, although there was no difference in Atm expression at,the transcriptional level. AS-IGF1R cells had detectable basal Atm kinase activity, but failed to induce kinase activity after irradiation. This suggests that IGF1R signalling can modulate the function of Atm, and supports the concept of targeted IGF1R downregulation as a potential treatment for malignant melanoma and other radioresistant tumours.	Weatherall Inst Mol Med, Mol Oncol Labs, IGF Grp, Oxford OX3 9DS, England; Tel Aviv Univ, George S Wise Fac Life Sci, Hybridoma Unit, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel	University of Oxford; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Macaulay, VM (corresponding author), Weatherall Inst Mol Med, Mol Oncol Labs, IGF Grp, Oxford OX3 9DS, England.	macaulay@icrf.icnet.uk	Bohula, Erin/AAW-7276-2020		NINDS NIH HHS [R01 NS31763] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1999, NAT GENET, V21, P359, DOI 10.1038/7684; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Chernicky CL, 2000, CANCER GENE THER, V7, P384, DOI 10.1038/sj.cgt.7700126; Dunn SE, 1997, CANCER RES, V57, P2687; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Fan ZH, 2000, CANCER GENE THER, V7, P1307, DOI 10.1038/sj.cgt.0243; Fukao T, 1999, BLOOD, V94, P1998; Fukuchi K, 2000, BBA-MOL CELL RES, V1496, P207, DOI 10.1016/S0167-4889(00)00018-5; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200; Guha C, 2000, GENE THER, V7, P852, DOI 10.1038/sj.gt.3301174; Hartmann A, 1996, INT J CANCER, V67, P313, DOI 10.1002/(SICI)1097-0215(19960729)67:3<313::AID-IJC1>3.0.CO;2-U; HARTMANN KKP, 1992, J CELL BIOCHEM, V48, P81, DOI 10.1002/jcb.240480112; Huang SM, 1999, CANCER RES, V59, P1935; Jenrette JM, 1996, SEMIN ONCOL, V23, P759; JONES RF, 1994, MOL CARCINOGEN, V9, P95, DOI 10.1002/mc.2940090207; Kanter-Lewensohn L, 2000, GROWTH FACTORS, V17, P193, DOI 10.3109/08977190009001068; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; KELLAND LR, 1989, INT J RADIAT BIOL, V55, P119, DOI 10.1080/09553008914550121; Khandwala HM, 2000, ENDOCR REV, V21, P215, DOI 10.1210/er.21.3.215; Khanna KK, 2000, JNCI-J NATL CANCER I, V92, P795, DOI 10.1093/jnci/92.10.795; KHANNA KK, 1993, ONCOGENE, V8, P3307; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kizilian N, 1999, BIOTECHNIQUES, V27, P926, DOI 10.2144/99275bm10; KOZAK RW, 1987, CELL IMMUNOL, V109, P318, DOI 10.1016/0008-8749(87)90315-7; KWOK TT, 1989, J NATL CANCER I, V81, P1020, DOI 10.1093/jnci/81.13.1020; LAVIN MF, 2000, NATURE CELL BIOL, V2, pE1; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; Lee CT, 1996, CANCER RES, V56, P3038; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu XD, 1998, CANCER RES, V58, P5432; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Nakamura S, 1997, EXP CELL RES, V235, P287, DOI 10.1006/excr.1997.3683; OLIVE PL, 1991, CANCER RES, V51, P4671; Pandita TK, 2000, ONCOGENE, V19, P1386, DOI 10.1038/sj.onc.1203444; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Pietras RJ, 1999, CANCER RES, V59, P1347; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Ramsay J, 1998, BRIT J CANCER, V77, P11, DOI 10.1038/bjc.1998.2; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; ROFSTAD EK, 1992, INT J RADIAT ONCOL, V23, P63, DOI 10.1016/0360-3016(92)90544-R; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Savitsky K, 1997, NUCLEIC ACIDS RES, V25, P1678, DOI 10.1093/nar/25.9.1678; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; SHILOH Y, 2001, IN PRESS COLD SPRING, V65; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; Tsuboi K, 1997, Brain Tumor Pathol, V14, P19, DOI 10.1007/BF02478864; Turner BC, 1997, CANCER RES, V57, P3079; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; VOJTESEK B, 1995, ONCOGENE, V10, P389; Wang H, 2000, ADV EXP MED BIOL, V465, P265; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Westphal CH, 1997, CANCER RES, V57, P1664; Whitesell L, 1999, METHODS, V18, P296, DOI 10.1006/meth.1999.0787; WOLLMAN R, 1994, INT J RADIAT ONCOL, V30, P91, DOI 10.1016/0360-3016(94)90523-1; Wouters BG, 1999, ONCOGENE, V18, P6540, DOI 10.1038/sj.onc.1203053; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Zhang LJ, 1999, J BIOL CHEM, V274, P13118, DOI 10.1074/jbc.274.19.13118; Zhang N, 1998, ONCOGENE, V17, P811, DOI 10.1038/sj.onc.1202007; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	76	110	114	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					4029	4040		10.1038/sj.onc.1204565	http://dx.doi.org/10.1038/sj.onc.1204565			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494131				2022-12-17	WOS:000169681500011
J	Kwek, SSS; Derry, J; Tyner, AL; Shen, ZY; Gudkov, AV				Kwek, SSS; Derry, J; Tyner, AL; Shen, ZY; Gudkov, AV			Functional analysis and intracellular localization of p53 modified by SUMO-1	ONCOGENE			English	Article						SUMO-1; p53; transactivation; cellular localization	UBIQUITIN-LIKE PROTEIN; NUCLEAR-PORE COMPLEX; CELL-CYCLE PROGRESSION; TUMOR-SUPPRESSOR P53; DNA-DAMAGE; COVALENT MODIFICATION; ADENOVIRUS TYPE-5; IN-VITRO; MDM2; CONJUGATION	p53 tumor suppressor is a subject of several posttranslational modifications, including phosphorylation, ubiquitination and acetylation, which regulate p53 function. A new covalent modification of p53 at lysine 386 by SUMO-1 was recently identified. To elucidate the function of sumoylated p53, we compared the properties of wild type p53 and sumoylation-deficient p53 mutant, K386R, No differences were found between wild type p53 and K386R mutant of p53 in transactivation or growth suppression assays. Moreover, overexpression of SUMO-1 has no effect on p53-regulated transcription. Biochemical fractionation showed that sumoylated p53 is localized in the nucleus and is tightly bound to chromatin structures. p53 and SUMO-1 colocalized in PML nuclear bodies in 293 cells and the nucleoli in MCF7 and HT1080 cells. However, sumoylation-deficient p53 mutant showed a similar pattern of intranuclear localization, suggesting that SUMO-1 does not target p53 to subnuclear structures. These data indicate that SUMO-1 modification of p53 at lysine 386 may not be essential for p53's cellular localization, transcriptional activation, or growth regulation.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gudkov, AV (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.			Shen, Zhiyuan/0000-0003-2834-0309; Gudkov, Andrei/0000-0003-2548-0154; Tyner, Angela/0000-0001-7448-8625	NATIONAL CANCER INSTITUTE [R01CA075179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056283] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008353, R29ES008353] Funding Source: NIH RePORTER; NCI NIH HHS [CA75179] Funding Source: Medline; NIDDK NIH HHS [R01 DK056283] Funding Source: Medline; NIEHS NIH HHS [ES08353] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Boddy MN, 1996, ONCOGENE, V13, P971; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; CARTER T, 1987, CANCER RES, V47, P803; Chehab NH, 2000, GENE DEV, V14, P278; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; FINLEY RL, 1995, DNA CLONING EXPRESSI, P169; FISCELLA M, 1993, ONCOGENE, V8, P1519; FUCHS B, 1995, ONCOGENE, V10, P789; GERACE L, 1982, J CELL BIOL, V95, P826, DOI 10.1083/jcb.95.3.826; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAHAM JM, 1997, SUBCELLULAR FRACTION, P71; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; KAY RR, 1972, EUR J BIOCHEM, V30, P145, DOI 10.1111/j.1432-1033.1972.tb02081.x; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kirsch DG, 1998, J CLIN ONCOL, V16, P3158, DOI 10.1200/JCO.1998.16.9.3158; Kondratov R. V., 1996, Molekulyarnaya Biologiya (Moscow), V30, P613; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Leppard KN, 1999, J GEN VIROL, V80, P997, DOI 10.1099/0022-1317-80-4-997; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Li WH, 2000, NUCLEIC ACIDS RES, V28, P1145, DOI 10.1093/nar/28.5.1145; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Liu L, 1999, MOL CELL BIOL, V19, P1202; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Okura T, 1996, J IMMUNOL, V157, P4277; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; REIMER G, 1987, ARTHRITIS RHEUM, V30, P793, DOI 10.1002/art.1780300709; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Rubbi CP, 2000, ONCOGENE, V19, P85, DOI 10.1038/sj.onc.1203378; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Shieh SY, 2000, GENE DEV, V14, P289; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Suzuki T, 1999, J BIOL CHEM, V274, P31131, DOI 10.1074/jbc.274.44.31131; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	69	110	116	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2587	2599		10.1038/sj.onc.1204362	http://dx.doi.org/10.1038/sj.onc.1204362			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420669				2022-12-17	WOS:000168652500010
J	Georgopoulos, NT; Proffitt, JL; Blair, GE				Georgopoulos, NT; Proffitt, JL; Blair, GE			Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins	ONCOGENE			English	Article						human papillomavirus; E7; MHC class I; TAP1; LMP2; transcriptional repression	CERVICAL CARCINOMAS; DOWN-REGULATION; CELL-LINE; EXPRESSION; TRANSACTIVATION; IDENTIFICATION; NEOPLASIA; ANTIGEN; CANCER; E1A	We have examined the possibility that the E7 proteins of the high-risk human papillomavirus (HPV) type 16 and 18 and the oncogenic adenovirus (Ad) type 12 E1A protein share the ability to down-regulate the expression of components of the antigen processing and presentation pathway, as a common strategy in the evasion of immune surveillance during the induction of cell transformation. Expression of the HPV 18 E7 oncoprotein, like Ad 12 E1A, resulted in repression of the major histocompatibility complex (MHC) class I heavy chain promoter, as well as repression of a bidirectional promoter that regulates expression of the genes encoding the transporter associated with antigen processing subunit 1 (TAP1) and a proteasome subunit, low molecular weight protein 2 (LMP2), HPV 16 E7 also caused a reduction in class I heavy chain promoter activity, however it did not have any significant effect on the activity of the bidirectional promoter. Interestingly, expression of the low-risk I-IPV 6b E7 protein resulted in an increase in MHC class I heavy chain promoter activity, while repressing the TAP1/LMP2 promoter, Interference with the class I pathway could also explain the ability of low-risk HPVs in inducing benign lesions.	Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Blair, GE (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England.		Blair, George Eric/A-5906-2008	Blair, George Eric/0000-0003-0440-1795; Georgopoulos, Nik/0000-0002-6330-4947				ACKRILL AM, 1988, ONCOGENE, V3, P483; ARENDS MJ, 1993, HUM PATHOL, V24, P432, DOI 10.1016/0046-8177(93)90093-V; BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; BARBOSA MS, 1991, J VIROL, V65, P292, DOI 10.1128/JVI.65.1.292-298.1991; Bartholomew Jennifer, 1995, P233, DOI 10.1017/CBO9780511525339.010; Blair GE, 1998, SEMIN VIROL, V8, P387, DOI 10.1006/smvy.1997.0140; Burger RA, 1996, JNCI-J NATL CANCER I, V88, P1361, DOI 10.1093/jnci/88.19.1361; BYRD PJ, 1982, J GEN VIROL, V60, P279, DOI 10.1099/0022-1317-60-2-279; CERUNDOLO V, 1995, EUR J IMMUNOL, V25, P554, DOI 10.1002/eji.1830250238; CONNOR ME, 1990, INT J CANCER, V46, P1029, DOI 10.1002/ijc.2910460614; COX JT, 1995, BAILLIERE CLIN OB GY, V9, P1, DOI 10.1016/S0950-3552(05)80357-8; CROMME FV, 1994, BRIT J CANCER, V69, P1176, DOI 10.1038/bjc.1994.231; CROMME FV, 1993, BRIT J CANCER, V67, P1372, DOI 10.1038/bjc.1993.254; CROMME FV, 1993, ONCOGENE, V8, P2969; CROMME FV, 1994, J EXP MED, V179, P335, DOI 10.1084/jem.179.1.335; DERY CV, 1987, ONCOGENE, V2, P15; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Elliott T, 1997, ADV IMMUNOL, V65, P47, DOI 10.1016/S0065-2776(08)60741-5; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; HERRMANN CH, 1987, ONCOGENE, V2, P25; KEATING PJ, 1995, BRIT J CANCER, V72, P405, DOI 10.1038/bjc.1995.346; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Proffitt JA, 1997, FEBS LETT, V400, P141, DOI 10.1016/S0014-5793(96)01375-0; PROFFITT JL, 1994, NUCLEIC ACIDS RES, V22, P4779, DOI 10.1093/nar/22.22.4779; Rey O, 2000, J VIROL, V74, P4912, DOI 10.1128/JVI.74.10.4912-4918.2000; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Stern PL, 1996, ADV CANCER RES, V69, P175, DOI 10.1016/S0065-230X(08)60863-5; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; van Endert PM, 1999, CURR OPIN IMMUNOL, V11, P82, DOI 10.1016/S0952-7915(99)80015-6; WILCZYNSKI SP, 1993, HUM PATHOL, V24, P96, DOI 10.1016/0046-8177(93)90068-R; WILCZYNSKI SP, 1988, VIROLOGY, V166, P624, DOI 10.1016/0042-6822(88)90539-9; Williams DB, 1996, TRENDS CELL BIOL, V6, P267, DOI 10.1016/0962-8924(96)10020-9; Zwerschke W, 2000, ADV CANCER RES, V78, P1	40	110	112	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4930	4935		10.1038/sj.onc.1203860	http://dx.doi.org/10.1038/sj.onc.1203860			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039910				2022-12-17	WOS:000089757800015
J	de Koning, JP; Soede-Bobok, AA; Ward, AC; Schelen, AM; Antonissen, C; van Leeuwen, D; Lowenberg, B; Touw, IP				de Koning, JP; Soede-Bobok, AA; Ward, AC; Schelen, AM; Antonissen, C; van Leeuwen, D; Lowenberg, B; Touw, IP			STAT3-mediated differentiation and survival of myeloid cells in response to granulocyte colony-stimulating factor: role for the cyclin-degendent kinase inhibitor p27(Kip1)	ONCOGENE			English	Article						G-CSF; STAT3; p27(Kip1); neutrophilic differentiation; survival	DISTINCT CYTOPLASMIC REGIONS; G-CSF RECEPTOR; TRANSCRIPTION FACTOR; ACTIVATION; STAT3; PROLIFERATION; GENE; GROWTH; SIGNALS; INVOLVEMENT	The signal transducer and activator of transcription (STAT) proteins have been implicated in cytokine-regulated proliferation, differentiation and cell survival. Granulocyte colony-stimulating factor (G-CSF), a regulator of granulocytic differentiation, induces a robust and sustained activation of STAT3. Here, we show that introduction of dominant negative (DN) forms of STAT3 interferes with G-CSF-induced differentiation and survival in murine 32D cells, G-CSF induces expression of the cyclin-dependent kinase (cdk) inhibitor p27(Kip1) (but not p21(Cip1)), which is completely blocked by DN-STAT3. The ability of tyrosine-to-phenylalanine substitution mutants of the G-CSF receptor to activate STAT3 strongly correlated with their capacity to induce p27 expression and their ability to mediate differentiation and survival, suggesting a causal relationship between STAT3 activation, p27 expression and the observed cellular responses. We identified a putative STAT binding site in the promoter region of p27 that showed both STAT3 binding in electrophoretic mobility shift assays and functional activity in luciferase reporter assays, Finally, we studied G-CSF-induced responses in primary bone marrow and spleen cells of p27-deficient mice. Compared with wildtype, myeloid progenitors from p27-deficient mice showed significantly increased proliferation and reduced differentiation in response to G-CSF. These findings indicate that STAT3 controls myeloid differentiation, at least partly, via upregulation of p27(Kip1).	Erasmus Univ, Inst Hematol, NL-3000 DR Rotterdam, Netherlands; Dr Daniel Den Hoed Canc Ctr, Dept Hematol, NL-3008 AE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	Touw, IP (corresponding author), Erasmus Univ, Inst Hematol, Room H Ee 13-14,POB 1738, NL-3000 DR Rotterdam, Netherlands.			Ward, Alister/0000-0001-7945-7975				Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Chakraborty A, 1999, BLOOD, V93, P15, DOI 10.1182/blood.V93.1.15.401a46_15_24; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; de Koning JP, 1998, BLOOD, V91, P1924, DOI 10.1182/blood.V91.6.1924.1924_1924_1933; deKoning JP, 1996, BLOOD, V87, P132; deKoning JP, 1996, BLOOD, V87, P1335, DOI 10.1182/blood.V87.4.1335.bloodjournal8741335; DEMETRI GD, 1991, BLOOD, V78, P2791; Dong F, 1998, J IMMUNOL, V161, P6503; DONG F, 1995, BLOOD, V85, P902, DOI 10.1182/blood.V85.4.902.bloodjournal854902; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NICOLA NA, 1987, INT J CELL CLONING, V5, P1, DOI 10.1002/stem.5530050102; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; OKUDA K, 1994, J BIOL CHEM, V269, P24602; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Tian SS, 1996, BLOOD, V88, P4435, DOI 10.1182/blood.V88.12.4435.bloodjournal88124435; TIAN SS, 1994, BLOOD, V84, P1760; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Ward AC, 1999, J BIOL CHEM, V274, P14956, DOI 10.1074/jbc.274.21.14956; Ward AC, 1996, BIOCHEM BIOPH RES CO, V224, P10, DOI 10.1006/bbrc.1996.0976; Ward AC, 1999, BLOOD, V93, P113, DOI 10.1182/blood.V93.1.113.401k33_113_124; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	46	110	111	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2000	19	29					3290	3298		10.1038/sj.onc.1203627	http://dx.doi.org/10.1038/sj.onc.1203627			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918585				2022-12-17	WOS:000088019300007
J	Smithgall, TE; Briggs, SD; Schreiner, S; Lerner, EC; Cheng, HY; Wilson, MB				Smithgall, TE; Briggs, SD; Schreiner, S; Lerner, EC; Cheng, HY; Wilson, MB			Control of myeloid differentiation and survival by Stats	ONCOGENE			English	Article						stat; cytokine; differentiation; survival; tyrosine kinase	ERYTHROLEUKEMIA CELL-LINE; PROTEIN-TYROSINE PHOSPHATASES; STIMULATING FACTOR-RECEPTOR; BCL-X-L; ERYTHROPOIETIN RECEPTOR; ERYTHROID-DIFFERENTIATION; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; LEUKEMIA-CELLS; GROWTH ARREST	Hematopoiesis involves a complex array of growth factors that regulate the survival and proliferation of immature progenitors, influence differentiation commitment, and modulate end-stage cell functions. This minireview is focused on the role of Stat activation in the development of myeloid cells in response to hematopoietic cytokines, Much of the evidence implicating Stats in these cellular processes comes from studies of mutant cytokine receptors selectively uncoupled from Stat activation, dominant-inhibitory Stat mutants, and mice with targeted disruptions of Stat genes. Together these approaches provide strong evidence that Stat activation, particularly of Stat3 and Stat5, plays an important role in myeloid differentiation and survival.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Smithgall, TE (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, E1240 Biomed Sci Tower, Pittsburgh, PA 15261 USA.			Briggs, Scott D/0000-0003-2852-3594				Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Briggs SD, 1999, J BIOL CHEM, V274, P26579, DOI 10.1074/jbc.274.37.26579; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chakraborty A, 1999, BLOOD, V93, P15, DOI 10.1182/blood.V93.1.15.401a46_15_24; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Cheng HY, 1999, MOL CELL BIOL, V19, P8335; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; Ernst M, 1999, J BIOL CHEM, V274, P9729, DOI 10.1074/jbc.274.14.9729; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; Gregoli PA, 1997, BLOOD, V90, P630, DOI 10.1182/blood.V90.2.630.630_630_640; Gregory RC, 1998, BLOOD, V92, P1104, DOI 10.1182/blood.V92.4.1104.416k38_1104_1118; Hibi M, 1996, J MOL MED-JMM, V74, P1, DOI 10.1007/BF00202068; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Lacombe C, 1998, HAEMATOLOGICA, V83, P724; Link DC, 1999, BLOOD, V94, p471A; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; Manfredini R, 1997, BLOOD, V89, P135, DOI 10.1182/blood.V89.1.135.135_135_145; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MIURA O, 1994, BLOOD, V84, P1501; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Nicholson SE, 1996, J BIOL CHEM, V271, P26947, DOI 10.1074/jbc.271.43.26947; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Saksela Kalle, 1997, Frontiers in Bioscience, V2, pD606; SENSIS Y, 1999, MOL CELL BIOL, V19, P7436; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; SHIOZAKI M, 1990, LEUKEMIA RES, V14, P287, DOI 10.1016/0145-2126(90)90137-X; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Smithgall TE, 1998, CRIT REV ONCOGENESIS, V9, P43, DOI 10.1615/CritRevOncog.v9.i1.40; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stevenson M, 1996, NAT STRUCT BIOL, V3, P303, DOI 10.1038/nsb0496-303; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; WINKELMANN JC, 1995, BLOOD, V85, P179, DOI 10.1182/blood.V85.1.179.bloodjournal851179; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; YU G, 1989, J BIOL CHEM, V264, P10276	61	110	119	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2612	2618		10.1038/sj.onc.1203477	http://dx.doi.org/10.1038/sj.onc.1203477			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851060				2022-12-17	WOS:000087459400017
J	Ait-Si-Ali, S; Polesskaya, A; Filleur, S; Ferreira, R; Duquet, A; Robin, P; Vervish, A; Trouche, D; Cabon, F; Harel-Bellan, A				Ait-Si-Ali, S; Polesskaya, A; Filleur, S; Ferreira, R; Duquet, A; Robin, P; Vervish, A; Trouche, D; Cabon, F; Harel-Bellan, A			CBP/p300 histone acetyl-transferase activity is important for the G1/S transition	ONCOGENE			English	Article						CBP/p300; histone acetyl-transferase; proliferation; E2F; G1/S transition; microinjection	CREB-BINDING PROTEIN; ADENOVIRAL ONCOPROTEIN E1A; SERUM RESPONSE FACTOR; B-MYB TRANSCRIPTION; ACETYLTRANSFERASE ACTIVITY; P300/CBP-ASSOCIATED FACTOR; FUNCTIONAL COLLABORATION; REPRESS TRANSCRIPTION; CELL-DIFFERENTIATION; CHROMATIN DISRUPTION	Transforming viral proteins such as E1A which force quiescent cells into S phase have two essential cellular target proteins, Rb and CBP/p300, Rb regulates the G1/S transition by controlling the transcription factor E2F, CBP/p300 is a transcriptional co-activator with intrinsic histone acetyl-transferase activity. This activity is regulated in a cell cycle dependent manner and shows a peak at the G1/S transition, suggesting a function for CBP/p300 in this crucial step of the cell cycle. Here, we have artificially modulated CBP/p300 levels in individual cells through microinjection of specific antibodies and expression vectors. We show that CBP/p300 is required for cell proliferation and has an essential function during the G1/S transition. Using the same microinjection system and GFP-reporter vectors, we demonstrate that CBP/p300 is essential for the activity of E2F, a transcription factor that controls the G1/S transition. In addition, our results suggest that CBP HAT activity is required both for the G1/S transition and for E2F activity. Thus CBP/p300 seems to be a versatile protein involved in opposing cellular processes, which raises the question of how its multiple activities are regulated.	CNRS, IFC 01, Lab Oncogenese Differenciat & Transduct Signal, F-94801 Villejuif, France; CNRS, IFC 01, Lab Cytoretrie, F-94801 Villejuif, France; CNRS, UPR 9006, LBME, F-31062 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Harel-Bellan, A (corresponding author), CNRS, IFC 01, Lab Oncogenese Differenciat & Transduct Signal, 7 Rue Guys Moquet, F-94801 Villejuif, France.		Trouche, Didier/B-2854-2008; Cabon, Florence/B-3284-2013; Harel-Bellan, Annick/M-9795-2015	Cabon, Florence/0000-0002-6149-082X; Harel-Bellan, Annick/0000-0002-2339-153X; Filleur, Stephanie/0000-0002-3420-5536; Trouche, Didier/0000-0003-1398-6481				Ait-Si-Ali S, 1998, NUCLEIC ACIDS RES, V26, P3869, DOI 10.1093/nar/26.16.3869; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bennett JD, 1996, ONCOGENE, V13, P1073; BERNARDS R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P33; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chiarugi V, 1998, ONCOL RES, V10, P55; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dyson N, 1989, Princess Takamatsu Symp, V20, P191; Eckner R, 1996, BIOL CHEM, V377, P685; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Fry CJ, 1999, J BIOL CHEM, V274, P15883, DOI 10.1074/jbc.274.22.15883; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Groisman R, 1996, J BIOL CHEM, V271, P5258; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hasegawa K, 1997, J BIOL CHEM, V272, P20049, DOI 10.1074/jbc.272.32.20049; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karuppayil SM, 1998, J BIOL CHEM, V273, P17303, DOI 10.1074/jbc.273.28.17303; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lee BH, 1997, P NATL ACAD SCI USA, V94, P4481, DOI 10.1073/pnas.94.9.4481; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Li Q, 1999, EMBO J, V18, P5634, DOI 10.1093/emboj/18.20.5634; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1999, SEMIN CELL DEV BIOL, V10, P197, DOI 10.1006/scdb.1999.0301; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Muraoka M, 1996, ONCOGENE, V12, P1565; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298; Scolnick DM, 1997, CANCER RES, V57, P3693; Shi Y, 1998, GENE DEV, V12, P943, DOI 10.1101/gad.12.7.943; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Smits PHM, 1996, ONCOGENE, V12, P1529; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; WEINBERG RA, 1992, CANCER SURV, V12, P43; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	67	110	112	3	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2000	19	20					2430	2437		10.1038/sj.onc.1203562	http://dx.doi.org/10.1038/sj.onc.1203562			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828885				2022-12-17	WOS:000087018400008
J	Gil, J; Alcami, J; Esteban, M				Gil, J; Alcami, J; Esteban, M			Activation of NF-kappa B by the dsRNA-dependent protein kinase, PKR involves the I kappa B kinase complex	ONCOGENE			English	Article						PKR; NF-kappa B; IKK; dsRNA	DOUBLE-STRANDED-RNA; VACCINIA VIRUS; TRANSCRIPTIONAL ACTIVATION; PROTEOLYTIC DEGRADATION; INDUCED APOPTOSIS; IKK-ALPHA; PHOSPHORYLATION; EXPRESSION; CELLS; REPLICATION	Besides its known role as a translational controlling factor, the double stranded RNA-dependent protein kinase (PKR) is a key transcriptional regulator exerting antiviral and antitumoural activities. We have recently described that induction of NF-kappa B by PKR is involved in apoptosis commitment. To define how PKR mediates NF-kappa B activation by dsRNA, we have used two different approaches, one based on expression of PKR by a vaccinia virus (VV) recombinant and the other based on induction of endogenous PKR by poly I:C (pIC) treatment. We found that NF-kappa B complexes induced by PKR are composed primarily of p50-p65 heterodimers and also of c-rel-p50 heterodimers. As described for other stimuli, following pIC treatment, PKR phosphorylates the NF-kappa B inhibitor I kappa B alpha at serine 32 before degradation. Expression by VV recombinants of IKK1 or IKK2 dominant negative mutants together with PKR showed inhibition of PER-induced NF-kappa B activation, as measured both by gel shift and luciferase reporter assays. Immunoprecipitation analysis revealed that PKR interacts with the IKK complex. Our findings demonstrate that physiological function(s) of PKR involve activation of the I kappa B kinase complex.	CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Madrid 28049, Spain; Hosp 12 Octubre, Ctr Invest, E-28041 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Hospital Universitario 12 de Octubre	Esteban, M (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Campus Univ Autonoma, Madrid 28049, Spain.		Esteban, Mariano/ABG-5375-2020; Alcami, Pepe/T-2242-2018; Gil, Jesus/C-7739-2012	Esteban, Mariano/0000-0003-0846-2827; Alcami, Pepe/0000-0003-0023-7377; Gil, Jesus/0000-0002-4303-6260				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Braganca J, 1998, BIOCHIMIE, V80, P673, DOI 10.1016/S0300-9084(99)80021-2; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Foo SY, 1999, TRENDS GENET, V15, P229; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gil J, 1999, MOL CELL BIOL, V19, P4653; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; LEAMAN DW, 1998, P NATL ACAD SCI USA, V219, P339; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lee SB, 1996, J INTERF CYTOK RES, V16, P1073, DOI 10.1089/jir.1996.16.1073; LEE SB, 1993, VIROLOGY, V192, P380, DOI 10.1006/viro.1993.1048; LEE SB, 1993, VIROLOGY, V193, P1037, DOI 10.1006/viro.1993.1223; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LEVIN D, 1978, P NATL ACAD SCI USA, V75, P1121, DOI 10.1073/pnas.75.3.1121; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lin KI, 1998, J CELL BIOL, V141, P1479, DOI 10.1083/jcb.141.7.1479; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MEURS EF, 1993, CELL, V62, P379; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; Rebouillat D, 1999, J INTERF CYTOK RES, V19, P295, DOI 10.1089/107999099313992; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROBINSON RA, 1976, JNCI-J NATL CANCER I, V57, P599, DOI 10.1093/jnci/57.3.599; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Salazar AM, 1996, NEUROSURGERY, V38, P1096, DOI 10.1097/00006123-199606000-00006; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Vazquez MI, 1998, J VIROL, V72, P10126; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; YOSHIDA I, 1992, ACTA VIROL, V36, P347; Zamanian-Daryoush M, 1999, ONCOGENE, V18, P315, DOI 10.1038/sj.onc.1202293; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1999, MOL CELL BIOL, V19, P4547	76	110	115	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2000	19	11					1369	1378		10.1038/sj.onc.1203448	http://dx.doi.org/10.1038/sj.onc.1203448			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723127	Bronze			2022-12-17	WOS:000085942700001
J	Budunova, IV; Perez, P; Vaden, VR; Spiegelman, VS; Slaga, TJ; Jorcano, JL				Budunova, IV; Perez, P; Vaden, VR; Spiegelman, VS; Slaga, TJ; Jorcano, JL			Increased expression of p50-NF-kappa B and constitutive activation of NF-kappa B transcription factors during mouse skin carcinogenesis	ONCOGENE			English	Article						NF-kappa B factors; I kappa B proteins; skin carcinogenesis	DNA-BINDING; ONCOPROTEIN BCL-3; P50 HOMODIMERS; PRECURSOR P105; REL-FAMILY; NUCLEAR-LOCALIZATION; P65 SUBUNIT; PROTEINS; CELLS; ALPHA	To elucidate the possible role of NF-kappa B in mouse skin carcinogenesis we studied the expression of p50 (NF-kappa B1), p52 (NF-kappa B2), p65 (ReIA) and I kappa B-alpha inhibitor as well as kappa B-binding activity in adult SENCAR mouse skin, skin papillomas, and squamous cell carcinomas (SCC) generated by a two-stage carcinogenesis protocol. We found that in normal epidermis all of the above proteins were mostly expressed in the cytoplasm of basal cells. Western blot analysis revealed a dramatic increase of p50 and p52 expression in mouse skin tumors starting from the middle stage of promotion. We also found that the level of I kappa B-alpha protein in many late papillomas and see was lower than in normal epidermis, Results of EMSA showed an increase in kappa B-binding activity in mouse skin tumors and suggested that p50 is the major component of constitutive kappa B-binding complexes in normal epidermis and in tumors. It has been shown that nuclear I kappa B protein Bcl-3 is able to increase p50/p50 homodimer binding to the different kappa B sites in mouse thymocytes. Our finding on Bcl-3 overexpression in late papillomas and SCC could explain the selective increase of p50-related kappa B-binding in mouse skin tumors, Thus, our results strongly suggest the important role of p50 in skin carcinogenesis.	AMC Canc Res Ctr, Denver, CO 80214 USA; CIEMAT, Dept Mol & Cell Biol, E-28040 Madrid, Spain	AMC Cancer Research Center; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas	Budunova, IV (corresponding author), AMC Canc Res Ctr, 1600 Pierce St, Denver, CO 80214 USA.		Perez, Paloma/K-8841-2017	Perez, Paloma/0000-0002-7166-2824; Spiegelman, Vladimir S/0000-0003-4847-155X	NATIONAL CANCER INSTITUTE [R01CA079065] Funding Source: NIH RePORTER; NCI NIH HHS [CA79065-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALMAIN A, 1982, NUCLEIC ACIDS RES, V10, P4259, DOI 10.1093/nar/10.14.4259; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Binder RL, 1998, CANCER RES, V58, P4314; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; DEJARDIN E, 1995, ONCOGENE, V11, P1835; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; Folgueira L, 1996, J VIROL, V70, P2332, DOI 10.1128/JVI.70.4.2332-2338.1996; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Gilmore TD, 1996, ONCOGENE, V13, P1367; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE J, 1993, ONCOGENE, V8, P2067; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; Karin M, 1998, CANCER J SCI AM, V4, pS92; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KOONG AC, 1994, CANCER RES, V54, P5273; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Leveillard Thierry, 1993, Gene Expression, V3, P135; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; MUKHOPADHYAY T, 1995, ONCOGENE, V11, P999; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHOUTEN GJ, 1995, EMBO J, V14, P1498, DOI 10.1002/j.1460-2075.1995.tb07136.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Slaga T J, 1995, Prog Clin Biol Res, V391, P1; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; Tobin D, 1996, ONCOGENE, V12, P785; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WATANABE M, 1993, ONCOGENE, V8, P2949; WEIH F, 1994, ONCOGENE, V9, P3289; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058	53	110	112	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7423	7431		10.1038/sj.onc.1203104	http://dx.doi.org/10.1038/sj.onc.1203104			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602501				2022-12-17	WOS:000084119600003
J	Hiramoto, T; Nakanishi, T; Sumiyoshi, T; Fukuda, T; Matsuura, S; Tauchi, H; Komatsu, K; Shibasaki, Y; Inui, H; Watatani, M; Yasutomi, M; Sumii, K; Kajiyama, G; Kamada, N; Miyagawa, K; Kamiya, K				Hiramoto, T; Nakanishi, T; Sumiyoshi, T; Fukuda, T; Matsuura, S; Tauchi, H; Komatsu, K; Shibasaki, Y; Inui, H; Watatani, M; Yasutomi, M; Sumii, K; Kajiyama, G; Kamada, N; Miyagawa, K; Kamiya, K			Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer	ONCOGENE			English	Article						mutation; RAD54; cancer	COMPARATIVE GENOMIC HYBRIDIZATION; NIJMEGEN BREAKAGE SYNDROME; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL REGULATOR; POSITIONAL CLONING; SYNDROME GENE; REPAIR; RECOMBINATION; SNF2; PROTEIN	Association of breast tumor susceptibility gene products BRCA1 and BRCA2 with the RAD51 recombination protein suggested that cancer could arise through defects in recombination, The identification of NBS1, responsible for Nijmegen breakage syndrome, from the MRE11/RAD50 recombination protein complex also supports this hypothesis. However, our mutation analysis revealed that known members of the RAD52 epistasis group are rarely mutated in human primary cancer. Here we describe the isolation of a novel member of the SNF2 superfamily, characterized with sequence motifs similar to those in DNA and RNA helicases. The gene, designated RAD54B, is significantly homologous to the RAD54 recombination gene. The expression of RAD54B was high in testis and spleen, which are active in meiotic and mitotic recombination. These findings suggest that RAD54B may play an active role in recombination processes in concert with other members of the RAD52 epistasis group. RAD54B maps to human chromosome 8q21.3-q22 in a region associated with cancer-related chromosomal abnormalities. Homozygous mutations at highly conserved positions of RAD54B were observed in human primary lymphoma and colon cancer.	Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Mol Pathol, Minami Ku, Hiroshima 734, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Dev Biol & Oncol, Minami Ku, Hiroshima 734, Japan; Hiroshima Univ, Sch Med, Dept Internal Med 1, Minami Ku, Hiroshima 734, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Radiat Biol, Minami Ku, Hiroshima 734, Japan; Univ Edinburgh, Western Gen Hosp, Mol Med Unit, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Kinki Univ, Sch Med, Dept Surg 1, Osaka 589, Japan; Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Canc Cytogenet, Minami Ku, Hiroshima 734, Japan	Hiroshima University; Hiroshima University; Hiroshima University; Hiroshima University; University of Edinburgh; Kindai University (Kinki University); Hiroshima University	Miyagawa, K (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Mol Pathol, Minami Ku, 1-2-3 Kasumi, Hiroshima 734, Japan.		Matsuura, Shinya/U-4182-2017	Matsuura, Shinya/0000-0001-5294-081X				Becker SA, 1996, CANCER RES, V56, P5092; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARK MW, 1992, YEAST, V8, P133, DOI 10.1002/yea.320080208; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; ElRifai W, 1996, CANCER RES, V56, P3230; EMERY HS, 1991, GENE, V104, P103, DOI 10.1016/0378-1119(91)90473-O; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; Golub EI, 1997, NUCLEIC ACIDS RES, V25, P4106, DOI 10.1093/nar/25.20.4106; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; KIM DH, 1995, INT J CANCER, V60, P812, DOI 10.1002/ijc.2910600615; Klein HL, 1997, GENETICS, V147, P1533; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; Pabst T, 1996, BLOOD, V88, P1026, DOI 10.1182/blood.V88.3.1026.bloodjournal8831026; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SHABTAI F, 1988, CANCER GENET CYTOGEN, V31, P113, DOI 10.1016/0165-4608(88)90018-0; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shinohara M, 1997, GENETICS, V147, P1545; SUGIMOTO K, 1991, BLOOD, V77, P1153; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	31	110	125	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3422	3426		10.1038/sj.onc.1202691	http://dx.doi.org/10.1038/sj.onc.1202691			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362364				2022-12-17	WOS:000080589300014
J	Ohtani, K; Iwanaga, R; Nakamura, M; Ikeda, M; Yabuta, N; Tsuruga, H; Nojima, H				Ohtani, K; Iwanaga, R; Nakamura, M; Ikeda, M; Yabuta, N; Tsuruga, H; Nojima, H			Cell growth-regulated expression of mammalian MCM5 and MCM6 genes mediated by the transcription factor E2F	ONCOGENE			English	Article						mammalian MCM; E2F; promoter; cell cycle; DNA replication	S-PHASE ENTRY; REPLICATION LICENSING SYSTEM; DNA-REPLICATION; MCM/P1 PROTEINS; BUDDING YEAST; HUMAN HOMOLOG; CYCLE; COMPONENT; APOPTOSIS; FAMILY	Initiation of DNA replication requires the function of MCM gene products, which participate in ensuring that DNA replication occurs only once in the cell cycle, Expression of all mammalian genes of the MCM family is induced by growth stimulation, unlike yeast, and the mRNA levels peak at G1/S boundary, In this study, we examined the transcriptional activities of isolated human MCM gene promoters. Human MCMS and MCM6 promoters with mutation in the E2F sites failed in promoter regulation following serum stimulation and exogenous E2F expression. In addition, me identified a novel E2F-Like sequence in human MCM6 promoter which cooperates with the authentic E2F sites in E2F-dependent regulation. Forced expression of E2F1 could induce expression of all members of the endogenous MCM genes in rat embryonal fibroblast REF52 cells. Our results demonstrated that the growth-regulated expression of mammalian MCM5 and MCM6 genes, and presumably other MCM members, is primarily regulated by E2F through binding to multiple E2F sites in the promoters.	Tokyo Med & Dent Univ, Human Gene Sci Ctr, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Grad Sch Dent, Dept Dev Biol, Tokyo 1138549, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Mol Genet, Suita, Osaka 5650871, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Osaka University	Nakamura, M (corresponding author), Tokyo Med & Dent Univ, Human Gene Sci Ctr, Tokyo 1138510, Japan.							BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Fujita M, 1996, BIOCHEM BIOPH RES CO, V219, P604, DOI 10.1006/bbrc.1996.0280; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; Kiyono T, 1996, BBA-GENE STRUCT EXPR, V1307, P31, DOI 10.1016/0167-4781(96)00057-7; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Kubota Y, 1997, EMBO J, V16, P3320, DOI 10.1093/emboj/16.11.3320; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; NEVINS JR, 1992, SCIENCE, V258, P424; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; Tsuruga H, 1997, GENES CELLS, V2, P381, DOI 10.1046/j.1365-2443.1997.1290327.x; Tsuruga H, 1997, BIOCHEM BIOPH RES CO, V236, P118, DOI 10.1006/bbrc.1997.6865; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	31	110	114	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2299	2309		10.1038/sj.onc.1202544	http://dx.doi.org/10.1038/sj.onc.1202544			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327050				2022-12-17	WOS:000079595500002
J	Herrmann, JL; Briones, F; Brisbay, S; Logothetis, CJ; McDonnell, TJ				Herrmann, JL; Briones, F; Brisbay, S; Logothetis, CJ; McDonnell, TJ			Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53	ONCOGENE			English	Article						proteasome; cell death; bcl-2; p53; prostate cancer	MULTICATALYTIC PROTEINASE COMPLEX; KAPPA-B-ALPHA; INDUCED APOPTOSIS; UBIQUITIN LIGASE; CANCER CELLS; IN-VIVO; C-JUN; DEGRADATION; PATHWAY; PHOSPHORYLATION	The ATP/ubiquitin-dependent 26S proteasome is a central regulator of cell cycle progression and stress responses. While investigating the application of peptide aldehyde proteasome inhibitors to block signal-induced I kappa B alpha degradation in human LNCaP prostate carcinoma cells, we observed that persistent inhibition of proteasomal activity signals a potent cell death program. Biochemically, this program included substantial upregulation of PAR-4 (prostate apoptosis response-4), a putative pro-apoptotic effector protein and stabilization of c-jun protein, a potent pro-death effector in certain cells. We also observed modest downregulation of bcl-X-L, a pro-survival effector protein. However, in contrast to some recent reports stable, high level, expression of functional bcl-2 protein in prostate carcinoma cells failed to signal protection against cell death induction by proteasome inhibitors. Also in disagreement to a recent report, no evidence was found for activation of the JNK stress kinase pathway, A role for p53, a protein regulated by the proteasome pathway, was ruled out, since comparable cell death induction by proteasome inhibitors occurred in PC-3 cells that db not express functional p53 protein. These data signify that the ubiquitin/proteasome pathway represents a potential therapeutic target for prostate cancers irrespective of bcl-2 expression or p53 mutations.	Univ Texas, MD Anderson Cancer Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Herrmann, JL (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Genitourinary Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.							BARTOLI F, 1994, J BIOL CHEM, V269, P15625; Beham A, 1997, ONCOGENE, V15, P2767, DOI 10.1038/sj.onc.1201464; Blagosklonny MV, 1996, CANCER RES, V56, P1851; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; Haldar S, 1996, CANCER RES, V56, P1253; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; Herrmann JL, 1997, EXP CELL RES, V234, P442, DOI 10.1006/excr.1997.3653; ISAACS WB, 1991, CANCER RES, V51, P4716; ISHIDA N, 1993, FEBS LETT, V324, P345, DOI 10.1016/0014-5793(93)80148-N; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Maki CG, 1996, CANCER RES, V56, P2649; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MCDONNELL TJ, 1993, MOL CARCINOGEN, V8, P209, DOI 10.1002/mc.2940080402; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Milligan SA, 1996, ARCH BIOCHEM BIOPHYS, V335, P388, DOI 10.1006/abbi.1996.9998; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rolfe M, 1997, J MOL MED-JMM, V75, P5, DOI 10.1007/s001090050081; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; Soldatenkov VA, 1997, CANCER RES, V57, P3881; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Tanimoto Y, 1997, J BIOCHEM-TOKYO, V121, P542; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TU SM, 1995, CANCER LETT, V93, P147, DOI 10.1016/0304-3835(95)03795-X; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; Westin P, 1997, INT J ONCOL, V10, P113; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x	52	110	115	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 3	1998	17	22					2889	2899		10.1038/sj.onc.1202221	http://dx.doi.org/10.1038/sj.onc.1202221			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879995	Bronze			2022-12-17	WOS:000077286400009
J	Sheikh, MS; Antinore, MJ; Huang, Y; Fornace, AJ				Sheikh, MS; Antinore, MJ; Huang, Y; Fornace, AJ			Ultraviolet-irradiation-induced apoptosis is mediated via ligand independent activation of tumor necrosis factor receptor 1	ONCOGENE			English	Article						UV; TNF alpha; caspase cascade; DNA damage	KAPPA-B ACTIVATION; RADIATION-INDUCED APOPTOSIS; DOMAIN-CONTAINING RECEPTOR; BREAST-CARCINOMA CELLS; DEATH DOMAIN; CYSTEINE PROTEASES; CD95 FAS/APO-1; PROTEIN; LIGHT; TRAIL	Ultraviolet (UV)-irradiation has been shown to induce jun N-terminal kinase activity via aggregation-mediated activation of tumor necrosis factor receptor 1 (TNFR1) but the role of TNFR1 in mediating UV-induced apoptosis has not been explored. Using p53-null cells, me demonstrate that UV-stimulated ligand independent activation of TNFR1 plays a major role in mediating the apoptotic effects of UV-irradiation. UV-irradiation and TNF alpha acted in a synergistic manner to induce apoptosis, UV-irradiation stimulated the aggregation-mediated activation of TNFR1 which was coupled with activation of caspase 8, the most proximal caspase in TNF alpha signaling pathway, CrmA and the dominant negative versions of FADD, caspase 8 and caspase 10, that block the apoptotic axis of TNFR1 at different levels, also independently inhibited the UV-induced apoptosis, The engagement of the membrane initiated events was specific for UV-irradiation since neither CrmA nor the dominant negative FADD, caspase 8 or caspase 10 blocked the ionizing radiation-induced apoptosis, Cisplatin and melphalan, the UV-mimetic agents known to elicit UV-type DNA damage, also induced apoptosis but differed from UV in that both of the former agents engaged the caspase cascade at a level distal to FADD. Consistent with these findings cisplatin also did not stimulate TNFR1 aggregation. Together these results indicate that DNA damage pel se was not sufficient to activate the membrane TNFR1. Based on our results we propose that the plasma membrane initiated events play a predominant role in mediating UV-irradiation-induced apoptosis and that UV-irradiation appears to engage the apoptotic axis of TNFR1 and perhaps those of other membrane death receptors to transduce its apoptotic signals.	NCI, Div Basic Sci, NIH, Bethesda, MD 20892 USA; NIA, Biol Chem Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Sheikh, MS (corresponding author), NCI, Div Basic Sci, NIH, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; BATES S, 1996, CURRENT OPIN GENET D, V6, P1; Brash DE, 1996, J INVEST DERMATOL S, V1, P136; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; FAN SJ, 1995, CANCER RES, V55, P1649; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Friedberg ECW GC, 1995, DNA REPAIR MUTAGENES, P19; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Keane MM, 1996, CANCER RES, V56, P4791; KOCK A, 1990, J EXP MED, V172, P1609, DOI 10.1084/jem.172.6.1609; KONDO S, 1995, CANCER RES, V55, P6166; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; MARTIN SJ, 1991, INT J RADIAT BIOL, V59, P1001, DOI 10.1080/09553009114550891; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; SCHWARZ A, 1995, J INVEST DERMATOL, V102, P422; Sheikh MS, 1996, CELL GROWTH DIFFER, V7, P1599; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Tobin D, 1998, P NATL ACAD SCI USA, V95, P565, DOI 10.1073/pnas.95.2.565; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	38	110	114	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2555	2563		10.1038/sj.onc.1202292	http://dx.doi.org/10.1038/sj.onc.1202292			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840918				2022-12-17	WOS:000077058900002
J	GonzalezAgosti, C; Xu, L; Pinney, D; Beauchamp, R; Hobbs, W; Gusella, J; Ramesh, V				GonzalezAgosti, C; Xu, L; Pinney, D; Beauchamp, R; Hobbs, W; Gusella, J; Ramesh, V			The merlin tumor suppressor localizes preferentially in membrane ruffles	ONCOGENE			English	Article						merlin; neurofibromatosis 2; meningioma; vestibular schwannoma; ERM; motility	NEUROFIBROMATOSIS TYPE-2 GENE; ERM FAMILY MEMBERS; PLASMA-MEMBRANE; NF2 GENE; SCHWANN-CELLS; MUSCLE-CELLS; EZRIN; MOESIN; ACTIN; PROTEIN	Merlin is a tumor suppressor whose inactivation underlies the familial schwannomas and meningiomas of neurofibromatosis 2 and their sporadic counterparts. It bears striking similarity to the ERM proteins, ezrin, radixin and moesin, members of the protein 4.1 superfamily that link proteins in the cytoskeleton and the plasma membrane, We have generated polyclonal and monoclonal antibodies that detect merlin as an similar to 66 kD protein in many different cell types, Using indirect immunofluorescence we have for the first time visualized endogenous merlin and localized it to the motile regions, such as leading or ruffling edges, in human fibroblast and meningioma cells. Merlin co-localizes with F-actin in these motile regions but is not associated with stress fibers. Merlin does not localize to the same structures as either ezrin or meosin in human meningioma cells, suggesting a function distinct from these ERMs. Thus, merlin is associated with motile regions of the cell and its participation in these structures may be intimately involved in control of proliferation in Schwann cells and meningeal cells.	MASSACHUSETTS GEN HOSP EAST,MOL NEUROGENET UNIT,CHARLESTOWN,MA 02129	Harvard University; Massachusetts General Hospital					NINDS NIH HHS [NS24279] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREOLI C, 1994, J CELL SCI, V107, P2509; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; BIRGBAUER E, 1991, THESIS MIT; BIRGBAUER E, 1991, THESIS MIT CAMBRIDGE; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; DENBAKKER MA, 1995, ONCOGENE, V10, P757; FRANCK Z, 1993, J CELL SCI, V105, P219; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GODA S, 1991, J NEUROCHEM, V56, P1354, DOI 10.1111/j.1471-4159.1991.tb11432.x; GonzalezAgosti C, 1996, CELL MOTIL CYTOSKEL, V34, P122, DOI 10.1002/(SICI)1097-0169(1996)34:2<122::AID-CM4>3.0.CO;2-D; GOSLIN K, 1989, J CELL BIOL, V109, P1621, DOI 10.1083/jcb.109.4.1621; Gusella JF, 1996, CURR OPIN GENET DEV, V6, P87, DOI 10.1016/S0959-437X(96)90016-7; HARLOW E, 1988, ANTIBODIES; HENRY MD, 1995, J CELL BIOL, V129, P1007, DOI 10.1083/jcb.129.4.1007; JACOBY LB, 1994, HUM MOL GENET, V3, P413, DOI 10.1093/hmg/3.3.413; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOGAN JA, 1990, CANCER GENET CYTOGEN, V45, P41, DOI 10.1016/0165-4608(90)90064-H; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; LUTCHMAN M, 1995, CANCER RES, V55, P2270; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SAINZ J, 1994, HUM MOL GENET, V3, P885, DOI 10.1093/hmg/3.6.885; SATO N, 1991, J CELL BIOL, V113, P321, DOI 10.1083/jcb.113.2.321; SATO N, 1992, J CELL SCI, V103, P131; SEKIDO Y, 1995, CANCER RES, V55, P1227; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPERTINI F, 1992, J IMMUNOL, V149, P65; TAKAISHI K, 1995, ONCOGENE, V11, P39; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TIKOO A, 1994, J BIOL CHEM, V269, P23387; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; WELLENREUTHER R, 1995, AM J PATHOL, V146, P827; WINCKLER B, 1994, J CELL SCI, V107, P2523	45	110	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1239	1247						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808698				2022-12-17	WOS:A1996VJ20200015
J	vanLeeuwen, FN; vanderKammen, RA; Habets, GGM; Collard, JG				vanLeeuwen, FN; vanderKammen, RA; Habets, GGM; Collard, JG			Oncogenic activity of Tiam1 and Rac1 in NIH3T3 cells	ONCOGENE			English	Article						Tiam1; oncogene; GDP dissociation stimulator	PROTEINS	We have recently identified the invasion-inducing Tiam1 gene by proviral insertional mutagenesis. The Tiam1 protein shares a Dbl homology (DH) domain with an increasing number of oncoproteins, some of which have been shown to function as GDP dissociation stimulators (GDS) for small GTPases of the Rho family. In vitro and in vivo analyses indicate that Tiam1 activates the Rho like GTPase Rad. Here we have analysed the consequences of overexpression of several mutant Tiam1 proteins in NIH3T3 fibroblasts. Similar to other proteins containing a DH domain, N-terminal truncation of the Tiam1 protein activates its oncogenic potential, establishing Tiam1 as a proto-oncogene. In addition, we show that sequences N-terminal of the catalytic DH domain are required for morphological transformation accompanied by the formation of membrane ruffling, but not for the induction of an oncogenic phenotype. Overexpression of constitutively active Rac1 (V12Rac1) in NIH3T3 cells produces a similar oncogenic phenotype, suggesting that the oncogenic effects of Tiam1 are a consequence of Rac activation.	NETHERLANDS CANC INST,DIV CELL BIOL,ANTONI VAN LEEUWENHOEKHUIS,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute			van Leeuwen, Frank/AAQ-6799-2020	van Leeuwen, Frank/0000-0003-1107-6513				CHAN AML, 1994, ONCOGENE, V9, P1057; COLLARD JG, 1985, INT J CANCER, V35, P207, DOI 10.1002/ijc.2910350211; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PERONA R, 1993, ONCOGENE, V8, P1285; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RON D, 1989, ONCOGENE, V4, P1067; SELF AJ, 1993, ONCOGENE, V8, P655; TOKSOZ D, 1994, ONCOGENE, V9, P621; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	29	110	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2215	2221						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570171				2022-12-17	WOS:A1995TK70200004
J	KHANNA, KK; BEAMISH, H; YAN, J; HOBSON, K; WILLIAMS, R; DUNN, I; LAVIN, MF				KHANNA, KK; BEAMISH, H; YAN, J; HOBSON, K; WILLIAMS, R; DUNN, I; LAVIN, MF			NATURE OF G1/S CELL-CYCLE CHECKPOINT DEFECT IN ATAXIA-TELANGIECTASIA	ONCOGENE			English	Article						ATAXIA-TELANGIECTASIA; CELL CYCLE; P53; CYCLIN-DEPENDENT-KINASE; P53/WAF1; RETINOBLASTOMA PROTEIN	IONIZING-RADIATION; DNA-DAMAGE; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; P53 PROTEIN; TYROSINE PHOSPHORYLATION; MAMMALIAN-CELLS; CDK2 ACTIVITY; EXPRESSION; INDUCTION	We have previously demonstrated that cells from patients with ataxia-telangiectasia (A-T) fail to show initial delay at several cell cycle checkpoints post-irradiation. In addition a defect in the induction of p53 by ionizing radiation was evident. We demonstrate here that the radiation signal transduction pathway operating through p53, its target gene WAF1, cyclin-dependent kinases and the retinoblastoma (Rb) protein is defective in A-T cells. The defective p53 induction after ionizing radiation, observed previously in A-T cells, was also reflected at the functional level using p53-DNA binding activity, transactivation and transfection with wild type p53. Correction of the defect at the G1/S checkpoint was observed when wild type p53 was constitutively expressed in A-T cells. Exposure of control cells to radiation gave rise to p53 induction and as a consequence increased expression of WAF1 mRNA and protein, but A-T cells were defective in this response. As expected the WAF1 response in irradiated control cells resulted in an inhibition of cyclin-dependent kinase activity including cyclin E-cdk2, which plays an important role in the transition from G1 to S phase. No inhibition of cyclin-dependent kinase activity was observed in A-T cells correlating with the delayed WAF1 response. On the contrary an enhancement of cyclin-dependent kinase activity was seen in A-T cells post-irradiation. An accumulation of the hypophosphorylated form of Rb protein occurred in irradiated control cells compatible with the G1/S phase delay observed in these cells after exposure to radiation. In unirradiated A-T cells the amount of Rb protein was much higher compared to controls and it was mainly in the hyperphosphorylated (functionally inactive) form. In addition, accumulation of the hypophosphorylated form of Rb in A-T cells postirradiation was defective, consistent with the lack of cell cycle arrest. Thus the failure of the G1/S checkpoint in A-T cells after exposure to ionizing radiation is consistent with a defective radiation signal transduction pathway operating through p53.	QUEENSLAND INST MED RES, QUEENSLAND CANC FUND RES UNIT, BANCROFT CTR, BRISBANE, QLD 4029, AUSTRALIA; MED SCH HERSTON, DEPT PATHOL, QUEENSLAND CANC FUND RES UNIT, HERSTON, QLD 4006, AUSTRALIA; UNIV QUEENSLAND, ROYAL BRISBANE HOSP, DEPT SURG, HERSTON, QLD 4029, AUSTRALIA	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland			Lavin, Martin F/F-5961-2014; Yan, Jun/F-1224-2010	Lavin, Martin F/0000-0002-5940-4769; Khanna, Kum Kum/0000-0001-8650-5381; Yan, Jun/0000-0001-9617-0335				BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BELT PBGM, 1989, GENE, V84, P407, DOI 10.1016/0378-1119(89)90515-5; CANMAN CE, 1994, CANCER RES, V54, P5054; CHEN P, 1983, THESIS U QUEENSLAND; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAN SJ, 1994, CANCER RES, V54, P5824; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALL FL, 1993, ONCOGENE, V8, P1377; HANAWALT PC, 1986, TRENDS GENET, V2, P124, DOI 10.1016/0168-9525(86)90201-5; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HONG JH, 1994, RADIAT RES, V140, P17, DOI 10.2307/3578563; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KHANNA KK, 1993, ONCOGENE, V8, P3307; KHARBANDA S, 1994, CANCER RES, V54, P1412; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAVIN MF, 1994, INT J RADIAT BIOL, V66, pS151; LAVIN MF, 1992, CELL BIOL, V77, P235; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI Y, 1994, ONCOGENE, V9, P2261; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MICHIELI P, 1994, CANCER RES, V54, P3391; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; NEVINS JR, 1992, SCIENCE, V258, P424; Pines J, 1991, Trends Cell Biol, V1, P117, DOI 10.1016/0962-8924(91)90116-Q; PRICE BD, 1994, CANCER RES, V54, P896; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; PRICE BD, 1993, ONCOGENE, V8, P3055; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	59	110	110	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	1995	11	4					609	618						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651723				2022-12-17	WOS:A1995RQ46900001
J	DECESARE, D; VALLONE, D; CARACCIOLO, A; SASSONECORSI, P; NERLOV, C; VERDE, P				DECESARE, D; VALLONE, D; CARACCIOLO, A; SASSONECORSI, P; NERLOV, C; VERDE, P			HETERODIMERIZATION OF C-JUN WITH ATF-2 AND C-FOS IS REQUIRED FOR POSITIVE AND NEGATIVE REGULATION OF THE HUMAN UROKINASE ENHANCER	ONCOGENE			English	Article						C-JUN; ATF-2; HETERODIMERIZATION UROKINASE; ENHANCER	ELEMENT-BINDING PROTEIN; RESPONSE ELEMENT; PLASMINOGEN-ACTIVATOR; TRANSCRIPTION FACTORS; STROMELYSIN PROMOTER; LEUCINE ZIPPER; CYCLIC-AMP; AP-1; PHOSPHORYLATION; CRE-BP1	Dimerization plays a pivotal role in modulating the activity of the c-Jun proto-oncogene product. Heterodimerization with activating transcription factor-2 (ATF-2) alters the DNA-binding specificity of c-Jun, allowing its targeting to several cAMP responsive element (CRE)related sequences, which control a subset of AP-1-responsive genes, Here me show that a c-Jun/ATF-2 heterodimer binds to the AP-1 site (nPA 5'-TRE) essential for the activity of the human urokinase enhancer, conferring on this element several distinctive regulatory properties. The c-Jun/ATF-2 heterodimer was identified by binding competition assays, u.v. cross linking, and monospecific antibodies, In vitro binding studies revealed that the uPA 5'-TRE sequence is recognized by the cyclic AMP-unresponsive ATF-2 factor, but not by the cyclic AMP-inducible CREB, In addition, in vivo studies suggest that ATF-2 can mediate, at the same time, the activation of the c-Jun/ATF-2 site and the repression of the canonical. collagenase AP-1 site. We report that heterodimerization with c-Fos does not increase the binding of c-Jun to the uPA 5'-TRE, in contrast to the increased binding at a consensus AP-1 site. Our data further suggest that c-Fos can act as a repressor of the c-Jun/ATF-2 binding site, revealing an important functional difference, with respect to canonical AP-I elements.	INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY; CU STRASBOURG,IGBMC,F-67404 ILLKIRCH GRAFFENS,FRANCE; UNIV COPENHAGEN,DEPT MOLEC CELL BIOL,DK-1353 COPENHAGEN K,DENMARK	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Copenhagen								ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; BENBROOK DM, 1990, ONCOGENE, V5, P295; Blasi F, 1990, Semin Cancer Biol, V1, P117; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; DEGROOT RP, 1992, ONCOGENE, V7, P2281; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HOEFFLER JP, 1992, J INVEST DERMATOL, V98, pS21, DOI 10.1111/1523-1747.ep12462126; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE JS, 1994, J BIOL CHEM, V4, P2887; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACGREGOR PF, 1990, ONCOGENE, V5, P451; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NOMURA N, 1993, J BIOL CHEM, V268, P4259; PESCINI R, 1994, J BIOL CHEM, V269, P1159; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RYSECK RP, 1991, ONCOGENE, V6, P533; SAKURAI A, 1991, BIOCHEM BIOPH RES CO, V181, P629, DOI 10.1016/0006-291X(91)91237-7; SANDGREN EP, 1991, CELL, V66, P245, DOI 10.1016/0092-8674(91)90615-6; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STACEY KJ, 1991, NUCLEIC ACIDS RES, V19, P6839; TAKEDA J, 1991, ONCOGENE, V6, P1009; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	47	110	110	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					365	376						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624151				2022-12-17	WOS:A1995RK95700017
J	CHEDID, M; MICHIELI, P; LENGEL, C; HUPPI, K; GIVOL, D				CHEDID, M; MICHIELI, P; LENGEL, C; HUPPI, K; GIVOL, D			A SINGLE NUCLEOTIDE SUBSTITUTION AT CODON-31 (SER/ARG) DEFINES A POLYMORPHISM IN A HIGHLY CONSERVED REGION OF THE P53-INDUCIBLE GENE WAF1/CIP1	ONCOGENE			English	Note							CYCLIN-DEPENDENT KINASES; EXPRESSION; INHIBITOR; GROWTH; CELLS; P21	The recently discovered WAF1/CTP1 gene is a mediator of p53 tumor suppressor activity. To analyse WAF1/ CIP1 for possible mutations, polymerase chain reaction (PCR) amplified cDNAs from several tumor cell lines were cloned and sequenced. A single point mutation which changes codon 31 from AGC to AGA (Ser to Arg) was found. This change resulted in the loss of a Bpu1102I and gain of an Esp3I restriction site, allowing for rapid screening of this mutation in human DNAs. Analysis of genomic DNAs from 50 randomly selected individuals revealed that this base pair substitution represents a polymorphism with an allelic frequency of 0.14. Transfection studies demonstrated that the expression of the Arg allele of WAF1/CIP1 was not associated with loss of tumor suppressor activity. Moreover, screening of 22 tumor DNA samples revealed no association between the tumor phenotype and the Arg allele of WAF1/CIP1 (two out of 22 tumor DNAs contained the Arg31 allele). This polymorphism will be a useful molecular marker in the analysis of loss of heterozygosity in human cancers, and further studies using a larger panel of tumors may reveal an association between this polymorphism and specific types of cancer.	NCI,GENET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	CHEDID, M (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,BETHESDA,MD 20892, USA.		Michieli, Paolo/A-2588-2011	Michieli, Paolo/0000-0002-3093-8871				BODNER SM, 1992, ONCOGENE, V7, P743; CHEDID M, 1994, J BIOL CHEM, V269, P10753; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUPPI K, 1994, IN PRESS ONCOGENE; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; MICHIELI P, 1994, CANCER RES, V54, P3391; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; NAZARSTEWART V, 1993, CANCER RES, V53, P2313; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TAKAHASHI T, 1992, CANCER RES, V52, P2340; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	17	110	115	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3021	3024						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084608				2022-12-17	WOS:A1994PG82200031
J	DEB, SP; MUNOZ, RM; BROWN, DR; SUBLER, MA; DEB, S				DEB, SP; MUNOZ, RM; BROWN, DR; SUBLER, MA; DEB, S			WILD-TYPE HUMAN P53 ACTIVATES THE HUMAN EPIDERMAL GROWTH-FACTOR RECEPTOR PROMOTER	ONCOGENE			English	Review							HUMAN PAPILLOMAVIRUS TYPE-16; PROTO-ONCOGENE; GENE-EXPRESSION; TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; RESPONSIVE ELEMENT; TRANSFORMED-CELLS; NUCLEAR-PROTEIN; BINDING PROTEIN; CARCINOMA-CELLS	We show that wild-type human p53 transactivates the human epidermal growth factor receptor (EGFR) promoter in vivo in a dose-dependent manner, implicating p53 in promotion of cell proliferation. This activation is sensitive to the expression of cellular oncoprotein MDM2 and human papillomavirus type 18 (HPV-18) E6 protein. The p53 response element is localized within -15 and -569 of the promoter. The EGFR promoter does not have a TATA box, and has low activity in Saos-2 cells in the absence of p53. Results from our in vivo transient transfection assays suggest that p53-binding sites, without any other known promoter element, can act as bidirectional promoters in the presence of wild-type p53. Gel retardation analyses suggest that p53 may serve to nucleate TBP on a promoter. We propose that p53 successfully nucleates the transcription complex, possibly via direct interaction with TFIID, and activates the EGFR promoter.	UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NIAID NIH HHS [AI31498-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031498] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARK AJL, 1985, P NATL ACAD SCI USA, V82, P8374, DOI 10.1073/pnas.82.24.8374; COLLINS VP, 1993, SEMIN CANCER BIOL, V4, P27; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V115, P185; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALEY J, 1987, ONCOGENE RES, V1, P375; HALEY JD, 1991, J BIOL CHEM, V266, P1746; HALL PA, 1993, ONCOGENE, V8, P203; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HUDSON LG, 1989, MOL ENDOCRINOL, V3, P400, DOI 10.1210/mend-3-2-400; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MAEKAWA T, 1989, J BIOL CHEM, V264, P5488; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MARTIN DW, 1993, BIOCHEM BIOPH RES CO, V195, P428, DOI 10.1006/bbrc.1993.2061; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MENDELSOHN J, 1992, NATL CANCER I MONOGR, V13, P125; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIETZ JA, 1992, EMBO J, V11, P5103; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NEAL DE, 1992, UROL INT, V48, P365, DOI 10.1159/000282357; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1981, MOL CELL BIOL, V1, P137; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SANTON JB, 1986, CANCER RES, V46, P4701; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHIO Y, 1992, P NATL ACAD SCI USA, V89, P5206; SHOBAT O, 1987, ONCOGENE, V1, P277; STOSCHECK CM, 1986, CANCER RES, V46, P1030; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUBLER MA, 1994, J VIROL, V68, P103, DOI 10.1128/JVI.68.1.103-110.1994; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; THOMPSON KL, 1992, MOL ENDOCRINOL, V6, P627, DOI 10.1210/me.6.4.627; Tripathy D, 1992, Cancer Treat Res, V63, P15; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1993, J CELL SCI, V105, P607; WANG WD, 1991, MOL CELL BIOL, V11, P4561, DOI 10.1128/MCB.11.9.4561; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHENG ZS, 1992, CELL GROWTH DIFFER, V3, P225	113	110	111	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1341	1349						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152794				2022-12-17	WOS:A1994NH40100005
J	LEE, TC; ZHANG, Y; SCHWARTZ, RJ				LEE, TC; ZHANG, Y; SCHWARTZ, RJ			BIFUNCTIONAL TRANSCRIPTIONAL PROPERTIES OF YY1 IN REGULATING MUSCLE ACTIN AND C-MYC GENE-EXPRESSION DURING MYOGENESIS	ONCOGENE			English	Article							ADENOVIRUS E1A PROTEIN; BINDING COMPLEXES; MESSENGER-RNA; PROMOTER; DIFFERENTIATION; ELEMENTS; ACTIVATION; MYOBLASTS; CELLS; IDENTIFICATION	Oncogene expression is generally incompatible with terminal cell differentiation as in myogenesis. We present evidence that this incompatibility can be caused in part by the dual activity of a Kruppel-related zinc finger, YY1 (formerly F-ACT1), in differentially regulating oncogene and muscle-specific gene expression. The c-myc and skeletal alpha-actin gene promoters contain YY1 binding sites thought to act either as positive or negative cis-acting elements. Through manipulating the intracellular level of YY1 by treating primary myoblasts with bromo-deoxyuridine (BrdU), which inhibited myogenesis and increased the YY1 protein content, or by transfecting YY1 cDNA expression vector, we show that it can simultaneously inhibit and activate expression of the skeletal alpha-actin and c-myc genes, respectively. The transrepression activity of YY1 solely depends on its C-terminal zinc finger region (amino acids 297-407) while its transactivation function requires an additional N-terminal domain (amino acids 1-90) normally masked in the full-length protein. We propose that the high level of YY1 in proliferating myoblasts might serve to maintain c-myc expression and suppress muscle actin expression, which can then be gradually reversed by downregulating YY1 activity toward myogenesis.	BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030; SUNY BUFFALO,DEPT BIOCHEM,BUFFALO,NY 14214	Baylor College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042267, P01HL049953] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50-HL42267, P01HL49953] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KAKKIS E, 1987, P NATL ACAD SCI USA, V84, P7031, DOI 10.1073/pnas.84.20.7031; KESSLER DJ, 1992, ONCOGENE, V7, P2447; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEE TC, 1992, NUCLEIC ACIDS RES, V20, P140, DOI 10.1093/nar/20.1.140; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LEE TC, 1992, BIOTECHNIQUES, V12, P486; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MEULIA T, 1992, MOL CELL BIOL, V12, P4590, DOI 10.1128/MCB.12.10.4590; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MOBERG KH, 1992, ONCOGENE, V7, P411; MODAK SP, 1993, ONCOGENE, V8, P645; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PIECHACZYK M, 1987, TRENDS GENET, V3, P47, DOI 10.1016/0168-9525(87)90166-1; PLET A, 1992, ONCOGENE, V7, P1847; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; SCHWARTZ RJ, 1981, BIOCHEMISTRY-US, V20, P4122, DOI 10.1021/bi00517a027; SEJERSEN T, 1985, J CELL PHYSIOL, V125, P465, DOI 10.1002/jcp.1041250315; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SPENCER CA, 1990, ADV CANCER RES, V56, P1; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WEINTRAUB H, 1972, J MOL BIOL, V70, P337, DOI 10.1016/0022-2836(72)90543-8; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0	38	110	117	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1047	1052						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134108				2022-12-17	WOS:A1994NC04800006
J	KUJUBU, DA; LIM, RW; VARNUM, BC; HERSCHMAN, HR				KUJUBU, DA; LIM, RW; VARNUM, BC; HERSCHMAN, HR			INDUCTION OF TRANSIENTLY EXPRESSED GENES IN PC-12 PHEOCHROMOCYTOMA CELLS	ONCOGENE			English	Article									UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT BIOL CHEM,BIOMED & ENVIRONM SCI LAB,WARREN HALL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT MED,DIV NEPHROL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024797, T32GM007104] Funding Source: NIH RePORTER; NIDDK NIH HHS [2T32 DK 07270-06A2] Funding Source: Medline; NIGMS NIH HHS [2T32 GM 07104, GM24797-09] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; CHANDLER C, 1980, J CELL PHYSL, V105, P75; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COLLETTA G, 1986, SCIENCE, V233, P458, DOI 10.1126/science.3726540; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; CURRAN T, 1984, CELL, V36, P259; END D, 1982, J CELL PHYSIOL, V111, P140, DOI 10.1002/jcp.1041110204; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V331, P433; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LIM RW, 1987, ONCOGENE, V1, P263; MILBRANDT J, 1986, P NATL ACAD SCI USA, V83, P4789, DOI 10.1073/pnas.83.13.4789; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SCHUBERT D, 1980, BRAIN RES, V190, P67, DOI 10.1016/0006-8993(80)91160-9; TIERCY JM, 1986, J CELL BIOL, V103, P2367, DOI 10.1083/jcb.103.6.2367; TRAYNOR AE, 1984, DEV BRAIN RES, V14, P197; YAMAMOTO KR, 1976, ANNU REV BIOCHEM, V45, P721, DOI 10.1146/annurev.bi.45.070176.003445	26	110	111	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	3					257	262						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J9705	3502572				2022-12-17	WOS:A1987J970500004
J	MILNER, J; COOK, A; SHELDON, M				MILNER, J; COOK, A; SHELDON, M			A NEW ANTI-P53 MONOCLONAL-ANTIBODY, PREVIOUSLY REPORTED TO BE DIRECTED AGAINST THE LARGE T-ANTIGEN OF SIMIAN VIRUS-40	ONCOGENE			English	Note											MILNER, J (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,DIV VIROL,CAMBRIDGE CB2 1QP,ENGLAND.							BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; METCALFE S, 1984, BRIT J CANCER, V49, P337, DOI 10.1038/bjc.1984.53; MILNER J, 1980, CELL BIOL INT REP, V4, P663, DOI 10.1016/0309-1651(80)90205-2; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; THOMAS R, 1983, VIROLOGY, V131, P502, DOI 10.1016/0042-6822(83)90516-0; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	11	110	110	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	4					453	455						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	K7483	3330789				2022-12-17	WOS:A1987K748300017
J	Li, B; Xu, WW; Han, L; Chan, KT; Tsao, SW; Lee, NPY; Law, S; Xu, LY; Li, EM; Chan, KW; Qin, YR; Guan, XY; He, QY; Cheung, ALM				Li, B.; Xu, W. W.; Han, L.; Chan, K. T.; Tsao, S. W.; Lee, N. P. Y.; Law, S.; Xu, L. Y.; Li, E. M.; Chan, K. W.; Qin, Y. R.; Guan, X. Y.; He, Q. Y.; Cheung, A. L. M.			MicroRNA-377 suppresses initiation and progression of esophageal cancer by inhibiting CD133 and VEGF	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; STEM-CELLS; FACTOR EXPRESSION; PROGNOSTIC VALUE; ANGIOGENESIS; ACTIVATION; CHEMORESISTANCE; METASTASIS; ADENOVIRUS; CARCINOMA	Esophageal cancer is one of the most lethal cancers worldwide with poor survival and limited therapeutic options. The discovery of microRNAs created a new milestone in cancer research. miR-377 is located in chromosome region 14q32, which is frequently deleted in esophageal squamous cell carcinoma (ESCC), but the biological functions, clinical significance and therapeutic implication of miR-377 in ESCC are largely unknown. In this study, we found that miR-377 expression was significantly downregulated in tumor tissue and serum of patients with ESCC. Both tumor tissue and serum miR-377 expression levels were positively correlated with patient survival. Higher serum miR-377 expression was inversely associated with pathologic tumor stage, distant metastasis, residual tumor status and chemoradiotherapy resistance. The roles of miR-377 in suppressing tumor initiation and progression, and the underlying molecular mechanisms were investigated. Results of in vitro and in vivo experiments showed that miR-377 overexpression inhibited the initiation, growth and angiogenesis of ESCC tumors as well as metastatic colonization of ESCC cells, whereas silencing of miR-377 had opposite effects. Mechanistically, miR-377 regulated CD133 and VEGF by directly binding to their 3' untranslated region. Moreover, systemic delivery of formulated miR-377 mimic not only suppressed tumor growth in nude mice but also blocked tumor angiogenesis and metastasis of ESCC cells to the lungs without overt toxicity to mice. Collectively, our study established that miR-377 plays a functional and significant role in suppressing tumor initiation and progression, and may represent a promising non-invasive diagnostic and prognostic biomarker and therapeutic strategy for patients with ESCC.	[Li, B.; Xu, W. W.; Han, L.; Tsao, S. W.; Cheung, A. L. M.] Univ Hong Kong, Sch Biomed Sci, Li Ka Shing Fac Med, 21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China; [Li, B.; Xu, W. W.; Han, L.; Cheung, A. L. M.] Univ Hong Kong, Shenzhen Inst Res & Innovat HKU SIRI, Shenzhen, Peoples R China; [Li, B.; Tsao, S. W.; Lee, N. P. Y.; Law, S.; Chan, K. W.; Guan, X. Y.; Cheung, A. L. M.] Univ Hong Kong, Ctr Canc Res, Pokfulam, Peoples R China; [Chan, K. T.; Lee, N. P. Y.; Law, S.] Univ Hong Kong, Dept Surg, Pokfulam, Peoples R China; [Xu, L. Y.; Li, E. M.] Shantou Univ Med Coll, Key Lab Mol Biol High Canc Incidence Coastal Chao, Shantou, Peoples R China; [Chan, K. W.] Univ Hong Kong, Dept Pathol, Pokfulam, Peoples R China; [Qin, Y. R.] Zhengzhou Univ, Affiliated Hosp 1, Dept Clin Oncol, Zhengzhou, Peoples R China; [Guan, X. Y.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Pokfulam, Peoples R China; [He, Q. Y.] Jinan Univ, Coll Life Sci & Technol, 601 West Huangpu Blvd, Guangzhou, Guangdong, Peoples R China; [Li, B.] Jinan Univ, Coll Life Sci & Technol, 601 West Huangpu Blvd, Guangzhou 510632, Guangdong, Peoples R China; [Xu, W. W.] Jinan Univ, Inst Tumor Pharmacol, Coll Pharm, 601 West Huangpu Blvd, Guangzhou 510632, Guangdong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; Zhengzhou University; University of Hong Kong; Jinan University; Jinan University; Jinan University	Cheung, ALM (corresponding author), Univ Hong Kong, Sch Biomed Sci, Li Ka Shing Fac Med, 21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	lmcheung@hku.hk	Law, Simon/C-4324-2009; He, Qing-Yu/H-7078-2014; /C-4230-2009; /A-3639-2009	Law, Simon/0000-0002-6518-5806; He, Qing-Yu/0000-0003-0503-9492; /0000-0003-3217-1456; /0000-0003-1874-9805	Research Grants Council of the Hong Kong SAR, China [HKU 763111M, HKU 17103814]; CRCG [201111159198, 201211159003]; National Natural Science Foundation of China [81472790]; University of Hong Kong SRT Cancer research program	Research Grants Council of the Hong Kong SAR, China(Hong Kong Research Grants Council); CRCG; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); University of Hong Kong SRT Cancer research program	We thank Professor Yutaka Shimada (University of Toyama, Toyama, Japan) and DSMZ for the KYSE cell lines; Prof G Srivastava, Department of Pathology, University of Hong Kong for the HKESC-1 cell line; Dr Hitoshi Kawamata (Dokkyo University School of Medicine, Tochigi, Japan) for the T.Tn cell line; and Mr. Yiwei Xu (Shantou University Medical College, Shantou, Guangdong, China) for collection of patient serum. We also thank Prof Quan Chen (Institute of Zoology, Chinese Academy of Sciences, Beijing, China) for CD133-knockdown and control plasmids as well as virus packaging plasmids, Prof Gregory M. Vercellotti (University of Minnesota Medical School, Minneapolis, MN) for miR-377-expressing constructs, and Dr Anna CM Tsang (School of Biomedical Sciences, University of Hong Kong) for help in flow cytometry. Flow cytometry and cell sorting were performed and analyzed using equipment maintained by the University of Hong Kong Li Ka Shing Faculty of Medicine Faculty Core Facility. This work recieves Grant Support from Research Grants Council of the Hong Kong SAR, China (GRF Project Nos. HKU 763111M and HKU 17103814); The University of Hong Kong SRT Cancer research program and CRCG (Project Nos. 201111159198, 201211159003); National Natural Science Foundation of China (Project No. 81472790). The study sponsors are not involved in study design, or collection, analysis, interpretation of data.	Anson Donald S, 2004, Genet Vaccines Ther, V2, P9, DOI 10.1186/1479-0556-2-9; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Campbell M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1852; Ceppi P, 2014, ONCOGENE, V33, P269, DOI 10.1038/onc.2013.55; Chen ML, 2012, CANCER EPIDEM BIOMAR, V21, P1126, DOI 10.1158/1055-9965.EPI-12-0020; Chen YC, 2015, ADV DRUG DELIVER REV, V81, P128, DOI 10.1016/j.addr.2014.05.009; Cheung A., 2015, GASTROINTEST CANC TA, V5, P79; Dong L, 2010, NEUROSCI LETT, V484, P210, DOI 10.1016/j.neulet.2010.08.057; Ebert G, 2011, GASTROENTEROLOGY, V141, P696, DOI 10.1053/j.gastro.2011.05.001; El-Khattouti A, 2015, CANCER LETT, V357, P83, DOI 10.1016/j.canlet.2014.10.043; Fang YX, 2014, ONCOGENE, V33, P135, DOI 10.1038/onc.2013.54; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Gangaraju VK, 2009, NAT REV MOL CELL BIO, V10, P116, DOI 10.1038/nrm2621; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Haller F, 2010, J PATHOL, V220, P71, DOI 10.1002/path.2610; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hang D, 2012, DIS ESOPHAGUS, V25, P638, DOI 10.1111/j.1442-2050.2011.01298.x; Hu YC, 2000, CANCER GENET CYTOGEN, V118, P112, DOI 10.1016/S0165-4608(99)00193-4; Ibrahim AF, 2011, CANCER RES, V71, P5214, DOI 10.1158/0008-5472.CAN-10-4645; Ihara Y, 2002, CANCER GENET CYTOGEN, V135, P177, DOI 10.1016/S0165-4608(01)00654-9; Jooss K, 2003, GENE THER, V10, P955, DOI 10.1038/sj.gt.3302037; Kawamata H, 2003, CANCER SCI, V94, P699, DOI 10.1111/j.1349-7006.2003.tb01505.x; Kohlhapp FJ, 2015, ONCOGENE, V34, P5857, DOI 10.1038/onc.2015.89; Li B, 2007, CARCINOGENESIS, V28, P2313, DOI 10.1093/carcin/bgm152; Li B, 2014, CLIN CANCER RES, V20, P2651, DOI 10.1158/1078-0432.CCR-13-2735; Li B, 2009, MOL CANCER THER, V8, P2635, DOI 10.1158/1535-7163.MCT-09-0162; Lu CL, 2015, J THORAC CARDIOV SUR, V150, P386, DOI 10.1016/j.jtcvs.2015.05.030; Lu J, 2017, ONCOGENE, V36, P231, DOI 10.1038/onc.2016.194; Ma S, 2008, ONCOGENE, V27, P1749, DOI 10.1038/sj.onc.1210811; Nakai H, 2003, NAT GENET, V34, P297, DOI 10.1038/ng1179; Nakajima TE, 2012, CANCER SCI, V103, P233, DOI 10.1111/j.1349-7006.2011.02142.x; Okamoto K, 2016, ONCOL REP, V36, P3333, DOI 10.3892/or.2016.5133; Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427; Peng J, 2013, J BUON, V18, P398; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Poeck H, 2008, NAT MED, V14, P1256, DOI 10.1038/nm.1887; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Song JH, 2012, GASTROENTEROLOGY, V143, P35, DOI 10.1053/j.gastro.2012.05.003; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Sun X, 2014, ONCOGENE, V33, P4967, DOI [10.1038/onc.2013.492, 10.1038/onc.2014.224]; Tang KH, 2013, CANCER RES, V73, P2322, DOI 10.1158/0008-5472.CAN-12-2991; Tang KH, 2012, HEPATOLOGY, V55, P807, DOI 10.1002/hep.24739; Tirino V, 2013, FASEB J, V27, P13, DOI 10.1096/fj.12-218222; Tong DKH, 2010, ANN SURG ONCOL, V17, P2184, DOI 10.1245/s10434-010-0995-2; Trang P, 2008, Oncogene, V27 Suppl 2, pS52, DOI 10.1038/onc.2009.353; Uchino K, 2013, JPN J CLIN ONCOL, V43, P596, DOI 10.1093/jjco/hyt052; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005; Won C, 2015, HEPATOLOGY, V62, P1160, DOI 10.1002/hep.27968; Xu WW, 2015, ONCOTARGET, V6, P1790, DOI 10.18632/oncotarget.2781; Zaiss AK, 2002, J VIROL, V76, P4580, DOI 10.1128/JVI.76.9.4580-4590.2002; Zhao JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021419	54	109	115	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					3986	4000		10.1038/onc.2017.29	http://dx.doi.org/10.1038/onc.2017.29			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28288140	Green Published, hybrid			2022-12-17	WOS:000405379900005
J	Roh-Johnson, M; Bravo-Cordero, JJ; Patsialou, A; Sharma, VP; Guo, P; Liu, H; Hodgson, L; Condeelis, J				Roh-Johnson, M.; Bravo-Cordero, J. J.; Patsialou, A.; Sharma, V. P.; Guo, P.; Liu, H.; Hodgson, L.; Condeelis, J.			Macrophage contact induces RhoA GTPase signaling to trigger tumor cell intravasation	ONCOGENE			English	Article						cancer; tumor cell intravasation; macrophages; RhoA biosensor; invadopodia; heterotypic cell contact	EXTRACELLULAR-MATRIX DEGRADATION; TRANSENDOTHELIAL MIGRATION; E-SELECTIN; ENDOTHELIAL-CELLS; CANCER-CELLS; MAMMARY-TUMORS; BREAST-CANCER; IN-VIVO; TYROSINE PHOSPHORYLATION; MELANOMA-CELLS	Most cancer patients die as a result of metastasis, thus it is important to understand the molecular mechanisms of dissemination, including intra- and extravasation. Although the mechanisms of extravasation have been vastly studied in vitro and in vivo, the process of intravasation is still unclear. Furthermore, how cells in the tumor microenvironment facilitate tumor cell intravasation is still unknown. Using high-resolution imaging, we found that macrophages enhance tumor cell intravasation upon physical contact. Macrophage and tumor cell contact induce RhoA activity in tumor cells, triggering the formation of actin-rich degradative protrusions called invadopodia, enabling tumor cells to degrade and break through matrix barriers during tumor cell transendothelial migration. Interestingly, we show that macrophage-induced invadopodium formation and tumor cell intravasation also occur in patient-derived tumor cells and in vivo models, revealing a conserved mechanism of tumor cell intravasation. Our results illustrate a novel heterotypic cell contact-mediated signaling role for RhoA, as well as yield mechanistic insight into the ability of cells within the tumor microenvironment to facilitate steps of the metastatic cascade.	[Roh-Johnson, M.; Bravo-Cordero, J. J.; Patsialou, A.; Sharma, V. P.; Guo, P.; Hodgson, L.; Condeelis, J.] Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; [Roh-Johnson, M.; Bravo-Cordero, J. J.; Patsialou, A.; Sharma, V. P.; Guo, P.; Hodgson, L.; Condeelis, J.] Gruss Lipper Biophoton Ctr, Bronx, NY USA; [Liu, H.] Univ Chicago, Ben May Dept Canc Res, Chicago, IL USA	Yeshiva University; Albert Einstein College of Medicine; University of Chicago	Roh-Johnson, M (corresponding author), Yeshiva Univ Albert Einstein Coll Med, 1300 Morris Pk Ave,Price Ctr 208, Bronx, NY 10461 USA.	minna.roh@einstein.yu.edu	Guo, Peng/E-9858-2015	Bravo-Cordero, Jose Javier/0000-0001-9481-1231; Liu, Huiping/0000-0003-4822-7995; Hodgson, Louis/0000-0001-9188-7580; Sharma, Ved P/0000-0001-9998-5070	NIH [CA150344, CA100324, GM093121, CA159663]; Susan G. Komen for the Cure(C) [KG111405]; FOGARTY INTERNATIONAL CENTER [D43TW001429] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA100324, U54CA163131, P30CA013330, F32CA159663, R01CA150344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM093121] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G. Komen for the Cure(C); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Brian Beaty for advice regarding invadopodium experiments; David Entenberg, Vera Desmarais, Jeffrey Wyckoff and the Analytical Imaging Facility for help with microscopy; Richard Stanley, Fernando Macian, Esther Arwert, Allison Harney and Veronika Micolski for guidance and reagents; Yarong Wang for help with animal injections; and the Albert Einstein shRNA Core, the Flow Cytometry Core facility and the Histology and Comparative Pathology Core for help with experiments. We also thank Jeffrey Segall, Dianne Cox, Anne Bresnick and Aviv Bergmann for helpful discussions, and the Condeelis, Segall, Cox and Hodgson labs for advice and reagents. This work was funded by NIH CA150344 (JC), NIH CA100324 (AP), NIH GM093121 (LH and JJB-C), Post-doctoral fellowship from Susan G. Komen for the Cure (c) KG111405 (VPS) and NIH CA159663 (MRJ).	Arthur WT, 2002, BIOL RES, V35, P239, DOI 10.4067/S0716-97602002000200016; Beaty BT, 2013, MOL BIOL CELL, V24, P1661, DOI 10.1091/mbc.E12-12-0908; Blouw B, 2008, EUR J CELL BIOL, V87, P555, DOI 10.1016/j.ejcb.2008.02.008; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Bravo-Cordero JJ, 2007, EMBO J, V26, P1499, DOI 10.1038/sj.emboj.7601606; Bravo-Cordero JJ, 2011, CURR BIOL, V21, P635, DOI 10.1016/j.cub.2011.03.039; Carmona-Fontaine C, 2008, NATURE, V456, P957, DOI 10.1038/nature07441; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; DAS SK, 1981, BLOOD, V58, P630; Gil-Henn H, 2013, ONCOGENE, V32, P2622, DOI 10.1038/onc.2012.284; Gligorijevic B, 2012, J CELL SCI, V125, P724, DOI 10.1242/jcs.092726; Haidari M, 2012, J BIOL CHEM, V287, P32981, DOI 10.1074/jbc.M112.395905; Haidari M, 2011, CARDIOVASC RES, V92, P456, DOI 10.1093/cvr/cvr240; Hu YY, 2001, J BIOL CHEM, V276, P48549, DOI 10.1074/jbc.M105513200; Hu YY, 2000, J IMMUNOL, V165, P2142, DOI 10.4049/jimmunol.165.4.2142; Jin FY, 2012, MOL CANCER RES, V10, P1021, DOI 10.1158/1541-7786.MCR-11-0498; KOOP S, 1995, CANCER RES, V55, P2520; KRAMER RH, 1979, P NATL ACAD SCI USA, V76, P5704, DOI 10.1073/pnas.76.11.5704; Laferriere J, 2001, J BIOL CHEM, V276, P33762, DOI 10.1074/jbc.M008564200; Lessey EC, 2012, BIOCHEMISTRY-US, V51, P7420, DOI 10.1021/bi300758e; Li B, 2006, FEBS LETT, V580, P4252, DOI 10.1016/j.febslet.2006.06.056; Linder S, 2011, ANNU REV CELL DEV BI, V27, P185, DOI 10.1146/annurev-cellbio-092910-154216; Lipschutz JH, 2001, CURR PROTOC CELL BIO; Liu HP, 2010, P NATL ACAD SCI USA, V107, P18115, DOI 10.1073/pnas.1006732107; Lovett DH, 2010, BIOCHEM BIOPH RES CO, V398, P482, DOI 10.1016/j.bbrc.2010.06.104; Mader CC, 2011, CANCER RES, V71, P1730, DOI 10.1158/0008-5472.CAN-10-1432; Magalhaes MAO, 2011, J CELL BIOL, V195, P903, DOI 10.1083/jcb.201103045; McGhee Ewan J, 2011, Small GTPases, V2, P239; Nethe M, 2012, J CELL SCI, V125, P3430, DOI 10.1242/jcs.100925; NICOLSON GL, 1982, J HISTOCHEM CYTOCHEM, V30, P214, DOI 10.1177/30.3.7061823; OHIGASHI H, 1989, JPN J CANCER RES, V80, P818, DOI 10.1111/j.1349-7006.1989.tb01720.x; Omelchenko T, 2012, CURR BIOL, V22, P278, DOI 10.1016/j.cub.2012.01.014; Oser M, 2010, J CELL SCI, V123, P3662, DOI 10.1242/jcs.068163; Patsialou A, 2013, INTRAVITAL IN PRESS; Patsialou A, 2009, CANCER RES, V69, P9498, DOI 10.1158/0008-5472.CAN-09-1868; Pertz O, 2006, NATURE, V440, P1069, DOI 10.1038/nature04665; Ponik SM, 2013, MOL BIOL CELL, V24, P1688, DOI 10.1091/mbc.E12-05-0386; Proebstl D, 2012, J EXP MED, V209, P1219, DOI 10.1084/jem.20111622; Reymond N, 2012, J CELL BIOL, V199, P653, DOI 10.1083/jcb.201205169; Reymond N, 2012, METHODS MOL BIOL, V827, P123, DOI 10.1007/978-1-61779-442-1_9; Robinson BD, 2009, CLIN CANCER RES, V15, P2433, DOI 10.1158/1078-0432.CCR-08-2179; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Roussos ET, 2011, J CELL SCI, V124, P2120, DOI 10.1242/jcs.086231; Sakurai-Yageta M, 2008, J CELL BIOL, V181, P985, DOI 10.1083/jcb.200709076; Saltel F, 2011, EUR J CELL BIOL, V90, P100, DOI 10.1016/j.ejcb.2010.05.011; Seals DF, 2005, CANCER CELL, V7, P155, DOI 10.1016/j.ccr.2005.01.006; Sharma VP, 2008, J LEUKOCYTE BIOL, V84, P440, DOI 10.1189/jlb.0907636; Sharma VP, 2013, METHODS MOL BIOL, V1046, P343, DOI 10.1007/978-1-62703-538-5_21; Spiering D, 2012, METHODS MOL BIOL, V827, P215, DOI 10.1007/978-1-61779-442-1_15; Stoletov K, 2007, P NATL ACAD SCI USA, V104, P17406, DOI 10.1073/pnas.0703446104; Timpson P, 2011, CANCER RES, V71, P747, DOI 10.1158/0008-5472.CAN-10-2267; Tremblay PL, 2006, ONCOGENE, V25, P6563, DOI 10.1038/sj.onc.1209664; Voura EB, 1998, MICROSC RES TECHNIQ, V43, P265, DOI 10.1002/(SICI)1097-0029(19981101)43:3<265::AID-JEMT9>3.0.CO;2-Z; Voura EB, 1998, CELL TISSUE RES, V293, P375, DOI 10.1007/s004410051129; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; Weiss TW, 2004, J MOL CELL CARDIOL, V36, P539, DOI 10.1016/j.yjmcc.2004.02.001; Witzel S, 2006, J CELL BIOL, V175, P791, DOI 10.1083/jcb.200606017; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823; Yamaguchi H, 2012, EUR J CELL BIOL, V91, P902, DOI 10.1016/j.ejcb.2012.04.005; Yoshida M, 2003, ARTERIOSCL THROM VAS, V23, P783, DOI 10.1161/01.ATV.0000067427.40133.59; Yu WF, 2008, J LEUKOCYTE BIOL, V84, P852, DOI 10.1189/jlb.0308171; Zervantonakis IK, 2012, P NATL ACAD SCI USA, V109, P13515, DOI 10.1073/pnas.1210182109	63	109	112	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2014	33	33					4203	4212		10.1038/onc.2013.377	http://dx.doi.org/10.1038/onc.2013.377			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MB	24056963	Green Accepted			2022-12-17	WOS:000341155800002
J	Kilbride, SM; Prehn, JHM				Kilbride, S. M.; Prehn, J. H. M.			Central roles of apoptotic proteins in mitochondrial function	ONCOGENE			English	Review						mitochondria; bioenergetics; apoptosis	CYTOCHROME-C RELEASE; CELL-DEATH; PERMEABILITY TRANSITION; ENDONUCLEASE-G; MEMBRANE PERMEABILIZATION; CASPASE ACTIVATION; OUTER-MEMBRANE; BCL-X; OXIDATIVE STRESS; SERINE-PROTEASE	Mitochondria have been classically characterized as organelles with responsibility for cellular energy production in the form of ATP, but they are also the organelles through which apoptotic signaling occurs. Cell stress stimuli can result in outer membrane permeabilization, after which mitochondria release numerous proteins involved in apoptotic signaling, including cytochrome c, apoptosis-inducing factor, endonuclease G, Smac/DIABLO and Omi/HtrA2. Cell fate is determined by signaling through apoptotic proteins within the Bcl-2 (B-cell lymphoma 2) protein family, which converges on mitochondria. Many cancerous cells display abnormal levels of Bcl-2 protein family member expression that results in defective apoptotic signaling. Alterations in bioenergetic function also contribute to cancer as well as numerous other disorders. Recent evidence indicates that several pro-apoptotic proteins localized within mitochondria, as well as proteins within the Bcl-2 protein family, can influence mitochondrial bioenergetic function. This review focuses on the emerging roles of these proteins in the control of mitochondrial activity.	[Kilbride, S. M.; Prehn, J. H. M.] Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Ctr Syst Med, Dublin 2, Ireland	Royal College of Surgeons - Ireland	Prehn, JHM (corresponding author), Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Ctr Syst Med, 123 St Stephens Green, Dublin 2, Ireland.	prehn@rcsi.ie	Prehn, Jochen HM/A-3928-2010	Prehn, Jochen HM/0000-0003-3479-7794	Health Research Board [RP/2008/14]; Science Foundation Ireland [08/IN1/1949]	Health Research Board; Science Foundation Ireland(Science Foundation IrelandEuropean Commission)	This work was funded by Health Research Board (RP/2008/14) and Science Foundation Ireland (08/IN1/1949) grants to JHMP.	Abu-Hamad S, 2008, J BIOL CHEM, V283, P13482, DOI 10.1074/jbc.M708216200; Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; AKAO Y, 1994, CANCER RES, V54, P2468; Alavian KN, 2011, NAT CELL BIOL, V13, P1224, DOI 10.1038/ncb2330; Andrews ZB, 2005, NAT REV NEUROSCI, V6, P829, DOI 10.1038/nrn1767; Arbour N, 2008, J NEUROSCI, V28, P6068, DOI 10.1523/JNEUROSCI.4940-07.2008; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Basnakian AG, 2006, EXP CELL RES, V312, P4139, DOI 10.1016/j.yexcr.2006.09.012; Belzacq AS, 2003, CANCER RES, V63, P541; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Boohaker RJ, 2011, AM J PHYSIOL-CELL PH, V300, pC1466, DOI 10.1152/ajpcell.00325.2010; Brown D, 2006, P NATL ACAD SCI USA, V103, P9918, DOI 10.1073/pnas.0603950103; Brunelle JK, 2009, J CELL SCI, V122, P437, DOI 10.1242/jcs.031682; Burge D, 2009, ARCH DIS CHILD-FETAL, V94, pF290, DOI 10.1136/adc.2008.145102; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chen YB, 2011, J CELL BIOL, V195, P263, DOI 10.1083/jcb.201108059; Chen ZX, 2007, CELL DEATH DIFFER, V14, P1617, DOI 10.1038/sj.cdd.4402165; Chen ZX, 2010, CELL DEATH DIFFER, V17, P408, DOI 10.1038/cdd.2009.132; Cheng J, 2011, AM J HUM GENET, V89, P56, DOI 10.1016/j.ajhg.2011.05.027; Cheung ECC, 2006, EMBO J, V25, P4061, DOI 10.1038/sj.emboj.7601276; Chinta SJ, 2009, FREE RADICAL BIO MED, V46, P939, DOI 10.1016/j.freeradbiomed.2009.01.010; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P1396, DOI 10.1038/sj.cdd.4401963; Clement MV, 2001, REDOX REP, V6, P211, DOI 10.1179/135100001101536346; Concannon CG, 2010, J CELL BIOL, V189, P83, DOI 10.1083/jcb.200909166; COTE J, 1993, SCIENCE, V261, P765, DOI 10.1126/science.7688144; DeCensi A, 2010, CANCER PREV RES, V3, P1451, DOI 10.1158/1940-6207.CAPR-10-0157; Dong XX, 2009, ACTA PHARMACOL SIN, V30, P379, DOI 10.1038/aps.2009.24; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Dussmann H, 2003, J CELL SCI, V116, P525, DOI 10.1242/jcs.00236; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Flanagan L, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.26; Galluzzi L, 2008, CELL DEATH DIFFER, V15, P1113, DOI 10.1038/cdd.2008.28; Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950; Gray MW, 2001, GENOME BIOL, V2; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao ZY, 2005, CELL, V121, P579, DOI 10.1016/j.cell.2005.03.016; Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; Hickman JA, 2008, J NEUROPHYSIOL, V99, P1515, DOI 10.1152/jn.00598.2007; Hosler JP, 2006, ANNU REV BIOCHEM, V75, P165, DOI 10.1146/annurev.biochem.75.062003.101730; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Huber HJ, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.2; Ishihara Y, 2006, J BIOL CHEM, V281, P6726, DOI 10.1074/jbc.M510382200; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; Jones RG, 2007, IMMUNITY, V27, P268, DOI 10.1016/j.immuni.2007.05.023; Joza N, 2005, MOL CELL BIOL, V25, P10261, DOI 10.1128/MCB.25.23.10261-10272.2005; Karbowski J, 2006, J THEOR BIOL, V242, P652, DOI 10.1016/j.jtbi.2006.04.012; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Kilbride SM, 2010, J BIOL CHEM, V285, P36199, DOI 10.1074/jbc.M110.138107; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Krantic S, 2007, PROG NEUROBIOL, V81, P179, DOI 10.1016/j.pneurobio.2006.12.002; Krishna S, 2011, BIOCHEM J, V435, P545, DOI 10.1042/BJ20101996; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Lemasters JJ, 2006, BBA-MOL BASIS DIS, V1762, P181, DOI 10.1016/j.bbadis.2005.10.006; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Low ICC, 2011, ANTIOXID REDOX SIGN, V15, P2975, DOI 10.1089/ars.2010.3851; Mammucari C, 2010, MECH AGEING DEV, V131, P536, DOI 10.1016/j.mad.2010.07.003; Martins LM, 2004, MOL CELL BIOL, V24, P9848, DOI 10.1128/MCB.24.22.9848-9862.2004; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; McDermott-Roe C, 2011, NATURE, V478, P114, DOI 10.1038/nature10490; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Mootha VK, 2001, EMBO J, V20, P661, DOI 10.1093/emboj/20.4.661; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; NICHONGHAILE T, 2012, SCIENCE, V334, P1129; Ohsato T, 2002, EUR J BIOCHEM, V269, P5765, DOI 10.1046/j.1432-1033.2002.03238.x; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P211, DOI 10.1007/s10863-007-9094-x; PEGORARO L, 1984, P NATL ACAD SCI-BIOL, V81, P7166, DOI 10.1073/pnas.81.22.7166; Perciavalle RM, 2012, NAT CELL BIOL, V14, P575, DOI 10.1038/ncb2488; Rego AC, 2001, CELL DEATH DIFFER, V8, P995, DOI 10.1038/sj.cdd.4400916; Rinkenberger JL, 2000, GENE DEV, V14, P23; Schafer P, 2004, J MOL BIOL, V338, P217, DOI 10.1016/j.jmb.2004.02.069; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Shulga N, 2010, J CELL SCI, V123, P894, DOI 10.1242/jcs.061846; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Strauss KM, 2005, HUM MOL GENET, V14, P2099, DOI 10.1093/hmg/ddi215; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Tsujimoto Y, 2006, BBA-BIOENERGETICS, V1757, P1297, DOI 10.1016/j.bbabio.2006.03.017; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Uren RT, 2005, J BIOL CHEM, V280, P2266, DOI 10.1074/jbc.M411106200; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; van Empel VPM, 2005, CIRC RES, V96, pE92, DOI 10.1161/01.RES.0000172081.30327.28; Vande Walle L, 2007, J PROTEOME RES, V6, P1006, DOI 10.1021/pr060510d; Velours J, 2009, INT J BIOCHEM CELL B, V41, P1783, DOI 10.1016/j.biocel.2009.01.011; Vempati UD, 2009, J BIOL CHEM, V284, P4383, DOI 10.1074/jbc.M805972200; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Waterhouse NJ, 2006, CELL DEATH DIFFER, V13, P607, DOI 10.1038/sj.cdd.4401772; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Wei G, 2006, CANCER CELL, V10, P331, DOI 10.1016/j.ccr.2006.09.006; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weisova P, 2011, ANTIOXID REDOX SIGN, V14, P1863, DOI 10.1089/ars.2010.3544; Whelan RS, 2012, P NATL ACAD SCI USA, V109, P6566, DOI 10.1073/pnas.1201608109; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Wu YF, 2004, NEUROSCI LETT, V364, P203, DOI 10.1016/j.neulet.2004.04.093; Wuilleme-Toumi S, 2005, LEUKEMIA, V19, P1248, DOI 10.1038/sj.leu.2403784; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307; Youdim MBH, 2006, NAT REV NEUROSCI, V7, P295, DOI 10.1038/nrn1883; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zamzami N, 2005, CELL DEATH DIFFER, V12, P1478, DOI 10.1038/sj.cdd.4401682; Zanna C, 2005, APOPTOSIS, V10, P997, DOI 10.1007/s10495-005-0742-5; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	128	109	112	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2013	32	22					2703	2711		10.1038/onc.2012.348	http://dx.doi.org/10.1038/onc.2012.348			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FU	22869150				2022-12-17	WOS:000319808000001
J	Su, Y; Wagner, ER; Luo, Q; Huang, J; Chen, L; He, BC; Zuo, GW; Shi, Q; Zhang, BQ; Zhu, G; Bi, Y; Luo, J; Luo, X; Kim, SH; Shen, J; Rastegar, F; Huang, E; Gao, Y; Gao, JL; Yang, K; Wietholt, C; Li, M; Qin, J; Haydon, RC; He, TC; Luu, HH				Su, Y.; Wagner, E. R.; Luo, Q.; Huang, J.; Chen, L.; He, B-C; Zuo, G-W; Shi, Q.; Zhang, B-Q; Zhu, G.; Bi, Y.; Luo, J.; Luo, X.; Kim, S. H.; Shen, J.; Rastegar, F.; Huang, E.; Gao, Y.; Gao, J-L; Yang, K.; Wietholt, C.; Li, M.; Qin, J.; Haydon, R. C.; He, T-C; Luu, H. H.			Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma	ONCOGENE			English	Article						osteosarcoma; tumorigenesis; metastasis; IGFBP5; animal model	MESENCHYMAL STEM-CELLS; BREAST-CANCER CELLS; OSTEOBLAST DIFFERENTIATION; RECOMBINANT ADENOVIRUSES; CLEAR-CELL; IN-VIVO; EXPRESSION; INHIBITOR; IGFBP-5; SYSTEM	Osteosarcoma (OS) is the most common primary malignancy of bone. There is a critical need to identify the events that lead to the poorly understood mechanism of OS development and metastasis. The goal of this investigation is to identify and characterize a novel marker of OS progression. We have established and characterized a highly metastatic OS subline that is derived from the less metastatic human MG63 line through serial passages in nude mice via intratibial injections. Microarray analysis of the parental MG63, the highly metastatic MG63.2 subline, as well as the corresponding primary tumors and pulmonary metastases revealed insulin-like growth factor binding protein 5 (IGFBP5) to be one of the significantly downregulated genes in the metastatic subline. Confirmatory quantitative RT-PCR on 20 genes of interest demonstrated IGFBP5 to be the most differentially expressed and was therefore chosen to be one of the genes for further investigation. Adenoviral mediated overexpression and knockdown of IGFBP5 in the MG63 and MG63.2 cell lines, as well as other OS lines (143B and MNNG/HOS) that are independent of our MG63 lines, were employed to examine the role of IGFBP5. We found that overexpression of IGFBP5 inhibited in vitro cell proliferation, migration and invasion of OS cells. Additionally, IGFBP5 overexpression promoted apoptosis and cell cycle arrest in the G1 phase. In an orthotopic xenograft animal model, overexpression of IGFBP5 inhibited OS tumor growth and pulmonary metastases. Conversely, siRNA-mediated knockdown of IGFBP5 promoted OS tumor growth and pulmonary metastases in vivo. Immunohistochemical staining of patient-matched primary and metastatic OS samples demonstrated decreased IGFBP5 expression in the metastases. These results suggest 1) a role for IGFBP5 as a novel marker that has an important role in the pathogenesis of OS, and 2) that the loss of IGFBP5 function may contribute to more metastatic phenotypes in OS. Oncogene (2011) 30, 3907-3917; doi:10.1038/onc.2011.97; published online 4 April 2011	[Luu, H. H.] Univ Chicago, Suzanne Berman Oncol Lab, Dept Surg, Med Ctr, Chicago, IL 60637 USA; [Su, Y.; Luo, Q.; Zhu, G.; Bi, Y.; Li, M.; Qin, J.; He, T-C] Chongqing Med Univ, Stem Cell Biol & Therapy Lab, Childrens Hosp, Chongqing, Peoples R China; [Su, Y.; Luo, Q.; Huang, J.; Chen, L.; He, B-C; Zuo, G-W; Shi, Q.; Zhang, B-Q; Zhu, G.; Bi, Y.; Luo, J.; Luo, X.; Li, M.; Qin, J.; He, T-C] Chinese Minist Educ, Key Lab Diagnost Med, Chongqing, Peoples R China; [Su, Y.; Luo, Q.; Huang, J.; Chen, L.; He, B-C; Zuo, G-W; Shi, Q.; Zhang, B-Q; Zhu, G.; Bi, Y.; Luo, J.; Luo, X.; Li, M.; Qin, J.; He, T-C] Chongqing Med Univ, Affiliated Hosp, Chongqing, Peoples R China; [Huang, E.] Chongqing Univ, Sch Bioengn, Chongqing, Peoples R China; [Gao, Y.] Shanghai Jiatong Univ, Dept Geriatr, Xinhua Hosp, Shanghai, Peoples R China; [Yang, K.] Third Mil Med Univ, Dept Cell Biol, Chongqing, Peoples R China; [Wietholt, C.] Univ Chicago, Dept Radiol, Med Ctr, Chicago, IL 60637 USA	University of Chicago; University of Chicago Medical Center; Chongqing Medical University; Chongqing Medical University; Chongqing University; Shanghai Jiao Tong University; Army Medical University; University of Chicago; University of Chicago Medical Center	Luu, HH (corresponding author), Univ Chicago, Suzanne Berman Oncol Lab, Dept Surg, Med Ctr, 5841 S Maryland Ave,MC3079, Chicago, IL 60637 USA.	hluu@surgery.bsd.uchicago.edu		Wagner, Eric/0000-0001-9241-5702	American Cancer Society; Brinson Foundation; National Institute of Health; Orthopaedic Research and Education Foundation; Natural Science Foundation of China [81001197]; Ministry of Science and Technology of China [2011CB707906]	American Cancer Society(American Cancer Society); Brinson Foundation; National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Orthopaedic Research and Education Foundation; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China)	We thank Dr Xinmin Li, PhD (Director of The UCLA Clinical Microarray Core) for his help with the microarray and cluster analysis. We also sincerely thank Dr Anthony Montag, Leslie Martin and Guarav Luther for the creation of the tissue array. We also thank Dr Theodore Karrison for help with the statistical analysis. This work was supported in part by research grants from The American Cancer Society (HHL and TCH), the Brinson Foundation (HHL, TCH, RCH), The National Institute of Health (HHL, TCH, RCH), the Orthopaedic Research and Education Foundation (HHL, RCH), the Natural Science Foundation of China (#81001197 to YS), and the 973 Program of the Ministry of Science and Technology of China (#2011CB707906 to JL and TCH).	Akkiprik M, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2116; Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200; Avnet S, 2009, CANCER RES, V69, P2443, DOI 10.1158/0008-5472.CAN-08-2645; Butt AJ, 2005, ENDOCRINOLOGY, V146, P3113, DOI 10.1210/en.2004-1408; Butt AJ, 2003, J BIOL CHEM, V278, P29676, DOI 10.1074/jbc.M301965200; Cheung C, 2005, INT J UROL, V12, P17, DOI 10.1111/j.1442-2042.2004.00993.x; DAVIS AM, 1994, J CLIN ONCOL, V12, P423, DOI 10.1200/JCO.1994.12.2.423; Fuchs B, 2002, CLIN ORTHOP RELAT R, P40; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298; Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130; Kaste SC, 1999, CANCER-AM CANCER SOC, V86, P1602, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1602::AID-CNCR31>3.0.CO;2-R; Letson G D, 2001, Cancer Control, V8, P239; Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135; Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200; Luo Q, 2007, GENE, V395, P160, DOI 10.1016/j.gene.2007.02.030; Luo XJ, 2008, CLIN ORTHOP RELAT R, V466, P2060, DOI 10.1007/s11999-008-0361-x; Luu HH, 2005, CANCER LETT, V229, P135, DOI 10.1016/j.canlet.2005.02.015; Luu HH, 2005, CLIN EXP METASTAS, V22, P319, DOI 10.1007/s10585-005-0365-9; Luu HH, 1998, CANCER RES, V58, P3561; Manara MC, 2007, CLIN CANCER RES, V13, P1322, DOI 10.1158/1078-0432.CCR-06-1518; Mankin HJ, 2004, CLIN ORTHOP RELAT R, P286, DOI 10.1097/01.blo.0000145991.65770.e6; Mukherjee A, 2007, GROWTH HORM IGF RES, V17, P179, DOI 10.1016/j.ghir.2007.01.005; Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200; Ragland BD, 2002, LAB INVEST, V82, P365, DOI 10.1038/labinvest.3780431; Rosenzweig SA, 2004, GROWTH HORM IGF RES, V14, P329, DOI 10.1016/j.ghir.2004.02.003; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Schneider MR, 2002, J ENDOCRINOL, V172, P423, DOI 10.1677/joe.0.1720423; Schneider MR, 2001, BIOCHEM BIOPH RES CO, V288, P435, DOI 10.1006/bbrc.2001.5785; Sharff KA, 2009, J BIOL CHEM, V284, P649, DOI 10.1074/jbc.M806389200; Song H, 2001, J MOL ENDOCRINOL, V26, P229, DOI 10.1677/jme.0.0260229; Stolf BS, 2003, CANCER LETT, V191, P193, DOI 10.1016/S0304-3835(02)00679-1; Su YX, 2009, CLIN EXP METASTAS, V26, P599, DOI 10.1007/s10585-009-9259-6; Takahash M, 2005, INT J ONCOL, V26, P923; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang HM, 2006, MODERN PATHOL, V19, P1149, DOI 10.1038/modpathol.3800637; Whelan JS, 1997, EUR J CANCER, V33, P1611, DOI 10.1016/S0959-8049(97)00251-7; Xu C, 2007, PROSTATE, V67, P1621, DOI 10.1002/pros.20655; Yonemoto T, 1998, CLIN ORTHOP RELAT R, P194	39	109	111	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	37					3907	3917		10.1038/onc.2011.97	http://dx.doi.org/10.1038/onc.2011.97			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820FG	21460855				2022-12-17	WOS:000294890400001
J	Puca, R; Nardinocchi, L; Givol, D; D'Orazi, G				Puca, R.; Nardinocchi, L.; Givol, D.; D'Orazi, G.			Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells	ONCOGENE			English	Review						HIPK2; p53; post-translational modifications; protein conformation; apoptosis; chemoresistance	INTERACTING PROTEIN KINASE-2; ACUTE MYELOID-LEUKEMIA; DNA-DAMAGE; TUMOR-SUPPRESSOR; IN-VIVO; P53SER46 PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVITY; P53-DEPENDENT APOPTOSIS; IONIZING-RADIATION; GENE-EXPRESSION	The p53 protein is the most studied tumor suppressor and the p53 pathway has been shown to mediate cellular stress responses that are disrupted when cancer develops. After DNA damage, p53 is activated as transcription factor to directly induce the expression of target genes involved in cell-cycle arrest, DNA repair, senescence and, importantly, apoptosis. Post-translational modifications of p53 are essential for the activation of p53 and for selection of target genes. The tumor suppressor homeodomain-interacting protein kinase-2 (HIPK2) is a crucial regulator of p53 apoptotic function by phosphorylating its N-terminal serine 46 (Ser46) and facilitating Lys382 acetylation at the C-terminus. HIPK2 is activated by numerous genotoxic agents and can be deregulated in tumors by several conditions including hypoxia. Recent findings suggest that HIPK2 active/inactive protein can affect p53 function in multiple and unexpected ways. This makes p53 as well as HIPK2 interesting targets for cancer therapy. Hence, understanding the role of HIPK2 as p53 activator may provide important insights in the process of tumor progression, and may also serve as the crucial point in the diagnostic and therapeutical aspects of cancer. Oncogene (2010) 29, 4378-4387; doi: 10.1038/onc.2010.183; published online 31 May 2010	[Puca, R.; Nardinocchi, L.; D'Orazi, G.] Natl Canc Inst Regina Elena, Dept Expt Oncol, Mol Oncogenesis Lab, Rome, Italy; [Puca, R.; Nardinocchi, L.; D'Orazi, G.] Univ G DAnnunzio, Dept Oncol & Neurosci, Sch Med, I-66013 Chieti, Italy; [Givol, D.] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	G d'Annunzio University of Chieti-Pescara; Weizmann Institute of Science	D'Orazi, G (corresponding author), Univ G DAnnunzio, Dept Oncol & Neurosci, Sch Med, Via Vestini 31, I-66013 Chieti, Italy.	gdorazi@unich.it	D'Orazi, Gabriella/T-2792-2019	D'Orazi, Gabriella/0000-0001-6876-9105	Italian Association for Cancer Research; University 'Gd'Annunzio'; Italian Foundation for Cancer Research (FIRC)	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); University 'Gd'Annunzio'; Italian Foundation for Cancer Research (FIRC)(Fondazione AIRC per la ricerca sul cancro)	This research conducted in our laboratory is supported by Grants from Italian Association for Cancer Research and from University 'Gd'Annunzio'. RP is a recipient of a fellowship from Italian Foundation for Cancer Research (FIRC).	Al-Beiti MAM, 2008, AUST NZ J OBSTET GYN, V48, P329, DOI 10.1111/j.1479-828X.2008.00874.x; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Benita Y, 2009, NUCLEIC ACIDS RES, V37, P4587, DOI 10.1093/nar/gkp425; Bernardi R, 2007, NAT REV MOL CELL BIO, V8, P1006, DOI 10.1038/nrm2277; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Britos-Bray M, 1998, BLOOD, V92, P4344, DOI 10.1182/blood.V92.11.4344.423a01_4344_4352; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Calzado MA, 2007, CELL CYCLE, V6, P139, DOI 10.4161/cc.6.2.3788; Calzado MA, 2009, BIOL CHEM, V390, P1079, DOI 10.1515/BC.2009.112; Calzado MA, 2009, NAT CELL BIOL, V11, P85, DOI 10.1038/ncb1816; Cecchinelli B, 2006, MOL CELL BIOL, V26, P4746, DOI 10.1128/MCB.00959-05; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Choi DW, 2008, J BIOL CHEM, V283, P4682, DOI 10.1074/jbc.M708873200; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; D'Orazi G, 2006, CLIN CANCER RES, V12, P735, DOI 10.1158/1078-0432.CCR-05-1557; Dauth I, 2007, CANCER RES, V67, P2274, DOI 10.1158/0008-5472.CAN-06-2884; Deshmukh H, 2008, ONCOGENE, V27, P4745, DOI 10.1038/onc.2008.110; Di Lello P, 2006, MOL CELL, V22, P731, DOI 10.1016/j.molcel.2006.05.007; Di Stefana V, 2005, FEBS LETT, V579, P5473, DOI 10.1016/j.febslet.2005.09.008; Di Stefano V, 2005, ONCOGENE, V24, P5431, DOI 10.1038/sj.onc.1208717; Di Stefano V, 2004, ONCOGENE, V23, P5185, DOI 10.1038/sj.onc.1207656; Di Stefano V, 2004, EXP CELL RES, V293, P311, DOI 10.1016/j.yexcr.2003.09.032; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Gresko E, 2006, EMBO J, V25, P1883, DOI 10.1038/sj.emboj.7601077; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAINAUT P, 1993, CANCER RES, V53, P1739; Haldar SM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000502; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Isono K, 2006, MOL CELL BIOL, V26, P2758, DOI 10.1128/MCB.26.7.2758-2771.2006; Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146; JOENGER AC, 2007, ONCOGENE, V26, P2226; Kamata T, 2009, CANCER SCI, V100, P1382, DOI 10.1111/j.1349-7006.2009.01207.x; Kikuchi A, 1999, CELL SIGNAL, V11, P777, DOI 10.1016/S0898-6568(99)00054-6; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Knights CD, 2006, J CELL BIOL, V173, P533, DOI 10.1083/jcb.200512059; Komiyama S, 2004, BIOCHEM BIOPH RES CO, V323, P816, DOI 10.1016/j.bbrc.2004.08.161; Kondo S, 2003, P NATL ACAD SCI USA, V100, P5431, DOI 10.1073/pnas.0530308100; Krieghoff-Henning E, 2008, BBA-MOL CELL RES, V1783, P2185, DOI 10.1016/j.bbamcr.2008.07.002; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lanni C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010171; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li QX, 2007, CANCER RES, V67, P66, DOI 10.1158/0008-5472.CAN-06-1671; Li QX, 2009, NAT CELL BIOL, V11, P1128, DOI 10.1038/ncb1927; Li XL, 2007, ONCOGENE, V26, P7231, DOI 10.1038/sj.onc.1210523; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MacLachan TK, 2002, P NATL ACAD SCI USA, V99, P9492, DOI 10.1073/pnas.132241599; Mantovani F, 2007, NAT STRUCT MOL BIOL, V14, P912, DOI 10.1038/nsmb1306; Marchetti A, 2004, CELL DEATH DIFFER, V11, P596, DOI 10.1038/sj.cdd.4401368; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; Mayo LD, 2005, J BIOL CHEM, V280, P25953, DOI 10.1074/jbc.M503026200; Meplan C, 2000, ONCOGENE, V19, P5227, DOI 10.1038/sj.onc.1203907; Moehlenbrink J, 2010, CANCER LETT, V292, P119, DOI 10.1016/j.canlet.2009.11.016; Moller A, 2003, ONCOGENE, V22, P8731, DOI 10.1038/sj.onc.1207079; Moller A, 2003, CANCER RES, V63, P4310; Nardinocchi L, 2010, CELL CYCLE, V9, P1270, DOI 10.4161/cc.9.7.11125; Nardinocchi L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006819; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pierantoni GM, 2007, J CLIN INVEST, V117, P693, DOI 10.1172/JCI29852; Pierantoni GM, 2002, BIOCHEM BIOPH RES CO, V290, P942, DOI 10.1006/bbrc.2001.6310; Pistritto G, 2007, CELL DEATH DIFFER, V14, P1837, DOI 10.1038/sj.cdd.4402186; Puca R, 2008, GYNECOL ONCOL, V109, P403, DOI 10.1016/j.ygyno.2008.02.018; Puca R, 2008, CANCER RES, V68, P3707, DOI 10.1158/0008-5472.CAN-07-6776; Puca R, 2010, FREE RADICAL BIO MED, V48, P1338, DOI 10.1016/j.freeradbiomed.2010.02.015; Puca R, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-85; Puca R, 2009, EXP CELL RES, V315, P67, DOI 10.1016/j.yexcr.2008.10.018; Rinaldo C, 2007, BIOCHEM CELL BIOL, V85, P411, DOI 10.1139/O07-071; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Rinaldo C, 2009, CANCER RES, V69, P6241, DOI 10.1158/0008-5472.CAN-09-0337; Rui YN, 2004, EMBO J, V23, P4583, DOI 10.1038/sj.emboj.7600475; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Seidel S, 2010, BRAIN, V133, P983, DOI 10.1093/brain/awq042; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shmueli A, 2007, MOL CELL, V25, P794, DOI 10.1016/j.molcel.2007.03.006; Taira N, 2007, MOL CELL, V25, P725, DOI 10.1016/j.molcel.2007.02.007; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Tomasini R, 2003, J BIOL CHEM, V278, P37722, DOI 10.1074/jbc.M301979200; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vazquez A, 2008, NAT REV DRUG DISCOV, V7, P979, DOI 10.1038/nrd2656; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang Y, 2001, BMC Mol Biol, V2, P8, DOI 10.1186/1471-2199-2-8; Wee HJ, 2008, BLOOD, V112, P3777, DOI 10.1182/blood-2008-01-134122; Wei GW, 2007, P NATL ACAD SCI USA, V104, P13040, DOI 10.1073/pnas.0703213104; Wesierska-Gadek J, 2007, J CELL BIOCHEM, V100, P865, DOI 10.1002/jcb.21211; Wiggins AK, 2004, J CELL BIOL, V167, P257, DOI 10.1083/jcb.200406131; Winter M, 2008, NAT CELL BIOL, V10, P812, DOI 10.1038/ncb1743; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yoshida K, 2006, J BIOL CHEM, V281, P5734, DOI 10.1074/jbc.M512074200; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120	99	109	114	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2010	29	31					4378	4387		10.1038/onc.2010.183	http://dx.doi.org/10.1038/onc.2010.183			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634DG	20514025				2022-12-17	WOS:000280559100002
J	Vetter, G; Saumet, A; Moes, M; Vallar, L; Le Bechec, A; Laurini, C; Sabbah, M; Arar, K; Theillet, C; Lecellier, CH; Friederich, E				Vetter, G.; Saumet, A.; Moes, M.; Vallar, L.; Le Bechec, A.; Laurini, C.; Sabbah, M.; Arar, K.; Theillet, C.; Lecellier, C-H; Friederich, E.			RETRACTED: miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers (Retracted article. See vol. 35, pg. 670, 2016)	ONCOGENE			English	Article; Retracted Publication						EMT; miR-661; SNAI1; StarD10; Nectin-1; breast cancer cell invasion	TRANSCRIPTION FACTOR SNAIL; E-CADHERIN; GENE-EXPRESSION; MIR-200 FAMILY; REPRESSORS ZEB1; METASTASIS; PHENOTYPE; MICRORNA; RECEPTORS; SIGNATURE	Epithelial to mesenchymal transition (EMT) is a key step toward metastasis. MCF7 breast cancer cells conditionally expressing the EMT master regulator SNAI1 were used to identify early expressed microRNAs (miRNAs) and their targets that may contribute to the EMT process. Potential targets of miRNAs were identified by matching lists of in silico predicted targets and of inversely expressed mRNAs. MiRNAs were ranked based on the number of predicted hits, highlighting miR-661, a miRNA with so far no reported role in EMT. MiR-661 was found required for efficient invasion of breast cancer cells by destabilizing two of its predicted mRNA targets, the cell-cell adhesion protein Nectin-1 and the lipid transferase StarD10, resulting, in turn, in the downregulation of epithelial markers. Reexpression of Nectin-1 or StarD10 lacking the 3'-untranslated region counteracted SNAI1-induced invasion. Importantly, analysis of public transcriptomic data from a cohort of 295 well-characterized breast tumor specimen revealed that expression of StarD10 is highly associated with markers of luminal subtypes whereas its loss negatively correlated with the EMT-related, basal-like subtype. Collectively, our non-a priori approach revealed a nonpredicted link between SNAI1-triggered EMT and the down-regulation of Nectin-1 and StarD10 through the up-regulation of miR-661, which may contribute to the invasion of breast cancer cells and poor disease outcome. Oncogene (2010) 29, 4436-4448; doi: 10.1038/onc.2010.181; published online 14 June 2010	[Vetter, G.; Moes, M.; Le Bechec, A.; Laurini, C.; Friederich, E.] Univ Luxembourg, FSTC, Life Sci Res Unit, Cytoskeleton & Cell Plast Lab, L-1511 Luxembourg, Luxembourg; [Saumet, A.; Theillet, C.] INSERM, Inst Rech Cancerol Montpellier, U896, Montpellier, France; [Vallar, L.] Ctr Rech Publ Sante, Microarray Ctr, Luxembourg, Luxembourg; [Sabbah, M.] Hop Saint Antoine, INSERM, U938, Paris, France; [Arar, K.] Sigma Aldrich, Evry, France; [Lecellier, C-H] CNRS, Inst Genet Mol Montpellier, UMR 5535, IFR 122, Montpellier, France	University of Luxembourg; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Luxembourg Institute of Health; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Merck KGaA; MilliporeSigma; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Friederich, E (corresponding author), Univ Luxembourg, FSTC, Life Sci Res Unit, Cytoskeleton & Cell Plast Lab, L-1511 Luxembourg, Luxembourg.	evelyne.friederich@uni.lu	Theillet, Charles/O-7634-2018	Vallar, Laurent/0000-0002-4404-1010; Theillet, Charles/0000-0001-5555-2759	Fond National de la Recherche (FNR) du Luxembourg (BIOSAN); Fondation Luxembourgeoise Contre le Cancer; Human Frontier Science Program [RGP0058/2005]; INSERM; CNRS, France; Ministere de la Culture, de l'Enseignement Superieur et de la Recherche, Luxembourg [BFR 08/046]; Fond National de la Recherche, Luxembourg	Fond National de la Recherche (FNR) du Luxembourg (BIOSAN)(Luxembourg National Research Fund); Fondation Luxembourgeoise Contre le Cancer; Human Frontier Science Program(Human Frontier Science Program); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); CNRS, France(Centre National de la Recherche Scientifique (CNRS)); Ministere de la Culture, de l'Enseignement Superieur et de la Recherche, Luxembourg; Fond National de la Recherche, Luxembourg(Luxembourg National Research Fund)	We thank M Yatskou, P Nazarov and A Muller (CRP-Sante, Luxembourg) for their help with the microarray data analysis. We thank C Hoffmann-Laporte (CRP-Sante, Luxembourg) for her help with confocal microscopy observations. We especially thank E Schaffner-Reckinger for critical reading of the article and P Savagner for helpful discussions. This work was supported by grants from the Fond National de la Recherche (FNR) du Luxembourg (BIOSAN), the Fondation Luxembourgeoise Contre le Cancer, Human Frontier Science Program (RGP0058/2005), INSERM and CNRS, France. A Saumet is a recipient of a fellowship from the Ministere de la Culture, de l'Enseignement Superieur et de la Recherche, Luxembourg (BFR 08/046). M Moes and A Le Bechec are supported by AFR grants from the Fond National de la Recherche, Luxembourg.	Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Brakeman PR, 2009, AM J PHYSIOL-RENAL, V296, pF564, DOI 10.1152/ajprenal.90328.2008; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cano A, 2008, TRENDS CELL BIOL, V18, P357, DOI 10.1016/j.tcb.2008.05.005; De Craene B, 2005, CANCER RES, V65, P6237, DOI 10.1158/0008-5472.CAN-04-3545; De Wever O, 2008, HISTOCHEM CELL BIOL, V130, P481, DOI 10.1007/s00418-008-0464-1; Divijendra S, 2009, CANCER RES, V69, P5639, DOI 10.1158/0008-5472.CAN-09-0898; Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933; Gebeshuber CA, 2009, EMBO REP, V10, P400, DOI 10.1038/embor.2009.9; Gregory PA, 2008, CELL CYCLE, V7, P3112, DOI 10.4161/cc.7.20.6851; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Lacroix M, 2006, ENDOCR-RELAT CANCER, V13, P1033, DOI 10.1677/ERC-06-0001; Lecellier CH, 2005, SCIENCE, V308, P557, DOI 10.1126/science.1108784; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Murphy NC, 2010, INT J CANCER, V126, P1445, DOI 10.1002/ijc.24826; Olayioye MA, 2005, J BIOL CHEM, V280, P27436, DOI 10.1074/jbc.M413330200; Olayioye MA, 2004, CANCER RES, V64, P3538, DOI 10.1158/0008-5472.CAN-03-3731; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Sabbah M, 2008, DRUG RESIST UPDATE, V11, P123, DOI 10.1016/j.drup.2008.07.001; Sakisaka T, 2007, CURR OPIN CELL BIOL, V19, P593, DOI 10.1016/j.ceb.2007.09.007; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Saumet A, 2009, BLOOD, V113, P412, DOI 10.1182/blood-2008-05-158139; Takai Y, 2008, NAT REV MOL CELL BIO, V9, P603, DOI 10.1038/nrm2457; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vetter G, 2009, BIOCHEM BIOPH RES CO, V385, P485, DOI 10.1016/j.bbrc.2009.05.025	34	109	117	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2010	29	31					4436	4448		10.1038/onc.2010.181	http://dx.doi.org/10.1038/onc.2010.181			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634DG	20543867	Green Submitted, Green Published, Green Accepted			2022-12-17	WOS:000280559100007
J	Shimura, T; Kakuda, S; Ochiai, Y; Nakagawa, H; Kuwahara, Y; Takai, Y; Kobayashi, J; Komatsu, K; Fukumoto, M				Shimura, T.; Kakuda, S.; Ochiai, Y.; Nakagawa, H.; Kuwahara, Y.; Takai, Y.; Kobayashi, J.; Komatsu, K.; Fukumoto, M.			Acquired radioresistance of human tumor cells by DNA-PK/AKT/GSK3 beta-mediated cyclin D1 overexpression	ONCOGENE			English	Article						cyclin D1; AKT; fractionated-radiation; radioresistance; DNA-PK	STRAND BREAK RESPONSE; CANCER STEM-CELLS; DNA-DAMAGE; NUCLEAR EXPORT; MAMMALIAN-CELLS; PROTEIN-KINASE; PHOSPHORYLATION; REPAIR; REPLICATION; INHIBITION	Recurrence is frequently associated with the acquisition of radioresistance by tumors and resulting failures in radiotherapy. We report, in this study, that long-term fractionated radiation (FR) exposures conferred radioresistance to the human tumor cells, HepG2 and HeLa with cyclin D1 overexpression. A positive feedback loop was responsible for the cyclin D1 overexpression in which constitutively active AKT was involved. AKT is known to inactivate glycogen synthase kinase-3 beta (GSK3 beta), which is essential for the proteasomal degradation of cyclin D1. The resulting cyclin D1 overexpression led to the forced progression of S-phase with the induction of DNA double strand breaks. Cyclin D1-dependent DNA damage activated DNA-dependent protein kinase (DNA-PK), which in turn activated AKT and inactivated GSK3 beta, thus completing a positive feedback loop of cyclin D1 overproduction. Cyclin D1 overexpression led to the activation of DNA damage response (DDR) consisted of ataxia telangiectasia mutated (ATM)- and Chk1-dependent DNA damage checkpoint and homologous recombination repair (HRR). Long-term FR cells repaired radiation-induced DNA damage faster than non-FR cells. Thus, acquired radioresistance of long-term FR cells was the result of alterations in DDR mediated by cyclin D1 overexpression. Inhibition of the AKT/GSK3 beta/cyclin D1/Cdk4 pathway by the AKT inhibitor, Cdk4 inhibitor or cyclin D1 targeting small interfering RNA (siRNA) suppressed the radioresistance. Present observations give a mechanistic insight for acquired radioresistance of tumor cells by cyclin D1 overexpression, and provide novel therapeutic targets for recurrent radioresistant tumors. Oncogene (2010) 29, 4826-4837; doi:10.1038/onc.2010.238; published online 21 June 2010	[Shimura, T.; Kakuda, S.; Ochiai, Y.; Nakagawa, H.; Kuwahara, Y.; Fukumoto, M.] Tohoku Univ, Dept Pathol, Inst Dev Aging & Canc, Sendai, Miyagi 9808575, Japan; [Kakuda, S.; Takai, Y.] Tohoku Univ, Grad Sch Med, Dept Therapeut Radiol, Sendai, Miyagi 9808575, Japan; [Kobayashi, J.; Komatsu, K.] Kyoto Univ, Dept Genome Dynam, Ctr Radiat Biol, Kyoto, Japan	Tohoku University; Tohoku University; Kyoto University	Fukumoto, M (corresponding author), Tohoku Univ, Dept Pathol, Inst Dev Aging & Canc, 4-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	fukumoto@idac.tohoku.ac.jp	Kobayashi, Junya/AAX-6390-2021; Fukumoto, Manabu/L-1444-2019	Kobayashi, Junya/0000-0003-4645-7500; 	Ministry of Education, Culture, Sports, Science and Technology; Ministry of Health, Labour and Welfare of Japan; Interdisciplinary Research, Tohoku University;  [Start-up-20810003];  [Wakate-B-21710054]	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Interdisciplinary Research, Tohoku University; ; 	We thank Dr Ohtsura Niwa and Dr Keiko Nakayama for their critical reading of the paper. We thank Dr J Alan Diehl for providing pFleX-cyclin D1 expression vectors. We thank Dr Shuntaro Ikawa for providing some chemicals. This study was in part supported by the Grant-in-Aid for young scientists (Start-up-20810003) and (Wakate-B-21710054), by the Grant-in-Aid from Ministry of Education, Culture, Sports, Science and Technology, by grants from the Ministry of Health, Labour and Welfare of Japan, and by the 'Frontier Science Research Program' in the Center for Interdisciplinary Research, Tohoku University.	Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Alao JP, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-24; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bani-Hani K, 2000, J NATL CANCER I, V92, P1316, DOI 10.1093/jnci/92.16.1316; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Baumann M, 2008, NAT REV CANCER, V8, P545, DOI 10.1038/nrc2419; Benzeno S, 2006, ONCOGENE, V25, P6291, DOI 10.1038/sj.onc.1209644; Bommi-Reddy A, 2008, P NATL ACAD SCI USA, V105, P16484, DOI 10.1073/pnas.0806574105; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; Cann KL, 2007, BIOCHEM CELL BIOL, V85, P663, DOI 10.1139/O07-135; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chang AR, 2008, HEAD NECK-J SCI SPEC, V30, P852, DOI 10.1002/hed.20788; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Duronio V, 2008, BIOCHEM J, V415, P333, DOI 10.1042/BJ20081056; FILMUS J, 1994, ONCOGENE, V9, P3627; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; GILLETT C, 1994, CANCER RES, V54, P1812; Gladden AB, 2005, J CELL BIOCHEM, V96, P906, DOI 10.1002/jcb.20613; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Higuchl E, 2007, HEAD NECK-J SCI SPEC, V29, P940, DOI 10.1002/hed.20632; Hitomi M, 1999, CURR BIOL, V9, P1075, DOI 10.1016/S0960-9822(99)80476-X; Kang T, 2008, CANCER CELL, V13, P36, DOI 10.1016/j.ccr.2007.12.002; Kim JJ, 2005, NAT REV CANCER, V5, P516, DOI 10.1038/nrc1650; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lin DI, 2008, ONCOGENE, V27, P1231, DOI 10.1038/sj.onc.1210738; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Pilch DR, 2003, BIOCHEM CELL BIOL, V81, P123, DOI 10.1139/o03-042; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Rich JN, 2007, CANCER RES, V67, P8980, DOI 10.1158/0008-5472.CAN-07-0895; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Sedelnikova OA, 2003, CANCER BIOL THER, V2, P233; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shimura T, 2008, J MOL BIOL, V375, P1152, DOI 10.1016/j.jmb.2007.11.006; Shimura T, 2007, J MOL BIOL, V367, P665, DOI 10.1016/j.jmb.2007.01.018; Takahashi-Yanaga F, 2008, CELL SIGNAL, V20, P581, DOI 10.1016/j.cellsig.2007.10.018; Toda Y, 1999, PATHOL INT, V49, P479, DOI 10.1046/j.1440-1827.1999.00875.x; Veuger SJ, 2003, CANCER RES, V63, P6008; Yang L, 2004, CANCER RES, V64, P4394, DOI 10.1158/0008-5472.CAN-04-0343	48	109	114	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2010	29	34					4826	4837		10.1038/onc.2010.238	http://dx.doi.org/10.1038/onc.2010.238			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643VB	20562919				2022-12-17	WOS:000281326400008
J	Mestdagh, P; Fredlund, E; Pattyn, F; Rihani, A; Van Maerken, T; Vermeulen, J; Kumps, C; Menten, B; De Preter, K; Schramm, A; Schulte, J; Noguera, R; Schleiermacher, G; Janoueix-Lerosey, I; Laureys, G; Powel, R; Nittner, D; Marine, JC; Ringner, M; Speleman, F; Vandesompele, J				Mestdagh, P.; Fredlund, E.; Pattyn, F.; Rihani, A.; Van Maerken, T.; Vermeulen, J.; Kumps, C.; Menten, B.; De Preter, K.; Schramm, A.; Schulte, J.; Noguera, R.; Schleiermacher, G.; Janoueix-Lerosey, I.; Laureys, G.; Powel, R.; Nittner, D.; Marine, J-C; Ringner, M.; Speleman, F.; Vandesompele, J.			An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours	ONCOGENE			English	Article						neuroblastoma; T-UCR; non-coding RNA	NONCODING RNAS; MICRORNAS; PCR; ANTAGONISTS; ASSOCIATE; PATHWAY; MAPS	Different classes of non-coding RNAs, including microRNAs, have recently been implicated in the process of tumourigenesis. In this study, we examined the expression and putative functions of a novel class of non-coding RNAs known as transcribed ultraconserved regions (T-UCRs) in neuroblastoma. Genome-wide expression pro. ling revealed correlations between specific T-UCR expression levels and important clinicogenetic parameters such as MYCN amplification status. A functional genomics approach based on the integration of multi-level transcriptome data was adapted to gain insights into T-UCR functions. Assignments of T-UCRs to cellular processes such as TP53 response, differentiation and proliferation were verified using various cellular model systems. For the first time, our results de. ne a T-UCR expression landscape in neuroblastoma and suggest widespread T-UCR involvement in diverse cellular processes that are deregulated in the process of tumourigenesis. Oncogene (2010) 29, 3583-3592; doi:10.1038/onc.2010.106; published online 12 April 2010	[Vandesompele, J.] Ghent Univ Hosp, Ctr Med Genet, MRB, B-9000 Ghent, East Flanders, Belgium; [Fredlund, E.; Ringner, M.] Lund Univ, Dept Oncol, Lund, Sweden; [Fredlund, E.; Ringner, M.] Lund Univ, Strateg Ctr Translat Canc Res, CREATE Hlth, Lund, Sweden; [Schramm, A.; Schulte, J.] Univ Hosp Essen, Essen, Germany; [Noguera, R.] Med Sch Valencia, Valencia, Spain; [Schleiermacher, G.] Inst Curie, Dept Paediat Oncol, Paris, France; [Schleiermacher, G.; Janoueix-Lerosey, I.] Inst Curie, INSERM, U830, Paris, France; [Laureys, G.] Ghent Univ Hosp, Dept Pediat Oncol, B-9000 Ghent, Belgium; [Powel, R.] PrimerDesign, Southampton, Hants, England; [Nittner, D.; Marine, J-C] VIB UGent, Lab Mol Canc Biol, Ghent, Belgium	Ghent University; Ghent University Hospital; Lund University; Lund University; University of Duisburg Essen; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; Ghent University; Ghent University Hospital; Flanders Institute for Biotechnology (VIB); Ghent University	Vandesompele, J (corresponding author), Ghent Univ Hosp, Ctr Med Genet, MRB, Pintelaan 185, B-9000 Ghent, East Flanders, Belgium.	Joke.Vandesompele@UGent.be	Janoueix-Lerosey, Isabelle/G-1758-2018; Marine, Jean Christophe/J-2237-2015; laureys, genevieve/AAG-2390-2021; Rihani, Ali/R-6608-2019; Schleiermacher, Gudrun/AAN-4711-2021; Schulte, Johannes H/G-3981-2010; Pattyn, Filip/A-4164-2015; Vandesompele, Jo/W-3411-2018; Ringnér, Markus/G-3641-2011; speleman, frank/AAR-5184-2020; De Preter, Katleen/I-7135-2013; Marine, Jean-Christophe/K-3292-2016; Menten, Björn/B-3072-2013; Schramm, Alexander/G-5688-2010	Janoueix-Lerosey, Isabelle/0000-0003-0434-3003; Rihani, Ali/0000-0002-6176-0519; Schleiermacher, Gudrun/0000-0002-0133-5879; Pattyn, Filip/0000-0003-0858-6651; Vandesompele, Jo/0000-0001-6274-0184; Ringnér, Markus/0000-0001-5469-8940; speleman, frank/0000-0002-6628-8559; De Preter, Katleen/0000-0002-7726-5096; Marine, Jean-Christophe/0000-0003-2433-9837; Schramm, Alexander/0000-0001-7670-7529; Schulte, Johannes Hubertus/0000-0003-0671-1201; Mestdagh, Pieter/0000-0001-7821-9684; Nittner, David/0000-0002-2939-2453	Gent University [BOF 01D31406, BOF 01F07207, BOF 01Z09407]; Belgian Kid's Fund; Fondation pour la recherche Nuovo-Soldati; RTICC/ISCIII [RD06/0020/0102]; American Cancer Association; Swedish Cancer Society; Fund for Scientific Research [G.0198.08, 31511809]; Belgian Foundation Against Cancer [SCIE2006-25]; Fund for Scientific Research-Flanders; Institute for the Promotion of Innovation by Science and Technology in Flanders [IWT - 081373]; European Community [037260, 201102]	Gent University; Belgian Kid's Fund; Fondation pour la recherche Nuovo-Soldati(Fondation pour la Recherche Medicale); RTICC/ISCIII(Instituto de Salud Carlos III); American Cancer Association; Swedish Cancer Society(Swedish Cancer Society); Fund for Scientific Research; Belgian Foundation Against Cancer; Fund for Scientific Research-Flanders(FWO); Institute for the Promotion of Innovation by Science and Technology in Flanders(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)); European Community(European Commission)	We are indebted to all the members of the SIOPEN and the GPOH for providing tumour samples or the clinical history of patients. This research was funded by the Gent University Research Fund (BOF 01D31406 to PM, BOF 01F07207 to FP, BOF 01Z09407 to J Vandesompele), the Belgian Kid's Fund and the Fondation pour la recherche Nuovo-Soldati (J Vermeulen), RD06/0020/0102 from RTICC/ISCIII to RN, the American Cancer Association to EF, the Swedish Cancer Society to MR, the Fund for Scientific Research (grant number: G.0198.08 and 31511809) and the Belgian Foundation Against Cancer, found of public interest (project SCIE2006-25). KDP is a postdoctoral researcher with the Fund for Scientific Research-Flanders. CK is supported by a doctoral grant from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT - 081373). We acknowledge the support of the European Community under the FP6 (project: STREP: EET-pipeline, number: 037260) and FP7 (ONCOMIRS, grant agreement number 201102). This publication reflects only authors' views; the commission is not liable for any use that may be made of the information herein. This article presents research results of the Belgian programme of Interuniversity Poles of Attraction, initiated by the Belgian State, Prime Minister's Office, Science Policy Programming.	Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bejerano G, 2004, SCIENCE, V304, P1321, DOI 10.1126/science.1098119; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Calin GA, 2007, CANCER CELL, V12, P215, DOI 10.1016/j.ccr.2007.07.027; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Corcoran DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005279; De Preter K, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-r84; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fredlund E, 2008, P NATL ACAD SCI USA, V105, P14094, DOI 10.1073/pnas.0804455105; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Lazcoz P, 2007, CANCER GENET CYTOGEN, V174, P1, DOI 10.1016/j.cancergencyto.2006.08.014; Lefever S, 2009, NUCLEIC ACIDS RES, V37, pD942, DOI 10.1093/nar/gkn777; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Mestdagh P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r64; Mestdagh P, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn725; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Pruitt KD, 2009, NUCLEIC ACIDS RES, V37, pD32, DOI 10.1093/nar/gkn721; Rozen S, 2000, Methods Mol Biol, V132, P365; Schulte JH, 2008, INT J CANCER, V122, P699, DOI 10.1002/ijc.23153; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Van Maerken T, 2006, CANCER RES, V66, P9646, DOI 10.1158/0008-5472.CAN-06-0792; Vandesompele J, 2005, J CLIN ONCOL, V23, P2280, DOI 10.1200/JCO.2005.06.104; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vermeulen J, 2009, LANCET ONCOL, V10, P663, DOI 10.1016/S1470-2045(09)70154-8; Zhao S, 2005, J COMPUT BIOL, V12, P1047, DOI 10.1089/cmb.2005.12.1047	32	109	118	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2010	29	24					3583	3592		10.1038/onc.2010.106	http://dx.doi.org/10.1038/onc.2010.106			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20383195				2022-12-17	WOS:000278835400013
J	Andrieu, C; Taieb, D; Baylot, V; Ettinger, S; Soubeyran, P; De-Thonel, A; Nelson, C; Garrido, C; So, A; Fazli, L; Bladou, F; Gleave, M; Iovanna, JL; Rocchi, P				Andrieu, C.; Taieb, D.; Baylot, V.; Ettinger, S.; Soubeyran, P.; De-Thonel, A.; Nelson, C.; Garrido, C.; So, A.; Fazli, L.; Bladou, F.; Gleave, M.; Iovanna, J. L.; Rocchi, P.			Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E	ONCOGENE			English	Article						prostate cancer; androgen independence; heat shock protein 27; eukaryotic translational initiation factor; ubiquitination	INITIATION-FACTOR 4E; INDEPENDENT PROGRESSION; PROTEASOMAL DEGRADATION; 4E-BINDING PROTEIN-1; LNCAP TUMORS; CYCLIN D1; TRANSLATION; GROWTH; HEAT-SHOCK-PROTEIN-27; APOPTOSIS	One strategy to improve therapies in advanced prostate cancer (PC) involves targeting genes that are activated by androgen withdrawal to delay the emergence of the androgen-independent (AI) phenotype. Heat shock protein 27 (Hsp27) expression becomes highly upregulated in PC cells after androgen withdrawal or chemotherapy, in which it functions as a cytoprotective chaperone to confer broadspectrum treatment resistance. The purpose of this study is to elucidate anti-apoptotic pathways regulated by Hsp27 that are activated during PC progression. Using two-hybrid experiment, we found that Hsp27 was having a major role in the protein translational initiation process. Furthermore, using complementary DNA (cDNA) microarray analysis, 4E binding protein 1 was identified as being proportionately and highly regulated by Hsp27. These data led us to analyze the protein synthesis initiation pathway, which is a prerequisite for cell growth and proliferation. Using northern and western blot analysis, we found that Hsp27 downregulation decreased eukaryotic translation initiation factor 4E (eIF4E) expression at the protein, but not mRNA, level. The cytoprotection afforded by Hsp27 overexpression was attenuated by eIF4E knockdown using specific eIF4E short interfering RNA (siRNA). Co-immunoprecipitation and co-immunofluorescence confirmed that Hsp27 colocalizes and interacts directly with eIF4E. Hsp27-eIF4E interaction decreases eIF4E ubiquitination and proteasomal degradation. By chaperoning eIF4E, Hsp27 seems to protect the protein synthesis initiation process to enhance cell survival during cell stress induced by castration or chemotherapy. Forced overexpression of eIF4E induces resistance to androgen-withdrawal and paclitaxel treatment in the prostate LNCaP cells in vitro. These findings identify Hsp27 as a modulator of eIF4E and establish a potential mechanism for the eIF4E-regulated apoptosis after androgen ablation and chemotherapy. Targeting Hsp27-eIF4E interaction may serve as a therapeutic target in advanced PC. Oncogene (2010) 29, 1883-1896; doi:10.1038/onc.2009.479; published online 18 January 2010	[Andrieu, C.; Taieb, D.; Baylot, V.; Soubeyran, P.; Iovanna, J. L.; Rocchi, P.] INSERM, Stress Cellulaire U624, F-13009 Marseille, France; [Andrieu, C.; Taieb, D.; Baylot, V.; Soubeyran, P.; Iovanna, J. L.; Rocchi, P.] Aix Marseille Univ, Marseille, France; [Ettinger, S.; Nelson, C.; So, A.; Fazli, L.; Gleave, M.] Vancouver Gen Hosp, Prostate Ctr, Vancouver, BC, Canada; [De-Thonel, A.; Garrido, C.] INSERM, U866, Fac Med, Dijon, France; [Bladou, F.] Hop St Marguerite, Serv Urol, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; University of British Columbia; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Rocchi, P (corresponding author), INSERM, U624, Prostate Canc Res Project, Parc Sci & Technol Luminy,163 Ave Luminy, F-13009 Marseille, Provence, France.	palma.rocchi@inserm.fr	Baylot, Virginie/AAR-1416-2021; Soubeyran, Philippe/P-1758-2018; Andrieu, Claudia/O-4432-2017; Taieb, Pr. David/M-5219-2017; Garrido, Carolina/GWM-5557-2022; Baylot, Virginie/HCI-7158-2022; Iovanna, Juan/M-9805-2017; Rocchi, Palma/P-5455-2014; Garrido, carmen/G-1633-2018	Baylot, Virginie/0000-0003-1313-2857; Iovanna, Juan/0000-0003-1822-2237; Rocchi, Palma/0000-0002-4383-4684; Garrido, carmen/0000-0003-1368-1493; de Thonel, Aurelie/0000-0003-0405-0745; Soubeyran, Philippe/0000-0002-5876-3217	l'Institut National de la Sante et de la Recherche Medicale ( INSERM); l'Association pour la Recherche sur le Cancer (ARC); l'Association pour la Recherche sur les Tumeurs de la Prostate (ARTP)	l'Institut National de la Sante et de la Recherche Medicale ( INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); l'Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); l'Association pour la Recherche sur les Tumeurs de la Prostate (ARTP)	We thank Dr Valentina Evdokimova (British Columbia Cancer Agency, Canada) for her helpful advice on eIF4E experiments. We thank Dr Takayuki Murata (McGill University, Canada) for providing the pcDNA3.1 FLAG-tagged eIF4E vectors. We thank Virginia Yago and Paul Jugpal (Prostate Centre, Canada) for their excellent technical assistance in animal and laboratory experimentation. We thank Dr Jonathan Nowak (Inserm U624, France) for his excellent help in confocal microscopy. This work was supported from grants by l'Institut National de la Sante et de la Recherche Medicale (INSERM), l'Association pour la Recherche sur le Cancer (ARC) and l'Association pour la Recherche sur les Tumeurs de la Prostate (ARTP).	Armengol G, 2007, CANCER RES, V67, P7551, DOI 10.1158/0008-5472.CAN-07-0881; Arora S, 2005, CANCER RES, V65, P3806, DOI 10.1158/0008-5472.CAN-04-4036; Averous J, 2006, ONCOGENE, V25, P6423, DOI 10.1038/sj.onc.1209887; Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Cornford PA, 2000, CANCER RES, V60, P7099; Frankfurt OS, 1997, CLIN CANCER RES, V3, P465; Fusi A, 2004, TUMORI J, V90, P535, DOI 10.1177/030089160409000601; Gallagher Eva, 2006, Clin J Oncol Nurs, V10, P233, DOI 10.1188/06.CJON.233-240; Garrido C, 2006, CELL CYCLE, V5, P2592, DOI 10.4161/cc.5.22.3448; Garrido C, 2003, CELL CYCLE, V2, P579, DOI 10.4161/cc.2.6.521; GLEAVE ME, 1992, CANCER RES, V52, P1598; Gleave ME, 1999, UROLOGY, V54, P36, DOI 10.1016/S0090-4295(99)00453-7; Graff JR, 2008, CANCER RES, V68, P631, DOI 10.1158/0008-5472.CAN-07-5635; Graff JR, 2009, CANCER RES, V69, P3866, DOI 10.1158/0008-5472.CAN-08-3472; Heesom KJ, 2001, CURR BIOL, V11, P1374, DOI 10.1016/S0960-9822(01)00422-5; HOTTE SJ, 2009, J CLIN ONCOL S, V27, pS15; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kamada M, 2007, MOL CANCER THER, V6, P299, DOI 10.1158/1535-7163.MCT-06-0417; Kiyama S, 2003, CANCER RES, V63, P3575; Liang JJN, 2000, FEBS LETT, V484, P98, DOI 10.1016/S0014-5793(00)02136-0; Lucas A, 2006, J UROLOGY, V176, pS72, DOI 10.1016/j.juro.2006.06.077; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Meli M, 2006, J MED CHEM, V49, P7721, DOI 10.1021/jm060836y; Miller H, 2005, ARTERIOSCL THROM VAS, V25, pE10, DOI 10.1161/01.ATV.0000156536.89752.8e; Mitchell BS, 2003, NEW ENGL J MED, V348, P2597, DOI 10.1056/NEJMp030092; Miyake H, 2000, CANCER RES, V60, P170; Miyake H, 2000, CANCER RES, V60, P3058; Murata T, 2006, J BIOL CHEM, V281, P20788, DOI 10.1074/jbc.M600563200; Oridate N, 2005, CANCER BIOL THER, V4, P318, DOI 10.4161/cbt.4.3.1504; Othumpangat S, 2005, J BIOL CHEM, V280, P25162, DOI 10.1074/jbc.M414303200; Parcellier A, 2003, MOL CELL BIOL, V23, P5790, DOI 10.1128/MCB.23.16.5790-5802.2003; Parcellier A, 2006, FASEB J, V20, P1179, DOI 10.1096/fj.05-4184fje; Petroulakis E, 2006, BRIT J CANCER, V94, P195, DOI 10.1038/sj.bjc.6602902; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Plescia J, 2005, CANCER CELL, V7, P457, DOI 10.1016/j.ccr.2005.03.035; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Rocchi P, 2005, CANCER RES, V65, P11083, DOI 10.1158/0008-5472.CAN-05-1840; Rocchi P, 2004, ONCOGENE, V23, P9111, DOI 10.1038/sj.onc.1208154; Rocchi P, 2004, CANCER RES, V64, P6595, DOI 10.1158/0008-5472.CAN-03-3998; Rocchi P, 2006, BJU INT, V98, P1082, DOI 10.1111/j.1464-410X.2006.06425.x; Rojo F, 2007, CLIN CANCER RES, V13, P81, DOI 10.1158/1078-0432.CCR-06-1560; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Topisirovic I, 2004, CANCER RES, V64, P8639, DOI 10.1158/0008-5472.CAN-04-2677; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369	48	109	117	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	13					1883	1896		10.1038/onc.2009.479	http://dx.doi.org/10.1038/onc.2009.479			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20101233				2022-12-17	WOS:000276199600002
J	Barsotti, AM; Prives, C				Barsotti, A. M.; Prives, C.			Pro-proliferative FoxM1 is a target of p53-mediated repression	ONCOGENE			English	Article						p53; FoxM1; transcriptional repression; p21; Rb; G2 arrest	M1 TRANSCRIPTION FACTOR; P53 TUMOR-SUPPRESSOR; MOUSE-LIVER REGENERATION; CELL-CYCLE PROGRESSION; WILD-TYPE P53; DNA-DAMAGE; DOWN-REGULATION; C-MYC; FUNCTIONAL DOMAINS; INDUCED SENESCENCE	The p53 tumor suppressor protein acts as a transcription factor to modulate cellular responses to a wide variety of stresses. In this study we show that p53 is required for the downregulation of FoxM1, an essential transcription factor that regulates many G2/M-specific genes and is overexpressed in a multitude of solid tumors. After DNA damage, p53 facilitates the repression of FoxM1 mRNA, which is accompanied by a decrease in FoxM1 protein levels. In cells with reduced p53 expression, FoxM1 is upregulated after DNA damage. Nutlin, a small-molecule activator of p53, suppresses FoxM1 levels in two cell lines in which DNA damage facilitates only mild repression. Mechanistically, p53-mediated inhibition of FoxM1 is partially p21 and retinoblastoma (Rb) family dependent, although in some cases p21-independent repression of FoxM1 was also observed. The importance of FoxM1 to cell fate was indicated by the observation that G2/M arrest follows FoxM1 ablation. Finally, our results indicate a potential contribution of p53-mediated repression of FoxM1 for maintenance of a stable G2 arrest. Oncogene (2009) 28, 4295-4305; doi: 10.1038/onc.2009.282; published online 14 September 2009	[Barsotti, A. M.; Prives, C.] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, 816 Fairchild, New York, NY 10027 USA.	clp3@columbia.edu			National Institutes of Health [CA77742]; NATIONAL CANCER INSTITUTE [R01CA077742] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Ella Freulich provided expert technical assistance. Members of the Prives laboratory are thanked for their support and encouragement. This work was supported by the National Institutes of Health Grant CA77742.	Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Bhonde MR, 2006, J BIOL CHEM, V281, P8675, DOI 10.1074/jbc.M511333200; Blanco-Bose WE, 2008, HEPATOLOGY, V48, P1302, DOI 10.1002/hep.22475; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan DW, 2008, J PATHOL, V215, P245, DOI 10.1002/path.2355; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Clair SS, 2006, CELL CYCLE, V5, P709, DOI 10.4161/cc.5.7.2628; Das S, 2008, CELL CYCLE, V7, P154, DOI 10.4161/cc.7.2.5236; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fu Z, 2008, NAT CELL BIOL, V10, P1076, DOI 10.1038/ncb1767; Giono LE, 2006, J CELL PHYSIOL, V209, P13, DOI 10.1002/jcp.20689; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Gottifredi V, 2001, MOL CELL BIOL, V21, P1066, DOI 10.1128/MCB.21.4.1066-1076.2001; Gridasova AA, 2005, MOL CELL BIOL, V25, P3247, DOI 10.1128/MCB.25.8.3247-3260.2005; Gusarova GA, 2007, J CLIN INVEST, V117, P99, DOI 10.1172/JCI27527; He XY, 2007, CANCER RES, V67, P11099, DOI 10.1158/0008-5472.CAN-07-2672; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Incassati A, 2006, ONCOGENE, V25, P2444, DOI 10.1038/sj.onc.1209276; Innocente SA, 2005, FEBS LETT, V579, P1001, DOI 10.1016/j.febslet.2004.12.073; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Jackson JG, 2006, MOL CELL BIOL, V26, P2501, DOI 10.1128/MCB.26.7.2501-2510.2006; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Kalin TV, 2006, CANCER RES, V66, P1712, DOI 10.1158/0008-5472.CAN-05-3138; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; KASTAN MB, 1991, CANCER RES, V51, P6304; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Kim IM, 2006, CANCER RES, V66, P2153, DOI 10.1158/0008-5472.CAN-05-3003; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; Krause K, 2001, BIOCHEM BIOPH RES CO, V284, P743, DOI 10.1006/bbrc.2001.5040; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Krupczak-Hollis K, 2004, DEV BIOL, V276, P74, DOI 10.1016/j.ydbio.2004.08.022; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Li SKM, 2008, J BIOL CHEM, V283, P16545, DOI 10.1074/jbc.M709604200; Linhart C, 2005, CELL CYCLE, V4, P1788, DOI 10.4161/cc.4.12.2173; Liu MG, 2006, CANCER RES, V66, P3593, DOI 10.1158/0008-5472.CAN-05-2912; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Park HJ, 2008, MOL CELL BIOL, V28, P5162, DOI 10.1128/MCB.00387-08; Penzo M, 2009, J CELL PHYSIOL, V218, P215, DOI 10.1002/jcp.21596; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Pilarsky C, 2004, NEOPLASIA, V6, P744, DOI 10.1593/neo.04277; Raj D, 2008, CARCINOGENESIS, V29, P194, DOI 10.1093/carcin/bgm219; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Robinson M, 2003, CANCER BIOL THER, V2, P406, DOI 10.4161/cbt.2.4.437; Sax JK, 2003, CANCER BIOL THER, V2, P416, DOI 10.4161/cbt.2.4.477; Shats I, 2004, J BIOL CHEM, V279, P50976, DOI 10.1074/jbc.M402502200; Spitkovsky D, 1997, CELL GROWTH DIFFER, V8, P699; Spurgers KB, 2006, J BIOL CHEM, V281, P25134, DOI 10.1074/jbc.M513901200; St Clair S, 2004, MOL CELL, V16, P725; Tan YJ, 2007, MOL CELL BIOL, V27, P1007, DOI 10.1128/MCB.01068-06; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Teh MT, 2002, CANCER RES, V62, P4773; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; WANG XD, 2005, J ORGAN DYSFUNCT, V1, P2; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; Wang ZW, 2007, CANCER RES, V67, P8293, DOI 10.1158/0008-5472.CAN-07-1265; Weymann A, 2009, HEPATOLOGY, V50, P207, DOI 10.1002/hep.22979; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059; Xia LM, 2009, J CELL BIOCHEM, V106, P247, DOI 10.1002/jcb.21996; Yi S, 2006, MOL CARCINOGEN, V45, P409, DOI 10.1002/mc.20231; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Yun JH, 2003, J BIOL CHEM, V278, P36966, DOI 10.1074/jbc.M305178200; Zeng JP, 2009, J PATHOL, V218, P419, DOI 10.1002/path.2530; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200	77	109	111	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2009	28	48					4295	4305		10.1038/onc.2009.282	http://dx.doi.org/10.1038/onc.2009.282			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DS	19749794	Green Accepted			2022-12-17	WOS:000272876300007
J	Bernardi, R; Papa, A; Pandolfi, PP				Bernardi, R.; Papa, A.; Pandolfi, P. P.			Regulation of apoptosis by PML and the PML-NBs	ONCOGENE			English	Review						apoptosis; PML nuclear bodies; tumor suppression; cancer; APL	PROMYELOCYTIC LEUKEMIA PROTEIN; FAS-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR PML; CELL-CYCLE ARREST; NUCLEAR-BODIES; DNA-DAMAGE; INTERACTING PROTEIN; RAR-ALPHA; CYTOPLASMIC PML; BINDING PROTEIN	The promyelocytic leukemia protein (PML) is a tumor suppressor identified in acute PML and implicated in the pathogenesis of a variety of tumors. PML is essential for the proper assembly of a nuclear macromolecular structure called the PML nuclear body (PML-NB). PML and PML-NBs are functionally promiscuous and have been associated with the regulation of several cellular functions. Above all these is the control of apoptosis, a function of PML whose physiological relevance is emphasized by in vivo studies that demonstrate that mice and cells lacking Pml are resistant to a vast variety of apoptotic stimuli. The function of PML in regulating apoptosis is not confined to a linear pathway; rather, PML works within a regulatory network that finely tunes various apoptotic pathways, depending on the cellular context and the apoptotic stimulus. Here, we will summarize earlier and recent advances on the molecular mechanisms by which PML regulates apoptosis and the implication of these findings for cancer pathogenesis.	[Bernardi, R.; Papa, A.; Pandolfi, P. P.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol & Med, Boston, MA 02115 USA; [Bernardi, R.; Papa, A.; Pandolfi, P. P.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Canc Genet Program, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Pandolfi, PP (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol & Med, New Res Bldg,330 Brookline Ave, Boston, MA 02115 USA.	ppandolf@bidmc.harvard.edu	bernardi, rosa/B-1650-2013	bernardi, rosa/0000-0002-3607-6336; Papa, Antonella/0000-0001-8653-7121	NCI	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank all past and present members of the Pandolfi lab at Memorial Sloan-Kettering Cancer Center and at Beth Israel Deaconess Medical Center for useful discussion and support. This work is supported by the NCI, through grants to PPP and RB.	Alsheich-Bartok O, 2008, ONCOGENE, V27, P3653, DOI 10.1038/sj.onc.1211036; Bellodi C, 2006, CELL CYCLE, V5, P2688, DOI 10.4161/cc.5.22.3504; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bernardi R, 2003, ONCOGENE, V22, P9048, DOI 10.1038/sj.onc.1207106; Bernardi R, 2007, NAT REV MOL CELL BIO, V8, P1006, DOI 10.1038/nrm2277; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Buschbeck M, 2007, ONCOGENE, V26, P3415, DOI 10.1038/sj.onc.1210128; Cao XF, 2008, MOL CANCER THER, V7, P923, DOI 10.1158/1535-7163.MCT-07-0540; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Chang HJ, 2007, PATHOL ONCOL RES, V13, P326, DOI 10.1007/BF02940312; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Cho YM, 1998, INT J MOL MED, V1, P717; Condemine W, 2006, CANCER RES, V66, P6192, DOI 10.1158/0008-5472.CAN-05-3792; Croxton R, 2006, CANCER RES, V66, P9026, DOI 10.1158/0008-5472.CAN-06-1047; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; DANIEL MT, 1993, BLOOD, V82, P1858; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Dellaire G, 2006, J CELL BIOL, V175, P55, DOI 10.1083/jcb.200604009; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Emelyanov AV, 2002, J BIOL CHEM, V277, P11156, DOI 10.1074/jbc.M111763200; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Fu CH, 2005, ONCOGENE, V24, P5401, DOI 10.1038/sj.onc.1208714; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Gurrieri C, 2004, BLOOD, V103, P2358, DOI 10.1182/blood-2003-07-2200; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hayakawa F, 2004, CANCER CELL, V5, P389, DOI 10.1016/S1535-6108(04)00082-0; Hayashi N, 2006, NEUROSCI LETT, V397, P5, DOI 10.1016/j.neulet.2005.11.057; Hofmann TG, 2003, CELL DEATH DIFFER, V10, P1290, DOI 10.1038/sj.cdd.4401313; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Komura N, 2007, EXP CELL RES, V313, P2753, DOI 10.1016/j.yexcr.2007.03.032; Krieghoff E, 2007, CELL CYCLE, V6, P771, DOI 10.4161/cc.6.7.4046; Kurki S, 2003, J CELL SCI, V116, P3917, DOI 10.1242/jcs.00714; Lackinger D, 2000, MUTAT RES-FUND MOL M, V457, P113, DOI 10.1016/S0027-5107(00)00133-0; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; McNally BA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002277; Meinecke I, 2007, P NATL ACAD SCI USA, V104, P5073, DOI 10.1073/pnas.0608773104; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Michaelson JS, 2003, J CELL SCI, V116, P345, DOI 10.1242/jcs.00234; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Milovic-Holm K, 2007, EMBO J, V26, P391, DOI 10.1038/sj.emboj.7601504; Moller A, 2003, CANCER RES, V63, P4310; Morgan M, 2002, J CELL BIOL, V157, P975, DOI 10.1083/jcb.200204039; Mu ZM, 1997, CARCINOGENESIS, V18, P2063, DOI 10.1093/carcin/18.11.2063; Mukhopadhyay D, 2006, J CELL BIOL, V174, P939, DOI 10.1083/jcb.200510103; Nadanaka S, 2007, MOL CELL BIOL, V27, P1027, DOI 10.1128/MCB.00408-06; Nguyen LA, 2005, BLOOD, V105, P292, DOI 10.1182/blood-2004-03-1185; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Petrie K, 2008, NAT CELL BIOL, V10, P507, DOI 10.1038/ncb0508-507; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Reineke EL, 2008, MOL CELL BIOL, V28, P997, DOI 10.1128/MCB.01848-07; Salomoni P, 2005, BLOOD, V105, P3686, DOI 10.1182/blood-2004-09-3782; Sanchez-Pulido L, 2007, TRENDS BIOCHEM SCI, V32, P400, DOI 10.1016/j.tibs.2007.08.001; Scaglioni PP, 2006, CELL, V126, P269, DOI 10.1016/j.cell.2006.05.041; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Seker H, 2003, ONCOGENE, V22, P1620, DOI 10.1038/sj.onc.1206140; Shen TH, 2006, MOL CELL, V24, P331, DOI 10.1016/j.molcel.2006.09.013; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; Stadler M, 1995, ONCOGENE, V11, P2565; Tagata Y, 2008, LEUKEMIA, V22, P273, DOI 10.1038/sj.leu.2405024; Takahashi Y, 2004, ONCOGENE, V23, P2819, DOI 10.1038/sj.onc.1207533; Tan JAT, 2008, J BIOL CHEM, V283, P18124, DOI 10.1074/jbc.M800512200; Tang J, 2005, CANCER BIOL THER, V4, P645, DOI 10.4161/cbt.4.6.1729; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wei XL, 2003, J BIOL CHEM, V278, P29288, DOI 10.1074/jbc.M212215200; Wu WS, 2003, J BIOL CHEM, V278, P12294, DOI 10.1074/jbc.M211849200; Yang ST, 2006, J BIOL CHEM, V281, P26645, DOI 10.1074/jbc.M604391200; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhu HY, 2003, J BIOL CHEM, V278, P49286, DOI 10.1074/jbc.M308302200	104	109	119	4	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	48					6299	6312		10.1038/onc.2008.305	http://dx.doi.org/10.1038/onc.2008.305			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	361YB	18931695				2022-12-17	WOS:000260162800010
J	Harada, H; Kizaka-Kondoh, S; Li, G; Itasaka, S; Shibuya, K; Inoue, M; Hiraoka, M				Harada, H.; Kizaka-Kondoh, S.; Li, G.; Itasaka, S.; Shibuya, K.; Inoue, M.; Hiraoka, M.			Significance of HIF-1-active cells in angiogenesis and radioresistance	ONCOGENE			English	Article						tumor hypoxia; angiogenesis; HIF-1; radiotherapy	UBIQUITIN-PROTEASOME PATHWAY; HYPOXIA-INDUCIBLE FACTOR-1; TUMOR-SUPPRESSOR PROTEIN; SELECTIVE CANCER-THERAPY; FACTOR 1-ALPHA; NECK-CANCER; TRANSCRIPTIONAL ACTIVATION; RADIATION ONCOLOGY; GROWTH; HEAD	Human solid tumors contain hypoxic regions that have considerably lower oxygen tension than the normal tissues. Hypoxia offers resistance to radiotherapy and anticancer chemotherapy, as well as predispose to increased tumor metastases. Furthermore, hypoxia induces hypoxia-inducible factor-1 (HIF-1), which in turn increases tumor angiogenesis. Thus, eradication of HIF-1-active/hypoxic tumor cells is very important for cancer therapy. We have previously reported that procaspase-3 fused with a von Hippel-Lindau (VHL)-mediated protein destruction motif of alpha subunit of HIF-1 (HIF-1 alpha) containing Pro564, named TAT-ODD-procaspase-3 (TOP3), specifically induced cell death to hypoxic cells in vivo as well as in vitro. We now report that TOP3 also eradicates the radiation-induced HIF-1-active tumor cells. HIF-1 activity in the xenografts of human tumor cells, which express luciferase under the transcriptional control of HIF-1, were monitored and quantified daily with an in vivo bioluminescence photon-counting device. HIF-1 activity in tumors was more rapidly increased by ionizing radiation (IR) compared to untreated tumors. TOP3 efficiently decreased the HIF-1-activity in irradiated tumors as well as unirradiated ones, indicating TOP3 eradicated tumor cells with HIF-1-activity induced by IR as well as hypoxia. Eradication of HIF-1-active/hypoxic cells in the xenografts during irradiation exhibited significant suppression in angiogenesis and strong enhancement in a long-term growth suppression of tumor xenografts. These results further strengthen the argument that HIF-1-active/hypoxic cells play crucial roles in angiogenesis and radioresistance.	Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Appl Therapy, Kyoto 6068507, Japan; Kyoto Univ, Nano Med Merger Educ Unit, Kyoto, Japan; Kyoto Univ, Grad Sch Med, COE Format Genom Anal Dis Model Anim Multiple Gen, Kyoto, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Dept Biochem, Osaka, Japan	Kyoto University; Kyoto University; Kyoto University; Osaka Medical Center for Cancer & Cardiovascular Diseases	Kizaka-Kondoh, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Appl Therapy, 54 Kawahara-cho, Kyoto 6068507, Japan.	skondoh@kuhp.kyoto-u.ac.jp	Kondoh, Shinae/AAF-8745-2020; Kondoh, Shinae/C-6937-2015	Kondoh, Shinae/0000-0003-3085-5782; Kondoh, Shinae/0000-0003-3085-5782				Abdollahi A, 2003, CANCER RES, V63, P3755; Brown JM, 1999, CANCER RES, V59, P5863; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; de Candia P, 2003, P NATL ACAD SCI USA, V100, P12337, DOI 10.1073/pnas.2031337100; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Geng L, 2001, CANCER RES, V61, P2413; Gorski DH, 1999, CANCER RES, V59, P3374; Harada H, 2002, CANCER RES, V62, P2013; Harada H, 2005, MOL IMAGING, V4, P182; Harada H, 2006, FEBS LETT, V580, P5718, DOI 10.1016/j.febslet.2006.09.025; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HOCKEL M, 1993, RADIOTHER ONCOL, V26, P45, DOI 10.1016/0167-8140(93)90025-4; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Inoue M, 2004, INT J ONCOL, V25, P713; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kizaka-Kondoh S, 2003, CANCER SCI, V94, P1021, DOI 10.1111/j.1349-7006.2003.tb01395.x; Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1; Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Overgaard J, 2005, LANCET ONCOL, V6, P757, DOI 10.1016/S1470-2045(05)70292-8; Raleigh JA, 1998, CANCER RES, V58, P3765; Rapisarda A, 2002, CANCER RES, V62, P4316; Rischin D, 2005, J CLIN ONCOL, V23, P79, DOI 10.1200/JCO.2005.01.072; Rowinsky EK, 1999, ONCOLOGY-NY, V13, P61; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sobhanifar S, 2005, CANCER RES, V65, P7259, DOI 10.1158/0008-5472.CAN-04-4480; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Vaupel P, 2004, SEMIN RADIAT ONCOL, V14, P198, DOI 10.1016/j.semradonc.2004.04.008; VAUPEL P, 1989, CANCER RES, V49, P6449; Welsh SJ, 2003, MOL CANCER THER, V2, P235; Yeo EJ, 2003, J NATL CANCER I, V95, P516, DOI 10.1093/jnci/95.7.516; Zackrisson B, 2003, ACTA ONCOL, V42, P443, DOI 10.1080/02841860310014886	38	109	112	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7508	7516		10.1038/sj.onc.1210556	http://dx.doi.org/10.1038/sj.onc.1210556			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17563752				2022-12-17	WOS:000251282100002
J	Kluiver, J; van den Berg, A; de Jong, D; Blokzijl, T; Harms, G; Bouwman, E; Jacobs, S; Poppema, S; Kroesen, BJ				Kluiver, J.; van den Berg, A.; de Jong, D.; Blokzijl, T.; Harms, G.; Bouwman, E.; Jacobs, S.; Poppema, S.; Kroesen, B-J			Regulation of pri-microRNA BIC transcription and processing in Burkitt lymphoma	ONCOGENE			English	Article						BIC; microRNA-155; Burkitt lymphoma; microRNA processing; B-cell receptor; ADAR	VIRUS-INDUCED LYMPHOMAS; B-CELL LYMPHOMAS; HIGH EXPRESSION; RNA; MIR-155; IDENTIFICATION; MODULATION; ONCOGENES; PRECURSOR; COMPLEX	BIC is a primary microRNA (pri-miR-155) that can be processed to mature miR-155. In this study, we show the crucial involvement of protein kinase C (PKC) and nuclear factor-kappa B (NF-kappa B) in the regulation of BIC expression upon B-cell receptor triggering. Surprisingly, Northern blot analysis did not reveal any miR-155 expression upon induction of BIC expression in the Burkitt lymphoma-derived Ramos cell line, whereas other microRNAs were clearly detectable. Ectopic expression of BIC in Ramos and HEK293 cells resulted in miR-155 expression in HEK293, but not in Ramos cells, suggesting a specific block of BIC to miR-155 processing in Ramos. In line with the results obtained with Ramos, lack of miR-155 expression after induction of BIC expression was also observed in other Burkitt lymphoma cell lines, indicating a generic and specific blockade in the processing of BIC in Burkitt lymphoma. In contrast, induction of BIC expression in normal tonsillar B cells resulted in very high levels of miR-155 expression and induction of BIC expression in Hodgkin's lymphoma cell lines. It also resulted in elevated levels of miR-155. Our data provide evidence for two levels of regulation for mature miR-155 expression: one at the transcriptional level involving PKC and NF-kappa B, and one at the processing level. Burkitt lymphoma cells not only express low levels of BIC, but also prevent processing of BIC via an, as yet, unknown mechanism.	Univ Groningen, Med Ctr, Dept Pathol & Lab Med, Sect Med Biol, NL-9713 GZ Groningen, Netherlands; Univ Groningen, Med Ctr, Dept Pathol & Lab Med, Sect Pathol, NL-9713 GZ Groningen, Netherlands	University of Groningen; University of Groningen	Kroesen, BJ (corresponding author), Univ Groningen, Med Ctr, Dept Pathol & Lab Med, Sect Med Biol, Hanzeplein 1, NL-9713 GZ Groningen, Netherlands.	b.j.kroesen@med.umcg.nl	van den Berg, Anke/H-1718-2011; Poppema, Sibrand/D-1204-2012; Jones, Jeffrey A/E-9827-2013; Kluiver, Joost/G-6406-2014	van den Berg, Anke/0000-0002-8894-2638; Kluiver, Joost/0000-0001-7650-2937				Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; CLURMAN BE, 1989, MOL CELL BIOL, V9, P2657, DOI 10.1128/MCB.9.6.2657; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Haasch D, 2002, CELL IMMUNOL, V217, P78, DOI 10.1016/S0008-8749(02)00506-3; Hammond SM, 2006, CURR OPIN GENET DEV, V16, P4, DOI 10.1016/j.gde.2005.12.005; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Jiang JM, 2006, GENE CHROMOSOME CANC, V45, P103, DOI 10.1002/gcc.20264; Kluiver J, 2006, GENE CHROMOSOME CANC, V45, P147, DOI 10.1002/gcc.20273; Kluiver J, 2005, J PATHOL, V207, P243, DOI 10.1002/path.1825; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Luciano DJ, 2004, RNA, V10, P1174, DOI 10.1261/rna.7350304; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; Obernosterer G, 2006, RNA, V12, P1161, DOI 10.1261/rna.2322506; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Ramkissoon SH, 2006, LEUKEMIA RES, V30, P643, DOI 10.1016/j.leukres.2005.09.001; Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367; Specht K, 2001, AM J PATHOL, V158, P419, DOI 10.1016/S0002-9440(10)63985-5; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; Tam W, 2002, J VIROL, V76, P4275, DOI 10.1128/JVI.76.9.4275-4286.2002; van den Berg A, 2003, GENE CHROMOSOME CANC, V37, P20, DOI 10.1002/gcc.10186; Yang WD, 2006, NAT STRUCT MOL BIOL, V13, P13, DOI 10.1038/nsmb1041; Zeng Y, 2005, J BIOL CHEM, V280, P27595, DOI 10.1074/jbc.M504714200	30	109	130	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2007	26	26					3769	3776		10.1038/sj.onc.1210147	http://dx.doi.org/10.1038/sj.onc.1210147			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17173072				2022-12-17	WOS:000247026400001
J	Basaki, Y; Hosoi, F; Oda, Y; Fotovati, A; Maruyama, Y; Oie, S; Ono, M; Izumi, H; Kohno, K; Sakai, K; Shimoyama, T; Nishio, K; Kuwano, M				Basaki, Y.; Hosoi, F.; Oda, Y.; Fotovati, A.; Maruyama, Y.; Oie, S.; Ono, M.; Izumi, H.; Kohno, K.; Sakai, K.; Shimoyama, T.; Nishio, K.; Kuwano, M.			Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells	ONCOGENE			English	Article						Akt; microarray; ovarian carcinoma; Y-box-binding protein-1	TRANSCRIPTION FACTOR YB-1; CHEMOKINE RECEPTORS; PROGNOSTIC-FACTOR; GENE-EXPRESSION; MESSENGER-RNA; TUMOR-GROWTH; DNA; CXCR4; INVOLVEMENT; INHIBITOR	Y-box-binding protein 1 (YB-1), which is a member of the DNA-binding protein family containing a cold-shock domain, has pleiotropic functions in response to various environmental stimuli. As we previously showed that YB-1 is a global marker of multidrug resistance in ovarian cancer and other tumor types. To identify YB-1-regulated genes in ovarian cancers, we investigated the expression profile of YB-1 small-interfering RNA (siRNA)-transfected ovarian cancer cells using a high-density oligonucleotide array. YB-1 knockdown by siRNA upregulated 344 genes, including MDR1, thymidylate synthetase, S100 calcium binding protein and cyclin B, and downregulated 534 genes, including CXCR4, N-myc downstream regulated gene 1, E-cadherin and phospholipase C. Exogenous serum addition stimulated YB-1 translocation from the cytoplasm to the nucleus, and treatment with Akt inhibitors as well as Akt siRNA and integrin-linked kinase (ILK) siRNA specifically blocked YB-1 nuclear localization. Inhibition of Akt activation downregulated CXCR4 and upregulated MDR1 (ABCB1) gene expression. Administration of Akt inhibitor resulted in decrease in nuclear YB-1-positive cancer cells in a xenograft animal model. Akt activation thus regulates the nuclear translocation of YB-1, affecting the expression of drug-resistance genes and other genes associated with the malignant characteristics in ovarian cancer cells. Therefore, the Akt pathway could be a novel target of disrupting the nuclear translocation of YB-1 that has important implications for further development of therapeutic strategy against ovarian cancers.	Kyushu Univ, Stn Collaborat Res 2, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Pathol Anat, Fukuoka 8128582, Japan; Kurume Univ, Res Ctr Innovat Canc Therapy, Kurume, Fukuoka 830, Japan; Univ Occupat & Environm Hlth, Dept Mol Biol, Kitakyushu, Fukuoka 807, Japan; Natl Canc Ctr, Res Inst, Div Pharmacol, Tokyo 104, Japan	Kyushu University; Kyushu University; Kurume University; University of Occupational & Environmental Health - Japan; National Cancer Center - Japan	Basaki, Y (corresponding author), Kyushu Univ, Stn Collaborat Res 2, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yubasaki@yahoo.co.jp						Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; Ashizuka M, 2002, MOL CELL BIOL, V22, P6375, DOI 10.1128/MCB.22.18.6375-6383.2002; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Caruz A, 1998, FEBS LETT, V426, P271, DOI 10.1016/S0014-5793(98)00359-7; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Darash-Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03-0935fje; Dooley S, 2006, J BIOL CHEM, V281, P1784, DOI 10.1074/jbc.M510215200; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; En-Nia A, 2005, J BIOL CHEM, V280, P7702, DOI 10.1074/jbc.M413353200; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; Fukuda T, 2004, NUCLEIC ACIDS RES, V32, P611, DOI 10.1093/nar/gkh223; Furukawa M, 1998, J BIOL CHEM, V273, P10550, DOI 10.1074/jbc.273.17.10550; Holm PS, 2002, J BIOL CHEM, V277, P10427, DOI 10.1074/jbc.M106955200; Hu LM, 2000, CLIN CANCER RES, V6, P880; Huang Jing, 2004, Human Genomics, V1, P287; Ise T, 1999, CANCER RES, V59, P342; Jiang YP, 2006, GYNECOL ONCOL, V103, P226, DOI 10.1016/j.ygyno.2006.02.036; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Kaneko Y, 2004, J CELL SCI, V117, P407, DOI 10.1242/jcs.00871; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Kryczek I, 2005, CANCER RES, V65, P465; Kuwano M, 2004, MOL CANCER THER, V3, P1485; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; Maruyama Y, 2006, CANCER RES, V66, P6233, DOI 10.1158/0008-5472.CAN-06-0183; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Mossink MH, 2003, ONCOGENE, V22, P7458, DOI 10.1038/sj.onc.1206947; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami T, 2002, CANCER RES, V62, P7328; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Porcile C, 2005, EXP CELL RES, V308, P241, DOI 10.1016/j.yexcr.2005.04.024; Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200; Scotton CJ, 2001, CANCER RES, V61, P4961; Scotton CJ, 2002, CANCER RES, V62, P5930; Sorokin AV, 2005, EMBO J, V24, P3602, DOI 10.1038/sj.emboj.7600830; Stein U, 2005, ONCOGENE, V24, P3606, DOI 10.1038/sj.onc.1208386; Stein U, 2001, J BIOL CHEM, V276, P28562, DOI 10.1074/jbc.M100311200; Stenina OI, 2000, J CLIN INVEST, V106, P579, DOI 10.1172/JCI9075; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590	42	109	118	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2736	2746		10.1038/sj.onc.1210084	http://dx.doi.org/10.1038/sj.onc.1210084			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17072343				2022-12-17	WOS:000246210600008
J	Du, W; Pogoriler, J				Du, W.; Pogoriler, J.			Retinoblastoma family genes	ONCOGENE			English	Review						Rb; E2F; development; tumorigenesis cell; proliferation and differentiation	E2F TARGET GENES; DEPENDENT KINASE INHIBITOR; TRANSCRIPTION FACTOR E2F; CELL-CYCLE PROGRESSION; RB MUTANT MICE; S-PHASE ENTRY; IN-VIVO; DROSOPHILA EMBRYOGENESIS; TUMOR-SUPPRESSOR; DNA-REPLICATION	The retinoblastoma gene Rb was the first tumor suppressor gene cloned, and it is well known as a negative regulator of the cell cycle through its ability to bind the transcription factor E2F and repress transcription of genes required for S phase. Although over 100 other proteins have been reported to interact with Rb, in most cases these interactions are much less well characterized. Therefore, this review will primarily focus on Rb and E2F interactions. In addition to cell cycle regulation, studies of Rb and E2F proteins in animal models have revealed important roles for these proteins in apoptosis and differentiation. Recent screens of Rb/E2F target genes have identified new targets in all these areas. In addition, the mechanisms determining how different subsets of target genes are regulated under different conditions have only begun to be addressed and offer exciting possibilities for future research.	Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Univ Chicago, Ctr Mol Oncol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Du, W (corresponding author), Univ Chicago, Ben May Inst Canc Res, 904 E 57th St, Chicago, IL 60637 USA.	wdu@huggins.bsd.uchicago.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074197] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM074197] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apostolova MD, 2002, J BIOL CHEM, V277, P34471, DOI 10.1074/jbc.M205827200; Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; Attwooll C, 2005, J BIOL CHEM, V280, P1199, DOI 10.1074/jbc.M412509200; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Bosco G, 2001, NAT CELL BIOL, V3, P289, DOI 10.1038/35060086; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200; Cayirlioglu P, 2001, DEVELOPMENT, V128, P5085; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cloud JE, 2002, MOL CELL BIOL, V22, P2663, DOI 10.1128/MCB.22.8.2663-2672.2002; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Dannenberg JH, 2004, GENE DEV, V18, P2952, DOI 10.1101/gad.322004; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dimova DK, 2003, GENE DEV, V17, P2308, DOI 10.1101/gad.1116703; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; Du W, 1999, EMBO J, V18, P916, DOI 10.1093/emboj/18.4.916; Du W, 2000, DEVELOPMENT, V127, P367; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Duronio RJ, 1998, MOL CELL BIOL, V18, P141, DOI 10.1128/MCB.18.1.141; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Firth LC, 2005, DEV CELL, V8, P541, DOI 10.1016/j.devcel.2005.01.017; Follette PJ, 1998, CURR BIOL, V8, P235, DOI 10.1016/S0960-9822(98)70089-2; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Frolov MV, 2003, GENE DEV, V17, P723, DOI 10.1101/gad.1031803; Frolov MV, 2001, GENE DEV, V15, P2146, DOI 10.1101/gad.903901; Gaubatz S, 2001, MOL CELL BIOL, V21, P1384, DOI 10.1128/MCB.21.4.1384-1392.2001; Giangrande PH, 2003, MOL CELL BIOL, V23, P3707, DOI 10.1128/MCB.23.11.3707-3720.2003; Giangrande PH, 2004, EMBO J, V23, P1336, DOI 10.1038/sj.emboj.7600134; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Iavarone A, 2004, NATURE, V432, P1040, DOI 10.1038/nature03068; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jost CA, 1996, VIROLOGY, V220, P78, DOI 10.1006/viro.1996.0288; Kang H, 2004, MOL CELL BIOL, V24, P1188, DOI 10.1128/MCB.24.3.1188-1199.2004; KATO J, 1993, GENE DEV, V7, P331; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Korenjak M, 2004, CELL, V119, P181, DOI 10.1016/j.cell.2004.09.034; Landsberg RL, 2003, P NATL ACAD SCI USA, V100, P2456, DOI 10.1073/pnas.0138064100; Lane ME, 1996, CELL, V87, P1225, DOI 10.1016/S0092-8674(00)81818-8; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 2005, MOL CELL BIOL, V25, P3563, DOI 10.1128/MCB.25.9.3563-3574.2005; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; Liu DX, 2005, GENE DEV, V19, P719, DOI 10.1101/gad.1296405; MacLellan WR, 2000, MOL CELL BIOL, V20, P8903, DOI 10.1128/MCB.20.23.8903-8915.2000; Maiti B, 2005, J BIOL CHEM, V280, P18211, DOI 10.1074/jbc.M501410200; Masselli A, 2006, ONCOGENE, V25, P1290, DOI 10.1038/sj.onc.1209161; Miyake S, 2000, MOL CELL BIOL, V20, P8889, DOI 10.1128/MCB.20.23.8889-8902.2000; Moon NS, 2005, DEV CELL, V9, P463, DOI 10.1016/j.devcel.2005.08.015; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Muller H, 1997, MOL CELL BIOL, V17, P5508; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Mundle SD, 2003, FASEB J, V17, P569, DOI 10.1096/fj.02-0431rev; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Nguyen DX, 2005, J CELL BIOCHEM, V94, P870, DOI 10.1002/jcb.20375; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Royzman I, 1999, GENE DEV, V13, P827, DOI 10.1101/gad.13.7.827; Royzman I, 1997, GENE DEV, V11, P1999, DOI 10.1101/gad.11.15.1999; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; Sage C, 2005, SCIENCE, V307, P1114, DOI 10.1126/science.1106642; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sawado T, 1998, BIOCHEM BIOPH RES CO, V251, P409, DOI 10.1006/bbrc.1998.9407; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Spike BT, 2004, EMBO J, V23, P4319, DOI 10.1038/sj.emboj.7600432; Stevaux O, 2005, CELL CYCLE, V4, P1272, DOI 10.4161/cc.4.9.1982; Stevaux O, 2002, EMBO J, V21, P4927, DOI 10.1093/emboj/cdf501; Takahashi Y, 2000, GENE DEV, V14, P804; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; Weng L, 2003, EMBO J, V22, P3865, DOI 10.1093/emboj/cdg373; Wikenheiser-Brokamp KA, 2004, DEVELOPMENT, V131, P4299, DOI 10.1242/dev.01232; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Young AP, 2004, ONCOGENE, V23, P814, DOI 10.1038/sj.onc.1207187; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666; Zhou L, 2003, DEV CELL, V4, P599, DOI 10.1016/S1534-5807(03)00085-6; Zhu JW, 2001, MOL CELL BIOL, V21, P8547, DOI 10.1128/MCB.21.24.8547-8564.2001; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; Ziebold U, 2003, MOL CELL BIOL, V23, P6542, DOI 10.1128/MCB.23.18.6542-6552.2003; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	118	109	118	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5190	5200		10.1038/sj.onc.1209651	http://dx.doi.org/10.1038/sj.onc.1209651			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936737	Green Accepted			2022-12-17	WOS:000240064100002
J	Tsutsumi, S; Namba, T; Tanaka, KI; Arai, Y; Ishihara, T; Aburaya, M; Mima, S; Hoshino, T; Mizushima, T				Tsutsumi, S; Namba, T; Tanaka, KI; Arai, Y; Ishihara, T; Aburaya, M; Mima, S; Hoshino, T; Mizushima, T			Celecoxib upregulates endoplasmic reticulum chaperones that inhibit celecoxib-induced apoptosis in human gastric cells	ONCOGENE			English	Article						celecoxib; endoplasmic reticulum chaperones; apoptosis; calcium	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; UNFOLDED-PROTEIN RESPONSE; STRESS-RESPONSE; CANCER CELLS; ER STRESS; MUCOSAL CELLS; CYCLOOXYGENASE-2 INHIBITOR; INTRACELLULAR CALCIUM; PROSTAGLANDIN E-2; GENE-EXPRESSION	Nonsteroidal anti-inflammatory drugs (NSAIDs) induce apoptosis in cancer cells and this effect is involved in their antitumor activity. We recently demonstrated that NSAIDs upregulate GRP78, an endoplasmic reticulum ( ER) chaperone, in gastric mucosal cells in primary culture. In the present study, induction of ER chaperones by NSAIDs and the effect of those chaperones on NSAID-induced apoptosis were examined in human gastric carcinoma cells. Celecoxib, an NSAID, upregulated ER chaperones ( GRP78 and its cochaperones ERdj3 and ERdj4) but also C/EBP homologous transcription factor ( CHOP), a transcription factor involved in apoptosis. Celecoxib also upregulated GRP78 in xenograft tumors, accompanying with the suppression of tumor growth in nude mice. Celecoxib caused phosphorylation of eukaryotic translation initiation factor 2 kinase ( PERK) and eukaryotic initiation factor-2 alpha (eIF2a) and production of activating transcription factor (ATF)4 mRNA. Suppression of ATF4 expression by small interfering RNA ( siRNA) partially inhibited the celecoxib-dependent upregulation of GRP78. Celecoxib increased the intracellular Ca2+ concentration, while 1,2-bis(2-aminophenoxy) ethane-N,N,N'N'-tetraacetic acid, an intracellular Ca2+ chelator, inhibited the upregulation of GRP78 and ATF4. These results suggest that the Ca2+- dependent activation of the PERK-eIF2 alpha-ATF4 pathway is involved in the upregulation of ER chaperones by celecoxib. Overexpression of GRP78 partially suppressed the apoptosis and induction of CHOP in the presence of celecoxib and this suppression was stimulated by coexpression of either ERdj3 or ERdj4. On the other hand, suppression of GRP78 expression by siRNA drastically stimulated cellular apoptosis and production of CHOP in the presence of celecoxib. These results show that upregulation of ER chaperones by celecoxib protects cancer cells from celecoxib-induced apoptosis, thus may decrease the potential antitumor activity of celecoxib.	Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Kumamoto 8620973, Japan	Kumamoto University	Mizushima, T (corresponding author), Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, 5-1,Oehonmachi, Kumamoto 8620973, Japan.	mizu@gpo.kumamoto-u.ac.jp	Tanaka, Ken-ichiro/J-8557-2013					Ben-Chetrit E, 2005, RHEUMATOL INT, V25, P332, DOI 10.1007/s00296-004-0442-4; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bush KT, 1997, J BIOL CHEM, V272, P9086; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; Dong DZ, 2005, CANCER RES, V65, P5785, DOI 10.1158/0008-5472.CAN-05-0754; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Fan XM, 2001, J GASTROEN HEPATOL, V16, P1098, DOI 10.1046/j.1440-1746.2001.02593.x; Farrow DC, 1998, CANCER EPIDEM BIOMAR, V7, P97; Fernandez PM, 2000, BREAST CANCER RES TR, V59, P15, DOI 10.1023/A:1006332011207; Gotoh T, 2001, CELL DEATH DIFFER, V8, P357, DOI 10.1038/sj.cdd.4400829; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hong M, 2004, J CELL BIOCHEM, V92, P723, DOI 10.1002/jcb.20118; Hoshino T, 2003, J BIOL CHEM, V278, P12752, DOI 10.1074/jbc.M212097200; Hu PJ, 2004, GUT, V53, P195, DOI 10.1136/gut.2003.021477; Huang YC, 2002, MOL PHARMACOL, V62, P1515, DOI 10.1124/mol.62.6.1515; Huo R, 2004, CELL TISSUE RES, V316, P359, DOI 10.1007/s00441-004-0885-7; Husain SS, 2002, AM J GASTROENTEROL, V97, P542; Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Johnson AJ, 2002, BIOCHEM J, V366, P831, DOI 10.1042/BJ20020279; KAO JPY, 1989, J BIOL CHEM, V264, P8179; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kawai S, 1998, EUR J PHARMACOL, V347, P87, DOI 10.1016/S0014-2999(98)00078-8; Kismet K, 2004, CANCER DETECT PREV, V28, P127, DOI 10.1016/j.cdp.2003.12.005; Koki Alane T, 2002, Cancer Control, V9, P28; Koomagi R, 1999, ANTICANCER RES, V19, P4333; Kulp SK, 2004, CANCER RES, V64, P1444, DOI 10.1158/0008-5472.CAN-03-2396; Kurisu J, 2003, GENES CELLS, V8, P189, DOI 10.1046/j.1365-2443.2003.00625.x; Landry SJ, 2003, BIOCHEMISTRY-US, V42, P4926, DOI 10.1021/bi027070y; Leahy KM, 2002, CANCER RES, V62, P625; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Lim JW, 2001, LAB INVEST, V81, P349, DOI 10.1038/labinvest.3780243; Lopez-Parra M, 2005, J HEPATOL, V42, P75, DOI 10.1016/j.jhep.2004.09.011; Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200; Mima S, 2005, CANCER RES, V65, P1868, DOI 10.1158/0008-5472.CAN-04-2770; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Okada K, 2000, CANCER GENET CYTOGEN, V118, P99, DOI 10.1016/S0165-4608(99)00182-X; Patel MI, 2005, CLIN CANCER RES, V11, P1999, DOI 10.1158/1078-0432.CCR-04-1877; PIAZZA GA, 1995, CANCER RES, V55, P3110; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Riendeau D, 1997, CAN J PHYSIOL PHARM, V75, P1088, DOI 10.1139/cjpp-75-9-1088; Ristimaki A, 1997, CANCER RES, V57, P1276; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Roybal CN, 2004, J BIOL CHEM, V279, P14844, DOI 10.1074/jbc.M312948200; Schroeder CR, 2004, CANCER BIOL THER, V3, P847, DOI 10.4161/cbt.3.9.1037; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shen Y, 2002, J BIOL CHEM, V277, P15947, DOI 10.1074/jbc.M112214200; SMALLEY WE, 1995, AM J EPIDEMIOL, V141, P539, DOI 10.1093/oxfordjournals.aje.a117469; Song MS, 2001, CANCER RES, V61, P8322; Sorensen HT, 2003, BRIT J CANCER, V88, P1687, DOI 10.1038/sj.bjc.6600945; Tanaka K, 2005, J BIOL CHEM, V280, P31059, DOI 10.1074/jbc.M502956200; Tomisato W, 2004, BIOCHEM BIOPH RES CO, V323, P1032, DOI 10.1016/j.bbrc.2004.08.205; Tomisato W, 2004, BIOCHEM PHARMACOL, V67, P575, DOI 10.1016/j.bcp.2003.09.020; Tomisato W, 2001, AM J PHYSIOL-GASTR L, V281, pG1092, DOI 10.1152/ajpgi.2001.281.4.G1092; Tsutsumi S, 2004, CELL DEATH DIFFER, V11, P1009, DOI 10.1038/sj.cdd.4401436; Tsutsumi S, 2002, BBA-MOL CELL RES, V1589, P168, DOI 10.1016/S0167-4889(02)00171-4; Wang JL, 2004, BIOCHEM PHARMACOL, V67, P1123, DOI 10.1016/j.bcp.2003.11.004; Williams CS, 2000, CANCER RES, V60, P6045; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; Xu WM, 2004, NAT CELL BIOL, V6, P1129, DOI 10.1038/ncb1188; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yu M, 2000, J BIOL CHEM, V275, P24984, DOI 10.1074/jbc.M000739200; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451; Zweifel BS, 2002, CANCER RES, V62, P6706	68	109	117	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1018	1029		10.1038/sj.onc.1209139	http://dx.doi.org/10.1038/sj.onc.1209139			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16205636				2022-12-17	WOS:000235361000007
J	Wasch, R; Engelbert, D				Wasch, R; Engelbert, D			Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells	ONCOGENE			English	Review						anaphase-promoting complex; proteolysis; cell cycle control; genomic instability	SISTER-CHROMATID SEPARATION; SPINDLE ASSEMBLY CHECKPOINT; CHRONIC MYELOID-LEUKEMIA; XENOPUS EGG EXTRACTS; ABL TYROSINE KINASE; HUMAN LUNG CANCERS; B-TYPE CYCLINS; UBIQUITIN LIGASE; AURORA-A; BREAST-CANCER	Genomic instability can be found in most cancer cells. Cell proliferation is under tight control to ensure accurate DNA replication and chromosome segregation. Cyclin-dependent kinases (Cdks) and their activating subunits, the cyclins, are the driving forces of the cell division cycle. Regulation of cyclin oscillation by ubiquitin-dependent proteolysis thereby has a central role in cell cycle regulation. The anaphase-promoting complex (APC) is a specific ubiquitin ligase and is essential for chromosome segregation, exit from mitosis and a stable subsequent G1 phase allowing cell differentiation or accurate DNA replication in the following S phase. The APC is activated by the regulatory subunits Cdc20 (APC(Cdc20)) and Cdh1 (APC(Cdh1)) to target securin, mitotic cyclins and other cell cycle regulatory proteins for proteasomal degradation. This review is focused on the role of APC-dependent proteolysis in cell cycle regulation and how its deregulation may lead to genomic instability of cancer cells.	Univ Freiburg, Med Ctr, Dept Hematol & Oncol, D-79106 Freiburg, Germany	University of Freiburg	Wasch, R (corresponding author), Univ Freiburg, Med Ctr, Dept Hematol & Oncol, Hugstetter Str 55, D-79106 Freiburg, Germany.	waesch@mm11.ukl.uni-freiburg.de	Waesch, Ralph/F-6282-2019					Adams J, 2002, CURR OPIN ONCOL, V14, P628, DOI 10.1097/00001622-200211000-00007; Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj.leu.2402417; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bardin AJ, 2001, NAT REV MOL CELL BIO, V2, P815, DOI 10.1038/35099020; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bastians H, 1999, MOL BIOL CELL, V10, P3927, DOI 10.1091/mbc.10.11.3927; Baumer M, 2000, FEBS LETT, V468, P142, DOI 10.1016/S0014-5793(00)01208-4; Beheshti B, 2001, NEOPLASIA, V3, P62, DOI 10.1038/sj.neo.7900125; Bembenek J, 2001, J BIOL CHEM, V276, P48237, DOI 10.1074/jbc.M108126200; Bermejo R, 2002, MOL BIOL CELL, V13, P3989, DOI 10.1091/mbc.E02-04-0217; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Burton JL, 2001, GENE DEV, V15, P2381, DOI 10.1101/gad.917901; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Carnero A, 2002, BRIT J CANCER, V87, P129, DOI 10.1038/sj.bjc.6600458; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chang DC, 2003, J BIOL CHEM, V278, P37865, DOI 10.1074/jbc.M306376200; Chung EN, 2003, NAT CELL BIOL, V5, P748, DOI 10.1038/ncb1022; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Cross FR, 1999, MOL CELL, V4, P11, DOI 10.1016/S1097-2765(00)80183-5; Cross FR, 2003, DEV CELL, V4, P741, DOI 10.1016/S1534-5807(03)00119-9; D'Angiolella V, 2003, GENE DEV, V17, P2520, DOI 10.1101/gad.267603; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; Donnellan R, 1998, J CLIN PATHOL-MOL PA, V51, P1; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Goldberg AL, 2002, NAT MED, V8, P338, DOI 10.1038/nm0402-338; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; Gu LY, 2002, ONCOGENE, V21, P5758, DOI 10.1038/sj.onc.1205695; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; Hamada M, 2003, BRIT J HAEMATOL, V121, P439, DOI 10.1046/j.1365-2141.2003.04311.x; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Huang JN, 2001, J CELL BIOL, V154, P85, DOI 10.1083/jcb.200102007; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Irniger S, 2002, FEBS LETT, V532, P7, DOI 10.1016/S0014-5793(02)03657-8; Ishii K, 1996, EMBO J, V15, P6629, DOI 10.1002/j.1460-2075.1996.tb01053.x; Jacobs HW, 2001, EMBO J, V20, P2376, DOI 10.1093/emboj/20.10.2376; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Jaquenoud M, 2002, EMBO J, V21, P6515, DOI 10.1093/emboj/cdf634; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Koga H, 2003, HEPATOLOGY, V37, P1086, DOI 10.1053/jhep.2003.50186; Konishi Y, 2004, SCIENCE, V303, P1026, DOI 10.1126/science.1093712; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lengronne A, 2002, MOL CELL, V9, P1067, DOI 10.1016/S1097-2765(02)00513-0; Li DH, 2003, CLIN CANCER RES, V9, P991; Lin R, 2003, ENDOCRINOLOGY, V144, P749, DOI 10.1210/en.2002-0026; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Loeb LA, 2001, CANCER RES, V61, P3230; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Masuda A, 2002, ONCOGENE, V21, P6884, DOI 10.1038/sj.onc.1205566; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Miller ME, 2001, J CELL SCI, V114, P1811; Miyoshi Y, 2000, CANCER LETT, V159, P211, DOI 10.1016/S0304-3835(00)00558-9; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nakamura M, 2003, CELL DEATH DIFFER, V10, P230, DOI 10.1038/sj.cdd.4401125; Ohta S, 2001, ONCOL REP, V8, P1063; Orlowski RZ, 2002, J CLIN ONCOL, V20, P4420, DOI 10.1200/JCO.2002.01.133; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Pfleger CM, 2000, GENE DEV, V14, P655; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Prinz S, 1998, CURR BIOL, V8, P750, DOI 10.1016/S0960-9822(98)70298-2; Raff JW, 2002, J CELL BIOL, V157, P1139, DOI 10.1083/jcb.200203035; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Robles LD, 2002, J BIOL CHEM, V277, P25431, DOI 10.1074/jbc.M201199200; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Ru HY, 2002, ONCOGENE, V21, P4673, DOI 10.1038/sj.onc.1205585; Rudner AD, 2000, J CELL BIOL, V149, P1361, DOI 10.1083/jcb.149.7.1361; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Saez C, 2002, ONCOGENE, V21, P8173, DOI 10.1038/sj.onc.1205954; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Sarafan-Vasseur N, 2002, ONCOGENE, V21, P2051, DOI 10.1038/sj.onc.1205257; Saunders WS, 2000, P NATL ACAD SCI USA, V97, P303, DOI 10.1073/pnas.97.1.303; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Sen S, 2002, JNCI-J NATL CANCER I, V94, P1320; Senderowicz AM, 2001, LEUKEMIA, V15, P1, DOI 10.1038/sj.leu.2401994; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Sorensen CS, 2000, MOL CELL BIOL, V20, P7613, DOI 10.1128/MCB.20.20.7613-7623.2000; Sorensen CS, 2001, MOL CELL BIOL, V21, P3692, DOI 10.1128/MCB.21.11.3692-3703.2001; Soria JC, 2000, CANCER RES, V60, P4000; Spruck CH, 2002, CANCER RES, V62, P4535; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Spruck CH, 2002, CELL CYCLE, V1, P248, DOI 10.4161/cc.1.4.132; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Stemmann O, 2001, CELL, V107, P715, DOI 10.1016/S0092-8674(01)00603-1; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Stroschein SL, 2001, GENE DEV, V15, P2822; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Sutherland RL, 2002, NEW ENGL J MED, V347, P1546, DOI 10.1056/NEJMNEJMp020124; Taguchi S, 2002, FEBS LETT, V519, P59, DOI 10.1016/S0014-5793(02)02711-4; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Tan AR, 2002, J CLIN ONCOL, V20, P4074, DOI 10.1200/JCO.2002.01.043; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Waizenegger IC, 2000, CELL, V103, P399, DOI 10.1016/S0092-8674(00)00132-X; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wang CX, 2000, BLOOD, V96, P259, DOI 10.1182/blood.V96.1.259.013k36_259_263; Wang Q, 2003, ONCOGENE, V22, P1486, DOI 10.1038/sj.onc.1206224; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Wassmann K, 1998, P NATL ACAD SCI USA, V95, P11193, DOI 10.1073/pnas.95.19.11193; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Wheatley SP, 1997, J CELL BIOL, V138, P385, DOI 10.1083/jcb.138.2.385; Williams GH, 1998, P NATL ACAD SCI USA, V95, P14932, DOI 10.1073/pnas.95.25.14932; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y; Yeong FM, 2000, MOL CELL, V5, P501, DOI 10.1016/S1097-2765(00)80444-X; Yokoi S, 2003, CANCER SCI, V94, P344, DOI 10.1111/j.1349-7006.2003.tb01444.x; Yudkovsky Y, 2000, BIOCHEM BIOPH RES CO, V271, P299, DOI 10.1006/bbrc.2000.2622; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zhou Y, 2003, J BIOL CHEM, V278, P12530, DOI 10.1074/jbc.M212853200; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	172	109	114	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					1	10		10.1038/sj.onc.1208017	http://dx.doi.org/10.1038/sj.onc.1208017			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15637585				2022-12-17	WOS:000226125800001
J	Qiu, GH; Tan, LKS; Loh, KS; Lim, CY; Srivastava, G; Tsai, ST; Tsao, SW; Tao, Q				Qiu, GH; Tan, LKS; Loh, KS; Lim, CY; Srivastava, G; Tsai, ST; Tsao, SW; Tao, Q			The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma	ONCOGENE			English	Article						3p21; NPC; BLU; RASSF1A; methylation; heat shock	EPSTEIN-BARR-VIRUS; HUMAN-CHROMOSOME 3P21.3; DE-NOVO METHYLATION; ABERRANT PROMOTER HYPERMETHYLATION; HOMOZYGOUS DELETION; LUNG-CANCER; CPG ISLANDS; SHORT ARM; REPRESSES TRANSCRIPTION; DNA METHYLATION	Loss of heterozygosity at 3p21 is common in various cancers including nasopharyngeal carcinoma (NPC). BLU is one of the candidate tumor suppressor genes (TSGs) in this region. Ectopic expression of BLU results in the inhibition of colony formation of cancer cells, suggesting that BLU is a tumor suppressor. We have identified a functional BLU promoter and found that it can be activated by environmental stresses such as heat shock, and is regulated by E2F. The promoter and first exon are located within a CpG island. BLU is highly expressed in testis and normal upper respiratory tract tissues including nasopharynx. However, in all seven NPC cell lines examined, BLU expression was downregulated and inversely correlated with promoter hypermethylation. Biallelic epigenetic inactivation of BLU was also observed in three cell lines. Hypermethylation was further detected in 19/29 (66%) of primary NPC tumors, but not in normal nasopharyngeal tissues. Treatment of NPC cell lines with 5-aza-2'-deoxycytidine activated BLU expression along with promoter demethylation. Although hypermethylation of RASSF1A, another TSG located immediately downstream of BLU, was detected in 20/27 (74%) of NPC tumors, no correlation between the hypermethylation of these two TSGs was observed (P=0.6334). In addition to methylation, homozygous deletion of BLU was found in 7/29 (24%) of tumors. Therefore, BLU is a stress-responsive gene, being disrupted in 83% (24/29) of NPC tumors by either epigenetic or genetic mechanisms. Our data are consistent with the interpretation that BLU is a TSG for NPC.	Div Johns Hopkins Singapore, Canc Epigenet Tumor Virol Lab, Singapore 117597, Singapore; Natl Univ Singapore, Dept Otolaryngol, Singapore 117548, Singapore; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Natl Cheng Kung Univ, Dept Otolaryngol, Tainan 70101, Taiwan; Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Johns Hopkins, Sydney Kimmel Comprehens Canc Ctr, Baltimore, MD USA	National University of Singapore; University of Hong Kong; National Cheng Kung University; University of Hong Kong; Johns Hopkins University; Johns Hopkins Medicine	Tao, Q (corresponding author), Div Johns Hopkins Singapore, Canc Epigenet Tumor Virol Lab, CRC MD11 Level 5,NUS,10 Med Dr, Singapore 117597, Singapore.	taoqia@jhs.com.sg	Tao, Qian/T-4743-2018; Tsao, George/C-4422-2009; QIU, GUO-HUA/B-5806-2011	Tao, Qian/0000-0001-5383-4808; QIU, GUO-HUA/0000-0001-6202-4284				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; AGATHANGGELOU A, 2002, AM ASS CANC RES 93 A; Armstrong RW, 2000, INT J EPIDEMIOL, V29, P991, DOI 10.1093/ije/29.6.991; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Balmain A, 2002, NATURE, V417, P235, DOI 10.1038/417235a; Baylin SB, 1998, ADV CANCER RES, V72, P141; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; Byun DS, 2001, CANCER RES, V61, P7034; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; CHAN ATC, 2004, IN PRESS J CLIN ONCO, V20; Chen YJ, 1999, GENE CHROMOSOME CANC, V25, P169, DOI 10.1002/(SICI)1098-2264(199906)25:2<169::AID-GCC13>3.3.CO;2-9; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Cheung ST, 1999, INT J CANCER, V83, P121, DOI 10.1002/(SICI)1097-0215(19990924)83:1<121::AID-IJC21>3.0.CO;2-F; Chien G, 2001, CANCER GENET CYTOGEN, V126, P63, DOI 10.1016/S0165-4608(00)00392-7; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Deng LW, 1998, GENE CHROMOSOME CANC, V23, P21, DOI 10.1002/(SICI)1098-2264(199809)23:1<21::AID-GCC4>3.0.CO;2-8; Dong SM, 2001, J NATL CANCER I, V93, P858, DOI 10.1093/jnci/93.11.858; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; Esteller M, 1999, CANCER RES, V59, P67; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Fang Y, 2001, GENE CHROMOSOME CANC, V30, P254, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1086>3.0.CO;2-D; Feng P, 2000, J GEN VIROL, V81, P2417, DOI 10.1099/0022-1317-81-10-2417; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; Goessl C, 2000, CANCER RES, V60, P5941; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Hu LF, 1996, GENE CHROMOSOME CANC, V17, P118, DOI 10.1002/(SICI)1098-2264(199610)17:2<118::AID-GCC7>3.0.CO;2-8; HUANG DP, 1991, CANCER GENET CYTOGEN, V54, P91, DOI 10.1016/0165-4608(91)90035-S; HUANG DP, 1994, CANCER RES, V54, P4003; Hui ABY, 1999, INT J CANCER, V82, P498, DOI 10.1002/(SICI)1097-0215(19990812)82:4<498::AID-IJC5>3.3.CO;2-J; Jalbout M, 2003, CANCER LETT, V193, P75, DOI 10.1016/S0304-3835(02)00697-3; Ji L, 2002, CANCER RES, V62, P2715; Kochetkova M, 2002, CANCER RES, V62, P4599; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kourea HP, 1999, AM J PATHOL, V155, P1855, DOI 10.1016/S0002-9440(10)65504-6; LeBoeuf RD, 1998, J BIOL CHEM, V273, P361, DOI 10.1074/jbc.273.1.361; Lee MG, 2001, CANCER RES, V61, P6688; Lerman MI, 2000, CANCER RES, V60, P6116; Liu L, 2000, J Tongji Med Univ, V20, P336; LIU L, 2000, J TONGJI MED U, V20, P342; Lo KW, 1996, CANCER RES, V56, P2721; Lo KW, 2000, CANCER RES, V60, P3348; Lo KW, 2001, CANCER RES, V61, P3877; LO KW, 1994, INT J ONCOL, V4, P1359; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Murray PG, 2004, ONCOGENE, V23, P1326, DOI 10.1038/sj.onc.1207313; Nass SJ, 2000, CANCER RES, V60, P4346; Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465; Nosaka K, 2000, CANCER RES, V60, P1043; Palmisano WA, 2000, CANCER RES, V60, P5954; Raab-Traub N, 1992, Semin Cancer Biol, V3, P297; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rosas SLB, 2001, CANCER RES, V61, P939; Singal R, 2001, BLOOD, V98, P3441, DOI 10.1182/blood.V98.12.3441; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Srivastava G, 2000, BLOOD, V95, P2443, DOI 10.1182/blood.V95.7.2443.007k18_2443_2445; SUN Y, 1993, ONCOGENE, V8, P791; Sung NS, 2000, INT J CANCER, V86, P244, DOI 10.1002/(SICI)1097-0215(20000415)86:2<244::AID-IJC14>3.3.CO;2-M; Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7; Tao Q, 1998, BLOOD, V91, P1373, DOI 10.1182/blood.V91.4.1373; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Tsang YS, 1999, INT J CANCER, V83, P305, DOI 10.1002/(SICI)1097-0215(19991029)83:3<305::AID-IJC3>3.0.CO;2-D; Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2; Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599; VANGROENINGEN CJ, 1986, CANCER RES, V46, P4831; Vokes EE, 1997, LANCET, V350, P1087, DOI 10.1016/S0140-6736(97)07269-3; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956; Yan PS, 2003, CANCER RES, V63, P6178; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; ZHANG SH, 1983, INT J CANCER, V31, P587, DOI 10.1002/ijc.2910310509	75	109	121	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4793	4806		10.1038/sj.onc.1207632	http://dx.doi.org/10.1038/sj.onc.1207632			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122337				2022-12-17	WOS:000221799200015
J	Toussaint-Smith, E; Donner, DB; Roman, A				Toussaint-Smith, E; Donner, DB; Roman, A			Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors	ONCOGENE			English	Article						angiogenesis; papillomavirus; oncogenes; tumor suppressors	ENDOTHELIAL GROWTH-FACTOR; CCAAT DISPLACEMENT PROTEIN; WILD-TYPE P53; TUMOR-SUPPRESSOR; CERVICAL-CANCER; GENE-EXPRESSION; TRANSGENIC MICE; MESSENGER-RNAS; FACTOR FAMILY; CELL-LINES	Human papillomavirus (HPV) 16 is involved in causing cervical cancer. The E6 and E7 proteins of HPV 16 immortalize human keratinocytes and this is due, at least in part, to inactivation of the tumor suppressor proteins p53 and pRB. The se tumor suppressor proteins also regulate the expression of pro- and antiangiogenic factors by cells. For this reason, experiments were conducted to determine whether the expression of E6 and E7 in primary keratinocytes alters the phenotype of these cells such that they express diminished levels of antiangiogenic factors and/or increased levels of proangiogenic factors. To avoid variances in experimental observations, pools of human foreskin keratinocytes from multiple sources were infected with recombinant retrovirus expressing HPV 16 E6 and E7 or control retrovirus. Gene array analysis, RT-PCR, ELISAs and Western blotting showed that in cells expressing HPV 16 E6 and E7, expression levels of two potent angiogenesis inhibitors, thrombospondin-1 and maspin, were lower compared to controls. Additionally, major angiogenesis inducers, interleukin-8 and vascular endothelial growth factor ( VEGF), were increased relative to controls. VEGF can be produced as multiple splice variants, all of which are required for the formation of patent blood vessels. The expression of HPV 16 E6 and E7 in keratinocytes augmented expression of VEGF 121, 145, 165 and 189. These observations show that HPV 16 E6 and E7 alter the phenotype of primary keratinocytes, diminishing expression of inhibitors and increasing expression of inducers of angiogenesis. This altered phenotype may permit keratinocytes infected by HPV 16 to play a role in the progression of cancer by permitting tumors to acquire a blood supply permissive of growth and spread.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Roman, A (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	aroman@iupui.edu			NATIONAL CANCER INSTITUTE [R55CA067891, R01CA067891, R01CA073023] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031494, U19AI031494] Funding Source: NIH RePORTER; NCI NIH HHS [CA73023, CA67891] Funding Source: Medline; NIAID NIH HHS [AI31494] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ai WD, 1999, J VIROL, V73, P4220, DOI 10.1128/JVI.73.5.4220-4229.1999; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; Bequet-Romero M, 2000, BIOCHEM BIOPH RES CO, V277, P55, DOI 10.1006/bbrc.2000.3628; Bouck N, 1996, BBA-REV CANCER, V1287, P63, DOI 10.1016/0304-419X(96)00005-4; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Boyer SN, 1996, CANCER RES, V56, P4620; CHARNOCKJONES DS, 1993, BIOL REPROD, V48, P1120, DOI 10.1095/biolreprod48.5.1120; Cinatl J, 1999, AM J PATHOL, V155, P285, DOI 10.1016/S0002-9440(10)65122-X; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; DESAINTES C, 1992, J VIROL, V66, P325, DOI 10.1128/JVI.66.1.325-333.1992; Dobbs SP, 1997, BRIT J CANCER, V76, P1410, DOI 10.1038/bjc.1997.571; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Furumoto Hiroyuki, 2002, Journal of Medical Investigation, V49, P124; Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513; Gomez-Manzano C, 2003, ANN NEUROL, V53, P109, DOI 10.1002/ana.10396; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Grassmann K, 1996, J VIROL, V70, P2339, DOI 10.1128/JVI.70.4.2339-2349.1996; GUIDI AJ, 1995, J NATL CANCER I, V87, P1237, DOI 10.1093/jnci/87.16.1237; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harada H, 2003, CANCER LETT, V191, P109, DOI 10.1016/S0304-3835(02)00592-X; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HU GY, 1995, CANCER GENE THER, V2, P19; Huang SM, 2002, J VIROL, V76, P8710, DOI 10.1128/JVI.76.17.8710-8721.2002; Igarashi H, 2002, CANCER-AM CANCER SOC, V95, P47, DOI 10.1002/cncr.10635; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; KIESER A, 1994, ONCOGENE, V9, P963; Kodama J, 1999, EUR J CANCER, V35, P485, DOI 10.1016/S0959-8049(98)00410-9; Kodama J, 2001, CLIN CANCER RES, V7, P2826; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lingen MW, 1996, AM J PATHOL, V149, P247; Lopez-Ocejo O, 2000, ONCOGENE, V19, P4611, DOI 10.1038/sj.onc.1203817; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Nees M, 2001, J VIROL, V75, P4283, DOI 10.1128/JVI.75.9.4283-4296.2001; Pattison S, 1997, J VIROL, V71, P2013, DOI 10.1128/JVI.71.3.2013-2022.1997; Ravi R, 2000, GENE DEV, V14, P34; Rheinwald J G, 1980, Methods Cell Biol, V21A, P229, DOI 10.1016/S0091-679X(08)60769-4; Rhim JS, 1998, CARCINOGENESIS, V19, P673, DOI 10.1093/carcin/19.4.673; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SmithMcCune K, 1997, CANCER RES, V57, P1294; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Tjiong MY, 1999, GYNECOL ONCOL, V73, P285, DOI 10.1006/gyno.1999.5358; Vikhanskaya F, 2001, ONCOGENE, V20, P7293, DOI 10.1038/sj.onc.1204896; Volpert OV, 1997, ONCOGENE, V14, P1495, DOI 10.1038/sj.onc.1200977; VONKNEBEL M, 1992, INT J CANCER, V51, P831, DOI 10.1002/ijc.2910510527; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051	53	109	115	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					2988	2995		10.1038/sj.onc.1207442	http://dx.doi.org/10.1038/sj.onc.1207442			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14968115	Bronze			2022-12-17	WOS:000220845200002
J	Lai, JP; Chien, J; Strome, SE; Staub, J; Montoya, DP; Greene, EL; Smith, DI; Roberts, LR; Shridhar, V				Lai, JP; Chien, J; Strome, SE; Staub, J; Montoya, DP; Greene, EL; Smith, DI; Roberts, LR; Shridhar, V			HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma	ONCOGENE			English	Article						head and neck squamous carcinoma; heparin-binding; growth factors; heparan sulfate glycosaminoglycans; hepatocyte growth factor; apoptosis; tumor cell invasion	HEPATOCYTE GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; LYMPH-NODE METASTASES; HEPARAN-SULFATE; BINDING; EXPRESSION; RECEPTOR; PHOSPHORYLATION; PROLIFERATION; MIGRATION	Recently, we cloned a novel sulfatase domain-containing downregulated gene, HSulf-1, which modulates heparin-binding growth factor signaling in ovarian cancer. Based on the pilot data showing the loss of HSulf-1 in head and neck squamous cell carcinoma cell lines (SCCHN), we sought to employ SCCHN as a model to de. ne the role of HSulf-1 in the molecular regulation of tumorigenecity. Three SCCHN lines (012SCC, WMMSCC, and 015SCC) had no detectable HSulf-1 mRNA. Clonal lines of HSulf-1-expressing 012SCC attenuated the activation of ERK/mitogen-activated protein kinase ( MAPK) signaling mediated by fibroblast growth factor (FGF-2) and both ERK/MAPK and Akt signaling mediated by hepatocyte growth factor (HGF). Consistent with this downregulation, phosphorylation of HGF receptor, c-Met, which is frequently overexpressed in SCCHN, was also attenuated in HSulf-1 clonal 012SCC cell lines. HGF markedly enhanced the motility and migration of vector-transfected cells in a transwell invasion chamber. However, HGF-mediated motility and invasion was attenuated in HSulf-1 clonal 012SCC cell lines. In addition, transfected cells displayed significant growth inhibition concomitant with a decrease in mitogenecity, as measured by thymidine incorporation and increased sensitivity to staurosporine- and cisplatin-induced apoptosis. The se data suggest that HSulf-1 normally functions as a negative regulator in cell growth and loss of HSulf-1 in SCCHN potentiates growth factor signaling, enhances motility, invasiveness and inhibits stress-induced apoptosis, with a resulting increase in tumorigenecity.	Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Dept Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; Cent S Univ, Xiang Ya Sch Med, Xiangya Hosp, Dept Otolaryngol, Changsha 410008, Hunan, Peoples R China; Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Dept Otorhinolaryngol Head & Neck Surg, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Div Nephrol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Central South University; Mayo Clinic; Mayo Clinic	Shridhar, V (corresponding author), Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Dept Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.	roberts.lewis@mayo.edu; shridv@exrch.mayo.edu	Chien, Jeremy/AID-8939-2022	Chien, Jeremy/0000-0003-4744-8374; Roberts, Lewis/0000-0001-7885-8574	NATIONAL CANCER INSTITUTE [K08CA082862] Funding Source: NIH RePORTER; NCI NIH HHS [CA82862] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Betz CS, 2002, PHOTOCH PHOTOBIO SCI, V1, P315, DOI 10.1039/b109817a; Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Chien J, 2001, INT J CANCER, V91, P46, DOI 10.1002/1097-0215(20010101)91:1<46::AID-IJC1008>3.0.CO;2-0; Chikamatsu K, 1999, INT J CANCER, V82, P532, DOI 10.1002/(SICI)1097-0215(19990812)82:4<532::AID-IJC11>3.0.CO;2-G; Cortesina G, 2000, INT J CANCER, V89, P286, DOI 10.1002/1097-0215(20000520)89:3<286::AID-IJC12>3.3.CO;2-L; Delehedde M, 2002, BIOCHEM J, V366, P235, DOI 10.1042/BJ20011718; Dent P, 2001, CLIN CANCER RES, V7, P775; Dong G, 2001, CANCER RES, V61, P5911; Fleigel J, 2002, OTOLARYNG HEAD NECK, V127, P271, DOI 10.1067/mhn.2002.127414; Galeazzi E, 1997, EUR ARCH OTO-RHINO-L, V254, pS138, DOI 10.1007/BF02439745; Gescher A, 2000, CRIT REV ONCOL HEMAT, V34, P127, DOI 10.1016/S1040-8428(00)00058-5; Gleich Lyon L, 2002, Cancer Control, V9, P369; HARDISSON D, 2003, EUR ARCH OTO-RHINO-L, V8, P8; Hughes RS, 1997, AM J CLIN ONCOL-CANC, V20, P449, DOI 10.1097/00000421-199710000-00004; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Katoh M, 2002, INT J ONCOL, V21, P1269; Khurana D, 2001, HEAD NECK-J SCI SPEC, V23, P899, DOI 10.1002/hed.1130; Lai JP, 2002, LARYNGOSCOPE, V112, P402, DOI 10.1097/00005537-200202000-00036; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; Liu DF, 2002, SEMIN THROMB HEMOST, V28, P67, DOI 10.1055/s-2002-20565; Lundin L, 2000, J BIOL CHEM, V275, P24653, DOI 10.1074/jbc.M908930199; LYON M, 1994, J BIOL CHEM, V269, P11216; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MODJTAHEDI H, 1995, BIOCHEM BIOPH RES CO, V207, P389, DOI 10.1006/bbrc.1995.1200; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Riedel F, 2000, HEAD NECK-J SCI SPEC, V22, P183, DOI 10.1002/(SICI)1097-0347(200003)22:2<183::AID-HED11>3.0.CO;2-R; Riedel F, 2002, INT J ONCOL, V21, P11; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Rubin JS, 2001, J BIOL CHEM, V276, P32977, DOI 10.1074/jbc.M105486200; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Shridhar V, 2002, CANCER RES, V62, P262; Simon C, 1998, LARYNGOSCOPE, V108, P1686, DOI 10.1097/00005537-199811000-00018; Strome SE, 2002, CLIN CANCER RES, V8, P281; Vlachtsis K, 2002, ONCOL REP, V9, P1133; Wakulich C, 2002, ORAL SURG ORAL MED O, V93, P573, DOI 10.1067/moe.2002.124461; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200	37	109	112	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1439	1447		10.1038/sj.onc.1207258	http://dx.doi.org/10.1038/sj.onc.1207258			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14973553				2022-12-17	WOS:000189035800011
J	Aki, T; Yamaguchi, K; Fujimiya, T; Mizukami, Y				Aki, T; Yamaguchi, K; Fujimiya, T; Mizukami, Y			Phosphoinositide 3-kinase accelerates autophagic cell death during glucose deprivation in the rat cardiomyocyte-derived cell line H9c2	ONCOGENE			English	Article						phosphoinositide 3-kinase; autophagy; glucose deprivation; cell death	PROTEIN-DEGRADATION; 3T3-L1 ADIPOCYTES; DISEASE; KINASE; HEPATOCYTES; MECHANISMS; MORPHOLOGY; APOPTOSIS; TRANSPORT; VACUOLES	We investigated cell death during glucose deprivation in rat cardiomyocyte-derived H9c2 cells. Electron microscopic analysis revealed accumulation of autophagic vacuoles during glucose deprivation. The addition of 3-methyladenine or LY294002, which are known to inhibit autophagosome formation, reduced cell death while Z-VAD-FMK, a caspase inhibitor, slightly affected cell death. Thus, cell death during glucose deprivation is not type I programmed cell death (apoptotic cell death) but type 11 programmed cell death (autophagic cell death). Moreover, we found that both insulin-like growth factor-I and the adenovirus-mediated overexpression of wild-type class I PI 3-kinase accelerated cell death as well as accumulation of autophagic vacuoles during glucose deprivation while dominant-negative PI 3-kinase reduced these phenomena. The results indicate that IGF-I/PI 3-kinase accelerates the accumulation of autophagic vacuoles and subsequent autophagic cell death during glucose deprivation, revealing the opposing role of IGF-I/PI 3-kinase in two distinct types of programmed cell death (apoptotic and autophagic cell death).	Yamaguchi Univ, Ctr Gene Res, Ube, Yamaguchi 7558505, Japan; Yamaguchi Univ, Inst Lab Anim, Ube, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Legal Med, Ube, Yamaguchi 7558505, Japan	Yamaguchi University; Yamaguchi University; Yamaguchi University	Aki, T (corresponding author), Yamaguchi Univ, Ctr Gene Res, 1-1-1 Minamikoguchi, Ube, Yamaguchi 7558505, Japan.			Mizukami, Yoichi/0000-0002-3290-0754				Aki T, 2001, BIOCHEM J, V358, P481, DOI 10.1042/0264-6021:3580481; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Izuishi K, 2000, CANCER RES, V60, P6201; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Katagiri H, 1997, AM J PHYSIOL-ENDOC M, V272, pE326, DOI 10.1152/ajpendo.1997.272.2.E326; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; KEGAL BK, 2000, J NEUROSCI, V20, P7268; Kitanaka C, 2002, J NATL CANCER I, V94, P358; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Munafo DB, 2001, J CELL SCI, V114, P3619; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; ZAKERI Z, 1995, CELL DEATH DIFFER, V2, P87	31	109	117	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8529	8535		10.1038/sj.onc.1207197	http://dx.doi.org/10.1038/sj.onc.1207197			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627994				2022-12-17	WOS:000186650300017
J	Tuck, AB; Hota, C; Wilson, SM; Chambers, AF				Tuck, AB; Hota, C; Wilson, SM; Chambers, AF			Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways	ONCOGENE			English	Article						osteopontin (OPN); migration; mammary epithelial cells; breast cancer; EGFR; signal transduction	EPIDERMAL GROWTH-FACTOR; BREAST-CANCER; ALPHA(V)BETA(3) INTEGRIN; CARCINOMA-CELLS; EXPRESSION; PHOSPHORYLATION; KINASE; SURVIVAL; BETA-1-INTEGRIN; TUMORIGENICITY	Osteopontin (OPN) is a secreted, integrin-binding glycophosphoprotein that has been implicated in breast cancer. We previously showed that OPN-induced cell migration of mammary epithelial cells (MEC) depends on binding to cell surface integrins and involves activation of the hepatocyte growth factor (HGF) receptor, Met. Here, we show that OPN-induced migration of MEC also requires activation of the epidermal growth factor (EGF) pathway. Synergism was seen between EGF and OPN in inducing cell migration. Furthermore, incubation of cells with exogenous OPN increased ligand (TGFalpha > EGF) and EGF receptor (EGFR) mRNA expression, as well as EGFR kinase activity. Treatment of cells with anti-TGFalpha or anti-EGFR antibody, or with tyrphostin-25 (EGFR inhibitor), significantly impaired the cell migration response to OPN. Other more broad-spectrum tyrosine kinase inhibitors and the growth factor/receptor interaction inhibitor, suramin, also inhibited OPN-induced migration. Using specific signal transduction pathway inhibitors, we have screened for involvement of MEK (MAP kinase kinase), phosphatidylinositol 3-kinase, phospholipase C (PLC), and protein kinase C (PKC). Results implicated all of these pathways in OPN-induced cell migration, the most pronounced effect being seen with PLC and PKC inhibitors. These results suggest that induction of MEC migration by OPN involves a cascade of events including at least two growth factor/receptor pathways and multiple downstream signal transduction pathways. A number of potential targets are thus provided for strategies aimed at blocking the malignancy-promoting effects of OPN.	Univ Western Ontario, London Hlth Sci Ctr, Dept Pathol, London, ON N6A 5A5, Canada; Univ Western Ontario, London Hlth Sci Ctr, Dept Oncol, London, ON N6A 5A5, Canada; London Reg Canc Ctr, London, ON N6A 4L6, Canada	London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); Western University (University of Western Ontario)	Tuck, AB (corresponding author), Univ Western Ontario, London Hlth Sci Ctr, Dept Pathol, Univ Campus,POB 5339,Stn B, London, ON N6A 5A5, Canada.		Chambers, Ann F/L-6285-2015	Chambers, Ann F/0000-0002-9509-5123				Adelsman MA, 1999, MOL BIOL CELL, V10, P2861, DOI 10.1091/mbc.10.9.2861; BAND V, 1990, CANCER RES, V50, P7351; BELLAHCENE A, 1995, AM J PATHOL, V146, P95; BROWN LF, 1994, AM J PATHOL, V145, P610; Comoglio P M, 1993, EXS, V65, P131; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DONATO NJ, 1989, J BIOL CHEM, V264, P20474; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; HIROTA S, 1995, LAB INVEST, V72, P64; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Kassis J, 1999, CLIN CANCER RES, V5, P2251; Kermorgant S, 2001, CARCINOGENESIS, V22, P1035, DOI 10.1093/carcin/22.7.1035; Lee JW, 2002, BBA-MOL CELL RES, V1542, P23, DOI 10.1016/S0167-4889(01)00161-6; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; MURRAY JC, 1986, NUCLEIC ACIDS RES, V14, P5117, DOI 10.1093/nar/14.12.5117; PRICE JE, 1990, CANCER RES, V50, P717; Price JT, 1999, CANCER RES, V59, P5475; Qiao H, 2000, CELL GROWTH DIFFER, V11, P123; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; SENGER DR, 1988, CANCER RES, V48, P5770; Singhal H, 1997, CLIN CANCER RES, V3, P605; Sodek J, 2000, CRIT REV ORAL BIOL M, V11, P279, DOI 10.1177/10454411000110030101; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Tuck AB, 2000, J CELL BIOCHEM, V78, P465, DOI 10.1002/1097-4644(20000901)78:3<465::AID-JCB11>3.0.CO;2-C; Tuck AB, 1999, ONCOGENE, V18, P4237, DOI 10.1038/sj.onc.1202799; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Tuck AB, 2001, J MAMMARY GLAND BIOL, V6, P419, DOI 10.1023/A:1014734930781; TUCK AB, 1991, J NATL CANCER I, V83, P485; TUCK AB, 1990, CLIN EXP METASTAS, V8, P417, DOI 10.1007/BF00058153; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Wells A, 2000, ADV CANCER RES, V78, P31; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; XUAN JW, 1995, J CELL BIOCHEM, V57, P680, DOI 10.1002/jcb.240570413; XUAN JW, 1994, J CELL BIOCHEM, V54, P247, DOI 10.1002/jcb.240540213	40	109	127	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	2003	22	8					1198	1205		10.1038/sj.onc.1206209	http://dx.doi.org/10.1038/sj.onc.1206209			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606946				2022-12-17	WOS:000181249700008
J	Lin, HM; Pestell, RG; Raz, A; Kim, HRC				Lin, HM; Pestell, RG; Raz, A; Kim, HRC			Galectin-3 enhances cyclin D-1 promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells	ONCOGENE			English	Article						galectin-3; cyclin D; promoter; cell cycle; anoikis; Rb	BINDING PROTEIN GALECTIN-3; KINASE-ACTIVITY; GENE-PRODUCT; D1 PROMOTER; TRANSCRIPTIONAL REGULATION; OVEREXPRESSION PROTECTS; RETINOBLASTOMA PROTEIN; G1 PHASE; EXPRESSION; ACTIVATION	Galectin-3 is a multifunctional carbohydrate-binding protein found in the nucleus, cytoplasm and the extracellular milieu. Nuclear galectin-3 expression is associated with cell proliferation, and its role in pre-mRNA splicing has been suggested. In this report, we investigated the role of galectin-3 on cyclin D-1 gene expression, a critical inducer of the cell cycle and a potential oncogene in human cancer. We found that galectin-3 induces cyclin D-1 promoter activity in human breast epithelial cells independent of cell adhesion through multiple cis-elements, including the SP1 and CRE sites. We present evidence that galectin-3 induction of the cyclin D, promoter may result from enhancement/stabilization of nuclear protein-DNA complex formation at the CRE site of the cyclin D-1 promoter. We also show that galectin-3 co-operates with, but does not depend on, pRb for cyclin D, promoter activation. The present study reveals a growth promoting activity of galectin-3 through cyclin D, induction, and suggests a novel function of nuclear galectin-3 in the regulation of gene transcription.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Breast Canc Program, Detroit, MI 48201 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Med & Dev & Mol Biol, Bronx, NY 10461 USA	Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Yeshiva University; Albert Einstein College of Medicine	Kim, HRC (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield, Detroit, MI 48201 USA.				NCI NIH HHS [CA-64139] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064139, R01CA064139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akahani S, 1997, CANCER RES, V57, P5272; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; Bresalier RS, 1997, CANCER, V80, P776; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kadrofske MM, 1998, ARCH BIOCHEM BIOPHYS, V349, P7, DOI 10.1006/abbi.1997.0447; Kim HRC, 1999, CANCER RES, V59, P4148; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Konstantinov KN, 1996, AM J PATHOL, V148, P25; Latella L, 2001, MOL CELL BIOL, V21, P5631, DOI 10.1128/MCB.21.16.5631-5643.2001; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Le Gall M, 1998, ONCOGENE, V17, P1271, DOI 10.1038/sj.onc.1202057; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LeMarer N, 1996, J CELL PHYSIOL, V168, P51, DOI 10.1002/(SICI)1097-4652(199607)168:1<51::AID-JCP7>3.0.CO;2-7; Lin HM, 1998, DNA CELL BIOL, V17, P197, DOI 10.1089/dna.1998.17.197; Lin HM, 2000, CARCINOGENESIS, V21, P1941, DOI 10.1093/carcin/21.11.1941; LOTAN R, 1994, INT J CANCER, V56, P474, DOI 10.1002/ijc.2910560404; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; Matarrese P, 2000, INT J CANCER, V85, P545, DOI 10.1002/(SICI)1097-0215(20000215)85:4<545::AID-IJC17>3.0.CO;2-N; Matarrese P, 2000, FEBS LETT, V473, P311, DOI 10.1016/S0014-5793(00)01547-7; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; Nangia-Makker P, 1998, BREAST CANCER RES TR, V49, P171, DOI 10.1023/A:1005913810250; Openo KP, 2000, EXP CELL RES, V255, P278, DOI 10.1006/excr.1999.4782; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; RAZ A, 1989, CANCER RES, V49, P3489; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; SATO S, 1992, J BIOL CHEM, V267, P6983; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; WANG L, 1995, BIOCHEM BIOPH RES CO, V217, P292, DOI 10.1006/bbrc.1995.2777; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Yoshii T, 2002, J BIOL CHEM, V277, P6852, DOI 10.1074/jbc.M107668200; Yu F, 2002, J BIOL CHEM, V277, P15819, DOI 10.1074/jbc.M200154200; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	47	109	118	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 14	2002	21	52					8001	8010		10.1038/sj.onc.1205820	http://dx.doi.org/10.1038/sj.onc.1205820			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439750				2022-12-17	WOS:000179097200009
J	Koliopanos, A; Kleeff, J; Xiao, Y; Safe, S; Zimmermann, A; Buchler, MW; Friess, H				Koliopanos, A; Kleeff, J; Xiao, Y; Safe, S; Zimmermann, A; Buchler, MW; Friess, H			Increased arythydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer	ONCOGENE			English	Article						pancreatic cancer; chemotherapy; arylhydrocarbon receptor; cytochrome-P450; cell cycle	ARYL-HYDROCARBON RECEPTOR; SIGNAL-TRANSDUCTION PATHWAYS; NUCLEAR TRANSLOCATOR ARNT; HUMAN AH RECEPTOR; D GENE-EXPRESSION; CELL-CYCLE; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; POLYCHLORINATED DIBENZOFURANS; ANTITUMORIGENIC ACTIVITY; GLUCOCORTICOID-RECEPTOR	The arylhydrocarbon receptor (AhR) was initially identified as a member of the adaptive metabolic and toxic response pathway to polycyclic aromatic hydrocarbons and to halogenated dibenzo-p-dioxins and dibenzofurans. In the present study, we sought to determine the functional significance of the AhR pathway in pancreatic carcinogenesis. AhR expression was analysed by Northern blotting. The exact site of AhR expression was analysed by in situ hybridization and immunohistochemistry. The effects of TCDD and four selective AhR agonists on pancreatic cancer cell lines were investigated by growth assays, apoptosis assays, and induction of the cyclin-dependent kinase inhibitor p21. There was strong AhR mRNA expression in 14 out of 15 pancreatic cancer samples, weak expression in chronic pancreatitis tissues, and faint expression in all normal pancreata. In pancreatic cancer tissues, AhR mRNA and protein expression were localized in the cytoplasm of pancreatic cancer cells. TCDD and the four AhR agonists inhibited pancreatic cancer cell growth in a dose-dependent manner, and decreased anchorage-independent cell growth. DAPI staining did not reveal nuclear fragmentation and CYP1A1 and was not induced by TCDD and AhR agonists. In contrast, TCDD and AhR agonists induced the expression of the cyclin-dependent kinase inhibitor p21. In conclusion, the relatively non-toxic AhR agonists caused growth inhibition in pancreatic cancer cells with high AhR expression levels via cell cycle arrest. In addition, almost all human pancreatic cancer tissues expressed this receptor at high levels, suggesting that these or related compounds may play a role in the therapy of pancreatic cancer in the future.	Heidelberg Univ, Dept Gen Surg, D-69120 Heidelberg, Germany; Univ Bern, Dept Visceral & Transplantat Surg, Inselspital, Bern, Switzerland; Univ Bern, Inst Pathol, Inselspital, Bern, Switzerland; Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Ruprecht Karls University Heidelberg; University of Bern; University of Bern; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Friess, H (corresponding author), Heidelberg Univ, Dept Gen Surg, Neuenheimer Feld 110, D-69120 Heidelberg, Germany.	helmut_friess@med.uni-heidelberg.de	Kleeff, Jorg/B-2124-2009	Kleeff, Jorg/0000-0003-3432-6669				Abe M, 2000, CANCER, V88, P2000, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2000::AID-CNCR4>3.0.CO;2-B; Andren-Sandberg A, 1999, ANN ONCOL, V10, P131, DOI 10.1023/A:1008377928466; Angus WGR, 1999, CARCINOGENESIS, V20, P947, DOI 10.1093/carcin/20.6.947; ASTROFF B, 1989, TOXICOLOGY, V59, P285, DOI 10.1016/0300-483X(89)90198-4; Becher H, 1996, CANCER CAUSE CONTROL, V7, P312, DOI 10.1007/BF00052936; Bertazzi PA, 2001, AM J EPIDEMIOL, V153, P1031, DOI 10.1093/aje/153.11.1031; Bertazzi PA, 1997, EPIDEMIOLOGY, V8, P646, DOI 10.1097/00001648-199710000-00006; BUCHLER M, 1991, CANCER-AM CANCER SOC, V68, P1507, DOI 10.1002/1097-0142(19911001)68:7<1507::AID-CNCR2820680707>3.0.CO;2-0; BUCKINGHAM J, 1997, DICT ORGANIC COMPOUN; CARVER LA, 1994, NUCLEIC ACIDS RES, V22, P3038, DOI 10.1093/nar/22.15.3038; Chen I, 1998, CARCINOGENESIS, V19, P1631, DOI 10.1093/carcin/19.9.1631; Cheung YL, 1999, CANCER LETT, V139, P199, DOI 10.1016/S0304-3835(99)00045-2; Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; DREISBACH RH, 1987, HDB POISONING PREVEN; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; FINGERHUT MA, 1991, NEW ENGL J MED, V324, P212, DOI 10.1056/NEJM199101243240402; FRIESS H, 1992, PANCREAS, V7, P516, DOI 10.1097/00006676-199209000-00002; FRIESS H, 1993, CANCER RES, V53, P2704; GEIGER LE, 1981, TOXICOL APPL PHARM, V59, P125, DOI 10.1016/0041-008X(81)90459-2; Goodman LS., 2018, GOODMAN GILMANS PHAR; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pa.35.040195.001515; HARRIS M, 1989, MOL PHARMACOL, V35, P729; HAYASHI S, 1994, CARCINOGENESIS, V15, P801, DOI 10.1093/carcin/15.5.801; Hayes, 1982, PESTICIDES STUDIED M, V247, P3140; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUFF J, 1994, ANNU REV PHARMACOL, V34, P343; *IARC WHO, 1987, IARC MON, V1; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 1987, IARC MON, V1; Jana NR, 1999, BIOCHEM BIOPH RES CO, V256, P462, DOI 10.1006/bbrc.1999.0367; JOHNSON ES, 1992, CRIT REV TOXICOL, V21, P451, DOI 10.3109/10408449209089883; JONES PBC, 1986, J BIOL CHEM, V261, P6647; Kashani M, 1998, PROSTATE, V37, P98; Kobayashi A, 1996, J BIOL CHEM, V271, P12310, DOI 10.1074/jbc.271.21.12310; KOJIMA T, 1994, CANCER RES, V54, P1446; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; KRISHNAN V, 1995, MOL CELL BIOL, V15, P6710; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; Kuil CW, 1998, J BIOL CHEM, V273, P8829, DOI 10.1074/jbc.273.15.8829; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; Ledirac N, 2000, TOXICOL APPL PHARM, V164, P273, DOI 10.1006/taap.2000.8920; Li W, 1998, BIOCHEM PHARMACOL, V56, P599, DOI 10.1016/S0006-2952(98)00208-1; Ma Q, 1996, MOL CELL BIOL, V16, P2144; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; McDougal A, 1997, CANCER LETT, V120, P53, DOI 10.1016/S0304-3835(97)00299-1; McDougal A, 2001, BREAST CANCER RES TR, V66, P147, DOI 10.1023/A:1010608000074; MORSE MA, 1990, CANCER RES, V50, P2613; NORMAN J, 1994, J SURG RES, V57, P33, DOI 10.1006/jsre.1994.1105; Oikawa K, 2001, CANCER RES, V61, P5707; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Patikoglou G, 1997, ANNU REV BIOPH BIOM, V26, P289, DOI 10.1146/annurev.biophys.26.1.289; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1979, CANCER RES, V39, P3341; POLAND AP, 1974, J BIOL CHEM, V249, P5599; QUATTROCHI LC, 1994, J BIOL CHEM, V269, P6949; Ramamoorthy K, 1999, CARCINOGENESIS, V20, P115, DOI 10.1093/carcin/20.1.115; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Rininger JA, 1997, CHEMOSPHERE, V34, P1557, DOI 10.1016/S0045-6535(96)00451-1; ROWLANDS C, 1993, CANCER RES, V53, P1802; Roy NK, 1997, ARCH BIOCHEM BIOPHYS, V344, P373, DOI 10.1006/abbi.1997.0238; Safe S, 1998, TOXICOL LETT, V103, P343; Safe S, 2001, TOXICOL LETT, V120, P1, DOI 10.1016/S0378-4274(01)00301-0; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; Sax N. I., 1989, DANGEROUS PROPERTIES; Sittig M, 1985, HDB TOXIC HAZARDOUS; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SKENE SA, 1989, HUM TOXICOL, V8, P173, DOI 10.1177/096032718900800301; Spink BC, 1998, J CELL BIOCHEM, V70, P289, DOI 10.1002/(SICI)1097-4644(19980901)70:3<289::AID-JCB1>3.3.CO;2-H; Steenland K, 1999, J NATL CANCER I, V91, P779, DOI 10.1093/jnci/91.9.779; STOEWSAND GS, 1988, CANCER LETT, V39, P199, DOI 10.1016/0304-3835(88)90105-X; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; Sun GL, 1997, CANCER CHEMOTH PHARM, V40, P239, DOI 10.1007/s002800050653; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; Takahashi Y, 1996, EUR J BIOCHEM, V242, P512, DOI 10.1111/j.1432-1033.1996.0512r.x; TAKEUCHI Y, 1993, AM J GASTROENTEROL, V88, P1928; VANG O, 1990, CARCINOGENESIS, V11, P1259, DOI 10.1093/carcin/11.8.1259; VICKERS PJ, 1989, MOL ENDOCRINOL, V3, P157, DOI 10.1210/mend-3-1-157; Wang F, 1999, BIOCHEMISTRY-US, V38, P11490, DOI 10.1021/bi982578f; WANG XH, 1995, EUR J PHARM-ENVIRON, V293, P191, DOI 10.1016/S0922-4106(05)80044-6; WANG XH, 1992, BIOCHEM PHARMACOL, V43, P1635; WATTENBERG LW, 1978, CANCER RES, V38, P1410; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; Windholz M., 1983, MERCK INDEX ENCY CHE, V10th; Wormke M, 2000, J STEROID BIOCHEM, V72, P197, DOI 10.1016/S0960-0760(00)00030-3; WU L, 1992, P NATL ACAD SCI USA, V89, P4811, DOI 10.1073/pnas.89.11.4811; ZACHAREWSKI TR, 1994, CANCER RES, V54, P2707	89	109	118	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6059	6070		10.1038/sj.onc.1205633	http://dx.doi.org/10.1038/sj.onc.1205633			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203118				2022-12-17	WOS:000177671300009
J	Pelletier, N; Champagne, N; Stifani, S; Yang, XJ				Pelletier, N; Champagne, N; Stifani, S; Yang, XJ			MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor Runx2	ONCOGENE			English	Article						histone acetyltransferase; MYST; MOZ; MORF; Runx1; Runx2	ACUTE MYELOID-LEUKEMIA; RECEPTOR COACTIVATOR; DOSAGE COMPENSATION; MONOCYTIC LEUKEMIA; HUMAN GENES; CELL-CYCLE; PROTEIN; CBP; YEAST; MLL	The monocytic leukemia zinc finger protein MOZ and its homologue MORF have been implicated in leukemogenesis. Both MOZ and MORF are histone acetyltransferases with weak transcriptional repression domains and strong transcriptional activation domains, suggesting that they may function as transcriptional coregulators. Here we describe that MOZ and MORF both interact with Runx2 (or Cbfa1), a Runt-domain transcription factor that is known to play important roles in T cell lymphomagenesis and bone development. Through its C-terminal SM (serine- and methionine-rich) domain, MORF binds to Runx2 in vitro and in vivo. Consistent with this, the SM domain of MORF also binds to Runx1 (or AML1), a Runx2 homologue that is frequently altered by leukemia-associated chromosomal translocations. While MORF does not acetylate Runx2, its SM domain potentiates Runx2-dependent transcriptional activation. Moreover, endogenous MORF is required for transcriptional activation by Runx2. Intriguingly, Runx2 negatively regulates the transcriptional activation potential of the SM domain. Like that of MORF, the SM domain of MOZ physically and functionally interacts with Runx2. These results thus identify Runx2 as an interaction partner of MOZ and MORF and suggest that both acetyltransferases are involved in regulating transcriptional activation mediated by Runx2 and its homologues.	McGill Univ, Mol Oncol Grp, Royal Victoria Hosp, Ctr Hlth, Montreal, PQ H3A 1A1, Canada; McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, Montreal, PQ, Canada	McGill University; Royal Victoria Hospital; McGill University	Yang, XJ (corresponding author), McGill Univ, Mol Oncol Grp, Royal Victoria Hosp, Ctr Hlth, Room H5-41,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	yangxj@molonc.mcgill.ca		Stifani, Stefano/0000-0002-2376-7701				Akhtar A, 2000, NATURE, V407, P405, DOI 10.1038/35030169; Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Blyth K, 2001, ONCOGENE, V20, P295, DOI 10.1038/sj.onc.1204090; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Carapeti M, 1999, CANCER GENET CYTOGEN, V113, P70, DOI 10.1016/S0165-4608(99)00007-2; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; Chaffanet M, 1999, GENE CHROMOSOME CANC, V26, P161, DOI 10.1002/(SICI)1098-2264(199910)26:2<161::AID-GCC8>3.3.CO;2-Y; Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2; Champagne N, 1999, J BIOL CHEM, V274, P28528, DOI 10.1074/jbc.274.40.28528; Champagne N, 2001, ONCOGENE, V20, P404, DOI 10.1038/sj.onc.1204114; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Howe L, 2001, GENE DEV, V15, P3144, DOI 10.1101/gad.931401; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jacobson S, 1999, CURR OPIN GENET DEV, V9, P175, DOI 10.1016/S0959-437X(99)80027-6; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; John S, 2000, GENE DEV, V14, P1196; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 2001, LEUKEMIA, V15, P89, DOI 10.1038/sj.leu.2401983; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lee HJ, 2001, J BIOL CHEM, V276, P16597, DOI 10.1074/jbc.C000909200; Liang J, 1998, BLOOD, V92, P2118, DOI 10.1182/blood.V92.6.2118.418k09_2118_2122; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; McLarrent FW, 2001, J BIOL CHEM, V276, P1578, DOI 10.1074/jbc.M007629200; Meijsing SH, 2001, GENE DEV, V15, P3169, DOI 10.1101/gad.929001; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nakatani Y, 2001, GENES CELLS, V6, P79, DOI 10.1046/j.1365-2443.2001.00411.x; Osada S, 2001, GENE DEV, V15, P3155, DOI 10.1101/gad.907201; Panagopoulos I, 2000, GENE CHROMOSOME CANC, V28, P415, DOI 10.1002/1098-2264(200008)28:4<415::AID-GCC7>3.0.CO;2-I; Panagopoulos I, 2001, HUM MOL GENET, V10, P395, DOI 10.1093/hmg/10.4.395; Ran QT, 2000, GENE, V258, P141, DOI 10.1016/S0378-1119(00)00410-8; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Rowley JD, 1997, BLOOD, V90, P535; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; Scott EK, 2001, CURR BIOL, V11, P99, DOI 10.1016/S0960-9822(01)00020-3; SEMENZA GL, 1998, MED GENETICS; Sharma M, 2000, J BIOL CHEM, V275, P35200, DOI 10.1074/jbc.M004838200; Sheridan AM, 2001, MOL CELL BIOL, V21, P4470, DOI 10.1128/MCB.21.14.4470-4481.2001; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Speck NA, 1999, CANCER RES, V59, p1789S; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Takechi S, 1999, BIOCHEM BIOPH RES CO, V266, P405, DOI 10.1006/bbrc.1999.1836; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Thomas T, 2000, DEVELOPMENT, V127, P2537; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Wheeler JC, 2000, SEMIN CELL DEV BIOL, V11, P369, DOI 10.1006/scdb.2000.0184; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yan Y, 2000, MOL CELL, V6, P1195, DOI 10.1016/S1097-2765(00)00116-7; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	77	109	118	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2729	2740		10.1038/sj.onc.1205367	http://dx.doi.org/10.1038/sj.onc.1205367			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965546				2022-12-17	WOS:000174996500013
J	Wentzensen, N; Ridder, R; Klaes, R; Vinokurova, S; Schaefer, U; Doeberitz, MV				Wentzensen, N; Ridder, R; Klaes, R; Vinokurova, S; Schaefer, U; Doeberitz, MV			Characterization of viral-cellular fusion transcripts in a large series of HPV16 and 18 positive anogenital lesions	ONCOGENE			English	Article						human papillomavirus (HPV); E6-E7 oncogenes; integration; insertional mutagenesis; fusion transcripts	HUMAN-PAPILLOMAVIRUS TYPE-16; GENE-EXPRESSION; CERVICAL-CANCER; FRAGILE SITES; INTEGRATION SITES; SEQUENCES; DNA; E7; E6; ONCOGENES	Persistent high risk type human papillomavirus (HR - HPVs) infections induce dysplasia or cancer of the anogenital tract, most notably of the uterine cervix. The viral genome usually persists and replicates as an episomal molecule in early dysplasia, whereas in advanced dysplasia or cervical cancer HPV genomes are frequently integrated into the chromosomal DNA of the host cell. Previous studies suggested that modification of critical cellular sequences by integration of HPV genomes might significantly contribute to the neoplastic transformation of anogenital epithelia (insertional mutagenesis). This prompted us to characterize the integration loci of high risk HPV genomes in a large set of genital lesions. We amplified E6/E7 oncogene transcripts derived from integrated HPV16 and HPV18 genomes and characterized in detail the co-transcribed cellular sequences! of 64 primary genital lesions and five cervical cancer cell lines. Database analyses of the cellular parts of these fusion transcripts revealed 51 different integration loci, including 26 transcribed genes (14 known genes, 12 EST sequences with unknown gene function). Seventeen sequences showed similarity to repetitive elements, and 26 sequences did not show any database match other than genomic sequence. Chromosomal integration loci were distributed over almost all human chromosomes. Although we found HPV sequences integrated into cancer related genes and close to fragile sites, no preferential site or integration motif could be identified. These data demonstrate that target directed insertional mutagenesis might occur in few HPV-induced anogenital lesions, however, it is rather the exception than the rule.	Heidelberg Univ, Dept Pathol, Div Mol Pathol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Doeberitz, MV (corresponding author), Heidelberg Univ, Dept Pathol, Div Mol Pathol, Im Neuenheimer Feld 110, D-69120 Heidelberg, Germany.	knebel@med.uni-heidelberg.de	Wentzensen, Nicolas/AAG-8522-2019					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Amati B, 2001, BBA-REV CANCER, V1471, pM135, DOI 10.1016/S0304-419X(01)00020-8; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; CANNIZZARO LA, 1988, CANCER GENET CYTOGEN, V33, P93, DOI 10.1016/0165-4608(88)90054-4; Carmody MW, 1996, MOL CELL PROBE, V10, P107, DOI 10.1006/mcpr.1996.0015; Chen M, 1996, NAT GENET, V12, P448, DOI 10.1038/ng0496-448; COUTURIER J, 1991, J VIROL, V65, P4534, DOI 10.1128/JVI.65.8.4534-4538.1991; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DOEBERITZ MV, 1991, P NATL ACAD SCI USA, V88, P1411, DOI 10.1073/pnas.88.4.1411; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2001, CANCER RES, V61, P2356; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; ELAWADY MK, 1987, VIROLOGY, V159, P389, DOI 10.1016/0042-6822(87)90478-8; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hopper JL, 2001, BREAST CANCER RES, V3, P154, DOI 10.1186/bcr290; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; Kessis TD, 1996, ONCOGENE, V13, P427; Klaes R, 1999, CANCER RES, V59, P6132; Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635; Li Y, 2000, INT J CANCER, V87, P473, DOI 10.1002/1097-0215(20000815)87:4<473::AID-IJC3>3.0.CO;2-1; Luft F, 2001, INT J CANCER, V92, P9, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1144>3.0.CO;2-L; MacDonald JS, 1999, SEMIN ONCOL, V26, P556; MEYER T, 1995, BIOTECHNIQUES, V19, P632; MINCHEVA A, 1987, MED MICROBIOL IMMUN, V176, P245, DOI 10.1007/bf00190531; POPESCU NC, 1987, CYTOGENET CELL GENET, V44, P58, DOI 10.1159/000132342; Remm M, 1999, J VIROL, V73, P3062, DOI 10.1128/JVI.73.4.3062-3070.1999; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; Scheffner M, 1994, Curr Top Microbiol Immunol, V186, P83; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SHIRASAWA H, 1989, J GEN VIROL, V70, P1913, DOI 10.1099/0022-1317-70-7-1913; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; SMITH PP, 1992, GENE CHROMOSOME CANC, V5, P150, DOI 10.1002/gcc.2870050209; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; Sutherland GR, 1999, AM J HUM GENET, V64, P354, DOI 10.1086/302267; Thorland EC, 2000, CANCER RES, V60, P5916; Tu YZ, 1999, BBA-GENE STRUCT EXPR, V1489, P452, DOI 10.1016/S0167-4781(99)00197-9; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	44	109	122	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					419	426		10.1038/sj.onc.1205104	http://dx.doi.org/10.1038/sj.onc.1205104			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821954				2022-12-17	WOS:000173311200010
J	Scherl-Mostageer, M; Sommergruber, W; Abseher, R; Hauptmann, R; Ambros, P; Schweifer, N				Scherl-Mostageer, M; Sommergruber, W; Abseher, R; Hauptmann, R; Ambros, P; Schweifer, N			Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer	ONCOGENE			English	Article						representational difference analysis; cDNA chip technology; laser microdissection; CUB domain; CDCP1	REPRESENTATIONAL DIFFERENCE ANALYSIS; HUMAN-CHROMOSOMES; SERIAL ANALYSIS; MESSENGER-RNA; CUB DOMAIN; EXPRESSION; HYBRIDIZATION; REARRANGEMENTS; SEQUENCES; GENOME	We report the identification of a novel human tumor associated gene, CDCP1 (Cub Domain Containing Protein), which was identified using representational difference analysis and cDNA chip technology. The gene consists of eight exons, the upstream region of which neither contains a TATA- nor a CCAAT-box, However, a CpG island is located around the transcription start, which is found in approximately 60% of known genes. The CDCP1 gene was mapped to chromosome 3p21-p23 by fluorescence in situ hybridization, For expression profiling real time quantitative RT - PCR was performed using cell lines and laser capture microdissected colon cancer biopsies. CDCP1 mRNA is approximately 6 kb and highly overexpressed in human colon cancer and lung cancer, CDCP1 represents a putative transmembrane protein, containing three CUB domains in the extracellular part most likely involved in cell adhesion or interacting with the extracellular matrix.	Boehringer Ingelheim KG, Dept Exploratory Res, Res & Dev, A-1121 Vienna, Austria; St Anna Childrens Hosp, CCRI, A-1080 Vienna, Austria	Boehringer Ingelheim; Saint Anna Children's Hospital	Schweifer, N (corresponding author), Boehringer Ingelheim KG, Dept Exploratory Res, Res & Dev, A-1121 Vienna, Austria.	norbert.schweifer@vie.boehringer-ingelheim.com	Ambros, Peter/AAA-1266-2021	Ambros, Peter/0000-0002-5507-7211				ABE K, 1992, MAMM GENOME, V2, P252, DOI 10.1007/BF00355435; Afshari CA, 1999, CANCER RES, V59, P4759; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Bornstein SR, 1998, MED KLIN, V93, P739, DOI 10.1007/BF03044814; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; Cross SH, 2000, MAMM GENOME, V11, P373, DOI 10.1007/s003350010071; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIALKOW PJ, 1976, BIOCHIM BIOPHYS ACTA, V458, P283, DOI 10.1016/0304-419X(76)90003-2; Gerstein M, 2000, CURR OPIN STRUC BIOL, V10, P574, DOI 10.1016/S0959-440X(00)00134-2; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Hubank M, 1999, METHOD ENZYMOL, V303, P325; Ishii M, 2000, GENOMICS, V68, P136, DOI 10.1006/geno.2000.6284; King RD, 1996, PROTEIN SCI, V5, P2298, DOI 10.1002/pro.5560051116; Knight SJL, 1997, EUR J HUM GENET, V5, P1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kurian KM, 1999, J PATHOL, V187, P267; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Parle-McDermott A, 2000, BRIT J CANCER, V83, P725, DOI 10.1054/bjoc.2000.1330; Romero A, 1997, NAT STRUCT BIOL, V4, P783, DOI 10.1038/nsb1097-783; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Stollberg J, 2000, GENOME RES, V10, P1241, DOI 10.1101/gr.10.8.1241; To KY, 2000, COMB CHEM HIGH T SCR, V3, P235; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; Wootton JC, 1996, METHOD ENZYMOL, V266, P554	42	109	119	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2001	20	32					4402	4408		10.1038/sj.onc.1204566	http://dx.doi.org/10.1038/sj.onc.1204566			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466621	Bronze			2022-12-17	WOS:000169912600014
J	Iwanaga, R; Ohtani, K; Hayashi, T; Nakamura, M				Iwanaga, R; Ohtani, K; Hayashi, T; Nakamura, M			Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I	ONCOGENE			English	Article						cell cycle; E2F; HTLV-I; NF-kappa B; tax; cyclin D2	RETINOBLASTOMA PROTEIN; TRANSCRIPTIONAL ACTIVATOR; HTLV-I; E2F; EXPRESSION; FAMILY; LINE; ACCUMULATION; GROWTH; GENES	The trans-activator protein Tax of human T-cell leukemia virus type I(HTLV-I) plays an important role in the development of adult T-cell leukemia through, at least in part, its ability to stimulate cell growth. We previously reported that Tax induced cell cycle progression from G0/G1 phase to S and G2/M phases in human T-cell line Kit 225 cells. To elucidate molecular mechanism of Tax-induced cell cycle progression, we systematically examined the effects of Tax on biochemical events associated with cell cycle progression, Introduction of Tax into resting Kit 225 cells induced activation of the G1/S transition regulation cascade consisting of activation of cyclin dependent kinase 2 (CDK2) and CDK4, phosphorylation of the Rb family proteins and an increase in free E2F, The kinase activation was found to result from Tax-induced expression of genes for cell cycle regulatory molecules including cyclin D2, cyclin E, E2F1, CDK2, CDK4 and CDK6, and Tax-induced reduction of CDK inhibitors p19(INK4d) and p27(Kip1), These modulations by Tax always paralleled the ability of Tax to activate the NF-kappaB transcription pathway. These results indicate the important role of Tax-mediated trans-activation of the genes for cell cycle regulatory molecules in Tax-induced cell cycle progression.	Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU)	Ohtani, K (corresponding author), Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, 1-4-45 Yushima, Tokyo 1138510, Japan.							AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; Akagi T, 1996, ONCOGENE, V12, P1645; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; GESSAIN A, 1985, LANCET, V2, P407; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HIRAI H, 1992, ONCOGENE, V7, P1737; HORI T, 1987, BLOOD, V70, P1069; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; LEE B, 1989, TOHOKU J EXP MED, V157, P1, DOI 10.1620/tjem.157.1; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; MINOWADA J, 1972, J NATL CANCER I, V49, P891; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NEVINS JR, 1992, SCIENCE, V258, P424; Ohtani K, 2000, J BIOL CHEM, V275, P11154, DOI 10.1074/jbc.275.15.11154; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; YOSHIDA M, 1995, J CANCER RES CLIN, V121, P521, DOI 10.1007/BF01197764; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	43	109	110	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2001	20	17					2055	2067		10.1038/sj.onc.1204304	http://dx.doi.org/10.1038/sj.onc.1204304			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360190				2022-12-17	WOS:000168116700001
J	Jee, SH; Shen, SC; Chiu, HC; Tsai, WL; Kuo, ML				Jee, SH; Shen, SC; Chiu, HC; Tsai, WL; Kuo, ML			Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency	ONCOGENE			English	Article						interleukin-6; anti-apoptosis; basal cell carcinoma cells; Mcl-1; cyclooxygenase; vascular endothelial growth factor	GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; HUMAN KERATINOCYTES; TNF-ALPHA; IN-VITRO; BCL-2; IL-6; EXPRESSION; TRANSCRIPTION; ANGIOGENESIS	Interleukin-6 (IL-6) is a pleiotropic cytokine that is capable of modulating the diverse functions of cells such as acute phase responses and inflammation. Excessive or insufficient production of IL-6 may contribute to certain diseases of the skin. The aim of this study was to investigate the possible role of IL-6 in the tumorigenesis of basal cell carcinoma (BCC), Initially, ffe transfected IL-6 expression vector, under the control of a CMV promoter, into human BCC cells and successfully obtained IL-6-overespressing clones (BCC/IL-6-c1 and BCC/IL-6-c2) and a mixture (BCC/IL-6). DNA synthesis assay determined using H-3-thymidine pulse incorporation revealed that IL-6-expressing BCC cells exhibited a much higher DNA synthesis rate than the neo control or parental BCC cells. Ne also detected a greater abundance of IL-6-expressing cell colonies formed in soft agar than in the vector control cells. Furthermore, BCC/IL-6 cells, but not vector control cells, were resistant to UV and photodynamic therapy (PDT)-induced apoptosis, as confirmed using DNA fragmentation and morphologic change analyses. Immunoblot analysis showed that Mcl-1, an anti-apoptotic protein, was specifically up-regulated IL-6 transfectants but not in the control cells, Transient transfection of IL-6 transfectants with antisense mcl-1 greatly enhanced their apoptosis frequency by UV treatment, In tumorigenesis assay, IL-6 transfected clones formed tumors in nude mice more rapidly than the control cells. These tumors appeared to be highly vascularized using pathological examination, Supportive of this finding, ffe found that IL-6 transfected cells expressed elevated levels of two angiogenic factors, cycloosygenase (Cos)-2 and vascular endothelial growth factor (VEGF). These results suggest that overexpression of IL-6 enhances the tumorigenic activity of BCC cells by both suppressing apoptosis and actively promoting angiogenesis.	Natl Taiwan Univ, Coll Med, Lab Mol & Cellular Toxicol, Inst Toxicol,Dept Dermatol, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Dermatol, Taipei, Taiwan; Taipei Med Univ, Sch Med, Dept Dermatol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; Taipei Medical University; National Taiwan University	Kuo, ML (corresponding author), Natl Taiwan Univ, Coll Med, Lab Mol & Cellular Toxicol, Inst Toxicol,Dept Dermatol, 1 Sec,1 Jen Ai Rd, Taipei, Taiwan.		Kuo, Min-Liang/C-4872-2009	CHIU, HSIEN-CHING/0000-0002-1409-8470; KUO, MIN-LIANG/0000-0002-7139-0144; JEE, SHIOU-HWA/0000-0001-6737-6297				Adler HL, 1999, J UROLOGY, V161, P182, DOI 10.1016/S0022-5347(01)62092-5; Akira S, 1992, Semin Cancer Biol, V3, P17; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; Ando T, 1998, ENDOCR RES, V24, P955, DOI 10.3109/07435809809032715; Aoki Y, 1999, BLOOD, V93, P4034, DOI 10.1182/blood.V93.12.4034.412k38_4034_4043; Aoyagi T, 1996, Int J Urol, V3, P392, DOI 10.1111/j.1442-2042.1996.tb00560.x; Avalos-Diaz E, 1999, REV RHUM, V66, P13; Barton BE, 1997, CLIN IMMUNOL IMMUNOP, V85, P16, DOI 10.1006/clin.1997.4420; Brash DE, 1997, TRENDS GENET, V13, P410, DOI 10.1016/S0168-9525(97)01246-8; CALLERY MP, 1990, J SURG RES, V48, P523, DOI 10.1016/0022-4804(90)90224-P; Cassell GH, 1998, EMERG INFECT DIS, V4, P475, DOI 10.3201/eid0403.980339; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Dietrich JB, 1997, ARCH PHYSIOL BIOCHEM, V105, P125, DOI 10.1076/apab.105.2.125.12927; Eberlein-Konig B, 1998, BRIT J DERMATOL, V139, P415; Elder DJE, 1996, CANCER RES, V56, P2273; Gniadecki R, 1998, ARCH DERMATOL RES, V290, P528, DOI 10.1007/s004030050347; HANADA N, 1995, NUCL ACID ENZYME, V40, P1713; HORII Y, 1993, KIDNEY INT, V43, pS71; HOUSSIAU F, 1992, RES IMMUNOL, V143, P740, DOI 10.1016/0923-2494(92)80014-C; Kinoshita T, 1999, CANCER, V85, P2526, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2526::AID-CNCR6>3.0.CO;2-3; Kondo S, 1998, J CELL PHYSIOL, V177, P493, DOI 10.1002/(SICI)1097-4652(199812)177:3<493::AID-JCP12>3.0.CO;2-B; KRICKER A, 1994, CANCER CAUSE CONTROL, V5, P367, DOI 10.1007/BF01804988; Kuo ML, 1998, ONCOGENE, V17, P2225, DOI 10.1038/sj.onc.1202133; Lear JT, 1998, J ROY SOC MED, V91, P585, DOI 10.1177/014107689809101110; LOTEM J, 1995, CELL GROWTH DIFFER, V6, P647; Lu C, 1996, CLIN CANCER RES, V2, P1417; Maione D, 1998, EMBO J, V17, P5588, DOI 10.1093/emboj/17.19.5588; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Okamoto M, 1997, INT J CANCER, V72, P149, DOI 10.1002/(SICI)1097-0215(19970703)72:1<149::AID-IJC21>3.0.CO;2-D; OTAKE S, 1996, J BONE MINER RES, V11, P88; Paquet P, 1996, INT ARCH ALLERGY IMM, V109, P308, DOI 10.1159/000237257; Prisco M, 1999, HORM METAB RES, V31, P80, DOI 10.1055/s-2007-978703; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REYNOLDS JE, 1994, CANCER RES, V54, P6348; REZAI AR, 1994, J NEURO-ONCOL, V19, P131, DOI 10.1007/BF01306454; Rifas L, 1999, J BONE MINER RES, V14, P1096, DOI 10.1359/jbmr.1999.14.7.1096; Schirmacher P, 1998, AM J PATHOL, V153, P639, DOI 10.1016/S0002-9440(10)65605-2; SCHLAG P, 1984, CANCER TREAT REV, V11, P131, DOI 10.1016/0305-7372(84)90052-5; SCHWARZE MMK, 1995, CANCER RES, V55, P2262; Seymour J F, 1996, Cancer Treat Res, V84, P167; SKELLY SM, 1994, J BIOTECHNOL, V34, P79, DOI 10.1016/0168-1656(94)90168-6; Soriani M, 1999, CARCINOGENESIS, V20, P727, DOI 10.1093/carcin/20.4.727; Swiergiel AH, 1999, BRAIN BEHAV IMMUN, V13, P252, DOI 10.1006/brbi.1999.0565; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; Tobin D, 1998, P NATL ACAD SCI USA, V95, P565, DOI 10.1073/pnas.95.2.565; Tseng JF, 1996, J CLIN ENDOCR METAB, V81, P1118, DOI 10.1210/jc.81.3.1118; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; Vasse M, 1999, ARTERIOSCL THROM VAS, V19, P1835, DOI 10.1161/01.ATV.19.8.1835; Wang JM, 1999, MOL CELL BIOL, V19, P6195; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Yen HT, 1996, ARCH DERMATOL RES, V288, P157, DOI 10.1007/BF02505826	54	109	121	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2001	20	2					198	208		10.1038/sj.onc.1204076	http://dx.doi.org/10.1038/sj.onc.1204076			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313947				2022-12-17	WOS:000166410900007
J	Raouf, A; Seth, A				Raouf, A; Seth, A			Ets transcription factors and targets in osteogenesis	ONCOGENE			English	Article						Ets1; Ets2; osteoblast; differentiation; mineralization; bone	RETINOIC ACID; C-ETS-1 PROTOONCOGENE; OSTEOBLASTIC DIFFERENTIATION; BINDING-SITES; C-FOS; EXPRESSION; CELL; PROTEIN; BONE; GENE	Bone formation in vivo is a complex phenomenon whereby recruitment and replication of mesenchymal precursors of osteoblasts, differentiation into preosteoblasts, osteoblasts, and mature osteoblasts ultimately result in the accumulation and mineralization of the extracellular matrix. MC3T3-E1, a clonal osteoblastic cell line, was derived from mouse calvaria and undergoes an ordered and time dependent developmental sequence leading to formation of multilayered bone nodules over a 30-35 day period. This developmental pattern is characterized by the replication of preosteoblasts followed by growth arrest and expression of mature osteoblastic characteristics such as matrix maturation and eventual formation of multilayered nodules with a mineralized extracellular matrix, We have found that Ets1 is expressed in proliferating preosteoblastic cells whereas Ets2 is expressed by differentiating and mature osteoblasts, In addition, the expression of Ets1 can be induced in MC3T3-E1 and fetal rat calvaria cells by retinoic acid (RA) which is known to exert profound effects on skeletal growth and development, bone turnover, and induce specific cellular responses in bone cells, Thus the multiple functions of RA in bone cells are likely to be mediated in part by Ets1. Also, Ets2 transgenic mice develop multiple neurocranial, viserocranial, and cervical skeletal abnormalities. Significantly, these abnormalities are similar to the skeletal anomalies found in trisomy-16 mice and in humans with Down's syndrome, wherein the dosage of Ets2 is known to be increased. These results indicate that Ets2 has an important role in skeletal development and that Ets2 overexpression in transgenics is responsible for the genesis of the same type of skeletal abnormalities that are seen in Down's syndrome. Thus the genetic programs regulated by Ets1 and Ets2 may significantly affect the development and differentiation of osteoblasts, and in fact, Ets1 has been shown to interact with the 'quintessential' osteoblast transcription factor CbfA1, This review will examine in detail the role and possible targets of Ets1 and Ets2 in osteoblast differentiation and bone formation.	Univ Toronto, Dept Lab Med & Pathobiol, MRC Grp Periodontal Physiol, Toronto, ON, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Lab Mol Pathol, Toronto, ON, Canada	University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Seth, A (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, MRC Grp Periodontal Physiol, Toronto, ON, Canada.							Aperlo C, 1996, MOL CELL BIOL, V16, P6851; ASCIONE R, 1992, INT J ONCOL, V1, P631; Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<73::AID-JCB11>3.0.CO;2-L; AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756-3282(95)00183-E; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; Chen ZQ, 1997, CANCER RES, V57, P2013; Choi JY, 1996, J CELL BIOCHEM, V61, P609, DOI 10.1002/(SICI)1097-4644(19960616)61:4<609::AID-JCB15>3.3.CO;2-Q; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; FANG MA, 1995, CALCIFIED TISSUE INT, V57, P450, DOI 10.1007/BF00301949; Frick KK, 1997, AM J PHYSIOL-CELL PH, V272, pC1450, DOI 10.1152/ajpcell.1997.272.5.C1450; Gilles F, 1996, EXP CELL RES, V222, P370, DOI 10.1006/excr.1996.0046; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; HARADA H, 1995, ENDOCRINOLOGY, V136, P5329, DOI 10.1210/en.136.12.5329; Hodge DR, 1996, ONCOGENE, V12, P11; ISEKI S, 1995, EXP CELL RES, V219, P339, DOI 10.1006/excr.1995.1237; Iwamoto M, 2000, J CELL BIOL, V150, P27, DOI 10.1083/jcb.150.1.27; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Karperien M, 1997, MOL ENDOCRINOL, V11, P1435, DOI 10.1210/me.11.10.1435; Kodama HA., 1981, JPN J ORAL BIOL, V23, P899, DOI DOI 10.2330/JORALBIOSCI1965.23.899; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KURIHARA N, 1986, ENDOCRINOLOGY, V118, P940, DOI 10.1210/endo-118-3-940; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; LINNEY E, 1992, CURR TOP DEV BIOL, V27, P309, DOI 10.1016/S0070-2153(08)60538-4; Mackie EJ, 1996, J CELL SCI, V109, P1597; MACKIE EJ, 1992, J CELL SCI, V103, P765; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; McKee MD, 1996, CONNECT TISSUE RES, V35, P197, DOI 10.3109/03008209609029192; McKee MD, 1996, MICROSC RES TECHNIQ, V33, P141, DOI 10.1002/(SICI)1097-0029(19960201)33:2<141::AID-JEMT5>3.0.CO;2-W; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; MULKINS MA, 1983, J BIOL CHEM, V258, P6219; NAKAYAMA Y, 1990, FEBS LETT, V261, P93, DOI 10.1016/0014-5793(90)80644-X; NG KW, 1988, J BONE MINER RES, V3, P53; OHISHI K, 1994, J CELL PHYSIOL, V161, P544, DOI 10.1002/jcp.1041610318; QUARLES LD, 1992, J BONE MINER RES, V7, P683; Raouf A, 2000, ONCOGENE, V19, P1969, DOI 10.1038/sj.onc.1203505; Robinson L, 1997, P NATL ACAD SCI USA, V94, P7170, DOI 10.1073/pnas.94.14.7170; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Sato Y, 1998, Hum Cell, V11, P207; Seth A, 2000, J BONE MINER RES, V15, P1683, DOI 10.1359/jbmr.2000.15.9.1683; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1994, ONCOGENE, V9, P469; SETH A, 1990, ONCOGENE, V5, P1761; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; TAKEUCHI Y, 1995, J CELL PHYSIOL, V162, P315, DOI 10.1002/jcp.1041620303; TOPOL LZ, 1992, CANCER LETT, V67, P71, DOI 10.1016/0304-3835(92)90010-S; TRAIANEDES K, 1993, J CELL PHYSIOL, V157, P243, DOI 10.1002/jcp.1041570206; Varga F, 1997, CALCIFIED TISSUE INT, V61, P404, DOI 10.1007/s002239900356; Vary CPH, 2000, EXP CELL RES, V257, P213, DOI 10.1006/excr.2000.4879; Venanzoni MC, 1996, ONCOGENE, V12, P1199; Walunas TL, 2000, J IMMUNOL, V164, P2857, DOI 10.4049/jimmunol.164.6.2857; Wang DY, 1997, IN VITRO CELL DEV-AN, V33, P248; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; ZHOU H, 1991, J BONE MINER RES, V6, P767	67	109	112	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2000	19	55					6455	6463		10.1038/sj.onc.1204037	http://dx.doi.org/10.1038/sj.onc.1204037			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175361				2022-12-17	WOS:000166595000007
J	Lopez-Borges, S; Lazo, PA				Lopez-Borges, S; Lazo, PA			The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein	ONCOGENE			English	Article						VRK1; p53; mdm-2; kinase; autophosphorylation; nuclear localization signal	DAMAGE-INDUCED PHOSPHORYLATION; DROSOPHILA CLOCK GENE; DNA-DAMAGE; MULTISITE PHOSPHORYLATION; SUBSTRATE DETERMINANTS; DOUBLE-TIME; IN-VITRO; ENCODES; DOMAIN; ACTIVATION	The tumour suppressor p53 protein integrates multiple signals regulating cell cycle progression and apoptosis, This regulation is mediated by several kinases that phosphorylate specific residues in the different functional domains of the p53 molecule. The human VRK1 protein is a new kinase related to a poxvirus kinase, and more distantly to the casein kinase 1 family. We have characterized the biochemical properties of human VRK1 from HeLa cells. VRK1 has a strong autophosphorylating activity in st several Ser and Thr residues. VRK-1 phosphorylates acidic proteins, such as phosvitin and casein, and basic proteins such as histone 2b and myelin basic protein. Because some transcription factors are regulated by phosphorylation, we tested as substrates the N-transactivation domains of p53 and c-Jun fused to GST. Human c-Jun is not phosphorylated by VRK1. VRK1 phosphorylates murine p53 in threonine 18. This threonine is within the p53 hydrophobic loop (residues 13-23) required for the interaction of p53 with the cleft of its inhibitor mdm-2. The VRK1 C-terminus domain (residues 268-396) that contains a nuclear localization signal targets the protein to the nucleus, as determined by using fusion proteins with the green fluorescent protein. We conclude that VRK1 is an upstream regulator of p53 that belongs to a nerv signalling pathway.	Univ Salamanca, CSIC, Ctr Invest Canc, Inst Biol Mol & Celular Canc, Salamanca 37007, Spain; Inst Salud Carlos III, CSIC, Ctr Nacl Biol Fundamental, Unidad Genet & Med Mol, Majadahonda 28220, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Salud Carlos III	Lazo, PA (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Inst Biol Mol & Celular Canc, Campus Miguel de Unamuno, Salamanca 37007, Spain.		Lazo, Pedro A./M-6435-2014	Lazo, Pedro A./0000-0001-8997-3025				BANHAM AH, 1992, VIROLOGY, V191, P803, DOI 10.1016/0042-6822(92)90256-O; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BEAUD G, 1995, J VIROL, V69, P1819, DOI 10.1128/JVI.69.3.1819-1826.1995; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Brown JM, 1999, CANCER RES, V59, P1391; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; Ferrer M, 1999, ONCOGENE, V18, P2253, DOI 10.1038/sj.onc.1202551; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Knippschild U, 1996, ONCOGENE, V13, P1387; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIN SQ, 1992, J VIROL, V66, P2717, DOI 10.1128/JVI.66.5.2717-2723.1992; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Meek DW, 1998, INT J RADIAT BIOL, V74, P729, DOI 10.1080/095530098141005; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Nezu J, 1997, GENOMICS, V45, P327, DOI 10.1006/geno.1997.4938; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Prives C, 1999, J PATHOL, V187, P112; REMPEL RE, 1990, J VIROL, V64, P574, DOI 10.1128/JVI.64.2.574-583.1990; REMPEL RE, 1992, J VIROL, V66, P4413, DOI 10.1128/JVI.66.7.4413-4426.1992; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TRAKTMAN P, 1989, J BIOL CHEM, V264, P21458; TUAZON PT, 1991, ADV SEC MESS PHOSPHO, V23, P123; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657	61	109	113	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2000	19	32					3656	3664		10.1038/sj.onc.1203709	http://dx.doi.org/10.1038/sj.onc.1203709			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951572	Bronze			2022-12-17	WOS:000088568300012
J	Suzuki, T; Ohsugi, Y; Uchida-Toita, M; Akiyama, T; Yoshida, M				Suzuki, T; Ohsugi, Y; Uchida-Toita, M; Akiyama, T; Yoshida, M			Tax oncoprotein of HTLV-1 binds to the human homologue of Drosophila discs large tumor suppressor protein, hDLG, and perturbs its function in cell growth control	ONCOGENE			English	Article						HTLV-1; Tax; adult T cell leukaemia; DLG; PDZ domain	VIRUS TYPE-I; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATOR TAX; CREB BINDING; NUCLEAR TRANSLOCATION; GENE-EXPRESSION; T-LYMPHOCYTES; PDZ DOMAINS; LEUKEMIA	HTLV-1 Tax oncoprotein interacts with various cellular factors and modulates transcription and the cell cycle. To identify more cellular targets, we employed the yeast two hybrid system with Tax using a human cDNA library, and isolated a cDNA encoding the human counterpart of Drosophila discs large tumor suppressor protein, hDLG. Tax binding to hDLG was confirmed in vitro and also in HTLV-l-infected T-cells. Furthermore, hDLG was found to be efficiently phosphorylated in Tax-transfected cells and HTLV-l-infected T-cells. The C-terminus of Tax and the PDZ domain of hDLG were responsible for the binding of Tax to hDLG. The C-terminal peptide of Tax prevented the binding of hDLG to APC tumor suppressor gene product, suggesting inhibition of hDLG function by Tax. Over-expression of hDLG in NIH3T3 cells by microinjection induced a reduction of BrdU incorporation into DNA, but coexpression of Tax suppressed this inhibitory effect of hDLG. These results suggest that hDLG arrested the cell cycle and that Tax canceled this inhibitory action of hDLG through targeting hDLG. Therefore, Tax affects this novel regulatory pathway of the cell cycle alteration, of which seems to play a role in the development of human cancer.	Univ Tokyo, Inst Med Sci, Dept Cellular & Mol Biol, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Mol & Cellular Biol, Dept Mol Genet Informat, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo	Yoshida, M (corresponding author), Banyu Tsukuba Res Inst, 3-Okubo, Tsukuba, Ibaraki 3002611, Japan.							BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POLAKIS P, 1995, CURR OPIN GENET DEV, V5, P66, DOI 10.1016/S0959-437X(95)90055-1; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SUZUKI T, 1994, ONCOGENE, V9, P3099; SUZUKI T, 1995, ONCOGENE, V10, P1199; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D; YOSHIDA M, 1995, J CANCER RES CLIN, V121, P521, DOI 10.1007/BF01197764; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	40	109	112	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	1999	18	44					5967	5972		10.1038/sj.onc.1203008	http://dx.doi.org/10.1038/sj.onc.1203008			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557085				2022-12-17	WOS:000083359100002
J	Clemens, MJ; Bushell, M; Morley, SJ				Clemens, MJ; Bushell, M; Morley, SJ			Degradation of eukaryotic polypeptide chain initiation factor (eIF) 4G in response to induction of apoptosis in human lymphoma cell lines	ONCOGENE			English	Review						apoptosis; eIF4G/initiation factors; initiation of protein synthesis	ACTIVATED PROTEIN-KINASE; MOUTH-DISEASE VIRUS; CAP-DEPENDENT TRANSLATION; UNCAPPED MESSENGER-RNAS; FAS-MEDIATED APOPTOSIS; NERVE GROWTH-FACTOR; BJA-B CELLS; FACTOR 4E; PROTEOLYTIC CLEAVAGE; PHAS-I	We have investigated the effect of inducing apoptosis in BJAB and Jurkat cells on the cellular content of several polypeptide chain initiation factors. Serum deprivation results in inhibition of protein synthesis and induction of apoptosis in BJAB cells; at early times, there is selective degradation of polypeptide initiation factor eIF4G but no major losses of other key initiation factors. The disappearance of full length eIF4G is accompanied by the appearance of smaller forms of the protein, including a major product of approximately 76 kDa. Apoptosis induced by cycloheximide results in similar effects. Both total cytoplasmic eIF4G and eIF4G associated with eIF4E are degraded with a half-life of 2-4 h under these conditions. Treatment of serum-starved or cycloheximide-treated cells with Z-VAD.FMK or Z-DEVD.FMK, which inhibit caspases required for apoptosis, protects eIF4G from degradation and blocks the appearance of the ca. 76 kDa product. Exposure of BJAB cells to rapamycin rapidly inhibits protein synthesis but does not lead to acute degradation of eIF4G. In both BJAB and Jurkat cells induction of apoptosis with anti-Fas antibody or etoposide also results in the selective loss of eIF4G, which is inhibitable by Z-VAD.FMK. These data suggest that eIF4G is selectively targeted for cleavage as cells undergo apoptosis and is a substrate for proteases activated during this process.	St George Hosp, Sch Med, Dept Biochem, Cellular & Mol Biol Grp, London SW17 0RE, England; Univ Sussex, Sch Biol Sci, Biochem Grp, Brighton BN1 9QG, E Sussex, England	St Georges University London; University of Sussex	Clemens, MJ (corresponding author), St George Hosp, Sch Med, Dept Biochem, Cellular & Mol Biol Grp, Cranmer Terrace, London SW17 0RE, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altmann M, 1997, EMBO J, V16, P1114, DOI 10.1093/emboj/16.5.1114; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Benton PA, 1996, J VIROL, V70, P5525, DOI 10.1128/JVI.70.8.5525-5532.1996; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Beretta L, 1996, J VIROL, V70, P8993, DOI 10.1128/JVI.70.12.8993-8996.1996; Berset C, 1998, P NATL ACAD SCI USA, V95, P4264, DOI 10.1073/pnas.95.8.4264; Boix J, 1998, EXP CELL RES, V238, P422, DOI 10.1006/excr.1997.3852; Borman AM, 1997, RNA, V3, P186; Brass N, 1997, HUM MOL GENET, V6, P33, DOI 10.1093/hmg/6.1.33; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COLLINS RJ, 1991, BRIT J CANCER, V64, P518, DOI 10.1038/bjc.1991.341; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; DeGracia DJ, 1996, J NEUROCHEM, V67, P2005; DEVANEY MA, 1988, J VIROL, V62, P4407, DOI 10.1128/JVI.62.11.4407-4409.1988; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Fadden P, 1997, J BIOL CHEM, V272, P10240; FEARNHEAD HO, 1995, FEBS LETT, V375, P283, DOI 10.1016/0014-5793(95)01228-7; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; GRAFF JR, 1995, INT J CANCER, V60, P255; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; Haghighat A, 1996, J VIROL, V70, P8444, DOI 10.1128/JVI.70.12.8444-8450.1996; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; HERSHEY JWB, 1994, BIOCHIMIE, V76, P847, DOI 10.1016/0300-9084(94)90186-4; Imataka H, 1997, EMBO J, V16, P817, DOI 10.1093/emboj/16.4.817; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Ishii H, 1997, INT J EXP PATHOL, V78, P123, DOI 10.1046/j.1365-2613.1997.170350.x; ISHII HH, 1995, IMMUNOL CELL BIOL, V73, P463, DOI 10.1038/icb.1995.72; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; JOSHIBARVE S, 1992, J BIOL CHEM, V267, P21038; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kamada S, 1997, ONCOGENE, V15, P285, DOI 10.1038/sj.onc.1201192; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kawanishi M, 1997, VIROLOGY, V228, P244, DOI 10.1006/viro.1996.8370; Kay JE, 1996, IMMUNOLOGY, V87, P390; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; KIRCHWEGER R, 1994, J VIROL, V68, P5677, DOI 10.1128/JVI.68.9.5677-5684.1994; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KRIEG J, 1988, J BIOL CHEM, V263, P11473; KULKARNI GV, 1994, J CELL SCI, V107, P1169; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Lavin MF, 1996, EXPERIENTIA, V52, P979, DOI 10.1007/BF01920107; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; LEDDACOLUMBANO GM, 1992, AM J PATHOL, V140, P545; LevyStrumpf N, 1997, MOL CELL BIOL, V17, P1615, DOI 10.1128/MCB.17.3.1615; Li BDL, 1997, CANCER-AM CANCER SOC, V79, P2385; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LLOYD RE, 1987, J VIROL, V61, P2480, DOI 10.1128/JVI.61.8.2480-2488.1987; LLOYD RE, 1988, J VIROL, V62, P4216, DOI 10.1128/JVI.62.11.4216-4223.1988; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; MADER S, 1995, MOL CELL BIOL, V15, P4990; MAO XH, 1992, J BIOL CHEM, V267, P20444; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; MERICK WC, 1996, TRANSLATIONAL CONTRO, P31; MERRICK WC, 1994, BIOCHIMIE, V76, P822, DOI 10.1016/0300-9084(94)90183-X; MILNER AE, 1995, APPL FLOW CYTOMETRY, P56; MIYAGI Y, 1995, CANCER LETT, V91, P247, DOI 10.1016/0304-3835(95)03737-H; MORLEY SJ, 1995, J CELL SCI, V108, P1751; Morley SJ, 1997, RNA, V3, P1085; MORLEY SJ, 1995, BIOCHEM J, V312, P627, DOI 10.1042/bj3120627; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Naranda T, 1997, MOL CELL BIOL, V17, P145, DOI 10.1128/MCB.17.1.145; Nathan CA, 1997, ONCOGENE, V15, P1087, DOI 10.1038/sj.onc.1201272; Nathan CAO, 1997, ONCOGENE, V15, P579, DOI 10.1038/sj.onc.1201216; NEUMAR RW, 1995, J NEUROCHEM, V65, P1391; Novoa I, 1997, BIOCHEMISTRY-US, V36, P7802, DOI 10.1021/bi9631172; OEHM A, 1992, J BIOL CHEM, V267, P10709; Ohlmann T, 1997, EMBO J, V16, P844, DOI 10.1093/emboj/16.4.844; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; OHLMANN T, 1995, NUCLEIC ACIDS RES, V23, P334; Ohta T, 1997, J BIOL CHEM, V272, P23111, DOI 10.1074/jbc.272.37.23111; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Perry DK, 1997, J BIOL CHEM, V272, P18530, DOI 10.1074/jbc.272.30.18530; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Rau M, 1996, J BIOL CHEM, V271, P8983, DOI 10.1074/jbc.271.15.8983; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rowan S, 1997, LEUKEMIA, V11, P457, DOI 10.1038/sj.leu.2400626; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; SINHA BK, 1995, DRUGS, V49, P11, DOI 10.2165/00003495-199549010-00002; SONENBERG N, TRANSLATIONAL CONTRO, P245; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WANG E, 1995, J CELL PHYSIOL, V163, P155, DOI 10.1002/jcp.1041630118; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yamanaka S, 1997, GENE DEV, V11, P321, DOI 10.1101/gad.11.3.321; YAN RQ, 1992, J BIOL CHEM, V267, P23226; Zakeri Z, 1996, MICROSC RES TECHNIQ, V34, P192; ZIEGLER E, 1995, VIROLOGY, V213, P549; ZIEGLER E, 1995, J VIROL, V69, P3465, DOI 10.1128/JVI.69.6.3465-3474.1995	113	109	112	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	1998	17	22					2921	2931		10.1038/sj.onc.1202227	http://dx.doi.org/10.1038/sj.onc.1202227			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879998				2022-12-17	WOS:000077286400012
J	Petermann, R; Mossier, BM; Aryee, DNT; Khazak, V; Golemis, EA; Kovar, H				Petermann, R; Mossier, BM; Aryee, DNT; Khazak, V; Golemis, EA; Kovar, H			Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II	ONCOGENE			English	Article						ewing tumors; transcription; transformation; two-hybrid-system; sigma factors	EWINGS-SARCOMA TRANSLOCATION; TRANSCRIPTION FACTOR-TFIIB; BINDING PROTEIN; DNA-BINDING; CHROMOSOME-TRANSLOCATION; EWS GENE; MYXOID LIPOSARCOMA; MALIGNANT-MELANOMA; ACTIVATION DOMAIN; MYELOID-LEUKEMIA	As a result of the t(11;22)(q24;q12) chromosomal translocation characterizing the Ewing family of tumors (ET), the amino terminal portion of EWS, an RNA binding protein of unknown function, is fused to the DNA-binding domain of the ets transcription factor Fli1. The hybrid EWS-Fli1 protein acts as a strong transcriptional activator and, in contrast to wildtype Fli1, is a potent transforming agent. Similar rearrangements involving EWS or the highly homologous TLS with various transcription factors have been found in several types of human tumors. Employing yeast two-hybrid cloning we isolated the seventh largest subunit of human RNA polymerase II (hsRPB7) as a protein that specifically interacts with the amino terminus of EWS, This association was confirmed by in vitro immunocoprecipitation. In nuclear extracts, hsRPB7 was found to copurify with EWS-Fli1 but not with Fli1, Overexpression of recombinant hsRPB7 specifically increased gene activation by EWS-chimeric transcription factors. Replacement of the EWS portion by hsRPB7 in the oncogenic fusion protein restored the transactivating potential of the chimera. Our results suggest that the interaction of the amino terminus of EWS with hsRPB7 contributes to the transactivation function of EWS-Fli1 and, since hsRPB7 has characteristics of a regulatory subunit of RNA polymerase II, may influence promoter selectivity.	St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Saint Anna Children's Hospital; Fox Chase Cancer Center	Kovar, H (corresponding author), St Anna Childrens Hosp, Childrens Canc Res Inst, Kinderspitalgasse 6, A-1090 Vienna, Austria.			Golemis, Erica/0000-0003-3618-3673; Kovar, Heinrich/0000-0001-6873-9109	NIGMS NIH HHS [GM 708041] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alliegro MC, 1996, DEV BIOL, V174, P288, DOI 10.1006/dbio.1996.0074; [Anonymous], 1991, Methods Enzymol, V194, P1; AURIAS A, 1983, CR ACAD SCI III-VIE, V296, P1105; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BERTOLOTTI A, 1998, MOL CELL BIOL, V13, P6984; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CARE CT, 1983, C R SEANCES ACAD 3, V296, P1101; CHODER M, 1993, MOL CELL BIOL, V13, P6984, DOI 10.1128/MCB.13.11.6984; Clark J, 1996, ONCOGENE, V12, P229; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fujimura Y, 1996, ONCOGENE, V12, P159; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; Hackl W, 1996, J MOL BIOL, V264, P843, DOI 10.1006/jmbi.1996.0681; ICHIKAWA H, 1994, CANCER RES, V54, P2865; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JEON IS, 1995, ONCOGENE, V10, P1229; KHAZAK V, 1995, MOL BIOL CELL, V6, P759, DOI 10.1091/mbc.6.7.759; KHAZAK V, 1998, IN PRESS MOL CELL BI; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESSNICK SL, 1995, ONCOGENE, V10, P423; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; OHNO T, 1993, CANCER RES, V53, P5869; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Panagopoulos I, 1996, ONCOGENE, V12, P489; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAO VN, 1993, ONCOGENE, V8, P2167; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STOLOW DT, 1995, NUCLEIC ACIDS RES, V23, P835, DOI 10.1093/nar/23.5.835; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	49	109	124	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	1998	17	5					603	610		10.1038/sj.onc.1201964	http://dx.doi.org/10.1038/sj.onc.1201964			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704926				2022-12-17	WOS:000075195300008
J	Bardelli, A; Longati, P; Gramaglia, D; Stella, MC; Comoglio, PM				Bardelli, A; Longati, P; Gramaglia, D; Stella, MC; Comoglio, PM			Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential	ONCOGENE			English	Article						HGF/MET-receptor; Gab1; transformation	HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR-RECEPTOR; MET RECEPTOR; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL-CELLS; PROTEIN; ONCOGENE; GENE	Activation of the HGF receptor, encoded by the c-MET protooncogene (Met receptor), triggers motility, matrix-invasion and branching morphogenesis in epithelial cells. It has recently been shown that the Met receptor interacts with Gab-1, an IRS-like adaptor protein, via the docking site (Y(1349)VHVNATY(1356)VNV) known to bind Grb2 and multiple SH2-containing signal transducers. Here we show that Gab1 is the major phosphorylation-substrate of the Met receptor and of its oncogenic variant Tpr-Met. A series of point mutations in the docking site established a direct correlation between the ability to recruit and phosphorylate Gab1 and the transforming potential, Interestingly. the mutations of either Y-1356 or N-1358 abolished the binding of both Grb2 and Gab1 in intact cells, Furthermore, peptides designed to block either the SH2 or the SH3 domains of Grb2 interfered,vith the receptor-Gab1 interaction, These data indicate that Gab1 coupling to the Met receptor requires binding of Grb2 and correlates with the transforming potential of Tpr-Met.	Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, I-10060 Candiolo, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Bardelli, A (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, I-10060 Candiolo, Italy.		GRAMAGLIA, DANIELA/A-6354-2012; BARDELLI, Alberto/J-9721-2018	BARDELLI, Alberto/0000-0003-1647-5070; Gramaglia, Daniela/0000-0001-6259-0059; Comoglio, Paolo/0000-0002-7056-5328				BARDELLI A, 1997, IN PRESS BIOCH BIOPH; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; FIXMAN ED, 1995, ONCOGENE, V10, P237; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GIORDANO S, 1997, IN PRESS P NATL ACAD; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; NALDINI L, 1991, EMBO J, V10, P2687; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PONZETTO P, 1996, J BIOL CHEM, V271, P14119; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Sambrook J, 1989, MOL CLONING LAB MANU; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	24	109	119	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3103	3111		10.1038/sj.onc.1201561	http://dx.doi.org/10.1038/sj.onc.1201561			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444958				2022-12-17	WOS:000070968000010
J	Xie, SH; Price, JE; Luca, M; Jean, D; Ronai, Z; BarEli, M				Xie, SH; Price, JE; Luca, M; Jean, D; Ronai, Z; BarEli, M			Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells	ONCOGENE			English	Article						CREB; dominant negative; malignant melanoma; metastasis; collagenase	HUMAN MELANOCYTES; MEDIATED INDUCTION; CYCLIC-AMP; BINDING; GENE; EXPRESSION; TRANSCRIPTION; PROTEINS; PHOSPHORYLATION; TYROSINASE	The ATF/CREB family of eukaryotic transcription factors contain the bZIP structural motif and mediate their transcriptional activities via heterodimerization with ATF and AP-1 family members, Quenching of CREB-associated proteins by a dominant-negative CREB that is mutated within its DNA-binding domain decreases radiation resistance of human melanoma cells, The purpose of this study was to determine the role of CREB in tumor growth and metastasis of human melanoma using KCREB. Highly metastatic MeWo were transfected with the and subsequently analysed for changes in their tumorigenic and metastatic potential, Expression of KCREB in MeWo human cells decreased their tumorigenic and metastatic potential in nude mice compared with parental and control transfected cells, The KCREB-transfected cells displayed downregulation of 72kDa collagenase type IV (MMP-2) mRNA expression and activity and decreased invasiveness through Matrigel-coated filters, Moreover, transcriptional activities mediated by the CAT gene driven by the MMP-2 promoter were decreased by 14-45-fold in KCREB-transfected cells, In addition, the cell-surface adhesion molecule MCAM/MUC18 that is involved in metastasis of human melanoma was downregulated in the KCREB-transfected cells, These data indicate that, through their transcriptional activities, CREB and its associated proteins play an important role in the acquisition of the metastatic phenotype of human melanoma cells.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT CELL BIOL,HOUSTON,TX 77030; MT SINAI SCH MED,RUTTENBERG CANC CTR,NEW YORK,NY 10029	University of Texas System; UTMD Anderson Cancer Center; Icahn School of Medicine at Mount Sinai			Jean, Didier/A-1615-2009	Jean, Didier/0000-0001-5823-7404; RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA 51995, CA 64137, CA 16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051995, R21CA064137, R29CA051995, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; Bernstein Lori R., 1994, Current Opinion in Oncology, V6, P106, DOI 10.1097/00001622-199401000-00015; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; BORRELLI E, 1992, Critical Reviews in Oncogenesis, V3, P321; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FIDLER IJ, 1990, CANCER RES, V50, P6130; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALABAN R, 1993, SEMIN CANCER BIOL, V4, P171; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HALABAN R, 1984, ARCH BIOCHEM BIOPHYS, V230, P383, DOI 10.1016/0003-9861(84)90121-8; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; Huang SY, 1996, ONCOGENE, V13, P2339; Huang SY, 1996, CLIN CANCER RES, V2, P1969; HUDSON JM, 1995, DNA CELL BIOL, V14, P759, DOI 10.1089/dna.1995.14.759; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LANSCHULZ WH, 1988, SCIENCE, V240, P1759; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LESTER BR, 1992, CURR OPIN ONCOL, V6, P106; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; Lu Chao, 1994, Current Opinion in Oncology, V6, P212, DOI 10.1097/00001622-199403000-00015; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; LUCA M, 1995, ONCOGENE, V11, P1399; MOHLER JL, 1991, CANCER RES, V50, P6580; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; PATRIN AW, 1991, P NATL ACAD SCI USA, V86, P1254; RADINSKY R, 1994, ONCOGENE, V9, P1977; RAY JM, 1995, EMBO J, V14, P908, DOI 10.1002/j.1460-2075.1995.tb07072.x; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RUTBERG SE, 1994, MOL CARCINOGEN, V10, P82, DOI 10.1002/mc.2940100205; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; SINGH RK, 1995, CANCER RES, V55, P3669; VANLEEUWEN RL, 1994, INT J CANCER, V57, P894, DOI 10.1002/ijc.2910570620; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WANDA T, 1991, J VIROL, V65, P557; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; WOLOSHIN PI, 1992, MOL ENDOCRINOL, V6, P1725, DOI 10.1210/me.6.10.1725; Xie SH, 1997, CANCER RES, V57, P2295; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; Yang YM, 1996, ONCOGENE, V12, P2223	46	109	113	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2069	2075		10.1038/sj.onc.1201358	http://dx.doi.org/10.1038/sj.onc.1201358			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366524				2022-12-17	WOS:A1997YC28400008
J	Alkema, MJ; Jacobs, H; vanLohuizen, M; Berns, A				Alkema, MJ; Jacobs, H; vanLohuizen, M; Berns, A			Perturbation of B and T cell development and predisposition to lymphomagenesis in E mu Bmi1 transgenic mice require the Bmi1 RING finger	ONCOGENE			English	Article						Bmi1; lymphoid development; lymphomagenesis; provirus tagging	E-MU-MYC; POLYCOMB GROUP GENES; C-MYC; ZINC-FINGER; LEUKEMIA-VIRUS; HOMEOBOX GENE; PROVIRAL INSERTION; AXIAL SKELETON; DROSOPHILA; EXPRESSION	Proviral activation of the Bmi1 gene has implicated Bmi1 as a collaborator of c-Myc in lymphomagenesis. To determine the effect of Bmi1 overexpression on hematopoiesis and lymphomagenesis transgenic mice were generated that overexpress different forms of the Bmi1 protein in their lymphoid compartment. E mu Bmi1 transgenic mice, overexpressing the wild type Bmi1 protein showed a perturbed lymphoid development and were highly susceptible to B and T cell lymphomagenesis. Mutational analysis of the Bmi1 protein demonstrated that the conserved N-terminal RING finger and central part of Bmi1 are essential for its oncogenic potential whereas the C-terminal Pro-Ser rich region is not required. We have used provirus tagging in the E mu Bmi1 mice to identify genes that cooperate with Bmi1 in lymphomagenesis. MoMLV infection in E mu Bmi1 transgenic mice accelerated Lymphoma development. Proviral activation of the Pim and Myc genes but not the Gfi1 gene were frequently observed in these tumors. These results demonstrate that Bmi1 is a potent oncogene and suggest that it plays an important role in early lymphoid development.	NETHERLANDS CANC INST, DIV MOL GENET, NL-1066 CX AMSTERDAM, NETHERLANDS; NETHERLANDS CANC INST, DIV MOL CARCINOGENESIS, NL-1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute; Netherlands Cancer Institute				Jacobs, Heinz/0000-0001-6227-9850				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Akasaka T, 1996, DEVELOPMENT, V122, P1513; ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BREUER ML, 1989, EMBO J, V8, P743, DOI 10.1002/j.1460-2075.1989.tb03434.x; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; Cohen KJ, 1996, MOL CELL BIOL, V16, P5527; DUBE ID, 1991, BLOOD, V78, P2996; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVERETT R, 1995, J VIROL, V69, P7339, DOI 10.1128/JVI.69.11.7339-7344.1995; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAUPT Y, 1993, ONCOGENE, V8, P3161; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; JACOBS H, 1994, EUR J IMMUNOL, V24, P934, DOI 10.1002/eji.1830240423; JAENISCH R, 1975, P NATL ACAD SCI USA, V72, P4008, DOI 10.1073/pnas.72.10.4008; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LEVY LS, 1993, VIROLOGY, V196, P892, DOI 10.1006/viro.1993.1553; LIAO XB, 1995, J VIROL, V69, P7132, DOI 10.1128/JVI.69.11.7132-7137.1995; MCKEON J, 1994, MOL GEN GENET, V244, P474, DOI 10.1007/BF00583898; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; NOMURA M, 1994, DIFFERENTIATION, V57, P39, DOI 10.1046/j.1432-0436.1994.5710039.x; PEARCE JJH, 1992, DEVELOPMENT, V114, P921; PELEGRI F, 1994, GENETICS, V136, P1341; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHINKAI Y, 1994, INT IMMUNOL, V6, P995, DOI 10.1093/intimm/6.7.995; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; vanderLugt NMT, 1996, MECH DEVELOP, V58, P153, DOI 10.1016/S0925-4773(96)00570-9; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Zornig M, 1996, ONCOGENE, V12, P1789	56	109	114	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	1997	15	8					899	910		10.1038/sj.onc.1201262	http://dx.doi.org/10.1038/sj.onc.1201262			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285685				2022-12-17	WOS:A1997XR76700003
J	Ogris, E; Gibson, DM; Pallas, DC				Ogris, E; Gibson, DM; Pallas, DC			Protein phosphatase 2A subunit assembly: the catalytic subunit carboxy terminus is important for binding cellular B subunit but not polyomavirus middle tumor antigen	ONCOGENE			English	Article						phosphatase; PP2A; polyomavirus middle tumor antigen	SMALL-T-ANTIGEN; A-SUBUNIT; TYROSINE PHOSPHORYLATION; REGULATORY SUBUNITS; DNA-REPLICATION; TYPE-2A; IDENTIFICATION; KINASE; GROWTH; FORMS	The carboxy terminus of protein phosphatase 2A (PP2A) catalytic subunit is highly conserved. Seven out of the last nine residues, including two potential in vivo phosphorylation sites, threonine 304 and tyrosine 307, are completely invariant in all known PP2As, Mutational analysis of the carboxy terminus in vivo was facilitated by efficient immunoprecipitation of trimeric PP2A holoenzyme via an epitope-tagged catalytic subunit, The results indicate that the catalytic submit carboxy terminus is important for complex formation with the PP2A 55 kDa regulatory B subunit, but not with polyomavirus oncogene, middle tumor antigen (MT), a viral B-type regulatory subunit, Replacing catalytic subunit threonine 304 or tyrosine 307 with a negatively charged amino acid abolished binding of the B subunit to the dimeric enzyme core and altered substrate specificity, Certain other amino acid substitutions of different size and/or charge also abolished or greatly reduced B subunit binding, Substitution of alanine at position 304 or phenylalanine at position 307 did not dramatically reduce B subunit binding or phosphatase activity in vitro, yet the latter substitutions are not found in naturally occurring PP2As, Thus, the wild-type residues are important for a yet unknown function in vivo, Additionally, deleting the carboxy terminal nine amino acids inhibited binding of the B subunit to the dimeric enzyme core, indicating a requirement for one or more of these amino acids for complex formation, MT interaction with the dimeric PP2A enzyme core was not inhibited by any of these mutations, Finally, unlike B subunit, MT does not activate the phosphatase activity of the PP2A heterodimer towards cdc2-phosphorylated histone HI.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Ogris, Egon/0000-0001-5950-9264	NCI NIH HHS [CA57327, R01 CA057327] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; CAYLA X, 1993, EUR J BIOCHEM, V214, P281, DOI 10.1111/j.1432-1033.1993.tb17922.x; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHERINGTON V, 1986, P NATL ACAD SCI USA, V83, P4307, DOI 10.1073/pnas.83.12.4307; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; FAVRE B, 1994, J BIOL CHEM, V269, P16311; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; GLENN GM, 1995, J VIROL, V69, P3729, DOI 10.1128/JVI.69.6.3729-3736.1995; GRUSSENMEYER T, 1987, J VIROL, V61, P3902, DOI 10.1128/JVI.61.12.3902-3909.1987; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1992, J BIOL CHEM, V267, P21864; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE J, 1993, J BIOL CHEM, V268, P19192; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MAYERJAEKEL RE, 1994, J CELL SCI, V107, P2609; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PALLAS DC, 1986, J VIROL, V60, P1075, DOI 10.1128/JVI.60.3.1075-1084.1986; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; RUNDELL K, 1987, J VIROL, V61, P1240, DOI 10.1128/JVI.61.4.1240-1243.1987; Sambrook J, 1989, MOL CLONING LAB MANU; SOLA MM, 1991, BIOCHIM BIOPHYS ACTA, V1094, P211, DOI 10.1016/0167-4889(91)90011-L; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STONE SR, 1988, NUCLEIC ACIDS RES, V16, P11365, DOI 10.1093/nar/16.23.11365; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; UEMURA T, 1993, GENE DEV, V7, P429, DOI 10.1101/gad.7.3.429; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992; USUI H, 1988, J BIOL CHEM, V263, P3752; XIE HY, 1994, J BIOL CHEM, V269, P1981	45	109	111	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					911	917		10.1038/sj.onc.1201259	http://dx.doi.org/10.1038/sj.onc.1201259			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285686				2022-12-17	WOS:A1997XR76700004
J	Takaoka, A; Adachi, M; Okuda, H; Sato, S; Yawata, A; Hinoda, Y; Takayama, S; Reed, JC; Imai, K				Takaoka, A; Adachi, M; Okuda, H; Sato, S; Yawata, A; Hinoda, Y; Takayama, S; Reed, JC; Imai, K			Anti-cell death activity promotes pulmonary metastasis of melanoma cells	ONCOGENE			English	Article						BCL-2; BAG-1; melanoma; pulmonary metastasis	HUMAN FOLLICULAR LYMPHOMA; CANCER METASTASIS; BCL-2; PROTEIN; APOPTOSIS; EXPRESSION; LECTINS; MATRIX; GENE	Bcl-2 inhibits apoptosis from a variety of stimuli, and a Bcl-2-binding protein BAG-1 also functions in protection from apoptosis in concert with Bcl-2, Here, we provide evidence that prolonged cell survival introduced by overexpression of Bcl-2 or BAG-1 proteins strongly promotes experimental pulmonary metastasis of melanoma B16-BL6 cells, In murine melanoma cell line B16-BL6, gene transfer-mediated expression of the Bcl-2 or BAG-1 led to prolonged cell survival against serum-starved apoptosis in vitro, The Bcl-2-expressing B16 cells, B16-Bcl-2 and the BAG-1-expressing B16 cells, B16-BAG-1 strongly enhanced pulmonary metastasis in allogenic BALB/c nude mice and whole lung weights were increased by 2.4-fold and 1.4-fold, respectively, compared with control transfectants, suggesting that Bcl-2 is a stronger positive modulator of metastasis, When the viable B16-Bcl-2 and control transfectants were injected subcutaneously into BALB/c nude mice, the colony numbers of pulmonary metastasis of the B16-Bcl-2 transfectant increased by 5.6-fold compared with the control transfectants, These enhanced metastatic potentials in the B16-Bcl-2 and the B16-BAG-1 transfectants were well correlated with anti-cell death activity against serum-starvation and enhanced cell viability on limiting dilution, Analysis of the transfectants however revealed that their growth rates, invasive ability and cell motility were not significantly altered by overexpression of either Bcl-2 or BAG-1 proteins, Taken together, these studies demonstrate that prolonged cell survival is a crucial factor to promote metastasis of melanoma, thereby contributing to tumor progression.	SAPPORO MED UNIV,SCH MED,DEPT INTERNAL MED 1,SAPPORO,HOKKAIDO 060,JAPAN; BURNHAM INST,CTR CANC RES,LA JOLLA,CA 92037	Sapporo Medical University; Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R01CA067329] Funding Source: NIH RePORTER; NCI NIH HHS [CA-67329] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1987, CANCER RES, V47, P3239; ALBRECHTBUEHLER G, 1977, CELL, V11, P359; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; COLLINS KA, 1995, AM J DERMATOPATH, V17, P429, DOI 10.1097/00000372-199510000-00001; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FIDLER IJ, 1990, CANCER RES, V50, P6130; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Glinsky GV, 1996, CANCER LETT, V101, P43, DOI 10.1016/0304-3835(96)04112-2; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MEROMSKY L, 1986, CANCER RES, V46, P5270; Nicolson GL, 1989, CURR OPIN CELL BIOL, V1, P1009, DOI 10.1016/0955-0674(89)90073-2; PARTIN AW, 1989, P NATL ACAD SCI USA, V86, P1254, DOI 10.1073/pnas.86.4.1254; POSTE G, 1980, CANCER RES, V40, P1636; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; RAZ A, 1990, INT J CANCER, V46, P871, DOI 10.1002/ijc.2910460520; RAZ A, 1987, CANCER METAST REV, V6, P433, DOI 10.1007/BF00144274; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAENZSANTAMARIA MC, 1994, J CUTAN PATHOL, V21, P393; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TRON VA, 1995, AM J PATHOL, V146, P643; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	29	109	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2971	2977		10.1038/sj.onc.1201147	http://dx.doi.org/10.1038/sj.onc.1201147			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205104				2022-12-17	WOS:A1997XF55500011
J	Soloway, PD; Alexander, CM; Werb, Z; Jaenisch, R				Soloway, PD; Alexander, CM; Werb, Z; Jaenisch, R			Targeted mutagenesis of Timp-1 reveals that lung tumor invasion is influenced by Timp-1 genotype of the tumor but not by that of the host	ONCOGENE			English	Article						Timp-1; metastasis; proteinase inhibitor; targeted mutant	B16-F10 MELANOMA-CELLS; EMBRYONIC STEM-CELLS; TISSUE INHIBITOR; MATRIX METALLOPROTEINASE; EXPRESSION; COLLAGENASE; LOCALIZATION; PROTEINASES; GELATINASES; SECRETION	Timp-1 has been implicated as a suppressor of tumor metastasis, To study the relative importance of Timp-1 expression by tumor vs host during tumor invasion, three pairs of co-isogenic, tumorigenic cells containing wildtype or mutant Timp-1 alleles were generated, These were used in experimental metastasis assays in wild-type or Timp-1-deficient mice, Timp-1 expression in tumorigenic cells could either increase or decrease tumor invasion of lungs in a tumor cell-specific manner, This suggests that depending on the tumor, Timp-1 can either suppress or potentiate metastasis. Mice deficient for Timp-1 were indistinguishable from wild-type mice in metastasis assays with all tumorigenic cells tested, Although Timp-1 is a secreted protein, and lung produces other Timps, the influence of Timp-1 on lung invasion by the tumorigenic cells tested is cell-autonomous, depending only on Timp-1 genotype of tumor and not that of host.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; UNIV CALIF SAN FRANCISCO,DEPT ANAT,RADIOBIOL & ENVIRONM HLTH LAB,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143	Massachusetts Institute of Technology (MIT); Whitehead Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Soloway, Paul/T-8243-2019	Soloway, Paul/0000-0003-1967-0437	NCI NIH HHS [CA57621] Funding Source: Medline; NEI NIH HHS [EY11279] Funding Source: Medline; NIGMS NIH HHS [GM15325] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057621] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011279] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015325] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER CM, 1992, J CELL BIOL, V118, P727, DOI 10.1083/jcb.118.3.727; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; CHEN JM, 1987, CELL, V48, P193, DOI 10.1016/0092-8674(87)90423-5; CLAVEL C, 1992, B CANCER, V79, P261; DOCHERTY AJ, 1995, NATURE, V318, P66; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HICKS NJ, 1984, INT J CANCER, V33, P835, DOI 10.1002/ijc.2910330620; HOWARD EW, 1991, J BIOL CHEM, V266, P13070; HOYHTYA M, 1994, INT J CANCER, V56, P500, DOI 10.1002/ijc.2910560408; KAN CC, 1985, P NATL ACAD SCI USA, V82, P2282, DOI 10.1073/pnas.82.8.2282; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LECO KJ, 1992, GENE, V117, P209, DOI 10.1016/0378-1119(92)90731-4; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; MAQUAT LE, 1995, RNA, V1, P453; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MONSKY WL, 1993, CANCER RES, V53, P3159; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; PONTON A, 1991, CANCER RES, V51, P2138; Sambrook J, 1989, MOL CLONING LAB MANU; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHULTZ RM, 1988, CANCER RES, V48, P5539; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; TSUBOI R, 1990, INT J CANCER, V46, P56, DOI 10.1002/ijc.2910460112; WANG X, 1994, CANCER RES, V54, P4726; WATERHOUSE P, 1993, MOL REPROD DEV, V35, P219, DOI 10.1002/mrd.1080350302; WELGUS HG, 1983, J BIOL CHEM, V258, P2259; WRIGHT JH, 1994, MOL CARCINOGEN, V10, P207, DOI 10.1002/mc.2940100405; ZUCKER S, 1992, INT J CANCER, V52, P366, DOI 10.1002/ijc.2910520307	34	109	113	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2307	2314						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957071				2022-12-17	WOS:A1996VX10800002
J	Nakamura, T; Sanokawa, R; Sasaki, Y; Ayusawa, D; Oishi, M; Mori, N				Nakamura, T; Sanokawa, R; Sasaki, Y; Ayusawa, D; Oishi, M; Mori, N			N-Shc: A neural-specific adapter molecule that mediates signaling from neurotrophin/Trk to Ras/MAPK pathway	ONCOGENE			English	Article						Shc family; signal transduction; phosphotyrosine; BDNF; TrkB; EGF receptor	GUANINE-NUCLEOTIDE EXCHANGE; PROTEIN-TYROSINE KINASE; GROWTH-FACTOR RECEPTOR; CENTRAL-NERVOUS-SYSTEM; MAP KINASE; MESSENGER-RNAS; BINDING-SITES; CONSTITUTIVE PHOSPHORYLATION; PC12 CELLS; RAS	Shc has been implicated in a variety of growth factor- and cytokine receptor-signaling through its specific binding to phosphotyrosine residues of the activated receptors. In neuronal cells, such as PC12, She has been shown to be involved in Ras-dependent MAP kinase activation following Trk receptor stimulation with NGF. While the ubiquitous role of She as an adaptor molecule in signal transduction is increasing in both neuronal and non-neuronal cells and tissues, the expression level of Shc is suprisingly low in the brain. We demonstrated here the isolation of a neural-specific member of the She family. This novel protein, named N-Shc (neuronal Shc), contains tao potential phosphotyrosine-binding domains, PTB and SH2, and is expressed exclusively in the brain; whereas Shc is present in all other non-neuronal tissues. As in Shc, N-Shc can bind activated EGF receptor, become tyrosine phosphorylated, and form a complex with Grb2 adapter protein following EGF stimulation. Furthermore, N-Shc can bind activated TrkB receptor following the stimulation with brain-derived neurotrophic factor (BDNF), which is the most abundant neurotrophin in the brain. These data suggest that N-Shc, rather than She, mediates neurotrophin and other neuronal signalings in the central nervous system.	UNIV TOKYO,INST MOL CELLULAR & BIOSCI,BUNKYO KU,TOKYO 113,JAPAN; YOKOHAMA CITY UNIV,KIHARA INST BIOL RES,TOTSUKA KU,YOKOHAMA,KANAGAWA 244,JAPAN; RES DEV CORP JAPAN,PRESTO,INHERITANCE & VARIAT GRP,KYOTO 61902,JAPAN	University of Tokyo; Yokohama City University; Japan Science & Technology Agency (JST)	Nakamura, T (corresponding author), SUMITOMO ELECT IND,BIOMED RES & DEV DEPT,SAKAE KU,YOKOHAMA,KANAGAWA 244,JAPAN.		Sasaki, Yasnory/L-7065-2018	Sasaki, Yasnory/0000-0003-2614-7038				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BURNS LA, 1993, J BIOL CHEM, V268, P17659; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GIOGETTI S, 1994, EUR J BIOCHEM, V223, P195; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; HEFTI F, 1992, NEUROTROPHIC FACTORS, P25; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HIMI T, 1994, NEUROSCIENCE, V60, P907, DOI 10.1016/0306-4522(94)90271-2; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MIRANDA RC, 1993, P NATL ACAD SCI USA, V90, P6439, DOI 10.1073/pnas.90.14.6439; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SALCINI AE, 1994, ONCOGENE, V9, P2827; Sasaki Y F, 1994, DNA Res, V1, P91, DOI 10.1093/dnares/1.2.91; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SAXTON TM, 1994, J IMMUNOL, V153, P623; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUZUKI K, 1995, FEBS LETT, V364, P283, DOI 10.1016/0014-5793(95)00393-N; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; WINITZ S, 1993, J BIOL CHEM, V268, P19196; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	64	109	116	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1111	1121						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808684				2022-12-17	WOS:A1996VJ20200001
J	Bhatia, K; Raj, A; Gutierrez, MI; Judde, JG; Spangler, G; Venkatesh, H; Magrath, IT				Bhatia, K; Raj, A; Gutierrez, MI; Judde, JG; Spangler, G; Venkatesh, H; Magrath, IT			Variation in the sequence of Epstein Barr virus nuclear antigen 1 in normal peripheral blood lymphocytes and in Burkitt's lymphomas	ONCOGENE			English	Article						EBV; EBNA-1; Burkitt's lymphoma; mutations; lymphomagenesis	CELLS; ASSOCIATION; EXPRESSION; TUMORS; EBV	We have examined sequence variations in the EBNA-1 protein of EBV in normal peripheral blood lymphocytes (PBL) and Burkitt's lymphomas (BL), We find two EBNA-1 strains P (prototype) and V (variant) which differ by 15 amino acids, Each strain has two subtypes defined by the amino acid at position 487 (P-ala, P-thr, V-pro and V-leu), In PBLs from 32 normal individuals, up to three of these subtypes were found in each sample, but the V strain did not occur in the absence of P strain viruses, nor was the V-leu subtype ever observed in normal PBL, In BLs only a single subtype was observed in each tumor, The P-thr and V-leu subtypes were more frequently seen than the P-ala and V-pro subtypes, which occurred in only two and one of the 36 tumor samples respectively, The P-thr was the most commonly observed peripheral blood of both American and as well as in African tumors, However, in 11 of 12 American tumors, the EBNA-1 subtype was V-leu, These data indicate that some EBNA-1 subtypes are more likely to lead to oncogenesis, and one subtype, V-leu, appears only to occur in tumors.			Bhatia, K (corresponding author), NATL CANC INST,LYMPHOMA BIOL SECT,PEDIAT BRANCH,NIH,BLDG 10,ROOM 13N240,10 CTR DR MSC 1928,BETHESDA,MD 20892, USA.							BHATIA KG, 1992, CANCER RES, V52, P4273; CHANG YS, 1990, J CLIN MICROBIOL, V28, P2398, DOI 10.1128/JCM.28.11.2398-2402.1990; COLES RE, 1994, ANN SURG ONCOL, V1, P405, DOI 10.1007/BF02303813; FRANK D, 1995, BLOOD, V85, P1396, DOI 10.1182/blood.V85.5.1396.bloodjournal8551396; GUTIERREZ MI, 1992, BLOOD, V79, P3261; HENLE W, 1967, J NATL CANCER I, V43, P1147; HENNESSY K, 1983, P NATL ACAD SCI-BIOL, V80, P5665, DOI 10.1073/pnas.80.18.5665; LABRECQUE LG, 1995, CANCER RES, V55, P39; Magrath I, 1992, Semin Cancer Biol, V3, P285; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PIZZO PA, 1978, NATURE, V272, P629, DOI 10.1038/272629a0; ROGERS RP, 1992, ADV CANCER RES, V58, P1, DOI 10.1016/S0065-230X(08)60288-2; SAMPLE J, 1990, J VIROL, V64, P4084, DOI 10.1128/JVI.64.9.4084-4092.1990; SHIRAMIZU B, 1991, BLOOD, V77, P1516; SNUDDEN DK, 1995, ONCOGENE, V10, P1545; STRAUS SE, 1993, ANN INTERN MED, V118, P45, DOI 10.7326/0003-4819-118-1-199301010-00009; SUZUSHIMA H, 1995, BLOOD, V85, P480, DOI 10.1182/blood.V85.2.480.bloodjournal852480; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WRIGHTHAM MN, 1995, VIROLOGY, V208, P521, DOI 10.1006/viro.1995.1183	20	109	115	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					177	181						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700544				2022-12-17	WOS:A1996UX31900020
J	GAO, X; CHEN, YQ; WU, N; GRIGNON, DJ; SAKR, W; PORTER, AT; HONN, KV				GAO, X; CHEN, YQ; WU, N; GRIGNON, DJ; SAKR, W; PORTER, AT; HONN, KV			SOMATIC MUTATIONS OF THE WAF1/CIP1 GENE IN PRIMARY PROSTATE-CANCER	ONCOGENE			English	Note						TUMOR SUPPRESSOR GENE; WAF1/CIP1; PROSTATIC ADENOCARCINOMA; MUTATION; POLYMERASE CHAIN REACTION	TUMOR; INHIBITOR; KINASES; P21	The WAF1/CIP1 gene, a potential tumor suppressor gene, has recently been cloned and identified as a p53 mediator and an inhibitor for G1 cyclin-dependent kinases (CDKs). We undertook this study to investigate the possible role of the WAF1/CIP1 gene in human prostatic carcinoma. Matched normal and cancer tissues from 18 patients with prostate cancer were screened for WAF1/CIP1 mutation by nested reverse transcription-polymerase chain reaction/single strand conformational polymorphism (RT-PCR/SSCP) and DNA sequencing. Shifted bands from three tumor, but not the matched normal specimens, were observed. Subsequent direct DNA sequencing of the PCR fragments identified four sequence alterations including a cytosine (C) to adenine (A) transversion and a guanine (G) to A transition and two A insertions. Our results demonstrated that mutations of the WAF1/CTP1 gene occur and may be important during the pathogenesis of human prostate cancer. This is the first report of WAF1/CIP1 mutation in a primary human cancer.	WAYNE STATE UNIV,SCH MED,DEPT RADIAT ONCOL,DIV CANC BIOL,DETROIT,MI 48202; WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48202	Wayne State University; Wayne State University			Chen, Yong Q/AAI-9864-2021	Chen, Yong Q/0000-0003-4747-4708				BHATIA K, 1995, CANCER RES, V55, P1431; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CHEDID M, 1994, ONCOGENE, V9, P3021; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHEN YQ, 1992, J BIOL CHEM, V267, P17314; CHEN YQ, 1994, CANCER RES, V54, P1574; CHEN YQ, 1994, CANCER MOL BIOL, V1, P357; CHI SG, 1994, J NATL CANCER I, V86, P926, DOI 10.1093/jnci/86.12.926; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GAO X, 1995, CANCER RES, V55, P1002; GAO X, 1995, INT J ONCOL, V6, P111; GAO X, 1993, CANCER RES, V53, P2723; GAO X, 1995, IN PRESS PATHOL ONCO; GAO X, 1995, CANCER MOL BIOL, V2, P475; GAO X, 1995, IN PRESS UROL; GAO X, 1994, CANCER MOL BIOL, V1, P297; GAO XA, 1994, ONCOGENE, V9, P2999; HAGMANN W, 1995, PROSTAGLANDINS, V49, P49, DOI 10.1016/0090-6980(94)00005-H; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; JIANG HP, 1994, ONCOGENE, V9, P3397; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LI YJ, 1995, ONCOGENE, V10, P599; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; STEINMAN RA, 1994, ONCOGENE, V9, P3389; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG W, 1995, CANCER RES, V55, P668; ZHOU XL, 1994, ONCOGENE, V9, P3737	39	109	116	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1395	1398						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478562				2022-12-17	WOS:A1995RY96700022
J	POLLOCK, PM; YU, F; QIU, L; PARSONS, PG; HAYWARD, NK				POLLOCK, PM; YU, F; QIU, L; PARSONS, PG; HAYWARD, NK			EVIDENCE FOR UV INDUCTION OF CDKN2 MUTATIONS IN MELANOMA CELL-LINES	ONCOGENE			English	Article						CDKN2 GENE; DIPYRIMIDINE; MELANOMA; TANDEM MUTATION; UV RADIATION	FAMILIAL MELANOMA; P53 MUTATIONS; STRAND BIAS; GENE; SKIN; SPECIFICITY; REPAIR; LOCUS; ASSIGNMENT; HOTSPOTS	The CDKN2 gene, encoding the cyclin dependent kinase inhibitor p16, is a tumour suppressor gene involved in melanoma and maps to chromosome band 9p22. Mutations or interstitial deletions of this gene have been found both in the germline of familial melanoma cases and somatically in melanoma cell lines. Previous mutation analyses of melanoma cell lines have indicated a high frequency of C:G to T:A transitions, with all of these mutations occurring at dipyrimidine sites. Including three melanoma cell lines carrying tandem CC to TT mutations, the spectrum of mutations so far reported indicates a possible role for u.v. radiation in the mutagenesis of this gene in some tumours. To further examine this hypothesis we have characterised mutations of the CDKN2 gene in 30 melanoma cell lines. Nineteen lines carried complete or partial homozygous deletions of the gene. Of the remaining cell lines, eight were shown by direct sequencing of PCR products from exon 1 and exon 2 to carry a total of nine different mutations of CDKN2. Two cell lines carried tandem CC to TT mutations and a high rate of C:G to T:A transitions was observed. This study provides further evidence for the role of u.v. light in the genesis of melanoma, with one target being the CDKN2 tumour suppressor gene.	QUEENSLAND INST MED RES,QUEENSLAND CANC FUND RES LABS,JOINT EXPTL ONCOL PROGRAM,HERSTON,QLD 4029,AUSTRALIA	QIMR Berghofer Medical Research Institute			Parsons, Peter G/H-8163-2015; hayward, nicholas k/C-1367-2015; hayward, nick/AAV-8802-2020	Parsons, Peter G/0000-0002-0473-3346; hayward, nicholas k/0000-0003-4760-1033; Pollock, Pamela/0000-0001-8420-1026				AIRNS P, 1994, SCIENCE, V265, P415; ARMSTRONG JD, 1990, P NATL ACAD SCI USA, V87, P9005, DOI 10.1073/pnas.87.22.9005; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BRASH DE, 1982, NATURE, V298, P189, DOI 10.1038/298189a0; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CHENG JQ, 1994, CANCER RES, V54, P5547; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; FRANKLIN WA, 1985, NUCLEIC ACIDS RES, V13, P5317, DOI 10.1093/nar/13.14.5317; GOLDSTEIN AM, 1994, AM J HUM GENET, V54, P489; GRUIS NA, 1993, MELANOMA RES, V3, P271; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HOLLAND EA, 1994, ONCOGENE, V9, P1361; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; ISSHIKI K, 1994, ONCOGENE, V9, P1649; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAMB A, 1995, SCIENCE, V267, P16, DOI 10.1126/science.267.5194.16; KANJILAL S, 1993, CANCER RES, V53, P2961; KRESS S, 1992, CANCER RES, V52, P6400; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; LIU QY, 1995, ONCOGENE, V10, P619; MAESTRO R, 1995, SCIENCE, V267, P15, DOI 10.1126/science.7809600; MCGREGOR WG, 1991, MOL CELL BIOL, V11, P1927, DOI 10.1128/MCB.11.4.1927; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MORI T, 1994, CANCER RES, V54, P3396; MURTY VVVS, 1992, GENOMICS, V13, P227, DOI 10.1016/0888-7543(92)90228-K; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; NOBORI T, 1964, NATURE, V368, P753; OHTA M, 1994, CANCER RES, V54, P5269; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; WALKER GJ, 1994, ONCOGENE, V9, P819; ZHANG SY, 1994, CANCER RES, V54, P5050; ZHOU XL, 1994, ONCOGENE, V9, P3737; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	39	109	110	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					663	668						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651729				2022-12-17	WOS:A1995RQ46900007
J	TSANG, NM; NAGASAWA, H; LI, CY; LITTLE, JB				TSANG, NM; NAGASAWA, H; LI, CY; LITTLE, JB			ABROGATION OF P53 FUNCTION BY TRANSFECTION OF HPV16 E6 GENE ENHANCES THE RESISTANCE OF HUMAN-DIPLOID FIBROBLASTS TO IONIZING-RADIATION	ONCOGENE			English	Note						TUMOR SUPPRESSOR GENES; RADIOSENSITIVITY; HUMAN PAPILLOMAVIRUS 16; P5A; RETINOBLASTOMA	HUMAN PAPILLOMAVIRUS TYPE-16; TUMOR-SUPPRESSOR GENE; SV40 T-ANTIGEN; ATAXIA-TELANGIECTASIA; SKIN FIBROBLASTS; HUMAN KERATINOCYTES; NORMAL INDIVIDUALS; TRANSFORMED-CELLS; CELLULAR PROTEIN; DNA-DAMAGE	In order to examine the role of p53 expression on the sensitivity of cells to radiation-induced reproductive failure, we examined the radiosensitivity of a human diploid fibroblast cell strain (AG1521) before and after transfection with the E6 or E6/E7 genes of human papillomavirus 16 (HPV16)(3). HPV E6 binds to p53, promoting its degradation and abrogating wild-type p53 function. AG1521 cells transfected with either E6 or E6/E7 showed no radiation induction of either p53 or WAF1/Cip1. The radioresistance of these cells were significantly increased; the D-0 of the survival curves rose from 130 +/- 4 cGy for wild type (neo-transfected) cells to 178-192 cGy for three subclones transfected with E6 alone, and 151-218 cGy for eight subclones transfected with E6/E7. The change in radiosensitivity took place before the process of cellular immortalization and transformation produced by transfection with these genes. Thus, the effect on radiosensitivity appears to be an early effect of the loss of p53 function in nontransformed cells, perhaps related to the loss of the G(1) checkpoint and of the capacity for programmed death amongst radiation damaged cells.	HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health			Li, Chuan-Yuan/H-4148-2013		NCI NIH HHS [CA-47542] Funding Source: Medline; NIEHS NIH HHS [ES-00002] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARLETT CF, 1988, INT J RADIAT BIOL, V54, P911, DOI 10.1080/09553008814552321; BARBOSA MS, 1989, ONCOGENE, V4, P1529; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FERTIL B, 1984, RADIAT RES, V99, P73, DOI 10.2307/3576448; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LANE DP, 1980, PROC R SOC SER B-BIO, V210, P451, DOI 10.1098/rspb.1980.0146; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEONARDO AD, 1994, GENE DEV, V8, P2540; LI CY, 1995, INT J ONCOL, V6, P233; LITTLE JB, 1985, RADIAT RES, V101, P81, DOI 10.2307/3576305; LITTLE JB, 1988, INT J RADIAT BIOL, V54, P899, DOI 10.1080/09553008814552311; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; MUNGER K, 1992, CANCER SURV, V12, P197; MUNGER K, 1989, J VIROL, V63, P4417; NAGASAWA H, 1987, J INVEST DERMATOL, V88, P149, DOI 10.1111/1523-1747.ep12525294; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; OCONNOR PM, 1993, CANCER RES, V53, P4776; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARRIS CN, 1990, CANCER LETT, V55, P171, DOI 10.1016/0304-3835(90)90029-W; Sambrook J., 1989, MOL CLONING LAB MANU; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SU LN, 1992, INT J RADIAT BIOL, V62, P201, DOI 10.1080/09553009214552021; SU LN, 1992, INT J RADIAT BIOL, V62, P461, DOI 10.1080/09553009214552341; TSANG NM, 1994, RADIAT RES, V140, P172, DOI 10.2307/3578900; WATANABE S, 1989, J VIROL, V63, P965, DOI 10.1128/JVI.63.2.965-969.1989; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	44	109	112	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2403	2408						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784090				2022-12-17	WOS:A1995RE54300017
J	COFFER, P; LUTTICKEN, C; VANPUIJENBROEK, A; KLOPDEJONGE, M; HORN, F; KRUIJER, W				COFFER, P; LUTTICKEN, C; VANPUIJENBROEK, A; KLOPDEJONGE, M; HORN, F; KRUIJER, W			TRANSCRIPTIONAL REGULATION OF THE JUNB PROMOTER - ANALYSIS OF STAT-MEDIATED SIGNAL-TRANSDUCTION	ONCOGENE			English	Article						JUNB; STAT; IL-6; IFN-GAMMA; SIGNAL TRANSDUCTION	DNA-BINDING; C-JUN; GENE-EXPRESSION; PROTEIN-KINASE; LEUCINE ZIPPER; NUCLEAR FACTOR; INTERLEUKIN-6; ACTIVATION; PHOSPHORYLATION; ELEMENTS	The product of the junB gene is a member of the AP-1 family of transcription factors that activate transcription by binding to TPA-responsive elements (TREs) within the promoters of target genes, Components of AP-1 are immediate-early genes whose expression is upregulated by a plethora of extracellular stimuli and are important in mediating cellular proliferation and differentiation, Such stimuli include the pleiotropic cytokine interleukin-6 (IL-6) which plays a role in immune and inflammatory responses and ciliary neurotrophic factor (CNTF) which enhances survival and differentiation of neurons and glia. We have analysed expression from junB promoter-CAT reporter constructs in HepG2 cells and found that a region between -196 and -91 can mediate response to IL-6 and CNTF and was able to confer responsiveness to a heterologous promoter, We further show by gel retardation analysis that distinct nuclear factors induced by IL-6 specifically bind to this interleukin-6 response element (IRE). This region contains both a putative ETS- and a STAT-transcription factor binding site, We show by mutational analysis and supershift data that the IL-6 induced complex indeed contains the transcription factor APRF/Stat3 that is both necessary and sufficient for activation, Interestingly this site does not appear to bind Stat1 itself, as shown by supershift analysis and a lack of response to IFN-gamma both at the DNA-binding and transcriptional level, Furthermore, we demonstrate that the junB IRE-binding activity induced by IL-6 requires tyrosine kinase activity, whereas induced transactivation of IRE-constructs additionally occurs through an H7-sensitive pathway that is p21ras-independent, implicating serine/threonine kinases in the transactivation of IRE-binding factors.	RHEIN WESTFAL TH AACHEN,INST BIOCHEM,D-52057 AACHEN,GERMANY; UNIV GRONINGEN,DEPT GENET,9750 AA HAREN,NETHERLANDS	RWTH Aachen University; University of Groningen	COFFER, P (corresponding author), HUBRECHT LAB DEV BIOL,UPPSALALAAN 8,3584 CT UTRECHT,NETHERLANDS.		Coffer, Paul/AAF-7970-2020; Coffer, Paul J/A-5769-2009					AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; APEL I, 1992, MOL CELL BIOL, V12, P3357; BOHMANN D, 1988, SCIENCE, V238, P1386; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COFFER P, 1994, ONCOGENE, V9, P911; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GRAHAM FL, 1973, MOL CELL BIOL, V2, P607; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; KITABAYASHI I, 1993, J BIOL CHEM, V268, P14482; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KUNZ D, 1989, NUCLEIC ACIDS RES, V17, P1121, DOI 10.1093/nar/17.3.1121; LAMPH WW, 1988, NATURE, V334, P592; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1991, ONCOGENE, V6, P533; SADOWSKI HB, 1993, SCIENCE, V261, P1738; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHEN S, 1993, MECH DEVELOP, V40, P177, DOI 10.1016/0925-4773(93)90075-9; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; YIN TG, 1994, J BIOL CHEM, V269, P3731; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	60	109	115	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					985	994						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898939				2022-12-17	WOS:A1995QL03800020
J	OSWALD, F; LOVEC, H; MOROY, T; LIPP, M				OSWALD, F; LOVEC, H; MOROY, T; LIPP, M			E2F-DEPENDENT REGULATION OF HUMAN MYC - TRANSACTIVATION BY CYCLIN-D1 AND CYCLIN-A OVERRIDES TUMOR-SUPPRESSOR PROTEIN FUNCTIONS	ONCOGENE			English	Article							E2F TRANSCRIPTION FACTOR; RETINOBLASTOMA GENE-PRODUCT; ADENOVIRUS E1A PROTEINS; HUMAN BREAST-CANCER; CELL-CYCLE; C-MYC; MESSENGER-RNA; MOLECULAR-CLONING; BINDING PROTEIN; DNA-BINDING	Transcription of the human proto-oncogene MYC is repressed in quiescent or non-dividing cells. Upon mitogenic stimulation expression of MYC is rapidly and transiently induced, maintained throughout G(1), and declines to a basal level throughout further cell cycle transitions. Regulation of MYC promoter activity critically depends on the presence of a binding site for transcription factor E2F. Human E2F has been implicated also in the control of cell cycle progression through it association with the retinoblastoma suppressor gene product RB, and with multimeric protein complexes containing the G(1)-S- and S-phase cyclins E and A, respectively. Using CAT reporter co-transfection assays we show here that transcription from the MYC P2 promoter is induced efficiently by E2F-1, but repressed by RB. Furthermore, overexpression of cyclin A strongly activates the MYC promoter and this effect is further enhanced by coexpression of E2F-1 and cyclin A. We also find that expression of G(1)-phase cyclin D1 leads to an E2F binding site-dependent trans-activation of the MYC promoter and that this activation can be abrogated by overexpression of RB. The interaction of D-type G(1) cyclins with RB resembles that of the adenovirus E1A protein with RB in that it can disrupt inhibitory E2F-RB complexes. Our results support a model in which intervention of distinct cyclins and their respective associated kinases promotes transcriptional activation of MYC throughout the cell cycle either by conversion of E2F within multimeric complexes into an active transcription factor or by liberation of free functional E2F.	MAX DELBRUCK CTR MOLEC MED, D-13122 BERLIN, GERMANY; UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY; UNIV MUNICH, INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Philipps University Marburg; University of Munich			Moroy, Tarik/D-9923-2011; Lipp, Martin/G-2235-2010; Oswald, Franz/AAO-9584-2020	Lipp, Martin/0000-0002-0087-2672				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DESTONE J, 1987, MOL CELL BIOL, V7, P1697; Dobner T, 1991, DNA Seq, V1, P409, DOI 10.3109/10425179109020799; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALL FL, 1993, ONCOGENE, V8, P1377; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HARPER JW, 1993, CELL, V75, P805; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JIANG W, 1993, ONCOGENE, V8, P3447; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KATO J, 1993, GENE DEV, V7, P331; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LIPP M, 1989, ONCOGENE, V4, P535; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LOVEC H, 1994, ONCOGENE, V9, P323; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEEKER TC, 1989, BLOOD, V74, P1801; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; NEVINS JR, 1992, SCIENCE, V258, P424; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; ROSENBERG CL, 1993, ONCOGENE, V8, P519; SCHUURING E, 1992, ONCOGENE, V7, P355; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SETO M, 1992, ONCOGENE, V7, P1401; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SPENCER CA, 1991, ADV CANCER RES, V56, P1; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	74	109	111	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					2029	2036						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208548				2022-12-17	WOS:A1994NR68500027
J	BORRELLO, MG; PELICCI, G; ARIGHI, E; DEFILIPPIS, L; GRECO, A; BONGARZONE, I; RIZZETTI, MG; PELICCI, PG; PIEROTTI, MA				BORRELLO, MG; PELICCI, G; ARIGHI, E; DEFILIPPIS, L; GRECO, A; BONGARZONE, I; RIZZETTI, MG; PELICCI, PG; PIEROTTI, MA			THE ONCOGENIC VERSIONS OF THE RET AND TRK TYROSINE KINASES BIND SHC AND GRB2 ADAPTER PROTEINS	ONCOGENE			English	Article							PAPILLARY THYROID CARCINOMAS; NERVE GROWTH-FACTOR; PROTO-ONCOGENE; NUCLEOTIDE EXCHANGE; SIGNAL TRANSDUCTION; PROTOONCOGENE; RECEPTOR; RAS; PRODUCT; ACTIVATION	Proto-TRK and proto-RET genes encode receptor type tyrosine kinases. Oncogenic rearrangements of both proto-oncogenes have been detected with a significant frequency in human papillary thyroid carcinomas. Chimeric Ret and Trk oncoproteins, encoded by different rearrangements of proto-TRK and proto-RET genes, display a constitutive phosphorylation on tyrosine. Moreover, it has been shown that phosphorylated tyrosine receptors, activated by their ligands, form multiprotein complexes responsible for transducing mitogenic or differentiation signals. We have therefore begun to analyse in this study the signal transduction pathways triggered by different Ret and Trk oncoproteins. We have shown that the SH2 domain of the adaptor protein She coimmunoprecipitates with all the Ret and Trk oncoproteins as well as with NGF-activated proto-Trk receptor. Tyrosine phosphorylation of Trk proteins both normal and oncogenic is necessary for their binding to She. In addition, in cells containing either Ret or TrK oncoproteins, She proteins are constitutively phosphorylated on tyrosine and bound to Grb2. Only in in vitro experiments were Ret and Trk oncoproteins shown to bind the SH2 region of Grb2. Finally, when proto-Trk product is stimulated by NGF, She phosphorylation and association with Grb2 are induced. In conclusion, we have shown that Ret and Trk oncoproteins can form multiprotein complexes, however, the functional meaning of the described interactions has to be elucidated.	UNIV PERUGIA,IST CLIN MED 1,MONTELUCE POLICLIN,I-06100 PERUGIA,ITALY	University of Perugia	BORRELLO, MG (corresponding author), IST NAZL TUMORI,DIV EXPTL ONCOL E,VIA VENEZIAN 1,I-20133 MILAN,ITALY.		Borrello, Maria Grazia/C-3161-2017; Bongarzone, Italia/B-9544-2017; Pelicci, Giuliana/AAA-8921-2022; Greco, Angela/C-1953-2017; Pelicci, Pier Giuseppe/AAL-6572-2020; De Filippis, Lidia/H-3098-2017	Borrello, Maria Grazia/0000-0002-6854-2848; Bongarzone, Italia/0000-0003-2530-9170; Pelicci, Giuliana/0000-0003-0986-8255; Greco, Angela/0000-0003-2994-0349; De Filippis, Lidia/0000-0002-2196-9430; Pierotti, Marco Alessandro/0000-0002-7431-8332				BARBACID M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P115, DOI 10.1016/0304-419X(91)90010-I; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GRECO A, 1992, ONCOGENE, V7, P237; GRECO A, 1993, CELL GROWTH DIFFER, V4, P539; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HASHIMOTO S, 1988, J CELL BIOL, V107, P1531, DOI 10.1083/jcb.107.4.1531; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZI C, 1992, ONCOGENE, V7, P2189; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIEROTTI MA, 1993, NATO ASI SER, P87; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SANTORO M, 1993, BRIT J CANCER, V68, P460, DOI 10.1038/bjc.1993.370; SANTORO M, 1990, ONCOGENE, V5, P1595; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEGATTO O, 1993, ONCOGENE, V8, P2105; SOZZI G, 1992, GENE CHROMOSOME CANC, V5, P212, DOI 10.1002/gcc.2870050307; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; SZENTIRMAY Z, 1990, ONCOGENE, V5, P701; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	36	109	111	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1661	1668						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183561				2022-12-17	WOS:A1994NL81500018
J	LU, D; THOMPSON, JD; GORSKI, GK; RICE, NR; MAYER, MG; YUNIS, JJ				LU, D; THOMPSON, JD; GORSKI, GK; RICE, NR; MAYER, MG; YUNIS, JJ			ALTERATIONS AT THE REL LOCUS IN HUMAN LYMPHOMA	ONCOGENE			English	Article							NF-KAPPA-B; DNA-BINDING SUBUNIT; C-REL; V-REL; RETICULOENDOTHELIOSIS VIRUS; PROTO-ONCOGENE; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; CELL-LINE	The rel proto-oncogene has been mapped to chromosome region 2p11.2-14, a site associated with nonrandom rearrangements in non-Hodgkin's lymphoma. We have characterized an abnormal rel mRNA from a cell line derived from a diffuse large cell lymphoma, in which the evolutionarily conserved N-terminal half of the rel coding region was fused with the C-terminal coding region of an unrelated gene. In addition, rearrangement or amplification of the rel locus was found in the lymphomatous tissue of two follicular and one diffuse large cell lymphoma. The findings suggest involvement of rel in the pathogenesis of large cell lymphoma.	HAHNEMANN UNIV,SCH MED,DEPT NEOPLAST DIS,DIV HUMAN GENET & MOLEC BIOL,PHILADELPHIA,PA 19102; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	Drexel University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	YUNIS, JJ (corresponding author), HAHNEMANN UNIV,SCH MED,DEPT NEOPLAST DIS,DIV HUMAN GENET & MOLEC BIOL,PHILADELPHIA,PA 19102, USA.				OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101, CA3314] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BLOOMFIELD CD, 1983, CANCER RES, V43, P2975; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRENNAND J, 1983, J BIOL CHEM, V258, P9593; BROWNELL E, 1988, ONCOGENE, V3, P93; BROWNELL E, 1988, ONCOGENE, V2, P527; BROWNELL E, 1985, MOL CELL BIOL, V5, P2826, DOI 10.1128/MCB.5.10.2826; BROWNELL E, 1989, ONCOGENE, V4, P935; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GOLLIN SM, 1986, CANCER GENET CYTOGEN, V20, P331, DOI 10.1016/0165-4608(86)90092-0; GRUMONT RJ, 1989, ONCOGENE RES, V4, P1; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HECHT BK, 1985, CANCER GENET CYTOGEN, V14, P205, DOI 10.1016/0165-4608(85)90186-4; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KARATHANASIS SK, 1983, P NATL ACAD SCI-BIOL, V80, P6147, DOI 10.1073/pnas.80.20.6147; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEIN E, 1968, CANCER RES, V28, P1300; KUBONISHI I, 1986, CANCER, V58, P1453, DOI 10.1002/1097-0142(19861001)58:7<1453::AID-CNCR2820580713>3.0.CO;2-B; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MINOWADA J, 1982, MALIGNANT LYMPHOMAS, P53; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; THEILEN GH, 1966, J NATL CANCER I, V37, P731; TONEGUZZO F, 1986, MOL CELL BIOL, V6, P703, DOI 10.1128/MCB.6.2.703; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; YUNIS JJ, 1989, NEW ENGL J MED, V320, P1047, DOI 10.1056/NEJM198904203201605; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204	52	109	110	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1235	1241						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650444				2022-12-17	WOS:A1991GV26000020
J	SHIMIZU, M; YOKOTA, J; MORI, N; SHUIN, T; SHINODA, M; TERADA, M; OSHIMURA, M				SHIMIZU, M; YOKOTA, J; MORI, N; SHUIN, T; SHINODA, M; TERADA, M; OSHIMURA, M			INTRODUCTION OF NORMAL CHROMOSOME-3P MODULATES THE TUMORIGENICITY OF A HUMAN RENAL-CELL CARCINOMA CELL-LINE YCR	ONCOGENE			English	Article									KANAGAWA CANC CTR,RES INST,CYTOGENET LAB,54-2 NAKAO CHO,ASAHI KU,YOKOHAMA 241,JAPAN; NATL CANC CTR,RES INST,CHUO KU,TOKYO 151,JAPAN; YOKOHAMA CITY UNIV,SCH MED,DEPT UROL,MINAMI KU,YOKOHAMA,KANAGAWA 232,JAPAN; HOSHI COLL PHARM,DEPT BIOCHEM,SHINAGAWA KU,TOKYO 142,JAPAN	Kanagawa Prefectural Cancer Center; National Cancer Center - Japan; Yokohama City University; Hoshi University								BENEDICT WF, 1984, CANCER RES, V44, P3471; BERGERHEIM U, 1989, CANCER RES, V49, P1390; CARROLL PR, 1987, CANCER GENET CYTOGEN, V26, P253, DOI 10.1016/0165-4608(87)90059-8; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; FOURNIER REK, 1977, P NATL ACAD SCI USA, V74, P319, DOI 10.1073/pnas.74.1.319; GREEN AR, 1988, BRIT J CANCER, V58, P115, DOI 10.1038/bjc.1988.176; HARPER ME, 1981, P NATL ACAD SCI-BIOL, V78, P4458, DOI 10.1073/pnas.78.7.4458; HARRIS H, 1988, CANCER RES, V48, P3302; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KOI M, 1989, JPN J CANCER RES, V80, P122, DOI 10.1111/j.1349-7006.1989.tb02278.x; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; KOVACS G, 1987, INT J CANCER, V40, P171, DOI 10.1002/ijc.2910400208; KUBOTA Y, 1987, FEBS LETT, V212, P159, DOI 10.1016/0014-5793(87)81577-6; OSHIMURA M, 1988, CANCER RES, V48, P1623; OSHIMURA M, 1985, NATURE, V316, P636, DOI 10.1038/316636a0; OSHIMURA M, IN PRESS J CELL BIOC; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SANDBERG AA, 1988, CANCER RES, V48, P1049; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; Stanbridge E.J., 1987, ADV VIRAL ONCOL, V6, P83; STANBRIDGE EJ, 1981, CANCER RES, V41, P573; STANBRIDGE EJ, 1986, CANCER RES, V46, P4759; SZUCS S, 1987, CANCER GENET CYTOGEN, V26, P369, DOI 10.1016/0165-4608(87)90072-0; VANDERHOUT AH, 1988, CANCER GENET CYTOGEN, V32, P281, DOI 10.1016/0165-4608(88)90292-0; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1989, CANCER RES, V49, P3598; YOSHIDA MA, 1986, CANCER RES, V46, P2139; YOSHIDA MA, 1988, JPN J CANCER RES, V79, P600, DOI 10.1111/j.1349-7006.1988.tb00029.x; YOSHIDA MC, 1975, P JPN ACAD, V51, P181; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	36	109	109	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1990	5	2					185	194						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU029	1969617				2022-12-17	WOS:A1990CU02900004
J	GAUWERKY, CE; HOXIE, J; NOWELL, PC; CROCE, CM				GAUWERKY, CE; HOXIE, J; NOWELL, PC; CROCE, CM			PRE-B-CELL LEUKEMIA WITH A T(8-14) AND A T(14-18) TRANSLOCATION IS PRECEDED BY FOLLICULAR LYMPHOMA	ONCOGENE			English	Article									WISTAR INST ANAT & BIOL,3601 SPRUCE ST,PHILADELPHIA,PA 19104; UNIV PENN,CTR CANC,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NCI NIH HHS [CA 39860, CA 15822] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039860, P01CA015822] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER A, 1982, P NATL ACAD SCI-BIOL, V79, P3260, DOI 10.1073/pnas.79.10.3260; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; CROCE CM, 1986, COLD SPRING HARB SYM, V51, P891, DOI 10.1101/SQB.1986.051.01.102; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DOLBY TW, 1980, P NATL ACAD SCI US, V77, P6026; ERIKSON J, 1982, P NATL ACAD SCI-BIOL, V79, P5611, DOI 10.1073/pnas.79.18.5611; GALLAGHER CJ, 1986, J CLIN ONCOL, V4, P1470, DOI 10.1200/JCO.1986.4.10.1470; HALUSKA FG, 1987, P NATL ACAD SCI USA, V84, P6835, DOI 10.1073/pnas.84.19.6835; HALUSKA FG, 1986, NATURE, V324, P158, DOI 10.1038/324158a0; KORSMEYER SJ, 1981, P NATL ACAD SCI-BIOL, V78, P7096, DOI 10.1073/pnas.78.11.7096; MANIATIS T, 1984, MOL CLONING LABORATO; MCBRIDE OW, 1982, J EXP MED, V155, P1480, DOI 10.1084/jem.155.5.1480; PEGORARO L, 1984, P NATL ACAD SCI-BIOL, V81, P7166, DOI 10.1073/pnas.81.22.7166; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RICHARDSON ME, 1987, BLOOD, V70, P444; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; WIMAN KG, 1984, P NATL ACAD SCI-BIOL, V81, P6798, DOI 10.1073/pnas.81.21.6798; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204; ZECH L, 1976, INT J CANCER, V17, P47, DOI 10.1002/ijc.2910170108	25	109	110	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					431	435						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	3131717				2022-12-17	WOS:A1988N434800003
J	Chen, T; Sun, Y; Ji, P; Kopetz, S; Zhang, W				Chen, T.; Sun, Y.; Ji, P.; Kopetz, S.; Zhang, W.			Topoisomerase II alpha in chromosome instability and personalized cancer therapy	ONCOGENE			English	Review							SPINDLE ASSEMBLY CHECKPOINT; ANAPHASE-PROMOTING COMPLEX; IN-SITU HYBRIDIZATION; BREAST-CANCER; CELL-CYCLE; MITOTIC CHECKPOINT; DNA TOPOISOMERASES; GENE-EXPRESSION; DOWN-REGULATION; CHROMATID COHESION	Genome instability is a hallmark of cancer cells. Chromosome instability (CIN), which is often mutually exclusive from hypermutation genotypes, represents a distinct subtype of genome instability. Hypermutations in cancer cells are due to defects in DNA repair genes, but the cause of CIN is still elusive. However, because of the extensive chromosomal abnormalities associated with CIN, its cause is likely a defect in a network of genes that regulate mitotic checkpoints and chromosomal organization and segregation. Emerging evidence has shown that the chromosomal decatenation checkpoint, which is critical for chromatin untangling and packing during genetic material duplication, is defective in cancer cells with CIN. The decatenation checkpoint is known to be regulated by a family of enzymes called topoisomerases. Among them, the gene encoding topoisomerase II alpha (TOP2A) is commonly altered at both gene copy number and gene expression level in cancer cells. Thus, abnormal alterations of TOP2A, its interacting proteins, and its modifications may have a critical role in CIN in human cancers. Clinically, a large arsenal of topoisomerase inhibitors has been used to suppress DNA replication in cancer. However, they often lead to the secondary development of leukemia because of their effect on the chromosomal decatenation checkpoint. Therefore, topoisomerase drugs must be used judiciously and administered on an individual basis. In this review, we highlight the biological function of TOP2A in chromosome segregation and the mechanisms that regulate this enzyme's expression and activity. We also review the roles of TOP2A and related proteins in human cancers, and raise a perspective for how to target TOP2A in personalized cancer therapy.	[Chen, T.; Ji, P.; Zhang, W.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Chen, T.] Fudan Univ, Zhongshan Hosp, Dept Endoscopy Ctr, Shanghai 200433, Peoples R China; [Sun, Y.] Tianjin Med Univ, Canc Inst & Hosp, Dept Pathol, Tianjin, Peoples R China; [Kopetz, S.] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Fudan University; Tianjin Medical University; University of Texas System; UTMD Anderson Cancer Center	Zhang, W (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 85,1515 Holcombe Blvd, Houston, TX 77030 USA.	wzhang@mdanderson.org	Kopetz, Scott/AAC-1387-2019	Kopetz, Scott/0000-0001-9647-3416	MD Anderson's National Cancer Institute core grant [CA16672]; National Foundation for Cancer Research; China Education Council; A Lavoy Moore Endowment Fund; Tianjin Municipal Science and Technology Commission [14JCYBJC27500]; NSFC [81472263]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	MD Anderson's National Cancer Institute core grant; National Foundation for Cancer Research; China Education Council; A Lavoy Moore Endowment Fund; Tianjin Municipal Science and Technology Commission; NSFC(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ms Ann Sutton in the Department of Scientific Publications for editing this manuscript. This work was partially supported by MD Anderson's National Cancer Institute core grant (CA16672), a Sister Institute Network Fund and a grant from the National Foundation for Cancer Research. Dr Tao Chen was supported by a Fellowship from the China Education Council. Dr Y Sun was supported by The A Lavoy Moore Endowment Fund, a grant from the Tianjin Municipal Science and Technology Commission (14JCYBJC27500), and a grant from NSFC (81472263).	Adams RR, 2001, J CELL BIOL, V153, P865, DOI 10.1083/jcb.153.4.865; Akimitsu N, 2003, GENES CELLS, V8, P393, DOI 10.1046/j.1365-2443.2003.00643.x; ANDOH T, 1993, BIOTECHNOL APPL BIOC, V18, P165; Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Azuma Y, 2003, J CELL BIOL, V163, P477, DOI 10.1083/jcb.200304088; Azuma Y, 2005, EMBO J, V24, P2172, DOI 10.1038/sj.emboj.7600700; Azuma Y, 2009, METHODS MOL BIOL, V582, P221, DOI 10.1007/978-1-60761-340-4_17; Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; Barber TD, 2008, P NATL ACAD SCI USA, V105, P3443, DOI 10.1073/pnas.0712384105; Belluti S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.287; Bhargava R, 2005, AM J CLIN PATHOL, V123, P889, DOI 10.1309/PCFK8YTQPYWD534F; Bordeleau L, 2010, BREAST CANCER RES TR, V119, P13, DOI 10.1007/s10549-009-0566-z; Bower JJ, 2010, ONCOGENE, V29, P4787, DOI 10.1038/onc.2010.232; Buffin E, 2005, CURR BIOL, V15, P856, DOI 10.1016/j.cub.2005.03.052; Carpenter AJ, 2004, MOL BIOL CELL, V15, P5700, DOI 10.1091/mbc.E04-08-0732; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chang CJ, 2003, J CELL SCI, V116, P4715, DOI 10.1242/jcs.00797; Chen J, 2012, GYNECOL ONCOL, V126, P109, DOI 10.1016/j.ygyno.2012.03.051; Chen J, 2012, CHIN J CANCER, V31, P215, DOI 10.5732/cjc.011.10364; CHEN M, 1995, ONCOL RES, V7, P103; CHEN M, 1993, CANCER RES, V53, P5946; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; Chikamori K, 2003, J BIOL CHEM, V278, P12696, DOI 10.1074/jbc.M300837200; CLARKE DJ, 1993, J CELL SCI, V105, P563; Coelho PA, 2008, PLOS BIOL, V6, P1758, DOI 10.1371/journal.pbio.0060207; Cortes F, 2003, MUTAT RES-REV MUTAT, V543, P59, DOI 10.1016/S1383-5742(02)00070-4; CUMMINGS J, 1995, MUTAT RES-GENET TOX, V344, P55, DOI 10.1016/0165-1218(95)90038-1; Dal Molin M, 2012, HUM PATHOL, V43, P585, DOI 10.1016/j.humpath.2011.06.009; Daum JR, 1998, J BIOL CHEM, V273, P30622, DOI 10.1074/jbc.273.46.30622; Dawlaty MM, 2008, CELL, V133, P103, DOI 10.1016/j.cell.2008.01.045; de Voer RM, 2013, GASTROENTEROLOGY, V145, P544, DOI 10.1053/j.gastro.2013.06.001; Deming PB, 2001, P NATL ACAD SCI USA, V98, P12044, DOI 10.1073/pnas.221430898; Depowski PL, 2000, MODERN PATHOL, V13, P542, DOI 10.1038/modpathol.3880094; Diaz-Martinez LA, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000053; Dorairaj JJ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-421; Duesberg P, 2003, CELL CYCLE, V2, P202, DOI 10.4161/cc.2.3.382; Duijf PHG, 2013, ONCOGENE, V32, P4727, DOI 10.1038/onc.2012.616; Dykhuizen EC, 2013, NATURE, V497, P624, DOI 10.1038/nature12146; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Escargueil AE, 2000, J BIOL CHEM, V275, P34710, DOI 10.1074/jbc.M005179200; Faggad A, 2009, MODERN PATHOL, V22, P579, DOI 10.1038/modpathol.2009.14; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Ferguson LR, 1998, ENVIRON MOL MUTAGEN, V27, P255; Ganapathi RN, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00089; Garcia-Higuera I, 2008, NAT CELL BIOL, V10, P802, DOI 10.1038/ncb1742; Geigl JB, 2008, TRENDS GENET, V24, P64, DOI 10.1016/j.tig.2007.11.006; Gilmore PM, 2003, BIOCHEM SOC T, V31, P257, DOI 10.1042/bst0310257; Gimenez-Abian JF, 2004, CURR BIOL, V14, P1187, DOI 10.1016/j.cub.2004.06.052; Glaros S, 2008, CANCER RES, V68, P3689, DOI 10.1158/0008-5472.CAN-07-6652; Gunduz E, 2006, MED HYPOTHESES, V67, P1313, DOI 10.1016/j.mehy.2006.05.032; Habu T, 2002, EMBO J, V21, P6419, DOI 10.1093/emboj/cdf659; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hande KR, 2008, UPDATE CANC THERAPEU, V3, P13, DOI DOI 10.1016/J.UCT.2008.02.001; Hasinoff BB, 2001, MOL PHARMACOL, V59, P453, DOI 10.1124/mol.59.3.453; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; Huang B, 2014, J CELL BIOCHEM, V115, P1077, DOI 10.1002/jcb.24703; Iida M, 2008, BIOCHEM J, V411, P27, DOI 10.1042/BJ20071394; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; ISHIDA R, 1991, CANCER RES, V51, P4909; Ishida R, 1996, J BIOL CHEM, V271, P30077, DOI 10.1074/jbc.271.47.30077; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Jeganathan K, 2007, J CELL BIOL, V179, P255, DOI 10.1083/jcb.200706015; Jeganathan KB, 2006, CELL CYCLE, V5, P366, DOI 10.4161/cc.5.4.2483; Ji P, 2010, ONCOGENE, V29, P3501, DOI 10.1038/onc.2010.114; Johnson M, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp480; Kaitna S, 2000, CURR BIOL, V10, P1172, DOI 10.1016/S0960-9822(00)00721-1; Kallio M, 1997, ENVIRON MOL MUTAGEN, V29, P16, DOI 10.1002/(SICI)1098-2280(1997)29:1<16::AID-EM3>3.0.CO;2-B; Kallio MJ, 2001, FASEB J, V15, P2721, DOI 10.1096/fj.01-0280fje; Kang R, 2013, CLIN CANCER RES, V19, P4046, DOI 10.1158/1078-0432.CCR-13-0495; Kennedy RD, 2005, CANCER RES, V65, P10265, DOI 10.1158/0008-5472.CAN-05-1841; Koivunen J, 2006, CANCER LETT, V235, P1, DOI 10.1016/j.canlet.2005.03.033; Kolb RH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050281; Kops GJPL, 2005, J CELL BIOL, V169, P49, DOI 10.1083/jcb.200411118; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Lan J, 2014, TUMOR BIOL, V35, P179, DOI 10.1007/s13277-013-1022-6; Lee BH, 2003, SCIENCE, V300, P482, DOI 10.1126/science.1081846; Lee WY, 1999, HISTOPATHOLOGY, V34, P106; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li H, 2008, J BIOL CHEM, V283, P6209, DOI 10.1074/jbc.M709007200; Li L, 2010, ANN ANAT, V192, P275, DOI 10.1016/j.aanat.2010.07.010; Li Y, 2012, CHIN J CANCER, V31, P364, DOI 10.5732/cjc.012.10086; Lin WC, 2013, BBA-MOL CELL RES, V1833, P3206, DOI 10.1016/j.bbamcr.2013.08.020; Lin YT, 2006, ONCOGENE, V25, P6901, DOI 10.1038/sj.onc.1209687; Liu DG, 2002, CANCER, V94, P2239, DOI 10.1002/cncr.10450; Liu H, 2013, CURR BIOL, V23, P1927, DOI 10.1016/j.cub.2013.07.078; Liu Y, 2010, EUR J CANCER, V46, P3007, DOI 10.1016/j.ejca.2010.07.016; London N, 2014, GENE DEV, V28, P140, DOI 10.1101/gad.233700.113; Lou ZK, 2005, NAT STRUCT MOL BIOL, V12, P589, DOI 10.1038/nsmb953; Luo KT, 2009, NAT CELL BIOL, V11, P204, DOI 10.1038/ncb1828; Luo XL, 2000, NAT STRUCT BIOL, V7, P224; Lynch HT, 2005, CANCER GENET CYTOGEN, V158, P119, DOI 10.1016/j.cancergencyto.2004.01.032; Maney T, 1998, J CELL BIOL, V142, P787, DOI 10.1083/jcb.142.3.787; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Meng H, 2012, PATHOL INT, V62, P391, DOI 10.1111/j.1440-1827.2012.02808.x; Michor F, 2005, SEMIN CANCER BIOL, V15, P43, DOI 10.1016/j.semcancer.2004.09.007; Mo YY, 1997, CANCER RES, V57, P5004; Mueller RE, 2004, GENE CHROMOSOME CANC, V39, P288, DOI 10.1002/gcc.20008; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Nilsson J, 2008, NAT CELL BIOL, V10, P1411, DOI 10.1038/ncb1799; Nitiss JL, 2009, NAT REV CANCER, V9, P338, DOI 10.1038/nrc2607; Obado SO, 2011, NUCLEIC ACIDS RES, V39, P1023, DOI 10.1093/nar/gkq839; Parker BC, 2013, CHIN J CANCER, V32, P594, DOI 10.5732/cjc.013.10178; Patel AN, 2011, BREAST CANCER RES TR, V126, P601, DOI 10.1007/s10549-010-0960-6; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PEDERSENBJERGAARD J, 1991, LANCET, V338, P359, DOI 10.1016/0140-6736(91)90490-G; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Prasanth SG, 2002, SCIENCE, V297, P1026, DOI 10.1126/science.1072802; Privette LM, 2008, NEOPLASIA, V10, P643, DOI 10.1593/neo.08176; Qi XM, 2006, CANCER RES, V66, P7540, DOI 10.1158/0008-5472.CAN-05-4639; Qi XM, 2011, J BIOL CHEM, V286, P35883, DOI 10.1074/jbc.M111.229260; Redwood C, 1998, J BIOL CHEM, V273, P3635, DOI 10.1074/jbc.273.6.3635; Reisman DN, 2003, CANCER RES, V63, P560; Ricke RM, 2008, TRENDS GENET, V24, P457, DOI 10.1016/j.tig.2008.07.002; RITKE MK, 1995, MOL PHARMACOL, V48, P798; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; Sandri MI, 1996, NUCLEIC ACIDS RES, V24, P4464, DOI 10.1093/nar/24.22.4464; Schmidt BH, 2012, NAT STRUCT MOL BIOL, V19, P1147, DOI 10.1038/nsmb.2388; Schmidt BH, 2010, NATURE, V465, P641, DOI 10.1038/nature08974; Seery LT, 1999, INT J CANCER, V84, P258, DOI 10.1002/(SICI)1097-0215(19990621)84:3<258::AID-IJC10>3.3.CO;2-8; Shain AH, 2012, P NATL ACAD SCI USA, V109, pE252, DOI 10.1073/pnas.1114817109; Shapiro PS, 1999, MOL CELL BIOL, V19, P3551; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shinagawa H, 2008, ANTIOXID REDOX SIGN, V10, P939, DOI 10.1089/ars.2007.1851; Stros M, 2009, NUCLEIC ACIDS RES, V37, P2070, DOI 10.1093/nar/gkp067; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; SUMNER AT, 1995, EXP CELL RES, V217, P440, DOI 10.1006/excr.1995.1107; Sumner AT, 1998, CHROMOSOMA, V107, P486, DOI 10.1007/s004120050333; Takahashi Y, 2006, GENETICS, V172, P783, DOI 10.1534/genetics.105.047167; Tang ZY, 2004, MOL CELL, V16, P387, DOI 10.1016/j.molcel.2004.09.031; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tipton AR, 2013, J BIOL CHEM, V288, P35149, DOI 10.1074/jbc.M113.522375; Tsai SC, 2000, NAT GENET, V26, P349, DOI 10.1038/81671; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Villman K, 2002, MODERN PATHOL, V15, P486, DOI 10.1038/modpathol.3880552; Wang H, 1997, BIOCHEM BIOPH RES CO, V237, P217, DOI 10.1006/bbrc.1997.7115; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang LHC, 2008, CHROMOSOMA, V117, P123, DOI 10.1007/s00412-007-0131-7; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Wang XS, 2013, CHIN J CANCER, V32, P155, DOI 10.5732/cjc.012.10114; Washiro M, 2008, J CANCER RES CLIN, V134, P793, DOI 10.1007/s00432-007-0348-0; Watanabe T, 2012, J CLIN ONCOL, V30, P2256, DOI 10.1200/JCO.2011.38.6490; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; Weaver BAA, 2003, J CELL BIOL, V162, P551, DOI 10.1083/jcb.200303167; Wendorff TJ, 2012, J MOL BIOL, V424, P109, DOI 10.1016/j.jmb.2012.07.014; Williams AO, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-36; Williams BC, 2003, MOL BIOL CELL, V14, P1379, DOI 10.1091/mbc.E02-09-0624; Wirth KG, 2006, J CELL BIOL, V172, P847, DOI 10.1083/jcb.200506119; Wu D, 2008, J PATHOL, V216, P167, DOI 10.1002/path.2391; Xia GH, 2004, EMBO J, V23, P3133, DOI 10.1038/sj.emboj.7600322; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yamasaki Lili, 2003, Cancer Treat Res, V115, P209; Yanagida M, 2005, PHILOS T R SOC B, V360, P609, DOI 10.1098/rstb.2004.1615; Yang D, 2011, JAMA-J AM MED ASSOC, V306, P1557, DOI 10.1001/jama.2011.1456; Yang GL, 2012, J SURG ONCOL, V106, P57, DOI 10.1002/jso.23040; Yang X, 2000, SCIENCE, V287, P131, DOI 10.1126/science.287.5450.131; Yuan CF, 2012, MOL CELL BIOCHEM, V359, P333, DOI 10.1007/s11010-011-1027-7	161	108	115	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4019	4031		10.1038/onc.2014.332	http://dx.doi.org/10.1038/onc.2014.332			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25328138	Green Accepted			2022-12-17	WOS:000358780500001
J	Havel, LS; Kline, ER; Salgueiro, AM; Marcus, AI				Havel, L. S.; Kline, E. R.; Salgueiro, A. M.; Marcus, A. I.			Vimentin regulates lung cancer cell adhesion through a VAV2-Rac1 pathway to control focal adhesion kinase activity	ONCOGENE			English	Article							NUCLEOTIDE EXCHANGE FACTOR; EPITHELIAL-MESENCHYMAL TRANSITIONS; ACTIN STRESS FIBERS; ENDOTHELIAL-CELLS; MATRIX ADHESION; GROWTH-FACTOR; INTERMEDIATE-FILAMENTS; CARCINOMA METASTASIS; PROSTATE-CANCER; RAC1 ACTIVATION	Vimentin is an intermediate filament protein whose expression correlates with increased metastatic disease, reduced patient survival and poor prognosis across multiple tumor types. Despite these well-characterized correlations, the molecular role of vimentin in cancer cell motility remains undefined. To approach this, we used an unbiased phosphoproteomics screen in lung cancer cell lines to discover cell motility proteins that show significant changes in phosphorylation upon vimentin depletion. We identified the guanine nucleotide exchange factor (GEF), VAV2, as having the greatest loss of phosphorylation owing to vimentin depletion. Since VAV2 serves as a GEF for the small Rho GTPase Rac1, a key player in cell motility and adhesion, we explored the vimentin-VAV2 pathway as a potential novel regulator of lung cancer cell motility. We show that VAV2 localizes to vimentin-positive focal adhesions (FAs) in lung cancer cells and complexes with vimentin and FA kinase (FAK). Vimentin loss impairs both pY142-VAV2 and downstream pY397-FAK activity showing that vimentin is critical for maintaining VAV2 and FAK activity. Importantly, vimentin depletion reduces the activity of the VAV2 target, Rac1, and a constitutively active Rac1 rescues defects in FAK and cell adhesion when vimentin or VAV2 is compromised. Based upon this data, we propose a model whereby vimentin promotes FAK stabilization through VAV2-mediated Rac1 activation. This model may explain why vimentin expressing metastatic lung cancer cells are more motile and invasive.	[Havel, L. S.; Kline, E. R.; Salgueiro, A. M.; Marcus, A. I.] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA	Emory University	Marcus, AI (corresponding author), Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, 1365C Clifton Rd,NE Room C4092, Atlanta, GA 30322 USA.	aimarcu@emory.edu			National Cancer Institute [1R01CA1428580]; Ruth L Kirschstein National Research Service Award [1F32CA168112-01]; Winship and Emory Integrated Cellular Imaging Core; NIH/NCI [P30CA138292]; NATIONAL CANCER INSTITUTE [P30CA138292, R01CA142858, F32CA168112] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ruth L Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Winship and Emory Integrated Cellular Imaging Core; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Cancer Institute (1R01CA1428580) awarded to AIM and through a Ruth L Kirschstein National Research Service Award (1F32CA168112-01) awarded to LSH Research reported in this publication was supported in part by the Winship and Emory Integrated Cellular Imaging Core and NIH/NCI under award number P30CA138292. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We would like to thank the Custom Cloning Core at Emory University for generating the mutant FAK constructs and Doris Powell in the laboratory of Paula Vertino for her technical assistance with the quantitative RT-PCR experiments. We would also like to thank Anthea Hammond for reviewing this manuscript. In addition, we thank Keith Burridge at the University of North Carolina for generously supplying us with the VAV2 plasmids.	Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Ahn J, 2013, MOL CANCER RES, V11, P952, DOI 10.1158/1541-7786.MCR-13-0003-T; Al-Saad S, 2008, BRIT J CANCER, V99, P1476, DOI 10.1038/sj.bjc.6604713; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; BERSHADSKY AD, 1987, CELL MOTIL CYTOSKEL, V8, P274, DOI 10.1002/cm.970080308; Bhattacharya R, 2009, J CELL SCI, V122, P1390, DOI 10.1242/jcs.043042; Burgstaller G, 2010, MOL BIOL CELL, V21, P3362, DOI 10.1091/mbc.E10-02-0094; Carr HS, 2013, MOL CELL BIOL, V33, P622, DOI 10.1128/MCB.00980-12; Chan KT, 2010, J BIOL CHEM, V285, P11418, DOI 10.1074/jbc.M109.090746; Chang FM, 2007, MOL BIOL CELL, V18, P253, DOI 10.1091/mbc.E06-03-0207; Chang L, 2004, NAT REV MOL CELL BIO, V5, P601, DOI 10.1038/nrm1438; Charrasse S, 2007, MOL BIOL CELL, V18, P1734, DOI 10.1091/mbc.E06-08-0766; Choma DP, 2007, J INVEST DERMATOL, V127, P31, DOI 10.1038/sj.jid.5700505; Citterio C, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002962; Dauphin M, 2013, LUNG CANCER, V81, P117, DOI 10.1016/j.lungcan.2013.03.011; Deakin NO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037990; Garrett TA, 2007, EXP CELL RES, V313, P3285, DOI 10.1016/j.yexcr.2007.05.027; Gonzales M, 2001, MOL BIOL CELL, V12, P85, DOI 10.1091/mbc.12.1.85; GREENBURG G, 1982, J CELL BIOL, V95, P333, DOI 10.1083/jcb.95.1.333; Helfand BT, 2011, MOL BIOL CELL, V22, P1274, DOI 10.1091/mbc.E10-08-0699; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hu L, 2004, ONCOGENE, V23, P298, DOI 10.1038/sj.onc.1206483; Ivaska J, 2005, EMBO J, V24, P3834, DOI 10.1038/sj.emboj.7600847; Kallergi G, 2007, CELL PHYSIOL BIOCHEM, V20, P977, DOI 10.1159/000110458; Kreis S, 2005, EXP CELL RES, V305, P110, DOI 10.1016/j.yexcr.2004.12.023; Lai SY, 2008, ORAL ONCOL, V44, P683, DOI 10.1016/j.oraloncology.2007.08.017; Li QF, 2006, J BIOL CHEM, V281, P34716, DOI 10.1074/jbc.M607715200; Lim JA, 2012, FEBS J, V279, P3573, DOI 10.1111/j.1742-4658.2012.08715.x; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Liu LK, 2010, MODERN PATHOL, V23, P213, DOI 10.1038/modpathol.2009.160; Liu ZD, 1997, BIOCHEM BIOPH RES CO, V231, P283, DOI 10.1006/bbrc.1997.6083; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; Mendez MG, 2010, FASEB J, V24, P1838, DOI 10.1096/fj.09-151639; MILLER SD, 2007, ONCOGENE, V31, P26; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Patz EF, 2004, J CLIN ONCOL, V22, P2202, DOI 10.1200/JCO.2004.12.046; Pisters KMW, 2005, J CLIN ONCOL, V23, P3270, DOI 10.1200/JCO.2005.11.478; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuebel KE, 1996, ONCOGENE, V13, P363; SEIFERT GJ, 1992, EUR J CELL BIOL, V59, P138; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Singh GK, 2002, JNCI-J NATL CANCER I, V94, P916, DOI 10.1093/jnci/94.12.916; Singh S, 2003, CANCER RES, V63, P2306; Soltermann A, 2008, CLIN CANCER RES, V14, P7430, DOI 10.1158/1078-0432.CCR-08-0935; STOKER M, 1985, J CELL SCI, V77, P209; Tamas P, 2003, J BIOL CHEM, V278, P5163, DOI 10.1074/jbc.M207555200; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsuruta D, 2003, J CELL SCI, V116, P4977, DOI 10.1242/jcs.00823; Wang JW, 2009, CANCER LETT, V281, P71, DOI 10.1016/j.canlet.2009.02.020; Wei JC, 2008, ANTICANCER RES, V28, P327; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; Wittmann T, 2003, J CELL BIOL, V161, P845, DOI 10.1083/jcb.200303082; Yamauchi J, 2005, P NATL ACAD SCI USA, V102, P14889, DOI 10.1073/pnas.0507125102; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhu QS, 2011, ONCOGENE, V30, P457, DOI 10.1038/onc.2010.421	56	108	112	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1979	1990		10.1038/onc.2014.123	http://dx.doi.org/10.1038/onc.2014.123			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24858039	Green Accepted			2022-12-17	WOS:000352725600012
J	Bharadwaj, U; Eckols, TK; Kolosov, M; Kasembeli, MM; Adam, A; Torres, D; Zhang, X; Dobrolecki, LE; Wei, W; Lewis, MT; Dave, B; Chang, JC; Landis, MD; Creighton, CJ; Mancini, MA; Tweardy, DJ				Bharadwaj, U.; Eckols, T. K.; Kolosov, M.; Kasembeli, M. M.; Adam, A.; Torres, D.; Zhang, X.; Dobrolecki, L. E.; Wei, W.; Lewis, M. T.; Dave, B.; Chang, J. C.; Landis, M. D.; Creighton, C. J.; Mancini, M. A.; Tweardy, D. J.			Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; UNPHOSPHORYLATED STAT3; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCER; GENE-EXPRESSION; DOWN-REGULATION; STEM-CELL; TRANSCRIPTION; BINDING; ACTIVATION	Signal transducer and activator of transcription (STAT) 3 regulates many cardinal features of cancer including cancer cell growth, apoptosis resistance, DNA damage response, metastasis, immune escape, tumor angiogenesis, the Warburg effect and oncogene addiction and has been validated as a drug target for cancer therapy. Several strategies have been used to identify agents that target Stat3 in breast cancer but none has yet entered into clinical use. We used a high-throughput fluorescence microscopy search strategy to identify compounds in a drug-repositioning library (Prestwick library) that block ligand-induced nuclear translocation of Stat3 and identified piperlongumine (PL), a natural product isolated from the fruit of the pepper Piper longum. PL inhibited Stat3 nuclear translocation, inhibited ligand-induced and constitutive Stat3 phosphorylation, and modulated expression of multiple Stat3-regulated genes. Surface plasmon resonance assay revealed that PL directly inhibited binding of Stat3 to its phosphotyrosyl peptide ligand. Phosphoprotein antibody array analysis revealed that PL does not modulate kinases known to activate Stat3 such as Janus kinases, Src kinase family members or receptor tyrosine kinases. PL inhibited anchorage-independent and anchorage-dependent growth of multiple breast cancer cell lines having increased pStat3 or total Stat3, and induced apoptosis. PL also inhibited mammosphere formation by tumor cells from patient-derived xenografts. PL's antitumorigenic function was causally linked to its Stat3-inhibitory effect. PL was non-toxic in mice up to a dose of 30 mg/kg/day for 14 days and caused regression of breast cancer cell line xenografts in nude mice. Thus, PL represents a promising new agent for rapid entry into the clinic for use in treating breast cancer, as well as other cancers in which Stat3 has a role.	[Bharadwaj, U.; Eckols, T. K.; Kolosov, M.; Kasembeli, M. M.; Adam, A.; Torres, D.; Tweardy, D. J.] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA; [Zhang, X.; Dobrolecki, L. E.; Wei, W.; Lewis, M. T.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Wei, W.; Lewis, M. T.; Mancini, M. A.; Tweardy, D. J.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Lewis, M. T.] Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; [Lewis, M. T.; Tweardy, D. J.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Dave, B.; Chang, J. C.; Landis, M. D.] Methodist Hosp, Res Inst, Methodist Canc Ctr, Houston, TX 77030 USA; [Creighton, C. J.] Baylor Coll Med, Dept Med, Hematol Oncol Sect, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine	Tweardy, DJ (corresponding author), Baylor Coll Med, Dept Med, Infect Dis Sect, BCM 286,Room N-1319,1 Baylor Plaza, Houston, TX 77030 USA.	dtweardy@bcm.edu	Tweardy, David/L-3929-2019; Dave, Bhuvanesh/ABF-8334-2020; Lewis, Michael T/A-9572-2009	Dave, Bhuvanesh/0000-0001-6741-1363; 	National Institutes of Health [CA149783, P50-CA058183, U54-CA149196]; BCM Cancer Center [P30 CA125123]; John S Dunn Gulf Coast Consortium for Chemical Genomics Screening Grant Program; NCRR [S10RR024574]; NIAID [AI036211]; NCI [P30 CA125123]; NATIONAL CANCER INSTITUTE [U54CA149196, P30CA125123, R41CA153658, R21CA149783, P50CA058183] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR024574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); BCM Cancer Center; John S Dunn Gulf Coast Consortium for Chemical Genomics Screening Grant Program; NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank various BCM core facilities for providing the infrastructure, instrumentation and expertise for performing many of our experiments; the Integrated Microscopy core (Director: Michael Mancini, PhD) for assistance with the HTFM screening assay; the Cytometry and Cell Sorting Core (Director: Joel M Sederstrom, MBS/Christine Beeton, PhD) for the Phosphoflow experiments; the Protein and Antibody Array Proteomics Core (Director: Shixia Huang, PhD) for the phosphoproteomic analysis. This project was supported, in part, by the following grants: National Institutes of Health grant CA149783 (DJT), P50-CA058183 (MTL), U54-CA149196 (MTL), the BCM Cancer Center Support Grant P30 CA125123, research grants from the John S Dunn Gulf Coast Consortium for Chemical Genomics Screening Grant Program (DJT), NCRR grant S10RR024574, NIAID AI036211 and NCI P30 CA125123 (BCM Cytometry and Cell Sorting Core funding).	Adams DJ, 2012, P NATL ACAD SCI USA, V109, P15115, DOI 10.1073/pnas.1212802109; Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333; Barry SP, 2010, INT J EXP PATHOL, V91, P506, DOI 10.1111/j.1365-2613.2010.00734.x; Barry SP, 2009, BIOCHEM BIOPH RES CO, V385, P324, DOI 10.1016/j.bbrc.2009.05.051; Bezerra DP, 2007, TOXICOL IN VITRO, V21, P1, DOI 10.1016/j.tiv.2006.07.007; Bolli R, 2011, J MOL CELL CARDIOL, V50, P589, DOI 10.1016/j.yjmcc.2011.01.002; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dave B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030207; Demaria M, 2010, AGING-US, V2, P823, DOI 10.18632/aging.100232; Doucette TA, 2012, NEURO-ONCOLOGY, V14, P1136, DOI 10.1093/neuonc/nos139; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grimshaw MJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2106; Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haviland R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024923; Hedvat M, 2009, CANCER CELL, V16, P487, DOI 10.1016/j.ccr.2009.10.015; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hochgrafe F, 2010, CANCER RES, V70, P9391, DOI 10.1158/0008-5472.CAN-10-0911; Huang Y, 2007, J BIOL CHEM, V282, P34958, DOI 10.1074/jbc.M704548200; Jang JH, 2012, ANTIOXID REDOX SIGN, V16, P383, DOI 10.1089/ars.2011.4134; Jarnicki A, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-14; Jing N, 2005, ANTI-CANCER DRUG, V16, P601, DOI 10.1097/00001813-200507000-00002; Johnston PA, 2011, MOL INTERV, V11, P18, DOI 10.1124/mi.11.1.4; Jung JE, 2009, J NEUROSCI, V29, P7003, DOI 10.1523/JNEUROSCI.1110-09.2009; Kim BK, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2247; Kim JK, 2005, J BIOL CHEM, V280, P32512, DOI 10.1074/jbc.M502431200; Kim SW, 2007, J NEUROSCI RES, V85, P1252, DOI 10.1002/jnr.21236; Koskela HLM, 2012, NEW ENGL J MED, V366, P1905, DOI 10.1056/NEJMoa1114885; Kotecha Nikesh, 2010, Curr Protoc Cytom, VChapter 10, DOI 10.1002/0471142956.cy1017s53; Lee SM, 2001, BIOCHIMIE, V83, P1057, DOI 10.1016/S0300-9084(01)01351-7; Litzenburger BC, 2011, CLIN CANCER RES, V17, P2314, DOI 10.1158/1078-0432.CCR-10-1903; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Nikulenkov F, 2012, CELL DEATH DIFFER, V19, P1992, DOI 10.1038/cdd.2012.89; Oshima Y, 2005, CARDIOVASC RES, V65, P428, DOI 10.1016/j.cardiores.2004.10.021; Pilati C, 2011, J EXP MED, V208, P1359, DOI 10.1084/jem.20110283; Quesnelle KM, 2007, J CELL BIOCHEM, V102, P311, DOI 10.1002/jcb.21475; Raj L, 2011, NATURE, V475, P231, DOI 10.1038/nature10167; Ram PT, 2001, ONCOGENE, V20, P1601, DOI 10.1038/sj.onc.1204186; Redell MS, 2005, CURR PHARM DESIGN, V11, P2873, DOI 10.2174/1381612054546699; Sarafian TA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009532; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Shao H, 2004, J BIOL CHEM, V279, P18967, DOI 10.1074/jbc.M314037200; Shao H, 2001, BLOOD, V98, P3853, DOI 10.1182/blood.V98.13.3853; Sharma SV, 2006, CANCER CELL, V10, P425, DOI 10.1016/j.ccr.2006.09.014; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159; Song LX, 2011, MOL CANCER THER, V10, P481, DOI 10.1158/1535-7163.MCT-10-0502; Timofeeva OA, 2012, J BIOL CHEM, V287, P14192, DOI 10.1074/jbc.M111.323899; Welte T, 2003, P NATL ACAD SCI USA, V100, P1879, DOI 10.1073/PNAS.0237137100; Xiong H, 2012, J BIOL CHEM, V287, P5819, DOI 10.1074/jbc.M111.295964; Xu XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004783; Yang J, 2005, CANCER RES, V65, P939; Yang JB, 2008, CELL RES, V18, P443, DOI 10.1038/cr.2008.41; Yang JB, 2007, GENE DEV, V21, P1396, DOI 10.1101/gad.1553707; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Zhang XM, 2013, CANCER RES, V73, P4885, DOI 10.1158/0008-5472.CAN-12-4081; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhou HK, 2011, BONE, V49, P404, DOI 10.1016/j.bone.2011.04.020	60	108	111	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1341	1353		10.1038/onc.2014.72	http://dx.doi.org/10.1038/onc.2014.72			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24681959	Green Accepted			2022-12-17	WOS:000350806500001
J	Luo, J; Lee, SO; Liang, L; Huang, CK; Li, L; Wen, S; Chang, C				Luo, J.; Lee, S. Ok; Liang, L.; Huang, C-K; Li, L.; Wen, S.; Chang, C.			Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling	ONCOGENE			English	Article						bone marrow mesenchymal stem cells; CCL5; androgen receptor; prostate cancer stem cells	STROMAL CELLS; GROWTH-FACTOR; DIFFERENTIATION; TUMORIGENESIS; MAINTENANCE; EXPRESSION; TUMORS; ROLES; CD133; MSCS	Although the contribution of the bone marrow mesenchymal stem cells (BM-MSCs) in cancer progression is emerging, their potential roles in prostate cancer (PCa) remain unclear. Here, we showed that PCa cells could recruit BM-MSCs and consequently the metastatic ability of PCa cells was increased. We also found that the increased metastatic ability of PCa cells could be due to the increased PCa stem cell population. Mechanism dissection studies found that the upregulation of Chemokine ligand 5 (CCL5) expression in BM-MSCs and PCa cells, after MSCs infiltrated into the PCa cells, subsequently downregulated androgen receptor (AR) signaling, which was due to inhibition of AR nuclear translocation. Interruption of such signaling led to suppression of the BM-MSCs-induced PCa stem cell population increase and thereby inhibited the metastatic ability of PCa cells. The PCa stem cell increase then led to the upregulation of matrix metalloproteinase 9, ZEB-1, CD133 and CXCR4 molecules, and enhanced the metastatic ability of PCa cells. Therefore, we conclude that the BM-MSCs-mediated increased metastatic ability of PCa cells can be due to the PCa stem cell increase via alteration of the CCL5-AR signaling pathway. Together, these results uncover the important roles of BM-MSCs as key components in the prostate tumor microenvironment to promote PCa metastasis and may provide a new potential target to suppress PCa metastasis by blocking BM-MSCs infiltration into PCa.	[Luo, J.; Lee, S. Ok; Liang, L.; Huang, C-K; Li, L.; Wen, S.; Chang, C.] Univ Rochester, Med Ctr, Dept Pathol, Dept Urol,Dept Radio Oncol,George Whipple Lab Can, Rochester, NY 14642 USA; [Luo, J.; Lee, S. Ok; Liang, L.; Huang, C-K; Li, L.; Wen, S.; Chang, C.] Univ Rochester, Med Ctr, Wilmot Canc Ctr, Rochester, NY 14642 USA; [Chang, C.] China Med Univ & Hosp, Sex Hormone Res Ctr, Taichung, Taiwan	University of Rochester; University of Rochester; China Medical University Taiwan; China Medical University Hospital - Taiwan	Chang, C (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, Dept Urol,Dept Radio Oncol,George Whipple Lab Can, 601 Elmwood Ave, Rochester, NY 14642 USA.	chang@urmc.rochester.edu	Luo, Jie/AAG-3091-2019	Wen, Simeng/0000-0001-7989-7700	NIH [CA122840, CA256700]; Taiwan Department of Health Clinical Trial and Research Center of Excellence [DOH102-TD-B-111-004]; NATIONAL CANCER INSTITUTE [R01CA122840] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Taiwan Department of Health Clinical Trial and Research Center of Excellence; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Karen Wolf for help with the manuscript preparation. This work was supported by NIH Grants (CA122840 and CA256700), and Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH102-TD-B-111-004) to China Medical University, Taiwan.	Altuwaijri S, 2007, ASIAN J ANDROL, V9, P181, DOI 10.1111/j.1745-7262.2007.00258.x; Augsten M, 2009, P NATL ACAD SCI USA, V106, P3414, DOI 10.1073/pnas.0813144106; Auletta JJ, 2012, BLOOD, V119, P1801, DOI 10.1182/blood-2011-10-384354; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Charoenfuprasert S, 2011, ONCOGENE, V30, P3570, DOI 10.1038/onc.2011.77; Chong JJH, 2011, CELL STEM CELL, V9, P527, DOI 10.1016/j.stem.2011.10.002; Dayyani F, 2011, JNCI-J NATL CANCER I, V103, P1665, DOI 10.1093/jnci/djr362; Delude C, 2011, NATURE, V480, pS43, DOI 10.1038/480S43a; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; Gao Y, 2010, ONCOGENE, V29, P2784, DOI 10.1038/onc.2010.38; Goldstein RH, 2010, CANCER RES, V70, P10044, DOI 10.1158/0008-5472.CAN-10-1254; Huang XP, 2010, CIRCULATION, V122, P2419, DOI 10.1161/CIRCULATIONAHA.110.955971; Jodele S, 2005, CANCER RES, V65, P3200, DOI 10.1158/0008-5472.CAN-04-3770; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kleeberger W, 2007, CANCER RES, V67, P9199, DOI 10.1158/0008-5472.CAN-07-0806; Kobayashi A, 2011, J EXP MED, V208, P2641, DOI 10.1084/jem.20110840; Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656; Lee CH, 2010, J CLIN INVEST, V120, P3340, DOI 10.1172/JCI43230; Lee SO, 2013, J MOL CELL BIOL, V5, P14, DOI 10.1093/jmcb/mjs042; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Liu SL, 2011, CANCER RES, V71, P614, DOI 10.1158/0008-5472.CAN-10-0538; Loebinger MR, 2009, CANCER RES, V69, P4134, DOI 10.1158/0008-5472.CAN-08-4698; Mak P, 2010, CANCER CELL, V17, P319, DOI 10.1016/j.ccr.2010.02.030; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12188, DOI 10.1073/pnas.0804701105; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003; Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020; Raaijmakers MHGP, 2010, NATURE, V464, P852, DOI 10.1038/nature08851; Richardson GD, 2004, J CELL SCI, V117, P3539, DOI 10.1242/jcs.01222; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Rybak AP, 2011, BBA-MOL CELL RES, V1813, P683, DOI 10.1016/j.bbamcr.2011.01.018; Shi XD, 2007, DEV BIOL, V312, P396, DOI 10.1016/j.ydbio.2007.09.042; Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004; Trerotola M, 2010, AM J TRANSL RES, V2, P135; Wegiel B, 2008, JNCI-J NATL CANCER I, V100, P1022, DOI 10.1093/jnci/djn214; Xu S, 2012, STEM CELLS, V30, P266, DOI 10.1002/stem.787; Ye HM, 2012, CANCER INVEST, V30, P513, DOI 10.3109/07357907.2012.692171; Yong RL, 2009, CANCER RES, V69, P8932, DOI 10.1158/0008-5472.CAN-08-3873; Yu XZ, 2011, CURR COLORECT CANC R, V7, P253, DOI 10.1007/s11888-011-0106-1; Zeng YP, 2006, CANCER RES, V66, P9566, DOI 10.1158/0008-5472.CAN-06-1488; Zhu P, 2006, CELL, V124, P615, DOI 10.1016/j.cell.2005.12.032	43	108	111	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2768	2778		10.1038/onc.2013.233	http://dx.doi.org/10.1038/onc.2013.233			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23792449				2022-12-17	WOS:000337231700010
J	Hsu, TI; Wang, MC; Chen, SY; Yeh, YM; Su, WC; Chang, WC; Hung, JJ				Hsu, T-I; Wang, M-C; Chen, S-Y; Yeh, Y-M; Su, W-C; Chang, W-C; Hung, J-J			Sp1 expression regulates lung tumor progression	ONCOGENE			English	Article						Sp1; metastasis; E-cadherin	TRANSCRIPTION FACTOR SP1; FACTOR-I-RECEPTOR; E-CADHERIN; BETA-CATENIN; SPECIFICITY PROTEIN-1; GENE-EXPRESSION; DOWN-REGULATION; CELL-GROWTH; CANCER; METASTASIS	The role of specificity protein 1 (Sp1) in controlling gene expression in lung tumor development and metastasis is not well understood. In this study, we showed that the Sp1 level was highly increased and required for lung tumor growth in transgenic mice bearing Kras-induced lung tumors under the control of doxycycline. Furthermore, the Sp1 level was highly upregulated in lung adenocarcinoma cells with low invasiveness and in patients with stage I lung cancer. We also demonstrated that Sp1 was downregulated in lung adenocarcinoma cells with high invasiveness and in patients with stage IV lung adenocarcinoma. Moreover, Sp1 inversely regulated migration, invasion and metastasis of lung adenocarcinoma cells in vivo. In addition, a decrease in the Sp1 level in highly invasive lung adenocarcinoma cells resulted from instability of the Sp1 protein. Furthermore, overexpression of Sp1 in highly invasive lung adenocarcinoma cells increased expression of E-cadherin, a suppressor of metastasis, and attenuated the translocation of beta-catenin into the cellular nucleus that leads to tumor malignancy. Taken together, Sp1 level accumulated strongly in early stage and then declined in late stage, which is important for lung cancer cell proliferation and metastasis during tumorigenesis. Oncogene (2012) 31, 3973-3988; doi: 10.1038/onc.2011.568; published online 12 December 2011	[Hung, J-J] Natl Cheng Kung Univ, Coll Biosci & Biotechnol, Inst Bioinformat & Biosignal Transduct, Ctr Gene Regulat & Signal Transduct, Tainan 701, Taiwan; [Hsu, T-I; Chang, W-C; Hung, J-J] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 701, Taiwan; [Wang, M-C; Hung, J-J] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan; [Hsu, T-I; Chen, S-Y; Chang, W-C; Hung, J-J] Natl Cheng Kung Univ, Coll Biosci Biotechnol, Inst Bioinformat & Biosignal Transduct, Tainan 701, Taiwan; [Yeh, Y-M; Su, W-C] Natl Cheng Kung Univ, Coll Med & Hosp, Dept Internal Med, Tainan 701, Taiwan; [Chang, W-C] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Taipei Medical University	Hung, JJ (corresponding author), Natl Cheng Kung Univ, Coll Biosci & Biotechnol, Inst Bioinformat & Biosignal Transduct, Ctr Gene Regulat & Signal Transduct, 1 Univ Rd, Tainan 701, Taiwan.	petehung@mail.ncku.edu.tw	Hsu, Tsung-I/AAK-9942-2020	Hsu, Tsung-I/0000-0002-7524-7740; Su, Wu-Chou/0000-0003-2953-4105	National Cheng-Kung University project of the Program for Promoting Academic Excellence and Developing World Class Research Centers; National Science Council, Taiwan [NSC 97-2320-B-006-016-MY3, NSC 97-2311-B-006-002-MY3]; Department of Health, Executive Yuan, Taiwan [DOH99-TD-B-111-002, DOH99-TD-B111-003]	National Cheng-Kung University project of the Program for Promoting Academic Excellence and Developing World Class Research Centers; National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Department of Health, Executive Yuan, Taiwan	This work was supported by the National Cheng-Kung University project of the Program for Promoting Academic Excellence and Developing World Class Research Centers, together with Grants NSC 97-2320-B-006-016-MY3 and NSC 97-2311-B-006-002-MY3 obtained from the National Science Council, Taiwan. The clinical work in this study was supported by the Department of Health, Executive Yuan, Taiwan (Grants DOH99-TD-B-111-002 and DOH99-TD-B111-003).	Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Bremnes RM, 2002, LUNG CANCER, V36, P115, DOI 10.1016/S0169-5002(01)00471-8; Bu YH, 2011, INT J CANCER, V128, P1836, DOI 10.1002/ijc.25524; Chang HC, 2004, CELL SIGNAL, V16, P675, DOI 10.1016/j.cellsig.2003.11.001; Chao YC, 2009, AM J RESP CRIT CARE, V179, P123, DOI 10.1164/rccm.200803-456OC; Chen JF, 2010, ANTICANCER RES, V30, P1113; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Chuang JY, 2008, MOL BIOL CELL, V19, P1139, DOI 10.1091/mbc.E07-09-0881; Chuang JY, 2009, INT J CANCER, V125, P2066, DOI 10.1002/ijc.24563; Clair SS, 2006, CELL CYCLE, V5, P709, DOI 10.4161/cc.5.7.2628; DeFino MC, 2010, BIOCHEM BIOPH RES CO, V393, P603, DOI 10.1016/j.bbrc.2010.02.026; Denlinger CE, 2010, J THORAC CARDIOV SUR, V140, P505, DOI 10.1016/j.jtcvs.2010.02.061; Duverger V, 2004, BRIT J CANCER, V90, P2025, DOI 10.1038/sj.bjc.6601824; Esteve PO, 2007, J BIOL CHEM, V282, P2615, DOI 10.1074/jbc.M606203200; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Hommura F, 2002, CANCER-AM CANCER SOC, V94, P752, DOI 10.1002/cncr.10213; Hung TL, 2003, CLIN CANCER RES, V9, P2605; Innocente SA, 2005, FEBS LETT, V579, P1001, DOI 10.1016/j.febslet.2004.12.073; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jiang YX, 2004, CLIN EXP METASTAS, V21, P755, DOI 10.1007/s10585-005-1198-2; Kumar AP, 1999, CANCER LETT, V137, P159, DOI 10.1016/S0304-3835(98)00351-6; Kwak HJ, 2006, MOL CANCER RES, V4, P209, DOI 10.1158/1541-7786.MCR-05-0140; Lee YC, 2011, AM J RESP CELL MOL, V45, P270, DOI 10.1165/rcmb.2010-0313OC; Leroy I, 2006, APOPTOSIS, V11, P113, DOI 10.1007/s10495-005-3089-z; Lin RK, 2007, ANTI-CANCER DRUG, V18, P1157, DOI 10.1097/CAD.0b013e3282a215e9; Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991; Lou Z, 2005, CANCER RES, V65, P1007; Maor S, 2006, J ENDOCRINOL, V191, P605, DOI 10.1677/joe.1.07016; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; Mitchell DC, 2007, ONCOGENE, V26, P1739, DOI 10.1038/sj.onc.1209963; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nicolas M, 2001, J BIOL CHEM, V276, P22126, DOI 10.1074/jbc.M010740200; Remsing LL, 2003, BIOCHEMISTRY-US, V42, P8313, DOI 10.1021/bi034091z; Rivard N, 2009, FRONT BIOSCI-LANDMRK, V14, P510, DOI 10.2741/3259; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; Sun XJ, 2009, CANCER RES, V69, P6445, DOI 10.1158/0008-5472.CAN-09-1001; Tsai MF, 2006, JNCI-J NATL CANCER I, V98, P825, DOI 10.1093/jnci/djj229; Wang YT, 2008, J MOL BIOL, V380, P869, DOI 10.1016/j.jmb.2008.05.043; Wierstra I, 2008, BIOCHEM BIOPH RES CO, V372, P1, DOI 10.1016/j.bbrc.2008.03.074; Yi TF, 2010, J BIOL CHEM, V285, P17811, DOI 10.1074/jbc.M110.130740; Zheng Y, 2009, CANCER RES, V69, P896, DOI 10.1158/0008-5472.CAN-08-2677	44	108	108	0	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	35					3973	3988		10.1038/onc.2011.568	http://dx.doi.org/10.1038/onc.2011.568			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999VJ	22158040	hybrid, Green Published			2022-12-17	WOS:000308342800006
J	Ramachandran, I; Thavathiru, E; Ramalingam, S; Natarajan, G; Mills, WK; Benbrook, DM; Zuna, R; Lightfoot, S; Reis, A; Anant, S; Queimado, L				Ramachandran, I.; Thavathiru, E.; Ramalingam, S.; Natarajan, G.; Mills, W. K.; Benbrook, D. M.; Zuna, R.; Lightfoot, S.; Reis, A.; Anant, S.; Queimado, L.			Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo	ONCOGENE			English	Article						Wnt inhibitory factor 1 (WIF1); Wnt; beta-catenin; cervical cancer; hypermethylation; apoptosis	EPIGENETIC INACTIVATION; SIGNAL-TRANSDUCTION; PROGNOSTIC VALUE; POOR-PROGNOSIS; BETA-CATENIN; E-CADHERIN; EXPRESSION; CD44; P53; PATHWAY	activation of Wingless-type (Wnt)beta-catenin signaling is widespread in human cervical cancer. However, the underlying mechanisms of Wnt activation and the therapeutic potential of Wnt inhibition remain largely unknown. Here, we demonstrate that the Wnt inhibitory factor 1 (WIF1), a secreted Wnt antagonist, is downregulated in all human primary cervical tumors and cell lines analyzed. Our data reveal that WIF1 downregulation occurs due to promoter hypermethylation and is an early event in cervical oncogenesis. WIF1 re-expression upon 5-aza-2'-deoxycytidine treatment or WIF1 gene transfer induces significant apoptosis and G(2)/M arrest, and inhibits cervical cancer cell proliferation in vitro. Consistent with this, treatment of established mice tumor xenografts with peritumoral WIF1 gene transfer results in a significant inhibition of cancer growth and invasion. WIF1 treatment causes a significant decrease in intracellular WNT1 and TCF-4 proteins revealing novel Wnt-regulatory mechanisms. Thus, WIF1 causes a major cellular re-distribution of beta-catenin and a significant inhibition of the Wnt/beta-catenin pathway in tumor cells, as documented by a remarkable reversion in the expression of Wnt/beta-catenin transcriptional target genes (E-cadherin, c-Myc, cyclin D1, CD44 and VEGF). Consequently, multiple critical events in tumor progression and metastasis such as cell proliferation, angiogenesis and invasion were inhibited by WIF1. In addition, WIF1 modulated the expression of specific anti-apoptotic and apoptotic proteins, thereby inducing significant apoptosis in vivo. Our findings demonstrate for the first time that WIF1 downregulation by epigenetic gene silencing is an important mechanism of Wnt activation in cervical oncogenesis. Of major clinical relevance, we show that peritumoral WIF1 gene transfer reduces not only cancer growth but also invasion in well-established tumors. Therefore, our data provide novel mechanistic insights into the role of WIF1 in cervical cancer progression, and the important preclinical validation of WIF1 as a potent drug target in cervical cancer treatment. Oncogene (2012) 31, 2725-2737; doi: 10.1038/onc.2011.455; published online 17 October 2011	[Ramachandran, I.; Thavathiru, E.; Mills, W. K.; Queimado, L.] Univ Oklahoma, Hlth Sci Ctr, Dept Otorhinolaryngol, Oklahoma City, OK 73104 USA; [Ramalingam, S.; Natarajan, G.; Anant, S.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA; [Benbrook, D. M.] Univ Oklahoma, Hlth Sci Ctr, Dept Obstet & Gynecol, Oklahoma City, OK 73104 USA; [Benbrook, D. M.] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; [Benbrook, D. M.] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA; [Reis, A.] Univ Oklahoma, Hlth Sci Ctr, Dept Dermatol, Oklahoma City, OK 73104 USA; [Anant, S.; Queimado, L.] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA; [Queimado, L.] Univ Oklahoma, Hlth Sci Ctr, Dept Pediat, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Queimado, L (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Otorhinolaryngol, 975 NE 10th St,BRC 1272, Oklahoma City, OK 73104 USA.	lurdes-queimado@ouhsc.edu	Anant, Shrikant/AAF-8020-2020; Queimado, Lurdes/L-7465-2013; Queimado, Lurdes/AAY-2545-2021; Ramalingam, Satish/H-1577-2018	Queimado, Lurdes/0000-0002-1106-4873; Queimado, Lurdes/0000-0002-1106-4873; Ramalingam, Satish/0000-0002-3076-279X	Oklahoma Center for the Advancement of Science and Technology [HR08-018]	Oklahoma Center for the Advancement of Science and Technology	We sincerely thank Dr Eric W Howard for kindly providing the pCI-blast vector. We are grateful to Dr Sripathi M Sureban and Dr Dharmalingam Subramaniam for their technical advice and graphic assistance. We also thank Mrs Geraldine A Chissoe and Mr Randal May (Advanced Immunohistochemistry and Morphology Core, OUHSC) for their technical assistance. We appreciate the helpful discussions of Dr Ileng Kumaran Ramachandran (CSHL) and Dr Sivakumar Ramadoss (UCLA). This work was supported by the Oklahoma Center for the Advancement of Science and Technology (LQ) (HR08-018). LQ holds a Presbyterian Health Foundation Endowed Chair in Otorhinolaryngology.	ABBASI AM, 1993, EUR J CANCER, V29A, P1995, DOI 10.1016/0959-8049(93)90461-N; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Ahn WS, 2004, INT J GYNECOL CANCER, V14, P322, DOI 10.1111/j.1048-891x.2004.014217.x; Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379; Bae DS, 2001, GYNECOL ONCOL, V81, P341, DOI 10.1006/gyno.2001.6196; Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096; Branca M, 2006, EUR J GYNAECOL ONCOL, V27, P215; Byun T, 2005, J CLIN PATHOL, V58, P515, DOI 10.1136/jcp.2004.018598; Chung MT, 2009, GYNECOL ONCOL, V112, P301, DOI 10.1016/j.ygyno.2008.10.004; DeLisser HM, 1997, AM J PATHOL, V151, P671; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Gherghe CM, 2011, FASEB J, V25, P1836, DOI 10.1096/fj.10-172981; Hemann MT, 2006, CELL DEATH DIFFER, V13, P1256, DOI 10.1038/sj.cdd.4401962; Horn LC, 2006, GYNECOL ONCOL, V103, P906, DOI 10.1016/j.ygyno.2006.05.046; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Jamora C, 2003, NATURE, V422, P317, DOI 10.1038/nature01458; Johnson CL, 2002, MOL CANCER THER, V1, P861; Jones M, 2000, J BIOL CHEM, V275, P7964, DOI 10.1074/jbc.275.11.7964; KAINZ C, 1995, EUR J CANCER, V31A, P1706, DOI 10.1016/0959-8049(95)00353-K; Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175; Kawakami K, 2009, CANCER RES, V69, P8603, DOI 10.1158/0008-5472.CAN-09-2534; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kim J, 2007, J THORAC CARDIOV SUR, V133, P733, DOI 10.1016/j.jtcvs.2006.09.053; Koskimaa HM, 2010, CANCER EPIDEM BIOMAR, V19, P2003, DOI 10.1158/1055-9965.EPI-09-0781; Laux H, 2004, LAB INVEST, V84, P1372, DOI 10.1038/labinvest.3700158; Lee EJ, 2009, INT J CANCER, V124, P287, DOI 10.1002/ijc.23913; Li J, 2008, ONCOGENE, V27, P6194, DOI 10.1038/onc.2008.297; Lin YC, 2007, HUM GENE THER, V18, P379, DOI 10.1089/hum.2006.005; Linderholm BK, 2001, CANCER RES, V61, P2256; Lu Shi, 2005, J Huazhong Univ Sci Technolog Med Sci, V25, P78; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Mathur SP, 2005, GYNECOL ONCOL, V98, P467, DOI 10.1016/j.ygyno.2005.05.003; Mikels AJ, 2006, ONCOGENE, V25, P7461, DOI 10.1038/sj.onc.1210053; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Orian-Rousseau V, 2010, EUR J CANCER, V46, P1271, DOI 10.1016/j.ejca.2010.02.024; Parkin DM, 2006, VACCINE, V24, P11, DOI 10.1016/j.vaccine.2006.05.111; Perez-Plasencia Carlos, 2008, Int Arch Med, V1, P10, DOI 10.1186/1755-7682-1-10; Phoophitphong T, 2007, J OBSTET GYNAECOL RE, V33, P840, DOI 10.1111/j.1447-0756.2007.00666.x; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Queimado L, 2008, ARCH OTOLARYNGOL, V134, P94, DOI 10.1001/archotol.134.1.94; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Shinohara A, 2001, GYNECOL ONCOL, V82, P450, DOI 10.1006/gyno.2001.6298; Silva-Filho AL, 2006, INT J GYNECOL CANCER, V16, P757, DOI 10.1111/j.1525-1438.2006.00362.x; Skurk C, 2005, CIRC RES, V96, P308, DOI 10.1161/01.RES.0000156273.30274.f7; Speiser P, 1997, INT J CANCER, V74, P185, DOI 10.1002/(SICI)1097-0215(19970422)74:2<185::AID-IJC8>3.0.CO;2-V; Tang YX, 2009, MOL CANCER THER, V8, P458, DOI 10.1158/1535-7163.MCT-08-0885; Taniguchi H, 2005, ONCOGENE, V24, P7946, DOI 10.1038/sj.onc.1208910; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Urakami S, 2006, CLIN CANCER RES, V12, P383, DOI 10.1158/1078-0432.CCR-05-1344; Uren A, 2005, CANCER RES, V65, P6199, DOI 10.1158/0008-5472.CAN-05-0455; Vijayalakshmi N, 2002, EUR J GYNAECOL ONCOL, V23, P135; Wang H, 2008, ONCOGENE, V27, P1905, DOI 10.1038/sj.onc.1210823; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449; Woodman CBJ, 2007, NAT REV CANCER, V7, P11, DOI 10.1038/nrc2050; Wright M, 1999, BIOCHEM BIOPH RES CO, V263, P384, DOI 10.1006/bbrc.1999.1344; Yee DS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-162; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Zuckerman V, 2009, J PATHOL, V219, P3, DOI 10.1002/path.2584	60	108	119	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	22					2725	2737		10.1038/onc.2011.455	http://dx.doi.org/10.1038/onc.2011.455			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	952DB	22002305				2022-12-17	WOS:000304769000003
J	Cheung, HH; Davis, AJ; Lee, TL; Pang, AL; Nagrani, S; Rennert, OM; Chan, WY				Cheung, H-H; Davis, A. J.; Lee, T-L; Pang, A. L.; Nagrani, S.; Rennert, O. M.; Chan, W-Y			Methylation of an intronic region regulates miR-199a in testicular tumor malignancy	ONCOGENE			English	Article						intronic methylation; miR-199a; testicular tumor; PODXL; malignancy	GERM-CELL TUMORS; OVARIAN-CANCER CELLS; DNA METHYLATION; MICRORNA EXPRESSION; PROSTATE-CANCER; BLADDER-CANCER; IDENTIFICATION; PODOCALYXIN; METASTASIS; CARCINOMA	In the testicular cancer cell line, NT2, we previously demonstrated that differentially methylated regions were located in introns or intergenic regions, and postulated these might regulate non-coding RNAs. Three microRNAs and three small nucleolar RNAs were differentially methylated; one, miR-199a, was associated with the progression and prognosis of gastric and ovarian cancers. In this report we document, by epigenomic profiling of testicular tissue, that miR-199a is transcribed as antisense of dynamin 3 (chromosome 1q24.3), and hypermethylation of this region is correlated with miR-199a-5p/3p repression and tumor malignancy. Re-expression of miR-199a in testicular cancer cells led to suppression of cell growth, cancer migration, invasion and metastasis. The miR-199a-5p, one of two mature miRNA species derived from miR-199a, is associated with tumor malignancy. We further identified the embryonal carcinoma antigen podocalyxin-like protein 1 (PODXL), an anti-adhesive protein expressed in aggressive tumors, as a target of miR-199a-5p. We demonstrated PODXL is overexpressed in malignant testicular tumor, and cellular depletion of PODXL resulted in suppression of cancer invasion. The inverse relationship between PODXL and miR-199a-5p expression suggests PODXL is a downstream effector mediating the action of miR199a-5p. This report identifies DNA methylation, miR-199a dysregulation and PODXL as critical factors in tumor malignancy. Oncogene (2011) 30, 3404-3415; doi:10.1038/onc.2011.60; published online 7 March 2011	[Cheung, H-H; Chan, W-Y] Chinese Univ Hong Kong, Sch Biomed Sci, Fac Med, Shatin, Hong Kong, Peoples R China; [Cheung, H-H; Davis, A. J.; Lee, T-L; Pang, A. L.; Nagrani, S.; Rennert, O. M.; Chan, W-Y] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Clin & Dev Genom, NIH, Bethesda, MD USA	Chinese University of Hong Kong; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Chan, WY (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Fac Med, Room 518B,Choh Ming Li Basic Med Sci Bldg, Shatin, Hong Kong, Peoples R China.	chanwy@cuhk.edu.hk	Chan, Wai Yee/R-7442-2018; Rennert, owen/AAI-7374-2020; Lee, Tin-Lap/A-7853-2009; Lee, Tin-Lap/W-6595-2019; Cheung, Hoi-Hung/G-7605-2011; Cheung, Hoi-Hung/AAE-2670-2020	Chan, Wai Yee/0000-0002-9714-0936; Lee, Tin-Lap/0000-0002-6654-0988; Lee, Tin-Lap/0000-0002-6654-0988; Cheung, Hoi-Hung/0000-0001-7178-9289; Davis, Andrew/0000-0001-9556-4498	National Institutes of Health (NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development; Chinese University of Hong Kong; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008820, ZIAHD008817] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Chinese University of Hong Kong(Chinese University of Hong Kong); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	We thank Dr Yun-Fai Chris Lau for providing the 833K cell line. This research was supported in part by the Intramural Research Program of the National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Chinese University of Hong Kong.	Aleman A, 2008, CLIN CANCER RES, V14, P8236, DOI 10.1158/1078-0432.CCR-08-0778; ANDREWS PW, 1984, LAB INVEST, V50, P147; Casey G, 2006, HUM MOL GENET, V15, P735, DOI 10.1093/hmg/ddi487; Chakrabarty A, 2007, P NATL ACAD SCI USA, V104, P15144, DOI 10.1073/pnas.0705917104; Chen R, 2008, ONCOGENE, V27, P4712, DOI 10.1038/onc.2008.112; Cheung HH, 2010, BRIT J CANCER, V102, P419, DOI 10.1038/sj.bjc.6605505; Cheung HH, 2009, BIRTH DEFECTS RES C, V87, P335, DOI 10.1002/bdrc.20163; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fornari F, 2010, CANCER RES, V70, P5184, DOI 10.1158/0008-5472.CAN-10-0145; Friedman LM, 2009, P NATL ACAD SCI USA, V106, P7915, DOI 10.1073/pnas.0812446106; Godwin JG, 2010, P NATL ACAD SCI USA, V107, P14339, DOI 10.1073/pnas.0912701107; Hayatsu N, 2008, BIOCHEM BIOPH RES CO, V374, P394, DOI 10.1016/j.bbrc.2008.07.049; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Ichimi T, 2009, INT J CANCER, V125, P345, DOI 10.1002/ijc.24390; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Kim S, 2008, J BIOL CHEM, V283, P18158, DOI 10.1074/jbc.M800186200; Koch LK, 2008, HUM PATHOL, V39, P1597, DOI 10.1016/j.humpath.2008.03.008; Lee DY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004527; Lee JW, 2008, CLIN CANCER RES, V14, P2535, DOI 10.1158/1078-0432.CCR-07-1231; Li LC, 2001, J UROLOGY, V166, P705, DOI 10.1016/S0022-5347(05)66047-8; Li YM, 2007, HUM PATHOL, V38, P1470, DOI 10.1016/j.humpath.2007.03.011; Lin EA, 2009, J BIOL CHEM, V284, P11326, DOI 10.1074/jbc.M807709200; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731; Netto GJ, 2008, MODERN PATHOL, V21, P1337, DOI 10.1038/modpathol.2008.127; Pang ALY, 2009, BIOL REPROD, V81, P302, DOI 10.1095/biolreprod.108.073221; Peltier HJ, 2008, RNA, V14, P844, DOI 10.1261/rna.939908; Rane S, 2009, CIRC RES, V104, P879, DOI 10.1161/CIRCRESAHA.108.193102; Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002; Santhakumar D, 2010, P NATL ACAD SCI USA, V107, P13830, DOI 10.1073/pnas.1008861107; Schopperle WM, 2003, BIOCHEM BIOPH RES CO, V300, P285; Singal R, 1997, P NATL ACAD SCI USA, V94, P13724, DOI 10.1073/pnas.94.25.13724; Smiraglia DJ, 2002, ONCOGENE, V21, P3909, DOI 10.1038/sj.onc.1205488; Somasiri A, 2004, CANCER RES, V64, P5068, DOI 10.1158/0008-5472.CAN-04-0240; Takeda T, 2000, MOL BIOL CELL, V11, P3219, DOI 10.1091/mbc.11.9.3219; Tsai WC, 2009, HEPATOLOGY, V49, P1571, DOI 10.1002/hep.22806; Tsai ZY, 2010, J CELL BIOCHEM, V109, P93, DOI 10.1002/jcb.22385; Ueda T, 2010, LANCET ONCOL, V11, P136, DOI 10.1016/S1470-2045(09)70343-2; Watts GS, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-47; Worley LA, 2008, MELANOMA RES, V18, P184, DOI 10.1097/CMR.0b013e3282feeac6; Yin G, 2010, ONCOGENE, V29, P3545, DOI 10.1038/onc.2010.111; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24	45	108	115	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	31					3404	3415		10.1038/onc.2011.60	http://dx.doi.org/10.1038/onc.2011.60			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	802KA	21383689	Green Accepted			2022-12-17	WOS:000293508100002
J	Dhawan, P; Ahmad, R; Chaturvedi, R; Smith, JJ; Midha, R; Mittal, MK; Krishnan, M; Chen, X; Eschrich, S; Yeatman, TJ; Harris, RC; Washington, MK; Wilson, KT; Beauchamp, RD; Singh, AB				Dhawan, P.; Ahmad, R.; Chaturvedi, R.; Smith, J. J.; Midha, R.; Mittal, M. K.; Krishnan, M.; Chen, X.; Eschrich, S.; Yeatman, T. J.; Harris, R. C.; Washington, M. K.; Wilson, K. T.; Beauchamp, R. D.; Singh, A. B.			Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation	ONCOGENE			English	Article						tight junction; claudin; EGFR; colon cancer; proliferation	INFLAMMATORY-BOWEL-DISEASE; EPITHELIAL TIGHT JUNCTIONS; EGF-RECEPTOR; TRANSEPITHELIAL RESISTANCE; DIFFERENTIAL EXPRESSION; JUXTACRINE ACTIVATION; ULCERATIVE-COLITIS; COLORECTAL-CANCER; TYROSINE KINASE; CROHNS-DISEASE	Claudin-2 is a unique member of the claudin family of transmembrane proteins, as its expression is restricted to the leaky epithelium in vivo and correlates with epithelial leakiness in vitro. However, recent evidence suggests potential functions of claudin-2 that are relevant to neoplastic transformation and growth. In accordance, here we report, on the basis of analysis of mRNA and protein expression using a total of 309 patient samples that claudin-2 expression is significantly increased in colorectal cancer and correlates with cancer progression. We also report similar increases in claudin-2 expression in inflammatory bowel disease-associated colorectal cancer. Most importantly, we demonstrate that the increased claudin-2 expression in colorectal cancer is causally associated with tumor growth as forced claudin-2 expression in colon cancer cells that do not express claudin-2 resulted in significant increases in cell proliferation, anchorage-independent growth and tumor growth in vivo. We further show that the colonic microenvironment regulates claudin-2 expression in a manner dependent on signaling through the EGF receptor (EGFR), a key regulator of colon tumorigenesis. In addition, claudin-2 expression is specifically decreased in the colon of waved-2 mice, naturally deficient in EGFR activation. Furthermore, genetic silencing of claudin-2 expression in Caco-2, a colon cancer cell line, prevents the EGF-induced increase in cell proliferation. Taken together, these results uncover a novel role for claudin-2 in promoting colon cancer, potentially via EGFR transactivation. Oncogene (2011) 30, 3234-3247; doi:10.1038/onc.2011.43; published online 7 March 2011	[Dhawan, P.; Ahmad, R.; Smith, J. J.; Midha, R.; Mittal, M. K.; Krishnan, M.; Beauchamp, R. D.; Singh, A. B.] Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37232 USA; [Dhawan, P.; Wilson, K. T.; Beauchamp, R. D.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; [Chaturvedi, R.; Harris, R. C.; Wilson, K. T.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; [Chen, X.] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37232 USA; [Eschrich, S.; Yeatman, T. J.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; [Washington, M. K.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Vanderbilt University	Singh, AB (corresponding author), Vanderbilt Univ, Med Ctr, Dept Surg, CCC-4513,1161 21st Ave S, Nashville, TN 37232 USA.	amar.singh@vanderbilt.edu	Eschrich, Steven/K-6848-2013; Smith, Jesse Joshua/AAN-5440-2020	Eschrich, Steven/0000-0002-9833-2788; Smith, Jesse Joshua/0000-0003-2538-5456; Beauchamp, Robert Daniel/0000-0002-8446-4114; Mittal, Mukul/0000-0002-9795-7372; Wilson, Keith/0000-0003-4421-1830	Pilot projects [5P50DK044757, P30DK058404]; NIH [CA119005, CA124977]; NATIONAL CANCER INSTITUTE [R21CA119005, R01CA124977] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT004821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK088902, P50DK044757, P30DK058404] Funding Source: NIH RePORTER	Pilot projects; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by 5P50DK044757 and P30DK058404 Pilot projects (ABS) and by NIH grants CA119005, CA124977 (PD). We thank Dr Ambra Pozzi and Mingjian Shi for providing waved-2 mice and Dr Wael El-Rifai for providing 5-FU.	Amasheh M, 2009, SCAND J GASTROENTERO, V44, P1226, DOI 10.1080/00365520903131973; Angelow S, 2007, J MEMBRANE BIOL, V215, P147, DOI 10.1007/s00232-007-9014-3; ANSFIELD F, 1977, CANCER-AM CANCER SOC, V39, P34, DOI 10.1002/1097-0142(197701)39:1<34::AID-CNCR2820390107>3.0.CO;2-2; Bos M, 1997, CLIN CANCER RES, V3, P2099; Buchert M, 2010, P NATL ACAD SCI USA, V107, P2628, DOI 10.1073/pnas.0903747107; Buzza MS, 2010, P NATL ACAD SCI USA, V107, P4200, DOI 10.1073/pnas.0903923107; Cereijido M, 2004, PHYSIOL REV, V84, P1229, DOI 10.1152/physrev.00001.2004; Cutler NS, 2003, CANCER RES, V63, P1748; D'Inca R, 1999, AM J GASTROENTEROL, V94, P2956, DOI 10.1111/j.1572-0241.1999.01444.x; Dahlhoff M, 2008, FEBS LETT, V582, P2911, DOI 10.1016/j.febslet.2008.07.026; DAVIES RJ, 1989, ARCH SURG-CHICAGO, V124, P480; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526; Escaffit F, 2005, J CELL PHYSIOL, V203, P15, DOI 10.1002/jcp.20189; Flores-Benitez D, 2007, AM J PHYSIOL-RENAL, V292, pF828, DOI 10.1152/ajprenal.00369.2006; Furuse M, 2001, J CELL BIOL, V153, P263, DOI 10.1083/jcb.153.2.263; Furuse M, 2006, TRENDS CELL BIOL, V16, P181, DOI 10.1016/j.tcb.2006.02.006; Guillemot L, 2006, MOL BIOL CELL, V17, P3569, DOI 10.1091/mbc.E06-02-0122; Heller F, 2005, GASTROENTEROLOGY, V129, P550, DOI 10.1053/j.gastro.2005.05.002; Helmrath MA, 1998, J SURG RES, V77, P17, DOI 10.1006/jsre.1998.5362; Holmes JL, 2006, GENE EXPR PATTERNS, V6, P581, DOI 10.1016/j.modgep.2005.12.001; Kim EC, 1998, AM J PHYSIOL-CELL PH, V275, pC988, DOI 10.1152/ajpcell.1998.275.4.C988; Kinugasa T, 2000, GASTROENTEROLOGY, V118, P1001, DOI 10.1016/S0016-5085(00)70351-9; Kinugasa T, 2007, ANTICANCER RES, V27, P3729; Krishnan M, 2010, ONCOGENE, V29, P305, DOI 10.1038/onc.2009.324; Lal-Nag M, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-8-235; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Mankertz J, 2004, BIOCHEM BIOPH RES CO, V314, P1001, DOI 10.1016/j.bbrc.2003.12.185; Mankertz J, 2009, CELL TISSUE RES, V336, P67, DOI 10.1007/s00441-009-0751-8; Mima S, 2008, CARCINOGENESIS, V29, P1994, DOI 10.1093/carcin/bgn134; MULLIN JM, 1992, J CELL PHYSIOL, V152, P35, DOI 10.1002/jcp.1041520106; MULLIN JM, 1986, AM J PHYSIOL, V251, pC597, DOI 10.1152/ajpcell.1986.251.4.C597; MULLIN JM, 1987, FEBS LETT, V221, P359, DOI 10.1016/0014-5793(87)80956-0; MULLIN JM, 2004, SCI STKE, pPE2, DOI DOI 10.1126/STKE.2162004PE2; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Peter Y, 2009, MOL CARCINOGEN, V48, P488, DOI 10.1002/mc.20485; Prasad S, 2005, LAB INVEST, V85, P1139, DOI 10.1038/labinvest.3700316; Rego RL, 2009, BRIT J CANCER, V102, P165; Reyes JL, 2002, KIDNEY INT, V62, P476, DOI 10.1046/j.1523-1755.2002.00479.x; Ridyard AE, 2007, J HISTOCHEM CYTOCHEM, V55, P1049, DOI 10.1369/jhc.7A7211.2007; Roberts RB, 2002, P NATL ACAD SCI USA, V99, P1521, DOI 10.1073/pnas.032678499; Sakaguchi T, 2002, J BIOL CHEM, V277, P21361, DOI 10.1074/jbc.M110261200; Shiou SR, 2007, CANCER RES, V67, P1571, DOI 10.1158/0008-5472.CAN-06-1680; Singh AB, 2004, J BIOL CHEM, V279, P3543, DOI 10.1074/jbc.M308682200; Singh AB, 2005, CELL SIGNAL, V17, P1183, DOI 10.1016/j.cellsig.2005.03.026; Singh AB, 2007, AM J PHYSIOL-CELL PH, V293, pC1660, DOI 10.1152/ajpcell.00274.2007; Singh AB, 2007, J BIOL CHEM, V282, P32890, DOI 10.1074/jbc.M702677200; Soler AP, 1999, CARCINOGENESIS, V20, P1425, DOI 10.1093/carcin/20.8.1425; Takehara M, 2009, BIOL PHARM BULL, V32, P825, DOI 10.1248/bpb.32.825; Weber CR, 2008, LAB INVEST, V88, P1110, DOI 10.1038/labinvest.2008.78; Yabana T, 2009, J PATHOL, V218, P350, DOI 10.1002/path.2535; Yamaoka T, 2008, P NATL ACAD SCI USA, V105, P11772, DOI 10.1073/pnas.0801463105; Zeissig S, 2007, GUT, V56, P61, DOI 10.1136/gut.2006.094375; Zhu YT, 2003, CANCER RES, V63, P522	54	108	109	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	29					3234	3247		10.1038/onc.2011.43	http://dx.doi.org/10.1038/onc.2011.43			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	795VW	21383692	Green Accepted			2022-12-17	WOS:000293006800003
J	Rojas, A; Liu, G; Coleman, I; Nelson, PS; Zhang, M; Dash, R; Fisher, PB; Plymate, SR; Wu, JD				Rojas, A.; Liu, G.; Coleman, I.; Nelson, P. S.; Zhang, M.; Dash, R.; Fisher, P. B.; Plymate, S. R.; Wu, J. D.			IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR	ONCOGENE			English	Article						IL-6; STAT3; tumorigenesis; EMT; IGF-IR; prostate	GROWTH-FACTOR-I; EPITHELIAL-MESENCHYMAL TRANSITIONS; GENE-3 PEG-3 PROMOTER; CANCER-CELLS; PEA3 SITES; EXPRESSION; INTERLEUKIN-6; RECEPTOR; RAS; INFLAMMATION	As an established mediator of inflammation, interleukin-6 (IL-6) is implicated to facilitate prostate cancer progression to androgen independence through transactivation of the androgen receptor. However, whether IL-6 has a causative role in de novo prostate tumorigenesis was never investigated. We now provide the first evidence that IL-6 can induce tumorigenic conversion and further progression to an invasive phenotype of non-tumorigenic benign prostate epithelial cells. Moreover, we find that paracrine IL-6 stimulates the autocrine IL-6 loop and autocrine activation of insulin-like type I growth factor receptor (IGF-IR) to confer the tumorigenic property and also that activation of signal transducer and activator of transcription 3 (STAT3) is critical in these processes. Inhibition of STAT3 activation or IGF-IR signaling suppresses IL-6-mediated malignant conversion and the associated invasive phenotype. Inhibition of STAT3 activation suppresses IL-6-induced upregulation of IGF-IR and its ligands, namely IGF-I and IGF-II. These findings indicate that IL-6 signaling cooperates with IGF-IR signaling in the prostate microenvironment to promote prostate tumorigenesis and progression to aggressiveness. Our findings suggest that STAT3 and IGF-IR may represent potential effective targets for prevention or treatment of prostate cancer. Oncogene (2011) 30, 2345-2355; doi: 10.1038/onc.2010.605; published online 24 January 2011	[Rojas, A.; Liu, G.; Plymate, S. R.; Wu, J. D.] Univ Washington, Dept Med, Seattle, WA 98104 USA; [Coleman, I.; Nelson, P. S.] Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98104 USA; [Zhang, M.] Univ Washington, Dept Mat Sci & Engn, Seattle, WA 98104 USA; [Dash, R.; Fisher, P. B.] Virginia Commonwealth Univ, Dept Human & Mol Genet, VCU Inst Mol Med, Richmond, VA USA; [Dash, R.; Fisher, P. B.] Virginia Commonwealth Univ, VCU Massy Canc Ctr, Richmond, VA USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Virginia Commonwealth University; Virginia Commonwealth University	Wu, JD (corresponding author), Univ Washington, Dept Med, 325 9th Ave,Box 359625, Seattle, WA 98104 USA.	wuj@uw.edu	Zhang, Miqin/F-5537-2010	Zhang, Miqin/0000-0001-8974-1494; dash, rupesh/0000-0001-5740-7053	National Institute of Health (NIH) [1K01CA116002, NIH 1R01CA149405, PO1 CA085859, P01 CA104177]; DOD-USARMC IDEA Development Award [W81XWH-06-1-0014]; Pacific Northwest Prostate Cancer [SPORE P50-CA097186]; NATIONAL CANCER INSTITUTE [P50CA097186, P01CA104177, K01CA116002, P01CA085859, R01CA097318, R01CA149405] Funding Source: NIH RePORTER	National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD-USARMC IDEA Development Award; Pacific Northwest Prostate Cancer(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the National Institute of Health (NIH) Temin Award 1K01CA116002, NIH 1R01CA149405 and DOD-USARMC IDEA Development Award W81XWH-06-1-0014 to JDW and partially supported by the Pacific Northwest Prostate Cancer SPORE P50-CA097186 (JDW) and the NIH Program Project Grant PO1 CA085859 (SRP) and P01 CA104177 (PBF). PBF holds the Thelma Newmeyer Corman Chair in Cancer Research at the VCU Massey Cancer Center.	Al-Shanti N, 2008, GROWTH FACTORS, V26, P61, DOI 10.1080/08977190802025024; Ara T, 2010, EUR J CANCER, V46, P1223, DOI 10.1016/j.ejca.2010.02.026; BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; Bardia A, 2009, CURR OPIN PHARMACOL, V9, P419, DOI 10.1016/j.coph.2009.06.002; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Berger T, 2010, P NATL ACAD SCI USA, V107, P2995, DOI 10.1073/pnas.1000101107; Burtrum D, 2003, CANCER RES, V63, P8912; Coe KJ, 2007, CHEM RES TOXICOL, V20, P1277, DOI 10.1021/tx7001349; Colomiere M, 2009, BRIT J CANCER, V100, P134, DOI 10.1038/sj.bjc.6604794; Corcoran NM, 2003, BJU INT, V91, P545, DOI 10.1046/j.1464-410X.2003.04025.x; Damon SE, 2001, ENDOCRINOLOGY, V142, P21, DOI 10.1210/en.142.1.21; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Dorff TB, 2010, CLIN CANCER RES, V16, P3028, DOI 10.1158/1078-0432.CCR-09-3122; Finley DS, 2009, J UROLOGY, V182, P1621, DOI 10.1016/j.juro.2009.06.015; Freedland SJ, 2007, EPIDEMIOL REV, V29, P88, DOI 10.1093/epirev/mxm006; Grivennikov S, 2008, CANCER CELL, V13, P7, DOI 10.1016/j.ccr.2007.12.020; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Haverkamp J, 2008, J CELL BIOCHEM, V103, P1344, DOI 10.1002/jcb.21536; Irigaray P, 2007, BIOMED PHARMACOTHER, V61, P665, DOI 10.1016/j.biopha.2007.10.008; Ishiguro H, 2009, P NATL ACAD SCI USA, V106, P16369, DOI 10.1073/pnas.0907044106; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kojima S, 2009, INT J UROL, V16, P161, DOI 10.1111/j.1442-2042.2008.02224.x; Long RM, 2005, CLIN SCI, V108, P1, DOI 10.1042/CS20040241; Nakashima J, 2000, CLIN CANCER RES, V6, P2702; O'Malley Rebecca L, 2006, Can J Urol, V13 Suppl 2, P11; Paule B, 2007, WORLD J UROL, V25, P477, DOI 10.1007/s00345-007-0175-6; Rosen DG, 2006, METHOD ENZYMOL, V407, P660, DOI 10.1016/S0076-6879(05)07052-7; Rowinsky EK, 2007, CLIN CANCER RES, V13, p5549S, DOI 10.1158/1078-0432.CCR-07-1109; Santer FR, 2010, ENDOCR-RELAT CANCER, V17, P241, DOI 10.1677/ERC-09-0200; Soon L, 1999, MOL CELL BIOL, V19, P3816; Su Z, 2001, NUCLEIC ACIDS RES, V29, P1661, DOI 10.1093/nar/29.8.1661; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 2000, ONCOGENE, V19, P3411, DOI 10.1038/sj.onc.1203666; Su ZZ, 2005, P NATL ACAD SCI USA, V102, P1059, DOI 10.1073/pnas.0409141102; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Sutcliffe S, 2007, UROL ONCOL-SEMIN ORI, V25, P242, DOI 10.1016/j.urolonc.2006.09.014; Tam L, 2007, BRIT J CANCER, V97, P378, DOI 10.1038/sj.bjc.6603871; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Traynor P, 2008, DIS MARKERS, V24, P157, DOI 10.1155/2008/918087; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Werner Haim, 2009, Archives of Physiology and Biochemistry, V115, P58, DOI 10.1080/13813450902783106; Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang XP, 2009, MOL CANCER THER, V8, P499, DOI 10.1158/1535-7163.MCT-08-0544	46	108	115	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	20					2345	2355		10.1038/onc.2010.605	http://dx.doi.org/10.1038/onc.2010.605			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	766NF	21258401	Green Accepted			2022-12-17	WOS:000290789200006
J	Ji, C; Yang, B; Yang, YL; He, SH; Miao, DS; He, L; Bi, ZG				Ji, C.; Yang, B.; Yang, Y-L; He, S-H; Miao, D-S; He, L.; Bi, Z-G			Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition	ONCOGENE			English	Article						C6 ceramide; cancer chemotherapy; Doxorubicin; AMPK; mTORC1 and apoptosis	HEPATOCELLULAR-CARCINOMA CELLS; PROTEIN-KINASE; IN-VITRO; GROWTH; DEATH; METABOLISM; EXPRESSION; PACLITAXEL; INDUCTION; MECHANISM	New chemotherapy-enhancing strategies are needed for better cancer therapy. Previous studies suggest that exogenous cell-permeable C6 ceramide may be a useful adjunct to the anti-tumor effects of chemotherapeutic agents (such as Taxol) against multiple cancers. Here we demonstrate that exogenous cell-permeable C6 ceramide largely sensitizes multiple progressive cancer cell lines to Doxorubicin-induced cell death and apoptosis. We found for the first time that Doxorubicin induces AMP-activated protein kinase (AMPK) activation in a reactive oxygen species-dependent manner. Activation of AMPK contributes to Doxorubicin-induced cancer cell death and apoptosis. Inhibition of AMPK by small interfering RNA knockdown or a pharmacological inhibitor reduces Doxorubicin-induced cancer cell apoptosis, whereas AMPK activator AICAR enhances it. Importantly, we found that C6 ceramide largely enhances Doxorubicin-induced activation of AMPK, which leads to mTOR complex 1 inhibition and chemo-sensitization. Our data suggest that the combination of C6 ceramide with traditional chemotherapy drugs such as Doxorubicin may have the potential to be used as a new therapeutic intervention against multiple cancers. Oncogene (2010) 29, 6557-6568; doi:10.1038/onc.2010.379; published online 30 August 2010	[Bi, Z-G] Nanjing Med Univ, Affiliated BenQ Hosp, Dept Dermatol, Nanjing 210019, Jiangsu, Peoples R China; [Ji, C.] Nanjing Med Univ, Affiliated Hosp 1, Dept Dermatol, Nanjing 210024, Jiangsu, Peoples R China; [Yang, B.] Fudan Univ, Huashan Hosp, Dept Dermatol, Shanghai 200433, Peoples R China; [Yang, Y-L] Nanjing Med Univ, Affiliated Hosp 1, Dept Otolaryngol, Nanjing, Jiangsu, Peoples R China; [He, S-H] Nanjing Med Univ, Affiliated Hosp 1, Clin Expt Ctr, Nanjing, Jiangsu, Peoples R China; [Miao, D-S] Nanjing Med Univ, Dept Human Anat, Nanjing, Jiangsu, Peoples R China; [He, L.] Kunming Med Univ, Yunnan Prov Inst Dermatol, Affiliated Hosp 1, Dept Dermatol, Kunming, Yunnan, Peoples R China	Nanjing Medical University; Nanjing Medical University; Fudan University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Kunming Medical University	Bi, ZG (corresponding author), Nanjing Med Univ, Affiliated BenQ Hosp, Dept Dermatol, Nanjing 210019, Jiangsu, Peoples R China.	surpassing_ji@yahoo.com.cn; heli2662@163.com; eltonbibenqhospital@yahoo.com.cn		Miao, Dengshun/0000-0002-2682-3502	National Natural Science Foundation of China [30271195, 30671894]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This research was supported in part by grants from the National Natural Science Foundation of China (30271195 and 30671894).	Arad M, 2007, CIRC RES, V100, P474, DOI 10.1161/01.RES.0000258446.23525.37; Auzenne E, 1998, MELANOMA RES, V8, P227, DOI 10.1097/00008390-199806000-00005; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Cao C, 2008, J BIOL CHEM, V283, P28897, DOI 10.1074/jbc.M804144200; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Chiang PC, 2010, BIOCHEM PHARMACOL, V79, P162, DOI 10.1016/j.bcp.2009.08.022; Grunwald V, 2002, CANCER RES, V62, P6141; Hortobagyi GN, 1997, DRUGS, V54, P1, DOI 10.2165/00003495-199700544-00003; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Jaswal JS, 2006, AM J PHYSIOL-HEART C, V291, pH1883, DOI 10.1152/ajpheart.01147.2005; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Jung SN, 2008, CARCINOGENESIS, V29, P713, DOI 10.1093/carcin/bgn032; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kim do Y, 2009, J AGR FOOD CHEM, V57, P10573; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Mehta S, 2000, CANCER CHEMOTH PHARM, V46, P85, DOI 10.1007/s002800000140; Morgillo F, 2006, CANCER RES, V66, P10100, DOI 10.1158/0008-5472.CAN-06-1684; Nithipongvanitch R, 2007, ANTIOXID REDOX SIGN, V9, P1001, DOI 10.1089/ars.2007.1632; Okoshi R, 2008, J BIOL CHEM, V283, P3979, DOI 10.1074/jbc.M705232200; Piguet AC, 2008, J HEPATOL, V49, P78, DOI 10.1016/j.jhep.2008.03.024; Qiu LH, 2006, ONCOL REP, V16, P907; Radin NS, 2003, BIOCHEM J, V371, P243, DOI 10.1042/BJ20021878; Rath G, 2009, INT J BIOCHEM CELL B, V41, P1165, DOI 10.1016/j.biocel.2008.10.021; Ravid A, 1999, CANCER RES, V59, P862; Romano MF, 2004, EUR J CANCER, V40, P2829, DOI 10.1016/j.ejca.2004.08.017; Ruderman NB, 2006, DIABETES, V55, pS48, DOI 10.2337/db06-S007; Steinberg GR, 2009, PHYSIOL REV, V89, P1025, DOI 10.1152/physrev.00011.2008; Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05; Yamauchi M, 2008, MOL ENDOCRINOL, V22, P893, DOI 10.1210/me.2007-0249; Yoon H, 2008, BIOCHEM BIOPH RES CO, V371, P495, DOI 10.1016/j.bbrc.2008.04.102; Yoon MJ, 2006, DIABETES, V55, P2562, DOI 10.2337/db05-1322; Zhang JF, 2007, TRANSPL IMMUNOL, V17, P162, DOI 10.1016/j.trim.2006.12.003; Zhu WQ, 2009, CIRCULATION, V119, P99, DOI 10.1161/CIRCULATIONAHA.108.799700	34	108	111	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	50					6557	6568		10.1038/onc.2010.379	http://dx.doi.org/10.1038/onc.2010.379			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	695OA	20802518				2022-12-17	WOS:000285380200005
J	Clark, J; Attard, G; Jhavar, S; Flohr, P; Reid, A; De-Bono, J; Eeles, R; Scardino, P; Cuzick, J; Fisher, G; Parker, MD; Foster, CS; Berney, D; Kovacs, G; Cooper, CS				Clark, J.; Attard, G.; Jhavar, S.; Flohr, P.; Reid, A.; De-Bono, J.; Eeles, R.; Scardino, P.; Cuzick, J.; Fisher, G.; Parker, M. D.; Foster, C. S.; Berney, D.; Kovacs, G.; Cooper, C. S.			Complex patterns of ETS gene alteration arise during cancer development in the human prostate	ONCOGENE			English	Article						prostate cancer; ERG; TMPRSS2; ERG fusion transcripts	IN-SITU HYBRIDIZATION; INTRAEPITHELIAL NEOPLASIA; RADICAL PROSTATECTOMY; CHROMOSOMAL-ANOMALIES; INDEPENDENT ORIGIN; TMPRSS2-ERG FUSION; EXPRESSION; CARCINOMA; HETEROGENEITY; SPECIMENS	An ERG gene 'break-apart' fluorescence in situ hybridization (FISH) assay has been used to screen whole-mount prostatectomy specimens for rearrangements at the ERG locus. In cancers containing ERG alterations the observed pattern of changes was often complex. Different categories of ERG gene alteration were found either together in a single cancerous region or within separate foci of cancer in the same prostate slice. In some cases the juxtaposition of particular patterns of ERG alterations suggested possible mechanisms of tumour progression. Prostates harbouring ERG alterations commonly also contained cancer that lacked rearrangements of the ERG gene. A single trans-urethral resection of the prostate specimen examined harboured both ERG and ETV1 gene rearrangements demonstrating that the observed complexity may, at least in part, be explained by multiple ETS gene alterations arising independently in a single prostate. In a search for possible precursor lesions clonal ERG rearrangements were found both in high grade prostatic intraepithelial neoplasia (PIN) and in atypical in situ epithelial lesions consistent with the diagnosis of low grade PIN. Our observations support the view that ERG gene alterations represent an initiating event that promotes clonal expansion initially to form regions of epithelial atypia. The complex patterns of ERG alteration found in prostatectomy specimens have important implications for the design of experiments investigating the clinical significance and mechanism of development of individual prostate cancers.	[Clark, J.; Attard, G.; Jhavar, S.; Flohr, P.; Reid, A.; De-Bono, J.; Eeles, R.; Parker, M. D.; Cooper, C. S.] Male Urol Canc Res Ctr, Inst Canc Res, Sutton SM2 5NG, Surrey, England; [Attard, G.; Reid, A.; De-Bono, J.; Eeles, R.] Royal Marsden NHS Trust Fdn Hosp, Sutton, Surrey, England; [Scardino, P.] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA; [Cuzick, J.; Fisher, G.] Univ London, Wolfson Inst Prevent Med, London, England; [Foster, C. S.] Univ Liverpool, Dept Pathol, Royal Liverpool Univ Hosp, Liverpool L69 3BX, Merseyside, England; [Berney, D.] St Bartholomews Hosp, Orchid Tissue Lab, London, England; [Kovacs, G.] Heidelberg Univ, Fac Med, Mol Oncol Lab, Heidelberg, Germany	University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Memorial Sloan Kettering Cancer Center; University of London; Queen Mary University London; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; University of London; Queen Mary University London; Ruprecht Karls University Heidelberg	Clark, J (corresponding author), Male Urol Canc Res Ctr, Inst Canc Res, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	jeremy.clark@icr.ac.uk		de Bono, Johann S/0000-0002-2034-595X; Berney, Daniel/0000-0001-5474-8696; Eeles, Rosalind/0000-0002-3698-6241; Attard, Gerhardt/0000-0002-4811-7983; Parker, Matthew/0000-0003-2999-3870	Cancer Research UK Funding Source: Medline; Medical Research Council [G0501019] Funding Source: Medline; MRC [G0501019] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AIHARA M, 1994, UROLOGY, V43, P60, DOI 10.1016/S0090-4295(94)80264-5; Arora R, 2004, CANCER-AM CANCER SOC, V100, P2362, DOI 10.1002/cncr.20243; ATTARD G, 2007, ONCOGENE        0716; Bostwick DG, 1998, CANCER, V83, P1995, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1995::AID-CNCR16>3.0.CO;2-2; BRAWER MK, 1991, UROLOGY, V38, P103, DOI 10.1016/S0090-4295(05)80067-6; Cerveira N, 2006, NEOPLASIA, V8, P826, DOI 10.1593/neo.06427; Chen ME, 2000, CANCER, V89, P1800, DOI 10.1002/1097-0142(20001015)89:8<1800::AID-CNCR21>3.0.CO;2-D; Cheng L, 1998, J NATL CANCER I, V90, P233, DOI 10.1093/jnci/90.3.233; Chun FKH, 2007, EUR UROL, V51, P949, DOI 10.1016/j.eururo.2006.07.008; Clark J, 2007, ONCOGENE, V26, P2667, DOI 10.1038/sj.onc.1210070; Cuzick J, 2006, BRIT J CANCER, V95, P1186, DOI 10.1038/sj.bjc.6603411; Demichelis F, 2007, ONCOGENE, V26, P5692, DOI 10.1038/sj.onc.1210630; Djavan B, 1999, Tech Urol, V5, P139; Egevad L, 2006, MODERN PATHOL, V19, P180, DOI 10.1038/modpathol.3800522; EPSTEIN JI, 1995, AM J SURG PATHOL, V19, P873, DOI 10.1097/00000478-199508000-00002; Foster CS, 2000, PROSTATE, P4; Foster CS, 2004, ONCOGENE, V23, P5871, DOI 10.1038/sj.onc.1207800; Foster CS, 2000, SCAND J UROL NEPHROL, V34, P19, DOI 10.1080/003655900750169284; GREENE DR, 1995, SEMIN SURG ONCOL, V11, P9, DOI 10.1002/ssu.2980110104; GRIGNON DJ, 1994, J CELL BIOCHEM, P267; Hermans KG, 2006, CANCER RES, V66, P10658, DOI 10.1158/0008-5472.CAN-06-1871; Iljin K, 2006, CANCER RES, V66, P10242, DOI 10.1158/0008-5472.CAN-06-1986; Jenkins RB, 1997, CANCER RES, V57, P524; Jhavar SG, 2005, J CLIN PATHOL, V58, P504, DOI 10.1136/jcp.2004.021808; KONISHI N, 1995, AM J PATHOL, V147, P1112; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; MCNEAL JE, 1988, PROSTATE, V13, P91, DOI 10.1002/pros.2990130202; McNeal JE, 1996, AM J SURG PATHOL, V20, P802, DOI 10.1097/00000478-199607000-00003; MILLER GJ, 1994, J UROLOGY, V152, P1709, DOI 10.1016/S0022-5347(17)32368-6; MIRCHANDANI D, 1995, AM J PATHOL, V147, P92; NAM RK, 2003, CANCER BIOL THER, V6, P40; Perner S, 2007, AM J SURG PATHOL, V31, P882, DOI 10.1097/01.pas.0000213424.38503.aa; Perner S, 2006, CANCER RES, V66, P8337, DOI 10.1158/0008-5472.CAN-06-1482; QIAN JQ, 1995, CANCER RES, V55, P5408; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; Sakai I, 2005, BJU INT, V96, P528, DOI 10.1111/j.1464-410X.2005.05678.x; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Srigley JR, 2000, ARCH PATHOL LAB MED, V124, P1034; Stephenson AJ, 2005, CANCER-AM CANCER SOC, V104, P290, DOI 10.1002/cncr.21157; Tomlins SA, 2006, CANCER RES, V66, P3396, DOI 10.1158/0008-5472.CAN-06-0168; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; VILLERS A, 1992, CANCER, V70, P2313, DOI 10.1002/1097-0142(19921101)70:9<2313::AID-CNCR2820700917>3.0.CO;2-T; Wang JH, 2006, CANCER RES, V66, P8347, DOI 10.1158/0008-5472.CAN-06-1966; Yoshimoto M, 2006, NEOPLASIA, V8, P465, DOI 10.1593/neo.06283; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158	47	108	119	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2008	27	14					1993	2003		10.1038/sj.onc.1210843	http://dx.doi.org/10.1038/sj.onc.1210843			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17922029				2022-12-17	WOS:000254359100004
J	Preet, A; Ganju, RK; Groopman, JE				Preet, A.; Ganju, R. K.; Groopman, J. E.			Delta(9)-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo	ONCOGENE			English	Article						tetrahydrocannabinol(THC); lung cancer; A549; migration; invasion; EGFR	FOCAL-ADHESION KINASE; CANNABINOID RECEPTOR; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; ANGIOGENESIS; ACTIVATION; EXPRESSION	Delta(9)-Tetrahydrocannabinol (THC) is the primary cannabinoid of marijuana and has been shown to either potentiate or inhibit tumor growth, depending on the type of cancer and its pathogenesis. Little is known about the activity of cannabinoids like THC on epidermal growth factor receptor-overexpressing lung cancers, which are often highly aggressive and resistant to chemotherapy. In this study, we characterized the effects of THC on the EGF-induced growth and metastasis of human non-small cell lung cancer using the cell lines A549 and SW-1573 as in vitro models. We found that these cells express the cannabinoid receptors CB1 and CB2, known targets for THC action, and that THC inhibited EGF-induced growth, chemotaxis and chemoinvasion. Moreover, signaling studies indicated that THC may act by inhibiting the EGF-induced phosphorylation of ERK1/2, JNK1/2 and AKT. THC also induced the phosphorylation of focal adhesion kinase at tyrosine 397. Additionally, in in vivo studies in severe combined immunodeficient mice, there was significant inhibition of the subcutaneous tumor growth and lung metastasis of A549 cells in THC-treated animals as compared to vehicle-treated controls. Tumor samples from THC-treated animals revealed antiproliferative and antiangiogenic effects of THC. Our study suggests that cannabinoids like THC should be explored as novel therapeutic molecules in controlling the growth and metastasis of certain lung cancers.	[Preet, A.; Ganju, R. K.; Groopman, J. E.] Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Groopman, JE (corresponding author), Harvard Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	rganju@bidmc.harvard.edu; jgroopma@bidmc.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA109527] Funding Source: NIH RePORTER; NCI NIH HHS [CA109527] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adjei AA, 2006, CLIN CANCER RES, V12, p4446S, DOI 10.1158/1078-0432.CCR-06-0623; Beckmann JD, 2001, J CELL PHYSIOL, V189, P171, DOI 10.1002/jcp.10013; Bifulco M, 2006, BRIT J PHARMACOL, V148, P123, DOI 10.1038/sj.bjp.0706632; Blazquez C, 2003, FASEB J, V17, P529, DOI 10.1096/fj.02-0795fje; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; CABRAL GA, 1987, ARCH TOXICOL, V60, P438, DOI 10.1007/BF00302387; CABRAL GA, 2006, CANCER RES, V66, P6615; CABRAL GA, 2006, CANCER CELL, V9, P301; Casanova ML, 2003, J CLIN INVEST, V111, P43, DOI 10.1172/JCI200316116; CLARKE N, 1998, MOL CELL BIOL, V21, P4016; Derkinderen P, 2001, J BIOL CHEM, V276, P38289; Di Marzo V, 2006, ANNU REV MED, V57, P553, DOI 10.1146/annurev.med.57.011205.135648; Diaz-Laviada I, 2005, MINI-REV MED CHEM, V5, P619, DOI 10.2174/1389557054368808; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Ghosh S, 2006, MOL IMMUNOL, V43, P2169, DOI 10.1016/j.molimm.2006.01.005; Guzman M., 2006, BR JR CANC, V95, P204; Hart S, 2004, CANCER RES, V64, P1943, DOI 10.1158/0008-5472.CAN-03-3720; Hauck CR, 2001, CANCER RES, V61, P7079; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kogan NM, 2005, MINI-REV MED CHEM, V5, P941, DOI 10.2174/138955705774329555; Li R, 2006, ONCOGENE, V25, P2628, DOI 10.1038/sj.onc.1209289; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2006, ONCOGENE, V25, P5969, DOI 10.1038/sj.onc.1209588; Molina JR, 2006, CHEST, V130, P1211, DOI 10.1378/chest.130.4.1211; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; MUNSON AE, 1975, J NATL CANCER I, V55, P597, DOI 10.1093/jnci/55.3.597; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sancho R, 2003, MOL PHARMACOL, V63, P429, DOI 10.1124/mol.63.2.429; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vaccani A, 2005, BRIT J PHARMACOL, V144, P1032, DOI 10.1038/sj.bjp.0706134; WILLIAMS R, 1993, J BIOL CHEM, V268, P18213; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697	38	108	109	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2008	27	3					339	346		10.1038/sj.onc.1210641	http://dx.doi.org/10.1038/sj.onc.1210641			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621270				2022-12-17	WOS:000252256000010
J	Yang, XJ; Ullah, M				Yang, X-J; Ullah, M.			MOZ and MORF, two large MYSTic HATs in normal and cancer stem cells	ONCOGENE			English	Review						lysine acetylation; MYST acetyltransferase; ING5; BR140; CBP; Runx1	ACUTE MYELOID-LEUKEMIA; ZINC-FINGER PROTEIN; HISTONE ACETYLTRANSFERASE COMPLEXES; TUMOR-SUPPRESSOR P33(ING1); ACUTE MONOCYTIC LEUKEMIA; GENE-EXPRESSION; PHD FINGER; TRANSCRIPTIONAL REGULATION; CAENORHABDITIS-ELEGANS; DOSAGE COMPENSATION	Genes of the human monocytic leukemia zinc-finger protein MOZ ( HUGO symbol, MYST3) and its paralog MORF ( MYST4) are rearranged in chromosome translocations associated with acute myeloid leukemia and/or benign uterine leiomyomata. Both proteins have intrinsic histone acetyltransferase activity and are components of quartet complexes with noncatalytic subunits containing the bromodomain, plant homeodomain-linked ( PHD) finger and proline-tryptophan-tryptophan-proline (PWWP)-containing domain, three types of structural modules characteristic of chromatin regulators. Although leukemia-derived fusion proteins such as MOZ-TIF2 promote self-renewal of leukemic stem cells, recent studies indicate that murine MOZ and MORF are important for proper development of hematopoietic and neurogenic progenitors, respectively, thereby highlighting the importance of epigenetic integrity in safeguarding stem cell identity.	McGill Univ, Ctr Hlth, Mol Oncol Grp, Royal Victoria Hosp,Dept Med, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital	Yang, XJ (corresponding author), McGill Univ, Ctr Hlth, Mol Oncol Grp, Royal Victoria Hosp,Dept Med, Room H5-41,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	xiang-jiao.yang@mcgill.ca						Antonchuk J, 2004, BLOOD, V104, P1306, DOI 10.1182/blood-2004-04-1522; Avvakumov N, 2007, ONCOGENE, V26, P5395, DOI 10.1038/sj.onc.1210608; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Boudreault AA, 2003, GENE DEV, V17, P1415, DOI 10.1101/gad.1056603; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Bristow CAP, 2003, NUCLEIC ACIDS RES, V31, P2735, DOI 10.1093/nar/gkg401; Camos M, 2006, CANCER RES, V66, P6947, DOI 10.1158/0008-5472.CAN-05-4601; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Ceol CJ, 2004, DEV CELL, V6, P563, DOI 10.1016/S1534-5807(04)00065-6; Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2; Chamberlin HM, 2000, DEVELOPMENT, V127, P713; Champagne N, 1999, J BIOL CHEM, V274, P28528, DOI 10.1074/jbc.274.40.28528; Champagne N, 2001, ONCOGENE, V20, P404, DOI 10.1038/sj.onc.1204114; Chang S, 2003, GENE DEV, V17, P2123, DOI 10.1101/gad.1117903; Collins HM, 2006, J BIOL CHEM, V281, P17124, DOI 10.1074/jbc.M602633200; Crump JG, 2006, DEVELOPMENT, V133, P2661, DOI 10.1242/dev.02435; Deguchi K, 2003, CANCER CELL, V3, P259, DOI 10.1016/S1535-6108(03)00051-5; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Doyon Y, 2004, CURR OPIN GENET DEV, V14, P147, DOI 10.1016/j.gde.2004.02.009; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Gong W, 2005, INT J BIOCHEM CELL B, V37, P1054, DOI 10.1016/j.biocel.2004.09.008; Goodman RH, 2000, GENE DEV, V14, P1553; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Grier DG, 2005, J PATHOL, V205, P154, DOI 10.1002/path.1710; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; Horn PJ, 2002, SCIENCE, V297, P1824, DOI 10.1126/science.1074200; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jason LJM, 2002, BIOESSAYS, V24, P166, DOI 10.1002/bies.10038; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Katsumoto T, 2006, GENE DEV, V20, P1321, DOI 10.1101/gad.1393106; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; Kindle KB, 2005, MOL CELL BIOL, V25, P988, DOI 10.1128/MCB.25.3.988-1002.2005; Kirito K, 2004, MOL CELL BIOL, V24, P6751, DOI 10.1128/MCB.24.15.6751-6762.2004; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 2001, LEUKEMIA, V15, P89, DOI 10.1038/sj.leu.2401983; Kojima K, 2003, BRIT J HAEMATOL, V120, P271, DOI 10.1046/j.1365-2141.2003.04059.x; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Lafon A, 2007, ONCOGENE, V26, P5373, DOI 10.1038/sj.onc.1210606; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; Liang J, 1998, BLOOD, V92, P2118, DOI 10.1182/blood.V92.6.2118.418k09_2118_2122; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; Loewith R, 2001, J BIOL CHEM, V276, P24068, DOI 10.1074/jbc.M102176200; Martin DGE, 2006, MOL CELL BIOL, V26, P3018, DOI 10.1128/MCB.26.8.3018-3028.2006; Maurer-Stroh S, 2003, TRENDS BIOCHEM SCI, V28, P69, DOI 10.1016/S0968-0004(03)00004-5; Mendjan S, 2006, MOL CELL, V21, P811, DOI 10.1016/j.molcel.2006.02.007; Merson TD, 2006, J NEUROSCI, V26, P11359, DOI 10.1523/JNEUROSCI.2247-06.2006; Miller CT, 2004, DEVELOPMENT, V131, P2443, DOI 10.1242/dev.01134; Moore SDP, 2004, CANCER RES, V64, P5570, DOI 10.1158/0008-5472.CAN-04-0050; Nabirochkina E, 2002, MECH DEVELOP, V114, P119, DOI 10.1016/S0925-4773(02)00035-7; Nagy Z, 2007, ONCOGENE, V26, P5341, DOI 10.1038/sj.onc.1210604; NUGYT AM, 2007, CIRC RES, V100, P425; Ohta K, 2007, BIOCHEM J, V402, P559, DOI 10.1042/BJ20061194; Oury F, 2006, SCIENCE, V313, P1408, DOI 10.1126/science.1130042; Panagopoulos I, 2001, HUM MOL GENET, V10, P395, DOI 10.1093/hmg/10.4.395; Parthun MR, 2007, ONCOGENE, V26, P5319, DOI 10.1038/sj.onc.1210602; Pelletier N, 2003, METHODS, V31, P24, DOI 10.1016/S1046-2023(03)00084-7; Pelletier N, 2002, ONCOGENE, V21, P2729, DOI 10.1038/sj.onc.1205367; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Perry J, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-6; Rea S, 2007, ONCOGENE, V26, P5385, DOI 10.1038/sj.onc.1210607; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200; Scott EK, 2001, CURR BIOL, V11, P99, DOI 10.1016/S0960-9822(01)00020-3; Seet BT, 2006, NAT REV MOL CELL BIO, V7, P473, DOI 10.1038/nrm1960; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Smith ER, 2005, MOL CELL BIOL, V25, P9175, DOI 10.1128/MCB.25.21.9175-9188.2005; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Squatrito M, 2006, TRENDS CELL BIOL, V16, P433, DOI 10.1016/j.tcb.2006.07.007; Stec I, 2000, FEBS LETT, V473, P1, DOI 10.1016/S0014-5793(00)01449-6; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Surapureddi S, 2002, P NATL ACAD SCI USA, V99, P11836, DOI 10.1073/pnas.182426699; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Taverna SD, 2006, MOL CELL, V24, P785, DOI 10.1016/j.molcel.2006.10.026; Thomas T, 2006, GENE DEV, V20, P1175, DOI 10.1101/gad.1382606; Thomas T, 2000, DEVELOPMENT, V127, P2537; Thomas T, 2007, CELL CYCLE, V6, P696, DOI 10.4161/cc.6.6.4013; THOMPSON KA, 1994, BIOCHEM BIOPH RES CO, V198, P1143, DOI 10.1006/bbrc.1994.1162; Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024; Wade PA, 2006, ENVIRON HEALTH PERSP, V114, pA140, DOI 10.1289/ehp.114-a140; Wang J, 2006, NATURE, V127, P1137; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yang XJ, 2007, EMBO REP, V8, P556, DOI 10.1038/sj.embor.7400977; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252	106	108	111	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5408	5419		10.1038/sj.onc.1210609	http://dx.doi.org/10.1038/sj.onc.1210609			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694082				2022-12-17	WOS:000248674300009
J	Ostler, K; Davis, E; Payne, S; Gosalia, B; Exposito-Cespedes, J; Le Beau, MM; Godley, LA				Ostler, K. R.; Davis, E. M.; Payne, S. L.; Gosalia, B. B.; Exposito-Cespedes, J.; Le Beau, M. M.; Godley, L. A.			Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins	ONCOGENE			English	Article						DNA methylation; DNMT3B; aberrant mRNA splicing; epigenetics	DNA METHYLTRANSFERASES DNMT3A; CHROMOSOMAL INSTABILITY; PROMOTER METHYLATION; CPG METHYLATION; MESSENGER-RNA; GENE; CHROMATIN; HYPOMETHYLATION; 3B; HYPERMETHYLATION	Cancer cells display an altered distribution of DNA methylation relative to normal cells. Certain tumor suppressor gene promoters are hypermethylated and transcriptionally inactivated, whereas repetitive DNA is hypomethylated and transcriptionally active. Little is understood about how the abnormal DNA methylation patterns of cancer cells are established and maintained. Here, we identify over 20 DNMT3B transcripts from many cancer cell lines and primary acute leukemia cells that contain aberrant splicing at the 50 end of the gene, encoding truncated proteins lacking the C-terminal catalytic domain. Many of these aberrant transcripts retain intron sequences. Although the aberrant transcripts represent a minority of the DNMT3B transcripts present, Western blot analysis demonstrates truncated DNMT3B isoforms in the nuclear protein extracts of cancer cells. To test if expression of a truncated DNMT3B protein could alter the DNA methylation patterns within cells, we expressed DNMT3B7, the most frequently expressed aberrant transcript, in 293 cells. DNMT3B7-expressing 293 cells have altered gene expression as identified by microarray analysis. Some of these changes in gene expression correlate with altered DNA methylation of corresponding CpG islands. These results suggest that truncated DNMT3B proteins could play a role in the abnormal distribution of DNA methylation found in cancer cells.	Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA; Univ Chicago, Canc Res Ctr, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Ostler, K (corresponding author), Univ Chicago, Dept Med, Hematol Oncol Sect, 5841 S Maryland Ave,MC 2115, Chicago, IL 60637 USA.	lgodley@medicine.bsd.uchicago.edu		Raimondi, Stacey/0000-0001-7667-6814	NCI NIH HHS [R01 CA129831, P01 CA040046, CA 40046, R01 CA129831-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040046, R01CA129831] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggerholm A, 2006, EUR J HAEMATOL, V76, P23, DOI 10.1111/j.1600-0609.2005.00559.x; Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Chan AOO, 2006, WORLD J GASTROENTERO, V12, P199, DOI 10.3748/wjg.v12.i2.199; Charlet-B N, 2002, MOL CELL, V10, P45, DOI 10.1016/S1097-2765(02)00572-5; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Ehrlich M, 2006, ONCOGENE, V25, P2636, DOI 10.1038/sj.onc.1209145; Ehrlich M, 2003, CLIN IMMUNOL, V109, P17, DOI 10.1016/S1521-6616(03)00201-8; Fan YH, 2005, CELL, V123, P1199, DOI 10.1016/j.cell.2005.10.028; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Geiman TM, 2004, NUCLEIC ACIDS RES, V32, P2716, DOI 10.1093/nar/gkh589; Geiman TM, 2004, BIOCHEM BIOPH RES CO, V318, P544, DOI 10.1016/j.bbrc.2004.04.058; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Hansen RS, 2003, HUM MOL GENET, V12, P2559, DOI 10.1093/hmg/ddg268; Jumaa H, 2003, NATURE, V423, P452, DOI 10.1038/nature01608; Kanai Y, 2003, CANCER LETT, V192, P75, DOI 10.1016/S0304-3835(02)00689-4; Kang ES, 2001, BIOCHEM BIOPH RES CO, V289, P862, DOI 10.1006/bbrc.2001.6057; Karpf AR, 2005, CANCER RES, V65, P8635, DOI 10.1158/0008-5472.CAN-05-1961; Kim GD, 2002, EMBO J, V21, P4183, DOI 10.1093/emboj/cdf401; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Lin HJ, 2006, MOL CELL BIOL, V26, P2976, DOI 10.1128/MCB.26.8.2976-2983.2006; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Parolini O, 2003, IMMUNOGENETICS, V55, P116, DOI 10.1007/s00251-003-0557-x; Reuther GW, 2002, J BIOL CHEM, V277, P30508, DOI 10.1074/jbc.M111330200; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Saito Y, 2002, P NATL ACAD SCI USA, V99, P10060, DOI 10.1073/pnas.152121799; Shirohzu H, 2002, AM J MED GENET, V112, P31, DOI 10.1002/ajmg.10658; Sigalotti L, 2002, J IMMUNOTHER, V25, P16, DOI 10.1097/00002371-200201000-00002; Ueda Y, 2006, DEVELOPMENT, V133, P1183, DOI 10.1242/dev.02293; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Wang J, 2006, CANCER RES, V66, P8361, DOI 10.1158/0008-5472.CAN-06-2031; Wang L, 2006, INT J ONCOL, V29, P201; Watermann DO, 2006, CANCER RES, V66, P4774, DOI 10.1158/0008-5472.CAN-04-3294; Wilkinson MF, 2002, NAT CELL BIOL, V4, pE144, DOI 10.1038/ncb0602-e144; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yamada Y, 2005, P NATL ACAD SCI USA, V102, P13580, DOI 10.1073/pnas.0506612102; Yanagisawa Y, 2002, BBA-GENE STRUCT EXPR, V1577, P457, DOI 10.1016/S0167-4781(02)00482-7; Yang Y, 2002, J BIOL CHEM, V277, P25756, DOI 10.1074/jbc.M202575200	52	108	114	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	38					5553	5563		10.1038/sj.onc.1210351	http://dx.doi.org/10.1038/sj.onc.1210351			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17353906	Green Accepted			2022-12-17	WOS:000248801900001
J	Igarashi, T; Izumi, H; Uchiumi, T; Nishio, K; Arao, T; Tanabe, M; Uramoto, H; Sugio, K; Yasumoto, K; Sasaguri, Y; Wang, KY; Otsuji, Y; Kohno, K				Igarashi, T.; Izumi, H.; Uchiumi, T.; Nishio, K.; Arao, T.; Tanabe, M.; Uramoto, H.; Sugio, K.; Yasumoto, K.; Sasaguri, Y.; Wang, K. Y.; Otsuji, Y.; Kohno, K.			Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines	ONCOGENE			English	Article						clock; ATF4; multidrug resistance; glutathione; chronotherapy	GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; ADENOSINE-TRIPHOSPHATASE ATP7B; MRP/GS-X PUMP; MULTIDRUG-RESISTANCE; CISPLATIN RESISTANCE; TUMOR SUPPRESSION; STRESS-RESPONSE; DNA-REPAIR; EXPRESSION; BINDING	The mechanisms underlying cellular drug resistance have been extensively studied, but little is known about its regulation. We have previously reported that activating transcription factor 4 (ATF4) is upregulated in cisplatin-resistant cells and plays a role in cisplatin resistance. Here, we find out a novel relationship between the circadian transcription factor Clock and drug resistance. Clock drives the periodical expression of many genes that regulate hormone release, cell division, sleep-awake cycle and tumor growth. We demonstrate that ATF4 is a direct target of Clock, and that Clock is overexpressed in cisplatin-resistant cells. Furthermore, Clock expression significantly correlates with cisplatin sensitivity, and that the downregulation of either Clock or ATF4 confers sensitivity of A549 cells to cisplatin and etoposide. Notably, ATF4-overexpressing cells show multidrug resistance and marked elevation of intracellular glutathione. The microarray study reveals that genes for glutathione metabolism are generally downregulated by the knockdown of ATF4 expression. These results suggest that the Clock and ATF4 transcription system might play an important role in multidrug resistance through glutathione-dependent redox system, and also indicate that physiological potentials of Clock-controlled redox system might be important to better understand the oxidative stress-associated disorders including cancer and systemic chronotherapy.	Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 2, Kitakyushu, Fukuoka 8078555, Japan; Kinki Univ, Sch Med, Dept Genome Biol, Osaka 589, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Surg 2, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Pathol 2, Kitakyushu, Fukuoka 8078555, Japan	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan; Kindai University (Kinki University); University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan	Kohno, K (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	k-kohno@med.uoeh-u.ac.jp		wang, ke-yong/0000-0001-8295-1229				Annereau JP, 2004, MOL PHARMACOL, V66, P1397, DOI 10.1124/mol.104.005009; Arao T, 2006, INT J CANCER, V118, P483, DOI 10.1002/ijc.21340; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Canaple L, 2003, CANCER RES, V63, P7545; Chaney SG, 1996, JNCI-J NATL CANCER I, V88, P1346, DOI 10.1093/jnci/88.19.1346; Cui YH, 1999, MOL PHARMACOL, V55, P929; Deeley RG, 2006, PHYSIOL REV, V86, P849, DOI 10.1152/physrev.00035.2005; Dickinson DA, 2002, BIOCHEM PHARMACOL, V64, P1019, DOI 10.1016/S0006-2952(02)01172-3; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Fojo T, 2003, ONCOGENE, V22, P7512, DOI 10.1038/sj.onc.1206951; Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092-8674(02)00961-3; FUJII R, 1994, JPN J CANCER RES, V85, P426, DOI 10.1111/j.1349-7006.1994.tb02376.x; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Gorbacheva VY, 2005, P NATL ACAD SCI USA, V102, P3407, DOI 10.1073/pnas.0409897102; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Husain A, 1998, CANCER RES, V58, P1120; Ishikawa T, 1996, J BIOL CHEM, V271, P14981, DOI 10.1074/jbc.271.25.14981; Kohno K, 2005, EUR J CANCER, V41, P2577, DOI 10.1016/j.ejca.2005.08.007; Komatsu M, 2000, CANCER RES, V60, P1312; Krishnamurthy P, 2006, ANNU REV PHARMACOL, V46, P381, DOI 10.1146/annurev.pharmtox.46.120604.141238; Kuo MT, 1998, BIOCHEM PHARMACOL, V55, P605, DOI 10.1016/S0006-2952(97)00494-2; Kusaba H, 1999, EUR J BIOCHEM, V262, P924, DOI 10.1046/j.1432-1327.1999.00469.x; LAI GM, 1989, JNCI-J NATL CANCER I, V81, P535, DOI 10.1093/jnci/81.7.535; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Liebermann DA, 2002, LEUKEMIA, V16, P527, DOI 10.1038/sj.leu.2402477; Masuoka HC, 2002, BLOOD, V99, P736, DOI 10.1182/blood.V99.3.736; Moore RY, 1997, ANNU REV MED, V48, P253, DOI 10.1146/annurev.med.48.1.253; Murakami T, 2001, INT J CANCER, V93, P869, DOI 10.1002/ijc.1418; Nakayama K, 2002, INT J CANCER, V101, P488, DOI 10.1002/ijc.10608; Ohga T, 1996, CANCER RES, V56, P4224; Renes J, 2000, DRUG RESIST UPDATE, V3, P289, DOI 10.1054/drup.2000.0156; Rutkowski DT, 2003, DEV CELL, V4, P442, DOI 10.1016/S1534-5807(03)00100-X; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; SABURI Y, 1989, CANCER RES, V49, P7020; Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984; TAKANO H, 1992, ANTI-CANCER DRUG, V3, P323, DOI 10.1097/00001813-199208000-00002; Tanabe M, 2003, CANCER RES, V63, P8592; TEW KD, 1994, CANCER RES, V54, P4313; Tipnis SR, 1999, BIOCHEM J, V337, P559, DOI 10.1042/0264-6021:3370559; Torigoe Takayuki, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P15, DOI 10.2174/1568011053352587; Uramoto H, 2002, J BIOL CHEM, V277, P31694, DOI 10.1074/jbc.M200266200; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; YAO KS, 1995, CANCER RES, V55, P4367; Yoshida A, 2006, CANCER RES, V66, P5772, DOI 10.1158/0008-5472.CAN-05-3916	46	108	113	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2007	26	33					4749	4760		10.1038/sj.onc.1210289	http://dx.doi.org/10.1038/sj.onc.1210289			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297441				2022-12-17	WOS:000248170400001
J	Goodrich, DW				Goodrich, D. W.			The retinoblastoma tumor-suppressor gene, the exception that proves the rule	ONCOGENE			English	Review						tumor-suppressor gene; cell cycle; differentiation; DNA damage repair; apoptosis	CYCLIN-DEPENDENT KINASES; S-PHASE ENTRY; SKELETAL-MUSCLE CELLS; ADIPOCYTE DIFFERENTIATION; PHOSPHORYLATION SITES; SUSCEPTIBILITY GENE; NERVOUS-SYSTEM; RB MUTANT; IN-VIVO; TRANSCRIPTIONAL COACTIVATOR	The retinoblastoma tumor-suppressor gene (Rb1) is centrally important in cancer research. Mutational inactivation of Rb1 causes the pediatric cancer retinoblastoma, while deregulation of the pathway in which it functions is common in most types of human cancer. The Rb1-encoded protein (pRb) is well known as a general cell cycle regulator, and this activity is critical for pRb-mediated tumor suppression. The main focus of this review, however, is on more recent evidence demonstrating the existence of additional, cell type-specific pRb functions in cellular differentiation and survival. These additional functions are relevant to carcinogenesis suggesting that the net effect of Rb1 loss on the behavior of resulting tumors is highly dependent on biological context. The molecular mechanisms underlying pRb functions are based on the cellular proteins it interacts with and the functional consequences of those interactions. Better insight into pRb-mediated tumor suppression and clinical exploitation of pRb as a therapeutic target will require a global view of the complex, interdependent network of pocket protein complexes that function simultaneously within given tissues.	New York State Dept Hlth, Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Goodrich, DW (corresponding author), New York State Dept Hlth, Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	david.goodrich@roswellpark.org			NCI NIH HHS [R01 CA070292-07, R01 CA070292, CA70292] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adegbola O, 2005, J BIOL CHEM, V280, P15497, DOI 10.1074/jbc.M411382200; Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Balsitis SJ, 2003, MOL CELL BIOL, V23, P9094, DOI 10.1128/MCB.23.24.9094-9103.2003; Barrientes S, 2000, ONCOGENE, V19, P562, DOI 10.1038/sj.onc.1203332; Batsche E, 2005, J BIOL CHEM, V280, P19746, DOI 10.1074/jbc.M413428200; Benevolenskaya EV, 2005, MOL CELL, V18, P623, DOI 10.1016/j.molcel.2005.05.012; BOOKSTEIN R, 1991, Critical Reviews in Oncogenesis, V2, P211; Borges HL, 2005, P NATL ACAD SCI USA, V102, P15587, DOI 10.1073/pnas.0503925102; Boutillier AL, 2000, ONCOGENE, V19, P2171, DOI 10.1038/sj.onc.1203532; Brown VD, 1999, MOL CELL BIOL, V19, P3246; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Clark AJ, 2004, BLOOD, V104, P1324, DOI 10.1182/blood-2004-02-0618; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2000, P NATL ACAD SCI USA, V97, P10826, DOI 10.1073/pnas.190343597; Classon M, 2000, P NATL ACAD SCI USA, V97, P10820, DOI 10.1073/pnas.190343497; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Dasgupta P, 2004, MOL CELL BIOL, V24, P9527, DOI 10.1128/MCB.24.21.9527-9541.2004; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Denchi EL, 2005, EMBO REP, V6, P661, DOI 10.1038/sj.embor.7400452; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Donovan SL, 2004, VISION RES, V44, P3323, DOI 10.1016/j.visres.2004.08.007; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; Dyer MA, 2005, NAT REV CANCER, V5, P91, DOI 10.1038/nrc1545; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Fattman CL, 2001, ONCOGENE, V20, P2918, DOI 10.1038/sj.onc.1204414; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Ferguson KL, 2002, EMBO J, V21, P3337, DOI 10.1093/emboj/cdf338; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Guo J, 2005, J BIOL CHEM, V280, P35992, DOI 10.1074/jbc.M504583200; Guo Z, 2001, CANCER RES, V61, P8395; Hansen JB, 2004, P NATL ACAD SCI USA, V101, P4112, DOI 10.1073/pnas.0301964101; Harbour JW, 2001, ARCH OPHTHALMOL-CHIC, V119, P1699; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; Harris H, 2004, NATURE, V427, P201, DOI 10.1038/427201a; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Hou ST, 2002, J BIOL CHEM, V277, P48764, DOI 10.1074/jbc.M206336200; HU NP, 1994, ONCOGENE, V9, P1021; Humbert PO, 2000, GENE DEV, V14, P690; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Iavarone A, 2004, NATURE, V432, P1040, DOI 10.1038/nature03068; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; Jiang Z, 2002, J CELL BIOL, V156, P185, DOI 10.1083/jcb.200106084; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Krutzfeldt M, 2005, MOL CELL, V18, P213, DOI 10.1016/j.molcel.2005.03.009; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Lemaire C, 2005, ONCOGENE, V24, P3297, DOI 10.1038/sj.onc.1208493; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Li FQ, 2000, MOL CELL BIOL, V20, P5129, DOI 10.1128/MCB.20.14.5129-5139.2000; LOHMANN DR, 1994, HUM GENET, V94, P349; Lohmann DR, 2004, AM J MED GENET C, V129C, P23, DOI 10.1002/ajmg.c.30024; Lu JM, 1998, J BIOL CHEM, V273, P31528, DOI 10.1074/jbc.273.47.31528; MacLellan WR, 2005, MOL CELL BIOL, V25, P2486, DOI 10.1128/MCB.25.6.2486-2497.2005; MacLellan WR, 2000, MOL CELL BIOL, V20, P8903, DOI 10.1128/MCB.20.23.8903-8915.2000; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MacPherson D, 2004, GENE DEV, V18, P1681, DOI 10.1101/gad.1203304; MacPherson D, 2003, MOL CELL BIOL, V23, P1044, DOI 10.1128/MCB.23.3.1044-1053.2003; Maddison LA, 2004, CANCER RES, V64, P6018, DOI 10.1158/0008-5472.CAN-03-2509; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Marino S, 2000, GENE DEV, V14, P994; Marino S, 2003, DEVELOPMENT, V130, P3359, DOI 10.1242/dev.00553; Mayhew CN, 2005, CANCER RES, V65, P4568, DOI 10.1158/0008-5472.CAN-04-4221; McConkey DJ, 1996, ONCOGENE, V13, P1693; Miccadei S, 2005, ONCOGENE, V24, P6993, DOI 10.1038/sj.onc.1208861; Miyake S, 2000, MOL CELL BIOL, V20, P8889, DOI 10.1128/MCB.20.23.8889-8902.2000; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nath N, 2003, ONCOGENE, V22, P5986, DOI 10.1038/sj.onc.1206843; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; Paggi MG, 2001, CANCER RES, V61, P4651; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; Sage C, 2005, SCIENCE, V307, P1114, DOI 10.1126/science.1106642; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Schweers BA, 2005, VISUAL NEUROSCI, V22, P553, DOI 10.1017/S0952523805225026; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Sever-Chroneos Z, 2001, MOL CELL BIOL, V21, P4032, DOI 10.1128/MCB.21.12.4032-4045.2001; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; Sherr CJ, 2000, CANCER RES, V60, P3689; Simpson MTW, 2001, J NEUROSCI, V21, P7089, DOI 10.1523/JNEUROSCI.21-18-07089.2001; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Spike BT, 2004, EMBO J, V23, P4319, DOI 10.1038/sj.emboj.7600432; Sun HF, 2006, MOL CELL BIOL, V26, P1527, DOI 10.1128/MCB.26.4.1527-1537.2006; Takahashi C, 2004, MOL CELL BIOL, V24, P10406, DOI 10.1128/MCB.24.23.10406-10415.2004; Takahashi C, 2003, MOL CELL BIOL, V23, P5256, DOI 10.1128/MCB.23.15.5256-5268.2003; Takaki T, 2005, J BIOCHEM, V137, P381, DOI 10.1093/jb/mvi050; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Vidal M, 2005, FEBS LETT, V579, P1834, DOI 10.1016/j.febslet.2005.02.030; Vooijs M, 1998, ONCOGENE, V17, P1, DOI 10.1038/sj.onc.1202169; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Wikenheiser-Brokamp KA, 2004, DEVELOPMENT, V131, P4299, DOI 10.1242/dev.01232; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Xiao H, 2005, ONCOGENE, V24, P8105, DOI 10.1038/sj.onc.1208958; Yamamoto H, 1999, CLIN CANCER RES, V5, P1805; Yu BD, 2003, P NATL ACAD SCI USA, V100, P14881, DOI 10.1073/pnas.2431391100; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang JK, 2004, CELL CYCLE, V3, P952; Zhang JK, 2004, NAT GENET, V36, P351, DOI 10.1038/ng1318; Zhou ZX, 2005, CANCER RES, V65, P787; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	142	108	111	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5233	5243		10.1038/sj.onc.1209616	http://dx.doi.org/10.1038/sj.onc.1209616			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936742	Green Accepted			2022-12-17	WOS:000240064100006
J	Kuphal, S; Poser, I; Jobin, C; Hellerbrand, C; Bosserhoff, AK				Kuphal, S; Poser, I; Jobin, C; Hellerbrand, C; Bosserhoff, AK			Loss of E-cadherin leads to upregulation of NF kappa B activity in malignant melanoma	ONCOGENE			English	Article						melanoma; E-cadherin; p-p38; NF kappa B	ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; LOBULAR BREAST CANCERS; CELL-CELL-ADHESION; BETA-CATENIN; EXPRESSION; P38; PATHWAY; GROWTH; GENE	Malignant transformation of melanocytes frequently coincides with loss of E-cadherin expression. Here, we show that loss of E-cadherin leads to induction of nuclear factor kappa B (NFkappaB) activity in melanoma cell lines. Melanoma cells show constitutively active NFkappaB, whereas no activity is found in primary melanocytes. After reexpression of E-cadherin in melanoma cells, strong downregulation of NFkappaB activity was found. Consistently, NFkappaB activity was induced in primary human melanocytes after inhibition of E-cadherin activity by functionally blocking anti-E-cadherin antibodies. Interestingly, reexpression of E-cadherin-blocked p38 MAPK activity and the p38 MAPK inhibitors SB203580 and SB202190 almost completely prevented NFkappaB activation in melanoma cells. Furthermore, cytoplasmatic beta-catenin induced p38 and NFkappaB activation in malignant melanoma. To our knowledge, this is the first report suggesting a correlation between E-cadherin and NFkappaB activity in melanocytes and melanoma cells. In summary, we conclude that loss of E-cadherin and cytoplasmatic beta-catenin induces p38-mediated NFkappaB activation, potentially revealing an important mechanism of tumorigenesis in malignant melanomas.	Univ Regensburg, Inst Pathol, D-93053 Regensburg, Germany; Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA	University of Regensburg; University of North Carolina; University of North Carolina Chapel Hill	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Kuphal, Silke/AAW-2702-2020; Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X				Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Berx G, 1996, ONCOGENE, V13, P1919; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bosserhoff AK, 1996, J BIOL CHEM, V271, P490, DOI 10.1074/jbc.271.1.490; Carpentier I, 1998, FEBS LETT, V425, P195, DOI 10.1016/S0014-5793(98)00226-9; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; COWIN P, 1994, P NATL ACAD SCI USA, V91, P10759, DOI 10.1073/pnas.91.23.10759; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Denkert C, 2002, CLIN EXP METASTAS, V19, P79, DOI 10.1023/A:1013857325012; Englaro W, 1998, J BIOL CHEM, V273, P9966, DOI 10.1074/jbc.273.16.9966; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Hellerbrand C, 1998, AM J PHYSIOL-GASTR L, V275, pG269, DOI 10.1152/ajpgi.1998.275.2.G269; Huang S, 2000, CLIN CANCER RES, V6, P2573; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; Kortylewski M, 2001, BIOCHEM J, V357, P297, DOI 10.1042/0264-6021:3570297; Li G, 2001, CANCER RES, V61, P3819; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Maulik N, 1998, FEBS LETT, V429, P365, DOI 10.1016/S0014-5793(98)00632-2; McNulty SE, 2001, PIGM CELL RES, V14, P456, DOI 10.1034/j.1600-0749.2001.140606.x; Melki JR, 2000, BLOOD, V95, P3208; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Orsulic S, 1999, J CELL SCI, V112, P1237; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Sanders DSA, 1999, J CLIN PATHOL-MOL PA, V52, P151, DOI 10.1136/mp.52.3.151; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Silye R, 1998, J PATHOL, V186, P350, DOI 10.1002/(SICI)1096-9896(199812)186:4<350::AID-PATH181>3.0.CO;2-K; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; Tamura G, 1996, JPN J CANCER RES, V87, P1153, DOI 10.1111/j.1349-7006.1996.tb03125.x; Tamura S, 1996, BRIT J SURG, V83, P1608, DOI 10.1002/bjs.1800831138; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wang DZ, 2001, J BIOL CHEM, V276, P3650, DOI 10.1074/jbc.M006115200; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Yang JM, 2001, CANCER RES, V61, P4901	41	108	111	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8509	8519		10.1038/sj.onc.1207831	http://dx.doi.org/10.1038/sj.onc.1207831			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378016				2022-12-17	WOS:000224870700011
J	Khanim, FL; Gommersall, LM; Wood, VHJ; Smith, KL; Montalvo, L; O'Neill, LP; Xu, Y; Peehl, DM; Stewart, PM; Turner, BM; Campbell, MJ				Khanim, FL; Gommersall, LM; Wood, VHJ; Smith, KL; Montalvo, L; O'Neill, LP; Xu, Y; Peehl, DM; Stewart, PM; Turner, BM; Campbell, MJ			Altered SMRT levels disrupt vitamin D-3 receptor signalling in prostate cancer cells	ONCOGENE			English	Article						histone deacetylation inhibitors; 1 alpha,25-dihydroxyvitamin D-3; prostate cancer; SMRT; GADD45 alpha	HISTONE DEACETYLASE INHIBITOR; TRANSCRIPTION FACTORS OCT-1; 1,25-DIHYDROXYVITAMIN D-3; RETINOIC ACID; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; PRIMARY CULTURES; GENE-EXPRESSION; P53-INDEPENDENT INDUCTION; 24-HYDROXYLASE ACTIVITY; PROMYELOCYTIC LEUKEMIA	We hypothesized that key antiproliferative target genes for the vitamin D receptor (VDR) were repressed by an epigenetic mechanism in prostate cancer cells resulting in apparent hormonal insensitivity. To explore this possibility, we examined nuclear receptor corepressor expression in a panel of nonmalignant and malignant cell lines and primary cultures, and found frequently elevated SMRT corepressor mRNA expression often associated with reduced sensitivity to 1alpha,25-dihydroxyvitamin D-3 (1alpha, 25(OH)(2)D-3). For example, PC-3 and DU-145 prostate cancer cell lines had 1.8-fold and twofold increases in SMRT mRNA relative to normal PrEC cells (P<0.05). Similarly, 10/15 primary tumour cultures ( including three matched to normal cells from the same donors) had elevated SMRT mRNA levels; generally NCoR1 and Alien were not as commonly elevated. Corepressor proteins often have associated histone deacetylases (HDAC) and reflectively the antiproliferative action of 1 alpha, 25(OH)(2)D-3 can be 'restored' by cotreatment with low doses of HDAC inhibitors such as trichostatin A (TSA, 15 nM) to induce apoptosis in prostate cancer cell lines. To decipher the transcriptional events that lead to these cellular responses, we undertook gene expression studies in PC-3 cells after cotreatment of 1 alpha, 25(OH)(2)D-3 plus TSA after 6 h. Examination of known VDR target genes and cDNA microarray analyses revealed cotreatment of 1 alpha, 25(OH)(2)D-3 plus TSA cooperatively upregulated eight (outof1176) genes, including MAPK-APK2 and GADD45 alpha. MRNA and protein time courses and inhibitor studies confirmed these patterns of regulation. Subsequently, we knocked down SMRT levels in PC-3 cells using a small interfering RNA ( siRNA) approach and found that GADD45 alpha induction by 1 alpha, 25(OH)(2)D-3 alone became very significantly enhanced. The same distortion of gene responsiveness, with repressed induction of GADD45 alpha was found in primary tumour cultures compared and to matched peripheral zone ( normal) cultures from the same donor. These data demonstrate that elevated SMRT levels are common in prostate cancer cells, resulting in suppression of target genes associated with antiproliferative action and apparent 1 alpha,25(OH)(2)D-3-insensitivity. This can be targeted therapeutically by combination treatments with HDAC inhibitors.	Univ Birmingham, Sch Med, Inst Biomed Res, Div Med Sci, Birmingham B15 2TH, W Midlands, England; Univ Birmingham, Sch Med, Inst Biomed Res, Div Immun & Infect, Birmingham B15 2TH, W Midlands, England; Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA	University of Birmingham; University of Birmingham; Stanford University	Campbell, MJ (corresponding author), Univ Birmingham, Sch Med, Inst Biomed Res, 2nd Floor, Birmingham B15 2TT, W Midlands, England.	m.j.campbell@bham.ac.uk	Campbell, Moray J/A-1311-2013; Campbell, Moray/ABF-1264-2021	Campbell, Moray/0000-0002-3355-0928				Akutsu N, 2001, MOL ENDOCRINOL, V15, P1127, DOI 10.1210/me.15.7.1127; Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Alsayed Y, 2001, J BIOL CHEM, V276, P4012, DOI 10.1074/jbc.M007431200; Beer TM, 2003, J CLIN ONCOL, V21, P123, DOI 10.1200/jco.2003.05.117; Belandia B, 2003, CELL, V114, P277, DOI 10.1016/S0092-8674(03)00599-3; Blutt SE, 2000, CANCER RES, V60, P779; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; Campbell MJ, 2000, ONCOGENE, V19, P5091, DOI 10.1038/sj.onc.1203888; Campbell MJ, 1998, ENDOCRINOLOGY, V139, P1972, DOI 10.1210/en.139.4.1972; Campbell MJ, 1997, J MOL ENDOCRINOL, V19, P15, DOI 10.1677/jme.0.0190015; Chen TC, 2003, TRENDS ENDOCRIN MET, V14, P423, DOI 10.1016/j.tem.2003.09.004; Cohen LA, 2002, ANTICANCER RES, V22, P1497; Danielsson C, 1997, J CELL BIOCHEM, V66, P552, DOI 10.1002/(SICI)1097-4644(19970915)66:4<552::AID-JCB14>3.0.CO;2-D; DeFouw LM, 2000, TISSUE CELL, V32, P238, DOI 10.1054/tice.2000.0111; Dwivedi PP, 2002, J BIOL CHEM, V277, P29643, DOI 10.1074/jbc.M204561200; Dwivedi PP, 2000, J BIOL CHEM, V275, P47, DOI 10.1074/jbc.275.1.47; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Germain P, 2002, NATURE, V415, P187, DOI 10.1038/415187a; Gnanapragasam VJ, 2001, BRIT J CANCER, V85, P1928, DOI 10.1054/bjoc.2001.2179; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; HANCHETTE CL, 1992, CANCER, V70, P2861, DOI 10.1002/1097-0142(19921215)70:12<2861::AID-CNCR2820701224>3.0.CO;2-G; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Hirose T, 2003, ONCOGENE, V22, P7762, DOI 10.1038/sj.onc.1207091; Hudelist G, 2003, BREAST CANCER RES TR, V78, P193, DOI 10.1023/A:1022930710850; Ingles SA, 1998, CANCER RES, V58, P1620; Jiang F, 2003, J BIOL CHEM, V278, P48030, DOI 10.1074/jbc.M308430200; Jiang WG, 2003, INT J CANCER, V106, P752, DOI 10.1002/ijc.11302; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Jin SQ, 2003, ONCOGENE, V22, P8536, DOI 10.1038/sj.onc.1206907; Kawashima H, 2003, BIOCHEM J, V369, P163, DOI 10.1042/BJ20020743; Kollara A, 2001, BREAST CANCER RES TR, V67, P245, DOI 10.1023/A:1017938608460; Konety BR, 1996, CELL GROWTH DIFFER, V7, P1563; Krishnan AV, 2003, RECENT RESULTS CANC, V164, P205; Kubota T, 1998, CANCER RES, V58, P3370; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Ly LH, 1999, ENDOCRINOLOGY, V140, P2071, DOI 10.1210/en.140.5.2071; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Miller CW, 1997, MOL CARCINOGEN, V19, P254, DOI 10.1002/(SICI)1098-2744(199708)19:4<254::AID-MC6>3.0.CO;2-C; Miller GJ, 1995, CLIN CANCER RES, V1, P997; Mori T, 2002, NEOPLASIA, V4, P268, DOI 10.1038/sj.neo.7900235; MUNKER R, 1986, J CLIN INVEST, V78, P424, DOI 10.1172/JCI112593; Oda Y, 2003, MOL ENDOCRINOL, V17, P2329, DOI 10.1210/me.2003-0063; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Peehl DM, 2004, J CELL BIOCHEM, V91, P185, DOI 10.1002/jcb.10691; Peehl DM, 2003, ENDOCR-RELAT CANCER, V10, P131, DOI 10.1677/erc.0.0100131; PEEHL DM, 1994, CANCER RES, V54, P805; Planas-Silva MD, 2001, CANCER RES, V61, P3858; Polek TC, 2003, ENDOCRINOLOGY, V144, P50, DOI 10.1210/en.2001-210109; Polly P, 2000, FASEB J, V14, P1455, DOI 10.1096/fj.14.10.1455; Quack M, 1999, MOL PHARMACOL, V55, P1077, DOI 10.1124/mol.55.6.1077; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rachez C, 2000, GENE, V246, P9, DOI 10.1016/S0378-1119(00)00052-4; Rashid SF, 2001, ONCOGENE, V20, P1860, DOI 10.1038/sj.onc.1204269; Rashid SF, 2001, STEROIDS, V66, P433, DOI 10.1016/S0039-128X(00)00203-8; Ratnam AV, 1996, J INVEST DERMATOL, V106, P522, DOI 10.1111/1523-1747.ep12343898; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; SCHMID HP, 1992, AM J SURG PATHOL, V16, P184, DOI 10.1097/00000478-199202000-00012; Schwartz GG, 1997, CANCER EPIDEM BIOMAR, V6, P727; SOMMERVILLE J, 1993, J CELL BIOL, V120, P277, DOI 10.1083/jcb.120.2.277; Tong WM, 1998, INT J CANCER, V75, P467, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;467::AID-IJC22&gt;3.0.CO;2-4; Wang DF, 2004, BIOORG MED CHEM LETT, V14, P707, DOI 10.1016/j.bmcl.2003.11.062; Wang XN, 2000, EXP CELL RES, V258, P425, DOI 10.1006/excr.2000.4939; Yamashita Y, 2003, INT J CANCER, V103, P572, DOI 10.1002/ijc.10699; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Yu JJ, 2003, EMBO J, V22, P3403, DOI 10.1093/emboj/cdg326; Zhang C, 2001, J BIOL CHEM, V276, P40614, DOI 10.1074/jbc.M106263200; Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440; Zhuang SH, 1997, MOL CELL ENDOCRINOL, V126, P83, DOI 10.1016/S0303-7207(96)03974-3; Zierold C, 2002, ARCH BIOCHEM BIOPHYS, V404, P18, DOI 10.1016/S0003-9861(02)00238-2; Zinser G, 2002, DEVELOPMENT, V129, P3067	72	108	110	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6712	6725		10.1038/sj.onc.1207772	http://dx.doi.org/10.1038/sj.onc.1207772			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15300237	Green Submitted			2022-12-17	WOS:000223653600003
J	Bernat, A; Avvakumov, N; Mymryk, JS; Banks, L				Bernat, A; Avvakumov, N; Mymryk, JS; Banks, L			Interaction between the HPV E7 oneoprotein and the transcriptional coactivator p300	ONCOGENE			English	Article						HPV; E7; p300 transcriptional coactivation	HUMAN-PAPILLOMAVIRUS TYPE-16; CREB-BINDING-PROTEIN; RETINOBLASTOMA TUMOR-SUPPRESSOR; E6 ONCOPROTEIN; HISTONE ACETYLTRANSFERASES; HUMAN KERATINOCYTES; P53 DEGRADATION; ADENOVIRUS E1A; CELL-GROWTH; E2 PROTEIN	Infection with high-risk human papillomaviruses (HPV) can lead to the development of cervical cancer. This process depends on the interaction of the virus-encoded oncoproteins, E6 and E7, with a variety of host regulatory proteins. As E7 shares both functional and structural similarities with the Adenovirus E1a (Ad E1a) protein, we were interested in investigating the possible interactions between E7 and the transcriptional coactivator p300, since it was originally identified as a target of Ad E1a. Using a variety of assays, we show that E7s from both high- and low-risk HPV types interact with p300. Mutational analysis of E7 maps the site of the interaction to a region spanning the pRb-binding domain and the CKII phosphorylation site. We also map the site of interaction on p300 largely to the CH1 domain. In addition, we demonstrate that the binding between 16E7 and p300 is direct, and can be detected in vivo by coimmunoprecipitation and mammalian two-hybrid assays. Finally, we show that E7 can abolish the p300-mediated E2 transactivation function, suggesting that complex formation between E7 and p300 may contribute to the regulation of E2 transcriptional activity.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Univ Western Ontario, London Reg Canc Ctr, Dept Microbiol & Immunol, London, ON N6A 4L6, Canada; Univ Western Ontario, London Reg Canc Ctr, Dept Oncol, London, ON N6A 4L6, Canada; Univ Western Ontario, London Reg Canc Ctr, Dept Physiol, London, ON N6A 4L6, Canada; Univ Western Ontario, London Reg Canc Ctr, Dept Pharmacol, London, ON N6A 4L6, Canada	International Center for Genetic Engineering & Biotechnology (ICGEB); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.			Bernat, Agnieszka/0000-0002-1232-4286				ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Avvakumov N, 2003, ONCOGENE, V22, P3833, DOI 10.1038/sj.onc.1206562; BANKS L, 1990, ONCOGENE, V5, P1383; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARBOSA MS, 1989, ONCOGENE, V4, P1529; Bernat A, 2002, J GEN VIROL, V83, P829, DOI 10.1099/0022-1317-83-4-829; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; CHOE J, 1989, J VIROL, V63, P1743, DOI 10.1128/JVI.63.4.1743-1755.1989; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DAVIES RC, 1992, J GEN VIROL, V73, P2135, DOI 10.1099/0022-1317-73-8-2135; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, MOL CELL BIOL, V16, P3454; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Georges SA, 2002, MOL CELL BIOL, V22, P127, DOI 10.1128/MCB.22.1.127-137.2002; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Goodman RH, 2000, GENE DEV, V14, P1553; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guccione E, 2002, VIROLOGY, V293, P20, DOI 10.1006/viro.2001.1290; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Huang SM, 2002, J VIROL, V76, P8710, DOI 10.1128/JVI.76.17.8710-8721.2002; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kung AL, 2000, GENE DEV, V14, P272; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lee D, 2000, J BIOL CHEM, V275, P7045, DOI 10.1074/jbc.275.10.7045; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Marcello A, 2000, J VIROL, V74, P9090, DOI 10.1128/JVI.74.19.9090-9098.2000; Massimi P, 1996, ONCOGENE, V12, P2325; Massimi P, 1997, J GEN VIROL, V78, P2607, DOI 10.1099/0022-1317-78-10-2607; McIntyre MC, 1996, VIROLOGY, V215, P73, DOI 10.1006/viro.1996.0008; Muller A, 2002, J VIROL, V76, P11042, DOI 10.1128/JVI.76.21.11042-11053.2002; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; MUNGER K, 1989, J VIROL, V63, P4417; Mymryk JS, 1998, NUCLEIC ACIDS RES, V26, P292, DOI 10.1093/nar/26.1.292; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIM D, 1994, ONCOGENE, V9, P1869; PIM D, 2001, VIRUSES CELL TRANSFO, P145; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Scoggin KES, 2001, MOL CELL BIOL, V21, P5520, DOI 10.1128/MCB.21.16.5520-5530.2001; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; Smith-McCune K, 1999, P NATL ACAD SCI USA, V96, P6999, DOI 10.1073/pnas.96.12.6999; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; Sternsdorf T, 1997, IMMUNOBIOLOGY, V198, P307, DOI 10.1016/S0171-2985(97)80051-4; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; Stubenrauch F, 1998, J VIROL, V72, P1071, DOI 10.1128/JVI.72.2.1071-1077.1998; Tanaka Y, 2000, MECH DEVELOP, V95, P133, DOI 10.1016/S0925-4773(00)00360-9; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Wang L, 2000, P NATL ACAD SCI USA, V97, P430, DOI 10.1073/pnas.97.1.430; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; Wong HK, 1996, J VIROL, V70, P332, DOI 10.1128/JVI.70.1.332-340.1996; Yan JP, 1998, J MOL BIOL, V281, P395, DOI 10.1006/jmbi.1998.1951; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zimmermann H, 2000, J GEN VIROL, V81, P2617, DOI 10.1099/0022-1317-81-11-2617; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291; Zwerschke W, 2000, J BIOL CHEM, V275, P9534, DOI 10.1074/jbc.275.13.9534	86	108	112	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7871	7881		10.1038/sj.onc.1206896	http://dx.doi.org/10.1038/sj.onc.1206896			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970734				2022-12-17	WOS:000185388200001
J	Bierie, B; Nozawa, M; Renou, JP; Shillingford, JM; Morgan, F; Oka, T; Taketo, MM; Cardiff, RD; Miyoshi, K; Wagner, KU; Robinson, GW; Hennighausen, L				Bierie, B; Nozawa, M; Renou, JP; Shillingford, JM; Morgan, F; Oka, T; Taketo, MM; Cardiff, RD; Miyoshi, K; Wagner, KU; Robinson, GW; Hennighausen, L			Activation of beta-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation	ONCOGENE			English	Article						beta-catenin; cell identity; transdifferentiation; neoplasia; prostate	HAIR FOLLICLE MORPHOGENESIS; SIGNALING PATHWAYS; STEM-CELLS; DIFFERENTIATION; EXPRESSION; GENE; PREGNANCY; EPIDERMIS; DELETION; GROWTH	The Wnt/beta-catenin signaling pathway is critical for normal mammalian development, the specification of epidermal cells and neoplastic transformation of intestinal epithelium. However, precise molecular information regarding cell-specific responses to beta-catenin signaling has been limited. This question was addressed using a mouse model in which exon 3 of the beta-catenin gene was deleted in several cell types with loxP-mediated recombination utilizing a Cre transgene under control of the mouse mammary tumor virus-long terminal repeat (MMTV-LTR). The stabilization of beta-catenin in prostate epithelium resulted in hyperplasias and extensive transdifferentiation into epidermal-like structures, which expressed keratins 1 and 6, filaggrin, loricrin and involucrin. The cell-specific loss of NKCC1 protein and reduced nuclear Stat5a is further suggestive of a loss of prostate epithelial characteristics. In addition to the prostate, hyperplasias and squamous metaplasias were detected in epithelia of the epididymis, vas deferens, coagulating gland, preputial gland and salivary gland. However, and in contrast to a recent study, no lesions reminiscent of high-grade prostate intraepithelial neoplasia were detected. Since beta-catenin was activated in several cell types and impinged upon the viability of these mice, it was not possible to evaluate the cumulative effect over more than 3 months. To assess long-term consequences of beta-catenin activation, mutant and control prostate tissues were transplanted into the mammary fat pads of wild-type males. Notably, squamous metaplasias, intra-acinous hyperplasia and possible neoplastic transformation were observed after a total of 18 weeks of beta-catenin stimulation. This suggests that the transdifferentiation into squamous metaplasias is an early response of endoderm-derived cells to beta-catenin, and that the development of intra-acinous hyperplasias or neoplastic foci is a later event.	NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA; INRA, Jouy En Josas, France; Kyoto Univ, Grad Sch Med, Dept Pharmacol, Kyoto 6068501, Japan; Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA; Univ Tokushima, Dept Biochem, Sch Dent, Tokushima 7708504, Japan; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Nebraska Med Ctr, Omaha, NE USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Kyoto University; University of California System; University of California Davis; Tokushima University; University of Nebraska System; University of Nebraska Medical Center	Hennighausen, L (corresponding author), NIDDK, Lab Genet & Physiol, NIH, Bldg 8,Room 101, Bethesda, MD 20892 USA.	hennighausen@nih.gov	Wagner, Kay-Uwe/B-6044-2009; Robinson, Gertraud/I-2136-2012	Hennighausen, Lothar/0000-0001-8319-9841; Miyoshi, Keiko/0000-0001-6910-4172; Wagner, Kay-Uwe/0000-0002-5081-0226	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK061000, ZIADK061000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHTSTATTER T, 1985, J HISTOCHEM CYTOCHEM, V33, P415, DOI 10.1177/33.5.2580881; Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; BARRESI G, 1984, VIRCHOWS ARCH A, V403, P59, DOI 10.1007/BF00689338; Baruch RR, 2001, CELL BIOL INT, V25, P411, DOI 10.1006/cbir.2000.0647; Brault V, 2001, DEVELOPMENT, V128, P1253; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; de Lau W, 2001, NAT GENET, V28, P3, DOI 10.1038/88233; DEOME KB, 1959, CANCER RES, V19, P515; Fischer DF, 1998, NUCLEIC ACIDS RES, V26, P5288, DOI 10.1093/nar/26.23.5288; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Gerstein AV, 2002, GENE CHROMOSOME CANC, V34, P9, DOI 10.1002/gcc.10037; Gounari F, 2002, ONCOGENE, V21, P4099, DOI 10.1038/sj.onc.1205562; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Harada N, 2002, CANCER RES, V62, P1971; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/ng0501-53; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Humphreys RC, 1999, CELL GROWTH DIFFER, V10, P685; Kallakury BVS, 2001, CLIN CANCER RES, V7, P3113; Kondo M, 2000, NATURE, V407, P383, DOI 10.1038/35030112; Krempler A, 2002, J BIOL CHEM, V277, P43216, DOI 10.1074/jbc.M207662200; Li XF, 1999, J BIOL CHEM, V274, P27249, DOI 10.1074/jbc.274.38.27249; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Miyoshi K, 2002, MOL ENDOCRINOL, V16, P2892, DOI 10.1210/me.2002-0128; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; Nevalainen MT, 2000, LAB INVEST, V80, P993, DOI 10.1038/labinvest.3780105; Niemann C, 2002, DEVELOPMENT, V129, P95; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; Polakis P, 2000, GENE DEV, V14, P1837; REESE JH, 1992, PROSTATE, V20, P73, DOI 10.1002/pros.2990200109; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Shen X, 2001, J BIOL CHEM, V276, P15362, DOI 10.1074/jbc.M009534200; Shillingford JM, 2002, MOL ENDOCRINOL, V16, P1309, DOI 10.1210/me.16.6.1309; Shillingford JM, 2002, MOL ENDOCRINOL, V16, P563, DOI 10.1210/me.16.3.563; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; Song HJ, 1999, GENOMICS, V55, P28, DOI 10.1006/geno.1998.5607; Voeller HJ, 1998, CANCER RES, V58, P2520; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Widelitz RB, 2000, DEV BIOL, V219, P98, DOI 10.1006/dbio.1999.9580	53	108	114	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2003	22	25					3875	3887		10.1038/sj.onc.1206426	http://dx.doi.org/10.1038/sj.onc.1206426			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813461				2022-12-17	WOS:000183612000007
J	Wells, J; Yan, PS; Cechvala, M; Huang, T; Farnham, PJ				Wells, J; Yan, PS; Cechvala, M; Huang, T; Farnham, PJ			Identification of novel pRb binding sites using CpG microarrays suggests that E2F recruits pRb to specific genomic sites during S phase	ONCOGENE			English	Article						pRb; E2F1; CpG island; chromatin immunoprecipitation	TARGET GENE SPECIFICITY; DNA-REPLICATION; RETINOBLASTOMA PROTEIN; CELL-CYCLE; CHROMATIN IMMUNOPRECIPITATION; EXPRESSION; COMPLEX; CLONING; FAMILY; REPAIR	The retinoblastoma (Rb) tumor suppressor protein is an important regulator of cell proliferation and differentiation. Many studies have shown that pRb can negatively regulate the activity of the E2F family of transcription factors during Go and G, phases of the cell cycle, perhaps by serving as a bridge between the E2Fs and transcriptional repressors such as histone deacetylases and methylases. However, pRb has also been shown to localize to discrete DNA foci during S phase, a time at which pRb is thought to be dissociated from E2F. Numerous other DNA binding proteins have been shown to interact with pRb, suggesting that pRb may control progression through S phase by binding to sites in the genome distinct from E2F target gene promoters. To test this hypothesis, we have identified novel pRb binding sites within the human genome using an unbiased approach which relies upon a combination of chromatin immunoprecipitation and CpG microarray analysis. To provide the greatest opportunity of finding distinct sets of pRb binding sites, we examined pRb binding in chromatin obtained from human Raji cells synchronized in either G(0)/G(1) phase or S phase. These experiments have allowed us to identify a large set of new genomic binding sites for the pRb protein. We found that some sites are occupied by pRb only during G(0)/G(1) phase, as would be predicted from previous models of pRb function. We also identified sites to which pRb bound only during S phase and other sites which were bound constitutively by pRb. Surprisingly, we found that E2F1 was present at most of the CpG islands bound by pRb, independent of the phase of the cell cycle. Thus, although pRb has the potential to interact with numerous transcription factors, our data suggest that the majority of DNA-bound pRb is recruited to E2F target promoters during both G(0)/G(1) and S phases.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA; Univ Missouri, Ellis Fischel Canc Ctr, Dept Pathol & Anat Sci, Columbia, MO 65203 USA	University of Wisconsin System; University of Wisconsin Madison; University of Missouri System; University of Missouri Columbia	Farnham, PJ (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	farnham@oncology.wisc.edu	Yan, Pearlly S/E-4339-2011	Yan, Pearlly S/0000-0003-1965-4920; Farnham, Peggy/0000-0003-4469-7914	NATIONAL CANCER INSTITUTE [P01CA022484, P30CA014520, R33CA084701, R29CA045240, R01CA045240] Funding Source: NIH RePORTER; NCI NIH HHS [CA14520-29, CA22484, R33CA84701, CA45240, CA1452] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albert T, 2001, J BIOL CHEM, V276, P20482, DOI 10.1074/jbc.M100265200; Antequera F, 1999, CURR BIOL, V9, pR661, DOI 10.1016/S0960-9822(99)80418-7; Bosco G, 2001, NAT CELL BIOL, V3, P289, DOI 10.1038/35060086; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Ponzio G, 1998, ONCOGENE, V17, P1159, DOI 10.1038/sj.onc.1202040; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Royzman I, 1999, GENE DEV, V13, P827, DOI 10.1101/gad.13.7.827; SAWAI M, 1990, EXP CELL RES, V187, P4, DOI 10.1016/0014-4827(90)90108-M; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Takahashi Y, 2000, GENE DEV, V14, P804; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Turner WJ, 2001, J VIROL, V75, P5638, DOI 10.1128/JVI.75.12.5638-5645.2001; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Yan PS, 2001, CANCER RES, V61, P8375; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	39	108	112	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1445	1460		10.1038/sj.onc.1206264	http://dx.doi.org/10.1038/sj.onc.1206264			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629508				2022-12-17	WOS:000181411900002
J	Span, PN; Manders, P; Heuvel, JJ; Thomas, CMG; Bosch, RR; Beex, LV; Sweep, CGJ				Span, PN; Manders, P; Heuvel, JJ; Thomas, CMG; Bosch, RR; Beex, LV; Sweep, CGJ			Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer	ONCOGENE			English	Article						breast neoplasms; quantitative real-time RT-PCR; gene expression regulation; oncogene; angiogenesis; extracellular matrix	PLASMINOGEN-ACTIVATOR; ENDOTHELIAL-CELLS; TRANSFORMING GENE; MESSENGER-RNA; MATRIX; UROKINASE; CARCINOMA; PHENOTYPE	The transcription factor Ets-1 regulates the expression of several angiogenic and extracellular matrix remodeling factors, and might be implicated in disease progression of breast cancer. In the present study, the prognostic value of Ets-1 expression was assessed by quantitative real-time fluorescence RT-PCR in 123 sporadic primary breast cancer samples of patients with a median follow-up time of 62 months. Ets-1 expression levels correlated significantly with VEGF and PAI-1 in the same tissue. In univariate (P = 0.0011) and multivariate (P = 0.005) analyses, Ets-1 expression showed significant prognostic value for relapse-free survival. Ets-1 is a strong, independent predictor of poor prognosis in breast cancer. This seems - at least in part - to be attributable to its role in transcriptional regulation of factors involved in angiogenesis (VEGF), and extracellular matrix remodeling (PAI-1).	Univ Nijmegen, Med Ctr, Dept Chem Endocrinol 530, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Med Ctr, Dept Med Oncol, Nijmegen, Netherlands; Univ Nijmegen, Med Ctr, Dept Obstet & Gynecol, Nijmegen, Netherlands; Univ Nijmegen, Med Ctr, Dept Endocrinol, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	Span, PN (corresponding author), Univ Nijmegen, Med Ctr, Dept Chem Endocrinol 530, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Manders, P./L-4501-2015; Span, Paul/G-4710-2012; Sweep, C.G.J./H-8096-2014; Span, Paul N./A-3143-2009; Thomas, C.M.G./L-4687-2015	Span, Paul/0000-0002-1930-6638; Sweep, C.G.J./0000-0003-1103-3070; 				Behrens P, 2001, J PATHOL, V194, P43, DOI 10.1002/path.844; Benz CC, 1998, ENDOCR-RELAT CANCER, V5, P271, DOI 10.1677/erc.0.0050271; COX DR, 1972, J R STAT SOC B, V34, P187; Davidson B, 2001, CLIN CANCER RES, V7, P551; Gilles C, 1997, CLIN EXP METASTAS, V15, P519, DOI 10.1023/A:1018427027270; Himelstein BP, 1998, CLIN EXP METASTAS, V16, P169; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Janicke F, 2001, J NATL CANCER I, V93, P913, DOI 10.1093/jnci/93.12.913; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Look MP, 2002, JNCI-J NATL CANCER I, V94, P116, DOI 10.1093/jnci/94.2.116; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; PERSYN JP, 1980, EUR J CANCER, V16, P1513; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Trojanowska M, 2000, ONCOGENE, V19, P6464, DOI 10.1038/sj.onc.1204043; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294	18	108	110	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8506	8509		10.1038/sj.onc.1206040	http://dx.doi.org/10.1038/sj.onc.1206040			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466970				2022-12-17	WOS:000179480100013
J	Yuan, JP; Eckerdt, F; Bereiter-Hahn, J; Kurunci-Csacsko, E; Kaufmann, M; Strebhardt, K				Yuan, JP; Eckerdt, F; Bereiter-Hahn, J; Kurunci-Csacsko, E; Kaufmann, M; Strebhardt, K			Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1	ONCOGENE			English	Article						phosphorylation; cyclin B1; mitotic kinases; polo-like kinase; cell cycle	PROTEIN-KINASE; CELL-CYCLE; NUCLEAR-LOCALIZATION; PROMOTING FACTOR; XENOPUS; P34CDC2; MATURATION; ACTIVATION; CDC2; PLK	The cyclin-dependent kinase 1 (Cdc2)/cyclin B1 complex performs cardinal roles for eukaryotic mitotic progression. Phosphorylation of four serine residues within cyclin B1 promotes the rapid nuclear translocation of Cdc2/cyclin B1 at the G(2)/M transition. Still, the role of individual phosphorylation sites and their corresponding kinases remain to be elucidated. Polo-like kinase I (Plk1) shows a spatial and temporal distribution which makes it a candidate kinase for the phosphorylation of cyclin B1. We could demonstrate the interaction of both proteins in mammalian cells. Plk1 phosphorylated wildtype cyclin 111 expressed in bacteria and in mammalian cells. Ser-133 within the cytoplasmic retention signal (CRS) of cyclin B1, which regulates the nuclear entry of the heterodimeric complex during prophase, is a target of Plk1. In contrast, MAPK (Erk2) and MPF phosphorylate Ser-126 and Ser-128 within the CRS. Phosphorylation of CRS by MAPK (Erk2) prior to Plk1 treatment induced enhanced phosphorylation of cyclin 131 by Plk1 suggesting a synergistic action of both enzymes towards cyclin B1. In addition, pretreatment of cyclin B1 by MAPK (Erk2) altered the phosphorylation pattern of Plk 1. Mutation of Ser-133 to Ala decreased the phosphorylation of cyclin 131 in vivo. An immunofluorescence study revealed that a mutation of Ser-133 reduced the nuclear import rate of cyclin B1. Still, multiple serine mutations are required to prevent nuclear translocation completely indicating that orchestrated phosphorylation within the CRS triggers rapid import of cyclin B1.	Univ Frankfurt, Dept Obstet & Gynecol, D-60590 Frankfurt, Germany; Univ Frankfurt, Dept Biol, D-60439 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Strebhardt, K (corresponding author), Univ Frankfurt, Dept Obstet & Gynecol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; Borgne A, 1999, J BIOL CHEM, V274, P11977, DOI 10.1074/jbc.274.17.11977; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Hock B, 1998, ONCOGENE, V17, P255, DOI 10.1038/sj.onc.1201907; Holtrich U, 2000, ONCOGENE, V19, P4832, DOI 10.1038/sj.onc.1203845; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LI JK, 1995, MOL BIOL CELL, V6, P1111, DOI 10.1091/mbc.6.9.1111; Lin CY, 2000, P NATL ACAD SCI USA, V97, P12589, DOI 10.1073/pnas.220423497; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yang J, 2001, J BIOL CHEM, V276, P3604, DOI 10.1074/jbc.M008151200; Yuan JP, 1997, AM J PATHOL, V150, P1165	37	108	112	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8282	8292		10.1038/sj.onc.1206011	http://dx.doi.org/10.1038/sj.onc.1206011			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447691				2022-12-17	WOS:000179323900006
J	Callus, BA; Mathey-Prevot, B				Callus, BA; Mathey-Prevot, B			SOCS36E, a novel Drosophila SOCS protein, suppresses JAK/STAT and EGF-R signalling in the imaginal wing disc	ONCOGENE			English	Article						Drosophila; EGF-R; JAK-STAT; signalling; SOCS	NEGATIVE REGULATOR; SH2 DOMAIN; PATHWAY; BOX; ACTIVATION; RECEPTORS; EMBRYOS; REVEALS; ENCODES; MEMBERS	We have cloned a novel SOCS gene from Drosophila, socs36E, which is most homologous to the mammalian socs-5 gene. Socs36E is expressed zygotically, predominantly during embryogenesis, in a highly dynamic pattern. In vivo expression of SOCS36E in transgenic flies results in several adult phenotypes. Engrailed-GAL4 directed expression causes loss of the wing anterior cross vein, humeral outgrowths, absence of halteres and eye pigmentation defects. Expression of SOCS36E under apterous-GAL4 control resulted in outstretched wings. Full penetrance of these phenotypes required the presence of the SH2 and SOCS-box domains of SOCS36E. The observed phenotypes were consistent with defects in JAK/STAT or EGF-R signalling and were exacerbated jak (hopscotch), din flies heterozygous for either the d-stat (stat92E) or d-egf-r (der) genes. Conversely, inactivating one copy of the d-cbl gene, a negative regulator of the d-EGF-R, partially rescued the wing phenotypes. These genetic interactions imply that SOCS36E can suppress activities of the JAK/STAT and EGF-R signalling pathways in the wing disc and suggest that SOCS36E interacts with multiple pathways in vivo.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Garvan Institute of Medical Research	Callus, BA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA.	b.callus@garvan.org.au			NHLBI NIH HHS [R01 HL 62434-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062434] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; Ciapponi L, 2001, GENE DEV, V15, P1540, DOI 10.1101/gad.886301; CLIFFORD R, 1994, GENETICS, V137, P531; Conley CA, 2000, DEVELOPMENT, V127, P3947; De Sepulveda P, 1999, EMBO J, V18, P904; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Harrison DA, 1998, GENE DEV, V12, P3252, DOI 10.1101/gad.12.20.3252; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Khalsa O, 1998, DEVELOPMENT, V125, P2723; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Pai LM, 2000, CELL, V103, P51, DOI 10.1016/S0092-8674(00)00104-5; Rorth P, 1998, MECH DEVELOP, V78, P113, DOI 10.1016/S0925-4773(98)00157-9; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Yan RQ, 1996, P NATL ACAD SCI USA, V93, P5842, DOI 10.1073/pnas.93.12.5842; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 2001, P NATL ACAD SCI USA, V98, P13261, DOI 10.1073/pnas.231486498	26	108	109	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2002	21	31					4812	4821		10.1038/sj.onc.1205618	http://dx.doi.org/10.1038/sj.onc.1205618			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101419				2022-12-17	WOS:000176716300010
J	Rottapel, R; Ilangumaran, S; Neale, C; La Rose, J; Ho, JMY; Nguyen, MHH; Barber, D; Dubreuil, P; de Sepulveda, P				Rottapel, R; Ilangumaran, S; Neale, C; La Rose, J; Ho, JMY; Nguyen, MHH; Barber, D; Dubreuil, P; de Sepulveda, P			The tumor suppressor activity of SOCS-1	ONCOGENE			English	Article						SOCS-1; Tel-Jak; KIT; BCR-ABL; tyrosine kinase	KINASE-ACTIVITY; NEGATIVE REGULATION; LYMPHOPROLIFERATIVE DISEASE; TYROSINE PHOSPHORYLATION; BOX MOTIF; C-CBL; PROTEIN; INDUCTION; DOMAIN; JAK2	SOCS-1 is an inducible SH2-containing inhibitor of Jak kinases and as such can potently suppress cytokine signaling. SOCS-1 deficient mice die within the first three weeks of life from a myeloproliferative disorder driven by excessive interferon signaling. We report here that SOCS-I inhibits proliferation signals induced by a variety of oncogenes active within the hematopoietic system. Ectopic expression of SOCS-I abolished proliferation mediated by a constitutively active form of the KIT receptor, TEL-JAK2, and v-ABL, and reduced metastasis from BCR-ABL transformed cells. SOCS-1, however, did not interfere with v-SRC or RASV12 mediated cellular transformation. A mutant form of SOCS-I unable to bind through its SH2 domain to tyrosine phosphorylated proteins could still inhibit KIT, but not TEL-JAK2, indicating multiple mechanisms for SOCS-1-mediated tumor suppression. We show that the steady state levels of TEL-JAK2 and to a greater extent v-ABL are diminished in the presence of SOCS-1. Lastly, we show that SOCS-1 -/- fibroblasts are more sensitive than wild type fibroblasts to either spontaneous or oncogene-induced transformation. These data suggest that loss-of-function of SOCS-1 may collaborate with a variety of hematopoietic oncogenes to facilitate tumor progression.	Univ Toronto, Dept Immunol, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; St Michaels Hosp, Toronto, ON M5B 1W8, Canada; INSERM, U119, F-13009 Marseille, France	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Institut National de la Sante et de la Recherche Medicale (Inserm)	Rottapel, R (corresponding author), Princess Margaret Hosp, Rm 10-116,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	rottapel@oci.utoronto.ca; sepulveda@marseille.inserm.fr	De sepulveda, paulo/K-6043-2015; Dubreuil, Patrice/V-4816-2019; dubreuil, patrice/F-5346-2011	De sepulveda, paulo/0000-0001-8295-5414; Dubreuil, Patrice/0000-0003-1155-1150; dubreuil, patrice/0000-0003-1155-1150; Ilangumaran, Subburaj/0000-0002-7563-576X; Rottapel, Robert/0000-0002-6024-5558				Alderton F, 2001, MOL PHARMACOL, V59, P1119, DOI 10.1124/mol.59.5.1119; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; De Sepulveda P, 1999, EMBO J, V18, P904; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FRANK DA, 1995, P NATL ACAD SCI USA, V92, P7779, DOI 10.1073/pnas.92.17.7779; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Frearson JA, 1997, BIOESSAYS, V19, P417, DOI 10.1002/bies.950190509; Ho JMY, 1999, BLOOD, V93, P4354, DOI 10.1182/blood.V93.12.4354.412k30_4354_4364; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Krystal G, 2000, SEMIN IMMUNOL, V12, P397, DOI 10.1006/smim.2000.0222; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Mauro MJ, 2001, CURR OPIN ONCOL, V13, P3, DOI 10.1097/00001622-200101000-00002; Monni R, 2001, ONCOGENE, V20, P849, DOI 10.1038/sj.onc.1204201; Morita Y, 2000, P NATL ACAD SCI USA, V97, P5405, DOI 10.1073/pnas.090084797; Nagai H, 2001, J HEPATOL, V34, P416, DOI 10.1016/S0168-8278(00)00038-6; Naka T, 1999, TRENDS BIOCHEM SCI, V24, P394, DOI 10.1016/S0968-0004(99)01454-1; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Ohya K, 1997, J BIOL CHEM, V272, P27178, DOI 10.1074/jbc.272.43.27178; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Rohrschneider LR, 2000, GENE DEV, V14, P505; Rottapel R, 2000, FR MOLEC B, V29, P246; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Siminovitch KA, 1998, SEMIN IMMUNOL, V10, P329, DOI 10.1006/smim.1998.0125; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; Tyers M, 1999, P NATL ACAD SCI USA, V96, P12230, DOI 10.1073/pnas.96.22.12230; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	53	108	110	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4351	4362		10.1038/sj.onc.1205537	http://dx.doi.org/10.1038/sj.onc.1205537			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080466				2022-12-17	WOS:000176317100001
J	Mizuno, K; Osada, H; Konishi, H; Tatematsu, Y; Yatabe, Y; Mitsudomi, T; Fujii, Y; Takahashi, T				Mizuno, K; Osada, H; Konishi, H; Tatematsu, Y; Yatabe, Y; Mitsudomi, T; Fujii, Y; Takahashi, T			Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers	ONCOGENE			English	Article						lung cancer; CHFR; hypermethylation; checkpoint; prophase	MITOTIC CHECKPOINT; EPIGENETIC INACTIVATION; EXPRESSION; MUTATION; ABNORMALITIES; GROWTH; HBUB1; P53	The CHFR gene, which was recently cloned by Scolnick and Halazonetis in search for a novel mitotic checkpoint gene with fork-head association motifs, has been suggested to play a key role in the mitotic prophase checkpoint. In this study, we demonstrated tumor-specific aberrant hypermethylation of the promoter region of the CHFR gene in a significant fraction of lung cancers in association with loss of detectable levels of CHFR transcripts. Aberrant hypermethylation was observed in seven of 37 primary lung cancer cases. Treatment with the demethylating agent 5-aza-2'-deoxycytidine restored expression of the CHFR gene in lung cancer cell lines exhibiting aberrant hypermethylation and loss of its expression. In contrast, genetic alterations were found to be infrequent in lung cancers. This is the first description of aberrant hypermethylation of the CHFR gene in any type of human cancer, and provides further evidence of the involvement of multiple checkpoint alterations in lung cancer.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Anat & Mol Diagnost Pathol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Thorac Surg, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Nagoya City Univ, Sch Med, Dept Surg 2, Mizuho Ku, Nagoya, Aichi 4678061, Japan	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center; Nagoya City University	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	tak@aichi-cc.jp	Takahashi, Takashi/I-7262-2014; YATABE, Yasushi/J-6461-2014; Osada, Hiroyuki/AAY-6254-2020	Takahashi, Takashi/0000-0003-0615-7001; YATABE, Yasushi/0000-0003-1788-559X; Mitsudomi, Tetsuya/0000-0001-9860-8505; Konishi, Hiroyuki/0000-0003-1131-4905				Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Gemma A, 2000, GENE CHROMOSOME CANC, V29, P213, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1027>3.0.CO;2-G; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Haruki N, 2000, CANCER RES, V60, P4689; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Masuda A, 1997, CANCER RES, V57, P4898; Matsuoka S, 2001, CANCER RES, V61, P5362; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; REDDEL RR, 1988, CANCER RES, V48, P1904; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; Sato M, 2000, JPN J CANCER RES, V91, P504, DOI 10.1111/j.1349-7006.2000.tb00974.x; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494	20	108	115	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2328	2333		10.1038/sj.onc.1205402	http://dx.doi.org/10.1038/sj.onc.1205402			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948416				2022-12-17	WOS:000174635600005
J	Baptiste, N; Friedlander, P; Chen, XB; Prives, C				Baptiste, N; Friedlander, P; Chen, XB; Prives, C			The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells	ONCOGENE			English	Review						p53; apoptosis; anti-neoplastics; proline-rich domain	WILD-TYPE P53; C-TERMINAL DOMAIN; TEMPERATURE-SENSITIVE MUTANT; COLORECTAL-CARCINOMA CELLS; SEQUENCE-SPECIFIC DNA; DOUBLE-STRAND BREAKS; P53-DEPENDENT APOPTOSIS; TRANSCRIPTIONAL ACTIVATION; CYCLE ARREST; P53-MEDIATED APOPTOSIS	In some cell types either DNA damage or p53 expression leads to minimal cell death, while combining the two leads to a strong apoptotic response. To further understand features of p53 that contribute to this increased cell death we used clones of H1299 cells that express wild-type or several mutant forms of p53 under a tetracycline-regulated promoter. In these cells the induction of wildtype p53 leads to significant apoptosis only when combined with exposure to a number of chemotherapeutic agents. A common target of p53, p21, is itself not sufficient to cause apoptosis in the presence of these chemotherapeutic compounds. Many agents also effectively increase cell death when a transcriptionally-defective p53, p53([gln22ser23]), is induced, although a dramatic exception is treatment with 5-FU, which strongly cooperates with wild-type but not p53([gln22ser23]). Our results with 5-FU thus show that genetically separable functions of p53 are involved in its ability to respond to DNA-damaging agents to induce apoptosis. Notably as well, deleting the C-terminal 30 amino acids of p53 does not affect this cooperative effect with DNA-damaging agents. By contrast, a p53 mutant lacking the PXXP-domain between residues 60-90, while at least partially transcriptionally-competent, cannot be rendered apoptotic by any compounds that we tested. Thus the PXXP domain provides an essential component of the ability of p53 to respond to DNA-damaging agents to cause cell death.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	Columbia University; University System of Georgia; Augusta University	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	prives@cubsps.bio.columbia.edu			NATIONAL CANCER INSTITUTE [R01CA077742] Funding Source: NIH RePORTER; NCI NIH HHS [CA77742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2000, PATHOL BIOL, V48, P227; Appella E, 2001, EUR J BIOCHEM, V268, P2763, DOI 10.1046/j.1432-1327.2001.02224.x; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Boulaire J, 2000, PATHOL BIOL, V48, P190; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chan TA, 2000, GENE DEV, V14, P1584; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chehab NH, 2000, GENE DEV, V14, P278; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; Darzynkiewicz Z, 1996, ANN NY ACAD SCI, V803, P93, DOI 10.1111/j.1749-6632.1996.tb26379.x; DEGTYAREVA N, 2000, J BIOL CHEM, V20, P20; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Engelborghs Y, 1998, EUR BIOPHYS J BIOPHY, V27, P437, DOI 10.1007/s002490050154; FADOK VA, 1992, J IMMUNOL, V148, P2207; Ferreira CG, 1999, ANN ONCOL, V10, P1011, DOI 10.1023/A:1008361818480; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gjerset RA, 2000, ADV EXP MED BIOL, V465, P273; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Grem JL, 2000, INVEST NEW DRUG, V18, P299, DOI 10.1023/A:1006416410198; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobayashi T, 1995, ONCOGENE, V11, P2311; Lee HY, 1997, P NATL ACAD SCI USA, V94, P526, DOI 10.1073/pnas.94.2.526; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038/sj.onc.1201585; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mee T, 1999, BRIT J CANCER, V81, P212, DOI 10.1038/sj.bjc.6690679; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MIYASHITA T, 1995, CELL, V80, P293; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; MYERS CE, 1990, CANC CHEMOTHERAPY PR, P356; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Parks D, 1997, NUCLEIC ACIDS RES, V25, P1289, DOI 10.1093/nar/25.6.1289; Peller S, 1998, SEMIN CANCER BIOL, V8, P379, DOI 10.1006/scbi.1998.0100; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Roemer K, 1996, ONCOGENE, V12, P2069; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; Seth P, 1997, CANCER GENE THER, V4, P383; Shieh SY, 2000, GENE DEV, V14, P289; Tang W, 1999, CANCER RES, V59, P2562; Thomas DM, 1998, CLIN EXP PHARMACOL P, V25, P887, DOI 10.1111/j.1440-1681.1998.tb02339.x; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; VANMAANEN JMS, 1988, J NATL CANCER I, V80, P1526, DOI 10.1093/jnci/80.19.1526; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Weller M, 1998, CELL TISSUE RES, V292, P435, DOI 10.1007/s004410051072; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zotchev SB, 2000, NUCLEIC ACIDS RES, V28, P4005, DOI 10.1093/nar/28.20.4005	115	108	111	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2002	21	1					9	21		10.1038/sj/onc/1205015	http://dx.doi.org/10.1038/sj/onc/1205015			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791172	Bronze			2022-12-17	WOS:000172887800002
J	White, E				White, E			Regulation of the cell cycle and apoptosis by the oncogenes of adenovirus	ONCOGENE			English	Review						adenovirus; apoptosis; Bcl-2; p53; E1A; E1B	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; UBIQUITIN-PROTEIN LIGASE; INTERLEUKIN-1-BETA CONVERTING-ENZYME; CYTOCHROME-C RELEASE; PORE-FORMING DOMAIN; E1B 19K PROTEIN; P53-DEPENDENT APOPTOSIS; CONFORMATIONAL-CHANGE; OLIGOMERIZES BAK		Rutgers State Univ, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Canc Inst New Jersey, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick	White, E (corresponding author), Rutgers State Univ, Howard Hughes Med Inst, 679 Hoes Lane,Room 140, Piscataway, NJ 08854 USA.	ewhite@cabm.rutgers.edu	White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065				Aritomi M, 1997, J BIOL CHEM, V272, P27886, DOI 10.1074/jbc.272.44.27886; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERENCSI K, 1994, LAB INVEST, V71, P350; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BROOKS MA, 1995, J VIROL, V69, P7688, DOI 10.1128/JVI.69.12.7688-7698.1995; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; Chiou SK, 1998, VIROLOGY, V244, P108, DOI 10.1006/viro.1998.9077; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; COOK JL, 1989, J IMMUNOL, V142, P4527; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; CUCONATI A, 2001, IN PRESS ONCOGENE; Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; DSaEipper C, 1996, CANCER RES, V56, P3879; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; DUERKSENHUGHES P, 1989, J IMMUNOL, V143, P4193; DUERKSENHUGHES PJ, 1991, J VIROL, V65, P1236, DOI 10.1128/JVI.65.3.1236-1244.1991; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Gazit E, 1998, P NATL ACAD SCI USA, V95, P12289, DOI 10.1073/pnas.95.21.12289; Gerber D, 2000, J BIOL CHEM, V275, P23602, DOI 10.1074/jbc.M002596200; Gilbert RJC, 1999, CELL, V97, P647, DOI 10.1016/S0092-8674(00)80775-8; GINSBERG HS, 1994, INFECT AGENT DIS, V3, P1; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Han JH, 1998, ONCOGENE, V17, P2993, DOI 10.1038/sj.onc.1202215; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HENRY H, 2001, IN PRESS ONCOGENE; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Huang HK, 2000, J BIOL CHEM, V275, P26661; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MANOJ KAS, 1999, J BACTERIOL, V181, P6103; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; MIYASHITA T, 1995, CELL, V80, P293; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; NEVINS JR, 1992, SCIENCE, V258, P424; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Rao L, 1997, ONCOGENE, V15, P1587, DOI 10.1038/sj.onc.1201323; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Routes JM, 2000, J IMMUNOL, V165, P4522, DOI 10.4049/jimmunol.165.8.4522; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; Sparer TE, 1996, J VIROL, V70, P2431, DOI 10.1128/JVI.70.4.2431-2439.1996; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; Sundararajan R, 2001, J VIROL, V75, P7506, DOI 10.1128/JVI.75.16.7506-7516.2001; SUNDARARAJAN R, 2001, IN PRESS J BIOL CHEM; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Taylor RM, 2000, BIOCHEMISTRY-US, V39, P12131, DOI 10.1021/bi000206c; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; THORNE M, 1997, NATURE, V386, P517; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; WHITE E, 1994, SEMIN VIROL, V5, P341, DOI 10.1006/smvy.1994.1038; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; White E, 1998, SEMIN VIROL, V8, P505, DOI 10.1006/smvy.1998.0155; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHITE E, 1995, CURR TOP MICROBIOL, V199, P33; Wold WSM, 1999, CURR OPIN IMMUNOL, V11, P380, DOI 10.1016/S0952-7915(99)80064-8; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; ZHANG YL, 1993, J BIOL CHEM, V268, P10176; Zhao RB, 2000, GENE DEV, V14, P981	122	108	108	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2001	20	54					7836	7846		10.1038/sj.onc.1204861	http://dx.doi.org/10.1038/sj.onc.1204861			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495JF	11753666				2022-12-17	WOS:000172336500003
J	Astuti, D; Agathanggelou, A; Honorio, S; Dallol, A; Martinsson, T; Kogner, P; Cummins, C; Neumann, HPH; Voutilainen, R; Dahia, P; Eng, C; Maher, ER; Latif, F				Astuti, D; Agathanggelou, A; Honorio, S; Dallol, A; Martinsson, T; Kogner, P; Cummins, C; Neumann, HPH; Voutilainen, R; Dahia, P; Eng, C; Maher, ER; Latif, F			RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours	ONCOGENE			English	Article						methylation; 3p tumour suppressor gene; neuroblastoma; phaeochromocytoma	HOMOZYGOUS DELETION; LUNG-CANCER; GENE-EXPRESSION; SHORT ARM; SUPPRESSOR; PHEOCHROMOCYTOMA; HETEROZYGOSITY; IDENTIFICATION; TUMORS; CHROMOSOME-3	Deletions of chromosome 3p are frequent in many types of neoplasia including neural crest tumours such as neuroblastoma (NB) and phaeochromocytoma. Recently we isolated several candidate tumour suppressor genes (TSGs) from a 120 kb critical interval at 3p21.3 defined by overlapping homozygous deletions in lung and breast tumour lines. Although mutation analysis of candidate TSGs in lung and breast cancers revealed only rare mutations, expression of one of the genes (RASSF1A) was absent in the majority of lung tumour cell lines analysed. Subsequently methylation of a CpG island in the promoter region of RASSF1A was demonstrated in a majority of small cell lung carcinomas and to a lesser extent in non-small cell lung carcinomas. To investigate the role of 3p TSGs in neural crest tumours, we (a) analysed phaeochromocytomas for 3p allele loss (n = 41) and RASSF1A methylation (n = 23) and (b) investigated 67 neuroblastomas for RASSF1A inactivation. 46% of phaeochromocytomas showed 3p allele loss (38.5% at 3p21.3). RASSF1A promoter region hypermethylation was found in 22% (5/23) of sporadic phaeochromocytomas and in 55% (37/67) of neuroblastomas analysed but RASSF1A mutations were not identified. In two neuroblastoma cell lines, methylation of RASSF1A correlated with loss of RASSF1A expression and RASSF1A expression was restored after treatment with the demethylating agent 5-azacytidine. As frequent methylation of the CASP8 gene has also been reported in neuroblastoma, we investigated whether RASSF1A and CASP8 methylation were independent or related events. CASP8 methylation was detected in 56% of neuroblastomas with RASSF1A methylation and 17% without RASSF1A methylation (P = 0.0031). These results indicate that (a) RASSF1A inactivation by hypermethylation is a frequent event in neural crest tumorigenesis, particularly neuroblastoma, and that RASSF1A is a candidate 3p21.3 neuroblastoma TSG and (b) a subset of neuroblastomas may be characterized by a CpG island methylator phenotype.	Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Gothenburg, Sahlgrenska Univ Hosp Ostra, Dept Clin Genet, S-41685 Gothenburg, Sweden; Karolinska Inst, Karolinska Hosp, Dept Woman & Child Hlth, Childhood Canc Res Unit, S-17176 Stockholm, Sweden; Birmingham Childrens Hosp, Birmingham, W Midlands, England; Univ Freiburg, Med Klin, D-79106 Freiburg, Germany; Kuopio Univ Hosp, Dept Pediat, FIN-70211 Kuopio, Finland; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Clin Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA; Univ Cambridge, CRC, Human Canc Genet Res Grp, Cambridge, England	University of Birmingham; Sahlgrenska University Hospital; University of Gothenburg; Karolinska Institutet; Karolinska University Hospital; University of Birmingham; University of Freiburg; Kuopio University Hospital; Harvard University; Dana-Farber Cancer Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Cambridge	Latif, F (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.		Martinsson, Tommy/J-4140-2013; MAHER, EAMONN R/A-9507-2008; Dallol, Ashraf/H-8661-2012	Martinsson, Tommy/0000-0002-9403-3123; MAHER, EAMONN R/0000-0002-6226-6918; Dallol, Ashraf/0000-0002-8803-228X; Eng, Charis/0000-0002-3693-5145; Voutilainen, Raimo/0000-0002-7858-665X; Kogner, Per/0000-0002-2202-9694; Cummins, Carole/0000-0001-5464-1944; Astuti, Dewi/0000-0003-4205-6160				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Astuti D, 2001, LANCET, V357, P1181, DOI 10.1016/S0140-6736(00)04378-6; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Ejeskar K, 1998, BRIT J CANCER, V77, P1787, DOI 10.1038/bjc.1998.297; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; Fullwood P, 1999, CANCER RES, V59, P4662; Hiatt KK, 2001, J BIOL CHEM, V276, P7240, DOI 10.1074/jbc.M009202200; Hoehner JC, 1998, LAB INVEST, V78, P29; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Klose A, 1998, HUM MOL GENET, V7, P1261, DOI 10.1093/hmg/7.8.1261; LATIF F, 1992, GENE CHROMOSOME CANC, V5, P119, DOI 10.1002/gcc.2870050205; Lerman MI, 2000, CANCER RES, V60, P6116; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Martinsson T, 1997, EUR J CANCER, V33, P1997, DOI 10.1016/S0959-8049(97)00278-5; Martinsson T, 1997, CANCER GENET CYTOGEN, V95, P183, DOI 10.1016/S0165-4608(96)00259-2; MOLEY JF, 1991, CANCER RES, V51, P1596; MORRISSEY C, 2001, IN PRESS CANC RES; Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103; Tanaka T, 1998, CANCER-AM CANCER SOC, V83, P1626, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1626::AID-CNCR19>3.0.CO;2-Y; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Vargas MP, 1997, HUM PATHOL, V28, P411, DOI 10.1016/S0046-8177(97)90028-9; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; Woodward ER, 1997, HUM MOL GENET, V6, P1051, DOI 10.1093/hmg/6.7.1051; ZEIGER MA, 1995, GENE CHROMOSOME CANC, V13, P151, DOI 10.1002/gcc.2870130303	27	108	115	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7573	7577		10.1038/sj.onc.1204968	http://dx.doi.org/10.1038/sj.onc.1204968			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709729				2022-12-17	WOS:000171976900014
J	Tannapfel, A; Busse, C; Weinans, L; Benicke, M; Katalinic, A; Geissler, F; Hauss, J; Wittekind, C				Tannapfel, A; Busse, C; Weinans, L; Benicke, M; Katalinic, A; Geissler, F; Hauss, J; Wittekind, C			INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas	ONCOGENE			English	Article						hepatocellular carcinoma; P14(ARF); p16(INK4a); p53; histopathology; prognosis	METHYLATION; CELL; EXPRESSION; FREQUENCY	The INK4a-ARF (CDKN2A)- locus on chromosome 9p21 encodes for two tumour suppressor proteins, P16(INK4a) and p14(ARF), that act as upstream regulators of the Rb-CDK4 and p53 pathways. To study the contribution of each pathway in tumorigenesis of hepatocellular carcinoma (HCC), we analysed the alterations of p14(ARF), p16(INC4a) and p53. After microdissection, DNA of 71 hepatocellular carcinomas was analysed for INK4-ARF inactivation and p53 mutation by DNA sequence analysis, methylation-specific PCR (MSP), restriction-enzyme related polymerase chain reaction (RE-PCR), mRNA expression and immunohistochemistry. In addition, microdeletion of p14(ARF) and p16(INC4a) were assessed by differential PCR. Inactivation of p14(ARF) was found in 11/71 cases (15%), alterations of p16(INK4a), occurred in 47/71 carcinomas (66%), which correlated with loss of mRNA transcription. Five tumours (7%) had homozygous deletions of the INK4a-ARF locus. We failed to detect specific mutations of both exons. P16(INK4a) methylation with an unmethylated p14(ARF) promotor appeared in 39 cases. Mutations of p53 were found in 30 of 71 HCC (42%), and only one of them harboured p14(ARF) inactivation. We failed to establish alterations of the INK4a-ARF locus or p53 status as independent prognostic factor in these tumours. Our data indicate, that p14(ARF) methylation occurs independently of p16(INK4a) alterations in a subset of HCC together with wild type p53. The INK4a-ARF-/p53-pathway was disrupted in 86% of HCC, either by p53 mutations or by INK4a-ARF inactivation, and may have co-operative effects in hepatocarcinogenesis.	Univ Leipzig, Inst Pathol, D-04103 Leipzig, Germany; Med Univ Lubeck, Inst Canc Epidemiol, D-23564 Lubeck, Germany; Univ Leipzig, Dept Abdominal Vasc & Transplantat Surg 2, D-04103 Leipzig, Germany	Leipzig University; University of Lubeck; Leipzig University	Tannapfel, A (corresponding author), Univ Leipzig, Inst Pathol, Liebigstr 26, D-04103 Leipzig, Germany.		Katalinic, Alexander/D-2512-2010	Katalinic, Alexander/0000-0003-0490-1554				[Anonymous], 1997, J CLIN PATHOL; Baur AS, 1999, BLOOD, V94, P1773, DOI 10.1182/blood.V94.5.1773.417a12_1773_1781; Baylin SB, 2001, J NATL CANCER I, V93, P664, DOI 10.1093/jnci/93.9.664; Bradley G, 2001, ONCOGENE, V20, P654, DOI 10.1038/sj.onc.1204131; Chaubert P, 1997, HEPATOLOGY, V25, P1376, DOI 10.1002/hep.510250613; Dai CY, 2000, GASTROENTEROLOGY, V119, P929, DOI 10.1053/gast.2000.17952; de Toledo SM, 2000, ONCOGENE, V19, P6185, DOI 10.1038/sj.onc.1204020; Esteller M, 2000, CANCER RES, V60, P129; Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700; HAMILTON SR, 2000, PATHOLOGY GENETICS, P173; Issa JPJ, 2001, CANCER RES, V61, P3573; Jackson PE, 2001, CANCER RES, V61, P33; Kaneto H, 2001, GUT, V48, P372, DOI 10.1136/gut.48.3.372; Kang GH, 2001, CANCER RES, V61, P2847; Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359; Matsuda Y, 1999, GASTROENTEROLOGY, V116, P394, DOI 10.1016/S0016-5085(99)70137-X; Orlow I, 1999, J NATL CANCER I, V91, P73, DOI 10.1093/jnci/91.1.73; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Schraml P, 2001, AM J PATHOL, V158, P593, DOI 10.1016/S0002-9440(10)64001-1; Tannapfel A, 2000, GUT, V47, P721, DOI 10.1136/gut.47.5.721; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154	21	108	113	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					7104	7109		10.1038/sj.onc.1204902	http://dx.doi.org/10.1038/sj.onc.1204902			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704835				2022-12-17	WOS:000171739300014
J	Dang, DT; Mahatan, CS; Dang, LH; Agboola, IA; Yang, VW				Dang, DT; Mahatan, CS; Dang, LH; Agboola, IA; Yang, VW			Expression of the gut-enriched Kruppel-like factor (Kruppel-like factor 4) gene in the human colon cancer cell line RKO is dependent on CDX2	ONCOGENE			English	Article						gut-enriched Kruppel-like factor; Kruppel-like factor 4; colon cancer; CDX2; adenomatous polyposis coli; dominant negative	MULTIPLE INTESTINAL NEOPLASIA; HOMEOBOX GENE; EPITHELIAL-CELLS; COLORECTAL-CANCER; BETA-CATENIN; EMBRYONIC INTESTINE; PROMOTER ACTIVITY; CYCLIN D1; DIFFERENTIATION; IDENTIFICATION	Gut-enriched Kruppel-like factor (GKLF or KLF4) is a zinc finger-containing, epithelial-specific transcription factor, that functions as a suppressor of cell proliferation. We previously showed that GKLF expression is decreased in intestinal and colonic adenomas, respectively, from multiple intestinal neoplasia (Min) mice and familial adenomatous polyposis (FAP) patients. This study shows that GKLF is induced upon activation of the adenomatous polyposis coli (APC) gene. However, among several human colon cancer cell lines surveyed, expression of GKLF is lowest in RKO, a line with wildtype APC and beta -catenin. RKO contains a mutated allele that encodes the putative tumor suppressor homeodomain protein, CDX2. We show that wild-type CDX2 activates the GKLF promoter and that the mutated CDX2 has a dominant negative effect on wild-type function. Our results may help explain the exceedingly low levels of GKLF expression detected in this cell line, which may in turn contribute to the tumor phenotype.	Johns Hopkins Univ, Sch Med, Div Gastroenterol, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Yang, VW (corresponding author), Johns Hopkins Univ, Sch Med, Div Gastroenterol, Dept Med, 720 Rutland Ave,Ross 918, Baltimore, MD 21205 USA.				NCI NIH HHS [R01 CA084197-02, R01 CA084197, CA84197] Funding Source: Medline; NIDDK NIH HHS [F32 DK010020, DK10020, R01 DK052230-04, DK52230, R01 DK052230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK010020, R01DK052230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Dang DT, 2000, FEBS LETT, V476, P203, DOI 10.1016/S0014-5793(00)01727-0; Duluc I, 1997, J CELL SCI, V110, P1317; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; EE HC, 1995, AM J PATHOL, V147, P586; Fang RX, 2000, GASTROENTEROLOGY, V118, P115, DOI 10.1016/S0016-5085(00)70420-3; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; JAMES R, 1994, J BIOL CHEM, V269, P15229; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lickert H, 2000, DEVELOPMENT, V127, P3805; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Mahatan CS, 1999, NUCLEIC ACIDS RES, V27, P4562, DOI 10.1093/nar/27.23.4562; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Polakis P, 2000, GENE DEV, V14, P1837; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Tamai Y, 1999, CANCER RES, V59, P2965; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Ton-That H, 1997, FEBS LETT, V419, P239, DOI 10.1016/S0014-5793(97)01465-8; Wicking C, 1998, ONCOGENE, V17, P657, DOI 10.1038/sj.onc.1201971; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200	45	108	117	1	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4884	4890		10.1038/sj.onc.1204645	http://dx.doi.org/10.1038/sj.onc.1204645			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521200	Green Accepted			2022-12-17	WOS:000170271800013
J	Javelaud, D; Besancon, F				Javelaud, D; Besancon, F			NF-kappa B activation results in rapid inactivation of JNK in TNF alpha-treated Ewing sarcoma cells: a mechanism for the anti-apoptotic effect of NF-kappa B	ONCOGENE			English	Article						NF-kappa B; JNK; apoptosis; TNF alpha; Ewing sarcoma	TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE ACTIVATION; C-JUN; TERMINAL KINASE; RECEPTOR SUPERFAMILY; MAP KINASES; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; DEATH; INDUCTION	We recently reported that inhibition of NF-kappaB activation as a consequence of the overexpression of a degradation-resistant form of I kappa -B alpha [I kappaB alpha (A32/36)] sensitized Ewing sarcoma cells to TNF alpha -induced killing. The c-Jun N-terminal kinases (JNK) have been shown to participate in death signaling triggered by certain stimuli and are activated by TNF. To obtain insight into the mechanism of the anti-apoptotic effect of NF-kappaB, we compared the profiles of JNK activation by TNF alpha in control cells and in cells in which NF-kappaB activation was impaired. We show here that JNK activation was transient in control cells but remained elevated in I kappa -B alpha (A32/36)-expressing cells. NF-kappaB repressed specifically the JNK pathway, since the kinetics of activation of the other TNF alpha -activated-MAP kinase p38 were identical in both cells, Prolongation of JNK activation in I kappaB alpha (A32/36)-expressing cells was not inhibited by the broad spectrum caspase inhibitor Z-VAD-FMK and thus was not the consequence of caspase activation, Pretreatment of control cells with the phosphatase inhibitor vanadate greatly prolonged JNK activation by TNF alpha and resulted in induction of apoptosis by this cytokine. Moreover, overexpression of a dominant-negative mutant of JNK1 decreased TNF alpha -induced apoptosis in cells expressing the super repressor of NF-kappaB, indicating that the sustained activation of JNK1 participated in death signaling triggered by TNF alpha, Our results provide evidence that the repression of JNK activation by NF-kappaB participates in the anti-apoptotic effect of this transcription factor in TNF alpha -treated Ewing sarcoma cells.	Inst Curie, INSERM, U365, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Besancon, F (corresponding author), Inst Curie, INSERM, U365, 26 Rue Ulm, F-75248 Paris 05, France.		Javelaud, Delphine/B-1129-2019	Javelaud, Delphine/0000-0002-7674-7739				Aggarwal BB, 2000, BIOCHEM PHARMACOL, V60, P1033, DOI 10.1016/S0006-2952(00)00393-2; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Patel R, 1998, J CELL SCI, V111, P2247; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VAN AD, 1996, SCIENCE, V274, P787; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yeh WC, 1999, IMMUNOL REV, V169, P283, DOI 10.1111/j.1600-065X.1999.tb01323.x; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	46	108	112	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4365	4372		10.1038/sj.onc.1204570	http://dx.doi.org/10.1038/sj.onc.1204570			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466617				2022-12-17	WOS:000169912600010
J	Annis, MG; Zamzami, N; Zhu, WJ; Penn, LZ; Kroemer, G; Leber, B; Andrews, DW				Annis, MG; Zamzami, N; Zhu, WJ; Penn, LZ; Kroemer, G; Leber, B; Andrews, DW			Endoplasmic reticulum localized Bcl-2 prevents apoptosis when redistribution of cytochrome c is a late event	ONCOGENE			English	Article						apoptosis; Bax; Bcl-2; cytochrome c; endoplasmic reticulum	MITOCHONDRIAL PERMEABILITY TRANSITION; CELL-DEATH; CASPASE ACTIVATION; FAMILY PROTEINS; RELEASE; COMPLEX; MYC; DNA; PRO-CASPASE-3; SUPPRESSION	The disruption of mitochondrial function is a key component of apoptosis in most cell types. Localization of Bcl-2 to the outer mitochondrial and endoplasmic reticulum membranes is consistent with a role in the inhibition of many forms of apoptosis, In Rat-1 cells, a Bcl-2 mutant targeted exclusively to the endoplasmic reticulum (Bcl-cb5) was effective at inhibiting apoptosis induced by serum starvation/myc, or ceramide but not apoptosis induced by etoposide, The former conditions cause a decrease in mitochondrial transmembrane potential (Delta psi (m)) as an early event that precedes the release of cytochrome c from mitochondria, By contrast, when cells are exposed to etoposide, a situation in which cytochrome c release and membrane localization of the pro-apoptotic protein Bax precede loss of Delta psi (m), wild type Bcl-2 but not Bcl-cb5 prevents apoptosis, Therefore, Bcl-2 functions in spatially distinct pathways of apoptosis distinguished by the order of cytochrome c release and loss of Delta psi (m).	McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Inst Gustave Roussy, CNRS UMR1599, F-94805 Villejuif, France; McMaster Univ, Dept Med & Lab Med, Hamilton, ON L8N 3Z5, Canada	McMaster University; University of Toronto; UNICANCER; Gustave Roussy; McMaster University	Andrews, DW (corresponding author), McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada.		KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; Leber, Brian/0000-0001-5502-1480; Andrews, David/0000-0002-9266-7157; Penn, Linda/0000-0001-8133-5459; Annis, Matthew/0000-0002-8776-004X				Adachi S, 1998, J BIOL CHEM, V273, P19892, DOI 10.1074/jbc.273.31.19892; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BOYD JM, 1995, ONCOGENE, V11, P1921; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; JANIAK F, 1994, J BIOL CHEM, V269, P9842; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lee ST, 1999, ONCOGENE, V18, P3520, DOI 10.1038/sj.onc.1202716; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scorrano L, 1999, J BIOL CHEM, V274, P24657, DOI 10.1074/jbc.274.35.24657; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Xanthoudakis S, 1999, EMBO J, V18, P2049, DOI 10.1093/emboj/18.8.2049; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	41	108	109	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					1939	1952		10.1038/sj.onc.1204288	http://dx.doi.org/10.1038/sj.onc.1204288			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360178				2022-12-17	WOS:000168043800002
J	Ruediger, R; Pham, HT; Walter, G				Ruediger, R; Pham, HT; Walter, G			Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene	ONCOGENE			English	Article						PP2A; A beta subunit; mutation; lung and colon cancer; tumor suppressor	ADENOVIRUS E4ORF4 PROTEIN; SERINE THREONINE PHOSPHATASES; REGULATORY B-SUBUNITS; PP2A CORE ENZYME; CATALYTIC SUBUNIT; MOLECULAR-CLONING; TUMOR-ANTIGENS; PPP2R1B GENE; SEQUENCE-ANALYSIS; DNA-REPLICATION	Protein phosphatase 2A (PP2A) consists of three subunits, A, B and C, The A and B subunits have regulatory functions while C is the catalytic subunit, PP2A core enzyme is composed of subunits A and C, and the holoenzyme of subunits A, B and C, All subunits exist as multiple isoforms or splice variants. The A subunit exists as two isoforms, A alpha and A beta. Here we report about the properties of eight A beta mutants, which were found in human lung and colon cancer. These mutants were reconstructed by site-directed mutagenesis and assayed for their ability to bind B and C subunits, Two mutants showed decreased binding of PR72, a member of the B " family of B subunits, but normal C subunit binding; two mutants exhibited decreased binding of the C subunit and of B " /PR72; and one mutant showed increased binding of both the C subunit and B " /PR72, Of three mutants that behaved like the wildtype A beta subunit, one is a polymorphic variant and another one is altered outside the binding region for B and C subunits, Importantly, we also found that the wildtype A alpha and A beta isoforms, although 85% identical, are remarkably different in their ability to bind B and C subunits, Our findings may have important implications in regard to the role of PP2A as a tumor suppressor.	Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Walter, G (corresponding author), Univ Calif San Diego, Dept Pathol, 0612,9500 Gilman Dr, La Jolla, CA 92093 USA.				NCI NIH HHS [CA-36111] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036111] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Andjelkovic N, 1996, EMBO J, V15, P7156, DOI 10.1002/j.1460-2075.1996.tb01107.x; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOSCH M, 1995, EUR J BIOCHEM, V230, P1037, DOI 10.1111/j.1432-1033.1995.tb20653.x; Brewis N, 2000, AM J PHYSIOL-HEART C, V279, pH1307, DOI 10.1152/ajpheart.2000.279.3.H1307; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Campbell IG, 1999, ONCOGENE, V18, P6367, DOI 10.1038/sj.onc.1203070; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHEN SC, 1989, J BIOL CHEM, V264, P7267; COHEN P, 1989, J BIOL CHEM, V264, P21435; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; Deng XM, 1998, J BIOL CHEM, V273, P34157, DOI 10.1074/jbc.273.51.34157; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; Hong YL, 2000, BIOCHEM BIOPH RES CO, V272, P84, DOI 10.1006/bbrc.2000.2733; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1992, J BIOL CHEM, V267, P21864; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KITAGAWA Y, 1988, BIOCHIM BIOPHYS ACTA, V951, P123, DOI 10.1016/0167-4781(88)90032-2; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Lebrin F, 1999, MOL CELL BIOCHEM, V191, P207, DOI 10.1023/A:1006888228156; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Marcellus RC, 2000, J VIROL, V74, P7869, DOI 10.1128/JVI.74.17.7869-7877.2000; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nagase T, 1997, J BIOCHEM, V122, P178; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; Ruediger R, 2001, ONCOGENE, V20, P10, DOI 10.1038/sj.onc.1204059; Ruediger R, 1997, VIROLOGY, V238, P432, DOI 10.1006/viro.1997.8873; Ruediger R, 1999, J VIROL, V73, P839, DOI 10.1128/JVI.73.1.839-842.1999; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shtrichman R, 2000, ONCOGENE, V19, P3757, DOI 10.1038/sj.onc.1203705; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; SILVA OBD, 1987, FEBS LETT, V221, P415, DOI 10.1016/0014-5793(87)80966-3; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; Strack S, 1999, FEBS LETT, V460, P462, DOI 10.1016/S0014-5793(99)01377-0; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Takagi Y, 2000, GUT, V47, P268, DOI 10.1136/gut.47.2.268; Tanabe O, 1996, FEBS LETT, V379, P107, DOI 10.1016/0014-5793(95)01500-0; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Yan Z, 2000, MOL CELL BIOL, V20, P1021, DOI 10.1128/MCB.20.3.1021-1029.2000; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023	65	108	115	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2001	20	15					1892	1899		10.1038/sj.onc.1204279	http://dx.doi.org/10.1038/sj.onc.1204279			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313937				2022-12-17	WOS:000167908400010
J	Eymin, B; Gazzeri, S; Brambilla, C; Brambilla, E				Eymin, B; Gazzeri, S; Brambilla, C; Brambilla, E			Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma	ONCOGENE			English	Article						carcinogenesis; cell cycle; E2F1; expression; lung tumour	S-PHASE ENTRY; ACTIVE TRANSCRIPTIONAL REPRESSION; NUCLEAR ACCUMULATION; P53; GENE; RETINOBLASTOMA; PROTEIN; DEGRADATION; APOPTOSIS; P16(INK4A)	The transcription factor E2F1 is a keg component of cell cycle that acts to transactivate genes required for S phase entry. Thus, it plays an important role in cellular proliferation, oncogenesis and differentiation. In order to investigate its potential implication in human lung carcinogenesis, we studied E2F1 protein expression by Western blotting and immunohistochemistry in a series of 58 human lung tumours of all histological types. We showed that E2F1 product was overexpressed in 92% (24/26) of small cell lung carcinoma (SCLC) and in 50% (5/10) of large cell neuroendocrine carcinoma (LCNEC) whereas it was undetectable in 90% (10/11) of adenocarcinoma and 82% (9/11) of squamous carcinoma when compared to corresponding normal lung. No amplification was found but an increase in E2F1 mRNA expression was detected in 75% (18/24) of SCLC overexpressing E2F1 product. In these tumours and in contrast with NSCLC, upregulation of E2F1 product was associated with its nuclear accumulation and with overexpression of several of its target-genes. Moreover, E2F1 overexpression in NE lung tumours was significantly associated with a high K167 index (P < 0.0001) as well as a Bcl-2:Bax ratio >1 (P<0.001), Overall, these results demonstrate a distinct pattern of E2F1 expression in human lung tumours and suggest that its deregulation could be involved in the carcinogenesis of SCLC.	Inst Albert Bonniot, Grp Rech Canc Poumon, EA 2021, Equipe INSERM 9924, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Brambilla, E (corresponding author), Inst Albert Bonniot, Grp Rech Canc Poumon, EA 2021, Equipe INSERM 9924, F-38706 La Tronche, France.		Eymin, Beatrice/M-1962-2013; Brambilla, Elisabeth MP/L-8796-2013; gazzeri, sylvie/M-1961-2013; gazzeri, sylvie/U-4669-2019; eymin, beatrice/U-4670-2019	Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; gazzeri, sylvie/0000-0001-5817-1839; eymin, beatrice/0000-0002-7311-3810				Allen KE, 1997, J CELL SCI, V110, P2819; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BRAMBILLA E, 1993, AM J PATHOL, V143, P199; Brambilla E, 1996, AM J PATHOL, V149, P1941; BRAMBILLA E, 1997, J PATHOL, V188, P351; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CHIBA I, 1990, ONCOGENE, V5, P1603; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; delaLuna S, 1996, J CELL SCI, V109, P2443; DeMuth JP, 1998, AM J RESP CELL MOL, V19, P18, DOI 10.1165/ajrcmb.19.1.3077; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GAZZERI S, 1994, INT J CANCER, V58, P24, DOI 10.1002/ijc.2910580106; Gazzeri S, 1998, CANCER RES, V58, P3926; Gazzeri S, 1998, ONCOGENE, V16, P497, DOI 10.1038/sj.onc.1201559; GERDES J, 1984, J IMMUNOL, V133, P1710; Gouyer V, 1998, AM J RESP CELL MOL, V18, P188, DOI 10.1165/ajrcmb.18.2.3008; Harper JW, 1999, NAT CELL BIOL, V1, pE5, DOI 10.1038/8952; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KELLEY MJ, 1997, J NATL CANCER I, V87, P756; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Travis W. D., 1999, WHO INT HISTOLOGICAL; Vandel L, 1999, EMBO J, V18, P4280, DOI 10.1093/emboj/18.15.4280; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Volm M, 1998, INT J CANCER, V79, P294, DOI 10.1002/(SICI)1097-0215(19980619)79:3<294::AID-IJC15>3.3.CO;2-0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xu HJ, 1996, CLIN CANCER RES, V2, P1169; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yang HL, 2000, CLIN CANCER RES, V6, P1579; Yatabe Y, 1998, CANCER RES, V58, P1042; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	55	108	113	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 29	2001	20	14					1678	1687		10.1038/sj.onc.1204242	http://dx.doi.org/10.1038/sj.onc.1204242			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313916	Green Submitted			2022-12-17	WOS:000167750900002
J	Ivanov, VN; Ronai, Z				Ivanov, VN; Ronai, Z			p38 protects human melanoma cells from UV-induced apoptosis through down-regulation of NF-kappa B activity and Fas expression	ONCOGENE			English	Article						p38; stress kinases; NF-kappa B; UV-irradiation; radiation resistance; TNF	NECROSIS-FACTOR-ALPHA; TERMINAL KINASE JNK; SIGNAL-TRANSDUCTION; LIGAND EXPRESSION; MAP KINASE; T-CELLS; TRANSCRIPTIONAL REGULATION; ACTIVATION; INHIBITION; PROMOTER	Identifying mechanisms that underlie the resistance of human melanoma to radiation and chemotherapy is expected to assist in developing new strategies for the treatment of this tumor type. We recently demonstrated that through up-regulation of TNF alpha, ATF2 increases the resistance of late stage melanoma cells to apoptosis induced by UV-irradiation, In elucidating the role of ATF2 kinases, we now demonstrate that ASK1/MKK6/p38 elicits suppression of Fas expression. ASK1/p38 downregulates the expression of a Fas via NF-kappa B/SP1 site on the Fas promoter. Deletion or mutation of NF-kappa B/SP1 within the Fas promoter abrogates p38 effect. ASK1/p38 silences the Fas promoter by inhibition of I kappa B alpha phosphorylation - thereby limiting NF-kappa B activity. Forced expression of a dominant negative form of p38 (p38-ASP) or treatment with p38 pharmacological inhibitor, SB203580, increases NF-kappa B activity, Fas expression and the levels of UVC-induced apoptosis in late stage melanoma cells. Inhibition of p38 activity also restored NF-kappa B activity and Fas expression in early-phase melanoma cells, suggesting that p38 elicited suppression of Fas expression is not restricted to late phase melanoma, Identifying p38-mediated down-regulation of Fas expression illustrates a novel regulatory pathway by which ASK1/MKK6/p38 alters the degree and nature of the UV-induced apoptosis of melanoma cells.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA.		Ivanov, Vladimir N/A-3081-2008	Ivanov, Vladimir N/0000-0003-3091-9774; RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R29CA051995, R01CA051995] Funding Source: NIH RePORTER; NCI NIH HHS [CA51995] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1996, J BIOL CHEM, V271, P23304, DOI 10.1074/jbc.271.38.23304; Alpert D, 1999, J BIOL CHEM, V274, P22176, DOI 10.1074/jbc.274.32.22176; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Birkenkamp KU, 1999, LEUKEMIA, V13, P1037, DOI 10.1038/sj.leu.2401447; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Cain BS, 1999, J SURG RES, V83, P7, DOI 10.1006/jsre.1998.5548; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Djavaheri-Mergny M, 1999, BIOCHEM J, V338, P607, DOI 10.1042/0264-6021:3380607; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Hsu SC, 1999, EUR J IMMUNOL, V29, P2948, DOI 10.1002/(SICI)1521-4141(199909)29:09<2948::AID-IMMU2948>3.0.CO;2-0; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Itoh S, 1999, J IMMUNOL, V162, P7434; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; Ivanov VN, 2000, ONCOGENE, V19, P933, DOI 10.1038/sj.onc.1203415; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; McClure RF, 1999, J BIOL CHEM, V274, P7756, DOI 10.1074/jbc.274.12.7756; Meier F., 1998, FRONT BIOSCI J VIS L, V3, P1005, DOI [10.2741/a341, DOI 10.2741/A341]; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Nguyen LT, 1999, IMMUNITY, V11, P379, DOI 10.1016/S1074-7613(00)80113-2; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NOGUCHI K, 1999, J BIOL CHEM, V274, P32850; Ozes ON, 1999, NATURE, V401, P82; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; Schafer PH, 1999, J IMMUNOL, V162, P659; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Shimizu H, 1999, J INVEST DERMATOL, V112, P769, DOI 10.1046/j.1523-1747.1999.00582.x; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; van Hogerlinden M, 1999, CANCER RES, V59, P3299; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	60	108	117	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					3003	3012		10.1038/sj.onc.1203602	http://dx.doi.org/10.1038/sj.onc.1203602			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871852	Green Published			2022-12-17	WOS:000087581400007
J	De Rosa, M; Fasano, C; Panariello, L; Scarano, MI; Belli, G; Iannelli, A; Ciciliano, F; Izzo, P				De Rosa, M; Fasano, C; Panariello, L; Scarano, MI; Belli, G; Iannelli, A; Ciciliano, F; Izzo, P			Evidence for a recessive inheritance of Turcot's syndrome caused by compound heterozygous mutations within the PMS2 gene	ONCOGENE			English	Article						Turcot syndrome; PMS2 gene; brain and colorectal tumors; microsatellite instability (MIN)	FAMILIAL ADENOMATOUS POLYPOSIS; NONPOLYPOSIS COLORECTAL-CANCER; AUTOSOMAL-DOMINANT INHERITANCE; MISMATCH REPAIR; COLON-CANCER; MUTATOR PHENOTYPE; HOMOLOG; INSTABILITY; TISSUES; TUMORS	Turcot's syndrome is a genetic disease characterized by the concurrence of primary brain tumors and colon cancers and/or multiple colorectal adenomas. We report a Turcot family with no parental consanguinity, in which two affected sisters, with no history of tumors in their parents, died of a brain tumor and of a colorectal tumor, respectively, at a very early age. The proband had a severe microsatellite instability (MIN) phenotype in both tumor and normal colon mucosa, and mutations in the TGF beta-RII and APC genes in the colorectal tumor. We identified two germline mutations within the PMS2 gene: a G deletion (1221delG) in exon 11 and a four-base-pair deletion (2361delCTTC) in exon 14, both of which were inherited from the patient's unaffected parents. These results represent the first evidence that two germline frameshift mutations in PMS2, an MMR gene which is only rarely involved in HNPCC, are not pathogenic per se, but become so when occurring together in a compound heterozygote, The compound heterozygosity for two mutations in the PMS2 gene has implications for the role of protein PMS2 in the mismatch repair mechanism, as well as for the presymptomatic molecular diagnosis of at-risk family members. Furthermore, our data support and enlarge the notion that high DNA instability in normal tissues might trigger the development of cancer in this syndrome.	Univ Naples Federico II, CEINGE Biotecnol Avanzate, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy	CEINGE Biotecnologie Avanzate; University of Naples Federico II	Izzo, P (corresponding author), Univ Naples Federico II, CEINGE Biotecnol Avanzate, Dipartimento Biochim & Biotecnol Med, Via S Pansini 5, I-80131 Naples, Italy.		Fasano, Carlo/R-2913-2016; Iannelli, Antonio/E-6521-2012; De Rosa, Marina/I-5954-2012; Fasano, Carlo/Y-3954-2019	Fasano, Carlo/0000-0002-6368-1398; Fasano, Carlo/0000-0002-6368-1398; Izzo, Paola/0000-0003-1549-0615				BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUDOWLE B, 1991, AM J HUM GENET, V48, P137; CRAIL H W, 1949, U S Nav Med Bull, V49, P123; Dietmaier W, 1997, CANCER RES, V57, P4749; DUPUIS MJM, 1995, NEW ENGL J MED, V332, P1518; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; ITOH H, 1993, INT J COLORECTAL DIS, V8, P87, DOI 10.1007/BF00299334; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEWIS JH, 1983, CANCER, V51, P524, DOI 10.1002/1097-0142(19830201)51:3<524::AID-CNCR2820510326>3.0.CO;2-I; MARCOWITZ S, 1995, SCIENCE, V268, P1336; MASTRONARDI L, 1991, NEUROSURGERY, V28, P449, DOI 10.1227/00006123-199103000-00021; Matsui T, 1998, DIS COLON RECTUM, V41, P797, DOI 10.1007/BF02236273; Miyaki M, 1997, ONCOGENE, V15, P2877, DOI 10.1038/sj.onc.1201668; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; MORI T, 1994, GENE CHROMOSOME CANC, V9, P168, DOI 10.1002/gcc.2870090304; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; Nicolaides NC, 1998, MOL CELL BIOL, V18, P1635, DOI 10.1128/MCB.18.3.1635; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; Panariello L, 1998, Hum Mutat, V12, P216; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Perucho M, 1996, BIOL CHEM, V377, P675; Scarano M I, 1999, Hum Mutat, V13, P256; Scarano MI, 1997, HUM MUTAT, V9, P191, DOI 10.1002/(SICI)1098-1004(1997)9:2<191::AID-HUMU16>3.0.CO;2-Y; TOPS CMJ, 1992, AM J MED GENET, V43, P888, DOI 10.1002/ajmg.1320430528; TURCOT J, 1959, Dis Colon Rectum, V2, P465, DOI 10.1007/BF02616938	28	108	114	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1719	1723		10.1038/sj.onc.1203447	http://dx.doi.org/10.1038/sj.onc.1203447			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763829				2022-12-17	WOS:000086083800012
J	Ahn, J; Murphy, M; Kratowicz, S; Wang, A; Levine, AJ; George, DL				Ahn, J; Murphy, M; Kratowicz, S; Wang, A; Levine, AJ; George, DL			Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction	ONCOGENE			English	Article						p53; repression; stathmin; FKBP25	TUMOR SUPPRESSION; EXPRESSION; PROTEIN; MDM2; APOPTOSIS; CELLS; PHOSPHORYLATION; IDENTIFICATION; PHOSPHOPROTEIN; DYNAMICS	The p53 tumor suppressor protein can function as an activator and a repressor of gene transcription. Currently, the mechanism of transcriptional repression by p53 is poorly understood. To aid in clarifying this mechanism, we carried out studies designed to identify specific target genes that are down-regulated following p53 induction. Among the negative p53-response genes revealed by our screening protocols are those encoding stathmin (Op18), a tubulin-associated protein implicated in cell signaling pathways, and an FK506/rapamycin-binding protein, FKBP25. Stathmin and FKBP25 exhibit decreased expression in both human and murine immortalized and transformed cell lines following induction of wild-type p53 by several stimuli that result in DNA damage. Candidate p53-repressed genes such as these provide the necessary markers to delineate the mechanism and biological consequences of transcriptional repression mediated by p53.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Fox Chase Canc Ctr, Dept Pharmacol, Philadelphia, PA 19111 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	University of Pennsylvania; Fox Chase Cancer Center; Princeton University	George, DL (corresponding author), Univ Penn, Sch Med, Dept Genet, 713 Stellar Chance Bldg,422 Curie Blvd, Philadelphia, PA 19104 USA.			Murphy, Maureen/0000-0001-7644-7296	NATIONAL CANCER INSTITUTE [P01CA041086] Funding Source: NIH RePORTER; NCI NIH HHS [CA466741, CA41086] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Bieche I, 1998, BRIT J CANCER, V78, P701, DOI 10.1038/bjc.1998.565; BRATTSAND G, 1993, LEUKEMIA, V7, P569; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Landers JE, 1997, CANCER RES, V57, P3562; Leach SD, 1998, CANCER RES, V58, P3231; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Olmsted JB, 1991, CURR OPIN CELL BIOL, V3, P52, DOI 10.1016/0955-0674(91)90165-U; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang CC, 1998, ONCOGENE, V16, P1617, DOI 10.1038/sj.onc.1201658	34	108	109	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5954	5958		10.1038/sj.onc.1202986	http://dx.doi.org/10.1038/sj.onc.1202986			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557083				2022-12-17	WOS:000083270700013
J	Higuchi, M; Proske, RJ; Yeh, ETH				Higuchi, M; Proske, RJ; Yeh, ETH			Inhibition of mitochondrial respiratory chain complex I by TNF results in cytochrome c release, membrane permeability transition, and apoptosis	ONCOGENE			English	Article						reactive oxygen species; caspases; apoptosis; necrosis; cytochrome	TUMOR-NECROSIS-FACTOR; MANGANOUS SUPEROXIDE-DISMUTASE; FAS-MEDIATED APOPTOSIS; CYTO-TOXICITY; ELECTRON-TRANSPORT; CELL-LINES; GENERATION; PROTEASE; BCL-2; INDUCTION	Mitochondria have been shown to play a key role in apoptosis induction. However, the sequence of changes that occur in the mitochondria in the initial step of apoptosis has not been clearly elucidated, Here, we showed that mitochondrial respiratory chain (MRC) complex I was inhibited during the early phase of TNF- or serum withdrawal apoptosis, The importance of complex I inhibition in apoptosis is also supported by the observation that rotenone, an inhibitor of complex I but not that of other complexes, could induce apoptosis in a manner comparable to TNF, We hypothesized that inhibition of complex I could affect electron flow through other complexes leading to cytochrome c release by an antioxidant-sensitive pathway and caspase 3 activation followed by the induction of membrane permeability transition (MPT). This hypothesis is supported by the following observations: (1) TNF and rotenone induced MPT and cytochrome c release; (2) TNF-induced complex I inhibition was observed prior to cytochrome c release and MPT induction; (3) MPT induction was inhibited by a caspase 3 inhibitor, z-DEVD-CH2F, and an antioxidant pyrrolidine dithiocarbamate (PDTC), whereas cytochrome c release was only inhibited by PDTC, Thus, these results suggest that MRC complex I plays a key role in apoptosis signalings.	Univ Texas, Hlth Sci Ctr, Inst Mol Med Prevent Human Dis, Res Ctr Cardiovasc Dis, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Div Mol Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Higuchi, M (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Mol Med Prevent Human Dis, Res Ctr Cardiovasc Dis, 2121 W Holcombe, Houston, TX 77030 USA.							Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; GABAI VL, 1992, TISSUE CELL, V24, P171, DOI 10.1016/0040-8166(92)90090-T; GRANGER DL, 1982, J CELL BIOL, V95, P527, DOI 10.1083/jcb.95.2.527; Guidarelli A, 1996, BIOCHEM J, V317, P371, DOI 10.1042/bj3170371; HARTLEY A, 1994, J NEUROCHEM, V63, P1987; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; HIGUCHI M, 1995, J IMMUNOL METHODS, V178, P173, DOI 10.1016/0022-1759(94)00254-T; HIGUCHI M, 1992, J IMMUNOTHER, V12, P41, DOI 10.1097/00002371-199207000-00005; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KSENZENKO M, 1983, FEBS LETT, V155, P19, DOI 10.1016/0014-5793(83)80200-2; KULL FC, 1981, CANCER RES, V41, P4885; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MACHO A, 1995, BLOOD, V86, P2481; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; PASTORINO JG, 1995, ARCH BIOCHEM BIOPHYS, V318, P175, DOI 10.1006/abbi.1995.1218; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; RICHTER C, 1993, FEBS LETT, V325, P104, DOI 10.1016/0014-5793(93)81423-W; RUTKA JT, 1988, INT J CANCER, V41, P573, DOI 10.1002/ijc.2910410417; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; SOUSSI B, 1990, BIOCHEM J, V265, P227, DOI 10.1042/bj2650227; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Tang DG, 1998, BIOCHEM BIOPH RES CO, V242, P380, DOI 10.1006/bbrc.1997.7969; TAYLOR DE, 1995, ARCH BIOCHEM BIOPHYS, V316, P70, DOI 10.1006/abbi.1995.1011; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	42	108	111	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2515	2524		10.1038/sj.onc.1202485	http://dx.doi.org/10.1038/sj.onc.1202485			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824162				2022-12-17	WOS:000076927300011
J	Okada, H; Watanabe, T; Niki, M; Takano, H; Chiba, N; Yanai, N; Tani, K; Hibino, H; Asano, S; Mucenski, ML; Ito, Y; Noda, T; Satake, M				Okada, H; Watanabe, T; Niki, M; Takano, H; Chiba, N; Yanai, N; Tani, K; Hibino, H; Asano, S; Mucenski, ML; Ito, Y; Noda, T; Satake, M			AML1(-/-) embryos do not express certain hematopoiesis-related gene transcripts including those of the PU.1 gene	ONCOGENE			English	Article						transcription factor; hematopoiesis; AML1; PEBP2 beta/CBF beta; PU.1; RT-PCR; gene targeting	ACUTE MYELOID-LEUKEMIA; CORE-BINDING-FACTOR; PROTEIN-PROTEIN INTERACTIONS; ACUTE LYMPHOBLASTIC-LEUKEMIA; FETAL LIVER HEMATOPOIESIS; FACTOR-RECEPTOR PROMOTER; DNA-BINDING; AML1 GENE; FUSION TRANSCRIPT; C-MYB	The AML1 and PEBP2 beta/CBF beta genes encode the DNA-binding and non-binding subunits, respectively, of the heterodimeric transcription factor, PEBP2/CBF. Targeting each gene results in an almost identical phenotype, namely the complete lack of definitive hematopoiesis in the fetal liver on embryonic day 11.5 (E11.5). We examined and compared the expression levels of various hematopoiesis-related genes in wild type embryos and in embryos mutated for AML1 or PEBP2 beta/CBF beta. The RNAs were prepared from the yolk sacs of E9.5 embryos, from the aorta-gonad- mesonephros regions of E11.5 embryos and from the livers of E11.5 embryos and RT-PCR was performed to detect various gene transcripts. Transcripts were detected for most of the hematopoiesis-related genes that encode transcription factors, cytokines and cytokine receptors, even in tissues from homozygously targeted embryos. On the other hand, PU.1 transcripts were never detected in any tissue of AML1(-/-) or PEBP2 beta/CBF beta(-/-) embryos. In addition, transcripts for the Vav, flk-2/flt-3, M-CSF receptor, G-CSF receptor and c-Myb genes were not detected in certain tissues of the (-/-) embryos. The results suggest that the expression of a particular set of hematopoiesis-related genes is closely correlated with the PEBP2/CBF function.	Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Toshima Ku, Tokyo 170, Japan; Univ Tokyo, Inst Med Sci, Dept Hematol Oncol, Minato Ku, Tokyo 108, Japan; Human Genome Sci Inc, Rockville, MD 20850 USA; Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 606, Japan	Tohoku University; Tohoku University; Japanese Foundation for Cancer Research; University of Tokyo; GlaxoSmithKline; Human Genome Sciences Inc; Kyoto University	Satake, M (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Immunol, Aoba Ku, Seiryo Machi, Sendai, Miyagi 9808575, Japan.							BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Chen HM, 1996, J BIOL CHEM, V271, P15743, DOI 10.1074/jbc.271.26.15743; CHEN HM, 1995, ONCOGENE, V11, P1549; ERICKSON P, 1992, BLOOD, V80, P1825; Frank R, 1995, ONCOGENE, V11, P2667; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KOOPMAN P, 1989, NATURE, V342, P940, DOI 10.1038/342940a0; LEIDEN JM, 1993, ANNU REV IMMUNOL, V11, P539, DOI 10.1146/annurev.iy.11.040193.002543; MACKAREHTSCHIAN K, 1995, IMMUNITY, V3, P147, DOI 10.1016/1074-7613(95)90167-1; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCCLANAHAN T, 1993, BLOOD, V81, P2903; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Mukouyama YS, 1998, IMMUNITY, V8, P105, DOI 10.1016/S1074-7613(00)80463-X; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; Nakai S, 1995, GENE DEV, V9, P3109, DOI 10.1101/gad.9.24.3109; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; Nimer S, 1996, BLOOD, V88, P66, DOI 10.1182/blood.V88.1.66.bloodjournal88166; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Ogilvy S, 1998, BLOOD, V91, P419, DOI 10.1182/blood.V91.2.419.419_419_430; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; Takahashi S, 1997, J BIOL CHEM, V272, P12611, DOI 10.1074/jbc.272.19.12611; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Zent CS, 1996, P NATL ACAD SCI USA, V93, P1044, DOI 10.1073/pnas.93.3.1044; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	53	108	113	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2287	2293		10.1038/sj.onc.1202151	http://dx.doi.org/10.1038/sj.onc.1202151			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811459				2022-12-17	WOS:000076723300002
J	Queva, C; Hurlin, PJ; Foley, KP; Eisenman, RN				Queva, C; Hurlin, PJ; Foley, KP; Eisenman, RN			Sequential expression of the MAD family of transcriptional repressors during differentiation and development	ONCOGENE			English	Article						differentiation; Mad family; Max; Myc; transcriptional repression	C-MYC PROTEIN; DNA-BINDING PROTEIN; N-MYC; EMBRYONIC LETHALITY; EPIDERMAL DIFFERENTIATION; RAS COTRANSFORMATION; TARGETED DISRUPTION; CELL-PROLIFERATION; ONCOGENIC ACTIVITY; NEOPLASTIC-CELLS	Members of the Myc proto-oncogene family encode transcription factors that function in multiple aspects of cell behavior, including proliferation, differentiation, transformation and apoptosis, Recent studies have shown that MYC activities are modulated by a network of nuclear bHLH-Zip proteins, The MAX protein is at the center of this network in that it associates with MYC as well as with the family of MAD proteins: MAD1, MXI1, MAD3 and MAD4, Whereas MYC-MAX complexes activate transcription, MAD-MAX complexes repress transcription through identical E-box binding sites, MAD proteins therefore act as antagonists of MYC, Here we report the expression patterns of the Mad gene family in the adult and developing mouse, High level of Mad gene expression in the adult is limited to tissues that display constant renewal of differentiated cell populations, In embryos, Marl transcripts are widely distributed with expression peaking during organogenesis at the onset of differentiation. A detailed analysis of their pattern of expression during chrondrocyte and neuronal differentiation in vivo, and during neuronal differentiation of P19 cells in vitro, shows that Mad family genes are sequentially induced, Mad3 transcripts and proteins are detected in proliferating cells prior to differentiation. Mxi1 and Mad4 transcripts are most abundant in cells that have further advanced along the differentiation pathway, whereas Mad1 is primarily expressed late in differentiation, Taken together, our data suggest that the different members of the MAD protein family exert their functions at distinct steps during the transition between proliferation and differentiation.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Eisenman, RN (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N,Mailstop A2-025,POB 19024, Seattle, WA 98109 USA.		Foley, Kevin/ABC-1041-2020		NCI NIH HHS [R01CA57138] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; Bellomo D, 1996, DEV DYNAM, V205, P471, DOI 10.1002/(SICI)1097-0177(199604)205:4<471::AID-AJA10>3.0.CO;2-4; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CANCEDDA R, 1995, INT REV CYTOL, V159, P265, DOI 10.1016/S0074-7696(08)62109-9; CERNI C, 1995, ONCOGENE, V11, P587; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; CHIN L, 1995, P NATL ACAD SCI USA, V92, P8488, DOI 10.1073/pnas.92.18.8488; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; CRAIG RW, 1993, CELL GROWTH DIFFER, V4, P349; Cultraro CM, 1997, MOL CELL BIOL, V17, P2353, DOI 10.1128/MCB.17.5.2353; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DOWNS KM, 1989, GENE DEV, V3, P860, DOI 10.1101/gad.3.6.860; Edgar BA, 1996, SCIENCE, V274, P1646, DOI 10.1126/science.274.5293.1646; FINN CA, 1967, J ENDOCRINOL, V39, P593, DOI 10.1677/joe.0.0390593; FOLEY KP, IN PRESS EMBO J; Harper SE, 1996, P NATL ACAD SCI USA, V93, P8536, DOI 10.1073/pnas.93.16.8536; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hurlin PJ, 1997, CURR TOP MICROBIOL, V224, P115; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; HURLIN PJ, 1994, COLD SPRING HARBOR S; JOHNSON JE, 1992, DEVELOPMENT, V114, P75; Kasten MM, 1996, MOL CELL BIOL, V16, P4215; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KRANENBURG O, 1995, ONCOGENE, V10, P87; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1994, ONCOGENE, V9, P1247; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; MOENS CB, 1993, DEVELOPMENT, V119, P485; MOENS CB, 1992, GENE DEV, V6, P691, DOI 10.1101/gad.6.5.691; MUKHERJEE B, 1992, GENE DEV, V7, P2110; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SAWAI S, 1993, DEVELOPMENT, V117, P1445; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; WAKAMATSU Y, 1993, NEURON, V10, P1, DOI 10.1016/0896-6273(93)90236-K; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	67	108	119	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	1998	16	8					967	977		10.1038/sj.onc.1201611	http://dx.doi.org/10.1038/sj.onc.1201611			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519870				2022-12-17	WOS:000072335900002
J	PinkasKramarski, R; Eilam, R; Alroy, I; Levkowitz, G; Lonai, P; Yarden, Y				PinkasKramarski, R; Eilam, R; Alroy, I; Levkowitz, G; Lonai, P; Yarden, Y			Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation	ONCOGENE			English	Article						EGF family; signal transduction; tyrosine kinase; NDF/neuregulin; nervous system	EPIDERMAL GROWTH-FACTOR; EMBRYONAL CARCINOMA-CELLS; FACTOR HEREGULIN; NERVOUS-SYSTEM; NEUREGULIN RECEPTORS; CARDIAC DEVELOPMENT; CELLULAR-RESPONSE; NEU; SURVIVAL; ISOFORMS	Two receptor tyrosine kinases, ErB-3 and ErbB-4, mediate signaling by Neu differentiation factors (NDFs, also called neuregulins), while ErbB-1 and ErbB-2 serve as co-receptors, We show that the two NDF/neuregulin differ in spatial and temporal expression The kinase-defective receptor, ErbB-3, is expressed primarily in epithelial layers of various organs, in the peripheral nervous system, and in adult brain, whereas ErbB-4 is restricted to the developing central nervous system and to the embryonic heart, An example of alternating expression of the two receptors is provided by the developing cerebellum: During postnatal cerebellar development, ErbB-4 expression slightly decreases along with a decline in NDF transcription, whereas ErbB-3 expression commences after the peak of neurogenesis, To study functional differences, we established primary brain cultures and found that ErbB-3 was expressed only in oligodendrocytes, whereas ErbB-4 expression was shared by oligodendrocytes, astrocytes and neurons, Blocking the action of endogenous NDF in vitro, by using a soluble form of ErbB-4, accelerated neurite outgrowth in both primary cultures and in neuronal-type cultures of the P19 teratocarcinoma, suggesting an inhibitory effect of NDF on neural differentiation, Apparently, ErbB-3 is associated with proliferation of P19 cells, whereas ErbB-4 correlates with a differentiated phenotype, We conclude that the two NDF receptors play distinct, rather than redundant, developmental and physiological roles.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT MOL GENET,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science			YARDEN, YOSEF/K-1467-2012; Levkowitz, Gil/AAB-9441-2019	Levkowitz, Gil/0000-0002-3896-1881; Pinkas-Kramarski, Ronit/0000-0002-1000-369X				ALIMANDI M, 1995, ONCOGENE, V10, P1813; BACUS SS, 1993, CANCER RES, V53, P5251; BAIN G, 1993, MOL BRAIN RES, V17, P23, DOI 10.1016/0169-328X(93)90068-Z; BARDE YA, 1980, P NATL ACAD SCI-BIOL, V77, P1199, DOI 10.1073/pnas.77.2.1199; Baulida J, 1996, J BIOL CHEM, V271, P5251; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; BENBARUCH N, 1997, HORMONES GROWTH FACT; BerminghamMcDonogh O, 1996, DEVELOPMENT, V122, P1427; CANNOLL PD, 1996, NEURON, V17, P229; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; CHEN MS, 1994, J COMP NEUROL, V349, P389, DOI 10.1002/cne.903490306; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; DANILENKO DM, 1995, J CLIN INVEST, V95, P842, DOI 10.1172/JCI117734; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Grinspan JB, 1996, J NEUROSCI, V16, P6107; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOGAN B, 1986, COLD SPRING HARBOR; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JIN JJ, 1993, CELL GROWTH DIFFER, V4, P227; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LANOIX J, 1991, CELL GROWTH DIFFER, V2, P391; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; Lemke G, 1996, MOL CELL NEUROSCI, V7, P247, DOI 10.1006/mcne.1996.0019; LEVI ADO, 1995, J NEUROSCI, V15, P1329; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; ORRURTREGER A, 1993, P NATL ACAD SCI USA, V90, P1867, DOI 10.1073/pnas.90.5.1867; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Perrimon N, 1997, CELL, V89, P13, DOI 10.1016/S0092-8674(00)80177-4; Pinkas-Kramarski R, 1997, J MAMMARY GLAND BIOL, V2, P97, DOI 10.1023/A:1026343528967; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT SA, 1992, ONCOGENE, V7, P1273; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; RODRIGUEZ ER, 1994, BIOCHEM BIOPH RES CO, V205, P652, DOI 10.1006/bbrc.1994.2715; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; Syroid DE, 1996, P NATL ACAD SCI USA, V93, P9229, DOI 10.1073/pnas.93.17.9229; Trachtenberg JT, 1996, NATURE, V379, P174, DOI 10.1038/379174a0; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VARTANIAN T, 1994, P NATL ACAD SCI USA, V91, P11626, DOI 10.1073/pnas.91.24.11626; Vartanian T, 1997, J CELL BIOL, V137, P211, DOI 10.1083/jcb.137.1.211; Verdi JM, 1996, NEURON, V16, P515, DOI 10.1016/S0896-6273(00)80071-9; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; ZHU XJ, 1995, EMBO J, V14, P5842, DOI 10.1002/j.1460-2075.1995.tb00272.x	67	108	117	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2803	2815		10.1038/sj.onc.1201466	http://dx.doi.org/10.1038/sj.onc.1201466			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419971				2022-12-17	WOS:A1997YJ80300006
J	Yokouchi, M; Suzuki, R; Masuhara, M; Komiya, S; Inoue, A; Yoshimura, A				Yokouchi, M; Suzuki, R; Masuhara, M; Komiya, S; Inoue, A; Yoshimura, A			Cloning and characterization of APS, an adaptor molecule containing PH and SH2 domains that is tyrosine phosphorylated upon B-cell receptor stimulation	ONCOGENE			English	Article						B lymphocytes; signal transduction; protein tyrosine kinase; SH2 domain; PH domain	T-CELL; ANTIGEN RECEPTOR; EXPRESSION CLONING; LYMPHOCYTES-B; ZETA-CHAIN; PROTEIN; KINASE; ACTIVATION; FAMILY; SIGNAL	Stimulation of B lymphocytes through their antigen receptor (BCR) results in rapid increases in tyrosine phosphorylation of a number of proteins, which leads to a cascade of biochemical changes that initiates B cell proliferation and differentiation or growth inhibition, A novel cDNA, designed APS, encoding an adaptor protein with a Pleckstrin homology (PH) domain, Src homology 2 (SH2) domain, and a tyrosine phosphorylation site was cloned from a B cell cDNA library using a yeast two hybrid system, APS is structurally similar to SH2-B, an SH2 protein that potentially binds to the immunoreceptor tyrosine-based activation motif (ITAM) as well as Lnk which is postulated to be a signal transducer that Links T-cell receptor to phospholipase C gamma, Grb2 and phosphatidylinositol 3-kinase, APS expressed only in human Burkitt's lymphoma cells among cell Lines me examined and tyrosine phosphorylated in response to BCR stimulation, APS bound to Shc irrespective of stimulation and bound to Grb2 after stimulation, suggesting that it plays a role in Linkage from BCR to Shc/Grb2 pathway, These results indicate that APS, SH2-B and Lnk form a new adaptor family that links immune receptors to signaling pathways involved in tyrosine-phosphorylation.	KURUME UNIV, FAC MED, INST LIFE SCI, KURUME, FUKUOKA 839, JAPAN; KURUME UNIV, FAC MED, DEPT ORTHOPAED SURG, KURUME, FUKUOKA 839, JAPAN	Kurume University; Kurume University			Yoshimura, Akihiko/K-5515-2013					BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; FUKUDA T, 1995, P NATL ACAD SCI USA, V92, P7302, DOI 10.1073/pnas.92.16.7302; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; HARPER JW, 1993, CELL, V75, P805; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Kimura T, 1996, MOL CELL BIOL, V16, P1471; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; OOI J, 1995, ONCOGENE, V10, P1621; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANGE RL, 1993, J BIOL CHEM, V268, P19797; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; Weiner M. P., 1994, STRATEGIES, V7, P41; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	43	108	114	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	1997	15	1					7	15		10.1038/sj.onc.1201163	http://dx.doi.org/10.1038/sj.onc.1201163			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233773				2022-12-17	WOS:A1997XH58600002
J	Frank, S; Munz, B; Werner, S				Frank, S; Munz, B; Werner, S			The human homologue of a bovine non-selenium glutathione peroxidase is a novel keratinocyte growth factor-regulated gene	ONCOGENE			English	Article						KGF; keratinocyte; skin; oxidative stress; peroxidase; psoriasis	FACTOR EXPRESSION; MESSENGER-RNA; TRANSFERASE; INDUCTION; CLONING; SKIN; PURIFICATION; SEQUENCE; FAMILY; CELLS	Keratinocyte growth factor is a potent and specific mitogen for different types of epithelial cells, including keratinocytes of the skin. Furthermore, it has been implicated in morphogenetic processes of several organs. To further define the mechanisms of KGF action in the skin, we attempted to identify genes which are regulated by KGF in keratinocytes. Using the differential display RT-PCR technology, a gene was identified which was strongly induced in these cells by treatment with KGF but not with serum growth factors or pro-inflammatory cytokines. Molecular cloning of the full-length cDNA revealed a strong homology of the corresponding gene product with a bovine non-selenium glutathione peroxidase. Upon transfection of COS cells with the full-length cDNA, a 27 kD cytoplasmic protein was obtained which had the expected size of glutathione peroxidase. Expression of the novel gene was detected in normal human skin and at particularly high levels in psoriatic skin, indicating a possible in vivo function of the protein in this tissue. Identification of a peroxidase as a KGF-regulated gene suggests that prevention from oxygen toxicity is a novel and specific mechanism of KGF action.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Max Planck Society				Werner, Sabine/0000-0001-7397-8710				ACETO A, 1992, BIOCHEM MED METAB B, V48, P212, DOI 10.1016/0885-4505(92)90067-9; ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; Ames B.N., 1993, DNA FREE RADICALS, P1; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BAUER D, 1994, PCR METH APPL, V4, P97; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRAUCHLE M, 1995, J INVEST DERMATOL, V105, P579, DOI 10.1111/1523-1747.ep12323521; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHRISTOPHERS E, 1987, DERMATOLOGY GENERAL, P461; Clark RAF, 1991, PHYSL BIOCH MOL BIOL, P576; CUNHA GR, 1994, INT CONGR SER, V1064, P45; ESWORTHY RS, 1994, GENE, V144, P317, DOI 10.1016/0378-1119(94)90400-6; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Flohe L., 1982, FREE RADICAL BIO MED, V5, P223; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; KANO T, 1987, CANCER RES, V47, P5626; LONTZ W, 1995, FREE RADICAL BIO MED, V18, P349, DOI 10.1016/0891-5849(94)E0124-2; Maniatis T., 1982, MOL CLONING; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; MATHIEU M, 1996, BIOL CHEM, V270, P24197; MICHIELS C, 1994, FREE RADICAL BIO MED, V17, P235, DOI 10.1016/0891-5849(94)90079-5; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MULLENBACH GT, 1987, NUCLEIC ACIDS RES, V15, P5484, DOI 10.1093/nar/15.13.5484; PANOS RJ, 1995, J CLIN INVEST, V96, P2026, DOI 10.1172/JCI118250; PENTLAND AP, 1994, ADV EXP MED BIOL, V366, P87; PETERS K, 1994, EMBO J, V13, P3269; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SCHOPF RE, 1992, MOLECULAR BASIS OF OXIDATIVE DAMAGE BY LEUKOCYTES, P333; SHICHI H, 1990, EXP EYE RES, V50, P513, DOI 10.1016/0014-4835(90)90040-2; SUKENAGA Y, 1987, NUCLEIC ACIDS RES, V15, P7178, DOI 10.1093/nar/15.17.7178; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; Wendel A, 1981, Methods Enzymol, V77, P325; WERNER S, 1994, J INVEST DERMATOL, V103, P469, DOI 10.1111/1523-1747.ep12395564; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918	39	108	112	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					915	921		10.1038/sj.onc.1200905	http://dx.doi.org/10.1038/sj.onc.1200905			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050990	Bronze			2022-12-17	WOS:A1997WK34400004
J	Gale, NW; Flenniken, A; Compton, DC; Jenkins, N; Copeland, NG; Gilbert, DJ; Davis, S; Wilkinson, DG; Yancopoulos, GD				Gale, NW; Flenniken, A; Compton, DC; Jenkins, N; Copeland, NG; Gilbert, DJ; Davis, S; Wilkinson, DG; Yancopoulos, GD			Elk-L3, a novel transmembrane ligand for the Eph family of receptor tyrosine kinases, expressed in embryonic floor plate, roof plate and hindbrain segments	ONCOGENE			English	Article						Eph; LERK; Sek; Elk; Nuk; Htk; floor plate; roof plate	INSITU HYBRIDIZATION; SONIC-HEDGEHOG; MIDLINE CELLS; MOUSE; GENE; ORGANIZATION; MEMBER; MAP; MOLECULES; POLARITY	The Eph family of receptor tyrosine kinases has 13 distinct members and seven ligands for these receptors have been described to date, These receptors and their ligands have been implicated in regulating neuronal axon guidance and in patterning of the developing nervous system and may also serve a patterning and compartmentalization role outside of the nervous system as well, The ligands are all membrane-attached, and this attachment appears to be crucial for their normal function; five of the known ligands are linked to the membrane,ia a glycosyl phosphotidylinositol (GPI) linkage, while tate of the ligands are transmembrane proteins, Despite the large number of Eph family receptors and ligands, they can be divided into just two major subclasses based on their binding specificities. All the GPI-anchored ligands bind and activate one subclass of the Eph receptors (that represented by Eck) while the two transmembrane ligands bind and activate the other major subclass of receptors (represented by Elk), Here we report the identification and characterization of the third, and most divergent, member of the transmembrane group of Eph ligands, which we term Elk-L3 (ElK-related receptor ligand number 3), Elk-L3 is notable for its remarkably restricted and prominent expression in the Boor plate and roof plate of the developing neural tube and its rhombomere-specific expression in the developing hindbrain, The Elk-L3 gene has been localized to mouse chromosome 11 and human chromosome 17.	REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591; NATL INST MED RES,MRC,DIV DEV NEUROBIOL,LONDON NW7 1AA,ENGLAND; NCI,FREDERICK CANC RES & DEV CTR,ABL,MAMMALIAN GENET LAB,FREDERICK,MD 21702	Regeneron; MRC National Institute for Medical Research; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Wilkinson, David/0000-0001-6757-7080				ALTABA AR, 1995, DEV BIOL, V170, P299; ALTABA ARI, 1992, DEVELOPMENT, V116, P81; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BRAUMBLLA R, 1995, MOL CELL NEUROSCI, V6, P487; BUCHBERG AM, 1989, GENETICS, V122, P153; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ELLIS J, 1995, MECH DEVELOP, V52, P319, DOI 10.1016/0925-4773(95)00411-S; ESPESETH A, 1995, MOL CELL NEUROSCI, V6, P199, DOI 10.1006/mcne.1995.1017; FLENNIKEN A, 1996, UNPUB; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; GANJU P, 1994, ONCOGENE, V9, P1613; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; Green EL, 1981, GENETICS PROBABILITY, P77; Heng Henry H. Q., 1994, V33, P35; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JESSELL TM, 1992, HARVEY LECT, V86, P87; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; NIETO MA, 1992, DEVELOPMENT, V116, P1137; Nieto MA, 1996, METHOD CELL BIOL, V51, P219, DOI 10.1016/S0091-679X(08)60630-5; Ruiz i Altaba A., 1993, CURR OPIN GENE DEV, V3, P633; RUIZ JC, 1994, MECH DEVELOP, V46, P87; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; VALENZUELA DM, 1995, GENOMICS, V25, P157, DOI 10.1016/0888-7543(95)80121-2; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; XU QL, 1994, DEVELOPMENT, V120, P287; Xu QL, 1995, DEVELOPMENT, V121, P4005	39	108	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1343	1352						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808709				2022-12-17	WOS:A1996VJ20200026
J	DAI, TN; RUBIE, E; FRANKLIN, CC; KRAFT, A; GILLESPIE, DAF; AVRUCH, J; KYRIAKIS, JM; WOODGETT, JR				DAI, TN; RUBIE, E; FRANKLIN, CC; KRAFT, A; GILLESPIE, DAF; AVRUCH, J; KYRIAKIS, JM; WOODGETT, JR			STRESS-ACTIVATED PROTEIN-KINASES BIND DIRECTLY TO THE DELTA-DOMAIN OF C-JUN IN RESTING CELLS - IMPLICATIONS FOR REPRESSION OF C-JUN FUNCTION	ONCOGENE			English	Article						JUN; AP-1; KINASE; SAPK	GLYCOGEN-SYNTHASE KINASE-3; TUMOR-NECROSIS-FACTOR; DNA-BINDING; V-JUN; PHOSPHORYLATION; TRANSCRIPTION; AP-1; INVITRO; FOS	The transactivating function of the c-Jun proto-oncogene component of the AP-1 transcription factor is acutely regulated by a wide variety of cellular signals via modulation of phosphorylation of two serines (63 and 73). The viral oncoprotein, v-Jun, while containing homologous serines, is not phosphorylated in cells. A novel family of stress-activated protein kinases (SAPKs), also termed Jun N-terminal domain kinases (JNKs), are responsible for mediating S63/73 phosphorylation in response to a variety of cellular stimuli including tumor necrosis factor-alpha, heat stress and u.v. light. The p54 alpha(1), alpha(2), p54 beta and p46 beta SAPKs are shown to bind directly to c-Jun but not to v-Jun, with an absolute requirement for c-Jun amino acids 31-47, a region deleted in v-Jun. Inactive SAPKs tightly bind c-Jun in resting cells and may be a manifestation of the 'delta' inhibitor, a previously described repressor of c-Jun function.	ONTARIO CANC INST,DIV CELL & MOLEC BIOL,TORONTO,ON M4X 1K9,CANADA; UNIV ALABAMA,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294; BEATSON INST CANC RES,CANC RES CAMPAIGN,BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND; MASSACHUSETTS GEN HOSP E,DIABET RES LABS,MED SERV,BOSTON,MA 02129	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Alabama System; University of Alabama Birmingham; Beatson Institute			Woodgett, Jim/F-1087-2010; Gillespie, David/R-4771-2019	Woodgett, Jim/0000-0003-3731-5797; Gillespie, David/0000-0002-6338-0544	NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046577, R29GM046577] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42533] Funding Source: Medline; NIGMS NIH HHS [GM 46577] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ADLER V, 1994, J BIOL CHEM, V269, P11186; ADLER V, 1992, J BIOL CHEM, V267, P17001; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; BLACK EJ, 1994, ONCOGENE, V9, P2363; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRACH MA, 1993, MOL CELL BIOL, V13, P4284, DOI 10.1128/MCB.13.7.4284; DEGROOT RP, 1993, ONCOGENE, V8, P841; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; FRANKLIN CC, 1993, CELL GROWTH DIFFER, V4, P377; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOEFFLER WK, 1994, NUCLEIC ACIDS RES, V22, P1305, DOI 10.1093/nar/22.7.1305; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PAPAVASSILIOU AG, 1992, ANAL BIOCHEM, V203, P302, DOI 10.1016/0003-2697(92)90317-Z; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; YAN MH, 1994, NATURE, V372, P798	35	108	109	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					849	855						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898927				2022-12-17	WOS:A1995QL03800006
J	TRAVERSE, S; COHEN, P; PATERSON, H; MARSHALL, C; RAPP, U; GRAND, RJA				TRAVERSE, S; COHEN, P; PATERSON, H; MARSHALL, C; RAPP, U; GRAND, RJA			SPECIFIC ASSOCIATION OF ACTIVATED MAP KINASE KINASE KINASE (RAF) WITH THE PLASMA-MEMBRANES OF RAS-TRANSFORMED RETINAL CELLS	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; MURINE SARCOMA-VIRUS; PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; PHOSPHORYLATION; LOCALIZATION; ONCOGENE; CASCADE; P21RAS; GENE	Plasma membrane-enriched fractions were prepared from human embryonic retinal cells transformed with either adenovirus El A and oncogenic ras DNA, or E1A and E1B DNA. Ras comprised 5-10 % of the membrane protein from the E1A/ras transformed cells, whereas the membranes from EIA/E1B transformed cells did not overexpress Ras. The membranes from E1a/ras cells contained MAP kinase kinase kinase (MAPKKK) activity, even after washing in 0.5 M NaCl, whereas the membranes from E1A/EIB cells did not. Neither membrane fraction contained MAP kinase kinase or MAP kinase activity after washing with 0.5M NaCl. Immunoblotting experiments revealed about 10-fold more c-Raf in the membranes from EIA/ras cells than from E1A/E1B cells, and 50-60% of the MAPKKK activity in Triton X100-solubilised membranes from E1A/ras cells was immunoprecipitated with anti-Raf antibodies. A striking enrichment of c-Raf in the plasma membranes of E1A/ras cells was also demonstrated by immunocytochemistry, where it was co-localized with Ras. The MAPKKK activity in E1A/ras membranes was unaffected by incubation with protein phosphatases or by inclusion of protein phosphatase inhibitors during isolation, nor was it activated by GTP-Ras or inhibited by GDP-Ras. The results support the view that Ras and c-Raf interact with one another, but that neither c-Raf phosphorylation nor its interaction with GTP-Ras are alone sufficient for activation. The identification of MAPKKK activity in the membranes of ras-transformed cells may prove useful in elucidating the mechanism by which Raf is activated by Ras.	UNIV BIRMINGHAM,SCH MED,DEPT CANC STUDIES,CANC RES CAMPAIGN LABS,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND; NCI,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	University of Birmingham; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	TRAVERSE, S (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND.							AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRD P, 1982, NATURE, V298, P69, DOI 10.1038/298069a0; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COHEN P, 1993, BIOCHEM SOC T, V214, P555; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FORCE T, 1993, IN PRESS P NATL ACAD; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALLIMORE PH, 1986, ANTICANCER RES, V6, P499; GOMEZ N, 1992, FEBS LETT, V314, P461, DOI 10.1016/0014-5793(92)81527-S; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GRAND RJA, 1987, ONCOGENE, V1, P305; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JWOOD KW, 1992, CELL, V68, P1041; KAVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; ROZAKISADCOCK M, 1993, NATURE, V363, P831; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLINGHAM MC, 1983, EXP CELL RES, V149, P141, DOI 10.1016/0014-4827(83)90387-7; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	41	108	108	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3175	3181						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414521				2022-12-17	WOS:A1993MC09300036
J	HAILAT, N; STRAHLER, J; MELHEM, R; ZHU, XX; BRODEUR, G; SEEGER, RC; REYNOLDS, CP; HANASH, S				HAILAT, N; STRAHLER, J; MELHEM, R; ZHU, XX; BRODEUR, G; SEEGER, RC; REYNOLDS, CP; HANASH, S			N-MYC GENE AMPLIFICATION IN NEUROBLASTOMA IS ASSOCIATED WITH ALTERED PHOSPHORYLATION OF A PROLIFERATION RELATED POLYPEPTIDE (OP18)	ONCOGENE			English	Article									UNIV MICHIGAN,SCH MED,DEPT PEDIAT HEMATOL,ANN ARBOR,MI 48109; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; UNIV SO CALIF,SCH MED,DEPT PEDIAT HEMATOL,LOS ANGELES,CA 90029; CHILDRENS HOSP LOS ANGELES,DEPT PEDIAT HEMATOL,LOS ANGELES,CA 90027	University of Michigan System; University of Michigan; Washington University (WUSTL); University of Southern California; Children's Hospital Los Angeles				Zhu, Charles/0000-0003-2922-0042; Reynolds, C. Patrick/0000-0002-2827-8536	NCI NIH HHS [CA22794, CA32146, CA26803] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022794, R01CA032146, P01CA026803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRODEUR GM, 1982, CANCER GENET CYTOGEN, V7, P137, DOI 10.1016/0165-4608(82)90010-3; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1981, CANCER RES, V41, P4678; CHRISTIANSEN H, 1990, ONCOGENE, V5, P437; DOYE V, 1989, J BIOL CHEM, V264, P12134; FERRARI AC, IN PRESS GENES CHROM; FEURSTEIN N, 1983, J BIOL CHEM, V258, P10786; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; HAILAT N, UNPUB; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HASKELL BE, 1987, CELL TISSUE RES, V247, P67, DOI 10.1007/BF00216548; KATO K, 1990, MOL CELL BIOL, V10, P486, DOI 10.1128/MCB.10.2.486; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; KUICK RD, 1987, ELECTROPHORESIS, V8, P199, DOI 10.1002/elps.1150080405; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; NISEN PD, 1988, J NATL CANCER I, V80, P633; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; SCHWAB M, 1984, NATURE, V308, P288, DOI 10.1038/308288a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P111; SHILOH Y, 1985, P NATL ACAD SCI USA, V82, P3761, DOI 10.1073/pnas.82.11.3761; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SOBEL A, 1989, J BIOL CHEM, V264, P3765; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; ZHU XX, 1989, J BIOL CHEM, V264, P14556	24	108	111	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1990	5	11					1615	1618						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EL401	2267130				2022-12-17	WOS:A1990EL40100001
J	BARNEKOW, A; JAHN, R; SCHARTL, M				BARNEKOW, A; JAHN, R; SCHARTL, M			SYNAPTOPHYSIN - A SUBSTRATE FOR THE PROTEIN TYROSINE KINASE PP60C-SRC IN INTACT SYNAPTIC VESICLES	ONCOGENE			English	Article									UNIV GIESSEN,INST MED VIROL,W-6300 GIESSEN,GERMANY; MAX PLANCK INST PSYCHIAT,W-8033 MARTINSRIED,GERMANY; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	Justus Liebig University Giessen; Max Planck Society; Max Planck Society				Schartl, Manfred/0000-0001-9882-5948; Jahn, Reinhard/0000-0003-1542-3498				BARNEKOW A, 1984, MOL CELL BIOL, V4, P1179, DOI 10.1128/MCB.4.6.1179; BARNEKOW A, 1986, EMBO J, V5, P701, DOI 10.1002/j.1460-2075.1986.tb04270.x; BARNEKOW A, 1984, BIOCHIM BIOPHYS ACTA, V782, P94, DOI 10.1016/0167-4781(84)90110-6; BARNEKOW A, 1989, Critical Reviews in Oncogenesis, V1, P277; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; ERIKSON RL, 1980, COLD SPRING HARB SYM, V4, P907; FINDIK D, 1988, FEBS LETT, V235, P51, DOI 10.1016/0014-5793(88)81232-8; GRANDORI C, 1988, J CELL BIOL, V107, P2125, DOI 10.1083/jcb.107.6.2125; HELL JW, 1988, EMBO J, V7, P3023, DOI 10.1002/j.1460-2075.1988.tb03166.x; HEUSER JE, 1981, J CELL BIOL, V88, P560; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; LEBEAU JM, 1987, MOL CELL BIOL, V7, P4115, DOI 10.1128/MCB.7.11.4115; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANESS PF, 1986, J NEUROSCI RES, V16, P127, DOI 10.1002/jnr.490160113; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MARTINEZ R, 1987, SCIENCE, V237, P441; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; PANG D T, 1988, Society for Neuroscience Abstracts, V14, P106; PANG DT, 1988, P NATL ACAD SCI USA, V85, P762, DOI 10.1073/pnas.85.3.762; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARSONS SJ, 1986, BIOCHEM BIOPH RES CO, V134, P734; RAULF F, 1989, ONCOGENE RES, V5, P39; REHM H, 1986, EMBO J, V5, P535, DOI 10.1002/j.1460-2075.1986.tb04243.x; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; SCHARTL M, 1982, DIFFERENTIATION, V23, P109, DOI 10.1111/j.1432-0436.1982.tb01273.x; SCHARTL M, 1989, ONCOGENE, V4, P1185; SCHARTL M, 1984, DEV BIOL, V105, P415, DOI 10.1016/0012-1606(84)90298-7; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; SUDOL M, 1988, BRAIN RES REV, V13, P391, DOI 10.1016/0165-0173(88)90014-8; SUDOL M, 1988, ONCOGENE RES, V2, P345; WALAAS SI, 1988, MOL BRAIN RES, V3, P215, DOI 10.1016/0169-328X(88)90044-7; ZIEMIECKI A, 1980, J GEN VIROL, V50, P211, DOI 10.1099/0022-1317-50-1-211	40	108	110	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					1019	1024						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	1695724				2022-12-17	WOS:A1990DP41500009
J	Grabosch, S; Bulatovic, M; Zeng, FTZ; Ma, TZ; Zhang, LX; Ross, M; Brozickl, J; Fang, YS; Tseng, G; Kim, E; Gambotto, A; Elishaev, E; Edwards, RP; Vlad, AM				Grabosch, Shannon; Bulatovic, Mirna; Zeng, Feitianzhi; Ma, Tianzhou; Zhang, Lixin; Ross, Malcolm; Brozickl, Joan; Fang, YuSi; Tseng, George; Kim, Eun; Gambotto, Andrea; Elishaev, Esther; Edwards, Robert P.; Vlad, Anda M.			Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles	ONCOGENE			English	Article							LONG-TERM SAFETY; CELLS; CHEMOTHERAPY; SURVIVAL; EXPRESSION; APOPTOSIS; ANTIBODY; THERAPY; TUMORS; PD-L1	The backbone of ovarian cancer treatment is platinum-based chemotherapy and aggressive surgical debulking. New therapeutic approaches using immunotherapy via immune checkpoint blockade, which have demonstrated clinical efficacy in other tumor types, have been less promising in ovarian cancer. To increase their clinical efficacy, checkpoint inhibitors are now being tested in clinical trials in combination with chemotherapy. Here, we evaluated the impact of cisplatin on tumor immunogenicity and its in vivo roles when used alone or in combination with anti-PD-L1, in two novel murine ovarian cancer cell models. The 2F8 and its platinum-resistant derivative 2F8cis model, display distinct inflammatory profiles and chemotherapy sensitivities, and mirror the primary and recurrent human disease, respectively. Acute and chronic exposure to cisplatin enhances tumor immunogenicity by increasing calreticulin, MHC class I, antigen presentation and T-cell infiltration. Cisplatin also upregulates PD-L1 expression in vitro and in vivo, demonstrating a dual, paradoxical immune modulatory effect and supporting the rationale for combination with immune checkpoint blockade. One of the pathways activated by cisplatin treatment is the cGAS/STING pathway. Chronic cisplatin treatment led to upregulation of cGAS and STING proteins in 2F8cis compared to parental 2F8 cells, while acute exposure to cisplatin further increases cGAS and STING levels in both 2F8 and 2F8cis cells. Overexpression of cGAS/STING modifies tumor immunogenicity by upregulating PD-L1, MHC I and calreticulin in tumor cells. Anti-PD-L1 alone in a platinum-sensitive model or with cisplatin in a platinum-resistant model increases survival. These studies have high translational potential in ovarian cancer.	[Grabosch, Shannon; Bulatovic, Mirna; Zeng, Feitianzhi; Zhang, Lixin; Ross, Malcolm; Brozickl, Joan; Edwards, Robert P.; Vlad, Anda M.] Magee Womens Res Inst, Pittsburgh, PA 15213 USA; [Grabosch, Shannon; Bulatovic, Mirna; Zeng, Feitianzhi; Zhang, Lixin; Ross, Malcolm; Edwards, Robert P.; Vlad, Anda M.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA; [Grabosch, Shannon; Ross, Malcolm; Edwards, Robert P.] Univ Pittsburgh, Magee Womens Hosp, Med Ctr, Pittsburgh, PA 15213 USA; [Zeng, Feitianzhi] Cent South Univ, Xiangya Sch Med, Changsha, Hunan, Peoples R China; [Ma, Tianzhou; Fang, YuSi; Tseng, George] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA; [Kim, Eun; Gambotto, Andrea] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA; [Elishaev, Esther] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA; [Ma, Tianzhou] Univ Maryland, Dept Epidemiol & Biostat, Sch Publ Hlth, Pittsburgh, MD 20742 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Central South University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Vlad, AM (corresponding author), Magee Womens Res Inst, Pittsburgh, PA 15213 USA.; Vlad, AM (corresponding author), Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA.	vladam@upmc.edu	Ma, Tianzhou/AAC-8221-2021; Bulatovic, Mirna/L-6826-2015	Ma, Tianzhou/0000-0003-3605-0811; Bulatovic, Mirna/0000-0002-5472-6144	NIH/NCI [R01 CA163462]; Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE [R01CA163462] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was partly supported by the NIH/NCI R01 CA163462, Pennsylvania Department of Health and a philanthropic donation from Mr. Matthew Fletcher Deitch.	Bakhoum SF, 2018, NATURE, V553, P467, DOI 10.1038/nature25432; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Bilbao R, 2003, GENE THER, V10, P1821, DOI 10.1038/sj.gt.3302084; Budiu RA, 2013, ONCOGENE, V32, P3664, DOI 10.1038/onc.2012.397; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cortez MA, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv303; Dasari S, 2014, EUR J PHARMACOL, V740, P364, DOI 10.1016/j.ejphar.2014.07.025; Demaria O, 2015, P NATL ACAD SCI USA, V112, P15408, DOI 10.1073/pnas.1512832112; Di Blasio S, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1192739; Dieu-Nosjean MC, 2014, TRENDS IMMUNOL, V35, P571, DOI 10.1016/j.it.2014.09.006; Ding L, 2015, BBA-MOL BASIS DIS, V1852, P2494, DOI 10.1016/j.bbadis.2015.08.011; Feili-Hariri M, 2003, HUM GENE THER, V14, P13, DOI 10.1089/10430340360464679; Feng MY, 2015, P NATL ACAD SCI USA, V112, P2145, DOI 10.1073/pnas.1424907112; Gaillard Stephanie L, 2016, Gynecol Oncol Res Pract, V3, P11; Gao WT, 2004, BIOTECHNOL PROGR, V20, P443, DOI 10.1021/bp0300467; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Grabosch S, 2017, GYNECOL ONCOL, V146, P137, DOI 10.1016/j.ygyno.2017.04.008; Hamanishi J, 2007, P NATL ACAD SCI USA, V104, P3360, DOI 10.1073/pnas.0611533104; Hamanishi J, 2016, INT IMMUNOL, V28, P339, DOI 10.1093/intimm/dxw020; Hamanishi J, 2015, J CLIN ONCOL, V33, P4015, DOI 10.1200/JCO.2015.62.3397; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HAVRILESKY LJ, 1995, OBSTET GYNECOL, V85, P1007, DOI 10.1016/0029-7844(95)00058-Y; Hughes PE, 2016, TRENDS IMMUNOL, V37, P462, DOI 10.1016/j.it.2016.04.010; Jiang Run-De, 2003, Ai Zheng, V22, P337; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lemos H, 2016, CANCER RES, V76, P2076, DOI 10.1158/0008-5472.CAN-15-1456; Markman M, 2000, Oncologist, V5, P26, DOI 10.1634/theoncologist.5-1-26; McDermott DF, 2015, J CLIN ONCOL, V33, P2013, DOI 10.1200/JCO.2014.58.1041; Merritt RE, 2003, J THORAC CARDIOV SUR, V126, P1609, DOI 10.1016/S0022-5223(03)00707-4; Mesnage SJL, 2017, ANN ONCOL, V28, P651, DOI 10.1093/annonc/mdw625; Mony JT, 2015, CANCER IMMUNOL IMMUN, V64, P1095, DOI 10.1007/s00262-015-1712-6; Nejad EB, 2016, CANCER RES, V76, P6017, DOI 10.1158/0008-5472.CAN-16-0881; Oliveros J. C., 2007, INTERACTIVE TOOL COM, DOI DOI 10.1017/S0266267108002022; Parker BS, 2016, NAT REV CANCER, V16, P131, DOI 10.1038/nrc.2016.14; Pujade-Lourraine E, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.TPS5600; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Tang CHA, 2016, CANCER RES, V76, P2137, DOI 10.1158/0008-5472.CAN-15-1885; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105; Varga A, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.5513; Webb JR, 2016, GYNECOL ONCOL, V141, P293, DOI 10.1016/j.ygyno.2016.03.008; Yang H, 2017, P NATL ACAD SCI USA, V114, pE4612, DOI 10.1073/pnas.1705499114	48	107	115	1	40	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2380	2393		10.1038/s41388-018-0581-9	http://dx.doi.org/10.1038/s41388-018-0581-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30518877	Green Accepted			2022-12-17	WOS:000462588000011
J	Lindstrom, MS; Jurada, D; Bursac, S; Orsolic, I; Bartek, J; Volarevic, S				Lindstrom, Mikael S.; Jurada, Deana; Bursac, Sladana; Orsolic, Ines; Bartek, Jiri; Volarevic, Sinisa			Nucleolus as an emerging hub in maintenance of genome stability and cancer pathogenesis	ONCOGENE			English	Review							DNA-DAMAGE-RESPONSE; RIBOSOMAL-RNA GENES; DOUBLE-STRAND BREAKS; TRANSCRIPTION-ASSOCIATED RECOMBINATION; REPLICATION FORK PROGRESSION; POLYMERASE-I TRANSCRIPTION; TUMOR-SUPPRESSOR PROTEIN; R-LOOP FORMATION; HUMAN-CELLS; TOPOISOMERASE-I	The nucleolus is the major site for synthesis of ribosomes, complex molecular machines that are responsible for protein synthesis. A wealth of research over the past 20 years has clearly indicated that both quantitative and qualitative alterations in ribosome biogenesis can drive the malignant phenotype via dysregulation of protein synthesis. However, numerous recent proteomic, genomic, and functional studies have implicated the nucleolus in the regulation of processes that are unrelated to ribosome biogenesis, including DNA-damage response, maintenance of genome stability and its spatial organization, epigenetic regulation, cell-cycle control, stress responses, senescence, global gene expression, as well as assembly or maturation of various ribonucleoprotein particles. In this review, the focus will be on features of rDNA genes, which make them highly vulnerable to DNA damage and intra- and interchromosomal recombination as well as built-in mechanisms that prevent and repair rDNA damage, and how dysregulation of this interplay affects genome-wide DNA stability, gene expression and the balance between euchromatin and heterochromatin. We will also present the most recent insights into how malfunction of these cellular processes may be a central driving force of human malignancies, and propose a promising new therapeutic approach for the treatment of cancer.	[Lindstrom, Mikael S.; Bartek, Jiri] Karolinska Inst, Div Genome Biol, Dept Med Biochem & Biophys, Stockholm, Sweden; [Jurada, Deana; Bursac, Sladana; Orsolic, Ines; Volarevic, Sinisa] Univ Rijeka, Sch Med, Dept Mol Med & Biotechnol, Rijeka, Croatia; [Jurada, Deana; Bursac, Sladana; Orsolic, Ines; Volarevic, Sinisa] Univ Rijeka, Sci Ctr Excellence Reprod & Regenerat Med, Rijeka, Croatia; [Bartek, Jiri] Danish Canc Soc Res Ctr, Copenhagen, Denmark	Karolinska Institutet; University of Rijeka; University of Rijeka; Danish Cancer Society	Bartek, J (corresponding author), Karolinska Inst, Div Genome Biol, Dept Med Biochem & Biophys, Stockholm, Sweden.; Volarevic, S (corresponding author), Univ Rijeka, Sch Med, Dept Mol Med & Biotechnol, Rijeka, Croatia.; Volarevic, S (corresponding author), Univ Rijeka, Sci Ctr Excellence Reprod & Regenerat Med, Rijeka, Croatia.; Bartek, J (corresponding author), Danish Canc Soc Res Ctr, Copenhagen, Denmark.	jb@cancer.dk; sinisa.volarevic@medri.uniri.hr	Jurada, Deana/R-6012-2018; Lindström, Mikael S/AAA-1451-2019; Bursać, Slađana/Q-7894-2018; Oršolić, Ines/AGE-5929-2022; Volarevic, Sinisa/O-4349-2018; Orsolic, Ines/R-5814-2018	Jurada, Deana/0000-0001-9581-6165; Lindström, Mikael S/0000-0003-1148-8497; Bursać, Slađana/0000-0002-6478-3409; Oršolić, Ines/0000-0003-4517-7187; Volarevic, Sinisa/0000-0003-4893-389X; Orsolic, Ines/0000-0003-4517-7187	Croatian Science Foundation (CSF) [2079]; Karolinska Institutet; Swedish Cancer Society [170176]; Swedish Research Council [VR-MH 2014-46602-117891-30]; King Gustaf V's Jubilee Foundation [134082]	Croatian Science Foundation (CSF); Karolinska Institutet(Karolinska Institutet); Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); King Gustaf V's Jubilee Foundation	We thank Dr. R. Loewith for critical reading of the manuscript. S.V's laboratory is funded by the Croatian Science Foundation (CSF) (grant number: 2079), J.B. laboratory in Stockholm is funded by grants from Karolinska Institutet; the Swedish Cancer Society (grant number: 170176); and the Swedish Research Council (VR-MH 2014-46602-117891-30). M.L. is supported by King Gustaf V's Jubilee Foundation (grant number: 134082).	Aguilera A, 2008, NAT REV GENET, V9, P204, DOI 10.1038/nrg2268; Aguilera A, 2012, MOL CELL, V46, P115, DOI 10.1016/j.molcel.2012.04.009; Ahmad Y, 2009, NUCLEIC ACIDS RES, V37, pD181, DOI 10.1093/nar/gkn804; Akamatsu Y, 2015, MOL CELL BIOL, V35, P1871, DOI 10.1128/MCB.01521-14; Akhmanova A, 2000, J CELL SCI, V113, P4463; Aldrich JC, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005148; Anger AM, 2013, NATURE, V497, P80, DOI 10.1038/nature12104; Antoniali G, 2014, ANTIOXID REDOX SIGN, V20, P621, DOI 10.1089/ars.2013.5491; Apicelli AJ, 2008, MOL CELL BIOL, V28, P1068, DOI 10.1128/MCB.00484-07; Azvolinsky A, 2009, MOL CELL, V34, P722, DOI 10.1016/j.molcel.2009.05.022; Badertscher L, 2015, CELL REP, V13, P2879, DOI 10.1016/j.celrep.2015.11.061; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bassermann F, 2008, CELL, V134, P256, DOI 10.1016/j.cell.2008.05.043; Berger C, 1997, CHROMOSOMA, V106, P479; Bermejo R, 2012, MOL CELL, V45, P710, DOI 10.1016/j.molcel.2012.03.001; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Boulon S, 2010, MOL CELL, V40, P216, DOI 10.1016/j.molcel.2010.09.024; Budkevich TV, 2008, NUCLEIC ACIDS RES, V36, P4736, DOI 10.1093/nar/gkn424; Burger K, 2010, J BIOL CHEM, V285, P12416, DOI 10.1074/jbc.M109.074211; Burns KH, 2003, SCIENCE, V300, P633, DOI 10.1126/science.1081813; Burrell RA, 2013, NATURE, V494, P492, DOI 10.1038/nature11935; Bursac S, 2014, BBA-MOL BASIS DIS, V1842, P817, DOI 10.1016/j.bbadis.2013.08.014; Bursac S, 2012, P NATL ACAD SCI USA, V109, P20467, DOI 10.1073/pnas.1218535109; Calkins AS, 2013, NUCLEIC ACIDS RES, V41, P7378, DOI 10.1093/nar/gkt502; Chapman JR, 2012, MOL CELL, V47, P497, DOI 10.1016/j.molcel.2012.07.029; Chen HB, 2016, ONCOTARGET, V7, P83241, DOI 10.18632/oncotarget.13082; Ciccia A, 2014, P NATL ACAD SCI USA, V111, P18631, DOI 10.1073/pnas.1422488112; Coffman FD, 2005, CELL CYCLE, V4, P1223, DOI 10.4161/cc.4.9.1961; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2011, ONCOGENE, V30, P2595, DOI 10.1038/onc.2010.646; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Daniel JA, 2013, MOL CELL, V50, P309, DOI 10.1016/j.molcel.2013.04.017; Danilova N, 2014, DIS MODEL MECH, V7, P895, DOI 10.1242/dmm.015495; Diesch J, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-43; Dimitrova DS, 2011, J CELL SCI, V124, P2743, DOI 10.1242/jcs.082230; Dominguez-Sola D, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014423; Donati G, 2013, CELL REP, V4, P87, DOI 10.1016/j.celrep.2013.05.045; DROLET M, 1995, P NATL ACAD SCI USA, V92, P3526, DOI 10.1073/pnas.92.8.3526; Durkin SG, 2007, ANNU REV GENET, V41, P169, DOI 10.1146/annurev.genet.41.042007.165900; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; El Hage A, 2010, GENE DEV, V24, P1546, DOI 10.1101/gad.573310; Feng JW, 2015, CELL REP, V13, P1295, DOI 10.1016/j.celrep.2015.10.016; Flach J, 2014, NATURE, V512, P198, DOI 10.1038/nature13619; Floutsakou I, 2013, GENOME RES, V23, P2003, DOI 10.1101/gr.157941.113; Frehlick LJ, 2007, BIOESSAYS, V29, P49, DOI 10.1002/bies.20512; French SL, 2003, MOL CELL BIOL, V23, P1558, DOI 10.1128/MCB.23.5.1558-1568.2003; Fumagalli S, 2012, GENE DEV, V26, P1028, DOI 10.1101/gad.189951.112; Gaillard H, 2015, NAT REV CANCER, V15, P276, DOI 10.1038/nrc3916; Gan WJ, 2011, GENE DEV, V25, P2041, DOI 10.1101/gad.17010011; Garcia-Muse T, 2016, NAT REV MOL CELL BIO, V17, P553, DOI 10.1038/nrm.2016.88; Gentilella A, 2017, MOL CELL, V67, P55, DOI 10.1016/j.molcel.2017.06.005; Gibbons JG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5850; Ginno PA, 2012, MOL CELL, V45, P814, DOI 10.1016/j.molcel.2012.01.017; Goodfellow Sarah J, 2013, Subcell Biochem, V61, P211, DOI 10.1007/978-94-007-4525-4_10; Gottipati P, 2008, MOL CELL BIOL, V28, P154, DOI 10.1128/MCB.00816-07; Govannucci E, 2007, GASTROENTEROLOGY, V132, P2208, DOI 10.1053/j.gastro.2007.03.050; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grob A, 2014, GENE DEV, V28, P220, DOI 10.1101/gad.234591.113; Grummt I, 2010, FEBS J, V277, P4626, DOI 10.1111/j.1742-4658.2010.07892.x; Guerrero PA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016401; Guetg C, 2010, EMBO J, V29, P2135, DOI 10.1038/emboj.2010.17; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hamperl S, 2014, DNA REPAIR, V19, P84, DOI 10.1016/j.dnarep.2014.03.023; Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003; Harding SM, 2015, CELL REP, V13, P251, DOI 10.1016/j.celrep.2015.08.085; Hatchi E, 2015, MOL CELL, V57, P636, DOI 10.1016/j.molcel.2015.01.011; Helmrich A, 2013, NAT STRUCT MOL BIOL, V20, P412, DOI 10.1038/nsmb.2543; Helmrich A, 2011, MOL CELL, V44, P966, DOI 10.1016/j.molcel.2011.10.013; Hemkens LG, 2009, DIABETOLOGIA, V52, P1732, DOI 10.1007/s00125-009-1418-4; Hernandez-Hernandez A, 2012, CYTOGENET GENOME RES, V136, P89, DOI 10.1159/000335752; Huertas P, 2003, MOL CELL, V12, P711, DOI 10.1016/j.molcel.2003.08.010; Hutten S, 2011, CHROMOSOMA, V120, P481, DOI 10.1007/s00412-011-0327-8; Ide S, 2010, SCIENCE, V327, P693, DOI 10.1126/science.1179044; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Killen MW, 2009, HUM MOL GENET, V18, P3417, DOI 10.1093/hmg/ddp282; Kim N, 2012, NAT REV GENET, V13, P204, DOI 10.1038/nrg3152; Kobayashi J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049245; Kobayashi T, 2006, GENES GENET SYST, V81, P155, DOI 10.1266/ggs.81.155; Koike A, 2010, CANCER RES, V70, P6746, DOI 10.1158/0008-5472.CAN-10-0382; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Kruhlak M, 2007, NATURE, V447, P730, DOI 10.1038/nature05842; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Lamm N, 2015, EMBO MOL MED, V7, P1138, DOI 10.15252/emmm.201404824; Lane AN, 2015, NUCLEIC ACIDS RES, V43, P2466, DOI 10.1093/nar/gkv047; Larsen DH, 2014, NAT CELL BIOL, V16, P792, DOI 10.1038/ncb3007; Larsen DH, 2016, NUCLEIC ACIDS RES, V44, P538, DOI 10.1093/nar/gkv1312; Lessard F, 2010, MOL CELL, V38, P539, DOI 10.1016/j.molcel.2010.03.015; Li XL, 2006, GENE DEV, V20, P1838, DOI 10.1101/gad.1438306; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Ma HH, 2013, MOL BIOL CELL, V24, P1334, DOI 10.1091/mbc.E12-12-0881; MacLeod RAF, 2000, LEUKEMIA, V14, P1803, DOI 10.1038/sj.leu.2401894; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; McStay B, 2008, ANNU REV CELL DEV BI, V24, P131, DOI 10.1146/annurev.cellbio.24.110707.175259; McStay B, 2016, GENE DEV, V30, P1598, DOI 10.1101/gad.283838.116; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Murayama A, 2008, CELL, V133, P627, DOI 10.1016/j.cell.2008.03.030; Narla A, 2010, BLOOD, V115, P3196, DOI 10.1182/blood-2009-10-178129; Nemeth A, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000889; Nishimura K, 2015, CELL REP, V10, P1310, DOI 10.1016/j.celrep.2015.01.055; O'Donohue MF, 2010, J CELL BIOL, V190, P853, DOI 10.1083/jcb.201005117; Ogawa LM, 2017, MOL BIOSYST, V13, P443, DOI 10.1039/c6mb00740f; Ogrunc M, 2014, CELL DEATH DIFFER, V21, P998, DOI 10.1038/cdd.2014.16; Ogushi S, 2008, SCIENCE, V319, P613, DOI 10.1126/science.1151276; Ogushi S, 2017, J CELL SCI, V130, P2416, DOI 10.1242/jcs.195875; Olausson KH, 2014, J BIOL CHEM, V289, P34601, DOI 10.1074/jbc.M114.569244; Orsolic I, 2016, SEMIN CANCER BIOL, V37-38, P36, DOI 10.1016/j.semcancer.2015.12.004; Padeken J, 2013, MOL CELL, V50, P236, DOI 10.1016/j.molcel.2013.03.002; Paredes S, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001376; Paredes S, 2009, P NATL ACAD SCI USA, V106, P17829, DOI 10.1073/pnas.0906811106; Paulsen RD, 2009, MOL CELL, V35, P228, DOI 10.1016/j.molcel.2009.06.021; Pederson T, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a000521; Peng JC, 2007, NAT CELL BIOL, V9, P25, DOI 10.1038/ncb1514; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Prado F, 2005, EMBO J, V24, P1267, DOI 10.1038/sj.emboj.7600602; Rudra D, 2004, GENE DEV, V18, P2431, DOI 10.1101/gad.1256704; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Saka K, 2016, NUCLEIC ACIDS RES, V44, P4211, DOI 10.1093/nar/gkw110; Sasaki M, 2011, NAT MED, V17, P944, DOI 10.1038/nm.2392; Saxena A, 2006, ONCOGENE, V25, P7274, DOI 10.1038/sj.onc.1209714; Schwab RA, 2015, MOL CELL, V60, P351, DOI 10.1016/j.molcel.2015.09.012; Scott DD, 2016, BIOCHEM CELL BIOL, V94, P419, DOI 10.1139/bcb-2016-0068; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2013, NAT REV MOL CELL BIO, V14, P197, DOI 10.1038/nrm3546; Sloan KE, 2013, CELL REP, V5, P237, DOI 10.1016/j.celrep.2013.08.049; Smirnov E, 2014, J STRUCT BIOL, V188, P259, DOI 10.1016/j.jsb.2014.10.001; Sokka M, 2015, NUCLEIC ACIDS RES, V43, P4975, DOI 10.1093/nar/gkv371; Sollier J, 2014, MOL CELL, V56, P777, DOI 10.1016/j.molcel.2014.10.020; Stults DM, 2008, GENOME RES, V18, P13, DOI 10.1101/gr.6858507; Stults DM, 2009, CANCER RES, V69, P9096, DOI 10.1158/0008-5472.CAN-09-2680; Tafforeau L, 2013, MOL CELL, V51, P539, DOI 10.1016/j.molcel.2013.08.011; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Takeuchi Y, 2003, GENE DEV, V17, P1497, DOI 10.1101/gad.1085403; Tchurikov NA, 2015, J MOL CELL BIOL, V7, P366, DOI 10.1093/jmcb/mju038; Toledo LI, 2013, CELL, V155, P1088, DOI 10.1016/j.cell.2013.10.043; Tschochner H, 2003, TRENDS CELL BIOL, V13, P255, DOI 10.1016/S0962-8924(03)00054-0; Tuduri S, 2009, NAT CELL BIOL, V11, P1315, DOI 10.1038/ncb1984; Urban V, 2016, J CELL BIOL, V214, P401, DOI 10.1083/jcb.201507099; van Koningsbruggen S, 2010, MOL BIOL CELL, V21, P3735, DOI 10.1091/mbc.E10-06-0508; van Sluis M, 2015, GENE DEV, V29, P1151, DOI 10.1101/gad.260703.115; Velimezi G, 2013, NAT CELL BIOL, V15, P967, DOI 10.1038/ncb2795; Visootsak J, 2004, J PEDIATR-US, V145, P819, DOI 10.1016/j.jpeds.2004.07.041; Wang JD, 2013, J BIOL CHEM, V288, P3174, DOI 10.1074/jbc.M112.414839; Wang M, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006994; Warmerdam DO, 2016, CELL REP, V14, P2519, DOI 10.1016/j.celrep.2016.02.048; Wechsler T, 2011, NATURE, V471, P642, DOI 10.1038/nature09790; Wild T, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000522; Wimberly H, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3115; Xie Q, 2017, NUCLEIC ACIDS RES, V45, P2472, DOI 10.1093/nar/gkw1208; Xie WB, 2012, P NATL ACAD SCI USA, V109, P8161, DOI 10.1073/pnas.1201262109; Xu BS, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006771; Xue SF, 2012, NAT REV MOL CELL BIO, V13, P355, DOI 10.1038/nrm3359; Yoo NJ, 2012, ACTA ONCOL, V51, P107, DOI 10.3109/0284186X.2011.592148; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Yuce O, 2013, MOL CELL BIOL, V33, P406, DOI 10.1128/MCB.01195-12; Yusufzai TM, 2004, MOL CELL, V13, P291, DOI 10.1016/S1097-2765(04)00029-2; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	160	107	110	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	18					2351	2366		10.1038/s41388-017-0121-z	http://dx.doi.org/10.1038/s41388-017-0121-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE7BW	29429989	hybrid, Green Published			2022-12-17	WOS:000431386000001
J	Amoroso, F; Capece, M; Rotondo, A; Cangelosi, D; Ferracin, M; Franceschini, A; Raffaghello, L; Pistoia, V; Varesio, L; Adinolfi, E				Amoroso, F.; Capece, M.; Rotondo, A.; Cangelosi, D.; Ferracin, M.; Franceschini, A.; Raffaghello, L.; Pistoia, V.; Varesio, L.; Adinolfi, E.			The P2X7 receptor is a key modulator of the PI3K/GSK3 beta/VEGF signaling network: evidence in experimental neuroblastoma	ONCOGENE			English	Article							INCREASES CELLULAR ATP; P2X(7) RECEPTOR; CANCER-CELLS; EXPRESSION; ACTIVATION; MYCN; DIFFERENTIATION; PROLIFERATION; METASTASIS; INHIBITION	Neuroblastoma (NB) is an aggressive pediatric tumor, responsible for 15% of cancer-related deaths in childhood, lacking an effective treatment in its advanced stages. The P2X7 receptor for extracellular ATP was associated to NB cell proliferation and recently emerged as a promoter of tumor engraftment, growth and vascularization. In an effort to identify new therapeutic options for neuroblastoma, we studied the role of P2X7 receptor in NB biology. We first analyzed the effect of P2X7 activation or down-modulation of the main biochemical ways involved in NB progression: the PI3K/Akt/GSK3 beta/MYCN and the HIF1 alpha/VEGF pathways. In ACN human NB cells, P2X7 stimulation enhanced PI3K/Akt, while decreasing GSK3 beta activity. In the same model, P2X7 silencing or antagonist administration reduced the activity of PI3K/Akt and increased that of GSK3 beta, leading to a decrease in cellular glycogen stores. Similarly, P2X7 downmodulation caused a reduction in HIF1 alpha levels and vascular endothelial growth factor (VEGF) secretion. Systemic administration of two different P2X7 antagonists (AZ10606120 or A740003) in nude/nude mice reduced ACN-derived tumor growth. An even stronger effect of P2X7 blockade was obtained in a syngeneic immune-competent neuroblastoma model: Neuro2A cells injected in AlbinoJ mice. Together with tumor regression, treatment with P2X7 antagonists caused downmodulation of the Akt/HIF1 alpha axis, leading to reduced VEGF content and decreased vessel formation. Interestingly, in both experimental models, P2X7 antagonists strongly reduced the expression of the probably best-accepted oncogene in NB: MYCN. Finally, we associated P2X7 overexpression with poor prognosis in advanced-stage NB patients. Taken together, our data suggest that P2X7 receptor is an upstream regulator of the main signaling pathways involved in NB growth, metabolic activity and angiogenesis, and a promising therapeutic target for neuroblastoma treatment.	[Amoroso, F.; Capece, M.; Rotondo, A.; Ferracin, M.; Franceschini, A.; Adinolfi, E.] Univ Ferrara, Sect Expt Pathol Oncol & Biol, Dept Morphol Surg & Expt Med, I-44121 Ferrara, Italy; [Cangelosi, D.; Varesio, L.] Ist Giannina Gaslini, Lab Mol Biol, I-16148 Genoa, Italy; [Raffaghello, L.; Pistoia, V.] Ist Giannina Gaslini, Lab Oncol, I-16148 Genoa, Italy	University of Ferrara; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS Istituto Giannina Gaslini	Adinolfi, E (corresponding author), Univ Ferrara, Sect Expt Pathol Oncol & Biol, Dept Morphol Surg & Expt Med, Via Luigi Borsari 46, I-44121 Ferrara, Italy.	elena.adinolfi@unife.it	Franceschini, Alessia/H-4992-2017; varesio, luigi/J-8261-2016; Cangelosi, Davide/K-2627-2016; Franceschini, Alessia/K-3426-2018; Adinolfi, Elena/F-9169-2010; Ferracin, Manuela/K-2097-2016	Franceschini, Alessia/0000-0001-7122-6232; varesio, luigi/0000-0001-5659-2218; Cangelosi, Davide/0000-0002-6010-5619; Franceschini, Alessia/0000-0001-7122-6232; Adinolfi, Elena/0000-0001-8129-9929; Ferracin, Manuela/0000-0002-1595-6887; Amoroso, Francesca Saveria/0000-0002-5946-2491; Raffaghello, Lizzia/0000-0003-2357-0607	AIRC [MFAG11630]; Regione Emilia Romagna of Italy (bando Alessandro Liberati)	AIRC(Fondazione AIRC per la ricerca sul cancro); Regione Emilia Romagna of Italy (bando Alessandro Liberati)	This work was supported by AIRC grant MFAG11630 and young researchers' funds of the Regione Emilia Romagna of Italy (bando Alessandro Liberati) to EA.	Adinolfi E, 2005, MOL BIOL CELL, V16, P3260, DOI 10.1091/mbc.E04-11-1025; Adinolfi E, 2002, BLOOD, V99, P706, DOI 10.1182/blood.V99.2.706; Adinolfi E, 2015, CURR MED CHEM, V22, P878, DOI 10.2174/0929867321666141012172913; Adinolfi E, 2012, J OSTEOPOROS, V2012, DOI 10.1155/2012/637863; Adinolfi E, 2012, CANCER RES, V72, P2957, DOI 10.1158/0008-5472.CAN-11-1947; Adinolfi E, 2010, FASEB J, V24, P3393, DOI 10.1096/fj.09-153601; Adinolfi E, 2009, J BIOL CHEM, V284, P10120, DOI 10.1074/jbc.M805805200; Agani F, 2013, CURR CANCER DRUG TAR, V13, P245, DOI 10.2174/1568009611313030003; Amoroso F, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.105; Aymeric L, 2010, CANCER RES, V70, P855, DOI 10.1158/0008-5472.CAN-09-3566; Baricordi OR, 1999, J BIOL CHEM, V274, P33206, DOI 10.1074/jbc.274.47.33206; Bartlett R, 2014, PHARMACOL REV, V66, P638, DOI 10.1124/pr.113.008003; Bianchi G, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.109; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Cheng KW, 2012, EMBO MOL MED, V4, P125, DOI 10.1002/emmm.201100193; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; Cheung NKV, 2013, NAT REV CANCER, V13, P397, DOI 10.1038/nrc3526; Chong JH, 2010, BIOCHEM BIOPH RES CO, V391, P498, DOI 10.1016/j.bbrc.2009.11.087; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Dent P, 2014, CANCER BIOL THER, V15, P481, DOI 10.4161/cbt.28465; Di Virgilio F, 2012, CANCER RES, V72, P5441, DOI 10.1158/0008-5472.CAN-12-1600; Di Virgilio F, 2009, PURINERG SIGNAL, V5, P251, DOI 10.1007/s11302-009-9145-3; Fardin P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-185; Favaro E, 2012, CELL METAB, V16, P751, DOI 10.1016/j.cmet.2012.10.017; Fransson S, 2013, INT J ONCOL, V42, P609, DOI 10.3892/ijo.2012.1732; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Ghalali A, 2014, CARCINOGENESIS, V35, P1547, DOI 10.1093/carcin/bgu019; Giuliani AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107224; Gomez-Villafuertes R, 2009, FEBS J, V276, P5307, DOI 10.1111/j.1742-4658.2009.07228.x; Gu LQ, 2010, ENDOCRINE, V38, P276, DOI 10.1007/s12020-010-9384-7; Gutierrez-Martin Y, 2011, J BIOL CHEM, V286, P11370, DOI 10.1074/jbc.M110.139410; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heine VM, 2010, CANCER RES, V70, P5220, DOI 10.1158/0008-5472.CAN-10-0554; Hogarty MD, 2012, CANCER CELL, V21, P145, DOI 10.1016/j.ccr.2012.01.018; Huang SD, 2009, CANCER CELL, V15, P328, DOI 10.1016/j.ccr.2009.02.023; Jelassi B, 2011, ONCOGENE, V30, P2108, DOI 10.1038/onc.2010.593; Kang J, 2008, ONCOGENE, V27, P3999, DOI 10.1038/onc.2008.15; Keystone EC, 2012, ANN RHEUM DIS, P71; Martins I, 2009, CELL CYCLE, V8, P3723, DOI 10.4161/cc.8.22.10026; Maurer U, 2014, J CELL SCI, V127, P1369, DOI 10.1242/jcs.138057; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Raffaghello L, 2006, CANCER RES, V66, P907, DOI 10.1158/0008-5472.CAN-05-3185; Schumacher D, 2013, CANCER CELL, V24, P130, DOI 10.1016/j.ccr.2013.05.008; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Stock TC, 2012, J RHEUMATOL, V39, P720, DOI 10.3899/jrheum.110874; Sun SH, 2010, MOL NEUROBIOL, V41, P351, DOI 10.1007/s12035-010-8120-x; Takai E, 2012, J CELL SCI, V125, P5051, DOI 10.1242/jcs.104976; Westhoff MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083128; Williams EL, 2013, CLIN CANCER RES, V19, P3545, DOI 10.1158/1078-0432.CCR-12-3226; Witney TH, 2014, CANCER RES, V74, P1319, DOI 10.1158/0008-5472.CAN-13-2768; Wu PY, 2009, CELL SIGNAL, V21, P881, DOI 10.1016/j.cellsig.2009.01.036	51	107	108	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2015	34	41					5240	5251		10.1038/onc.2014.444	http://dx.doi.org/10.1038/onc.2014.444			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CT1QL	25619831	Green Submitted			2022-12-17	WOS:000362575400004
J	Chan, SH; Huang, WC; Chang, JW; Chang, KJ; Kuo, WH; Wang, MY; Lin, KY; Uen, YH; Hou, MF; Lin, CM; Jang, TH; Tu, CW; Lee, YR; Lee, YH; Tien, MT; Wang, LH				Chan, S-H; Huang, W-C; Chang, J-W; Chang, K-J; Kuo, W-H; Wang, M-Y; Lin, K-Y; Uen, Y-H; Hou, M-F; Lin, C-M; Jang, T-H; Tu, C-W; Lee, Y-R; Lee, Y-H; Tien, M-T; Wang, L-H			MicroRNA-149 targets GIT1 to suppress integrin signaling and breast cancer metastasis	ONCOGENE			English	Article							EXPRESSION PROFILES; FOCAL ADHESIONS; CELL-MIGRATION; TRAFFICKING; PROGRESSION; PROTEINS; DOMAIN	Metastasis is the predominant cause of death in breast cancer patients. Several lines of evidence have shown that microRNAs (miRs) can have an important role in cancer metastasis. Using isogenic pairs of low and high metastatic lines derived from a human breast cancer line, we have identified miR-149 to be a suppressor of breast cancer cell invasion and metastasis. We also identified GIT1 (G-protein-coupled receptor kinase-interacting protein 1) as a direct target of miR-149. Knockdown of GIT1 reduced migration/invasion and metastasis of highly invasive cells. Re-expression of GIT1 significantly rescued miR-149-mediated inhibition of cell migration/invasion and metastasis. Expression of miR-149 impaired fibronectin-induced focal adhesion formation and reduced phosphorylation of focal adhesion kinase and paxillin, which could be restored by re-expression of GIT1. Inhibition of GIT1 led to enhanced protein degradation of paxillin and alpha 5 beta 1 integrin via proteasome and lysosome pathways, respectively. Moreover, we found that GIT1 depletion in metastatic breast cancer cells greatly reduced alpha 5 beta 1-integrin-mediated cell adhesion to fibronectin and collagen. Low level of miR-149 and high level of GIT1 was significantly associated with advanced stages of breast cancer, as well as with lymph node metastasis. We conclude that miR-149 suppresses breast cancer cell migration/invasion and metastasis by targeting GIT1, suggesting potential applications of the miR-149-GIT1 pathway in clinical diagnosis and therapeutics.	[Chan, S-H; Huang, W-C; Chang, J-W; Lin, C-M; Jang, T-H; Wang, L-H] Natl Hlth Res Inst, Inst Mol & Genom Med, Miaoli, Taiwan; [Huang, W-C; Wang, L-H] Natl Cent Univ, Dept Life Sci, Taoyuan, Taiwan; [Chang, K-J; Kuo, W-H; Wang, M-Y] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; [Lin, K-Y; Uen, Y-H] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan; [Hou, M-F] Kaohsiung Med Univ, Chung Ho Mem Hosp, Dept Surg, Kaohsiung, Taiwan; [Tu, C-W] Chiayi Christian Hosp, Dept Surg, Chiayi, Taiwan; [Lee, Y-R] Chiayi Christian Hosp, Dept Med Res, Chiayi, Taiwan; [Lee, Y-H] Natl Taiwan Univ Hosp, Hsin Chu Branch, Dept Pathol, Hsinchu, Taiwan; [Tien, M-T] Ind Technol Res Inst, Biomed Technol & Device Res Labs, Hsinchu, Taiwan; [Wang, L-H] Mt Sinai Sch Med, Dept Microbiol, New York, NY USA	National Health Research Institutes - Taiwan; National Central University; National Taiwan University; National Taiwan University Hospital; Chi Mei Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Chia-Yi Christian Hospital; Chia-Yi Christian Hospital; National Taiwan University; National Taiwan University Hospital; Industrial Technology Research Institute - Taiwan; Icahn School of Medicine at Mount Sinai	Wang, LH (corresponding author), Natl Hlth Res Inst, Inst Mol & Genom Med, 35 Keyan Rd, Zhunan Town 35053, Miaoli, Taiwan.	lu-hai.wang@nhri.org.tw	Wang, Lu-Hai/E-3986-2010; Chan, Shih-Hsuan/AAW-6857-2020; Chan, Shih-Hsuan/AAD-4317-2021	Hou, Ming-Feng/0000-0001-6030-9702; Chang, King jen/0000-0001-9811-3422; KUO, WEN-HUNG/0000-0002-9881-4605; Lee, Ying-Ray/0000-0002-0349-0960; Chan, Shih-Hsuan/0000-0002-8703-5139	National Science Council, Taiwan [01D2-MMNSC16]; Department of Health, Taiwan [DOH100-TD-111-004]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Department of Health, Taiwan	We thank the Pathology Core Laboratory and Microarray Core Laboratory of the National Health Research Institutes for H&E and immunohistochemical staining and miRNA array analysis, respectively. This work was supported by grants from National Science Council, Taiwan (01D2-MMNSC16) and the Department of Health, Taiwan (DOH100-TD-111-004).	Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; Li D, 2011, OMICS, V15, P673, DOI 10.1089/omi.2011.0064; Lin KT, 2012, CANCER RES, V72, P3000, DOI 10.1158/0008-5472.CAN-11-2502; Liu SC, 2000, J CELL SCI, V113, P3563; Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005; Luo ZH, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-3; Manabe R, 2002, J CELL SCI, V115, P1497; Narla RK, 2001, CLIN CANCER RES, V7, P2124; Negrini M, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1867; Packeisen J, 2002, J CLIN PATHOL, V55, P613, DOI 10.1136/jcp.55.8.613; Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957; Ramsay AG, 2007, CANCER METAST REV, V26, P567, DOI 10.1007/s10555-007-9078-7; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Schlenker O, 2009, J MOL BIOL, V386, P280, DOI 10.1016/j.jmb.2008.12.050; Schmalzigaug R, 2007, CELL SIGNAL, V19, P1733, DOI 10.1016/j.cellsig.2007.03.010; Silahtaroglu AN, 2007, NAT PROTOC, V2, P2520, DOI 10.1038/nprot.2007.313; Sreekumar Rahul, 2011, Frontiers in Genetics, V2, P58, DOI 10.3389/fgene.2011.00058; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Thievessen I, 2013, J CELL BIOL, V202, P163, DOI 10.1083/jcb.201303129; Wang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041693; White DE, 2007, J MAMMARY GLAND BIOL, V12, P135, DOI 10.1007/s10911-007-9045-5; Yin GY, 2005, J BIOL CHEM, V280, P27705, DOI 10.1074/jbc.M502271200	28	107	112	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2014	33	36					4496	4507		10.1038/onc.2014.10	http://dx.doi.org/10.1038/onc.2014.10			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MY	24608434	hybrid, Green Published			2022-12-17	WOS:000341158800005
J	Sun, T; Wang, X; He, HH; Sweeney, CJ; Liu, SX; Brown, M; Balk, S; Lee, GSM; Kantoff, PW				Sun, T.; Wang, X.; He, H. H.; Sweeney, C. J.; Liu, S. X.; Brown, M.; Balk, S.; Lee, G-S M.; Kantoff, P. W.			MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A	ONCOGENE			English	Article						microRNA; miR-221; castration resistant prostate cancer; androgen receptor signaling	BREAST-CANCER; MESENCHYMAL TRANSITION; TAMOXIFEN RESISTANCE; RECEPTOR; EXPRESSION; GENES; PROGRESSION; CASTRATION; MICRORNAS; PROTEINS	Hormone-sensitive prostate cancer typically progresses to castration resistant prostate cancer (CRPC) after the androgen deprivation therapy. We investigated the impact of microRNAs (miRs) in the transition of prostate cancer to CRPC. MiR-221/-222 was highly expressed in bone metastatic CRPC tumor specimens. We previously demonstrated that transient overexpression of miR-221/-222 in LNCaP promoted the development of the CRPC phenotype. In current study, we show that stably overexpressing miR-221 confers androgen independent (AI) cell growth in LNCaP by rescuing LNCaP cells from growth arrest at G1 phase due to the lack of androgen. Overexpressing of miR-221 in LNCaP reduced the transcription of a subgroup of androgen-responsive genes without affecting the androgen receptor (AR) or AR-androgen integrity. By performing systematic biochemical and bioinformatical analyses, we identified two miR-221 targets, HECTD2 and RAB1A, which could mediate the development of CRPC phenotype in multiple prostate cancer cell lines. Downregulation of HECTD2 significantly affected the androgen-induced and AR-mediated transcription, and downregulation of HECTD2 or RAB1A enhances AI cell growth. As a result of the elevated expression of miR-221, expression of many cell cycle genes was altered and pathways promoting epithelial to mesenchymal transition/tumor metastasis were activated. We hypothesize that a major biological consequence of upregulation of miR-221 is reprogramming of AR signaling, which in turn may mediate the transition to the CRPC phenotype.	[Sun, T.; Wang, X.; He, H. H.; Sweeney, C. J.; Brown, M.; Lee, G-S M.; Kantoff, P. W.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [He, H. H.; Liu, S. X.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA; [Balk, S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Canc Biol Program,Dept Med, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Lee, GSM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	Gwo-shu_lee@dfci.harvard.edu; philip_kantoff@dfci.harvard.edu	He, Hansen/ABD-8439-2020; Brown, Myles/AAX-5332-2021; Brown, Myles/B-6906-2008	He, Hansen/0000-0003-2898-3363; Brown, Myles/0000-0002-8213-1658; Kantoff, Philip/0000-0001-7275-0597	SPORE in Prostate Cancer [2 P50 CA090381-06]; Department of Defense (DoD) Prostate Cancer Training [W81XWH-09-1-0372]; NATIONAL CANCER INSTITUTE [P50CA090381, P01CA163227] Funding Source: NIH RePORTER	SPORE in Prostate Cancer; Department of Defense (DoD) Prostate Cancer Training; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a SPORE in Prostate Cancer 2 P50 CA090381-06 and TS was supported by a Department of Defense (DoD) Prostate Cancer Training Award W81XWH-09-1-0372. We thank Dr Peter T Nelson at University of Kentucky and Dr Zissimos Mourelatos at University of Pennsylvania for kindly providing us the anti-AGO antibody. We also thank Dr Wang-xia Wang for technical suggestions on AGO-RIP-Chip experiments.	American Cancer Society, 2012, CANC FACTS FIGS 2012; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Bohrer LR, 2010, ENDOCRINOLOGY, V151, P5136, DOI 10.1210/en.2010-0436; Chen Z, 2011, EMBO J, V30, P2405, DOI 10.1038/emboj.2011.154; Coppola V, 2010, ENDOCR-RELAT CANCER, V17, pF1, DOI 10.1677/ERC-09-0172; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fornari F, 2008, ONCOGENE, V27, P5651, DOI 10.1038/onc.2008.178; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Haas AK, 2007, J CELL SCI, V120, P2997, DOI 10.1242/jcs.014225; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; HE L, 2004, NAT REV GENET, V5, P522; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jia L, 2003, MOL CANCER RES, V1, P385; Jiang F, 2004, PROSTATE, V59, P426, DOI 10.1002/pros.20000; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Love HD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008384; Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200; Mizuno H, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-137; Nelson PT, 2007, RNA, V13, P1787, DOI 10.1261/rna.646007; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Pfeil K, 2004, PROSTATE, V58, P259, DOI 10.1002/pros.10332; Rao X, 2011, ONCOGENE, V30, P1082, DOI 10.1038/onc.2010.487; Rini Brian I, 2002, Curr Treat Options Oncol, V3, P437, DOI 10.1007/s11864-002-0008-1; Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5; Santagata S, 2004, CANCER RES, V64, P6854, DOI 10.1158/0008-5472.CAN-04-2500; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Stinson S, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001538; Sun T, 2012, PROSTATE, V72, P1093, DOI 10.1002/pros.22456; Sun T, 2009, CANCER RES, V69, P3356, DOI 10.1158/0008-5472.CAN-08-4112; Taneja SS, 2002, J CELL BIOCHEM, V84, P188, DOI 10.1002/jcb.1278; Terasawa K, 2009, FEBS J, V276, P3269, DOI 10.1111/j.1742-4658.2009.07041.x; Vitelli F, 1999, GENOMICS, V55, P335, DOI 10.1006/geno.1998.5666; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Wang WX, 2010, RNA, V16, P394, DOI 10.1261/rna.1905910; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Watahiki A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024950; Weide T, 2003, BIOCHEM BIOPH RES CO, V306, P79, DOI 10.1016/S0006-291X(03)00918-5; Whitfield ML, 2006, NAT REV CANCER, V6, P99, DOI 10.1038/nrc1802; Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Yuan X, 2009, UROL ONCOL-SEMIN ORI, V27, P36, DOI 10.1016/j.urolonc.2008.03.021; Zhang CZ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-229; Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200	50	107	111	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2790	2800		10.1038/onc.2013.230	http://dx.doi.org/10.1038/onc.2013.230			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23770851	Green Accepted			2022-12-17	WOS:000337231700012
J	Morello, V; Cabodi, S; Sigismund, S; Camacho-Leal, MP; Repetto, D; Volante, M; Papotti, M; Turco, E; Defilippi, P				Morello, V.; Cabodi, S.; Sigismund, S.; Camacho-Leal, M. P.; Repetto, D.; Volante, M.; Papotti, M.; Turco, E.; Defilippi, P.			beta 1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells	ONCOGENE			English	Article						EGFR; beta 1 integrin; lung cancer	GROWTH-FACTOR-RECEPTOR; IN-VIVO; TUMOR PROGRESSION; INTEGRIN; KINASE; EXPRESSION; PATHWAY; PHOSPHORYLATION; ACTIVATION; MIGRATION	Lung cancer is the leading cause of cancer death worldwide. The epidermal growth factor receptor (EGFR) represents the main target for non-small cell lung cancer (NSCLC) therapy, as its overexpression or constitutive activation contributes to malignancy and correlates with poor prognosis. Our previous work demonstrated that in epithelial cells beta 1 integrin is required for propagating EGFR signaling from the plasma membrane to the nucleus. In this study, we silenced beta 1 integrin in human NSCLC A549 cells. The beta 1 integrin-silenced cells show a defective activation of the EGFR signaling cascade, leading to decreased in vitro proliferation, enhanced sensitivity to cisplatin and Gefitinib, impaired migration and invasive behavior. Inhibitory effects on tumor growth and on the EGFR pathway were also observed in in vivo experiments. Moreover, beta 1 integrin silencing increases the amount of EGFR on the cell surface, suggesting that beta 1 integrin is required for efficient constitutive EGFR turnover at the cell membrane. Although the rate of EGF internalization and recycling is not affected in silenced cells, EGFR signaling is recovered only by expression of the Rab-coupling protein RCP, indicating that beta 1 integrin sustains the endocytic machinery required for EGFR signaling. Overall, these results show that beta 1 integrin is an essential regulator of EGFR signaling and tumorigenic properties of lung cancer cells, and that its silencing might represent an adjuvant approach to anti-EGFR therapy. Oncogene (2011) 30, 4087-4096; doi:10.1038/onc.2011.107; published online 11 April 2011	[Morello, V.; Cabodi, S.; Camacho-Leal, M. P.; Repetto, D.; Turco, E.; Defilippi, P.] Univ Turin, Ctr Mol Biotechnol, I-10125 Turin, Italy; [Sigismund, S.] Ist FIRC Oncol Mol, Milan, Italy; [Volante, M.; Papotti, M.] Univ Turin, Orbassano, TO, Italy	University of Turin; IFOM - FIRC Institute of Molecular Oncology; University of Turin	Defilippi, P (corresponding author), Univ Turin, Ctr Mol Biotechnol, Via Nizza 52, I-10125 Turin, Italy.	paola.defilippi@unito.it	DEFILIPPI, Paola/L-2232-2014; Sigismund, Sara/H-3687-2017	Sigismund, Sara/0000-0002-1396-4453; Morello, Virginia/0000-0002-3001-0993	AIRC; AICR; EU; MUR; Regione Piemonte-Progetti Sanita; Oncoprot; PiSTEM; Druidi and CIPE; Compagnia San Paolo, Torino	AIRC(Fondazione AIRC per la ricerca sul cancro); AICR; EU(European Commission); MUR(Ministry of Education, Universities and Research (MIUR)); Regione Piemonte-Progetti Sanita; Oncoprot; PiSTEM; Druidi and CIPE; Compagnia San Paolo, Torino(Compagnia di San Paolo)	We thank Dr Jim Norman (The Beatson Institute for Cancer Research, Glasgow, UK) for kindly providing the RCP construct. We also thank Elona Saraci for initial experiments and Giusy Tornillo for the 3D invasion assays. This work was supported by AIRC, AICR, EU FP7 Metafight, MUR (PRIN, ex-60%), Regione Piemonte-Progetti Sanita, Oncoprot, PiSTEM, Druidi and CIPE, Compagnia San Paolo, Torino.	Adachi M, 2000, CLIN CANCER RES, V6, P96; Arteaga CL, 2001, CURR OPIN ONCOL, V13, P491, DOI 10.1097/00001622-200111000-00012; Bill HM, 2004, MOL CELL BIOL, V24, P8586, DOI 10.1128/MCB.24.19.8586-8599.2004; Brambilla E, 2001, EUR RESPIR J, V18, P1059, DOI 10.1183/09031936.01.00275301; Brockbank EC, 2005, BRIT J CANCER, V92, P102, DOI 10.1038/sj.bjc.6602255; Cabodi S, 2010, ADV EXP MED BIOL, V674, P43; Cabodi S, 2009, J CELL PHYSIOL, V218, P294, DOI 10.1002/jcp.21603; Caswell PT, 2008, J CELL BIOL, V183, P143, DOI 10.1083/jcb.200804140; Caswell PT, 2009, NAT REV MOL CELL BIO, V10, P843, DOI 10.1038/nrm2799; Cordes N, 2007, INT J RADIAT BIOL, V83, P753, DOI 10.1080/09553000701639694; Cusinato F, 1999, BBA-MOL CELL RES, V1451, P35, DOI 10.1016/S0167-4889(99)00092-0; Damiano L, 2010, ONCOGENE, V29, P3677, DOI 10.1038/onc.2010.128; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Dingemans AMC, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-152; Erba EB, 2005, MOL CELL PROTEOMICS, V4, P1107, DOI 10.1074/mcp.M500070-MCP200; Friedl P, 2004, INT J DEV BIOL, V48, P441, DOI 10.1387/ijdb.041821pf; Friedl P, 2010, J CELL BIOL, V188, P11, DOI 10.1083/jcb.200909003; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Huck L, 2010, P NATL ACAD SCI USA, V107, P15559, DOI 10.1073/pnas.1003034107; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Klein EA, 2007, METHOD ENZYMOL, V426, P155, DOI 10.1016/S0076-6879(07)26008-2; Kornilova E, 1996, J BIOL CHEM, V271, P30340, DOI 10.1074/jbc.271.48.30340; Maione P, 2010, EXPERT OPIN PHARMACO, V11, P2997, DOI 10.1517/14656566.2010.511615; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Nguyen KSH, 2009, CLIN LUNG CANCER, V10, P281, DOI 10.3816/CLC.2009.n.039; Okamura M, 2007, HUM PATHOL, V38, P1081, DOI 10.1016/j.humpath.2007.01.003; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Sigismund S, 2008, DEV CELL, V15, P209, DOI 10.1016/j.devcel.2008.06.012; SORKIN A, 1991, J CELL BIOL, V112, P55, DOI 10.1083/jcb.112.1.55; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Streuli CH, 2009, BIOCHEM J, V418, P491, DOI 10.1042/BJ20081948; Tosoni D, 2005, CELL, V123, P875, DOI 10.1016/j.cell.2005.10.021; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Walker JL, 2005, CANCER METAST REV, V24, P383, DOI 10.1007/s10555-005-5130-7; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Xue CS, 2006, CANCER RES, V66, P192, DOI 10.1158/0008-5472.CAN-05-1242; Yoshida T, 2010, BIOCHEM PHARMACOL, V80, P613, DOI 10.1016/j.bcp.2010.05.014	42	107	110	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	39					4087	4096		10.1038/onc.2011.107	http://dx.doi.org/10.1038/onc.2011.107			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	826ME	21478906	Green Submitted			2022-12-17	WOS:000295357500004
J	Shen, RR; Hahn, WC				Shen, R. R.; Hahn, W. C.			Emerging roles for the non-canonical IKKs in cancer	ONCOGENE			English	Review						NF-kappa B; cancer; IKK	NF-KAPPA-B; INNATE IMMUNE-RESPONSE; KINASE-RELATED KINASES; TUMOR-SUPPRESSOR CYLD; INTERFERON REGULATORY FACTOR-3; UBIQUITIN-LIKE DOMAIN; BREAST-CANCER; I INTERFERON; ANTIVIRAL RESPONSE; ADAPTER PROTEIN	The I kappa B Kinase (IKK)-related kinases TBK1 and IKK epsilon have essential roles as regulators of innate immunity by modulating interferon and NF-kappa B signaling. Recent work has also implicated these non-canonical IKKs in malignant transformation. IKK epsilon is amplified in similar to 30% of breast cancers and transforms cells through the activation of NF-kappa B. TBK1 participates in RalB-mediated inflammatory responses and cell survival, and is essential for the survival of non-small cell lung cancers driven by oncogenic KRAS. The delineation of target substrates and downstream activities for TBK1 and IKK epsilon has begun to define their role(s) in promoting tumorigenesis. In this review, we will highlight the mechanisms by which IKKe and TBK1 orchestrate pathways involved in inflammation and cancer. Oncogene (2011) 30, 631-641; doi:10.1038/onc.2010.493; published online 1 November 2010	[Shen, R. R.; Hahn, W. C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Hahn, W. C.] Broad Inst Harvard & MIT, Cambridge, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Hahn, WC (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,Dana 1538, Boston, MA 02115 USA.	william_hahn@dfci.harvard.edu			US NIH [R01 CA130988]; NATIONAL CANCER INSTITUTE [R33CA128625, R01CA130988] Funding Source: NIH RePORTER	US NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the members of the Hahn laboratory for advice. This work was supported in part by the US NIH (R01 CA130988).	Adli M, 2006, J BIOL CHEM, V281, P26976, DOI 10.1074/jbc.M603133200; An HZ, 2006, IMMUNITY, V25, P919, DOI 10.1016/j.immuni.2006.10.014; Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Balachandran S, 2004, NATURE, V432, P401, DOI 10.1038/nature03124; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Basseres DS, 2010, CANCER RES, V70, P3537, DOI 10.1158/0008-5472.CAN-09-4290; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bibeau-Poirier A, 2006, J IMMUNOL, V177, P5059, DOI 10.4049/jimmunol.177.8.5059; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Caillaud A, 2005, J BIOL CHEM, V280, P17671, DOI 10.1074/jbc.M411389200; Camonis JH, 2005, TRENDS CELL BIOL, V15, P327, DOI 10.1016/j.tcb.2005.04.002; Chau TL, 2008, TRENDS BIOCHEM SCI, V33, P171, DOI 10.1016/j.tibs.2008.01.002; Cheng TF, 2006, J IMMUNOL, V176, P7462, DOI 10.4049/jimmunol.176.12.7462; Chiang SH, 2009, CELL, V138, P961, DOI 10.1016/j.cell.2009.06.046; Chien YC, 2006, CELL, V127, P157, DOI 10.1016/j.cell.2006.08.034; Clement JF, 2008, CELL RES, V18, P889, DOI 10.1038/cr.2008.273; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Cui J, 2010, CELL, V141, P483, DOI 10.1016/j.cell.2010.03.040; Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9; Eddy SF, 2005, CANCER RES, V65, P11375, DOI 10.1158/0008-5472.CAN-05-1602; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fujita F, 2003, MOL CELL BIOL, V23, P7780, DOI 10.1128/MCB.23.21.7780-7793.2003; Gatot JS, 2007, J BIOL CHEM, V282, P31131, DOI 10.1074/jbc.M701690200; Ghosh S, 2008, NAT REV IMMUNOL, V8, P837, DOI 10.1038/nri2423; Gravel SP, 2005, J BIOL CHEM, V280, P7477, DOI 10.1074/jbc.M410392200; Greten FR, 2007, CELL, V130, P918, DOI 10.1016/j.cell.2007.07.009; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Guo BC, 2007, J BIOL CHEM, V282, P11817, DOI 10.1074/jbc.M700017200; Guo JP, 2010, J BIOL CHEM, V285, P3676, DOI 10.1074/jbc.M109.078212; Guo JP, 2009, AM J PATHOL, V175, P324, DOI 10.2353/ajpath.2009.080767; Gustin JA, 2004, J BIOL CHEM, V279, P1615, DOI 10.1074/jbc.M306976200; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; Hammerman PS, 2004, CANCER RES, V64, P8341, DOI 10.1158/0008-5472.CAN-04-2284; Harris J, 2006, J IMMUNOL, V177, P2527, DOI 10.4049/jimmunol.177.4.2527; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Hiscott J, 2006, ONCOGENE, V25, P6844, DOI 10.1038/sj.onc.1209941; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Hutti JE, 2009, MOL CELL, V34, P461, DOI 10.1016/j.molcel.2009.04.031; Ikeda F, 2007, EMBO J, V26, P3451, DOI 10.1038/sj.emboj.7601773; Ikenoue T, 2003, CANCER RES, V63, P8132; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kim HS, 2007, CELL SIGNAL, V19, P454, DOI 10.1016/j.cellsig.2006.09.003; Korherr C, 2006, P NATL ACAD SCI USA, V103, P4240, DOI 10.1073/pnas.0511319103; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Kravchenko VV, 2003, J BIOL CHEM, V278, P26612, DOI 10.1074/jbc.M303001200; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Lee DF, 2008, CLIN CANCER RES, V14, P5656, DOI 10.1158/1078-0432.CCR-08-0123; Lerebours F, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-41; Li J, 2010, AM J PATHOL, V176, P699, DOI 10.2353/ajpath.2010.090502; Lim KH, 2006, CURR BIOL, V16, P2385, DOI 10.1016/j.cub.2006.10.023; Lin RT, 2006, J BIOL CHEM, V281, P2095, DOI 10.1074/jbc.M510326200; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Mattioli I, 2006, J BIOL CHEM, V281, P6175, DOI 10.1074/jbc.M508045200; May MJ, 2004, J BIOL CHEM, V279, P45528, DOI 10.1074/jbc.M408579200; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Michallet MC, 2008, IMMUNITY, V28, P651, DOI 10.1016/j.immuni.2008.03.013; Moreno R, 2010, NUCLEIC ACIDS RES, V38, P6029, DOI 10.1093/nar/gkq439; Mori M, 2004, J BIOL CHEM, V279, P9698, DOI 10.1074/jbc.M310616200; Munoz MC, 2009, J ENDOCRINOL, V201, P185, DOI 10.1677/JOE-08-0276; Novak U, 2009, BLOOD, V113, P4918, DOI 10.1182/blood-2008-08-174110; Oganesyan G, 2006, NATURE, V439, P208, DOI 10.1038/nature04374; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Parvatiyar K, 2010, J BIOL CHEM, V285, P14999, DOI 10.1074/jbc.M110.109819; Pasparakis M, 2006, CELL DEATH DIFFER, V13, P861, DOI 10.1038/sj.cdd.4401870; Paz S, 2009, MOL CELL BIOL, V29, P3401, DOI 10.1128/MCB.00880-08; Peant B, 2009, PROSTATE, V69, P706, DOI 10.1002/pros.20912; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Renner F, 2010, MOL CELL, V37, P503, DOI 10.1016/j.molcel.2010.01.018; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Ryzhakov G, 2007, EMBO J, V26, P3180, DOI 10.1038/sj.emboj.7601743; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Soulat D, 2008, EMBO J, V27, P2135, DOI 10.1038/emboj.2008.126; Takaoka A, 2007, NATURE, V448, P501, DOI 10.1038/nature06013; Tenoever BR, 2007, SCIENCE, V315, P1274, DOI 10.1126/science.1136567; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Van Laere SJ, 2006, CLIN CANCER RES, V12, P3249, DOI 10.1158/1078-0432.CCR-05-2800; Wietek C, 2006, J BIOL CHEM, V281, P34973, DOI 10.1074/jbc.M607018200; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yang K, 2006, MOL BIOL CELL, V17, P1461, DOI 10.1091/mbc.E05-09-0853; Yarilina A, 2008, NAT IMMUNOL, V9, P378, DOI 10.1038/ni1576; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhang MY, 2008, J BIOL CHEM, V283, P18621, DOI 10.1074/jbc.M801451200	112	107	115	2	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2011	30	6					631	641		10.1038/onc.2010.493	http://dx.doi.org/10.1038/onc.2010.493			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	719GY	21042276	Green Accepted			2022-12-17	WOS:000287192000001
J	Queiroz, KCS; Ruela-de-Sousa, RR; Fuhler, GM; Aberson, HL; Ferreira, CV; Peppelenbosch, MP; Spek, CA				Queiroz, K. C. S.; Ruela-de-Sousa, R. R.; Fuhler, G. M.; Aberson, H. L.; Ferreira, C. V.; Peppelenbosch, M. P.; Spek, C. A.			Hedgehog signaling maintains chemoresistance in myeloid leukemic cells	ONCOGENE			English	Article						Hedgehog; multidrug resistance; P-glycoprotein; leukemia	DRUG-RESISTANCE; STEM-CELLS; MULTIDRUG-RESISTANCE; PATHWAY; INHIBITION; RADIATION; THERAPY; GROWTH; TARGET	The development of resistance against chemotherapy remains one of the major challenges in the clinical management of leukemia. There is still limited insight into the molecular mechanisms that maintain the chemotherapy-resistant phenotype, despite the obvious clinical relevance that such knowledge would have. In this study, we show that the chemotherapy-resistant phenotype of myeloid leukemia cells correlates with activation of the Hedgehog (Hh) pathway, whereas in chemosensitive cells, such activation is less pronounced. Importantly, the overexpression of Hh pathway components induces chemoprotection and inhibition of the pathway reverts chemoresistance of Lucena-1 cells, apparently by interfering with P-glycoprotein-dependent drug resistance. Our data thus identify the Hh pathway as an essential component of multidrug resistance (MDR) myeloid leukemia and suggest that targeting the Hh pathway might be an interesting therapeutic avenue for overcoming MDR resistance in myeloid leukemia. Oncogene (2010) 29, 6314-6322; doi:10.1038/onc.2010.375; published online 30 August 2010	[Queiroz, K. C. S.; Aberson, H. L.; Spek, C. A.] Univ Amsterdam, Acad Med Ctr, Ctr Expt & Mol Med, NL-1105 AZ Amsterdam, Netherlands; [Queiroz, K. C. S.; Ruela-de-Sousa, R. R.; Ferreira, C. V.] Univ Estadual Campinas, Inst Biol, Dept Biochem, Sao Paulo, Brazil; [Queiroz, K. C. S.; Ruela-de-Sousa, R. R.; Fuhler, G. M.; Peppelenbosch, M. P.] Erasmus MC Univ Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Universidade de Sao Paulo; Universidade Estadual de Campinas; Erasmus University Rotterdam; Erasmus MC	Queiroz, KCS (corresponding author), Univ Amsterdam, Acad Med Ctr, Ctr Expt & Mol Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	k.c.desouzaqueiroz@amc.uva.nl	Fuhler, Gwenny/AAC-7122-2019; Queiroz, Karla/L-6438-2014; Spek, Arnold/AAC-5866-2019; Ruela de Sousa, Roberta/C-6825-2012	Fuhler, Gwenny/0000-0001-9221-4855; Spek, Arnold/0000-0002-2149-4068; Ruela de Sousa, Roberta/0000-0002-3762-2247; Peppelenbosch, Maikel/0000-0001-9112-6028	CNPq; Top-Institute pharma; Maag-, Lever-, Darmstichting	CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Top-Institute pharma; Maag-, Lever-, Darmstichting	KCS Queiroz is supported by the Maag-, Lever-, Darmstichting. CV Ferreira is supported by a research fellowship from CNPq. MP Peppelenbosch and CA Spek acknowledge the support of the Top-Institute pharma. We are grateful to Professor Vivian Rumjanek (Federal University of Rio de Janeiro) for donating Lucena-1 cells.	Bijlsma MF, 2006, PLOS BIOL, V4, P1397, DOI 10.1371/journal.pbio.0040232; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; DEAN M, 1997, BIOCHIM BIOPHYS ACTA, V1332, P43; Diehl KM, 2007, MOL CANCER THER, V6, P418, DOI 10.1158/1535-7163.MCT-06-0603; Dierks C, 2008, CANCER CELL, V14, P238, DOI 10.1016/j.ccr.2008.08.003; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; Higgins CF, 2007, NATURE, V446, P749, DOI 10.1038/nature05630; Hofmann I, 2009, CELL STEM CELL, V4, P559, DOI 10.1016/j.stem.2009.03.016; Kobune M, 2009, CANCER SCI, V100, P948, DOI 10.1111/j.1349-7006.2009.01111.x; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lauth M, 2007, CURR OPIN INVEST DR, V8, P457; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Lowenberg B, 2007, J CLIN ONCOL, V25, P1, DOI 10.1200/JCO.2006.08.6462; Martelli AM, 2003, LEUKEMIA, V17, P1794, DOI 10.1038/sj.leu.2403044; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; O'Hare T, 2006, CURR OPIN GENET DEV, V16, P92, DOI 10.1016/j.gde.2005.11.002; Rumjanek VM, 2001, AN ACAD BRAS CIENC, V73, P57, DOI 10.1590/S0001-37652001000100007; Sims-Mourtada J, 2006, CLIN CANCER RES, V12, P6565, DOI 10.1158/1078-0432.CCR-06-0176; Svard J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737; Zhao Y, 2007, NATURE, V450, P252, DOI 10.1038/nature06225	22	107	115	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2010	29	48					6314	6322		10.1038/onc.2010.375	http://dx.doi.org/10.1038/onc.2010.375			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	688SW	20802532				2022-12-17	WOS:000284874700002
J	Reddy, NM; Kleeberger, SR; Bream, JH; Fallon, PG; Kensler, TW; Yamamoto, M; Reddy, SP				Reddy, N. M.; Kleeberger, S. R.; Bream, J. H.; Fallon, P. G.; Kensler, T. W.; Yamamoto, M.; Reddy, S. P.			Genetic disruption of the Nrf2 compromises cell-cycle progression by impairing GSH-induced redox signaling	ONCOGENE			English	Article						oxidative stress; Nrf2; cell cycle; G(2)/M-checkpoint; Akt	ALVEOLAR EPITHELIAL-CELLS; DNA-DAMAGE; S-GLUTATHIONYLATION; DEPENDENT PHOSPHORYLATION; OXIDATIVE STRESS; MICE LACKING; KINASE-B; LUNG; MECHANISMS; EXPRESSION	Genetic disruption of Nrf2 greatly enhances susceptibility to prooxidant- and carcinogen-induced experimental models of various human disorders; but the mechanisms by which this transcription factor confers protection are unclear. Using Nrf2-proficient (Nrf2(+/+)) and Nrf2-deficient (Nrf2(-/-)) primary epithelial cultures as a model, we now show that Nrf2 deficiency leads to oxidative stress and DNA lesions, accompanied by impairment of cell-cycle progression, mainly G(2)/M-phase arrest. Both N-acetylcysteine and glutathione (GSH) supplementation ablated the DNA lesions and DNA damage-response pathways in Nrf2(-/-) cells; however only GSH could rescue the impaired colocalization of mitosis-promoting factors and the growth arrest. Akt activation was deregulated in Nrf2(-/-) cells, but GSH supplementation restored it. Inhibition of Akt signaling greatly diminished the GSH-induced Nrf2(-/-) cell proliferation and wild-type cell proliferation. GSH depletion impaired Akt signaling and mitosis-promoting factor colocalization in Nrf2(+/+) cells. Collectively, our findings uncover novel functions for Nrf2 in regulating oxidative stress-induced cell-cycle arrest, especially G(2)/M-checkpoint arrest, and proliferation, and GSH-regulated redox signaling and Akt are required for this process.	[Reddy, N. M.; Kensler, T. W.; Reddy, S. P.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; [Kleeberger, S. R.] Natl Inst Environm Hlth Sci, NIH, Res Triangle Pk, NC USA; [Bream, J. H.; Fallon, P. G.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; [Yamamoto, M.] Tohoku Univ, Grad Sch Med, Dept Med Biochem, Sendai, Miyagi 980, Japan	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Tohoku University	Reddy, SP (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Room E7610,615 N Wolfe St, Baltimore, MD 21205 USA.	sreddy@jhsph.edu	Kleeberger, Steven R/F-1807-2019; Reddy, Narsa/AHE-5604-2022; Yamamoto, Masayuki/A-4873-2010; Kensler, Thomas W/D-8686-2014	Kleeberger, Steven R/0000-0003-2948-8452; Yamamoto, Masayuki/0000-0002-9073-9436; Kensler, Thomas W/0000-0002-6676-261X; Bream, Jay/0000-0002-9149-7643	NIH [HL66109, ES11863]; SCCOR [P50 HL073994]; NIEHS [P30 ES 038819]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL073994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES100513, R01ES011863] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); SCCOR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by NIH grants HL66109, ES11863 and SCCOR P50 HL073994 (to SPR), and NIEHS center grant P30 ES 038819. We acknowledge the help provided for FACS analysis by Becton Dickinson Immune Function Laboratory, Johns Hopkins Bloomberg School of Public Health.	Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Buchold GM, 2007, MOL REPROD DEV, V74, P997, DOI 10.1002/mrd.20716; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chen XL, 2003, J BIOL CHEM, V278, P703, DOI 10.1074/jbc.M203161200; Cho HY, 2006, ANTIOXID REDOX SIGN, V8, P76, DOI 10.1089/ars.2006.8.76; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Clavreul N, 2006, ARTERIOSCL THROM VAS, V26, P2454, DOI 10.1161/01.ATV.0000242791.28953.4c; Conour JE, 2004, PHYSIOL GENOMICS, V18, P196, DOI 10.1152/physiolgenomics.00058.2004; Cross JV, 2004, BIOCHEM J, V381, P675, DOI 10.1042/BJ20040591; Dalle-Donne I, 2007, FREE RADICAL BIO MED, V43, P883, DOI 10.1016/j.freeradbiomed.2007.06.014; Dalle-Donne I, 2007, FREE RADICAL BIO MED, V42, P583, DOI 10.1016/j.freeradbiomed.2006.11.026; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Fratelli M, 2005, P NATL ACAD SCI USA, V102, P13998, DOI 10.1073/pnas.0504398102; Fratelli M, 2004, EXPERT REV PROTEOMIC, V1, P365, DOI 10.1586/14789450.1.3.365; Gallogly MM, 2007, CURR OPIN PHARMACOL, V7, P381, DOI 10.1016/j.coph.2007.06.003; Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4; Ghezzi P, 2005, ANTIOXID REDOX SIGN, V7, P964, DOI 10.1089/ars.2005.7.964; Golubnitschaja O, 2007, AMINO ACIDS, V32, P359, DOI 10.1007/s00726-006-0473-0; Helt CE, 2005, J BIOL CHEM, V280, P1186, DOI 10.1074/jbc.M410873200; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Katayama K, 2005, MOL CELL BIOL, V25, P5725, DOI 10.1128/MCB.25.13.5725-5737.2005; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Kim SS, 2006, MOL CELL BIOL, V26, P6983, DOI 10.1128/MCB.00796-06; King FW, 2004, CELL CYCLE, V3, P634; Kissel H, 2005, DEV CELL, V8, P353, DOI 10.1016/j.devcel.2005.01.021; Klatt P, 2002, METHOD ENZYMOL, V348, P157, DOI 10.1016/S0076-6879(02)48635-1; Laine H, 2007, J NEUROSCI, V27, P1434, DOI 10.1523/JNEUROSCI.4956-06.2007; Li N, 2004, J IMMUNOL, V173, P3467, DOI 10.4049/jimmunol.173.5.3467; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Marshall RP, 2002, CHEST, V121, p68S, DOI 10.1378/chest.121.3_suppl.68S; McAllister KA, 2002, BREAST CANCER RES, V4, P54, DOI 10.1186/bcr422; Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414; Meulmeester E, 2005, CELL CYCLE, V4, P1166, DOI 10.4161/cc.4.9.1981; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003; Okumura E, 2002, NAT CELL BIOL, V4, P111, DOI 10.1038/ncb741; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Parra MT, 2002, CHROMOSOMA, V111, P53, DOI 10.1007/s00412-002-0185-5; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Putkey FR, 2002, DEV CELL, V3, P351, DOI 10.1016/S1534-5807(02)00255-1; Qian XS, 2006, EUR J IMMUNOL, V36, P906, DOI 10.1002/eji.200535253; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; Reddy NM, 2007, PHYSIOL GENOMICS, V32, P74, DOI 10.1152/physiolgenomics.00126.2007; Reddy NM, 2007, AM J RESP CELL MOL, V37, P3, DOI 10.1165/rcmb.2007-0004RC; Reynaert NL, 2006, P NATL ACAD SCI USA, V103, P13086, DOI 10.1073/pnas.0603290103; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Serrano-Mollar A, 2007, AM J RESP CRIT CARE, V176, P1261, DOI 10.1164/rccm.200610-1491OC; Shelton MD, 2005, ANTIOXID REDOX SIGN, V7, P348, DOI 10.1089/ars.2005.7.348; Shtivelman E, 2003, MOL CANCER RES, V1, P959; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Su TT, 2006, ANNU REV GENET, V40, P187, DOI 10.1146/annurev.genet.40.110405.090428; Sugahara K, 2006, RESPIROLOGY, V11, pS28, DOI 10.1111/j.1440-1843.2006.00804.x; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Thimmulappa RK, 2006, BIOCHEM BIOPH RES CO, V351, P883, DOI 10.1016/j.bbrc.2006.10.102; Timmers C, 2007, MOL CELL BIOL, V27, P65, DOI 10.1128/MCB.02147-06; Townsend DM, 2006, MOL PHARMACOL, V69, P501, DOI 10.1124/mol.105.018523; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Velu CS, 2007, BIOCHEMISTRY-US, V46, P7765, DOI 10.1021/bi700425y; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; Ward NE, 2000, BIOCHEMISTRY-US, V39, P10319, DOI 10.1021/bi000781g; Yoshida Y, 2003, GENE DEV, V17, P1201, DOI 10.1101/gad.1088003	71	107	110	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2008	27	44					5821	5832		10.1038/onc.2008.188	http://dx.doi.org/10.1038/onc.2008.188			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QC	18542053	Green Accepted			2022-12-17	WOS:000259722400006
J	Szabo, R; Molinolo, A; List, K; Bugge, TH				Szabo, R.; Molinolo, A.; List, K.; Bugge, T. H.			Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development	ONCOGENE			English	Article						placenta development; labyrinth formation; membrane proteolysis; trophoblast differentiation; basement membrane; protease inhibition	SERINE-PROTEASE INHIBITOR; BARRIER FUNCTION; EXPRESSION; HEPSIN; GENE; IDENTIFICATION; DEFICIENT; LETHALITY; HAI-1	Hepatocyte growth factor activator inhibitor-1 (HAI-1) is a Kunitz-type transmembrane serine protease inhibitor that forms inhibitor complexes with several trypsin-like serine proteases and is required for mouse placental development and embryo survival. Here we show that the essential function of HAI-1 in placentation and all other embryonic processes is to restrict the activity of the type II transmembrane serine protease, matriptase. Enzymatic gene trapping of matriptase combined with HAI-1 immunohistochemistry revealed that matriptase is co-expressed with HAI-1 in both extraembryonic and embryonic tissues. As early as embryonic day 8.5, matriptase and HAI-1 were expressed in a population of chorionic trophoblasts. Ablation of HAI-1 disrupted the epithelial integrity of this cell population, causing disorganized laminin deposition and altered expression of E-cadherin and beta-catenin. This led to a complete loss of undifferentiated chorionic trophoblasts after embryonic day 9.5 and prevented the formation of the placental labyrinth. Genetic ablation of matriptase activity in HAI-1-deficient embryos, however, restored the integrity of chorionic trophoblasts and enabled placental labyrinth formation and development to term. Furthermore, matriptase/HAI-1 double-deficient mice were phenotypically indistinguishable from matriptase single-deficient litter-mates. Oncogene	Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Bugge, TH (corresponding author), Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Unit, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Room 211, Bethesda, MD 20892 USA.	thomas.bugge@nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000699] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ascenzi P, 2003, CURR PROTEIN PEPT SC, V4, P231, DOI 10.2174/1389203033487180; Fan B, 2005, J BIOL CHEM, V280, P34513, DOI 10.1074/jbc.M502119200; Gailani D, 1997, BLOOD COAGUL FIBRIN, V8, P134, DOI 10.1097/00001721-199703000-00008; Gao F, 2004, DEVELOPMENT, V131, P1479, DOI 10.1242/dev.01048; Herter S, 2005, BIOCHEM J, V390, P125, DOI 10.1042/BJ20041955; Hooper JD, 2003, BIOCHEM J, V373, P689, DOI 10.1042/BJ20030390; Huang ZF, 1997, BLOOD, V90, P944, DOI 10.1182/blood.V90.3.944.944_944_951; Ishiguro K, 2000, J CLIN INVEST, V106, P873, DOI 10.1172/JCI10489; Itoh H, 2004, GASTROENTEROLOGY, V127, P1423, DOI 10.1053/j.gastro.2004.08.027; Kaufmann MH, 1999, ANATOMICAL BASIS MOU; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; List K, 2006, AM J PATHOL, V168, P1513, DOI 10.2353/ajpath.2006.051071; List K, 2002, ONCOGENE, V21, P3765, DOI 10.1038/sj.onc.1205502; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; Oberst MD, 2005, AM J PHYSIOL-CELL PH, V289, pC462, DOI 10.1152/ajpcell.00076.2005; Oberst MD, 2003, J BIOL CHEM, V278, P26773, DOI 10.1074/jbc.M304282200; Oberst MD, 2003, J HISTOCHEM CYTOCHEM, V51, P1017, DOI 10.1177/002215540305100805; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Ohmuraya M, 2005, GASTROENTEROLOGY, V129, P696, DOI 10.1053/j.gastro.2005.05.057; Riley P, 1998, NAT GENET, V18, P271, DOI 10.1038/ng0398-271; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; Szabo R, 2005, BIOCHEM J, V390, P231, DOI 10.1042/BJ20050299; Tanaka H, 2005, MOL CELL BIOL, V25, P5687, DOI 10.1128/MCB.25.13.5687-5698.2005; Velasco G, 2002, J BIOL CHEM, V277, P37637, DOI 10.1074/jbc.M203007200; Wu QY, 1998, J CLIN INVEST, V101, P321, DOI 10.1172/JCI1617; Zeeuwen PLJM, 2002, HUM MOL GENET, V11, P2867, DOI 10.1093/hmg/11.23.2867	26	107	109	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1546	1556		10.1038/sj.onc.1209966	http://dx.doi.org/10.1038/sj.onc.1209966			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16983341				2022-12-17	WOS:000244782500004
J	Syed, DN; Afaq, F; Kweon, MH; Hadi, N; Bhatia, N; Spiegelman, VS; Mukhtar, H				Syed, D. N.; Afaq, F.; Kweon, M-H; Hadi, N.; Bhatia, N.; Spiegelman, V. S.; Mukhtar, H.			Green tea polyphenol EGCG suppresses cigarette smoke condensate-induced NF-kappa B activation in normal human bronchial epithelial cells	ONCOGENE			English	Article						(-)-epigallocatechin-3-gallate; cigarette smoke condensate; normal human bronchial epithelial cells; nuclear factor-kappa B	LUNG-CANCER; NITRIC-OXIDE; GROWTH; EXPRESSION; TARGET; TUMOR; PROLIFERATION; INFLAMMATION; INDUCTION; TUMORIGENESIS	Cigarette smoke is a powerful inducer of inflammatory responses resulting in disruption of major cellular pathways with transcriptional and genomic alterations driving the cells towards carcinogenesis. Cell culture and animal model studies indicate that (-)-epigallocatechin-3-gallate (EGCG), the major polyphenol present in green tea, possesses potent anti-inflammatory and antiproliferative activity capable of selectively inhibiting cell growth and inducing apoptosis in cancer cells without adversely affecting normal cells. Here, we demonstrate that EGCG pretreatment (20-80 mu M) of normal human bronchial epithelial cells (NHBE) resulted in significant inhibition of cigarette smoke condensate (CSC)-induced cell proliferation. Nuclear factor-kappa B (NF-kappa B) controls the transcription of genes involved in immune and inflammatory responses. In most cells, NF-kappa B prevents apoptosis by mediating cell survival signals. Pretreatment of NHBE cells with EGCG suppressed CSC-induced phosphorylation of I kappa B alpha, and activation and nuclear translocation of NF-kappa B/p65. NHBE cells transfected with a luciferase reporter plasmid containing an NF-kappa B-inducible promoter sequence showed an increased reporter activity after CSC exposure that was specifically inhibited by EGCG pretreatment. Immunoblot analysis showed that pretreatment of NHBE cells with EGCG resulted in a significant downregulation of NF-kappa B-regulated proteins cyclin D1, MMP-9, IL-8 and iNOS. EGCG pretreatment further inhibited CSC-induced phosphorylation of ERK1/2, JNK and p38 MAPKs and resulted in a decreased expression of PI3K, AKT and mTOR signaling molecules. Taken together, our data indicate that EGCG can suppress NF-kappa B activation as well as other pro-survival pathways such as PI3K/AKT/mTOR and MAPKs in NHBE cells, which may contribute to its ability to suppress inflammation, proliferation and angiogenesis induced by cigarette smoke.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Mukhtar, H (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Room B25,1300 Univ Ave, Madison, WI 53706 USA.	hmukhtar@wisc.edu		Spiegelman, Vladimir S/0000-0003-4847-155X	NATIONAL CANCER INSTITUTE [R01CA078809, P30CA014520, R01CA101039] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 78809, R01 CA 101039, 5P30 CA 14520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson GP, 2003, TRENDS PHARMACOL SCI, V24, P71, DOI 10.1016/S0165-6147(02)00052-4; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Doss MX, 2005, J NUTR BIOCHEM, V16, P259, DOI 10.1016/j.jnutbio.2004.11.003; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ho YS, 2005, TOXICOL APPL PHARM, V205, P133, DOI 10.1016/j.taap.2004.09.019; HUNNINGHAKE GW, 1983, AM REV RESPIR DIS, V128, P833; Jin ZH, 2004, J BIOL CHEM, V279, P23837, DOI 10.1074/jbc.M402566200; Johnson MK, 2000, MUTAT RES-DNA REPAIR, V459, P211, DOI 10.1016/S0921-8777(99)00074-9; Kisley LR, 2002, CANCER RES, V62, P6850; Konopka TE, 2001, CANCER RES, V61, P3182; Kurie JM, 1996, CLIN CANCER RES, V2, P1787; Kyosseva SV, 2004, INT REV NEUROBIOL, V59, P201; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Magnani M., 2000, Current Drug Targets, V1, P387, DOI 10.2174/1389450003349056; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Miller DP, 2003, INT J CANCER, V104, P758, DOI 10.1002/ijc.10989; Mossman BT, 2006, AM J RESP CELL MOL, V34, P666, DOI 10.1165/rcmb.2006-0047SF; Nishikawa M, 1999, AM J RESP CELL MOL, V20, P189, DOI 10.1165/ajrcmb.20.2.3305; Ozlu T, 2005, TUBERK TORAK, V53, P200; Patel JD, 2005, J CLIN ONCOL, V23, P3212, DOI 10.1200/JCO.2005.11.486; PERRY WJ, 2003, LUNG CANCER S1, V41, pS155; Philip M, 2004, SEMIN CANCER BIOL, V14, P433, DOI 10.1016/j.semcancer.2004.06.006; Rao CV, 2004, MUTAT RES-FUND MOL M, V555, P107, DOI 10.1016/j.mrfmmm.2004.05.022; Rusznak C, 2001, CLIN EXP ALLERGY, V31, P226, DOI 10.1046/j.1365-2222.2001.01000.x; Sahnoun Z, 1998, THERAPIE, V53, P315; Sasco AJ, 2004, LUNG CANCER, V45, pS3, DOI 10.1016/j.lungcan.2004.07.998; Shiraga M, 2002, CANCER RES, V62, P5967; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Takeyama K, 2001, AM J PHYSIOL-LUNG C, V280, pL165, DOI 10.1152/ajplung.2001.280.1.L165; Tsao AS, 2003, CANCER EPIDEM BIOMAR, V12, P660; Tsurutani J, 2005, CARCINOGENESIS, V26, P1182, DOI 10.1093/carcin/bgi072; Valen G, 2001, J AM COLL CARDIOL, V38, P307, DOI 10.1016/S0735-1097(01)01377-8; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; Vlahos R, 2006, AM J PHYSIOL-LUNG C, V290, pL931, DOI 10.1152/ajplung.00201.2005; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Wislez M, 2005, CANCER RES, V65, P3226, DOI 10.1158/0008-5472.CAN-04-4420; Wistuba II, 2002, ONCOGENE, V21, P7298, DOI 10.1038/sj.onc.1205806; Xu WM, 2002, CELL RES, V12, P311, DOI 10.1038/sj.cr.7290133; Yamamoto T, 2003, J PHARMACOL EXP THER, V307, P230, DOI 10.1124/jpet.103.054676; Yang CS, 2005, EXP LUNG RES, V31, P135, DOI 10.1080/01902140490495525; Zhang Q, 2005, AM J RESP CELL MOL, V32, P72, DOI 10.1165/rcmb.2004-0198OC; Zhong CY, 2005, CARCINOGENESIS, V26, P2187, DOI 10.1093/carcin/bgi189	43	107	120	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					673	682		10.1038/sj.onc.1209829	http://dx.doi.org/10.1038/sj.onc.1209829			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16862172				2022-12-17	WOS:000243902200005
J	De Toni, F; Racaud-Sultan, C; Chicanne, G; Mansat-De Mas, V; Cariven, C; Mesange, F; Salles, JP; Demur, C; Allouche, M; Payrastre, B; Manenti, S; Ysebaert, L				De Toni, F.; Racaud-Sultan, C.; Chicanne, G.; Mansat-De Mas, V.; Cariven, C.; Mesange, F.; Salles, J-P; Demur, C.; Allouche, M.; Payrastre, B.; Manenti, S.; Ysebaert, L.			A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia	ONCOGENE			English	Article						leukemia; chemoresistance; adhesion; Wnt; GSK3 beta	GLYCOGEN-SYNTHASE KINASE-3-BETA; NF-KAPPA-B; FRIZZLED-RELATED PROTEIN-1; ACUTE MYELOGENOUS LEUKEMIA; TUMOR-NECROSIS-FACTOR; BETA-CATENIN; STEM-CELLS; DRUG-RESISTANCE; CANCER CELLS; ACTIVATION	Relapses following chemotherapy are a major hindrance to patients' survival in acute myeloid leukemia (AML). To investigate the role of the hematopoietic niche in the chemoresistance of leukemic cells, we examined two pathways: one mediated by adhesion molecules/integrins, and the other by soluble factors of the morphogen Wnt pathway. In our study, both the adhesion of leukemic blasts to fibronectin and the addition of Wnt antagonists induced, independently, resistance of AML cells to daunorubicin in a cell survival assay. Using pharmacological inhibitors and siRNA, we showed that both resistance pathways required the activity of the glycogen synthase kinase 3 beta (GSK3 beta). Moreover, the AML cell protection downstream of GSK3 beta was mediated by NF-kappa B. A link between the adhesion and the Wnt pathway was found, as adhesion of U937 on human osteoblasts, a component of the hematopoietic niche, triggered the secretion of the Wnt antagonist sFRP-1 and supported resistance to daunorubicin. The osteoblast-conditioned medium could also confer chemoresistance to U937 cells cultured in suspension, and this cell protective effect was abrogated after depletion of sFRP-1. In the context of this potential double in vivo resistance, modulators of the common signal GSK3 beta and of its target NF-kappa B could represent important novel therapeutic tools.	CHU Purpan, INSERM, U563,CPTP, Dept Oncogenesis & Hematopoiet Cells,Hosp Purpan, F-31024 Toulouse 3, France; CHU Purpan, INSERM, Hematol Lab, Unite 563, F-31024 Toulouse 3, France; CHU Purpan, INSERM, IFR 30, Unite 563,Dept Lipoprot & Mediateurs Lipid, F-31024 Toulouse 3, France; CHU Purpan, INSERM, Serv Hematol Clin, Unite 563, F-31024 Toulouse 3, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Racaud-Sultan, C (corresponding author), CHU Purpan, INSERM, U563,CPTP, Dept Oncogenesis & Hematopoiet Cells,Hosp Purpan, Pl Baylac, F-31024 Toulouse 3, France.	claire.racaud@toulouse.inserm.fr	De Mas, Véronique/P-2414-2014; Ysebaert, Loic/H-1554-2016; manenti, stephane/P-1518-2014; SALLES, Jean Pierre/K-2998-2014	Ysebaert, Loic/0000-0001-8478-5623; manenti, stephane/0000-0002-4793-3196; Racaud-Sultan, Claire/0000-0002-6549-1088; , Bernard/0000-0002-8693-0190; Chicanne, Gaetan/0000-0002-7081-2595				Bendall LJ, 1998, LEUKEMIA, V12, P1375, DOI 10.1038/sj.leu.2401136; Bournat JC, 2000, J NEUROSCI RES, V61, P21, DOI 10.1002/1097-4547(20000701)61:1<21::AID-JNR3>3.0.CO;2-7; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Chung EJ, 2002, BLOOD, V100, P982, DOI 10.1182/blood.V100.3.982; Czyz J, 2001, DIFFERENTIATION, V68, P167, DOI 10.1046/j.1432-0436.2001.680404.x; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Demarchi F, 2003, J BIOL CHEM, V278, P39583, DOI 10.1074/jbc.M305676200; Deng J, 2004, MOL CARCINOGEN, V39, P139, DOI 10.1002/mc.10169; Fukuhara K, 2002, J CLIN ENDOCR METAB, V87, P1729, DOI 10.1210/jc.87.4.1729; Ghosh JC, 2005, CLIN CANCER RES, V11, P4580, DOI 10.1158/1078-0432.CCR-04-2624; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Guzman ML, 2002, P NATL ACAD SCI USA, V99, P16220, DOI 10.1073/pnas.252462599; Han XZ, 2004, J BIOL CHEM, V279, P2832, DOI 10.1074/jbc.M308102200; Hazlehurst LA, 2003, ONCOGENE, V22, P7396, DOI 10.1038/sj.onc.1206943; Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hwang SG, 2002, LEUKEMIA RES, V26, P863, DOI 10.1016/S0145-2126(02)00018-8; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Kenny PA, 2003, INT J CANCER, V107, P688, DOI 10.1002/ijc.11491; Landowski TH, 2003, ONCOGENE, V22, P2417, DOI 10.1038/sj.onc.1206315; Lee JL, 2004, J BIOL CHEM, V279, P14602, DOI 10.1074/jbc.M309008200; Liao XB, 2003, MOL CANCER THER, V2, P1215; Matsunaga T, 2003, NAT MED, V9, P1158, DOI 10.1038/nm909; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Ougolkov AV, 2005, CANCER RES, V65, P2076, DOI 10.1158/0008-5472.CAN-04-3642; Prindull G, 2004, BLOOD, V103, P2892, DOI 10.1182/blood-2003-08-2807; Recher C, 2004, CANCER RES, V64, P3191, DOI 10.1158/0008-5472.CAN-03-3005; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; Shou J, 2002, ONCOGENE, V21, P878, DOI 10.1038/sj.onc.1205138; Siggelkow H, 1999, J CELL BIOCHEM, V75, P22, DOI 10.1002/(SICI)1097-4644(19991001)75:1<22::AID-JCB3>3.0.CO;2-6; Simon M, 2005, ONCOGENE, V24, P2410, DOI 10.1038/sj.onc.1208431; Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200; Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044; Yoganathan N, 2002, PHARMACOL THERAPEUT, V93, P233, DOI 10.1016/S0163-7258(02)00192-4	39	107	115	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3113	3122		10.1038/sj.onc.1209346	http://dx.doi.org/10.1038/sj.onc.1209346			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16407823				2022-12-17	WOS:000237951000003
J	Chen, YR; Fu, YN; Lin, CH; Yang, ST; Hu, SF; Chen, YT; Tsai, SF; Huang, SF				Chen, YR; Fu, YN; Lin, CH; Yang, ST; Hu, SF; Chen, YT; Tsai, SF; Huang, SF			Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants	ONCOGENE			English	Article						NSCLC; EGFR; mutation; gefitinib; tyrosine phosphorylation	GROWTH-FACTOR-RECEPTOR; NONSMALL CELL LUNG; TYROSINE KINASE; CANCER; MUTATIONS; ENDOCYTOSIS; INHIBITOR; GENE; RESPONSIVENESS; EXPRESSION	Mutations in the kinase domain of epidermal growth factor receptor ( EGFR) are associated with clinical responsiveness to gefitinib in patients with non-small-cell lung cancers (NSCLC). Recently, we have identified many novel EGFR mutations in NSCLC tissues. In this study, we found that gefitinib could suppress the tyrosine phosphorylation of most EGFR mutants better than the wild-type receptor. However, gefitinib had quite variable growth-suppressive effects on different EGFR mutant-expressing cells. All tested EGFR mutants have high basal phosphorylation at multiple tyrosine residues. Upon EGF stimulation, the mutated EGFRs did not have apparently stronger phosphorylation at tyrosines 845, 992, 1068, and 1173 than the wild-type receptor. However, stronger phosphorylation at tyrosine 1045 was observed in the S768I, L861Q, E709G, and G719S mutants. The E746-A750 deletion mutant was less responsive to EGF than the wild-type and other mutant receptors. The S768I, L861Q, E709G, and G719S mutants were refractory to EGF-induced ubiquitination and had more sustained tyrosine phosphorylation. E709G and G719S also lacked EGF-induced receptor downregulation. Our results indicate that, in addition to sensitivity to gefitinib, EGFR mutations also caused various changes in EGFR's regulatory mechanisms, which may contribute to the constitutive activation of EGFR mutants and oncogenesis in NSCLC.	Natl Hlth Res Inst, Div Mol & Gen Med, Zhunan 350, Taiwan; Natl Yang Ming Univ, Inst Genet & Gen Res Ctr, Taipei 112, Taiwan; Chang Gung Mem Hosp, Dept Pathol, Taipei 10591, Taiwan; Municipal Wan Fang Hosp, Dept Pathol, Taipei, Taiwan; Taipei Med Univ, Sch Med, Dept Pathol, Taipei, Taiwan	National Health Research Institutes - Taiwan; National Yang Ming Chiao Tung University; Chang Gung Memorial Hospital; Taipei Municipal WanFang Hospital; Taipei Medical University	Huang, SF (corresponding author), Natl Hlth Res Inst, Div Mol & Gen Med, 35,Keyan Rd, Zhunan 350, Taiwan.	sfhuang@nhri.org.tw	Chen, Yi-Rong/CAF-2186-2022; Tsai, Shih-Feng/E-3997-2010; Huang, Shiu-Feng Kathy/E-3977-2010; Chen, Yi-Rong/CAH-7991-2022; Chen, Yi-Rong/E-3991-2010	Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002				Amann J, 2005, CANCER RES, V65, P226; Brabender J, 2001, CLIN CANCER RES, V7, P1850; Chen YR, 2002, J BIOL CHEM, V277, P39334, DOI 10.1074/jbc.M202070200; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Fontanini G, 1998, CLIN CANCER RES, V4, P241; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Herbst RS, 2003, CLIN CANCER RES, V9, P5813; Herbst RS, 2002, J CLIN ONCOL, V20, P3815, DOI 10.1200/JCO.2002.03.038; Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Huang SF, 2004, CLIN CANCER RES, V10, P8195, DOI 10.1158/1078-0432.CCR-04-1245; Jiang XJ, 2003, TRAFFIC, V4, P529, DOI 10.1034/j.1600-0854.2003.t01-1-00109.x; Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Lai WW, 2001, ANN THORAC SURG, V72, P1868, DOI 10.1016/S0003-4975(01)03207-6; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Nakagawa K, 2003, ANN ONCOL, V14, P922, DOI 10.1093/annonc/mdg250; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; RUSCH V, 1993, CANCER RES, V53, P2379; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637	29	107	117	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1205	1215		10.1038/sj.onc.1209159	http://dx.doi.org/10.1038/sj.onc.1209159			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16205628				2022-12-17	WOS:000235537500008
J	Langenfeld, EM; Kong, Y; Langenfeld, J				Langenfeld, EM; Kong, Y; Langenfeld, J			Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5	ONCOGENE			English	Article						BMP-2; lung cancer; Smad-1/5; proliferation; Id-1; metastasis	CANCER CELL-PROLIFERATION; OSTEOBLAST-LIKE CELLS; GENE-EXPRESSION; TOOTH DEVELOPMENT; ACTIVITY GRADIENT; A549 CELLS; DIFFERENTIATION; TRANSFORMATION; INDUCTION; ID-1	Morphogenetic protein 2 (BMP-2) is normally expressed in the embryo promoting the development of several organs. Aberrant expression of BMP-2 occurs in approximately 98% of lung carcinomas, however, its role in regulating tumor growth is poorly understood. We show that BMP-2 induces Id-1 expression in lung cancer cell lines through its activation of Smad-1/ 5, which is dependent on cell culture conditions. A549 cells in DMEM/5% FCS BMP-2 activated S mad-1/5 and caused a transient increase in proliferation. In serum-free medium, BMP-2 induced significantly less Smad-1/ 5 activation and Id-1 expression, and produced significant growth inhibition. The affect of BMP-2 on tumor growth in vivo was substantially more significant. Recombinant BMP-2 coinjected with A549 cells, into nude mice increased proliferation and produced an increase in Id-1 expression. Forced expression of BMP-2 in A549 cells significantly enhanced tumor growth in the lungs following intravenous injection but not of subcutaneous tumors. Tumors in the lung were found to have an activatedSmad 1/5 and expressed Id-1. Subcutaneous tumors expressed less activated Smad-1/5 and Id-1 than that of controls. Human lung carcinomas were also found to express an activated Smad-1/5 and Id-1. We provide evidence that BMP-2 promotes tumor growth. This paper highlights that cell culture experiments may not reveal the full biological affects of BMP-2, and its activity varies depending of the local environment.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, Div Thorac Surg, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, Div Surg Sci, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Langenfeld, J (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, Div Thorac Surg, MEB 536,1 Robert Wood Johnson Pl,POB 19, New Brunswick, NJ 08903 USA.	langenje@umdnj.edu			NCI NIH HHS [K22 CA91919-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K22CA091919] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Andl T, 2004, DEVELOPMENT, V131, P2257, DOI 10.1242/dev.01125; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Clement JH, 2000, J CANCER RES CLIN, V126, P271, DOI 10.1007/s004320050342; CUNNINGHAM NS, 1992, P NATL ACAD SCI USA, V89, P11740, DOI 10.1073/pnas.89.24.11740; Dahn RD, 2000, SCIENCE, V289, P438, DOI 10.1126/science.289.5478.438; Fong S, 2003, P NATL ACAD SCI USA, V100, P13543, DOI 10.1073/pnas.2230238100; Ghosh-Choudhury N, 2000, BIOCHEM BIOPH RES CO, V272, P705, DOI 10.1006/bbrc.2000.2844; Han MJ, 2003, DEVELOPMENT, V130, P5123, DOI 10.1242/dev.00710; Ide H, 1997, CANCER RES, V57, P5022; Jiao K, 2003, GENE DEV, V17, P2362, DOI 10.1101/gad.1124803; Kameda T, 1999, GENES CELLS, V4, P175, DOI 10.1046/j.1365-2443.1999.00250.x; LANGENFELD E, 2005, IN PRESS ANN THORACI; Langenfeld EM, 2004, MOL CANCER RES, V2, P141; Langenfeld EM, 2003, CARCINOGENESIS, V24, P1445, DOI 10.1093/carcin/bgg100; Lee TKW, 2003, CARCINOGENESIS, V24, P1729, DOI 10.1093/carcin/bgg145; Lou J, 2000, BIOCHEM BIOPH RES CO, V268, P757, DOI 10.1006/bbrc.2000.2210; Mathura JR, 2000, INVEST OPHTH VIS SCI, V41, P592; Mizuseki K, 2003, P NATL ACAD SCI USA, V100, P5828, DOI 10.1073/pnas.1037282100; Myers DC, 2002, DEV BIOL, V243, P81, DOI 10.1006/dbio.2001.0523; Nakayama K, 2003, J BONE MINER RES, V18, P827, DOI 10.1359/jbmr.2003.18.5.827; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Nifuji A, 1999, J BONE MINER RES, V14, P2057, DOI 10.1359/jbmr.1999.14.12.2057; Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200; Norton JD, 2000, J CELL SCI, V113, P3897; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; Ouyang XS, 2002, CARCINOGENESIS, V23, P721, DOI 10.1093/carcin/23.5.721; Paine-Saunders S, 2002, J BIOL CHEM, V277, P2089, DOI 10.1074/jbc.M109151200; Pizette S, 2001, DEVELOPMENT, V128, P4463; Pouliot F, 2003, CANCER RES, V63, P277; Rothhammer T, 2005, CANCER RES, V65, P448; Souza CJH, 2002, REPRODUCTION, V123, P363, DOI 10.1530/rep.0.1230363; Sutherland DJ, 2003, DEVELOPMENT, V130, P5705, DOI 10.1242/dev.00801; Suzawa M, 1999, ENDOCRINOLOGY, V140, P2125, DOI 10.1210/en.140.5.2125; Suzawa M, 2002, J BONE MINER RES, V17, P240, DOI 10.1359/jbmr.2002.17.2.240; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Tada A, 1998, ONCOL REP, V5, P1137; Tamaki K, 1998, J CELL PHYSIOL, V177, P355, DOI 10.1002/(SICI)1097-4652(199811)177:2<355::AID-JCP17>3.0.CO;2-8; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Tucker AS, 1998, SCIENCE, V282, P1136, DOI 10.1126/science.282.5391.1136; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/0092-8674(93)90678-J; Weaver M, 1999, DEVELOPMENT, V126, P4005; Willette RN, 1999, J VASC RES, V36, P120, DOI 10.1159/000025634; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Yamashita H, 1996, BONE, V19, P569, DOI 10.1016/S8756-3282(96)00259-1; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7	48	107	123	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					685	692		10.1038/sj.onc.1209110	http://dx.doi.org/10.1038/sj.onc.1209110			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16247476				2022-12-17	WOS:000235068800004
J	Tomasini, R; Seux, M; Nowak, J; Bontemps, C; Carrier, A; Dagorn, JC; Pebusque, MJ; Iovanna, JL; Dusetti, NJ				Tomasini, R; Seux, M; Nowak, J; Bontemps, C; Carrier, A; Dagorn, JC; Pebusque, MJ; Iovanna, JL; Dusetti, NJ			TP53INP1 is a novel p73 target gene that induces cell cycle arrest and cell death by modulating p73 transcriptional activity	ONCOGENE			English	Article						TP53INP1; p73; apoptosis; transcriptional activity	TUMOR-SUPPRESSOR P53; INDUCED PROTEIN SIP; C-ABL; P53-DEPENDENT APOPTOSIS; REGULATES P73; CANCER-CELLS; DNA-DAMAGE; EXPRESSION; P63; CISPLATIN	TP53INP1 is an alternatively spliced gene encoding two nuclear protein isoforms (TP53INP1 alpha and TP53INP1 beta), whose transcription is activated by p53. When overexpressed, both isoforms induce cell cycle arrest in G1 and enhance p53-mediated apoptosis. TP53INP1s also interact with the p53 gene and regulate p53 transcriptional activity. We report here that TP53INP1 expression is induced during experimental acute pancreatitis in p53(-/-) mice and in cisplatin-treated p53(-/-) mouse embryo fibroblasts (MEFs). We demonstrate that ectopic expression of p73, a p53 homologue, leads to TP53INP1 induction in p53-deficient cells. In turn, TP53INP1s alters the transactivation capacity of p73 on several p53-target genes, including TP53INP1 itself, demonstrating a functional association between p73 and TP53INP1s. Also, when overexpressed in p53-deficient cells, TP53INP1s inhibit cell growth and promote cell death as assessed by cell cycle analysis and colony formation assays. Finally, we show that TP53INP1s potentiate the capacity of p73 to inhibit cell growth, that effect being prevented when the p53 mutant R175H is expressed or when p73 expression is blocked by a siRNA. These results suggest that TP53INP1s are functionally associated with p73 to regulate cell cycle progression and apoptosis, independently from p53.	Univ Mediterranee, IFR 137,Inst Cancerol & Immunol Marseille, INSERM, U624, F-13288 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Dusetti, NJ (corresponding author), Univ Mediterranee, IFR 137,Inst Cancerol & Immunol Marseille, INSERM, U624, Parc Sci & Technol Luminy,Case 915, F-13288 Marseille, France.	dusetti@marseille.inserm.fr	tomasini, richard/F-1130-2017; Dusetti, Nelson/O-7919-2017; Iovanna, Juan/M-9805-2017	tomasini, richard/0000-0003-0869-0811; Dusetti, Nelson/0000-0002-6161-8483; Iovanna, Juan/0000-0003-1822-2237				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Chau BN, 2004, MOL CELL BIOL, V24, P4438, DOI 10.1128/MCB.24.10.4438-4447.2004; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Courtois S, 2004, ONCOGENE, V23, P631, DOI 10.1038/sj.onc.1206929; Das S, 2003, ONCOGENE, V22, P8394, DOI 10.1038/sj.onc.1206908; Das S, 2003, J BIOL CHEM, V278, P18313, DOI 10.1074/jbc.M211704200; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dusetti NJ, 2000, BIOCHEM BIOPH RES CO, V277, P660, DOI 10.1006/bbrc.2000.3734; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Gong JG, 1999, NATURE, V399, P806; Hamer G, 2001, ONCOGENE, V20, P4298, DOI 10.1038/sj.onc.1204568; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; IOVANNA J, 1991, J BIOL CHEM, V266, P24664; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; MIYASHITA T, 1995, CELL, V80, P293; NIEDERAU C, 1985, GASTROENTEROLOGY, V88, P1192, DOI 10.1016/S0016-5085(85)80079-2; Obad S, 2004, ONCOGENE, V23, P4050, DOI 10.1038/sj.onc.1207524; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Oniscu A, 2004, J CLIN PATHOL, V57, P492, DOI 10.1136/jcp.2003.012559; Rodicker F, 2003, CANCER RES, V63, P2737; Sablina AA, 2003, J BIOL CHEM, V278, P27362, DOI 10.1074/jbc.M300547200; Shimodaira H, 2003, P NATL ACAD SCI USA, V100, P2420, DOI 10.1073/pnas.0438031100; Shinbo J, 2002, BIOCHEM BIOPH RES CO, V295, P501, DOI 10.1016/S0006-291X(02)00707-6; Stiewe T, 2001, APOPTOSIS, V6, P447, DOI 10.1023/A:1012433522902; Strano S, 2001, FEBS LETT, V490, P163, DOI 10.1016/S0014-5793(01)02119-6; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Tomasin R, 2001, J BIOL CHEM, V276, P44185, DOI 10.1074/jbc.M105647200; Tomasini R, 2003, J BIOL CHEM, V278, P37722, DOI 10.1074/jbc.M301979200; Tomasini R, 2002, EUR J CELL BIOL, V81, P294, DOI 10.1078/0171-9335-00248; Torigoe Takayuki, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P15, DOI 10.2174/1568011053352587; Tsuji K, 2002, J BIOL CHEM, V277, P2951, DOI 10.1074/jbc.M108535200; Tullo A, 2003, ONCOGENE, V22, P8738, DOI 10.1038/sj.onc.1206967; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607	40	107	115	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8093	8104		10.1038/sj.onc.1208951	http://dx.doi.org/10.1038/sj.onc.1208951			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16044147				2022-12-17	WOS:000233809400002
J	Luwor, RB; Lu, Y; Li, XQ; Mendelsohn, J; Fan, Z				Luwor, RB; Lu, Y; Li, XQ; Mendelsohn, J; Fan, Z			The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression	ONCOGENE			English	Article						HIF-1 alpha; VEGF; EGF receptor; Akt; Ras; PTEN	CELL LUNG-CANCER; FACTOR 1-ALPHA HIF-1-ALPHA; TYROSINE KINASE INHIBITOR; SMOOTH-MUSCLE-CELLS; TUMOR-CELLS; FACTOR (HIF)-1-ALPHA; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; NITRIC-OXIDE; SOLID TUMORS	We have previously shown that the antiepidermal growth factor receptor monoclonal antibody cetuximab (C225; Erbitux), which was recently approved for the treatment of metastatic colorectal cancer, has antiangiogenic properties, inhibiting vascular endothelial growth factor (VEGF) secretion in culture and in animal models. Here, we have furthered the study by demonstrating that cetuximab reduces cellular levels of hypoxia-inducible factor-1 alpha (HIF-1 alpha), a transcriptional regulator of VEGF expression, in A431 epidermoid carcinoma cells under both normoxic and hypoxic culture conditions. Expression of a constitutively active Ras in A431 cells rendered cellular resistance to the cetuximab-mediated reduction of the HIF-1 alpha level. Cell lines with naturally occurring phosphatase and tensin homologue deleted on chromosome 10 mutations or deletions were also resistant to cetuximab-mediated reduction of the HIF-1 alpha level. Pharmacologic inhibition of phosphatidylinositol 3-kinase with LY294002 reduced the HIF-1 alpha level in both normoxic and hypoxic A431 cells, whereas inhibition of the mitogen- activated protein kinase kinase by PD98059 reduced the level of HIF-1 alpha only in normoxic A431 cells. In addition, cetuximab reduced the cellular level of HIF-1 alpha in the presence of a proteasome inhibitor, lactacystin, indicating that cetuximab acts mainly at the level of protein synthesis. The reduction of HIF-1 alpha in response to cetuximab treatment was accompanied by transcriptional inhibition of VEGF expression, measured by a luciferase assay in A431 cells transfected with a vector containing the VEGF hypoxia response element. Taken together, our results indicate that the previously demonstrated inhibition of VEGF by cetuximab occurs at the level of transcription in response to a reduced level of HIF-1 alpha and justify further testing of therapeutic strategies that combine cetuximab with approaches inhibiting the function of VEGF or the VEGF receptor.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 036, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 036, 1515 Holcombe Blvd, Houston, TX 77030 USA.	zfan@mdanderson.org		Luwor, Rodney/0000-0002-3020-4245				Albanell J, 2001, CANCER RES, V61, P6500; Alvarez-Tejado M, 2001, J BIOL CHEM, V276, P22368, DOI 10.1074/jbc.M011688200; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bacus SS, 2002, ONCOGENE, V21, P3532, DOI 10.1038/sj.onc.1205438; Beitner-Johnson D, 2001, CELL SIGNAL, V13, P23, DOI 10.1016/S0898-6568(00)00128-5; Bianco R, 2003, ONCOGENE, V22, P2812, DOI 10.1038/sj.onc.1206388; Blancher C, 2001, CANCER RES, V61, P7349; Blancher C, 2000, CANCER RES, V60, P7106; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Ciardiello F, 2000, CLIN CANCER RES, V6, P3739; Clarke K, 2001, BRIT J CANCER, V84, P1322, DOI 10.1054/bjoc.2001.1805; Cohen MH, 2004, CLIN CANCER RES, V10, P1212, DOI 10.1158/1078-0432.CCR-03-0564; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; FAN Z, 1993, CANCER RES, V53, P4322; FAN Z, 1993, CANCER RES, V53, P4637; Fan Zhen, 1998, Current Opinion in Oncology, V10, P67, DOI 10.1097/00001622-199801000-00011; Feldser D, 1999, CANCER RES, V59, P3915; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Giaccone G, 2004, J CLIN ONCOL, V22, P777, DOI 10.1200/JCO.2004.08.001; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harper ME, 2002, PROSTATE, V52, P59, DOI 10.1002/pros.10069; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Herbst RS, 2004, J CLIN ONCOL, V22, P785, DOI 10.1200/JCO.2004.07.215; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Huang SM, 2002, CANCER RES, V62, P4300; Huang SM, 2002, MOL CANCER THER, V1, P507; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jiang BH, 1997, CANCER RES, V57, P5328; Jin W, 2003, BRIT J CANCER, V89, P185, DOI 10.1038/sj.bjc.6601048; Jung YD, 2002, EUR J CANCER, V38, P1133, DOI 10.1016/S0959-8049(02)00013-8; Karashima T, 2002, CLIN CANCER RES, V8, P1253; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Liang K, 2003, INT J RADIAT ONCOL, V57, P246, DOI 10.1016/S0360-3016(03)00511-X; Liu BL, 2001, ONCOGENE, V20, P1913, DOI 10.1038/sj.onc.1204277; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Milas L, 2000, CLIN CANCER RES, V6, P701; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Palmer LA, 2000, MOL PHARMACOL, V58, P1197, DOI 10.1124/mol.58.6.1197; Perrotte P, 1999, CLIN CANCER RES, V5, P257; Petit AMV, 1997, AM J PATHOL, V151, P1523; Post DE, 2001, GENE THER, V8, P1801, DOI 10.1038/sj.gt.3301605; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Richard DE, 2000, J BIOL CHEM, V275, P26765; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Ruas JL, 2005, J CELL SCI, V118, P301, DOI 10.1242/jcs.01617; Sandau KB, 2000, BIOCHEM BIOPH RES CO, V278, P263, DOI 10.1006/bbrc.2000.3789; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Shaheen RM, 2001, BRIT J CANCER, V85, P584, DOI 10.1054/bjoc.2001.1936; She QB, 2003, CLIN CANCER RES, V9, P4340; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Shimada K, 2004, MOL CARCINOGEN, V39, P1, DOI 10.1002/mc.10158; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Sweeney P, 2002, CLIN CANCER RES, V8, P2714; Tacchini L, 2001, CARCINOGENESIS, V22, P1363, DOI 10.1093/carcin/22.9.1363; Thornton RD, 2000, BIOCHEM J, V350, P307, DOI 10.1042/0264-6021:3500307; Traxler P, 2004, CANCER RES, V64, P4931, DOI 10.1158/0008-5472.CAN-03-3681; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vlietstra RJ, 1998, CANCER RES, V58, P2720; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhang SXL, 2003, FASEB J, V17, P1709, DOI 10.1096/fj.02-1111fje; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	78	107	111	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4433	4441		10.1038/sj.onc.1208625	http://dx.doi.org/10.1038/sj.onc.1208625			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806152				2022-12-17	WOS:000229976900012
J	Valabrega, G; Montemurro, F; Sarotto, I; Petrelli, A; Rubini, P; Tacchetti, C; Aglietta, M; Comoglio, PM; Giordano, S				Valabrega, G; Montemurro, F; Sarotto, I; Petrelli, A; Rubini, P; Tacchetti, C; Aglietta, M; Comoglio, PM; Giordano, S			TGF alpha expression impairs trastuzumab-induced HER2 downregulation	ONCOGENE			English	Article						HER2; Cbl ubiquitin ligase; TGF alpha; receptor degradation	METASTATIC BREAST-CANCER; EPIDERMAL-GROWTH-FACTOR; MONOCLONAL-ANTIBODY; C-CBL; PROTOONCOGENE PRODUCT; ERBB RECEPTORS; LUNG-CANCER; CELL; UBIQUITINATION; CHEMOTHERAPY	The HER2 gene encodes a tyrosine kinase receptor overexpressed in 25-30% of human breast cancers. Clinical trials have shown the efficacy of the anti-HER2 monoclonal antibody Trastuzumab in metastatic breast cancer patients. Nevertheless, 70% of patients are unresponsive from start of treatment and nearly all become unresponsive during treatment. Possible mechanisms for these failures could depend on impairment of the machinery responsible for receptor downregulation. To test this hypothesis, we analysed the genomic sequences encoding regions known to be critical for HER2 downregulation, of both HER2 and of the ubiquitin ligase Cbl. We investigated 63 breast cancers, and found no mutations in these regions. We thus considered alternative mechanisms - such as TGF alpha production - possibly interfering with HER2 downregulation. In selected cases, by comparing breast cancer neoplastic tissue before and after Trastuzumab treatment, we found induction of TGF alpha expression. Moreover, by in vitro expression of exogenous TGF alpha in breast cancer cells, we observed a dramatic reduction in Trastuzumab-induced HER2 endocytosis, downregulation and cell growth inhibition. Our results suggest that unresponsiveness to Trastuzumab may not be due to intrinsic defects in the machinery responsible for HER2 downregulation, but can be associated with a TGF alpha-related mechanism of escape to HER2 downregulation.	Univ Turin, Sch Med, IRCC, Div Mol Oncol, I-10060 Candiolo, Italy; Univ Turin, Sch Med, IRCC, Div Med Oncol, I-10060 Candiolo, Italy; Univ Turin, Sch Med, IRCC, Dept Pathol, I-10060 Candiolo, Italy; Univ Genoa, Anat Sect, FIRC Inst Mol Oncol, Dept Expt Med, I-16132 Genoa, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; IFOM - FIRC Institute of Molecular Oncology; University of Genoa	Giordano, S (corresponding author), Univ Turin, Sch Med, IRCC, Div Mol Oncol, Str Prov 142,Km 3-95, I-10060 Candiolo, Italy.	silvia.giordano@ircc.it	Montemurro, Filippo/AAC-1957-2019; Valabrega, Giorgio/J-7313-2018; sarotto, ivana/AAB-7797-2020; Giordano, Silvia/J-9858-2018	Giordano, Silvia/0000-0003-1854-1086; Comoglio, Paolo/0000-0002-7056-5328; Montemurro, Filippo/0000-0003-4231-2291; AGLIETTA, Massimo/0000-0002-2255-7972; VALABREGA, Giorgio/0000-0001-5444-6305; TACCHETTI, CARLO/0000-0003-4602-000X				Alwan HAJ, 2003, J BIOL CHEM, V278, P35781, DOI 10.1074/jbc.M301326200; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cooley S, 1999, EXP HEMATOL, V27, P1533, DOI 10.1016/S0301-472X(99)00089-2; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Johannes L, 2002, TRAFFIC, V3, P443, DOI 10.1034/j.1600-0854.2002.30701.x; Klapper LN, 2000, CANCER RES, V60, P3384; Kumar-Sinha C, 2003, CANCER RES, V63, P132; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Levkowitz G, 2000, J BIOL CHEM, V275, P35532, DOI 10.1074/jbc.M002661200; Levkowitz G, 1996, ONCOGENE, V12, P1117; Leyland-Jones B, 2002, LANCET ONCOL, V3, P137, DOI 10.1016/S1470-2045(02)00676-9; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Molina MA, 2001, CANCER RES, V61, P4744; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Normanno N, 2002, ANN ONCOL, V13, P65, DOI 10.1093/annonc/mdf020; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Rabouille C, 1999, METH MOL B, V117, P125; Shah NP, 2003, ONCOGENE, V22, P7389, DOI 10.1038/sj.onc.1206942; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; TACCHETTI C, 1987, J CELL BIOL, V105, P999, DOI 10.1083/jcb.105.2.999; Tubbs RR, 2001, J CLIN ONCOL, V19, P2714, DOI 10.1200/JCO.2001.19.10.2714; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; zum Buschenfelde CM, 2002, CANCER RES, V62, P2244	32	107	109	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3002	3010		10.1038/sj.onc.1208478	http://dx.doi.org/10.1038/sj.onc.1208478			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735715				2022-12-17	WOS:000228649500009
J	Ciemerych, MA; Sicinski, P				Ciemerych, MA; Sicinski, P			Cell cycle in mouse development	ONCOGENE			English	Review						mouse embryo; development; cell cycle	DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA GENE FAMILY; SKIN TUMOR-DEVELOPMENT; B-TYPE CYCLIN; MICE LACKING; TRANSCRIPTION FACTORS; S-PHASE; PROTEIN-KINASE; E2F FAMILY; DNA-REPLICATION	Mice likely represent the most- studied mammalian organism, except for humans. Genetic engineering in embryonic stem cells has allowed derivation of mouse strains lacking particular cell cycle proteins. Analyses of these mutant mice, and cells derived from them, facilitated the studies of the functions of cell cycle apparatus at the organismal and cellular levels. In this review, we give some background about the cell cycle progression during mouse development. We next discuss some insights about in vivo functions of the cell cycle proteins, gleaned from mouse knockout experiments. Our text is meant to provide examples of the recent experiments, rather than to supply an extensive and complete list.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Warsaw, Fac Biol, Inst Zool, Dept Embryol, PL-02096 Warsaw, Poland	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University of Warsaw	Sicinski, P (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.	peter_sicinski@dfci.harvard.edu		Ciemerych, Maria A./0000-0003-0387-4179	NCI NIH HHS [R01 CA085296] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085296] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADENOT PG, 1991, MOL REPROD DEV, V28, P23, DOI 10.1002/mrd.1080280105; Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; AGUZZI A, 1996, TRANSGENICS, V2, P29; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Arata Y, 2000, J BIOL CHEM, V275, P6337, DOI 10.1074/jbc.275.9.6337; BACHVAROVA R, 1980, DEV BIOL, V74, P1, DOI 10.1016/0012-1606(80)90048-2; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Biggers JD, 1997, HUM REPROD UPDATE, V3, P125, DOI 10.1093/humupd/3.2.125; Blaisdell J, 2004, PHARMACOGENETICS, V14, P527, DOI 10.1097/01.fpc.0000114759.08559.51; BOLTON VN, 1984, J EMBRYOL EXP MORPH, V79, P139; BOUNIOL C, 1995, EXP CELL RES, V218, P57, DOI 10.1006/excr.1995.1130; BouniolBaly C, 1997, EXP CELL RES, V236, P201, DOI 10.1006/excr.1997.3708; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Brandeis M, 1998, P NATL ACAD SCI USA, V95, P4344, DOI 10.1073/pnas.95.8.4344; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Burns KH, 2003, MOL ENDOCRINOL, V17, P2053, DOI 10.1210/me.2003-0038; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHAPMAN DL, 1993, DEVELOPMENT, V118, P229; CHAPMAN DL, 1992, MOL REPROD DEV, V33, P259, DOI 10.1002/mrd.1080330305; Chen B, 2003, MOL ENDOCRINOL, V17, P1368, DOI 10.1210/me.2003-0036; Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; Chen P, 2003, NAT CELL BIOL, V5, P422, DOI 10.1038/ncb976; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CHOI T, 1991, DEVELOPMENT, V113, P789; Ciemerych MA, 1999, ZYGOTE, V7, P293, DOI 10.1017/S0967199499000696; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Clark AJ, 2004, BLOOD, V104, P1324, DOI 10.1182/blood-2004-02-0618; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cloud JE, 2002, MOL CELL BIOL, V22, P2663, DOI 10.1128/MCB.22.8.2663-2672.2002; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; COPP AJ, 1978, J EMBRYOL EXP MORPH, V48, P109; Coverley D, 2000, J CELL SCI, V113, P1929; Cross JC, 2000, SEMIN CELL DEV BIOL, V11, P105, DOI 10.1006/scdb.2000.0156; Dagnino L, 1997, MECH DEVELOP, V66, P13, DOI 10.1016/S0925-4773(97)00083-X; Dagnino L, 1997, CELL GROWTH DIFFER, V8, P553; Dahme T, 2002, EUR J BIOCHEM, V269, P5030, DOI 10.1046/j.1432-1033.2002.03210.x; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; de Marval PLM, 2004, MOL CELL BIOL, V24, P7538, DOI 10.1128/MCB.24.17.7538-7547.2004; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; DONAHUE RP, 1972, J EXP ZOOL, V180, P305, DOI 10.1002/jez.1401800303; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; Draviam VM, 2001, J CELL BIOL, V152, P945, DOI 10.1083/jcb.152.5.945; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Eggan K, 2001, P NATL ACAD SCI USA, V98, P6209, DOI 10.1073/pnas.101118898; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eppig JJ, 1996, REPROD FERT DEVELOP, V8, P485, DOI 10.1071/RD9960485; Faast R, 2004, ONCOGENE, V23, P491, DOI 10.1038/sj.onc.1207133; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Felzien LK, 1999, MOL CELL BIOL, V19, P4241; Ferguson KL, 2002, EMBO J, V21, P3337, DOI 10.1093/emboj/cdf338; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FLACH G, 1982, EMBO J, V1, P681, DOI 10.1002/j.1460-2075.1982.tb01230.x; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Fuchimoto D, 2001, BIOL REPROD, V65, P986, DOI 10.1095/biolreprod65.4.986; Furstenthal L, 2001, J CELL BIOL, V152, P1267, DOI 10.1083/jcb.152.6.1267; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GALLANT P, 1994, EMBO J, V13, P595, DOI 10.1002/j.1460-2075.1994.tb06297.x; Garcia I, 2000, CELL GROWTH DIFFER, V11, P91; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; Georgia S, 2004, J CLIN INVEST, V114, P963, DOI 10.1172/JCI200422098; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOEDBLOED JF, 1977, ACTA ANAT, V98, P162; Gopalkrishnan RV, 1996, ONCOGENE, V13, P2671; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARPER JW, 1993, CELL, V75, P805; HARRISON DJ, 1995, ONCOGENE, V10, P1615; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Hogan B., 1994, MANIPULATING MOUSE E, P19; HOWLETT SK, 1985, J EMBRYOL EXP MORPH, V87, P175; HU NP, 1994, ONCOGENE, V9, P1021; Huard JMT, 1999, DEVELOPMENT, V126, P1927; Hulit J, 2004, MOL CELL BIOL, V24, P7598, DOI 10.1128/MCB.24.17.7598-7611.2004; Humbert PO, 2000, GENE DEV, V14, P690; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; Iglesias A, 2004, J CLIN INVEST, V113, P1398, DOI 10.1172/JCI200418879; Iwamori N, 2002, FEBS LETT, V526, P119, DOI 10.1016/S0014-5793(02)03121-6; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Janatpour MJ, 2000, DEVELOPMENT, V127, P549; Jiang Z, 1997, ONCOGENE, V14, P1789, DOI 10.1038/sj.onc.1201014; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Jirawatnotai S, 2003, J BIOL CHEM, V278, P17021, DOI 10.1074/jbc.M301206200; KAKIZUKA A, 1992, GENE DEV, V6, P578, DOI 10.1101/gad.6.4.578; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Kherrouche Z, 2001, BIOCHEM BIOPH RES CO, V288, P22, DOI 10.1006/bbrc.2001.5718; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kohn MJ, 2004, MOL CELL BIOL, V24, P7197, DOI 10.1128/MCB.24.16.7197-7205.2004; Kohn MJ, 2003, DEVELOPMENT, V130, P1295, DOI 10.1242/dev.00355; Kohoutek J, 2004, BIOL REPROD, V70, P139, DOI 10.1095/biolreprod.103.017335; KONG YF, 1995, MOL CELL BIOL, V15, P5205; Korsisaari N, 2002, J CELL SCI, V115, P4275, DOI 10.1242/jcs.00121; Kowalczyk A, 2004, J CELL BIOL, V167, P209, DOI 10.1083/jcb.200404181; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Kusek JC, 2000, INT J DEV BIOL, V44, P267; KUSHNER JA, IN PRESS MOL CELL BI; Lam EWF, 2000, J BIOL CHEM, V275, P3479, DOI 10.1074/jbc.275.5.3479; Lammer C, 1998, J CELL SCI, V111, P2445; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Leclerc V, 1996, MOL BIOL CELL, V7, P505, DOI 10.1091/mbc.7.4.505; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Li FX, 2003, P NATL ACAD SCI USA, V100, P12935, DOI 10.1073/pnas.2231861100; LI Y, 1994, ONCOGENE, V9, P2261; Lincoln AJ, 2002, NAT GENET, V30, P446, DOI 10.1038/ng856; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Lipinski MM, 2001, EMBO J, V20, P3402, DOI 10.1093/emboj/20.13.3402; Liu D, 2000, DEV BIOL, V224, P388, DOI 10.1006/dbio.2000.9776; Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Lozano JC, 2002, BIOCHEM BIOPH RES CO, V291, P406, DOI 10.1006/bbrc.2002.6458; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; MACAULEY A, 1993, DEVELOPMENT, V117, P873; MacPherson D, 2004, GENE DEV, V18, P1681, DOI 10.1101/gad.1203304; MacPherson D, 2003, MOL CELL BIOL, V23, P1044, DOI 10.1128/MCB.23.3.1044-1053.2003; MACQUEEN HA, 1983, J EMBRYOL EXP MORPH, V77, P297; Maher ER, 2000, J CLIN INVEST, V105, P247, DOI 10.1172/JCI9340; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; Mayer W, 2000, J CELL BIOL, V148, P629, DOI 10.1083/jcb.148.4.629; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; Mettus RV, 2003, ONCOGENE, V22, P8413, DOI 10.1038/sj.onc.1206888; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; Mitra J, 1996, J CELL SCI, V109, P2407; Moore GD, 1996, MOL REPROD DEV, V45, P264, DOI 10.1002/(SICI)1098-2795(199611)45:3&lt;264::AID-MRD2&gt;3.0.CO;2-Q; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; Murga M, 2001, IMMUNITY, V15, P959, DOI 10.1016/S1074-7613(01)00254-0; Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nguyen TB, 2002, J BIOL CHEM, V277, P41960, DOI 10.1074/jbc.M203951200; Nieduszynski CA, 2002, GENOME BIOL, V3; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; OOKATA K, 1993, J CELL SCI, V105, P873; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pagano M, 2004, MOL CELL, V14, P414, DOI 10.1016/S1097-2765(04)00268-0; Palena A, 2000, MECH DEVELOP, V97, P211, DOI 10.1016/S0925-4773(00)00420-2; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Poolman RA, 1998, INT J CARDIOL, V67, P133, DOI 10.1016/S0167-5273(98)00320-9; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; Ramocki MB, 1998, J BIOL CHEM, V273, P17696, DOI 10.1074/jbc.273.28.17696; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Ravnik SE, 1996, DEV BIOL, V173, P69, DOI 10.1006/dbio.1996.0007; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Ren SJ, 2004, CELL, V117, P239, DOI 10.1016/S0092-8674(04)00300-9; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; Rickert P, 1996, ONCOGENE, V12, P2631; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rodriguez-Puebla ML, 2002, AM J PATHOL, V161, P405, DOI 10.1016/S0002-9440(10)64196-X; Rogers KT, 1996, P NATL ACAD SCI USA, V93, P7594, DOI 10.1073/pnas.93.15.7594; Rossi DJ, 2001, EMBO J, V20, P2844, DOI 10.1093/emboj/20.11.2844; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Savatier P, 1996, ONCOGENE, V12, P309; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2004, ONCOGENE, V23, P379, DOI 10.1038/sj.onc.1207074; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SMITH RKW, 1986, J REPROD FERTIL, V76, P393, DOI 10.1530/jrf.0.0760393; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; Solvason N, 2000, INT IMMUNOL, V12, P631, DOI 10.1093/intimm/12.5.631; SORENSEN RA, 1976, DEV BIOL, V50, P531, DOI 10.1016/0012-1606(76)90172-X; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Spike BT, 2004, EMBO J, V23, P4319, DOI 10.1038/sj.emboj.7600432; Stewart CL, 1997, DEV GENET, V21, P91, DOI 10.1002/(SICI)1520-6408(1997)21:1&lt;91::AID-DVG11&gt;3.0.CO;2-D; Storre J, 2002, EMBO REP, V3, P695, DOI 10.1093/embo-reports/kvf141; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Sweeney C, 1996, DEVELOPMENT, V122, P53; Takahashi C, 2003, MOL CELL BIOL, V23, P5256, DOI 10.1128/MCB.23.15.5256-5268.2003; Tanaka K, 1997, EXP CELL RES, V237, P264, DOI 10.1006/excr.1997.3788; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Tetzlaff MT, 2004, MOL CELL BIOL, V24, P2487, DOI 10.1128/MCB.24.6.2487-2498.2004; Tevosian SG, 1996, CELL GROWTH DIFFER, V7, P43; Tong W, 1998, CELL GROWTH DIFFER, V9, P787; Tong W, 2001, MOL CELL BIOL, V21, P1319, DOI 10.1128/MCB.21.4.1319-1328.2001; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; TSAI LH, 1993, ONCOGENE, V8, P1593; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wianny F, 1998, DEV DYNAM, V212, P49, DOI 10.1002/(SICI)1097-0177(199805)212:1<49::AID-AJA5>3.0.CO;2-2; WICKRAMASINGHE D, 1995, DEVELOPMENT, V121, P2047; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; Winston N, 2000, DEV BIOL, V223, P139, DOI 10.1006/dbio.2000.9721; WRIGHT SJ, 1988, J EXP ZOOL, V247, P155, DOI 10.1002/jez.1402470207; WU CL, 1995, MOL CELL BIOL, V15, P2536; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; WU S, 1995, DEV BIOL, V170, P195, DOI 10.1006/dbio.1995.1207; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yanagimachi R., 1994, P189; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yang R, 1997, CANCER RES, V57, P913; Ye X, 2001, P NATL ACAD SCI USA, V98, P1682, DOI 10.1073/pnas.041596198; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001; ZHANG YH, 1995, ONCOGENE, V10, P2085; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000; Zindy F, 1997, CELL GROWTH DIFFER, V8, P1139; Zindy F, 2001, MOL CELL BIOL, V21, P3244, DOI 10.1128/MCB.21.9.3244-3255.2001; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	290	107	110	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2877	2898		10.1038/sj.onc.1208608	http://dx.doi.org/10.1038/sj.onc.1208608			22	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838522				2022-12-17	WOS:000228465800012
J	Gauld, SB; Cambier, JC				Gauld, SB; Cambier, JC			Src-family kinases in B-cell development and signaling	ONCOGENE			English	Review						Src kinase; B-lymphocyte; antigen receptor; signaling; development	PROTEIN-TYROSINE KINASE; LYN-DEFICIENT MICE; RECEPTOR-MEDIATED SIGNALS; PHOSPHORYLATED IG-ALPHA; ANTIGEN RECEPTOR; NEGATIVE REGULATION; PROCESSIVE AMPLIFICATION; ADAPTER PROTEIN; CUTTING EDGE; ACTIVATION	The Src-family protein tyrosine kinases (SFKs) are known to play key roles in initiating signal transduction by the B-cell antigen receptor (BCR). In addition, numerous studies have shown that this family of molecules also contributes to signaling by BCR surrogates during B-lymphocyte lineage development and maturation. Paradoxically, ablation of SFKs not only results in obvious defects in B-cell development but also in the onset of autoimmunity. Thus SFKs, most notably Lyn, play both activating and inhibitory roles in B-cell function. Confounding analyses of SFK function in B cells is the varied coexpression of family members that mediate redundant as well as unique functions. In this review, we will focus mainly on the role of Lyn in mediating positive and negative roles in B-cell activation and how these affect immune signaling and disease progression.	Univ Colorado, Hlth Sci Ctr, Integrated Dept Immunol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health	Cambier, JC (corresponding author), Univ Colorado, Hlth Sci Ctr, Integrated Dept Immunol, 1400 Jackson St, Denver, CO 80206 USA.	cambierj@njc.org		Cambier, John/0000-0002-7803-242X				Adachi T, 1998, J IMMUNOL, V160, P4662; Awasthi-Kalia M, 2001, BIOCHEM BIOPH RES CO, V287, P77, DOI 10.1006/bbrc.2001.5536; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Buhl AM, 1997, J EXP MED, V186, P1897, DOI 10.1084/jem.186.11.1897; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; Campbell KS, 1995, MOL IMMUNOL, V32, P1283, DOI 10.1016/0161-5890(95)00088-7; Chan VWF, 1998, CURR BIOL, V8, P545, DOI 10.1016/S0960-9822(98)70223-4; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; Cornall RJ, 1999, CURR TOP MICROBIOL, V244, P57; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; DeFranco AL, 1998, SEMIN IMMUNOL, V10, P299, DOI 10.1006/smim.1998.0122; Fong DC, 2000, J IMMUNOL, V165, P4453, DOI 10.4049/jimmunol.165.8.4453; Fuentes-Panana EM, 2004, IMMUNOL REV, V197, P26, DOI 10.1111/j.0105-2896.2004.0105.x; Fujimoto M, 2000, IMMUNITY, V13, P47, DOI 10.1016/S1074-7613(00)00007-8; Fujimoto M, 1999, IMMUNITY, V11, P191, DOI 10.1016/S1074-7613(00)80094-1; Fujimoto M, 1999, J IMMUNOL, V162, P7088; Fujimoto M, 2001, J BIOL CHEM, V276, P44820, DOI 10.1074/jbc.M107559200; Fujimoto M, 2000, IMMUNOL RES, V22, P281, DOI 10.1385/IR:22:2-3:281; Gupta N, 2003, MOL BIOL CELL, V14, P432, DOI 10.1091/mbc.02-05-0078; Hasegawa M, 2001, J IMMUNOL, V167, P2469, DOI 10.4049/jimmunol.167.5.2469; Hibbs ML, 2002, J EXP MED, V196, P1593, DOI 10.1084/jem.20020515; Hong JJ, 2002, J BIOL CHEM, V277, P31703, DOI 10.1074/jbc.M201362200; Hsueh RC, 2000, ADV IMMUNOL, V75, P283, DOI 10.1016/S0065-2776(00)75007-3; Janas ML, 1999, J IMMUNOL, V163, P4192; JOHNSON SA, 1995, J IMMUNOL, V155, P4596; Katagiri T, 1999, J IMMUNOL, V163, P1321; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Lang P, 2001, SCIENCE, V291, P1537, DOI 10.1126/science.291.5508.1537; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P2818, DOI 10.1002/eji.1830241136; Lee KH, 2003, SCIENCE, V302, P1218, DOI 10.1126/science.1086507; Lee KH, 2002, SCIENCE, V295, P1539, DOI 10.1126/science.1067710; Maeda A, 1999, ONCOGENE, V18, P2291, DOI 10.1038/sj.onc.1202552; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; Meade J, 2002, EUR J IMMUNOL, V32, P1029, DOI 10.1002/1521-4141(200204)32:4<1029::AID-IMMU1029>3.0.CO;2-M; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343; O'Rourke LM, 1998, IMMUNITY, V8, P635, DOI 10.1016/S1074-7613(00)80568-3; Okazaki T, 2001, P NATL ACAD SCI USA, V98, P13866, DOI 10.1073/pnas.231486598; Otipoby KL, 2001, J BIOL CHEM, V276, P44315, DOI 10.1074/jbc.M105446200; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; Pao LI, 1998, J IMMUNOL, V160, P3305; Pao LI, 1997, J IMMUNOL, V158, P2663; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; Pracht C, 2002, EUR J IMMUNOL, V32, P1614, DOI 10.1002/1521-4141(200206)32:6<1614::AID-IMMU1614>3.0.CO;2-A; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RESH MD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P307, DOI 10.1016/0304-419X(93)90012-2; ROIFMAN CM, 1993, BIOCHEM BIOPH RES CO, V194, P222, DOI 10.1006/bbrc.1993.1807; Saijo K, 2003, NAT IMMUNOL, V4, P274, DOI 10.1038/ni893; Sato S, 1997, P NATL ACAD SCI USA, V94, P13158, DOI 10.1073/pnas.94.24.13158; Sen G, 1999, EUR J IMMUNOL, V29, P3319; Shrivastava P, 2004, BLOOD, V103, P1425, DOI 10.1182/blood-2003-03-0716; Smith KGC, 1998, J EXP MED, V187, P807, DOI 10.1084/jem.187.5.807; Sproul TW, 2000, J IMMUNOL, V165, P6020, DOI 10.4049/jimmunol.165.11.6020; Tatosyan AG, 2000, BIOCHEMISTRY-MOSCOW+, V65, P49; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; Wang JY, 1996, J EXP MED, V184, P831, DOI 10.1084/jem.184.3.831; WECHSLER RJ, 1995, J IMMUNOL, V154, P1919; WENG WK, 1994, J BIOL CHEM, V269, P32514; Whyburn LR, 2003, J IMMUNOL, V171, P1850, DOI 10.4049/jimmunol.171.4.1850; Wienands J, 1996, P NATL ACAD SCI USA, V93, P7865, DOI 10.1073/pnas.93.15.7865; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; Yamanashi Y, 2000, GENE DEV, V14, P11; Yanagi S, 1996, J BIOL CHEM, V271, P30487, DOI 10.1074/jbc.271.48.30487	69	107	109	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2004	23	48					8001	8006		10.1038/sj.onc.1208075	http://dx.doi.org/10.1038/sj.onc.1208075			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863JR	15489917				2022-12-17	WOS:000224558300010
J	Hwang, YS; Jeong, M; Park, JS; Kim, MH; Lee, DB; Shin, BA; Mukaida, N; Ellis, LM; Kim, HR; Ahn, BW; Jung, YD				Hwang, YS; Jeong, M; Park, JS; Kim, MH; Lee, DB; Shin, BA; Mukaida, N; Ellis, LM; Kim, HR; Ahn, BW; Jung, YD			Interleukin-1 beta stimulates IL-8 expression through MAP kinase and ROS signaling in human gastric carcinoma cells	ONCOGENE			English	Article						IL-8; MAPK; ROS; gastric cancer; IL-1 beta	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; HELICOBACTER-PYLORI; MESSENGER-RNA; TRANSCRIPTION FACTOR; ACTIVATION; ANGIOGENESIS; CANCER; LINE; GENE	Recent studies have suggested that the expression of interleukin-8 (IL-8) directly correlates with the vascularity of human gastric carcinomas. In this study, the effect of IL-1beta on IL-8 expression in human gastric cancer TMK-1 cells and the underlying signal transduction pathways were investigated. IL-1beta induced the IL-8 expression in a time- and concentration-dependent manner. IL-1beta induced the activation of extracellular signal-regulated kinases-1/2 and P38 mitogen-activated protein kinase ( MAPK), but not the activation of c-jun amino-terminal kinse and Akt. Specific inhibitors of MEK-1 (PD980590) and P38 MAPK (SB203580) were found to suppress the IL-8 expression and the IL-8 promoter activity. Expression of vectors encoding a mutated-type MEK-1 and P38 MAPK resulted in decrease in the IL-8 promoter activity. IL-1beta also induced the production of reactive oxygen species (ROS). N-acetyl cysteine (NAC) prevented the IL-1beta-induced ROS production and IL-8 expression. In addition, exogenous H2O2 could induce the IL-8 expression. Deletional and site-directed mutagenesis studies on the IL-8 promoter revealed that activator protein-1 (AP-1) and nuclear factor (NF)-kappaB sites were required for the IL-1beta-induced IL-8 transcription. Electrophoretic mobility shift assay confirmed that IL-1beta increased the DNA-binding activity of AP-1 and NF-kappaB. Inhibitor ( PD980590, SB203580) and ROS scavenger ( NAC) studies revealed that the upstream signalings for the transcription factors AP-1 and NF-kappaB were MAPK and ROS, respectively. Conditioned media from the TMK-1 cells pretreated with IL-1beta could remarkably stimulate the in vitro growth of HUVEC and this effect was partially abrogated by IL-8-neutralizing antibodies. The above results suggest that MAPK-AP-1 and ROS-NF-kappaB signaling pathways are involved in the IL-1beta-induced IL-8 expression and that these paracrine signaling pathways induce endothelial cell proliferation.	Chonnam Natl Univ, Sch Med, Chonnam Univ Res Inst Med Sci, Dept Biochem, Kwangju 501190, South Korea; Kanazawa Univ, Canc Res Inst, Div Mol Bioregulat, Kanazawa, Ishikawa 9200934, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	Chonnam National University; Kanazawa University; University of Texas System; UTMD Anderson Cancer Center	Jung, YD (corresponding author), Chonnam Natl Univ, Sch Med, Chonnam Univ Res Inst Med Sci, Dept Biochem, 5 Hakdong, Kwangju 501190, South Korea.	ydjung@chonnam.ac.kr	KIM, MI HA/E-9765-2013; Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851				Anthonsen MW, 2001, J BIOL CHEM, V276, P35344, DOI 10.1074/jbc.M105264200; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Duval C, 2003, FREE RADICAL BIO MED, V35, P1589, DOI 10.1016/j.freeradbiomed.2003.09.008; Emrick MA, 2001, J BIOL CHEM, V276, P46469, DOI 10.1074/jbc.M107708200; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Ganesh S, 1996, CANCER-AM CANCER SOC, V77, P1035, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1035::AID-CNCR5>3.0.CO;2-G; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Goede V, 1998, LAB INVEST, V78, P1385; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; Guiraldes E, 2001, J PEDIATR GASTR NUTR, V33, P127, DOI 10.1097/00005176-200108000-00006; Harris GK, 2003, MUTAT RES-FUND MOL M, V533, P183, DOI 10.1016/j.mrfmmm.2003.08.025; Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200; Hirschi K K, 1997, EXS, V79, P419; Hofmeister R, 1997, J BIOL CHEM, V272, P27730, DOI 10.1074/jbc.272.44.27730; Jung YD, 2002, CYTOKINE, V18, P206, DOI 10.1006/cyto.2002.1034; KASAHARA T, 1991, IMMUNOLOGY, V74, P60; Katsuyama K, 2001, J BIOCHEM, V129, P585, DOI 10.1093/oxfordjournals.jbchem.a002894; Kitadai Y, 1999, BRIT J CANCER, V81, P647, DOI 10.1038/sj.bjc.6690742; Kitadai Y, 1998, AM J PATHOL, V152, P93; Klezovitch O, 2001, J BIOL CHEM, V276, P46864, DOI 10.1074/jbc.M107943200; KUNSCH C, 1994, J IMMUNOL, V153, P153; Lo YYC, 1998, J CELL BIOCHEM, V69, P19, DOI 10.1002/(SICI)1097-4644(19980401)69:1<19::AID-JCB3>3.0.CO;2-Y; Maeda S, 2001, J BIOL CHEM, V276, P44856, DOI 10.1074/jbc.M105381200; Mastronarde JG, 1998, J INFECT DIS, V177, P1275, DOI 10.1086/515279; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; OCHIAI A, 1985, JPN J CANCER RES, V76, P1064; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Rennekampff HO, 2000, J SURG RES, V93, P41, DOI 10.1006/jsre.2000.5892; Schwarz M, 1997, KIDNEY INT, V52, P1521, DOI 10.1038/ki.1997.482; Shin EY, 2001, EXP MOL MED, V33, P276, DOI 10.1038/emm.2001.45; Singh RK, 2000, HISTOL HISTOPATHOL, V15, P843, DOI 10.14670/HH-15.843; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Straubinger RK, 2003, INFECT IMMUN, V71, P2693, DOI 10.1128/IAI.71.5.2693-2703.2003; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Wang MC, 1999, J GASTROENTEROL, V34, P10; Welsh N, 1996, J BIOL CHEM, V271, P8307, DOI 10.1074/jbc.271.14.8307; Wolf JS, 2001, CLIN CANCER RES, V7, P1812; Wu LL, 2004, CLIN CHIM ACTA, V339, P1, DOI 10.1016/j.cccn.2003.09.010; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506	40	107	111	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6603	6611		10.1038/sj.onc.1207867	http://dx.doi.org/10.1038/sj.onc.1207867			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15208668				2022-12-17	WOS:000223530800007
J	Joseph, J; Mudduluru, G; Antony, S; Vashistha, S; Ajitkumar, P; Somasundaram, K				Joseph, J; Mudduluru, G; Antony, S; Vashistha, S; Ajitkumar, P; Somasundaram, K			Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB	ONCOGENE			English	Article						sodium butyrate; histone deacetyalse inhibitor; chromatin remodeling; microarray; expression profiling; cytokine signaling; metastasis	HISTONE DEACETYLASE INHIBITOR; KAPPA-B ACTIVATION; CHAIN FATTY-ACIDS; INTERFERON-GAMMA; PROSTATE-CANCER; IFN-GAMMA; IN-VITRO; GROWTH-INHIBITION; EPITHELIAL-CELLS; CROHNS-DISEASE	Histone deacetylase (HDAC) inhibitors induce growth arrest and apoptosis in a variety of human cancer cells. Sodium butyrate (NaB), a short chain fatty acid, is a HDAC inhibitor and is produced in the colonic lumen as a consequence of microbial degradation of dietary fibers. In order to dissect out the mechanism of NaB-induced growth inhibition of cancer cells, we carried out expression pro. ling of a human lung carcinoma cell line (H460) treated with NaB using a cDNA microarray. Of the total 1728 genes analysed, there were 32 genes with a mean expression value of 2.0-fold and higher and 66 genes with a mean expression value 3.0-fold and lower in NaB-treated cells. For a few selected genes, we demonstrate that their expression pattern by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis is matching with the results obtained by microarray analysis. Closer view at the expression pro. le of NaB-treated cells revealed the downregulation of a total of 16 genes associated with cytokine signaling, in particular, interferon gamma (IFNgamma) pathway. In good correlation, NaB-pretreated cells failed to induce interferon regulatory factor 1, an INFgamma target gene, efficiently upon IFNgamma addition. These results suggest that NaB inhibits proinflammatory cytokine signaling pathway, thus providing proof of mechanism for its anti-inflammatory activity. We also found that NaB induced three genes, which are known metastatic suppressors, and downregulated 11 genes, which have been shown to promote metastasis. Upregulation of metastatic suppressor Kangai 1 (KAI1) by NaB in a time-dependent manner was confirmed by RT-PCR analysis. The differential regulation of metastasis-associated genes by NaB provides explanation for the anti-invasive properties of NaB. Therefore, our study presents new evidence for pathways regulated by NaB, thus providing evidence for the mechanism behind anti-inflammatory and antimetastatic activities of NaB.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Somasundaram, K (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.	skumar@mcbl.iisc.ernet.in						Ailenberg M, 2002, BIOCHEM BIOPH RES CO, V298, P110, DOI 10.1016/S0006-291X(02)02420-8; Andoh A, 1999, JPEN-PARENTER ENTER, V23, pS70, DOI 10.1177/014860719902300518; BREESE E, 1993, IMMUNOLOGY, V78, P127; BUGAUT M, 1993, ANNU REV NUTR, V13, P217, DOI 10.1146/annurev.nu.13.070193.001245; Butler LM, 2000, CANCER RES, V60, P5165; Chai F, 2000, CARCINOGENESIS, V21, P7, DOI 10.1093/carcin/21.1.7; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; CHAROLLAIS RH, 1990, J CELL PHYSIOL, V145, P46, DOI 10.1002/jcp.1041450108; Cheung VG, 1999, NAT GENET, V21, P15, DOI 10.1038/4439; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Clarke KO, 2001, CANCER LETT, V171, P57, DOI 10.1016/S0304-3835(01)00574-2; CUMMINGS JH, 1981, GUT, V22, P763, DOI 10.1136/gut.22.9.763; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Das S, 2003, ONCOGENE, V22, P8394, DOI 10.1038/sj.onc.1206908; Das S, 2003, J BIOL CHEM, V278, P18313, DOI 10.1074/jbc.M211704200; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; DeRisi J, 1996, NAT GENET, V14, P457; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FAIS S, 1991, GUT, V32, P403, DOI 10.1136/gut.32.4.403; Fuss IJ, 1996, J IMMUNOL, V157, P1261; Gore SD, 2000, EXPERT OPIN INV DRUG, V9, P2923, DOI 10.1517/13543784.9.12.2923; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Iacomino G, 2001, BIOCHEM BIOPH RES CO, V285, P1280, DOI 10.1006/bbrc.2001.5323; Inan MS, 2000, GASTROENTEROLOGY, V118, P724, DOI 10.1016/S0016-5085(00)70142-9; Jove R, 2000, ONCOGENE, V19, P2466, DOI 10.1038/sj.onc.1203549; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; KAWAMATA H, 1995, INT J CANCER, V63, P680, DOI 10.1002/ijc.2910630513; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kim MS, 2000, CANCER LETT, V157, P23, DOI 10.1016/S0304-3835(00)00465-1; Klampfer L, 2003, MOL CANCER RES, V1, P855; Lallemand F, 1996, BIOCHEM BIOPH RES CO, V229, P163, DOI 10.1006/bbrc.1996.1774; LEARY JA, 1995, INT J CANCER, V64, P189, DOI 10.1002/ijc.2910640308; Lehninger A., 1993, PRINCIPLES BIOCH; Liu LT, 2003, CANCER RES, V63, P3069; Luhrs H, 2002, SCAND J GASTROENTERO, V37, P458, DOI 10.1080/003655202317316105; Luhrs H, 2002, ANTICANCER RES, V22, P1561; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Masuda T, 2000, IN VITRO CELL DEV-AN, V36, P387; McIntosh GH, 1996, J GASTROEN HEPATOL, V11, P113, DOI 10.1111/j.1440-1746.1996.tb00046.x; MCINTYRE A, 1993, GUT, V34, P386, DOI 10.1136/gut.34.3.386; Medina V, 1997, CANCER RES, V57, P3697; Miele ME, 1997, CLIN EXP METASTAS, V15, P259, DOI 10.1023/A:1018473415458; MORITA A, 1982, CANCER RES, V42, P4540; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pellizzaro C, 2001, INT J CANCER, V91, P654, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1117>3.0.CO;2-I; Phillips KK, 1998, MOL CARCINOGEN, V21, P111, DOI 10.1002/(SICI)1098-2744(199802)21:2<111::AID-MC5>3.0.CO;2-Q; Ranganna K, 2000, MOL CELL BIOCHEM, V205, P149, DOI 10.1023/A:1007078200482; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; RINKERSCHAEFFER CW, 1994, CANCER RES, V54, P6249; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Saemann MD, 2000, FASEB J, V14, P2380; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schreiber S, 1998, GUT, V42, P477, DOI 10.1136/gut.42.4.477; Segain JP, 2000, GUT, V47, P397, DOI 10.1136/gut.47.3.397; Siavoshian S, 2000, GUT, V46, P507, DOI 10.1136/gut.46.4.507; Tabuchi Y, 2000, CELL STRUCT FUNCT, V25, P297, DOI 10.1247/csf.25.297; TSAO D, 1982, CANCER RES, V42, P1052; Urnov FD, 2003, J CELL BIOCHEM, V88, P684, DOI 10.1002/jcb.10397; Velazquez OC, 1997, ADV EXP MED BIOL, V427, P123; Wajapeyee N, 2003, J BIOL CHEM, V278, P52093, DOI 10.1074/jbc.M305624200; Wang JX, 1999, CANCER RES, V59, P2766; Weidle UH, 2000, ANTICANCER RES, V20, P1471; Whiteley LO, 1996, DIGEST DIS SCI, V41, P1458, DOI 10.1007/BF02088573; Widmer J, 1996, BIOCHEM J, V316, P915, DOI 10.1042/bj3160915; Xiao HY, 1997, BIOCHEM BIOPH RES CO, V237, P457, DOI 10.1006/bbrc.1997.7158; Yim JH, 2003, J INTERF CYTOK RES, V23, P501, DOI 10.1089/10799900360708623; Yin L, 2001, J BIOL CHEM, V276, P44641, DOI 10.1074/jbc.M105170200	71	107	113	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6304	6315		10.1038/sj.onc.1207852	http://dx.doi.org/10.1038/sj.onc.1207852			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15318170	Green Accepted			2022-12-17	WOS:000223399000015
J	Castellone, MD; Guarino, V; De Falco, V; Carlomagno, F; Basolo, F; Faviana, P; Kruhoffer, M; Orntoft, T; Russel, JP; Rothstein, JL; Fusco, A; Santoro, M; Melillo, RM				Castellone, MD; Guarino, V; De Falco, V; Carlomagno, F; Basolo, F; Faviana, P; Kruhoffer, M; Orntoft, T; Russel, JP; Rothstein, JL; Fusco, A; Santoro, M; Melillo, RM			Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas	ONCOGENE			English	Article						thyroid tumor; RET/PTC oncogenes; chemokine receptor	RET TYROSINE KINASE; LUNG-CANCER CELLS; BREAST-CANCER; SIGNALING PATHWAY; INVASIVE GROWTH; HIGH PREVALENCE; BRAF MUTATIONS; IN-VITRO; KAPPA-B; METASTASIS	To identify genes involved in the transformation of thyroid follicular cells, we explored, using DNA oligonucleotide microarrays, the transcriptional response of PC CI3 rat thyroid epithelial cells to the ectopic expression of the RET/PTC oncogenes. We found that RET/PTC was able to induce the expression of CXCR4, the receptor for the chemokine CXCL12/SDF-1alpha/beta. We observed that CXCR4 expression correlated with the transforming ability of the oncoprotein and depended on the integrity of the RET/PTC-RAS/ERK signaling pathway. We found that CXCR4 was expressed in RET/PTC-positive human thyroid cancer cell lines, but not in normal thyroid cells. Furthermore, we found CXCR4 expression in human thyroid carcinomas, but not in normal thyroid samples by immunohistochemistry. Since CXCR4 has been recently implicated in tumor proliferation, motility and invasiveness, we asked whether treatment with SDF-1alpha was able to induce a biological response in thyroid cells. We observed that SDF-1alpha induced S-phase entry and survival of thyroid cells. Invasion through a reconstituted extracellular matrix was also supported by SDF-1alpha and inhibited by a blocking antibody to CXCR4. Taken together, these results suggest that human thyroid cancers bearing RET/PTC rearrangements may use the CXCR4/SDF-1alpha: receptor-ligand pathway to proliferate, survive and migrate.	CNR G Salvatore, Ist Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Dipartimento Oncol, Pisa, Italy; Aarhus Univ Hosp, Mol Diagnost Lab, Dept Clin Biochem, DK-8000 Aarhus, Denmark; Thomas Jefferson Univ, Dept Microbiol Immunol, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Otolaryngol Head & Neck Surg, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); Aarhus University; Jefferson University; Jefferson University	Melillo, RM (corresponding author), CNR G Salvatore, Ist Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy.	rosmelil@unina.it	Faviana, Pinuccia/L-5620-2019; Faviana, Pinuccia/ABA-8436-2021; DE FALCO, VALENTINA/C-2061-2015; melillo, rosa marina/O-5255-2015; Basolo, Fulvio/AAC-2727-2019; FAVIANA, PINUCCIA/R-7928-2017	Faviana, Pinuccia/0000-0003-4283-1083; DE FALCO, VALENTINA/0000-0002-8972-7921; Basolo, Fulvio/0000-0003-1657-5020; FAVIANA, PINUCCIA/0000-0003-4283-1083; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037; Fusco, Alfredo/0000-0003-3332-5197; MELILLO, Rosa Marina/0000-0002-9233-5275				Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Aust G, 2001, J CLIN ENDOCR METAB, V86, P3368, DOI 10.1210/jc.86.7.3368; Bachelder RE, 2002, CANCER RES, V62, P7203; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Barbero S, 2003, CANCER RES, V63, P1969; Basolo F, 2002, INT J CANCER, V97, P608, DOI 10.1002/ijc.10116; Bernards R, 2003, NATURE, V425, P247, DOI 10.1038/425247a; Buckwalter TLF, 2002, ONCOGENE, V21, P8166, DOI 10.1038/sj.onc.1205938; Burger M, 2003, ONCOGENE, V22, P8093, DOI 10.1038/sj.onc.1207097; Carlomagno F, 2002, CANCER RES, V62, P7284; Carlomagno F, 2002, CANCER RES, V62, P1077; Castellone MD, 2003, ONCOGENE, V22, P246, DOI 10.1038/sj.onc.1206112; Cerutti J, 1996, CLIN CANCER RES, V2, P119; Chen YC, 2003, CANCER RES, V63, P4801; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; CURCIO F, 1994, P NATL ACAD SCI USA, V91, P9004, DOI 10.1073/pnas.91.19.9004; De Clercq E, 2003, NAT REV DRUG DISCOV, V2, P581, DOI 10.1038/nrd1134; De Vita G, 2000, CANCER RES, V60, P3727; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Kijima T, 2002, CANCER RES, V62, P6304; Kimura ET, 2003, CANCER RES, V63, P1454; Knauf JA, 2003, ONCOGENE, V22, P4406, DOI 10.1038/sj.onc.1206602; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kroll TG, 2002, AM J PATHOL, V160, P1941, DOI 10.1016/S0002-9440(10)61142-X; Lorenz K, 2003, NATURE, V426, P574, DOI 10.1038/nature02158; Ludwig L, 2001, CANCER RES, V61, P4526; Medico E, 2001, CANCER RES, V61, P5861; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami H, 2002, J BIOL CHEM, V277, P32781, DOI 10.1074/jbc.M202336200; Murakami T, 2002, CANCER RES, V62, P7328; Murphy PM, 2001, NEW ENGL J MED, V345, P833, DOI 10.1056/NEJM200109133451113; Namba H, 2003, J CLIN ENDOCR METAB, V88, P4393, DOI 10.1210/jc.2003-030305; Nikiforov YE, 2002, ENDOCR PATHOL, V13, P3, DOI 10.1385/EP:13:1:03; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; Oh JW, 2001, J IMMUNOL, V166, P2695, DOI 10.4049/jimmunol.166.4.2695; Ohta K, 2001, J CLIN ENDOCR METAB, V86, P2170, DOI 10.1210/jc.86.5.2170; Pelicci G, 2002, MOL CELL BIOL, V22, P7351, DOI 10.1128/MCB.22.20.7351-7363.2002; Powell DJ, 1998, CANCER RES, V58, P5523; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Russell JP, 2003, ONCOGENE, V22, P4569, DOI 10.1038/sj.onc.1206759; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; Santoro M, 1996, ONCOGENE, V12, P1821; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; Scotton CJ, 2002, CANCER RES, V62, P5930; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Taichman RS, 2002, CANCER RES, V62, P1832; Tamamura H, 2003, FEBS LETT, V550, P79, DOI 10.1016/S0014-5793(03)00824-X; Wang JW, 2003, MOL ENDOCRINOL, V17, P1425, DOI 10.1210/me.2003-0041; Xu XL, 2003, CANCER RES, V63, P4561; Zeelenberg IS, 2003, CANCER RES, V63, P3833; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200	58	107	116	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5958	5967		10.1038/sj.onc.1207790	http://dx.doi.org/10.1038/sj.onc.1207790			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15184868				2022-12-17	WOS:000222941100010
J	Li, L; Hooi, D; Chhabra, SR; Pritchard, D; Shaw, PE				Li, L; Hooi, D; Chhabra, SR; Pritchard, D; Shaw, PE			Bacterial N-acylhomoserine lactone-induced apoptosis in breast carcinoma cells correlated with down-modulation of STAT3	ONCOGENE			English	Article						apoptosis; autocrine signal; Janus kinases; cell cycle	PSEUDOMONAS-AERUGINOSA; CONSTITUTIVE ACTIVATION; SIGNALING PATHWAY; CANCER CELLS; C-MYC; SURVIVAL; GROWTH; KINASE; SRC; DIFFERENTIATION	Cell growth is promoted by mitogens and survival factors, which activate intracellular signalling pathways to control cell cycle progression and cellular integrity. Proliferation signals are transmitted through Ras and Rho family small G-proteins coupled to mitogen-activated protein kinase ( MAPK) cascades, while survival signals are propagated by lipid-dependent kinases such as phosphatidylinositide 3-kinases (PI3Ks) and protein kinase B (Akt/PKB). Recently, signal transducer and activator of transcription ( STAT) proteins were identified as positive regulators of proliferation in a variety of cell types. Persistent activation of these pathways is associated with tumour cell growth, whereas their inhibition can halt proliferation and precipitate apoptotic cell death. The human pathogen Pseudomonas aeruginosa uses quorum-sensing signal molecules (QSSMs) to regulate virulence gene expression. QSSMs also suppress host immune responses although the mechanism of suppression is unknown. Here, we demonstrate that the QSSM N-(3-oxododecanoyl)-L-homoserine lactone (OdDHL) from P. aeruginosa blocks proliferation and induces apoptosis in human BC cell lines. Analyses of signalling events reveal that OdDHL has little or no effect on MAPK cascades, partially inhibits the Akt/PKB pathway and ablates STAT3 activity. Pharmacological inhibition of each pathway independently indicates that STAT3 activity is critical for BC cell proliferation and survival, while a constitutively active STAT3 confers resistance to OdDHL. These results support the notion of OdDHL as a bioactive molecule in eukaryotic systems and a paradigm for a novel class of antiproliferative compounds.	Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England; Univ Nottingham, Sch Pharm, Immune Modulat Res Grp, Nottingham NG7 2RD, England	University of Nottingham; University of Nottingham	Shaw, PE (corresponding author), Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England.	peter.shaw@nottingham.ac.uk		SHAW, Peter/0000-0002-2598-4283				Bild AH, 2002, EMBO J, V21, P3255, DOI 10.1093/emboj/cdf351; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gooch JL, 1999, CANCER LETT, V144, P31, DOI 10.1016/S0304-3835(99)00208-6; Haan S, 2000, BIOCHEM J, V345, P417, DOI 10.1042/0264-6021:3450417; Hasegawa T, 2003, BLOOD, V101, P1164, DOI 10.1182/blood-2002-05-1505; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; Kotenko SV, 2000, ONCOGENE, V19, P2557, DOI 10.1038/sj.onc.1203524; Lackmann M, 1998, GROWTH FACTORS, V16, P39, DOI 10.3109/08977199809017490; Li L, 2002, J BIOL CHEM, V277, P17397, DOI 10.1074/jbc.M109962200; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; Liu HT, 2003, BLOOD, V102, P344, DOI 10.1182/blood-2002-11-3396; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; Pesci EC, 1997, J BACTERIOL, V179, P3127, DOI 10.1128/jb.179.10.3127-3132.1997; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Seidel HM, 2000, ONCOGENE, V19, P2645, DOI 10.1038/sj.onc.1203550; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Smith RS, 2002, J BACTERIOL, V184, P1132, DOI 10.1128/jb.184.4.1132-1139.2002; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; Telford G, 1998, INFECT IMMUN, V66, P36, DOI 10.1128/IAI.66.1.36-42.1998; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WINSON MK, 1995, P NATL ACAD SCI USA, V92, P9427, DOI 10.1073/pnas.92.20.9427; Yamauchi T, 2000, J BIOL CHEM, V275, P33937, DOI 10.1074/jbc.M000743200	39	107	111	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4894	4902		10.1038/sj.onc.1207612	http://dx.doi.org/10.1038/sj.onc.1207612			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15064716				2022-12-17	WOS:000222104200010
J	Dallol, A; Krex, D; Hesson, L; Eng, C; Maher, ER; Latif, F				Dallol, A; Krex, D; Hesson, L; Eng, C; Maher, ER; Latif, F			Frequent epigenetic inactivation of the SLIT2 gene in gliomas	ONCOGENE			English	Article						SLIT2; glioma; methylation	TUMOR-SUPPRESSOR GENE; BREAST CANCERS; LATERAL POSITION; DNA METHYLATION; ROBO RECEPTORS; AXON GUIDANCE; HUMAN HOMOLOG; CPG ISLAND; RASSF1A; 3P21.3	The SLIT family of genes consists of large extracellular matrix-secreted and membrane-associated glycoproteins. The Slits (Slit1-3) are ligands for the repulsive guidance receptors, the roho gene family. The Slit-Robo interactions mediate the repulsive cues on axons and growth cones during neural development. In a recent report, we demonstrated that promoter region CpG island of human SLIT2 was frequently hypermethylated in lung, breast and colorectal tumours and the silenced gene transcript suppressed the malignant phenotype in in vitro assays. In this report we undertook epigenetic, genetic and expression analysis of SLIT2 gene in a large series of gliomas and glioma cell lines. Promoter region CpG island of SLIT2 was found to be methylated in 71% (5/7) of glioma cell lines and was unmethylated in five DNA samples from normal brain tissues. The hypermethylation of the SLIT2 promoter region in glioma cell lines correlated with loss of expression and treatment with the demethylating agent 5-aza-2'-deoxycytidine reactivated SLIT2 gene expression. In primary gliomas, SLIT2 was methylated in 59% (37/63) of tumours analysed. In addition, SLIT2 expression was downregulated in methylated gliomas relative to unmethylated tumour samples, as demonstrated by quantitative real-time RT-PCR. Loss of heterozygosity analysis revealed that SLIT2 methylated gliomas retained both alleles of a microsatellite marker within 100 kb of the SLIT2 gene at 4p15.2. Exogenous expression of SLIT2 in a glioma cell tine that was heavily methylated for SLIT2 decreased in vitro colony formation. Our data indicate that SLIT2 is frequently inactivated by promoter region CpG island hypermethylation in gliomas and may be a good candidate for a glioma tumour suppressor gene (TSG) located at 4p15.2. Furthermore, our data suggest that a detailed analysis of both the cancer genome and epigenome will be required to identify key TSGs involved in glioma development.	Univ Birmingham, Sect Med & Mol Genet, Div Reprod & Child Hlth, Birmingham B15 2TT, W Midlands, England; Tech Univ Dresden, Dept Neurosurg, Univ Klinikum Carl Gustav Carus, D-01307 Dresden, Germany; Ohio State Univ, Clin Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA; Univ Birmingham, Canc Res UK, Renal Mol Oncol Res Grp, Birmingham B15 2TG, W Midlands, England	University of Birmingham; Technische Universitat Dresden; Carl Gustav Carus University Hospital; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Cancer Research UK; University of Birmingham	Latif, F (corresponding author), Univ Birmingham, Sect Med & Mol Genet, Div Reprod & Child Hlth, Birmingham B15 2TT, W Midlands, England.		Dallol, Ashraf/H-8661-2012; Hesson, Luke/HDM-0311-2022; MAHER, EAMONN R/A-9507-2008; Krex, Dietmar/E-6833-2014	Dallol, Ashraf/0000-0002-8803-228X; MAHER, EAMONN R/0000-0002-6226-6918; Eng, Charis/0000-0002-3693-5145				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Burton EC, 2002, CANCER RES, V62, P6205; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Dallol A, 2003, CANCER RES, V63, P1054; Dallol A, 2002, CANCER RES, V62, P5874; Dallol A, 2002, ONCOGENE, V21, P3020, DOI 10.1038/sj.onc.1205421; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; GREGER V, 1994, HUM GENET, V94, P491; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Lo KW, 2001, CANCER RES, V61, P3877; Louis DN, 2002, CANCER CELL, V1, P125, DOI 10.1016/S1535-6108(02)00040-5; Lusher ME, 2002, CANCER RES, V62, P5906; Morrissey C, 2001, CANCER RES, V61, P7277; Rajagopalan S, 2000, CELL, V103, P1033, DOI 10.1016/S0092-8674(00)00207-5; Simpson JH, 2000, CELL, V103, P1019, DOI 10.1016/S0092-8674(00)00206-3; Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Xian J, 2001, P NATL ACAD SCI USA, V98, P15062, DOI 10.1073/pnas.251407098; Yin D, 2002, ONCOGENE, V21, P8372, DOI 10.1038/sj.onc.1206031	28	107	115	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4611	4616		10.1038/sj.onc.1206687	http://dx.doi.org/10.1038/sj.onc.1206687			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881718				2022-12-17	WOS:000184054700017
J	Zeller, C; Hinzmann, B; Seitz, S; Prokoph, H; Burkhard-Goettges, E; Fischer, J; Jandrig, B; Schwarz, LE; Rosenthal, A; Scherneck, S				Zeller, C; Hinzmann, B; Seitz, S; Prokoph, H; Burkhard-Goettges, E; Fischer, J; Jandrig, B; Schwarz, LE; Rosenthal, A; Scherneck, S			SASH1: a candidate tumor suppressor gene on chromosome 6q24.3 is downregulated in breast cancer	ONCOGENE			English	Article						breast cancer; LOH analysis; 6q24.3; tumor suppressor genes; SAM; SH3	OVARIAN-CANCER; CELL-LINES; ALLELIC LOSS; IN-SITU; PROTEIN; CARCINOMA; 6Q; IDENTIFICATION; SUSCEPTIBILITY; REGION	Loss of heterozygosity (LOH) and in silico expression analysis were applied to identify genes significantly downregulated in breast cancer within the genomic interval 6q23-25. Systematic comparison of candidate EST sequences with genomic sequences from this interval revealed the genomic structure of a potential target gene on 6q24.3, which we called SAM and SH3 domain containing I (SASH1). Loss of the gene-internal marker D6S311, found in 30% of primary breast cancer, was significantly correlated with poor survival and increase in tumor size. Two SASH1 transcripts of approximately 4.4 and 7.5 kb exist and are predominantly transcribed in the human breast, lung, thyroid, spleen, placenta and thymus. In breast cancer cell tines, SASH1 is only expressed at low levels. SASH1 is downregulated in the majority (74%) of breast tumors in comparison with corresponding normal breast epithelial tissues. In addition, SASH1 is also downregulated in tumors of the lung and thyroid. Analysis of the protein domain structure revealed that SASH1 is a member of a recently described family of SH3/SAM adapter molecules and thus suggests a role in signaling pathways. We assume that SASH1 is a new tumor suppressor gene possibly involved in tumorigenesis of breast and other solid cancers. We were unable to find mutations in the coding region of the gene in primary breast cancers showing LOH within the critical region. We therefore hypothesize that other mechanisms as for instance methylation of the promoter region of SASH1 are responsible for the loss of expression of SASH1 in primary and metastatic breast cancer.	Max Delbruck Ctr Mol Med, Dept Tumor Genet, D-13125 Berlin, Germany; MetaGen Pharmaceut GmbH, D-13347 Berlin, Germany; Robert Roessle Hosp, Dept Med Informat, D-13122 Berlin, Germany; Robert Roessle Hosp, Dept Surg & Surg Oncol, D-13122 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Zeller, C (corresponding author), Max Delbruck Ctr Mol Med, Dept Tumor Genet, Robert Roessle Str 10, D-13125 Berlin, Germany.	c.zeller@mdc-berlin.de						Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; Acevedo CM, 2002, CANCER-AM CANCER SOC, V94, P793, DOI 10.1002/cncr.10275; Barghorn A, 2001, AM J PATHOL, V158, P1903, DOI 10.1016/S0002-9440(10)64658-5; Beer S, 2001, BBA-GENE STRUCT EXPR, V1520, P89, DOI 10.1016/S0167-4781(01)00242-1; Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Claudio J, 2001, ONCOGENE, V20, P5373, DOI 10.1038/sj.onc.1204698; de Jong MM, 2002, J MED GENET, V39, P225, DOI 10.1136/jmg.39.4.225; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; Goeze A, 2002, J PATHOL, V196, P8, DOI 10.1002/path.1009; Hofmann W, 2002, INT J CANCER, V97, P472, DOI 10.1002/ijc.1626; Huang LW, 2000, HUM PATHOL, V31, P367, DOI 10.1016/S0046-8177(00)80252-X; Kim CA, 2002, NAT STRUCT BIOL, V9, P453, DOI 10.1038/nsb802; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; Pagotto U, 2000, CANCER RES, V60, P6794; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rodriguez C, 2000, GENE CHROMOSOME CANC, V27, P76, DOI 10.1002/(SICI)1098-2264(200001)27:1<76::AID-GCC10>3.0.CO;2-E; Sachs L, 1992, ANGEW STAT, V7; Schmitt AO, 1999, NUCLEIC ACIDS RES, V27, P4251, DOI 10.1093/nar/27.21.4251; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Shridhar V, 1999, ONCOGENE, V18, P3913, DOI 10.1038/sj.onc.1202756; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; Srikantan V, 1999, INT J CANCER, V84, P331, DOI 10.1002/(SICI)1097-0215(19990621)84:3<331::AID-IJC23>3.0.CO;2-J; Stallmach I, 2002, VIRCHOWS ARCH, V440, P77, DOI 10.1007/s004280100523; Theile M, 1996, ONCOGENE, V13, P677; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; Uchida T, 2001, BIOCHEM BIOPH RES CO, V288, P137, DOI 10.1006/bbrc.2001.5722; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Wan MH, 1999, ONCOGENE, V18, P1545, DOI 10.1038/sj.onc.1202476; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; WURSTERHILL DH, 1984, CANCER GENET CYTOGEN, V13, P303, DOI 10.1016/0165-4608(84)90075-X; YOO HW, 1993, GENOMICS, V15, P21, DOI 10.1006/geno.1993.1005; Zhang YM, 1998, HUM GENET, V103, P727; ZUPPAN P, 1991, AM J HUM GENET, V48, P1065	40	107	115	3	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2003	22	19					2972	2983		10.1038/sj.onc.1206474	http://dx.doi.org/10.1038/sj.onc.1206474			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771949				2022-12-17	WOS:000182824800013
J	Im, E; von Lintig, FC; Chen, J; Zhuang, SH; Qui, WS; Chowdhury, S; Worley, PF; Boss, GR; Pilz, RB				Im, E; von Lintig, FC; Chen, J; Zhuang, SH; Qui, WS; Chowdhury, S; Worley, PF; Boss, GR; Pilz, RB			Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells	ONCOGENE			English	Article						Rheb; B-Raf kinase; MAP kinase; mammalian cells	EPIDERMAL GROWTH-FACTOR; SMALL GTPASES; A-RAF; PROTEIN; IDENTIFICATION; GENE; FIBROBLASTS; PATHWAY; YEAST; CAMP	Rheb (Ras homolog enriched in brain) is a member of the Ras family of proteins, and is in the immediate Ras/Rap/Ral subfamily. We found in three different mammalian cell lines that Rheb was highly activated, to levels much higher than for Ras or Rap 1, and that Rheb's activation state was unaffected by changes in growth conditions. Rheb's high activation was not secondary to unique glycine to arginine, or glycine to serine substitutions at positions 14 and 15, corresponding to Ras residues 12 and 13, since Rheb R14G and R14G, S15G mutants had similarly high activation levels as wild type Rheb. These data are consistent with earlier work which showed that purified Rheb has similar GTPase activity as Ras, and suggest a relative intracellular deficiency of Rheb GTPase activating proteins (GAPs) compared to Rheb activators. Further evidence for relatively low intracellular GAP activity was that increased Rheb expression led to a marked increase in Rheb activation. Rheb, like Ras and Rap1, bound B-Raf kinase, but in contrast to Ras and Rap 1, Rheb inhibited B-Raf kinase activity and prevented B-Raf-dependent activation of the transcription factor Elk-l. Thus, Rheb appears to be a unique member of the Ras/Rap/Ral subfamily, and in mammatian systems may serve to regulate B-Raf kinase activity.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Johns Hopkins Univ, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21205 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Johns Hopkins University; Johns Hopkins University	Pilz, RB (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.			Boss, Gerry/0000-0002-9758-8714	NCI NIH HHS [CA81115, CA76968] Funding Source: Medline; NIGMS NIH HHS [GM55586] Funding Source: Medline; NIMH NIH HHS [MH53608] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA076968, R21CA081115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CATLING AD, 1994, J BIOL CHEM, V269, P30014; Clark GJ, 1997, J BIOL CHEM, V272, P10608; Dupuy AJ, 2001, J BIOL CHEM, V276, P11804, DOI 10.1074/jbc.M008970200; EYCHENE A, 1995, ONCOGENE, V10, P1159; Gromov PS, 1995, FEBS LETT, V377, P221, DOI 10.1016/0014-5793(95)01349-0; Guha A, 1996, ONCOGENE, V12, P507; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kuroda S, 1996, J BIOL CHEM, V271, P14680, DOI 10.1074/jbc.271.25.14680; Mach KE, 2000, GENETICS, V155, P611; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Mizuki N, 1996, GENOMICS, V34, P114, DOI 10.1006/geno.1996.0248; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; Papin C, 1996, ONCOGENE, V12, P2213; PAPIN C, 1995, ONCOGENE, V10, P1647; Pilz RB, 1997, CELL GROWTH DIFFER, V8, P53; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Qiu WS, 2000, J BIOL CHEM, V275, P31921, DOI 10.1074/jbc.M003327200; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHEELE JS, 1994, J BIOL CHEM, V269, P18599; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; TIAN W, 2000, AM J PHYSIOL, V278, P372; Urano J, 2001, METHOD ENZYMOL, V333, P217; Urano J, 2000, J BIOL CHEM, V275, P11198, DOI 10.1074/jbc.275.15.11198; von Lintig FC, 2000, ONCOGENE, V19, P4029, DOI 10.1038/sj.onc.1203741; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yee WM, 1997, MOL CELL BIOL, V17, P921, DOI 10.1128/MCB.17.2.921	43	107	112	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2002	21	41					6356	6365		10.1038/sj.onc.1205792	http://dx.doi.org/10.1038/sj.onc.1205792			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214276				2022-12-17	WOS:000177829000012
J	Gunduz, M; Ouchida, M; Fukushima, K; Ito, S; Jitsumori, Y; Nakashima, T; Nagai, N; Nishizaki, K; Shimizu, K				Gunduz, M; Ouchida, M; Fukushima, K; Ito, S; Jitsumori, Y; Nakashima, T; Nagai, N; Nishizaki, K; Shimizu, K			Allelic loss and reduced expression of the ING3, a candidate tumor suppressor gene at 7q31, in human head and neck cancers	ONCOGENE			English	Article						loss of heterozygosity; ING3; tumor suppressor gene; reduced expression; ING family; head and neck cancer	HUMAN-CHROMOSOME 7Q31.1; SQUAMOUS-CELL; FREQUENT LOSS; HETEROZYGOSITY; P33(ING1); PROTEIN; REGION; DNA	Loss of heterozygosity (LOH) has been frequently detected at chromosome 7q31 region in human head and neck squamous cell carcinomas (HNSCC) and many other cancers, suggesting the existence of tumor suppressor genes (TSG). We analysed LOH at 7q3I region in 49 HNSCC by using six polymorphic microsatellite markers and found allelic deletion in 48% (22/46) of the informative cases. We detected two preferentially deleted regions, one is around D7S643 and the other around D7S486. When we redefined the map of 7q31 region according to the contiguous sequences, a recently identified gene, ING3, was found in the proximity of D7S643. ING3 protein harbors the PHD domain highly homologous among ING family proteins, in which we previously found mutations in a related gene, ING1. As only one missense mutation of the ING3 gene was found in HNSCC, we examined the expression level. Reverse-transcription-PCR analysis demonstrated decreased or no expression of ING3 mRNA in 50% of primary tumors as compared with that of matched normal samples. Especially, about 63% of tongue and larynx tumors showed the decrease and a tendency of higher mortality was observed in cases with decreased ING3 expression. All these findings suggest a possibility that the ING3 gene functions as a TSG in a subset of HNSCC.	Okayama Univ, Grad Sch Med & Dent, Dept Mol Genet, Okayama 7008558, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Otolaryngol, Okayama 7008558, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Oral Pathol, Okayama 7008558, Japan	Okayama University; Okayama University; Okayama University	Shimizu, K (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Mol Genet, Shikata 2-5-1, Okayama 7008558, Japan.	shinke47@md.okayama-u.ac.jp						BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; Bieche I, 1997, CLIN CANCER RES, V3, P1009; COWAN JM, 1992, J NATL CANCER I, V84, P793, DOI 10.1093/jnci/84.10.793; Edelson MI, 1997, ONCOGENE, V14, P2979, DOI 10.1038/sj.onc.1201271; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Gunduz M, 2000, CANCER RES, V60, P3143; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Kohno T, 1999, CANCER RES, V59, P4170; Kukita A, 1999, BLOOD, V94, P1987, DOI 10.1182/blood.V94.6.1987.418k26_1987_1997; Latil A, 1995, CLIN CANCER RES, V1, P1385; Lin JC, 1996, ONCOGENE, V13, P2001; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Shimada Y, 1998, CYTOGENET CELL GENET, V83, P232, DOI 10.1159/000015188; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; TAKAHASHI S, 1995, CANCER RES, V55, P4114; Tanino M, 1999, MOL CARCINOGEN, V26, P286; Tatarelli C, 2000, GENOMICS, V68, P1, DOI 10.1006/geno.2000.6272; Toyama T, 1999, ONCOGENE, V18, P5187, DOI 10.1038/sj.onc.1202905; Wang F, 1998, CHINESE MED J-PEKING, V111, P671; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; Zenklusen JC, 2001, NAT GENET, V27, P392, DOI 10.1038/86891; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zenklusen JC, 2000, ONCOGENE, V19, P1729, DOI 10.1038/sj.onc.1203488; Zeremski M, 1999, J BIOL CHEM, V274, P32172, DOI 10.1074/jbc.274.45.32172; Zhang JS, 1998, ONCOGENE, V17, P789, DOI 10.1038/sj.onc.1201996	32	107	115	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4462	4470		10.1038/sj.onc.1205540	http://dx.doi.org/10.1038/sj.onc.1205540			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080476				2022-12-17	WOS:000176317100011
J	Jiang, N; Meng, YH; Zhang, SL; Mensah-Osman, E; Sheng, SJ				Jiang, N; Meng, YH; Zhang, SL; Mensah-Osman, E; Sheng, SJ			Maspin sensitizes breast carcinoma cells to induced apoptosis	ONCOGENE			English	Article						tumor suppressor; serpin; staurosporine; caspases; maspin/PAI-1 chimera; PAI-1/maspin chimera; cell motility	TUMOR-NECROSIS-FACTOR; MAMMARY EPITHELIAL-CELLS; ALPHA-INDUCED APOPTOSIS; NF-KAPPA-B; PLASMINOGEN-ACTIVATOR; POLY(ADP-RIBOSE) POLYMERASE; THYMOSIN BETA-10; PROTEIN-KINASE; CANCER CELLS; SERPIN	Maspin, a novel serine protease inhibitor (serpin), suppresses the growth and metastasis of breast tumor in vivo. However, the underlying molecular mechanism is unclear. In the current study, we report the first evidence that endogenous maspin expression in mammary carcinoma cells MDA-MB-435 enhanced staurosporine (STS)-induced apoptosis as judged by the increased fragmentation of DNA, increased protcolytic inactivation of poly-[ADP-ribose]-polymerase (PARP), as well as the increased activation of caspase-8 and caspase-3. In parallel, recombinant maspin did not directly regulate the proteolytic activities of either caspase-3 or caspase-8 in vitro. Consistent with this result, maspin expressing normal mammary epithelial cells underwent more rapid STS-induced apoptosis as compared to breast carcinoma cells. Interestingly, maspin transfectant cells did not undergo spontaneous apoptosis in the absence of STS. Moreover, neither purified maspin protein added from outside nor endogenous maspin secreted to the cell culture media sensitized cells to STS-induced apoptosis. To investigate the structural determinants of maspin in its apoptosis-sensitizing effect, MDA-MB-435 cells were also transfected with maspin/PAI-1 and PAI-1/maspin chimeric constructs resulting from swapping the N-terminal and the C-terminal domains between maspin and PAI-1 (plasminogen activator inhibitor type 1). The resulting stable transfectant clones expressing maspin/PAI-1 and PAI-1/maspin, respectively, did not undergo spontaneous apoptosis, and were similarly inhibited as maspin transfectant cells in motility assay. Interestingly, however, expression of both maspin/PAI-1 and PAI-1/maspin in MDA-MB-435 cells failed to sensitize these cells to STS-induced apoptosis. Taken together, our evidence provides now insights into the complex molecular mechanisms of maspin that may suppress breast tumor progression not only at the step of invasion and motility, but also by regulating tumor cell apoptosis. The sensitizing effect of maspin on apoptosis is to be contrasted by the pro-survival effect of several other serpins.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Wayne State University	Sheng, SJ (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.	ssheng@med.wayne.edu						Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; Biliran H, 2001, CANCER RES, V61, P8676; Biswas DK, 2001, P NATL ACAD SCI USA, V98, P10386, DOI 10.1073/pnas.151257998; Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Bromme HJ, 1996, MOL CELL BIOCHEM, V164, P261; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chen CY, 2001, CELL GROWTH DIFFER, V12, P297; D'Amours D, 1998, RADIAT RES, V150, P3, DOI 10.2307/3579638; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; Dickinson JL, 1998, CELL DEATH DIFFER, V5, P163, DOI 10.1038/sj.cdd.4400324; Gomez-Angelats M, 2000, J BIOL CHEM, V275, P19609, DOI 10.1074/jbc.M909563199; HALL AK, 1995, CELL MOL BIOL RES, V41, P167; HOPKINS PCR, 1994, SCIENCE, V265, P1893; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Kanamori H, 2000, J BIOL CHEM, V275, P5867, DOI 10.1074/jbc.275.8.5867; Kwaan HC, 2000, BRIT J CANCER, V82, P1702; Lawrence DA, 1997, ADV EXP MED BIOL, V425, P99; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Li JJ, 1998, CARCINOGENESIS, V19, P833, DOI 10.1093/carcin/19.5.833; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; McGowen R, 2000, CANCER RES, V60, P4771; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pemberton PA, 1997, J HISTOCHEM CYTOCHEM, V45, P1697, DOI 10.1177/002215549704501213; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Sager R, 1996, CURR TOP MICROBIOL, V213, P51; Schleef RR, 2000, J BIOL CHEM, V275, P26385, DOI 10.1074/jbc.C000389200; Seftor REB, 1998, CANCER RES, V58, P5681; Shao ZM, 1998, EXP CELL RES, V241, P394, DOI 10.1006/excr.1998.4066; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; TRAVIS J, 1990, BIOL CHEM H-S, V371, P3; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; YU FX, 1993, J BIOL CHEM, V268, P502; Zhang M, 2000, ONCOGENE, V19, P6053, DOI 10.1038/sj.onc.1204006; Zhang M, 1997, MOL MED, V3, P49, DOI 10.1007/BF03401667; Zhang M, 1999, DEV BIOL, V215, P278, DOI 10.1006/dbio.1999.9442; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	45	107	110	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2002	21	26					4089	4098		10.1038/sj.onc.1205507	http://dx.doi.org/10.1038/sj.onc.1205507			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037665				2022-12-17	WOS:000176186000003
J	Tsygankov, AY; Teckchandani, AM; Feshchenko, EA; Swaminathan, G				Tsygankov, AY; Teckchandani, AM; Feshchenko, EA; Swaminathan, G			Beyond the RING: CBL proteins as multivalent adapters	ONCOGENE			English	Review						Cbl; adapter; SH2; SH3; tyrosine phosphorylation; ubiquitination	GROWTH-FACTOR RECEPTOR; CELL ANTIGEN RECEPTOR; PHOSPHOTYROSINE-BINDING DOMAIN; PROTOONCOGENE C-CBL; TYROSINE-PHOSPHORYLATED CBL; INTEGRIN SIGNALING PATHWAY; PHOSPHATIDYLINOSITOL 3'-KINASE PATHWAY; ANCHORAGE-INDEPENDENT GROWTH; MEDIATED NEGATIVE REGULATION; NUCLEOTIDE-RELEASING FACTOR	Following discovery of c-Cbl, a cellular form of the transforming retroviral protein v-Cbl, multiple Cbl-related proteins have been identified in vertebrate and invertebrate organisms. c-Cbl and its homologues are capable of interacting with numerous proteins involved in cell signaling, including various molecular adapters and protein tyrosine kinases. It appears that Cbl proteins play several functional roles, acting both as multivalent adapters and inhibitors of various protein tyrosine kinases. The latter function is linked, to a substantial extent, to the E3 ubiquitin-ligase activity of Cbl proteins. Experimental evidence for these functions, interrelations between them, and their biological significance are addressed in this review, with the main accent placed on the adapter functions of Cbl proteins.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Tsygankov, AY (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, Kresge Bldg,Room 506,3400 N Broad St, Philadelphia, PA 19140 USA.	tsygan@astro.temple.edu	Tsygankov, Alexander Y/K-6205-2017	Teckchandani, Anjali/0000-0002-2237-9598	NATIONAL CANCER INSTITUTE [R01CA078499] Funding Source: NIH RePORTER; NCI NIH HHS [CA78499] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler CE, 2000, J BIOL CHEM, V275, P36472, DOI 10.1074/jbc.M005424200; Ahmed Z, 2000, FEBS LETT, V475, P31, DOI 10.1016/S0014-5793(00)01621-5; Alsayed Y, 2000, J IMMUNOL, V164, P1800, DOI 10.4049/jimmunol.164.4.1800; Alsayed Y, 2000, EXP HEMATOL, V28, P826, DOI 10.1016/S0301-472X(00)00170-3; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Amsen D, 2000, EUR J IMMUNOL, V30, P2832, DOI 10.1002/1521-4141(200010)30:10<2832::AID-IMMU2832>3.0.CO;2-D; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Andoniou CE, 1996, ONCOGENE, V12, P1981; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Anzai N, 1999, BLOOD, V93, P3317, DOI 10.1182/blood.V93.10.3317.410k12_3317_3326; Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; Astier A, 2000, J IMMUNOL, V164, P6091, DOI 10.4049/jimmunol.164.12.6091; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Baldin V, 2000, Prog Cell Cycle Res, V4, P49; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Beitz LO, 1999, J BIOL CHEM, V274, P32662, DOI 10.1074/jbc.274.46.32662; Bhat A, 1997, J BIOL CHEM, V272, P16170, DOI 10.1074/jbc.272.26.16170; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Borinstein SC, 2000, CELL SIGNAL, V12, P769, DOI 10.1016/S0898-6568(00)00129-7; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Brizzi MF, 1996, ONCOGENE, V13, P2067; Brizzi MF, 1998, EXP HEMATOL, V26, P1229; Broome MA, 1999, ONCOGENE, V18, P2908, DOI 10.1038/sj.onc.1202873; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; Bunnell SC, 1996, J BIOL CHEM, V271, P25646, DOI 10.1074/jbc.271.41.25646; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; Campana D, 1996, Hum Cell, V9, P317; Cerboni C, 1998, EUR J IMMUNOL, V28, P1005, DOI 10.1002/(SICI)1521-4141(199803)28:03<1005::AID-IMMU1005>3.0.CO;2-O; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; Chu J, 1998, BLOOD, V92, P1697, DOI 10.1182/blood.V92.5.1697.417a06_1697_1706; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Cohen S, 1999, BLOOD, V93, P2013, DOI 10.1182/blood.V93.6.2013.406k25_2013_2024; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DASILVA AJ, 1992, MOL IMMUNOL, V29, P1417, DOI 10.1016/0161-5890(92)90215-J; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; Deckert M, 1998, IMMUNITY, V9, P595, DOI 10.1016/S1074-7613(00)80657-3; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; Dennehy KM, 1998, EUR J IMMUNOL, V28, P1617, DOI 10.1002/(SICI)1521-4141(199805)28:05<1617::AID-IMMU1617>3.0.CO;2-7; DombroskyFerlan PM, 1997, ONCOGENE, V14, P2019, DOI 10.1038/sj.onc.1201031; Donovan JA, 1996, J BIOL CHEM, V271, P26369, DOI 10.1074/jbc.271.42.26369; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Elly C, 1999, ONCOGENE, V18, P1147, DOI 10.1038/sj.onc.1202411; Erdreich-Epstein A, 1997, EXP CELL RES, V237, P288, DOI 10.1006/excr.1997.3795; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Fang D, 2001, J BIOL CHEM, V276, P4872, DOI 10.1074/jbc.M008901200; Fernandez B, 1999, J BIOL CHEM, V274, P20244, DOI 10.1074/jbc.274.29.20244; Fernandez JA, 1999, J BIOL CHEM, V274, P1401, DOI 10.1074/jbc.274.3.1401; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Finkelstein LD, 2000, BIOCHEM J, V345, P385, DOI 10.1042/0264-6021:3450385; FitzerAttas CJ, 1997, J BIOL CHEM, V272, P8551, DOI 10.1074/jbc.272.13.8551; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Fournier TM, 2000, MOL BIOL CELL, V11, P3397, DOI 10.1091/mbc.11.10.3397; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Garcia-Guzman M, 2000, ONCOGENE, V19, P4058, DOI 10.1038/sj.onc.1203750; Gesbert F, 1998, J BIOL CHEM, V273, P3986, DOI 10.1074/jbc.273.7.3986; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Graham LJ, 1998, BIOCHEM BIOPH RES CO, V249, P537, DOI 10.1006/bbrc.1998.9177; Graham LJ, 2000, FEBS LETT, V470, P273, DOI 10.1016/S0014-5793(00)01341-7; Grishin A, 2000, ONCOGENE, V19, P97, DOI 10.1038/sj.onc.1203254; Han DC, 2001, ONCOGENE, V20, P346, DOI 10.1038/sj.onc.1204068; Hanazono Y, 1996, ACTA HAEMATOL-BASEL, V95, P236; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; Hazeki K, 1999, EUR J IMMUNOL, V29, P3302, DOI 10.1002/(SICI)1521-4141(199910)29:10<3302::AID-IMMU3302>3.0.CO;2-G; Hehner SP, 2000, J BIOL CHEM, V275, P18160, DOI 10.1074/jbc.275.24.18160; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/S0968-0004(96)30015-7; Howlett CJ, 1999, BIOCHEM BIOPH RES CO, V257, P129, DOI 10.1006/bbrc.1999.0427; Hunter S, 1997, MOL ENDOCRINOL, V11, P1213, DOI 10.1210/me.11.9.1213; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; Izadi KD, 1998, EXP CELL RES, V245, P330, DOI 10.1006/excr.1998.4259; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JONGEWARD GD, 1995, GENETICS, V139, P1553; Kamei T, 2000, INT J ONCOL, V17, P335; Kanagasundaram V, 1996, BIOCHEM J, V320, P69, DOI 10.1042/bj3200069; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kato M, 1998, AM J RESP CELL MOL, V18, P675, DOI 10.1165/ajrcmb.18.5.2885; Kato M, 2000, INT ARCH ALLERGY IMM, V122, P33, DOI 10.1159/000053629; KAWATA M, 1988, J BIOL CHEM, V263, P18965; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Khwaja A, 1996, ONCOGENE, V12, P2491; Kim M, 1999, GENE, V239, P145, DOI 10.1016/S0378-1119(99)00356-X; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; Kirsch KH, 2001, J BIOL CHEM, V276, P4957, DOI 10.1074/jbc.M005784200; Kitanaka A, 1996, BLOOD, V88, P590, DOI 10.1182/blood.V88.2.590.bloodjournal882590; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Klapper LN, 2000, CANCER RES, V60, P3384; Kontani K, 1996, J BIOL CHEM, V271, P1534; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Krawczyk C, 2000, IMMUNITY, V13, P463, DOI 10.1016/S1074-7613(00)00046-7; Lafont F, 2001, P NATL ACAD SCI USA, V98, P3180, DOI 10.1073/pnas.051003498; Lakkakorpi PT, 1997, EXP CELL RES, V237, P296, DOI 10.1006/excr.1997.3797; Lamorte L, 2000, ONCOGENE, V19, P5973, DOI 10.1038/sj.onc.1203977; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Lavagna-Sevenier C, 1998, LEUKEMIA, V12, P301, DOI 10.1038/sj.leu.2400921; Lavagna-Sevenier C, 1998, J BIOL CHEM, V273, P14962, DOI 10.1074/jbc.273.24.14962; Lazaar AL, 2001, J IMMUNOL, V166, P155, DOI 10.4049/jimmunol.166.1.155; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 2000, J BIOL CHEM, V275, P35532, DOI 10.1074/jbc.M002661200; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Levkowitz G, 1996, ONCOGENE, V12, P1117; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Lin HM, 2001, INT IMMUNOL, V13, P13, DOI 10.1093/intimm/13.1.13; Liu YC, 1997, J BIOL CHEM, V272, P168; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Liu YH, 1999, J IMMUNOL, V162, P7095; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Mallone R, 2001, INT IMMUNOL, V13, P397, DOI 10.1093/intimm/13.4.397; Manie SN, 1997, EXP HEMATOL, V25, P45; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; Marengere LEM, 1997, J IMMUNOL, V159, P70; Matsuo T, 1996, FEBS LETT, V397, P113, DOI 10.1016/S0014-5793(96)01151-9; Matsuo T, 1996, FEBS LETT, V382, P11, DOI 10.1016/0014-5793(96)00122-6; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Michel F, 2000, J IMMUNOL, V165, P3820, DOI 10.4049/jimmunol.165.7.3820; Michel F, 1998, J BIOL CHEM, V273, P31932, DOI 10.1074/jbc.273.48.31932; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; MUSHINSKI JF, 1994, ONCOGENE, V9, P2489; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Naccache PH, 1997, J LEUKOCYTE BIOL, V62, P901, DOI 10.1002/jlb.62.6.901; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; NOBES CD, 1995, J CELL SCI, V108, P225; Oda A, 1996, BLOOD, V88, P1330, DOI 10.1182/blood.V88.4.1330.bloodjournal8841330; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Ojaniemi M, 1998, ONCOGENE, V16, P3159, DOI 10.1038/sj.onc.1201859; Okuda K, 1996, ONCOGENE, V13, P1147; Osada M, 1999, MOL CELL BIOL, V19, P6333; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Pai LM, 2000, CELL, V103, P51, DOI 10.1016/S0092-8674(00)00104-5; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Park RK, 1999, BLOOD, V94, P2112; PARKER PJ, 1995, CURR BIOL, V5, P577, DOI 10.1016/S0960-9822(95)00113-8; Pedraza-Alva G, 2001, J BIOL CHEM, V276, P729, DOI 10.1074/jbc.M008494200; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Rao N, 2000, J IMMUNOL, V164, P4616, DOI 10.4049/jimmunol.164.9.4616; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; Ribon V, 1996, MOL CELL BIOL, V16, P45; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Robertson H, 2000, ONCOGENE, V19, P3299, DOI 10.1038/sj.onc.1203624; Rollet-Labelle E, 2000, J IMMUNOL, V164, P1020, DOI 10.4049/jimmunol.164.2.1020; Saci A, 2000, BIOCHEM J, V351, P669, DOI 10.1042/0264-6021:3510669; Salgia R, 1996, EXP HEMATOL, V24, P310; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; Salojin K, 1997, J EXP MED, V186, P887, DOI 10.1084/jem.186.6.887; Salojin KV, 1999, J IMMUNOL, V163, P844; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; Sattler M, 1997, J BIOL CHEM, V272, P10248; Sattler M, 1996, ONCOGENE, V12, P839; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; Scaife RM, 2000, J CELL SCI, V113, P215; Schlottmann KE, 1996, J LEUKOCYTE BIOL, V60, P546, DOI 10.1002/jlb.60.4.546; Scholz G, 2000, J BIOL CHEM, V275, P14615, DOI 10.1074/jbc.275.19.14615; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Slavik JM, 1999, J BIOL CHEM, V274, P3116, DOI 10.1074/jbc.274.5.3116; Smit L, 1996, ONCOGENE, V13, P381; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; Suzuki H, 1997, J IMMUNOL, V159, P5881; Take H, 2000, BIOCHEM BIOPH RES CO, V268, P321, DOI 10.1006/bbrc.2000.2147; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Tang J, 1999, P NATL ACAD SCI USA, V96, P9775, DOI 10.1073/pnas.96.17.9775; Teckchandani AM, 2001, ONCOGENE, V20, P1739, DOI 10.1038/sj.onc.1204246; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 1999, J IMMUNOL, V162, P7133; Tse KF, 2000, LEUKEMIA, V14, P1766, DOI 10.1038/sj.leu.2401905; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; Uddin S, 1996, BIOCHEM BIOPH RES CO, V225, P833, DOI 10.1006/bbrc.1996.1259; Uddin S, 1997, BIOCHEM BIOPH RES CO, V235, P83, DOI 10.1006/bbrc.1997.6741; Uemura N, 1997, LEUKEMIA, V11, P376, DOI 10.1038/sj.leu.2400590; Uemura N, 1999, J BIOL CHEM, V274, P37525, DOI 10.1074/jbc.274.53.37525; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; Ueno H, 1997, ONCOGENE, V14, P3067, DOI 10.1038/sj.onc.1201153; Umehara H, 1998, INT IMMUNOL, V10, P833, DOI 10.1093/intimm/10.6.833; van Leeuwen JEM, 1999, MOL CELL BIOL, V19, P6652; van Leeuwen JEM, 1999, J BIOL CHEM, V274, P5153, DOI 10.1074/jbc.274.8.5153; Wang BC, 2000, J BIOL CHEM, V275, P5222, DOI 10.1074/jbc.275.7.5222; Wang HY, 2001, J BIOL CHEM, V276, P26004, DOI 10.1074/jbc.M010738200; Wang L, 2000, EXP HEMATOL, V28, P1503, DOI 10.1016/S0301-472X(00)00632-9; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wisniewski D, 1996, LEUKEMIA, V10, P1436; Wong ESM, 2001, J BIOL CHEM, V276, P5866, DOI 10.1074/jbc.M006945200; Wunderlich L, 1999, CELL SIGNAL, V11, P253, DOI 10.1016/S0898-6568(98)00054-0; Yankee TM, 1999, J IMMUNOL, V163, P5827; Yasuda T, 2000, J EXP MED, V191, P641, DOI 10.1084/jem.191.4.641; Yokouchi M, 1999, ONCOGENE, V18, P759, DOI 10.1038/sj.onc.1202326; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yoon CH, 2000, MOL BIOL CELL, V11, P4019, DOI 10.1091/mbc.11.11.4019; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; Zell T, 1998, CURR BIOL, V8, P814, DOI 10.1016/S0960-9822(98)70323-9; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zhang ZH, 1999, J BIOL CHEM, V274, P4883, DOI 10.1074/jbc.274.8.4883; Zhang ZH, 1999, CURR BIOL, V9, P203, DOI 10.1016/S0960-9822(99)80090-6; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	257	107	115	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2001	20	44					6382	6402		10.1038/sj.onc.1204781	http://dx.doi.org/10.1038/sj.onc.1204781			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607840				2022-12-17	WOS:000171640600013
J	Pervaiz, S; Cao, J; Chao, OSP; Chin, YY; Clement, MV				Pervaiz, S; Cao, J; Chao, OSP; Chin, YY; Clement, MV			Activation of the RacGTPase inhibits apoptosis in human tumor cells	ONCOGENE			English	Article						superoxide anion; NADPH oxidase; Ha-Ras; anti-cancer drugs	SIGNAL-TRANSDUCTION; SUPEROXIDE ANION; RAS; PROTEINS; FAMILY; GENE	The small GTP-binding protein Rac is a downstream effector of the oncogene product p21-ras. Rac is involved in actin polymerization, Jun kinase activation, and intracellular superoxide anion production, through distinct pathways in tumor cells. Here we investigated the role of activated Rac in the response of tumor cells to apoptosis triggered by anti-cancer drugs or the cell surface death receptor CD95. Using M14 melanoma cells stably transfected with a constitutively active form of Rac1, we show that activated Rac inhibits tumor cell response to apoptosis. The inhibitory effect of activated Rac on apoptotic signaling is mediated by the interaction of Rac with intracellular oxidase and the subsequent production of superoxide, which is supported by experiments performed with M14 and NIH3T3 cells transiently transfected with the loss-of-function mutants of Rac in an activated RacV12 background. Consistent with these findings, we also demonstrate that inhibition of the Rac pathway in the HaRas-expressing T24 bladder carcinoma cell line induces a decrease in superoxide anion concentration, and results in a significant increase in tumor cell sensitivity to apoptosis. These findings demonstrate the existence of a novel Rac-dependent survival pathway mediated by intracellular superoxide in tumor cells.	Natl Univ Singapore, Inst Med, Oncol Res Inst, Clin Res Ctr, Singapore 117597, Singapore; Natl Univ Singapore, Dept Biochem, Singapore 119260, Singapore; Natl Univ Singapore, Dept Physiol, Singapore 119260, Singapore	National University of Singapore; National University of Singapore; National University of Singapore	Clement, MV (corresponding author), Natl Univ Singapore, Inst Med, Oncol Res Inst, Clin Res Ctr, Block MD11,12-01, Singapore 117597, Singapore.		Pervaiz, Shazib/C-4188-2015					Boehm JE, 1999, J BIOL CHEM, V274, P28632, DOI 10.1074/jbc.274.40.28632; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Clement MV, 1999, FREE RADICAL RES, V30, P247, DOI 10.1080/10715769900300271; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Clement MV, 1998, FEBS LETT, V440, P13, DOI 10.1016/S0014-5793(98)01410-0; Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; Finkel T, 1999, J LEUKOCYTE BIOL, V65, P337, DOI 10.1002/jlb.65.3.337; Hirpara JL, 2001, J BIOL CHEM, V276, P514, DOI 10.1074/jbc.M004687200; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MUSLEH W, 1994, NEUROPHARMACOLOGY, V33, P929, DOI 10.1016/0028-3908(94)90191-0; Pervaiz S, 1998, CANCER LETT, V128, P11, DOI 10.1016/S0304-3835(98)00021-4; Pervaiz S, 1999, BLOOD, V93, P4096, DOI 10.1182/blood.V93.12.4096.412k44_4096_4108; Pervaiz S, 1999, FEBS LETT, V459, P343, DOI 10.1016/S0014-5793(99)01258-2; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Toporik A, 1998, BIOCHEMISTRY-US, V37, P7147, DOI 10.1021/bi9800404; WALKER PR, 1991, CANCER RES, V51, P1078	28	107	119	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6263	6268		10.1038/sj.onc.1204840	http://dx.doi.org/10.1038/sj.onc.1204840			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593437				2022-12-17	WOS:000171206300020
J	Rashid, SF; Moore, JS; Walker, E; Driver, PM; Engel, J; Edwards, CE; Brown, G; Uskokovic, MR; Campbell, MJ				Rashid, SF; Moore, JS; Walker, E; Driver, PM; Engel, J; Edwards, CE; Brown, G; Uskokovic, MR; Campbell, MJ			Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D-3 and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A	ONCOGENE			English	Article; Proceedings Paper	91st Annual Meeting of the American-Association-for-Cancer-Research	APR 01-05, 2000	SAN FRANCISCO, CALIFORNIA	Amer Assoc Canc Res		histone deacetylation inhibitors; 1 alpha,25 Dihydroxyvitamin D-3; prostate cancer; growth inhibition; apoptosis	VITAMIN-D-RECEPTOR; D-RESPONSIVE ELEMENTS; HISTONE DEACETYLASE; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; 1,25-DIHYDROXYVITAMIN D-3; INDUCED-DIFFERENTIATION; 24-HYDROXYLASE ACTIVITY; PROMYELOCYTIC LEUKEMIA; PROMOTER SELECTIVITY; GENE POLYMORPHISM	Prostate cancer is a major cause of male cancer death. In vitro and in vivo data support a role for 1 alpha ,25 Dihydroxyvitamin D-3 (1 alpha ,25(OH)(2)D-3) in regulating the growth and differentiation of the normal prostate gland yet prostate cancer cells appear significantly less sensitive to this action. Vitamin D-3 receptor (VDR) content or mutational status do not correlate clearly with the antiproliferative effects of 1 alpha ,25(OH)(2)D-3 and therefore it is unclear why prostate cancer cell lines are significantly less sensitive to this action. We hypothesized that the antiproliferative responses of prostate cancer cells to 1 alpha ,25(OH)(2)D-3 are suppressed by a process involving histone deacetylation, Sodium butyrate (NaB) and trichostatin A (TSA) are inhibitors of histone deacetylase (HDAC) activity. Low doses of NaB or TSA (300 muM and 15 nM respectively), which alone were relatively inactive, synergized with 1 alpha ,25(OH)(2)D-3 in liquid and semi-solid agar to inhibit the growth of LNCaP, PC-3 and DU-145 prostate cancer cells. Still greater synergy was observed between vitamin D-3 hexafluoride analogs and either NaB or TSA, The mechanism appeared to involve neither the cyclin-dependent kinase inhibitor, p21((waf1/cip1)) nor cell cycle arrest, but rather induction of apoptosis, These data suggest that cells dysregulate the normal pro-apoptotic signals of 1 alpha ,25(OH)(2)D-3 during prostate cancer development by a mechanism involving histone deacetylation, Combination therapy with potent vitamin D-3 analogs and clinically approved HDAC inhibitors may overcome this lesion and improve the treatment of both androgen-dependent and independent prostate cancer.	Univ Birmingham, Sch Med, Div Med Sci, Dept Med, Birmingham B15 2TH, W Midlands, England; Univ Birmingham, Sch Med, Div Immun & Infect, Birmingham B15 2TH, W Midlands, England; Hoffmann La Roche Inc, Nutley, NJ 07110 USA	University of Birmingham; University of Birmingham; Roche Holding	Campbell, MJ (corresponding author), Univ Birmingham, Sch Med, Div Med Sci, Dept Med, Birmingham B15 2TH, W Midlands, England.		FRCPI, Mark D Kilby MB BS DSc MD FRCOG/AAW-9704-2020; Campbell, Moray/ABF-1264-2021; Campbell, Moray J/A-1311-2013	FRCPI, Mark D Kilby MB BS DSc MD FRCOG/0000-0001-9987-4223; Campbell, Moray/0000-0002-3355-0928; Brown, Geoffrey/0000-0003-0821-0275				Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; ANZANO MA, 1994, CANCER RES, V54, P1653; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bernhard D, 1999, FASEB J, V13, P1991, DOI 10.1096/fasebj.13.14.1991; Campbell MJ, 1999, BRIT J CANCER, V79, P101, DOI 10.1038/sj.bjc.6690018; Campbell MJ, 1998, ENDOCRINOLOGY, V139, P1972, DOI 10.1210/en.139.4.1972; Campbell MJ, 1999, MOL CELL ENDOCRINOL, V149, P169, DOI 10.1016/S0303-7207(98)00245-7; Campbell MJ, 1997, J MOL ENDOCRINOL, V19, P15, DOI 10.1677/jme.0.0190015; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; Cohen LA, 1999, ANTICANCER RES, V19, P4999; Danielsson C, 1997, J CELL BIOCHEM, V66, P552, DOI 10.1002/(SICI)1097-4644(19970915)66:4<552::AID-JCB14>3.0.CO;2-D; deVos S, 1997, PROSTATE, V32, P115; Ellerhorst J, 1999, INT J ONCOL, V14, P225; Evans SRT, 1999, INT J ONCOL, V14, P979; EWING CM, 1995, CANCER RES, V55, P4813; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Habuchi T, 2000, CANCER RES, V60, P305; HANCHETTE CL, 1992, CANCER, V70, P2861, DOI 10.1002/1097-0142(19921215)70:12<2861::AID-CNCR2820701224>3.0.CO;2-G; Hedlund TE, 1996, J STEROID BIOCHEM, V58, P277, DOI 10.1016/0960-0760(96)00030-1; Hedlund TE, 1997, CLIN CANCER RES, V3, P1331; Ingles SA, 1997, J NATL CANCER I, V89, P166, DOI 10.1093/jnci/89.2.166; IOWA Y, 1999, CANCER RES, V59, P4266; ISAACS WB, 1994, COLD SPRING HARB SYM, V59, P653, DOI 10.1101/SQB.1994.059.01.075; Jurutka PW, 2000, MOL ENDOCRINOL, V14, P401, DOI 10.1210/me.14.3.401; Kerry DM, 1996, J BIOL CHEM, V271, P29715, DOI 10.1074/jbc.271.47.29715; Koike M, 1997, CANCER RES, V57, P4545; Konety BR, 1996, CELL GROWTH DIFFER, V7, P1563; Krill D, 1999, UROLOGY, V54, P171, DOI 10.1016/S0090-4295(99)00103-X; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Lea MA, 1998, ANTICANCER RES, V18, P2717; Li X, 1995, CELL PROLIFERAT, V28, P571, DOI 10.1111/j.1365-2184.1995.tb00045.x; Liang JY, 1999, PROSTATE, V38, P228; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Ly LH, 1999, ENDOCRINOLOGY, V140, P2071, DOI 10.1210/en.140.5.2071; Mackey TJ, 1998, UROLOGY, V52, P1085, DOI 10.1016/S0090-4295(98)00360-4; MAIYAR AC, 1992, MOL CELL ENDOCRINOL, V84, P99, DOI 10.1016/0303-7207(92)90076-I; Medina V, 1997, CANCER RES, V57, P3697; Miller CW, 1997, MOL CARCINOGEN, V19, P254, DOI 10.1002/(SICI)1098-2744(199708)19:4<254::AID-MC6>3.0.CO;2-C; Miller GJ, 1995, CLIN CANCER RES, V1, P997; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P7379, DOI 10.1073/pnas.95.13.7379; Munker R, 1996, BLOOD, V88, P2201, DOI 10.1182/blood.V88.6.2201.bloodjournal8862201; Nayeri S, 1997, BIOCHEM J, V327, P561, DOI 10.1042/bj3270561; Pace BS, 2000, EXP HEMATOL, V28, P283, DOI 10.1016/S0301-472X(99)00153-8; PEEHL DM, 1994, CANCER RES, V54, P805; PEEHL DM, 1993, ENDOC J, V132, P1952; Polly P, 2000, FASEB J, V14, P1455, DOI 10.1096/fj.14.10.1455; Quack M, 1999, MOL PHARMACOL, V55, P1077, DOI 10.1124/mol.55.6.1077; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rashid SF, 2001, STEROIDS, V66, P433, DOI 10.1016/S0039-128X(00)00203-8; Rosenthal DS, 1998, CA-CANCER J CLIN, V48, P3, DOI 10.3322/canjclin.48.1.3; Schwartz GG, 1998, CANCER EPIDEM BIOMAR, V7, P391; SCHWARTZ GG, 1990, ANTICANCER RES, V10, P1307; Tamimi Y, 1996, BRIT J CANCER, V74, P120, DOI 10.1038/bjc.1996.325; TANAKA Y, 1989, BIOCHEM PHARMACOL, V38, P3859, DOI 10.1016/0006-2952(89)90596-0; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Verlinden L, 1998, MOL CELL ENDOCRINOL, V142, P57, DOI 10.1016/S0303-7207(98)00117-8; Watanabe M, 1999, ANTICANCER RES, V19, P4511; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; YONEDA T, 1984, BIOCHEM BIOPH RES CO, V121, P796, DOI 10.1016/0006-291X(84)90748-4; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YOSHIDA M, 1992, ANTICANCER RES, V12, P1947; ZHANG SH, 1997, MOL CELL ENDOCRINOL, V126, P83; Zhuang SH, 1998, ENDOCRINOLOGY, V139, P1197, DOI 10.1210/en.139.3.1197	66	107	115	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2001	20	15					1860	1872		10.1038/sj.onc.1204269	http://dx.doi.org/10.1038/sj.onc.1204269			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313934				2022-12-17	WOS:000167908400007
J	del Peso, L; Gonzalez, VM; Hernandez, R; Barr, FG; Nunez, G				del Peso, L; Gonzalez, VM; Hernandez, R; Barr, FG; Nunez, G			Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase Akt	ONCOGENE			English	Article						Akt; FKHR; PAX3-FKHR; transcription	TUMOR ALVEOLAR RHABDOMYOSARCOMA; CAENORHABDITIS-ELEGANS; PHOSPHATIDYLINOSITOL 3-KINASE; INSULIN; PAX3; PHOSPHORYLATION; SIGNALS; DAF-16; GENE; TRANSLOCATION	Akt, a proto-oncogene that encodes a cytosolic serine/threonine kinase, can phosphorylate and modulate the activity of several proteins involved in cellular metabolism and survival. Recently, two mammalian highly related forkhead transcription factors FKHRL1 and AFX and their nematode homologue Daf-16 have been found to be targets of this kinase, Here we show that Akt, but not inactive Akt, represses the transcriptional activity of FKHR, another member of the forkhead family. FKHR mutants with alanine substitutions at three Akt phosphorylation consensus sites (T24, S256 and S319) were inhibited by Akt, but mutation of all three sites rendered FKHR resistant to suppression. By contrast, the transcriptional activity of the oncogenic PAX3-FKHR fusion protein, containing two consensus phosphorylation sites, was not inhibited by Akt, Importantly, Akt inhibited the translocation of FKHR to the nucleus, providing a mechanism by which Akt might regulate the transcriptional activity of FKHR, Consistent with this model, the localization of the PAX3-FKHR fusion protein was nuclear and was not altered by Akt, These results provide evidence that Akt inhibits the transcriptional activity of FKHR by controlling its trafficking into the nucleus and that oncogenic PAX3-FKHR can escape this negative regulation by Akt.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Pennsylvania	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.		del Peso, Luis/K-9391-2014; Gonzalez, Victor M/F-7396-2010; Nuñez, Gabriel/A-7160-2014	del Peso, Luis/0000-0003-4014-5688; Gonzalez, Victor M/0000-0001-7538-0552; 	NATIONAL CANCER INSTITUTE [P01CA075136, K04CA064421, R01CA064202] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA64202, P01-CA75136-01A1, CA-64421] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; BENNICELLI JL, 1995, ONCOGENE, V11, P119; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Coffer PJ, 1998, BIOCHEM J, V335, P1; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SUBLETT JE, 1995, ONCOGENE, V11, P545; Wang W, 1998, CANCER RES, V58, P4426	24	107	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7328	7333		10.1038/sj.onc.1203159	http://dx.doi.org/10.1038/sj.onc.1203159			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602488				2022-12-17	WOS:000084119400018
J	Corcoran, MM; Mould, SJ; Orchard, JA; Ibbotson, RE; Chapman, RM; Boright, AP; Platt, C; Tsui, LC; Scherer, SW; Oscier, DG				Corcoran, MM; Mould, SJ; Orchard, JA; Ibbotson, RE; Chapman, RM; Boright, AP; Platt, C; Tsui, LC; Scherer, SW; Oscier, DG			Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations	ONCOGENE			English	Article						CDK6; 7q translocations; SMZL; SLVL	CHRONIC LYMPHOCYTIC-LEUKEMIA; MOLECULAR DELINEATION; VILLOUS LYMPHOCYTES; GROWTH ARREST; HUMAN CANCER; CELL; GENE; REGION; DNA; HUMAN-CHROMOSOME-7	The increased or inappropriate expression of genes with oncogenic properties through specific chromosome translocations is an important event in the pathogenesis of B-cell lymphoproliferative diseases. Recent studies have found deletions or translocations of chromosome 7q to be the most common cytogenetic abnormality observed in SLVL, a leukemic variant of SMZL, with the q21-q22 region being most frequently affected. In three patients with translocations between chromosomes 2 and 7, the cloning of the breakpoints at 7q21 revealed that each was located within a small region of DNA 3.6 kb upstream of the transcription start site of cyclin dependent kinase 6 (CDK6). In each case the translocation event was consistent with aberrant VJ recombination between the immunoglobulin light chain region (Ig kappa) on chromosome 2p12 and DNA sequences at 7q21, resembling the heptamer recombination site. The t(7;21) breakpoint in an additional patient with splenic marginal zone lymphoma (SMZL), resided 66 kb telomeric to the t(2;7) breakpoints juxtaposing CDK6 to an uncharacterized transcript. In two of the SLVL patient samples, the CDK6 protein was found to be markedly over expressed. These results suggest that dysregulation of CDK6 gene expression contributes to the pathogenesis of SLVL and SMZL.	Royal Bournemouth Hosp, Dept Haematol, Bournemouth BH7 7DW, Dorset, England; Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Oscier, DG (corresponding author), Royal Bournemouth Hosp, Dept Haematol, Castle Lane E, Bournemouth BH7 7DW, Dorset, England.		Tsui, Lap-chee/A-1081-2010; Scherer, Stephen W./B-3785-2013	Scherer, Stephen W./0000-0002-8326-1999				BULLRICH F, 1995, CANCER RES, V55, P1199; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chilosi M, 1998, AM J PATHOL, V152, P209; Corcoran MM, 1998, BLOOD, V91, P1382, DOI 10.1182/blood.V91.4.1382; Costello JF, 1997, CANCER RES, V57, P1250; Dascalescu CM, 1999, CANCER GENET CYTOGEN, V109, P21, DOI 10.1016/S0165-4608(98)00139-3; Easton J, 1998, CANCER RES, V58, P2624; Fischer K, 1997, BLOOD, V89, P2036, DOI 10.1182/blood.V89.6.2036; Goossens T, 1998, P NATL ACAD SCI USA, V95, P2463, DOI 10.1073/pnas.95.5.2463; HENG HHQ, 1994, CYTOGENET CELL GENET, V66, P135, DOI 10.1159/000133685; Hernandez JM, 1997, GENE CHROMOSOME CANC, V18, P147, DOI 10.1002/(SICI)1098-2264(199702)18:2<147::AID-GCC10>3.0.CO;2-H; Hernandez JM, 1997, CANCER GENET CYTOGEN, V93, P147, DOI 10.1016/S0165-4608(96)00183-5; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; JAFFE EF, 1997, AM J SURG PATHOL, V21, P109; Kaldis P, 1998, MOL BIOL CELL, V9, P2545, DOI 10.1091/mbc.9.9.2545; Konig A, 1997, BLOOD, V90, P4307; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KUMAR S, 1995, HUM GENET, V95, P641; KUNZ J, 1994, GENOMICS, V22, P439, DOI 10.1006/geno.1994.1407; Latham KM, 1996, MOL CELL BIOL, V16, P4445; LORENZ W, 1988, MOL IMMUNOL, V25, P479, DOI 10.1016/0161-5890(88)90168-X; Mishmar D, 1998, P NATL ACAD SCI USA, V95, P8141, DOI 10.1073/pnas.95.14.8141; OFFIT K, 1995, BLOOD, V86, P2365, DOI 10.1182/blood.V86.6.2365.bloodjournal8662365; Oscier DG, 1996, CANCER GENET CYTOGEN, V92, P24, DOI 10.1016/S0165-4608(96)00025-8; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Schneider E, 1998, ONCOGENE, V17, P2733, DOI 10.1038/sj.onc.1202504; SZEPESI A, 1994, BLOOD, V84, P3413; Tambini CE, 1997, GENOMICS, V41, P84, DOI 10.1006/geno.1997.4636; Timmermann S, 1997, CELL GROWTH DIFFER, V8, P361; Wahbi K, 1997, LEUKEMIA, V11, P1214, DOI 10.1038/sj.leu.2400716; Wong KF, 1998, CANCER GENET CYTOGEN, V102, P145, DOI 10.1016/S0165-4608(97)00367-1; Zeng WR, 1997, ONCOGENE, V14, P2355, DOI 10.1038/sj.onc.1201076	33	107	109	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6271	6277		10.1038/sj.onc.1203033	http://dx.doi.org/10.1038/sj.onc.1203033			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597225				2022-12-17	WOS:000083934100010
J	Lakin, ND; Hann, BC; Jackson, SP				Lakin, ND; Hann, BC; Jackson, SP			The ataxia-telangiectasia related protein ATR mediates DNA-dependent phosphorylation of p53	ONCOGENE			English	Article						p53; ATR; ATM; DNA-PK; ataxia telangiectasia; DNA damage	CELL-CYCLE CHECKPOINTS; IONIZING-RADIATION; KINASE; DAMAGE; GENE; SENSITIVITY; 3-KINASE; UV	Levels of the tumour suppressor protein p53 are increased in response to a variety of DNA damaging agents. DNA damage-induced phosphorylation of p53 occurs at serine-15 in vivo. Phosphorylation of p53 at serine-15 leads to a stabilization of the polypeptide by inhibiting its interaction with Mdm2, a protein that targets p53 for ubiquitin-dependent degradation, However, the mechanisms by which DNA damage is signalled to p53 remain unclear. Here, we report the identification of a novel DNA-activated protein kinase that phosphorylates p53 on serine-15, Fractionation of HeLa nuclear extracts and biochemical analyses indicate that this kinase is distinct from the DNA-dependent protein kinase (DNA-PK) and corresponds to the human cell cycle checkpoint protein ATR. Immunoprecipitation studies of recombinant ATR reveal that catalytic activity of this polypeptide is required for DNA-stimulated phosphorylation of p53 on serine-15. These data suggest that ATR may function upstream of p53 in a signal transduction cascade initiated upon DNA damage and provide a biochemical assay system for ATR activity.	Univ Cambridge, Canc Res Campaign, Inst Canc & Dev Biol, Dept Zool, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 1QR, England; Univ Dundee, Dept Biochem, Canc Res Campaign Labs, Dundee DD1 4HN, Scotland	CRUK Cambridge Institute; University of Cambridge; University of Cambridge; University of Dundee	Jackson, SP (corresponding author), Univ Cambridge, Canc Res Campaign, Inst Canc & Dev Biol, Dept Zool, Tennis Court Rd, Cambridge CB2 1QR, England.		Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014	Jackson, Stephen Philip/0000-0001-9317-7937; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARTUSO M, 1995, ONCOGENE, V11, P1427; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; DVIR A, 1993, J BIOL CHEM, V268, P10440; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GOTTLIEB TM, 1997, BIOCHIM BIOPHYS ACTA, V1287, P77; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jackson SP, 1996, CANCER SURV, V28, P261; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lakin ND, 1996, ONCOGENE, V13, P2707; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; POWIS G, 1994, CANCER RES, V54, P2419; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rotman G, 1997, CANCER SURV, V29, P285; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SMITH GCM, 1999, IN PRESS GENES DEV; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445	34	107	110	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	1999	18	27					3989	3995		10.1038/sj.onc.1202973	http://dx.doi.org/10.1038/sj.onc.1202973			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435622				2022-12-17	WOS:000081327800009
J	Xu, Y; Krishnan, A; Wan, XS; Majima, H; Yeh, CC; Ludewig, G; Kasarskis, EJ; St Clair, DK				Xu, Y; Krishnan, A; Wan, XS; Majima, H; Yeh, CC; Ludewig, G; Kasarskis, EJ; St Clair, DK			Mutations in the promoter reveal a cause for the reduced expression of the human manganese superoxide dismutase gene in cancer cells	ONCOGENE			English	Article						tumor suppressor gene; mutation; promoter; transcription factors; MnSOD; reactive oxygen species	TRANSCRIPTION FACTOR; MALIGNANT PHENOTYPE; BINDING PROTEINS; TRANSGENIC MICE; DNA-BINDING; ACTIVATION; SP1; SUPPRESSION; OVEREXPRESSION; SITES	Manganese superoxide dismutase (MnSOD) has been shown to play an important role in preventing the development of cancer. MnSOD activity is reduced in many transformed cells and tumor tissues. We previously showed that the reduced level of MnSOD activity in cancer cells was not due to a defect in the primary structure of MnSOD protein, but rather was due to defects in gene expression. To elucidate the cause for the reduced expression of human MnSOD in cancer, we investigated the nucleotide sequence in the regulatory region of the MnSOD gene in a normal human cell line and various human tumor cell lines. A DNA fragment spanning 3.4 kb 5' flanking region of the MnSOD gene isolated from a normal human genomic DNA library was used to determine the DNA sequence of MnSOD promoter. PCR primers were used for amplification of the 3.4 kb 5' flanking region of the human MnSOD gene in cancer cells. Sequence analysis identified three heterozygous mutations in the proximal region of the promoter in five human tumor cell lines; These mutations, clustered around the GC-rich region of the human MnSOD promoter, change the binding pattern of AP-2 and lead to a reduction in transcription activity using a luciferase reporter assay system. These results suggest that the reduced level of MnSOD expression in some tumor cells is, at least in part, due to a defect in the DNA sequence of the promoter region.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	St Clair, DK (corresponding author), Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA.		Majima, Hideyuki J./K-3778-2019; Ludewig, Gabriele/A-2745-2008	Ludewig, Gabriele/0000-0003-2385-7720	NCI NIH HHS [CA 59835, CA 49797] Funding Source: Medline; NHLBI NIH HHS [HL 03544] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA049797, R01CA049797, R01CA059835] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K02HL003544] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amstad PA, 1997, CARCINOGENESIS, V18, P479, DOI 10.1093/carcin/18.3.479; Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dharmavaram RM, 1997, J BIOL CHEM, V272, P26918, DOI 10.1074/jbc.272.43.26918; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FLAMAN JM, 1994, NUCLEIC ACIDS RES, V22, P3259, DOI 10.1093/nar/22.15.3259; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; Halliwell B., 1989, FREE RADICAL BIO MED, P86; HO YS, 1991, AM J RESP CELL MOL, V4, P278, DOI 10.1165/ajrcmb/4.3.278; IKEDA K, 1993, GENE, V136, P341; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; JONES PL, 1995, GENE, V153, P155, DOI 10.1016/0378-1119(94)00666-G; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; Keller JN, 1998, J NEUROSCI, V18, P687; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LI JJ, 1995, ONCOGENE, V10, P1989; Li M, 1997, ONCOGENE, V15, P1535, DOI 10.1038/sj.onc.1201325; LopezRodriguez C, 1997, J BIOL CHEM, V272, P29120, DOI 10.1074/jbc.272.46.29120; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MEYRICK B, 1994, AM J RESP CELL MOL, V10, P113, DOI 10.1165/ajrcmb.10.1.8292376; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Moffat GJ, 1996, J BIOL CHEM, V271, P1054, DOI 10.1074/jbc.271.2.1054; OBERLEY LW, 1979, CANCER RES, V39, P1141; OBERLEY LW, 1984, J THEOR BIOL, V106, P403, DOI 10.1016/0022-5193(84)90038-9; OBERLEY LW, 1989, FREE RADICAL BIO MED, V6, P379, DOI 10.1016/0891-5849(89)90083-X; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; SAFFORD SE, 1994, CANCER RES, V54, P4261; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; StClair DK, 1997, ONCOL REP, V4, P753; STCLAIR DK, 1994, FREE RADICAL BIO MED, V16, P275, DOI 10.1016/0891-5849(94)90153-8; StClair DK, 1996, ONCOL REP, V3, P429; STCLAIR DK, 1992, MOL CARCINOGEN, V6, P238, DOI 10.1002/mc.2940060404; STCLAIR DK, 1991, CANCER RES, V51, P939; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; Tang W, 1997, J BIOL CHEM, V272, P13146, DOI 10.1074/jbc.272.20.13146; THOMSEN DR, 1984, P NATL ACAD SCI-BIOL, V81, P659, DOI 10.1073/pnas.81.3.659; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; URANO M, 1995, CANCER RES, V55, P2490; WAN XS, 1994, DNA CELL BIOL, V13, P1127, DOI 10.1089/dna.1994.13.1127; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WISPE JR, 1992, J BIOL CHEM, V267, P23937; Yen HC, 1996, J CLIN INVEST, V98, P1253, DOI 10.1172/JCI118909; YEN HC, 1997, J BIOMED LAB SCI, V9, P40; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852	53	107	117	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					93	102		10.1038/sj.onc.1202265	http://dx.doi.org/10.1038/sj.onc.1202265			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926924				2022-12-17	WOS:000078166000011
J	Levy-Strumpf, N; Kimchi, A				Levy-Strumpf, N; Kimchi, A			Death associated proteins (DAPs): from gene identification to the analysis of their apoptotic and tumor suppressive functions	ONCOGENE			English	Article						apoptosis; DAP-kinase; cathepsin D; interferon-gamma; metastasis; functional gene cloning	PROGRAMMED CELL-DEATH; INITIATION-FACTOR 4G; INTERFERON-GAMMA; KINASE; EXPRESSION; MEDIATOR	The process of apoptosis (programmed cell death) has become the subject of intensive and extensive research over the past few years. Various approaches are being used to identify and study genes which function as positive mediators of apoptosis, Here, we address a novel approach of gene cloning aimed at isolating intracellular death promoting genes by utilizing a functional screen. This method, called TKO, was based on transfection of cells with an anti-sense cDNA library, followed by the selection of transfectants which survived in the continuous presence of a killing cytokine - interferon-gamma. It led to the identification of five novel apoptotic genes and to the finding that a known protease-cathepsin D, is actively recruited to the death process. The five novel apoptotic genes (named DAP genes for: Death Associated Proteins) code for proteins which display a diverse spectrum of biochemical activities. The List comprises a novel type of calcium/calmodulin-regulated kinase which carries ankyrin repeats and a death domain (DAP-kinase), a nucleotide-binding protein (DAP-3), a small proline-rich cytoplasmic protein (DAP-1), and a novel homolog of the eIF4G translation initiation factor (DAP-5), Extensive studies proved that these genes are critical for mediating cell death initiated by interferon-gamma, and in some of the tested cases also cell death induced by Fas/APO-1, TNF-alpha, and a detachment from extracellular matrix. Moreover, one of these genes, DAP-kinase, was recently found to display strong tumor suppressive activities, coupling the control of apoptosis to metastasis. The advantage of functional approaches of gene cloning is that they select the relevant rate limiting genes along the death pathways in a complete unbiased manner. As a consequence, novel targets and unpredicted mechanisms emerged, A few examples illustrating this important point will be discussed, One relates to the calcium/calmodulin-dependent DAP-kinase, which is localized to the actin microfilaments. It was found that the correct localization of DAP-kinase to the microfilament network was critical for the execution of the apoptotic process, and more specifically for the disruption of the stress fibers-a typical hallmark of apoptosis, Another important breakthrough step in our understanding of apoptotic processes relates to the identification and analysis of the DAP-5 gene. The structure/ function features of this novel translation regulator resemble the proteolytically cleaved eIF4G which appears in cells upon infection with some RNA viruses and which directs cap-independent translation, Thus, the rescue of DAP-5 highlighted the importance of regulation of protein translation in certain apoptotic systems, Finally, the isolation of cathespin D by our method suggests that lysosomal proteases are recruited during apoptosis, in addition to the well known caspase family of proteases, and that a unique pattern of regulation affecting the processing of this protease takes place. The major challenge now is to analyse how these diverse DAP gene activities constitute biochemical pathway(s) leading to programmed cell death, and what is their functional position with respect to other known positive mediators and suppressors of apoptosis such as the Bcl2 and caspase family members.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Kimchi, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.			Levy-Strumpf, Naomi/0000-0002-5454-8800				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FEINSTEIN E, 1995, GENOMICS, V29, P305, DOI 10.1006/geno.1995.1255; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Imataka H, 1997, EMBO J, V16, P817, DOI 10.1093/emboj/16.4.817; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; KISSIL J, 1999, IN PRESS EMBO J; KISSIL JL, 1995, J BIOL CHEM, V270, P27932, DOI 10.1074/jbc.270.46.27932; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; Kissil JL, 1997, CYTOGENET CELL GENET, V77, P252, DOI 10.1159/000134587; KOGEL D, 1998, IN PRESS ONCOGENE, V17; Laird PW, 1997, MOL MED TODAY, V3, P223, DOI 10.1016/S1357-4310(97)01019-8; LevyStrumpf N, 1997, MOL CELL BIOL, V17, P1615, DOI 10.1128/MCB.17.3.1615; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yamanaka S, 1997, GENE DEV, V11, P321, DOI 10.1101/gad.11.3.321	33	107	112	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 24	1998	17	25					3331	3340		10.1038/sj.onc.1202588	http://dx.doi.org/10.1038/sj.onc.1202588			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916995				2022-12-17	WOS:000078048200014
J	Garriga, J; Peng, JM; Parreno, M; Price, DH; Henderson, EE; Grana, X				Garriga, J; Peng, JM; Parreno, M; Price, DH; Henderson, EE; Grana, X			Upregulation of cyclin T1/CDK9 complexes during T cell activation	ONCOGENE			English	Article						PITALRE; CDK; RNA polymerase II; HIV; Tat; peripheral blood lymphocytes	HUMAN-IMMUNODEFICIENCY-VIRUS; RNA-POLYMERASE-II; CDC2-RELATED KINASE PITALRE; CARBOXYL-TERMINAL DOMAIN; TAT-ASSOCIATED KINASE; PROTEIN-KINASE; IN-VITRO; P-TEFB; LARGE SUBUNIT; PHOSPHORYLATION	Cyclin T1 has been identified recently as a regulatory subunit of CDK9 and as a component of the transcription elongation factor P-TEFb, Cyclin TL/CDK9 complexes phosphorylate the carboxy terminal domain (CTD) of RNA polymerase II (RNAP II) in vitro. Here we report that the levels of cyclin T1 are dramatically upregulated by two independent signaling pathways triggered respectively by PMA and PHA in primary human peripheral blood lymphocytes (PBLs), Activation of these two pathways in tandem is sufficient for PBLs to enter and progress through the cell cycle. However, the expression of cyclin T1 is not growth and/or cell cycle regulated in other cell types, indicating that regulation of cyclin T1 expression is dependent on tissue-specific signaling pathways, Upregulation of cyclin T1 in stimulated PBLs results in induction of the CTD kinase activity of the cyclin T1/CDK9 complex, which in turn correlates directly with phosphorylation of RNAP II in vivo, linking for the first time activation of the cyclin T1/CDK9 pair with phosphorylation of RNAP II in vivo. In addition, we report here that endogenous CDK9 and cyclin T1 complexes associate with HIV-1 generated Tat in relevant cells and under physiological conditions (HIV-1 infected T cells). This, together with our results showing that HIV-1 replication in stimulated PBLs correlates with the levels of cyclin T1 protein and associated CTD kinase activity, suggests that the cyclin T1/CDK9 pair is one of the HIV-1 required host cellular cofactors generated during T cell activation.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Iowa	Grana, X (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.		Peng, Junmin/N-2614-2018; Price, David H/F-6173-2010	Peng, Junmin/0000-0003-0472-7648; Price, David/0000-0002-5597-385X; Grana, Xavier/0000-0001-7134-0473	NATIONAL CANCER INSTITUTE [R55CA075909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500, R29GM054894] Funding Source: NIH RePORTER; NCI NIH HHS [CA/DO75909-01] Funding Source: Medline; NIGMS NIH HHS [GM35500, GM54894] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashihara T, 1979, Methods Enzymol, V58, P248; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; FINZI, 1998, CELL, V93, P665; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Garriga J, 1996, BIOCHEM J, V319, P293, DOI 10.1042/bj3190293; Garriga J, 1996, BIOCHEM J, V320, P983, DOI 10.1042/bj3200983; GRANA X, 1994, ONCOGENE, V9, P2097; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; GRANA X, 1995, ONCOGENE, V11, P211; Guan MX, 1996, J VIROL, V70, P7341, DOI 10.1128/JVI.70.10.7341-7346.1996; HERRMANN CH, 1993, VIROLOGY, V197, P601, DOI 10.1006/viro.1993.1634; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.biochem.63.1.717; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Liu ZJ, 1998, MOL CELL BIOL, V18, P3445, DOI 10.1128/MCB.18.6.3445; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Nekhai S, 1997, J VIROL, V71, P7436, DOI 10.1128/JVI.71.10.7436-7441.1997; Peng JM, 1998, J BIOL CHEM, V273, P13855, DOI 10.1074/jbc.273.22.13855; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Xiong Y, 1996, Biochim Biophys Acta, V1288, P01; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	38	107	107	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 17	1998	17	24					3093	3102		10.1038/sj.onc.1202548	http://dx.doi.org/10.1038/sj.onc.1202548			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872325				2022-12-17	WOS:000077517400003
J	Vonlanthen, S; Heighway, J; Tschan, MP; Borner, MM; Altermatt, HJ; Kappeler, A; Tobler, A; Fey, MF; Thatcher, N; Yarbrough, WG; Betticher, D				Vonlanthen, S; Heighway, J; Tschan, MP; Borner, MM; Altermatt, HJ; Kappeler, A; Tobler, A; Fey, MF; Thatcher, N; Yarbrough, WG; Betticher, D			Expression of p16INK4a/p16 alpha and p19ARF/p16 beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression	ONCOGENE			English	Article						CDKN2; p16INK4a/p16 alpha; p19ARF/p16 beta; p53; methylation; non-small cell lung carcinoma	TUMOR-SUPPRESSOR GENE; INK4A LOCUS; P16(INK4) PROTEIN; DNA METHYLATION; CYCLE ARREST; P16 MTS1; INACTIVATION; RB; SENESCENCE; MUTATIONS	The CDKN2 locus expresses two different mRNA transcripts, designated alpha and beta. The protein product of the or transcript is the cell cycle inhibitor and tumour suppressor p16INK4a. The beta transcript is translated in an alternate reading frame (ARF) and in humans encodes a 15 kDa protein (p19ARF). Immunohistochemical and Western analysis of p16INK4a has shown that the protein is downregulated in a significant number of tumours, but less is known on the expression of the p19ARF, We have examined the expression of p16INK4a and p19ARF in resectable non-small cell lung cancer (NSCLC) by immunostaining (n=49) and multiplex RT-PCR (n=28). In order to investigate the mechanism responsible for p16INK4a downregulation, exon 1 alpha methylation was analysed in a PCR-based assay. Of 49 tumours examined by immunostaining, 24 and 20 tumours expressed p16INK4a and p19ARF at nil to low levels, respectively, p19ARF was localized primarily to the nuclei of tumour cells, but was also seen to varying degrees in nuclei of lymphocytes, chondrocytes, fibroblasts, and epithelial cells. No tumour with normal p16INK4a had decreased p19ARF expression, Among 16 tumours with nil to low p16INK4a expression, 11 tumours exhibited full methylation of at least one site within exon 1 alpha and these tumours showed normal p19ARF expression. In contrast, no methylation of exon 1 alpha was observed in five tumours which also lacked p19ARF, In normal lung, p16INK4a and p19ARF were not expressed at detectable levels, the multiplex RT-PCR results were balanced, and sites within exon 1 alpha were strongly methylated. In tumours, imbalanced multiplex RT-PCR data (p16INK4a < p19ARF) predicted methylation of exon 1 alpha (P = 0.0006) as well as downregulation of p16INK4a, p19ARF downregulation was inversely correlated with p53 overexpression (P = 0.025), whilst negative immunostaining for p16INK4a was inversely correlated with pRb downregulation (P = 0.003) and directly correlated with p53 overexpression as assessed by immunostaining (P = 0.015), Our results show that: (1) p16INK4a and p19ARF expression are altered in almost half of resectable NSCLC; (2) methylation within exon 1 alpha is a frequent, but not the only mechanism of p16INK4a downregulation; and that (3) the inverse association of p19ARF and p53 alteration is consistent with a linked pathway.	Univ Bern, Dept Clin Res, CH-3012 Bern, Switzerland; Univ Bern, Inst Med Oncol, CH-3012 Bern, Switzerland; Univ Bern, Inst Pathol, CH-3012 Bern, Switzerland; Christie Hosp, Dept Med Oncol, Manchester, Lancs, England; Univ N Carolina, Dept Surg, Div Otorhinolaryngol, Chapel Hill, NC USA	University of Bern; University of Bern; University of Bern; Christie NHS Foundation Trust; Christie Hospital; University of North Carolina; University of North Carolina Chapel Hill	Betticher, D (corresponding author), Univ Bern, Inst Med Oncol, Inselspital, CH-3010 Bern, Switzerland.	daniel.betticher@insel.ch	Borner, Markus/B-7583-2011; Betticher, Daniel C/G-5849-2013	Tschan, Mario P./0000-0001-5897-3647				Arap W, 1997, ONCOGENE, V15, P2013, DOI 10.1038/sj.onc.1201389; Betticher DC, 1997, INT J CANCER, V74, P556, DOI 10.1002/(SICI)1097-0215(19971021)74:5<556::AID-IJC14>3.0.CO;2-4; Betticher DC, 1996, BRIT J CANCER, V73, P294, DOI 10.1038/bjc.1996.52; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BORNER MM, 1998, IN PRESS BR J CANC; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; GERADTS J, 1995, CANCER RES, V55, P6006; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GONZALEZZULUETA M, 1995, J NATL CANCER I, V87, P1383, DOI 10.1093/jnci/87.18.1383; GRUIS NA, 1995, AM J PATHOL, V146, P1199; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Hara E, 1996, MOL CELL BIOL, V16, P859; Herman JG, 1997, CANCER RES, V57, P837; HERMAN JG, 1995, CANCER RES, V55, P4525; Heyman M, 1996, BLOOD, V87, P1657, DOI 10.1182/blood.V87.4.1657.bloodjournal8741657; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; Liggett WH, 1996, CANCER RES, V56, P4119; MAO L, 1995, CANCER RES, V55, P2995; Marchetti A, 1997, J PATHOL, V181, P178, DOI 10.1002/(SICI)1096-9896(199702)181:2<178::AID-PATH741>3.0.CO;2-5; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1995, ONCOGENE, V11, P1211; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; SHAPIRO GI, 1995, CANCER RES, V55, P505; Shores C., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P277; Singer-Sam J., 1993, Experientia Supplementum (Basel), V64, P358; STONE S, 1995, ONCOGENE, V11, P987; STONE S, 1995, CANCER RES, V55, P2988; Swafford DS, 1997, MOL CELL BIOL, V17, P1366, DOI 10.1128/MCB.17.3.1366; TAM SW, 1994, CANCER RES, V54, P5816; *UICC AM JOINT COM, 1987, MAN STAG CANC; World Health Organization, 1981, HIST TYP LUNG TUM; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	46	107	113	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2779	2785		10.1038/sj.onc.1202501	http://dx.doi.org/10.1038/sj.onc.1202501			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840942				2022-12-17	WOS:000077146700011
J	Herrmann, C; Block, C; Geisen, C; Haas, K; Weber, C; Winde, G; Moroy, T; Muller, O				Herrmann, C; Block, C; Geisen, C; Haas, K; Weber, C; Winde, G; Moroy, T; Muller, O			Sulindac sulfide inhibits Ras signaling	ONCOGENE			English	Article						non-steroidal anti-inflammatory drugs; sulindac; p21ras	GTPASE-ACTIVATING PROTEIN; FAMILIAL ADENOMATOUS POLYPOSIS; GUANINE-NUCLEOTIDE EXCHANGE; COLON-CANCER CELLS; MALIGNANT TRANSFORMATION; DIFFERENTIAL REGULATION; PLASMA-MEMBRANE; GENE-PRODUCT; IN-VIVO; HA-RAS	The non-steroidal anti-inflammatory drug sulindac is used in cancer prevention and therapy, but the molecular aspects of its anti-tumor effect remain unresolved. In vivo the prodrug sulindac, is converted into the metabolite sulindac sulfide. We found that sulindac sulfide strongly inhibits Ras induced malignant transformation and Ras/Raf dependent transactivation, Sulindac sulfide decreases the Ras induced activation of its main effector, the c-Raf-1 kinase, In vitro sulindac sulfide directly binds to the Ras gene product p21ras in a non-covalent manner. Moreover, we can show that sulindac sulfide inhibits the interaction of p21ras with the p21ras binding domain of the Raf protein. In addition, sulindac sulfide can impair the nucleotide exchange on p21ras by CDC25 as well as the acceleration of the p21ras GTPase reaction by p120GAP. Due to its action at the most critical site in Ras signaling me propose sulindac sulfide as a lead compound in the search for novel anti-cancer drugs which directly inhibit Ras mediated cell proliferation and malignant transformation.	Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44139 Dortmund, Germany; Univ Essen Gesamthsch Klinikum, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany; Univ Wurzburg, Inst Med Strahltnkunde & Zellforsch, D-97078 Wurzburg, Germany; Univ Munster, Chirurg Klin, D-48129 Munster, Germany	Max Planck Society; University of Duisburg Essen; University of Wurzburg; University of Munster	Muller, O (corresponding author), Max Planck Inst Mol Physiol, Abt Strukturelle Biol, Rheinlanddamm 201, D-44139 Dortmund, Germany.		Moroy, Tarik/D-9923-2011; Winde, Guenther/AAA-3610-2020					Ahmadian MR, 1997, BIOCHEMISTRY-US, V36, P4535, DOI 10.1021/bi962556y; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOS JL, 1989, CANCER RES, V49, P4682; Chiu CH, 1997, CANCER RES, V57, P4267; CRAVCHIK A, 1993, GENE, V137, P139, DOI 10.1016/0378-1119(93)90262-2; Flory E, 1998, J VIROL, V72, P2788, DOI 10.1128/JVI.72.4.2788-2794.1998; GIARDIELLO FM, 1994, CANCER METAST REV, V13, P279, DOI 10.1007/BF00666098; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; Goldberg Y, 1996, ONCOGENE, V12, P893; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; LOVEC H, 1994, ONCOGENE, V9, P323; Luk GD, 1996, SCHWEIZ MED WSCHR, V126, P801; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; PASRICHA PJ, 1995, GASTROENTEROLOGY, V109, P994, DOI 10.1016/0016-5085(95)90411-5; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PIAZZA GA, 1995, CANCER RES, V55, P3110; Piazza GA, 1997, CANCER RES, V57, P2909; Piazza GA, 1997, CANCER RES, V57, P2452; QIAO L, 1995, BBA-LIPID LIPID MET, V1258, P215, DOI 10.1016/0005-2760(95)00100-Q; RAO CV, 1995, CANCER RES, V55, P1464; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schweins T, 1996, BIOCHEMISTRY-US, V35, P14225, DOI 10.1021/bi961118o; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Thompson HJ, 1997, CANCER RES, V57, P267; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Vane JR, 1996, SCAND J RHEUMATOL, P9; WINDE G, 1995, DIS COLON RECTUM, V38, P813, DOI 10.1007/BF02049838; Wixler V, 1996, FEBS LETT, V385, P131, DOI 10.1016/0014-5793(96)00363-8; Wright JD, 1996, CLIN PHARMACOKINET, V30, P445, DOI 10.2165/00003088-199630060-00003	44	107	113	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	1998	17	14					1769	1776		10.1038/sj.onc.1202085	http://dx.doi.org/10.1038/sj.onc.1202085			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778042				2022-12-17	WOS:000076303300002
J	Eshleman, JR; Casey, G; Kochera, ME; Sedwick, WD; Swinler, SE; Veigl, ML; Willson, JKV; Schwartz, S; Markowitz, SD				Eshleman, JR; Casey, G; Kochera, ME; Sedwick, WD; Swinler, SE; Veigl, ML; Willson, JKV; Schwartz, S; Markowitz, SD			Chromosome number and structure both are markedly stable in RER colorectal cancers and are not destabilized by mutation of p53	ONCOGENE			English	Article						RER; colorectal cancer; p53; karyotype instability; genomic instability	CARCINOMA CELL-LINES; WILD-TYPE P53; HUMAN UROEPITHELIAL CELLS; TUMOR-SUPPRESSOR GENES; MICROSATELLITE INSTABILITY; CYTOGENETIC ANALYSIS; CARCINOGENESIS; AMPLIFICATION; PATHOGENESIS; MALIGNANCIES	Fourteen colorectal cancer cell lines, categorized according to the presence or absence of microsatellite instability, were further analysed tor chromosomal stability by karyotyping, NonRER (microsatellite stable) cell lines typically displayed highly aberrant karyotypes with alterations not only of chromosome number but also of chromosome structure including chromosomal deletions, inversions, and translocations. RER (microsatellite unstable) cell lines, in contrast, displayed significantly fewer alterations of chromosome number, Moreover, RER cell lines also displayed significantly fewer cytogenetically evident alterations of chromosome structure, Compared to NonRER colon cancers, RER colon cancers are significantly less likely to have undergone chromosomal gain, loss, or breakage. Characterization of p53 gene status by gene sequencing was performed in an attempt to determine if p53 gene status correlated with the chromosomal stability of the RER cancers. Gene mutations in p53 were present in all of the NonRER colon cancers, However, p53 gene mutations were also found present in four of nine of the RER colon cancers, Unexpectedly, RER colon cancers bearing mutant p53 demonstrated the same stability of chromosome number, and the same stability of chromosome structure, as the RER colon cancers with wild-type p53, Therefore, in RER colon cancers specific p53 independent mechanisms actively maintain the stability of both chromosome number and structure.	Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA	Johns Hopkins University; Cleveland Clinic Foundation; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eshleman, JR (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Ross Bldg,Rm 632,720 Rutland Ave, Baltimore, MD 21205 USA.				NATIONAL CANCER INSTITUTE [R01CA072160, R01CA067409, K08CA066628] Funding Source: NIH RePORTER; NCI NIH HHS [CA 67409, CA 72160, CA66628] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BAKER SJ, 1990, CANCER RES, V50, P7717; BHATTACHARYYA NP, 1995, HUM MOL GENET, V4, P2057, DOI 10.1093/hmg/4.11.2057; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRANCH P, 1995, CANCER RES, V55, P2304; CAMPO E, 1994, CANCER-AM CANCER SOC, V73, P2913, DOI 10.1002/1097-0142(19940615)73:12<2913::AID-CNCR2820731207>3.0.CO;2-L; CARIELLO NF, 1994, CANCER RES, V54, P4454; CASEY G, 1993, CANCER LETT, V69, P151, DOI 10.1016/0304-3835(93)90168-9; Casey G, 1996, ONCOGENE, V13, P1971; CASEY G, 1991, ONCOGENE, V6, P1791; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Eshleman JR, 1996, ONCOGENE, V12, P1425; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FREI JV, 1992, CANCER, V69, P1108; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GAIDANO G, 1994, AM J PATHOL, V144, P1312; Glaab WE, 1997, CARCINOGENESIS, V18, P1, DOI 10.1093/carcin/18.1.1; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KAO CH, 1993, CARCINOGENESIS, V14, P2297, DOI 10.1093/carcin/14.11.2297; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOURI M, 1990, CANCER, V65, P1825, DOI 10.1002/1097-0142(19900415)65:8<1825::AID-CNCR2820650827>3.0.CO;2-H; LEHMAN TA, 1994, DRUG METAB REV, V26, P221, DOI 10.3109/03602539409029793; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOEB LA, 1991, CANCER RES, V51, P3075; LOTHE RA, 1993, CANCER RES, V53, P5849; MCBAIN JA, 1984, CANCER RES, V44, P5813; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Sullivan BA, 1996, AM J HUM GENET, V59, P167; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	37	107	108	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					719	725		10.1038/sj.onc.1201986	http://dx.doi.org/10.1038/sj.onc.1201986			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715273				2022-12-17	WOS:000075337200006
J	Sun, L; Carpenter, G				Sun, L; Carpenter, G			Epidermal growth factor activation of NF-kappa B is mediated through I kappa B alpha degradation and intracellular free calcium	ONCOGENE			English	Article						EGF; NF-kB; calcium	C-FOS GENE; MOUSE-LIVER; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; BINDING-PROTEINS; EXPRESSION; CELLS; INDUCTION; SITES; TRANSFORMATION	The transcription factor NF-kappa B is normally sequestered in the cytoplasm by its inhibitory subunit I kappa B. Most extracellular signals activate NF-kappa B through a mechanism involving the phosphorylation and proteasome-dependent degradation of I kappa B, EGF activates NF-kappa B in A-431 carcinoma cells, which overexpress EGF receptors and in mouse embryo fibroblasts, which have a normal complement of receptors, Supershift experiments indicate that the NF-kappa B complexes induced by EGF are composed of p50/p50 homodimers and p65/p50 heterodimers, but not c-rel, EGF stimulation enhances the degradation of I kappa B alpha, but not I kappa-B beta nor an N-terminal deletion mutant of II;Ba. Treatment of cells with a proteasome inhibitor, such as ALLN or MG132, blocks EGF-mediated NF-kappa B activation, indicating that EGF-induced NF-kappa B activation requires proteasome-dependent I kappa B degradation, Also, Bapta A/M (a cell-permeable chelator of intracellular calcium) blocks EGF-induced NF-kappa B activation and I kappa B alpha degradation, suggesting a requirement of intracellular free Ca2+ for this growth factor response, Protein kinase C inhibition, in contrast, did not influence EGF activation of NF-kappa B.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [T32CA009582, R01CA075195] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA75195, T32 CA09582] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Cabannes E, 1997, ONCOGENE, V15, P29, DOI 10.1038/sj.onc.1201162; CARPENTER G, 1993, FORUM, V3, P616; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FISHER DA, 1990, ENDOCR REV, V11, P418, DOI 10.1210/edrv-11-3-418; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GALANG CK, 1994, ONCOGENE, V9, P2913; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; IZUMI H, 1994, EXP CELL RES, V214, P654, DOI 10.1006/excr.1994.1303; JI L, 1994, MOL CELL BIOL, V14, P7967, DOI 10.1128/MCB.14.12.7967; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Kanno T, 1996, J IMMUNOL, V157, P5277; LAROSA F, 1993, MOL CELL BIOL, V14, P1039; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Obata H, 1996, BIOCHEM BIOPH RES CO, V224, P27, DOI 10.1006/bbrc.1996.0979; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; SCHMIDT KN, 1995, J BIOL CHEM, V270, P27136, DOI 10.1074/jbc.270.45.27136; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHOUTEN GJ, 1997, EMBO J, V16, P3133; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THEVENIN C, 1990, New Biologist, V2, P793; WILHELM D, 1995, IMMUNOBIOLOGY, V193, P143, DOI 10.1016/S0171-2985(11)80537-1	47	107	110	2	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2095	2102		10.1038/sj.onc.1201731	http://dx.doi.org/10.1038/sj.onc.1201731			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572490	Bronze			2022-12-17	WOS:000073177200007
J	Capoulade, C; Bressac-de Paillerets, B; Lefrere, I; Ronsin, M; Feunteun, J; Tursz, T; Wiels, J				Capoulade, C; Bressac-de Paillerets, B; Lefrere, I; Ronsin, M; Feunteun, J; Tursz, T; Wiels, J			Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells	ONCOGENE			English	Article						MDM2; p53; Burkitt's lymphoma; enhanced translation	ACUTE LYMPHOBLASTIC-LEUKEMIA; TUMOR-SUPPRESSOR GENE; HEMATOLOGIC MALIGNANCIES; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; INDUCED APOPTOSIS; ONCOPROTEIN MDM2; MUTANT P53; PROTEIN; MUTATIONS	Numerous studies have indicated that inactivation of p53 is one of the essential requirements for the unrestrained growth of tumoral cells, When the status of the p53 gene was examined in various types of lymphoid malignancies, mutations in p53 have been predominantly detected in Burkitt's lymphoma (BL) cells, therefore suggesting that alteration of p53 could specifically contribute to the malignant phenotype of these tumoral cells, In addition to mutations, functional inactivation of p53 can also occur through interaction of the wild-type gene product with various viral or cellular proteins, The cellular MDM2 protein, for example, is able to inhibit p53 tumor suppressor function by concealing its transactivation domain, Mdm2 gene amplification has been described in several types of sarcomas, resulting in overexpression of the MDM2 protein, In this study, we have examined the status of MDM2 and p53 in 20 BL cell lines, Four were found to contain wild-type p53 and to overexpress MDM2 protein, Within these BL cells, both molecules are physically associated since they can be co-precipitated and p53 is inactivated as cells neither arrest in G1 nor enter apoptosis following gamma-radiation. We also report that the high level of the MDM2 protein in BL cells is neither associated with an amplification of the mdm2 gene nor with an elevated level of RNA or an increased protein stability, but is rather due to an enhanced translation ability of the mdm2 RNA, These results indicate that in certain BL cells, overexpression of MDM2 protein regulated at the posttranscriptional level, induces an escape from p53-controlled cell growth.	Inst Gustave Roussy, CNRS, URA 1156, Lab Biol Tumeurs Humaines, F-94805 Villejuif, France; Inst Gustave Roussy, CNRS, URA 1967, Lab Genet Oncol, F-94805 Villejuif, France; Inst Gustave Roussy, CNRS, URA 1967, Lab Diagnost Mol, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Wiels, J (corresponding author), Inst Gustave Roussy, CNRS, URA 1156, Lab Biol Tumeurs Humaines, Rue Camille Desmoulins, F-94805 Villejuif, France.		Wiels, Joëlle/AGL-2319-2022; Feunteun, Jean/AAZ-1267-2020; Paillerets, Brigitte Bressac-de/D-8954-2018	Wiels, Joëlle/0000-0002-3313-2937; Paillerets, Brigitte Bressac-de/0000-0003-0245-8608; Feunteun, Jean/0000-0003-1212-9189				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BERBERICH S, 1994, ONCOGENE, V9, P1469; BHATIA KG, 1992, CANCER RES, V52, P4273; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HSU B, 1995, ONCOGENE, V11, P175; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KASTAN MB, 1991, CANCER RES, V51, P6304; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Landers JE, 1997, CANCER RES, V57, P3562; LANDERS JE, 1994, ONCOGENE, V9, P2745; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CANCER RES, V53, P2231; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LUNA RMD, 1995, NATURE, V378, P203; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; Marks DI, 1996, BRIT J HAEMATOL, V92, P890, DOI 10.1046/j.1365-2141.1996.439978.x; Marks DI, 1997, J CLIN ONCOL, V15, P1158, DOI 10.1200/JCO.1997.15.3.1158; Marks DI, 1996, BLOOD, V87, P1155, DOI 10.1182/blood.V87.3.1155.bloodjournal8731155; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OCONNOR PM, 1993, CANCER RES, V53, P4776; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; PREUDHOMME C, 1995, J CLIN ONCOL, V13, P812, DOI 10.1200/JCO.1995.13.4.812; RAMQVIST T, 1993, ONCOGENE, V8, P1495; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SHEIKH MS, 1993, CANCER RES, V53, P3226; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOUSDEN KH, 1993, J GEN VIROL, V74, P803, DOI 10.1099/0022-1317-74-5-803; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; WIMAN KG, 1991, ONCOGENE, V6, P1633; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHOU MX, 1995, BLOOD, V85, P1608, DOI 10.1182/blood.V85.6.1608.bloodjournal8561608	53	107	109	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1603	1610		10.1038/sj.onc.1201702	http://dx.doi.org/10.1038/sj.onc.1201702			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569028				2022-12-17	WOS:000072743200011
J	Stoll, SW; Benedict, M; Mitra, R; Hiniker, A; Elder, JT; Nunez, G				Stoll, SW; Benedict, M; Mitra, R; Hiniker, A; Elder, JT; Nunez, G			EGF receptor signaling inhibits keratinocyte apoptosis: evidence for mediation by Bcl-X-L	ONCOGENE			English	Article						apoptosis; EGF receptor; Bcl-X-L; keratinocytes; signal transduction	EPIDERMAL GROWTH-FACTOR; MAMMARY EPITHELIAL-CELLS; TYROSINE KINASE; MONOCLONAL-ANTIBODY; AUTO-INDUCTION; FACTOR-ALPHA; EXPRESSION; BINDING; ERYTHROPOIETIN; INSULIN	Signaling through the epidermal growth factor receptor (EGFR) has been primarily implicated in the growth of epithelial cells including keratinocytes. However, the mechanism by which EGFR stimulation promotes keratinocyte cell growth is poorly understood, Here we report that human keratinocytes undergo apoptosis when incubated with the blocking EGFR monoclonal antibody 225 IgG, or PD153035, a highly specific EGFR tyrosine kinase inhibitor, Endogenous mRNA and protein levels of Bcl-X-L, a member the Bcl-2 family which suppresses apoptosis, were specifically inhibited by EGFR blockade, Furthermore, stimulation of EGFR signaling through two natural ligands, transforming growth factor (TGF)-alpha and epidermal growth factor (EGF), increased the expression of Bcl-X-L in quiescent keratinocytes and HaCaT cells, Finally, ectopic expression of Bcl-X-L in HaCaT cells increased survival after EGFR blockade when compared to untransfected cells or HaCaT keratinocytes transfected with empty vector. These results suggest that the anti-apoptotic protein Bcl-X-L plays an important role in the maintenance of keratinocyte survival in response to EGFR signaling.	Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI 48109 USA.		Nuñez, Gabriel/A-7160-2014		NCI NIH HHS [CA-64556] Funding Source: Medline; NIAMS NIH HHS [R29 AR40016, R01 AR 42248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064556] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR040016, R01AR042248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOYER SH, 1992, BLOOD, V80, P2503; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; DANILENKO DM, 1995, J CLIN INVEST, V95, P842, DOI 10.1172/JCI117734; Elder J T, 1995, Adv Dermatol, V10, P99; ELDER JT, 1991, J INVEST DERMATOL, V96, P425, DOI 10.1111/1523-1747.ep12469889; ELDER JT, 1990, J INVEST DERMATOL, V94, P19, DOI 10.1111/1523-1747.ep12873313; ELDER JT, 1994, EPIDERMAL GROWTH FAC, P205; EVAN GI, 1996, APOPTOSIS CELL CYCLE; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fry DW, 1997, BIOCHEM PHARMACOL, V54, P877, DOI 10.1016/S0006-2952(97)00242-6; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOTTLIEB AB, 1992, J INVEST DERMATOL, V98, P302, DOI 10.1111/1523-1747.ep12499782; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HASHIMOTO K, 1994, J BIOL CHEM, V269, P20060; HEBDA PA, 1988, J INVEST DERMATOL, V91, P440, DOI 10.1111/1523-1747.ep12476480; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KLEIN SB, 1992, J CELL PHYSIOL, V151, P326, DOI 10.1002/jcp.1041510214; KOBRIN MS, 1994, BIOCHEM BIOPH RES CO, V202, P1705, DOI 10.1006/bbrc.1994.2131; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LANG RA, 1990, IMMUNOL TODAY, V11, P244, DOI 10.1016/0167-5699(90)90098-T; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; Mitra RS, 1997, LAB INVEST, V76, P99; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Naef M, 1996, INT J CANCER, V66, P315; NANNEY LB, 1986, J INVEST DERMATOL, V86, P260, DOI 10.1111/1523-1747.ep12285389; Nass SJ, 1996, BIOCHEM BIOPH RES CO, V227, P248, DOI 10.1006/bbrc.1996.1497; NICKOLOFF BJ, 1989, BRIT J DERMATOL, V121, P161, DOI 10.1111/j.1365-2133.1989.tb01795.x; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PORTA DG, 1997, EMBO J, V16, P1647; POUMAY Y, 1995, J INVEST DERMATOL, V104, P574; RACHWAL WJ, 1995, BRIT J CANCER, V72, P56, DOI 10.1038/bjc.1995.277; Ram TG, 1996, MOL CARCINOGEN, V15, P227, DOI 10.1002/(SICI)1098-2744(199603)15:3<227::AID-MC8>3.0.CO;2-E; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; Rodeck U, 1997, J CELL SCI, V110, P113; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Stoll S, 1997, J CLIN INVEST, V100, P1271, DOI 10.1172/JCI119641; STOSCHECK CM, 1992, J INVEST DERMATOL, V99, P645, DOI 10.1111/1523-1747.ep12668143; SUNADA H, 1986, P NATL ACAD SCI USA, V83, P3825, DOI 10.1073/pnas.83.11.3825; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TILLY JL, 1992, MOL ENDOCRINOL, V6, P1942, DOI 10.1210/me.6.11.1942; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; WENCZAK BA, 1992, J CLIN INVEST, V90, P2392, DOI 10.1172/JCI116130; WRONESMITH T, 1995, AM J PATHOL, V146, P1079; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; Xian WJ, 1997, ONCOGENE, V14, P1435, DOI 10.1038/sj.onc.1200980; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	60	107	114	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	1998	16	11					1493	1499		10.1038/sj.onc.1201657	http://dx.doi.org/10.1038/sj.onc.1201657			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9580112				2022-12-17	WOS:000072572400013
J	Beer, HD; Florence, C; Dammeier, J; McGuire, L; Werner, S; Duan, DR				Beer, HD; Florence, C; Dammeier, J; McGuire, L; Werner, S; Duan, DR			Mouse fibroblast growth factor 10: cDNA cloning, protein characterization, and regulation of mRNA expression	ONCOGENE			English	Article						keratinocyte growth factor; secretion; wound repair; heparin; growth factor; regulation	LARGE INDUCTION; FACTOR FAMILY; FGF FAMILY; KERATINOCYTE; RECEPTOR; KGF; CELLS; GENE; DIFFERENTIATION; MORPHOGENESIS	Fibroblast growth factor 7 (FGF-7) or keratinocyte growth factor (KGF), is a potent and specific mitogen for epithelial cells, We have recently identified a novel human FGF-7 homologue, named FGF-10. To study the expression of this new FGF family member and its regulation in wound repair, we cloned the mouse FGF-10 (mFGF-10) cDNA, The encoded protein is 92% identical to human FGF-10 and 91% identical to rat FGF-10, When expressed in mammalian 293 cells, the mFGF-10 protein was glycosylated but remained cell- or extracellular matrix-associated. Upon addition of heparin, mFGF-10 protein was released into the media, mRNA encoding mFGF-10 was relatively abundant in lung, skin, brain and heart, In the skin, both FGF-7 and mFGF-10 were expressed in the dermal, but not the epidermal compartment, In contrast to FGF-7, mFGF-10 expression was not induced during cutaneous wound repair, In cultured fibroblasts, expression of mFGF-10 was strongly repressed by transforming growth factor beta and tumor necrosis factor alpha, whereas epidermal growth factor and interleukin-1 beta had no effect, These results demonstrate a differential regulation of mFGF-10 and FGF-7 expression in vitro and during the wound healing process.	HUMAN GENOME SCI INC,ROCKVILLE,MD 20850; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	GlaxoSmithKline; Human Genome Sciences Inc; Max Planck Society				Beer, Hans-Dietmar/0000-0002-8085-713X; Werner, Sabine/0000-0001-7397-8710; Dammeier, Johanna/0000-0002-6040-2779				BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BRAUCHLE M, 1994, ONCOGENE, V9, P3199; BRAUCHLE M, 1995, J INVEST DERMATOL, V105, P597; BROOKES S, 1989, ONCOGENE, V4, P429; CHEDID M, 1994, J BIOL CHEM, V269, P19753; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; JIMENEZ PA, 1997, UNPUB; Kiefer P, 1996, ONCOGENE, V12, P1503; KIEFER P, 1993, EMBO J, V12, P4159, DOI 10.1002/j.1460-2075.1993.tb06100.x; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; MARCHESE C, 1990, J CELL PHYSIOL, V144, P326, DOI 10.1002/jcp.1041440219; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; PIERCE GF, 1994, J EXP MED, V179, P831, DOI 10.1084/jem.179.3.831; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; Sambrook J, 1989, MOL CLONING LAB MANU; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; SMOLA H, 1993, J CELL BIOL, V122, P417, DOI 10.1083/jcb.122.2.417; STAIANOCOICO L, 1993, J EXP MED, V178, P865, DOI 10.1084/jem.178.3.865; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; UENO H, 1993, J BIOL CHEM, V268, P22814; WERNER S, 1994, J INVEST DERMATOL, V103, P469, DOI 10.1111/1523-1747.ep12395564; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Wu LC, 1996, ARCH SURG-CHICAGO, V131, P660; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918	34	107	110	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 30	1997	15	18					2211	2218		10.1038/sj.onc.1201383	http://dx.doi.org/10.1038/sj.onc.1201383			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393979				2022-12-17	WOS:A1997YD01900009
J	Kovar, H; Jug, G; Aryee, DNT; Zoubek, A; Ambros, P; Gruber, B; Windhager, R; Gadner, H				Kovar, H; Jug, G; Aryee, DNT; Zoubek, A; Ambros, P; Gruber, B; Windhager, R; Gadner, H			Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors	ONCOGENE			English	Article						Ewing tumors; p16; Rb; cyclin D; prognosis	KINASE-4 INHIBITOR GENE; P53 MUTATIONS; HOMOZYGOUS DELETIONS; CHIMERIC TRANSCRIPTS; CDK4 AMPLIFICATION; SOMATIC MUTATIONS; P16/MTS1 GENE; ABSENCE; CANCER; EXPRESSION	The pRB cell cycle regulatory cascade is frequently perturbed in neoplasia by overexpression of a component of the pRB-phosphorylating cyclin D1/CDK4 complex or by inactivation of pRB or the CDK4 inhibitors p16 and p15, We investigated the status and expression of p16, p15, CCND1, CDK4 and RE genes in the Ewing family of tumors, P16 loss was observed in 8 of 27 tumors (30%) and in 12 of 23 (52%) tumor cell lines from unrelated patients, There were no discrepancies in the p16 status between primary tumors and the corresponding cell lines and between cell Lines established from consecutive tumor samples, p15 was codeleted in most cases but p15 mRNA was absent also in cell lines retaining the gene, In addition, posttranscriptional p16 inactivation was observed in two cases, Although no evidence for CDK4 or CCND1 amplification was obtained, expression of these genes varied considerably in the cell lines in a case specific manner, In wild-type p16 cell lines, pRB expression was lost in one case, Our data indicate that, despite the absence of cytogenetically detectable 9p21 chromosomal aberrations, p16 deletions constitute the most frequent secondary molecular aberration in Ewing tumors so far, These results are discussed in the context of the stage of disease and the clinical outcome of the patients, The potential prognostic impact of these findings remains to be further evaluated.	UNIV VIENNA, DEPT ORTHOPED, A-1090 VIENNA, AUSTRIA	University of Vienna	Kovar, H (corresponding author), ST ANNA CHILDRENS HOSP, CHILDRENS CANC RES INST, KINDERSPITALGASSE 6, A-1090 VIENNA, AUSTRIA.		Ambros, Peter/AAA-1266-2021	Ambros, Peter/0000-0002-5507-7211; Windhager, Reinhard/0000-0002-6321-1804; Kovar, Heinrich/0000-0001-6873-9109				AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; BARTKOVA J, 1995, CANCER RES, V55, P949; BELTINGER CP, 1995, CANCER RES, V55, P2053; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHEN TC, 1995, J PATHOL, V176, P243, DOI 10.1002/path.1711760306; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DURO D, 1995, ONCOGENE, V11, P21; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HE J, 1994, CANCER RES, V54, P5804; Hengstschlager M, 1996, DNA CELL BIOL, V15, P41, DOI 10.1089/dna.1996.15.41; HIRAMA T, 1995, BLOOD, V86, P841; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hui AM, 1996, HEPATOLOGY, V24, P575, DOI 10.1053/jhep.1996.v24.pm0008781327; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KHATIB ZA, 1993, CANCER RES, V53, P5535; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; MAELANDSMO GM, 1995, BRIT J CANCER, V72, P393, DOI 10.1038/bjc.1995.344; MALKIN D, 1994, CANCER RES, V54, P2077; MAO L, 1995, CANCER RES, V55, P2995; MORI T, 1994, CANCER RES, V54, P3396; OHNISHI H, 1995, BLOOD, V86, P1269, DOI 10.1182/blood.V86.4.1269.bloodjournal8641269; PETER M, 1997, IN PRESS ONCOGENE; RAFFEL C, 1993, NEUROSURGERY, V33, P301, DOI 10.1227/00006123-199308000-00018; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SCHULZE A, 1994, ONCOGENE, V9, P3475; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; STONE S, 1995, CANCER RES, V55, P2988; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; VOGAN K, 1993, CANCER RES, V53, P5269; WADA M, 1993, BLOOD, V82, P3163; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	41	107	115	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	1997	15	18					2225	2232		10.1038/sj.onc.1201397	http://dx.doi.org/10.1038/sj.onc.1201397			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393981				2022-12-17	WOS:A1997YD01900011
J	Nikiforov, YE; Nikiforova, MN; Gnepp, DR; Fagin, JA				Nikiforov, YE; Nikiforova, MN; Gnepp, DR; Fagin, JA			Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident	ONCOGENE			English	Article						thyroid tumors; radiation; Chernobyl; ras; p53	POINT MUTATIONS; HA-RAS; GENOMIC INSTABILITY; LUNG-CANCER; ONCOGENE; GENE; CARCINOMAS; IRRADIATION; DISASTER; PATTERN	Starting 4 years after the Chernobyl accident, a dramatic increase in incidence of thyroid carcinoma was noticed in children from contaminated areas, The incidence of benign thyroid lesions in the exposed population was also increased, To study the possible role of ras and p53 genes in radiation-induced thyroid tumorigenesis, 33 papillary carcinomas, one follicular carcinoma and 22 benign lesions removed from children aged 5-19 were screened for point mutations of H- K-, and N-ras, as well as of p53 (exons 5-8) using single strand conformation polymorphism (SSCP) analysis, Pas point mutations were detected in 1/1 case of follicular carcinoma (N-ras codon 61 CAA(gln)-->AAA(lys)), and in 3/7 follicular adenomas (N-ras codon 61 CAA(gin)-->CGA(arg) x 2, CAA(gln)-->AAA(lys). None of the cases of papillary thyroid carcinoma was positive for ras oncogene abnormalities, The lack of K-ras mutations was confirmed by allele-specific oligonucleotide hybridization (ASOH), and by sequencing in five cases, Somatic point mutations in p53 were found by SSCP in 2/33 papillary thyroid carcinomas, with one missense mutation (exon 5, codon 160 ATG(met)-->GTG(val)) and another silent mutation (codon 182, TGC(cys)-->TGT(cys)). Immunohistochemically, focally positive p53 staining was found in four papillary carcinomas being primarily confined to solid and poorly-differentiate areas in tumors, These data demonstrate that as opposed to the few reports on tumors arising after therapeutic external irradiation, ras mutations are not primary events in the development of post-Chernobyl thyroid papillary carcinomas, p53 mutations do not appear to be important in the development of these tumors, but may in some cases have a role in progression to a more aggressive phenotype that has not yet fully manifested in these pediatric neoplasms.	UNIV CINCINNATI, COLL MED, DIV ENDOCRINOL & METAB, CINCINNATI, OH 45267 USA; CEDARS SINAI MED CTR, DIV ENDOCRINOL, LOS ANGELES, CA 90048 USA; RHODE ISL HOSP, DEPT PATHOL, PROVIDENCE, RI 02903 USA	University System of Ohio; University of Cincinnati; Cedars Sinai Medical Center; Lifespan Health Rhode Island; Rhode Island Hospital					NATIONAL CANCER INSTITUTE [R01CA050706, R29CA050706] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042792] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50706] Funding Source: Medline; NIDDK NIH HHS [DK 42792] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOGDANOVA T, 1995, THYROID S1, V5, pS28; CHALLETON C, 1995, ONCOGENE, V11, P601; CHEN CH, 1993, CANCER RES, V53, P1511; CONARD RA, 1970, J AMER MED ASSOC, V214, P316, DOI 10.1001/jama.214.2.316; DENKO N, 1995, SOMAT CELL MOLEC GEN, V21, P241, DOI 10.1007/BF02255779; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DOBYNS BM, 1992, WORLD J SURG, V16, P126, DOI 10.1007/BF02067128; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; DUFFY BJ, 1950, J CLIN ENDOCRINOL, V10, P1296, DOI 10.1210/jcem-10-10-1296; EZAKI H, 1991, J RADIAT RES, V32, P193, DOI 10.1269/jrr.32.SUPPLEMENT_193; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; FURMANCHUK AW, 1992, HISTOPATHOLOGY, V21, P401, DOI 10.1111/j.1365-2559.1992.tb00423.x; GREENBLATT MS, 1994, CANCER RES, V54, P4855; ILYIN LA, 1990, J RADIOL PROTECT, V10, P13; ITO T, 1993, CANCER RES, V53, P2940; KASTAN MB, 1991, CANCER RES, V51, P6304; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Klugbauer S, 1995, ONCOGENE, V11, P2459; KRONENBERG A, 1994, INT J RADIAT BIOL, V66, P603, DOI 10.1080/09553009414551691; LEMOINE NR, 1988, ONCOGENE, V3, P541; Lemoine NR, 1989, THYROID TUMOURS, P4; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; Nikiforov Y, 1996, J CLIN ENDOCR METAB, V81, P9, DOI 10.1210/jc.81.1.9; NIKIFOROV Y, 1994, CANCER-AM CANCER SOC, V74, P748, DOI 10.1002/1097-0142(19940715)74:2<748::AID-CNCR2820740231>3.0.CO;2-H; NIKIFOROV YE, 1995, CANCER-AM CANCER SOC, V76, P900, DOI 10.1002/1097-0142(19950901)76:5<900::AID-CNCR2820760527>3.0.CO;2-X; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; SAMPSON R J, 1969, Journal of the American Medical Association, V209, P65, DOI 10.1001/jama.209.1.65; SCHNEIDER AB, 1980, CANCER, V46, P1218, DOI 10.1002/1097-0142(19800901)46:5<1218::AID-CNCR2820460523>3.0.CO;2-H; SHORE RE, 1985, J NATL CANCER I, V74, P1177; TAYLOR JA, 1994, LANCET, V343, P86, DOI 10.1016/S0140-6736(94)90818-4; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2; WILLIAMS D, 1994, NATURE, V371, P556, DOI 10.1038/371556a0; Winship T, 1970, CLIN P CHILDRENS HOS, V26, P327; WRIGHT PA, 1991, ONCOGENE, V6, P471; ZHANG PL, 1994, MOL CARCINOGEN, V9, P46, DOI 10.1002/mc.2940090109	38	107	111	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	1996	13	4					687	693						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761289				2022-12-17	WOS:A1996VD43300003
J	Andoniou, CE; Thien, CBF; Langdon, WY				Andoniou, CE; Thien, CBF; Langdon, WY			The two major sites of cbl tyrosine phosphorylation in abl-transformed cells select the crkL SH2 domain	ONCOGENE			English	Article						tyrosine kinase; cbl oncogene; cell transformation; crk adaptor	CHRONIC MYELOGENOUS LEUKEMIA; V-CBL; PROTEIN; ONCOGENE; TRUNCATION; RETROVIRUS; GENE; RAS	We recently found that the 120-kD protein product of the c-cbl oncogene is tyrosine phosphorylated in tumor cells generated by bcr-abl or v-abl and that p120(cbl) will associate with these proteins bl vivo, We also found an oncogenic form of cbl protein in the 70Z/3 pre-B cell lymphoma which exhibits deregulated tyrosine phosphorylation. These findings have led us to broaden our study of cbl's involvement in abl-mediated tumorigenesis. Here we show by immunodepletion that cbl is the major 120-kD tyrosine phosphorylated protein in cells which express activated forms of the abl oncogene. We also demonstrate that tyrosine phosphorylation of p120(cbl) in bcr-abl transformed cells does not alter its subcellular localization. In addition we show that the oncogenic 70Z/3 form of cbl exhibits enhanced tyrosine phosphorylation in v-abl infected cells and that cbl is heavily tyrosine phosphorylated in hemopoietic cells transformed by v-src. Finally this study identifies two sites that are essential for the tyrosine phosphorylation of cbl in abl-transformed cells. These sites conform to the preferred abl kinase substrate sequence of YXXP and we show that following phosphorylation they mediate an association with the crkL SH2 domain.	UNIV WESTERN AUSTRALIA, QUEEN ELIZABETH II MED CTR, DEPT PATHOL, NEDLANDS, WA 6009, AUSTRALIA	University of Western Australia			Andoniou, Christopher/B-6296-2013; Thien, Christine/GQP-0424-2022	Andoniou, Christopher/0000-0003-0566-3180; Thien, Christine/0000-0003-3884-5546				AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; HOLMES KL, 1986, J EXP MED, V164, P443, DOI 10.1084/jem.164.2.443; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; JONGEWARD GD, 1995, GENETICS, V139, P1553; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; MANDANAS RA, 1993, BLOOD, V82, P1838; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MUSHINSKI JF, 1994, ONCOGENE, V9, P2489; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SAWYERS CL, 1992, CANCER SURV, V15, P37; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	42	107	108	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	1996	12	9					1981	1989						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649859				2022-12-17	WOS:A1996UK49800017
J	HERZINGER, T; FUNK, JO; HILLMER, K; EICK, D; WOLF, DA; KIND, P				HERZINGER, T; FUNK, JO; HILLMER, K; EICK, D; WOLF, DA; KIND, P			ULTRAVIOLET-B IRRADIATION-INDUCED G2 CELL-CYCLE ARREST IN HUMAN KERATINOCYTES BY INHIBITORY PHOSPHORYLATION OF THE CDC2 CELL-CYCLE KINASE	ONCOGENE			English	Article						UV IRRADIATION; P53; G2/M CHECKPOINT; CDC2; KERATINOCYTES; SKIN CANCER	WEE1 PROTEIN-KINASE; FISSION YEAST; IONIZING-RADIATION; CHECKPOINTS	In response to genotoxic stress, cell cycle progression can be arrested at certain checkpoints which serve to maintain genomic integrity. We have investigated the mechanism of ultraviolet B (UVB) irradiation-induced cell cycle arrest in normal human keratinocytes and in the HaCaT keratinocyte cell line which carries mutant p53 tumour suppressor protein. While only normal keratinocytes showed a delay in G1 following sublethal UVB irradiation both cell types exhibited prolonged G2 arrest attributable to rapid inhibition of cyclin B-associated cdc2 kinase activity. This inhibition coincided with increased tyrosine phosphorylation of cdc2 and was reversed by the cdc25C phosphatase in vitro. The data indicate that WE-induced G2 arrest in mammalian cells is mediated by inhibitory tyrosine phosphorylation of cdc2 and acts as a defense mechanism against DNA damage irrespective of the cells' p53 status.	GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT,INST KLIN MOLEK BIOL & TUMORGENET,D-81377 MUNICH,GERMANY; UNIV MUNICH,DERMATOL KLIN & POLIKLIN,MOLEK PATHOL ABT,D-80337 MUNICH,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich			Wolf, Dieter/AAE-5890-2021	Wolf, Dieter/0000-0002-3761-1070				BARBET NC, 1993, NATURE, V364, P824, DOI 10.1038/364824a0; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CARMICHAEL J, 1987, CANCER RES, V47, P943; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DATTA R, 1992, CELL GROWTH DIFFER, V3, P637; FREDERICK JE, 1993, PHOTOCHEM PHOTOBIOL, V57, P175, DOI 10.1111/j.1751-1097.1993.tb02274.x; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GUILLOUF C, 1995, ONCOGENE, V10, P2263; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HERZINGER T, 1995, ONCOGENE, V10, P2079; HOFFMANN I, 1993, EMBO J, V12, P553; KASTAN MB, 1991, CANCER RES, V551, P6304; KAUFMANN WK, 1993, FASEB J, V7, P1188, DOI 10.1096/fasebj.7.12.8375618; KHARBANDA S, 1994, CANCER RES, V54, P1412; KO CB, 1994, BRIT J DERMATOL, V130, P269, DOI 10.1111/j.1365-2133.1994.tb02920.x; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LIU M, 1995, ONCOGENE, V10, P1955; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; PALAYOOR ST, 1995, RADIAT RES, V141, P235, DOI 10.2307/3579000; PARKER LL, 1993, NATURE, V363, P736, DOI 10.1038/363736a0; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; STEWART N, 1995, ONCOGENE, V10, P109; WOLF DA, 1993, MOL ENDOCRINOL, V7, P924, DOI 10.1210/me.7.7.924; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	37	107	108	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2151	2156						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478536				2022-12-17	WOS:A1995TF29700027
J	KIRCHHOFF, S; KOROMILAS, AE; SCHAPER, F; GRASHOFF, M; SONENBERG, N; HAUSER, H				KIRCHHOFF, S; KOROMILAS, AE; SCHAPER, F; GRASHOFF, M; SONENBERG, N; HAUSER, H			IRF-1 INDUCED CELL-GROWTH INHIBITION AND INTERFERON INDUCTION REQUIRES THE ACTIVITY OF THE PROTEIN-KINASE PKR	ONCOGENE			English	Article						IRF-1; INTERFERON-BETA; PROLIFERATION; PROTEIN KINASE PKR; TUMOR SUPPRESSOR	REGULATORY FACTOR-I; IFN-INDUCIBLE GENES; CONSTITUTIVE EXPRESSION; TRANSCRIPTION FACTOR; BETA PROMOTERS; P68 KINASE; RESISTANCE; ELEMENTS; ACTIVATION; VIRUS	Expression of the tumor suppressor IRF-1 results in the inhibition of cell growth and transcriptional activation of the IFN-beta gene. IFN production is not responsible for the IRF-1 mediated cell growth inhibition. It is shown here that activation of IRF-1 causes induction of PKR expression, PKR is a serine/threonine kinase with tumor suppressor activity. IRF-1 mediated cell growth inhibition and IFN induction correlates with PKR expression. A catalytically inactive dominant negative PKR mutant abolishes both activities of IRF-1. These data demonstrate that the tumor suppressor activity of IRF-1 is mediated, at least in part, by PKR.	GESELL BIOTECHNOL FORSCH MBH,GENET EUKARYOTES,D-38124 BRAUNSCHWEIG,GERMANY; MCGILL UNIV,JEWISH GEN HOSP,LADY DAVIS INST MED RES,DEPT ONCOL & EXPTL MED,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA	Gesellschaft fur Biotechnologische Forschung mbH; Lady Davis Institute; McGill University; McGill University; McGill University			Schaper, Fred/F-1403-2013	Schaper, Fred/0000-0002-8899-5414				BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOULTWOOD J, 1993, BLOOD, V82, P2611; CHANG CH, 1992, IMMUNOGENETICS, V35, P378; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; DAIGNEAULT L, 1992, NUCLEIC ACIDS RES, V20, P2749, DOI 10.1093/nar/20.11.2749; DINTER H, 1987, EMBO J, V6, P599, DOI 10.1002/j.1460-2075.1987.tb04796.x; DIRKS W, 1989, J INTERFERON RES, V9, P125, DOI 10.1089/jir.1989.9.125; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HISCOTT J, 1989, J VIROL, V63, P2504; HOVANESSIAN AG, 1991, J INTERFERON RES, V11, P199, DOI 10.1089/jir.1991.11.199; ICELY PL, 1991, J BIOL CHEM, V266, P16073; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LACOSTE J, 1990, J VIROL, V64, P4726, DOI 10.1128/JVI.64.10.4726-4734.1990; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NOURBAKHSH M, 1993, EMBO J, V12, P451, DOI 10.1002/j.1460-2075.1993.tb05677.x; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RUFFNER H, 1993, P NATL ACAD SCI USA, V90, P11503, DOI 10.1073/pnas.90.24.11503; Sambrook J., 1989, MOL CLONING LAB MANU; SEN GC, 1992, J BIOL CHEM, V267, P5017; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YAMADA G, 1991, P NATL ACAD SCI USA, V88, P532, DOI 10.1073/pnas.88.2.532; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	44	107	111	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					439	445						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7543195				2022-12-17	WOS:A1995RN53000003
J	TOKSOZ, D; WILLIAMS, DA				TOKSOZ, D; WILLIAMS, DA			NOVEL HUMAN ONCOGENE IBC DETECTED BY TRANSFECTION WITH DISTINCT HOMOLOGY REGIONS TO SIGNAL-TRANSDUCTION PRODUCTS	ONCOGENE			English	Article							MOLECULAR-CLONING; TRANSFORMING GENE; MYELOID-LEUKEMIA; TYROSINE KINASE; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; CDC24 GENE; CELL-CYCLE; SEQUENCE; DBL	In order to isolate transforming genes involved in leukemias, DNA from a CML acute phase sample was transfected into NIH-3T3 Cells and found to be tumorigenic in nude mice. Partial genomic cloning using human repeat sequence as probe followed by cDNA cloning of this oncogene, termed Ibc, was undertaken. The lbc cDNA sequence shows no identity to known proteins and codes for a predicted hydrophilic protein product of 47 kD, which contains several consensus kinase phosphorylation sites. The N-terminus encodes a consensus E-F hand motif followed by a region of homology to the transforming human oncogene dbl associated with regulatory activity for the ras superfamily of small G proteins, while the C-terminus contains homology with pleckstrin and rac protein kinase in a region which overlaps with the recently defined PH (pleckstrin homology) domain. Lbc expression is restricted to human hematopoietic cells and skeletal muscle, lung and heart. Transfection of 3T3 cells with an expression vector encoding lbc cDNA results in focus formation, demonstrating its biological activity. These data indicate that the lbc oncogene encodes a novel product implicated in distinct cellular signal transduction functions.	INDIANA UNIV, RILEY HOSP CHILDREN, SCH MED, HOWARD HUGHES MED RES INST, INDIANAPOLIS, IN USA	Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children	TOKSOZ, D (corresponding author), HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT HEMATOL ONCOL, 320 LONGWOOD AVE, BOSTON, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER; NHLBI NIH HHS [2PO1-HL32262] Funding Source: Medline; PHS HHS [U03634] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS JM, 1992, ONCOGENE, V7, P611; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; Maniatis T., 1982, MOL CLONING; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1991, NEW BIOL, V3, P372; RON D, 1989, ONCOGENE, V4, P1067; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKEBE Y, 1988, MOL CELL BIOL, V466, P1431; TOKSOZ D, 1987, ONCOGENE, V1, P409; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	42	107	112	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					621	628						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290273				2022-12-17	WOS:A1994MW24800030
J	RAO, VN; OHNO, T; PRASAD, DDK; BHATTACHARYA, G; REDDY, ESP				RAO, VN; OHNO, T; PRASAD, DDK; BHATTACHARYA, G; REDDY, ESP			ANALYSIS OF THE DNA-BINDING AND TRANSCRIPTIONAL ACTIVATION FUNCTIONS OF HUMAN FLI-1 PROTEIN	ONCOGENE			English	Article							ETS-RELATED PROTEIN; PUTATIVE ONCOGENE SPI-1; MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; C-FOS; C-ETS-1 PROTOONCOGENE; DOMAIN PROTEIN; GENE FAMILY; ERG GENE; V-ETS	Three of the ets oncogene superfamily members v-ets, Spi-1/PU.1 and Fli-1, have been shown to he directly involved in retroviral-mediated acute erythroleukemias. The Fli-1 gene was found to be rearranged in 75% of the erythroleukemias induced by Friend murine leukemia virus (F-MuLV), suggesting that it could play a key role in cellular transformation. We have previously isolated and characterized the human Fli-1 gene and have found it to be highly homologous (80%) to the human erg-2 gene. Human Fli-1 was also shown to be rearranged in Ewing's sarcoma cases, in which the amino-terminal region of the Fli-1 gene was replaced with a novel coding region of a putative RNA-binding protein, EWS. In this report, we show that the recombinant Fli-1 protein expressed in bacteria binds to DNA in a sequence-specific manner. It appears that Fli-1 and erg proteins fall into the category of ets proteins that recognize limited ets target sequences, unlike c-ets-1, ets-2 and Elk-1. The Fli-1 gene was found to activate the transcription of the reporter gene that was linked to Fli-1 target sequences, suggesting that Fli-1 is a sequence-specific transcriptional activator. Deletion analysis revealed the presence of two autonomous transcriptional activation domains, one at the amino-terminal region (amino-terminal transcriptional activation domain, ATA) and the other at the carboxy-terminal region (carboxy-terminal transcriptional activation domain, CTA). Secondary structural analysis of ATA and CTA domains revealed the presence of helix-loop-helix (H-L-H) and/or turn-loop-turn (T-L-T) regions. From these results it appears that a portion of the Fli-1 ATA domain (H-L-H region) was replaced by the amino-terminal domain of EWS gene in Ewing's sarcoma cases. Therefore alteration in the transcriptional activation function of Fli-1 may be responsible for human malignancies such as sarcomas, leukemias and lymphomas in which this gene is rearranged.	JEFFERSON CANC INST,BLUMLE LIFE SCI BLDG,233 S 10 ST,PHILADELPHIA,PA 19107	Jefferson University					NCI NIH HHS [CA 51083, CA 57157] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057157, P01CA051083] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; CLARK SP, 1983, P NATL ACAD SCI-BIOL, V80, P5037, DOI 10.1073/pnas.80.16.5037; COQUILLAND M, 1988, ONCOGENE RES, V2, P335; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DIAZ MO, 1986, SCIENCE, V231, P265, DOI 10.1126/science.3455787; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; PRASAD DDK, 1992, CANCER RES, V52, P5833; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; RAO VN, 1992, ONCOGENE, V11, P2335; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; REDDY ESP, 1992, GUIDE BOOK ONCOGENES; REDDY ESP, 1990, CANCER RES, V50, P5013; ROBERTSON M, 1988, NATURE, V336, P522, DOI 10.1038/336522a0; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SELLERI L, 1991, P NATL ACAD SCI USA, V88, P887, DOI 10.1073/pnas.88.3.887; SIDDIQUE H, 1993, ONCOGENE, V8; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TREIZENBERG SJ, 1988, GENE DEV, V2, P718; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YUNIS JJ, 1989, GENOMICS, V5, P84, DOI 10.1016/0888-7543(89)90090-6; [No title captured]	59	107	107	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2167	2173						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336942				2022-12-17	WOS:A1993LP17100017
J	DEGROOT, RP; AUWERX, J; BOUROUIS, M; SASSONECORSI, P				DEGROOT, RP; AUWERX, J; BOUROUIS, M; SASSONECORSI, P			NEGATIVE REGULATION OF JUN/AP-1 - CONSERVED FUNCTION OF GLYCOGEN-SYNTHASE KINASE-3 AND THE DROSOPHILA KINASE SHAGGY	ONCOGENE			English	Article							DNA-BINDING ACTIVITY; JUN PROTO-ONCOGENE; TRANSCRIPTION FACTOR AP-1; CELLULAR FOS PROTEINS; C-JUN; MAMMALIAN-CELLS; GENE FAMILY; V-JUN; PHOSPHORYLATION; EXPRESSION	Transcription factor AP-1 is constituted by the products of the various fos and jun genes. AP-1 activity is modulated by second messengers and appears to involve post-translational modifications of Fos and Jun. It has been shown that phosphorylation mediated by glycogen synthase kinase 3 (GSK-3) is involved in negative regulation of c-Jun DNA-binding function in vitro. Here we show that two forms of GSK-3 function to decrease the DNA-binding activity as well as the transcriptional activation elicited by.c-Jun in vivo. Similarly, the other members of the jun family, JunB, JunD and v-Jun, are negatively regulated by GSK-3 in vivo, although to a slightly lesser extent than c-Jun. We have also tested the proteins encoded by the Drosophila shaggy gene (sgg) in our assays. The sgg proteins share homology with the mammalian GSK-3 and appear to be important for the normal segregation of bristle precursor cells in the imaginal epithelium in Drosophila. Here we show that the products of the sgg gene can also function as negative regulators of Jun/AP-1.	FAC MED STRASBOURG,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,UNITE 184,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE; CATHOLIC UNIV LEUVEN,DEPT DEV BIOL,EXPTL MED & ENDOCRINOL LAB,B-3000 LOUVAIN,BELGIUM	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; KU Leuven				Auwerx, Johan/0000-0002-5065-5393				ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOUROUIS M, 1989, NATURE, V341, P442, DOI 10.1038/341442a0; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BUSCH SJ, 1990, ONCOGENE, V5, P1549; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1984, CELL, V36, P259; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOEFFLER WK, 1992, IN PRESS EMBO J; HUGHES K, 1991, IN PRESS ADV PROT PH, V6; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAMPH WW, 1988, NATURE, V334, P592; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MELLSTROM B, 1991, ONCOGENE, V6, P1959; MULLER R, 1987, ONCOGENE RES, V2, P19; NARANJO JR, 1991, ONCOGENE, V6, P223; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; PERKINS KK, 1990, GENE DEV, V4, P822, DOI 10.1101/gad.4.5.822; PERRIMON N, 1989, DEV BIOL, V135, P287, DOI 10.1016/0012-1606(89)90180-2; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SIEGFRIED E, 1990, TRENDS GENET, V6, P357, DOI 10.1016/0168-9525(90)90277-D; SIMPSON P, 1989, DEVELOPMENT, V106, P57; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; Woodgett J R, 1990, Semin Cancer Biol, V1, P389; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZHANG K, 1990, P NATL ACAD SCI USA, V87, P6281, DOI 10.1073/pnas.87.16.6281	54	107	107	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					841	847						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8384355				2022-12-17	WOS:A1993KT22000004
J	PALMERO, I; HOLDER, A; SINCLAIR, AJ; DICKSON, C; PETERS, G				PALMERO, I; HOLDER, A; SINCLAIR, AJ; DICKSON, C; PETERS, G			CYCLIN-D1 AND CYCLIN-D2 ARE DIFFERENTIALLY EXPRESSED IN HUMAN B-LYMPHOID CELL-LINES	ONCOGENE			English	Article							EPSTEIN-BARR VIRUS; T(11-14) CHROMOSOME-TRANSLOCATION; BURKITTS-LYMPHOMA; LYMPHOCYTIC LYMPHOMA; CENTROCYTIC LYMPHOMA; CANDIDATE ONCOGENE; MOLECULAR-CLONING; BCL-1 LOCUS; GENE; DNA	The cyclin D1 gene can be transcriptionally activated in lymphoid tumours as a result of chromosomal rearrangements but is normally silent in B and T lymphocytes. By isolating cyclin D1-related cDNAs from a B-lymphoid cell tine, we identified clones that contain the coding sequences of human cyclin D2. The predicted 289 amino acid protein shares 63% identity with human cyclin D1. Although cyclin D2 transcripts were detected in many lymphoid cell lines, it was not ubiquitously expressed and there was no apparent correlation with cyclin D1 levels. For example, two B-cell leukaemia lines, JVM-2 and Karpas 620, both of which have 11q13 translocations and express cyclin D1, contained markedly different amounts of cyclin D2. An obvious distinction between these cells is that the JVM-2 line, which expresses high levels of cyclin D2, was immortalized by Epstein-Barr virus (EBV). We subsequently found that cyclin D2 is consistently expressed in group III Burkitt's lymphoma (BL) and in lymphoblastoid cell lines immortalized by EBV, but not in group I BLs, in which expression of the EBV genome is more restricted. The data imply that the D-type cyclins may have non-overlapping functions at specific stages of lymphocyte differentiation and that the expression of cyclin D2 may be influenced, directly or indirectly, by EBV.	IMPERIAL CANC RES FUND, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND; ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, LONDON W2 1PG, ENGLAND	Cancer Research UK; Imperial College London; Ludwig Institute for Cancer Research			Palmero, Ignacio/B-4346-2013	Sinclair, Alison/0000-0001-8510-8691				ALTIOK E, 1992, P NATL ACAD SCI USA, V89, P905, DOI 10.1073/pnas.89.3.905; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BODESCOT M, 1987, J VIROL, V61, P3424, DOI 10.1128/JVI.61.11.3424-3430.1987; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLEMENTS GB, 1975, INT J CANCER, V16, P125, DOI 10.1002/ijc.2910160114; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; HINUMA Y, 1967, P SOC EXP BIOL MED, V124, P107; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; KLEIN G, 1989, CELL, V58, P5, DOI 10.1016/0092-8674(89)90394-2; KODURU PRK, 1989, ONCOGENE, V4, P929; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; Lenoir G M, 1985, IARC Sci Publ, P309; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEDEIROS LJ, 1990, BLOOD, V76, P2086; MEEKER TC, 1989, BLOOD, V74, P1801; MELO JV, 1986, INT J CANCER, V38, P531, DOI 10.1002/ijc.2910380413; MENEZES J, 1975, BIOMEDICINE, V22, P276; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NACHEVA E, 1990, BRIT J HAEMATOL, V74, P70, DOI 10.1111/j.1365-2141.1990.tb02540.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; RABBITTS PH, 1988, ONCOGENE, V3, P99; RIMOKH R, 1990, GENE CHROMOSOME CANC, V2, P223, DOI 10.1002/gcc.2870020310; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; SHOWE LC, 1987, ANNU REV IMMUNOL, V5, P253, DOI 10.1146/annurev.iy.05.040187.001345; TAKADA K, 1989, J VIROL, V63, P445, DOI 10.1128/JVI.63.1.445-449.1989; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WILLIAMS ME, 1991, BLOOD, V78, P493; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	55	107	111	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					1049	1054						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455931				2022-12-17	WOS:A1993KT22000029
J	SAKAMOTO, KM; BARDELEBEN, C; YATES, KE; RAINES, MA; GOLDE, DW; GASSON, JC				SAKAMOTO, KM; BARDELEBEN, C; YATES, KE; RAINES, MA; GOLDE, DW; GASSON, JC			5' UPSTREAM SEQUENCE AND GENOMIC STRUCTURE OF THE HUMAN PRIMARY RESPONSE GENE, EGR-1 TIS8	ONCOGENE			English	Note							COLONY-STIMULATING FACTOR; ZINC FINGER PROTEIN; NERVE GROWTH-FACTOR; WILMS-TUMOR LOCUS; C-FOS; BINDING DOMAINS; CELLS; IDENTIFICATION; EXPRESSION; ENCODES	EGR-1/TIS8 is a primary response gene that encodes a zinc finger containing protein and is induced in a number of cell types by a variety of ligands. We have isolated and mapped the human EGR-1/TIS8 gene and sequenced the 5' upstream flanking region. A 'TATA' homology and several putative regulatory elements, including two Sp1 sites, five serum response-like elements, two cAMP response-like elements, an EGR-1 binding site (EBS), and a tetra-decanoyl phorbol acetate (TPA)-responsive element have been identified within 700 nucleotides of the upstream region. We demonstrated that a 500-base pair fragment, which includes several of these possible regulatory sequences, is functional and responsive to TPA in transient transfection assays. A further understanding of the regulation and function of human EGR-1/TIS8 gene expression may provide insight into the mechanisms that control normal and neoplastic proliferation of human cells.	CHILDRENS HOSP, DEPT HEMATOL ONCOL, LOS ANGELES, CA 90054 USA; JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	Children's Hospital Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SAKAMOTO, KM (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA.				NCI NIH HHS [CA 32737, CA 40163] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040163, P01CA032737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOUD CN, 1981, BLOOD, V58, P1148; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHO KO, 1989, MOL CELL BIOL, V9, P135, DOI 10.1128/MCB.9.1.135; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN CM, 1982, MOL CELL BIOL, V8, P1979; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1987, ONCOGENE, V1, P263; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NIMER SD, 1988, MOL CELL BIOL, V8, P1979, DOI 10.1128/MCB.8.5.1979; ORLOFSKY A, 1987, EMBO J, V6, P2947, DOI 10.1002/j.1460-2075.1987.tb02599.x; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SVETMOLDAVSKY GJ, 1980, EXP HEMATOL S7, V8, P76; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; VERMA IM, 1987, ADV CANCER RES, V49, P29, DOI 10.1016/S0065-230X(08)60793-9; WATERS CM, 1990, ONCOGENE, V5, P669; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381	34	107	112	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1991	6	5					867	871						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	2052361				2022-12-17	WOS:A1991GT82500025
J	ISOMURA, M; KIKUCHI, A; OHGA, N; TAKAI, Y				ISOMURA, M; KIKUCHI, A; OHGA, N; TAKAI, Y			REGULATION OF BINDING OF RHOB P20 TO MEMBRANES BY ITS SPECIFIC REGULATORY PROTEIN, GDP DISSOCIATION INHIBITOR	ONCOGENE			English	Article							BOTULINUM ADP-RIBOSYLTRANSFERASE; BOVINE BRAIN; GUANINE-NUCLEOTIDE; GENE-PRODUCT; SUBCELLULAR-DISTRIBUTION; CLOSTRIDIUM-BOTULINUM; KINETIC-ANALYSIS; RAS; RIBOSYLATION; SEQUENCE	We have previously purified from bovine brain cytosol a novel regulatory protein for the GTP-binding proteins of the rho gene family. This regulatory protein, designated as rho GDP dissociation inhibitor (GDI), makes a complex stoichiometrically with the GDP-bound form of the rho gene products and thereby regulates the GDP/GTP exchange reaction by inhibiting the dissociation of GDP from and the subsequent binding of GTP to them. We show here that rho GDI also regulates the binding of rhoB p20, a member of the rho gene products, to various membranes including rat brain synaptic plasma membranes and human erythrocyte ghosts. Both the GDP- and GTP-bound forms of rhoB p20 bound to the membranes. This binding was not inhibited by prior treatment of the membranes with boiling or tryptic digestion, suggesting that a protein molecule of the membranes is not essential for the binding of rhoB p20 to the membranes. rho GDI inhibited the binding of the GDP-bound form of rhoB p20, but not that of the GTP-bound form, to the membranes. Moreover, rho GDI induced the dissociation of the GDP-bound form, but not that of the GTP-bound form, of rhoB p20 exogenously bound to the membranes from them. These results suggest that the rho gene products bind to the membranes, presumably in a reversible manner and that this binding is regulated by their specific GDI.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University								ADAMVIZI V, 1988, FEBS LETT, V238, P277, DOI 10.1016/0014-5793(88)80496-4; AKTORIES K, 1987, BIOCHEM J, V247, P363, DOI 10.1042/bj2470363; ARAKI S, 1990, J BIOL CHEM, V265, P13007; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUNU, 1989, FEBS LETT, V243, P70; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; FUKUMOTO Y, 1990, IN PRESS ONCOGENE; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HALL A, 1986, J BIOL CHEM, V261, P963; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOSHIJIMA M, 1990, MOL BRAIN RES, V7, P9, DOI 10.1016/0169-328X(90)90067-N; HOSHINO M, 1987, J BIOCHEM-TOKYO, V102, P503, DOI 10.1093/oxfordjournals.jbchem.a122082; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KIM S, 1989, MOL BRAIN RES, V6, P167, DOI 10.1016/0169-328X(89)90051-X; KURODA S, 1989, BIOCHEM BIOPH RES CO, V163, P674, DOI 10.1016/0006-291X(89)92276-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MATSUOKA I, 1989, J BIOL CHEM, V264, P706; MIZOGUCHI A, 1989, MOL BRAIN RES, V5, P31, DOI 10.1016/0169-328X(89)90015-6; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; OHASHI Y, 1987, J BIOL CHEM, V262, P1430; OHGAN, 1989, BIOCHEM BIOPH RES CO, V163, P1523; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SHOJI I, 1989, BIOCHEM BIOPH RES CO, V162, P273, DOI 10.1016/0006-291X(89)91992-X; Steck T L, 1974, Methods Enzymol, V31, P172; TAKAI Y, 1988, PROGR ENDOCRINOLOGY, V2, P995; UEDA T, 1979, J CELL BIOL, V83, P308, DOI 10.1083/jcb.83.2.308; UEDA T, 1990, J BIOL CHEM, V265, P9373; YAMAMOTO J, 1990, MOL BRAIN RES, V8, P105, DOI 10.1016/0169-328X(90)90054-H; YAMAMOTO K, 1988, J BIOL CHEM, V263, P9926; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	38	107	108	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					119	124						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1899476				2022-12-17	WOS:A1991EY03900016
J	Zhou, CF; Ma, J; Huang, L; Yi, HY; Zhang, YM; Wu, XG; Yan, RM; Liang, L; Zhong, M; Yu, YH; Wu, S; Wang, W				Zhou, Chen-Fei; Ma, Jing; Huang, Lei; Yi, Hong-Yan; Zhang, Yan-Mei; Wu, Xiang-Guang; Yan, Rui-Ming; Liang, Li; Zhong, Mei; Yu, Yan-Hong; Wu, Sha; Wang, Wei			Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1	ONCOGENE			English	Article							TUMOR LYMPHANGIOGENESIS; MESENCHYMAL TRANSITION; CANCER METASTASIS; EXPRESSION; INVASION; PROLIFERATION; GROWTH; ANGIOGENESIS; ENDOTHELIUM; RECURRENCE	Cancer-secreted exosomal miRNAs are emerging mediators of cancer-stromal cross-talk in the tumor environment. Our previous miRNAs array of cervical squamous cell carcinoma (CSCC) clinical specimens identified upregulation of miR-221-3p. Here, we show that miR-221-3p is closely correlated with peritumoral lymphangiogenesis and lymph node (LN) metastasis in CSCC. More importantly, miR-221-3p is characteristically enriched in and transferred by CSCC-secreted exosomes into human lymphatic endothelial cells (HLECs) to promote HLECs migration and tube formation in vitro, and facilitate lymphangiogenesis and LN metastasis in vivo according to both gain-of-function and loss-of-function experiments. Furthermore, we identify vasohibin-1 (VASH1) as a novel direct target of miR-221-3p through bioinformatic target prediction and luciferase reporter assay. Re-expression and knockdown of VASH1 could respectively rescue and simulate the effects induced by exosomal miR-221-3p. Importantly, the miR-221-3p-VASH1 axis activates the ERK/AKT pathway in HLECs independent of VEGF-C. Finally, circulating exosomal miR-221-3p levels also have biological function in promoting HLECs sprouting in vitro and are closely associated with tumor miR-221-3p expression, lymphatic VASH1 expression, lymphangiogenesis, and LN metastasis in CSCC patients. In conclusion, CSCC-secreted exosomal miR-221-3p transfers into HLECs to promote lymphangiogenesis and lymphatic metastasis via downregulation of VASH1 and may represent a novel diagnostic biomarker and therapeutic target for metastatic CSCC patients in early stages.	[Zhou, Chen-Fei; Ma, Jing; Wu, Xiang-Guang; Wang, Wei] Guangzhou Med Univ, Dept Obstet & Gynecol, Affiliated Hosp 1, Guangzhou 510120, Guangdong, Peoples R China; [Zhou, Chen-Fei; Ma, Jing; Yi, Hong-Yan; Yan, Rui-Ming; Zhong, Mei; Yu, Yan-Hong; Wang, Wei] Southern Med Univ, Nanfang Hosp, Dept Obstet & Gynecol, Sch Clin Med 1, Guangzhou 510515, Guangdong, Peoples R China; [Huang, Lei] Newcastle Univ, Fac Med Sci, Inst Cellular Med, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Zhang, Yan-Mei; Wu, Sha] Southern Med Univ, Sch Basic Med Sci, Dept Immunol, Guangdong Prov Key Lab Prote, Guangzhou 510515, Guangdong, Peoples R China; [Liang, Li] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China	Guangzhou Medical University; Southern Medical University - China; Newcastle University - UK; Southern Medical University - China; Southern Medical University - China	Wang, W (corresponding author), Guangzhou Med Univ, Dept Obstet & Gynecol, Affiliated Hosp 1, Guangzhou 510120, Guangdong, Peoples R China.; Wang, W (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Obstet & Gynecol, Sch Clin Med 1, Guangzhou 510515, Guangdong, Peoples R China.; Wu, S (corresponding author), Southern Med Univ, Sch Basic Med Sci, Dept Immunol, Guangdong Prov Key Lab Prote, Guangzhou 510515, Guangdong, Peoples R China.	shawu99@outlook.com; smugowwang@126.com	Wu, Xiang-Guang/AAC-1937-2020; liang, li/AAB-9126-2022; Yu, Yan/GYV-4514-2022; wu, xiangguang/AAC-6193-2020	wu, xiangguang/0000-0001-8276-4810; huang, lei/0000-0002-1996-944X	National Natural Science Foundation of China [81672589, 81372781]; National Natural Science foundation of Guangdong province [2017A030313872]; Shenzhen Science and Technology Program [JCYJ20160429161218745]; National Key Research and Development Program of China [2016YFC1302901]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science foundation of Guangdong province(National Natural Science Foundation of Guangdong Province); Shenzhen Science and Technology Program; National Key Research and Development Program of China	This work was supported by the National Natural Science Foundation of China (grant numbers: 81672589, 81372781), the National Natural Science foundation of Guangdong province (grant number: 2017A030313872), the Shenzhen Science and Technology Program (grant number: JCYJ20160429161218745), and the National Key Research and Development Program of China (grant number: 2016YFC1302901).	Achen MG, 2005, CANCER CELL, V7, P121, DOI 10.1016/j.ccr.2005.01.017; Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480; Bang C, 2014, J CLIN INVEST, V124, P2136, DOI 10.1172/JCI70577; Beavis AL, 2016, GYNECOL ONCOL, V143, P302, DOI 10.1016/j.ygyno.2016.08.236; Bono P, 2004, CLIN CANCER RES, V10, P7144, DOI 10.1158/1078-0432.CCR-03-0826; Cairns RA, 2004, CANCER RES, V64, P2054, DOI 10.1158/0008-5472.CAN-03-3196; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Dadras SS, 2005, MODERN PATHOL, V18, P1232, DOI 10.1038/modpathol.3800410; Felicetti F, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0811-2; Fu B, 2015, INT J ONCOL, V46, P1169, DOI 10.3892/ijo.2015.2837; Gombos Z, 2005, CLIN CANCER RES, V11, P8364, DOI 10.1158/1078-0432.CCR-05-1238; Hannafon BN, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0753-x; Hashimoto K, 2018, P NATL ACAD SCI USA, V115, P2204, DOI 10.1073/pnas.1717363115; Heishi T, 2010, AM J PATHOL, V176, P1950, DOI 10.2353/ajpath.2010.090829; Hosaka T, 2009, AM J PATHOL, V175, P430, DOI 10.2353/ajpath.2009.080788; Ito S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073931; Jafri MA, 2017, SEMIN CANCER BIOL, V44, P117, DOI 10.1016/j.semcancer.2017.02.004; Josson S, 2015, ONCOGENE, V34, P2690, DOI 10.1038/onc.2014.212; Keklikoglou I, 2015, ONCOGENE, V34, P4867, DOI 10.1038/onc.2014.408; Kim YJ, 2015, RADIAT ONCOL J, V33, P109, DOI 10.3857/roj.2015.33.2.109; Kneitz B, 2014, CANCER RES, V74, P2591, DOI 10.1158/0008-5472.CAN-13-1606; Kuehbacher A, 2007, CIRC RES, V101, P59, DOI 10.1161/CIRCRESAHA.107.153916; Lee YJ, 2017, GYNECOL ONCOL, V144, P536, DOI 10.1016/j.ygyno.2017.01.001; Lehuede C, 2016, CANCER RES, V76, P5201, DOI 10.1158/0008-5472.CAN-16-0266; Li L, 2016, CANCER RES, V76, P1770, DOI 10.1158/0008-5472.CAN-15-1625; Liu D, 2014, CANCER RES, V74, P5597, DOI 10.1158/0008-5472.CAN-13-3598; Liu D, 2014, INT J ONCOL, V45, P1232, DOI 10.3892/ijo.2014.2510; Liu LP, 2015, GUT, V64, P26, DOI 10.1136/gutjnl-2013-306388; Liu YQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-017-0751-3; Maeng YS, 2016, ONCOGENE, V35, P196, DOI 10.1038/onc.2015.73; Manier S, 2017, BLOOD, V129, P2429, DOI 10.1182/blood-2016-09-742296; Mao SY, 2016, J OBSTET GYNAECOL RE, V42, P1317, DOI 10.1111/jog.13058; Melo SA, 2015, NATURE, V523, P177, DOI 10.1038/nature14581; Nedaeinia R, 2017, CANCER GENE THER, V24, P48, DOI 10.1038/cgt.2016.77; Que T, 2015, ONCOGENE, V34, P4952, DOI 10.1038/onc.2014.419; Redis RS, 2012, PHARMACOL THERAPEUT, V136, P169, DOI 10.1016/j.pharmthera.2012.08.003; Sato Y, 2013, J BIOCHEM, V153, P5, DOI 10.1093/jb/mvs128; Shukla Girish C, 2011, Mol Cell Pharmacol, V3, P83; Stacker SA, 2014, NAT REV CANCER, V14, P159, DOI 10.1038/nrc3677; Takahashi RU, 2017, CLIN CHEM LAB MED, V55, P648, DOI 10.1515/cclm-2016-0708; Takanami I, 2006, ONCOL REP, V15, P437; Vaccarella S, 2013, EUR J CANCER, V49, P3262, DOI 10.1016/j.ejca.2013.04.024; Wang J, 2015, MOL CLIN ONCOL, V3, P363, DOI 10.3892/mco.2014.465; Wang T, 2014, HUM PATHOL, V45, P1839, DOI 10.1016/j.humpath.2014.05.001; Watanabe K, 2004, J CLIN INVEST, V114, P898, DOI 10.1172/JC1200421152; Wei WF, 2017, CELL DEATH DIS, V8, DOI 10.1038/s41419-017-0077-5; Wu LF, 2017, FEBS J, V284, P3000, DOI 10.1111/febs.14162; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007; Zhuang GL, 2012, EMBO J, V31, P3513, DOI 10.1038/emboj.2012.183	49	106	115	1	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1256	1268		10.1038/s41388-018-0511-x	http://dx.doi.org/10.1038/s41388-018-0511-x			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30254211	Green Published, hybrid			2022-12-17	WOS:000459249800008
J	Yang, H; Liu, P; Zhang, J; Peng, X; Lu, Z; Yu, S; Meng, Y; Tong, WM; Chen, J				Yang, H.; Liu, P.; Zhang, J.; Peng, X.; Lu, Z.; Yu, S.; Meng, Y.; Tong, W-M; Chen, J.			Long noncoding RNA MIR31HG exhibits oncogenic property in pancreatic ductal adenocarcinoma and is negatively regulated by miR-193b	ONCOGENE			English	Article							EXPRESSION; MICRORNAS; PROLIFERATION; PROGRESSION; LOC554202; MIGRATION; PROMOTES; TARGETS; SITES	Long noncoding RNAs (lncRNAs) play important regulatory roles in a variety of diseases, including many tumors. However, the functional roles of these transcripts and mechanisms responsible for their deregulation in pancreatic ductal adenocarcinoma (PDAC) are not thoroughly understood. In this study, we discovered that lncRNA MIR31HG is markedly upregulated in PDAC. Knockdown of MIR31HG significantly suppressed PDAC cell growth, induced apoptosis and G1/S arrest, and inhibited invasion, whereas enhanced expression of MIR31HG had the opposite effects. Online database analysis tools showed that miR-193b could target MIR31HG and we found an inverse correlation between MIR31HG and miR-193b in PDAC specimens. Inhibition of miR-193b expression significantly upregulated the MIR31HG level, while overexpression of miR-193b suppressed MIR31HG's expression and function, suggesting that MIR31HG is negatively regulated by miR-193b. Moreover, using luciferase reporter and RIP assays, we provide evidence that miR-193b directly targeted MIR31HG by binding to two microRNA binding sites in the MIR31HG sequence. On the other hand, MIR31HG may act as an endogenous 'sponge' by competing for miR-193b binding to regulate the miRNA targets. Collectively, these results demonstrate that MIR31HG functions as an oncogenic lncRNA that promotes tumor progression, and miR-193b targets not only protein-coding genes but also the lncRNA, MIR31HG.	[Yang, H.; Liu, P.; Lu, Z.; Yu, S.; Meng, Y.; Chen, J.] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Pathol, 1 Shuai Fu Yuan Hu Tong, Beijing 100730, Peoples R China; [Yang, H.; Liu, P.; Zhang, J.; Peng, X.; Lu, Z.; Yu, S.; Meng, Y.; Tong, W-M; Chen, J.] Peking Union Med Coll, Beijing 100730, Peoples R China; [Zhang, J.; Peng, X.] Chinese Acad Med Sci, Inst Basic Med Sci, State Key Lab Med Mol Biol, Beijing, Peoples R China; [Zhang, J.; Peng, X.; Tong, W-M] Chinese Acad Med Sci, Sch Basic Med, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China; [Tong, W-M] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Pathol, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS	Chen, J (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Pathol, 1 Shuai Fu Yuan Hu Tong, Beijing 100730, Peoples R China.; Chen, J (corresponding author), Peking Union Med Coll, Beijing 100730, Peoples R China.; Tong, WM (corresponding author), Chinese Acad Med Sci, Sch Basic Med, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China.; Tong, WM (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Dept Pathol, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China.; Tong, WM (corresponding author), Peking Union Med Coll, 5 Dong Dan San Tiao, Beijing 100005, Peoples R China.	wmtong@ibms.pumc.edu.cn; xhblk@163.com			National Nature Science Foundations of China [81472326, 81172334, 31021091]; China 973 [2011CBA01104]	National Nature Science Foundations of China(National Natural Science Foundation of China (NSFC)); China 973(National Basic Research Program of China)	We sincerely thank Dr Yamei Niu for technical support and critical comments on the manuscript, Weilong Zhang for detailed bioinformatics analysis of MIR31HG, and Yongsong Yue for technical support of ISH. This work was supported by the National Nature Science Foundations of China (81472326 and 81172334 to JC, 31021091 to W-MT) and the China 973 (2011CBA01104 to W-MT).	Augoff K, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-5; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Braconi C, 2011, ONCOGENE, V30, P4750, DOI 10.1038/onc.2011.193; Brummer A, 2014, BIOESSAYS, V36, P617, DOI 10.1002/bies.201300104; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028; Cheetham SW, 2013, BRIT J CANCER, V108, P2419, DOI 10.1038/bjc.2013.233; Chen JM, 2011, AM J PATHOL, V179, P2162, DOI 10.1016/j.ajpath.2011.07.010; Chen X, 2013, BIOINFORMATICS, V29, P2617, DOI 10.1093/bioinformatics/btt426; Da Sacco L, 2013, INT J MOL SCI, V14, P480, DOI 10.3390/ijms14010480; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Gastaldi C, 2014, CARCINOGENESIS, V35, P1110, DOI 10.1093/carcin/bgt490; Guo G, 2015, ONCOGENE, V34, P1768, DOI 10.1038/onc.2014.131; Hansen TB, 2011, EMBO J, V30, P4414, DOI 10.1038/emboj.2011.359; Harries LW, 2012, BIOCHEM SOC T, V40, P902, DOI 10.1042/BST20120020; Ikeda Y, 2012, MOL CANCER RES, V10, P259, DOI 10.1158/1541-7786.MCR-11-0035; Izaurralde E, 2012, EMBO REP, V13, P662, DOI 10.1038/embor.2012.91; Jeggari A, 2012, BIOINFORMATICS, V28, P2062, DOI 10.1093/bioinformatics/bts344; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032; Kim K, 2013, ONCOGENE, V32, P1616, DOI 10.1038/onc.2012.193; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Leucci E, 2013, SCI REP-UK, V3, DOI 10.1038/srep02535; Lin ST, 2013, P NATL ACAD SCI USA, V110, P17468, DOI 10.1073/pnas.1317182110; Liu XH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-92; Montes M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7967; Muers M, 2011, NAT REV GENET, V12, DOI 10.1038/nrg3088; Novikova IV, 2013, J MOL BIOL, V425, P3731, DOI 10.1016/j.jmb.2013.02.030; Paraskevopoulou MD, 2013, NUCLEIC ACIDS RES, V41, pD239, DOI 10.1093/nar/gks1246; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Shi YG, 2014, BIOCHEM BIOPH RES CO, V446, P448, DOI 10.1016/j.bbrc.2014.02.144; Siegel R, 2013, CA-CANCER J CLIN, V2013, P63; Tahira AC, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-141; Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Wang K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4596; Wang L, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt006; Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456; Xi SC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013764; Xu CW, 2010, EUR J CANCER, V46, P2828, DOI 10.1016/j.ejca.2010.06.127; Yang F, 2013, J CANCER RES CLIN, V139, P437, DOI 10.1007/s00432-012-1324-x; Yang F, 2013, MOL CELL, V49, P1083, DOI 10.1016/j.molcel.2013.01.010; Yang X, 2014, GUT, V63, P881, DOI 10.1136/gutjnl-2013-305266; Zhang G, 2012, J CONTROL SCI ENG, V2012, P7, DOI DOI 10.1371/J0URNAL.P0NE.0044568	45	106	112	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3647	3657		10.1038/onc.2015.430	http://dx.doi.org/10.1038/onc.2015.430			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26549028	Green Published, hybrid			2022-12-17	WOS:000379622800004
J	Lemieux, E; Cagnol, S; Beaudry, K; Carrier, J; Rivard, N				Lemieux, E.; Cagnol, S.; Beaudry, K.; Carrier, J.; Rivard, N.			Oncogenic KRAS signalling promotes the Wnt/beta-catenin pathway through LRP6 in colorectal cancer	ONCOGENE			English	Article							INTESTINAL EPITHELIAL-CELLS; ACTIVATED PROTEIN-KINASES; BETA-CATENIN; TUMOR PROGRESSION; REGULATED KINASE; K-RAS; WNT; TUMORIGENESIS; APC; MUTATIONS	Aberrant regulation of the Wnt/beta-catenin signaling pathway is one of the major causes of colorectal cancer (CRC). Loss-of-function mutations in APC are commonly found in CRC, leading to inappropriate activation of canonical Wnt signaling. Conversely, gain-of-function mutations in KRAS and BRAF genes are detected in up to 60% of CRCs. Whereas KRAS/mitogen-activated protein kinase (MAPK) and canonical Wnt/beta-catenin pathways are critical for intestinal tumorigenesis, mechanisms integrating these two important signaling pathways during CRC development are unknown. Results herein demonstrate that transformation of normal intestinal epithelial cells (IECs) by oncogenic forms of KRAS, BRAF or MEK1 was associated with a marked increase in beta-catenin/TCF4 and c-MYC promoter transcriptional activities and mRNA levels of c-Myc, Axin2 and Lef1. Notably, expression of a dominant-negative mutant of T-Cell Factor 4 (.NTCF4) severely attenuated IEC transformation induced by oncogenic MEK1 and markedly reduced their tumorigenic and metastatic potential in immunocompromised mice. Interestingly, the Frizzled co-receptor LRP6 was phosphorylated in a MEK-dependent manner in transformed IECs and in human CRC cell lines. Expression of LRP6 mutant in which serine/threonine residues in each particular ProlineProlineProlineSerine/ThreonineProline motif were mutated to alanines (LRP6-5A) significantly reduced beta-catenin/TCF4 transcriptional activity. Accordingly, MEK inhibition in human CRC cells significantly diminished beta-catenin/TCF4 transcriptional activity and c-MYC mRNA and protein levels without affecting beta-catenin expression or stability. Lastly, LRP6 phosphorylation was also increased in human colorectal tumors, including adenomas, in comparison with healthy adjacent normal tissues. Our data indicate that oncogenic activation of KRAS/BRAF/MEK signaling stimulates the canonical Wnt/beta-catenin pathway, which in turn promotes intestinal tumor growth and invasion. Moreover, LRP6 phosphorylation by ERK1/2 may provide a unique point of convergence between KRAS/MAPK and Wnt/beta-catenin signalings during oncogenesis.	[Lemieux, E.; Cagnol, S.; Beaudry, K.; Rivard, N.] Univ Sherbrooke, Fac Med & Hlth Sci, Dept Anat & Cell Biol, Sherbrooke, PQ J1E 4K8, Canada; [Carrier, J.] Univ Sherbrooke, Fac Med & Hlth Sci, Dept Med, Gastroenterol Serv, Sherbrooke, PQ J1E 4K8, Canada	University of Sherbrooke; University of Sherbrooke	Rivard, N (corresponding author), Univ Sherbrooke, Fac Med & Hlth Sci, Dept Anat & Cell Biol, Canc Res Pavil,3201 Jean Mignault, Sherbrooke, PQ J1E 4K8, Canada.	Nathalie.Rivard@USherbrooke.ca			Canadian Institutes of Health Research [MT-14405]; Canadian Research Chair	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Research Chair(Canada Research Chairs)	We thank Guillaume Arguin and Gerald Bernatchez for technical assistance. The biobank of colorectal cancer specimens was supported by a Team grant on digestive epithelium from the Canadian Institutes of Health Research. This research was supported by a grant from the Canadian Institutes of Health Research Grant to Nathalie Rivard (MT-14405). Etienne Lemieux is a student scholar from the Fonds de la Recherche en Sante du Quebec (FRSQ). Nathalie Rivard and Julie C Carrier are members of the FRSQ-Funded Centre de Recherche du CHUS. Nathalie Rivard is a recipient of a Canadian Research Chair in colorectal cancer and inflammatory cell signalling. This research was supported by a grant from the Canadian Institutes of Health Research to NR (MT-14405).	Aliaga JC, 1999, AM J PHYSIOL-GASTR L, V277, pG631, DOI 10.1152/ajpgi.1999.277.3.G631; Ashton GH, 2010, DEV CELL, V19, P259, DOI 10.1016/j.devcel.2010.07.015; Bennecke M, 2010, CANCER CELL, V18, P135, DOI 10.1016/j.ccr.2010.06.013; Bergeron S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-271; Bienz M, 2005, CURR BIOL, V15, pR64, DOI 10.1016/j.cub.2004.12.058; Boucher MJ, 2004, AM J PHYSIOL-GASTR L, V286, pG736, DOI 10.1152/ajpgi.00453.2003; Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; Cagnol S, 2013, ONCOGENE, V32, P564, DOI 10.1038/onc.2012.88; Carragher LAS, 2010, EMBO MOL MED, V2, P458, DOI 10.1002/emmm.201000099; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Dasari A, 2010, CLIN CANCER RES, V16, P3811, DOI 10.1158/1078-0432.CCR-09-2283; Daugherty RL, 2007, PHYSIOLOGY, V22, P303, DOI 10.1152/physiol.00020.2007; Deng GR, 2004, CLIN CANCER RES, V10, P191, DOI 10.1158/1078-0432.CCR-1118-3; Dienstmann R, 2011, ANTI-CANCER AGENT ME, V11, P285, DOI 10.2174/187152011795347469; Eggstein S, 1999, GUT, V44, P834, DOI 10.1136/gut.44.6.834; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Ettenberg SA, 2010, P NATL ACAD SCI USA, V107, P15473, DOI 10.1073/pnas.1007428107; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084; Fodde R, 2010, J PATHOL, V221, P239, DOI 10.1002/path.2718; Gopalbhai K, 1998, J CELL PHYSIOL, V174, P35, DOI 10.1002/(SICI)1097-4652(199801)174:1<35::AID-JCP5>3.0.CO;2-H; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115; Harris TJC, 2005, TRENDS CELL BIOL, V15, P234, DOI 10.1016/j.tcb.2005.03.002; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928; Horst D, 2012, CANCER RES, V72, P1547, DOI 10.1158/0008-5472.CAN-11-3222; Ikenoue T, 2005, CANCER RES, V65, P4562, DOI 10.1158/0008-5472.CAN-04-4114; Ikenoue T, 2004, CANCER RES, V64, P3428, DOI 10.1158/0008-5472.CAN-03-3591; Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Komatsu K, 2005, GASTROENTEROLOGY, V129, P577, DOI 10.1053/j.gastro.2005.06.003; Krejci P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035826; Langlois MJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015742; Lee SH, 2004, APMIS, V112, P233, DOI 10.1111/j.1600-0463.2004.apm11204-0502.x; Lee SH, 2010, NAT MED, V16, P665, DOI 10.1038/nm.2143; Lemieux E, 2009, INT J CANCER, V125, P1575, DOI 10.1002/ijc.24485; Li WQ, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-2; Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110; Luo FJ, 2009, INT J EXP PATHOL, V90, P558, DOI 10.1111/j.1365-2613.2009.00667.x; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159-8290.CD-13-0070; Naishiro Y, 2001, CANCER RES, V61, P2751; Nandan MO, 2008, GASTROENTEROLOGY, V134, P120, DOI 10.1053/j.gastro.2007.10.023; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Niault TS, 2010, CARCINOGENESIS, V31, P1165, DOI 10.1093/carcin/bgp337; Obrador-Hevia A, 2010, J PATHOL, V221, P57, DOI 10.1002/path.2685; Perez-Moreno M, 2006, DEV CELL, V11, P601, DOI 10.1016/j.devcel.2006.10.010; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Pretlow TP, 2005, BBA-REV CANCER, V1756, P83, DOI 10.1016/j.bbcan.2005.06.002; Proffitt KD, 2012, J BIOL CHEM, V287, P34167, DOI 10.1074/jbc.M112.381970; Rad R, 2013, CANCER CELL, V24, P15, DOI 10.1016/j.ccr.2013.05.014; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Ramos JW, 2008, INT J BIOCHEM CELL B, V40, P2707, DOI 10.1016/j.biocel.2008.04.009; Rivard N, 1999, AM J PHYSIOL-CELL PH, V277, pC652, DOI 10.1152/ajpcell.1999.277.4.C652; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Saucier C, 2010, CANCER METAST BIOL T, V14, P205, DOI 10.1007/978-90-481-8833-8_8; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Simoneau M, 2011, CELL SIGNAL, V23, P269, DOI 10.1016/j.cellsig.2010.09.011; Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033; Smakman N, 2005, BBA-REV CANCER, V1756, P103, DOI 10.1016/j.bbcan.2005.07.001; Taketo MM, 2006, CANCER SCI, V97, P355, DOI 10.1111/j.1349-7006.2006.00190.x; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200; Tian XR, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/567305; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Voisin L, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-337; Wang CH, 2013, DEV BIOL, V378, P122, DOI 10.1016/j.ydbio.2013.03.020; Wolf J, 2008, FEBS LETT, V582, P255, DOI 10.1016/j.febslet.2007.12.013; Worthley Daniel L, 2010, Clin Biochem Rev, V31, P31; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Yang J, 2006, J BIOL CHEM, V281, P17751, DOI 10.1074/jbc.M600831200; Yochum GS, 2008, MOL CELL BIOL, V28, P7368, DOI 10.1128/MCB.00744-08; Yuen ST, 2002, CANCER RES, V62, P6451; Zeller E, 2013, ARCH TOXICOL, V87, P611, DOI 10.1007/s00204-013-1035-3	86	106	106	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2015	34	38					4914	4927		10.1038/onc.2014.416	http://dx.doi.org/10.1038/onc.2014.416			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9QZ	25500543	Green Published, hybrid			2022-12-17	WOS:000361693000002
J	Ouyang, H; Gore, J; Deitz, S; Korc, M				Ouyang, H.; Gore, J.; Deitz, S.; Korc, M.			microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-beta actions	ONCOGENE			English	Article						pancreatic cancer; miR-10b; EGF receptor; cell invasion	EPIDERMAL-GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; DUCTAL ADENOCARCINOMA; FACTOR RECEPTOR; SIGNALING PATHWAYS; BREAST-CANCER; LUNG-CANCER; MOUSE MODEL; METASTASIS; TUMORIGENESIS	Increased microRNA-10b (miR-10b) expression in the cancer cells in pancreatic ductal adenocarcinoma (PDAC) is a marker of disease aggressiveness. In the present study, we determined that plasma miR-10b levels are significantly increased in PDAC patients by comparison with normal controls. By gene profiling, we identified potential targets downregulated by miR-10b, including Tat-interacting protein 30 (TIP30). Immunoblotting and luciferase reporter assays confirmed that TIP30 was a direct miR-10b target. Downregulation of TIP30 by miR-10b or siRNA-mediated silencing of TIP30 enhanced epidermal growth factor (EGF)-dependent invasion. The actions of miR-10b were abrogated by expressing a modified TIP30 cDNA resistant to miR-10b. EGF-induced EGF receptor (EGFR) tyrosine phosphorylation and extracellular signal-regulated kinase phosphorylation were enhanced by miR-10b, and these effects were mimicked by TIP30 silencing. The actions of EGF in the presence of miR-10b were blocked by EGFR kinase inhibition with erlotinib and by dual inhibition of PI3K (phosphatidylinositol 3'-kinase) and MEK. Moreover, miR-10b, EGF and transforming growth factor-beta (TGF-beta) combined to markedly increase cell invasion, and this effect was blocked by the combination of erlotinib and SB505124, a type I TGF-beta receptor inhibitor. miR-10b also enhanced the stimulatory effects of EGF and TGF-beta on cell migration and epithelial-mesenchymal transition (EMT) and decreased the expression of RAP2A, EPHB2, KLF4 and NF1. Moreover, miR-10b overexpression accelerated pancreatic cancer cell (PCC) proliferation and tumor growth in an orthotopic model. Thus, plasma miR-10b levels may serve as a diagnostic marker in PDAC, whereas intra-tumoral miR-10b promotes PCC proliferation and invasion by suppressing TIP30, which enhances EGFR signaling, facilitates EGF-TGF-beta cross-talk and enhances the expression of EMT-promoting genes, whereas decreasing the expression of several metastasis-suppressing genes. Therefore, therapeutic targeting of miR-10b in PDAC may interrupt growth-promoting deleterious EGF-TGF-beta interactions and antagonize the metastatic process at various levels.	Indiana Univ Sch Med, Dept Med, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46202 USA; Indiana Univ Sch Med, Dept Biochem, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46202 USA; Indiana Univ Sch Med, Dept Mol Biol, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46202 USA; Indiana Univ Sch Med, Pancreat Canc Signature Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Korc, M (corresponding author), Indiana Univ Sch Med, Dept Med, 980 W Walnut St, Indianapolis, IN 46202 USA.	mkorc@iupui.edu			NIH [R37-CA-075059]; NATIONAL CANCER INSTITUTE [R37CA075059, R01CA075059] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is dedicated to the fond memory of Victor Fung, Ph.D., a former Program Officer at NCI and former Scientific Review Officer of the Cancer Etiology study section of CSR, NIH, for his wisdom, compassion, integrity, his love of sciences and the arts, his incredible culinary skills, and above all, his contributions to the career development of so many investigators during his own distinguished career. The work was supported, in part, by an NIH grant R37-CA-075059 to M K. HO was a Ph.D. candidate in the Program in Experimental and Molecular Medicine at the Geisel School of Medicine at Dartmouth. We thank the IUSCC Cancer Center at Indiana University School of Medicine for the use of the Tissue Procurement and Distribution Core, which provided pancreatic tissues and patient plasma for microRNA assays. We also thank Dr Hua Xiao at the Michigan State University for generously providing the anti-TIP30 antibody.	Ardito CM, 2012, CANCER CELL, V22, P304, DOI 10.1016/j.ccr.2012.07.024; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Bloomston M, 2007, JAMA-J AM MED ASSOC, V297, P1901, DOI 10.1001/jama.297.17.1901; Carriere C, 2011, GASTROENTEROLOGY, V141, P1091, DOI 10.1053/j.gastro.2011.05.041; Chai GL, 2010, CANCER SCI, V101, P1997, DOI 10.1111/j.1349-7006.2010.01616.x; Chou YT, 2010, CANCER RES, V70, P8822, DOI 10.1158/0008-5472.CAN-10-0638; Danilov AV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026815; Davies M, 2005, J CELL BIOCHEM, V95, P918, DOI 10.1002/jcb.20458; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; du Rieu MC, 2010, CLIN CHEM, V56, P603, DOI 10.1373/clinchem.2009.137364; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fang Y, 2010, P NATL ACAD SCI USA, V107, P13450, DOI 10.1073/pnas.1002120107; Friess H, 1995, CLIN CANCER RES, V1, P1413; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Gloerich M, 2012, NAT CELL BIOL, V14, P793, DOI 10.1038/ncb2537; Greither T, 2010, INT J CANCER, V126, P73, DOI 10.1002/ijc.24687; Hata A, 2010, ADV EXP MED BIOL, V700, P15, DOI 10.1007/978-1-4419-7823-3_2; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hinoda Y, 2003, J GASTROENTEROL, V38, P1162, DOI 10.1007/s00535-003-1224-6; Ibrahim SA, 2012, INT J CANCER, V131, pE884, DOI 10.1002/ijc.27629; Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317; Iorio MV, 2009, CANCER RES, V69, P2195, DOI 10.1158/0008-5472.CAN-08-2920; Ito M, 2003, CANCER RES, V63, P8763; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kang JS, 2009, TRENDS CELL BIOL, V19, P385, DOI 10.1016/j.tcb.2009.05.008; Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371; Kolch W, 2010, NAT REV CANCER, V10, P618, DOI 10.1038/nrc2900; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; Korc M, 1998, Surg Oncol Clin N Am, V7, P25; KORC M, 1986, P NATL ACAD SCI USA, V83, P5141, DOI 10.1073/pnas.83.14.5141; Korc M, 2007, AM J SURG, V194, pS84, DOI 10.1016/j.amjsurg.2007.05.004; Lau SKM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036753; Lee EJ, 2007, INT J CANCER, V120, P1046, DOI 10.1002/ijc.22394; Leveille N, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1519; Li A, 2013, ONCOGENE, V32, P2273, DOI 10.1038/onc.2012.253; Li QJ, 2012, TUMOR BIOL, V33, P1455, DOI 10.1007/s13277-012-0396-1; Lim JE, 2003, ANN SURG, V237, P74, DOI 10.1097/00000658-200301000-00011; Lin J, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.134; Liu F, 2012, MOL CANCER THER, V11, P2138, DOI 10.1158/1535-7163.MCT-12-0562; Liu LX, 2012, FEBS J, V279, P3800, DOI 10.1111/j.1742-4658.2012.08741.x; Luga V, 2009, BIOCHEM J, V421, P119, DOI 10.1042/BJ20081131; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618; Matsuda K, 2002, CANCER RES, V62, P5611; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Moriarty CH, 2010, J BIOL CHEM, V285, P20541, DOI 10.1074/jbc.M110.121012; Nakata K, 2011, SURGERY, V150, P916, DOI 10.1016/j.surg.2011.06.017; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Neupane D, 2008, CLIN CANCER RES, V14, P7614, DOI 10.1158/1078-0432.CCR-08-1366; Nishida N, 2013, CELL RES, V23, P1157, DOI 10.1038/cr.2013.87; Nishida N, 2012, ANN SURG ONCOL, V19, P3065, DOI 10.1245/s10434-012-2246-1; Nishida N, 2011, CLIN CANCER RES, V17, P2725, DOI 10.1158/1078-0432.CCR-10-2132; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Preis M, 2011, CRIT REV EUKAR GENE, V21, P115, DOI 10.1615/CritRevEukarGeneExpr.v21.i2.20; Preis M, 2011, CLIN CANCER RES, V17, P5812, DOI 10.1158/1078-0432.CCR-11-0695; Seike M, 2009, P NATL ACAD SCI USA, V106, P12085, DOI 10.1073/pnas.0905234106; Sempere LF, 2011, CANCER BIOL THER, V12, P198, DOI 10.4161/cbt.12.3.15979; Senior PV, 2010, INT J COLORECTAL DIS, V25, P687, DOI 10.1007/s00384-010-0916-7; Setoyama T, 2011, CLIN CANCER RES, V17, P5527, DOI 10.1158/1078-0432.CCR-11-1477; Shen J, 2013, NATURE, V497, P383, DOI 10.1038/nature12080; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Szafranska AE, 2008, CLIN CHEM, V54, P1716, DOI 10.1373/clinchem.2008.109603; Teixeira Ana L., 2012, Frontiers in Genetics, V3, P286, DOI 10.3389/fgene.2012.00286; Tian YY, 2010, J BIOL CHEM, V285, P7986, DOI 10.1074/jbc.M109.062877; Tong X, 2009, AM J PATHOL, V174, P1931, DOI 10.2353/ajpath.2009.080846; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Wagner JP, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003994; Wang J, 2009, CANCER PREV RES, V2, P807, DOI 10.1158/1940-6207.CAPR-09-0094; Webster RJ, 2009, J BIOL CHEM, V284, P5731, DOI 10.1074/jbc.M804280200; YAMANAKA Y, 1993, HUM PATHOL, V24, P1127, DOI 10.1016/0046-8177(93)90194-L; Yori JL, 2011, NEOPLASIA, V13, P601, DOI 10.1593/neo.11260; Yu GZ, 2011, J CANCER RES CLIN, V137, P73, DOI 10.1007/s00432-010-0861-4; Zhang CL, 2011, J BIOL CHEM, V286, P9373, DOI 10.1074/jbc.M110.207720; Zhang CL, 2010, CANCER RES, V70, P10224, DOI 10.1158/0008-5472.CAN-10-3057; Zhang H, 2008, INT J CANCER, V123, P810, DOI 10.1002/ijc.23638; Zhao J, 2007, HUM PATHOL, V38, P293, DOI 10.1016/j.humpath.2006.08.005	81	106	114	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2014	33	38					4664	4674		10.1038/onc.2013.405	http://dx.doi.org/10.1038/onc.2013.405			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3VX	24096486	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000342007200005
J	Farnsworth, RH; Lackmann, M; Achen, MG; Stacker, SA				Farnsworth, R. H.; Lackmann, M.; Achen, M. G.; Stacker, S. A.			Vascular remodeling in cancer	ONCOGENE			English	Review						angiogenesis; metastasis; endothelial cell; lymph node; tumor microenvironment; stroma	ENDOTHELIAL GROWTH-FACTOR; SENTINEL LYMPH-NODE; GLOMERULOID MICROVASCULAR PROLIFERATION; PROMOTES TUMOR-METASTASIS; SQUAMOUS-CELL CARCINOMA; VEGF-D PROMOTES; STEM-LIKE CELLS; BREAST-CANCER; PROGENITOR CELLS; BONE-MARROW	The growth and dissemination of tumors rely on an altered vascular network, which supports their survival and expansion and provides accessibility to the vasculature and a route of transport for metastasizing tumor cells. The remodeling of vascular structures through generation of new vessels (for example, via tumor angiogenesis) is a well studied, even if still quite poorly understood, process in human cancer. Antiangiogenic therapies have provided insight into the contribution of angiogenesis to the biology of human tumors, yet have also revealed the ease with which resistance to antiangiogenic drugs can develop, presumably involving alterations to vascular signaling mechanisms. Furthermore, cellular and/or molecular changes to pre-existing vessels could represent subtle pre-metastatic alterations to the vasculature, which are important for cancer progression. These changes, and associated molecular markers, may forecast the behavior of individual tumors and contribute to the early detection, diagnosis and prognosis of cancer. This review, which primarily focuses on the blood vasculature, explores current knowledge of how tumor vessels can be remodeled, and the cellular and molecular events responsible for this process.	[Farnsworth, R. H.; Lackmann, M.] Monash Univ, Dept Biochem & Mol Biol, Prot Interact & Canc Res Lab, Clayton, Vic, Australia; [Achen, M. G.; Stacker, S. A.] Peter MacCallum Canc Ctr, Tumour Angiogenesis Program, East Melbourne, Vic 8006, Australia; [Achen, M. G.; Stacker, S. A.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3052, Australia	Monash University; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne	Stacker, SA (corresponding author), Peter MacCallum Canc Ctr, Tumour Angiogenesis Program, Locked Bag 1,ABeckett St, East Melbourne, Vic 8006, Australia.	steven.stacker@petermac.org		Achen, Marc/0000-0002-3791-803X; Farnsworth, Rae/0000-0002-7930-1206; Stacker, Steven/0000-0003-4096-9273	Research Fellowships and a Program Grant from the National Health and Medical Research Council of Australia	Research Fellowships and a Program Grant from the National Health and Medical Research Council of Australia	MGA and SAS are supported by Research Fellowships and a Program Grant from the National Health and Medical Research Council of Australia. We apologize to authors whose work could not be quoted due to space limitations.	Achen MG, 2006, BRIT J CANCER, V94, P1355, DOI 10.1038/sj.bjc.6603120; Achen MG, 2008, ANN NY ACAD SCI, V1131, P225, DOI 10.1196/annals.1413.020; Achen MG, 2012, GROWTH FACTORS, V30, P283, DOI 10.3109/08977194.2012.704917; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Ahn GO, 2009, ANGIOGENESIS, V12, P159, DOI 10.1007/s10456-009-9135-7; Aird WC, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006429; ALGIRE GH, 1945, J NATL CANCER I, V6, P73, DOI 10.1093/jnci/6.1.73; Alitalo K, 2011, NAT MED, V17, P1371, DOI 10.1038/nm.2545; Alvero AB, 2009, STEM CELLS, V27, P2405, DOI 10.1002/stem.191; Aranguren XL, 2008, J CLIN INVEST, V118, P505, DOI [10.1172/JC131153, 10.1172/JCI31153]; Arapandoni-Dadioti P, 1999, CANCER LETT, V137, P145, DOI 10.1016/S0304-3835(98)00343-7; Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bertolini F, 2006, NAT REV CANCER, V6, P833, DOI 10.1039/nrc1971; Birner P, 2003, BRAIN PATHOL, V13, P133, DOI 10.1111/j.1750-3639.2003.tb00013.x; Bruno S, 2006, AM J PATHOL, V169, P2223, DOI 10.2353/ajpath.2006.060498; Bussolati B, 2008, FASEB J, V22, P3696, DOI 10.1096/fj.08-102590; Bussolati B, 2010, CURR VASC PHARMACOL, V8, P220, DOI 10.2174/157016110790887036; Bussolati B, 2009, J CELL MOL MED, V13, P309, DOI 10.1111/j.1582-4934.2008.00338.x; Cao RH, 2004, CIRC RES, V94, P664, DOI 10.1161/01.RES.0000118600.91698.BB; Cardone RA, 2005, NAT REV CANCER, V5, P786, DOI 10.1038/nrc1713; Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Carriere V, 2005, CANCER RES, V65, P11639, DOI 10.1158/0008-5472.CAN-05-1190; Cassoni P, 2008, J Cell Mol Med, V12, P564, DOI 10.1111/j.1582-4934.2007.00206.x; Chung MK, 2012, ANN SURG ONCOL, V19, P1595, DOI 10.1245/s10434-011-2154-9; Cipponi A, 2012, CANCER RES, V72, P3997, DOI 10.1158/0008-5472.CAN-12-1377; Clasper S, 2008, CANCER RES, V68, P7293, DOI 10.1158/0008-5472.CAN-07-6506; Cochran AJ, 2006, NAT REV IMMUNOL, V6, P659, DOI 10.1038/nri1919; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; Cutsem E, 2005, SCIENCE, V307, P58; de Chaisemartin L, 2011, CANCER RES, V71, P6391, DOI 10.1158/0008-5472.CAN-11-0952; De Palma M, 2003, NAT MED, V9, P789, DOI 10.1038/nm871; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; De Palma M, 2007, TRENDS IMMUNOL, V28, P519, DOI 10.1016/j.it.2007.09.004; Dieu-Nosjean MC, 2008, J CLIN ONCOL, V26, P4410, DOI 10.1200/JCO.2007.15.0284; Dirkx AEM, 2006, FASEB J, V20, P621, DOI 10.1096/fj.05-4493com; Duda DG, 2007, NAT PROTOC, V2, P805, DOI 10.1038/nprot.2007.111; Dvorak AM, 1996, J LEUKOCYTE BIOL, V59, P100, DOI 10.1002/jlb.59.1.100; Farnsworth RH, 2011, CANCER RES, V71, P6547, DOI 10.1158/0008-5472.CAN-11-0200; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1966, ANN SURG, V164, P491, DOI 10.1097/00000658-196609000-00012; Fridman WH, 2011, CANCER RES, V71, P5601, DOI 10.1158/0008-5472.CAN-11-1316; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gao DC, 2008, SCIENCE, V319, P195, DOI 10.1126/science.1150224; Gerald D, 2013, CANCER RES, V73, P1649, DOI 10.1158/0008-5472.CAN-12-4697; Gerhardt H, 2008, J MOL MED, V86, P135, DOI 10.1007/s00109-007-0258-2; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; GIMBRONE MA, 1969, NATURE, V222, P33, DOI 10.1038/222033a0; Girard JP, 2012, NAT REV IMMUNOL, V12, P762, DOI 10.1038/nri3298; Goffin JR, 2003, BRIT J CANCER, V89, P1031, DOI 10.1038/sj.bjc.6601195; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Grange C, 2011, CANCER RES, V71, P5346, DOI 10.1158/0008-5472.CAN-11-0241; Greene HSN, 1941, J EXP MED, V73, P461, DOI 10.1084/jem.73.4.461; Griffioen AW, 2008, CANCER IMMUNOL IMMUN, V57, P1553, DOI 10.1007/s00262-008-0524-3; Guidi AJ, 2000, J NATL CANCER I, V92, P486, DOI 10.1093/jnci/92.6.486; Halford MM, 2012, COLORECTAL CANCER, V1, P149, DOI 10.2217/CRC.12.9; Hamzah J, 2008, NATURE, V453, P410, DOI 10.1038/nature06868; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harrell MI, 2007, AM J PATHOL, V170, P774, DOI 10.2353/ajpath.2007.060761; Hayasaka H, 2010, CANCER SCI, V101, P2302, DOI 10.1111/j.1349-7006.2010.01687.x; Herve MA, 2008, AM J PATHOL, V172, P167, DOI 10.2353/ajpath.2008.070181; Hindley JP, 2012, CANCER RES, V72, P5473, DOI 10.1158/0008-5472.CAN-12-1912; Hirakawa S, 2005, J EXP MED, V201, P1089, DOI 10.1084/jem.20041896; Hirakawa S, 2007, BLOOD, V109, P1010, DOI 10.1182/blood-2006-05-021758; Hirakawa S, 2009, AM J PATHOL, V175, P2235, DOI 10.2353/ajpath.2009.090420; Hirakawa S, 2009, CANCER SCI, V100, P983, DOI 10.1111/j.1349-7006.2009.01142.x; Hockel M, 2001, SEMIN ONCOL, V28, P36, DOI 10.1016/S0093-7754(01)90211-8; Hoffman JA, 2003, CANCER CELL, V4, P383, DOI 10.1016/S1535-6108(03)00273-3; Hoshida T, 2006, CANCER RES, V66, P8065, DOI 10.1158/0008-5472.CAN-06-1392; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Hurwitz Herbert, 2004, Clin Colorectal Cancer, V4 Suppl 2, pS62, DOI 10.3816/CCC.2004.s.010; Ishii H, 2010, ORAL ONCOL, V46, P373, DOI 10.1016/j.oraloncology.2010.02.014; Jakob C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027402; Joukov V, 1996, EMBO J, V15, P290; Joyce JA, 2003, CANCER CELL, V4, P393, DOI 10.1016/S1535-6108(03)00271-X; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kaplan RN, 2006, CANCER RES, V66, P11089, DOI 10.1158/0008-5472.CAN-06-2407; Karnezis T, 2012, CANCER CELL, V21, P181, DOI 10.1016/j.ccr.2011.12.026; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kerjaschki D, 2011, J CLIN INVEST, V121, P2000, DOI 10.1172/JCI44751; Keskitalo S, 2007, CIRC RES, V100, P1460, DOI 10.1161/01.RES.0000269042.58594.f6; Konerding MA, 1998, AM J PATHOL, V152, P1607; Konerding MA, 1999, BRIT J CANCER, V80, P724, DOI 10.1038/sj.bjc.6690416; Kurahara H, 2010, J SURG ONCOL, V102, P809, DOI 10.1002/jso.21744; Kushner EJ, 2013, CURR OPIN HEMATOL, V20, P231, DOI 10.1097/MOH.0b013e328360614b; Laakkonen P, 2002, NAT MED, V8, P751, DOI 10.1038/nm720; Lee SY, 2012, ANN ACAD MED SINGAP, V41, P21; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Liao S, 2006, J IMMUNOL, V177, P3369, DOI 10.4049/jimmunol.177.5.3369; Liu PA, 2011, J IMMUNOTHER, V34, P320, DOI 10.1097/CJI.0b013e318213cd12; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Mancuso P, 2009, CLIN CANCER RES, V15, P267, DOI 10.1158/1078-0432.CCR-08-0432; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Martinet L, 2011, CANCER RES, V71, P5678, DOI 10.1158/0008-5472.CAN-11-0431; McAllister SS, 2010, J CLIN ONCOL, V28, P4022, DOI 10.1200/JCO.2010.28.4257; McColl BK, 2007, FASEB J, V21, P1088, DOI 10.1096/fj.06-7060com; Moeller BJ, 2007, CANCER METAST REV, V26, P241, DOI 10.1007/s10555-007-9056-0; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Nagy JA, 2006, LAB INVEST, V86, P767, DOI 10.1038/labinvest.3700436; Nagy JA, 2012, CLIN EXP METASTAS, V29, P657, DOI 10.1007/s10585-012-9500-6; Nagy JA, 2010, SEMIN THROMB HEMOST, V36, P321, DOI 10.1055/s-0030-1253454; Nolan DJ, 2007, GENE DEV, V21, P1546, DOI 10.1101/gad.436307; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; PAKU S, 1991, LAB INVEST, V65, P334; Patenaude A, 2010, MICROVASC RES, V79, P217, DOI 10.1016/j.mvr.2010.01.007; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Peinado H, 2011, SEMIN CANCER BIOL, V21, P139, DOI 10.1016/j.semcancer.2011.01.002; Peters BA, 2005, NAT MED, V11, P261, DOI 10.1038/nm1200; Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013; Pezzolo A, 2007, J CLIN ONCOL, V25, P376, DOI 10.1200/JCO.2006.09.0696; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Potenta S, 2008, BRIT J CANCER, V99, P1375, DOI 10.1038/sj.bjc.6604662; Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621; Purhonen S, 2008, P NATL ACAD SCI USA, V105, P6620, DOI 10.1073/pnas.0710516105; Qian CN, 2007, CELL CYCLE, V6, P514, DOI 10.4161/cc.6.5.3931; Qian CN, 2006, CANCER RES, V66, P10365, DOI 10.1158/0008-5472.CAN-06-2977; Qian CN, 2013, NAT REV UROL, V10, P300, DOI 10.1038/nrurol.2013.26; Qin L, 2012, ADV CANCER RES, V113, P191, DOI 10.1016/B978-0-12-394280-7.00006-3; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Raza A, 2010, AM J HEMATOL, V85, P593, DOI 10.1002/ajh.21745; Reyes M, 2002, J CLIN INVEST, V109, P337, DOI 10.1172/JCI200214327; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Ruddell A, 2008, ONCOGENE, V27, P3145, DOI 10.1038/sj.onc.1210973; Ruddell A, 2003, AM J PATHOL, V163, P2233, DOI 10.1016/S0002-9440(10)63581-X; Rybak SM, 2003, CANCER RES, V63, P2812; Schiffer D, 1999, J NEURO-ONCOL, V44, P99, DOI 10.1023/A:1006206920822; Schrama D, 2001, IMMUNITY, V14, P111, DOI 10.1016/S1074-7613(09)00094-6; Seaman S, 2007, CANCER CELL, V11, P539, DOI 10.1016/j.ccr.2007.04.017; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Shaked Y, 2005, CANCER CELL, V7, P101, DOI 10.1016/j.ccr.2004.11.023; Shaked Y, 2008, CANCER CELL, V14, P263, DOI 10.1016/j.ccr.2008.08.001; Shaked Y, 2006, SCIENCE, V313, P1785, DOI 10.1126/science.1127592; Shen RL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001652; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Sleeman JP, 2007, CLIN EXP METASTAS, V24, P707, DOI 10.1007/s10585-007-9122-6; Sleeman JP, 2011, INT J CANCER, V128, P2511, DOI 10.1002/ijc.26027; Soderberg KA, 2005, P NATL ACAD SCI USA, V102, P16315, DOI 10.1073/pnas.0506190102; Song S, 2005, NAT CELL BIOL, V7, P870, DOI 10.1038/ncb1288; SRIVASTAVA A, 1988, AM J PATHOL, V133, P419; Stacker SA, 1999, J BIOL CHEM, V274, P32127, DOI 10.1074/jbc.274.45.32127; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Straume O, 2002, CANCER RES, V62, P6808; Stubbs M, 2000, MOL MED TODAY, V6, P15, DOI 10.1016/S1357-4310(99)01615-9; Sullivan R, 2007, CANCER METAST REV, V26, P319, DOI 10.1007/s10555-007-9062-2; Sundberg C, 2001, AM J PATHOL, V158, P1145, DOI 10.1016/S0002-9440(10)64062-X; Tammela T, 2007, CIRC RES, V100, P1468, DOI 10.1161/01.RES.0000269043.51272.6d; Van den Eynden GG, 2006, BRIT J CANCER, V95, P1362, DOI 10.1038/sj.bjc.6603443; Van den Eynden GG, 2005, BRIT J CANCER, V93, P1128, DOI 10.1038/sj.bjc.6602828; Van der Auwera I, 2005, CLIN CANCER RES, V11, P7637, DOI 10.1158/1078-0432.CCR-05-1142; van der Schaft DWJ, 2007, CANCER LETT, V254, P128, DOI 10.1016/j.canlet.2007.03.001; von Baumgarten L, 2011, CLIN CANCER RES, V17, P6192, DOI 10.1158/1078-0432.CCR-10-1868; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537; Wels J, 2008, GENE DEV, V22, P559, DOI 10.1101/gad.1636908; Wirzenius M, 2007, J EXP MED, V204, P1431, DOI 10.1084/jem.20062642; Woolard J, 2009, MICROCIRCULATION, V16, P572, DOI 10.1080/10739680902997333; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Yoder MI, 2009, CURR OPIN HEMATOL, V16, P269, DOI 10.1097/MOH.0b013e32832bbcab; Yu JL, 2003, BREAST CANCER RES, V5, P83, DOI 10.1186/bcr573; Yu JL, 2002, CANCER RES, V62, P1838; Yu P, 2004, NAT IMMUNOL, V5, P141, DOI 10.1038/ni1029; Zhang LL, 2006, CANCER RES, V66, P5696, DOI 10.1158/0008-5472.CAN-05-3876; Zhao YC, 2012, MED ONCOL, V29, P2594, DOI 10.1007/s12032-012-0205-0	174	106	113	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3496	3505		10.1038/onc.2013.304	http://dx.doi.org/10.1038/onc.2013.304			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23912450				2022-12-17	WOS:000338941100002
J	Beauchamp, EM; Platanias, LC				Beauchamp, E. M.; Platanias, L. C.			The evolution of the TOR pathway and its role in cancer	ONCOGENE			English	Review						mTOR; cancer; leukemia	MESSENGER-RNA TRANSLATION; PHOSPHATIDYLINOSITOL KINASE HOMOLOG; SMALL-MOLECULE INHIBITORS; TUBEROUS SCLEROSIS GENE; RAPAMYCIN COMPLEX 2; RICH AKT SUBSTRATE; EXTENDS LIFE-SPAN; MAMMALIAN TARGET; MYELOID-LEUKEMIA; CELL-GROWTH	The target of rapamycin (TOR) pathway is highly conserved among eukaryotes and has evolved to couple nutrient sensing to cellular growth. TOR is found in two distinct signaling complexes in cells, TOR complex 1 (TORC1) and TOR complex 2 (TORC2). These complexes are differentially regulated and act as effectors for the generation of signals that drive diverse cellular processes such as growth, proliferation, protein synthesis, rearrangement of the cytoskeleton, autophagy, metabolism and survival. Mammalian TOR (mTOR) is very important for development in embryos, while in adult organisms it is linked to aging and lifespan effects. In humans, the mTOR pathway is implicated in the tumorigenesis of multiple cancer types and its deregulation is associated with familial cancer syndromes. Because of its high biological relevance, different therapeutic strategies have been developed to target this signaling cascade, resulting in the emergence of unique pharmacological inhibitors that are either already approved for use in clinical oncology or currently under preclinical or clinical development. Multimodal treatment strategies that simultaneously target multiple nodes of the pathway and/or negative feedback regulatory loops may ultimately provide the best therapeutic advantage in targeting this pathway for the treatment of malignancies.	[Beauchamp, E. M.; Platanias, L. C.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Chicago, IL 60611 USA; [Platanias, L. C.] Jesse Brown VA Med Ctr, Dept Med, Chicago, IL USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Platanias, LC (corresponding author), Robert H Lurie Comprehens Canc Ctr, 303 East Super St,Lurie 3-107, Chicago, IL 60611 USA.	l-platanias@northwestern.edu						Agarwal NK, 2012, ONCOGENE, DOI [10.1038/onc.2012.287, DOI 10.1038/0NC.2012.287)]; Aimbetov R, 2012, ONCOGENE, V31, P2115, DOI 10.1038/onc.2011.404; Altman JK, 2011, CLIN CANCER RES, V17, P4378, DOI 10.1158/1078-0432.CCR-10-2285; Altman JK, 2010, MOL PHARMACOL, V78, P778, DOI 10.1124/mol.110.064642; Avruch J, 2009, AM J PHYSIOL-ENDOC M, V296, pE592, DOI 10.1152/ajpendo.90645.2008; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Baryawno N, 2010, CANCER RES, V70, P266, DOI 10.1158/0008-5472.CAN-09-0578; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101; Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Brachmann SM, 2009, P NATL ACAD SCI USA, V106, P22299, DOI 10.1073/pnas.0905152106; Bray K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041831; Broderick DK, 2004, CANCER RES, V64, P5048, DOI 10.1158/0008-5472.CAN-04-1170; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Buck E, 2008, CANCER RES, V68, P8322, DOI 10.1158/0008-5472.CAN-07-6720; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Buonamici S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001599; Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200; Camposano SE, 2009, ANN HUM GENET, V73, P141, DOI 10.1111/j.1469-1809.2008.00496.x; Carayol N, 2010, P NATL ACAD SCI USA, V107, P12469, DOI 10.1073/pnas.1005114107; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Chen B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042598; Chen CC, 2010, DEV CELL, V18, P592, DOI 10.1016/j.devcel.2010.03.008; Chen CH, 2011, J BIOL CHEM, V286, P40386, DOI 10.1074/jbc.M111.282590; Chen CH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001731; CHEN YQ, 1994, BIOCHEM BIOPH RES CO, V203, P1, DOI 10.1006/bbrc.1994.2140; Chiarini F, 2009, CANCER RES, V69, P3520, DOI 10.1158/0008-5472.CAN-08-4884; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105; Dibble CC, 2012, MOL CELL, V47, P535, DOI 10.1016/j.molcel.2012.06.009; Dibble CC, 2009, MOL CELL BIOL, V29, P5657, DOI 10.1128/MCB.00735-09; Egan DF, 2011, AUTOPHAGY, V7, P645, DOI 10.4161/auto.7.6.15123; Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120; Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149; Fonseca BD, 2007, J BIOL CHEM, V282, P24514, DOI 10.1074/jbc.M704406200; Frias MA, 2006, CURR BIOL, V16, P1865, DOI 10.1016/j.cub.2006.08.001; Galanis E, 2005, J CLIN ONCOL, V23, P5294, DOI 10.1200/JCO.2005.23.622; Gangloff YG, 2004, MOL CELL BIOL, V24, P9508, DOI 10.1128/MCB.24.21.9508-9516.2004; Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668; Gentzler RD, 2012, EXPERT OPIN THER TAR, V16, P481, DOI 10.1517/14728222.2012.677439; Glidden EJ, 2012, J BIOL CHEM, V287, P581, DOI 10.1074/jbc.M111.304337; GREEN AJ, 1994, HUM MOL GENET, V3, P1833, DOI 10.1093/hmg/3.10.1833; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Guertin DA, 2009, CANCER CELL, V15, P148, DOI 10.1016/j.ccr.2008.12.017; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hambardzumyan D, 2008, GENE DEV, V22, P436, DOI 10.1101/gad.1627008; Hansen M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040024; Hansen M, 2007, WESTERN HUM REV, V61, P6; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Helliwell SB, 1998, GENETICS, V148, P99; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hentges KE, 2001, P NATL ACAD SCI USA, V98, P13796, DOI 10.1073/pnas.241184198; Hess G, 2009, J CLIN ONCOL, V27, P3822, DOI 10.1200/JCO.2008.20.7977; Hietakangas V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-282; Hong-Brown LQ, 2010, J CELL BIOCHEM, V109, P1172, DOI 10.1002/jcb.22496; Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498; Huang JX, 2009, CANCER RES, V69, P6107, DOI 10.1158/0008-5472.CAN-09-0975; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Inoki K, 2012, ANNU REV PHARMACOL, V52, P381, DOI 10.1146/annurev-pharmtox-010611-134537; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Janes MR, 2010, NAT MED, V16, P205, DOI 10.1038/nm.2091; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jia K, 2004, DEVELOPMENT, V131, P3897, DOI 10.1242/dev.01255; Johnstone CN, 2005, GENOMICS, V85, P338, DOI 10.1016/j.ygeno.2004.11.002; Jones DTW, 2012, NATURE, V488, P100, DOI 10.1038/nature11284; Jones KT, 2009, PLOS BIOL, V7, P604, DOI 10.1371/journal.pbio.1000060; Juhasz G, 2008, J CELL BIOL, V181, P655, DOI 10.1083/jcb.200712051; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; Kapahi P, 2010, CELL METAB, V11, P453, DOI 10.1016/j.cmet.2010.05.001; Kaur S, 2008, P NATL ACAD SCI USA, V105, P4808, DOI 10.1073/pnas.0710907105; Kaur S, 2012, P NATL ACAD SCI USA, V109, P7723, DOI 10.1073/pnas.1118122109; Khokhar NZ, 2011, CURR OPIN ONCOL, V23, P578, DOI 10.1097/CCO.0b013e32834b892d; Kim E, 2008, NAT CELL BIOL, V10, P935, DOI 10.1038/ncb1753; Kobayashi T, 1999, CANCER RES, V59, P1206; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Kovacina KS, 2003, J BIOL CHEM, V278, P10189, DOI 10.1074/jbc.M210837200; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Laplante M, 2012, CELL METAB, V16, P202, DOI 10.1016/j.cmet.2012.07.008; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Laplante M, 2009, CURR BIOL, V19, pR1046, DOI 10.1016/j.cub.2009.09.058; Lee JH, 2010, SCIENCE, V327, P1223, DOI 10.1126/science.1182228; Lekmine F, 2003, J BIOL CHEM, V278, P27772, DOI 10.1074/jbc.M301364200; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; Lindmo K, 2006, J CELL SCI, V119, P605, DOI 10.1242/jcs.02855; Liu TJ, 2009, MOL CANCER THER, V8, P2204, DOI 10.1158/1535-7163.MCT-09-0160; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Long XM, 2002, CURR BIOL, V12, P1448, DOI 10.1016/S0960-9822(02)01091-6; Ly C, 2003, CANCER RES, V63, P5716; Lynch M, 2004, J BIOL CHEM, V279, P3327, DOI 10.1074/jbc.M310872200; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Mahalingam M, 2001, PROG MOLEC, V27, P131; Masri J, 2007, CANCER RES, V67, P11712, DOI 10.1158/0008-5472.CAN-07-2223; Mavrakis KJ, 2008, GENE DEV, V22, P2178, DOI 10.1101/gad.1690808; Max X, 2008, CELL, V133, P303, DOI 10.1016/j.cell.2008.02.031; Mayerhofer M, 2005, FASEB J, V19, P960, DOI 10.1096/fj.04-1973fje; Menon S, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002739; Mirzoeva OK, 2009, CANCER RES, V69, P565, DOI 10.1158/0008-5472.CAN-08-3389; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9; Murakami M, 2004, MOL CELL BIOL, V24, P6710, DOI 10.1128/mcb.24.15.6710-6718.2004; NELLIST M, 1993, CELL, V75, P1305; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; Nobukuni T, 2007, CURR OPIN CELL BIOL, V19, P135, DOI 10.1016/j.ceb.2007.02.019; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Oldham S, 2000, GENE DEV, V14, P2689, DOI 10.1101/gad.845700; Oshiro N, 2007, J BIOL CHEM, V282, P20329, DOI 10.1074/jbc.M702636200; Pan KZ, 2007, AGING CELL, V6, P111, DOI 10.1111/j.1474-9726.2006.00266.x; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pearce LR, 2011, BIOCHEM J, V436, P169, DOI 10.1042/BJ20102103; Pei L, 2011, MOL MED REP, V4, P817, DOI 10.3892/mmr.2011.503; Pei YX, 2012, CANCER CELL, V21, P155, DOI 10.1016/j.ccr.2011.12.021; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Petroulakis E, 2009, CANCER CELL, V16, P439, DOI 10.1016/j.ccr.2009.09.025; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Pugh TJ, 2012, NATURE, V488, P106, DOI 10.1038/nature11329; Pyronnet S, 2000, BIOCHEM PHARMACOL, V60, P1237, DOI 10.1016/S0006-2952(00)00429-9; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Reinke A, 2004, J BIOL CHEM, V279, P14752, DOI 10.1074/jbc.M313062200; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; SABATINI DM, 1995, J BIOL CHEM, V270, P20875, DOI 10.1074/jbc.270.36.20875; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Saci A, 2011, MOL CELL, V42, P50, DOI 10.1016/j.molcel.2011.03.017; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sanchez-Cespedes M, 2011, FAM CANCER, V10, P447, DOI 10.1007/s10689-011-9443-0; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; Schroder W, 2004, GENE, V339, P17, DOI 10.1016/j.gene.2004.07.001; Sehgal SN, 2003, TRANSPLANT P, V35, p7S, DOI 10.1016/S0041-1345(03)00211-2; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Shiota C, 2006, DEV CELL, V11, P583, DOI 10.1016/j.devcel.2006.08.013; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Soukas AA, 2009, GENE DEV, V23, P496, DOI 10.1101/gad.1775409; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; Thedieck K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001217; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Urban J, 2007, MOL CELL, V26, P663, DOI 10.1016/j.molcel.2007.04.020; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang LF, 2007, J BIOL CHEM, V282, P20036, DOI 10.1074/jbc.M702376200; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Wang XR, 2007, MOL CELL BIOL, V27, P7405, DOI 10.1128/MCB.00760-07; Wang Y, 2012, CANCER CELL, V21, P374, DOI 10.1016/j.ccr.2011.12.028; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; Woo SY, 2007, J BIOL CHEM, V282, P25604, DOI 10.1074/jbc.M704343200; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Wu X, 2012, NATURE, V482, P529, DOI 10.1038/nature10825; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Xu Q, 2003, BLOOD, V102, P972, DOI 10.1182/blood-2002-11-3429; Yang L, 2008, CLIN CANCER RES, V14, P3993, DOI 10.1158/1078-0432.CCR-07-4152; Yang Q, 2006, P NATL ACAD SCI USA, V103, P6811, DOI 10.1073/pnas.0602282103; Yang Q, 2006, GENE DEV, V20, P2820, DOI 10.1101/gad.1461206; Yao JC, 2011, NEW ENGL J MED, V364, P514, DOI 10.1056/NEJMoa1009290; Yen CH, 2012, MOL MED, V18, P286, DOI 10.2119/molmed.2011.00331; Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zhao JH, 2008, AUTOPHAGY, V4, P378, DOI 10.4161/auto.5633; Zhao YC, 2011, MOL CELL, V44, P304, DOI 10.1016/j.molcel.2011.08.029; Zid BM, 2009, CELL, V139, P149, DOI 10.1016/j.cell.2009.07.034; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	195	106	108	1	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					3923	3932		10.1038/onc.2012.567	http://dx.doi.org/10.1038/onc.2012.567			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	23246968				2022-12-17	WOS:000323748100001
J	Shrestha, Y; Schafer, EJ; Boehm, JS; Thomas, SR; He, F; Du, J; Wang, S; Barretina, J; Weir, BA; Zhao, JJ; Polyak, K; Golub, TR; Beroukhim, R; Hahn, WC				Shrestha, Y.; Schafer, E. J.; Boehm, J. S.; Thomas, S. R.; He, F.; Du, J.; Wang, S.; Barretina, J.; Weir, B. A.; Zhao, J. J.; Polyak, K.; Golub, T. R.; Beroukhim, R.; Hahn, W. C.			PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling	ONCOGENE			English	Article						PAK1; transformation; MAPK; MET; merlin	COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; ANTITUMOR-ACTIVITY; OVARIAN-CARCINOMA; TYROSINE KINASE; PROTEIN-KINASE; EGF RECEPTOR; IN-VIVO; PATHWAY; CELLS	Activating mutations in the RAS family or BRAF frequently occur in many types of human cancers but are rarely detected in breast tumors. However, activation of the RAS-RAF-MEK-ERK MAPK pathway is commonly observed in human breast cancers, suggesting that other genetic alterations lead to activation of this signaling pathway. To identify breast cancer oncogenes that activate the MAPK pathway, we screened a library of human kinases for their ability to induce anchorage-independent growth in a derivative of immortalized human mammary epithelial cells (HMLE). We identified p21-activated kinase 1 (PAK1) as a kinase that permitted HMLE cells to form anchorage-independent colonies. PAK1 is amplified in several human cancer types, including 30-33% of breast tumor samples and cancer cell lines. The kinase activity of PAK1 is necessary for PAK1-induced transformation. Moreover, we show that PAK1 simultaneously activates MAPK and MET signaling; the latter via inhibition of merlin. Disruption of these activities inhibits PAK1-driven anchorage-independent growth. These observations establish PAK1 amplification as an alternative mechanism for MAPK activation in human breast cancer and credential PAK1 as a breast cancer oncogene that coordinately regulates multiple signaling pathways, the cooperation of which leads to malignant transformation. Oncogene (2012) 31, 3397-3408; doi:10.1038/onc.2011.515; published online 21 November 2011	[Shrestha, Y.; Schafer, E. J.; Thomas, S. R.; Barretina, J.; Weir, B. A.; Polyak, K.; Beroukhim, R.; Hahn, W. C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Shrestha, Y.; Schafer, E. J.; Boehm, J. S.; Thomas, S. R.; He, F.; Du, J.; Barretina, J.; Weir, B. A.; Golub, T. R.; Beroukhim, R.; Hahn, W. C.] Broad Inst Harvard & MIT, Cambridge, MA USA; [He, F.; Du, J.; Golub, T. R.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA; [Wang, S.] Dana Farber Harvard Canc Ctr, Cytogenet Core Facil, Boston, MA USA; [Barretina, J.; Polyak, K.; Golub, T. R.; Hahn, W. C.] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02215 USA; [Zhao, J. J.; Beroukhim, R.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA; [Polyak, K.; Beroukhim, R.; Hahn, W. C.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Polyak, K.; Beroukhim, R.; Hahn, W. C.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Hahn, WC (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Dana 1538, Boston, MA 02215 USA.	William_Hahn@dfci.harvard.edu	; Barretina, Jordi/A-7192-2013	Boehm, Jesse/0000-0002-6795-6336; Barretina, Jordi/0000-0002-3478-4080	Department of Defense [W81XWH-08-1-0767]; US National Cancer Institute [R33 CA128625, R01 CA130988]; Cancer Center Support Grant [NIH 5 P30 CA06516]; NATIONAL CANCER INSTITUTE [RC2CA148268, R33CA128625, R01CA130988, P30CA006516] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); US National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Nicole A Spardy, Christine L Nguyen and Yaara C Zwang for critical reading of the manuscript. We also thank the Dana-Farber/Harvard Cancer Center Cytogenetics Core for their assistance with fluorescence in situ hybridization studies. This work was supported in part by a Department of Defense Breast Cancer Research Program Pre-doctoral Fellowship (W81XWH-08-1-0767, YS), grants from the US National Cancer Institute (R33 CA128625 and R01 CA130988, WCH) and a Cancer Center Support Grant no. NIH 5 P30 CA06516 (Cytogenetics Core).	Appledorn DM, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-13; Arias-Romero LE, 2010, ONCOGENE, V29, P5839, DOI 10.1038/onc.2010.318; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Boehm JS, 2005, MOL CELL BIOL, V25, P6464, DOI 10.1128/MCB.25.15.6464-6474.2005; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; Bostner J, 2007, ONCOGENE, V26, P6997, DOI 10.1038/sj.onc.1210506; Brown LA, 2008, GENE CHROMOSOME CANC, V47, P481, DOI 10.1002/gcc.20549; Chattopadhyay I, 2010, MUTAT RES-GEN TOX EN, V696, P130, DOI 10.1016/j.mrgentox.2010.01.001; Christensen JG, 2003, CANCER RES, V63, P7345; Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj.onc.1205302; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Du JY, 2009, NAT BIOTECHNOL, V27, P77, DOI 10.1038/nbt.1513; Dummler B, 2009, CANCER METAST REV, V28, P51, DOI 10.1007/s10555-008-9168-1; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Freihoff D, 1999, BRIT J CANCER, V79, P754, DOI 10.1038/sj.bjc.6690121; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Kim DH, 2006, ONCOL REP, V16, P1053; Kim SY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008979; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Knoll JH, 2005, CURR PROTOC HUM GENE; Lambros MBK, 2005, J PATHOL, V205, P29, DOI 10.1002/path.1681; Lau KS, 2009, MOL CELLS, V28, P315, DOI 10.1007/s10059-009-0143-7; McClatchey AI, 2007, ANNU REV PATHOL-MECH, V2, P191, DOI 10.1146/annurev.pathol.2.010506.091940; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Miron A, 2010, CANCER RES, V70, P5674, DOI 10.1158/0008-5472.CAN-08-2660; Mirzoeva OK, 2009, CANCER RES, V69, P565, DOI 10.1158/0008-5472.CAN-08-3389; Miyakis S, 1998, BIOCHEM BIOPH RES CO, V251, P609, DOI 10.1006/bbrc.1998.9527; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Scheid MP, 2001, J MAMMARY GLAND BIOL, V6, P83, DOI 10.1023/A:1009520616247; Schraml P, 2003, AM J PATHOL, V163, P985, DOI 10.1016/S0002-9440(10)63458-X; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sos ML, 2009, P NATL ACAD SCI USA, V106, P18351, DOI 10.1073/pnas.0907325106; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Tu HF, 2011, ORAL ONCOL, V47, P211, DOI 10.1016/j.oraloncology.2011.01.003; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Weinman EJ, 2006, ANNU REV PHYSIOL, V68, P491, DOI 10.1146/annurev.physiol.68.040104.131050; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Zang MW, 2008, J BIOL CHEM, V283, P31429, DOI 10.1074/jbc.M802855200; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200	60	106	113	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	29					3397	3408		10.1038/onc.2011.515	http://dx.doi.org/10.1038/onc.2011.515			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	976FN	22105362	Green Accepted, Green Submitted			2022-12-17	WOS:000306566400001
J	Niu, X; Zhang, T; Liao, L; Zhou, L; Lindner, DJ; Zhou, M; Rini, B; Yan, Q; Yang, H				Niu, X.; Zhang, T.; Liao, L.; Zhou, L.; Lindner, D. J.; Zhou, M.; Rini, B.; Yan, Q.; Yang, H.			The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C	ONCOGENE			English	Article						von Hippel-Lindau; hypoxia-inducible factor; JARID1C/KDM5C/SMCX; trimethyl H3K4; gene expression	HYPOXIA-INDUCIBLE-FACTOR; RENAL-CELL CARCINOMA; HIF-ALPHA; INHIBITION; STABILIZATION; INACTIVATION; METHYLATION; ACTIVATION; COMPONENT; REVEALS	In clear-cell renal cell carcinoma (ccRCC), inactivation of the tumor suppressor von Hippel-Lindau (VHL) occurs in the majority of the tumors and is causal for the pathogenesis of ccRCC. Recently, a large-scale genomic sequencing study of ccRCC tumors revealed that enzymes that regulate histone H3 lysine 4 trimethylation (H3K4Me3), such as JARID1C/KDM5C/SMCX and MLL2, were mutated in ccRCC tumors, suggesting that H3K4Me3 might have an important role in regulating gene expression and tumorigenesis. In this study we report that in VHL-deficient ccRCC cells, the overall H3K4Me3 levels were significantly lower than that of VHL+/+ counterparts. Furthermore, this was hypoxia-inducible factor (HIF) dependent, as depletion of HIF subunits by small hairpin RNA in VHL-deficient ccRCC cells restored H3K4Me3 levels. In addition, we demonstrated that only loss of JARID1C, not JARID1A or JARID1B, abolished the difference of H3K4Me3 levels between VHL-/- and VHL+/+ cells, and JARID1C displayed HIF-dependent expression pattern. JARID1C in VHL-/- cells was responsible for the suppression of HIF-responsive genes insulin-like growth factor-binding protein 3 (IGFBP3), DNAJC12, COL6A1, growth and differentiation factor 15 (GDF15) and density-enhanced phosphatase 1. Consistent with these findings, the H3K4Me3 levels at the promoters of IGFBP3, DNAJC12, COL6A1 and GDF15 were lower in VHL-/- cells than in VHL+/+ cells, and the differences disappeared after JARID1C depletion. Although HIF2 alpha is an oncogene in ccRCC, some of its targets might have tumor suppressive activity. Consistent with this, knockdown of JARID1C in 786-O VHL-/- ccRCC cells significantly enhanced tumor growth in a xenograft model, suggesting that JARID1C is tumor suppressive and its mutations are tumor promoting in ccRCC. Thus, VHL inactivation decreases H3K4Me3 levels through JARID1C, which alters gene expression and suppresses tumor growth. Oncogene (2012) 31, 776-786; doi:10.1038/onc.2011.266; published online 4 July 2011	[Niu, X.; Zhang, T.; Liao, L.; Zhou, L.; Yang, H.] Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; [Lindner, D. J.; Rini, B.] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44195 USA; [Zhou, M.] Cleveland Clin, Dept Pathol, Cleveland, OH 44195 USA; [Yan, Q.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Yale University	Yang, H (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Canc Biol, NB-40,9500 Euclid Ave, Cleveland, OH 44195 USA.	yangh2@ccf.org	Zhou, Liang/F-7201-2014; Lindner, Daniel/ABB-5440-2020; Zhou, Liang/N-8220-2013; Yan, Qin/E-8893-2012	Yan, Qin/0000-0003-4077-453X	American Cancer Society; Cleveland Clinic; V scholar Award; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024989] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); Cleveland Clinic; V scholar Award; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	The 786-O and RCC4 cell lines were kind gifts from Dr William Kaelin Jr. This work was supported by American Cancer Society Pilot Award (to HY) and the seed fund from Cleveland Clinic to HY. QY is a Breast Cancer Alliance Young Investigator who was also supported by V scholar Award. We thank Dr Donal Luse for his critical reading of the manuscript.	Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; Beyer S, 2008, J BIOL CHEM, V283, P36542, DOI 10.1074/jbc.M804578200; Cheung I, 2010, P NATL ACAD SCI USA, V107, P8824, DOI 10.1073/pnas.1001702107; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Isaacs JS, 2004, J BIOL CHEM, V279, P16128, DOI 10.1074/jbc.M313342200; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwase S, 2007, CELL, V128, P1077, DOI 10.1016/j.cell.2007.02.017; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Krieg AJ, 2010, MOL CELL BIOL, V30, P344, DOI 10.1128/MCB.00444-09; Li N, 2008, P NATL ACAD SCI USA, V105, P17055, DOI 10.1073/pnas.0807765105; Linehan WM, 2004, CLIN CANCER RES, V10, p6282S, DOI 10.1158/1078-0432.CCR-050013; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mersman DP, 2009, GENE DEV, V23, P951, DOI 10.1101/gad.1769209; Mikhaylova O, 2008, MOL CELL BIOL, V28, P2701, DOI 10.1128/MCB.01231-07; Nakamura E, 2006, AM J PATHOL, V168, P574, DOI 10.2353/ajpath.2006.050867; Negrotto S, 2011, CANCER RES, V71, P1431, DOI 10.1158/0008-5472.CAN-10-2422; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238; Rini BI, 2005, BJU INT, V96, P286, DOI 10.1111/j.1464-410X.2005.05616.x; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Schraml P, 2009, MODERN PATHOL, V22, P31, DOI 10.1038/modpathol.2008.132; Semenza G.L., 2007, SCI STKE, V2007, pcm8; Semenza GL, 1997, KIDNEY INT, V51, P553, DOI 10.1038/ki.1997.77; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Tahiliani M, 2007, NATURE, V447, P601, DOI 10.1038/nature05823; Thoma CR, 2009, NAT CELL BIOL, V11, P994, DOI 10.1038/ncb1912; Wellmann S, 2008, BIOCHEM BIOPH RES CO, V372, P892, DOI 10.1016/j.bbrc.2008.05.150; Xia XB, 2009, P NATL ACAD SCI USA, V106, P4260, DOI 10.1073/pnas.0810067106; Yan Q, 2007, MOL CELL BIOL, V27, P2092, DOI 10.1128/MCB.01514-06; Yang H, 2007, MOL CELL, V28, P15, DOI 10.1016/j.molcel.2007.09.010; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001; Zhou X, 2010, CANCER RES, V70, P4214, DOI 10.1158/0008-5472.CAN-09-2942; Zimmer M, 2004, MOL CANCER RES, V2, P89	46	106	108	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	6					776	786		10.1038/onc.2011.266	http://dx.doi.org/10.1038/onc.2011.266			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21725364	Green Accepted			2022-12-17	WOS:000300222100010
J	Meng, L; Gabai, VL; Sherman, MY				Meng, L.; Gabai, V. L.; Sherman, M. Y.			Heat-shock transcription factor HSF1 has a critical role in human epidermal growth factor receptor-2-induced cellular transformation and tumorigenesis	ONCOGENE			English	Article						HSF1; HER2; growth arrest; senescence; p21; survivin	CANCER-CELLS; MOLECULAR CHAPERONES; SENESCENCE PATHWAYS; PROTEIN HSP72; GENE; ONCOGENESIS; EXPRESSION; APOPTOSIS; SURVIVIN; DEATH	The heat-shock transcription factor HSF1 was recently shown to have a key role in the development of tumors associated with activation of Ras or inactivation of p53. Here, we show that HSF1 is required for the cell transformation and tumorigenesis induced by the human epidermal growth factor receptor-2 (HER2) oncogene responsible for aggressive breast tumors. Upon expression of HER2, untransformed human mammary epithelial MCF-10A cells underwent neoplastic transformation, formed foci in culture and tumors in nude mouse xenografts. However, expression of HER2 in MCF-10A cells with knockdown of HSF1 did not cause either foci formation or tumor growth in xenografts. The antitumorigenic effect of downregulation of HSF1 was associated with HER2-induced accumulation of the cyclin-dependent kinase inhibitor p21 and decrease in the mitotic regulator survivin, which resulted in growth inhibition and cell senescence. In fact, either knockout of p21 or overexpression of survivin alleviated these effects of HSF1 knockdown. The proliferation of certain human HER2-positive breast cancer lines also requires HSF1, as its knockdown led to upregulation of p21 and/or decrease in survivin, precipitating growth arrest. Similar effects were observed with a small-molecular-weight inhibitor of the heat-shock response NZ28. The effects of HSF1 knockdown on the growth arrest and senescence of HER2-expressing cells were associated with downregulation of heat-shock protein (Hsp) 72 and Hsp27. Therefore, HSF1 is critical for proliferation of HER2-expressing cells, most likely because it maintains the levels of HSPs, which in turn control regulators of senescence p21 and survivin. Oncogene (2010) 29, 5204-5213; doi:10.1038/onc.2010.277; published online 12 July 2010	[Meng, L.; Gabai, V. L.; Sherman, M. Y.] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Sherman, MY (corresponding author), Boston Univ, Sch Med, Dept Biochem, 72 E Concord St,K-323, Boston, MA 02118 USA.	gabai@bu.edu; sherma1@bu.edu	Gabai, Vladimir L/I-1650-2013	Gabai, Vladimir L/0000-0003-4505-4718; Sherman, Michael/0000-0003-3345-073X	National Institute of Health [CA081244]; NATIONAL CANCER INSTITUTE [R01CA081244] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Institute of Health CA081244. We thank Dr B Park and Dr C Spangenberg for their kind supply of MCF-10A cells and HER2-overexpressing retroviral vector.	Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Bachman KE, 2004, CANCER BIOL THER, V3, P221, DOI 10.4161/cbt.3.2.666; Cahill CM, 1996, J BIOL CHEM, V271, P24874; Cahill CM, 1997, ADV EXP MED BIOL, V400, P625; Cai L, 2003, CELL RES, V13, P93, DOI 10.1038/sj.cr.7290154; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; Gabai VL, 2009, MOL CELL BIOL, V29, P559, DOI 10.1128/MCB.01041-08; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Khaleque M, 2008, ONCOGENE, V27, P1886, DOI 10.1038/sj.onc.1210834; Khaleque MA, 2005, ONCOGENE, V24, P6564, DOI 10.1038/sj.onc.1208798; Lacroix M, 2006, ENDOCR-RELAT CANCER, V13, P293, DOI 10.1677/erc.1.01172; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Min JN, 2007, ONCOGENE, V26, P5086, DOI 10.1038/sj.onc.1210317; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; Mosser DD, 2004, ONCOGENE, V23, P2907, DOI 10.1038/sj.onc.1207529; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Roninson IB, 2003, CANCER RES, V63, P2705; Singh IS, 2002, J BIOL CHEM, V277, P4981, DOI 10.1074/jbc.M108154200; Singh IS, 2000, J BIOL CHEM, V275, P9841, DOI 10.1074/jbc.275.13.9841; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; Trost TM, 2005, CANCER RES, V65, P840; Wu GJ, 2005, CANCER RES, V65, P758; Xie Y, 2002, J BIOL CHEM, V277, P11802, DOI 10.1074/jbc.M109296200; Xie Y, 2002, BIOCHEM BIOPH RES CO, V291, P1071, DOI 10.1006/bbrc.2002.6562; Yaglom JA, 2007, CANCER RES, V67, P2373, DOI 10.1158/0008-5472.CAN-06-3796; Zaarur N, 2006, CANCER RES, V66, P1783, DOI 10.1158/0008-5472.CAN-05-3692	31	106	107	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	37					5204	5213		10.1038/onc.2010.277	http://dx.doi.org/10.1038/onc.2010.277			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650QZ	20622894	Green Accepted			2022-12-17	WOS:000281867200009
J	White-Gilbertson, S; Mullen, T; Senkal, C; Lu, P; Ogretmen, B; Obeid, L; Voelkel-Johnson, C				White-Gilbertson, S.; Mullen, T.; Senkal, C.; Lu, P.; Ogretmen, B.; Obeid, L.; Voelkel-Johnson, C.			Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells	ONCOGENE			English	Article						TRAIL; ceramide; apoptosis; ceramide synthase; longevity assurance homologue	LONGEVITY ASSURANCE GENE-1; INDUCED APOPTOSIS; FAMILY-MEMBERS; HUMAN HEAD; RESISTANCE; DEATH; METASTASIS; ACTIVATION; GROWTH; IDENTIFICATION	We have previously shown that the death receptor ligand TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) induces an increase of intracellular C-16-ceramide in sensitive SW480 but not in resistant SW620 cells. Resistance in SW620 cells was overcome by exogenous ceramide, leading us to propose that defective ceramide signaling contributes to TRAIL resistance. In this study we found that the increase in C16-ceramide in SW480 cells was inhibited by fumonisin B1, an inhibitor of ceramide synthases (CerS). Protein analysis revealed that TRAIL-resistant SW620 cells expressed lower levels of ceramide synthase 6 (CerS6, also known as longevity assurance homologue 6), which prompted us to investigate the effect of CerS6 modulation on TRAIL phenotype. RNAi against CerS6 resulted in a specific and significant decrease of the C-16-ceramide species, which was sufficient to inhibit TRAIL-induced apoptosis. In cells with decreased levels of CerS6, caspase-3 was activated but failed to translocate into the nucleus. CerS6 localized primarily to the perinuclear region, suggesting this enzyme may be important in regulation of nuclear permeability. Moderate elevation in CerS6 expression was sufficient to reverse TRAIL resistance in SW620 cells. These results suggest that modulation of CerS6 expression may constitute a new therapeutic strategy to alter apoptotic susceptibility.	[White-Gilbertson, S.; Lu, P.; Voelkel-Johnson, C.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29403 USA; [Mullen, T.; Obeid, L.] Med Univ S Carolina, Dept Med, Charleston, SC 29403 USA; [Senkal, C.; Ogretmen, B.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29403 USA; [Obeid, L.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Voelkel-Johnson, C (corresponding author), Med Univ S Carolina, Dept Microbiol & Immunol, POB 250504,173 Ashley Ave, Charleston, SC 29403 USA.	johnsocv@musc.edu		obeid, lina/0000-0002-0734-0847	NCI NIH HHS [R01 CA088932-07, CA-097132, R01 CA088932, CA-088932, P01 CA097132-060004, P01CA097132, P01 CA097132] Funding Source: Medline; NCRR NIH HHS [P20 RR017698, P20 RR017698-02, P20 RR017698-01, P20 RR017698-03, C06 RR018823, 1P20-RR17698] Funding Source: Medline; NIA NIH HHS [R01 AG016583, AG016583] Funding Source: Medline; NIDCR NIH HHS [DE016572, R01 DE016572, R01 DE016572-04] Funding Source: Medline; NIEHS NIH HHS [1T32ES012878, T32 ES012878] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088932, P01CA097132] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR018823, P20RR017698] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE016572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES012878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016583] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ashkenazi A, 2008, J CLIN INVEST, V118, P1979, DOI 10.1172/JCI34359; BARUA S, 2008, MOL PHARM IN PRESS, DOI DOI 10.1021/MP80057J; Basnakian AG, 2005, AM J PHYSIOL-RENAL, V288, pF308, DOI 10.1152/ajprenal.00204.2004; Beckman M, 2004, APOPTOSIS, V9, P363, DOI 10.1023/B:APPT.0000025813.75258.b5; Birbes H, 2005, BIOCHEM J, V386, P445, DOI 10.1042/BJ20041627; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Charles AG, 2001, CANCER CHEMOTH PHARM, V47, P444, DOI 10.1007/s002800000265; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; de Jong S, 2001, CANCER METAST REV, V20, P51, DOI 10.1023/A:1013112624971; Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200; Eto M, 2003, PROSTATE, V57, P66, DOI 10.1002/pros.10275; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Ferrando-May E, 2001, CELL DEATH DIFFER, V8, P495, DOI 10.1038/sj.cdd.4400837; Garzotto M, 1999, CANCER RES, V59, P5194; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; Huerta S, 2007, J SURG RES, V142, P184, DOI 10.1016/j.jss.2006.12.551; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Kamada S, 2005, MOL CELL BIOL, V25, P9469, DOI 10.1128/MCB.25.21.9469-9477.2005; Kamada S, 2005, J BIOL CHEM, V280, P857, DOI 10.1074/jbc.C400538200; Karahatay S, 2007, CANCER LETT, V256, P101, DOI 10.1016/j.canlet.2007.06.003; Kelley SK, 2001, J PHARMACOL EXP THER, V299, P31; Kitatani K, 2006, J BIOL CHEM, V281, P36793, DOI 10.1074/jbc.M608137200; Koschny R, 2007, J MOL MED, V85, P923, DOI 10.1007/s00109-007-0194-1; Koybasi S, 2004, J BIOL CHEM, V279, P44311, DOI 10.1074/jbc.M406920200; Kroesen BJ, 2003, J BIOL CHEM, V278, P14723, DOI 10.1074/jbc.M210756200; MacFarlane M, 2003, TOXICOL LETT, V139, P89, DOI 10.1016/S0378-4274(02)00422-8; Mizutani Y, 2005, BIOCHEM J, V390, P263, DOI 10.1042/BJ20050291; Moulin M, 2007, APOPTOSIS, V12, P1703, DOI 10.1007/s10495-007-0096-2; Ndozangue-Touriguine O, 2008, ONCOGENE, V27, P6012, DOI 10.1038/onc.2008.197; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; Peter Marcus E, 2004, Biochem J, V382, pe1; Pewzner-Jung Y, 2006, J BIOL CHEM, V281, P25001, DOI 10.1074/jbc.R600010200; Provenzani A, 2006, CARCINOGENESIS, V27, P1323, DOI 10.1093/carcin/bgi377; Riebeling C, 2003, J BIOL CHEM, V278, P43452, DOI 10.1074/jbc.M307104200; Selzner M, 2001, CANCER RES, V61, P1233; Senkal CE, 2007, MOL CANCER THER, V6, P712, DOI 10.1158/1535-7163.MCT-06-0558; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Siskind LJ, 2000, J BIOL CHEM, V275, P38640, DOI 10.1074/jbc.C000587200; Stiban J, 2008, J LIPID RES, V49, P625, DOI 10.1194/jlr.M700480-JLR200; Thomas RL, 1999, J BIOL CHEM, V274, P30580, DOI 10.1074/jbc.274.43.30580; Tran EJ, 2006, CELL, V125, P1041, DOI 10.1016/j.cell.2006.05.027; Ueda N, 2001, J AM SOC NEPHROL, V12, P2384, DOI 10.1681/ASN.V12112384; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; Voelkel-Johnson C, 2005, MOL CANCER THER, V4, P1320, DOI 10.1158/1535-7163.MCT-05-0086; Widlak P, 2005, J CELL BIOCHEM, V94, P1078, DOI 10.1002/jcb.20409; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wilson MR, 1998, CELL DEATH DIFFER, V5, P646, DOI 10.1038/sj.cdd.4400394; Xu ZW, 2005, J LIPID RES, V46, P1229, DOI 10.1194/jlr.M500001-JLR200; Yasuhara N, 1997, GENES CELLS, V2, P55, DOI 10.1046/j.1365-2443.1997.1010302.x	50	106	109	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	8					1132	1141		10.1038/onc.2008.468	http://dx.doi.org/10.1038/onc.2008.468			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE	19137010	Green Accepted			2022-12-17	WOS:000263722900008
J	Gort, EH; van Haaften, G; Verlaan, I; Groot, AJ; Plasterk, RHA; Shvarts, A; Suijkerbuijk, KPM; van Laar, T; van der Wall, E; Raman, V; van Diest, PJ; Tijsterman, M; Vooijs, M				Gort, E. H.; van Haaften, G.; Verlaan, I.; Groot, A. J.; Plasterk, R. H. A.; Shvarts, A.; Suijkerbuijk, K. P. M.; van Laar, T.; van der Wall, E.; Raman, V.; van Diest, P. J.; Tijsterman, M.; Vooijs, M.			The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2 alpha	ONCOGENE			English	Article						hypoxia; HIF-2 alpha; TWIST1; C. elegans; cancer	ENDOTHELIAL GROWTH-FACTOR; CAENORHABDITIS-ELEGANS; GENE-EXPRESSION; C-ELEGANS; TRANSCRIPTIONAL RESPONSE; FUNCTIONAL-ANALYSIS; DROSOPHILA EMBRYO; FACTOR-1 HIF-1; UP-REGULATION; FACTOR-I	Hypoxia-inducible factors (HIFs) are highly conserved transcription factors that play a crucial role in oxygen homeostasis. Intratumoral hypoxia and genetic alterations lead to HIF activity, which is a hallmark of solid cancer and is associated with poor clinical outcome. HIF activity is regulated by an evolutionary conserved mechanism involving oxygen-dependent HIF alpha protein degradation. To identify novel components of the HIF pathway, we performed a genome-wide RNA interference screen in Caenorhabditis elegans, to suppress HIF-dependent phenotypes, like egg-laying defects and hypoxia survival. In addition to hif-1 (HIF alpha) and aha-1 (HIF beta), we identified hlh-8, gska-3 and spe-8. The hlh-8 gene is homologous to the human oncogene TWIST1. We show that TWIST1 expression in human cancer cells is enhanced by hypoxia in a HIF-2 alpha-dependent manner. Furthermore, intronic hypoxia response elements of TWIST1 are regulated by HIF-2 alpha, but not HIF-1 alpha. These results identify TWIST1 as a direct target gene of HIF-2 alpha, which may provide insight into the acquired metastatic capacity of hypoxic tumors.	[Gort, E. H.; Verlaan, I.; Groot, A. J.; Shvarts, A.; Suijkerbuijk, K. P. M.; van Laar, T.; van Diest, P. J.; Vooijs, M.] Univ Med Ctr Utrecht, Dept Pathol, NL-3508 GA Utrecht, Netherlands; [van Haaften, G.; Plasterk, R. H. A.; Tijsterman, M.] Ctr Biomed Genet, Hubrecht Lab, Utrecht, Netherlands; [van der Wall, E.] Univ Med Ctr Utrecht, Dept Med Oncol, NL-3508 GA Utrecht, Netherlands; [Raman, V.] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA	Utrecht University; Utrecht University Medical Center; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center; Johns Hopkins University	Vooijs, M (corresponding author), Univ Med Ctr Utrecht, Dept Pathol, Heidelberglaan 100, NL-3508 GA Utrecht, Netherlands.	m.vooijs@umcutrecht.nl	Tijsterman, Marcel/H-5663-2018; van Haaften, Gijs/G-7832-2012; Vooijs, Marc/K-3522-2019	Tijsterman, Marcel/0000-0001-8465-9002; van Haaften, Gijs/0000-0003-3033-0329; Suijkerbuijk, Karijn/0000-0003-3604-5430				Bardos JI, 2004, BIOESSAYS, V26, P262, DOI 10.1002/bies.20002; Bishop T, 2004, PLOS BIOL, V2, P1549, DOI 10.1371/journal.pbio.0020289; Bos R, 2003, CANCER, V97, P1573, DOI 10.1002/cncr.11246; Corsi AK, 2002, DEVELOPMENT, V129, P2761; Dekanty A, 2005, J CELL SCI, V118, P5431, DOI 10.1242/jcs.02648; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Erbel PJA, 2003, P NATL ACAD SCI USA, V100, P15504, DOI 10.1073/pnas.2533374100; Esteban MA, 2006, CANCER RES, V66, P3567, DOI 10.1158/0008-5472.CAN-05-2670; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gort EH, 2006, ONCOGENE, V25, P6123, DOI 10.1038/sj.onc.1209643; Greijer AE, 2005, J PATHOL, V206, P291, DOI 10.1002/path.1778; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harfe BD, 1998, GENE DEV, V12, P2623, DOI 10.1101/gad.12.16.2623; Hockel M, 2001, SEMIN ONCOL, V28, P36, DOI 10.1016/S0093-7754(01)90211-8; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; IP YT, 1992, GENE DEV, V6, P1728, DOI 10.1101/gad.6.9.1728; Jiang HQ, 2001, P NATL ACAD SCI USA, V98, P7916, DOI 10.1073/pnas.141234698; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kamath RS, 2003, METHODS, V30, P313, DOI 10.1016/S1046-2023(03)00050-1; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kress S, 1998, J CANCER RES CLIN, V124, P315, DOI 10.1007/s004320050175; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Mottet D, 2003, J BIOL CHEM, V278, P31277, DOI 10.1074/jbc.M300763200; Padilla PA, 2002, MOL BIOL CELL, V13, P1473, DOI 10.1091/mbc.01-12-0594; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Ravi R, 2000, GENE DEV, V14, P34; Salem Y, 2005, CELL SIGNAL, V17, P341, DOI 10.1016/j.cellsig.2004.08.001; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shen C, 2005, J BIOL CHEM, V280, P20580, DOI 10.1074/jbc.M501894200; Shen C, 2003, ANN NY ACAD SCI, V995, P191, DOI 10.1111/j.1749-6632.2003.tb03222.x; Shen C, 2006, GENETICS, V174, P1205, DOI 10.1534/genetics.106.063594; Shibata T, 1998, INT J RADIAT ONCOL, V42, P913, DOI 10.1016/S0360-3016(98)00298-3; SZYMANSKI P, 1995, EMBO J, V14, P2229, DOI 10.1002/j.1460-2075.1995.tb07217.x; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; To KKW, 2005, J BIOL CHEM, V280, P38102, DOI 10.1074/jbc.M504342200; TRENT C, 1983, GENETICS, V104, P619; van Haaften G, 2004, P NATL ACAD SCI USA, V101, P12992, DOI 10.1073/pnas.0403131101; Vaupel P, 2005, TRANSFUS CLIN BIOL, V12, P5, DOI 10.1016/j.tracli.2004.11.005; Vaupel P, 2001, SEMIN ONCOL, V28, P29, DOI 10.1016/S0093-7754(01)90210-6; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang V, 2005, CANCER RES, V65, P3299, DOI 10.1158/0008-5472.CAN-04-4130; Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje; Wilkie AOM, 2001, NAT REV GENET, V2, P458, DOI 10.1038/35076601; Woelfle U, 2003, CANCER RES, V63, P5679; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	54	106	116	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1501	1510		10.1038/sj.onc.1210795	http://dx.doi.org/10.1038/sj.onc.1210795			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17873906				2022-12-17	WOS:000253815800001
J	Wang, H; Mannava, S; Grachtchouk, V; Zhuang, D; Soengas, MS; Gudkov, AV; Prochownik, EV; Nikiforov, MA				Wang, H.; Mannava, S.; Grachtchouk, V.; Zhuang, D.; Soengas, M. S.; Gudkov, A. V.; Prochownik, E. V.; Nikiforov, M. A.			c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle	ONCOGENE			English	Article						myc; cell cycle; shRNA	S-PHASE CHECKPOINT; NEOPLASTIC PHENOTYPE; MELANOMA-CELLS; TARGET GENES; APOPTOSIS; REVEALS; SKIN; TUMORIGENESIS; INACTIVATION; SUPPRESSION	A major role for c-Myc in the proliferation of normal cells is attributed to its ability to promote progression through G(1) and into S phase of the cell cycle. The absolute requirement of c-Myc for cell cycle progression in human tumor cells has not been comprehensively addressed. In the present work, we used a lentiviral-based short hairpin RNA (shRNA) expression vector to stably reduce c-Myc expression in a large number of human tumor cell lines and in three different types of normal human cells. In all cases, cell proliferation was severely inhibited, with normal cells ultimately undergoing G(0)/G(1) growth arrest. In contrast, tumor cells demonstrated a much more variable cell cycle response with cells from several lines accumulating in S or G(2)/M phases. Moreover, in some tumor lines, the phase of cell cycle arrest caused by inhibition of c-Myc could be altered by depleting tumor suppressor protein p53 or its transcriptional target p21(CIP/WAF). Our data suggest that, as in the case of normal cells, c-Myc is essential for sustaining proliferation of human tumor cells. However its rate-limiting role in cell cycle control is variable and is reliant upon the status of other cell cycle regulators.	[Mannava, S.; Grachtchouk, V.; Zhuang, D.; Soengas, M. S.; Nikiforov, M. A.] Univ Michigan, Dept Dermatol, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Wang, H.; Prochownik, E. V.] Childrens Hosp Pittsburgh, Hematol Oncol Sect, Rangos Res Ctr, Pittsburgh, PA 15213 USA; [Gudkov, A. V.] Cleveland Clin, Lerner Res Inst, Dept Mol Genet, Cleveland, OH 44106 USA	University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Cleveland Clinic Foundation	Nikiforov, MA (corresponding author), Univ Michigan, Dept Dermatol, Ctr Comprehens Canc, 1150 W Med Ctr Dr,MS1 Room 6427, Ann Arbor, MI 48109 USA.	mikhailn@umich.edu	Soengas, Maria S/H-6455-2015	Soengas, Maria S/0000-0003-0612-6299; Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [R01 CA140624, R01 CA105033, R01-CA105033, R01-CA120244-A1, R01 CA120244, R01-CA078259, R01 CA120244-05, R01 CA107237, R01 CA078259] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA140624, R01CA120244, R01CA105033, R01CA107237, R01CA078259] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Agarwal ML, 1998, P NATL ACAD SCI USA, V95, P14775, DOI 10.1073/pnas.95.25.14775; Arvanitis C, 2006, SEMIN CANCER BIOL, V16, P313, DOI 10.1016/j.semcancer.2006.07.012; Athar M, 2006, EXP DERMATOL, V15, P667, DOI 10.1111/j.1600-0625.2006.00473.x; Baena E, 2005, P NATL ACAD SCI USA, V102, P7286, DOI 10.1073/pnas.0409260102; Bernard Sandra, 2006, V42, P329, DOI 10.1007/004; Bettess MD, 2005, MOL CELL BIOL, V25, P7868, DOI 10.1128/MCB.25.17.7868-7878.2005; Boiko AD, 2006, GENE DEV, V20, P236, DOI 10.1101/gad.1372606; Boxer RB, 2004, CANCER CELL, V6, P577, DOI 10.1016/j.ccr.2004.10.013; Chen JP, 2001, J GASTROEN HEPATOL, V16, P22, DOI 10.1046/j.1440-1746.2001.02361.x; Citro G, 1998, CANCER RES, V58, P283; D'Agnano I, 2001, ONCOGENE, V20, P2814, DOI 10.1038/sj.onc.1204392; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dang CV, 1999, MOL CELL BIOL, V19, P1; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Gottifredi V, 2005, SEMIN CELL DEV BIOL, V16, P355, DOI 10.1016/j.semcdb.2005.02.011; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hermeking H, 2003, CURR CANCER DRUG TAR, V3, P163, DOI 10.2174/1568009033481949; Ivanova N, 2006, NATURE, V442, P533, DOI 10.1038/nature04915; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Li F, 2006, CANCER RES, V66, P5608, DOI 10.1158/0008-5472.CAN-05-4242; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Malynn BA, 2000, GENE DEV, V14, P1390; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McGuffie EM, 2000, CANCER RES, V60, P3790; Meyer N, 2006, SEMIN CANCER BIOL, V16, P275, DOI 10.1016/j.semcancer.2006.07.011; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5793, DOI 10.1128/MCB.22.16.5793-5800.2002; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Paz MF, 2003, CANCER RES, V63, P1114; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Ponzielli R, 2005, EUR J CANCER, V41, P2485, DOI 10.1016/j.ejca.2005.08.017; Prathapam T, 2006, P NATL ACAD SCI USA, V103, P2695, DOI 10.1073/pnas.0511186103; Prochownik Edward V, 2004, Expert Rev Anticancer Ther, V4, P289, DOI 10.1586/14737140.4.2.289; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; Rothermund K, 2005, CANCER RES, V65, P2097, DOI 10.1158/0008-5472.CAN-04-2928; Sharma SV, 2006, CLIN CANCER RES, V12, p4392S, DOI 10.1158/1078-0432.CCR-06-0096; Oskarsson T, 2006, GENE DEV, V20, P2024, DOI 10.1101/gad.381206; SKORSKI T, 1995, J EXP MED, V182, P1645, DOI 10.1084/jem.182.6.1645; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Stark GR, 2006, MOL BIOTECHNOL, V32, P227, DOI 10.1385/MB:32:3:227; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; VITA M, SEMIN CANC BIOL, V16, P318; Yin XY, 2002, J BIOL CHEM, V277, P19998, DOI 10.1074/jbc.M200860200; Zhou ZQ, 2001, TRENDS CELL BIOL, V11, pS10, DOI 10.1016/S0962-8924(01)82037-7	54	106	110	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1905	1915		10.1038/sj.onc.1210823	http://dx.doi.org/10.1038/sj.onc.1210823			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17906696	Green Accepted			2022-12-17	WOS:000254150600010
J	Wang, RF; Miyahara, Y; Wang, HY				Wang, R-F; Miyahara, Y.; Wang, H. Y.			Toll-like receptors and immune regulation: implications for cancer therapy	ONCOGENE			English	Review						toll-like receptors; tumor immunology; cancer immunotherapy; immune tolerance; innate immunity; regulatory T cells	SINGLE-STRANDED RNA; GROWTH-FACTOR-BETA; SUPPRESSOR T-CELLS; NF-KAPPA-B; RIG-I; ADAPTER PROTEIN; ANTIVIRAL RESPONSES; DENDRITIC CELLS; INNATE; INFLAMMATION	Toll-like receptors (TLRs) function as pathogen pattern recognition molecules that sensor and initiate innate and adaptive immune responses against microbes and cancer cells. Recognition of pathogen-derived ligands by TLRs expressed on many types of cells, including dendritic cells and T cells, triggers the nuclear factor (NF)-kappa B and type-1 interferon pathways, leading to the production of proinflammatory cytokines that are essential in stimulating CD4(+) T cells to differentiate to T helper (Th) 1, Th2 Th17 and regulatory T (Treg) cells. Recent studies indicate that Treg cells play a critical role in suppressing immune responses and inducing immune tolerance to cancer and infectious diseases. Of particular interest, the human TLR8 signaling pathway is essential for reversing the suppressive function of Treg cells. Thus, TLRs regulate cancer immunity and tolerance through innate immune responses mediated by Treg, dendritic and other immune cells. In this review, we focus on the current understanding of TLRs and Treg cells with emphasis on their roles in cancer immunity. Related information on non-TLR immune receptors will be briefly discussed.	[Wang, R-F; Miyahara, Y.; Wang, H. Y.] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; [Wang, R-F; Miyahara, Y.; Wang, H. Y.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Wang, R-F; Miyahara, Y.; Wang, H. Y.] Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Wang, RF (corresponding author), Baylor Coll Med, Ctr Cell & Gene Therapy, ALKEK Bldg,N1120, Houston, TX 77030 USA.	Rongfuw@bcm.tmc.edu						Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Baldridge JR, 2004, EXPERT OPIN BIOL TH, V4, P1129, DOI 10.1517/14712598.4.7.1129; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Blander JM, 2006, NATURE, V440, P808, DOI 10.1038/nature04596; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Crellin NK, 2005, J IMMUNOL, V175, P8051, DOI 10.4049/jimmunol.175.12.8051; Crozat K, 2004, P NATL ACAD SCI USA, V101, P6835, DOI 10.1073/pnas.0401347101; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Fehervari Z, 2004, INT IMMUNOL, V16, P1769, DOI 10.1093/intimm/dxh178; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; FRANCOIS BJ, 2003, NAT REV IMMUNOL, V3, P189; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hamilton SE, 2006, NAT IMMUNOL, V7, P475, DOI 10.1038/ni1326; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Honda K, 2005, NATURE, V434, P1035, DOI 10.1038/nature03547; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Hu JW, 2006, CANCER RES, V66, P8887, DOI 10.1158/0008-5472.CAN-05-3448; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jackson DC, 2004, P NATL ACAD SCI USA, V101, P15440, DOI 10.1073/pnas.0406740101; Jahrsdorfer B, 2005, J LEUKOCYTE BIOL, V77, P378, DOI 10.1189/jlb.0604373; Jahrsdorfer B, 2005, CLIN CANCER RES, V11, P1490, DOI 10.1158/1078-0432.CCR-04-1890; Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441; Janssen EM, 2005, NATURE, V434, P88, DOI 10.1038/nature03337; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517; Karin M, 2006, CELL, V124, P823, DOI 10.1016/j.cell.2006.02.016; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; KINIWA Y, 2007, IN PRESS CLIN CANC; Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970; Kubo T, 2004, J IMMUNOL, V173, P7249, DOI 10.4049/jimmunol.173.12.7249; Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808; Lin RT, 2006, J VIROL, V80, P6072, DOI 10.1128/JVI.02495-05; Liyanage UK, 2002, J IMMUNOL, V169, P2756, DOI 10.4049/jimmunol.169.5.2756; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Mariathasan S, 2007, NAT REV IMMUNOL, V7, P31, DOI 10.1038/nri1997; MARINON F, 2006, NATURE, V440, P237; Martinon F, 2005, TRENDS IMMUNOL, V26, P447, DOI 10.1016/j.it.2005.06.004; Martinon F, 2004, CELL, V117, P561, DOI 10.1016/j.cell.2004.05.004; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Netea MG, 2004, J IMMUNOL, V172, P3712, DOI 10.4049/jimmunol.172.6.3712; Nurieva R, 2007, NATURE, V448, P480, DOI 10.1038/nature05969; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Peng G, 2007, IMMUNITY, V27, P334, DOI 10.1016/j.immuni.2007.05.020; Peng GY, 2005, SCIENCE, V309, P1380, DOI 10.1126/science.1113401; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Roncarolo MG, 2000, CURR OPIN IMMUNOL, V12, P676, DOI 10.1016/S0952-7915(00)00162-X; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x; Salaun B, 2006, J IMMUNOL, V176, P4894, DOI 10.4049/jimmunol.176.8.4894; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Speiser DE, 2005, J CLIN INVEST, V115, P739, DOI 10.1172/JCI200523373; Stockfleth E, 2003, BRIT J DERMATOL, V149, P53, DOI 10.1046/j.0366-077X.2003.05626.x; Sun JC, 2003, SCIENCE, V300, P339, DOI 10.1126/science.1083317; Sun JL, 2005, JNCI-J NATL CANCER I, V97, P525, DOI 10.1093/jnci/dji070; Sun Xing Cai, 2004, BMC Physiol, V4, P8, DOI 10.1186/1472-6793-4-8; Sutmuller RPM, 2006, TRENDS IMMUNOL, V27, P387, DOI 10.1016/j.it.2006.06.005; Sutmuller RPM, 2006, J CLIN INVEST, V116, P485, DOI 10.1172/JCI25439; Sutterwala FS, 2006, IMMUNITY, V24, P317, DOI 10.1016/j.immuni.2006.02.004; Tabiasco J, 2006, J IMMUNOL, V177, P8708, DOI 10.4049/jimmunol.177.12.8708; Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186; Ting JPY, 2005, ANNU REV IMMUNOL, V23, P387, DOI 10.1146/annurev.immunol.23.021704.115616; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Walker MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441; Wan YSY, 2005, P NATL ACAD SCI USA, V102, P5126, DOI 10.1073/pnas.0501701102; Wang HY, 2007, CURR OPIN IMMUNOL, V19, P217, DOI 10.1016/j.coi.2007.02.004; Wang HY, 2005, J IMMUNOL, V174, P2661, DOI 10.4049/jimmunol.174.5.2661; Wang YJ, 2004, PROTEOMICS, V4, P20, DOI 10.1002/pmic.200300549; WANG ZK, 2001, MAT PHYS MECH, V4, P22; Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002; Weiner HL, 2001, IMMUNOL REV, V182, P207, DOI 10.1034/j.1600-065X.2001.1820117.x; Wille-Reece U, 2005, P NATL ACAD SCI USA, V102, P15190, DOI 10.1073/pnas.0507484102; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Woo EY, 2001, CANCER RES, V61, P4766; Xu JF, 2005, CANCER EPIDEM BIOMAR, V14, P2563, DOI 10.1158/1055-9965.EPI-05-0356; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yarovinsky F, 2005, SCIENCE, V308, P1626, DOI 10.1126/science.1109893; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Yuan XP, 2006, CANCER RES, V66, P2630, DOI 10.1158/0008-5472.CAN-05-1682; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	108	106	118	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2008	27	2					181	189		10.1038/sj.onc.1210906	http://dx.doi.org/10.1038/sj.onc.1210906			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248OO	18176599				2022-12-17	WOS:000252163600004
J	Junttila, MR; Ala-Aho, R; Jokilehto, T; Peltonen, J; Kallajoki, M; Grenman, R; Jaakkola, P; Westermarck, J; Kahari, VM				Junttila, M. R.; Ala-aho, R.; Jokilehto, T.; Peltonen, J.; Kallajoki, M.; Grenman, R.; Jaakkola, P.; Westermarck, J.; Kahari, V-M			p38 alpha and p38 delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells	ONCOGENE			English	Article						p38; mitogen-activated protein kinase; matrix metalloproteinase; squamous cell carcinoma	P38 MAP KINASE; COLLAGENASE-3 MMP-13; MATRIX METALLOPROTEINASES; SELECTIVE ACTIVATION; IN-VIVO; C-JUN; EXPRESSION; CANCER; P53; APOPTOSIS	Recent studies indicate that the specificity of p38 mitogen-activated protein kinase (MAPK)-mediated cellular stress responses is determined by the expression pattern of the distinct p38 isoforms. Here, we have analysed the function of distinct p38 isoforms in the growth and invasion of head and neck squamous cell carcinomas (HNSCCs). Activation of p38 MAPK by arsenite resulted in inactivation of the ERK1,2 signaling pathway by dephosphorylation of MEK1,2 in primary human epidermal keratinocytes (HEKs), whereas in HNSCC cells this p38-mediated inhibition of the ERK1,2 pathway was absent. Quantitation of p38 pathway component mRNA expression in HNSCC cell lines (n = 42) compared to HEKs ( n 8) revealed that p38 alpha and p38 delta isoforms are predominantly expressed in both cell types and that MKK3 is the primary upstream activator expressed. Inhibition of endogenous p38 alpha or p38 delta activity by adenoviral delivery of corresponding dominant-negative p38 isoforms potently reduced MMP-13 and MMP-1 expressions, and suppressed the invasion of HNSCC cells through collagen. Dominant-negative p38 alpha and p38 delta inhibited squamous cell carcinoma (SCC) cell proliferation and inhibition of p38 alpha activity also compromised survival of SCC cells. p38 alpha and p38 delta were predominantly expressed in HNSCCs ( n 24) and nonneoplastic epithelium in vivo (n = 6), with MKK3 being the primary upstream activator. Activation and expression of p38 alpha and p38 delta by tumor cells was detected in HNSCCs in vivo (n = 16). Adenoviral expression of dominant-negative p38 alpha or p38 delta in cutaneous SCC cells potently inhibited their implantation in skin of severe combined immunodeficiency mice and growth of xenografts in vivo. Our results indicate that p38 alpha and p38 delta specifically promote the malignant phenotype of SCC cells by regulating cell survival, proliferation and invasion, suggesting these p38 MAPK isoforms as potential therapeutic targets in HNSCCs.	Turku Univ, Dept Dermatol, FI-20521 Turku, Finland; Turku Univ, Cent Hosp, Dept Pathol, FI-20521 Turku, Finland; Turku Univ, Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, Turku, Finland; Univ Turku, Inst Biomed, Dept Anat, FIN-20520 Turku, Finland; Univ Turku, MediCity Res Lab, Turku, Finland; Turku Grad Sch Biomed Sci, Turku, Finland; Univ Turku, Ctr Biotechnol, Turku, Finland; Univ Turku, Dept Med Biochem & Mol Biol, Turku, Finland; Abo Akad Univ, Turku, Finland	University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; Abo Akademi University	Kahari, VM (corresponding author), Turku Univ, Dept Dermatol, POB 52, FI-20521 Turku, Finland.	veli-matti.kahari@utu.fi	Peltonen, Juha/O-7159-2019; Westermarck, Jukka/AAL-6464-2020; Jaakkola, Panu M/B-4355-2012; Kahari, Veli-Matti/E-5144-2011	Peltonen, Juha/0000-0002-5732-4167; Westermarck, Jukka/0000-0001-7478-3018; Jaakkola, Panu/0000-0002-2365-4985; Kahari, Veli-Matti/0000-0003-2421-9368				Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Ala-aho R, 2004, ONCOGENE, V23, P5111, DOI 10.1038/sj.onc.1207678; Ala-Aho R, 2002, ONCOGENE, V21, P1187, DOI 10.1038/sj.onc.1205198; Ambrosino C, 2003, MOL CELL BIOL, V23, P370, DOI 10.1128/MCB.23.1.370-381.2003; Boyce S.T., 1983, J INVEST DERMATOL S, V81, P33; BRACHMAN DG, 1992, CANCER RES, V52, P4832; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Efimova T, 2003, J BIOL CHEM, V278, P34277, DOI 10.1074/jbc.M302759200; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Hale KK, 1999, J IMMUNOL, V162, P4246; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huang FY, 2000, INT J ENG SCI, V38, P275, DOI 10.1016/S0020-7225(99)00041-5; Hunter KD, 2005, NAT REV CANCER, V5, P127, DOI 10.1038/nrc1549; Johannes R.E., 1997, SPC LIVE REEF FISH I, V3, P13; Johansson N, 2000, J CELL SCI, V113, P227; Keesler GA, 1998, PROTEIN EXPRES PURIF, V14, P221, DOI 10.1006/prep.1998.0947; LANSFORD CD, 1999, HUMAN CELL CULTURE, V2, P185; Li SP, 2003, CANCER RES, V63, P3473; Liu QH, 2004, AM J PHYSIOL-HEART C, V286, pH2204, DOI 10.1152/ajpheart.01050.2003; Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; Pruitt K, 2002, J BIOL CHEM, V277, P31808, DOI 10.1074/jbc.M203964200; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; Simon C, 1998, CANCER RES, V58, P1135; SOMERS KD, 1992, CANCER RES, V52, P5997; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Westermarck J, 2000, CANCER RES, V60, P7156; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	39	106	110	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2007	26	36					5267	5279		10.1038/sj.onc.1210332	http://dx.doi.org/10.1038/sj.onc.1210332			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17334397				2022-12-17	WOS:000248674200010
J	Inoue, Y; Itoh, Y; Abe, K; Okamoto, T; Daitoku, H; Fukamizu, A; Onozaki, K; Hayashi, H				Inoue, Y.; Itoh, Y.; Abe, K.; Okamoto, T.; Daitoku, H.; Fukamizu, A.; Onozaki, K.; Hayashi, H.			Smad3 is acetylated by p300/CBP to regulate its transactivation activity	ONCOGENE			English	Article						acetylation; CBP; p300; Smad2; Smad3; TGF-beta	GROWTH-FACTOR-BETA; TRANSCRIPTIONAL COACTIVATOR P/CAF; TGF-BETA; DNA-BINDING; RECEPTOR; PHOSPHORYLATION; ACTIVATION; IDENTIFICATION; SUPERFAMILY; ANTAGONIST	Smad proteins are crucial for the intracellular signaling of transforming growth factor-P (TGF-beta). Upon their receptor-induced activation, Smad proteins are phosphorylated and translocated to the nucleus to activate the transcription of a select set of target genes. Here, we show that the co-activator p300/CBP bound and acetylated Smad3 as well as Smad2 in vivo, and that the acetylation was stimulated by TGF-beta. A major acetylation site of Smad3 by p300/CBP is Lys-378 in the MH2 domain (Smad3C) known to be critical for the regulation of transcriptional activity. Replacement of Lys-378 with Arg decreased the transcriptional activity of GAL4-Smad3C in a luciferase assay. Moreover, p300/CBP potentiated the transcriptional activity of GAL4-Smad3C, but not the acetylation-resistant GAL4-Smad3C(K378R) mutant. These results suggest that acetylation of Smad3 by p300/CBP regulates positively its transcriptional activity.	Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Mol Hlth Sci, Mizuho Ku, Nagoya, Aichi 4678603, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Mol & Cellular Biol, Mizuho Ku, Nagoya, Aichi 4678603, Japan; Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 305, Japan	Nagoya City University; Nagoya City University; University of Tsukuba	Hayashi, H (corresponding author), Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Mol Hlth Sci, Mizuho Ku, 3-1 Tanabe Dori, Nagoya, Aichi 4678603, Japan.	hhayashi@phar.nagoya-cu.ac.jp	fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Callahan JF, 2002, J MED CHEM, V45, P999, DOI 10.1021/jm010493y; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Enari M, 2006, GENE DEV, V20, P1087, DOI 10.1101/gad.1381906; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hasan S, 2002, J MOL MED, V80, P463, DOI 10.1007/s00109-002-0341-7; Hattori T, 2003, ONCOGENE, V22, P1273, DOI 10.1038/sj.onc.1206204; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097-2765(01)00332-X; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Inoue Y, 2004, J INTERF CYTOK RES, V24, P43, DOI 10.1089/107999004772719909; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kawabata H, 2002, J BIOL CHEM, V277, P8099, DOI 10.1074/jbc.M108250200; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; Miyazono K, 2000, J CELL SCI, V113, P1101; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Takahashi N, 2002, EUR J BIOCHEM, V269, P4559, DOI 10.1046/j.1432-1033.2002.03157.x; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521	34	106	115	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2007	26	4					500	508		10.1038/sj.onc.1209826	http://dx.doi.org/10.1038/sj.onc.1209826			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16862174				2022-12-17	WOS:000243731600003
J	Cereghetti, GM; Scorrano, L				Cereghetti, G. M.; Scorrano, L.			The many shapes of mitochondrial death	ONCOGENE			English	Review						mitochondria; cytochrome c release; fusion; fission; cristae; apoptosis	DOMINANT OPTIC ATROPHY; DYNAMIN-RELATED PROTEIN; CYTOCHROME-C RELEASE; MARIE-TOOTH NEUROPATHY; PROGRAMMED CELL-DEATH; ENDOPLASMIC-RETICULUM; OPA1 GENE; GTPASE ACTIVITY; OUTER-MEMBRANE; BAX ACTIVATION	Mitochondria integrate apoptotic signalling by releasing cytochrome c and other proapoptotic cofactors needed for activation of effector caspases. Previously overlooked morphological changes, mitochondrial fragmentation and cristae remodelling, emerged as subroutines of the mitochondrial programme of apoptosis in mammalian cells, as well as in developmental cell death of Caenorhabditis elegans. Mitochondrial morphology results from fusion and fission processes, controlled by a growing set of 'mitochondria-shaping' proteins. Their levels and function appear to influence mitochondrial pathways of cell death, but mechanisms are largely unknown. An emerging model implicates different signals converging on mitochondria-shaping proteins to activate or deactivate them during apoptosis. In turn, the se proteins can orchestrate changes in mitochondrial shape to insure cytochrome c release and progression of the apoptotic cascade. These therefore appear an appealing novel therapeutic target to modulate cell death in cancer.	Venetian Inst Mol Med, Dulbecco Telethon Inst, I-35129 Padua, Italy	Fondazione Telethon; Dulbecco Telethon Institute (DTI); Veneto Institute Molecular Medicine	Scorrano, L (corresponding author), Venetian Inst Mol Med, Dulbecco Telethon Inst, Via Orus 2, I-35129 Padua, Italy.	luca.scorrano@unipd.it	Scorrano, Luca/K-3967-2019; Scorrano, Luca/A-6652-2008	Scorrano, Luca/0000-0002-8515-8928; Scorrano, Luca/0000-0002-8515-8928	Telethon [TCP02016] Funding Source: Medline	Telethon(Fondazione Telethon)		Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; Amati-Bonneau P, 2005, ANN NEUROL, V58, P958, DOI 10.1002/ana.20681; Arnoult D, 2005, CURR BIOL, V15, P2112, DOI 10.1016/j.cub.2005.10.041; Arnoult D, 2005, J BIOL CHEM, V280, P35742, DOI 10.1074/jbc.M505970200; Bach D, 2003, J BIOL CHEM, V278, P17190, DOI 10.1074/jbc.M212754200; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; CEREGHETTI GM, 2006, UNPUB; Chami M, 2004, J BIOL CHEM, V279, P54581, DOI 10.1074/jbc.M409663200; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Chen KH, 2004, NAT CELL BIOL, V6, P872, DOI 10.1038/ncb1161; Chung JG, 2001, CANCER RES, V61, P8873; Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101; CIPOLAT S, 2006, UNPUB; Claeys K, 2005, J PERIPHER NERV SYST, V10, P16; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; De Vos KJ, 2005, CURR BIOL, V15, P678, DOI 10.1016/j.cub.2005.02.064; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Delettre C, 2002, MOL GENET METAB, V75, P97, DOI 10.1006/mgme.2001.3278; Delettre C, 2001, HUM GENET, V109, P584, DOI 10.1007/s00439-001-0633-y; Fannjiang Y, 2004, GENE DEV, V18, P2785, DOI 10.1101/gad.1247904; Ferre M, 2005, HUM MUTAT, V25, P423, DOI 10.1002/humu.20161; Fong WG, 2000, GENOMICS, V70, P113, DOI 10.1006/geno.2000.6364; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Frey TG, 2000, TRENDS BIOCHEM SCI, V25, P319, DOI 10.1016/S0968-0004(00)01609-1; FREZZA C, 2006, UNPUB; Germain M, 2005, EMBO J, V24, P1546, DOI 10.1038/sj.emboj.7600592; Griparic L, 2004, J BIOL CHEM, V279, P18792, DOI 10.1074/jbc.M400920200; Harder Z, 2004, CURR BIOL, V14, P340, DOI 10.1016/j.cub.2004.02.004; Ingerman E, 2005, J CELL BIOL, V170, P1021, DOI 10.1083/jcb.200506078; Ishihara N, 2004, J CELL SCI, V117, P6535, DOI 10.1242/jcs.01565; Jagasia R, 2005, NATURE, V433, P754, DOI 10.1038/nature03316; James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2004, J CELL BIOL, V166, P1027, DOI 10.1083/jcb.200407046; Karbowski M, 2004, J CELL BIOL, V164, P493, DOI 10.1083/jcb.200309082; Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141; Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Li C, 2002, P NATL ACAD SCI USA, V99, P9830, DOI 10.1073/pnas.152571899; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; Malka F, 2005, EMBO REP, V6, P853, DOI 10.1038/sj.embor.7400488; Marchbank NJ, 2002, J MED GENET, V39, DOI 10.1136/jmg.39.8.e47; McNiven MA, 2000, MOL BIOL CELL, V11, p219A; Meeusen S, 2004, SCIENCE, V305, P1747, DOI 10.1126/science.1100612; Meeusen SL, 2005, CURR OPIN CELL BIOL, V17, P389, DOI 10.1016/j.ceb.2005.06.014; MORRIS RL, 1995, J CELL BIOL, V131, P1315, DOI 10.1083/jcb.131.5.1315; Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367; Neuspiel M, 2005, J BIOL CHEM, V280, P25060, DOI 10.1074/jbc.M501599200; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Olichon A, 2002, FEBS LETT, V523, P171, DOI 10.1016/S0014-5793(02)02985-X; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Pacher P, 2001, EMBO J, V20, P4107, DOI 10.1093/emboj/20.15.4107; Perfettini JL, 2005, TRENDS CELL BIOL, V15, P179, DOI 10.1016/j.tcb.2005.02.005; Pesch UEA, 2001, HUM MOL GENET, V10, P1359, DOI 10.1093/hmg/10.13.1359; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Satoh M, 2003, BIOCHEM BIOPH RES CO, V300, P482, DOI 10.1016/S0006-291X(02)02874-7; Scorrano L, 2005, J BIOENERG BIOMEMBR, V37, P165, DOI 10.1007/s10863-005-6572-x; Scorrano L, 2003, CELL DEATH DIFFER, V10, P1287, DOI 10.1038/sj.cdd.4401310; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Shimizu S, 2002, JPN J OPHTHALMOL, V46, P336, DOI 10.1016/S0021-5155(02)00484-7; Sik A, 2004, J BIOL CHEM, V279, P15323, DOI 10.1074/jbc.M313756200; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Sugioka R, 2004, J BIOL CHEM, V279, P52726, DOI 10.1074/jbc.M408910200; Suzuki M, 2003, J MOL BIOL, V334, P445, DOI 10.1016/j.jmb.2003.09.064; Szabadkai G, 2004, MOL CELL, V16, P59, DOI 10.1016/j.molcel.2004.09.026; Thiselton DL, 2002, INVEST OPHTH VIS SCI, V43, P1715; Thiselton DL, 2001, HUM GENET, V109, P498, DOI 10.1007/s004390100600; Toomes C, 2001, HUM MOL GENET, V10, P1369, DOI 10.1093/hmg/10.13.1369; Varadi A, 2004, J CELL SCI, V117, P4389, DOI 10.1242/jcs.01299; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493; Yoon Y, 2001, MOL BIOL CELL, V12, P2894, DOI 10.1091/mbc.12.9.2894; Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697; Yu TZ, 2005, J CELL SCI, V118, P4141, DOI 10.1242/jcs.02537; Zhang PJ, 2001, NAT CELL BIOL, V3, P922, DOI 10.1038/ncb1001-922; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341	87	106	109	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	34					4717	4724		10.1038/sj.onc.1209605	http://dx.doi.org/10.1038/sj.onc.1209605			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892085				2022-12-17	WOS:000239687000009
J	Lindgren, D; Liedberg, F; Andersson, A; Chebil, G; Gudjonsson, S; Borg, A; Mansson, W; Fioretos, T; Hoglund, M				Lindgren, D; Liedberg, F; Andersson, A; Chebil, G; Gudjonsson, S; Borg, A; Mansson, W; Fioretos, T; Hoglund, M			Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q	ONCOGENE			English	Article						expression profiling; FGFR3; chromosome 9; urothelial carcinoma; bladder cancer	TRANSITIONAL-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR-3; GENE-EXPRESSION; URINARY-BLADDER; MICROARRAY DATA; CANCER; IDENTIFICATION; PAPILLARY; PATHWAYS; PROGRESSION	We used gene expression pro. ling, mutation analyses of FGFR3 and TP53, and LOH analyses of chromosome 9 and the TP53 region on chromosome arm 17p, to molecularly characterize 75 Ta and T1 bladder carcinomas. We identified four major cellular processes related to cell cycle, protein synthesis, immune response, and extra cellular components that contribute to the expressional heterogeneity of early-stage urothelial cell carcinoma ( UCC). Activating FGFR3 mutations were found at the highest frequency in G1 tumors ( 80%), and showed a strong correlation with FGFR3 expression. In contrast, G3 tumors displayed mutations in less than 10% of the cases and a low level of FGFR3 expression. Even though LOH on chromosome 9 was not associated with any specific expression pattern, our data indicate that loss of chromosome 9 is associated with tumor development rather than initiation. The combined analyses suggest the existence of two types of UCC tumors, one which is characterized by FGFR3 mutation or expression, high expression of protein synthesis genes, and low expression of cell cycle genes. Furthermore, the presented data underscore FGFR3 receptor involvement in urothelial cell transformation as the presence of FGFR3 mutations has a major impact on the global gene expression pro. le of bladder carcinomas.	Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Urol, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Oncol, S-22185 Lund, Sweden; Helsingborg Hosp AB, Dept Pathol & Cytol, Helsingborg, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Helsingborgs Hospital	Lindgren, D (corresponding author), Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden.	david.lindgren@med.lu.se	Gudjonsson, S./K-6878-2015	Gudjonsson, S./0000-0002-5147-595X; Fioretos, Thoas/0000-0002-3235-6154; Hoglund, Mattias/0000-0001-9283-4421; Hagstrom-Andersson, Anna/0000-0002-2904-1311				Bakkar AA, 2003, CANCER RES, V63, P8108; Baud E, 1999, INT J ONCOL, V14, P441; Belkin AM, 2000, MICROSC RES TECHNIQ, V51, P280, DOI 10.1002/1097-0029(20001101)51:3<280::AID-JEMT7>3.0.CO;2-O; Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; Blaveri E, 2005, CLIN CANCER RES, V11, P4044, DOI 10.1158/1078-0432.CCR-04-2409; Brausi M, 2002, EUR UROL, V41, P523, DOI 10.1016/S0302-2838(02)00068-4; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Cordon-Cardo C, 1998, CANCER SURV, V32, P115; Duggan B, 2004, CURR OPIN UROL, V14, P277, DOI 10.1097/00042307-200409000-00006; Dyrskjot L, 2003, NAT GENET, V33, P90, DOI 10.1038/ng1061; Dyrskjot L, 2005, CLIN CANCER RES, V11, P4029, DOI 10.1158/1078-0432.CCR-04-2095; Dyrskjot L, 2004, CANCER RES, V64, P4040, DOI 10.1158/0008-5472.CAN-03-3620; Hafner C, 2002, INT J CANCER, V101, P1, DOI 10.1002/ijc.10544; Haukaas S, 1999, BJU INT, V83, P957; Herr HW, 2000, J UROLOGY, V163, P60, DOI 10.1016/S0022-5347(05)67972-4; Heyer LJ, 1999, GENOME RES, V9, P1106, DOI 10.1101/gr.9.11.1106; Hoglund M, 2001, CANCER RES, V61, P8241; Kim JH, 2005, LAB INVEST, V85, P532, DOI 10.1038/labinvest.3700250; Knowles MA, 1999, ELECTROPHORESIS, V20, P269, DOI 10.1002/(SICI)1522-2683(19990201)20:2<269::AID-ELPS269>3.3.CO;2-Z; Modlich O, 2004, CLIN CANCER RES, V10, P3410, DOI 10.1158/1078-0432.CCR-03-0134; Mor O, 2003, ONCOGENE, V22, P7702, DOI 10.1038/sj.onc.1207039; Mostofi F, 1999, HISTOLOGICAL TYPING; PROUT GR, 1992, J UROLOGY, V148, P1413, DOI 10.1016/S0022-5347(17)36924-0; Richter J, 1998, AM J PATHOL, V153, P1615, DOI 10.1016/S0002-9440(10)65750-1; Saal LH, 2002, GENOME BIOL, V3; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sanchez-Carbayo M, 2003, AM J PATHOL, V163, P505, DOI 10.1016/S0002-9440(10)63679-6; Sobin, 2009, UICC TNM CLASSIFICAT; SPRUCK CH, 1994, CANCER RES, V54, P784; Thykjaer T, 2001, CANCER RES, V61, P2492; Trudel S, 2005, BLOOD, V105, P2941, DOI 10.1182/blood-2004-10-3913; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vajo Z, 2000, ENDOCR REV, V21, P23, DOI 10.1210/er.21.1.23; van Rhijn BSW, 2004, CANCER RES, V64, P1911, DOI 10.1158/0008-5472.CAN-03-2421; van Rhijn BWG, 2003, J CLIN ONCOL, V21, P1912, DOI 10.1200/JCO.2003.05.073; van Rhijn BWG, 2002, EUR J HUM GENET, V10, P819, DOI 10.1038/sj.ejhg.5200883; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wild PJ, 2005, CLIN CANCER RES, V11, P4415, DOI 10.1158/1078-0432.CCR-05-0259; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	39	106	110	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2685	2696		10.1038/sj.onc.1209249	http://dx.doi.org/10.1038/sj.onc.1209249			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16532037				2022-12-17	WOS:000237099400013
J	Ren, J; Bharti, A; Raina, D; Chen, W; Ahmad, R; Kufe, D				Ren, J; Bharti, A; Raina, D; Chen, W; Ahmad, R; Kufe, D			MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90	ONCOGENE			English	Article						MUC1; heregulin; c-Src; HSP70; HSP90; mitochondria	CARCINOMA-ASSOCIATED ANTIGEN; GROWTH-FACTOR RECEPTOR; BETA-CATENIN; BREAST-CARCINOMA; MONOCLONAL-ANTIBODY; GENE-TRANSCRIPTION; CYTOPLASMIC TAIL; TYROSINE KINASE; PROTEIN IMPORT; MAMMARY-GLAND	The MUC1 heterodimeric transmembrane glycoprotein is aberrantly overexpressed by most human carcinomas. The MUC1 C-terminal subunit localizes to mitochondria and blocks stress-induced activation of the intrinsic apoptotic pathway. How MUC1 is delivered to mitochondria is not known. The present studies demonstrate that MUC1 forms intracellular complexes with HSP70 and HSP90. We show that the MUC1 cytoplasmic domain binds directly to HSP70 in vitro. By contrast, binding of MUC1 to HSP90 in vitro is induced by c-Src-mediated phosphorylation of the MUC1 cytoplasmic domain. c-Src also increases binding of MUC1 to HSP90 in cells. In concert with these results, we show that heregulin (HRG), a ligand for ErbB receptors, activates c-Src and, in turn, stimulates binding of MUC1 to HSP90. We also show that inhibitors of c-Src or HSP90 block HRG-induced targeting of MUC1 to mitochondria and integration of MUC1 into the mitochondrial outer membrane. These findings indicate that MUC1 is delivered to mitochondria by a mechanism involving activation of the ErbB receptor-c-Src pathway and transport by the molecular chaperone HSP70/HSP90 complex.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			NCI NIH HHS [CA97098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldus SE, 2004, CLIN CANCER RES, V10, P2790, DOI 10.1158/1078-0432.CCR-03-0163; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; Croce MV, 2003, J HISTOCHEM CYTOCHEM, V51, P781, DOI 10.1177/002215540305100609; Datta R, 2000, J BIOL CHEM, V275, P31733, DOI 10.1074/jbc.M910231199; GENDLER S, 1988, J BIOL CHEM, V263, P12820; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Huang L, 2003, CANCER BIOL THER, V2, P702; Kharbanda S, 1996, CANCER RES, V56, P3617; Kinlough CL, 2004, J BIOL CHEM, V279, P53071, DOI 10.1074/jbc.M409360200; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; LEVITAN F, 2005, IN PRESS J BIOL CHEM; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 2003, MOL CANCER RES, V1, P765; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; MERLO GR, 1989, CANCER RES, V49, P6966; Moro F, 1999, EMBO J, V18, P3667, DOI 10.1093/emboj/18.13.3667; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Park SJ, 2005, EMBO J, V24, P1557, DOI 10.1038/sj.emboj.7600586; PEREY L, 1992, CANCER RES, V52, P2563; Rahn JJ, 2001, CANCER, V91, P1973, DOI 10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Ryan MT, 2001, METHOD CELL BIOL, V65, P189, DOI 10.1016/S0091-679X(01)65012-X; Schroeder JA, 2004, ONCOGENE, V23, P5739, DOI 10.1038/sj.onc.1207713; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; Truscott KN, 2003, CURR BIOL, V13, pR326, DOI 10.1016/S0960-9822(03)00239-2; Vadlamudi RK, 2003, FEBS LETT, V543, P76, DOI 10.1016/S0014-5793(03)00404-6; Wada J, 1998, P NATL ACAD SCI USA, V95, P144, DOI 10.1073/pnas.95.1.144; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yin L, 2003, J BIOL CHEM, V278, P35458, DOI 10.1074/jbc.M301987200; Young JC, 2000, EMBO J, V19, P5930, DOI 10.1093/emboj/19.21.5930; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3	43	106	114	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					20	31		10.1038/sj.onc.1209012	http://dx.doi.org/10.1038/sj.onc.1209012			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16158055				2022-12-17	WOS:000234406400003
J	Bhatt, AS; Erdjument-Bromage, H; Tempst, P; Craik, CS; Moasser, MM				Bhatt, AS; Erdjument-Bromage, H; Tempst, P; Craik, CS; Moasser, MM			Adhesion signaling by a novel mitotic substrate of src kinases	ONCOGENE			English	Article						src; Trask; MT-SP1; matriptase; yes; CDCP1	PROTEIN-TYROSINE KINASES; HUMAN-COLON-CARCINOMA; HUMAN COLORECTAL-CANCER; C-SRC; SERINE-PROTEASE; TRANSGENIC MICE; MAMMARY-TUMORS; CELLS; ACTIVATION; MITOSIS	Src kinases are activated and relocalize to the cytoplasm during mitosis, but their mitotic function has remained elusive. We describe here a novel mitotic substrate of src kinases. Trask (transmembrane and associated with src kinases) is a 140 kDa type I transmembrane glycoprotein unrelated to currently known protein families. Src kinases phosphorylate Trask in vitro and mediate its mitotic hyperphosphorylation in vivo. Trask associates with both yes and src, is localized to the cell membrane during interphase, and undergoes cytoplasmic relocalization during mitosis. Overexpression of Trask leads to cell rounding and a loss of adhesion phenotype. Consistent with a function in cell adhesion, Trask interacts with a number of adhesion and matrix proteins including cadherins, syndecans, and the membrane-type serine protease 1 (MT-SP1), and is proteolytically cleaved by MT-SP1. Trask is unique among cell adhesion molecules in that it is under cell cycle regulation and thus links src kinases with the mitotic regulation of cell adhesion. This suggests a potential pathway by which hyperactive src kinases in tumors can deregulate adhesion signaling and mediate the metastatic phenotype.	Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Memorial Sloan Kettering Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Moasser, MM (corresponding author), Univ Calif San Francisco, Sch Med, Dept Med, UCSF Box 0875,2340 Sutter St,Rm 144, San Francisco, CA 94143 USA.	mmoasser@medicine.ucsf.edu		Bhatt, Ami/0000-0001-8099-2975; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Tempst, Paul/0000-0002-6680-3987	NATIONAL CANCER INSTITUTE [R01CA113952, P01CA072006] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72006, R01 CA113952-01, R01 CA113952-02, P01 CA072006, R01 CA113952] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BAGRODIA S, 1994, J BIOL CHEM, V269, P10247; Bhatt AS, 2003, BIOL CHEM, V384, P257, DOI 10.1515/BC.2003.029; Boyer B, 2002, ONCOGENE, V21, P2347, DOI 10.1038/sj.onc.1205298; Brown TA, 2004, J BIOL CHEM, V279, P14772, DOI 10.1074/jbc.M309678200; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Geromanos S, 2000, ANAL CHEM, V72, P777, DOI 10.1021/ac991071n; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; Hooper JD, 2003, ONCOGENE, V22, P1783, DOI 10.1038/sj.onc.1206220; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Jones RJ, 2002, BRIT J CANCER, V87, P1128, DOI 10.1038/sj.bjc.6600594; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Mamidipudi V, 2004, MOL CELL BIOL, V24, P6788, DOI 10.1128/MCB.24.15.6788-6798.2004; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Mizenina OA, 2004, CELL CYCLE, V3, P796; Moasser MM, 1999, CANCER RES, V59, P6145; MUSTELIN T, 2002, SCI STKE, V115, pPE3; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PARK J, 1995, MOL CELL BIOL, V15, P2374; PARK JS, 1993, ONCOGENE, V8, P2627; PENA SV, 1995, GASTROENTEROLOGY, V108, P117, DOI 10.1016/0016-5085(95)90015-2; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Santin AD, 2004, INT J CANCER, V112, P14, DOI 10.1002/ijc.20408; Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566; Sugimura M, 2000, JPN J CANCER RES, V91, P395, DOI 10.1111/j.1349-7006.2000.tb00958.x; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tatsuka M, 1996, MOL CARCINOGEN, V15, P300, DOI 10.1002/(SICI)1098-2744(199604)15:4<300::AID-MC7>3.0.CO;2-J; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849	44	106	117	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5333	5343		10.1038/sj.onc.1208582	http://dx.doi.org/10.1038/sj.onc.1208582			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007225	Green Accepted			2022-12-17	WOS:000231158500007
J	Mattioli, M; Agnelli, L; Fabris, S; Baldini, L; Morabito, F; Bicciato, S; Verdelli, D; Intini, D; Nobili, L; Cro, L; Pruneri, G; Callea, V; Stelitano, C; Maiolo, AT; Lombardi, L; Neri, A				Mattioli, M; Agnelli, L; Fabris, S; Baldini, L; Morabito, F; Bicciato, S; Verdelli, D; Intini, D; Nobili, L; Cro, L; Pruneri, G; Callea, V; Stelitano, C; Maiolo, AT; Lombardi, L; Neri, A			Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma	ONCOGENE			English	Article						gene expression profiling; IGH translocations; MGUS; multiple myeloma; plasma cell leukemia	GROWTH-FACTOR RECEPTOR-3; CHROMOSOMAL TRANSLOCATIONS; T(4/14) TRANSLOCATION; CYCLIN D1; B-CELLS; C-MAF; PROTEIN; DYSREGULATION; FGFR3; PROLIFERATION	Multiple myeloma (MM) is the most common form of plasma cell dyscrasia, characterized by a marked heterogeneity of genetic lesions and clinical course. It may develop from a premalignant condition (monoclonal gammopathy of undetermined significance, MGUS) or progress from intramedullary to extramedullary forms (plasma cell leukemia, PCL). To provide insights into the molecular characterization of plasma cell dyscrasias and to investigate the contribution of specific genetic lesions to the biological and clinical heterogeneity of MM, we analysed the gene expression profiles of plasma cells isolated from seven MGUS, 39MM and six PCL patients by means of DNA microarrays. MMs resulted highly heterogeneous at transcriptional level, whereas the differential expression of genes mainly involved in DNA metabolism and proliferation distinguished MGUS from PCLs and the majority of MM cases. The clustering of MM patients was mainly driven by the presence of the most recurrent translocations involving the immunoglobulin heavy-chain locus. Distinct gene expression patterns have been found to be associated with different lesions: the overexpression of CCND2 and genes involved in cell adhesion pathways was observed in cases with deregulated MAF and MAFB, whereas genes upregulated in cases with the t(4; 14) showed apoptosis-related functions. The peculiar. finding in patients with the t(11; 14) was the downregulation of the a-subunit of the IL-6 receptor. In addition, we identified a set of cancer germline antigens specifically expressed in a subgroup of MM patients characterized by an aggressive clinical evolution, a finding that could have implications for patient classification and immunotherapy.	Univ Milan, Osped Maggiore, IRCCS, UO Ematol 1,Dipartimento Sci Med, I-20122 Milan, Italy; Univ Milan, Osped Maggiore, IRCCS, Lab Ematol Sperimentale & Genet Mol, I-20122 Milan, Italy; Azienda Osped Bianchi Melacrino Morelli, Div Ematol, Reggio Di Calabria, Italy; Azienda Osped Bianchi Melacrino Morelli, Ctr Trapianto Midollo, Reggio Di Calabria, Italy; Univ Padua, Dipartimento Proc Chim Ingn, Padua, Italy; Ist Europeo Oncol, Div Patol, Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of Padua; IRCCS European Institute of Oncology (IEO)	Neri, A (corresponding author), Univ Milan, Osped Maggiore Milano, IRCCS, Dipartimento Sci Med,Ctr G Marcora,UO Ematol 2, Via Francesco Sforza 35, I-20122 Milan, Italy.	neri.a@policlinico.mi.it	Morabito, Francesco Carlo/AAB-9698-2019; Bicciato, Silvio/C-9825-2009; Morabito, Fortunato/I-7819-2012; Pruneri, Giancarlo/AAC-7767-2022; Neri, Antonino/I-9690-2014; nobili, rita lucia/I-9513-2014; Agnelli, Luca/H-8238-2012; Mattioli, Michela/K-3951-2013; BICCIATO, Silvio/J-4466-2019	Morabito, Francesco Carlo/0000-0003-0734-9136; Bicciato, Silvio/0000-0002-1944-7078; Pruneri, Giancarlo/0000-0002-7963-7172; Neri, Antonino/0000-0001-9047-5912; nobili, rita lucia/0000-0001-9965-2444; Mattioli, Michela/0000-0002-1692-9178; BICCIATO, Silvio/0000-0002-1944-7078; Baldini, Luca/0000-0003-2964-9981; Fabris, Sonia/0000-0003-1341-0503; Critelli, Salvatore/0000-0001-7325-0228; Agnelli, Luca/0000-0003-0582-6170; Cro, Lilla Marcella/0000-0002-6007-5667				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; ANDERSON KC, 2002, AM SOC HEMATOL ED PR, P214; Barille-Nion Sophie, 2003, Hematology Am Soc Hematol Educ Program, P248; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Burger JA, 1999, BLOOD, V94, P3658, DOI 10.1182/blood.V94.11.3658.423k11_3658_3667; Califano A, 2000, BIOINFORMATICS, V16, P341, DOI 10.1093/bioinformatics/16.4.341; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Chen XY, 2002, J BIOL CHEM, V277, P10512, DOI 10.1074/jbc.M108765200; Chesi M, 1996, BLOOD, V88, P674, DOI 10.1182/blood.V88.2.674.bloodjournal882674; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; Coles LS, 1996, NUCLEIC ACIDS RES, V24, P2311, DOI 10.1093/nar/24.12.2311; Davies FE, 2003, BLOOD, V102, P4504, DOI 10.1182/blood-2003-01-0016; De Backer O, 1999, CANCER RES, V59, P3157; De Vos J, 2002, ONCOGENE, V21, P6848, DOI 10.1038/sj.onc.1205868; DELEEUW B, 1994, CANCER GENET CYTOGEN, V73, P89, DOI 10.1016/0165-4608(94)90191-0; Dring AM, 2004, CLIN CANCER RES, V10, P5692, DOI 10.1158/1078-0432.CCR-04-0467; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fabris S, 2005, GENE CHROMOSOME CANC, V42, P117, DOI 10.1002/gcc.20123; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fonseca R, 2002, BLOOD, V99, P3735, DOI 10.1182/blood.V99.10.3735; Garlisi CG, 2001, AM J RESP CELL MOL, V24, P90, DOI 10.1165/ajrcmb.24.1.4224; Hanamura I, 2001, JPN J CANCER RES, V92, P638, DOI 10.1111/j.1349-7006.2001.tb01142.x; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood-2004-01-0037; Ho P Joy, 2002, Rev Clin Exp Hematol, V6, P276, DOI 10.1046/j.1468-0734.2002.00081.x; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535-6108(04)00019-4; Imaizumi Tadaatsu, 2004, J Atheroscler Thromb, V11, P15; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; Keats JJ, 2003, BLOOD, V101, P1520, DOI 10.1182/blood-2002-06-1675; Klein U, 2001, J EXP MED, V194, P1625, DOI 10.1084/jem.194.11.1625; McShane LM, 2002, BIOINFORMATICS, V18, P1462, DOI 10.1093/bioinformatics/18.11.1462; Moreau P, 2002, BLOOD, V100, P1579, DOI 10.1182/blood-2002-03-0749; Mukai J, 2000, J BIOL CHEM, V275, P17566, DOI 10.1074/jbc.C000140200; Rasmussen T, 2003, BRIT J HAEMATOL, V123, P253, DOI 10.1046/j.1365-2141.2003.04577.x; Rawstron AC, 2000, BLOOD, V96, P3880, DOI 10.1182/blood.V96.12.3880.h8003880_3880_3886; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Robbiani DF, 2004, NEW ENGL J MED, V351, P197, DOI 10.1056/NEJM200407083510223; Ronchetti D, 1999, BLOOD, V93, P1330, DOI 10.1182/blood.V93.4.1330.404k04_1330_1337; Sahara N, 2002, BRIT J HAEMATOL, V117, P882, DOI 10.1046/j.1365-2141.2002.03513.x; Schadt EE, 2001, J CELL BIOCHEM, V84, P120, DOI 10.1002/jcb.10073; Seidl S, 2003, LANCET ONCOL, V4, P557, DOI 10.1016/S1470-2045(03)01195-1; Shaughnessy J, 2001, BLOOD, V98, P217, DOI 10.1182/blood.V98.1.217; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Stewart JP, 2004, BRIT J HAEMATOL, V126, P72, DOI 10.1111/j.1365-2141.2004.04996.x; Suzuki A, 2003, ONCOGENE, V22, P6177, DOI 10.1038/sj.onc.1206899; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; van Baren N, 1999, BLOOD, V94, P1156; Zhan FH, 2003, BLOOD, V101, P1128, DOI 10.1182/blood-2002-06-1737; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745	53	106	107	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2461	2473		10.1038/sj.onc.1208447	http://dx.doi.org/10.1038/sj.onc.1208447			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735737	Green Published			2022-12-17	WOS:000228180600004
J	Jordan, CT; Guzman, ML				Jordan, CT; Guzman, ML			Mechanisms controlling pathogenesis and survival of leukemic stem cells	ONCOGENE			English	Review						leukemia; stem cell; myeloid; leukemogenesis; NF-kappa B; LSC	ACUTE MYELOID-LEUKEMIA; NF-KAPPA-B; ABILITY IN-VITRO; CHRONIC MYELOCYTIC-LEUKEMIA; COLONY-STIMULATING FACTOR; MYELOGENOUS LEUKEMIA; MYELOPROLIFERATIVE DISEASE; SIGNALING PATHWAYS; PROGENITOR CELLS; BCR-ABL	Stem cells are an integral component of normal mammalian physiology and have been intensively studied in many systems. Intriguingly, substantial evidence indicates that stem cells also play an important role in the initiation and pathogenesis of at least some cancers. In particular, myeloid leukemias have been extensively characterized with regard to stem and progenitor cell involvement. Thus, as a focal point for both scientific and therapeutic endeavors, leukemic stem cells (LSC) represent a critical area of investigation. LSC appear to retain many characteristics of normal hematopoietic stem cells (HSC) as evidenced by a hierarchical developmental pattern, a mostly quiescent cell cycle pro. le, and an immunophenotype very similar to HSC. Consequently, de. ning unique properties of LSC remains a high priority in order to elucidate the molecular mechanisms driving stem cell transformation, and for developing therapeutic strategies that specifically target the LSC population. In this review, we discuss emerging concepts in the field and describe how various molecular and cellular characteristics of leukemia cells might be exploited as a means to preferentially ablate malignant stem cells.	Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA	University of Rochester	Jordan, CT (corresponding author), Univ Rochester, Med Ctr, Dept Med, 601 Elmwood Ave,Box 703, Rochester, NY 14642 USA.	craig_jordan@urmc.rochester.edu	jordan, craig/D-7666-2014	jordan, craig/0000-0003-0869-3465	NCI NIH HHS [R01-CA90446] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090446] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Birkenkamp KU, 2004, LEUKEMIA, V18, P103, DOI 10.1038/sj.leu.2403145; Blair A, 1997, BLOOD, V89, P3104, DOI 10.1182/blood.V89.9.3104; Blair A, 1998, BLOOD, V92, P4325, DOI 10.1182/blood.V92.11.4325; Blair A, 2000, EXP HEMATOL, V28, P660, DOI 10.1016/S0301-472X(00)00155-7; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; BRACH MA, 1992, MOL PHARMACOL, V41, P60; Braun BS, 2004, P NATL ACAD SCI USA, V101, P597, DOI 10.1073/pnas.0307203101; BRUCE WR, 1963, NATURE, V199, P79, DOI 10.1038/199079a0; Chan IT, 2004, J CLIN INVEST, V113, P528, DOI 10.1172/JCI200420476; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; Costello RT, 2000, CANCER RES, V60, P4403; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Cuenco GM, 2001, ONCOGENE, V20, P8236, DOI 10.1038/sj.onc.1205095; Dash A, 2001, BEST PRACT RES CL HA, V14, P49, DOI 10.1053/beha.2000.0115; Dash AB, 2002, P NATL ACAD SCI USA, V99, P7622, DOI 10.1073/pnas.102583199; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; Dias S, 2001, P NATL ACAD SCI USA, V98, P10857, DOI 10.1073/pnas.191117498; Dick J E, 1996, Semin Immunol, V8, P197, DOI 10.1006/smim.1996.0025; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; FIALKOW PJ, 1967, P NATL ACAD SCI USA, V58, P1468, DOI 10.1073/pnas.58.4.1468; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; FOULDS L, 1975, NEOPLASTIC DEV; FOULDS L, 1969, NEOPLASTIC DEV; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Guan YH, 2003, BLOOD, V101, P3142, DOI 10.1182/blood-2002-10-3062; GUTTERIDGE JMC, 1985, BIOCHEM PHARMACOL, V34, P4099, DOI 10.1016/0006-2952(85)90200-X; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Guzman ML, 2002, P NATL ACAD SCI USA, V99, P16220, DOI 10.1073/pnas.252462599; Guzman ML, 2001, BLOOD, V97, P2177, DOI 10.1182/blood.V97.7.2177; Hamann PR, 2002, BIOCONJUGATE CHEM, V13, P47, DOI 10.1021/bc010021y; HARRISON DE, 1991, BLOOD, V78, P1237; Hazlehurst LA, 2001, CANCER METAST REV, V20, P43, DOI 10.1023/A:1013156407224; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Holyoake T, 1999, BLOOD, V94, P2056, DOI 10.1182/blood.V94.6.2056; Holyoake TL, 2002, LEUKEMIA, V16, P549, DOI 10.1038/sj.leu.2402444; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Jin LQ, 2003, BLOOD, V102, p620A; Jordan CT, 2000, LEUKEMIA, V14, P1777, DOI 10.1038/sj.leu.2401903; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Kroon E, 2001, EMBO J, V20, P350, DOI 10.1093/emboj/20.3.350; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Laurent G, 2001, BLOOD, V98, P913, DOI 10.1182/blood.V98.4.913; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; Lemischka IR, 1997, STEM CELLS, V15, P63, DOI 10.1002/stem.5530150810; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; Manz MG, 2002, P NATL ACAD SCI USA, V99, P11872, DOI 10.1073/pnas.172384399; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Mayotte N, 2002, BLOOD, V100, P4177, DOI 10.1182/blood-2002-04-1244; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; O'Dwyer M E, 2000, Lancet Oncol, V1, P207, DOI 10.1016/S1470-2045(00)00149-2; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; PARK CH, 1971, JNCI-J NATL CANCER I, V46, P411; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Perry MC, 2001, CHEMOTHERAPY SOURCE; Ravandi F, 2002, BRIT J HAEMATOL, V116, P57, DOI 10.1046/j.1365-2141.2002.03236.x; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Romano MF, 2000, GENE THER, V7, P1234, DOI 10.1038/sj.gt.3301216; Ruiter GA, 2003, ANTI-CANCER DRUG, V14, P167, DOI 10.1097/00001813-200302000-00011; SCHOFIELD R, 1983, BIOMED PHARMACOTHER, V37, P375; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; Stirewalt DL, 2001, BLOOD, V97, P3589, DOI 10.1182/blood.V97.11.3589; Stucki A, 2001, BLOOD, V97, P2121, DOI 10.1182/blood.V97.7.2121; Sunwoo JB, 2001, CLIN CANCER RES, V7, P1419; Tallman MS, 2002, BLOOD, V99, P759, DOI 10.1182/blood.V99.3.759; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Testa U, 2004, LEUKEMIA, V18, P219, DOI 10.1038/sj.leu.2403224; Thorsteinsdottir U, 2001, MOL CELL BIOL, V21, P224, DOI 10.1128/MCB.21.1.224-234.2001; Tomasson MH, 2000, J CLIN INVEST, V105, P423, DOI 10.1172/JCI8902; Tomasson MH, 2001, BLOOD, V97, P1435, DOI 10.1182/blood.V97.5.1435; Turco MC, 2004, LEUKEMIA, V18, P11, DOI 10.1038/sj.leu.2403171; Van Etten RA, 2001, CURR OPIN HEMATOL, V8, P224, DOI 10.1097/00062752-200107000-00008; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang JCY, 1998, BLOOD, V91, P2406, DOI 10.1182/blood.V91.7.2406.2406_2406_2414; Wierenga PK, 2003, EXP HEMATOL, V31, P421, DOI 10.1016/S0301-472X(03)00049-3; WODINSKY ISIDORE, 1967, CANCER CHEMOTHER REP, V51, P415; Xu Q, 2003, BLOOD, V102, P972, DOI 10.1182/blood-2002-11-3429; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zhao RC, 2001, BLOOD, V97, P2406, DOI 10.1182/blood.V97.8.2406; Zhao S, 2004, LEUKEMIA, V18, P267, DOI 10.1038/sj.leu.2403220; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028; Zhu Z, 2003, LEUKEMIA, V17, P604, DOI 10.1038/sj.leu.2402831	93	106	111	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7178	7187		10.1038/sj.onc.1207935	http://dx.doi.org/10.1038/sj.onc.1207935			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378078	Green Published			2022-12-17	WOS:000223998800004
J	Bae, SC; Choi, JK				Bae, SC; Choi, JK			Tumor suppressor activity of RUNX3	ONCOGENE			English	Article						RUNX3; cancer; TGF-beta; methylation	GROWTH-FACTOR-BETA; EPSTEIN-BARR-VIRUS; TRANSCRIPTION FACTOR; FREQUENT LOSS; C-MYC; FUNCTIONAL COOPERATION; CANCER CELLS; GENE; EXPRESSION; MUTATIONS	Recent analyses have revealed that RUNX family members play important roles in both normal developmental processes and carcinogenesis. Of the three known RUNX family members, RUNX3 has been shown to be involved in neurogenesis of the dorsal root ganglia, T-cell differentiation and tumorigenesis of gastric epithelium. Deletion of the Runx3 locus in mice resulted in hyperplasia of the gastric epithelium due to the stimulation of proliferation and suppression of apoptosis that was accompanied by a reduced sensitivity to TGF-beta1. In primary human gastric cancer specimens, RUNX3 is frequently inactivated by allele loss or gene silencing due to promoter hypermethylation. The tumorigenicity of human gastric cancer cell lines in nude mice decreased as the level of RUNX3 expression increased, which indicates that RUNX3 is a bona. de tumor suppressor of gastric cancers.	Chungbuk Natl Univ, Inst Tumor Res, Sch Med, Dept Biochem, Cheongju 361763, South Korea	Chungbuk National University	Bae, SC (corresponding author), Chungbuk Natl Univ, Inst Tumor Res, Sch Med, Dept Biochem, Cheongju 361763, South Korea.	scbae@med.chungbuk.ac.kr						ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; Bae SC, 2000, GENE, V241, P255, DOI 10.1016/S0378-1119(99)00488-6; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Brownhill R, 2002, SCI ENG ETHICS, V8, P43, DOI 10.1007/s11948-002-0032-3; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cameron ER, 2003, BLOOD CELL MOL DIS, V30, P194, DOI 10.1016/S1079-9796(03)00031-7; Chalaux E, 1999, FEBS LETT, V457, P478, DOI 10.1016/S0014-5793(99)01051-0; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Cohen MM, 2003, AM J MED GENET A, V116A, P1, DOI 10.1002/ajmg.a.10750; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Furihata C, 1997, JPN J CANCER RES, V88, P363, DOI 10.1111/j.1349-7006.1997.tb00390.x; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; HERZOG CR, 1995, ONCOGENE, V11, P1811; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; IMAI S, 1994, P NATL ACAD SCI USA, V91, P9131, DOI 10.1073/pnas.91.19.9131; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; JOHANNSEN E, 1995, J VIROL, V69, P253, DOI 10.1128/JVI.69.1.253-262.1995; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kaiser C, 1999, J VIROL, V73, P4481, DOI 10.1128/JVI.73.5.4481-4484.1999; Kato N, 2003, AM J PATHOL, V163, P387, DOI 10.1016/S0002-9440(10)63668-1; Kim R, 2003, J VIROL, V77, P2056, DOI 10.1128/JVI.77.3.2056-2062.2003; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nam S, 2002, MOL CELL BIOL, V22, P547, DOI 10.1128/MCB.22.2.547-554.2002; North T, 1999, DEVELOPMENT, V126, P2563; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Robertson AJ, 2002, MECH DEVELOP, V117, P327, DOI 10.1016/S0925-4773(02)00201-0; SANO T, 1991, CANCER RES, V51, P2926; Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Spender LC, 2002, J VIROL, V76, P4919, DOI 10.1128/JVI.76.10.4919-4927.2002; Spieker N, 2001, GENE CHROMOSOME CANC, V31, P172, DOI 10.1002/gcc.1130.abs; Stewart M, 2002, J VIROL, V76, P4364, DOI 10.1128/JVI.76.9.4364-4369.2002; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; TANAKA K, 1993, ONCOGENE, V8, P2253; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; UCHINO S, 1992, CANCER RES, V52, P3099; Waki T, 2003, CANCER SCI, V94, P360, DOI 10.1111/j.1349-7006.2003.tb01447.x; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weith A, 1996, CYTOGENET CELL GENET, V72, P114; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Wotton S, 2002, CANCER RES, V62, P7181; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yokomizo T, 2001, GENES CELLS, V6, P13, DOI 10.1046/j.1365-2443.2001.00393.x; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597	70	106	122	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4336	4340		10.1038/sj.onc.1207286	http://dx.doi.org/10.1038/sj.onc.1207286			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156190				2022-12-17	WOS:000221586000019
J	Zelent, A; Greaves, M; Enver, T				Zelent, A; Greaves, M; Enver, T			Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia	ONCOGENE			English	Review						prenatal; co-repressor; histone deacetylase; translocation	ACUTE MYELOID-LEUKEMIA; MULTIPLE CHROMOSOMAL TRANSLOCATIONS; ACUTE PROMYELOCYTIC LEUKEMIA; T-CELL-RECEPTOR; TRANSCRIPTION FACTORS; DNA-BINDING; FUNCTIONAL COOPERATION; EMBRYONIC LETHALITY; RUNT DOMAIN; AML1 GENE	Balanced chromosomal translocations are frequently associated with haematopoietic neoplasms and often involve genes that encode transcription factors, which play critical roles in normal haematopoiesis. Fusion oncoproteins that arise from chimeric genes generated by such translocations are usually stable and consistent molecular markers for a given disease subtype and contribute to the leukaemogenic processes. The t(12; 21)(p13; q22) chromosomal translocation is the most frequent illegitimate gene recombination in paediatric cancer, occurring in approximately 25% of common ( c) B-cell precursor acute lymphoblastic leukaemia (cALL) cases. The rearrangement results in the in-frame fusion of the 50 region of the ETS-related gene, TEL (ETV6), to almost the entire AML1 (RUNX1) locus and is associated with favourable prognosis following conventional therapeutic strategies. We discuss here the prenatal origins of the TEL/AML1 translocation as an initiating mutation, the role of TEL-AML1 in cellular transformation and the molecular mechanisms by which the chimeric protein imposes altered patterns of gene expression.	Inst Canc Res, Chester Beatty Labs, Sect Haematol Oncol, London SW3 6JB, England; Univ Oxford, Weatherall Inst Mol Med, MRC, Mol Haematol Unit, Oxford, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Oxford	Zelent, A (corresponding author), Inst Canc Res, Chester Beatty Labs, Sect Haematol Oncol, 237 Fulham Rd, London SW3 6JB, England.	arthur.zelent@icr.ac.uk	Zelent, Arthur/B-3532-2009	Zelent, Arthur/0000-0002-7968-9888				Alexander FE, 2001, CANCER RES, V61, P2542; Andreasson P, 2001, CANCER GENET CYTOGEN, V130, P93, DOI 10.1016/S0165-4608(01)00518-0; Armstrong SA, 2003, CANCER CELL, V3, P173, DOI 10.1016/S1535-6108(03)00003-5; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Barr FG, 1998, NAT GENET, V19, P121, DOI 10.1038/475; Berger R, 1997, CANCER GENET CYTOGEN, V94, P8, DOI 10.1016/S0165-4608(96)00351-2; Bernardin F, 2002, CANCER RES, V62, P3904; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Bushweller JH, 2003, BLOOD, V102, p171A; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Enver T, 1998, CELL, V94, P9, DOI 10.1016/S0092-8674(00)81215-5; ERICKSON P, 1992, BLOOD, V80, P1825; Fears S, 1996, GENE CHROMOSOME CANC, V17, P127, DOI 10.1002/(SICI)1098-2264(199610)17:2<127::AID-GCC8>3.3.CO;2-L; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Ford AM, 2001, BLOOD, V98, P558, DOI 10.1182/blood.V98.3.558; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Ghia P, 1998, IMMUNOL TODAY, V19, P480, DOI 10.1016/S0167-5699(98)01330-9; Gilliland DG, 2002, CURR OPIN HEMATOL, V9, P274, DOI 10.1097/00062752-200207000-00003; GOLUB T, 1996, BIOCHIM BIOPHYS ACTA, V1288, P7; Golub TR, 1996, CURR TOP MICROBIOL, V211, P279; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Greaves M, 1999, EUR J CANCER, V35, P173, DOI 10.1016/S0959-8049(98)00433-X; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Greaves MF, 1997, LANCET, V349, P344, DOI 10.1016/S0140-6736(96)09412-3; Greaves MF, 2003, BLOOD, V102, P2321, DOI 10.1182/blood-2002-12-3817; GREAVES MF, 1988, LEUKEMIA, V2, P120; Grimwade D, 2004, LEUKEMIA, V18, P375, DOI 10.1038/sj.leu.2403234; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guidez F, 2000, BLOOD, V96, P2557; Guidez F, 1999, BLOOD, V94, p693A; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Hjalgrim LL, 2002, BRIT J CANCER, V87, P994, DOI 10.1038/sj.bjc.6600601; Hope KJ, 2003, ARCH MED RES, V34, P507, DOI 10.1016/j.arcmed.2003.08.007; Hotfilder M, 2002, BLOOD, V100, P640, DOI 10.1182/blood.V100.2.640; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Imai Y, 2004, MOL CELL BIOL, V24, P1033, DOI 10.1128/MCB.24.3.1033-1043.2004; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Knudson A G, 1992, Semin Cancer Biol, V3, P99; Konrad M, 2003, BLOOD, V101, P3635, DOI 10.1182/blood-2002-10-3252; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Lutterbach B, 1999, P NATL ACAD SCI USA, V96, P12822, DOI 10.1073/pnas.96.22.12822; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Maia AT, 2004, GENE CHROMOSOME CANC, V39, P335, DOI 10.1002/gcc.20003; Maia AT, 2001, BLOOD, V98, P478, DOI 10.1182/blood.V98.2.478; Maris JM, 2002, CANCER CELL, V2, P447, DOI 10.1016/S1535-6108(02)00206-4; Mavrothalassitis G, 2000, ONCOGENE, V19, P6524, DOI 10.1038/sj.onc.1204045; McLean TW, 1996, BLOOD, V88, P4252; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; MORROW M, 2004, IN PRESS BLOOD; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okada H, 1998, ONCOGENE, V17, P2287, DOI 10.1038/sj.onc.1202151; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Petrie K, 2003, J BIOL CHEM, V278, P16059, DOI 10.1074/jbc.M212935200; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Ramakers-van Woerden NL, 2000, BLOOD, V96, P1094; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Romana SP, 1996, LEUKEMIA, V10, P167; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; Roulston D, 1998, BLOOD, V92, P2879, DOI 10.1182/blood.V92.8.2879.420k22_2879_2885; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Smith MT, 2002, BLOOD, V100, P4590, DOI 10.1182/blood-2001-12-0264; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Strick R, 2000, P NATL ACAD SCI USA, V97, P4790, DOI 10.1073/pnas.070061297; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; Takahashi Y, 1998, J PEDIAT HEMATOL ONC, V20, P190, DOI 10.1097/00043426-199805000-00002; Taketani T, 2004, BLOOD, V103, P1085, DOI 10.1182/blood-2003-02-0418; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Thompson JR, 2001, LANCET, V358, P1935, DOI 10.1016/S0140-6736(01)06959-8; TSUZUKI S, 2004, IN PRESS P NATL ACAD; Uchida H, 1997, J IMMUNOL, V158, P2251; Van Rompaey L, 2000, ONCOGENE, V19, P5244, DOI 10.1038/sj.onc.1203899; VIDALI G, 1978, P NATL ACAD SCI USA, V75, P2239, DOI 10.1073/pnas.75.5.2239; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wang LL, 2001, ONCOGENE, V20, P3716, DOI 10.1038/sj.onc.1204479; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Wiemels JL, 1999, BLOOD, V94, P1057, DOI 10.1182/blood.V94.3.1057.415k10_1057_1062; Wiemels JL, 2000, GENE CHROMOSOME CANC, V29, P219, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1028>3.0.CO;2-D; Wiemels JL, 1999, CANCER RES, V59, P4075; Wiemels JL, 1999, CANCER RES, V59, P4095; Wiemels JL, 2001, P NATL ACAD SCI USA, V98, P4004, DOI 10.1073/pnas.061408298; Wiemels JL, 1999, LANCET, V354, P1499, DOI 10.1016/S0140-6736(99)09403-9; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303	115	106	108	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4275	4283		10.1038/sj.onc.1207672	http://dx.doi.org/10.1038/sj.onc.1207672			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156184				2022-12-17	WOS:000221586000013
J	Hensen, EF; Jordanova, ES; van Minderhout, IJHM; Hogendoorn, PCW; Taschner, PEM; van der Mey, AGL; Devilee, P; Cornelisse, CJ				Hensen, EF; Jordanova, ES; van Minderhout, IJHM; Hogendoorn, PCW; Taschner, PEM; van der Mey, AGL; Devilee, P; Cornelisse, CJ			Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families	ONCOGENE			English	Article						paraganglioma; phaeochromocytoma; imprinting; SDHD; inheritance; monosomy 11	COMPARATIVE GENOMIC HYBRIDIZATION; BECKWITH-WIEDEMANN SYNDROME; NONCHROMAFFIN PARAGANGLIOMAS; HEREDITARY PARAGANGLIOMA; NECK PARAGANGLIOMAS; GLOMUS TUMORS; GENE; DNA; HEAD; HETEROZYGOSITY	Germline mutations in succinate dehydrogenase subunits B, C and D (SDHB, SDHC and SDHD), genes encoding subunits of mitochondrial complex II, cause hereditary paragangliomas and phaeochromocytomas. In SDHB (1p36)- and SDHC (1q21)-linked families, disease inheritance is autosomal dominant. In SDHD (11q23)linked families, the disease phenotype is expressed only upon paternal transmission of the mutation, consistent with maternal imprinting. However, SDHD shows biallelic expression in brain, kidney and lymphoid tissues (Baysal et al., 2000). Moreover, consistent loss of the wild-type (wt) maternal allele in SDHD-linked tumours suggests expression of the maternal SDHD allele in normal paraganglia. Here we demonstrate exclusive loss of the entire maternal chromosome 11 in SDHD-linked paragangliomas and phaeochromocytomas, suggesting that combined loss of the wt SDHD allele and maternal 11p region is essential for tumorigenesis. We hypothesize that this is driven by selective loss of one or more imprinted genes in the 11p15 region. In paternally, but not in maternally derived SDHD mutation carriers, this can be achieved by a single event, that is, non-disjunctional loss of the maternal chromosome 11. Thus, the exclusive paternal transmission of the disease can be explained by a somatic genetic mechanism targeting both the SDHD gene on 11q23 and a paternally imprinted gene on 11p15.5, rather than imprinting of SDHD.	Leiden Univ, Med Ctr, Dept Pathol, NL-2333 ZA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Otolaryngol & Head & Neck Surg, NL-2333 ZA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Human Genet, NL-2333 ZA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Cornelisse, CJ (corresponding author), Leiden Univ, Med Ctr, Dept Pathol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.	c.j.cornelisse@lumc.nl	Hogendoorn, Pancras/O-6494-2019; Hogendoorn, Pancras C.W./H-5859-2015; Taschner, Peter/J-8853-2014; DEVILEE, PETER/ABR-2140-2022	Hogendoorn, Pancras/0000-0002-1513-8104; Hogendoorn, Pancras C.W./0000-0002-1513-8104; Taschner, Peter/0000-0001-9621-465X; Jordanova, Ekaterina S./0000-0002-8121-1322; Jordanova, Ekaterina/0000-0003-3890-7102				ABELN ECA, 1994, BRIT J CANCER, V70, P255, DOI 10.1038/bjc.1994.289; Astrom K, 2003, HUM GENET, V113, P228, DOI 10.1007/s00439-003-0969-6; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Balmain A, 2003, NAT GENET, V33, P238, DOI 10.1038/ng1107; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Baysal BE, 1997, AM J HUM GENET, V60, P121; BEERMAN H, 1990, INT J CANCER, V45, P34, DOI 10.1002/ijc.2910450108; Biggs PJ, 2003, ONCOGENE, V22, P3288, DOI 10.1038/sj.onc.1206384; Burns JL, 2001, DEVELOPMENT, V128, P3819; COOKE HJ, 1979, NUCLEIC ACIDS RES, V6, P3177, DOI 10.1093/nar/6.10.3177; Dannenberg H, 2001, AM J PATHOL, V158, P1937, DOI 10.1016/S0002-9440(10)64662-7; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dekker PBD, 2003, HUM PATHOL, V34, P690, DOI 10.1016/S0046-8177(03)00237-5; Devilee P, 2001, TRENDS GENET, V17, P569, DOI 10.1016/S0168-9525(01)02416-7; DEVILEE P, 1994, GENE CHROMOSOME CANC, V11, P71, DOI 10.1002/gcc.2870110202; Edstrom E, 2000, AM J PATHOL, V156, P651, DOI 10.1016/S0002-9440(10)64769-4; Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013; Fournet JC, 2001, AM J PATHOL, V158, P2177, DOI 10.1016/S0002-9440(10)64689-5; Gicquel C, 1997, J CLIN ENDOCR METAB, V82, P2559, DOI 10.1210/jc.82.8.2559; Haralambieva E, 2002, J PATHOL, V198, P163, DOI 10.1002/path.1197; Jordanova ES, 2002, GENE CHROMOSOME CANC, V35, P38, DOI 10.1002/gcc.10093; Li YM, 1998, J BIOL CHEM, V273, P28247, DOI 10.1074/jbc.273.43.28247; Lui WO, 2002, ONCOGENE, V21, P1117, DOI 10.1038/sj.onc.1205149; MARIMAN ECM, 1993, HUM GENET, V91, P357, DOI 10.1007/BF00217356; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Runge S, 2000, J BIOL CHEM, V275, P29562, DOI 10.1074/jbc.M001156200; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; van Schothorst EM, 1998, AM J HUM GENET, V63, P468, DOI 10.1086/301951; van Schothorst EM, 1998, HUM PATHOL, V29, P1045, DOI 10.1016/S0046-8177(98)90411-7; VANDERMEY AGL, 1991, BRIT J CANCER, V63, P298, DOI 10.1038/bjc.1991.69; VANDERMEY AGL, 1989, LANCET, V2, P1291; WAYE JS, 1987, CHROMOSOMA, V95, P182, DOI 10.1007/BF00330349; WAZIRI M, 1983, J PEDIATR-US, V102, P873, DOI 10.1016/S0022-3476(83)80014-6; Weksberg R, 1996, MED PEDIATR ONCOL, V27, P462, DOI 10.1002/(SICI)1096-911X(199611)27:5<462::AID-MPO13>3.0.CO;2-C	36	106	113	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4076	4083		10.1038/sj.onc.1207591	http://dx.doi.org/10.1038/sj.onc.1207591			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064708				2022-12-17	WOS:000221520200005
J	Carretero, J; Medina, PP; Pio, R; Montuenga, LM; Sanchez-Cespedes, M				Carretero, J; Medina, PP; Pio, R; Montuenga, LM; Sanchez-Cespedes, M			Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene	ONCOGENE			English	Article						LKB1/STK11; Peutz-Jeghers syndrome; lung adenocarcinomas	PEUTZ-JEGHERS-SYNDROME; SYNDROME KINASE LKB1; SOMATIC MUTATIONS; TOBACCO-SMOKE; DNA-DAMAGE; GROWTH; ADENOCARCINOMA; PATTERNS; ARREST; COMMON	Germline mutations of the LKB1 gene are responsible for Peutz-Jeghers syndrome (PJS), an autosomal dominant inherited disorder bestowing an increased risk of cancer. We have recently demonstrated that LKB1 inactivating mutations are not confined to PJS, but also appear in lung adenocarcinomas of sporadic origin, including primary tumors and lung cancer cell lines. To accurately determine the frequency of inactivating LKB1 gene mutations in lung tumors we have sequenced the complete coding region of LKB1 in 21 additional lung cancer cell lines. Here we describe the mutational status of LKB1 gene in 30 lung cancer cell lines from different histopathological types, including 11 lung adenocarcinomas (LADs) and 11 small cell lung cancers (SCLCs). LKB1 gene alterations were present in six (54%) of the LAD cell lines tested but in none of the other histological types. Similar to our previous observations in primary tumors, all point mutations were of the nonsense or frameshift type, leading to an abnormal, truncated protein. Moreover, 2 cell lines (A427 and H2126) harbored large gene deletions that spanned several exons. Hence, we have identified additional lung cancer cell lines carrying inactivating mutations of the LKB1 tumor suppressor gene, further attesting to the significance of this gene in the development of LADs and providing new natural LKB1 knockouts for studies of the biological function of the LKB1 protein.	CNIO, Mol Pathol Program, Lymphoma & Lung Canc Grp, Madrid 28029, Spain; Univ Navarra, Sch Med, Fdn Appl Med Res, Dept Biochem, E-31080 Pamplona, Spain; Univ Navarra, Sch Med, Fdn Appl Med Res, Dept Histol & Pathol, E-31080 Pamplona, Spain; Univ Navarra, Sch Med, Fdn Appl Med Res, Div Oncol, E-31080 Pamplona, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); University of Navarra; University of Navarra; University of Navarra	Sanchez-Cespedes, M (corresponding author), CNIO, Mol Pathol Program, Lymphoma & Lung Canc Grp, Calle Melchor Fernandez Almagro 3, Madrid 28029, Spain.	msanchez@cnio.es	Pio, Ruben/F-5353-2017; Carretero, Julian/N-5214-2014; Montuenga, Luis M/AAF-7783-2020; Vico, Pedro Pablo Medina/D-1688-2013; Sanchez-Cespedes, Montse/H-8485-2012	Pio, Ruben/0000-0002-6831-6111; Carretero, Julian/0000-0001-7269-8506; Montuenga, Luis M/0000-0002-8739-1387; Vico, Pedro Pablo Medina/0000-0002-7834-7093; Sanchez-Cespedes, Montse/0000-0002-6045-5627				Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H; Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jimenez AI, 2003, CANCER RES, V63, P1382; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Marignani PA, 2001, J BIOL CHEM, V276, P32415, DOI 10.1074/jbc.C100207200; Miyaki M, 2000, CANCER RES, V60, P6311; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Sanchez-Cespedes M, 2003, LUNG CANCER, V40, P111, DOI 10.1016/S0169-5002(03)00033-3; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sanchez-Cespedes M, 2001, CANCER RES, V61, P1309; Smith DP, 2001, HUM MOL GENET, V10, P2869, DOI 10.1093/hmg/10.25.2869; Spicer J, 2003, ONCOGENE, V22, P4752, DOI 10.1038/sj.onc.1206669; Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031	24	106	109	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					4037	4040		10.1038/sj.onc.1207502	http://dx.doi.org/10.1038/sj.onc.1207502			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15021901	Green Published			2022-12-17	WOS:000221382000017
J	Catto, JWF; Azzouzi, AR; Amira, N; Rehman, I; Feeley, KM; Cross, SS; Fromont, G; Sibony, M; Hamdy, FC; Cussenot, O; Meuth, M				Catto, JWF; Azzouzi, AR; Amira, N; Rehman, I; Feeley, KM; Cross, SS; Fromont, G; Sibony, M; Hamdy, FC; Cussenot, O; Meuth, M			Distinct patterns of microsatellite instability are seen in tumours of the urinary tract	ONCOGENE			English	Article						microsatellite instability; HNPCC; bladder cancer; upper urinary tract cancer	TRANSITIONAL-CELL CARCINOMA; BLADDER-CANCER; TETRANUCLEOTIDE REPEATS; COLORECTAL-CANCER; YOUNG-PATIENTS; HMLH1; PHENOTYPES; EXPRESSION; MUTATIONS; COLON	To date, two forms of microsatellite instability (MSI) have been described in human cancer. MSI typical of hereditary nonpolyposis colon cancer (HNPCC), is due to deficient DNA mismatch repair (MMR) and is defined with mono- and dinucleotide repeat microsatellites. A second variety of instability is best seen at selective tetranucleotide repeats (EMAST; elevated microsatellite alterations at select tetranucleotides). While MSI occurs infrequently in bladder cancers, EMAST is common. Sporadic tumours with the largest proportion showing MSI are those found most frequently in HNPCC kindreds. While bladder cancer is not frequently seen in HNPCC, upper urinary tract tumours (UTTs) are. Having previously found a low frequency of MSI in bladder cancer, we sought to determine the relative levels of MSI and EMAST in transitional cell carcinoma (TCC) of the upper and lower urinary tracts. Microsatellite analysis was performed at 10 mono- and dinucleotide and eight tetranucleotide loci, in 89 bladder and 71 UTT TCC. Contrasting patterns of instability were seen in urinary tumours. In bladder cancer, MSI was rare and EMAST was common. The presence of EMAST was not related to tumour grade, stage, subsequent outcome or immunohistochemical expression of the MMR proteins. In UTT, while MSI occurred frequently, EMAST was seen less frequently than in bladder cancer. When TCC of the upper and lower urinary tracts are compared, MSI-H is more frequent in UTT and EMAST more frequent in bladder cancer. Our findings show that, as for colorectal cancer, the pattern of MSI varies with location in the urinary tract. In addition, we have confirmed that MSI and EMAST are discrete forms of MSI, and that the presence of EMAST does not affect tumour phenotype.	Univ Sheffield, Inst Canc Studies, Sheffield S10 2TN, S Yorkshire, England; Univ Sheffield, Acad Urol Unit, Sheffield S10 2TN, S Yorkshire, England; Fac Med, Dept Urol, CeRePP EA3104, Paris, France; Royal Hallamshire Hosp, Dept Pathol, Sheffield S10 2JF, S Yorkshire, England; Univ Sheffield, Acad Pathol Unit, Sheffield S10 2TN, S Yorkshire, England; Inst Mutualiste Montsouris, Serv Anatomopathol, Paris, France; Hop Tenon, Serv Anatomopathol, F-75970 Paris, France	University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; Institute Mutualiste Montsouris; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite	Catto, JWF (corresponding author), Royal Hallamshire Hosp, Acad Urol Unit, I Floor,Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.		fromont, gaelle/N-8708-2016	catto, james/0000-0003-2787-8828; Hamdy, Freddie/0000-0003-2627-2154; Cross, Simon/0000-0003-2044-1754; cussenot, olivier/0000-0002-9912-0533				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Ahrendt SA, 2000, CANCER RES, V60, P2488; Arzimanoglou II, 1998, CANCER-AM CANCER SOC, V82, P1808, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1808::AID-CNCR2>3.0.CO;2-J; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; Boland CR, 1998, CANCER RES, V58, P5248; Bonnal C, 2000, UROLOGY, V55, P287, DOI 10.1016/S0090-4295(99)00399-4; Catto JWF, 2003, INT J CANCER, V105, P484, DOI 10.1002/ijc.11109; Christensen M, 1998, INT J CANCER, V79, P396, DOI 10.1002/(SICI)1097-0215(19980821)79:4<396::AID-IJC15>3.0.CO;2-3; Danaee H, 2002, ONCOGENE, V21, P4894, DOI 10.1038/sj.onc.1205619; Dietmaier W, 1997, CANCER RES, V57, P4749; Furihata M, 2000, INT J ONCOL, V16, P491; Furihata M, 2001, J UROLOGY, V165, P1760, DOI 10.1016/S0022-5347(05)66409-9; Gleeson CM, 1996, CANCER RES, V56, P259; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201; Hartmann A, 2002, CANCER RES, V62, P6796; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Kuismanen SA, 1999, P NATL ACAD SCI USA, V96, P12661, DOI 10.1073/pnas.96.22.12661; Li MM, 1996, AM J PATHOL, V149, P229; LINNENBACH AJ, 1994, NATURE, V367, P419, DOI 10.1038/367419b0; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; Ottini L, 1997, CANCER RES, V57, P4523; Samowitz WS, 2001, AM J PATHOL, V158, P1517, DOI 10.1016/S0002-9440(10)64102-8; Slebos RJC, 2002, CANCER RES, V62, P6052; Steiner G, 1997, NAT MED, V3, P621, DOI 10.1038/nm0697-621; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#; Xu LH, 2001, INT J CANCER, V91, P200, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1031>3.0.CO;2-0	28	106	107	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8699	8706		10.1038/sj.onc.1206964	http://dx.doi.org/10.1038/sj.onc.1206964			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647464	Bronze			2022-12-17	WOS:000186844900007
J	Rangel, LBA; Sherman-Baust, CA; Wernyj, RP; Schwartz, DR; Cho, KR; Morin, PJ				Rangel, LBA; Sherman-Baust, CA; Wernyj, RP; Schwartz, DR; Cho, KR; Morin, PJ			Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression	ONCOGENE			English	Article						ovarian cancer; biomarkers; HOST; gene expression; SAGE	EPITHELIAL-CELLS; MESSENGER-RNA; TUMOR; OVEREXPRESSION; CARCINOMA; STAGE; H19; COTRANSPORTER; CYSTADENOMAS; PATTERNS	A better understanding of changes in gene expression during ovarian tumorigenesis and the identification of specific tumor markers may lead to novel strategies for diagnosis and therapy for this disease. Using our serial analysis of gene expression ( SAGE) data, as well as public SAGE databases that contained a total of 137 SAGE libraries representing a wide variety of normal and neoplastic tissues, we identified five novel SAGE tags specifically expressed in ovarian cancer. Database analysis, cloning and, sequencing of the corresponding expressed sequence tags revealed details about these transcripts that we named human ovarian cancer-specific transcripts (HOSTs). HOST1 was found to be identical to the gene encoding ovarian marker CA125 (MUC16). HOST2 is a novel gene containing multiple copies of retroviral-related sequences without an obvious open reading frame. HOST3 encodes the tight-junction protein claudin-16 (CLDN16). HOST4 encodes a poorly characterized proteoglycan link protein (LP), and HOST5 codes for a type II sodium-dependent phosphate transporter (SLC34A2). Except for MUC16, these genes have not previously been shown to be expressed in ovarian or other cancers. Northern blot analysis confirmed that HOST genes are rarely expressed in normal tissues or nonovarian cancers, but are frequently expressed in ovarian cancer-derived cell lines and primary tumors. Moreover, HOST genes are upregulated in all four major subtypes of ovarian cancer compared to cultivated ovarian surface epithelial cells, as concluded by real-time reverse transcription (RT)-PCR using a panel of microdissected ovarian tumors. The sodium-dependent phosphate transporter (HOST5/SLC34A2) expression was associated with increased differentiation in ovarian serous tumors. While the roles of HOSTs in ovarian malignant transformation remain unclear, we propose that HOSTs may represent alternative targets for diagnosis and therapy and of this deadly disease.	NIA, Cellular & Mol Biol Lab, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Fed Rio de Janeiro, Dept Basic & Clin Pharmacol, Rio De Janeiro, Brazil; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21287 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Michigan System; University of Michigan; Universidade Federal do Rio de Janeiro; Johns Hopkins University; Johns Hopkins Medicine	Morin, PJ (corresponding author), NIA, Cellular & Mol Biol Lab, Gerontol Res Ctr, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	morinp@grc.nia.nih.gov	Rangel, Leticia B/E-6241-2018	Rangel, Leticia B/0000-0002-6150-4064; Cho, Kathleen/0000-0003-0500-9998	NATIONAL INSTITUTE ON AGING [Z01AG000512] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Bast RC, 1998, INT J BIOL MARKER, V13, P179, DOI 10.1177/172460089801300402; Berek JS, 1999, ANN ONCOL, V10, P87, DOI 10.1023/A:1008323922057; Boon K, 2002, P NATL ACAD SCI USA, V99, P11287, DOI 10.1073/pnas.152324199; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Erdmann VA, 2000, NUCLEIC ACIDS RES, V28, P197, DOI 10.1093/nar/28.1.197; Folz RJ, 2000, BIOTECHNIQUES, V29, P762, DOI 10.2144/00294st01; Gregoire L, 1998, IN VITRO CELL DEV-AN, V34, P636; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hashimoto M, 2000, AM J PATHOL, V157, P21, DOI 10.1016/S0002-9440(10)64512-9; Hellstrom I, 2003, CANCER RES, V63, P3695; Hoskins WJ, 1995, J CELL BIOCHEM, P189; Hough CD, 2001, CANCER RES, V61, P3869; Hough CD, 2000, CANCER RES, V60, P6281; Ismail RS, 2000, CANCER RES, V60, P6744; Lal A, 1999, CANCER RES, V59, P5403; Lottin S, 2002, CARCINOGENESIS, V23, P1885, DOI 10.1093/carcin/23.11.1885; Luo MP, 1997, GYNECOL ONCOL, V67, P277, DOI 10.1006/gyno.1997.4880; MAKAR AP, 1995, GYNECOL ONCOL, V56, P175, DOI 10.1006/gyno.1995.1027; MANN WJ, 1988, J NATL CANCER I, V80, P208, DOI 10.1093/jnci/80.3.208; Mashima H, 2001, DIABETES, V50, pS39, DOI 10.2337/diabetes.50.2007.S39; Mazurek A, 1998, EUR J CANCER PREV, V7, P23; Murer H, 2000, PHYSIOL REV, V80, P1373, DOI 10.1152/physrev.2000.80.4.1373; OZOLS RF, 1980, CANCER-AM CANCER SOC, V45, P572, DOI 10.1002/1097-0142(19800201)45:3<572::AID-CNCR2820450325>3.0.CO;2-3; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Rangel LBA, 2003, CLIN CANCER RES, V9, P2567; RIGGINS GJ, 2002, GENETIC BASIS HUMAN, P131; Sawiris GP, 2002, CANCER RES, V62, P2923; Schummer M, 1999, GENE, V238, P375, DOI 10.1016/S0378-1119(99)00342-X; Schwartz DR, 2002, CANCER RES, V62, P4722; Sherman-Baust CA, 2003, CANCER CELL, V3, P377, DOI 10.1016/S1535-6108(03)00058-8; Shimizu Y, 1998, CANCER-AM CANCER SOC, V82, P893, DOI 10.1002/(SICI)1097-0142(19980301)82:5<893::AID-CNCR14>3.0.CO;2-W; Shridhar V, 2001, CANCER RES, V61, P5895; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; Yin BWT, 2001, J BIOL CHEM, V276, P27371, DOI 10.1074/jbc.M103554200; Yousef GM, 2003, CANCER RES, V63, P2223	37	106	136	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2003	22	46					7225	7232		10.1038/sj.onc.1207008	http://dx.doi.org/10.1038/sj.onc.1207008			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562052				2022-12-17	WOS:000185955000015
J	Hooper, JD; Zijlstra, A; Aimes, RT; Liang, HY; Claassen, GF; Tarin, D; Testa, JE; Quigley, JP				Hooper, JD; Zijlstra, A; Aimes, RT; Liang, HY; Claassen, GF; Tarin, D; Testa, JE; Quigley, JP			Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen	ONCOGENE			English	Article						subtractive immunization; metastasis; SIMA135/CDCP1; proteomics; colon cancer; CUB	MONOCLONAL-ANTIBODIES; SERINE PROTEASES; PROTEINS; BINDING; ACTIVATION; EXPRESSION; PHENOTYPE; DOMAINS; CANCER; GROWTH	We have previously used a subtractive immunization (SI) approach to generate monoclonal antibodies (mAbs) against proteins preferentially expressed by the highly metastatic human epidermoid carcinoma cell line, M(+)HEp3. Here we report the immunopurification, identification and characterization of SIMA135/CDCP1 (subtractive immunization M(+)HEp3 associated 135kDa protein/CUB domain containing protein 1) using one of these mAbs designated 41-2. Protein expression levels of SIMA135/CDCP1 correlated with the metastatic ability of variant HEp3 cell lines. Protein sequence analysis predicted a cell surface location and type I orientation of SIMA135/CDCP1, which was confirmed directly by immunocytochemistry. Analysis of deglycosylated cell lysates indicated that up to 40 kDa of the apparent molecular weight of SIMA135/CDCP1 is because of N-glycosylation. Western blot analysis using a antiphosphotyrosine antibody demonstrated that SIMA135/CDCP1 from HEp3 cells is tyrosine phosphorylated. Selective inhibitor studies indicated that an Src kinase family member is involved in the tyrosine phosphorylation of the protein. In addition to high expression in M(+)HEp3 cells, the SIMA135/CDCP1 protein is expressed to varying levels in 13 other human tumor cell lines, manifesting only a weak correlation with the reported metastatic ability of these tumor cell lines. The protein is not detected in normal human fibroblasts and endothelial cells. Northern blot analysis indicated that SIMA135/CDCP1 mRNA has a restricted expression pattern in normal human tissues with highest levels of expression in skeletal muscle and colon. Immunohistochemical analysis indicated apical and basal plasma membrane expression of SIMA135/CDCP1 in epithelial cells in normal colon. in colon tumor, SIMA135/CDCP1 expression appeared dysregulated showing extensive cell surface as well as cytoplasmic expression. Consistent with in vitro shedding experiments on HEp3 cells, SIMA135/CDCP1 was also detected within the lumen of normal and cancerous colon crypts, suggesting that protein shedding may occur in vivo. Thus, specific immunodetection followed by proteomic analysis allows for the identification and partial characterization of a heretofore uncharacterized human cell surface antigen.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	Scripps Research Institute; University of California System; University of California San Diego	Quigley, JP (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jquigley@scripps.edu	Hooper, John/C-1481-2016; Hooper, John/B-4153-2011; zijlstra, andries/G-4564-2013	Hooper, John/0000-0003-1054-8486; zijlstra, andries/0000-0001-8460-8803	NATIONAL CANCER INSTITUTE [R01CA065660] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, T32HL007195, T32HL007695] Funding Source: NIH RePORTER; NCI NIH HHS [CA65660] Funding Source: Medline; NHLBI NIH HHS [T32 HL07195, HL31950, T32 HL07695] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADHAM IM, 1990, HUM GENET, V84, P125; Bajorath J, 2000, PROTEINS, V39, P103, DOI 10.1002/(SICI)1097-0134(20000501)39:2<103::AID-PROT1>3.3.CO;2-7; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; BROOKS PC, 1993, J CELL BIOL, V122, P1351, DOI 10.1083/jcb.122.6.1351; Chen CB, 2001, J BIOL CHEM, V276, P25894, DOI 10.1074/jbc.M103539200; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Goebeler M, 1996, J CELL SCI, V109, P1957; Gorelik E, 2001, CANCER METAST REV, V20, P245, DOI 10.1023/A:1015535427597; Grogan MJ, 2002, ANNU REV BIOCHEM, V71, P593, DOI 10.1146/annurev.biochem.71.110601.135334; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hansen SG, 1999, VIROLOGY, V254, P124, DOI 10.1006/viro.1998.9543; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; KING SW, 1988, BIOTECHNIQUES, V6, P856; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Maruo Y, 2002, INT J CANCER, V100, P486, DOI 10.1002/ijc.10514; MATTHEW WD, 1983, COLD SPRING HARB SYM, V48, P625, DOI 10.1101/SQB.1983.048.01.066; Mayer BJ, 2001, J CELL SCI, V114, P1253; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NIELSENPREISS SM, 1993, J CELL BIOCHEM, V51, P219, DOI 10.1002/jcb.240510214; OSSOWSKI L, 1983, CELL, V33, P323, DOI 10.1016/0092-8674(83)90414-2; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Riggott MJ, 1996, J NEUROSCI METH, V68, P235; Rye PD, 2001, TUMOR BIOL, V22, P269, DOI 10.1159/000050626; Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Sieron AL, 2000, BIOCHEMISTRY-US, V39, P3231, DOI 10.1021/bi992312o; Sleister HM, 2002, J IMMUNOL METHODS, V261, P213, DOI 10.1016/S0022-1759(01)00567-1; Soos G, 1997, ANTICANCER RES, V17, P4253; Stocker J W, 1976, Contemp Top Immunobiol, V5, P191; TESTA JE, 1992, CANCER RES, V52, P5597; Testa JE, 1999, CANCER RES, V59, P3812; Wajih N, 2002, CIRC RES, V90, P46, DOI 10.1161/hh0102.102756; WILLIAMS CV, 1992, BIOTECHNIQUES, V12, P842; Yammani RR, 2001, J BIOL CHEM, V276, P44777, DOI 10.1074/jbc.M106419200; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	106	115	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1783	1794		10.1038/sj.onc.1206220	http://dx.doi.org/10.1038/sj.onc.1206220			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660814				2022-12-17	WOS:000181678200005
J	Sedgwick, B; Lindahl, T				Sedgwick, B; Lindahl, T			Recent progress on the Ada response for inducible repair of DNA alkylation damage	ONCOGENE			English	Article						DNA repair; O-6-methylguanine; DNA glycosylases	COLI ALKB MUTANTS; ESCHERICHIA-COLI; ADAPTIVE RESPONSE; EXCISION-REPAIR; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; CONTROLS SENSITIVITY; SPONTANEOUS MUTATION; METHYLATING AGENTS; FUNCTIONAL SWITCH		Canc Res Uk London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Cancer Research UK	Lindahl, T (corresponding author), Canc Res Uk London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.							AKIMARU H, 1990, J MOL BIOL, V216, P261, DOI 10.1016/S0022-2836(05)80318-3; ARAVIND L, 2001, GENOME BIOL, V2; Berdal KG, 1998, EMBO J, V17, P363, DOI 10.1093/emboj/17.2.363; BHASIN N, 1995, MUTAT RES-DNA REPAIR, V336, P79, DOI 10.1016/0921-8777(94)00044-7; BODELL WJ, 1979, BIOCHEMISTRY-US, V18, P2860, DOI 10.1021/bi00580a029; BOITEUX S, 1982, BIOCHIMIE, V64, P637, DOI 10.1016/S0300-9084(82)80103-X; CALMELS S, 1987, CARCINOGENESIS, V8, P1085, DOI 10.1093/carcin/8.8.1085; CHEN BRJ, 1994, J BACTERIOL, V176, P6255, DOI 10.1128/jb.176.20.6255-6261.1994; Cheng XD, 2001, NUCLEIC ACIDS RES, V29, P3784, DOI 10.1093/nar/29.18.3784; CLARKE ND, 1984, MOL GEN GENET, V197, P368, DOI 10.1007/BF00329931; Colombi D, 1997, J BACTERIOL, V179, P3139, DOI 10.1128/jb.179.10.3139-3145.1997; CRUTZEN PJ, 1990, SCIENCE, V250, P1669, DOI 10.1126/science.250.4988.1669; Daniels DS, 2000, MUTAT RES-DNA REPAIR, V460, P151, DOI 10.1016/S0921-8777(00)00024-0; DEMPLE B, 1985, P NATL ACAD SCI USA, V82, P2688, DOI 10.1073/pnas.82.9.2688; Dinglay S, 2000, GENE DEV, V14, P2097; Falnes PO, 2002, NATURE, V419, P178, DOI 10.1038/nature01048; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Gasparutto D, 2002, DNA REPAIR, V1, P437, DOI 10.1016/S1568-7864(02)00016-2; Harrison KL, 1999, CHEM RES TOXICOL, V12, P106, DOI 10.1021/tx980057n; HIX S, 1995, FREE RADICAL BIO MED, V19, P293, DOI 10.1016/0891-5849(95)00026-T; Hollis T, 2000, MUTAT RES-DNA REPAIR, V460, P201, DOI 10.1016/S0921-8777(00)00027-6; KATAOKA H, 1983, J BACTERIOL, V153, P1301, DOI 10.1128/JB.153.3.1301-1307.1983; KUNISAKI N, 1979, APPL ENVIRON MICROB, V37, P279, DOI 10.1128/AEM.37.2.279-282.1979; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; LANDINI P, 1994, J BACTERIOL, V176, P6583, DOI 10.1128/JB.176.21.6583-6589.1994; Landini P, 2000, J BACTERIOL, V182, P6543, DOI 10.1128/JB.182.23.6543-6549.2000; LARSON K, 1985, MUTAT RES, V150, P77, DOI 10.1016/0027-5107(85)90103-4; Lin YX, 2001, BIOCHEMISTRY-US, V40, P4261, DOI 10.1021/bi002109p; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; Lizcano JM, 2000, ANAL BIOCHEM, V286, P75, DOI 10.1006/abio.2000.4782; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Matthews RG, 1997, CURR OPIN CHEM BIOL, V1, P332, DOI 10.1016/S1367-5931(97)80070-1; Monti P, 2002, J BIOL CHEM, V277, P28663, DOI 10.1074/jbc.M203384200; MOORE MH, 1994, EMBO J, V13, P1495, DOI 10.1002/j.1460-2075.1994.tb06410.x; MOROHOSHI F, 1993, J BACTERIOL, V175, P6010, DOI 10.1128/JB.175.18.6010-6017.1993; MOROHOSHI F, 1995, MUTAT RES-DNA REPAIR, V337, P97, DOI 10.1016/0921-8777(95)00013-A; MYERS LC, 1994, CURR OPIN STRUC BIOL, V4, P51, DOI 10.1016/S0959-440X(94)90059-0; O'Rourke EJ, 2000, J BIOL CHEM, V275, P20077, DOI 10.1074/jbc.M001071200; Posnick LM, 1999, J BACTERIOL, V181, P6756, DOI 10.1128/JB.181.21.6756-6762.1999; Posnick LM, 1999, J BACTERIOL, V181, P6763, DOI 10.1128/JB.181.21.6763-6771.1999; POTTER PM, 1989, NUCLEIC ACIDS RES, V17, P8047, DOI 10.1093/nar/17.20.8047; Prescott AG, 2000, NAT PROD REP, V17, P367, DOI 10.1039/a902197c; Privezentzev CV, 2000, BIOCHEMISTRY-US, V39, P14263, DOI 10.1021/bi001337g; REBECK GW, 1989, J BACTERIOL, V171, P4563, DOI 10.1128/jb.171.9.4563-4568.1989; Rebeil R, 2001, P NATL ACAD SCI USA, V98, P9038, DOI 10.1073/pnas.161278998; Ryle MJ, 2002, CURR OPIN CHEM BIOL, V6, P193, DOI 10.1016/S1367-5931(02)00302-2; SAGET BM, 1994, P NATL ACAD SCI USA, V91, P9730, DOI 10.1073/pnas.91.21.9730; SAKASHITA H, 1995, P JPN ACAD B-PHYS, V71, P198, DOI 10.2183/pjab.71.198; SAKUMI K, 1989, J MOL BIOL, V205, P373, DOI 10.1016/0022-2836(89)90348-3; SAMSON L, 1992, MOL MICROBIOL, V6, P825, DOI 10.1111/j.1365-2958.1992.tb01533.x; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Schofield CJ, 1999, CURR OPIN STRUC BIOL, V9, P722, DOI 10.1016/S0959-440X(99)00036-6; Sedgwick B, 1997, CARCINOGENESIS, V18, P1561, DOI 10.1093/carcin/18.8.1561; SEDGWICK B, 1991, MUTAT RES, V250, P211, DOI 10.1016/0027-5107(91)90178-Q; SEDGWICK B, 1988, J BIOL CHEM, V263, P4430; SEEBERG E, 1999, BASE EXCISION REPAIR, P151; Singer B., 1983, MOL BIOL MUTAGENS CA; TAKAHASHI K, 1987, MUTAT RES, V180, P163, DOI 10.1016/0027-5107(87)90211-9; Taverna P, 1996, J BACTERIOL, V178, P5105, DOI 10.1128/jb.178.17.5105-5111.1996; TEO I, 1986, CELL, V45, P315, DOI 10.1016/0092-8674(86)90396-X; THORNBURG LD, 1993, BIOCHEMISTRY-US, V32, P14023, DOI 10.1021/bi00213a036; Trewick SC, 2002, NATURE, V419, P174, DOI 10.1038/nature00908; VAUGHAN P, 1991, CARCINOGENESIS, V12, P263, DOI 10.1093/carcin/12.2.263; VAUGHAN P, 1993, MUTAT RES, V293, P249, DOI 10.1016/0921-8777(93)90076-S; VOLKERT MR, 1994, J BACTERIOL, V176, P7638, DOI 10.1128/JB.176.24.7638-7645.1994; Vora RA, 1998, PROTEINS, V32, P3; WEI YF, 1995, J BACTERIOL, V177, P5009, DOI 10.1128/jb.177.17.5009-5015.1995; Yamagata Y, 1996, CELL, V86, P311, DOI 10.1016/S0092-8674(00)80102-6; YAMAMOTO Y, 1978, J BACTERIOL, V135, P144, DOI 10.1128/JB.135.1.144-152.1978; YANG CS, 1996, BIOL REACT INTERMED, V5, P385; Zhang ZH, 2000, NAT STRUCT BIOL, V7, P127	71	106	111	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	2002	21	58					8886	8894		10.1038/sj.onc.1205998	http://dx.doi.org/10.1038/sj.onc.1205998			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483506				2022-12-17	WOS:000179889500001
J	Liu, YM; Ludes-Meyers, J; Zhang, Y; Munoz-Medellin, D; Kim, HT; Lu, CH; Ge, GQ; Schiff, R; Hilsenbeck, SG; Osborne, CK; Brown, PH				Liu, YM; Ludes-Meyers, J; Zhang, Y; Munoz-Medellin, D; Kim, HT; Lu, CH; Ge, GQ; Schiff, R; Hilsenbeck, SG; Osborne, CK; Brown, PH			Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth	ONCOGENE			English	Article						AP-1; breast cancer; estrogen; peptide growth factor	DOMINANT-NEGATIVE MUTANT; C-JUN; ESTROGEN-RECEPTOR; RESISTANT PHENOTYPE; RETINOIC ACID; DNA-BINDING; CELL-GROWTH; FOS; ACTIVATION; TRANSFORMATION	AP-1 transcription factors play a critical role in signal transduction pathways in many cells. We have investigated the role of AP-1 in controlling proliferative signals in breast cells, and have previously shown that AP-1 complexes are activated by peptide and steroid growth factors in both normal and malignant breast cells. In this study, we investigated the role of AP-1 in transducing proliferative signals induced by peptide and steroid growth factors. We used MCF-7 clones that express a specific inhibitor of AP-1, a dominant-negative cJun mutant (TAM67), under the control of an inducible promoter to investigate the role of AP-1 in regulating breast cancer growth. In the presence of doxycycline (Dox), the AP-1 inhibitor was not expressed, and the MCF-7 clones proliferated normally in response to serum stimulation. However, when Dox was withdrawn, TAM67 was expressed, AP-1 activity was inhibited, and serum-induced proliferation was blocked. We next investigated whether the mitogenic response to specific growth factors also requires AP-1. MCF-7 Tet-Off-TAM67 cells were grown in the presence of increasing concentrations of IGF-1, EGF, heregulin-beta, bFGF, or estrogen under un-induced and induced conditions. These studies showed that the AP-1 inhibitor completely blocked proliferation in response to the peptide growth factors (IGF-1, EGF, heregulin-beta, and bFGF), and partially blocked the response to estrogen. To investigate the effect of AP-1 blockade on in vivo tumor growth, we injected the MCF-7 Tet-Off TAM67 cells into nude mice receiving doxycycline to suppress the expression of the AP-1 inhibitor. After the mice developed tumors, they were randomized to either continue to receive Dox or not. In mice not receiving Dox, the expression of TAM67 was induced, and tumor growth was inhibited, while the tumors in mice receiving Dox continued to grow. Analysis of the tumors from these mice showed that the expression of TAM67 caused reduced proliferation of the breast cancer cells without inducing apoptosis. These results demonstrate that AP-1 blockade supresses mitogenic signals from multiple different peptide growth factors as well as estrogen, and inhibits the growth of MCF-7 breast cancer cells both in vitro and in vivo. These results suggest that novel agents specifically targeting AP-1 or its activating kinases could be promising agents for the treatment of breast cancer.	Baylor Coll Med, Dept Med, Breast Ctr, Houston, TX 77030 USA; Baylor Coll Med, Breast Ctr, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX 78284 USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Health San Antonio	Brown, PH (corresponding author), Baylor Coll Med, Dept Med, Breast Ctr, 1 Baylor Plaza,MS 600, Houston, TX 77030 USA.			Brown, Powel/0000-0002-3398-163X	NATIONAL CANCER INSTITUTE [P50CA058183] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58183] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLIS CD, 1981, BIOCHEMISTRY-US, V20, P3828, DOI 10.1021/bi00516a025; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BASELGA J, 1994, BREAST CANCER RES TR, V29, P127, DOI 10.1007/BF00666188; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; DREBIN JA, 1988, ONCOGENE, V2, P387; Dumont JA, 1996, CELL GROWTH DIFFER, V7, P351; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HARRIS JR, 1993, CANC PRINCIPLES PRAC, P1264; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Liebermann DA, 1998, INT J ONCOL, V12, P685; Lin F, 2000, CANCER RES, V60, P3271; Ludes-Meyers JH, 2001, ONCOGENE, V20, P2771, DOI 10.1038/sj.onc.1204377; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PAULSON JR, 1982, J BIOL CHEM, V257, P6064; RAPP UR, 1994, ONCOGENE, V9, P3493; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SARUP JC, 1991, GROWTH REGULAT, V1, P72; Schiff R, 2000, J NATL CANCER I, V92, P1926, DOI 10.1093/jnci/92.23.1926; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Yang LM, 1997, CANCER RES, V57, P4652	34	106	113	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7680	7689		10.1038/sj.onc.1205883	http://dx.doi.org/10.1038/sj.onc.1205883			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400010				2022-12-17	WOS:000178756200007
J	Jepson, S; Komatsu, M; Haq, B; Arango, ME; Huang, DM; Carraway, CAC; Carraway, KL				Jepson, S; Komatsu, M; Haq, B; Arango, ME; Huang, DM; Carraway, CAC; Carraway, KL			Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27(kip), but does not activate mitogen-activated kinase or protein kinase B/Akt pathways	ONCOGENE			English	Article						Muc4; ErbB2; tyrosine phosphorylation; apoptosis; p27(kip); signaling	SURFACE SIALOMUCIN COMPLEX; RECEPTOR TYROSINE KINASE; GLYCOPROTEIN COMPLEX; SIGNALING NETWORK; MOLECULAR-CLONING; OCULAR SURFACE; RAT MUC4; GROWTH; LOCALIZATION; CELLS	Muc4/sialomucin complex (SMC) is a multifunctional glycoprotein complex which can repress apoptosis in transfected tumor cells. Its transmembrane subunit acts as an intramembrane ligand for the receptor tyrosine kinase ErbB2 to induce the phosphorylation of ErbB2 and, by acting synergistically with the ErbB3 ligand neuregulin, can potentiate the phosphorylation of ErbB2 and ErbB3. In the present study we show that Muc4/SMC alone robustly induces the phosphorylation of ErbB2 to enhance the tyrosine phosphate epitope (Tyr1248) recognized by anti-phospho-ErbB2. Although this tyrosine phosphorylation has been implicated in cell transformation, it does not activate any of the three mitogen-activated protein kinases (MAPKs) or protein kinase B/Akt of the phosphatidyl inositol 3-kinase pathway. Instead, Muc4/SMC expression induces up-regulation of the cell cycle inhibitor p27(kip), consistent with the expression of Muc4/SMC in differentiated, rather than proliferative, epithelial cells. Interestingly, a combination of Muc4/SMC and neuregulin down-regulate p27(kip) and activate protein kinase B/Akt. These observations suggest that Muc4/SMC acts as a regulator of differentiation by inducing a limited phosphorylation of ErbB2 and a modulator of proliferation when acting synergistically with neuregulin to induce a more extensive phosphorylation on both ErbB2 and ErbB3.	Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Biochem, Miami, FL 33101 USA	University of Miami; University of Miami	Carraway, KL (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat, R-124,POB 016960, Miami, FL 33101 USA.	Kcarrawa@med.miami.edu		Komatsu, Masanobu/0000-0001-7548-137X	NATIONAL CANCER INSTITUTE [R01CA074072] Funding Source: NIH RePORTER; NCI NIH HHS [CA74072] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Arango ME, 2001, INVEST OPHTH VIS SCI, V42, P2749; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Carraway KL, 2002, PROG NUCLEIC ACID RE, V71, P149, DOI 10.1016/S0079-6603(02)71043-X; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 2001, CURR OPIN CELL BIOL, V13, P125, DOI 10.1016/S0955-0674(00)00188-5; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CARRAWAY KL, 1986, MOL CELL BIOCHEM, V72, P109; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HULL SR, 1990, BIOCHEM J, V265, P121, DOI 10.1042/bj2650121; Idris N, 1999, BIOL REPROD, V61, P1431, DOI 10.1095/biolreprod61.6.1431; Idris N, 2001, J CELL PHYSIOL, V189, P162, DOI 10.1002/jcp.10012; Idris N, 2000, J CELL PHYSIOL, V185, P310, DOI 10.1002/1097-4652(200011)185:2<310::AID-JCP16>3.0.CO;2-W; Klapper LN, 2000, ADV CANCER RES, V77, P25; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 2001, ONCOGENE, V20, P461, DOI 10.1038/sj.onc.1204106; Komatsu M, 1999, CANCER RES, V59, P2229; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Li P, 2001, TISSUE CELL, V33, P111, DOI 10.1054/tice.2000.0162; McNeer RR, 1998, J CELL PHYSIOL, V176, P110, DOI 10.1002/(SICI)1097-4652(199807)176:1<110::AID-JCP13>3.3.CO;2-U; McNeer RR, 1998, BIOCHEM J, V330, P737, DOI 10.1042/bj3300737; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Pflugfelder SC, 2000, INVEST OPHTH VIS SCI, V41, P1316; Price-Schiavi A, 1998, BIOCHEM J, V335, P457, DOI 10.1042/bj3350457; Price-Schiavi SA, 1998, J BIOL CHEM, V273, P35228, DOI 10.1074/jbc.273.52.35228; RICCI A, 1995, ONCOGENE, V11, P1519; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rossi EA, 1996, J BIOL CHEM, V271, P33476, DOI 10.1074/jbc.271.52.33476; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Weed DT, 2001, OTOLARYNG HEAD NECK, V124, P127, DOI 10.1067/mhn.2001.112575; WU K, 1994, J BIOL CHEM, V269, P11950; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	40	106	112	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7524	7532		10.1038/sj.onc.1205970	http://dx.doi.org/10.1038/sj.onc.1205970			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386815				2022-12-17	WOS:000178618200008
J	Arentson, E; Faloon, P; Seo, J; Moon, E; Studts, JM; Fremont, DH; Choi, KH				Arentson, E; Faloon, P; Seo, J; Moon, E; Studts, JM; Fremont, DH; Choi, KH			Oncogenic potential of the DNA replication licensing protein CDT1	ONCOGENE			English	Article						CDT1; retroviral insertional activation; oncogene	APRT LOCUS; CELL-CYCLE; COILED COILS; GENE; HETEROZYGOSITY; SEQUENCES; MUTATION; CANCER; YEAST; RETINOBLASTOMA	The expression of a gene, designated as Retroviral insertion site (Ris)2, was activated by retroviral DNA integration in an immortalized primitive erythroid cell line, EB-PE. Ris2 was also expressed at high levels in all human tumor cell lines analysed. Consistently, NIH3T3 fibroblasts overexpressing Ris2 formed tumors in Rag2(-/-) mice when injected subcutaneously. The putative RIS2 protein shows a high sequence similarity to Xenopus CDT1, Drosophila DUP, and human CDT1, a newly identified DNA replication licensing protein, suggesting that Ris2 is a mouse homologue of CDT1. Cells overexpressing Ris2/Cdt1 exhibited a quicker entry into S phase when released from serum starvation compared to controls. Our results suggest that CDT1, an essential licensing protein for DNA replication, can function as an oncogene in mammals.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Ajou Univ, Dept Biol Sci, Suwon 441749, South Korea	Washington University (WUSTL); Ajou University	Choi, KH (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid Ave,Campus Box 8118, St Louis, MO 63110 USA.	kchoi@pathology.wustl.edu		Fremont, Daved/0000-0002-8544-2689				BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; Blow JJ, 2000, NATURE, V404, P560, DOI 10.1038/35007187; Choi K, 1998, DEVELOPMENT, V125, P725; DEWYSE P, 1989, SOMAT CELL MOLEC GEN, V15, P19, DOI 10.1007/BF01534666; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Fujita Masatoshi, 1999, Frontiers in Bioscience, V4, pd816, DOI 10.2741/Fujita; GUPTA PK, 1994, ADV EXP MED BIOL, V370, P653; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HARWOOD J, 1995, SOMAT CELL MOLEC GEN, V21, P151, DOI 10.1007/BF02254767; HIRAMA T, 1995, BLOOD, V86, P841; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lygerou Z, 2000, SCIENCE, V290, P2271; Madine M, 2001, NAT CELL BIOL, V3, pE49, DOI 10.1038/35055158; MAINE GT, 1984, GENETICS, V106, P365; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; MOIR D, 1982, GENETICS, V100, P547; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Nusse R, 1991, Curr Top Microbiol Immunol, V171, P43; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PHEAR G, 1989, J MOL BIOL, V209, P577, DOI 10.1016/0022-2836(89)90595-0; QUINTANA DG, 1999, FRONT BIOSCI, V4, P805, DOI DOI 10.2741/QUINTANA; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Shao CS, 1999, P NATL ACAD SCI USA, V96, P9230, DOI 10.1073/pnas.96.16.9230; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Stambrook PJ, 1996, ENVIRON MOL MUTAGEN, V28, P471; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Van Sloun PPH, 1998, NUCLEIC ACIDS RES, V26, P4888, DOI 10.1093/nar/26.21.4888; Whittaker AJ, 2000, GENE DEV, V14, P1765; Wijnhoven SWP, 1998, P NATL ACAD SCI USA, V95, P13759, DOI 10.1073/pnas.95.23.13759; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Yuen D, 1998, BLOOD, V91, P3202, DOI 10.1182/blood.V91.9.3202.3202_3202_3209; ZHU Y, 1993, MOL CARCINOGEN, V8, P138, DOI 10.1002/mc.2940080304	45	106	110	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1150	1158		10.1038/sj.onc.1205175	http://dx.doi.org/10.1038/sj.onc.1205175			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850834				2022-12-17	WOS:000173729400002
J	White, DE; Cardiff, RD; Dedhar, S; Muller, WJ				White, DE; Cardiff, RD; Dedhar, S; Muller, WJ			Mammary epithelial-specific expression of the integrin linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice	ONCOGENE			English	Article						integrin linked kinase; ILK; transgenic mice; mammary epithelium; breast cancer; tumorigenesis	AP-1 TRANSCRIPTION FACTOR; GLYCOGEN-SYNTHASE KINASE; PROTEIN-KINASE; CELL-ADHESION; BETA-CATENIN; PHENOTYPE; OVEREXPRESSION; INHIBITION; ACTIVATION; B/AKT	The integrin linked kinase (ILK) is a cytoplasmic effector of integrin receptors, involved in the regulation of integrin binding properties as well as the activation of cell survival and proliferative pathways, including those involving MAP kinase, PKB/Akt and GSK-3 beta. Overexpression of ILK in cultured intestinal and mammary epithelial cells has been previously shown to induce changes characteristic of oncogenic transformation, including anchorage-independent growth, invasiveness, suppression of anoikis and tumorigenicity in nude mice. In order to determine if ILK overexpression can result in the formation of mammary tumors in vivo, we generated transgenic mice expressing ILK in the mammary epithelium, under the transcriptional control of the mouse mammary tumor virus (MMTV) long terminal repeat (LTR). By the age of 6 months, female MMTV/ILK mice developed a hyperplastic mammary phenotype, which was accompanied by the constitutive phosphorylation of PKB/Akt, GSK-3 beta and MAP kinase. Focal mammary tumors subsequently appeared in 34% of the animals at an average age of 18 months. Given the focal nature and long latency of the tumors, however, additional genetic events are likely required for tumor induction in the MMTV/ILK mice. These results provide the first direct demonstration of a potential oncogenic role for ILK, which is upregulated in human tumors and tumor cell lines.	McMaster Univ, MOBIX, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Med Sci, Hamilton, ON L8S 4K1, Canada; Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA; British Columbia Canc Agcy, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6H 3Z6, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8S 4K1, Canada	McMaster University; McMaster University; University of California System; University of California Davis; British Columbia Cancer Agency; University of British Columbia; University of British Columbia; McMaster University	Muller, WJ (corresponding author), McMaster Univ, MOBIX, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.	mullerw@mcmaster.ca		Dedhar, Shoukat/0000-0003-4355-1657				Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chung DH, 1998, VIRCHOWS ARCH, V433, P113, DOI 10.1007/s004280050225; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Graff JR, 2001, CLIN CANCER RES, V7, P1987; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Huang Y, 2000, J CELL BIOL, V150, P861, DOI 10.1083/jcb.150.4.861; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Janji B, 2000, ONCOGENE, V19, P3069, DOI 10.1038/sj.onc.1203640; Janji B, 1999, INT J CANCER, V83, P255, DOI 10.1002/(SICI)1097-0215(19991008)83:2<255::AID-IJC18>3.3.CO;2-O; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Schmeichel KL, 1998, J MAMMARY GLAND BIOL, V3, P201, DOI 10.1023/A:1018751124382; Seger D, 2001, J BIOL CHEM, V276, P16998, DOI 10.1074/jbc.M003766200; Shaw LM, 1999, J MAMMARY GLAND BIOL, V4, P367, DOI 10.1023/A:1018766317055; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Somasiri A, 2001, J CELL SCI, V114, P1125; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; Streuli CH, 1998, J MAMMARY GLAND BIOL, V3, P151, DOI 10.1023/A:1018742822565; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yoganathan TN, 2000, BIOCHEM PHARMACOL, V60, P1115, DOI 10.1016/S0006-2952(00)00444-5; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zutter MM, 1998, J MAMMARY GLAND BIOL, V3, P191, DOI 10.1023/A:1018798907544	37	106	114	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2001	20	48					7064	7072		10.1038/sj.onc.1204910	http://dx.doi.org/10.1038/sj.onc.1204910			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704830				2022-12-17	WOS:000171739300009
J	Yang, XL; Li, DM; Chen, WL; Xu, T				Yang, XL; Li, DM; Chen, WL; Xu, T			Human homologue of Drosophila lats, LATS1, negatively regulate growth by inducing G(2)/M arrest or apoptosis	ONCOGENE			English	Article						Lats1 tumor suppressor; growth inhibition; regulation of G(2)/M	CELL-CYCLE CHECKPOINTS; TUMOR-SUPPRESSOR GENE; POTENTIAL MEDIATOR; CANCER-CELLS; DNA-DAMAGE; P53; EXPRESSION; PROTEIN; 14-3-3-SIGMA; GADD45	The lats gene encodes a family of proteins conserved from insects to humans. Drosophila carrying lats mutant cells or mice deficient for Lats1 develop tumors in various tissues. The mammalian LATS1 protein was previously shown to bind to CDC2, suggesting that LATS1 may modulate G(2)/M cell cycle progression by affecting CDC2 activity. In this study, we introduced human LATS1 into LATS(-/-) MEF cells by adenovirus-mediated gene transfer. Overexpression of LATS1 causes G(2)/M arrest through inhibition of CDC2 kinase activity. Furthermore, overexpression of LATS1 significantly suppressed the human tumor cell growth in vitro and tumorigenicity in vivo by inducing either cell cycle arrest in G(2)/M or apoptosis. These observations suggest that LATS1 is a potent growth suppressor and, like other tumor suppressors, it suppresses growth by inducing cell cycle arrest or apoptosis.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet,Howard Hughes Med Inst, New Haven, CT 06536 USA	Howard Hughes Medical Institute; Yale University	Xu, T (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet,Howard Hughes Med Inst, 295 Congress Ave, New Haven, CT 06536 USA.	tian.xu@yale.edu						AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; He LS, 1998, CANCER RES, V58, P4238; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; QUELLE DE, 1995, ONCOGENE, V11, P635; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wechsler DS, 1997, CANCER RES, V57, P4905; XU TA, 1995, DEVELOPMENT, V121, P1053; Yabuta N, 2000, GENOMICS, V63, P263, DOI 10.1006/geno.1999.6065; Yang XL, 1996, INT J CANCER, V65, P338, DOI 10.1002/(SICI)1097-0215(19960126)65:3<338::AID-IJC11>3.0.CO;2-6; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Yang XL, 2000, EXP CELL RES, V256, P491, DOI 10.1006/excr.2000.4829; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667	24	106	113	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6516	6523		10.1038/sj.onc.1204817	http://dx.doi.org/10.1038/sj.onc.1204817			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641775				2022-12-17	WOS:000171404200003
J	Zhang, YW; Morita, I; Ikeda, M; Ma, KW; Murota, S				Zhang, YW; Morita, I; Ikeda, M; Ma, KW; Murota, S			Connexin43 suppresses proliferation of osteosarcoma U2OS cells through post-transcriptional regulation of p27	ONCOGENE			English	Article						gap junction; connexin 43; tumor suppressive effect; p27; Rb; cell cycle	JUNCTIONAL INTERCELLULAR COMMUNICATION; ANTI-HYPOXIA/REOXYGENATION AGENTS; VEIN ENDOTHELIAL-CELLS; TYROSINE KINASE; GROWTH-CONTROL; TRANSFORMED-CELLS; GAP-JUNCTIONS; NEOPLASTIC PHENOTYPE; EPITHELIAL-CELLS; GENE-EXPRESSION	Many lines of evidence indicate that connexin genes expressing gap junction (GJ) proteins inhibit tumor cell proliferation. However, the precise molecular mechanisms remain unclear, In this study, we show that overexpression of connexin43 (Cx43) suppressed proliferation of human osteosarcoma U2OS cells through inhibition of the cell cycle transition from G1 to S phase. This inhibition was attributed to a significant accumulation of the hypophosphorylated retinoblastoma (Rb) protein, which was causally related to decreases in the kinase activities of cyclin-dependent kinases (CDKs) 2 and 4, Enforced Cx43 expression markedly increased the level of the CDK inhibitor p27, This increase resulted from an increased synthesis and a reduced degradation of the p27 proteins, but not influence of the p27 mRNA, Moreover, we show that the Cx43-modulated GJ function was the main contributor to the elevation in p27 levels, in which cAMP was involved. These data suggest that Cx43 appears to inhibit proliferation of U2OS cells by increasing the levels of p27 proteins via post-transcriptional regulatory mechanisms.	Tokyo Med & Dent Univ, Dept Cellular Physiol Chem, Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Sect Mol Embryol, Bunkyo Ku, Tokyo 1138549, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Morita, I (corresponding author), Tokyo Med & Dent Univ, Dept Cellular Physiol Chem, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.							BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; Beyer E C, 1993, Int Rev Cytol, V137C, P1; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; BRADSHAW SL, 1993, GROWTH REGULAT, V3, P26; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; CHEN SC, 1995, CELL GROWTH DIFFER, V6, P681; CORNIL I, 1991, P NATL ACAD SCI USA, V88, P6028, DOI 10.1073/pnas.88.14.6028; DuflotDancer A, 1997, ONCOGENE, V15, P2151, DOI 10.1038/sj.onc.1201393; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FITZGERALD DJ, 1990, TERATOGEN CARCIN MUT, V10, P89; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; Grossel MJ, 1999, J BIOL CHEM, V274, P29960, DOI 10.1074/jbc.274.42.29960; Huang RP, 1998, CANCER RES, V58, P5089; Kandel ER, 2000, BRAIN RES REV, V32, P3, DOI 10.1016/S0165-0173(99)00062-4; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Koffler L, 2000, J CELL BIOCHEM, V79, P347, DOI 10.1002/1097-4644(20001201)79:3<347::AID-JCB10>3.0.CO;2-2; Krutovskikh VA, 2000, ONCOGENE, V19, P505, DOI 10.1038/sj.onc.1203340; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; MARTIN W, 1991, CANCER RES, V51, P5348; Martyn KD, 1997, CELL GROWTH DIFFER, V8, P1015; Mehta PP, 1996, MOL CARCINOGEN, V15, P18, DOI 10.1002/(SICI)1098-2744(199601)15:1<18::AID-MC4>3.0.CO;2-O; MEHTA PP, 1986, CELL, V44, P187, DOI 10.1016/0092-8674(86)90497-6; MEHTA PP, 1991, J MEMBRANE BIOL, V124, P207, DOI 10.1007/BF01994355; MESNIL M, 1995, CANCER RES, V55, P629; Omori Y, 1998, INT J CANCER, V78, P446, DOI 10.1002/(SICI)1097-0215(19981109)78:4<446::AID-IJC10>3.3.CO;2-4; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; PAUL DL, 1995, CURR OPIN CELL BIOL, V7, P665, DOI 10.1016/0955-0674(95)80108-1; Proulx AA, 1997, CELL GROWTH DIFFER, V8, P533; Rae RS, 1998, MOL CARCINOGEN, V22, P120, DOI 10.1002/(SICI)1098-2744(199806)22:2<120::AID-MC7>3.0.CO;2-Q; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Statuto M, 1997, J BIOL CHEM, V272, P24710, DOI 10.1074/jbc.272.39.24710; Temme A, 1997, CURR BIOL, V7, P713, DOI 10.1016/S0960-9822(06)00302-2; TROSKO JE, 1993, LIFE SCI, V53, P1, DOI 10.1016/0024-3205(93)90606-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yamasaki H, 1999, CR ACAD SCI III-VIE, V322, P151, DOI 10.1016/S0764-4469(99)80038-9; Yamasaki H, 1995, MUTAT RES-FUND MOL M, V333, P181, DOI 10.1016/0027-5107(95)00144-1; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; Zhang YW, 2000, PLANTA MED, V66, P119, DOI 10.1055/s-2000-11126; Zhang YW, 2000, PLANTA MED, V66, P114, DOI 10.1055/s-2000-11128; Zhang YW, 1999, PROSTAG LEUKOTR ESS, V61, P33, DOI 10.1054/plef.1999.0070; Zhang YW, 1999, J CELL PHYSIOL, V180, P305, DOI 10.1002/(SICI)1097-4652(199909)180:3<305::AID-JCP1>3.0.CO;2-Z; ZHU DG, 1992, P NATL ACAD SCI USA, V89, P10218, DOI 10.1073/pnas.89.21.10218	45	106	113	1	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4138	4149		10.1038/sj.onc.1204563	http://dx.doi.org/10.1038/sj.onc.1204563			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464280				2022-12-17	WOS:000169857200004
J	Komatsu, M; Jepson, S; Arango, ME; Carraway, CAC; Carraway, KL				Komatsu, M; Jepson, S; Arango, ME; Carraway, CAC; Carraway, KL			Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor	ONCOGENE			English	Article						Muc4; apoptosis; ErbB2; xenotransplanted tumor; tumor growth; sialomucin complex	SURFACE GLYCOPROTEIN COMPLEX; MAMMARY ADENOCARCINOMA CELLS; SIALOMUCIN COMPLEX; EXTRACELLULAR-MATRIX; RAT MUC4; MOLECULAR-CLONING; EPITHELIAL-CELLS; FACTOR-BETA; EXPRESSION; MEMBRANE	Overexpression of the membrane mucin MUC4/Sialo-mucin complex (SMC) has been observed during malignant progression of mammary tumors in both humans and rats, suggesting that deregulation of MUC4/SMC expression might facilitate development of these malignancies, As previously reported, overexpression of SMC results in suppression of both cell adhesion and immune killing of tumor cells, SMC also acts as a ligand for ErbB2/Neu, modulating phosphorylation of the receptor tyrosine kinase in the presence and absence of heregulin. The present studies investigated the effect of Muc4/SMC up-regulation on primary tumor growth using a tetracycline-inducible SMC expression system in a xenotransplanted tumor model. SMC upregulation provoked rapid growth of transfected A375 melanoma in nude mice. Up-regulation of SMC, however, did not significantly increase proliferation of A375 cells in vitro, Instead, a strong suppression of apoptosis was observed in situ in SMC-overexpressing tumors, These data suggest that Muc4/SMC expression promotes tumor growth in vivo at least in part via suppression of tumor cell apoptosis, Importantly, reduction of apoptosis was also observed in vitro, indicating that anti-apoptotic effect of SMC is independent of tumor-host interactions, These findings strongly suggest that SMC up-regulation alters intracellular signaling to favor cell survival, providing for the first time evidence for the regulation of programmed cell death by a gene of the MUC family.	Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami; University of Miami	Carraway, KL (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA.			Komatsu, Masanobu/0000-0001-7548-137X	NCI NIH HHS [CA52498, CA74072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074072, R01CA052498] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arteaga CL, 1996, BREAST CANCER RES TR, V38, P49, DOI 10.1007/BF01803783; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BHAVANANDAN V P, 1991, Glycobiology, V1, P493, DOI 10.1093/glycob/1.5.493; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Carraway CAC, 1999, J BIOL CHEM, V274, P25659, DOI 10.1074/jbc.274.36.25659; CARRAWAY KL, 1992, J CELL SCI, V103, P299; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; Carraway KL, 2000, FRONT BIOSCI, V5, pD95, DOI 10.2741/Carraway; DHAWAN J, 1995, SOMAT CELL MOLEC GEN, V21, P233, DOI 10.1007/BF02255778; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; Hanahan D, 1996, EUR J CANCER, V32A, P2386, DOI 10.1016/S0959-8049(96)00401-7; HUGGINS JW, 1980, CANCER RES, V40, P1873; Idris N, 2000, J CELL PHYSIOL, V185, P310, DOI 10.1002/1097-4652(200011)185:2<310::AID-JCP16>3.0.CO;2-W; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 1999, CANCER RES, V59, P2229; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; PANDEY P, 1995, CANCER RES, V55, P4000; PASSMAN RS, 1994, J CLIN INVEST, V94, P2421, DOI 10.1172/JCI117609; Price-Schiavi SA, 1998, J BIOL CHEM, V273, P35228, DOI 10.1074/jbc.273.52.35228; Price-Schiavi SA, 2000, J BIOL CHEM, V275, P17800, DOI 10.1074/jbc.275.23.17800; Rossi EA, 1996, J BIOL CHEM, V271, P33476, DOI 10.1074/jbc.271.52.33476; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; Tlsty TD, 1998, CURR OPIN CELL BIOL, V10, P647, DOI 10.1016/S0955-0674(98)80041-0; VANDEWIELVANKEMENADE E, 1993, J IMMUNOL, V151, P767; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; WU K, 1994, J BIOL CHEM, V269, P11950; WU K, 1994, ONCOGENE, V9, P3139; ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2	39	106	115	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					461	470		10.1038/sj.onc.1204106	http://dx.doi.org/10.1038/sj.onc.1204106			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313977				2022-12-17	WOS:000166562500006
J	Morin, MJ				Morin, MJ			From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents	ONCOGENE			English	Article						tyrosine kinase inhibitors; anti-tumor; antiangiogenesis	GROWTH-FACTOR RECEPTOR; CHRONIC MYELOGENOUS LEUKEMIA; IN-VIVO; SELECTIVE INHIBITOR; SIGNAL-TRANSDUCTION; ANTICANCER AGENTS; POTENT INHIBITOR; CANCER-THERAPY; PHASE-I; C-KIT	The confluence of two distinct but related activities in the past 10 years has dramatically accelerated efforts towards the discovery and development of novel drugs to treat cancer. The first is a rapidly emerging understanding that a number of distinct tyrosine kinases play roles in diverse but fundamentally important aspects of tumor progression (growth, survival, metastasis and angiogenesis). The second is the discovery that small molecule compounds have the capacity to potently and selectively inhibit the biochemical function of tyrosine kinases by competing for ATP binding at the enzyme catalytic site. These observations have been conjoined in major efforts to bring forward into clinical development novel cancer drugs with the potential to provide both clinical efficacy and improved tolerability. The focus of this review is on the development of small molecule tyrosine kinase inhibitors, and does not extend to other approaches that could be applied to disrupt the same pathways in clinical tumors (receptor and/or ligand-competitive antibodies, intrabodies, antisense ribonucleotides, ribozymes, phosphatase inhibitors or SH2/SH3-directed agents). Selected tyrosine kinase inhibitors, known or believed to be in development in cancer treatment trials, are summarized as are some of the key issues that must be addressed if these compounds are to be developed into clinically useful cancer chemotherapeutic agents.	Pfizer Global R&D, Groton, CT 06340 USA	Pfizer	Morin, MJ (corresponding author), Pfizer Global R&D, Groton, CT 06340 USA.							ALLEN LF, 2000, P NCI EO RTC AACR S, V384; Ashman LK, 1999, INT J BIOCHEM CELL B, V31, P1037, DOI 10.1016/S1357-2725(99)00076-X; BARBACCI EG, 1997, P AN ASS CANC RES, V38, P3143; BARTLETT RR, 1985, INT J IMMUNOPHARMACO, V7, P7, DOI 10.1016/0192-0561(85)90003-7; BASELGA J, 2000, P AN M AM SOC CLIN, V19, P686; Bold G, 2000, J MED CHEM, V43, P2310, DOI 10.1021/jm9909443; BONOMI P, 2000, P NCI EO RTC AACR S, V386; Bridges AJ, 1999, CURR MED CHEM, V6, P825; Cherrington JM, 2000, ADV CANCER RES, V79, P1, DOI 10.1016/S0065-230X(00)79001-4; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; COHEN RB, 2000, P AN M AM SOC CLIN, V19, P1862; Cohen S, 2000, ARTHRITIS RHEUM, V43, pS270; Connell RD, 2000, EXPERT OPIN THER PAT, V10, P767, DOI 10.1517/13543776.10.6.767; CROPP G, 1999, P AN M AM SOC CLIN, V18, P619; Dowsett M, 2000, EUR J CANCER, V36, P170, DOI 10.1016/S0959-8049(99)00264-6; Drevs J, 2000, CANCER RES, V60, P4819; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Eckhardt SG, 1999, J CLIN ONCOL, V17, P1095, DOI 10.1200/JCO.1999.17.4.1095; Eisenhauer EA, 1998, ANN ONCOL, V9, P1047, DOI 10.1023/A:1008497110734; FERRY D, 2000, P AN M AM SOC CLIN, V19, pE5; Fong TAT, 1999, CANCER RES, V59, P99; Fry DW, 2000, ANTI-CANCER DRUG DES, V15, P3; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Garber K, 2000, J NATL CANCER I, V92, P967, DOI 10.1093/jnci/92.12.967; Ghosh S, 1999, ANTI-CANCER DRUG DES, V14, P403; Gibbs JB, 2000, J CLIN INVEST, V105, P9, DOI 10.1172/JCI9084; GOSS G, 2000, P AN M AM SOC CLIN, V19, P880; Hamby JM, 1999, PHARMACOL THERAPEUT, V82, P169, DOI 10.1016/S0163-7258(98)00053-9; Hamilton LC, 1999, BRIT J PHARMACOL, V127, P1589, DOI 10.1038/sj.bjp.0702708; HAMMOND LA, 2000, P NCI EO TRC AACR S, V385; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Hudes G, 1999, J CLIN ONCOL, V17, P1093, DOI 10.1200/JCO.1999.17.4.1093; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; IWATA K, 1997, P AM ASSOC CANC RES, V38, P4248; Karp DD, 1999, P AN M AM SOC CLIN, V18, P1499; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KELLY HC, 2000, P AM ASSOC CANC RES, V41, P3896; Kuo EA, 1996, J MED CHEM, V39, P4608, DOI 10.1021/jm9604437; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; Laird AD, 2000, CANCER RES, V60, P4152; Lawrence DS, 1998, PHARMACOL THERAPEUT, V77, P81, DOI 10.1016/S0163-7258(97)00052-1; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Levitzki A, 1998, ANTI-CANCER DRUG DES, V13, P731; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MATTAR T, 1993, FEBS LETT, V334, P161, DOI 10.1016/0014-5793(93)81704-4; MEDINA L, 2000, P AM ASSOC CANC RES, V41, P3078; Mendel DB, 2000, ANTI-CANCER DRUG DES, V15, P29; Moyer JD, 1997, CANCER RES, V57, P4838; NELSON JM, 2000, P AM ASSOC CANC RES, V41, P1533; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415; Pollack VA, 1999, J PHARMACOL EXP THER, V291, P739; Randal J, 2000, J NATL CANCER I, V92, P520, DOI 10.1093/jnci/92.7.520; ROSEN L, 2000, P AN M AM SOC CLIN, V19, P708; ROSEN L, 1999, P AN M AM SOC CLIN, V18, P618; Sausville EA, 2000, ANTI-CANCER DRUG DES, V15, P1; Sedlacek HH, 2000, DRUGS, V59, P435, DOI 10.2165/00003495-200059030-00004; Shawver LK, 1997, CLIN CANCER RES, V3, P1167; Sherwood V., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P723; SIROTNAK FM, 2000, P AM ASSOC CANC RES, V41, P3076; Siu L.L., 1999, P AN M AM SOC CLIN, V18, P1498; SIU LL, 2000, P NCI EO RTC AACR S, V387; Smolen JS, 2000, RHEUMATOLOGY, V39, P48, DOI 10.1093/oxfordjournals.rheumatology.a031495; Sungaran R, 2000, BLOOD, V95, P3094, DOI 10.1182/blood.V95.10.3094.009k05_3094_3101; TALPAZ M, 2000, P AN M AM SOC CLIN, V19, P6; Thompson WD, 1999, J PATHOL, V187, P503, DOI 10.1002/(SICI)1096-9896(199904)187:5<503::AID-PATH279>3.0.CO;2-2; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vincent P. W., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P117; Wakeling AE, 1996, BREAST CANCER RES TR, V38, P67, DOI 10.1007/BF01803785; Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698; WARD WHJ, 1994, BIOCHEM PHARMACOL, V48, P659, DOI 10.1016/0006-2952(94)90042-6; Wedge SR, 2000, CANCER RES, V60, P970; WEDGE SR, 2000, P AM ASSOC CANC RES, V41, P3610; WEDGE SR, 1999, P AM ASSOC CANC RES, V40, P2741; Wood JM, 2000, CANCER RES, V60, P2178; WOODBURN JR, 1997, P ANN M AM ASS CANC, V38, pA4251; Workman P., 2000, CURR OPIN ONCOL ENDO, V2, P21; XU XL, 1995, J BIOL CHEM, V270, P12398, DOI 10.1074/jbc.270.21.12398; Zhou SY, 1998, METH MOL B, V87, P87	83	106	124	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6574	6583		10.1038/sj.onc.1204102	http://dx.doi.org/10.1038/sj.onc.1204102			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426642				2022-12-17	WOS:000167704000003
J	Mavrothalassitis, G; Ghysdael, J				Mavrothalassitis, G; Ghysdael, J			Proteins of the ETS family with transcriptional repressor activity	ONCOGENE			English	Review						ets; repression; transcription; proliferation	ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; DROSOPHILA EYE DEVELOPMENT; TERNARY COMPLEX FACTORS; SERUM RESPONSE ELEMENT; DNA-BINDING ACTIVITY; GENE FAMILY; DOMAIN PROTEIN; EGF RECEPTOR; TYROSINE KINASE	ETS proteins form one of the largest families of signal-dependent transcriptional regulators, mediating cellular proliferation, differentiation and tumorigenesis, Most of the known ETS proteins have been shown to activate transcription. However, four ETS proteins (YAN, ERF, NET and TEL) can act as transcriptional repressors. In three cases (ERF, NET and TEL) distinct repression domains have been identified and there are indications that NET and TEL may mediate transcription via Histone Deacetylase recruitment. All four proteins appear to be regulated by MAPKs, though for YAN and ERF this regulation seems to be restricted to ERKs, YAN, ERF and TEL have been implicated in cellular proliferation although there are indications suggesting a possible involvement of YAN and TEL in differentiation as well. Other ETS-domain proteins have been shown to repress transcription in a context specific manner, and there are suggestions that the ETS DNA-binding domain may act as a transcriptional repressor. Transcriptional repression by ETS domain proteins adds an other level in the orchestrated regulation by this diverse family of transcription factors that often recognize similar if not identical binding sites on DNA and are believed to regulate critical genes in a variety of biological processes. Definitive assessment of the importance of this novel regulatory level will require the identification of ETS proteins target genes and the further analysis of transcriptional control and biological function of these proteins in defined pathways.	Univ Crete, Sch Med, Heraklion 71409, Crete, Greece; FORTH, IMBB, Heraklion 71409, Crete, Greece; Ctr Univ Orsay, Inst Curie, CNRS, UMR 146, F-91405 Orsay, France	University of Crete; Foundation for Research & Technology - Hellas (FORTH); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Mavrothalassitis, G (corresponding author), Univ Crete, Sch Med, Heraklion 71409, Crete, Greece.		GHYSDAEL, Jacques/F-3377-2013					Athanasiou M, 2000, CANCER GENE THER, V7, P1188, DOI 10.1038/sj.cgt.7700220; Baens M, 1996, GENOME RES, V6, P404, DOI 10.1101/gr.6.5.404; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BORRAS FE, 1995, J BIOL CHEM, V270, P24385, DOI 10.1074/jbc.270.41.24385; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; Busslinger M, 2000, CURR OPIN IMMUNOL, V12, P151, DOI 10.1016/S0952-7915(99)00065-5; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Carron C, 2000, BLOOD, V95, P3891; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Cowley DO, 2000, GENE DEV, V14, P366; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Day RN, 1998, J BIOL CHEM, V273, P31909, DOI 10.1074/jbc.273.48.31909; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; Dominguez M, 1998, CURR BIOL, V8, P1039, DOI 10.1016/S0960-9822(98)70441-5; Ducret C, 1999, MOL CELL BIOL, V19, P7076; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Foos G, 1998, J BIOL CHEM, V273, P18871, DOI 10.1074/jbc.273.30.18871; Ghosh A, 1998, CELL, V95, P303, DOI 10.1016/S0092-8674(00)81762-6; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Giovane A, 1997, MOL CELL BIOL, V17, P5667, DOI 10.1128/MCB.17.10.5667; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Goldman D, 1998, BIOCHEM J, V335, P267, DOI 10.1042/bj3350267; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Guidez F, 2000, BLOOD, V96, P2557; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; HALDER G, 1995, CURR OPIN GENET DEV, V5, P602, DOI 10.1016/0959-437X(95)80029-8; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; Im YH, 2000, CANCER RES, V60, P1536; ITO Y, 1997, ONCOGENES TRANSCRIPT, V2, P107; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kim DH, 1996, BLOOD, V88, P785, DOI 10.1182/blood.V88.3.785.bloodjournal883785; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KLEMSZ M, 1994, GENOMICS, V20, P291, DOI 10.1006/geno.1994.1169; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lai ZC, 1997, GENETICS, V147, P1131; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; Le Gallic L, 1999, MOL CELL BIOL, V19, P4121; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Maldonado E, 1999, CELL, V99, P455, DOI 10.1016/S0092-8674(00)81533-0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Martin ME, 1996, J BIOL CHEM, V271, P25617, DOI 10.1074/jbc.271.41.25617; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Metcalf D, 1999, ANN NY ACAD SCI, V872, P289, DOI 10.1111/j.1749-6632.1999.tb08473.x; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; Ogawa M, 1999, INT J HEMATOL, V69, P2; OHagan RC, 1996, ONCOGENE, V13, P1323; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Papas Takis S., 1997, Leukemia (Basingstoke), V11, P557; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; POIREL H, 2000, IN PRESS ONCOGENE; Potter MD, 2000, BLOOD, V95, P3341, DOI 10.1182/blood.V95.11.3341.011k44_3341_3348; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Price MD, 1999, DEV GENES EVOL, V209, P207, DOI 10.1007/s004270050245; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Rebay I, 2000, GENETICS, V154, P695; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; RIESGOESCOVAR JR, 1994, J COMP PHYSIOL A, V175, P687; Ritchie KA, 1999, LEUKEMIA, V13, P1790, DOI 10.1038/sj.leu.2401494; Rogge R, 1995, DEVELOPMENT, V121, P3947; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; Rossi F, 1996, CURR BIOL, V6, P866, DOI 10.1016/S0960-9822(02)00610-3; Roy S, 1998, J BIOL CHEM, V273, P14059, DOI 10.1074/jbc.273.23.14059; Rubnitz JE, 1999, LEUKEMIA, V13, P6, DOI 10.1038/sj.leu.2401258; SCHOLZ H, 1993, GENETICS, V135, P455; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; SPYROPOULOS, 2000, ONCOGENE; Tomasson MH, 1999, BLOOD, V93, P1707, DOI 10.1182/blood.V93.5.1707.405k24_1707_1714; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Uchida H, 1999, ONCOGENE, V18, P1015, DOI 10.1038/sj.onc.1202383; Van Buskirk C, 1999, TRENDS CELL BIOL, V9, P1, DOI 10.1016/S0962-8924(98)01413-5; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wasylyk B, 1997, MOL B INT U, P253; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; Wolberger C, 1998, CURR OPIN GENET DEV, V8, P552, DOI 10.1016/S0959-437X(98)80010-5; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Young MW, 1997, PERSPECT DEV NEUROBI, V4, P345; YUAN CC, 1989, J VIROL, V63, P205, DOI 10.1128/JVI.63.1.205-215.1989; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	110	106	110	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2000	19	55					6524	6532		10.1038/sj.onc.1204045	http://dx.doi.org/10.1038/sj.onc.1204045			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL	11175368				2022-12-17	WOS:000166595000014
J	Tee, AR; Proud, CG				Tee, AR; Proud, CG			DNA-damaging agents cause inactivation of translational regulators linked to mTOR signalling	ONCOGENE			English	Article						DNA damage; apoptosis; mTOR; p70 S6 kinase; initiation factor; mRNA translation	DEPENDENT PROTEIN-KINASE; INITIATION-FACTOR 4G; P70 S6 KINASE; MESSENGER-RNA TRANSLATION; INDUCED APOPTOSIS; CELL-PROLIFERATION; SIGNALING PATHWAY; FACTOR 4E; FACTOR SUBUNIT; PHAS-I	Treatment of cells with DNA-damaging agents, such as etoposide, can cause growth arrest or apoptosis, Treatment of Swiss 3T3 or RAT-1 cells with etoposide led to the dephosphorylation of both p70 S6 kinase and eukaryotic initiation factor (eIF) 4E-binding protein 1 (4E-BP1), resulting in decreased p70 S6 kinase activity and an increase in 4E-BP1 binding to eIF4E, These effects were not prevented by the general caspase inhibitor, Z-VAD.FMK, These findings indicate caspase-independent inhibition of signalling pathways that involve the mammalian target of rapamycin (mTOR), Similar effects were observed in response to two other DNA-damaging agents, cisplatin and mitomycin-C, These events preceded apoptosis, which was assessed by caspase-3 activity assays and FAGS analysis, This shows that inhibition of mTOR signalling is not a consequence of apoptosis, although it may play a role in the events that precede cell death. 4E-BP1 was cleaved during apoptosis yielding a fragment that retained the ability to bind eIF4E. Cleavage of 4E-BP1 was inhibited by treatment of the cells with Z-VAD.FMK, indicating it is caspase-dependent. Insulin elicited full activation of p70 S6 kinase and phosphorylation of 4E-PB1 in etoposide-treated cells prior to the onset of apoptosis, but not during cell death. This suggests that mTOR signalling becomes irreversibly inhibited only after entry into apoptosis.	Univ Dundee, Dept Anat & Physiol, Inst Med Sci, Dundee DD1 5EH, Scotland	University of Dundee	Proud, CG (corresponding author), Univ Dundee, Dept Anat & Physiol, Inst Med Sci, Wellcome Trust Bldg Complex,Dow St, Dundee DD1 5EH, Scotland.			Proud, Christopher/0000-0003-0704-6442; Tee, Andrew/0000-0002-5577-4631				Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Bushell M, 2000, EUR J BIOCHEM, V267, P1083, DOI 10.1046/j.1432-1327.2000.01101.x; Bushell M, 1999, FEBS LETT, V451, P332, DOI 10.1016/S0014-5793(99)00614-6; Campbell LE, 1999, BIOCHEM J, V344, P433, DOI 10.1042/0264-6021:3440433; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Clemens MJ, 1998, ONCOGENE, V17, P2921, DOI 10.1038/sj.onc.1202227; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; DARZYNKIEWICZ Z, 1994, CELL BIOL LAB HDB, P261; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Donze O, 1999, VIROLOGY, V256, P322, DOI 10.1006/viro.1999.9618; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; Flynn A, 1996, CANCER SURV, V27, P293; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gil J, 1999, MOL CELL BIOL, V19, P4653; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; Ishizuka T, 1997, BIOCHEM BIOPH RES CO, V230, P386, DOI 10.1006/bbrc.1996.5967; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Johnson KL, 1999, IMMUNOL CELL BIOL, V77, P242, DOI 10.1046/j.1440-1711.1999.00821.x; KASTAN MB, 1991, CANCER RES, V51, P6304; Kleijn M, 1998, EUR J BIOCHEM, V253, P531, DOI 10.1046/j.1432-1327.1998.2530531.x; Kleijn M, 1996, FEBS LETT, V396, P165, DOI 10.1016/0014-5793(96)01097-6; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MADER S, 1995, MOL CELL BIOL, V15, P4990; Marissen WE, 1998, MOL CELL BIOL, V18, P7565, DOI 10.1128/MCB.18.12.7565; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; McWhinney CD, 1997, J MOL CELL CARDIOL, V29, P2513, DOI 10.1006/jmcc.1997.0489; Meyuhas Oded, 1996, V30, P363; Morley SJ, 1998, FEBS LETT, V438, P41, DOI 10.1016/S0014-5793(98)01269-1; MOULE SK, 1995, BIOCHEM J, V311, P595, DOI 10.1042/bj3110595; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Palom Y, 1998, ONCOL RES, V10, P509; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; Proud CG, 1997, BIOCHEM J, V328, P329; Qu BH, 1999, J BIOL CHEM, V274, P31179, DOI 10.1074/jbc.274.44.31179; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Satoh S, 1999, BIOCHEM J, V342, P65, DOI 10.1042/0264-6021:3420065; Scheper GC, 1997, J BIOL CHEM, V272, P26850, DOI 10.1074/jbc.272.43.26850; Schweizer U, 1999, NUCLEIC ACIDS RES, V27, P3183, DOI 10.1093/nar/27.15.3183; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; SHI YF, 1995, CANCER RES, V55, P1982; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; SULLIVAN D M, 1987, NCI (National Cancer Institute) Monographs, P73; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Takizawa T, 1999, J BIOCHEM-TOKYO, V125, P391, DOI 10.1093/oxfordjournals.jbchem.a022299; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Tronov VA, 1999, BIOCHEMISTRY-MOSCOW+, V64, P345; Vries RGJ, 1997, J BIOL CHEM, V272, P32779, DOI 10.1074/jbc.272.52.32779; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; WELSH GI, 1992, BIOCHEM J, V284, P19, DOI 10.1042/bj2840019; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451	68	106	109	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2000	19	26					3021	3031		10.1038/sj.onc.1203622	http://dx.doi.org/10.1038/sj.onc.1203622			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871854				2022-12-17	WOS:000087581400009
J	Bader, S; Walker, M; Heindrich, B; Bird, A; Bird, C; Hooper, M; Wyllie, A				Bader, S; Walker, M; Heindrich, B; Bird, A; Bird, C; Hooper, M; Wyllie, A			Somatic frameshift mutations in the MBD4 gene of sporadic colon cancers with mismatch repair deficiency	ONCOGENE			English	Article						MBD4; colorectal cancer; RER; mismatch repair	MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; DNA METHYLATION; RECEPTOR; CPG; CARCINOGENESIS	Defects of mismatch repair are thought to be responsible for carcinogenesis in hereditary non-polyposis colorectal cancer and about 15% of sporadic colon cancers. The phenotype is seen as microsatellite instability and is known to be caused either by mutations in mismatch repair genes or by aberrant methylation of these genes stabilizing their downregulation. Lack of repair of microsatellite sequence errors, created during replication, leads to a mutation-prone phenotype, Where mutations occur within mononucleotide tracts within exons they cause translation frameshifts, premature cessation of translation and abnormal protein expression. Such mutations have been observed in the TGF beta RII, BAX, IGFIIR, MSH3 and MSH6 genes in colon and other cancers, We describe here frameshift mutations affecting the gene for the methyl-CpG binding thymine glycosylase, MBD4, in over 40% of microsatellite unstable sporadic colon cancers. The mutations all appear heterozygous but their location would ensure truncation of the protein between the methyl-CpG binding and glycosylase domains, thus potentially generating a dominant negative effect. It is thus possible that such mutations enhance mutation frequency at other sites in these tumours, A suggestion has been made that MBD4 (MED1) mutations may lead to an increased rate of microsatellite instability but this mechanism appears unlikely due to the nature of mutations we have found.	Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie CRC Labs, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Bader, S (corresponding author), Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie CRC Labs, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland.		Hendrich, Brian/AAG-5898-2020	Hendrich, Brian/0000-0002-0231-3073; Bird, Adrian/0000-0002-8600-0372	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; Bubb VJ, 1996, ONCOGENE, V12, P2641; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 1999, MAMM GENOME, V10, P906, DOI 10.1007/s003359901112; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Zingg JM, 1997, CARCINOGENESIS, V18, P869, DOI 10.1093/carcin/18.5.869	19	106	110	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					8044	8047		10.1038/sj.onc.1203229	http://dx.doi.org/10.1038/sj.onc.1203229			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637515				2022-12-17	WOS:000084634600013
J	Saintigny, Y; Rouillard, D; Chaput, B; Soussi, T; Lopez, BS				Saintigny, Y; Rouillard, D; Chaput, B; Soussi, T; Lopez, BS			Mutant p53 proteins stimulate spontaneous and radiation-induced intrachromosomal homologous recombination independently of the alteration of the transactivation activity and of the G1 checkpoint	ONCOGENE			English	Article						p53; radiation; cell cycle; homologous recombination	WILD-TYPE P53; CELL-CYCLE ARREST; MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; IONIZING-RADIATION; GENE AMPLIFICATION; RAD51 PROTEIN; MUTATION; CONFORMATION; DEFECTS	We report here a systematic analysis of the effects of different p53 mutations on both spontaneous and radiation-stimulated homologous recombination in mouse L cells. In order to monitor different recombination pathways, we used both direct and inverted repeat recombination substrates. In each line bearing one of these substrates, we expressed p53 proteins mutated at positions: 175, 248 or 273, p53 mutations leading to an increased spontaneous recombination rate also stimulate radiation-induced recombination. The effect on recombination may be partially related to the conformation of the p53 protein. Moreover, p53 mutations act on recombination between direct repeats as well as between inverted repeats indicating that strand invasion mechanisms are stimulated. Although all of the p53 mutations affect the p53 transactivation activity measured on the WAF1 and MDM2 gene promoters, no correlation between the transactivation activity and the extent of homologous recombination can be drawn. Finally, some p53 mutations do not affect the G1 arrest after radiation but stimulate radiation-induced recombination. These results show that the role of p53 on transactivation and G1 cell cycle checkpoint is separable from its involvement in homologous recombination. A direct participation of p53 in the recombination mechanism itself is discussed.	CEA, DSV, DRR, CNRS,Unite Mixte Rech 217, F-92265 Fontenay Aux Roses, France; Inst Curie, F-75231 Paris 05, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Lopez, BS (corresponding author), CEA, DSV, DRR, CNRS,Unite Mixte Rech 217, 60-68 Av Gen Leclerc, F-92265 Fontenay Aux Roses, France.		Saintigny, Yannick/C-2697-2008; Lopez, Bernard S/O-7308-2017	Saintigny, Yannick/0000-0002-3839-3562; Lopez, Bernard S/0000-0001-5088-0155; soussi, thierry/0000-0001-8184-3293				AMOR M, 1988, P NATL ACAD SCI USA, V85, P1600, DOI 10.1073/pnas.85.5.1600; Arnheim N., 1983, P38; BALTIMORE D, 1981, CELL, V26, P295, DOI 10.1016/0092-8674(81)90196-3; BECKER RS, 1990, CELL, V63, P987, DOI 10.1016/0092-8674(90)90502-6; BENJAMIN MB, 1992, MOL CELL BIOL, V12, P2730, DOI 10.1128/MCB.12.6.2730; Bertini I, 1997, J BIOL INORG CHEM, V2, P1; BOLLAG RJ, 1989, ANNU REV GENET, V23, P199, DOI 10.1146/annurev.ge.23.120189.001215; BOUFFLER SD, 1995, CANCER RES, V55, P3883; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Hainaut Pierre, 1995, Current Opinion in Oncology, V7, P76; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Ivanov EL, 1996, GENETICS, V142, P693; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; KLEIN HL, 1995, BIOESSAYS, V17, P147, DOI 10.1002/bies.950170210; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT S, 1999, IN PRESS MUTATION RE; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; LIEBHABER SA, 1981, NATURE, V290, P26, DOI 10.1038/290026a0; LIN FLM, 1987, MOL CELL BIOL, V7, P129, DOI 10.1128/MCB.7.1.129; LISKAY RM, 1984, COLD SPRING HARB SYM, V49, P183, DOI 10.1101/SQB.1984.049.01.021; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Luria SE, 1943, GENETICS, V28, P491; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PARK MS, 1995, J BIOL CHEM, V270, P15467, DOI 10.1074/jbc.270.26.15467; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sambrook J, 1989, MOL CLONING LAB MANU; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Smith Martin L., 1995, Current Opinion in Oncology, V7, P69; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; TYLER J, 1996, NATURE, V381, P643; WANG YY, 1988, MOL CELL BIOL, V8, P196, DOI 10.1128/MCB.8.1.196; Wiesmuller L, 1996, J VIROL, V70, P737; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	49	106	111	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3553	3563		10.1038/sj.onc.1202941	http://dx.doi.org/10.1038/sj.onc.1202941			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380877	Bronze, Green Published			2022-12-17	WOS:000080891700001
J	Bolognese, F; Wasner, M; Lange-zu Dohna, C; Gurtner, A; Ronchi, A; Muller, H; Manni, I; Mossner, J; Piaggio, G; Mantovani, R; Engeland, K				Bolognese, F; Wasner, M; Lange-zu Dohna, C; Gurtner, A; Ronchi, A; Muller, H; Manni, I; Mossner, J; Piaggio, G; Mantovani, R; Engeland, K			The cyclin B2 promoter depends on NF-Y, a trimer whose CCAAT-binding activity is cell-cycle regulated	ONCOGENE			English	Article						NF-Y; cell cycle; cyclin B2	II GENE-TRANSCRIPTION; S-PHASE; GROWTH-REGULATION; BREAST-CANCER; A GENE; EXPRESSION; REPRESSION; PROTEIN; DIFFERENTIATION; ACTIVATION	Cyclin B2 is a regulator of p34cdc2 kinase, involved in G2/M progression of the cell cycle, whose gene is strictly regulated at the transcriptional level in cycling cells, The mouse promoter was cloned and three conserved CCAAT boxes were found. In this study, we analysed the mechanisms leading to activation of the cyclin B2 CCAAT boxes: a combination of (i) genomic footprinting, (ii) transfections with single, double and triple mutants, (iii) EMSAs with nuclear extracts, antibodies and NF-Y recombinant proteins and (iv) transfections with an NF-YA dominant negative mutant established the positive role of the three CCAAT sequences and proved that NF-Y plays a crucial role in their activation. NF-Y, an ubiquitous trimer containing histone fold subunits, activates several other promoters regulated during the cell cycle. To analyse the levels of NF-Y subunits in the different phases of the cycle, we separated MEL cells by elutriation, obtaining fractions >80% pure. The mRNA and protein levels of the histone-fold containing IVF-YB and NF-YC were invariant, whereas the NF-YA protein, but not its mRNA, was maximal in mid-S and decreased in G2/M. EMSA confirmed that the CCAAT-binding activity followed the amount of NF-YA, indicating that this subunit is limiting within the NF-Y complex, and suggesting that post-transcriptional mechanisms regulate NF-YA levels. Our results support a model whereby fine tuning of this activator is important for phase-specific transcription of CCAAT-containing promoters.	Univ Milan, Dipartimento Genet & Biol Microrganismi, I-20133 Milan, Italy; Univ Leipzig, Zentrum Innere Med, D-04103 Leipzig, Germany; Ctr Ricerca Sperimentale, Ist Regina Elena, I-00158 Rome, Italy; Ist Europeo Oncol, I-20141 Milan, Italy	University of Milan; Leipzig University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS European Institute of Oncology (IEO)	Mantovani, R (corresponding author), Univ Milan, Dipartimento Genet & Biol Microrganismi, Via Celoria 26, I-20133 Milan, Italy.		Engeland, Kurt/AAW-9965-2020; Piaggio, Giulia/AAD-7336-2022; gurtner, aymone/AAB-8843-2020; Piaggio, Giulia/J-7214-2018; Gurtner, Aymone/J-7217-2018; Manni, Isabella/ABH-6460-2020	Engeland, Kurt/0000-0003-3525-0440; gurtner, aymone/0000-0002-7661-9059; Piaggio, Giulia/0000-0003-2114-1892; Gurtner, Aymone/0000-0002-7661-9059; Manni, Isabella/0000-0003-4823-0596; Muller, Heiko/0000-0001-9873-3146	Telethon [1035] Funding Source: Medline	Telethon(Fondazione Telethon)		Baxevanis AD, 1998, NUCLEIC ACIDS RES, V26, P372, DOI 10.1093/nar/26.1.372; Bellorini M, 1997, GENE, V193, P119, DOI 10.1016/S0378-1119(97)00109-1; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DEY A, 1992, MOL CELL BIOL, V12, P3590, DOI 10.1128/MCB.12.8.3590; Eggers A, 1998, J BIOL CHEM, V273, P18499, DOI 10.1074/jbc.273.29.18499; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; FARINA A, INP RESS ONCOGENE; FILATOV D, 1995, J BIOL CHEM, V270, P25239, DOI 10.1074/jbc.270.42.25239; GONG JP, 1994, CANCER RES, V54, P4285; Good LF, 1996, BIOL SIGNAL, V5, P163; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Huet X, 1996, MOL CELL BIOL, V16, P3789; INOSTROZA JA, 1992, CELL, V70, P477; Isaacs RJ, 1996, J BIOL CHEM, V271, P16741, DOI 10.1074/jbc.271.28.16741; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Kim EC, 1997, CELL GROWTH DIFFER, V8, P1329; Kishimoto T, 1997, Prog Cell Cycle Res, V3, P241; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LI XY, 1992, J BIOL CHEM, V267, P8984; Liberati C, 1998, J BIOL CHEM, V273, P16880, DOI 10.1074/jbc.273.27.16880; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Liu QQ, 1998, CIRC RES, V82, P251; Lu CC, 1996, VIROLOGY, V225, P387, DOI 10.1006/viro.1996.0613; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; MARZIALI G, IN PRESS; Mermelstein F, 1996, GENE DEV, V10, P1033, DOI 10.1101/gad.10.8.1033; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PIAGGIO G, 1995, EXP CELL RES, V216, P396, DOI 10.1006/excr.1995.1050; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; vanGinkel PR, 1997, J BIOL CHEM, V272, P18367, DOI 10.1074/jbc.272.29.18367; VIVILLE S, 1991, J IMMUNOL, V146, P3211; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Zwicker J, 1997, NUCLEIC ACIDS RES, V25, P4926, DOI 10.1093/nar/25.24.4926; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	52	106	109	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1845	1853		10.1038/sj.onc.1202494	http://dx.doi.org/10.1038/sj.onc.1202494			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086339				2022-12-17	WOS:000079090000008
J	Bergmann, A; Agapite, J; Steller, H				Bergmann, A; Agapite, J; Steller, H			Mechanisms and control of programmed cell death in invertebrates	ONCOGENE			English	Review						C-elegans; Drosophila; apoptosis; programmed cell death; ced genes	APOPTOSIS INHIBITORY PROTEIN; DROSOPHILA EYE DEVELOPMENT; CAENORHABDITIS-ELEGANS; CYTOCHROME-C; TYROSINE KINASE; GENETIC-CONTROL; NERVOUS-SYSTEM; BCL-2; REAPER; CED-4	Apoptosis is a morphologically distinct form of programmed cell death that plays important roles in development, tissue homeostasis and a wide variety of diseases, including cancer, AIDS, stroke, myopathies and various neurodegenerative disorders (see Thompson (1995) for review). It is now clear that apoptosis occurs by activating an intrinsic cell suicide program which is constitutively expressed in most animal cells, and that key components of this program have been conserved in evolution from worms to insects to man. Genetic studies of programmed cell death in experimentally highly accessible invertebrate model systems have provided important clues about the molecular nature of the death program, and the intracellular mechanisms that control its activation. This review summarizes some of the key findings in this area, but also touches on some of the many unresolved questions and challenges that remain.	MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Steller, H (corresponding author), MIT, Howard Hughes Med Inst, Dept Biol, 77 Massachusetts ave,Bldg 68-430, Cambridge, MA 02139 USA.							ABRAMS JM, 1993, DEVELOPMENT, V117, P29; AGAPITE J, 1997, MOL CELLULAR APPROAC, P264; Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BAKSHI A, 1985, CELL, V41, P889; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BOS JL, 1989, CANCER RES, V49, P4682; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CAMPOS AR, 1992, DEVELOPMENT, V114, P355; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; Chen P, 1996, J BIOL CHEM, V271, P25735, DOI 10.1074/jbc.271.42.25735; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Davidson FF, 1998, NATURE, V391, P587, DOI 10.1038/35385; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dickson BJ, 1996, GENETICS, V142, P163; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, DEVELOPMENT, V112, P591; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; Evans EK, 1997, EMBO J, V16, P7372, DOI 10.1093/emboj/16.24.7372; Foley K, 1998, DEVELOPMENT, V125, P1075; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; Gregory-Evans K, 1998, TRENDS GENET, V14, P103, DOI 10.1016/S0168-9525(98)01402-4; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOFFMAN B, 1994, ONCOGENE, V9, P1807; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jiang CG, 1997, DEVELOPMENT, V124, P4673; Karim FD, 1996, GENETICS, V143, P315; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KNOWLES BA, 1994, TRENDS GENET, V10, P235, DOI 10.1016/0168-9525(94)90170-8; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; KURADA P, 1995, NEURON, V14, P571, DOI 10.1016/0896-6273(95)90313-5; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; LAMBLIN AF, 1998, IN PRESS; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; MacCorkle RA, 1998, P NATL ACAD SCI USA, V95, P3655, DOI 10.1073/pnas.95.7.3655; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; McCall K, 1998, SCIENCE, V279, P230, DOI 10.1126/science.279.5348.230; McCall K, 1997, TRENDS GENET, V13, P222, DOI 10.1016/S0168-9525(97)01126-8; McCarthy JV, 1998, J BIOL CHEM, V273, P24009, DOI 10.1074/jbc.273.37.24009; McNabb SL, 1997, NEURON, V19, P813, DOI 10.1016/S0896-6273(00)80963-0; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; Miller DT, 1998, DEVELOPMENT, V125, P2327; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nordstrom W, 1996, DEV BIOL, V180, P213, DOI 10.1006/dbio.1996.0296; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; Ottilie S, 1997, CELL DEATH DIFFER, V4, P526, DOI 10.1038/sj.cdd.4400288; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Robinow S, 1997, DEV BIOL, V190, P206, DOI 10.1006/dbio.1997.8696; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sawamoto K, 1998, CELL DEATH DIFFER, V5, P262, DOI 10.1038/sj.cdd.4400342; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SELLECK SB, 1991, NEURON, V6, P83, DOI 10.1016/0896-6273(91)90124-I; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STELLER H, 1987, CELL, V50, P1139, DOI 10.1016/0092-8674(87)90180-2; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STELLER H, 1994, NEURON, V13, P1269, DOI 10.1016/0896-6273(94)90413-8; Steller H, 1998, P NATL ACAD SCI USA, V95, P5421, DOI 10.1073/pnas.95.10.5421; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Thress K, 1998, EMBO J, V17, P6135, DOI 10.1093/emboj/17.21.6135; TRUMAN JW, 1992, J NEUROBIOL, V23, P1295, DOI 10.1002/neu.480230917; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Vucic D, 1997, MOL CELL BIOL, V17, P667, DOI 10.1128/MCB.17.2.667; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhou L, 1997, P NATL ACAD SCI USA, V94, P5131, DOI 10.1073/pnas.94.10.5131; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	130	106	110	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 24	1998	17	25					3215	3223		10.1038/sj.onc.1202586	http://dx.doi.org/10.1038/sj.onc.1202586			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916984				2022-12-17	WOS:000078048200003
J	Knowlden, JM; Gee, JMW; Seery, LT; Farrow, L; Gullick, WJ; Ellis, IO; Blamey, RW; Robertson, JFR; Nicholson, RI				Knowlden, JM; Gee, JMW; Seery, LT; Farrow, L; Gullick, WJ; Ellis, IO; Blamey, RW; Robertson, JFR; Nicholson, RI			C-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer	ONCOGENE			English	Article						c-erbB3; c-erbB4; ER; EGFR; cell proliferation; endocrine response; RT-PCR	EPIDERMAL GROWTH-FACTOR; POLYMERASE CHAIN-REACTION; ESTROGEN-RECEPTOR; MONOCLONAL-ANTIBODY; CELL-LINES; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; FAMILY MEMBERS; HEREGULIN; DIFFERENTIATION	We examined c-erbB3 and c-erbB4 mRNA expression in 47 primary breast cancer samples by simultaneous RT-PCR and have investigated correlations between these parameters and the expression of both ER and EGFR mRNA and protein as measured by RT-PCR and ICA and with Ki67 immunostaining, A direct association was found between c-erbB3 and c-erbB4 mRNA and ER marker status measured by either RT-PCR (c-erbB3 P = 0.0003; c-erbB4 P = 0.02) or ICA (c-erbB-3 P = 0.002; c-erbB4 P = 0.01). Inverse associations were seen between c-erbB3 and c-erbB4 mRNA marker status and EGFR membrane protein (c-erbB3: P = 0.003; c-erbB4: P = 0.003) and mRNA (c-erbB4: P = 0.009) status. These associations were reinforced by Spearman Rank Correlation Tests. A significant relationship was seen between Ki67 and c-erbB4 mRNA status and level. Measurements of c-erbB3 protein levels in tumour samples removed from a further 89 patients of known response to endocrine therapy: (i) confirmed the relationship between c-erbB3 and ER and (ii) identified that patients whose ER positive tumours expressed high levels of c-erbB3 were most likely to benefit from endocrine measures. A non-significant trend was recorded between c-erbB3 levels and Ki67 immunostaining, These results clearly demonstrate that increased c-erbB3 and c-erbB4 expression appears to be associated with the prognostically-favourable ER phenotype.	Univ Wales, Coll Med, Tenovus Canc Res Ctr, Cardiff CF4 4XX, S Glam, Wales; Hammersmith Hosp, Imperial Canc Res Fund, Mol Oncol Unit, London W12 0NN, England; City Hosp, Dept Histopathol, Nottingham NG5 1PB, England; City Hosp, Dept Surg, Nottingham NG5 1PB, England	Cardiff University; Cancer Research UK; Imperial College London; University of Nottingham; University of Nottingham	Knowlden, JM (corresponding author), Univ Wales, Coll Med, Tenovus Canc Res Ctr, Heath Pk, Cardiff CF4 4XX, S Glam, Wales.		Gee, Julia MW/N-3995-2014	Gee, Julia MW/0000-0001-6483-2015; Ellis, Ian/0000-0001-5292-8474				ALIMANDI M, 1995, ONCOGENE, V10, P1813; BACUS SS, 1993, CANCER RES, V53, P5251; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; Brotherick I, 1995, CANCER IMMUNOL IMMUN, V41, P280, DOI 10.1007/BF01517215; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHAN SDH, 1995, J BIOL CHEM, V270, P22608, DOI 10.1074/jbc.270.38.22608; DAFFADA AAI, 1994, J MOL ENDOCRINOL, V13, P265, DOI 10.1677/jme.0.0130265; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FRYE RA, 1989, ONCOGENE, V4, P1153; FUQUA SAW, 1990, J NATL CANCER I, V82, P858, DOI 10.1093/jnci/82.10.858; GASPARINI G, 1994, EUR J CANCER, V30A, P16, DOI 10.1016/S0959-8049(05)80010-3; GEE JMW, 1994, INT J CANCER, V59, P619, DOI 10.1002/ijc.2910590508; GEE JMW, 1996, HORMONE DEPENDENT CA, P169; GERDES J, 1984, J IMMUNOL, V133, P1710; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; Gullick WJ, 1996, CANCER SURV, V27, P339; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HAYWARD JL, 1977, CANCER, V39, P1289, DOI 10.1002/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F; JORDAN VC, 1993, BRIT J PHARMACOL, V110, P507, DOI 10.1111/j.1476-5381.1993.tb13840.x; KLIJN JGM, 1992, ENDOCR REV, V13, P3, DOI 10.1210/er.13.1.3; Knowlden JM, 1997, CLIN CANCER RES, V3, P2165; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LONARDO F, 1990, New Biologist, V2, P992; MANNING DL, 1995, ACTA ONCOL, V34, P641, DOI 10.3109/02841869509094041; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; NICHOLSON RI, 1994, BREAST CANCER RES TR, V29, P117, DOI 10.1007/BF00666187; NICHOLSON RI, 1991, EUR J CANCER, V27, P908, DOI 10.1016/0277-5379(91)90145-4; NICHOLSON RI, 1993, EUR J CANCER, V29A, P1018, DOI 10.1016/S0959-8049(05)80215-1; NICHOLSON RI, 1992, RECENT ADV ENDOCRINO, P150; NICHOLSON RI, 1996, HORMONES CANC, P227; OBRIAN JP, 1991, MOL CELL BIOL, V11, P5016; OSBORNE CK, 1991, J NATL CANCER I, V83, P1477, DOI 10.1093/jnci/83.20.1477; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RAJKUMAR T, 1994, BRIT J CANCER, V70, P459, DOI 10.1038/bjc.1994.328; RAJKUMAR T, 1993, J PATHOL, V170, P271, DOI 10.1002/path.1711700309; RAJKUMAR T, 1995, BREAST, V4, P84, DOI 10.1016/0960-9776(95)90001-2; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WOLF DM, 1993, BREAST CANCER RES TR, V27, P27, DOI 10.1007/BF00683191	49	106	113	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1949	1957		10.1038/sj.onc.1202107	http://dx.doi.org/10.1038/sj.onc.1202107			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788438				2022-12-17	WOS:000076423500008
J	Hu, MCT; Qiu, WR; Wang, YP				Hu, MCT; Qiu, WR; Wang, YP			JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases	ONCOGENE			English	Article						p53; c-Jun kinase; phosphorylation; tumor suppressor protein	TUMOR-SUPPRESSOR PROTEIN; WILD-TYPE P53; JUN ACTIVATION DOMAIN; MAP KINASE; IN-VIVO; PHOSPHORYLATION SITES; SIGNAL-TRANSDUCTION; GROWTH SUPPRESSION; INDUCED APOPTOSIS; CELLS	The function of the tumor suppressor protein p53 is modulated by post-translational events, primarily by phosphorylation. p53 is phosphorylated at multiple sites by a variety of protein kinases depending on the cellular environment. It has been suggested that serine 34 of mouse p53 is specifically phosphorylated by a stress-activated protein kinase in response to ultraviolet radiation. Since serine 34 is a major site of phosphorylation of mouse p53 in vivo and its specific protein kinase is still not definitively identified yet, we have examined the c-Jun N-terminal kinase 1 (JNK1) activity on p53 by expressing JNK1 in 293T cells. We show here that activated JNK1 phosphorylates mouse p53 specifically at serine 34 in vitro, while a dominanant-negative JNK1 mutant does not phosphorylate p53. More importantly, JNK1 associates with p53 in vivo, with or without activation, confirming that JNK1 is indeed a p53 kinase. Interestingly, activated JNK2 and JNK3 also phosphorylate serine 34 of mouse p53. Furthermore, JNK2 and JNK3 also associate with p53 in vivo, indicating that not only JNK1, but also JNK2 and JNK3 are p53 N-terminal serine 34 kinases. Phosphorylation of p53 by JNKs may play an important role in nuclear signal transduction in response to environmental stress or tumorigenic agents.			Hu, MCT (corresponding author), AMGEN INC, DEPT CELL BIOL, THOUSAND OAKS, CA 91320 USA.							ALESSI DR, 1993, ONCOGENE, V8, P2015; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRYAN RG, 1994, MOL CELL BIOL, V14, P7933, DOI 10.1128/MCB.14.12.7933; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hecker D, 1996, ONCOGENE, V12, P953; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; JAMAL S, 1995, ONCOGENE, V10, P2095; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIU TJ, 1994, CANCER RES, V54, P3662; LIU TJ, 1995, CANCER RES, V55, P3117; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULLER E, 1995, ONCOGENE, V10, P1175; MULLER E, 1993, ONCOGENE, V8, P2193; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; YANG CL, 1995, CANCER RES, V55, P4210	55	106	108	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	1997	15	19					2277	2287		10.1038/sj.onc.1201401	http://dx.doi.org/10.1038/sj.onc.1201401			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393873				2022-12-17	WOS:A1997YE15700003
J	Floettmann, JE; Rowe, M				Floettmann, JE; Rowe, M			Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-kappa B activation	ONCOGENE			English	Article						EBV; LMP1; NF-KB; TNF-receptor; TRAF; signaling	CELL-DEATH; TRANSFORMING PROTEIN; LYMPHOCYTE-TRANSFORMATION; MONOCLONAL-ANTIBODIES; TRANSIENT EXPRESSION; CYTOPLASMIC DOMAIN; SEQUENCE VARIATION; NUCLEAR PROTEIN-2; TNF RECEPTOR; PHENOTYPE	The Epstein-Barr virus Latent Membrane Protein-1 (LMP1) has structural features and functions consistent with it being a constitutively active cell surface receptor. The known association of LMP1 with members of the TRAF family of proteins suggests that LMP1 transduces signals similarly to the Tumour Necrosis Factor Receptor (TNFR) family of cell surface receptors that signal by forming dimers or trimers in response to binding of extracellular ligands. However, interactions between LMP1 and the TRAFs have so far only been described for the C-terminal activation region 1 (CTAR1) of LMP1 and no direct interactions of the TRAFs with the second NF-kappa B activation domain (CTAR2) have been reported. We have now mapped the NF-kappa B activation domain of CTAR2 to a highly conserved stretch of 6 amino acids at the far C-terminus (codons 379 to 384 in B95.8 LMP1). In addition, we constructed chimeric receptor molecules which contain the ligand-binding extracellular domain and the transmembrane domain of rat CD2 fused to the C-terminus of LMP1 encoding the CTAR1 and/or the CTAR2 domain. Interestingly, the function of a chimera encoding CTAR2 alone, as well as the function of a chimera encoding both CTAR1 and CTAR2 was found to be inducible upon antibody-mediated crosslinking. These inducible chimeric proteins also allowed us to demonstrate that LMP1 mediated NF-kappa B activation is an immediate event following activation of LMP1.	UNIV WALES COLL MED,DEPT MED,CARDIFF CF4 4XX,S GLAM,WALES	Cardiff University			Rowe, Martin/B-2880-2009	Rowe, Martin/0000-0003-4139-7326				Ansieau S, 1996, P NATL ACAD SCI USA, V93, P14053, DOI 10.1073/pnas.93.24.14053; ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BRATTSAND G, 1990, J IMMUNOL, V144, P3651; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CLARK SJ, 1988, J EXP MED, V167, P1861, DOI 10.1084/jem.167.6.1861; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; Devergne O, 1996, MOL CELL BIOL, V16, P7098; ELIOPOULOS A, 1997, IN PRESS ONCOGENE, V14; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Franken M, 1996, J VIROL, V70, P7819, DOI 10.1128/JVI.70.11.7819-7826.1996; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HUEN DS, 1995, ONCOGENE, V10, P549; JEFFERIES WA, 1985, J EXP MED, V162, P117, DOI 10.1084/jem.162.1.117; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KIEFF E, 1996, FIELDS VIROLOGY, V2, P2343; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; MILLER WE, 1994, J GEN VIROL, V75, P2729, DOI 10.1099/0022-1317-75-10-2729; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; Palefsky JM, 1996, J INFECT DIS, V173, P710, DOI 10.1093/infdis/173.3.710; PENG M, 1992, ONCOGENE, V7, P1775; PILON M, 1991, J IMMUNOL, V146, P1047; RICKINSON A, 1996, FIELDS VIROLOGY, V2, P2397; ROBERTSON ES, 1995, EBV REPORT, V2, P73; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; Wang S, 1996, CANCER RES, V56, P4610; YOUNG DC, 1993, ANAL BIOCHEM, V215, P24, DOI 10.1006/abio.1993.1549	46	106	108	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1851	1858		10.1038/sj.onc.1201359	http://dx.doi.org/10.1038/sj.onc.1201359			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362452				2022-12-17	WOS:A1997XZ72500012
J	Brunton, VG; Ozanne, BW; Paraskeva, C; Frame, MC				Brunton, VG; Ozanne, BW; Paraskeva, C; Frame, MC			A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer	ONCOGENE			English	Article						EGF receptor; c-Src; FAK; colon cancer	PROTEIN-TYROSINE KINASE; CARCINOMA CELL-LINE; FACTOR-ALPHA; FAMILY KINASES; FACTOR EGF; PP60C-SRC; EXPRESSION; ACTIVATION; MIGRATION; PHOSPHORYLATION	We have examined the function of the epidermal growth factor (EGF) receptor, c-Src and focal adhesion kinase (FAK) in the progression of colon cancer using an in vitro progression model. A non-tumorigenic cell line was derived from a premalignant colonic adenoma (PC/AA) from which a clonogenic variant was established (AA/C1). Following sequential treatment with sodium butyrate and the carcinogen N-methyl-N'-nitro-N-nitrosoguanidine an anchorage-independent line was isolated which, with time in culture, became tumorigenic when injected into athymic nude mice (AA/C1/SB10). We have shown that both EGF receptor and FAK protein levels were elevated in the carcinoma cells as compared to the adenoma cells, while the expression and activity of c-Src were unaltered during the adenoma to carcinoma transition. EGP induced the movement of the carcinoma cells into a reconstituted basement membrane which was not seen with the premalignant adenoma cells. This increased motility was accompanied by an EGF-induced increase in c-Src kinase activity, relocalisation of c-Src to the cell periphery and phosphorylation of FAK in the carcinoma cells but not in the adenoma cells. This suggests that c-Src plays a role in the biological behaviour of colonic carcinoma cells induced by migratory factors such as EGF, perhaps acting in conjunction with FAK to regulate focal adhesion turnover and tumour cell motility. Furthermore, although c-Src has been implicated in colonic tumour progression, we demonstrate here that in the adenoma to carcinoma in vitro model c-Src is not the driving force for this progression but co-operates with other molecules in carcinoma development.	UNIV BRISTOL,SCH MED SCI,DEPT PATHOL & MICROBIOL,BRISTOL BS8 1TD,AVON,ENGLAND	University of Bristol	Brunton, VG (corresponding author), BEATSON INST CANC RES,CRC,BEATSON LABS,GARSCUBE ESTATE,SWITCHBACK RD,GLASGOW G61 1BD,LANARK,SCOTLAND.							AKASAKA T, 1995, J INVEST DERMATOL, V105, P104, DOI 10.1111/1523-1747.ep12313396; BELL L, 1992, J CLIN INVEST, V89, P315, DOI 10.1172/JCI115578; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BUCHDUNGER E, 1994, P NATL ACAD SCI USA, V91, P2334, DOI 10.1073/pnas.91.6.2334; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CARDIELLO F, 1993, INT J CANCER, V54, P952; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHAKRABARTY S, 1995, CLIN EXP METASTAS, V13, P191, DOI 10.1007/BF00132207; CHEN JD, 1993, EXP CELL RES, V209, P216, DOI 10.1006/excr.1993.1304; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; FUJII K, 1995, EXP CELL RES, V216, P261, DOI 10.1006/excr.1995.1032; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KARAMERIS A, 1993, PATHOL RES PRACT, V189, P133, DOI 10.1016/S0344-0338(11)80082-8; KARNES WE, 1992, GASTROENTEROLOGY, V102, P474, DOI 10.1016/0016-5085(92)90093-E; LUNDJOHANSEN M, 1990, CANCER RES, V50, P6039; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MANNING AM, 1991, ONCOGENE, V6, P1471; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; OWENS LV, 1995, CANCER RES, V55, P2752; PLUMB JA, 1989, CANCER RES, V49, P4435; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; RAJAGOPAL S, 1995, INT J CANCER, V62, P661, DOI 10.1002/ijc.2910620603; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SIZELAND AM, 1992, MOL BIOL CELL, V3, P1235, DOI 10.1091/mbc.3.11.1235; SUNDARESHAN P, 1991, CANCER COMMUN, V3, P149, DOI 10.3727/095535491820873380; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; WATKINS LF, 1991, INT J CANCER, V47, P455, DOI 10.1002/ijc.2910470325; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1993, ONCOGENE, V8, P3063	48	106	119	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					283	293		10.1038/sj.onc.1200827	http://dx.doi.org/10.1038/sj.onc.1200827			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018114				2022-12-17	WOS:A1997WD51600004
J	Suzuki, A; Matsuzawa, A; Iguchi, T				Suzuki, A; Matsuzawa, A; Iguchi, T			Down regulation of Bcl-2 is the first step on Fas-mediated apoptosis of male reproductive tract	ONCOGENE			English	Article						Bcl-2; Fas; 1pr mutant mouse; apoptosis; in vivo apoptosis-model	CELL-DEATH; EXPRESSION; ANTIGEN; RECEPTOR; LIGAND; APO-1; MICE; CLONING; MEMBER; GENE	Suppression of apoptosis by Bcl-2, an oncogene product, has been previously reported, Although the down regulation of Bcl-2 has been encountered in various types of apoptosis, the time course of changes in the expression of Bcl-2 has yet to be determined, In the present study, we established and analysed an in vivo model of apoptosis, The mouse male reproductive tract, specifically the prostate and epididymis, which is regulated by sex steroid hormones, especially testosterone, showed regression induced by chromosomal DNA fragmentation, apoptotic cell death, after gonadectomy, Following this apoptosis, down regulation of Bcl-2 and the new expression of Fas were seen, Using functional Fas-lacking mice, we demonstrated that this regression of the male reproductive tract is triggered by Fas-mediated apoptosis, In addition, time course experiments revealed that down regulation of Bcl-2 when apoptosis occurs heralds Fas expression, We propose here that apoptotic death signal transduction in total involve, a number of steps, the first and most important of which is down regulation of Bcl-2.	UNIV TOKYO,INST MED SCI,LAB ANIM RES CTR,MINATO KU,TOKYO 108,JAPAN; YOKOHAMA CITY UNIV,DEPT BIOL,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN	University of Tokyo; Yokohama City University	Suzuki, A (corresponding author), DAIICHI PHARMACEUT CO LTD,DRUG SAFETY RES LAB,TOKYO R&D CTR,EDOGAWA KU,16-13 KITAKASAI 1,TOKYO 134,JAPAN.		Matsuzawa, Atsushi/GLU-1387-2022; Iguchi, Taisen/AAL-4225-2021					AKAO Y, 1994, CANCER RES, V54, P2468; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; IGUCHI T, 1992, INT REV CYTOL, V139, P1, DOI 10.1016/S0074-7696(08)61409-6; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KAMADA S, 1995, CANCER RES, V55, P354; KONDO S, 1994, BRIT J CANCER, V70, P421, DOI 10.1038/bjc.1994.321; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LICHTER P, 1992, GENOMICS, V14, P179, DOI 10.1016/S0888-7543(05)80302-7; MAPARA MY, 1993, EUR J IMMUNOL, V23, P702, DOI 10.1002/eji.1830230320; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1994, PHILOS T ROY SOC B, V345, P281, DOI 10.1098/rstb.1994.0107; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OTANI H, 1993, J BIOL CHEM, V268, P22733; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SMITH PK, 1985, ANAL BIOCHEM, V170, P203; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Suzuki A, 1996, EMBO J, V15, P211, DOI 10.1002/j.1460-2075.1996.tb00351.x; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WILSON DL, 1977, ANAL BIOCHEM, V83, P33, DOI 10.1016/0003-2697(77)90506-1; Wyllie A H, 1980, Int Rev Cytol, V68, P251	30	106	112	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					31	37						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700551				2022-12-17	WOS:A1996UX31900004
J	Iwashita, T; Asai, N; Murakami, H; Matsuyama, M; Takahashi, M				Iwashita, T; Asai, N; Murakami, H; Matsuyama, M; Takahashi, M			Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation	ONCOGENE			English	Article						ret proto-oncogene; receptor tyrosine kinase; MEN2A; MEN2B	KINASE-ACTIVITY; PROTOONCOGENE PRODUCTS; RECEPTOR; PHOSPHORYLATION; NEUROBLASTOMA; ASSOCIATION; PP60C-SRC; SEQUENCE; ABILITY; DOMAINS	The c-ret proto-oncogene with multiple endocrine neoplasia (MEN) 2A or 2B mutation can transform NIH3T3 cells with high efficiencies as a consequence of its constitutive activation. The MEN2A mutation induces ligand-independent homodimerization of the Ret protein on the cell surface while the MEN2B mutation appears to alter the catalytic activity without dimerization. In the present study, we investigated the role of tyrosine residues present in the kinase domain for the transforming activity of the mutant Ret proteins. Substitution of phenylalanine for tyrosine 905 (Y905F) that corresponds to tyrosine 416 of the Src protein abolished the transforming activity of Ret with the MEN2A mutation (MEN2A-Ret) but not with the MEN2B mutation (MEN2B-Ret). On the other hand, the transforming activity of MEN2B-Ret but not MEN2A-Ret significantly decreased by changing tyrosine 864 or 952 to phenylalanine. In addition, double mutations of these tyrosines (Y864/952F) completely abolished the activity of MEN2B-Ret. The Y905F and Y864/952F mutations resulted in severe impairment of the kinase activity of MEN2A-Ret and MEN2B-Ret, respectively. These results thus indicated that tyrosine residues essential for the transforming activity are different between MEN2A-Ret and MEN2B-Ret.	NAGOYA UNIV,SCH MED,DEPT PATHOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Nagoya University			Takahashi, Masahide/AAN-4770-2020; ASAI, Naoya/I-7377-2014; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; 				ASAI N, 1995, MOL CELL BIOL, V15, P1613; BOLINO A, 1995, ONCOGENE, V10, P2415; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; Geer P.V.D., 1991, MOL CELL BIOL, V11, P4698; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; IWAMOTO T, 1993, ONCOGENE, V8, P1087; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; MARUYAMA S, 1994, JPN J CANCER RES, V85, P879, DOI 10.1111/j.1349-7006.1994.tb02962.x; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1995, ONCOGENE, V10, P641; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571	27	106	109	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					481	487						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637703				2022-12-17	WOS:A1996TV59700003
J	GalchevaGargova, Z; Theroux, SJ; Davis, RJ				GalchevaGargova, Z; Theroux, SJ; Davis, RJ			The epidermal growth factor receptor is covalently linked to ubiquitin	ONCOGENE			English	Article						EGF; signal transduction; ubiquitin	TYROSINE KINASE-ACTIVITY; COATED PIT FORMATION; FACTOR BETA-RECEPTOR; MEDIATED ENDOCYTOSIS; PROTEIN-DEGRADATION; HUMAN-FIBROBLASTS; AFFINITY; PHOSPHORYLATION; BINDING; INTERNALIZATION	Incubation of cultured human fibroblasts with epidermal growth factor (EGF) causes a proliferative response that is mediated by the binding of the growth factor to specific cell surface receptors, One event that occurs rapidly following EGF binding is the covalent modification of the EGF receptor (EGF-R) by phosphorylation on Ser, Thr, and Tyr residues, Here we report the identification of ubiquitination as a second form of EGF-stimulated covalent modification of the receptor, The EGF receptor was not ubiquitinated in serum-starved cells, However, treatment with EGF caused a rapid increase in EGF-R ubiquitination, In contrast, no EGF-stimulated ubiquitination was found in experiments using cells that express a mutant tyrosine kinase-negative EGF-R. Similarly, ubiquitination of the EGF-R was not observed at 4 degrees C or if the cells are depleted of intracellular K+. Together, these data establish ubiquitination as a form of EGF-stimulated covalent modification of the EGF-R.	UNIV MASSACHUSETTS, SCH MED,HOWARD HUGHES MED INST,PROGRAM MOLEC MED, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01605 USA; ASSUMPTION COLL, WORCESTER, MA 01609 USA; HOWARD HUGHES MED INST, COCONUT GROVE, FL 33133 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Assumption College; Howard Hughes Medical Institute					NCI NIH HHS [R01-CA58396] Funding Source: Medline; NIGMS NIH HHS [R15-GM49465] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM049465] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; BENVENISTE M, 1989, J CELL BIOL, V109, P2105, DOI 10.1083/jcb.109.5.2105; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; COCHET C, 1984, J BIOL CHEM, V259, P2553; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; DAVIS RJ, 1993, ADV LIPID RES, V25, P131; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DAVIS RJ, 1984, J BIOL CHEM, V259, P8545; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FAN Z, 1994, J BIOL CHEM, V269, P27595; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; GLENNEY JJ, 1993, J CELL BIOL, V121, P61; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HOU D, 1994, J BIOL CHEM, V269, P14244; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOETSCHER H, 1990, J BIOL CHEM, V265, P20131; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1993, J BIOL CHEM, V268, P577; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; SELVA E, 1993, J BIOL CHEM, V268, P2250; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WILEY HS, 1982, J BIOL CHEM, V257, P4222; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	44	106	107	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2649	2655						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545122				2022-12-17	WOS:A1995TP18800021
J	Ishino, M; Ohba, T; Sasaki, H; Sasaki, T				Ishino, M; Ohba, T; Sasaki, H; Sasaki, T			Molecular cloning of a cDNA encoding a phosphoprotein, Efs, which contains a Src homology 3 domain and associates with Fyn	ONCOGENE			English	Article						Src homology; fyn; yes; tyrosine phosphorylation; embryo	IDENTIFICATION; PROTEIN; CONSTRUCTION; SUBSTRATE; PAXILLIN; SEQUENCE; SYSTEM; CELLS	Src homology 2 and 3 (SH2 and SH3) domains mediate protein-protein interactions in intracellular signaling by protein-tyrosine kinases (PTKs), We have isolated cDNA clones from mouse embryo cDNA expression library that encode a new signaling protein which we call Efs (Embryonal Fyn-associated Substrate), The deduced amino acid sequence of 560 residues in length revealed one SH3 domain at its amino-terminal region, two proline-rich motifs with the consensus sequences of binding to Src-family SH3s, and a cluster of YXXP motifs that are possibly tyrosine-phosphorylated to serve as ligands binding to SH2 domains, Structure and alignment of these characteristic sequences are homologous to those of p130(Cas), but Efs and p130(Cas) are different proteins, Expression of the Efs gene was higher in placenta, embryo and brain than in other adult tissues, Transfection of COS-7 cells with a plasmid encoding an epitope-tagged Efs resulted in the expression of a 83 kDa protein, The epitope-tagged Efs was hyperphosphorylated when cotransfected with a vector expressing Fyn, In an in vitro kinase assay with the PCC4 cell lysate, Efs became phosphorylated on tyrosine residues and coprecipitated with p59(fyn) and p62(yes); the result suggests that Efs is a physiological substrate of these PTKs.	SAPPORO MED UNIV, SCH MED, CANC RES INST, DEPT BIOCHEM, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN	Sapporo Medical University								ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAUMANN G, 1994, EUR J IMMUNOL, V24, P1799, DOI 10.1002/eji.1830240812; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FLYNN DC, 1995, J BIOL CHEM, V270, P3894, DOI 10.1074/jbc.270.8.3894; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; SUDOL M, 1994, ONCOGENE, V9, P2145; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; WENG ZG, 1993, J BIOL CHEM, V268, P14956; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; YAMSHITA Y, 1992, TUMOR RES, V27, P59; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	36	106	107	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2331	2338						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570184				2022-12-17	WOS:A1995TK70200017
J	HABUCHI, T; DEVLIN, J; ELDER, PA; KNOWLES, MA				HABUCHI, T; DEVLIN, J; ELDER, PA; KNOWLES, MA			DETAILED DELETION MAPPING OF CHROMOSOME-9Q IN BLADDER-CANCER - EVIDENCE FOR 2 TUMOR-SUPPRESSOR LOCI	ONCOGENE			English	Note						BLADDER CANCER; CHROMOSOME 9; LOSS OF HETEROZYGOSITY; TUMOR SUPPRESSOR GENE	TRANSITIONAL-CELL CARCINOMA; GORLIN SYNDROME; GENE	Loss of heterozygosity (LOH) at loci on chromosome 9p and/or 9q is the most frequent genetic alteration in transitional cell carcinoma (TCC) of the bladder. However, localisation of the tumour suppressor locus or loci on 9q has been hampered by the relative infrequency of tumours with subchromosomal deletions. We have used 24 microsatellite markers to examine LOH in 70 new cases of TCC of the bladder and upper urinary tract. Forty tumours (57%) showed LOH at one or more loci on 9q and partial deletions were detected in five tumoms (7%). Combined data from the five cases with partial deletions place one tumour suppressor locus at 9q34 between D9S61 and D9S66 (an estimated distance of 13-14 cM). This region is frequently deleted in other sporadic tumours and encompasses one of the loci for tuberous sclerosis(TSC1). One tumour contained a distinct deletion between D9S153 and D9S109 (9q13-q31), which encompasses the locus for the familial nevoid basal cell carcinoma syndrome (Gorlin syndrome). This may indicate the presence of another tumour suppressor locus on 9q for TCC. Our findings significantly reduce the regions of 90 within which suppressor genes for TCC may reside. The possible involvement of two deletion targets on 90 in addition to the locus at 9p21 implicated in TCC may explain why LOH at all loci on chromosome 9 is frequent in TCC.	MARIE CURIE RES INST,MOLEC GENET LAB,OXTED RH8 0TL,SURREY,ENGLAND									AHSEE KW, 1994, CANCER RES, V54, P1617; BERNUES M, 1993, CANCER GENET CYTOGEN, V69, P76, DOI 10.1016/0165-4608(93)90120-B; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1995, CANCER RES, V55, P224; CAIRNS P, 1993, CANCER RES, V53, P1230; CARBONARA C, 1994, HUM MOL GENET, V3, P1829, DOI 10.1093/hmg/3.10.1829; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; DELSAL G, 1994, P NATL ACAD SCI USA, V91, P1848, DOI 10.1073/pnas.91.5.1848; DEVLIN J, 1994, ONCOGENE, V9, P2757; FARNDON PA, 1992, LANCET, V339, P581, DOI 10.1016/0140-6736(92)90868-4; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; GOUDIE DR, 1993, NAT GENET, V3, P165, DOI 10.1038/ng0293-165; GREEN AJ, 1994, HUM MOL GENET, V3, P1833, DOI 10.1093/hmg/3.10.1833; HABUCHI T, 1993, INT J CANCER, V53, P579, DOI 10.1002/ijc.2910530409; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAO CH, 1993, GENE CHROMOSOME CANC, V8, P155, DOI 10.1002/gcc.2870080304; KEEN AJ, 1994, ONCOGENE, V9, P2083; KNOWLES MA, 1994, CANCER RES, V54, P531; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; LOUGHRAN O, 1994, CANCER RES, V54, P5045; MERLO A, 1994, CANCER RES, V54, P2322; MIURA K, 1995, CANCER RES, V55, P1828; MIYAO N, 1993, CANCER RES, V53, P4066; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLUMI AF, 1990, CANCER RES, V50, P7081; OSBORNE RJ, 1994, BRIT J CANCER, V69, P429, DOI 10.1038/bjc.1994.79; POVEY S, 1994, ANN HUM GENET, V58, P177, DOI 10.1111/j.1469-1809.1994.tb01887.x; QUINN AG, 1994, GENE CHROMOSOME CANC, V11, P222, DOI 10.1002/gcc.2870110404; RUPPERT JM, 1993, CANCER RES, V53, P5093; SCHULTZ DC, 1995, CANCER RES, V55, P2150; SHANLEY SM, 1995, HUM MOL GENET, V4, P129; SMEETS W, 1987, CANCER GENET CYTOGEN, V29, P29, DOI 10.1016/0165-4608(87)90028-8; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; STADLER WM, 1994, CANCER RES, V54, P2060; VANDERRIET P, 1994, CANCER RES, V54, P25; VANNI R, 1988, CANCER GENET CYTOGEN, V30, P35, DOI 10.1016/0165-4608(88)90090-8	37	106	115	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1671	1674						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478593				2022-12-17	WOS:A1995TC53500027
J	BRACEY, TS; MILLER, JC; PREECE, A; PARASKEVA, C				BRACEY, TS; MILLER, JC; PREECE, A; PARASKEVA, C			GAMMA-RADIATION-INDUCED APOPTOSIS IN HUMAN COLORECTAL ADENOMA AND CARCINOMA CELL-LINES CAN OCCUR IN THE ABSENCE OF WILD-TYPE P53	ONCOGENE			English	Note						APOPTOSIS; CELL CYCLE; COLORECTAL; GAMMA RADIATION; G2 ARREST; P53	TUMOR-SUPPRESSOR GENE; THYMOCYTE APOPTOSIS; IONIZING-RADIATION; DNA-DAMAGE; DEATH; IRRADIATION; ACTIVATION; CHECKPOINT; MUTATIONS; CANCER	The tumour suppressor gene p53 codes for a transcription factor which is thought to play a critical role in the induction of G1 cell cycle arrest and programmed cell death (apoptosis) following DNA damage by ionizing radiation, The aim of this investigation was to determine whether a p53 independent radiation-induced apoptosis pathway exists in human colon epithelial cell lines. This report describes the induction, by gamma-radiation, of apoptosis in the colorectal adenoma cell line S/RG/C2, and in the colorectal carcinoma cell line PC/JW, both of which lack wild type p53, In addition, flow cytometry revealed that both cell lines failed to arrest in G1 after radiation. Thus, although loss of wild type p53 may abrogate GI arrest, radiation-induced apoptosis can still occur in human colonic tumour cell lines through a p53 independent mechanism.	UNIV BRISTOL, SCH MED SCI,DEPT PATHOL & MICROBIOL,CRC, COLORECTAL TUMOUR BIOL RES GRP, BRISTOL BS8 1TD, AVON, ENGLAND; BRISTOL ONCOL CTR, BIOPHYS GRP, BRISTOL BS2 8ED, AVON, ENGLAND	University of Bristol; Bristol Haematology & Oncology Centre								ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BAKER SJ, 1990, CANCER RES, V50, P7717; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; BRACHMAN DG, 1993, CANCER RES, V53, P3667; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HEERDT BG, 1994, CANCER RES, V54, P3288; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE JM, 1994, ONCOGENE, V9, P3731; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWENTHAL JW, 1985, J IMMUNOL, V135, P1119; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MERRITT AJ, 1994, CANCER RES, V54, P614; OCONNOR PM, 1993, CANCER RES, V53, P4776; Okada S, 1970, RAD BIOCH, P247; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; PARASKEVA C, 1989, CANCER RES, V49, P1282; POTTEN CS, 1977, NATURE, V269, P518, DOI 10.1038/269518a0; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P229, DOI 10.1080/09553009414550261; SEKI H, 1994, EUR J IMMUNOL, V24, P2914, DOI 10.1002/eji.1830241150; SHINOHARA K, 1993, RADIAT RES, V135, P197, DOI 10.2307/3578295; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	38	106	107	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	1995	10	12					2391	2396						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784088				2022-12-17	WOS:A1995RE54300015
J	BUSTELO, XR; SUEN, KL; LEFTHERIS, K; MEYERS, CA; BARBACID, M				BUSTELO, XR; SUEN, KL; LEFTHERIS, K; MEYERS, CA; BARBACID, M			VAV COOPERATES WITH RAS TO TRANSFORM RODENT FIBROBLASTS BUT IS NOT A RAS GDP/GTP EXCHANGE FACTOR	ONCOGENE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; SACCHAROMYCES-CEREVISIAE; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING; ESCHERICHIA-COLI; PROTO-ONCOGENE; ACTIVATION; KINASE	Vav is a proto-oncogene specifically expressed in cells of hematopoietic origin. Its gene product contains a series of structural motifs, including SH2 and SH3 domains, suggestive of a role in signal transduction. The Vav protein also possesses a Dbl-homology (DH) domain previously found in regulators of the Ras superfamily of small GTP-binding proteins. Recently, Vav has been reported to be the major Ras GDP/GTP exchange factor (GEF) in hematopoietic cells [Gulbins et al., Science 260, 822 (1993); J. Immunol. 152, 2123 (1994)]. The following observations are inconsistent with such a role: (i) Vav proteins do not exhibit Ras GEF activity in standard GDP/GTP exchange assays; (ii) Cells overexpressing Vav do not have increased levels of GTP-bound Ras proteins; (iii) Overexpression of Vav does not overcome the growth inhibitory activity of RasN17, a mutant that blocks Ras signaling by inhibiting Ras GEFs; (iv) Transformation of NIH3T3 cells by Vav oncoproteins is not inhibited by a farnesyl transferase inhibitor that completely blocks transformation by both Ras and its well characterized GEF, RasCDC25 and (v) The morphology of Vav-transformed NIH3T3 cells is dramatically different from that induced by Ras and RasCDC25. Whereas these observations make it unlikely that Vav functions either as a RasGEF or as an upstream regulatory element of Ras, we have observed that Vav can cooperate with normal Ras proteins to transform NIH3T3 cells. These results suggest that Vav and Ras may mediate signal transduction by distinct, but interactive mitogenic pathways.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT CHEM,PRINCETON,NJ 08543	Bristol-Myers Squibb; Bristol-Myers Squibb			Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GULBINS E, 1994, J IMMUNOL, V152, P2123; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; PUI L, 1992, CURR BIOL, V2, P275; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1991, NEW BIOL, V3, P372; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUKUMAR S, 1988, SCIENCE, V240, P524, DOI 10.1126/science.3282307	42	106	106	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2405	2413						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036025				2022-12-17	WOS:A1994NX62900036
J	OKUNO, H; AKAHORI, A; SATO, H; XANTHOUDAKIS, S; CURRAN, T; IBA, H				OKUNO, H; AKAHORI, A; SATO, H; XANTHOUDAKIS, S; CURRAN, T; IBA, H			ESCAPE FROM REDOX REGULATION ENHANCES THE TRANSFORMING ACTIVITY OF FOS	ONCOGENE			English	Article							DNA-BINDING ACTIVITY; GROWTH-STIMULATING ACTIVITY; CHICKEN-EMBRYO FIBROBLASTS; JUN PROTO-ONCOGENE; C-JUN; LEUCINE ZIPPER; V-FOS; GENE FAMILY; PROTEINS; PHOSPHORYLATION	Fos and Jun form dimeric complexes that bind to DNA sequences containing activator protein 1 (AP-1) sites and regulate gene expression. The in vitro DNA-binding activity of these proteins is sensitive to reduction-oxidation (redox). Reduction of a single conserved cysteine residue, located in the DNA-binding domain, either by reducing agents or by a nuclear redox factor (Ref-1), is required for AP-1 DNA-binding activity. Replacing the critical cysteine with serine results in a protein that can bind to DNA in vitro even under oxidizing conditions. To determine whether redox control affects the function of Fos in vivo, we have constructed, and compared the properties of, retroviral vectors expressing either a truncated Fos protein (F118-211) or a truncated Fos protein in which the critical cysteine was replaced by serine (FC154S). In infected chicken embryo fibroblasts (CEFs), both vectors expressed similar levels of Fos protein, which formed heterodimers with Jun at equivalent efficiencies. However, extracts from cells expressing FC154S exhibited a threefold increase in AP-1 DNA-binding activity compared with cells expressing F118-211. Furthermore, this enhanced binding activity was resistant to treatment with the oxidizing agent diamide. Infection of CEFs by virus expressing FC154S resulted in increased numbers of transformed colonies and an increase in colony size compared with those obtained following infection by virus expressing Fos 118-211. These results suggest that redox regulation may limit the total level of functional Fos-Jun complexes in vivo and that escape from this control enhances transforming activity.	UNIV TOKYO,INST MED SCI,DEPT TUMOR VIRUS RES,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN; ROCHE INST MOLEC BIOL,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110	University of Tokyo			Curran, Tom/F-5234-2018; Curran, Tom/C-1164-2008; Curran, Thomas/AAE-7631-2019; Curran, Tom/D-7515-2011	Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; OKUNO, HIROYUKI/0000-0001-6237-6503				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1991, ONCOGENE, V6, P2179; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; CURRAN T, 1984, CELL, V36, P259; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GENTZ R, 1988, SCIENCE, V239, P1150; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; IBA H, 1988, ONCOGENE RES, V2, P121; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; KENUWEIN T, 1987, CELL, V48, P647; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OKUNO H, 1991, ONCOGENE, V6, P1491; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A; YOSHIDA T, 1989, ONCOGENE RES, V5, P79; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	43	106	108	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					695	701						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437852				2022-12-17	WOS:A1993KN00800021
J	JONES, MH; NAKAMURA, Y				JONES, MH; NAKAMURA, Y			DELETION MAPPING OF CHROMOSOME-3P IN FEMALE GENITAL-TRACT MALIGNANCIES USING MICROSATELLITE POLYMORPHISMS	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; PRIMARY BREAST-CANCER; SHORT ARM; SIMPLE SEQUENCES; OVARIAN-CANCER; LUNG-CANCER; DNA MARKERS; HETEROZYGOSITY; ALLELOTYPE; PROGRESSION	We have constructed deletion maps of chromosome 3p for cancers of the female genital tract (uterine endometrium, uterine cervix and ovary). The tumours were tested for loss of heterozygosity using CA-repeat polymorphisms. The high degree of informativeness of these markers allowed the construction of detailed deletion maps from a relatively small number of samples. A common region of deletion was identified at chromosome 3p13-21.1 in endometrial cancer and at 3p13-14.3 in cervical cancer; 5 out of 13 (38%) endometrial cancers and six out of eight (75%) cervical cancers showed loss of heterozygosity at these regions. In ovarian cancer a separate common region of deletion was identified at 3p21.1-22; two out of four (50%) ovarian cancers had alleles deleted at this region. These data suggest the presence of a tumour-suppressor gene(s) for endometrial and cervical cancer at 3p13-21.3 and a separate gene at 3p21.1-22 that is involved in the carcinogenesis of ovarian cancer.	JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,1-37-1 KAMI IKEBUKURO,TOSHIMA KU,TOKYO 170,JAPAN	Japanese Foundation for Cancer Research				Jones, Michael/0000-0002-2251-1990				ANGLARD P, 1991, CANCER RES, V51, P1071; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; EHLEN T, 1990, ONCOGENE, V5, P219; JONES MH, 1992, IN PRESS GENES CHROM; JONES MH, 1992, IN PRESS HUM MOL GEN; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; LITT M, 1989, AM J HUM GENET, V44, P397; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; MORITA R, 1991, CANCER RES, V51, P820; NAKAMURA Y, 1987, SCIENCE, V325, P939; PATHAK S, 1982, NEW ENGL J MED, V301, P592; SATO T, 1991, CANCER RES, V51, P5794; SATO T, 1991, CANCER RES, V51, P5118; SATO T, 1990, CANCER RES, V50, P7184; SMEETS DFCM, 1986, HUM GENET, V72, P215, DOI 10.1007/BF00291880; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; TAUTZ D, 1984, NUCLEIC ACIDS RES, V12, P4127, DOI 10.1093/nar/12.10.4127; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; TRENT JM, 1985, CANCER GENET CYTOGEN, V14, P153, DOI 10.1016/0165-4608(85)90226-2; WANG N, 1984, CANCER GENET CYTOGEN, V11, P479, DOI 10.1016/0165-4608(84)90028-1; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V11, P91, DOI 10.1016/0165-4608(84)90102-X; YAMAKAWA K, 1991, GENOMICS, V9, P536, DOI 10.1016/0888-7543(91)90421-A; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YAMAKAWA K, 1991, GENOMICS, V11, P565, DOI 10.1016/0888-7543(91)90063-K; YOKOJAMA S, 1992, IN PRESS CANCER RES, V52; YOKOTA J, 1989, CANCER RES, V49, P3598	30	106	107	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1631	1634						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630822				2022-12-17	WOS:A1992JE81300020
J	HORAK, E; SMITH, K; BROMLEY, L; LEJEUNE, S; GREENALL, M; LANE, D; HARRIS, AL				HORAK, E; SMITH, K; BROMLEY, L; LEJEUNE, S; GREENALL, M; LANE, D; HARRIS, AL			MUTANT P53, EGF-RECEPTOR AND C-ERBB-2 EXPRESSION IN HUMAN BREAST-CANCER	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTORS; CELLULAR PROTEIN P53; TRANSFORMED-CELLS; TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; COLORECTAL CARCINOMAS; MONOCLONAL-ANTIBODIES; ALLELE LOSS; GENE; ONCOGENE	p53 expression was studied in 111 primary breast cancers with a monoclonal antibody (PAb240) that reacts with an epitope in mutant p53. Epidermal growth factor receptors (EGFr) and oestrogen receptors (ER) measured by ligand binding, c-erhB-2 expression assessed by immunochemistry and lymph node status were compared with p53 staining. Fifty-nine tumours (53%) were positive for p53, and this correlated with EGFr expression (P < 0.02), which is a known poor prognostic factor. Eighteen out of 59 p53+ tumours expressed c-erbB-2 versus 4 out of 52 p53- tumours assessed on paraffin sections. However, assessing c-erhB-2 by Southern blotting and immunochemistry on frozen sections showed that 20 out of 59 p53+ tumours overexpressed or had amplified c-erbB-2 compared with 15 out of 52 p53- tumours (not significant). Mean EGFr concentration in p53+ tumours was 31 fmol per mg of membrane protein versus 14 fmol mg-1 in p53- tumours. Cytoplasmic staining was the most frequent pattern found for p53, but some cases showed cytoplasmic plus nuclear staining, or focal cells with predominantly nuclear staining. Thus, abnormal p53 is the commonest oncogene abnormality described in breast cancer. The association with EGFr expression suggests that these oncogenes interact in the pathogenesis of breast cancer.	JOHN RADCLIFFE HOSP,IMPERIAL CANC RES FUND,INST MOLEC MED,CLIN ONCOL UNIT,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT PATHOL,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,DEPT SURG,OXFORD OX3 9DU,ENGLAND; IMPERIAL CANC RES FUND,S MIMMS EN6 3LD,HERTS,ENGLAND	University of Oxford; University of Oxford; University of Oxford			Harris, Adrian L/ABA-3343-2020; Lane, David P/C-4920-2008	Harris, Adrian L/0000-0003-1376-8409; Lane, David/0000-0003-0551-3545				ALI IU, 1989, ONCOGENE, V4, P89; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARNES DM, 1988, BRIT J CANCER, V58, P448, DOI 10.1038/bjc.1988.238; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; BOS JL, 1989, CANCER RES, V49, P4682; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CATTORETTI G, 1988, BRIT J CANCER, V57, P353, DOI 10.1038/bjc.1988.81; CHIMCO WJ, 1988, NATURE, V332, P805; CHUMAKOV P, 1990, CELL BIOCH S14C, V106, P269; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; Crawford L V, 1984, Mol Biol Med, V2, P261; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1988, ONCOGENE, V3, P313; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P3927; GREEN AR, 1988, BRIT J CANCER, V58, P115, DOI 10.1038/bjc.1988.176; GRIMAUX M, 1990, INT J CANCER, V45, P255, DOI 10.1002/ijc.2910450209; GUERIN M, 1989, INT J CANCER, V43, P201, DOI 10.1002/ijc.2910430205; GUSTERSON BA, 1988, BRIT J CANCER, V58, P453, DOI 10.1038/bjc.1988.239; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1988, ONCOGENE HDB, P403; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MACKAY J, 1988, LANCET, V2, P1384; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MASON DY, 1989, J CLIN PATHOL, V42, P1194, DOI 10.1136/jcp.42.11.1194; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; NICHOLSON S, 1989, LANCET, V1, P182; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PATERSON MC, 1991, CANCER RES, V51, P556; PEREZ R, 1984, BREAST CANCER RES TR, V4, P189, DOI 10.1007/BF01806484; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; PROSSER J, 1990, ONCOGENE, V5, P1563; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; SAINSBURY JRC, 1987, LANCET, V1, P1398; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHOHAT O, 1987, ONCOGENE, V1, P277; SLAMON DJ, 1989, CANCER CEL, V7, P371; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; VALVERIUS EM, 1989, MOL ENDOCRINOL, V3, P203, DOI 10.1210/mend-3-1-203; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VARLEY JM, 1991, ONCOGENE, V6, P413; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WEINBERG RA, 1989, CANCER RES, V49, P3713; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WRIGHT C, 1989, CANCER RES, V49, P2087; WYSS R, 1987, ANTICANCER RES, V7, P721; YEE LD, 1989, SEMIN DIAGN PATHOL, V6, P110; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0	65	106	106	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2277	2284						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1685017				2022-12-17	WOS:A1991GX73500015
J	STACEY, DW; ROUDEBUSH, M; DAY, R; MOSSER, SD; GIBBS, JB; FEIG, LA				STACEY, DW; ROUDEBUSH, M; DAY, R; MOSSER, SD; GIBBS, JB; FEIG, LA			DOMINANT INHIBITORY RAS MUTANTS DEMONSTRATE THE REQUIREMENT FOR RAS ACTIVITY IN THE ACTION OF TYROSINE KINASE ONCOGENES	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; GUANINE-NUCLEOTIDE EXCHANGE; SIGNAL TRANSDUCTION; CELL-PROLIFERATION; H-RAS; SACCHAROMYCES-CEREVISIAE; MONOCLONAL-ANTIBODIES; GENE FAMILY; PRODUCT P21; EXPRESSION	Two inhibitory Ras mutant proteins [(Asn 17) Ras and RAS(T)] were microinjected into NIH3T3 cells in order to compare their inhibitory activity with that of a neutralizing anti-ras antibody. Both mutants were able to block efficiently the mitogenic effects of serum added to quiescent NIH3T3 cells. Furthermore, each of the inhibitors blocked cell cycle progression at the same point as the injected anti-ras antibody, just prior to the initiation of a new round of DNA synthesis. Finally, as with the injected anti-ras antibody, each of the inhibitors was efficiently able to block proliferation and reverse the transformed morphology of cells transformed by tyrosine kinase oncogenes, while cells transformed by serine kinase oncogenes were unaffected. Therefore, results with all three reagents clearly indicate that cellular Ras activity is required in the late G1 phase of the cell cycle and is essential for the maintenance of the transformed phenotype induced by tyrosine but not serine kinase oncogenes. These studies demonstrate the utility of dominant inhibitory mutants as a means of interfering with the activity of cellular oncogenes.	TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111; MERCK SHARP & DOHME LTD,DEPT CANC RES,W POINT,PA 19486	Tufts University; Merck & Company	STACEY, DW (corresponding author), CLEVELAND CLIN EDUC FDN,DEPT MOLEC BIOL,9500 EUCLID AVE,CLEVELAND,OH 44106, USA.			Roudebush, Margaret/0000-0001-9005-3672				BALTUS E, 1988, P NATL ACAD SCI USA, V85, P502, DOI 10.1073/pnas.85.2.502; BOS JL, 1989, CANCER RES, V49, P4682; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FURTH ME, 1987, ONCOGENE, V1, P47; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; HATTORI S, 1987, MOL CELL BIOL, V7, P1999, DOI 10.1128/MCB.7.5.1999; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; KUNG HF, 1986, EXP CELL RES, V162, P363, DOI 10.1016/0014-4827(86)90341-1; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAPAGEORGE AG, 1986, MOL CELL BIOL, V6, P1843, DOI 10.1128/MCB.6.5.1843; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; SANTOS E, 1988, J BIOL CHEM, V263, P9853; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SRIVASTAVA SK, 1989, MOL CELL BIOL, V9, P1779, DOI 10.1128/MCB.9.4.1779; STACEY DW, 1988, COLD SPRING HARB SYM, V53, P871, DOI 10.1101/SQB.1988.053.01.100; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STACEY DW, 1987, EXP CELL RES, V171, P232, DOI 10.1016/0014-4827(87)90266-7; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028	37	106	107	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2297	2304						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766676				2022-12-17	WOS:A1991GX73500018
J	CHAMPIONARNAUD, P; RONSIN, C; GILBERT, E; GESNEL, MC; HOUSSAINT, E; BREATHNACH, R				CHAMPIONARNAUD, P; RONSIN, C; GILBERT, E; GESNEL, MC; HOUSSAINT, E; BREATHNACH, R			MULTIPLE MESSENGER-RNAS CODE FOR PROTEINS RELATED TO THE BEK FIBROBLAST GROWTH-FACTOR RECEPTOR	ONCOGENE			English	Article							TYROSINE KINASE; CELL-GROWTH; NUCLEOTIDE-SEQUENCE; GENE FAMILY; FACTOR CDNA; EXPRESSION; CLONING; DIFFERENTIATION; MEMBER; FORMS	The BEK transmembrane protein tyrosine kinase is a receptor for both acidic and basic fibroblast growth factors. We identify several different transcripts which code for BEK-related proteins. These proteins differ from BEK in regions expected to control receptor activity. Thus, some of the proteins have altered extracellular, ligand-binding domains, and others an altered carboxyterminal tail. Still other forms of BEK differ only in their juxtamembrane domains. Sequencing of parts of the BEK gene shows that alternative splicing of the premessenger can account for at least some of this diversity. In particular, an apparently tissue specific, mutually exclusive splicing of two internal exons permits both the previously described K-SAM mRNA and the BEK mRNA to be derived from the same premessenger.	CHR NANTES, INSERM, U211, PLATEAU TECH, QUAI MONCOUSU, F-44035 NANTES 01, FRANCE; UNIV NANTES, FAC SCI, F-44035 NANTES, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Nantes Universite	BREATHNACH, R (corresponding author), CHR NANTES, INSERM, U211, PLATEAU TECH, QUAI MONCOUSU, F-44035 NANTES 01, FRANCE.		Breathnach, Richard/K-7599-2015					ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FRIESEL R, 1986, J BIOL CHEM, V261, P7581; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JEANNY JC, 1987, EXP CELL RES, V171, P63, DOI 10.1016/0014-4827(87)90251-5; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARICS I, 1989, ONCOGENE, V4, P335; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; NEUFELD G, 1988, J CELL BIOL, V106, P1385, DOI 10.1083/jcb.106.4.1385; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; OLWIN BB, 1988, J CELL BIOL, V107, P761, DOI 10.1083/jcb.107.2.761; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; Sambrook J., 1989, MOL CLONING LAB MANU; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	35	106	107	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1991	6	6					979	987						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1648704				2022-12-17	WOS:A1991GU62200012
J	OLOFSSON, B; CHARDIN, P; TOUCHOT, N; ZAHRAOUI, A; TAVITIAN, A				OLOFSSON, B; CHARDIN, P; TOUCHOT, N; ZAHRAOUI, A; TAVITIAN, A			EXPRESSION OF THE RAS-RELATED RALA, RHO12 AND RAB GENES IN ADULT-MOUSE TISSUES	ONCOGENE			English	Note											OLOFSSON, B (corresponding author), UNIV PARIS 07,FAC MED LARIBOISIERE ST LOUIS,GENET & EXPRESS ONCOGENES LAB,INSERM UNITE 248,F-75010 PARIS,FRANCE.							AMARA SG, 1984, MOL CELL BIOL, V4, P2151, DOI 10.1128/MCB.4.10.2151; ANDERSON PS, 1987, MOL CELL BIOL, V7, P3620, DOI 10.1128/MCB.7.10.3620; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARROWMAN MM, 1986, NATURE, V319, P504, DOI 10.1038/319504a0; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BURGOYNE RD, 1987, NATURE, V328, P112, DOI 10.1038/328112a0; BURGOYNE RD, 1987, NATURE, V326, P448, DOI 10.1038/326448a0; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUERRERO I, 1986, LEUKEMIA RES, V10, P851, DOI 10.1016/0145-2126(86)90306-1; GUERRERO I, 1985, P NATL ACAD SCI USA, V82, P7810, DOI 10.1073/pnas.82.23.7810; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; KAMATA T, 1984, NATURE, V310, P147, DOI 10.1038/310147a0; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LEV Z, 1985, MOL CELL BIOL, V5, P1540, DOI 10.1128/MCB.5.6.1540; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MILCAREK C, 1985, MOL CELL BIOL, V5, P2514, DOI 10.1128/MCB.5.10.2514; OLOFSSON B, 1986, EUR J BIOCHEM, V160, P261, DOI 10.1111/j.1432-1033.1986.tb09965.x; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SEGAL D, 1986, MOL CELL BIOL, V6, P2241, DOI 10.1128/MCB.6.6.2241; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEGEV N, 1987, MOL CELL BIOL, V7, P2367, DOI 10.1128/MCB.7.7.2367; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; ZAHRAOUI A, 1988, NUCLEIC ACIDS RES, V16, P1204, DOI 10.1093/nar/16.3.1204	33	106	106	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					231	234						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	2457862				2022-12-17	WOS:A1988Q053400016
J	Napolitano, A; Pellegrini, L; Dey, A; Larson, D; Tanji, M; Flores, EG; Kendrick, B; Lapid, D; Powers, A; Kanodia, S; Pastorino, S; Pass, HI; Dixit, V; Yang, H; Carbone, M				Napolitano, A.; Pellegrini, L.; Dey, A.; Larson, D.; Tanji, M.; Flores, E. G.; Kendrick, B.; Lapid, D.; Powers, A.; Kanodia, S.; Pastorino, S.; Pass, H. I.; Dixit, V.; Yang, H.; Carbone, M.			Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; CROCIDOLITE ASBESTOS; UBIQUITIN HYDROLASE; DEUBIQUITINASE BAP1; MUTATIONS; CELLS; POLARIZATION; MECHANISMS; SUPPRESSOR; REGULATOR	Germline BAP1 mutations predispose to several cancers, in particular malignant mesothelioma. Mesothelioma is an aggressive malignancy generally associated with professional exposure to asbestos. However, to date, we found that none of the mesothelioma patients carrying germline BAP1 mutations were professionally exposed to asbestos. We hypothesized that germline BAP1 mutations might influence the asbestos-induced inflammatory response that is linked to asbestos carcinogenesis, thereby increasing the risk of developing mesothelioma after minimal exposure. Using a BAP1(+/-) mouse model, we found that, compared with their wild-type littermates, BAP1(+/-) mice exposed to low-dose asbestos fibers showed significant alterations of the peritoneal inflammatory response, including significantly higher levels of pro-tumorigenic alternatively polarized M2 macrophages, and lower levels of several chemokines and cytokines. Consistent with these data, BAP1(+/-) mice had a significantly higher incidence of mesothelioma after exposure to very low doses of asbestos, doses that rarely induced mesothelioma in wild-type mice. Our findings suggest that minimal exposure to carcinogenic fibers may significantly increase the risk of malignant mesothelioma in genetically predisposed individuals carrying germline BAP1 mutations, possibly via alterations of the inflammatory response.	[Napolitano, A.; Pellegrini, L.; Larson, D.; Tanji, M.; Flores, E. G.; Kendrick, B.; Lapid, D.; Powers, A.; Pastorino, S.; Yang, H.; Carbone, M.] Univ Hawaii Manoa, Ctr Canc, Univ Hawaii, Honolulu, HI 96822 USA; [Napolitano, A.] Univ Hawaii Manoa, Dept Mol Biosci & Bioengn, Honolulu, HI 96822 USA; [Dey, A.; Dixit, V.] Genentech Inc, Dept Discovery Oncol, San Francisco, CA 94080 USA; [Kanodia, S.] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA; [Kanodia, S.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA; [Pass, H. I.] NYU, Dept Cardiothorac Surg, New York, NY USA	Cancer Research Center of Hawaii; University of Hawaii System; University of Hawaii Manoa; University of Hawaii System; University of Hawaii Manoa; Roche Holding; Genentech; Cedars Sinai Medical Center; Cedars Sinai Medical Center; New York University	Carbone, M (corresponding author), Univ Hawaii, Ctr Canc, Canc Biol, 701 Ilalo St, Honolulu, HI 96813 USA.	mcarbone@cc.hawaii.edu	Pellegrini, Laura/K-7940-2016; dixit, vishva m/A-4496-2012; Napolitano, Andrea/I-3146-2019	Pellegrini, Laura/0000-0002-8833-2987; dixit, vishva m/0000-0001-6983-0326; Napolitano, Andrea/0000-0002-7509-1555; Pass, Harvey/0000-0003-3222-3471	National Institute of Health [R01CA106567, P01CA114047, P30CA071789, R01CA160715-0A]; DoD CDMRP PRMRP Career Development Award; V Foundation; UHCC Pathology Shared Resource [P30 CA071789]; Mesothelioma Applied Research Foundation; United-4A Cure; Hawaii Community Foundation; University of Hawaii Foundation; Honeywell International Inc.; NATIONAL CANCER INSTITUTE [R01CA198138, P01CA114047, R01CA160715, P30CA016087, P30CA071789, R01CA106567] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD CDMRP PRMRP Career Development Award; V Foundation; UHCC Pathology Shared Resource; Mesothelioma Applied Research Foundation; United-4A Cure; Hawaii Community Foundation; University of Hawaii Foundation; Honeywell International Inc.; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institute of Health (grant numbers R01CA106567, P01CA114047, P30CA071789 to MC and R01CA160715-0A to HY); the DoD CDMRP PRMRP Career Development Award to HY, and the V Foundation to MC and HY, the P30 CA071789 (UHCC Pathology Shared Resource); the Mesothelioma Applied Research Foundation to HY, the United-4A Cure, the Hawaii Community Foundation to HY, and the University of Hawaii Foundation, which received donations to support mesothelioma research from Honeywell International Inc., to MC.	Altomare DA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018828; Baumann F, 2015, J THORAC ONCOL, V10, P731, DOI 10.1097/JTO.0000000000000506; Baumann F, 2015, CARCINOGENESIS, V36, P76, DOI 10.1093/carcin/bgu227; Bott M, 2011, NAT GENET, V43, P668, DOI 10.1038/ng.855; Burt BM, 2011, CANCER-AM CANCER SOC, V117, P5234, DOI 10.1002/cncr.26143; Carbone M, 2013, NAT REV CANCER, V13, P153, DOI 10.1038/nrc3459; Carbone M, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-179; Carbone M, 2012, CLIN CANCER RES, V18, P598, DOI 10.1158/1078-0432.CCR-11-2259; Carbone M, 2012, J CELL PHYSIOL, V227, P44, DOI 10.1002/jcp.22724; Comertpay S, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0301-3; Cornelissen R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106742; Cybulski C, 2014, INT J CANCER, V135, P1756, DOI 10.1002/ijc.28988; DAVIS MR, 1992, INT J CANCER, V52, P881, DOI 10.1002/ijc.2910520609; de Reynies A, 2014, CLIN CANCER RES, V20, P1323, DOI 10.1158/1078-0432.CCR-13-2429; Dey A, 2012, SCIENCE, V337, P1541, DOI 10.1126/science.1221711; Guo GW, 2015, CANCER RES, V75, P264, DOI 10.1158/0008-5472.CAN-14-1008; Henley SJ, 2013, INT J OCCUP ENV HEAL, V19, P1, DOI 10.1179/2049396712Y.0000000016; Ismail IH, 2014, CANCER RES, V74, P4282, DOI 10.1158/0008-5472.CAN-13-3109; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Kim R, 2007, IMMUNOLOGY, V121, P1, DOI 10.1111/j.1365-2567.2007.02587.x; Kroczynska B, 2006, P NATL ACAD SCI USA, V103, P14128, DOI 10.1073/pnas.0604544103; Lee HS, 2014, NAT COMMUN, V5, P5128; Lo Iacono M, 2015, J THORAC ONCOL, V10, P492, DOI 10.1097/JTO.0000000000000436; Lujambio A, 2013, CELL, V153, P449, DOI 10.1016/j.cell.2013.03.020; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; Marsella JM, 1997, ENVIRON HEALTH PERSP, V105, P1069, DOI 10.2307/3433511; Misaghi S, 2009, MOL CELL BIOL, V29, P2181, DOI 10.1128/MCB.01517-08; Nasu M, 2015, J THORAC ONCOL, V10, P565, DOI 10.1097/JTO.0000000000000471; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Occupational Safety & Health Administration, 2014, OSHA FACTSHEET ASB; Pantano F, 2013, J CELL MOL MED, V17, P1415, DOI 10.1111/jcmm.12109; Qi F, 2013, AM J PATHOL, V183, P1654, DOI 10.1016/j.ajpath.2013.07.029; Scheuermann JC, 2010, NATURE, V465, P243, DOI 10.1038/nature08966; SEBASTIEN P, 1982, SCIENCE, V216, P1410, DOI 10.1126/science.6283630; Simeonova PP, 1997, J IMMUNOL, V159, P3921; Tanaka S, 2000, EXP LUNG RES, V26, P241; Testa JR, 2011, NAT GENET, V43, P1022, DOI 10.1038/ng.912; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; Xu JF, 2014, CANCER RES, V74, P4388, DOI 10.1158/0008-5472.CAN-14-1328; Yoshikawa Y, 2012, CANCER SCI, V103, P868, DOI 10.1111/j.1349-7006.2012.02223.x; Yu H, 2014, P NATL ACAD SCI USA, V111, P285, DOI 10.1073/pnas.1309085110; Yu H, 2010, MOL CELL BIOL, V30, P5071, DOI 10.1128/MCB.00396-10; Zarrizi R, 2014, CANCER RES, V74, P6499, DOI 10.1158/0008-5472.CAN-14-0221; Zauderer MG, 2013, J THORAC ONCOL, V8, P1430, DOI 10.1097/JTO.0b013e31829e7ef9; Zhang MY, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-19	45	105	106	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1996	2002		10.1038/onc.2015.243	http://dx.doi.org/10.1038/onc.2015.243			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26119930	Green Accepted			2022-12-17	WOS:000374010300012
J	Kanu, N; Gronroos, E; Martinez, P; Burrell, RA; Goh, XY; Bartkova, J; Maya-Mendoza, A; Mistrik, M; Rowan, AJ; Patel, H; Rabinowitz, A; East, P; Wilson, G; Santos, CR; McGranahan, N; Gulati, S; Gerlinger, M; Birkbak, NJ; Joshi, T; Alexandrov, LB; Stratton, MR; Powles, T; Matthews, N; Bates, PA; Stewart, A; Szallasi, Z; Larkin, J; Bartek, J; Swanton, C				Kanu, N.; Groenroos, E.; Martinez, P.; Burrell, R. A.; Goh, X. Yi; Bartkova, J.; Maya-Mendoza, A.; Mistrik, M.; Rowan, A. J.; Patel, H.; Rabinowitz, A.; East, P.; Wilson, G.; Santos, C. R.; McGranahan, N.; Gulati, S.; Gerlinger, M.; Birkbak, N. J.; Joshi, T.; Alexandrov, L. B.; Stratton, M. R.; Powles, T.; Matthews, N.; Bates, P. A.; Stewart, A.; Szallasi, Z.; Larkin, J.; Bartek, J.; Swanton, C.			SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair	ONCOGENE			English	Article							HOMOLOGOUS RECOMBINATION; MUTATIONAL PROCESSES; DAMAGE RESPONSE; COPY NUMBER; HISTONE; GENE; METHYLATION; INSTABILITY; FACT; HETEROGENEITY	Defining mechanisms that generate intratumour heterogeneity and branched evolution may inspire novel therapeutic approaches to limit tumour diversity and adaptation. SETD2 (Su(var), Enhancer of zeste, Trithorax-domain containing 2) trimethylates histone-3 lysine-36 (H3K36me3) at sites of active transcription and is mutated in diverse tumour types, including clear cell renal carcinomas (ccRCCs). Distinct SETD2 mutations have been identified in spatially separated regions in ccRCC, indicative of intratumour heterogeneity. In this study, we have addressed the consequences of SETD2 loss-of-function through an integrated bioinformatics and functional genomics approach. We find that bi-allelic SETD2 aberrations are not associated with microsatellite instability in ccRCC. SETD2 depletion in ccRCC cells revealed aberrant and reduced nucleosome compaction and chromatin association of the key replication proteins minichromosome maintenance complex component (MCM7) and DNA polymerase delta hindering replication fork progression, and failure to load lens epithelium-derived growth factor and the Rad51 homologous recombination repair factor at DNA breaks. Consistent with these data, we observe chromosomal breakpoint locations are biased away from H3K36me3 sites in SETD2 wild-type ccRCCs relative to tumours with bi-allelic SETD2 aberrations and that H3K36me3-negative ccRCCs display elevated DNA damage in vivo. These data suggest a role for SETD2 in maintaining genome integrity through nucleosome stabilization, suppression of replication stress and the coordination of DNA repair.	[Kanu, N.; Birkbak, N. J.; Swanton, C.] UCL Canc Inst, London, England; [Groenroos, E.; Martinez, P.; Burrell, R. A.; Goh, X. Yi; Rowan, A. J.; Patel, H.; Rabinowitz, A.; East, P.; Wilson, G.; Santos, C. R.; McGranahan, N.; Gulati, S.; Gerlinger, M.; Birkbak, N. J.; Matthews, N.; Bates, P. A.; Stewart, A.; Swanton, C.] Canc Res UK London Res Inst, London WC2A 3PX, England; [Bartkova, J.; Maya-Mendoza, A.; Bartek, J.] Danish Canc Soc, Res Ctr, DK-2100 Copenhagen, Denmark; [Mistrik, M.; Bartek, J.] Palacky Univ, Inst Mol & Translat Med, Fac Med & Dent, CR-77147 Olomouc, Czech Republic; [Birkbak, N. J.; Joshi, T.; Szallasi, Z.] Tech Univ Denmark, Ctr Biol Sequence Anal, Dept Syst Biol, Kongens Lyngby, Denmark; [Alexandrov, L. B.; Stratton, M. R.] Wellcome Trust Sanger Inst, Canc Genome Project, Cambridge, Cambridgeshire, England; [Powles, T.] Univ London, Expt Canc Med Ctr, Barts Canc Inst, London, England; [Szallasi, Z.] Childrens Hosp, Boston, MA 02115 USA; [Larkin, J.] Royal Marsden Hosp, Dept Med, London SW3 6JJ, England	University of London; University College London; Cancer Research UK; Danish Cancer Society; Palacky University Olomouc; Technical University of Denmark; University of Cambridge; Wellcome Trust Sanger Institute; University of London; Queen Mary University London; Harvard University; Boston Children's Hospital; Royal Marsden NHS Foundation Trust	Bartek, J (corresponding author), Danish Canc Soc, Res Ctr, Strandblvd 49, DK-2100 Copenhagen, Denmark.	jb@cancer.dk; charles.swanton@cancer.org.uk	McGranahan, Nicholas/ABD-6561-2021; Alexandrov, Ludmil/AAS-1454-2021; Gronroos, Eva/P-6951-2015; Bates, Paul A/AAF-8561-2020	McGranahan, Nicholas/0000-0001-9537-4045; Alexandrov, Ludmil/0000-0003-3596-4515; Bates, Paul A/0000-0003-0621-0925; Larkin, James/0000-0001-5569-9523; Mistrik, Martin/0000-0002-2321-0348; Szallasi, Zoltan/0000-0001-5395-7509; Birkbak, Nicolai/0000-0003-1613-9587; Gerlinger, Marco/0000-0003-2719-299X; Maya-Mendoza, Apolinar/0000-0001-7452-9896; Gronroos, Eva/0000-0001-8303-5409; Santos, Claudio/0000-0002-8766-2247; Swanton, Charles/0000-0002-4299-3018; Martinez, Pierre/0000-0001-7069-4413; Patel, Harshil/0000-0003-2707-7940	NHGRI [H3K36me3, H3K27me3]; Cancer Research UK; Breast Cancer Research Foundation; Medical Research Council [G0902275, G0701935/2]; Danish Cancer Society; Lundbeck Foundation [R93-A8990]; Ministry of the interior of the Czech Republic [VG20102014001]; National Program of Sustainability [LO1304]; Danish Council for Independent Research [DFF-1331-00262]; NIHR RMH/ICR Biomedical Research Centre for Cancer; EC [259303, 259892]; UCL Overseas Research Scholarship; European Research Council; Prostate Cancer Foundation; National Institute for Health Research University College London Hospitals Biomedical Research Centre; Rosetrees Trust; MRC [G0902275, G0701935] Funding Source: UKRI; Cancer Research UK [17786, 19310, 10748, 18377] Funding Source: researchfish; Medical Research Council [G0701935] Funding Source: researchfish; Rosetrees Trust [M179] Funding Source: researchfish; The Francis Crick Institute [10001, 10169, 10359, 10170, 10174, 10172, 10303, 10002] Funding Source: researchfish	NHGRI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Cancer Research UK(Cancer Research UK); Breast Cancer Research Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Danish Cancer Society(Danish Cancer Society); Lundbeck Foundation(Lundbeckfonden); Ministry of the interior of the Czech Republic; National Program of Sustainability; Danish Council for Independent Research(Det Frie Forskningsrad (DFF)); NIHR RMH/ICR Biomedical Research Centre for Cancer; EC(European CommissionEuropean Commission Joint Research Centre); UCL Overseas Research Scholarship; European Research Council(European Research Council (ERC)European Commission); Prostate Cancer Foundation; National Institute for Health Research University College London Hospitals Biomedical Research Centre(General Electric); Rosetrees Trust(Rosetrees Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Rosetrees Trust(Rosetrees Trust); The Francis Crick Institute	We thank Dr Simon Boulton and our colleagues for critical discussions of this work. The results published here are in part based upon data generated by The Cancer Genome Atlas pilot project established by the NCI and NHGRI. Information about TCGA and the investigators and institutions who constitute the TCGA research network can be found at http://cancergenome.nih.gov/ (dbGaP accession number: phs000178.v5.p5). We acknowledge the Encyclopedia of DNA Elements (ENCODE) Consortium, funded by the NHGRI, from which we obtained data for H3K36me3 and H3K27me3 analyses. We thank all funding boards for their continued support. The research leading to these results is supported by Cancer Research UK (XYG, RAB, EG, PM, PE, SG, C Santos, AJR, NM, PAB, AS and C Swanton), Breast Cancer Research Foundation (C Swanton and NK), Medical Research Council (ID: G0902275 to MG and C Santos; ID: G0701935/2 to AJR and C Swanton), the Danish Cancer Society (AMM, J Bartkova and J Bartek), the Lundbeck Foundation (R93-A8990 to J Bartek), the Ministry of the interior of the Czech Republic (grant VG20102014001 to MM and J Bartek), the National Program of Sustainability (grant LO1304 to MM and J Bartek), the Danish Council for Independent Research (grant DFF-1331-00262 to J Bartek), NIHR RMH/ICR Biomedical Research Centre for Cancer (JL), the EC Framework 7 (PREDICT 259303 to XYG, EG, PM, MG, TJ and C Swanton; DDResponse 259892 to J Bartek and J Bartkova and RESPONSIFY ID: 259303 to C Swanton), UCL Overseas Research Scholarship (SG). C Swanton is also supported by the European Research Council, Rosetrees Trust and The Prostate Cancer Foundation. This research is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.	Abe T, 2011, J BIOL CHEM, V286, P30504, DOI 10.1074/jbc.M111.264721; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alexandrov LB, 2013, CELL REP, V3, P246, DOI 10.1016/j.celrep.2012.12.008; Altavilla G, 2010, ONCOL REP, V24, P927, DOI 10.3892/or_00000938; Anders S, 2012, GENOME RES, V22, P2008, DOI 10.1101/gr.133744.111; Aymard F, 2014, NAT STRUCT MOL BIOL, V21, P366, DOI 10.1038/nsmb.2796; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bengtsson H, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-245; Bernstein BE, 2010, NAT BIOTECHNOL, V28, P1045, DOI 10.1038/nbt1010-1045; Bjerke L, 2013, CANCER DISCOV, V3, P512, DOI 10.1158/2159-8290.CD-12-0426; Burrell RA, 2013, NATURE, V494, P492, DOI 10.1038/nature11935; Cahill DP, 1999, TRENDS BIOCHEM SCI, V24, pM57, DOI 10.1016/S0968-0004(99)01466-8; Carvalho S, 2014, ELIFE, V3, DOI 10.7554/eLife.02482; Carvalho S, 2013, NUCLEIC ACIDS RES, V41, P2881, DOI 10.1093/nar/gks1472; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Daugaard M, 2012, NAT STRUCT MOL BIOL, V19, P803, DOI 10.1038/nsmb.2314; de Almeida SF, 2011, NAT STRUCT MOL BIOL, V18, P977, DOI 10.1038/nsmb.2123; Duns G, 2010, CANCER RES, V70, P4287, DOI 10.1158/0008-5472.CAN-10-0120; Edmunds JW, 2008, EMBO J, V27, P406, DOI 10.1038/sj.emboj.7601967; Esnault C, 2014, GENE DEV, V28, P943, DOI 10.1101/gad.239327.114; Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136; Fontebasso AM, 2013, ACTA NEUROPATHOL, V125, P659, DOI 10.1007/s00401-013-1095-8; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Govindan R, 2012, CELL, V150, P1121, DOI 10.1016/j.cell.2012.08.024; Groth A, 2007, SCIENCE, V318, P1928, DOI 10.1126/science.1148992; Guo GW, 2012, NAT GENET, V44, P17, DOI 10.1038/ng.1014; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Larkin J, 2012, NAT REV UROL, V9, P147, DOI 10.1038/nrurol.2011.236; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Li F, 2013, CELL, V153, P590, DOI 10.1016/j.cell.2013.03.025; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li JX, 2002, J BIOL CHEM, V277, P49383, DOI 10.1074/jbc.M209294200; Li M, 2005, P NATL ACAD SCI USA, V102, P17636, DOI 10.1073/pnas.0506350102; Lukas J, 2011, NAT CELL BIOL, V13, P1161, DOI 10.1038/ncb2344; Martinez P, 2013, J PATHOL, V230, P356, DOI 10.1002/path.4214; Mejlvang J, 2014, J CELL BIOL, V204, P29, DOI 10.1083/jcb.201305017; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Myers RM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001046; Ortiz-Estevez M, 2012, BIOINFORMATICS, V28, P1793, DOI 10.1093/bioinformatics/bts248; Pfister SX, 2014, CELL REP, V7, P2006, DOI 10.1016/j.celrep.2014.05.026; Pradeepa MM, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002717; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Roylance R, 2011, CANCER EPIDEM BIOMAR, V20, P2183, DOI 10.1158/1055-9965.EPI-11-0343; Shen L, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-284; Simon JM, 2014, GENOME RES, V24, P241, DOI 10.1101/gr.158253.113; Statham AL, 2010, BIOINFORMATICS, V26, P1662, DOI 10.1093/bioinformatics/btq247; Suwaki N, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002004; Tan BCM, 2006, EMBO J, V25, P3975, DOI 10.1038/sj.emboj.7601271; Tort F, 2006, CANCER RES, V66, P10258, DOI 10.1158/0008-5472.CAN-06-2178; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Weaver BA, 2008, CANCER CELL, V14, P431, DOI 10.1016/j.ccr.2008.11.011; Young DB, 2005, J BIOL CHEM, V280, P27587, DOI 10.1074/jbc.M411689200; Zaret K, 2005, CURR PROT MOL BIOL	58	105	108	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2015	34	46					5699	5708		10.1038/onc.2015.24	http://dx.doi.org/10.1038/onc.2015.24			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GC	25728682	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000364594600002
J	Palumbo, T; Faucz, FR; Azevedo, M; Xekouki, P; Iliopoulos, D; Stratakis, CA				Palumbo, T.; Faucz, F. R.; Azevedo, M.; Xekouki, P.; Iliopoulos, D.; Stratakis, C. A.			Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN-AKT pathway	ONCOGENE			English	Article						microRNAs; growth-hormone producing adenomas; Carney complex; acromegaly; pituitary hyperplasia; protein kinase A	MCCUNE-ALBRIGHT-SYNDROME; CELL SELF-RENEWAL; CARNEY COMPLEX; MICRORNA GENES; BREAST-CANCER; BMI-1; EXPRESSION; ADENOMAS; PROLIFERATION; MUTATIONS	MicroRNAs (miRNAs) have been involved in the pathogenesis of different types of cancer; however, their function in pituitary tumorigenesis remains poorly understood. Cyclic-AMP-dependent protein kinase-defective pituitaries occasionally form aggressive growth-hormone (GH)-producing pituitary tumors in the background of hyperplasia caused by haploinsufficiency of the protein kinase's main regulatory subunit, PRKAR1A. The molecular basis for this development remains unknown. We have identified a 17-miRNA signature of pituitary tumors formed in the background of hyperplasia (caused in half of the cases by PRKAR1A-mutations). We selected two miRNAs on the basis of their functional screen analysis: inhibition of miR-26b expression and upregulation of miR-128 suppressed the colony formation ability and invasiveness of pituitary tumor cells. Furthermore, we identified that miR-26b and miR-128 affected pituitary tumor cell behavior through regulation of their direct targets, PTEN and BMI1, respectively. In addition, we found that miR-128 through BMI1 direct binding on the PTEN promoter affected PTEN expression levels and AKT activity in the pituitary tumor cells. Our in vivo data revealed that inhibition of miR-26b and overexpression of miR-128 could suppress pituitary GH3 tumor growth in xenografts. Taken together, we have identified a miRNA signature for GH-producing pituitary tumors and found that miR-26b and miR-128 regulate the activity of the PTEN-AKT pathway in these tumors. This is the first suggestion of the possible involvement of miRNAs regulating the PTEN-AKT pathway in GH-producing pituitary tumor formation in the context of hyperplasia or due to germline PRKAR1A defects. MiR-26b suppression and miR-128 upregulation could have therapeutic potential in GH-producing pituitary tumor patients. Oncogene (2013) 32, 1651-1659; doi: 10.1038/onc.2012.190; published online 21 May 2012	[Palumbo, T.; Iliopoulos, D.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA; [Palumbo, T.; Iliopoulos, D.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA; [Faucz, F. R.; Azevedo, M.; Xekouki, P.; Stratakis, C. A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Endocrinol & Genet, Program Dev Endocrinol & Genet, Bethesda, MD USA; [Faucz, F. R.] Pontificia Univ Catolica Parana, Grp Adv Mol Invest, Grad Program Hlth Sci, Ctr Biol & Sci, Curitiba, Parana, Brazil	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Pontificia Universidade Catolica do Parana	Iliopoulos, D (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA.	Dimitrios_iliopoulos@dfci.harvard.edu; stratakc@mail.nih.gov	Iliopoulos, Dimitrios/AAE-9106-2019; Xekouki, Paraskevi/AAM-2485-2021; Stratakis, Constantine A./AAP-4745-2020; Faucz, Fabio R/C-1607-2009	Faucz, Fabio/0000-0001-7959-9842	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008920] Funding Source: NIH RePORTER; Intramural NIH HHS [ZIA HD008920-02] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Amaral FC, 2009, J CLIN ENDOCR METAB, V94, P320, DOI 10.1210/jc.2008-1451; Asa SL, 1998, ENDOCR REV, V19, P798, DOI 10.1210/er.19.6.798; Asa SL, 2002, NAT REV CANCER, V2, P836, DOI 10.1038/nrc926; Bandres E, 2009, CLIN CANCER RES, V15, P2281, DOI 10.1158/1078-0432.CCR-08-1818; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Boikos Sosipatros A, 2006, Pituitary, V9, P203, DOI 10.1007/s11102-006-0265-2; Bossis I, 2004, J MED GENET, V41, P596, DOI 10.1136/jmg.2004.020214; Bottoni A, 2005, J CELL PHYSIOL, V204, P280, DOI 10.1002/jcp.20282; Bottoni A, 2007, J CELL PHYSIOL, V210, P370, DOI 10.1002/jcp.20832; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Farrell WE, 2011, J CLIN ENDOCR METAB, V96, pE1905, DOI 10.1210/jc.2011-1127; Galland F, 2006, J CLIN ENDOCR METAB, V91, P4957, DOI 10.1210/jc.2006-0561; Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629; Guo BH, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-10; Hatziapostolou M, 2011, CELL, V147, P1233, DOI 10.1016/j.cell.2011.10.043; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; Horvath A, 2010, HUM MUTAT, V31, P369, DOI 10.1002/humu.21178; Huse JT, 2009, GENE DEV, V23, P1327, DOI 10.1101/gad.1777409; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Incoronato M, 2010, CANCER RES, V70, P3638, DOI 10.1158/0008-5472.CAN-09-3341; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kashuba VI, 2004, P NATL ACAD SCI USA, V101, P4906, DOI 10.1073/pnas.0401238101; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; KOVACS K, 1984, VIRCHOWS ARCH A, V403, P77, DOI 10.1007/BF00689340; Liu WL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-467; Lukacs RU, 2010, CELL STEM CELL, V7, P682, DOI 10.1016/j.stem.2010.11.013; Mai PL, 2007, J MED CASE REPORTS B, V1, P1; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Pack SD, 2005, GENE CHROMOSOME CANC, V43, P72, DOI 10.1002/gcc.20162; Pack SD, 2000, J CLIN ENDOCR METAB, V85, P3860, DOI 10.1210/jc.85.10.3860; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rahbari R, 2011, ANN SURG ONCOL, V18, P1158, DOI 10.1245/s10434-010-1359-7; Sinha AU, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-88; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Stilling G, 2010, ENDOCRINE, V38, P67, DOI 10.1007/s12020-010-9346-0; Stratakis CA, 2010, CLIN GENET, V78, P457, DOI 10.1111/j.1399-0004.2010.01406.x; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; Xia DR, 2007, J BIOL CHEM, V282, P3507, DOI 10.1074/jbc.M610141200	49	105	114	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2013	32	13					1651	1659		10.1038/onc.2012.190	http://dx.doi.org/10.1038/onc.2012.190			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22614013	Green Accepted			2022-12-17	WOS:000316855800005
J	Luo, Y; Zheng, C; Zhang, J; Lu, D; Zhuang, J; Xing, S; Feng, J; Yang, D; Yan, X				Luo, Y.; Zheng, C.; Zhang, J.; Lu, D.; Zhuang, J.; Xing, S.; Feng, J.; Yang, D.; Yan, X.			Recognition of CD146 as an ERM-binding protein offers novel mechanisms for melanoma cell migration	ONCOGENE			English	Article						cell migration; CD146; ERM proteins; RhoA; RhoGDI1	PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE; ANTI-CD146 MONOCLONAL-ANTIBODY; PLASMA-MEMBRANE; INHIBITS ANGIOGENESIS; ADHESION MOLECULE; RHO-FAMILY; EXPRESSION; EZRIN/RADIXIN/MOESIN; ACTIVATION; MUC18	Tumor cell migration is a well-orchestrated multistep process that drives cancer development and metastasis. Previous data indicated that CD146 expression correlates with malignant progression and metastatic potential of human melanoma cells. However, the exact molecular mechanism of how CD146 promotes melanoma cell migration still remains poorly understood. Here, we report that CD146 physically interacts with actin-linking ezrin-radixin-moesin (ERM) proteins and recruits ERM proteins to cell protrusions, promoting the formation and elongation of microvilli. Moreover, CD146-promoted melanoma cell migration is linked to RhoA activation and ERM phosphorylation. CD146 recruits Rho guanine nucleotide dissociation inhibitory factors 1 (RhoGDI1) through ERM proteins and thus sequesters RhoGDI1 from RhoA, which leads to upregulated RhoA activity and increased melanoma cell motility. CD146-activated RhoA also promotes further ERM phosphorylation and activation through Rho-phosphatidylinositol-4-phosphate-5-kinase-phosphatidylinositol 4,5-biphosphate pathway, which reinforces CD146/ERM association. Thus, our results provide a mechanistic basis to understand the role of CD146 in regulating human melanoma cell motility. Oncogene (2012) 31, 306-321; doi:10.1038/onc.2011.244; published online 4 July 2011	[Luo, Y.; Zheng, C.; Zhang, J.; Lu, D.; Zhuang, J.; Xing, S.; Feng, J.; Yang, D.; Yan, X.] Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; [Luo, Y.; Zheng, C.; Zhang, J.; Lu, D.; Zhuang, J.; Xing, S.; Feng, J.; Yang, D.; Yan, X.] Chinese Acad Sci, Inst Biophys, Chinese Acad Sci Univ Tokyo Joint Lab Struct Viro, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Institute of Biophysics, CAS	Yan, X (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.	yanxy@ibp.ac.cn	Zheng, Chaogu/P-2753-2019; Lu, Di/D-9836-2018	Zheng, Chaogu/0000-0002-5048-4520; Lu, Di/0000-0002-4083-1656; Luo, Yongting/0000-0001-7834-8742	National 863 Grant [2006AA02A245]; National Basic Research Program of China (973 Program) [2009CB521704, 2011CB933503]; National Important Science and Technology Specific Projects [2008ZX10004-005, 2008ZX10002-017, 2009ZX09102-247]; National Natural Science Foundation of China [91029732]; Chinese Academy of Sciences [KSCX2-YW-R-121, KSCX2-YW-R-173, KSCX2-YW-M15]	National 863 Grant; National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Important Science and Technology Specific Projects; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Academy of Sciences(Chinese Academy of Sciences)	We thank Dr J Johnson for providing the CD146-transfected Mel-888<SUP>CD146</SUP> cells and CD146 gene contained in pUC-CD146 plasmids. This work is partly supported by grants from the National 863 Grant (2006AA02A245), the National Basic Research Program of China (973 Program) (2009CB521704, 2011CB933503), the National Important Science and Technology Specific Projects (2008ZX10004-005, 2008ZX10002-017, 2009ZX09102-247), the National Natural Science Foundation of China (91029732) and the Knowledge Innovation Program of the Chinese Academy of Sciences (KSCX2-YW-R-121, KSCX2-YW-R-173, KSCX2-YW-M15).	Aldovini D, 2006, INT J CANCER, V119, P1920, DOI 10.1002/ijc.22082; Lacalle RA, 2007, J CELL BIOL, V179, P1539, DOI 10.1083/jcb.200705044; Anfosso F, 1998, J BIOL CHEM, V273, P26852, DOI 10.1074/jbc.273.41.26852; Bani MR, 1996, CANCER RES, V56, P3075; Barreiro O, 2004, FRONT BIOSCI-LANDMRK, V9, P1849, DOI 10.2741/1285; Barrero-Villar M, 2008, J IMMUNOL, V181, P6882, DOI 10.4049/jimmunol.181.10.6882; Bartolome RA, 2008, CANCER RES, V68, P8221, DOI 10.1158/0008-5472.CAN-08-0561; Bidlingmaier S, 2009, CANCER RES, V69, P1570, DOI 10.1158/0008-5472.CAN-08-1363; Boureux A, 2007, MOL BIOL EVOL, V24, P203, DOI 10.1093/molbev/msl145; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Bretscher A, 1997, J CELL SCI, V110, P3011; Bu PC, 2006, MOL CANCER THER, V5, P2872, DOI 10.1158/1535-7163.MCT-06-0260; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; DerMardirossian C, 2005, TRENDS CELL BIOL, V15, P356, DOI 10.1016/j.tcb.2005.05.001; Dovas A, 2005, BIOCHEM J, V390, P1, DOI 10.1042/BJ20050104; Gadea G, 2007, J CELL BIOL, V178, P23, DOI 10.1083/jcb.200701120; Gervais L, 2008, DEVELOPMENT, V135, P3829, DOI 10.1242/dev.029009; Guezguez B, 2006, FEBS LETT, V580, P3649, DOI 10.1016/j.febslet.2006.05.048; Hebert M, 2008, J IMMUNOL, V181, P5963, DOI 10.4049/jimmunol.181.9.5963; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Johnson JP, 1997, INT J CANCER, V73, P769; JOHNSON JP, 1993, MELANOMA RES, V3, P337, DOI 10.1097/00008390-199310000-00006; Kristiansen G, 2003, ANAL CELL PATHOL, V25, P77, DOI 10.1155/2003/574829; Lee JH, 2004, J CELL BIOL, V167, P327, DOI 10.1083/jcb.200403091; Li G, 2002, CRIT REV ORAL BIOL M, V13, P62, DOI 10.1177/154411130201300107; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Masiero L, 1999, J CELL SCI, V112, P3205; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; McClatchey AI, 2003, NAT REV CANCER, V3, P877, DOI 10.1038/nrc1213; McClatchey AI, 2009, TRENDS CELL BIOL, V19, P198, DOI 10.1016/j.tcb.2009.02.006; Molina-Ortiz I, 2009, J BIOL CHEM, V284, P15147, DOI 10.1074/jbc.M807834200; Niggli V, 2008, INT J BIOCHEM CELL B, V40, P344, DOI 10.1016/j.biocel.2007.02.012; Oleksy A, 2006, J BIOL CHEM, V281, P32891, DOI 10.1074/jbc.M606220200; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Ouhtit A, 2009, BBA-REV CANCER, V1795, P130, DOI 10.1016/j.bbcan.2009.01.002; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Ridley AJ, 2006, TRENDS CELL BIOL, V16, P522, DOI 10.1016/j.tcb.2006.08.006; Saci A, 2005, MOL CELL, V17, P205, DOI 10.1016/j.molcel.2004.12.012; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; Shih IM, 1997, CANCER RES, V57, P3835; SHIH IM, 1994, CANCER RES, V54, P2514; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Witze ES, 2008, SCIENCE, V320, P365, DOI 10.1126/science.1151250; Worthylake RA, 2003, J BIOL CHEM, V278, P13578, DOI 10.1074/jbc.M211584200; Wu GJ, 2004, GENE, V327, P201, DOI 10.1016/j.gene.2003.11.018; Wu GJ, 2001, GENE, V279, P17, DOI 10.1016/S0378-1119(01)00736-3; Xie SH, 1997, CANCER RES, V57, P2295; Yan XY, 2003, BLOOD, V102, P184, DOI 10.1182/blood-2002-04-1004; Yang NY, 2006, J BIOL CHEM, V281, P32574, DOI 10.1074/jbc.M604338200; Zheng CG, 2009, INT J BIOCHEM CELL B, V41, P2163, DOI 10.1016/j.biocel.2009.03.014	55	105	124	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	3					306	321		10.1038/onc.2011.244	http://dx.doi.org/10.1038/onc.2011.244			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ	21725352				2022-12-17	WOS:000299542100004
J	Hannigan, GE; McDonald, PC; Walsh, MP; Dedhar, S				Hannigan, G. E.; McDonald, P. C.; Walsh, M. P.; Dedhar, S.			Integrin-linked kinase: Not so 'pseudo' after all	ONCOGENE			English	Review						integrin-linked kinase; phosphorylation; cancer	SMOOTH-MUSCLE CONTRACTION; PROTEIN-KINASE; CANCER-CELLS; MOLECULAR DISSECTION; DEPENDENT REGULATION; THERAPEUTIC TARGET; B/AKT ACTIVATION; PLASMA-MEMBRANE; FOCAL ADHESIONS; BREAST-CANCER	Integrin-linked kinase (ILK) is a highly evolutionarily conserved intracellular protein that was originally identified as an integrin-interacting protein, and extensive genetic and biochemical studies have shown that ILK expression is vital during both embryonic development and tissue homeostasis. At the cellular and tissue levels, ILK regulates signaling pathways for cell adhesion-mediated cell survival (anoikis), apoptosis, proliferation and mitosis, migration, invasion, and vascularization and tumor angiogenesis. ILK also has central roles in cardiac and smooth-muscle contractility, and ILK dysregulation causes cardiomyopathies in humans. ILK protein levels are increased in several human cancers and often the expression level predicts poor patient outcome. Abundant evidence has accumulated suggesting that, of the diverse functions of ILK, some may require kinase activity whereas others depend on protein-protein interactions and are, therefore, independent of kinase activity. However, the past several years have seen an ongoing debate about whether ILK indeed functions as a protein serine/threonine kinase. This debate centers on the atypical protein kinase domain of ILK, which lacks some amino-acid residues thought to be essential for phosphotransferase activity. However, similar deficiencies are present in the catalytic domains of other kinases now known to possess protein kinase activity. Numerous studies have shown that ILK phosphorylates peptide substrates in vitro, corresponding to ILK-mediated phosphorylations in intact cells, and a recent report characterizing in vitro phosphotransferase activity of highly purified, full-length ILK, accompanied by detailed enzyme kinetic analyses, shows that, at least in vitro, ILK is a bona fide protein kinase. However, several genetic studies suggest that, not all biological functions of ILK require kinase activity, and that it can function as an adaptor/scaffold protein. Here, we review evidence for and against ILK being an active kinase, and provide a framework for strategies to further analyze the kinase and adaptor functions of ILK in different cellular contexts. Oncogene (2011) 30, 4375-4385; doi:10.1038/onc.2011.177; published online 23 May 2011	[McDonald, P. C.; Dedhar, S.] BC Canc Res Ctr, Dept Integrat Oncol, Vancouver, BC V5Z 1L3, Canada; [Hannigan, G. E.] Monash Inst Med Res, Ctr Canc Res, Melbourne, Vic, Australia; [Walsh, M. P.] Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada; [Dedhar, S.] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada	British Columbia Cancer Agency; Monash University; University of Calgary; University of British Columbia	Dedhar, S (corresponding author), BC Canc Res Ctr, Dept Integrat Oncol, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	sdedhar@bccrc.ca		Dedhar, Shoukat/0000-0003-4355-1657	Canadian Institutes of Health Research; Canadian Cancer Society Research Institute; National Health and Medical Research Council (NHMRC) of Australia	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by funding from the Canadian Institutes of Health Research (to SD and MPW), the Canadian Cancer Society Research Institute (to SD) and the National Health and Medical Research Council (NHMRC) of Australia (to GEH).	Acconcia F, 2007, P NATL ACAD SCI USA, V104, P6782, DOI 10.1073/pnas.0701999104; Akhtar N, 2009, DEVELOPMENT, V136, P1019, DOI 10.1242/dev.028423; ALLEN BG, 1994, TRENDS BIOCHEM SCI, V19, P362, DOI 10.1016/0968-0004(94)90112-0; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Bendig G, 2006, GENE DEV, V20, P2361, DOI 10.1101/gad.1448306; Boppart MD, 2011, BBA-MOL BASIS DIS, V1812, P439, DOI 10.1016/j.bbadis.2011.01.002; Boudeau J, 2006, TRENDS CELL BIOL, V16, P443, DOI 10.1016/j.tcb.2006.07.003; Boulbes D, 2010, MOL CANCER RES, V8, P896, DOI 10.1158/1541-7786.MCR-09-0409; Cabodi S, 2010, NAT REV CANCER, V10, P858, DOI 10.1038/nrc2967; Chiswell BP, 2008, P NATL ACAD SCI USA, V105, P20677, DOI 10.1073/pnas.0811415106; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deng JT, 2002, BIOCHEM J, V367, P517, DOI 10.1042/BJ20020522; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; Dobreva I, 2008, J PROTEOME RES, V7, P1740, DOI 10.1021/pr700852r; Erdodi F, 2003, BIOCHEM BIOPH RES CO, V306, P382, DOI 10.1016/S0006-291X(03)00976-8; Eswaran J, 2009, P NATL ACAD SCI USA, V106, P20198, DOI 10.1073/pnas.0901989106; Eto M, 2009, J BIOL CHEM, V284, P35273, DOI 10.1074/jbc.R109.059972; Fielding AB, 2011, ONCOGENE, V30, P521, DOI 10.1038/onc.2010.431; Fielding AB, 2008, J CELL BIOL, V180, P681, DOI 10.1083/jcb.200710074; Filipenko NR, 2005, ONCOGENE, V24, P5837, DOI 10.1038/sj.onc.1208737; Fukuda K, 2009, MOL CELL, V36, P819, DOI 10.1016/j.molcel.2009.11.028; Grashoff C, 2003, EMBO REP, V4, P432, DOI 10.1038/sj.embor.embor801; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hannigan GE, 2007, CIRC RES, V100, P1408, DOI 10.1161/01.RES.0000265233.40455.62; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; Huang JA, 2006, BIOCHEM J, V396, P193, DOI 10.1042/BJ20051772; Jin HC, 2006, NATURE, V442, P576, DOI 10.1038/nature04856; Knight ZA, 2007, CELL, V128, P425, DOI 10.1016/j.cell.2007.01.021; Knoll R, 2007, CIRCULATION, V116, P515, DOI 10.1161/CIRCULATIONAHA.107.689984; Kogata N, 2009, GENE DEV, V23, P2278, DOI 10.1101/gad.535409; Kumar AS, 2004, ONCOGENE, V23, P3454, DOI 10.1038/sj.onc.1207473; Lange A, 2009, NATURE, V461, P1002, DOI 10.1038/nature08468; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Leung-Hagesteijn C, 2001, EMBO J, V20, P2160, DOI 10.1093/emboj/20.9.2160; Liu J, 2006, J THORAC ONCOL, V1, P771, DOI 10.1097/01243894-200610000-00004; Lorenz K, 2007, J CELL BIOL, V177, P501, DOI 10.1083/jcb.200608125; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Maydan M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012356; McDonald PC, 2008, J CELL SCI, V121, P3121, DOI 10.1242/jcs.017996; McDonald PC, 2008, CANCER RES, V68, P1618, DOI 10.1158/0008-5472.CAN-07-5869; Montanez E, 2009, EMBO J, V28, P3132, DOI 10.1038/emboj.2009.295; Mukherjee K, 2008, CELL, V133, P328, DOI 10.1016/j.cell.2008.02.036; Muranyi A, 2002, BIOCHEM J, V366, P211, DOI 10.1042/BJ20020401; Muranyi AL, 2010, LEUKEMIA RES, V34, P1358, DOI 10.1016/j.leukres.2010.01.006; Murata-Hori M, 1999, FEBS LETT, V451, P81, DOI 10.1016/S0014-5793(99)00550-5; Niiro N, 2001, J BIOL CHEM, V276, P29567, DOI 10.1074/jbc.M102753200; Nikolopoulos SN, 2002, J BIOL CHEM, V277, P1568, DOI 10.1074/jbc.M108612200; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Oloumi A, 2006, ONCOGENE, V25, P7747, DOI 10.1038/sj.onc.1209752; Oloumi A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2592; Pasquali C, 2007, MOL CELL PROTEOMICS, V6, P1829, DOI 10.1074/mcp.T600066-MCP200; Pereira JA, 2009, J CELL BIOL, V185, P147, DOI 10.1083/jcb.200809008; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Pontier SM, 2010, ONCOGENE, V29, P3374, DOI 10.1038/onc.2010.86; Postel R, 2008, DEV BIOL, V318, P92, DOI 10.1016/j.ydbio.2008.03.024; Quelo I, 2004, J BIOL CHEM, V279, P43893, DOI 10.1074/jbc.M406310200; Rallis C, 2010, DEVELOPMENT, V137, P3591, DOI 10.1242/dev.050070; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; Suh HN, 2011, J CELL PHYSIOL, V226, P3422, DOI 10.1002/jcp.22697; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Taylor SS, 2010, P NATL ACAD SCI USA, V107, P8047, DOI 10.1073/pnas.1003436107; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Troussard AA, 2006, CANCER RES, V66, P393, DOI 10.1158/0008-5472.CAN-05-2304; Wang HV, 2008, J CELL BIOL, V180, P1037, DOI 10.1083/jcb.200707175; Weber LP, 1999, J PHYSIOL-LONDON, V516, P805, DOI 10.1111/j.1469-7793.1999.0805u.x; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; White DE, 2006, GENE DEV, V20, P2355, DOI 10.1101/gad.1458906; Wickstrom SA, 2010, DEV CELL, V19, P574, DOI 10.1016/j.devcel.2010.09.007; Wickstrom SA, 2010, EMBO J, V29, P281, DOI 10.1038/emboj.2009.376; Wilson DP, 2005, BIOCHEM J, V392, P641, DOI 10.1042/BJ20051173; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008-5472.CAN-04-2940; Younes MN, 2005, MOL CANCER THER, V4, P1146, DOI 10.1158/1535-7163.MCT-05-0078; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007	82	105	107	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	43					4375	4385		10.1038/onc.2011.177	http://dx.doi.org/10.1038/onc.2011.177			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HQ	21602880				2022-12-17	WOS:000296356500001
J	Rexer, BN; Ham, AJL; Rinehart, C; Hill, S; Granja-Ingram, ND; Gonzalez-Angulo, AM; Mills, GB; Dave, B; Chang, JC; Liebler, DC; Arteaga, CL				Rexer, B. N.; Ham, A-J L.; Rinehart, C.; Hill, S.; Granja-Ingram, N. de Matos; Gonzalez-Angulo, A. M.; Mills, G. B.; Dave, B.; Chang, J. C.; Liebler, D. C.; Arteaga, C. L.			Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition	ONCOGENE			English	Article						breast cancer; HER2; lapatinib; Src kinases; tyrosine phosphorylation	GROWTH-FACTOR RECEPTOR; BREAST-CANCER; TRASTUZUMAB RESISTANCE; LAPATINIB GW572016; CYCLIN D1; PHOSPHORYLATION; ACTIVATION; IDENTIFICATION; DASATINIB; ERBB2	Despite the initial effectiveness of the tyrosine kinase inhibitor lapatinib against HER2 gene-amplified breast cancers, most patients eventually relapse after treatment, implying that tumors acquire mechanisms of drug resistance. To discover these mechanisms, we generated six lapatinib-resistant HER2-overexpressing human breast cancer cell lines. In cells that grew in the presence of lapatinib, HER2 autophosphorylation was undetectable, whereas active phosphoinositide-3 kinase (PI3K)-Akt and mitogen-activated protein kinase (MAPK) were maintained. To identify networks maintaining these signaling pathways, we profiled the tyrosine phosphoproteome of sensitive and resistant cells using an immunoaffinity-enriched mass spectrometry method. We found increased phosphorylation of Src family kinases (SFKs) and putative Src substrates in several resistant cell lines. Treatment of these resistant cells with Src kinase inhibitors partially blocked PI3K-Akt signaling and restored lapatinib sensitivity. Further, SFK mRNA expression was upregulated in primary HER2+ tumors treated with lapatinib. Finally, the combination of lapatinib and the Src inhibitor AZD0530 was more effective than lapatinib alone at inhibiting pAkt and growth of established HER2-positive BT-474 xenografts in athymic mice. These data suggest that increased Src kinase activity is a mechanism of lapatinib resistance and support the combination of HER2 antagonists with Src inhibitors early in the treatment of HER2+ breast cancers in order to prevent or overcome resistance to HER2 inhibitors. Oncogene (2011) 30, 4163-4174; doi:10.1038/onc.2011.130; published online 18 April 2011	[Rexer, B. N.; Rinehart, C.; Arteaga, C. L.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; [Ham, A-J L.; Hill, S.; Liebler, D. C.] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37212 USA; [Ham, A-J L.; Liebler, D. C.] Vanderbilt Univ, Sch Med, Ayers Inst Precancer Detect & Diag, Nashville, TN 37212 USA; [Granja-Ingram, N. de Matos] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37212 USA; [Gonzalez-Angulo, A. M.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Gonzalez-Angulo, A. M.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Med Oncol, Houston, TX 77030 USA; [Dave, B.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Chang, J. C.] Methodist Hosp, Dept Med, Houston, TX 77030 USA; [Arteaga, C. L.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37212 USA; [Arteaga, C. L.] Vanderbilt Ingram Canc Ctr, Dept Breast Canc Res Program, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Vanderbilt University; Vanderbilt University	Arteaga, CL (corresponding author), VUMC, Div Oncol, 2220 Pierce Ave,777 PRB, Nashville, TN 37232 USA.	carlos.arteaga@vanderbilt.edu	Dave, Bhuvanesh/ABF-8334-2020	Dave, Bhuvanesh/0000-0001-6741-1363; Liebler, Daniel/0000-0002-7873-3031	NIH [R01 CA80195]; Dinah Armstrong Kukes Fund/Phi Mu foundation; Department of Defense [BC087465]; ASCO; Kleberg Center for Molecular Markers at MD Anderson Cancer Center; NCI [1K23CA121994-01]; Susan G Komen Foundation [FAS0703849]; ACS [CRP-07-234]; Lee Jeans Translational Breast Cancer Research Program; Breast Cancer SPORE [P50 CA98131]; Vanderbilt-Ingram Cancer Center [P30 CA68485];  [T32 CA119910]; NATIONAL CANCER INSTITUTE [K08CA143153, R01CA080195, K23CA121994, P30CA068485, T32CA119910, P50CA098131] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dinah Armstrong Kukes Fund/Phi Mu foundation; Department of Defense(United States Department of Defense); ASCO; Kleberg Center for Molecular Markers at MD Anderson Cancer Center; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); ACS(American Cancer Society); Lee Jeans Translational Breast Cancer Research Program; Breast Cancer SPORE; Vanderbilt-Ingram Cancer Center; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH R01 CA80195 (CLA), Dinah Armstrong Kukes Fund/Phi Mu foundation (BNR), T32 CA119910 (BNR), Department of Defense BC087465 Post-Doctoral Fellowship (BNR), ASCO Young Investigator Award (BNR), Kleberg Center for Molecular Markers at MD Anderson Cancer Center, ASCO Career Development Award (AMG), NCI 1K23CA121994-01 (AMG), Susan G Komen Foundation FAS0703849 (AMG, GBM), ACS Clinical Research Professorship CRP-07-234 (CLA), Lee Jeans Translational Breast Cancer Research Program (CLA), Breast Cancer SPORE P50 CA98131 and Vanderbilt-Ingram Cancer Center Support Grant P30 CA68485.	Amin DN, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000389; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Bose R, 2006, P NATL ACAD SCI USA, V103, P9773, DOI 10.1073/pnas.0603948103; Burris HA, 2005, J CLIN ONCOL, V23, P5305, DOI 10.1200/JCO.2005.16.584; Dave B, 2011, J CLIN ONCOL, V29, P166, DOI 10.1200/JCO.2009.27.7814; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Erlichman C, 2009, MOL CANCER THER, V8, DOI 10.1158/1535-7163.TARG-09-B56; Finn RS, 2008, ANN ONCOL, V19, P1379, DOI 10.1093/annonc/mdn291; Finn RS, 2007, BREAST CANCER RES TR, V105, P319, DOI 10.1007/s10549-006-9463-x; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Green TP, 2009, MOL ONCOL, V3, P248, DOI 10.1016/j.molonc.2009.01.002; Hennequin LF, 2006, J MED CHEM, V49, P6465, DOI 10.1021/jm060434q; Hochgrafe F, 2010, CANCER RES, V70, P9391, DOI 10.1158/0008-5472.CAN-10-0911; Huang F, 2007, CANCER RES, V67, P2226, DOI 10.1158/0008-5472.CAN-06-3633; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Ishizawar RC, 2007, ONCOGENE, V26, P3503, DOI 10.1038/sj.onc.1210138; Jones RJ, 2009, BREAST CANCER RES TR, V114, P211, DOI 10.1007/s10549-008-9997-1; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Kim H, 2005, ONCOGENE, V24, P7599, DOI 10.1038/sj.onc.1208898; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Lachmann A, 2009, BIOINFORMATICS, V25, P684, DOI 10.1093/bioinformatics/btp026; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Lenferink AEG, 2001, CANCER RES, V61, P6583; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Luo W, 2008, J PROTEOME RES, V7, P3447, DOI 10.1021/pr800187n; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; Marcotte R, 2009, MOL CELL BIOL, V29, P5858, DOI 10.1128/MCB.01731-08; Moasser MM, 2007, ONCOGENE, V26, P6577, DOI 10.1038/sj.onc.1210478; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Old WM, 2005, MOL CELL PROTEOMICS, V4, P1487, DOI 10.1074/mcp.M500084-MCP200; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V331, P1, DOI 10.1016/j.bbrc.2005.03.012; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Rusnak DW, 2001, MOL CANCER THER, V1, P85; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Sheffield LG, 1998, BIOCHEM BIOPH RES CO, V250, P27, DOI 10.1006/bbrc.1998.9214; Tabb DL, 2007, J PROTEOME RES, V6, P654, DOI 10.1021/pr0604054; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Vadlamudi RK, 2003, FEBS LETT, V543, P76, DOI 10.1016/S0014-5793(03)00404-6; Wang SZE, 2006, CANCER CELL, V10, P25, DOI 10.1016/j.ccr.2006.05.023; Xu WP, 2007, MOL CELL BIOL, V27, P220, DOI 10.1128/MCB.00899-06; Yakes FM, 2002, CANCER RES, V62, P4132; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Zhang B, 2007, J PROTEOME RES, V6, P3549, DOI 10.1021/pr070230d; Zhang B, 2006, J PROTEOME RES, V5, P2909, DOI 10.1021/pr0600273; Zhang HT, 1998, ONCOGENE, V16, P2835, DOI 10.1038/sj.onc.1201820	53	105	111	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	40					4163	4174		10.1038/onc.2011.130	http://dx.doi.org/10.1038/onc.2011.130			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	833ZK	21499296	Green Accepted			2022-12-17	WOS:000295924600003
J	Schramedei, K; Morbt, N; Pfeifer, G; Lauter, J; Rosolowski, M; Tomm, JM; von Bergen, M; Horn, F; Brocke-Heidrich, K				Schramedei, K.; Moerbt, N.; Pfeifer, G.; Laeuter, J.; Rosolowski, M.; Tomm, J. M.; von Bergen, M.; Horn, F.; Brocke-Heidrich, K.			MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4	ONCOGENE			English	Article						miR-21; ANP32A; SMARCA4; prostate; post-transcriptional regulation	CELL-PROLIFERATION; MICRO-RNA; EXPRESSION; PROTEIN; MIR-21; BRG1; IDENTIFICATION; INVASION; COMPLEX; PREDICTION	MicroRNA-21 (miR-21) is a key regulator of oncogenic processes. It is significantly elevated in the majority of human tumors and functionally linked to cellular proliferation, survival and migration. In this study, we used two experimental-based strategies to search for novel miR-21 targets. On the one hand, we performed a proteomic approach using two-dimensional differential gel electrophoresis (2D-DIGE) to identify proteins suppressed upon enhanced miR-21 expression in LNCaP human prostate carcinoma cells. The tumor suppressor acidic nuclear phosphoprotein 32 family, member A (ANP32A) (alias pp32 or LANP) emerged as the most strongly downregulated protein. On the other hand, we applied a mathematical approach to select correlated gene sets that are negatively correlated with primary-miR-21 (pri-miR-21) expression in published transcriptome data from 114 B-cell lymphoma cases. Among these candidates, we found tumor suppressor SMARCA4 (alias BRG1) together with the already validated miR-21 target, PDCD4. ANP32A and SMARCA4, which are both involved in chromatin remodeling processes, were confirmed as direct miR-21 targets by immunoblot analysis and reporter gene assays. Furthermore, knock down of ANP32A mimicked the effect of enforced miR-21 expression by enhancing LNCaP cell viability, whereas overexpression of ANP32A in the presence of high miR-21 levels abrogated the miR-21 mediated effect. In A172 glioblastoma cells, enhanced ANP32A expression compensated for the effects of anti-miR- 21 treatment on cell viability and apoptosis. In addition, miR-21 expression clearly increased the invasiveness of LNCaP cells, an effect also seen in part upon downregulation of ANP32A. In conclusion, these results suggest that downregulation of ANP32A contributes to the oncogenic function of miR-21. Oncogene (2011) 30, 2975-2985; doi:10.1038/onc.2011.15; published online 14 February 2011	[Schramedei, K.; Pfeifer, G.; Horn, F.; Brocke-Heidrich, K.] Univ Leipzig, Inst Clin Immunol, Fac Med, D-04103 Leipzig, Germany; [Moerbt, N.; Tomm, J. M.; von Bergen, M.] UFZ Helmholtz Ctr Environm Res, UFZ, Dept Prote, Leipzig, Germany; [Laeuter, J.; Rosolowski, M.] Univ Leipzig, Inst Med Informat Stat & Epidemiol IMISE, Fac Med, D-04103 Leipzig, Germany; [von Bergen, M.] UFZ Helmholtz Ctr Environm Res, UFZ, Dept Metabol, Leipzig, Germany	Leipzig University; Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Leipzig University; Helmholtz Association; Helmholtz Center for Environmental Research (UFZ)	Brocke-Heidrich, K (corresponding author), Univ Leipzig, Inst Clin Immunol, Fac Med, Johannisallee 30, D-04103 Leipzig, Germany.	kheid@medizin.uni-leipzig.de	von Bergen, Martin/D-7960-2011; Tomm, Janina M/F-8888-2014	von Bergen, Martin/0000-0003-2732-2977; Tomm, Janina M/0000-0001-8161-1812	DFG [BR2892/3-1]; Medical Faculty, University of Leipzig	DFG(German Research Foundation (DFG)); Medical Faculty, University of Leipzig	We thank Riccardo Dalla-Favera (New York) for kindly providing SUDHL-2 cells. The work was partly supported by the DFG grant BR2892/3-1 and a junior research grant by the Medical Faculty, University of Leipzig.	Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bai JN, 2001, ONCOGENE, V20, P2153, DOI 10.1038/sj.onc.1204294; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Brody JR, 2007, MODERN PATHOL, V20, P1238, DOI 10.1038/modpathol.3800974; Brody JR, 1999, J BIOL CHEM, V274, P20053, DOI 10.1074/jbc.274.29.20053; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; Cohet N, 2010, J CELL PHYSIOL, V223, P667, DOI 10.1002/jcp.22072; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Fujita S, 2008, J MOL BIOL, V378, P492, DOI 10.1016/j.jmb.2008.03.015; Fulci V, 2007, BLOOD, V109, P4944, DOI 10.1182/blood-2006-12-062398; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Hoffarth S, 2008, CELL DEATH DIFFER, V15, P161, DOI 10.1038/sj.cdd.4402256; Hummel M, 2006, NEW ENGL J MED, V354, P2419, DOI 10.1056/NEJMoa055351; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jehmlich N, 2008, ISME J, V2, P1122, DOI 10.1038/ismej.2008.64; John Bino, 2006, V342, P101, DOI 10.1385/1-59745-123-1:101; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kiriakidou M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704; Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582-4934.2008.00556.x; Lauter J, 2009, BIOMETRICAL J, V51, P235, DOI 10.1002/bimj.200800207; Lawrie CH, 2007, INT J CANCER, V121, P1156, DOI 10.1002/ijc.22800; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Li T, 2009, BIOCHEM BIOPH RES CO, V383, P280, DOI 10.1016/j.bbrc.2009.03.077; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Martin G, 2007, J BIOSCIENCES, V32, P1049, DOI 10.1007/s12038-007-0106-0; MATSUOKA K, 1994, P NATL ACAD SCI USA, V91, P9670, DOI 10.1073/pnas.91.21.9670; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Morbt N, 2009, PROTEOMICS, V9, P4920, DOI 10.1002/pmic.200800836; Navarro A, 2008, BLOOD, V111, P2825, DOI 10.1182/blood-2007-06-096784; Pan W, 2009, J BIOL CHEM, V284, P6946, DOI 10.1074/jbc.M805801200; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Rodriguez-Nieto S, 2009, CARCINOGENESIS, V30, P547, DOI 10.1093/carcin/bgp035; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Santos PM, 2007, OMICS, V11, P233, DOI 10.1089/omi.2007.0009; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Selcuklu SD, 2009, BIOCHEM SOC T, V37, P918, DOI 10.1042/BST0370918; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Sethupathy P, 2006, NAT METHODS, V3, P881, DOI 10.1038/NMETH954; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Ulitzur N, 1997, P NATL ACAD SCI USA, V94, P5084, DOI 10.1073/pnas.94.10.5084; VAESEN M, 1994, BIOL CHEM H-S, V375, P113, DOI 10.1515/bchm3.1994.375.2.113; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wong AKC, 2000, CANCER RES, V60, P6171; Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851; Yang Y, 2010, MOL BIOSYST, V6, P1873, DOI 10.1039/c004401f; Yang Y, 2009, PROTEOMICS, V9, P1374, DOI 10.1002/pmic.200800551; Yao Q, 2009, BIOCHEM BIOPH RES CO, V388, P539, DOI 10.1016/j.bbrc.2009.08.044; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24	62	105	110	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	26					2975	2985		10.1038/onc.2011.15	http://dx.doi.org/10.1038/onc.2011.15			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	785QZ	21317927	hybrid, Green Published			2022-12-17	WOS:000292245100008
J	Frezzetti, D; De Menna, M; Zoppoli, P; Guerra, C; Ferraro, A; Bello, AM; De Luca, P; Calabrese, C; Fusco, A; Ceccarelli, M; Zollo, M; Barbacid, M; Di Lauro, R; De Vita, G				Frezzetti, D.; De Menna, M.; Zoppoli, P.; Guerra, C.; Ferraro, A.; Bello, A. M.; De Luca, P.; Calabrese, C.; Fusco, A.; Ceccarelli, M.; Zollo, M.; Barbacid, M.; Di Lauro, R.; De Vita, G.			Upregulation of miR-21 by Ras in vivo and its role in tumor growth	ONCOGENE			English	Article						microRNA; miR-21; Ras; anaplastic thyroid carcinoma; non-small-cell lung cancer	LUNG-CANCER; MICRORNA GENES; DNA-DAMAGE; CELL-CYCLE; INDUCTION; PROFILES; AP-1; RNA	miR-21 is a microRNA (miRNA) frequently overexpressed in human cancers. Here we show that miR-21 is upregulated both in vitro and in vivo by oncogenic Ras, thus linking this miRNA to one of the most frequently activated oncogenes in human cancers. Ras regulation of miR-21 occurs with a delayed kinetic and requires at least two Ras downstream pathways. A screen of human thyroid cancers and non-small-cell lung cancers for the expression of miR-21 reveals that it is overexpressed mainly in anaplastic thyroid carcinomas, the most aggressive form of thyroid cancer, whereas in lung its overexpression appears to be inversely correlated with tumor progression. We also show that a LNA directed against miR-21 slows down tumor growth in mice. Consistently, a search for mRNAs downregulated by miR-21 shows an enrichment for mRNAs encoding cell cycle checkpoints regulators, suggesting an important role for miR-21 in oncogenic Ras-induced cell proliferation. Oncogene (2011) 30, 275-286; doi:10.1038/onc.2010.416; published online 18 October 2010	[Frezzetti, D.; Fusco, A.; Di Lauro, R.; De Vita, G.] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; [Frezzetti, D.; Zoppoli, P.; De Luca, P.; Ceccarelli, M.] IRGS Biogem Scarl, Ariano Irpino, Italy; [De Menna, M.] European Sch Mol Med, SEMM, Naples, Italy; [De Menna, M.; Ferraro, A.; Bello, A. M.; Zollo, M.] Ctr Ingn Genet & Biotecnol Avanzate, CEINGE, Naples, Italy; [Zoppoli, P.; Ceccarelli, M.] Univ Sannio, Dept Biol & Environm Studies, Benevento, Italy; [Guerra, C.; Barbacid, M.] CNIO, Mol Oncol Program, Madrid, Spain; [Ferraro, A.; Fusco, A.] Naples Oncogenom Ctr, NOGEC, Naples, Italy; [De Luca, P.] Stn Zool Anton Dohrn, Naples, Italy; [Calabrese, C.] Univ Naples 2, Monaldi Hosp, Dept Cardiothorac & Resp Sci, Naples, Italy; [Fusco, A.] CNR, Ist Endocrinol & Oncol Sperimentale, I-80125 Naples, Italy; [Zollo, M.] Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Naples, Italy	University of Naples Federico II; CEINGE Biotecnologie Avanzate; University of Sannio; Centro Nacional de Investigaciones Oncologicas (CNIO); Stazione Zoologica Anton Dohrn di Napoli; Universita della Campania Vanvitelli; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II	De Vita, G (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy.	rdilauro@unina.it; gdevita@unina.it	Ceccarelli, Michele/AGP-1739-2022; De Luca, Pasquale/AAL-5673-2021; De Vita, Gabriella/H-4422-2011; Zoppoli, Pietro/J-9954-2018; Guerra, Carmen/K-5852-2014; Ferraro, Angelo/A-4172-2014; Frezzetti, Daniela/AAI-2410-2019; Bello, Anna Maria/AAA-9139-2020; Ferraro, Angelo/H-3193-2019; Di Lauro, Roberto/A-2746-2012	De Luca, Pasquale/0000-0003-4289-6784; De Vita, Gabriella/0000-0002-7302-1174; Zoppoli, Pietro/0000-0002-7860-9655; Ferraro, Angelo/0000-0002-2044-7569; Frezzetti, Daniela/0000-0002-7500-5506; Bello, Anna Maria/0000-0001-6975-3340; Ferraro, Angelo/0000-0002-2044-7569; Di Lauro, Roberto/0000-0001-9493-3036; Fusco, Alfredo/0000-0003-3332-5197; Ceccarelli, Michele/0000-0002-4702-6617; Guerra, Carmen/0000-0002-3891-046X; Calabrese, Cecilia/0000-0003-4293-4461; De Menna, Marta/0000-0002-6306-3485	EU [LSHG-CT-2006-037900]; Associazione Italiana per la Ricerca sul Cancro (AIRC); AIRC, EUFP7 Tumic	EU(European Commission); Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); AIRC, EUFP7 Tumic(Fondazione AIRC per la ricerca sul cancro)	We thank Pietro Carotenuto (CROM, Centro Ricerche Oncologiche Mercogliano, Italy), Ilaria Pedicelli (Department of Cardio-Thoracic and Respiratory Sciences, Second University of Naples, Monaldi Hospital, Naples, Italy) and Nicolina De Rosa (Department of Pathology, Monaldi Hospital, Naples, Italy) for collection and technical help in the analysis of lung cancer samples. This work was supported by EU-Project-SIROCCO (Grant LSHG-CT-2006-037900), Associazione Italiana per la Ricerca sul Cancro (AIRC) to RDL and AIRC, EUFP7 Tumic to MZ.	Abulaiti A, 2006, CANCER RES, V66, P10505, DOI 10.1158/0008-5472.CAN-06-2351; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; De Vita G, 2005, MOL ENDOCRINOL, V19, P76, DOI 10.1210/me.2004-0172; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fujita S, 2008, J MOL BIOL, V378, P492, DOI 10.1016/j.jmb.2008.03.015; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He XY, 2007, CANCER RES, V67, P11099, DOI 10.1158/0008-5472.CAN-07-2672; John B, 2005, PLOS BIOL, V3, P1328, DOI 10.1371/journal.pbio.0030264; Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135; Knauf JA, 2006, J BIOL CHEM, V281, P3800, DOI 10.1074/jbc.M511690200; Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582-4934.2008.00556.x; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Liu Z, 2008, J CLIN ENDOCR METAB, V93, P3106, DOI 10.1210/jc.2008-0273; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Markou A, 2008, CLIN CHEM, V54, P1696, DOI 10.1373/clinchem.2007.101741; Martinsson-Ahlzen HS, 2008, MOL CELL BIOL, V28, P5698, DOI 10.1128/MCB.01833-07; Miller KA, 2009, CANCER RES, V69, P3689, DOI 10.1158/0008-5472.CAN-09-0024; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Seike M, 2009, P NATL ACAD SCI USA, V106, P12085, DOI 10.1073/pnas.0905234106; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Talotta F, 2009, ONCOGENE, V28, P73, DOI 10.1038/onc.2008.370; Visone R, 2007, ONCOGENE, V26, P7590, DOI 10.1038/sj.onc.1210564; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103	33	105	118	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					275	286		10.1038/onc.2010.416	http://dx.doi.org/10.1038/onc.2010.416			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20956945				2022-12-17	WOS:000286418800003
J	Pradelli, LA; Beneteau, M; Chauvin, C; Jacquin, MA; Marchetti, S; Munoz-Pinedo, C; Auberger, P; Pende, M; Ricci, JE				Pradelli, L. A.; Beneteau, M.; Chauvin, C.; Jacquin, M. A.; Marchetti, S.; Munoz-Pinedo, C.; Auberger, P.; Pende, M.; Ricci, J-E			Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation	ONCOGENE			English	Article						apoptosis; protein translation; glycolysis; AMPK; mTOR; Mcl-1	POSITRON-EMISSION-TOMOGRAPHY; CANCER-THERAPY; GLUCOSE-METABOLISM; EXPRESSION; SURVIVAL; TRAIL; NECROSIS; MTOR; AKT; MODULATION	Most cancer cells exhibit increased glycolysis for generation of their energy supply. This specificity could be used to preferentially kill these cells. In this study, we identified the signaling pathway initiated by glycolysis inhibition that results in sensitization to death receptor (DR)-induced apoptosis. We showed, in several human cancer cell lines (such as Jurkat, HeLa, U937), that glucose removal or the use of nonmetabolizable form of glucose (2-deoxyglucose) dramatically enhances apoptosis induced by Fas or by tumor necrosis factor-related apoptosis-inducing ligand. This sensitization is controlled through the adenosine monophosphate (AMP)-activated protein kinase (AMPK), which is the central energy-sensing system of the cell. We established the fact that AMPK is activated upon glycolysis block resulting in mammalian target of rapamycin (mTOR) inhibition leading to Mcl-1 decrease, but no other Bcl-2 anti-apoptotic members. Interestingly, we determined that, upon glycolysis inhibition, the AMPK-mTOR pathway controlled Mcl-1 levels neither through transcriptional nor through posttranslational mechanism but rather by controlling its translation. Therefore, our results show a novel mechanism for the sensitization to DR-induced apoptosis linking glucose metabolism to Mcl-1 down-expression. In addition, this study provides a rationale for the combined use of DR ligands with AMPK activators or mTOR inhibitors in the treatment of human cancers. Oncogene (2010) 29, 1641-1652; doi:10.1038/onc.2009.448; published online 7 December 2009	[Pradelli, L. A.; Beneteau, M.; Jacquin, M. A.; Ricci, J-E] Fac Med Nice, INSERM, Equipe AVENIR 3, U895,C3M, F-06107 Nice 2, France; [Pradelli, L. A.; Beneteau, M.; Jacquin, M. A.; Marchetti, S.; Auberger, P.; Ricci, J-E] Univ Nice Sophia Antipolis, Nice, France; [Chauvin, C.; Pende, M.] INSERM, U845, Paris, France; [Chauvin, C.; Pende, M.] Univ Paris 05, Fac Med, UMRS 845, Paris, France; [Munoz-Pinedo, C.] Inst Invest Biomed Bellvitge IDIBELL, Ctr Mol Oncol, Barcelona, Spain; [Marchetti, S.; Auberger, P.] Fac Med Nice, INSERM, Equipe 2, U895,C3M, F-06034 Nice, France; [Ricci, J-E] Ctr Hosp Univ Nice, Dept Anesthesie Reanimat, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice	Ricci, JE (corresponding author), Fac Med Nice, INSERM, Equipe AVENIR 3, U895,C3M, 28 Ave Valombrose, F-06107 Nice 2, France.	ricci@unice.fr	AUBERGER, Patrick/G-1491-2013; Pende, Mario/AFR-1348-2022; Munoz-Pinedo, Cristina/B-6118-2008; Ricci, Jean Ehrland/I-7117-2016; Marchetti, Sandrine/P-6479-2016; RICCI, Jean Ehrland/AAS-4379-2020	AUBERGER, Patrick/0000-0002-2481-8275; Pende, Mario/0000-0002-7864-8937; Munoz-Pinedo, Cristina/0000-0002-9120-664X; Ricci, Jean Ehrland/0000-0003-1585-8117; Marchetti, Sandrine/0000-0001-8326-5730; RICCI, Jean Ehrland/0000-0003-1585-8117	Association pour la Recherche sur le Cancer; l'Agence Nationale de la Recherche [ANR-09-JCJC-0003-01]; Conseil regional Provence-Alpes-Cote-d'Azur; La Fondation de France; Fondo de Investigaciones Sanitarias of Spain; INSERM-CHU de Nice	Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); l'Agence Nationale de la Recherche(French National Research Agency (ANR)); Conseil regional Provence-Alpes-Cote-d'Azur(Region Provence-Alpes-Cote d'AzurRegion Auvergne-Rhone-Alpes); La Fondation de France(Fondation de France); Fondo de Investigaciones Sanitarias of Spain(Instituto de Salud Carlos III); INSERM-CHU de Nice(Institut National de la Sante et de la Recherche Medicale (Inserm))	We thank Magali Herrant for her input, Audrey Paul and Celine Gracia for their technical assistance, Issam Ben Sahra, Vanessa Lavallard and Drs Anne-Odile Hueber, Frederic Bost, Stephane Rocchi and Marcel Deckert for providing tools and advises, Dr Ulrich Maurer for providing GSK3 inhibitor and Dr DR Green for Bcl-2 overexpressing Jurkat cells. This study was supported by the Association pour la Recherche sur le Cancer and by l'Agence Nationale de la Recherche (ref ANR-09-JCJC-0003-01). LAP and MAJ received a fellowship from the Conseil regional Provence-Alpes-Cote-d'Azur. MB is supported by a fellowship from La Fondation de France, CM-P is supported by the Fondo de Investigaciones Sanitarias of Spain and J-ER is a recipient of a contrat d'interface INSERM-CHU de Nice.	Alves NL, 2006, IMMUNITY, V24, P703, DOI 10.1016/j.immuni.2006.03.018; Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273; Chi MMY, 2000, J BIOL CHEM, V275, P40252, DOI 10.1074/jbc.M005508200; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P1396, DOI 10.1038/sj.cdd.4401963; Corradetti MN, 2006, ONCOGENE, V25, P6347, DOI 10.1038/sj.onc.1209885; Detterbeck FC, 2004, CHEST, V126, P1656, DOI 10.1378/chest.126.5.1656; Eguchi Y, 1997, CANCER RES, V57, P1835; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Gambhir SS, 2002, NAT REV CANCER, V2, P683, DOI 10.1038/nrc882; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; HALICKA HD, 1995, CANCER RES, V55, P444; Han J, 2006, J BIOL CHEM, V281, P10153, DOI 10.1074/jbc.M510349200; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Koschny R, 2007, J MOL MED, V85, P923, DOI 10.1007/s00109-007-0194-1; Kruyt FAE, 2008, CANCER LETT, V263, P14, DOI 10.1016/j.canlet.2008.02.003; Lavallard VJ, 2009, CANCER RES, V69, P3013, DOI 10.1158/0008-5472.CAN-08-2731; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Long YC, 2006, J CLIN INVEST, V116, P1776, DOI 10.1172/JCI29044; Luciano F, 2002, LEUKEMIA, V16, P700, DOI 10.1038/sj.leu.2402401; Marchetti S, 2009, EMBO J, V28, P2449, DOI 10.1038/emboj.2009.183; MAURER F, 1906, HDB VERGLEICHENDEN 1, V3, P1; Mills JR, 2008, P NATL ACAD SCI USA, V105, P10853, DOI 10.1073/pnas.0804821105; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; Munoz-Pinedo C, 2003, J BIOL CHEM, V278, P12759, DOI 10.1074/jbc.M212392200; Nam SY, 2002, ONCOGENE, V21, P337, DOI 10.1038/sj.onc.1205068; Nencioni A, 2005, BLOOD, V105, P3255, DOI 10.1182/blood-2004-10-3984; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Takeda K, 2007, ONCOGENE, V26, P3745, DOI 10.1038/sj.onc.1210374; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; VOLLAND S, 1992, INT J CANCER, V52, P384, DOI 10.1002/ijc.2910520310; Wei G, 2006, CANCER CELL, V10, P331, DOI 10.1016/j.ccr.2006.09.006; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Zhao Y, 2007, MOL CELL BIOL, V27, P4328, DOI 10.1128/MCB.00153-07; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	38	105	113	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	2010	29	11					1641	1652		10.1038/onc.2009.448	http://dx.doi.org/10.1038/onc.2009.448			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	19966861				2022-12-17	WOS:000275694700009
J	Teufel, DP; Bycroft, M; Fersht, AR				Teufel, D. P.; Bycroft, M.; Fersht, A. R.			Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2	ONCOGENE			English	Article						CBP; IHD; Mdm4; fluorescence anisotropy; phospho-peptides; transactivation	ACTIVATION DOMAINS; IN-VIVO; BINDING; PROTEIN; STABILIZATION; TRANSCRIPTION; COACTIVATORS; ACETYLATION; COMPLEX; CBP	The transcriptional activity of the tumour suppressor, p53, requires direct binding between its transactivation domain (TAD, 1-57) and the transcriptional coactivator, p300. We systematically assessed the role of TAD phosphorylation on binding of the p300 domains CH3, Taz1, Kix and IBiD. Thr18 phosphorylation increased the affinity up to sevenfold for CH3 and Taz1, with smaller increases from phosphorylation of Ser20, Ser15, Ser37, Ser33, Ser46 and Thr55. Binding of Kix and IBiD was less sensitive to phosphorylation. Strikingly, hepta-phosphorylation of all Ser and Thr residues increased binding 40- and 80-fold with CH3 and Taz1, respectively, but not with Kix or IBiD. Substitution of all phospho-sites with aspartates partially mimicked the effects of hepta-phosphorylation. Mdm2, the main negative regulator of p53, competes with p300 for binding to TAD. Binding of Mdm2 to TAD was reduced significantly only on phosphorylation of Thr18 (sevenfold) or by hepta-phosphorylation (24-fold). The relative affinities of Mdm2 and p300 for p53 TAD can thus be changed by up to three orders of magnitude by phosphorylation. Accordingly, phosphorylation of Thr18 and hepta-phosphorylation dramatically shifts the balance towards favouring the binding of p300 with p53, and is thus likely to be an important factor in its regulation. Oncogene (2009) 28, 2112-2118; doi:10.1038/onc.2009.71; published online 13 April 2009	[Fersht, A. R.] Univ Cambridge, Ctr Mrc, Dept Chem, MRC Ctr Prot Engn, Cambridge CB2 0QH, England	MRC Laboratory Molecular Biology; University of Cambridge	Fersht, AR (corresponding author), Univ Cambridge, Ctr Mrc, Dept Chem, MRC Ctr Prot Engn, Hills Rd, Cambridge CB2 0QH, England.	arf25@cam.ac.uk	Bycroft, Mark/D-9446-2017; Fersht, Alan R/B-2189-2008	Bycroft, Mark/0000-0002-0673-2216; Teufel, Daniel/0000-0002-6527-2117	MRC [MC_U105474168] Funding Source: UKRI; Medical Research Council [MC_U105474168, U.1054.00.012(74168)] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Bean LJH, 2002, J BIOL CHEM, V277, P1864, DOI 10.1074/jbc.M108881200; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Brown CJ, 2008, CELL CYCLE, V7, P608, DOI 10.4161/cc.7.5.5488; Chao C, 2006, EMBO J, V25, P2615, DOI 10.1038/sj.emboj.7601167; Chi SW, 2005, J BIOL CHEM, V280, P38795, DOI 10.1074/jbc.M508578200; Di Lello P, 2006, MOL CELL, V22, P731, DOI 10.1016/j.molcel.2006.05.007; Dornan D, 2001, EMBO REP, V2, P139, DOI 10.1093/embo-reports/kve025; Dornan D, 2003, J BIOL CHEM, V278, P13431, DOI 10.1074/jbc.M211460200; Johnson TM, 2006, CELL DEATH DIFFER, V13, P902, DOI 10.1038/sj.cdd.4401902; Knights CD, 2003, J BIOL CHEM, V278, P52890, DOI 10.1074/jbc.M300279200; Lai ZH, 2000, ARCH BIOCHEM BIOPHYS, V381, P278, DOI 10.1006/abbi.2000.1998; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Legge GB, 2004, J MOL BIOL, V343, P1081, DOI 10.1016/j.jmb.2004.08.087; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu G, 2003, J BIOL CHEM, V278, P17557, DOI 10.1074/jbc.M210696200; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Marine JC, 2004, CELL CYCLE, V3, P900; Melcher K, 2000, J MOL BIOL, V301, P1097, DOI 10.1006/jmbi.2000.4034; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Polley S, 2008, J MOL BIOL, V376, P8, DOI 10.1016/j.jmb.2007.11.082; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Schon O, 2002, J MOL BIOL, V323, P491, DOI 10.1016/S0022-2836(02)00852-5; Teufel DP, 2007, P NATL ACAD SCI USA, V104, P7009, DOI 10.1073/pnas.0702010104; Teufel DP, 2003, BIOCHEMISTRY-US, V42, P1451, DOI 10.1021/bi026852o; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Wells M, 2008, P NATL ACAD SCI USA, V105, P5762, DOI 10.1073/pnas.0801353105; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; Zor T, 2002, J BIOL CHEM, V277, P42241, DOI 10.1074/jbc.M207361200	33	105	108	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2009	28	20					2112	2118		10.1038/onc.2009.71	http://dx.doi.org/10.1038/onc.2009.71			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	448BI	19363523	Green Accepted			2022-12-17	WOS:000266235800005
J	Dar, AA; Belkhiri, A; El-Rifai, W				Dar, A. A.; Belkhiri, A.; El-Rifai, W.			The aurora kinase A regulates GSK-3 beta in gastric cancer cells	ONCOGENE			English	Article						AURKA; GSK-3 beta; beta-catenin; gastric cancer	BETA-CATENIN; FREQUENT OVEREXPRESSION; BARRETTS-ESOPHAGUS; OVARIAN-CANCER; CYCLIN D1; PATHWAY; CARCINOMA; TARGET; GENE; ACTIVATION	Aurora kinase A (AURKA) is located at 20q13, a region that is frequently amplified in gastric cancer. In this study, we have investigated the role of AURKA in regulating glycogen synthase kinase (GSK)-3 beta and beta-catenin/TCF complex in gastric cancer cells. Our results demonstrate a significant increase in the phosphorylation of GSK-3 beta at Ser 9 following the overexpression of AURKA in AGS cells. The immuno-precipitation with antibodies specific for AURKA and GSK-3 beta indicated that the two proteins coexist in the same protein complex. The recombinant human AURKA protein phosphorylated the GSK-3 beta protein at Ser 9 in a concentration-dependent manner, in vitro. The phosphorylation of beta-catenin (Ser33/37/Thr41) by GSK-3 beta is known to target beta-catenin towards degradation. In line with our findings, the increase in phospho-GSK-3 beta level was accompanied by a significant decrease in beta-catenin phosphorylation (Ser33/37/Thr41) and accumulation of beta-catenin protein. The knockdown of AURKA reversed the phosphorylation of GSK-3 beta and the beta-catenin protein levels. The immunofluorescence analysis demonstrated colocalization of AURKA and GSK-3 beta proteins and a significant increase in the nuclear beta-catenin levels in cells overexpressing AURKA. The beta-catenin/TCF transcription activity was measured using the pTopFlash and its mutant pFopFlash luciferase reporter vectors. Indeed, AURKA overexpression led to a significant increase in the pTopFlash reporter activity, whereas kinase dead AURKA mutant (D274A) had no effect. Consistent with these findings, we detected a significant mRNA up-regulation of several direct targets of the beta-catenin/TCF transcription complex (cyclin D1, c-MYC, c-MYC-binding protein, CLDN1, FGF18 and vascular endothelial growth factor), and a two-fold increase in the proliferation rate in AURKA overexpressing cells. We conclude that the AURKA/GSK-3 beta interaction is important in regulating beta-catenin, underscoring a novel oncogenic potential for AURKA in gastric tumorigenesis.	[El-Rifai, W.] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Dar, A. A.; Belkhiri, A.; El-Rifai, W.] Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37232 USA; [El-Rifai, W.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	El-Rifai, W (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, 1255 Light Hall,2215 Garland Ave, Nashville, TN 37232 USA.	wael.el-rifai@vanderbilt.edu			National Cancer Institute [CA95103]; Vanderbilt-Ingram Cancer Center; NATIONAL CANCER INSTITUTE [P50CA095103, R01CA131225] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Vanderbilt-Ingram Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by a pilot fund from the National Cancer Institute GI SPORE grant CA95103 and the Vanderbilt-Ingram Cancer Center support funds. The contents of this work are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute or Vanderbilt University Medical Center.	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Clements WM, 2002, CANCER RES, V62, P3503; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Dar AA, 2008, CANCER-AM CANCER SOC, V112, P1688, DOI 10.1002/cncr.23371; Earle CC, 1999, EUR J CANCER, V35, P1059, DOI 10.1016/S0959-8049(99)00076-3; El-Rifai W, 2002, CANCER RES, V62, P6823; El-Rifai W, 2001, GASTROENTEROLOGY, V121, P592, DOI 10.1053/gast.2001.27215; Gamallo C, 1999, AM J PATHOL, V155, P527, DOI 10.1016/S0002-9440(10)65148-6; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Giet R, 1999, J CELL SCI, V112, P3591; Giles FJ, 2007, BLOOD, V109, P500, DOI 10.1182/blood-2006-05-025049; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hojilla CV, 2007, J CELL SCI, V120, P1050, DOI 10.1242/jcs.003335; Hu W, 2005, ONCOL RES, V15, P49, DOI 10.3727/096504005775082101; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kamada K, 2004, ONCOL REP, V12, P593; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Kikuchi A, 2006, EXP MOL MED, V38, P1, DOI 10.1038/emm.2006.1; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NAKATSURU S, 1992, HUM MOL GENET, V1, P559, DOI 10.1093/hmg/1.8.559; Ogawa E, 2008, ANN SURG ONCOL, V15, P547, DOI 10.1245/s10434-007-9653-8; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sourbier C, 2006, CANCER RES, V66, P5130, DOI 10.1158/0008-5472.CAN-05-1469; Sparks AB, 1998, CANCER RES, V58, P1130; Tanaka T, 1999, CANCER RES, V59, P2041; Terris B, 1999, ONCOGENE, V18, P6583, DOI 10.1038/sj.onc.1203051; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tong T, 2004, CLIN CANCER RES, V10, P7304, DOI 10.1158/1078-0432.CCR-04-0806; Varis A, 2001, CANCER GENET CYTOGEN, V127, P53, DOI 10.1016/S0165-4608(00)00423-4; Voeller HJ, 1998, CANCER RES, V58, P2520; Wang Chenguang, 2004, Cancer Treat Res, V119, P217; Washington K, 1998, MODERN PATHOL, V11, P805; Yamada T, 2000, CANCER RES, V60, P4761; Yang H, 2006, INT J CANCER, V119, P2304, DOI 10.1002/ijc.22154; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	49	105	107	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					866	875		10.1038/onc.2008.434	http://dx.doi.org/10.1038/onc.2008.434			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19060929	Green Accepted			2022-12-17	WOS:000263320000009
J	Podar, K; Gouill, SL; Zhang, J; Opferman, JT; Zorn, E; Tai, YT; Hideshima, T; Amiot, M; Chauhan, D; Harousseau, JL; Anderson, KC				Podar, K.; Gouill, S. L.; Zhang, J.; Opferman, J. T.; Zorn, E.; Tai, Y-T; Hideshima, T.; Amiot, M.; Chauhan, D.; Harousseau, J-L; Anderson, K. C.			A pivotal role for Mcl-1 in Bortezomib-induced apoptosis	ONCOGENE			English	Article						Mcl-1; apoptosis; Bortezomib	PROTEASOME INHIBITOR PS-341; MULTIPLE-MYELOMA CELLS; DOWN-REGULATION; IN-VIVO; SURVIVAL; ACTIVATION; GROWTH; BCL-2; PROTEIN; DIFFERENTIATION	Bortezomib is a proteasome inhibitor for the treatment of relapsed/refractory multiple myeloma (MM). Mechanisms of resistance to Bortezomib are undefined. Myeloid cell leukemia-1 (Mcl-1) is an antiapoptotic protein, which protects tumor cells against spontaneous and chemotherapy-induced apoptosis. In MM, specific downregulation of Mcl-1 induces apoptosis. Here, we examined the role of Mcl-1 in Bortezomib- and doxorubicin-induced apoptosis. We demonstrate that Bortezomib, but not doxorubicin, triggers caspase-dependent generation of a 28 kDa Mcl-1 fragment, in several MM cell lines, including MM.1S cells. Conversely, transient transfection of MM.1S cells with a previously reported 28 kDa Mcl-1(128-350) fragment, but not with the Mcl-1(1-127) fragment, induces apoptosis. Therefore, both downregulation of full-length antiapoptotic Mcl-1, as well as Bortezomib- induced generation of Mcl-1(128-350) cleaved protein, contribute to MM cell apoptosis. To verify further these findings, we next compared effects triggered by Bortezomib, doxorubicin and melphalan in Mcl-1(wt/wt) and Mcl-1(Delta/null) murine embryonic fibroblasts (MEFs). Our results show that Bortezomib, but not doxorubicin or melphalan, triggers Mcl-1 cleavage in Mcl-1(wt/wt), but not Mcl-1(Delta/null) MEFs and induces sub-G(1) phase cells; caspase-3 and -9, and PARP cleavage as well as morphological signs of apoptosis. Taken together, these results support an important role of Mcl-1 and a Mcl-1 fragment in Bortezomib- induced cell death in general, and in MM in particular. To prevent relapse of MM in patients treated with Bortezomib, we therefore recommend the combination of Bortezomib with agents that induce MM cell death independent of Mcl-1.	[Podar, K.; Gouill, S. L.; Zhang, J.; Tai, Y-T; Hideshima, T.; Chauhan, D.; Anderson, K. C.] Harvard Univ, Sch Med, Jerome Lipper Multiple Myeloma CtrDept Med Oncol, Dana Farber Canc Inst,Dept Med Oncol, Boston, MA 02215 USA; [Gouill, S. L.; Amiot, M.; Harousseau, J-L] CHU Nantes, Hotel Dieu, Serv Hematol Clin, F-44035 Nantes 01, France; [Gouill, S. L.; Amiot, M.] INSERM, U 0601, Inst Biol, Quai Moncousu 9, F-44035 Nantes 01, France; [Opferman, J. T.] St Jude Childrens Hosp, Dept Biochem, Memphis, TN 38105 USA; [Zorn, E.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst,Ctr Hematol Oncol,Dept Med, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); St Jude Children's Research Hospital; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	Podar, K (corresponding author), Harvard Univ, Sch Med, Jerome Lipper Multiple Myeloma CtrDept Med Oncol, Dana Farber Canc Inst,Dept Med Oncol, 44 Binney St, Boston, MA 02215 USA.	klaus_podar@dfci.harvard.edu; kenneth_anderson@dfci.harvard.edu	Podar, Klaus/ABD-1112-2020; Opferman, Joseph T/M-5331-2018; Amiot, Martine/K-9076-2015	Podar, Klaus/0000-0002-7414-3632; Opferman, Joseph T/0000-0002-1147-5621; le gouill, steven/0000-0001-9840-2128; Amiot, Martine/0000-0003-0428-7355	NATIONAL CANCER INSTITUTE [R01CA050947, P01CA078378] Funding Source: NIH RePORTER; NCI NIH HHS [R0 CA 50947, P0-1 CA 78378, P50 CA 10070] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199; Bataille R, 1997, NEW ENGL J MED, V336, P1657, DOI 10.1056/NEJM199706053362307; Chauhan D, 2005, MOL CANCER THER, V4, P686, DOI 10.1158/1535-7163.MCT-04-0338; Chauhan D, 2004, BLOOD, V104, P2458, DOI 10.1182/blood-2004-02-0547; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; Domina AM, 2004, ONCOGENE, V23, P5301, DOI 10.1038/sj.onc.1207692; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Gomez-Bougie P, 2004, EUR J IMMUNOL, V34, P3156, DOI 10.1002/eji.200424981; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2003, ONCOGENE, V22, P8386, DOI 10.1038/sj.onc.1207170; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hurley LH, 2002, NAT REV CANCER, V2, P188, DOI 10.1038/nrc749; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Jang YM, 2004, FEBS LETT, V577, P483, DOI 10.1016/j.febslet.2004.10.053; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Le Gouill S, 2004, CELL CYCLE, V3, P1259; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; LeBlanc R, 2002, CANCER RES, V62, P4996; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; MAURER F, 1906, HDB VERGLEICHENDEN 1, V3, P1; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Opferman JT, 2006, CELL DEATH DIFFER, V13, P1260, DOI 10.1038/sj.cdd.4401978; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Orlowski RZ, 2005, BLOOD, V105, P3058, DOI 10.1182/blood-2004-07-2911; Pei XY, 2004, CLIN CANCER RES, V10, P3839, DOI 10.1158/1078-0432.CCR-03-0561; Perez-Galan P, 2006, BLOOD, V107, P257, DOI 10.1182/blood-2005-05-2091; Podar K, 2004, CANCER RES, V64, P7500, DOI 10.1158/0008-5472.CAN-04-0124; Podar K, 2004, BLOOD, V103, P3474, DOI 10.1182/blood-2003-10-3527; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Raje N, 2005, BLOOD, V106, P1042, DOI 10.1182/blood-2005-01-0320; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Rinkenberger JL, 2000, GENE DEV, V14, P23; Roccaro AM, 2006, CANCER RES, V66, P184, DOI 10.1158/0008-5472.CAN-05-1195; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; ZAMAI L, 1993, CYTOMETRY, V14, P891, DOI 10.1002/cyto.990140807; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	46	105	111	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2008	27	6					721	731		10.1038/sj.onc.1210679	http://dx.doi.org/10.1038/sj.onc.1210679			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653083				2022-12-17	WOS:000252884500001
J	Brooks, CL; Li, M; Hu, M; Shi, Y; Gu, W				Brooks, C. L.; Li, M.; Hu, M.; Shi, Y.; Gu, W.			The p53-Mdm2-HAUSP complex is involved in p53 stabilization by HAUSP	ONCOGENE			English	Article						HAUSP; p53; deubiquitination; Mdm2 degradation	MDM2; PATHWAY; DEUBIQUITINATION; UBIQUITINATION; RECOGNITION; CONTRIBUTES; USP7/HAUSP	The ubiquitin-specific protease HAUSP is a critical component of the p53-Mdm2 pathway by acting as a specific deubiquitinase for both p53 and Mdm2. Recent structural studies have indicated that p53 and Mdm2 bind to the N-terminal TRAF-like domain of HAUSP in a mutually exclusive manner. To understand the mechanism of HAUSP-mediated effects, we have created a p53 mutant that lacks HAUSP binding based on the crystal structure analysis. Indeed, this mutant p53 protein can be degraded by Mdm2 but fails to interact with HAUSP both in vitro and in vivo. Surprisingly, however, we have found that direct interaction between HAUSP and p53 is not absolutely required for it to antagonize efficiently Mdm2-mediated ubiquitination of p53 and that HAUSP is capable of enzymatically functioning in trans on p53 by using Mdm2 as a bridge. Further, we show that a trimeric protein complex containing p53, Mdm2 and HAUSP can exist in vivo, despite mutually exclusive binding, with Mdm2 serving as a binding mediator for p53 and HAUSP. These findings reveal the complication of HAUSP-mediated effects in the p53-Mdm2 interplay. It also has important implications for the development of novel chemotherapeutic compounds aimed at blocking this protein-protein interaction.	Columbia Univ, Coll Phys & Surg, Inst Canc Genet, Dept Pathol, New York, NY USA; Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Princeton, NJ 08544 USA	Columbia University; Princeton University	Gu, W (corresponding author), Columbia Univ, Coll Phys & Surg, Inst Canc Genet, 1130 Nicholas Ave, New York, NY 10032 USA.	wg8@columbia.edu			NATIONAL CANCER INSTITUTE [R01CA098821, R01CA129627, R01CA104843, R01CA131439, R01CA085533, P01CA097403] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA097403, R01 CA098821, R01 CA085533, R01 CA104843, R01 CA131439, R01 CA129627] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; CUMMINS JM, 2004, NATURE, V428, P486, DOI [DOI 10.1038/NATURE02501, 10.1038/nature02501]; Hu M, 2006, PLOS BIOL, V4, P228, DOI 10.1371/journal.pbio.0040027; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Marchenko ND, 2007, EMBO J, V26, P923, DOI 10.1038/sj.emboj.7601560; Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912; Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Sheng Y, 2006, NAT STRUCT MOL BIOL, V13, P285, DOI 10.1038/nsmb1067; Tang J, 2006, NAT CELL BIOL, V8, P855, DOI 10.1038/ncb1442; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472	14	105	116	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2007	26	51					7262	7266		10.1038/sj.onc.1210531	http://dx.doi.org/10.1038/sj.onc.1210531			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17525743	Green Accepted			2022-12-17	WOS:000250955600010
J	Amiri, A; Noei, F; Jeganathan, S; Kulkarni, G; Pinke, DE; Lee, JM				Amiri, A.; Noei, F.; Jeganathan, S.; Kulkarni, G.; Pinke, D. E.; Lee, J. M.			eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration	ONCOGENE			English	Article						eEF1A2; Akt; filopodia; protein translation; actin; cell motility	ELONGATION-FACTOR EEF1A2; BINDING PROTEIN; CELL-MIGRATION; FACTOR 1A; TRANSLATION; KINASES; GROWTH; GENE; OVEREXPRESSION; FACTOR-1-ALPHA	eEF1A2 ( eukaryotic protein elongation factor 1 alpha 2) is a protein translation factor that is likely a human oncogene by virtue of its capacity to transform mammalian cells and its high expression in tumors of the ovary, breast and lung. Here, we show that expression of eEF1A2 is sufficient to stimulate the formation of filopodia in BT 549 human breast cancer cells and non-transformed Rat2 cells. Filopodia formation in eEF1A2-expressing cells is dependent on the activity of phosphatidylinositol-3 kinase ( PI3K), and the ROCK and Akt kinases. Furthermore, eEF1A2 expression is sufficient to activate Akt in a PI3K-dependent fashion and inactivation of eEF1A2 by short interfering RNA reduces Akt activity. Using breast cancer cell line BT 549, we show that eEF1A2 expression stimulates cell migration and invasion in a largely PI3K- and Akt-dependent manner. These results suggest that eEF1A2 regulates oncogenesis through Akt and PI3K-dependent cytoskeletal remodeling.	Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Lee, JM (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	jlee@uottawa.ca						ADAMS AT, 1985, EXP CELL BIOL, V53, P181; Anand N, 2002, NAT GENET, V31, P301, DOI 10.1038/ng904; Arboleda MJ, 2003, CANCER RES, V63, P196; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; CHANG R, 2006, J CELL BIOCH; Chen J, 2004, P NATL ACAD SCI USA, V101, P14479, DOI 10.1073/pnas.0404438101; Chodniewicz D, 2004, EXP CELL RES, V301, P31, DOI 10.1016/j.yexcr.2004.08.006; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; CREWS CM, 1994, J BIOL CHEM, V269, P15411; Edmonds BT, 1996, J CELL SCI, V109, P2705; Enomoto A, 2005, DEV CELL, V9, P389, DOI 10.1016/j.devcel.2005.08.001; Fitzsimmons S, 2003, ONCOGENE, V22, P1737, DOI 10.1038/sj.onc.1206295; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gross SR, 2005, NAT STRUCT MOL BIOL, V12, P772, DOI 10.1038/nsmb979; Heilmeyer LMG, 2003, IUBMB LIFE, V55, P59, DOI 10.1080/1521654031000090896; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Jimeno J, 2004, ANTI-CANCER DRUG, V15, P321, DOI 10.1097/00001813-200404000-00003; Kahns S, 1998, NUCLEIC ACIDS RES, V26, P1884, DOI 10.1093/nar/26.8.1884; KNUDSEN SM, 1993, EUR J BIOCHEM, V215, P549, DOI 10.1111/j.1432-1033.1993.tb18064.x; KULKARNI G, 2006, BREAST CANC RES TREA; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Lau J, 2006, MOL CELL BIOCHEM, V286, P17, DOI 10.1007/s11010-005-9006-5; Lee Jonathan M, 2003, Reprod Biol Endocrinol, V1, P69, DOI 10.1186/1477-7827-1-69; LEE S, 1993, J BIOL CHEM, V268, P24453; Li R, 2006, ONCOGENE, V25, P2628, DOI 10.1038/sj.onc.1209289; Meijer HJG, 2003, ANNU REV PLANT BIOL, V54, P265, DOI 10.1146/annurev.arplant.54.031902.134748; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Munshi R, 2001, GENETICS, V157, P1425; Nathrath MH, 2002, ONCOGENE, V21, P5975, DOI 10.1038/sj.onc.1205764; Overduin M, 2001, Mol Interv, V1, P150; OWEN CH, 1992, J STRUCT BIOL, V109, P248, DOI 10.1016/1047-8477(92)90037-B; PENCIL SD, 1993, BREAST CANCER RES TR, V25, P165, DOI 10.1007/BF00662141; Pendaries C, 2006, EMBO J, V25, P1024, DOI 10.1038/sj.emboj.7601001; Qian Y, 2004, AM J PHYSIOL-CELL PH, V286, pC153, DOI 10.1152/ajpcell.00142.2003; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rodrigues SP, 2005, MOL CANCER RES, V3, P183; Svitkina TM, 2003, J CELL BIOL, V160, P409, DOI 10.1083/jcb.200210174; Thornton S, 2003, J MOL MED, V81, P536, DOI 10.1007/s00109-003-0461-8; Tomlinson VAL, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-113; Tornieri K, 2006, CELL MOTIL CYTOSKEL, V63, P173, DOI 10.1002/cm.20115; Verhagen PCMS, 2002, INT J CANCER, V102, P142, DOI 10.1002/ijc.10677; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; Yang L, 2004, CANCER RES, V64, P4394, DOI 10.1158/0008-5472.CAN-04-0343; YANG WN, 1993, J BIOL CHEM, V268, P392; Zhou GL, 2003, MOL CELL BIOL, V23, P8058, DOI 10.1128/MCB.23.22.8058-8069.2003	50	105	110	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2007	26	21					3027	3040		10.1038/sj.onc.1210101	http://dx.doi.org/10.1038/sj.onc.1210101			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17130842				2022-12-17	WOS:000246395400008
J	Hwang, SI; Thumar, J; Lundgren, DH; Rezaul, K; Mayya, V; Wu, L; Eng, J; Wright, ME; Han, DK				Hwang, S-I; Thumar, J.; Lundgren, D. H.; Rezaul, K.; Mayya, V.; Wu, L.; Eng, J.; Wright, M. E.; Han, D. K.			Direct cancer tissue proteomics: a method to identify candidate cancer biomarkers from formalin-fixed paraffin-embedded archival tissues	ONCOGENE			English	Article						direct tissue proteomics (DTP); LC-MS/MS; prostate cancer; Wnt; formalin-fixed paraffin-embedded tissues; prostate-specific antigen (PSA)	PROSTATE-SPECIFIC ANTIGEN; ANDROGEN RECEPTOR; MASS-SPECTROMETRY; STATISTICAL-MODEL; GENE-EXPRESSION; LUNG-CANCER; PROTEIN; IDENTIFICATION; SPECIFICITY; PREVENTION	Successful treatment of multiple cancer types requires early detection and identification of reliable biomarkers present in specific cancer tissues. To test the feasibility of identifying proteins from archival cancer tissues, we have developed a methodology, termed direct tissue proteomics (DTP), which can be used to identify proteins directly from formalin-fixed paraffin-embedded prostate cancer tissue samples. Using minute prostate biopsy sections, we demonstrate the identification of 428 prostate-expressed proteins using the shotgun method. Because the DTP method is not quantitative, we employed the absolute quanti. cation method and demonstrate picogram level quantification of prostate-specific antigen. In depth bioinformatics analysis of these expressed proteins affords the categorization of metabolic pathways that may be important for distinct stages of prostate carcinogenesis. Furthermore, we validate Wnt-3 as an upregulated protein in cancerous prostate cells by immunohistochemistry. We propose that this general strategy provides a roadmap for successful identification of critical molecular targets of multiple cancer types.	Univ Connecticut, Sch Med, Ctr Vasc Biol, Dept Cell Biol, Farmington, CT 06030 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA	University of Connecticut; Fred Hutchinson Cancer Center; University of California System; University of California Davis	Han, DK (corresponding author), Univ Connecticut, Sch Med, Ctr Vasc Biol, Dept Cell Biol, 263 Farmington Ave, Farmington, CT 06030 USA.	han@nso.uchc.edu	Eng, Jimmy K/I-4202-2012	Eng, Jimmy K/0000-0001-6352-6737; Mayya, Viveka/0000-0001-5668-9124; Wright, Michael/0000-0002-4243-2931	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR019436] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070694, R01HL067569] Funding Source: NIH RePORTER; NCRR NIH HHS [RR019436] Funding Source: Medline; NHLBI NIH HHS [HL 67569, P01 HL70694] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cantin GT, 2004, J CHROMATOGR A, V1053, P7, DOI 10.1016/j.chroma.2004.06.046; Coombs GS, 1998, CHEM BIOL, V5, P475, DOI 10.1016/S1074-5521(98)90004-7; Cox C, 2005, P NATL ACAD SCI USA, V102, P4542, DOI 10.1073/pnas.0408593102; Cronauer MV, 2005, INT J ONCOL, V26, P1033; DePinho RA, 2004, NAT GENET, V36, P932, DOI 10.1038/ng0904-932; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FORD TF, 1985, BRIT J UROL, V57, P50, DOI 10.1111/j.1464-410X.1985.tb08984.x; George DJ, 2002, UROLOGY, V60, P115, DOI 10.1016/S0090-4295(02)01589-3; Gerber SA, 2003, P NATL ACAD SCI USA, V100, P6940, DOI 10.1073/pnas.0832254100; Gleason D F, 1988, NCI Monogr, P15; GLEASON DF, 1992, HUM PATHOL, V23, P273, DOI 10.1016/0046-8177(92)90108-F; Griffin TJ, 2003, ANAL CHEM, V75, P867, DOI 10.1021/ac026127j; Gupta A, 2004, J UROLOGY, V171, P2384, DOI 10.1097/01.ju.0000124331.16739.12; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Han DK, 2001, NAT BIOTECHNOL, V19, P946, DOI 10.1038/nbt1001-946; Hood BL, 2005, MOL CELL PROTEOMICS, V4, P1741, DOI 10.1074/mcp.M500102-MCP200; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Lundgren DH, 2003, MOL CELL PROTEOMICS, V2, P1164, DOI 10.1074/mcp.M300059-MCP200; Mayya V, 2005, MOL CELL PROTEOMICS, V4, P214, DOI 10.1074/mcp.T400015-MCP200; Meyerson M, 2005, J CLIN ONCOL, V23, P3219, DOI 10.1200/JCO.2005.15.511; Nantermet PV, 2004, J BIOL CHEM, V279, P1310, DOI 10.1074/jbc.M310206200; Nelson PS, 2000, ELECTROPHORESIS, V21, P1823; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Parnes HL, 2005, J CLIN ONCOL, V23, P368, DOI 10.1200/JCO.2005.08.027; Patterson SD, 2004, ARTHRITIS RHEUM-US, V50, P3741, DOI 10.1002/art.20796; Peng JM, 2003, J PROTEOME RES, V2, P43, DOI 10.1021/pr025556v; Petricoin EF, 2002, NAT REV DRUG DISCOV, V1, P683, DOI 10.1038/nrd891; Posadas EM, 2005, ANN ONCOL, V16, P16, DOI 10.1093/annonc/mdi004; Raben David, 2004, Clin Lung Cancer, V6, P48, DOI 10.3816/CLC.2004.n.021; Rezaul K, 2005, MOL CELL PROTEOMICS, V4, P169, DOI 10.1074/mcp.M400115-MCP200; Sawyers CL, 2002, CURR OPIN GENET DEV, V12, P111, DOI 10.1016/S0959-437X(01)00273-8; Sharpless NE, 2005, NATURE, V436, P636, DOI 10.1038/436636a; Smith RA, 2005, CA-CANCER J CLIN, V55, P31, DOI 10.3322/canjclin.55.1.31; Stephens P, 2005, NAT GENET, V37, P590, DOI 10.1038/ng1571; Sweat GT, 2005, POSTGRAD MED, V117, P45, DOI 10.3810/pgm.2005.04.1618; TANNEBERGER S, 1977, ARCH GESCHWULSTFORSC, V47, P755; Tarro G, 2005, J CELL PHYSIOL, V203, P1, DOI 10.1002/jcp.20195; Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102; Velasco AM, 2004, ENDOCRINOLOGY, V145, P3913, DOI 10.1210/en.2004-0311; Verras M, 2004, CANCER RES, V64, P8860, DOI 10.1158/0008-5472.CAN-04-2370; Wardwell NR, 2005, SEMIN ONCOL, V32, P259, DOI 10.1053/j.seminoncol.2005.02.009; Wilson JF, 2004, ANN INTERN MED, V140, P317, DOI 10.7326/0003-4819-140-4-200402170-00036; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Wright ME, 2005, MOL CELL PROTEOMICS, V4, P545, DOI 10.1074/mcp.R500008-MCP200; Wright ME, 2004, GENOME BIOL, V5; Zangar RC, 2004, DIS MARKERS, V20, P135, DOI 10.1155/2004/754640; Zhu HN, 2004, CANCER RES, V64, P7918, DOI 10.1158/0008-5472.CAN-04-2704	47	105	110	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					65	76		10.1038/sj.onc.1209755	http://dx.doi.org/10.1038/sj.onc.1209755			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799640				2022-12-17	WOS:000243236500007
J	Wang, J; Ou, ZL; Hou, YF; Luo, JM; Shen, ZZ; Ding, J; Shao, ZM				Wang, J.; Ou, Z-L; Hou, Y-F; Luo, J-M; Shen, Z-Z; Ding, J.; Shao, Z-M			Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential	ONCOGENE			English	Article						breast cancer; metastasis; Duffy antigen receptor for chemokines (DARC)	ENDOTHELIAL-CELLS; PROSTATE-CANCER; NEGATIVE INDIVIDUALS; TUMOR REJECTION; BINDING PROTEIN; ANGIOGENESIS; INTERLEUKIN-8; TUMORIGENICITY; IDENTIFICATION; GENE	In addition to the role in regulating leukocyte trafficking, chemokines recently have been shown to be involved in cancer growth and metastasis. Chemokine network in tumor neovascularity may be regulated by decoy receptors. Duffy antigen receptor for chemokines (DARC) is a specific decoy receptor binding with the angiogenic CC and CXC chemokines. To investigate the effects of DARC on the tumorigenesis and the metastasis potential of human breast cancer cells, human DARC cDNA was reintroduced into the MDA-MB-231 and MDA-MB-435HM cells which have a high capability of spontaneous pulmonary metastasis. We demonstrated that DARC overexpression induced inhibition of tumorigenesis and/ or metastasis through interfering with the tumor angiogenesis in vivo. This inhibition is associated with decreasing CCL2 protein levels, and MVD and MMP-9 expression in xenograft tumors. In human breast cancer samples, we also demonstrated that low expression of the DARC protein is significantly associated with estrogen receptor (ER) status, MVD, lymph node metastasis, distant metastasis and poor survival. Our results suggest for the first time that DARC is a negative regulator of growth in breast cancer, mainly by sequestration of angiogenic chemokines and subsequent inhibition of tumor neovascularity.	Fudan Univ, Canc Hosp,Shanghai Med Coll, Inst Canc,Dept Oncol, Dept Breast Surg,Breast Canc Inst, Shanghai 200032, Peoples R China; Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 200031, Peoples R China	Fudan University; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS	Shao, ZM (corresponding author), Fudan Univ, Canc Hosp,Shanghai Med Coll, Inst Canc,Dept Oncol, Dept Breast Surg,Breast Canc Inst, 399 Ling Ling Rd, Shanghai 200032, Peoples R China.	zhimingshao@yahoo.com						Addison CL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-28; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Brat DJ, 2005, NEURO-ONCOLOGY, V7, P122, DOI 10.1215/S1152851704001061; Braun SE, 2000, J IMMUNOL, V164, P4025, DOI 10.4049/jimmunol.164.8.4025; Castilho L, 2004, VOX SANG, V87, P190, DOI 10.1111/j.1423-0410.2004.00554.x; Chaudhuri A, 2004, BRIT J HAEMATOL, V127, P356, DOI 10.1111/j.1365-2141.2004.05208.x; Chaudhuri A, 1997, BLOOD, V89, P701, DOI 10.1182/blood.V89.2.701; CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835; Comerford L, 2005, IMMUNOL LETT, V96, P163, DOI 10.1016/j.imlet.2004.08.018; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; Du JG, 2002, J LEUKOCYTE BIOL, V71, P141; Giovarelli M, 2000, J IMMUNOL, V164, P3200, DOI 10.4049/jimmunol.164.6.3200; HORUK R, 1994, J BIOL CHEM, V269, P17730; Inoue K, 2000, CLIN CANCER RES, V6, P2104; Kawakami K, 2001, J EXP MED, V194, P1743, DOI 10.1084/jem.194.12.1743; Kim SJ, 2001, NEOPLASIA, V3, P33, DOI 10.1038/sj.neo.7900124; Lentsch AB, 2002, FASEB J, V16, P1093, DOI 10.1096/fj.02-0066hyp; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; NEOTE K, 1994, BLOOD, V84, P44; NEOTE K, 1993, J BIOL CHEM, V268, P12247; Nibbs R, 2003, SEMIN IMMUNOL, V15, P287, DOI 10.1016/j.smim.2003.08.006; PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311; Saji H, 2001, CANCER, V92, P1085, DOI 10.1002/1097-0142(20010901)92:5<1085::AID-CNCR1424>3.0.CO;2-K; Salcedo R, 2000, BLOOD, V96, P34, DOI 10.1182/blood.V96.1.34.013a49_34_40; Schutyser E, 2002, J BIOL CHEM, V277, P24584, DOI 10.1074/jbc.M112275200; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; SZABO MC, 1995, J BIOL CHEM, V270, P25348, DOI 10.1074/jbc.270.43.25348; Tang T, 1998, DNA SEQUENCE, V9, P129, DOI 10.3109/10425179809072188; Tournamille C, 2004, IMMUNOGENETICS, V55, P682, DOI 10.1007/s00251-003-0633-2; TOURNAMILLE C, 1995, NAT GENET, V10, P224, DOI 10.1038/ng0695-224; Urquidi V, 2002, CLIN CANCER RES, V8, P61; Vicari AP, 2002, CYTOKINE GROWTH F R, V13, P143, DOI 10.1016/S1359-6101(01)00033-8	32	105	115	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	54					7201	7211		10.1038/sj.onc.1209703	http://dx.doi.org/10.1038/sj.onc.1209703			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16785997				2022-12-17	WOS:000242046900009
J	Nowell, S; Falany, CN				Nowell, S; Falany, CN			Pharmacogenetics of human cytosolic sulfotransferases	ONCOGENE			English	Review						sulfotransferase; tamoxifen; minoxidil	THERMOSTABLE PHENOL SULFOTRANSFERASE; BREAST-CANCER PATIENTS; HUMAN-PLATELET; SULT1A1 GENE; ORAL DEHYDROEPIANDROSTERONE; SULFATION PHARMACOGENETICS; BIOCHEMICAL-PROPERTIES; POSTMENOPAUSAL WOMEN; PARTIAL-PURIFICATION; HUMAN MEGAKARYOCYTES	Cytosolic sulfotransferases (SULTs) are phase II detoxification enzymes that are involved in the biotransformation of a wide variety of structurally diverse endo- and xenobiotics, including many therapeutic agents and endogenous steroids. Single-nucleotide polymorphisms (SNPs) in SULTs have functional consequences on the translated protein. For the most part, these SNPs are fairly uncommon in the population, but some, most notably for SULT isoform 1A1, are commonly found and have been associated with cancer risk for a variety of tumor sites and also with response to therapeutic agents. SNPs in the hydroxysteroid sulfotransferase, SULT2A1, have been identified in African-American subjects and influence the ratio of plasma DHEA: DHEA-S. This modi. cation could potentially influence cancer risk in steroidogenic tissues. SNPs in many SULTs are ethnically distributed, another factor that could influence SULT pharmacogenetics. Finally, genetic variation has also been identified in 3'-phosphoadenoside 5'-phosphosulfate synthetase (PAPPS), the enzymes responsible for producing the obligatory cosubstrate for all sulfotransferases. Taken together, this variability could substantially influence the disposition of drugs metabolized by SULTs. Elucidation of the basis and effect of variability in sulfation could greatly impact individualized therapy in the future.	Univ Arkansas Med Sci, Coll Publ Hlth, Little Rock, AR 72205 USA; Univ Alabama, Birmingham, AL USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Alabama System; University of Alabama Birmingham	Nowell, S (corresponding author), Univ Arkansas Med Sci, Coll Publ Hlth, 820 Little Rock,4301 W Markham St, Little Rock, AR 72205 USA.	sanowell@uams.edu; cfalany@uab.edu						ANDERSON RJ, 1988, J LAB CLIN MED, V112, P773; [Anonymous], 1985, JAMA, V254, P3461; Arlt W, 1999, J CLIN ENDOCR METAB, V84, P2170, DOI 10.1210/jc.84.6.2170; Besset S, 2000, FASEB J, V14, P345, DOI 10.1096/fasebj.14.2.345; Brittelli A, 1999, EUR J CLIN PHARMACOL, V55, P691, DOI 10.1007/s002280050695; CAMPBELL NRC, 1987, BIOCHEM PHARMACOL, V36, P1435, DOI 10.1016/0006-2952(87)90108-0; CAPPIELLO M, 1989, EUR J CLIN PHARMACOL, V37, P317, DOI 10.1007/BF00679793; Duanmu Z, 2001, DRUG METAB DISPOS, V29, P1130; Falany CN, 1995, ANN NY ACAD SCI, V774, P59, DOI 10.1111/j.1749-6632.1995.tb17372.x; FALANY CN, 1994, J STEROID BIOCHEM, V48, P369, DOI 10.1016/0960-0760(94)90077-9; Falany JL, 1996, CANCER RES, V56, P1551; Falany JL, 1998, CHEM-BIOL INTERACT, V109, P329, DOI 10.1016/S0009-2797(97)00143-9; Fang HL, 2003, DRUG METAB DISPOS, V31, P1378, DOI 10.1124/dmd.31.11.1378; Glatt H, 2000, CHEM-BIOL INTERACT, V129, P141, DOI 10.1016/S0009-2797(00)00202-7; Glatt H, 2004, N-S ARCH PHARMACOL, V369, P55, DOI 10.1007/s00210-003-0826-0; Hashimoto Y, 1992, Tanpakushitsu Kakusan Koso, V37, P1701; Hempel N, 2004, MOL PHARMACOL, V66, P1690, DOI 10.1124/mol.104.003350; Hume R, 1996, HISTOCHEM CELL BIOL, V105, P147, DOI 10.1007/BF01696154; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; Kester MHA, 1999, J CLIN ENDOCR METAB, V84, P1357, DOI 10.1210/jc.84.4.1357; Khetawat G, 2000, BLOOD, V95, P2289, DOI 10.1182/blood.V95.7.2289.007k03_2289_2296; Kotov A, 1999, J STEROID BIOCHEM, V68, P137, DOI 10.1016/S0960-0760(99)00022-9; KUDLACEK PE, 1995, BIOCHEM BIOPH RES CO, V210, P363, DOI 10.1006/bbrc.1995.1670; Li X, 2001, J ENDOCRINOL, V171, P525, DOI 10.1677/joe.0.1710525; Liyou NE, 2003, J HISTOCHEM CYTOCHEM, V51, P1655, DOI 10.1177/002215540305101209; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MARAZZITI D, 1995, CHRONOBIOL INT, V12, P100, DOI 10.3109/07420529509064505; Marazziti D, 1998, NEUROPSYCHOBIOLOGY, V38, P1, DOI 10.1159/000026509; Mariotto A, 2002, CANCER CAUSE CONTROL, V13, P101, DOI 10.1023/A:1014380323037; MORTOLA JF, 1990, J CLIN ENDOCR METAB, V71, P696, DOI 10.1210/jcem-71-3-696; Nagata K, 2000, ANNU REV PHARMACOL, V40, P159, DOI 10.1146/annurev.pharmtox.40.1.159; Ning BT, 2005, PHARMACOGENET GENOM, V15, P465, DOI 10.1097/01.fpc.0000166823.74378.79; Nishiyama T, 2002, BIOCHEM PHARMACOL, V63, P1817, DOI 10.1016/S0006-2952(02)00994-2; Nowell S, 2002, J NATL CANCER I, V94, P1635; Nowell S, 2000, PHARMACOGENETICS, V10, P789, DOI 10.1097/00008571-200012000-00004; Ozawa S, 1998, CHEM-BIOL INTERACT, V109, P237, DOI 10.1016/S0009-2797(97)00135-X; Parker CR, 1999, STEROIDS, V64, P640, DOI 10.1016/S0039-128X(99)00046-X; Raftogianis RB, 1997, BIOCHEM BIOPH RES CO, V239, P298, DOI 10.1006/bbrc.1997.7466; Spink BC, 2000, CARCINOGENESIS, V21, P1947, DOI 10.1093/carcin/21.11.1947; SUNDARAM RS, 1989, CLIN PHARMACOL THER, V46, P501, DOI 10.1038/clpt.1989.178; SUNDARAM RS, 1989, DRUG METAB DISPOS, V17, P255; TARANTINO MD, 1994, ANN NY ACAD SCI, V714, P293, DOI 10.1111/j.1749-6632.1994.tb12059.x; Thomae B. A., 2002, Pharmacogenomics Journal, V2, P48, DOI 10.1038/sj.tpj.6500089; VANLOON J, 1984, BIOCHEM GENET, V22, P997, DOI 10.1007/BF00499627; Visser TJ, 1998, CHEM-BIOL INTERACT, V109, P279, DOI 10.1016/S0009-2797(97)00139-7; Wegman P, 2005, BREAST CANCER RES, V7, pR284, DOI 10.1186/bcr993; WEINSHILBOUM R, 1990, PHARMACOL THERAPEUT, V45, P93, DOI 10.1016/0163-7258(90)90010-Y; WEINSHILBOUM R, 1994, CHEM-BIOL INTERACT, V92, P233, DOI 10.1016/0009-2797(94)90066-3; WILBORN T, 2005, IN PRESS J STEROID B; Xu ZH, 2000, BIOCHEM BIOPH RES CO, V268, P437, DOI 10.1006/bbrc.2000.2123; Xu ZH, 2003, BIOCHEM PHARMACOL, V65, P1787, DOI 10.1016/S0006-2952(03)00104-7; Xu ZH, 2002, PHARMACOGENETICS, V12, P11, DOI 10.1097/00008571-200201000-00003; YOUNG WF, 1985, J NEUROCHEM, V44, P1131, DOI 10.1111/j.1471-4159.1985.tb08734.x; ZOU JY, 1990, J NEUROCHEM, V55, P1154, DOI 10.1111/j.1471-4159.1990.tb03119.x; 1986, CA CANC J CLIN, V36, P42	55	105	110	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	11					1673	1678		10.1038/sj.onc.1209376	http://dx.doi.org/10.1038/sj.onc.1209376			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020JL	16550167				2022-12-17	WOS:000235904700009
J	Bin Fang, W; Brantley-Sieders, DM; Parker, MA; Reith, AD; Chen, J				Bin Fang, W; Brantley-Sieders, DM; Parker, MA; Reith, AD; Chen, J			A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis	ONCOGENE			English	Article						EphA2 receptor tyrosine kinase; ephrin-A1; ligand; kinase activity; tumor malignancy; metastasis	TYROSINE KINASE; CELL-ADHESION; MULTISTAGE CARCINOGENESIS; PANCREATIC ADENOCARCINOMA; MALIGNANT-CELLS; SMALL GTPASES; KIT RECEPTOR; E-CADHERIN; IN-VIVO; PROTEIN	Receptor tyrosine kinases of the Eph family are upregulated in several different types of cancer. One family member in particular, the EphA2 receptor, has been linked to breast, prostate, lung and colon cancer, as well as melanoma. However, mechanisms by which EphA2 contributes to tumor progression are far from clear. In certain tumor cell lines, EphA2 receptor is underphosphorylated, raising the question of whether ligand-induced receptor phosphorylation and its kinase activity play a role in oncogenesis. To test directly the role of EphA2 receptor phosphorylation/kinase activity in tumor progression, we generated EphA2 receptor variants that were either lacking the cytoplasmic domain or carrying a point mutation that inhibits its kinase activity. Expression of these EphA2 mutants in breast cancer cells resulted in decreased tumor volume and increased tumor apoptosis in primary tumors. In addition, the numbers of lung metastases were significantly reduced in both experimental and spontaneous metastasis models. Reduced tumor volume and metastasis are not due to defects in tumor angiogenesis, as there is no significant difference in tumor vessel density between wild-type tumors and tumors expressing EphA2-signaling-defective mutants. In contrast, tumor cells expressing the EphA2 mutants are defective in RhoA GTPase activation and cell migration. Taken together, these results suggest that receptor phosphorylation and kinase activity of the EphA2 receptor, at least in part, contribute to tumor malignancy.	Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Nashville, TN 37232 USA; UCL Branch, Ludwig Inst Canc Res, London, England; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Ludwig Institute for Cancer Research; University of London; University College London; Vanderbilt University; Vanderbilt University	Chen, J (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, A-4323 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	jin.chen@vanderbilt.edu		Chen, Jin/0000-0002-5557-2079	NATIONAL CANCER INSTITUTE [T32CA078136, R01CA095004, R01CA114301] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL074517] Funding Source: NIH RePORTER; NCI NIH HHS [CA114301, CA95004, 2T32 CA78136] Funding Source: Medline; NHLBI NIH HHS [5F32 HL074517] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berclaz G, 1996, BIOCHEM BIOPH RES CO, V226, P869, DOI 10.1006/bbrc.1996.1442; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Birgbauer E, 2000, DEVELOPMENT, V127, P1231; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Brantley-Sieders D, 2004, CURR PHARM DESIGN, V10, P3431, DOI 10.2174/1381612043383160; Brantley-Sieders Dana M., 2004, Angiogenesis, V7, P17, DOI 10.1023/B:AGEN.0000037340.33788.87; Brantley-Sieders DM, 2004, J CELL SCI, V117, P2037, DOI 10.1242/jcs.01061; Carles-Kinch K, 2002, CANCER RES, V62, P2840; Cheng N, 2002, MOL CANCER RES, V1, P2; Cheng N, 2003, NEOPLASIA, V5, P445, DOI 10.1016/S1476-5586(03)80047-7; Coffman KT, 2003, CANCER RES, V63, P7907; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; Davy A, 2000, EMBO J, V19, P5396, DOI 10.1093/emboj/19.20.5396; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; Dobrzanski P, 2004, CANCER RES, V64, P910, DOI 10.1158/0008-5472.CAN-3430-2; Duxbury MS, 2004, BIOCHEM BIOPH RES CO, V320, P1096, DOI 10.1016/j.bbrc.2004.06.054; Duxbury MS, 2004, ONCOGENE, V23, P1448, DOI 10.1038/sj.onc.1207247; Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Grunwald IC, 2001, NEURON, V32, P1027, DOI 10.1016/S0896-6273(01)00550-5; Gu C, 2001, MOL CELL BIOL, V21, P4579, DOI 10.1128/MCB.21.14.4579-4597.2001; Gurniak CB, 1996, ONCOGENE, V13, P777; Holder N, 1999, DEVELOPMENT, V126, P2033; Huai JS, 2001, J BIOL CHEM, V276, P6689, DOI 10.1074/jbc.M008127200; Ireton RC, 2005, CURR CANCER DRUG TAR, V5, P149, DOI 10.2174/1568009053765780; Kinch MS, 2003, CLIN CANCER RES, V9, P613; Koolpe M, 2002, J BIOL CHEM, V277, P46974, DOI 10.1074/jbc.M208495200; Kullander K, 2001, NEURON, V29, P73, DOI 10.1016/S0896-6273(01)00181-7; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lozano E, 2003, BIOESSAYS, V25, P452, DOI 10.1002/bies.10262; Madhusudan S, 2004, CLIN BIOCHEM, V37, P618, DOI 10.1016/j.clinbiochem.2004.05.006; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; Manning G, 2002, TRENDS BIOCHEM SCI, V27, P514, DOI 10.1016/S0968-0004(02)02179-5; Miao H, 2005, J BIOL CHEM, V280, P923, DOI 10.1074/jbc.M411383200; Miyazaki T, 2003, INT J CANCER, V103, P657, DOI 10.1002/ijc.10860; Munarini N, 2002, J CELL SCI, V115, P25; Nakamoto M, 2002, MICROSC RES TECHNIQ, V59, P58, DOI 10.1002/jemt.10177; Noren NK, 2004, CELL SIGNAL, V16, P655, DOI 10.1016/j.cellsig.2003.10.006; Noren NK, 2004, P NATL ACAD SCI USA, V101, P5583, DOI 10.1073/pnas.0401381101; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; REITH AD, 1993, ONCOGENE, V8, P45; Ridley AJ, 2001, J CELL SCI, V114, P2713; Saito T, 2004, ONCOL REP, V11, P605; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; Walker-Daniels J, 2003, AM J PATHOL, V162, P1037, DOI 10.1016/S0002-9440(10)63899-0; Walker-Daniels J, 2002, MOL CANCER RES, V1, P79; Wicki A, 2001, INT J CANCER, V91, P763, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1128>3.0.CO;2-B; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zelinski DP, 2001, CANCER RES, V61, P2301; Zisch AH, 1997, CELL TISSUE RES, V290, P217, DOI 10.1007/s004410050926	54	105	118	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 24	2005	24	53					7859	7868		10.1038/sj.onc.1208937	http://dx.doi.org/10.1038/sj.onc.1208937			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16103880				2022-12-17	WOS:000233463000005
J	Duquette, ML; Pham, P; Goodman, MF; Maizels, N				Duquette, ML; Pham, P; Goodman, MF; Maizels, N			AID binds to transcription-induced structures in c-MYC that map to regions associated with translocation and hypermutation	ONCOGENE			English	Article						AID; hypermutation; translocation; Burkitt's lymphoma	INDUCED CYTIDINE DEAMINASE; CLASS-SWITCH RECOMBINATION; SINGLE-STRANDED-DNA; ABERRANT SOMATIC HYPERMUTATION; CENTER B-CELLS; B29 IG-BETA; CHROMOSOMAL TRANSLOCATIONS; MULTIPLE-MYELOMA; BURKITTS-LYMPHOMA; NEOPLASTIC DEVELOPMENT	Translocation and aberrant hypermutation of c-MYC are common in B-cell lymphomas. Activation-induced Cytidine Deaminase (AID) initiates switch recombination and somatic hypermutation in B cells by targeted deamination of transcribed genes. We show that transcription of the immunoglobulin S regions and c-MYC results in formation of similar DNA structures, 'G-loops', which contain a cotranscriptional RNA: DNA hybrid on the C-rich strand and single-stranded regions and G4 DNA on the G-rich strand. AID binds specifically to G-loops within transcribed S regions and c-MYC, and G-loops in c-MYC map to the regions associated with translocation breakpoints and aberrant hypermutation in B-cell lymphomas. Aberrant targeting of AID to DNA structures formed upon c-MYC transcription may therefore contribute to the genetic instability of c-MYC in B-cell malignancies.	Univ Washington, Dept Immunol, Sch Med, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Sch Med, Seattle, WA 98195 USA; Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA; Univ So Calif, Dept Chem, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Southern California; University of Southern California	Maizels, N (corresponding author), Univ Washington, Dept Immunol, Sch Med, Room H474A,1959 NE Pacific St, Seattle, WA 98195 USA.	maizels@u.washington.edu	Duquette, Michelle/B-6899-2009; yang, xiao-jun/B-1927-2009		NIEHS NIH HHS [R01 ES13192] Funding Source: Medline; NIGMS NIH HHS [R01 GM065988, R37 GM21422, R01 GM39799, R01 GM65988, R01 GM039799, R01 GM041712] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES013192] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065988, R01GM041712, R37GM021422, R01GM039799] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akasaka H, 2000, CANCER RES, V60, P2335; APEL TW, 1992, ONCOGENE, V7, P1267; Avet-Loiseau H, 2001, BLOOD, V98, P3082, DOI 10.1182/blood.V98.10.3082; Beale RCL, 2004, J MOL BIOL, V337, P585, DOI 10.1016/j.jmb.2004.01.046; Bemark M, 2000, ONCOGENE, V19, P3404, DOI 10.1038/sj.onc.1203686; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Chaudhuri J, 2004, NAT REV IMMUNOL, V4, P541, DOI 10.1038/nri1395; CHOW LT, 1989, METHOD ENZYMOL, V180, P239; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Conticello SG, 2005, MOL BIOL EVOL, V22, P367, DOI 10.1093/molbev/msi026; Duquette ML, 2004, GENE DEV, V18, P1618, DOI 10.1101/gad.1200804; Durandy A, 2003, EUR J IMMUNOL, V33, P2069, DOI 10.1002/eji.200324133; Fenton JAL, 2002, BLOOD, V99, P716, DOI 10.1182/blood.V99.2.716; Gaidano G, 2003, BLOOD, V102, P1833, DOI 10.1182/blood-2002-11-3606; Gordon MS, 2000, P NATL ACAD SCI USA, V97, P5504, DOI 10.1073/pnas.090087097; Gordon MS, 2003, P NATL ACAD SCI USA, V100, P4126, DOI 10.1073/pnas.0735266100; Greeve J, 2003, BLOOD, V101, P3574, DOI 10.1182/blood-2002-08-2424; Hanakahi LA, 1999, J BIOL CHEM, V274, P15908, DOI 10.1074/jbc.274.22.15908; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; Larson ED, 2005, CURR BIOL, V15, P470, DOI 10.1016/j.cub.2004.12.077; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; MAIZELS N, 2004, MOL BIOL B CELLS, P327; Michel B, 2004, P NATL ACAD SCI USA, V101, P12783, DOI 10.1073/pnas.0401586101; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Montesinos-Rongen M, 2004, BLOOD, V103, P1869, DOI 10.1182/blood-2003-05-1465; MULLER JR, 1995, CANCER RES, V55, P5012; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Muschen M, 2000, CANCER RES, V60, P5640; Muschen M, 2000, J EXP MED, V192, P1833, DOI 10.1084/jem.192.12.1833; Muto T, 2000, GENOMICS, V68, P85, DOI 10.1006/geno.2000.6268; NERI A, 1988, P NATL ACAD SCI USA, V85, P2748, DOI 10.1073/pnas.85.8.2748; Neuberger MS, 2003, TRENDS BIOCHEM SCI, V28, P305, DOI 10.1016/S0968-0004(03)00111-7; Pasqualucci L, 2004, BLOOD, V104, P3318, DOI 10.1182/blood-2004-04-1558; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Pham P, 2003, NATURE, V424, P103, DOI 10.1038/nature01760; Potter M, 2003, IMMUNOL REV, V194, P177, DOI 10.1034/j.1600-065X.2003.00061.x; POTTER M, 1992, CARCINOGENESIS, V13, P1681, DOI 10.1093/carcin/13.10.1681; Preudhomme C, 2000, ONCOGENE, V19, P2023, DOI 10.1038/sj.onc.1203521; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Raffeld M, 1995, Curr Top Microbiol Immunol, V194, P265; Ramiro AR, 2005, NAT IMMUNOL, V6, P117, DOI 10.1038/ni0205-117; Ramiro AR, 2004, CELL, V118, P431, DOI 10.1016/j.cell.2004.08.006; Ramiro AR, 2003, NAT IMMUNOL, V4, P452, DOI 10.1038/ni920; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Roix JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177; Senthilkumar K, 2003, J AM CHEM SOC, V125, P13658, DOI 10.1021/ja037027d; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; SMELAND EB, 1988, EUR J IMMUNOL, V18, P1847, DOI 10.1002/eji.1830181131; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; Unniraman S, 2004, NAT IMMUNOL, V5, P1117, DOI 10.1038/ni1127	61	105	107	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5791	5798		10.1038/sj.onc.1208746	http://dx.doi.org/10.1038/sj.onc.1208746			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15940261	Bronze			2022-12-17	WOS:000231590400001
J	Lung, HL; Bangarusamy, DK; Xie, D; Cheung, AKL; Cheng, Y; Kumaran, MK; Miller, L; Liu, ETB; Guan, XY; Sham, JS; Fang, Y; Li, LQ; Wang, N; Protopopov, AI; Zabarovsky, ER; Tsao, SW; Stanbridge, EJ; Lung, ML				Lung, HL; Bangarusamy, DK; Xie, D; Cheung, AKL; Cheng, Y; Kumaran, MK; Miller, L; Liu, ETB; Guan, XY; Sham, JS; Fang, Y; Li, LQ; Wang, N; Protopopov, AI; Zabarovsky, ER; Tsao, SW; Stanbridge, EJ; Lung, ML			THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma	ONCOGENE			English	Article						chromosome 11; THY1; nasopharyngeal carcinoma; microcell hybrid; oligo-microarray	HUMAN OVARIAN-CANCER; CELL-LINE; REGION; ADHESION	Using oligonucleotide microarray analysis, THY1, mapping close to a previously defined 11q22-23 nasopharyngeal carcinoma (NPC) critical region was identified as showing consistent downregulated expression in the tumour segregants, as compared to their parental tumour-suppressing microcell hybrids (MCHs). Gene expression and protein analyses show that THY1 was not expressed in the NPC HONE1 recipient cells, tumour segregants, and other NPC cell lines; THY1 was exclusively expressed in the non-tumourigenic MCHs. The mechanism of THY1 gene inactivation in these cell lines was attributed to hypermethylation. Clinical study showed that in 65% of NPC specimens there was either downregulation or loss of THY1 gene expression. Using a tissue microarray and immunohistochemical staining, 44% of the NPC cases showed downregulated expression of THY1 and 9% lost THY1 expression. The frequency of THY1 downregulated expression in lymph node metastatic NPC was 63%, which was significantly higher than in the primary tumour (33%). After transfection of THY1 gene into HONE1 cells, a dramatic reduction of colony formation ability was observed. These findings suggest that THY1 is a good candidate tumour suppressor gene in NPC, which is significantly associated with lymph node metastases.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China; Genome Inst Singapore, Inst Biomed Sci, Singapore, Singapore; Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; Sun Yat Sen Univ, Inst Canc, Guangzhou, Peoples R China; Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Karolinska Inst, Ctr Genom & Bioinformat, Ctr Microbiol & Tumor Biol, Stockholm, Sweden; Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	Hong Kong University of Science & Technology; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); University of Hong Kong; Sun Yat Sen University; University of Rochester; Karolinska Institutet; University of Hong Kong; University of California System; University of California Irvine	Lung, ML (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China.	bomaria@ust.hk	Miller, Lance/A-5633-2009; Cheung, Arthur Kwok Leung/H-8940-2013; Cheng, Yue/E-9853-2010; Lung, Hong Lok/C-4494-2009; Zabarovsky, Eugene R/A-6645-2010; Guan, Xin-Yuan/A-3639-2009; Lung, Maria Li/C-4495-2009	Cheng, Yue/0000-0002-2472-1879; Guan, Xin-Yuan/0000-0002-4485-6017; Miller, Lance/0000-0003-3799-2528; Lung, Maria Li/0000-0003-2559-3626				Abeysinghe HR, 2004, CANCER GENET CYTOGEN, V149, P1, DOI 10.1016/S0165-4608(03)00234-6; Abeysinghe HR, 2003, CANCER GENET CYTOGEN, V143, P125, DOI 10.1016/S0165-4608(02)00855-5; Barda-Saad M, 1999, EXP HEMATOL, V27, P834, DOI 10.1016/S0301-472X(99)00010-7; Barker TH, 2004, EXP CELL RES, V295, P488, DOI 10.1016/j.yexcr.2004.01.026; BONEWALD L, 1984, J IMMUNOGENET, V11, P283; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Chan KT, 2004, CANCER CHEMOTH PHARM, V53, P519, DOI 10.1007/s00280-004-0767-4; Cheng Y, 2002, GENE CHROMOSOME CANC, V34, P97, DOI 10.1002/gcc.10048; Cheng Y, 2000, GENE CHROMOSOME CANC, V28, P82, DOI 10.1002/(SICI)1098-2264(200005)28:1<82::AID-GCC10>3.0.CO;2-8; CRAWFORD JM, 1986, LAB INVEST, V54, P122; Diaz-Romero J, 2005, J CELL PHYSIOL, V202, P731, DOI 10.1002/jcp.20164; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r66; Lung HL, 2004, INT J CANCER, V112, P628, DOI 10.1002/ijc.20454; Protopopov AI, 2002, J GENE MED, V4, P397, DOI 10.1002/jgm.283; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Robertson G P, 1999, Mol Cell Biol Res Commun, V2, P1, DOI 10.1006/mcbr.1999.0141; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Xie D, 2003, INT J CANCER, V107, P896, DOI 10.1002/ijc.11514	20	105	118	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6525	6532		10.1038/sj.onc.1208812	http://dx.doi.org/10.1038/sj.onc.1208812			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007174				2022-12-17	WOS:000232204100006
J	Zhu, HB; Zhang, LD; Dong, FQ; Guo, W; Wu, SH; Teraishi, F; Davis, JJ; Chiao, P; Fang, BL				Zhu, HB; Zhang, LD; Dong, FQ; Guo, W; Wu, SH; Teraishi, F; Davis, JJ; Chiao, P; Fang, BL			Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors	ONCOGENE			English	Article						proteasome inhibitor; apoptosis; Bik; PS341; bortezomib	NF-KAPPA-B; CYTOCHROME-C; PROTEIN; RELEASE; PATHWAY; PROTEOLYSIS; ACTIVATION; SURVIVAL; DEATH; BIK	Proteasome inhibitors have emerged as promising anticancer therapeutic agents. Bortezomib (PS-341), a specific proteasome inhibitor, exhibits antitumor activity against a wide range of malignancies and has been approved by the US Food and Drug Administration for the treatment of relapsed or refractory multiple myeloma. However, the molecular mechanisms of bortezomib-mediated apoptosis remain unclear. To characterize the mechanisms of apoptosis induction by proteasome inhibitors, we examined levels of Bcl-2 protein family members (Bik/NBK, Bax, Bak, Bcl-2, and Bcl-XL), release of cytochrome c, and activation of caspase-9 and -3 in human colon cancer cell lines DLD1, LOVO, SW620, and HCT116; human lung cancer cell line H1299; and human ovarian cancer cell line SKOV3 after they were treated with bortezomib. The result showed that bortezomib induced rapid accumulation of Bik/NBK but not other Bcl-2 family members in all six cell lines. Bortezomib-mediated Bik/NBK accumulation and apoptosis were also observed in human embryonic kidney cells 293 and normal human bronchial epithelial cells. Moreover, dramatic Bik/NBK accumulation and apoptosis induction were observed when cells were treated with proteasome inhibitor MG132 and calpain inhibitor I (ALLN). Furthermore, no detectable changes in I kappa B alpha levels or in NF kappa B functionality were found after treatment with bortezomib. Finally, Bik/NBK accumulation was caused by stabilization of the protein from degradation and was associated with bortezomib cytotoxicity and apoptosis induction. Pretreatment of DLD1 cells with Bik/NBK siRNA reduced bortezomib-mediated Bik/NBK accumulation and cell death. Our results suggested that Bik/NBK is one of the mediators of proteasome inhibitor-induced apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Unit 445, Houston, TX 77030 USA; Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Surg Oncol, Hangzhou, Peoples R China; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Program Gene Therapy & Virol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Zhejiang University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Fang, BL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Unit 445, 1515 Holcombe Blvd, Houston, TX 77030 USA.	Bfang@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA098582, P30CA016672, R01CA092487] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 092487-01A1, R01 CA092487, CA-16672, R01 CA 098582-01A1, R01 CA098582] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2002, ONCOLOGIST, V7, P9, DOI 10.1634/theoncologist.7-1-9; Adams J, 2002, CURR OPIN ONCOL, V14, P628, DOI 10.1097/00001622-200211000-00007; BOYD JM, 1995, ONCOGENE, V11, P1921; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Hur JY, 2004, P NATL ACAD SCI USA, V101, P2351, DOI 10.1073/pnas.0307337101; Kagawa S, 2001, CANCER RES, V61, P3330; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Lara PN, 2004, SEMIN ONCOL, V31, P40, DOI 10.1053/j.seminoncol.2003.12.013; Lenz HJ, 2003, CANCER TREAT REV, V29, P41, DOI 10.1016/S0305-7372(03)00082-3; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pei XY, 2003, LEUKEMIA, V17, P2036, DOI 10.1038/sj.leu.2403109; Schmidt C, 2003, MOL CELL, V12, P1287, DOI 10.1016/S1097-2765(03)00390-3; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Wu SH, 2004, CANCER RES, V64, P1110, DOI 10.1158/0008-5472.CAN-03-2790; Yu J, 2003, CANCER BIOL THER, V2, P694	21	105	110	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4993	4999		10.1038/sj.onc.1208683	http://dx.doi.org/10.1038/sj.onc.1208683			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15824729	Green Accepted			2022-12-17	WOS:000230646500012
J	Afaq, F; Ahmad, N; Mukhtar, H				Afaq, F; Ahmad, N; Mukhtar, H			Suppression of UVB-induced phosphorylation of mitogen-activated protein kinases and nuclear factor kappa B by green tea polyphenol in SKH-1 hairless mice	ONCOGENE			English	Article						photochemopreventive; UVB; GTP; MAPKs; NF-kappa B; SKH-1	HUMAN EPIDERMAL-KERATINOCYTES; C-JUN; GROWTH-FACTOR; MOUSE SKIN; GENE-EXPRESSION; (-)-EPIGALLOCATECHIN-3-GALLATE TREATMENT; SIGNAL-TRANSDUCTION; MEDIATED ACTIVATION; DENDRITIC CELLS; MAP KINASES	Studies from our laboratory have shown that epigallocatechin-3-gallate, the major polyphenol present in green tea, inhib its ultraviolet (UV)B-exposure-mediated phosphorylation of mitogen-activated protein kinases (MAPKs) (Toxicol. Appl. Pharmacol. 176: 110-117, 2001) and activation of nuclear factor kappa B (NF-kappaB) (Oncogene 22: 1035-1044,2003) pathways in normal human epidermal keratinocytes. This study was designed to investigate the relevance of these findings to the in vivo situations in SKH-1 hairless mouse model, which is regarded to have relevance to human situations. SKH-1 hairless mice were topically treated with GTP (5 mg/0.2 ml acetone/mouse) and were exposed to UVB 30 min later (180 mJ/cm(2)). These treatments were repeated every alternate day for 2 weeks, for a total of seven treatments. The animals were killed 24 h after the last UVB exposure. Topical application of GTP resulted in significant decrease in UVB-induced bifold-skin thickness, skin edema and infiltration of leukocytes. Employing Western blot analysis and immunohistochemical studies, we found that GTP resulted in inhibition of UVB-induced: (i) phosphorylation of extracellular-signal-regulated kinases (ERK1/2),(ii) c-Jun N-terminal kinases, and (iii) p38 protein expression. Since NF-kappaB plays a major role in inflammation and cell proliferation, we assessed the effect of GTP on UVB-mediated modulations in the NF-kappaB pathway. Our data demonstrated that GTP inhibited UVB-induced: (i) activation of NF-kappaB,(ii) activation of IKKalpha, and (iii) phosphorylation and degradation of IkappaBalpha. Our data suggest that GTP protects against the adverse effects of UV radiation via modulations in MAPK and NF-kappaB signaling pathways, and provides molecular basis for the photochemopreventive effect of GTP in an in vivo animal model system.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Mukhtar, H (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, B25,1300 Univ Ave, Madison, WI 53706 USA.	hmukhtar@wisc.edu	Ahmad, Nihal/AAR-4249-2021	Ahmad, Nihal/0000-0002-4239-9887				Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; Afaq F, 2003, ONCOGENE, V22, P1035, DOI 10.1038/sj.onc.1206206; Afaq F, 2003, TOXICOL APPL PHARM, V186, P28, DOI 10.1016/S0041-008X(02)00014-5; Afaq F, 2002, SKIN PHARMACOL APPL, V15, P297, DOI 10.1159/000064533; Afaq F, 2002, FRONT BIOSCI-LANDMRK, V7, pD784, DOI 10.2741/afaq; AGARWAL R, 1992, CANCER RES, V52, P3582; Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Bachelor MA, 2002, ONCOGENE, V21, P7092, DOI 10.1038/sj.onc.1205855; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Balasubramanian S, 1999, ONCOGENE, V18, P1297, DOI 10.1038/sj.onc.1202417; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Chen WX, 1998, J BIOL CHEM, V273, P32176, DOI 10.1074/jbc.273.48.32176; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; Chen YC, 2002, J CELL BIOCHEM, V86, P331, DOI 10.1002/jcb.10230; Chouinard N, 2002, BIOCHEM J, V365, P133, DOI 10.1042/BJ20020072; Clydesdale GJ, 2001, IMMUNOL CELL BIOL, V79, P547, DOI 10.1046/j.1440-1711.2001.01047.x; de Gruijl FR, 2002, SKIN PHARMACOL APPL, V15, P316, DOI 10.1159/000064535; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dhar A, 2002, MOL CELL BIOCHEM, V234, P185, DOI 10.1023/A:1015948505117; Dubois B, 2001, CELL IMMUNOL, V214, P173, DOI 10.1006/cimm.2001.1898; Elmets CA, 2001, J AM ACAD DERMATOL, V44, P425, DOI 10.1067/mjd.2001.112919; F'guyer S, 2003, PHOTODERMATOL PHOTO, V19, P56, DOI 10.1034/j.1600-0781.2003.00019.x; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; GENSLER HL, 1992, CARCINOGENESIS, V13, P9, DOI 10.1093/carcin/13.1.9; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hildesheim J, 2002, CANCER RES, V62, P7305; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Iordanov MS, 2002, MOL CELL BIOL, V22, P5380, DOI 10.1128/MCB.22.15.5380-5394.2002; Jemal A, 2000, JNCI-J NATL CANCER I, V92, P811, DOI 10.1093/jnci/92.10.811; Kang S, 2003, J INVEST DERMATOL, V120, P835, DOI 10.1046/j.1523-1747.2003.12122.x; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Katiyar SK, 2000, CLIN CANCER RES, V6, P3864; Katiyar SK, 2001, TOXICOL APPL PHARM, V176, P110, DOI 10.1006/taap.2001.9276; Katiyar SK, 2001, CARCINOGENESIS, V22, P287, DOI 10.1093/carcin/22.2.287; KATIYAR SK, 1995, PHOTOCHEM PHOTOBIOL, V62, P855; Katiyar SK, 2001, J LEUKOCYTE BIOL, V69, P719; Katiyar SK, 1997, JNCI-J NATL CANCER I, V89, P556, DOI 10.1093/jnci/89.8.556; KATIYAR SK, 1992, CANCER RES, V52, P6890; Kaufman CK, 2000, J CELL BIOL, V149, P999, DOI 10.1083/jcb.149.5.999; Kim J, 2001, SKIN PHARMACOL APPL, V14, P11, DOI 10.1159/000056329; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LEARN DB, 1993, PHOTODERMATOL PHOTO, V9, P147; Lefort K, 2001, ONCOGENE, V20, P7375, DOI 10.1038/sj.onc.1204923; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; Mittal A, 2003, CARCINOGENESIS, V24, P1379, DOI 10.1093/carcin/bgg095; Mukhtar H, 1996, PHOTOCHEM PHOTOBIOL, V63, P355, DOI 10.1111/j.1751-1097.1996.tb03040.x; Nghiem DX, 2002, J INVEST DERMATOL, V119, P600, DOI 10.1046/j.1523-1747.2002.01845.x; Nomura M, 2001, J BIOL CHEM, V276, P46624, DOI 10.1074/jbc.M107897200; Potapova O, 2001, J BIOL CHEM, V276, P28546, DOI 10.1074/jbc.M102075200; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; She QB, 2002, J BIOL CHEM, V277, P24039, DOI 10.1074/jbc.M109907200; Stahl W, 2002, SKIN PHARMACOL APPL, V15, P291, DOI 10.1159/000064532; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Vink AA, 1997, P NATL ACAD SCI USA, V94, P5255, DOI 10.1073/pnas.94.10.5255; WANG ZY, 1991, CARCINOGENESIS, V12, P1527, DOI 10.1093/carcin/12.8.1527; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamazaki S, 2001, J BIOL CHEM, V276, P27657, DOI 10.1074/jbc.M103426200; Yang TY, 2002, IEEE T ADV PACKAGING, V25, P54, DOI 10.1109/TADVP.2002.1017686; Zhu WH, 2002, AM J PATHOL, V161, P823, DOI 10.1016/S0002-9440(10)64242-3	72	105	107	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2003	22	58					9254	9264		10.1038/sj.onc.1207035	http://dx.doi.org/10.1038/sj.onc.1207035			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681684				2022-12-17	WOS:000187400400007
J	Aglipay, JA; Lee, SW; Okada, S; Fujiuchi, N; Ohtsuka, T; Kwak, JC; Wang, Y; Johnstone, RW; Deng, CX; Qin, J; Ouchi, T				Aglipay, JA; Lee, SW; Okada, S; Fujiuchi, N; Ohtsuka, T; Kwak, JC; Wang, Y; Johnstone, RW; Deng, CX; Qin, J; Ouchi, T			A member of the Pyrin family, IFI16, is a novel BRCA1-associated protein involved in the p53-mediated apoptosis pathway	ONCOGENE			English	Article						BRCA1; IFI16; p53; apoptosis	CELL-CYCLE; BRCA1; PHOSPHORYLATION; CANCER; TRANSCRIPTION; BREAST; DOMAIN; P53; CHECKPOINT; MUTATION	We identified IFI16 as a BRCA1-associated protein involved in p53-mediated apoptosis. IFI16 contains the Pyrin/PAAD/DAPIN domain, commonly found in cell death-associated proteins. BRCA1 (aa 502-802) interacted with the IFI16 Pyrin domain (aa 1-130). We found that IFI16 was localized in the nucleoplasm and nucleoli. Clear nucleolar IFI16 localization was not observed in HCC1937 BRCA1 mutant cells, but reintroduction of wild-type BRCA1 restored IFI16 nuclear relocalization following IR (ionizing radiation). Coexpression of IFI16 and BRCA1 enhanced DNA damage-induced apoptosis in mouse embryonic fibroblasts from BRCA1 mutant mice expressing wild-type p53, although mutant IFI16 deficient in binding to BRCA1 did not induce apoptosis. Furthermore, tetracycline-induced IFI16 collaborated in inducing apoptosis when adenovirus p53 was expressed in DNA-damaged p53-deficient EJ cells. These results indicate a BRCA1-IFI16 role in p53-mediated transmission of DNA damage signals and apoptosis.	NYU, Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Beth Israel Deaconess Med Ctr, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic, Australia; NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD USA	Icahn School of Medicine at Mount Sinai; New York University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Baylor College of Medicine; Baylor College of Medicine; Peter Maccallum Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Ouchi, T (corresponding author), NYU, Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.	Toru.Ouchi@mssm.edu	deng, chuxia/N-6713-2016; Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237	NCI NIH HHS [CA80058, CA84199, CA78356, CA90631, CA79892] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084199, R01CA090631, R01CA079892, R01CA078356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; Aravind L, 2001, SCIENCE, V291, P1279, DOI 10.1126/science.291.5507.1279; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; Fairbrother WJ, 2001, PROTEIN SCI, V10, P1911, DOI 10.1110/ps.13801; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Johnstone RW, 1998, J BIOL CHEM, V273, P17172, DOI 10.1074/jbc.273.27.17172; Johnstone RW, 2000, ONCOGENE, V19, P6033, DOI 10.1038/sj.onc.1204005; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; KAELIN WG, 1994, CELL, V644, P521; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Lee SW, 2000, P NATL ACAD SCI USA, V97, P8302, DOI 10.1073/pnas.150024397; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876; Okada S, 2003, J BIOL CHEM, V278, P2015, DOI 10.1074/jbc.M208685200; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pawlowski K, 2001, TRENDS BIOCHEM SCI, V26, P85, DOI 10.1016/S0968-0004(00)01729-1; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Staub E, 2001, TRENDS BIOCHEM SCI, V26, P83, DOI 10.1016/S0968-0004(00)01717-5; Tomlinson GE, 1998, CANCER RES, V58, P3237; TRAPANI JA, 1992, IMMUNOGENETICS, V36, P369; Wang Y, 2000, GENE DEV, V14, P927; Xu B, 2002, CANCER RES, V62, P4588; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7	35	105	111	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8931	8938		10.1038/sj.onc.1207057	http://dx.doi.org/10.1038/sj.onc.1207057			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654789				2022-12-17	WOS:000186982200014
J	Yang, G; Thompson, JA; Fang, BL; Liu, JS				Yang, G; Thompson, JA; Fang, BL; Liu, JS			Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer	ONCOGENE			English	Article						siRNA; H-ras; retrovirus; ovarian cancer	SMALL INTERFERING RNA; MAMMALIAN-CELLS; EPITHELIAL TUMORS; STABLE SUPPRESSION; HAIRPIN RNAS; MUTATIONS; ACTIVATION; PROTOONCOGENE; CARCINOMAS; ONCOGENES	To examine the role of H-ras in the development of human ovarian cancer, we used small inhibitory RNA (siRNA) to silence its expression in human ovarian cancer cell lines and assessed the effects of its silencing on proliferation, apoptosis, and tumorgrowth. First, we developed a retrovirus-based delivery system that allowed long-term stable expression of the desired siRNA. Retrovirus-mediated expression of siRNA against green fluorescence protein (GFP) reduced its expression more than 90% in four cancer cell lines. We then constructed three retroviruses that expressed siRNAs targeting the H-rasV(12) mutation (H1/siRNA) or either of two wild-type sequences of the H-ras gene (H2/siRNA and H3/siRNA) and used these retroviruses to infect T80H and SKOV-3 cells. In T80H cells (a genetically transformed human ovarian surface epithelial cell tine whose tumorigenicity depends on H-rasV(12) expression), infection with the H1/siRNA and H2/siRNA, but not with H3/siRNA, decreased T80H proliferation, increased G(0)/G(1) arrest and apoptosis, blocked transformation in vitro, and suppressed tumor growth in nude mice. In SKOV-3 cells (a human ovarian cancer cell line that contains high levels of wild-type H-ras protein but no H-rasV(12) mutation), introduction of the H2/siRNA construct, but not H1/siRNA or H3/siRNA, produced similar effects, demonstrating that the suppression of tumorgrowth by siRNA was sequence-specific. We conclude that H-ras is involved in maintenance of tumorgrowth of human ovarian cancer, and that retrovirus-mediated siRNA expression against H-Pas expression is a powerful toot to dissect ras-signaling pathways and may be used therapeutically against ovarian cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Liu, JS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Box 85,1515 Holcombe Blvd, Houston, TX 77030 USA.							ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Barton GM, 2002, P NATL ACAD SCI USA, V99, P14943, DOI 10.1073/pnas.242594499; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Cuatrecasas M, 1998, CANCER-AM CANCER SOC, V82, P1088; Cuatrecasas M, 1997, CANCER, V79, P1581, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1581::AID-CNCR21>3.0.CO;2-T; Devroe Eric, 2002, BMC Biotechnol, V2, P15, DOI 10.1186/1472-6750-2-15; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ENOMOTO T, 1991, AM J PATHOL, V139, P777; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; ICHIKAWA Y, 1994, CANCER RES, V54, P33; JACQUE JM, 2002, NATURE, V26, P26; LIU J, 2003, UNPUB; Liu JS, 2000, ONCOGENE, V19, P2767, DOI 10.1038/sj.onc.1203599; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; MOK SCH, 1993, CANCER RES, V53, P1489; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Patton SE, 1998, CANCER RES, V58, P2253; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TENERIELLO MG, 1993, CANCER RES, V53, P3103; Varras MN, 1999, ONCOLOGY-BASEL, V56, P89, DOI 10.1159/000011946; VISVANATHAN KV, 1988, ONCOGENE RES, V3, P77; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	34	105	128	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5694	5701		10.1038/sj.onc.1206858	http://dx.doi.org/10.1038/sj.onc.1206858			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944918				2022-12-17	WOS:000184865900019
J	Hinata, K; Gervin, AM; Zhang, YJ; Khavari, PA				Hinata, K; Gervin, AM; Zhang, YJ; Khavari, PA			Divergent gene regulation and growth effects by NF-kappa B in epithelial and mesenchymal cells of human skin	ONCOGENE			English	Article						NF-kappa B; skin; gene expression profiling; GIF; p21(CIP1)	NECROSIS-FACTOR-ALPHA; IKK-ALPHA; INCONTINENTIA PIGMENTI; TRANSCRIPTION FACTORS; MICE LACKING; CYCLIN D1; EPIDERMIS; DISEASE; PROTEIN; PROLIFERATION	NF-kappaB regulates normal and pathological processes, including neoplasia, in a tissue-context-dependent manner. In skin, NF-kappaB is implicated in epidermal homeostasis as well as in the pathogenesis of squamous cell carcinoma; however, its function in the underlying mesenchymal dermis has been unclear. To gain insight into NF-kappaB roles in these two adjacent cutaneous tissue compartments, NF-kappaB effects on expression of 12 435 genes were determined in epidermal keratinocytes and dermal fibroblasts. Although NF-kappaB induced proinflammatory and antiapoptotic genes in both settings, it exhibited divergent effects on growth regulatory genes. In keratinocytes, but not in fibroblasts, NF-kappaB induced p21(CIP1), which was sufficient to inhibit growth of both cell types. Levels of growth inhibitory factor (GIF), in contrast, were increased by NF-kappaB in both settings but inhibited growth only in keratinocytes. These findings indicate that transcription factors such as NF-kappaB can program tissue-selective effects via both differential target gene induction as well as by inducing common targets that exert differing effects depending on cellular lineage.	Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA	Stanford University	Khavari, PA (corresponding author), Stanford Univ, Sch Med, Program Epithelial Biol, 269 Campus Dr,Room 2145, Stanford, CA 94305 USA.		Zhang, Junyi/HDN-7815-2022	Zhang, Jennifer Y./0000-0002-4485-1750				Abeyama K, 2000, J CLIN INVEST, V105, P1751, DOI 10.1172/JCI9745; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; Choate KA, 1996, NAT MED, V2, P1263, DOI 10.1038/nm1196-1263; Deng H, 1997, NAT BIOTECHNOL, V15, P1388, DOI 10.1038/nbt1297-1388; ERICKSON JC, 1994, BRAIN RES, V649, P297, DOI 10.1016/0006-8993(94)91076-6; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Govind S, 1999, ONCOGENE, V18, P6875, DOI 10.1038/sj.onc.1203223; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HARPER JW, 1993, CELL, V75, P805; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kaufman CK, 2000, J CELL BIOL, V149, P999, DOI 10.1083/jcb.149.5.999; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kouba DJ, 2001, J BIOL CHEM, V276, P6214, DOI 10.1074/jbc.M004511200; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Pomerantz JL, 2000, NATURE, V406, P26, DOI 10.1038/35017673; Qin JZ, 1999, J BIOL CHEM, V274, P37957, DOI 10.1074/jbc.274.53.37957; SCHAFER BW, 1990, NATURE, V344, P454, DOI 10.1038/344454a0; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; Seitz CS, 2000, CANCER RES, V60, P4085; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Seitz CS, 2000, J CLIN INVEST, V105, P253, DOI 10.1172/JCI7630; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; van Hogerlinden M, 1999, CANCER RES, V59, P3299; Vieira KBL, 1996, CANCER RES, V56, P2452; Zurovec M, 1998, ONCOGENE, V16, P3133, DOI 10.1038/sj.onc.1201860	36	105	111	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					1955	1964		10.1038/sj.onc.1206198	http://dx.doi.org/10.1038/sj.onc.1206198			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673201				2022-12-17	WOS:000181967700006
J	Hesson, L; Dallol, A; Minna, JD; Maher, ER; Latif, F				Hesson, L; Dallol, A; Minna, JD; Maher, ER; Latif, F			NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers	ONCOGENE			English	Article						RASSF1A; NORE1; methylation	FREQUENT EPIGENETIC INACTIVATION; HUMAN-CHROMOSOME 3P21.3; PROMOTER HYPERMETHYLATION; CPG ISLAND; LUNG; CARCINOMA; REGION; IDENTIFICATION; EFFECTOR; BREAST	We recently demonstrated that RASSF1A, a new tumour-suppressor gene located at 3p21.3 is frequently inactivated by promoter region hypermethylation in a variety of human cancers including lung, breast, kidney and neuroblastoma. We have identified another member of the RASSF1 gene family by in silico sequence analysis using BLAST searches. NORE1 located at 1q32.1 exists in three isoforms (NORE1Aalpha, NORE1Abeta and NORE1B). Both NORE1A and NORE1B isoforms have separate CpG islands spanning their first exons. NORE1Aalpha Produces a 418 aa protein containing a Ras-association (RA) domain and a diacylglycerol (DAG) binding domain. NORE1Abeta produces a C-terminal truncation of the RA domain. NORE1B also contains the RA domain but not the DAG domain. NORE1 is the human homologue of the mouse Ras effector Nore1. No inactivating somatic mutations were found in lung tumour lines; however, NORE1A promoter region CpG island was hypermethylated in primary tumours and tumour cell lines. NORE1A promoter was methylated in 10/25 breast, 4/40 SCLC, 3/17 NSCLC, 1/6 colorectal and 3/9 kidney tumour cell lines, while NORE1B promoter was unmethylated in the same tumour cell lines. While 24% (6/25) of primary NSCLC underwent NORE1A methylation, methylation in SCLC was a rare event (0/22); (P = 0.0234). NORE1A expression in tumour cell lines was reactivated after treatment with a demethylating agent. There was no correlation between NORE1A and RASSF1A methylation status in NSCLC. Our results demonstrate that NOREIA is inactivated in a subset of human cancers by CpG island promoter hypermethylation, and in lung cancer this hypermethylation may be histological type specific.	Univ Birmingham, Sect Med & Mol Genet, Dept Paediat & Child Hlth, Sch Med, Birmingham B15 2TT, W Midlands, England; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Birmingham, Canc Res UK, Renal Mol Oncol Res Grp, Sch Med, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Cancer Research UK; University of Birmingham	Latif, F (corresponding author), Univ Birmingham, Sect Med & Mol Genet, Dept Paediat & Child Hlth, Sch Med, Edgbaston, Birmingham B15 2TT, W Midlands, England.		MAHER, EAMONN R/A-9507-2008; Hesson, Luke/HDM-0311-2022; Dallol, Ashraf/H-8661-2012	MAHER, EAMONN R/0000-0002-6226-6918; Dallol, Ashraf/0000-0002-8803-228X	NCI NIH HHS [P50CA70907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Downward J, 2001, NATURE, V411, P759, DOI 10.1038/35081138; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Lee MG, 2001, CANCER RES, V61, P6688; Lerman MI, 2000, CANCER RES, V60, P6116; Lo KW, 2001, CANCER RES, V61, P3877; Maruyama R, 2002, CLIN CANCER RES, V8, P514; Morrissey C, 2001, CANCER RES, V61, P7277; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200	22	105	115	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					947	954		10.1038/sj.onc.1206191	http://dx.doi.org/10.1038/sj.onc.1206191			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584574				2022-12-17	WOS:000180864300017
J	Tsai, MS; Shamon-Taylor, LA; Mehmi, I; Tang, CK; Lupu, R				Tsai, MS; Shamon-Taylor, LA; Mehmi, I; Tang, CK; Lupu, R			Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer	ONCOGENE			English	Article						HRG antisense; tumorigenicity; metastasis; breast cancer	MATRIX-METALLOPROTEINASE-9 EXPRESSION; SIGNAL-TRANSDUCTION; ONCOGENE PRODUCT; GROWTH-FACTOR; RECEPTOR; ERBB-2; DIFFERENTIATION; ACTIVATION; PATHWAYS; LIGAND	The growth factor heregulin (HRG), expressed in about 30% of breast cancer tumors, activates the erbB-2 receptor via induction of heterodimeric complexes of erbB-2 with erbB-3 or erB-4. HRG induces tumorigenicity and metastasis of breast cancer cells. Our investigation into whether HRG is a factor likely to promote tumor formation independently of erbB-2 overexpression concludes that blockage of HRG expression suppresses the aggressive phenotype of MDA-MB-231 breast cancer cells by inhibiting cell proliferation, preventing anchorage-independent growth, and suppressing the invasive potential of the cells in vitro. More importantly, we observed a marked reduction in tumor formation, tumor size, and a lack of metastasis in vivo. These studies were achieved by blocking HRG expression in MDA-MB-231 cells using an HRG antisense cDNA. In the search for the mechanism by which blockage of HRG reverts this aggressive phenotype, we discovered that the cells in which HRG is blocked exhibit a marked decrease in erbB activation and a significant reduction in MMP-9 activity, demonstrating a direct causal role in HRG induction of tumorigenicity. Our study is the first report and serves as a proof of the concept that HRG is a key promoter of breast cancer tumorigenicity and metastasis independently of erbB-2 overexpression and should be deemed a potential target in developing therapies for breast cancer.	Northwestern Univ, Evanston NW Healthcare Res Inst, Sch Med, Evanston, IL 60201 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA	Northwestern University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Georgetown University	Lupu, R (corresponding author), Northwestern Univ, Evanston NW Healthcare Res Inst, Sch Med, 1001 Univ Pl, Evanston, IL 60201 USA.	rlupu@enh.org			NIDDK NIH HHS [DK49049] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049049] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALIMANDI M, 1995, ONCOGENE, V10, P1813; ATLAS E, 2003, IN PRESS MOL CANC RE; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; CARDILLO M, 1995, HEREGULIN INDUCES ME; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; Guerra-Vladusic FK, 1999, INT J ONCOL, V15, P883; Hijazi MM, 2000, INT J ONCOL, V17, P629; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; Hua J, 1996, CANCER RES, V56, P5279; Lee KS, 1996, CLIN EXP METASTAS, V14, P512; Lim SJ, 2000, ONCOGENE, V19, P6271, DOI 10.1038/sj.onc.1204014; Liu WM, 1999, CANCER RES, V59, P5695; LUPU R, 1995, SEMIN CANCER BIOL, V6, P135, DOI 10.1006/scbi.1995.0016; LUPU R, 1992, BIOCHEMISTRY-US, V31, P7330, DOI 10.1021/bi00147a018; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; PIERCE JH, 1991, ONCOGENE, V6, P1189; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Stern DF, 2000, BREAST CANCER RES, V2, P176, DOI 10.1186/bcr51; Tang CK, 1996, CANCER RES, V56, P3350; Tripathy D, 1992, Cancer Treat Res, V63, P15; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Tsai MS, 2000, CANCER RES, V60, P5603; Tsang KJ, 2001, INT J ONCOL, V18, P369; Yao J, 2001, ONCOGENE, V20, P8066, DOI 10.1038/sj.onc.1204944	33	105	113	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					761	768		10.1038/sj.onc.1206130	http://dx.doi.org/10.1038/sj.onc.1206130			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569369				2022-12-17	WOS:000180642100014
J	Skorski, T				Skorski, T			BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability	ONCOGENE			English	Review						DNA damage; DNA repair; apoptosis; checkpoint	DOUBLE-STRAND BREAKS; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITOR; CHRONIC MYELOGENOUS LEUKEMIA; ABL-MEDIATED RESISTANCE; CELL-CYCLE CHECKPOINTS; HUMAN RAD51 PROTEIN; BONE-MARROW-CELLS; BCR-ABL; HOMOLOGOUS RECOMBINATION	BCR/ABL regulates cell proliferation, apoptosis, differentiation and adhesion. In addition, BCR/ABL can induce resistance to cytostatic drugs and irradiation by modulation of DNA repair mechanisms, cell cycle checkpoints and Bcl-2 protein family members. Upon DNA damage BCR/ABL not only enhances reparation of DNA lesions (e.g. homologous recombination repair), but also prolongs activation of cell cycle checkpoints (e.g. G2/M) providing more time for repair of otherwise lethal lesions. Moreover, by modification of antiapoptotic members of the Bcl-2 family (e.g. upregulation of BCL-x(L) BCR/ABL provides a cytoplasmic 'umbrella' protecting mitochondria from the 'rain' of apoptotic signals coming from the damaged DNA in the nucleus, thus preventing release of cytochrome c and activation of caspases. The unrepaired and/or aberrantly repaired (but not lethal) DNA lesions resulting from spontaneous and/or drug-induced damage can accumulate in BCR/ABL transformed cells leading to genomic instability and malignant progression of the disease. Inhibition of BCR/ABL kinase activity by STI571 (Gleevec, imatinib mesylate) reverses drug resistance and, in combination with standard chemotherapeutics can exert strong antileukemia effect.	Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Skorski, T (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Philadelphia, PA 19122 USA.	tskorski@astro.temple.edu						Aitken RJ, 2001, REPRODUCTION, V122, P497, DOI 10.1530/rep.0.1220497; Albala JS, 1997, GENOMICS, V46, P476, DOI 10.1006/geno.1997.5062; Albrecht T, 1996, BRIT J HAEMATOL, V95, P501, DOI 10.1046/j.1365-2141.1996.d01-1934.x; ALIMENA G, 1987, CANCER GENET CYTOGEN, V26, P39, DOI 10.1016/0165-4608(87)90131-2; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; AMOS TAS, 1995, BRIT J HAEMATOL, V91, P387, DOI 10.1111/j.1365-2141.1995.tb05308.x; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Arnaudeau C, 2001, NUCLEIC ACIDS RES, V29, P662, DOI 10.1093/nar/29.3.662; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Beck Z, 2000, LEUKEMIA LYMPHOMA, V38, P587, DOI 10.3109/10428190009059278; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Bishop AJR, 2001, BBA-REV CANCER, V1471, pM109, DOI 10.1016/S0304-419X(01)00018-X; BLASIAK J, 2002, IN PRESS LEUK RES, V1538; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bracey TS, 1997, CLIN CANCER RES, V3, P1371; Bucka A, 2001, NUCLEIC ACIDS RES, V29, P2464, DOI 10.1093/nar/29.12.2464; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; Campbell MJ, 1999, J MOL BIOL, V286, P437, DOI 10.1006/jmbi.1998.2457; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chan TA, 2000, GENE DEV, V14, P1584; CherbonnelLasserre C, 1996, ONCOGENE, V13, P1489; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; Collis SJ, 2001, NUCLEIC ACIDS RES, V29, P1534, DOI 10.1093/nar/29.7.1534; Coultas L, 2000, APOPTOSIS, V5, P491, DOI 10.1023/A:1009617727938; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; de Groot Rolf P., 2000, Molecular Cell Biology Research Communications, V3, P299, DOI 10.1006/mcbr.2000.0231; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Deutsch E, 2001, BLOOD, V97, P2084, DOI 10.1182/blood.V97.7.2084; Dibiase SJ, 2000, CANCER RES, V60, P1245; Donato NJ, 2001, BLOOD, V97, P2846, DOI 10.1182/blood.V97.9.2846; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Dubrez L, 1998, BLOOD, V91, P2415, DOI 10.1182/blood.V91.7.2415.2415_2415_2422; DUBREZ L, 1995, LEUKEMIA, V9, P1013; El-Deiry Wafik S., 1997, Current Opinion in Oncology, V9, P79; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Elliott B, 2001, MOL CELL BIOL, V21, P2671, DOI 10.1128/MCB.21.8.2671-2682.2001; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Falkenburg JHF, 1999, BLOOD, V94, P1201, DOI 10.1182/blood.V94.4.1201.416k08_1201_1208; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Fischer T, 1998, BONE MARROW TRANSPL, V21, P1029, DOI 10.1038/sj.bmt.1701229; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; Flores-Rozas H, 2000, TRENDS BIOCHEM SCI, V25, P196, DOI 10.1016/S0968-0004(00)01568-1; FUCHS EJ, 1995, CANCER RES, V55, P463; GAIGER A, 1995, BLOOD, V86, P2371, DOI 10.1182/blood.V86.6.2371.bloodjournal8662371; GALE RP, 1994, ANN INTERN MED, V120, P646, DOI 10.7326/0003-4819-120-8-199404150-00004; Gebow D, 2000, MOL CELL BIOL, V20, P4028, DOI 10.1128/MCB.20.11.4028-4035.2000; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Grdina D J, 2000, Drug Metabol Drug Interact, V16, P237; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GUINN BA, 1995, LEUKEMIA RES, V19, P519, DOI 10.1016/0145-2126(95)00024-I; HARRISON DJ, 1995, J PATHOL, V175, P7, DOI 10.1002/path.1711750103; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Hoover RR, 2001, ONCOGENE, V20, P5826, DOI 10.1038/sj.onc.1204549; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Jakupciak JP, 2000, J BIOL CHEM, V275, P40003, DOI 10.1074/jbc.M007153200; Jasin M, 2000, CANCER INVEST, V18, P78, DOI 10.3109/07357900009023065; Jeong SJ, 2001, RADIAT RES, V156, P751, DOI 10.1667/0033-7587(2001)156[0751:PTKIMR]2.0.CO;2; Johnson PA, 1999, CANCER RES, V59, P2696; JONES NJ, 1995, GENOMICS, V26, P619, DOI 10.1016/0888-7543(95)80187-Q; Kano Y, 2001, BLOOD, V97, P1999, DOI 10.1182/blood.V97.7.1999; KELMAN Z, 1989, BLOOD, V74, P2318; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim C, 2001, GENE, V276, P127, DOI 10.1016/S0378-1119(01)00639-4; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Kohno K, 1997, GENE, V188, P175, DOI 10.1016/S0378-1119(96)00835-9; Kolibaba KS, 1997, BIOCHIM BIOPHYS ACTA, V1333, P217; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Kolomietz E, 2001, BLOOD, V97, P3581, DOI 10.1182/blood.V97.11.3581; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LANEUVILLE P, 1992, BLOOD, V80, P1788; Laval J, 1996, PATHOL BIOL, V44, P14; Li GM, 1999, ONCOL RES, V11, P393; Li XR, 1997, MOL CELL BIOL, V17, P2723, DOI 10.1128/MCB.17.5.2723; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Majsterek I, 2002, CELL BIOL INT, V26, P363, DOI 10.1006/cbir.2002.0865; Makin G, 2000, CELL TISSUE RES, V301, P143, DOI 10.1007/s004419900160; Maru Y, 2001, MUTAT RES-FUND MOL M, V483, P83, DOI 10.1016/S0027-5107(01)00229-9; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; Modesti M, 2001, CURR BIOL, V11, pR229, DOI 10.1016/S0960-9822(01)00112-9; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; NAKAI H, 1992, CANCER RES, V52, P6588; Namsaraev E, 1997, MOL CELL BIOL, V17, P5359, DOI 10.1128/MCB.17.9.5359; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; NIEBOROWSKASKORSKA M, 1994, FOLIA HISTOCHEM CYTO, V32, P35; Nishii K, 1996, ONCOGENE, V13, P2225; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; Papavasiliou FN, 2000, NATURE, V408, P216, DOI 10.1038/35041599; Papazisis KT, 2000, CANCER LETT, V160, P107, DOI 10.1016/S0304-3835(00)00569-3; Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Pittman DL, 1998, GENOMICS, V49, P103, DOI 10.1006/geno.1998.5226; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Quackenbush RC, 2000, BLOOD, V95, P2913, DOI 10.1182/blood.V95.9.2913.009k32_2913_2921; Raderschall E, 2002, CANCER RES, V62, P219; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; RINEHART FP, 1981, BIOCHEMISTRY-US, V20, P3003, DOI 10.1021/bi00514a003; Riordan FA, 1998, ONCOGENE, V16, P1533, DOI 10.1038/sj.onc.1201680; Roger R, 1996, BLOOD, V87, P1113, DOI 10.1182/blood.V87.3.1113.bloodjournal8731113; Rohlfs EM, 2000, HUM GENET, V107, P385, DOI 10.1007/s004390000372; ROWLEY JD, 1982, ADV CANCER RES, V36, P103, DOI 10.1016/S0065-230X(08)60423-6; Salloukh HF, 2000, ONCOGENE, V19, P4362, DOI 10.1038/sj.onc.1203804; Salloukh HF, 2000, LEUKEMIA, V14, P1401, DOI 10.1038/sj.leu.2401855; Salomoni P, 2000, BLOOD, V96, P676; SANTUCCI MA, 1993, INT J RADIAT ONCOL, V26, P831, DOI 10.1016/0360-3016(93)90498-K; Sattler M, 2000, J BIOL CHEM, V275, P24273, DOI 10.1074/jbc.M002094200; Sawyers CL, 1997, BAILLIERE CLIN HAEM, V10, P223, DOI 10.1016/S0950-3536(97)80004-2; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Shapiro GI, 1999, J CLIN INVEST, V104, P1645, DOI 10.1172/JCI9054; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Skorski T, 1996, P NATL ACAD SCI USA, V93, P13137, DOI 10.1073/pnas.93.23.13137; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SKORSKI T, 1993, J CLIN INVEST, V92, P194, DOI 10.1172/JCI116549; Skorski T, 1997, J NATL CANCER I, V89, P124, DOI 10.1093/jnci/89.2.124; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Slupianek A, 2002, MOL CELL BIOL, V22, P4189, DOI 10.1128/MCB.22.12.4189-4201.2002; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; SONOYAMA J, 2002, J BIOL CHEM, V4, P4; Stuppia L, 1997, CANCER GENET CYTOGEN, V98, P28, DOI 10.1016/S0165-4608(96)00413-X; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Takeda N, 1999, P NATL ACAD SCI USA, V96, P203, DOI 10.1073/pnas.96.1.203; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; THACKER J, 1995, HUM MOL GENET, V4, P113, DOI 10.1093/hmg/4.1.113; Thiesing JT, 2000, BLOOD, V96, P3195, DOI 10.1182/blood.V96.9.3195.h8003195_3195_3199; Topaly J, 2001, LEUKEMIA, V15, P342, DOI 10.1038/sj.leu.2402041; van der Kuip H, 2001, BLOOD, V98, P1532, DOI 10.1182/blood.V98.5.1532; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; von Willebrand M, 1998, J BIOL CHEM, V273, P3994, DOI 10.1074/jbc.273.7.3994; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; Wang D, 1998, MUTAT RES-FUND MOL M, V400, P99, DOI 10.1016/S0027-5107(98)00066-9; Wang HC, 2001, ONCOGENE, V20, P2212, DOI 10.1038/sj.onc.1204350; Wiese C, 2002, CANCER RES, V62, P1279; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	159	105	110	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2002	21	56					8591	8604		10.1038/sj.onc.1206087	http://dx.doi.org/10.1038/sj.onc.1206087			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476306				2022-12-17	WOS:000179734300009
J	Delhalle, S; Deregowski, V; Benoit, V; Merville, MP; Bours, V				Delhalle, S; Deregowski, V; Benoit, V; Merville, MP; Bours, V			NF-kappa B-dependent MnSOD expression protects adenocarcinoma cells from TNF-alpha-induced apoptosis	ONCOGENE			English	Article						NF-kappa B; TNF-alpha; MnSOD; apoptosis; cancer	MANGANESE SUPEROXIDE-DISMUTASE; NECROSIS-FACTOR-ALPHA; BREAST-CANCER CELLS; NUCLEAR-FACTOR; EPITHELIAL-CELLS; BCL-2 FAMILY; TRANSCRIPTION FACTORS; GENE-EXPRESSION; DOWN-REGULATION; UP-REGULATION	NFkappaB is known to exert a cytoprotective action against TNF-alpha-induced apoptosis. To study the role of NF-kappaB in various TNF-alpha-treated epithelial cell lines, we generated stable transfectants overexpressing a mutated unresponsive form of the IkappaBalpha inhibitor (MT cells), As NF-kappaB prevented TNF-alpha-induced apoptosis in various epithelial cancer cell lines, we searched for NF-kappaB target gene products responsible for this difference of sensitivity. We observed an increased Bcl-X-L expression level in OVCAR-3 cells compared with OVCAR-3 cells expressing a mutated IkappaBalpha inhibitor (MT cells). Induction of the antioxidant enzyme MnSOD was detected only, in TNF-a-treated OVCAR, MCF7A/Z and HCT116 cells but not in MT cells. Moreover, reactive oxygen species were involved in TNF-a-induced apoptosis, as various antioxidants partially protected these cells from apoptosis. At last, transfection of the MnSOD cDNA in MT cells, which do not express this protein after TNF-alpha stimulation, partially restored resistance to TNF-alpha-induced cell death, as observed by clonogenic assays. However, transfection of the Bel-X-L cDNA did not induce any protective effect. Therefore, MnSOD expression is induced by NF-kappaB in epithelial cancer cells in response to TNF-alpha, and is at least partially responsible for their resistance to TNF-alpha-induced apoptosis, presumably through the clearance of death-inducing ROS.	Univ Liege, CHU B35, Ctr Cellular & Mol Therapy, Lab Med Chem & Human Genet, B-4000 Liege, Belgium	University of Liege	Bours, V (corresponding author), Univ Liege, CHU B35, Ctr Cellular & Mol Therapy, Lab Med Chem & Human Genet, Sart Tilman, B-4000 Liege, Belgium.			BENOIT, Valerie/0000-0002-1098-9452				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aggarwal BB, 2000, BIOCHEM PHARMACOL, V60, P1033, DOI 10.1016/S0006-2952(00)00393-2; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bernard D, 2001, CANCER RES, V61, P2656; BEYAERT R, 1998, TUMOR NECROSIS FACTO, P335; Bonizzi G, 2000, BIOCHEM PHARMACOL, V59, P7, DOI 10.1016/S0006-2952(99)00290-7; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Darville MI, 2000, ENDOCRINOLOGY, V141, P153, DOI 10.1210/en.141.1.153; DEJARDIN E, 1995, ONCOGENE, V11, P1835; Drane P, 2001, ONCOGENE, V20, P430, DOI 10.1038/sj.onc.1204101; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Fiers W, 1988, Dev Biol Stand, V69, P143; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; GIBBS LS, 1992, FREE RADICAL BIO MED, V12, P107, DOI 10.1016/0891-5849(92)90003-Y; Goossens V, 1999, BIOFACTORS, V10, P145, DOI 10.1002/biof.5520100210; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; GWINNER W, 1995, KIDNEY INT, V48, P354, DOI 10.1038/ki.1995.303; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; JACOBY DB, 1994, FREE RADICAL BIO MED, V16, P821, DOI 10.1016/0891-5849(94)90198-8; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kifle Y, 1996, J NEUROCHEM, V66, P2128; Kim KH, 2001, ANTIOXID REDOX SIGN, V3, P361, DOI 10.1089/15230860152409013; LARSEN CJ, 1994, ANN GENET-PARIS, V37, P121; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LI JJ, 1995, ONCOGENE, V10, P1989; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MacMillan-Crow LA, 2001, FREE RADICAL RES, V34, P325, DOI 10.1080/10715760100300281; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; OBERLEY LW, 1979, CANCER RES, V39, P1141; Oberley LW, 2001, ANTIOXID REDOX SIGN, V3, P461, DOI 10.1089/15230860152409095; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; VAN AD, 1996, SCIENCE, V274, P787; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Zhao YF, 2001, CANCER RES, V61, P6082; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	56	105	108	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3917	3924		10.1038/sj.onc.1205489	http://dx.doi.org/10.1038/sj.onc.1205489			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032830				2022-12-17	WOS:000175847200011
J	Mathai, JP; Germain, M; Marcellus, RC; Shore, GC				Mathai, JP; Germain, M; Marcellus, RC; Shore, GC			Induction and endoplasmic reticulum location of BIK/NBK in response to apoptotic signaling by E1A and p53	ONCOGENE			English	Article						BIK; E1A; p53; caspase; apoptosis	CYTOCHROME-C; CELL-DEATH; MITOCHONDRIAL-MEMBRANES; TUMOR-SUPPRESSOR; BCL-2 FAMILY; PROTEIN; ADENOVIRUS; ACTIVATION; RELEASE; INTERACTS	A DNA microarray analysis identified the BH3-only BCL-2 family member, BIK/NBK, as a transcript that is upregulated during induction of apoptosis by oncogenic E1A. E1A depended on wild-type p53 to induce BIK and activate the death program. Further, p53 independently induced BIK RNA and protein, and BIK alone stimulated cell death in p53-null cells, dependent on the activation of caspases. BIK function, however, was abrogated by a disabling point mutation within the BH3 domain. Collectively, these results argue that BIK is a downstream apoptotic effector of p53 in response to a physiological p53-mediated death stimulus provided by E1A. Elevated BCL-2 functioned downstream of p53 and BIK induction to inhibit the E1A death pathway, with the ratio of anti-apoptotic BCL-2 and pro-apoptotic BIK determining cell death or survival in E1A-expressing cells. Cells expressing BCL-2 or treated with the pan caspase inhibitor, zVAD-fmk, allowed accumulation of high levels of cytotoxic BIK compared to control cells. Of note, a significant fraction of either ectopic or endogenous BIK was found associated with the endoplasmic reticulum, suggesting that this organelle, in addition to mitochondria, may be a target of BIK function.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; GeminX Biotechnol Inc, Montreal, PQ H2X 3P9, Canada	McGill University	Shore, GC (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg,3655 Promenade Sir William, Montreal, PQ H3G 1Y6, Canada.	Gordon.Shore@mcgill.ca						ABERICI A, 1999, J BIOL CHEM, V274, P30764; AKAO Y, 1994, CANCER RES, V54, P2468; Attardi LD, 2000, GENE DEV, V14, P704; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; Boulakia CA, 1996, ONCOGENE, V12, P529; BOYD JM, 1995, ONCOGENE, V11, P1921; Breckenridge DG, 2000, CRIT REV EUKAR GENE, V10, P273; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Han J, 1996, MOL CELL BIOL, V16, P5857; HEDGE R, 1998, J BIOL CHEM, V273, P7783; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Juin P, 2000, NAT MED, V6, P498, DOI 10.1038/74966; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MIYASHITA T, 1995, CELL, V80, P293; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; NG FWH, 1998, MOL CELL BIOL, V20, P6731; NG FWH, 1998, J BIOL CHEM, V139, P327; Nguyen M, 2000, MOL CELL BIOL, V20, P6731, DOI 10.1128/MCB.20.18.6731-6740.2000; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; Nguyen M, 1998, J BIOL CHEM, V273, P33099, DOI 10.1074/jbc.273.50.33099; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Orth R, 1997, J BIOL CHEM, V272, P8841; Passer BJ, 1999, J BIOL CHEM, V274, P24007, DOI 10.1074/jbc.274.34.24007; Prives C, 1999, J PATHOL, V187, P112; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Tagami S, 2000, ONCOGENE, V19, P5736, DOI 10.1038/sj.onc.1203948; Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	54	105	106	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2534	2544		10.1038/sj.onc.1205340	http://dx.doi.org/10.1038/sj.onc.1205340			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971188				2022-12-17	WOS:000174918400010
J	Abdulkarim, B; Sabri, S; Deutsch, E; Chagraoui, H; Maggiorella, L; Thierry, J; Eschwege, F; Vainchenker, W; Chouaib, S; Bourhis, J				Abdulkarim, B; Sabri, S; Deutsch, E; Chagraoui, H; Maggiorella, L; Thierry, J; Eschwege, F; Vainchenker, W; Chouaib, S; Bourhis, J			Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers	ONCOGENE			English	Article						HPV E6/E7; p53; human carcinoma; Cidofovir; ionizing radiation	HUMAN-PAPILLOMAVIRUS TYPE-16; CERVICAL-CARCINOMA CELLS; ACYCLIC NUCLEOSIDE PHOSPHONATES; TUMOR-SUPPRESSOR PROTEIN; RETINOBLASTOMA PROTEIN; HUMAN KERATINOCYTES; E7 PROTEIN; INHIBITION; DNA; DEGRADATION	High-risk human papillomaviruses (HPVs) have been associated to the development of cervical and some other human cancers. Most of them express E6 and E7 oncoproteins, able to bind to p53 and retinoblastoma (pRb) tumor suppressor proteins respectively and neutralize their function. Restoration of these pathways by blocking E6 and E7 expression would provide a selective therapeutic effect. Here, we show that a clinically approved antiviral agent Cidofovir reduced E6 and E7 expression in cervical carcinoma Me180 and head and neck squamous cell carcinoma HEP2 cells at the transcriptional level. Cidofovir induced the accumulation of active p53 and pRb associated to induction of cyclin dependent kinase inhibitor p21(WAF1/CIP1) in Me180 and HEP2 cells. p53 induction was also shown in Hela HPV-positive cervical carcinoma cell line. In addition, S phase cell cycle accumulation with concomitant decrease of cyclin A expression were associated to the antiproliferative activity of Cidofovir in HPV-treated cells. Combining Cidofovir to irradiation both in vivo and in nude mice xenografts resulted in a marked radiosensitization in HPV-positive cells, which was not observed in virus negative cells. This study provides the basis for a new anticancer strategy to enhance the antitumor effect of ionizing radiation in HPV-related cancers, without increase deleterious effects.	Inst Gustave Roussy, Lab UPRES EA 27 10, F-94805 Villejuif, France; Inst Gustave Roussy, Unite METSI, F-94805 Villejuif, France; Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France; Inst Gustave Roussy, INSERM, U487, F-94805 Villejuif, France	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Bourhis, J (corresponding author), Inst Gustave Roussy, Lab UPRES EA 27 10, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	bourhis@igr.fr	THIERY, Jerome/N-2469-2018; Chouaib, Salem/F-7939-2016; Sabri, Siham/K-1101-2015	THIERY, Jerome/0000-0002-0998-3627; deutsch, eric/0000-0002-8223-3697; Bourhis, Jean/0000-0001-5162-1171; Sabri, Siham/0000-0001-5792-689X; Vainchenker, William/0000-0003-4705-202X				Abdulkarim B, 2001, LANCET ONCOL, V2, P622, DOI 10.1016/S1470-2045(01)00520-4; Alvarez-Salas LM, 1998, P NATL ACAD SCI USA, V95, P1189, DOI 10.1073/pnas.95.3.1189; Andrei G, 1998, ONCOL RES, V10, P523; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Boyer SN, 1996, CANCER RES, V56, P4620; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; BUTZ K, 1995, ONCOGENE, V10, P927; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Chiba I, 1996, ONCOGENE, V12, P1663; Crook T, 1998, ONCOGENE, V16, P1429, DOI 10.1038/sj.onc.1201699; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; DIPAOLO JA, 1993, CRIT REV ONCOGENESIS, V4, P337; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Francis DA, 2000, J VIROL, V74, P2679, DOI 10.1128/JVI.74.6.2679-2686.2000; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gallardo D, 1996, CANCER RES, V56, P4891; Gillam R, 1999, C++ REP, V11, P9; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; GOUBIN F, 1995, ONCOGENE, V10, P2281; He JK, 1997, CANCER RES, V57, P3993; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; HICKMAN ES, 1994, ONCOGENE, V9, P2177; Hietanen S, 2000, P NATL ACAD SCI USA, V97, P8501, DOI 10.1073/pnas.97.15.8501; HU GY, 1995, CANCER GENE THER, V2, P19; Hwang ES, 1996, ONCOGENE, V12, P795; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Johnson JA, 1999, ANTIMICROB AGENTS CH, V43, P1198, DOI 10.1128/AAC.43.5.1198; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kamradt MC, 2000, BRIT J CANCER, V82, P1709; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liekens S, 2001, INT J CANCER, V92, P161, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1183>3.0.CO;2-K; Mantovani F, 1999, ONCOGENE, V18, P3309, DOI 10.1038/sj.onc.1202688; MORAN E, 1993, CURR OPIN GENE DEV, V13, P261; Neyts J, 1998, CANCER RES, V58, P384; Pisarev VM, 1997, MOL PHARMACOL, V52, P63, DOI 10.1124/mol.52.1.63; Safrin S, 1997, REV MED VIROL, V7, P145, DOI 10.1002/(SICI)1099-1654(199709)7:3<145::AID-RMV196>3.0.CO;2-0; Santin AD, 1998, CANCER-AM CANCER SOC, V83, P2346, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2346::AID-CNCR14>3.0.CO;2-G; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHIFFMAN MH, 1995, J NATL CANCER I, V87, P1345, DOI 10.1093/jnci/87.18.1345; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Smith-McCune K, 1999, P NATL ACAD SCI USA, V96, P6999, DOI 10.1073/pnas.96.12.6999; Spitz FR, 1996, CLIN CANCER RES, V2, P1665; STEELE C, 1992, CANCER RES, V52, P4706; STEELE C, 1993, CANCER RES, V53, P2330; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; TAN TMC, 1995, CANCER RES, V55, P4599; Venturini F, 1999, NUCLEIC ACIDS RES, V27, P1585, DOI 10.1093/nar/27.7.1585; Villa LL, 1997, ADV CANCER RES, V71, P321, DOI 10.1016/S0065-230X(08)60102-5; Wu LL, 2000, MOL CELL BIOL, V20, P7059, DOI 10.1128/MCB.20.19.7059-7067.2000; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	64	105	108	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2334	2346		10.1038/sj.onc.1205006	http://dx.doi.org/10.1038/sj.onc.1205006			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948417				2022-12-17	WOS:000174635600006
J	Jackson, JG; Zhang, XH; Yoneda, T; Yee, D				Jackson, JG; Zhang, XH; Yoneda, T; Yee, D			Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines	ONCOGENE			English	Article						breast neoplasms; insulin-like growth factors; cell migration; insulin receptor substrate; adhesion	GROWTH-FACTOR-I; IGF-I; EPITHELIAL-CELLS; EXPRESSION; ADHESION; INTEGRINS; MIGRATION; CARCINOMA; PHENOTYPE; PROTEINS	Insulin-like growth factors (IGFs) regulate breast cancer cell proliferation, protect cells from apoptosis, and enhance metastasis. In this study, we examined the IGF signaling pathway in two breast cancer cell lines selected for metastatic behavior. LCC6 was, selected for growth as, an ascites tumor in athymic mice from parental MDA-MB-435 cells (435P). The MDA-231BO cell line was derived from osseous metastases that formed after intracardiac injection of the MDA-MB-231 cell line in athymic mice. Compared to the parental cell Rues, IGF-I treatment enhanced IRS-2 phosphorylation over IRS-I in the metastatic variants. IGF-I stimulated cell migration in the variant cells, but not in the parental cells. To. determine the role for IRS-2 in IGF-mediated motility, we transfected MDA-231BO cells with, an anti-sense IRS-2 construct. Transfected cells had decreased levels of IRS-2. with diminished IGF-mediated motility and anchorage independent growth when compared to control cells. However, adherence to fibronectin was. enhanced in the transfected cells compared to MD A-231BO cells. Our data show that breast cancer cells selected for metastatic behavior in vivo have increased IRS-2 activation and signaling. In these cells, IGF-I enhances cell adhesion and motility suggesting that IRS-2 may mediate these aspects of the malignant phenotype.	Univ Minnesota, Ctr Canc, Div Hematol Oncol & Transplantat, Dept Med, Minneapolis, MN 55455 USA; Univ Texas, Hlth Sci Ctr, Div Med Oncol, Dept Med, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Div Endocrinol, Dept Med, San Antonio, TX 78229 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Yee, D (corresponding author), Univ Minnesota, Ctr Canc, Div Hematol Oncol & Transplantat, Dept Med, Mayo Mail Code 806,420 Delaware St SE, Minneapolis, MN 55455 USA.			Yee, Douglas/0000-0002-3387-4009; Jackson, James Griffith/0000-0002-2640-6442	NATIONAL CANCER INSTITUTE [R01CA074285, P30CA054174] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA74285, P30CA54174] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andre F, 1999, INT J CANCER, V83, P497, DOI 10.1002/(SICI)1097-0215(19991112)83:4<497::AID-IJC11>3.3.CO;2-4; Clark SF, 2000, J BIOL CHEM, V275, P3819, DOI 10.1074/jbc.275.6.3819; Clemmons DR, 1999, ENDOCRINOLOGY, V140, P4616, DOI 10.1210/en.140.10.4616; CULLEN KJ, 1990, CANCER RES, V50, P48; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Dunn SE, 1998, CANCER RES, V58, P3353; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; FIGUEROA JA, 1993, J CELL PHYSIOL, V157, P229, DOI 10.1002/jcp.1041570204; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Gui GPH, 1997, BRIT J CANCER, V75, P623, DOI 10.1038/bjc.1997.113; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; Jackson JG, 1999, GROWTH HORM IGF RES, V9, P280, DOI 10.1054/ghir.1999.0113; Jackson JG, 2000, CLIN CANCER RES, V6, P1135; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lebrun P, 2000, J BIOL CHEM, V275, P38371, DOI 10.1074/jbc.M006162200; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Lee YJ, 1999, J BIOL CHEM, V274, P22401, DOI 10.1074/jbc.274.32.22401; Leonessa F, 1996, BRIT J CANCER, V73, P154, DOI 10.1038/bjc.1996.29; LONG L, 1995, CANCER RES, V55, P1006; Long L, 1998, EXP CELL RES, V238, P116, DOI 10.1006/excr.1997.3814; Reiss K, 2001, ONCOGENE, V20, P490, DOI 10.1038/sj.onc.1204112; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; SMITH LK, 1995, MOL CELL ENDOCRINOL, V113, P73, DOI 10.1016/0303-7207(95)03622-E; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; TANTI JF, 1994, J BIOL CHEM, V269, P6051; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486; Yu GH, 1998, AM J CLIN PATHOL, V109, P315, DOI 10.1093/ajcp/109.3.315; Zutter MM, 1998, J MAMMARY GLAND BIOL, V3, P191, DOI 10.1023/A:1018798907544	32	105	111	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7318	7325		10.1038/sj.onc.1204920	http://dx.doi.org/10.1038/sj.onc.1204920			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704861				2022-12-17	WOS:000171894200004
J	Latonen, L; Taya, Y; Laiho, M				Latonen, L; Taya, Y; Laiho, M			UV-radiation induces dose-dependent regulation of p53 response and modulates p53-HDM2 interaction in human fibroblasts	ONCOGENE			English	Article						p53; HDM2; phosphorylation; UV-damage	TUMOR-SUPPRESSOR P53; PROTEASOME-MEDIATED DEGRADATION; DNA-DAMAGE; CELL-CYCLE; MDM2 GENE; ULTRAVIOLET-RADIATION; POTENTIAL MEDIATOR; DOUBLE MINUTE-2; GROWTH ARREST; FEEDBACK LOOP	We address here the effects of increasing fluencies of UV-radiation on stability, modifications, activity and HDM2-interactions of endogenous p53 tumor suppressor and on cellular damage response of human diploid fibroblasts. Low amounts of UVB/C-radiation induced a transient cell cycle arrest of the cells which correlated with rapid but transient increase in p53 levels. In contrast, high UV-fluency caused cell apoptosis and a slower but sustained increase in p53. Regulation of p53 target genes was highly dependent on the radiation dose used. Whereas low doses induced p21/Cip1/Waf1 and HDM2, high doses induced only GADD45 and BAX increasing the BAX:BCL-2 ratio. The levels of HDM2, a negative regulator of p53, increased only by the low dose of UVC and p53-HDM2 association was promoted. In the absence of HDM2-induction after the high dose of UV-radiation p53-HDM2-interaction was promoted, but HDM2 failed to downregulate p53. p53 site-specific modifications (Ser15, Ser33, Ser37, Lys382) varied kinetically and were dependent on the fluency of the radiation used. Maximal phosphorylation of p53 on Ser15 and Ser33 correlated with increased levels of HDM2-free p53. The results suggest that regulation of p53 and HDM2 by UV-radiation is highly dose-dependent and contributes to the outcome of the cellular response.	Univ Helsinki, Dept Virol, Haartman Inst, FIN-00014 Helsinki, Finland; Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan	University of Helsinki; National Cancer Center - Japan	Laiho, M (corresponding author), Univ Helsinki, Dept Virol, Haartman Inst, POB 63, FIN-00014 Helsinki, Finland.	Marikki.Laiho@Helsinki.Fi	Latonen, Leena/C-8787-2016	Latonen, Leena/0000-0003-4502-2193				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Barley RDC, 1998, ONCOGENE, V17, P533, DOI 10.1038/sj.onc.1202271; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Buschmann T, 2000, CANCER RES, V60, P896; Chang D, 1999, CELL GROWTH DIFFER, V10, P155; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haapajarvi T, 1997, MOL CELL BIOL, V17, P3074, DOI 10.1128/MCB.17.6.3074; Haapajarvi T, 1999, EXP CELL RES, V248, P272, DOI 10.1006/excr.1999.4403; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; JUVEN T, 1993, ONCOGENE, V8, P3411; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Loignon M, 1997, CANCER RES, V57, P3390; Lu X, 1996, ONCOGENE, V13, P413; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Maki CG, 1996, CANCER RES, V56, P2649; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Saucedo LJ, 1998, CELL GROWTH DIFFER, V9, P119; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; TYRRELL RM, 1994, MOL ASPECTS MED, V15, P3; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Zhao RB, 2000, GENE DEV, V14, P981	54	105	109	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2001	20	46					6784	6793		10.1038/sj.onc.1204883	http://dx.doi.org/10.1038/sj.onc.1204883			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709713				2022-12-17	WOS:000171551600015
J	Friedrich, K; Wieder, T; Von Haefen, C; Radetzki, S; Janicke, R; Schulze-Osthoff, K; Dorken, B; Daniel, PT				Friedrich, K; Wieder, T; Von Haefen, C; Radetzki, S; Janicke, R; Schulze-Osthoff, K; Dorken, B; Daniel, PT			Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance	ONCOGENE			English	Article						caspase-3; chemotherapeutics; apoptosis; drug resistance; MCF-7 cells	GENE BAX-ALPHA; CYTOCHROME-C; THYMOCYTE APOPTOSIS; PROTEASE ACTIVITY; ANTICANCER DRUGS; TUMOR-GROWTH; HL-60 CELLS; IN-VIVO; DEATH; EXPRESSION	In this study, we asked whether overexpression of caspase-3, a central downstream executioner of apoptotic pathways, might sensitize breast cancer cells with acquired drug resistance (MT1/ADR) to drug-induced apoptosis, As control, we employed caspase-3 negative and caspase-3-transfected MCF-7 cells, Whereas mock-transfected MCF-7 cells were resistent to epirubicin, etoposide and paclitaxel (taxol), the same drugs led to breakdown of nuclear DNA in caspase-3-transfected MCF-7 cells, MT1/ADR cells express low levels of wild type caspase-3 but show defective caspase activation and apoptosis upon drug exposure. These cells also display a Less efficient activation of the mitochondrial permeability transition. Caspase-3-transfected MT1/ADR clones showed a 2.8-fold increase in the protein level and a 3.7-fold higher specific enzyme activity. Procaspase-3 overexpression was not toxic and did not affect background apoptosis, Interestingly, procaspase-3-transfected MT1/ADR cells were more sensitive to cytotoxic drags as compared with vector-transfected controls and DNA fragmentation nearly reached the levels of the original drug sensitive MT1 cells. Thus, overexpression of caspase-3 enhances chemosensitivity especially in situations where activation of the mitochondrial apoptosome is disturbed.	Humboldt Univ, Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Univ Munster, Dept Immunol & Cell Biol, D-48149 Munster, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munster	Daniel, PT (corresponding author), Humboldt Univ, Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Lindenberger Weg 80,Campus Berlin Buch, D-13125 Berlin, Germany.		Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Daniel PT, 1999, BLOOD, V94, P1100, DOI 10.1182/blood.V94.3.1100.415a16_1100_1107; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; Hiwasa T, 1998, ANTI-CANCER DRUG, V9, P82, DOI 10.1097/00001813-199801000-00010; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Ibrado AM, 1996, CANCER RES, V56, P4743; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1989, BIOTECHNIQUES, V7, P984; MILLER AD, 1989, BIOTECHNIQUES, V7, P989; MIYASHITA T, 1993, BLOOD, V81, P151; NAUNDORF H, 1992, BREAST CANCER RES TR, V23, P87, DOI 10.1007/BF01831480; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Perkins C, 1998, CANCER RES, V58, P4561; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stein U, 1997, INT J CANCER, V72, P885, DOI 10.1002/(SICI)1097-0215(19970904)72:5<885::AID-IJC28>3.0.CO;2-6; Sturm I, 2000, INT J CANCER, V87, P517, DOI 10.1002/1097-0215(20000815)87:4<517::AID-IJC9>3.0.CO;2-B; Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364; Suzuki A, 1998, EUR J PHARMACOL, V343, P87, DOI 10.1016/S0014-2999(97)01520-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uckert W, 1998, HUM GENE THER, V9, P2619, DOI 10.1089/10430349850019454; Wagener C, 1996, INT J CANCER, V67, P138, DOI 10.1002/(SICI)1097-0215(19960703)67:1<138::AID-IJC22>3.0.CO;2-9; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; WIEDER T, 1994, FEBS LETT, V345, P207, DOI 10.1016/0014-5793(94)00433-1; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	48	105	115	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2749	2760		10.1038/sj.onc.1204342	http://dx.doi.org/10.1038/sj.onc.1204342			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420687				2022-12-17	WOS:000168712000003
J	Rosenberg, C; Van Gurp, RJHLM; Geelen, E; Oosterhuis, JW; Looijenga, LHJ				Rosenberg, C; Van Gurp, RJHLM; Geelen, E; Oosterhuis, JW; Looijenga, LHJ			Overrepresentation of the short arm of chromosome 12 is related to invasive growth of human testicular seminomas and nonseminomas	ONCOGENE			English	Article						seminomas; nonseminomas; carcinoma in situ; 12p; gain	GERM-CELL TUMORS; COMPARATIVE GENOMIC HYBRIDIZATION; MOLECULAR CYTOGENETIC ANALYSIS; IN-SITU HYBRIDIZATION; CARCINOMA-INSITU; TESTIS; IDENTIFICATION; AMPLIFICATION; CANCER; PLOIDY	Overrepresentation of 12p-sequences, mostly due to isochromosome formation, is the only consistent chromosomal alteration found in invasive testicular germ cell tumors of adolescents and young adults (TGCTs), both seminomas and the various histological elenlents of nonseminomas, The biological role of extra 12p in the pathogenesis of this cancer is unclear, and it is also unknown so far, whether it is an early event, i,e,, already present in carcinoma ill situ, or related to invasive growth. Using comparative genomic hybridization (CGH) with DOP-PCR amplified DNA isolated from micro-dissected tumor cells, and double fluorescent in situ hybridization (FISH) on frozen tissue sections, we investigated the presence of overrepresentation of 12p sequences in different development stages of four seminomas and seven nonseminomas, in total 17 invasive components, in addition to the carcinoma in situ of each. CGH demonstrated relative gain of 12p-sequences in all invasive components except one, confirmed by FISH in most samples. In contrast, no gain was found in the carcinoma in situ samples by any of the methods. These findings show that overrepresentation of 12p is not an early event in the development of TGCTs, but relates to invasive growth.	Univ Rotterdam Hosp Daniel, Pathol Lab Expt Patho Oncol, Josephine Nefkens Inst, NL-3000 DR Rotterdam, Netherlands; Leiden Univ, Med Ctr, Dept Cytochem & Cytometry, Leiden, Netherlands	Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Looijenga, LHJ (corresponding author), Univ Rotterdam Hosp Daniel, Pathol Lab Expt Patho Oncol, Josephine Nefkens Inst, FGG EUR Bldg Be,Room 430B,POB 1738, NL-3000 DR Rotterdam, Netherlands.		Looijenga, Leendert/B-8145-2019; rosenberg, carla/N-4148-2015	Looijenga, Leendert/0000-0002-8146-1911; rosenberg, carla/0000-0003-3253-4448				ADAMI HO, 1994, INT J CANCER, V59, P33, DOI 10.1002/ijc.2910590108; ATKIN NB, 1982, LANCET, V2, P1349; DEGRAAFF WE, 1992, LAB INVEST, V66, P166; GONDOS B, 1993, EUR UROL, V23, P68; JORGENSEN N, 1995, LAB INVEST, V72, P223; KORN MW, 1996, GENE CHROMOSOME CANC, V17, P8; LOOIJENGA LHJ, 1990, CYTOGENET CELL GENET, V53, P216, DOI 10.1159/000132934; Looijenga LHJ, 1999, REV REPROD, V4, P90, DOI 10.1530/ror.0.0040090; Looijenga LHJ, 2000, J PATHOL, V191, P187, DOI 10.1002/(SICI)1096-9896(200006)191:2<187::AID-PATH584>3.0.CO;2-T; MOLLER H, 1989, J NATL CANCER I, V81, P1668, DOI 10.1093/jnci/81.21.1668-a; Mosselman S, 1996, P NATL ACAD SCI USA, V93, P2884, DOI 10.1073/pnas.93.7.2884; Mostert MC, 1998, ONCOGENE, V16, P2617, DOI 10.1038/sj.onc.1201787; Mostert MMC, 1996, CANCER GENET CYTOGEN, V87, P95, DOI 10.1016/0165-4608(95)00233-2; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; Ottesen AM, 1997, GENE CHROMOSOME CANC, V20, P412; RODRIGUEZ E, 1993, GENE CHROMOSOME CANC, V8, P230, DOI 10.1002/gcc.2870080405; Roelofs H, 2000, AM J PATHOL, V157, P1155, DOI 10.1016/S0002-9440(10)64631-7; Rosenberg C, 1999, LAB INVEST, V79, P1447; Rosenberg C, 1998, CYTOMETRY, V32, P337, DOI 10.1002/(SICI)1097-0320(19980801)32:4<337::AID-CYTO11>3.3.CO;2-9; Sandberg AA, 1996, J UROLOGY, V155, P1531, DOI 10.1016/S0022-5347(01)66124-X; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; SUIJKERBUIJK RF, 1993, CANCER GENET CYTOGEN, V70, P85, DOI 10.1016/0165-4608(93)90173-J; SUIJKERBUIJK RF, 1994, CANCER GENET CYTOGEN, V78, P145, DOI 10.1016/0165-4608(94)90082-5; Summersgill B, 1998, BRIT J CANCER, V77, P305, DOI 10.1038/bjc.1998.47; TELENIUS H, 1992, GENOMICS, V13, P718, DOI 10.1016/0888-7543(92)90147-K; vanEchten J, 1997, CANCER GENET CYTOGEN, V96, P1; VANECHTENARENDS J, 1994, CANCER GENET CYTOGEN, V77, P194; VANKESSEL AG, 1989, CANCER GENET CYTOGEN, V40, P129, DOI 10.1016/0165-4608(89)90154-4; VORECHOVSKY I, 1989, NEOPLASMA, V36, P697; VOS A, 1990, CANCER GENET CYTOGEN, V46, P75, DOI 10.1016/0165-4608(90)90011-X; [No title captured]	31	105	109	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5858	5862		10.1038/sj.onc.1203950	http://dx.doi.org/10.1038/sj.onc.1203950			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127816	Bronze			2022-12-17	WOS:000165563100004
J	Hannan, KM; Hannan, RD; Smith, SD; Jefferson, LS; Lun, MY; Rothblum, LI				Hannan, KM; Hannan, RD; Smith, SD; Jefferson, LS; Lun, MY; Rothblum, LI			Rb and p130 regulate RNA polymerase I transcription: Rb disrupts the interaction between UBF and SL-1	ONCOGENE			English	Article						retinoblastoma protein; ribosomal RNA; transcription; UBF; DNA-binding	RIBOSOMAL DNA-TRANSCRIPTION; RETINOBLASTOMA SUSCEPTIBILITY GENE; TATA-BINDING PROTEIN; III TRANSCRIPTION; CELL-CYCLE; MOLECULAR-CLONING; NEONATAL CARDIOMYOCYTES; LUNG-CANCER; MOUSE P130; P107	We have previously demonstrated that the protein encoded by the retinoblastoma susceptibility gene (Rb) functions as a regulator of transcription by RNA polymerase I (rDNA transcription) by inhibiting UBF-mediated transcription. In the present study, we have examined the mechanism by which Rb represses UBF-dependent rDNA transcription and determined if other Rb-like proteins have similar effects. We demonstrate that authentic or recombinant UBF and Rb interact directly and this requires a functional A/B pocket. DNase footprinting and band-shift assays demonstrated that the interaction between Rb and UBF does not inhibit the binding of UBF to DNA, However, the formation of an UBF/Rb complex does block the interaction of UBF with SL-1, as indicated by using the 48 kDa subunit as a marker for SL-1, Additional evidence is presented that another pocket protein, p130 but not p107, can be found in a complex with UBF, Interestingly, the cellular content of p130 inversely correlated with the rate of rDNA transcription in two physiological systems, and overexpression of p130 inhibited rDNA transcription. These results suggest that p130 may regulate rDNA transcription in a similar manner to Rb.	Weis Ctr Res, Geisinger Clin, Henry Hood Res Program, Danville, PA 17822 USA; Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Rothblum, LI (corresponding author), Weis Ctr Res, Geisinger Clin, Henry Hood Res Program, 100 N Acad Ave, Danville, PA 17822 USA.			Hannan, Ross/0000-0002-2166-4493; Hannan, Katherine/0000-0003-4186-8167	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015658] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK15658] Funding Source: Medline; NIGMS NIH HHS [GM48991] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Baldi A, 1996, P NATL ACAD SCI USA, V93, P4629, DOI 10.1073/pnas.93.10.4629; Baldi A, 1997, CLIN CANCER RES, V3, P1691; BECKMANN H, 1995, SCIENCE, V270, P1506, DOI 10.1126/science.270.5241.1506; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BIGNON YJ, 1990, CELL GROWTH DIFFER, V1, P647; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; Chen G, 1996, J BIOL CHEM, V271, P9567, DOI 10.1074/jbc.271.16.9567; Chu WM, 1997, J BIOL CHEM, V272, P14755, DOI 10.1074/jbc.272.23.14755; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; COPENHAVER GP, 1994, NUCLEIC ACIDS RES, V22, P2651, DOI 10.1093/nar/22.13.2651; Farshid M, 1994, J Viral Hepat, V1, P45, DOI 10.1111/j.1365-2893.1994.tb00061.x; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HAMEL PA, 1993, FASEB J, V7, P846, DOI 10.1096/fasebj.7.10.8344484; Hannan KM, 2000, ONCOGENE, V19, P3487, DOI 10.1038/sj.onc.1203690; Hannan KM, 1998, AM J PHYSIOL-CELL PH, V275, pC130, DOI 10.1152/ajpcell.1998.275.1.C130; Hannan R, 1999, NUCLEIC ACIDS RES, V27, P1205, DOI 10.1093/nar/27.4.1205; Hannan RD, 1996, J BIOL CHEM, V271, P3213, DOI 10.1074/jbc.271.6.3213; Hannan RD, 1996, P NATL ACAD SCI USA, V93, P8750, DOI 10.1073/pnas.93.16.8750; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; Hempel WM, 1996, MOL CELL BIOL, V16, P557; HENSEL CH, 1990, CANCER RES, V50, P3067; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HISATAKE K, 1991, NUCLEIC ACIDS RES, V19, P4631, DOI 10.1093/nar/19.17.4631; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; KUHN A, 1994, EMBO J, V13, P416, DOI 10.1002/j.1460-2075.1994.tb06276.x; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; LeCouter JE, 1996, ONCOGENE, V12, P1433; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEVINE HB, 1993, PSYCHOANAL QUART, V62, P651; LIU Y, 1994, INT J CANCER, V58, P663, DOI 10.1002/ijc.2910580508; MCSTAY B, 1991, GENE DEV, V5, P1957, DOI 10.1101/gad.5.11.1957; MCSTAY B, 1991, EMBO J, V10, P2297, DOI 10.1002/j.1460-2075.1991.tb07766.x; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; OMAHONY DJ, 1991, P NATL ACAD SCI USA, V88, P3180, DOI 10.1073/pnas.88.8.3180; PAULE MR, 1994, TRANSCRIPTION MECHAN, P83; PERTILE P, 1995, CELL GROWTH DIFFER, V6, P1659; PIKAARD CS, 1990, MOL CELL BIOL, V10, P3810, DOI 10.1128/MCB.10.7.3810; PUTNAM CD, 1992, MOL CELL BIOL, V12, P4970, DOI 10.1128/MCB.12.11.4970; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RADEBAUGH CA, 1994, MOL CELL BIOL, V14, P597, DOI 10.1128/MCB.14.1.597; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Smith S. David, 1993, Gene Expression, V3, P229; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; Sutcliffe JE, 1999, MOL CELL BIOL, V19, P4255; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; White RJ, 1997, TRENDS BIOCHEM SCI, V22, P77, DOI 10.1016/S0968-0004(96)10067-0; XIE WQ, 1992, NUCLEIC ACIDS RES, V20, P1587, DOI 10.1093/nar/20.7.1587	64	105	106	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					4988	4999		10.1038/sj.onc.1203875	http://dx.doi.org/10.1038/sj.onc.1203875			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042686				2022-12-17	WOS:000089834300006
J	Kawabe, T; Tsuyama, N; Kitao, S; Nishikawa, K; Shimamoto, A; Shiratori, M; Matsumoto, T; Anno, K; Sato, T; Mitsui, Y; Seki, M; Enomoto, T; Goto, M; Ellis, NA; Ide, T; Furuichi, Y; Sugimoto, M				Kawabe, T; Tsuyama, N; Kitao, S; Nishikawa, K; Shimamoto, A; Shiratori, M; Matsumoto, T; Anno, K; Sato, T; Mitsui, Y; Seki, M; Enomoto, T; Goto, M; Ellis, NA; Ide, T; Furuichi, Y; Sugimoto, M			Differential regulation of human RecQ family helicases in cell transformation and cell cycle	ONCOGENE			English	Article						RecQ helicase; cell transformation; immunoblotting; genomic stability	ROTHMUND-THOMSON-SYNDROME; EPSTEIN-BARR-VIRUS; SV40-TRANSFORMED HUMAN FIBROBLASTS; WERNER-SYNDROME PROTEIN; ESCHERICHIA-COLI RECQ; SYNDROME GENE-PRODUCT; BLOOM-SYNDROME CELLS; DNA HELICASE; GENOMIC INSTABILITY; HUMAN HOMOLOG	Three human RecQ DNA helicases, WRN, BLM and RTS, are involved in the genetic disorders associated with genomic instability and a high incidence of cancer. RecQL1 and RecQL5 also belong to the human RecQ helicase family, but their correlation with genetic disorders, if any, is unknown. We report here that in human B cells transformed by Epstein-Barr virus (EBV), human fibroblasts and umbilical endothelial cells transformed by simian virus 40, the expression of WRN, BLM, RTS and RecQL1 was sharply up-regulated. In B cells this expression was stimulated within 5-40 h by the tumor promoting agent phorbol myristic acetate (PMA). Interestingly, RecQL5 beta, an alternative splicing product of RecQL5 with a nuclear localization signal, is expressed in resting B cells without significant modulation of its synthesis by EBV or PMA, suggesting it has a role in resting cells. We also roughly determined the number of copies per cell for the five RecQ helicase in B cells. In addition, levels of the different RecQ helicases are modulated in different ways during the cell cycle of actively proliferating fibroblasts and umbilical endothelial cells. Our results support the view that the levels of WRN, BLM, RTS and RecQL1 are differentially upregulated to guarantee genomic stability in cells that are transformed or actively proliferating.	AGENE Res Inst, Kamakura, Kanagawa 2470063, Japan; Hiroshima Univ, Sch Med, Dept Cellular & Mol Biol, Minami Ku, Hiroshima 7348551, Japan; Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3058566, Japan; Tohoku Univ, Mol Cell Biol Lab, Grad Sch Pharmaceut Sci, Sendai, Miyagi 9808578, Japan; Tokyo Metropolitan Otsuka Hosp, Dept Rheumatol, Toshima Ku, Tokyo 1700005, Japan; Mem Sloan Kettering Canc Ctr, Lab Canc Susceptibil, Dept Human Genet, New York, NY 10021 USA	Hiroshima University; National Institute of Advanced Industrial Science & Technology (AIST); Tohoku University; Memorial Sloan Kettering Cancer Center	Furuichi, Y (corresponding author), AGENE Res Inst, 200 Kajiwara, Kamakura, Kanagawa 2470063, Japan.							ABB J, 1979, J IMMUNOL, V122, P1639; AMANUMA K, 1991, BIOCHIM BIOPHYS ACTA, V1092, P336, DOI 10.1016/S0167-4889(97)90009-4; Balajee AS, 1999, MOL BIOL CELL, V10, P2655, DOI 10.1091/mbc.10.8.2655; BERTOGLIO JH, 1983, J IMMUNOL, V131, P2279; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CLEVERS HC, 1985, J IMMUNOL, V135, P3827; Cooper MP, 2000, GENE DEV, V14, P907; Courcelle J, 1999, MOL GEN GENET, V262, P543, DOI 10.1007/s004380051116; EGELER RM, 1992, CANCER, V70, P683, DOI 10.1002/1097-0142(19920801)70:3<683::AID-CNCR2820700324>3.0.CO;2-C; Ellis NA, 1999, AM J HUM GENET, V65, P1368, DOI 10.1086/302616; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Goto M, 1999, HUM GENET, V105, P301, DOI 10.1007/s004390051105; HANAOKA F, 1985, ADV EXP MED BIOL, V190, P439; Huang RP, 1997, J CELL BIOCHEM, V66, P489, DOI 10.1002/(SICI)1097-4644(19970915)66:4<489::AID-JCB8>3.0.CO;2-H; IDE T, 1984, EXP CELL RES, V150, P321, DOI 10.1016/0014-4827(84)90575-5; IDE T, 1983, EXP CELL RES, V143, P343, DOI 10.1016/0014-4827(83)90060-5; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kataoka H, 1997, DIFFERENTIATION, V62, P203; Kitao S, 1999, GENOMICS, V61, P268, DOI 10.1006/geno.1999.5959; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; KUCHINO T, 1975, J VIROL, V15, P1302, DOI 10.1128/JVI.15.6.1302-1307.1975; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lindor NM, 1996, CLIN GENET, V49, P124; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Matsumoto T, 1997, HUM GENET, V100, P123, DOI 10.1007/s004390050477; MATSUO M, 1982, J GERONTOL, V37, P33, DOI 10.1093/geronj/37.1.33; MILLER G, 1990, VIROLOGY, P1921; Moser MJ, 2000, NUCLEIC ACIDS RES, V28, P648, DOI 10.1093/nar/28.2.648; NAKAYAMA H, 1984, MOL GEN GENET, V195, P474, DOI 10.1007/BF00341449; Neff NF, 1999, MOL BIOL CELL, V10, P665, DOI 10.1091/mbc.10.3.665; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; SALK D, 1985, ADV EXP MED BIOL, V190, P541; Schulz VP, 1996, HUM GENET, V97, P750; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Shimamoto A, 2000, NUCLEIC ACIDS RES, V28, P1647, DOI 10.1093/nar/28.7.1647; Shiratori M, 1999, J CELL BIOL, V144, P1, DOI 10.1083/jcb.144.1.1; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Spender LC, 1999, J VIROL, V73, P4678, DOI 10.1128/JVI.73.6.4678-4688.1999; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Suzuki N, 1999, NUCLEIC ACIDS RES, V27, P2361, DOI 10.1093/nar/27.11.2361; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Tada S, 1996, CELL STRUCT FUNCT, V21, P123, DOI 10.1247/csf.21.123; Tahara H, 1997, ONCOGENE, V15, P1911, DOI 10.1038/sj.onc.1201377; TAHARA H, 1995, ONCOGENE, V10, P835; TSUYAMA N, 1991, CELL STRUCT FUNCT, V16, P55, DOI 10.1247/csf.16.55; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; UMEZU K, 1993, J MOL BIOL, V230, P1145, DOI 10.1006/jmbi.1993.1231; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; YAMAGUCHI N, 1975, J VIROL, V15, P1297, DOI 10.1128/JVI.15.6.1297-1301.1975; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	60	105	112	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4764	4772		10.1038/sj.onc.1203841	http://dx.doi.org/10.1038/sj.onc.1203841			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032027				2022-12-17	WOS:000089528800011
J	Ariumi, Y; Kaida, A; Lin, JY; Hirota, M; Masui, O; Yamaoka, S; Taya, Y; Shimotohno, K				Ariumi, Y; Kaida, A; Lin, JY; Hirota, M; Masui, O; Yamaoka, S; Taya, Y; Shimotohno, K			HTLV-1 Tax oncoprotein represses the p53-mediated trans-activation function through coactivator CBP sequestration	ONCOGENE			English	Article						p53; Tax; HTLV-1; CBP; CREB; NF-kappa B	T-CELL LEUKEMIA; P53 TUMOR-SUPPRESSOR; VIRUS TYPE-1 TAX; HUMAN PAPILLOMAVIRUS TYPE-16; TRANSCRIPTIONAL ACTIVATION; ABERRANT EXPRESSION; BINDING PROTEIN; PHOSPHORYLATION; DNA; TRANSACTIVATION	The human T-cell leukemia virus type 1 (HTLV-1) Tax oncoprotein repressed the transcriptional activity of wildtype p53 through its N-terminal trans-activation domain, Although Tax did not directly bind to p53, this repression required the activation of CREB pathway by Tax, In contrast to a recent report by Pise-Masison et al, (1998a,b) we found that the phosphorylation of p53 on Ser 15 is not a major cause of the Tax-mediated inactivation of p53, However, Tax with a mutation in the coactivator CBP-binding site (K88A), which activates NF-kappa B but not the CREB pathway, could not repress the p53 trans-activation function, Moreover, Tax inhibited p53 binding to CBP in vitro and inhibited synergistic activation of transcription by CBP and p53, Thus, Tax is likely to compete with p53 in binding with CBP, thereby repressing its trans-activation function.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Tokyo Med & Dent Univ, Bunkyo Ku, Tokyo 1138519, Japan; Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 1040045, Japan	Kyoto University; Tokyo Medical & Dental University (TMDU); National Cancer Center - Japan	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.		Masui, Osamu/AAH-4111-2019; Ariumi, Yasuo/F-5804-2013					Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Akagi T, 1996, ONCOGENE, V12, P1645; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; FUCHS B, 1995, ONCOGENE, V10, P789; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu L, 1999, MOL CELL BIOL, V19, P1202; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; NAGAI H, 1991, JPN J CANCER RES, V82, P1421, DOI 10.1111/j.1349-7006.1991.tb01815.x; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; ORDEN KV, 1999, J BIOL CHEM, V274, P26321; ORDEN KV, 1999, ONCOGENE, V18, P3766; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; REID RL, 1993, ONCOGENE, V8, P3029; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Scolnick DM, 1997, CANCER RES, V57, P3693; SEGAWA K, 1993, ONCOGENE, V8, P543; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TAKEUCHI K, 1985, J GEN VIROL, V66, P1825, DOI 10.1099/0022-1317-66-8-1825; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YAMATO K, 1993, JPN J CANCER RES, V84, P4, DOI 10.1111/j.1349-7006.1993.tb02775.x; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	55	105	107	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	2000	19	12					1491	1499		10.1038/sj.onc.1203450	http://dx.doi.org/10.1038/sj.onc.1203450			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734308				2022-12-17	WOS:000086108100001
J	Schnabel, CA; Jacobs, Y; Cleary, ML				Schnabel, CA; Jacobs, Y; Cleary, ML			HoxA9-mediated immortalization of myeloid progenitors requires functional interactions with TALE cofactors Pbx and Meis	ONCOGENE			English	Article						Hox; Pbx; Meis; homeodomain; DNA binding; hematopoietic	COOPERATIVE DNA-BINDING; HOX HOMEOBOX GENES; PROTEINS; HOMEODOMAIN; LEUKEMIA; T(7-11)(P15-P15); TRANSFORMATION; TRANSLOCATION; EXPRESSION; PARTNERS	Specific Hox genes are implicated in leukemic transformation, and their selective genetic collaboration with TALE homeobox genes, Pbx and Meis, accentuates their oncogenic potential. The molecular mechanisms under-lying these coordinate functions, however, have not been characterized. In this study, we demonstrate that HoxA9 requires its Pbx interaction motif as well as its amino terminus to enhance the clonogenic potential of myeloid progenitors in vitro. We further show that HoxA9 forms functional trimeric DNA binding complexes with Pbx and Meis-like proteins on a modified enhancer. DNA binding complexes containing HoxA9 and TALE homeoproteins display cooperative transcriptional activity and are present in leukemic cells. Trimeric complex formation on its own, however, is not sufficient for HoxA9-mediated immortalization. Rather, structure-function analyses demonstrate that domains of HoxA9 which are necessary for cellular transformation are coincident with those required for trimer-mediated transcriptional activation. Furthermore, the amino terminus of HoxA9 provides essential transcriptional effector properties and its requirement for myeloid transformation can be functionally replaced by the VP16 activation domain. These data suggest that biochemical interactions between HoxA9 and TALE homeoproteins mediate cellular transformation in hematopoietic cells, and that their transcriptional activity in higher order DNA binding complexes provides a molecular basis for their collaborative roles in leukemo-genesis.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University	Cleary, ML (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.				NATIONAL CANCER INSTITUTE [R37CA042971, R01CA042971, T32CA009151] Funding Source: NIH RePORTER; NCI NIH HHS [CA42971, CA09151] Funding Source: Medline; NIAID NIH HHS [AI-07290] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; Bischof LJ, 1998, J BIOL CHEM, V273, P7941, DOI 10.1074/jbc.273.14.7941; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Gonzalez-Crespo S, 1998, NATURE, V394, P196, DOI 10.1038/28197; HAWLEY RG, 1994, GENE THER, V1, P136; JACOBS Y, 1999, IN PRESS MOL CELL BI; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Lawrence HJ, 1996, STEM CELLS, V14, P281, DOI 10.1002/stem.140281; LU QA, 1995, MOL CELL BIOL, V15, P3786; Maconochie MK, 1997, GENE DEV, V11, P1885, DOI 10.1101/gad.11.14.1885; MAGLI MC, 1991, P NATL ACAD SCI USA, V88, P6348, DOI 10.1073/pnas.88.14.6348; Magli MC, 1997, J CELL PHYSIOL, V173, P168, DOI 10.1002/(SICI)1097-4652(199711)173:2<168::AID-JCP16>3.0.CO;2-C; Mann RS, 1998, CURR OPIN GENET DEV, V8, P423, DOI 10.1016/S0959-437X(98)80113-5; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nakamura T, 1996, ONCOGENE, V13, P2235; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; Schnabel CA, 1996, MOL CELL BIOL, V16, P2678; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109	36	105	107	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 3	2000	19	5					608	616		10.1038/sj.onc.1203371	http://dx.doi.org/10.1038/sj.onc.1203371			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698505				2022-12-17	WOS:000085192000002
J	Lee, SG; Rho, HM				Lee, SG; Rho, HM			Transcriptional repression of the human p53 gene by hepatitis B viral X protein	ONCOGENE			English	Article						HBx; repression; human p53 promoter; E-box element; c-Myc	HELIX-LOOP-HELIX; TUMOR-SUPPRESSOR GENE; PROMOTER ACTIVITY; VIRUS; BINDING; ELEMENT; LIVER; REPLICATION; EXPRESSION; SEQUENCE	Hepatitis B viral X protein (HBx) and the human p53 protein (p53) have been known as a transactivator and as a tumor suppressor, respectively, These two proteins have also been known to interact with each other to neutralize their authentic functions and the p53 represses the E-IBV enhancer/X promoter activity. Here we report that the promoter activity of the human p53 gene was strongly repressed by the HBx using the chloramphenicol acetyl transferase (CAT) assay, Analyses of serial deletion, site-directed mutagenesis and the heterologous promoter system showed that the site responsible for the repression was the E-box element in the promoter of the p53 gene, In addition, HBx as expected also repressed the activation of the p53 promoter by c-Myc through the E-box element, Northern blot analyses also showed that the expression of the p53 gene in the HepG2-K8 cell line, which expresses HBV genes including HBx, was much more repressed than that of the control cell HepG2. These results with previous data suggest that the shift of the reciprocal inhibitory activities at the levels of protein-protein interaction and transcription between HBx and p53 may play a decisive role in the HBV-related hepatocarcinogenesis.	Seoul Natl Univ, Dept Biol Mol, Seoul 151742, South Korea; Seoul Natl Univ, Res Ctr Cell Differentiat, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Rho, HM (corresponding author), Seoul Natl Univ, Dept Biol Mol, Seoul 151742, South Korea.		Lee, Seok-Geun/B-3408-2011	Lee, Seok-Geun/0000-0002-0060-5777				AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; CASELMANN WH, 1996, ADV VIRUS RES, V47, P303; Choi BH, 1999, J BIOL CHEM, V274, P2858, DOI 10.1074/jbc.274.5.2858; Choi CY, 1997, J BIOL CHEM, V272, P16934, DOI 10.1074/jbc.272.27.16934; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; FEITELSON MA, 1993, ONCOGENE, V8, P1109; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KIM SH, 1992, J GEN VIROL, V73, P2421, DOI 10.1099/0022-1317-73-9-2421; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE HB, 1993, PSYCHOANAL QUART, V62, P651; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Mutoh H, 1997, P NATL ACAD SCI USA, V94, P3560, DOI 10.1073/pnas.94.8.3560; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Ray RB, 1997, J BIOL CHEM, V272, P10983; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; SUN XG, 1995, MOL CELL BIOL, V15, P4489; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Wang HD, 1997, MOL CELL BIOL, V17, P6838, DOI 10.1128/MCB.17.12.6838; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20	32	105	122	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					468	471		10.1038/sj.onc.1203312	http://dx.doi.org/10.1038/sj.onc.1203312			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656696				2022-12-17	WOS:000084873700019
J	Terris, B; Pineau, P; Bregeaud, L; Valla, D; Belghiti, J; Tiollais, P; Degott, C; Dejean, A				Terris, B; Pineau, P; Bregeaud, L; Valla, D; Belghiti, J; Tiollais, P; Degott, C; Dejean, A			Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas	ONCOGENE			English	Article						beta-catenin; hepatocellular carcinoma; APC; immunohistochemistry	FAMILIAL ADENOMATOUS POLYPOSIS; SOMATIC MUTATIONS; COLORECTAL-CANCER; TUMOR; APC; ACTIVATION; EXPRESSION; HEPATITIS; DELETIONS; PATHWAY	Several lines of evidence indicate that beta-catenin acquires oncogenic activity when its intracellular concentration increases as a result of either mutation in the beta-catenin gene itself or inactivation of the adenomatous polyposis coli (APC) gene. In an attempt to elucidate the molecular mechanisms underlying hepatocellular carcinogenesis, we have studied the frequency of beta-catenin gene alterations in exon 3, a region known to represent a mutation hot spot, and its inappropriate protein expression by immunohistochemistry in 73 hepatocellular carcinomas (HCCs). The results were correlated with different clinical and pathological data, particularly with the presence or not of an associated cirrhosis, Fourteen (19%) HCCs showed beta-catenin gene alterations with missense mutations in nine cases and interstitial deletions in five cases. These genetic alterations were present in both cirrhotic and non-cirrhotic groups. By contrast, we did not find any beta-catenin gene alterations in the nine fibromellar carcinomas we examined. Nuclear accumulation of the protein was observed in 18 of them (25%), Remarkably, these included ten of the 14 tumors harboring somatic mutations in the beta-catenin gene (P<0.001). Our results indicate that accumulation of beta-catenin resulting from genetic mutations is a frequent event in non-fibrolamellar type hepatocellular carcinoma. The close association between increased beta-catenin protein stability and mutation indicates that immunohistochemistry may he a powerful method for the detection of the mutated protein in future clinical practice.	Hop Beaujon, Serv Anat Pathol, Clichy, France; Hop Beaujon, Serv Hepatol, Clichy, France; Hop Beaujon, Serv Chirurg Digest, Clichy, France; Inst Pasteur, INSERM, Unite Recombinaison & Express Genet, U163, F-75724 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Terris, B (corresponding author), Hop Beaujon, Serv Anat Pathol, Clichy, France.		Terris, Benoit/P-1497-2017; Dejean, Anne/L-5145-2018; Pineau, Pascal/AAP-5614-2020	Pineau, Pascal/0000-0002-9407-1592; Valla, Dominique/0000-0002-4460-7643				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Alman BA, 1997, AM J PATHOL, V151, P329; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Boige V, 1997, CANCER RES, V57, P1986; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; Fukuchi T, 1998, CANCER RES, V58, P3526; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gruner BA, 1998, J PEDIAT HEMATOL ONC, V20, P274, DOI 10.1097/00043426-199805000-00018; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Inomata M, 1996, CANCER RES, V56, P2213; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; Iwao K, 1998, CANCER RES, V58, P1021; Kitaeva MN, 1997, CANCER RES, V57, P4478; Koch A, 1999, CANCER RES, V59, P269; LAURENTPUIG P, 1992, HEPATOLOGY, V16, P1171, DOI 10.1016/0270-9139(92)90010-7; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.3.CO;2-N; Miyoshi Y, 1998, CANCER RES, V58, P2524; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller O, 1998, GENE CHROMOSOME CANC, V22, P37; MURAKAMI Y, 1991, CANCER RES, V51, P5520; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Nollet F, 1996, GENOMICS, V32, P413, DOI 10.1006/geno.1996.0136; Oda H, 1996, CANCER RES, V56, P3320; OKUDA K, 1989, GASTROENTEROLOGY, V97, P140, DOI 10.1016/0016-5085(89)91427-3; Piao Z, 1997, CANCER-AM CANCER SOC, V80, P865; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sparks AB, 1998, CANCER RES, V58, P1130; Terris B, 1996, J CLIN PATHOL-CL MOL, V49, pM203; TREVISANI F, 1995, CANCER-AM CANCER SOC, V75, P2220, DOI 10.1002/1097-0142(19950501)75:9<2220::AID-CNCR2820750906>3.0.CO;2-4; Voeller HJ, 1998, CANCER RES, V58, P2520; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; ZHANG X, 1994, CANCER RES, V54, P4177; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	38	105	108	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6583	6588		10.1038/sj.onc.1203051	http://dx.doi.org/10.1038/sj.onc.1203051			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597262				2022-12-17	WOS:000083709200022
J	Sanchez-Cespedes, M; Reed, AL; Buta, M; Wu, L; Westra, WH; Herman, JG; Yang, SC; Jen, J; Sidransky, D				Sanchez-Cespedes, M; Reed, AL; Buta, M; Wu, L; Westra, WH; Herman, JG; Yang, SC; Jen, J; Sidransky, D			Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer	ONCOGENE			English	Article						non small cell lung cancer; p16 inactivation; p14(ARF) inactivation; p53 gene mutations	TUMOR-SUPPRESSOR; CPG ISLAND; GENE; P53; METHYLATION; TRANSCRIPT; P19(ARF); PROTEIN; HEAD	Inactivation of the P16 (INK4A)/retinoblastoma (RB) or TP53 biochemical pathway is frequent event in most human cancers. Recent evidence has shown that P14ARF binds to MDM2 leading to an increased availability of wild type T53 protein. Functional studies also support a putative tumor suppressor gene function for p14(ARF) suggesting that p14(ARF) or p53 inactivation may be functionally equivalent in tumorigenesis. To study the relative contribution of each pathway in tumorigenesis, we analysed and compared alterations of the p16, p14(ARF) and p53 genes in 38 primary non-small cell lung cancers (NSCLCs) (19 adenocarcinomas and 19 squamous carcinoma). The p16 tumor suppressor gene was inactivated in 22 of 38 (58%) tumors. Twelve of these samples (31%) had homozygous deletions by microsatellite analysis; eight of them (21%) had p16 promoter hypermethylation detected by Methylation Specific PCR (MSP) and the remaining two (5%) harbored a point mutation in exon 2 by sequence analysis. The absence of P16 protein in every case was confirmed by immunohistochemistry. Fourteen of the 22 tumors with p16 inactivation also inactivated the g14(ARF) gene (12 with homozygous deletions extending into INK4a/ARF and two with exon 2 mutations). Mutations of p53 were found in 18 (47%) of the tumors and nine of them (50%) harbored p14(ARF) inactivation. Thus, an inverse correlation was not found between p14(ARF) and g53 genetic alterations (P = 0.18; Fisher Exact Test). Our data confirm that the p16 gene is frequently inactivated in NSCLC. Assuming that 9p deletion occurs first, the common occurrence of p53 and p14(ARF) alterations suggests that p14(ARF) inactivation is not functionally equivalent to abrogation of the TP53 pathway by p53 mutation.	Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Canc Res, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Canc Res, 818 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.		Sanchez-Cespedes, Montse/H-8485-2012	Sanchez-Cespedes, Montse/0000-0002-6045-5627	NCI NIH HHS [CA 58184] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARHRENDT SA, 1999, P NATL ACAD SCI USA, V96, P7382; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; Gazzeri S, 1998, CANCER RES, V58, P3926; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kinoshita I, 1996, CANCER RES, V56, P5557; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kratzke R A, 1992, Cancer Treat Res, V63, P61; Kratzke RA, 1996, CANCER RES, V56, P3415; Larsen CJ, 1996, ONCOGENE, V12, P2041; LING L, 1999, NAT GENET, V21, P128; MAO L, 1995, CANCER RES, V55, P2995; Markl IDC, 1998, CANCER RES, V58, P5348; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MITSUDOMI T, 1996, JAPAN J CANC CHEM, V23, P990; Munro J, 1999, CANCER RES, V59, P2516; Reed AL, 1996, CANCER RES, V56, P3630; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Sidransky D, 1996, CURR BIOL, V6, P523, DOI 10.1016/S0960-9822(02)00532-8; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; STONE S, 1995, CANCER RES, V55, P2988; VANDERRIET P, 1994, CANCER RES, V54, P1156	24	105	106	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5843	5849		10.1038/sj.onc.1203003	http://dx.doi.org/10.1038/sj.onc.1203003			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557071				2022-12-17	WOS:000083270700001
J	Devereux, TR; Anna, CH; Foley, JF; White, CM; Sills, RC; Barrett, JC				Devereux, TR; Anna, CH; Foley, JF; White, CM; Sills, RC; Barrett, JC			Mutation of beta-catenin is an early event in chemically induced mouse hepatocellular carcinogenesis	ONCOGENE			English	Article						beta-catenin mutations; chemical carcinogenesis; mouse liver tumors; beta-catenin expression; H-ras	TUMOR-SUPPRESSOR PROTEIN; LIVER-TUMORS; SOMATIC MUTATIONS; RAS PROTOONCOGENE; B6C3F1 MICE; METHYLENE-CHLORIDE; COLON TUMORS; APC; CANCER; ACTIVATION	beta-catenin activation, and subsequent upregulation of Wnt-signaling, is an important event in the development of certain human and rodent cancers. Recently, mutations in the beta-catenin gene in the region of the serine-threonine glycogen kinase (GSK)-3 beta phosphorylation target sites have been identified in hepatocellular neoplasms from humans and transgenic mice. In this study we: examined 152 hepatocellular neoplasms from B6C3F1 mice included in five chemical treatment groups and controls for mutations in the beta-catenin gene. Twenty of 29 hepatocellular neoplasms from mice treated with methyleugenol had point mutations at codons 32, 33, 33 or 41. sites which are mutated in colon and other cancers. Likewise, nine of 24 methylene chloride-induced hepatocellular neoplasms and 18 of 42 oxazepam-induced neoplasms exhibited similar mutations. In contrast,only three of 18 vinyl carbamate-induced liver tumors, one of 18 TCDD-induced liver tumors, and two of 22 spontaneous liver neoplasms had mutations in beta-catenin. Thus. there appears to be a chemical specific involvement of beta-catenin activation in mouse hepatocellular carcinogenesis. Expression analyses using Western blot and immunohistochemisty indicate that beta-catenin protein accumulates along cell membranes following mutation. The finding of mutations in both adenomas and carcinomas from diverse chemical treatment groups and the immunostaining of beta-catenin protein in an altered hepatocellular focus suggest that these alterations are early events in mouse hepatocellular carcinogenesis.	NIEHS, Mol Carcinogenesis Lab, Mol Toxicol Grp, Res Triangle Pk, NC 27709 USA; NIEHS, Lab Expt Pathol, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Devereux, TR (corresponding author), NIEHS, Mol Carcinogenesis Lab, Mol Toxicol Grp, MD D4-04,POB 12233, Res Triangle Pk, NC 27709 USA.			Foley, Julie/0000-0001-9726-2821	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES023006, Z01ES025001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Dashwood RH, 1998, CANCER RES, V58, P1127; DAVIS LM, 1994, CARCINOGENESIS, V15, P1637; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DEVEREUX TR, 1994, CARCINOGENESIS, V15, P1083, DOI 10.1093/carcin/15.5.1083; DEVEREUX TR, 1993, CARCINOGENESIS, V14, P795, DOI 10.1093/carcin/14.5.795; FUJIMORI M, 1991, CANCER RES, V51, P89; Fukuchi T, 1998, CANCER RES, V58, P3526; Gressani KM, 1998, CARCINOGENESIS, V19, P1045, DOI 10.1093/carcin/19.6.1045; GUMBINER BM, 1997, CURR BIOL, V7, P443; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HORII A, 1992, CANCER RES, V52, P6696; JEN J, 1994, CANCER RES, V54, P5523; KARI FW, 1993, CARCINOGENESIS, V14, P819, DOI 10.1093/carcin/14.5.819; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; MANENTI G, 1995, MOL CARCINOGEN, V13, P191, DOI 10.1002/mc.2940130309; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MARONPOT RR, 1995, TOXICOLOGY, V101, P125, DOI 10.1016/0300-483X(95)03112-S; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; *NAT TOX PROGR, 1993, 443 NTP TR US D HHS; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Pennisi E, 1998, SCIENCE, V281, P1438, DOI 10.1126/science.281.5382.1438; Rubinfeld B, 1997, CANCER RES, V57, P4624; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Takahashi M, 1998, CANCER RES, V58, P42; WATSON MA, 1995, CARCINOGENESIS, V16, P1705, DOI 10.1093/carcin/16.8.1705; WISEMAN RW, 1986, P NATL ACAD SCI USA, V83, P5825, DOI 10.1073/pnas.83.16.5825	31	105	109	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4726	4733		10.1038/sj.onc.1202858	http://dx.doi.org/10.1038/sj.onc.1202858			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467420				2022-12-17	WOS:000082154400010
J	Yao, YJ; Ping, XL; Zhang, H; Chen, FF; Lee, PK; Ahsan, H; Chen, CJ; Lee, PH; Pleacocke, M; Santella, RM; Tsou, HC				Yao, YJ; Ping, XL; Zhang, H; Chen, FF; Lee, PK; Ahsan, H; Chen, CJ; Lee, PH; Pleacocke, M; Santella, RM; Tsou, HC			PTEN/MMAC1 mutations in hepatocellular carcinomas	ONCOGENE			English	Article						PTEN/MMAC1; mutation; liver; tumor	BANNAYAN-ZONANA-SYNDROME; TUMOR-SUPPRESSOR GENE; HEPATITIS-B VIRUS; COWDEN-DISEASE; GERMLINE MUTATIONS; AFLATOXIN EXPOSURE; PROSTATE-CANCER; P53 MUTATIONS; BREAST-CANCER; HUMAN LIVER	Mutations in the PTEN/MMAC1 gene have been identified in several types of human cancers and cancer cell lines, including brain, endometrial, prostate, breast, thyroid, and melanoma. In this study, we screened a total of 96 hepatocellular carcinoma (HCC) samples from Taiwan, where HCC is the leading cancer in males and third leading cancer in females, for mutations in the PTEN/MMAC1 gene. Complete sequence analysis of these samples demonstrated a missense mutation in exon 5 (K144I) and exon 7 (V255A) from HCC samples B6-21 and B6-2, respectively. A putative splice site mutation was also detected in intron 3 from sample B6-2. Both B6-21 and B6-2 were previously shown to contain missense mutations in the coding sequences of the p53 gene. Functional studies with the two missense mutations demonstrated that while mutation V255A in exon 7 resulted in a loss of phosphatase activity, mutation K144I in exon 5 retained its phosphatase activity. Additionally, we identified a silent mutation (P96P) in exon 5 of the PTEN/MMAC1 gene from HCC sample B6-22. These data provide the first evidence that the PTEN/MMAC1 gene is mutated in a subset of HCC samples.	Columbia Univ Coll Phys & Surg, Sch Publ Hlth, Dept Dermatol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Sch Publ Hlth, Div Environm Hlth Sci, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Sch Publ Hlth, Div Epidemiol, New York, NY 10032 USA; Natl Taiwan Univ, Coll Publ Hlth, Inst Epidemiol, Taipei 10764, Taiwan; Natl Taiwan Univ, Coll Publ Hlth, Dept Surg, Taipei 10764, Taiwan	Columbia University; Columbia University; Columbia University; National Taiwan University; National Taiwan University	Tsou, HC (corresponding author), Columbia Presbyterian Hosp, Dept Dermatol, 630 W 168th St,VC1526, New York, NY 10032 USA.		Chen, Chien-Jen/C-6976-2008; Chen, Chien-Jen/N-4723-2019	LEE, PO-HUANG/0000-0001-5831-035X	NATIONAL CANCER INSTITUTE [R01CA070519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR044535] Funding Source: NIH RePORTER; NCI NIH HHS [CA70519] Funding Source: Medline; NIAMS NIH HHS [P0-30 AR44535] Funding Source: Medline; NIA NIH HHS [AG00760] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; Cairns P, 1997, CANCER RES, V57, P4997; Chen CJ, 1996, HEPATOLOGY, V24, P38, DOI 10.1002/hep.510240108; Chen CJ, 1997, J GASTROEN HEPATOL, V12, pS294, DOI 10.1111/j.1440-1746.1997.tb00513.x; COONEY KA, 1998, UNPUB; Dahia PLM, 1997, CANCER RES, V57, P4710; FUJIMOTO Y, 1994, CANCER RES, V54, P281; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Guldberg P, 1997, CANCER RES, V57, P3660; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liu WG, 1997, NAT GENET, V16, P328, DOI 10.1038/ng0897-328; Lunn RM, 1997, CANCER RES, V57, P3471; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Miyoshi Y, 1998, CANCER RES, V58, P2524; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; NISHIDA N, 1994, CANCER RES, V54, P3107; PEERS FG, 1976, INT J CANCER, V17, P167, DOI 10.1002/ijc.2910170204; Peng Shian-Yang, 1993, Journal of the Formosan Medical Association, V92, P866; Rhei E, 1997, CANCER RES, V57, P3657; Risinger JI, 1997, CANCER RES, V57, P4736; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Teng DHF, 1997, CANCER RES, V57, P5221; Tsou HC, 1998, HUM GENET, V102, P467, DOI 10.1007/s004390050723; Tsou HC, 1997, AM J HUM GENET, V61, P1036, DOI 10.1086/301607; YEH FS, 1989, CANCER RES, V49, P2506; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	36	105	116	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3181	3185		10.1038/sj.onc.1202659	http://dx.doi.org/10.1038/sj.onc.1202659			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340391				2022-12-17	WOS:000080388000015
J	Benedict, WF; Lerner, SP; Zhou, J; Shen, XH; Tokunaga, H; Czerniak, B				Benedict, WF; Lerner, SP; Zhou, J; Shen, XH; Tokunaga, H; Czerniak, B			Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer	ONCOGENE			English	Article						bladder cancer; RB; p16; prognosis	ALTERED EXPRESSION; RB PROTEIN; PRB ALTERATIONS; CELL-CARCINOMA; HIGH-FREQUENCY; GENE-PRODUCT; LUNG CANCERS; TUMORS; INACTIVATION; MUTATIONS	Recent studies have shown that patients whose bladder cancer exhibit overexpression of RB protein as measured by immunohistochemical analysis do equally poorly as those with loss of RB function. We hypothesized that loss of p16 protein function could be related to RB overexpression, since p16 can induce transcriptional downregulation of RB and its loss may lead to aberrant RB regulation. Conversely, loss of RB function has been associated with high p16 protein expression in several other tumor types, In the present study RB negative bladder tumors also exhibited strong nuclear p16 staining while each tumor with strong, homogeneous RB nuclear staining were p16 negative, supporting our hypothesis. To expand on these immunohistochemical studies additional cases were selected in which the status of the p16 encoding gene had been determined at the molecular level. Absent p16 and high RB protein expression was found in the tumors having loss of heterozygosity within 9p21 and a structural change (mutation or deletion) of the remaining p16 encoding gene allele, confirming the staining results. These results strongly support the hypothesis that the RB nuclear overexpression recently associated with poor prognosis in bladder cancer is also associated with toss of p16 function and implies that loss of p16 function could be equally deleterious as RB loss in bladder and likely other cancers.	Univ Texas, MD Anderson Cancer Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Benedict, WF (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Genitourinary Med Oncol, 1515 Holcombe Blvd,Box 13, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA054672, R01CA066723, R29CA066723] Funding Source: NIH RePORTER; NCI NIH HHS [CA66723, CA54672] Funding Source: Medline; NEI NIH HHS [EY06195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BENEDICT WF, 1990, J CLIN INVEST, V85, P988, DOI 10.1172/JCI114575; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; Chaturvedi V, 1997, ONCOGENE, V14, P2059, DOI 10.1038/sj.onc.1201044; CORDONCARDO C, 1992, J NATL CANCER I, V84, P1251, DOI 10.1093/jnci/84.16.1251; CordonCardo C, 1997, CANCER RES, V57, P1217; Cote RJ, 1998, CANCER RES, V58, P1090; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Fang XJ, 1998, ONCOGENE, V16, P1, DOI 10.1038/sj.onc.1201525; Grossman HB, 1998, CLIN CANCER RES, V4, P829; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; ISHIKAWA J, 1991, CANCER RES, V51, P5376; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kratzke RA, 1996, CANCER RES, V56, P3415; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PACKENHAM JP, 1995, MOL CARCINOGEN, V14, P147, DOI 10.1002/mc.2940140303; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Reed AL, 1996, CANCER RES, V56, P3630; Sakaguchi M, 1996, INT J CANCER, V65, P442, DOI 10.1002/(SICI)1097-0215(19960208)65:4<442::AID-IJC8>3.0.CO;2-X; SHAPIRO GI, 1995, CANCER RES, V55, P505; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; WILLIAMSON MP, 1995, HUM MOL GENET, V4, P1569, DOI 10.1093/hmg/4.9.1569; Wong DJ, 1997, CANCER RES, V57, P2619; Xu HJ, 1996, CLIN CANCER RES, V2, P1169; XU HJ, 1993, INT J CANCER, V53, P781, DOI 10.1002/ijc.2910530513; XU HJ, 1989, ONCOGENE, V4, P807; XU HJ, 1991, ONCOGENE, V6, P1139; YEAGER T, 1995, CANCER RES, V55, P493; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	35	105	108	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1197	1203		10.1038/sj.onc.1202452	http://dx.doi.org/10.1038/sj.onc.1202452			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022125	Bronze			2022-12-17	WOS:000078510700008
J	Xu, XX; Yi, TL; Tang, B; Lambeth, JD				Xu, XX; Yi, TL; Tang, B; Lambeth, JD			Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2	ONCOGENE			English	Article						Dab2; p96; DOC 2; Grb2; SH3 domain; ovarian cancer	NUCLEOTIDE EXCHANGE FACTOR; RECEPTOR TYROSINE KINASES; SRC HOMOLOGY-3 DOMAINS; SON-OF-SEVENLESS; SIGNAL-TRANSDUCTION; DROSOPHILA-ABL; ADAPTER PROTEIN; FACTOR HSOS1; RAS; IDENTIFICATION	Disabled-2 (Dab2), a mammalian structural homolog of Drosophila Disabled (Dab), is a mitogen-responsive phosphoprotein, It has been speculated to be a negative regulator of growth since its expression is lost in ovarian carcinomas, Dab2 contains a C-terminal proline-rich domain with sequences similar to those found in Sos, a guanine nucleotide exchange factor for Ras, The proline-rich sequences of Sos mediate the interaction of Sos with Grb2, an adaptor protein which coupled tyrosine kinase receptors to Sos, Herein, we have investigated the possibility that Dab2 interacts with Grb2, In experiments of co-immunoprecipitation from BAC1.2F5 macrophage cell lysates, significant quantities of Grb2 were associated with both Sos and Dab2, although Dab2 and Sos were not present in the same complex, Transfection of Dab2 into a Dab2-negative cell line (293 cells) decreased the amount of Grb2 associated with Sos, suggesting that Dab2 competes with Sos for binding to Grb2, Proline-rich peptides corresponding to Dab2 (#661-669) and to Sos (#1146-1161) inhibited the binding of Dab2 to Grb2, but were less effective in disrupting the Grb2-Sos complex, The expressed proline-rich domain of Dab2 (#600-730) bound Grb2, but other regions of Dab2 failed to bind Grb2. Both of the individual SH3 domains of Grb(2) bound to Sos (N-terminal SH3 domain > > C-terminal SH3 domain), but binding to Dab2 required the intact Grb2, suggesting cooperative binding using both SH3 domains of Grb2, These data indicate that Dab2 binds to the SH3 domains of Grb2 via its C-terminal proline-rich sequences, Dab2 may modulate growth factor/Ras pathways by competing with Sos for binding to Grb2.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA; Cleveland Clin Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA	Emory University; Emory University; Cleveland Clinic Foundation	Xu, XX (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.				NATIONAL CANCER INSTITUTE [R01CA046508, R01CA075389] Funding Source: NIH RePORTER; NCI NIH HHS [R 01 CA75389-01, R01CA46508] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertsen HM, 1996, GENOMICS, V33, P207, DOI 10.1006/geno.1996.0185; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUDAY L, 1995, ONCOGENE, V11, P1327; Byrne JL, 1996, ONCOGENE, V13, P2055; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LEMMON MA, 1994, J BIOL CHEM, V269, P31653; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1995, NATURE, V374, P94, DOI 10.1038/374094a0; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MIKI H, 1994, J BIOL CHEM, V269, P5489; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WITTEKIND M, 1994, BIOCHEMISTRY-US, V33, P13531, DOI 10.1021/bi00250a004; WONG KK, 1993, INT J ONCOL, V3, P13; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; XU XX, 1993, MOL CELL BIOL, V270, P14184; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; YI TL, 1991, BLOOD, V78, P2222	53	105	109	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	1998	16	12					1561	1569		10.1038/sj.onc.1201678	http://dx.doi.org/10.1038/sj.onc.1201678			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569023				2022-12-17	WOS:000072743200006
J	Michael, D; Beer, DG; Wilke, CW; Miller, DE; Glover, TW				Michael, D; Beer, DG; Wilke, CW; Miller, DE; Glover, TW			Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas	ONCOGENE			English	Article						Barrett's esophagus; fragile sites; FRA3B; gene deletion; human chromosome 3	RENAL-CELL CARCINOMA; TUMOR-SUPPRESSOR LOCUS; COMMON FRAGILE SITES; LUNG-CANCER; SHORT ARM; 3P14.2; GENE; DNA; BREAKAGE; LINES	The FHIT gene, which spans the common fragile site FRA3B, has been shown to produce aberrant transcripts in a variety of tumor types, Homozygous deletions within the FHIT locus have been detected only in tumor-derived cell lines and LOH has been described in numerous primary tumors, Based on these findings and its location on 3p, FHIT has been proposed as a tumor suppressor gene, To further study the relationship of FRA3B to the findings regarding the FHIT gene and to determine the extent of FHIT mRNA alterations in early stages of tumor development, the status of the FHIT gene was evaluated in the premalignant condition of Barrett's esophagus and associated esophageal adenocarcinomas, FHIT expression was investigated by RT-PCR in normal esophageal, Barrett's metaplasia and adenocarcinoma tissues from 15 patients, Alterations of FHIT transcripts were observed in 12/14 (86%) of Barrett's metaplasia and in 14/15 (93%) of the adenocarcinomas from the same patients, Characterization of the altered transcripts revealed FHIT mRNA lacking one or more exons, with deletion of exons 5-7 being most frequent, Analysis of genomic DNA from 20 patients showed homozygous deletions involving exon 5 of FHIT in 4/20 (20%) esophageal adenocarcinomas, and 7/20 (35%) tumors demonstrated hemizygous loss, Genomic deletions also involved the BE758-6 locus, indicating that a large region is deleted. Fluorescence ill situ hybridization (FISH) analysis demonstrated that this region of deletion is localized within FRA3B, Our results extend the range of tumor types in which altered FHIT transcripts have been demonstrated and show that these alterations can be seen in the premalignant stage of esophageal tumor development, These results indicate that the fragility and recombination-prone nature of FRA3B is related to tumor-specific chromosomal instability affecting the FHIT gene in esophageal adenocarcinoma development.	UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PEDIAT,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT SURG,THORAC SURG SECT,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NCI NIH HHS [CA 71606, CA 43222] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071606, R01CA043222] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; BIRNBOIM HC, 1982, SCIENCE, V215, P1247, DOI 10.1126/science.6276978; Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DIERICK HA, 1995, GENOMICS, V28, P462, DOI 10.1006/geno.1995.1175; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Druck T, 1997, CANCER RES, V57, P504; Gantz I, 1996, CYTOGENET CELL GENET, V74, P286, DOI 10.1159/000134436; GLOVER TW, 1987, AM J HUM GENET, V41, P882; GLOVER TW, 1988, AM J HUM GENET, V43, P265; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; Gustashaw KM., 1991, ACT CYTOGENETICS LAB, V2; JONES MH, 1992, ONCOGENE, V7, P1631; Kastury K, 1996, CANCER RES, V56, P978; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LEBEAU MM, 1984, NATURE, V308, P607, DOI 10.1038/308607a0; LISITSYN NA, 1995, P NATL ACAD SCI USA, V92, P151, DOI 10.1073/pnas.92.1.151; NAWROZ H, 1994, CANCER RES, V54, P1152; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Negrini M, 1996, CANCER RES, V56, P3173; NESHAT K, 1994, GASTROENTEROLOGY, V106, P1589, DOI 10.1016/0016-5085(94)90415-4; NIGRO JM, 1991, CELL, V64, P607, DOI 10.1016/0092-8674(91)90244-S; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Paradee W, 1996, GENOMICS, V35, P87, DOI 10.1006/geno.1996.0326; RASSOOL FV, 1991, P NATL ACAD SCI USA, V88, P6657, DOI 10.1073/pnas.88.15.6657; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sambrook J, 1989, MOL CLONING LAB MANU; SANCHEZ Y, 1994, P NATL ACAD SCI USA, V91, P3383, DOI 10.1073/pnas.91.8.3383; SATO T, 1991, CANCER RES, V51, P5794; Shridhar R, 1996, CANCER RES, V56, P4347; SOZZI G, 1996, CELL, V85, P7; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; Thiagalingam S, 1996, CANCER RES, V56, P2936; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; WANG ND, 1993, GENOMICS, V17, P341, DOI 10.1006/geno.1993.1330; WEITBERG AB, 1983, NEW ENGL J MED, V308, P26, DOI 10.1056/NEJM198301063080107; WEITZMAN SA, 1985, SCIENCE, V227, P1231, DOI 10.1126/science.3975611; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; Yanagisawa K, 1996, CANCER RES, V56, P5579; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; ZEIGER MA, 1994, GENE CHROMOSOME CANC, V11, P15, DOI 10.1002/gcc.2870110104	42	105	114	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1653	1659						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349498				2022-12-17	WOS:A1997XY63100004
J	Nakagawa, H; Wang, TC; Zukerberg, L; Odze, R; Togawa, K; May, GHW; Wilson, J; Rustgi, AK				Nakagawa, H; Wang, TC; Zukerberg, L; Odze, R; Togawa, K; May, GHW; Wilson, J; Rustgi, AK			The targeting of the cyclin D1 oncogene by an Epstein-Barr virus promoter in transgenic mice causes dysplasia in the tongue, esophagus and forestomach	ONCOGENE			English	Article						cyclin D1; oncogene; squamous epithelial cells; transgenic mice	SQUAMOUS-CELL CARCINOMA; NECK-CANCER; P53 GENE; EXPRESSION; PROGRESSION; OVEREXPRESSION; AMPLIFICATION; FIBROBLASTS; G(1); HEAD	Cyclin D1 in cooperation with its major catalytic partners, cyclin-dependent kinases cdk4 and cdk6, facilitates progression through the G(1) phase of the eukaryotic cell cycle, in part through phosphorylation of the retinoblastoma protein, Cyclin D1's oncogenic properties have been suggested by its cooperation with ras or adenovirus E1a to transform cultured cells, as well its overexpression in transgenic mice that leads to breast cancer. Activated by a number of different mechanisms in human cancers, the cyclin D1 gene is frequently amplified in squamous epithelial cancers derived from the head/neck and esophageal regions. In order to study the functional consequences of cyclin D1 overexpression in these squamous epithelial specific sites, we have linked the Epstein-Barr virus ED-L2 promoter to the human cyclin D1 cDNA and utilized this transgene to generate founder lines. This transgene is transcribed specifically in the tongue, esophagus and forestomach, all sharing a stratified squamous epithelium. The transgene protein product localizes to the basal and suprabasal compartments of these squamous epithelial tissues, and mice from different lines develop dysplasia, a prominent precursor to carcinoma, by 16 months of age in contrast to age-matched wild-type mice, This transgenic model is useful in demonstrating cyclin D1 may be a tumor initiating event in aero-upper digestive squamous epithelial tissues.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,GASTROINTESTINAL UNIT,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HEMATOL ONCOL UNIT,BOSTON,MA; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PATHOL,BOSTON,MA; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115; UNIV GLASGOW,INST BIOMED & LIFE SCI,ROBERTSON LAB BIOTECHNOL,GLASGOW,LANARK,SCOTLAND	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Glasgow					NATIONAL CANCER INSTITUTE [R01CA067463] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, P30DK040561] Funding Source: NIH RePORTER; NCI NIH HHS [CA67463] Funding Source: Medline; NIDDK NIH HHS [DK43351, DK40561] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1995, CANCER RES, V55, P949; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CHUNG KY, 1993, CANCER RES, V53, P1676; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; JARES P, 1994, CANCER RES, V54, P4813; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; LIU QY, 1995, ONCOGENE, V10, P619; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORI T, 1994, CANCER RES, V54, P3396; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NAKAGAWA H, 1995, CANCER-AM CANCER SOC, V76, P541, DOI 10.1002/1097-0142(19950815)76:4<541::AID-CNCR2820760402>3.0.CO;2-I; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; VANDERRIET P, 1994, CANCER RES, V54, P1156; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WILLIAMS ME, 1992, CANCER RES, V52, pS5541; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	32	105	110	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 13	1997	14	10					1185	1190		10.1038/sj.onc.1200937	http://dx.doi.org/10.1038/sj.onc.1200937			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM782	9121767				2022-12-17	WOS:A1997WM78200007
J	Viglietto, G; Romano, A; Maglione, D; Rambaldi, M; Paoletti, I; Lago, CT; Califano, D; Monaco, C; Mineo, A; Santelli, G; Manzo, G; Botti, G; Chiappetta, G; Persico, MG				Viglietto, G; Romano, A; Maglione, D; Rambaldi, M; Paoletti, I; Lago, CT; Califano, D; Monaco, C; Mineo, A; Santelli, G; Manzo, G; Botti, G; Chiappetta, G; Persico, MG			Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor	ONCOGENE			English	Article						VEGF; PlGF; angiogenesis; germ cell tumors; vascular count	HUMAN COLON-CANCER; PERMEABILITY FACTOR; TYROSINE KINASE; STROMA GENERATION; BREAST-CARCINOMA; MESSENGER-RNAS; UP-REGULATION; FACTOR PIGF; IN-VIVO; ANGIOGENESIS	Neoangiogenesis is a prerequisite for tumor growth and metastasis. In germ cell cancer patients with the disease limited to the testicle (stage A), tumor-associated neovascularization is predictive of metastatic disease (stage B). To investigate the molecular mechanisms underlying neovascularization in human germ cell tumors (GCTs), we analysed the expression of two angiogenic growth factors, vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF), and of their receptors (FLT-1) and Flk-1/KDR) in a panel of testicular tumors. In this study we show a marked increase in VEGF expression in 36/44 (81.8%) primary testicular-derived GCTs, as compared to normal testis, that significantly correlates with a high density of intratumor microvessels (r = 0.72461, P < 0.001; n = 24). As determined by RT-PCR and/or Western blot, the predominant VEGF isoforms expressed in GCTs are the VEGF(121) and VEGF(165) which are more efficiently secreted by the cells, and thus more active in eliciting angiogenesis. Conversely, in the case of PIGF, only a weak correlation with the vascular density of tumors is observed (r = 0.26599, P < 0.05; n = 24). Northern blot analysis also revealed significant up-regulation of VEGF/ PIGF receptors in highly vascularized germ cell tumors, compared to normal testes. These findings suggest that VEGF may act in a paracrine manner to induce neovascularization, oedema extravasation and cyst formation in human germ cell tumors. The correlation between VEGF expression and the vascular density of tumors, suggest that the evaluation of VEGF expression may be of help in predicting patients at risk for metastatic diseases. Finally, we demonstrate that VEGF up-regulation may occur at the RNA level since no gene amplification is observed; conversely, in in vitro models such as the embryonal stem cell line NTERA-2 and the choriocarcinoma JEG-3 cell line, VEGF (but not PIGF) mRNA expression is regulated by hypoxic stress.	CNR,INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	Viglietto, G (corresponding author), FDN SENATORE PASCALE,IST NAZL TUMORI,VIA M SEMMOLA,I-80131 NAPLES,ITALY.		Califano, Daniela/Y-6313-2018; Viglietto, Giuseppe/AAC-2852-2019	Califano, Daniela/0000-0001-6945-3209; Viglietto, Giuseppe/0000-0003-2327-7515; Botti, Gerardo/0000-0002-6287-733X				ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671; ANDREWS PW, 1988, BIOCHIM BIOPHYS ACTA, V948, P17, DOI 10.1016/0304-419X(88)90003-0; BREIER G, 1992, DEVELOPMENT, V114, P521; BROWN LF, 1993, CANCER RES, V53, P4727; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; DVORAK HF, 1987, LAB INVEST, V57, P673; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Jacobsen GK., 1989, ATLAS GERM CELL TUMO; KATO Y, 1991, ENDOCRINOLOGY, V128, P401, DOI 10.1210/endo-128-1-401; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KENDALL RL, 1994, BIOCHEM BIOPH RES CO, V201, P326, DOI 10.1006/bbrc.1994.1705; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; OLIVAREZ D, 1994, CANCER RES, V54, P2800; PARK JE, 1994, J BIOL CHEM, V269, P25646; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1993, CANCER RES, V53, P5822; Sambrook J, 1989, MOL CLONING LAB MANU; SAMOTO K, 1995, CANCER RES, V55, P1189; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SIGEGRIST W, 1994, CANCER RES, V54, P2604; SRIVASTAVA A, 1988, AM J PATHOL, V133, P419; TAKAHASHI A, 1994, CANCER RES, V54, P4233; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; TERMAN BI, 1994, GROWTH FACTORS, V11, P187, DOI 10.3109/08977199409046916; TERMAN BI, 1991, ONCOGENE, V6, P1677; Tisher E, 1991, J BIOL CHEM, V266, P11947; Toi M, 1995, CLIN CANCER RES, V1, P961; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEIDNER N, 1993, AM J PATHOL, V143, P401; ZHANG HT, 1995, J NATL CANCER I, V87, P213, DOI 10.1093/jnci/87.3.213	49	105	110	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					577	587						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760299				2022-12-17	WOS:A1996VB32800015
J	Vider, BZ; Zimber, A; Chastre, E; Prevot, S; Gespach, C; Estlein, D; Wolloch, Y; Tronick, SR; Gazit, A; Yaniv, A				Vider, BZ; Zimber, A; Chastre, E; Prevot, S; Gespach, C; Estlein, D; Wolloch, Y; Tronick, SR; Gazit, A; Yaniv, A			Evidence for the involvement of the Wnt 2 gene in human colorectal cancer	ONCOGENE			English	Article						Wnt genes; colorectal cancer	MAMMARY ONCOGENE INT-1; WINGLESS PROTEIN; DEVELOPMENTAL REGULATORS; PROVIRAL ACTIVATION; CELL-LINE; EXPRESSION; XENOPUS; EMBRYOS; TRANSFORMATION; FAMILY	Colorectal cancer (CRC) is onte of the most frequent cancers in humans. It develops via a multistage process involving alterations of both protooncogenes and tumor suppressor genes. In the present report we determined the level of expression of several Wnt genes in CRC by RT-PCR and direct sequencing. While Wnt-1 was not detectably expressed in any colonic tissues, Wnt-5a gene was efficiently expressed both in nontumorous as well as in colonic tumor tissues. In contrast, the Wnt-2 gene, which was expressed at low levels in normal colon, exhibited overexpression in all tumor tissue samples at the different Dukes' stages of CRC progression, including premalignant polyps and liver metastases. Overexpression of the Wnt-2 gene occurred also in other digestive neoplasms such as gastric and esophageal carcinomas, as well as in diverticulitis associated with stenosis or pseudo-tumor.	TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN MICROBIOL,IL-69978 TEL AVIV,ISRAEL; HEBREW UNIV JERUSALEM,DEPT ANIM SCI,IL-76100 REHOVOT,ISRAEL; HOSP ST ANTOINE,INSERM,U55,EQUIPE CANCEROGENESE & DIFFERENCIAT EPITHELIUM GA,F-75571 PARIS 12,FRANCE; HASHARON HOSP,DEPT SURG B,PETAH TIQWA,ISRAEL; SANTA CRUZ BIOTECHNOL,SANTA CRUZ,CA 95060	Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Rabin Medical Center			CHASTRE, Eric/L-8446-2018	CHASTRE, Eric/0000-0002-8993-1228				BLASBAND A, 1992, ONCOGENE, V7, P153; BOS JL, 1989, CANCER RES, V49, P4682; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BUHLER TA, 1993, DEV BIOL, V155, P87, DOI 10.1006/dbio.1993.1009; BURKITT DP, 1978, AM J CLIN NUTR, V31, P118; CABALLERO OL, 1995, NUCLEIC ACIDS RES, V23, P192, DOI 10.1093/nar/23.1.192; CHAKRABARTI A, 1992, DEVELOPMENT, V115, P355; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK CC, 1993, GENOMICS, V18, P249, DOI 10.1006/geno.1993.1463; COHN KH, 1991, LANCET, V338, P722, DOI 10.1016/0140-6736(91)91444-Y; DEVITA G, 1993, EUR J CANCER, V29A, P887, DOI 10.1016/S0959-8049(05)80432-0; Dickinson ME, 1992, CURR OPIN GENET DEV, V2, P562, DOI 10.1016/S0959-437X(05)80172-8; DUKAS K, 1993, ANAL BIOCHEM, V215, P66, DOI 10.1006/abio.1993.1555; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY GJ, 1993, MUTAT RES, V290, P3, DOI 10.1016/0027-5107(93)90027-D; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HUGUET EL, 1994, CANCER RES, V54, P2615; HULSKEN J, 1994, CURR OPIN CELL BIOL, V6, P711, DOI 10.1016/0955-0674(94)90098-1; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KITAJEWSKI J, 1992, MOL CELL BIOL, V12, P784, DOI 10.1128/MCB.12.2.784; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LEJEUNE S, 1995, CLIN CANCER RES, V1, P215; LYNCH HT, 1992, CANCER, V70, P1300, DOI 10.1002/1097-0142(19920901)70:3+<1300::AID-CNCR2820701517>3.0.CO;2-O; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MOON RT, 1993, BIOESSAYS, V15, P91, DOI 10.1002/bies.950150204; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OLSON DJ, 1994, CELL GROWTH DIFFER, V5, P197; PAINTER NS, 1971, BMJ-BRIT MED J, V2, P450, DOI 10.1136/bmj.2.5759.450; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PARKIN NT, 1993, GENE DEV, V7, P2181, DOI 10.1101/gad.7.11.2181; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; PORTE H, 1995, INT J CANCER, V64, P1; RAMAKRISHNA NR, 1993, DEVELOPMENT, P95; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; RODRIGUEZ E, 1994, CANCER RES, V54, P3398; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, 1992, ONCOGENE, V7, P487; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; VANOOYEN A, 1985, EMBO J, V4, P2905, DOI 10.1002/j.1460-2075.1985.tb04021.x; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; WANG LM, 1993, CANCER RES, V53, P717; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; ZAKANY J, 1993, NATURE, V362, P546, DOI 10.1038/362546a0	62	105	112	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					153	158						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552386				2022-12-17	WOS:A1996TQ01400019
J	KAGAN, J; STEIN, J; BABAIAN, RJ; JOE, YS; PISTERS, LL; GLASSMAN, AB; VONESCHENBACH, AC; TRONCOSO, P				KAGAN, J; STEIN, J; BABAIAN, RJ; JOE, YS; PISTERS, LL; GLASSMAN, AB; VONESCHENBACH, AC; TRONCOSO, P			HOMOZYGOUS DELETIONS AT 8P22 AND 8P21 IN PROSTATE-CANCER IMPLICATE THESE REGIONS AS THE SITES FOR CANDIDATE TUMOR-SUPPRESSOR GENES	ONCOGENE			English	Article						CHROMOSOME 8P; LOH; MICROSATELLITE; PROSTATE CANCER; TUMOR SUPPRESSOR GENE (TSG)	DINUCLEOTIDE REPEAT POLYMORPHISM; ALLELIC LOSS; CHROMOSOME REARRANGEMENTS; ADENOCARCINOMA; LOCALIZATION; CARCINOMA; LOCUS	Frequent loss of an allele at specific chromosomal regions implicates these regions as sites of tumor suppressor genes (TSG) that become inactivated during tumor progression. We have studied chromosome 8p allele losses in 32 primary human prostate carcinomas with 16 polymorphic microsatellite sequences. Overall, 22 of 32 (69%) informative specimens showed loss of allele in at least one locus. The most frequent losses of heterozygosity (LOH) occurred at the LPL locus (46%) on chromosome 8p22 and at the DSS360 (45%) and NEFL (43%) loci on chromosome 8p21. Homozygous deletions were detected at the LPL and NEFL loci at 8p22 and 8p21, respectively. The minimal region with frequent LOH and homozygous deletion, around the LPL locus, was restricted between the MSR locus and the D8S258 marker, separated by less than 9 cM. The second region was restricted between markers D8S1128 and D8S131 separated by 12 cM. The results suggest the existence of two chromosome 8p sites for candidate TSGs in prostate cancer.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT UROL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	KAGAN, J (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DIV LAB MED,HEMATOPATHOL PROGRAM,BOX 72,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							ARPS S, 1993, CANCER GENET CYTOGEN, V66, P93, DOI 10.1016/0165-4608(93)90234-D; ATKIN NB, 1985, HUM GENET, V70, P359, DOI 10.1007/BF00295378; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BOOKSTEIN R, 1994, GENOMICS, V24, P317, DOI 10.1006/geno.1994.1622; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BOVA GS, 1993, CANCER RES, V53, P3869; BUETOW KH, 1994, NAT GENET, V6, P391, DOI 10.1038/ng0494-391; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CHANG M, 1994, AM J PATHOL, V144, P1; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; FUJIWARA Y, 1995, ONCOGENE, V10, P891; GIBAS Z, 1985, CANCER GENET CYTOGEN, V16, P301, DOI 10.1016/0165-4608(85)90237-7; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; ICHIKAWA T, 1994, CANCER RES, V54, P2299; KAGAN J, 1994, INT J ONCOL, V5, P921; KAMINO K, 1993, HUM MOL GENET, V2, P1751, DOI 10.1093/hmg/2.10.1751; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; LUNDGREN R, 1988, CANCER GENET CYTOGEN, V35, P103, DOI 10.1016/0165-4608(88)90128-8; LUNDGREN R, 1992, GENE CHROMOSOME CANC, V4, P16, DOI 10.1002/gcc.2870040103; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; MURRAY JE, 1993, COMMUNICATION; PYKETT MJ, 1994, CANCER GENET CYTOGEN, V76, P23, DOI 10.1016/0165-4608(94)90064-7; Rogaev E., 1992, Human Molecular Genetics, V1, P781, DOI 10.1093/hmg/1.9.781; SADLER LA, 1991, NUCLEIC ACIDS RES, V19, P6058, DOI 10.1093/nar/19.21.6058-a; THOMFOHRDE J, 1992, GENOMICS, V14, P144; TRAPMAN J, 1994, CANCER RES, V54, P6061; WAGNER MJ, 1991, GENOMICS, V10, P114, DOI 10.1016/0888-7543(91)90491-V; WEBBER JL, 1990, NUCLEIC ACIDS RES, V18, P4038; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Wood S, 1993, Cytogenet Cell Genet, V64, P134; WOOD S, 1992, GENOMICS, V13, P232, DOI 10.1016/0888-7543(92)90230-P; YU CE, 1994, HUM MOL GENET, V3, P211; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370	40	105	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2121	2126						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478532				2022-12-17	WOS:A1995TF29700023
J	MUTHUSWAMY, SK; MULLER, WJ				MUTHUSWAMY, SK; MULLER, WJ			DIRECT AND SPECIFIC INTERACTION OF C-SRC WITH NEU IS INVOLVED IN SIGNALING BY THE EPIDERMAL GROWTH-FACTOR RECEPTOR	ONCOGENE			English	Article						NEU; EGFR; C-SRC; SH2; RECEPTOR SIGNALING	TYROSINE KINASE-ACTIVITY; EGF RECEPTOR; AUTOPHOSPHORYLATION SITES; MITOGENIC RESPONSIVENESS; MAMMARY-TUMORS; BREAST-CANCER; ONCOGENE; FAMILY; PHOSPHORYLATION; PROTEIN	Transgenic mice expressing either the activated or wild type neu oncogene heritably develop metastatic mammary tumors. Tumor development in this transgenic mouse model correlates with activation of the Neu tyrosine kinase. Recently, we have shown that these Neu-induced mammary tumors possess elevated c-Src tyrosine kinase activity. Here, we demonstrate that c-Src requires tyrosine phosphorylated Neu for its ability to associate with Neu in vivo and this association is likely the result of a direct physical binding of c-Src SH2 domain to the tyrosine phosphorylated Neu. By contrast, the c-Src SH2 domain did not interact directly with tyrosine phosphorylated EGFR. Moreover, in established cell lines expressing elevated levels of EGFR, EGF stimulation results in transphosphorylation of Neu and formation of complexes between c-Src and tyrosine phosphorylated Neu. Taken together, these observations suggest that activation of c-Src by these two closely related EGFR family members results from a direct and specific interaction of c-Src with tyrosine phosphorylated Neu.	MCMASTER UNIV, INST MOLEC BIOL & BIOTECHNOL, DEPT BIOL, HAMILTON, ON, CANADA; MCMASTER UNIV, INST MOLEC BIOL & BIOTECHNOL, DEPT PATHOL, HAMILTON, ON, CANADA	McMaster University; McMaster University			Muthuswamy, Senthil K/AGY-2834-2022	Muthuswamy, Senthil K/0000-0001-6564-9634				BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; JANES PW, 1994, ONCOGENE, V9, P3601; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1994, ADV CANCER RES, V64, P111, DOI 10.1016/S0065-230X(08)60836-2; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; PATERSON MC, 1991, CANCER RES, V51, P556; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROMANO A, 1994, ONCOGENE, V8, P2105; RON D, 1992, BIOTECHNIQUES, V13, P866; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SEGATTO O, 1993, ONCOGENE, V8, P2105; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SONGYANG Z, 1993, CELL, V77, P767; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536	56	105	109	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					271	279						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7542762				2022-12-17	WOS:A1995RK95700008
J	RAYGALLET, D; MAO, C; TAVITIAN, A; MOREAUGACHELIN, F				RAYGALLET, D; MAO, C; TAVITIAN, A; MOREAUGACHELIN, F			DNA-BINDING SPECIFICITIES OF SPI-1/PU.1 AND SPI-B TRANSCRIPTION FACTORS AND IDENTIFICATION OF A SPI-1/SPI-B BINDING-SITE IN THE C-FES/C-FPS PROMOTER	ONCOGENE			English	Article						SPI-1/PU.1 AND SPI-B; DNA BINDING SITE SELECTION; C-FES/C-FPS	PU.1 REGULATES EXPRESSION; ETS-DOMAIN; PUTATIVE ONCOGENE; ESCHERICHIA-COLI; GENE; PROTEIN; PROTOONCOGENE; ACTIVATION; FAMILY; CELLS	Spi-1/PU.1 and Spi-B encode hematopoietic-specific transcription factors that are the most distantly related members of the Ets family. The Ets proteins share a conserved 85 amino acids DNA binding domain, the Ets domain and recognize various DNA target sites around a common core 5'-GGAA/T-3'. The DNA binding specificities of Spi-1 and Spi-B were investigated by using the method of polymerase chain reaction (PCR)-mediated random site selection. The deduced Spi-1 and Spi-B consensus binding sites are very similar suggesting that the functional activities of Spi-1 and Spi-B cannot be distinguished on the basis of their DNA binding specificities. We identified a putative Spi-1/Spi-B binding site in the promoter region of the c-fes/c-fps protooncogene which encodes a tyrosine kinase expressed predominantly in myeloid cells. In vitro translated Spi-1 and Spi-B proteins were capable to bind this site similarly and to activate the c-fes promoter in HeLa transfected cells. We showed that Spi-1 binds the Spi-1/Spi-B binding site of c-fes in HL-60 cells suggesting that Spi-1 may be involved in the regulation of c-fes transcription in myeloid cells. Intriguingly, we detected only Spi-l binding to this site in the Raji cell line which express both Spi-1 and Spi-B proteins. This suggests that Spi-1 and Spi-B exhibit different DNA binding activities in vivo although they share similar DNA binding specificities in vitro.	FAC MED LARIBOISIERE, INSERM, U248, 10 AVE VERDUN, F-75010 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Ray-Gallet, Dominique/A-9224-2019					ALCALAY M, 1990, ONCOGENE, V5, P267; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; CARMIER JF, 1986, CELL, V44, P159, DOI 10.1016/0092-8674(86)90494-0; CARVALHO M, 1993, J VIROL, V67, P3885, DOI 10.1128/JVI.67.7.3885-3890.1993; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DELGADO MD, 1994, ONCOGENE, V9, P1723; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GORMAN CM, 1982, VIROLOGY, V52, P456; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JUCKER M, 1992, ONCOGENE, V7, P943; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LAUX G, 1994, EMBO J, V13, P5624, DOI 10.1002/j.1460-2075.1994.tb06900.x; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MAO XH, 1994, J BIOL CHEM, V269, P18216; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; PFAFF SL, 1985, VIROLOGY, V146, P307, DOI 10.1016/0042-6822(85)90014-5; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RAY D, 1990, ONCOGENE, V5, P663; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; ROEBROEK AJM, 1986, MOL BIOL REP, V11, P117, DOI 10.1007/BF00364823; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROEBROEK AJM, 1987, J VIROL, V61, P2009, DOI 10.1128/JVI.61.6.2009-2016.1987; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; YU G, 1989, J BIOL CHEM, V264, P10276; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	61	105	105	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					303	313						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624145				2022-12-17	WOS:A1995RK95700011
J	FORRESTER, K; LUPOLD, SE; OTT, VL; CHAY, CH; BAND, V; WANG, XW; HARRIS, CC				FORRESTER, K; LUPOLD, SE; OTT, VL; CHAY, CH; BAND, V; WANG, XW; HARRIS, CC			EFFECTS OF P53 MUTANTS ON WILD-TYPE P53-MEDIATED TRANSACTIVATION ARE CELL-TYPE DEPENDENT	ONCOGENE			English	Article						P53; P53 MUTANTS; TRANSACTIVATION; CELL TYPE SPECIFICITY	TRANSCRIPTIONAL ACTIVITY; GENE AMPLIFICATION; PROTEIN COMPLEXES; RAS MUTATIONS; CYCLE CONTROL; BINDING-SITE; DNA-DAMAGE; LINES; CANCER; EXPRESSION	The spectrum of p53 mutations differs among human cancer types. We have hypothesized that the p53 mutational spectrum observed in particular tumor types reflects the functional ability of different p53 mutants to modulate wild-type (WT) p53-dependent gene transcription. Missense p53 mutants representing several mutational hotspot codons were cotransfected with WT p53 and analysed for their effects on p53-dependent transactivation of a reporter construct containing a specific p53 binding sequence (PG(13)-CAT) in human tumor cell lines lacking endogenous p53. Our results show that the ability of p53 mutants to inhibit WT p53-mediated transactivation is cell type dependent. In cell lines derived from a lung adenocarcinoma and mesothelioma, the transactivation function of WT p53 was strongly inhibited by all p53 mutants examined. However, in cell lines derived from a prostate carcinoma and an osteosarcoma, the mutants examined generally had only minimal dominant negative effects. In cell lines derived from a hepatocellular carcinoma and an ovarian carcinoma, two mutants (248(trp) and 273(his)) enhanced WT p53 mediated-transactivation of the reporter construct. Additional mutants retained the ability to inhibit WT p53-mediated transactivation in these cell lines. In addition, in a series of four breast tumor cell lines, the p53 mutants examined had similar effects on WT p53 transactivation ability including enhanced transactivation activity in the 273(his) cotransfectants. The p53 mutants were incapable of transactivating the PG(13)-CAT reporter in the absence of WT p53 expression. Therefore, the dominant negative effects of p53 mutants on WT p53 function may vary depending on the particular cell type. In addition, mutants with stronger inhibitory capabilities may confer a selective advantage during the tumorigenic process.	NCI,HUMAN CARCINOGENESIS LAB,BETHESDA,MD 20892; TUFTS UNIV NEW ENGLAND MED CTR,DEPT RADIOL ONCOL & BIOCHEM,BOSTON,MA 02111	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tufts Medical Center			Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAND V, 1990, CANCER RES, V50, P7351; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; CHEN JY, 1993, ONCOGENE, V8, P2159; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREBOURG T, 1992, CANCER RES, V52, P6976; FREBOURG T, 1994, CANCER RES, V54, P878; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBLATT MS, 1994, CANCER RES, V55, P4855; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEHMAN TA, 1991, CANCER RES, V51, P4090; LIU XL, 1994, CARCINOGENESIS, V15, P1969, DOI 10.1093/carcin/15.9.1969; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; METCALF RA, 1992, CANCER RES, V52, P2610; MILLER CW, 1993, ONCOGENE, V8, P1815; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1993, ONCOGENE, V8, P2001; MIYASHITA T, 1995, CELL, V80, P293; MUKHOPADHYAY T, 1993, CANCER RES, V53, P4362; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PONCHEL F, 1994, CANCER RES, V54, P2064; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TIBBETTS LM, 1984, P AM ASSOC CANC RES, V25, P45; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOJTESEK B, 1993, J CELL SCI, V105, P607; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; YAGINUMA Y, 1992, CANCER RES, V52, P4196; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHANG W, 1993, CANCER RES, V53, P4772	69	105	105	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2103	2111						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784055				2022-12-17	WOS:A1995RB70300005
J	LANFRANCONE, L; PELICCI, G; BRIZZI, MF; AROUICA, MG; CASCIARI, C; GIULI, S; PEGORARO, L; PAWSON, T; PELICCI, PG				LANFRANCONE, L; PELICCI, G; BRIZZI, MF; AROUICA, MG; CASCIARI, C; GIULI, S; PEGORARO, L; PAWSON, T; PELICCI, PG			OVEREXPRESSION OF SHC PROTEINS POTENTIATES THE PROLIFERATIVE RESPONSE TO THE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AND RECRUITMENT OF GRB2/SOS AND GRB2/P140 COMPLEXES TO THE BETA-RECEPTOR SUBUNIT	ONCOGENE			English	Article						GM-CSF; SIGNAL; SHE; GRB2	GUANINE-NUCLEOTIDE EXCHANGE; GM-CSF RECEPTOR; EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; ADAPTER PROTEIN; MOLECULAR-CLONING; CELL-LINE; KINASE; RAS	The high affinity receptor for GM-CSF consists of a unique a subunit and a beta subunit that is shared with receptors for IL-3 and IL-5. Activation of GM-CSF receptor (GMR) triggers two distinct cytoplasmic signalling pathways, JAK2, and Pas, and is sufficient to maintain proliferation of growth factor-dependent cell lines, She proteins are phosphorylated upon activation of GMR and may be involved in the transmission of GM-CSF signals to Pas. To define the role of She proteins in cells stimulated with GM-CSF, we investigated both the network of interactions that involve She after GM-CSF stimulation and the effects of overexpressing She proteins on the proliferative response to GM-CSF. Two cytoplasmic complexes, Grb2/Sos and Grb2/p140 bind through the Grb2 SH2 domain to phosphorylated She, and are thereby recruited to the beta subunit, Both complexes are stable, even in the absence of ligand, and depend on the direct association of p140 and Sos respectively with the SH3 domains of Grb2, p140 is an uncharacterized protein constitutively phosphorylated on tyrosine and, in its Grb2-bonnd form, expressed only in hematopoietic cells, the oligomeric complex formed by phosphorylated beta subunit-phosphorylated Shc-Grb2-SoS-p140 is also induced by IL-3 and L-5 stimulation of growth-factor dependent cell lines, Overexpression of wild-type She proteins in growth factor-dependent cells increases both MAP kinase activation and proliferation in response to GM-CSF, These effects require the association of She with Grb2, Taken together these results indicate that phosphorylation of She proteins is a crucial step in the transmission of GM-CSP proliferative stimuli, since it creates a high affinity binding site for the Grb2/SoS complex, whose function is to activate Ras and, for the Grb2/p140 complex, whose function remains unknown.	DIPARTIMENTO SCI BIOMED & ONCOL UMANA,SEZ CLIN,I-10126 TURIN,ITALY; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,TORONTO,ON M5G 1X5,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	LANFRANCONE, L (corresponding author), UNIV PERUGIA,IST MED INTERNA & SCI ONCOL,I-06122 PERUGIA,ITALY.		Pelicci, Giuliana/AAA-8921-2022; Brizzi, Maria Felice/J-7882-2016; Pelicci, Pier Giuseppe/AAL-6572-2020; Lanfrancone, Luisa/AAC-8671-2019; Pawson, Tony J/E-4578-2013	Pelicci, Giuliana/0000-0003-0986-8255; Lanfrancone, Luisa/0000-0002-4523-3815; CASCIARI, CRISTINA/0000-0002-9170-370X				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BATZER LN, 1993, NATURE, V363, P85; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DAMEN JE, 1993, BLOOD, V82, P2296; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPUR AG, 1992, ONCOGENE, V7, P1347; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; KASTELEIN RA, 1993, ONCOGENE, V8, P231; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KITAMURA T, 1991, INT IMMUNOL, V3, P571, DOI 10.1093/intimm/3.6.571; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LIOUBIN NM, 1994, MOL CELL BIOL, V14, P5682; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; METCALF D, 1993, BLOOD, V82, P3515; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAJIMA A, 1993, BLOOD, V82, P1960; OKUDA K, 1992, BLOOD, V79, P2880; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SALCINI AE, 1994, IN PRESS ONCOGENE; Sambrook J., 1989, MOL CLONING LAB MANU; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SAXTON TM, 1994, J IMMUNOL, V153, P623; SEGATTO O, 1993, ONCOGENE, V8, P2105; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SONYANG Z, 1994, MOL CELL BIOL, V14, P2777; SORENSEN PHB, 1989, BLOOD, V73, P406; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WELHAM MJ, 1992, J IMMUNOL, V149, P1683	44	105	107	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					907	917						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898932				2022-12-17	WOS:A1995QL03800012
J	DEED, RW; BIANCHI, SM; ATHERTON, GT; JOHNSTON, D; SANTIBANEZKOREF, M; MURPHY, JJ; NORTON, JD				DEED, RW; BIANCHI, SM; ATHERTON, GT; JOHNSTON, D; SANTIBANEZKOREF, M; MURPHY, JJ; NORTON, JD			AN IMMEDIATE EARLY HUMAN GENE ENCODES AN ID-LIKE HELIX LOOP HELIX PROTEIN AND IS REGULATED BY PROTEIN-KINASE-C ACTIVATION IN DIVERSE CELL-TYPES	ONCOGENE			English	Article							DNA-BINDING; NEGATIVE REGULATOR; MURINE HOMOLOG; SARCOMA-VIRUS; 3T3 CELLS; MYC; EXPRESSION; FIBROBLASTS; SEQUENCE; MUSCLE	Transcription factors characterized by the presence of a helix-loop-helix (HLH) domain play a central role in the regulation of cell growth/differentiation and tumorigenesis. We report here the cDNA sequence of a human early-response gene, designated HLH 1R21, encoding a 15-kDa HLH protein that lacks a basic, DNA-binding domain and which by a number of criteria appears to be the human homologue of mouse HLH 462. Like its murine counterpart, HLH 1R21 protein functions as an Id (inhibitor of DNA binding) transcription factor by inhibiting the binding of E2A-containing protein complexes to muscle creatine kinase E-box enhancer oligonucleotide in vitro. However HLH 1R21 does not inhibit the binding of HLH Max protein to a Max-binding oligonucleotide in vitro, indicating that it has limited promiscuity in its ability to antagonize the function of other HLH transcription factors. In addition, HLH 1R21 mRNA transcripts are regulated by phorbol ester treatment of a diverse range of human cell lines and, when overexpressed in mouse NIH3T3 cells, HLH 1R21 induces a morphologically transformed phenotype.	CHRISTIE HOSP NHS TRUST,PATERSON INST CANC RES,CRC DEPT GENE REGULAT,WILMSLOW RD,MANCHESTER M20 9BX,ENGLAND; CHRISTIE HOSP NHS TRUST,PATERSON INST CANC RES,CRC DEPT CANC GENET,MANCHESTER M20 9BX,ENGLAND; KINGS COLL,IMMUNOL SECT,LONDON W8 7AH,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of London; King's College London			Atherton, Graham/GZK-4237-2022	Atherton, Graham/0000-0002-7425-3153				BECKENGESER G, 1991, HUM GENE THER, V2, P61, DOI 10.1089/hum.1991.2.1-61; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; GOLDFARB M, 1991, ONCOGENE, V6, P65; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HARVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSAIO WL, 1989, MOL CELL BIOL, V9, P2641; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; MILLER AD, 1984, CELL, V36, P51; MURPHY JJ, 1990, BIOCHIM BIOPHYS ACTA, V1049, P261; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NORTON JD, 1984, J VIROL, V50, P439, DOI 10.1128/JVI.50.2.439-444.1984; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; VISVADER J, 1991, TRENDS BIOCHEM SCI, V16, P330, DOI 10.1016/0968-0004(91)90137-K; VLODAVSKY GM, 1980, CELL, V19, P606; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAMADA KM, 1976, P NATL ACAD SCI USA, V73, P1217, DOI 10.1073/pnas.73.4.1217	36	105	107	2	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					599	607						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437843				2022-12-17	WOS:A1993KN00800010
J	YU, DH; HAMADA, JI; ZHANG, H; NICOLSON, GL; HUNG, MC				YU, DH; HAMADA, JI; ZHANG, H; NICOLSON, GL; HUNG, MC			MECHANISMS OF C-ERBB2/NEU ONCOGENE-INDUCED METASTASIS AND REPRESSION OF METASTATIC PROPERTIES BY ADENOVIRUS 5 E1A GENE-PRODUCTS	ONCOGENE			English	Article							TYROSINE KINASE-ACTIVITY; RAT EMBRYO CELLS; TUMOR-CELLS; PROTO-ONCOGENE; C-ERBB-2 GENE; NEU ONCOGENE; CANCER METASTASIS; CARCINOMA-CELLS; OVARIAN-CANCER; INVITRO ASSAY	c-erbB2/neu is a transforming oncogene that encodes a 185-kDa transmembrane glycoprotein. In many but not all studies, amplification and/or overexpression of the human c-erbB2/neu oncogene has been correlated with poor prognosis and the number of lymph node metastases in node-positive breast cancer patients. We have shown that expression of the activated rat c-erbB2/neu oncogene in mouse embryo fibroblast 3T3 cells is sufficient to induce experimental metastases in nude mice. Important steps in the metastatic event are tumor cell adhesion to endothelial cells and invasion of basement membranes. Therefore, we further examined the ability of c-erbB2/neu oncogene-transformed 3T3 cells to adhere to microvessel endothelial cells and secrete basement membrane-degradative enzymes. The c-erbB2/neu oncogene-transformed 3T3 cells were shown to be more adherent and have higher gelatinase activities. Since we had previously shown that the adenovirus 5 E1A gene product can suppress c-erbB2/neu-induced transformation of 3T3 cells, we examined the possibility that E1A can abrogate the metastatic properties of c-erbB2/neu-transformed 3T3 cells. We found that introduction of the EIA gene into c-erbB2/neu-transformed 3T3 cells reduced the formation of experimental metastatic tumors and inhibited metastasis-associated properties, such as adhesion to microvessel endothelial cells, migration through a layer of reconstituted basement membrane (Matrigel) and secretion of basement membrane-degradative enzymes. The results indicate that the mechanism by which the c-erbB2/neu gene induces higher metastatic potential is to promote adhesion and invasion steps of the metastatic cascade. The EIA gene, which functions by inhibiting these steps, is thus a suppressor gene for c-erbB2/neu-induced experimental metastasis.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,BOX 79,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381	NCI NIH HHS [R35-CA 44352, R03-CA54989, R01-CA41524] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA054989, R35CA044352, R01CA041524] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1987, CANCER RES, V47, P3239; AUERBACH R, 1987, CANCER RES, V47, P1492; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1990, CANCER RES, V50, P4087; DEMILIA J, 1989, ONCOGENE, V4, P1233; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; FRISCH SM, 1990, ONCOGENE, V5, P75; GARBISA S, 1987, CANCER RES, V47, P1523; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HAMADA JI, 1992, IN PRESS BR J CANCER; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; INOKUCHI J, 1990, CANCER RES, V50, P6731; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LICHTNER RB, 1989, EXP CELL BIOL, V57, P146; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1986, CANCER RES, V46, P1; LIOTTA LA, 1989, MECHANISMS CANCER IN; MENSING H, 1983, EUR J CELL BIOL, V29, P268; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NAKAJIMA M, 1989, CANCER RES, V49, P1698; Nicolson GL, 1989, CURR OPIN CELL BIOL, V1, P1009, DOI 10.1016/0955-0674(89)90073-2; NICOLSON G L, 1991, Current Opinion in Oncology, V3, P75, DOI 10.1097/00001622-199102000-00012; NICOLSON GL, 1989, INVAS METAST, V9, P102; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PARK JB, 1989, CANCER RES, V49, P6605; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; REPESH LA, 1989, INVAS METAST, V9, P192; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P77; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WALLICH R, 1985, NATURE, V315, P301, DOI 10.1038/315301a0; WEINER DB, 1990, CANCER RES, V50, P421; WEXLER DH, 1986, J NATL CANCER I, V36, P641; YAN DH, 1991, ONCOGENE, V6, P343; YOKOTA J, 1988, ONCOGENE, V2, P283; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YUSA K, 1990, J NATL CANCER I, V82, P1633, DOI 10.1093/jnci/82.20.1633; ZHANG X, 1989, ONCOGENE, V4, P985	55	105	107	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2263	2270						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1359495				2022-12-17	WOS:A1992JW66500019
J	HIRAI, SI; BOURACHOT, B; YANIV, M				HIRAI, SI; BOURACHOT, B; YANIV, M			BOTH JUN AND FOS CONTRIBUTE TO TRANSCRIPTION ACTIVATION BY THE HETERODIMER	ONCOGENE			English	Article											HIRAI, SI (corresponding author), INST PASTEUR,DEPT BIOL MOLEC,CNRS,UA 1149,UNITE VIRUS ONCOGENES,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.			Bourachot, Brigitte/0000-0001-7816-0539				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BOHMANN D, 1987, SCIENCE, V228, P1380; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIRAI S-I, 1989, New Biologist, V1, P181; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; MECHTA F, 1989, New Biologist, V1, P297; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; TURNER R, 1989, NATURE, V243, P1689; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WASYLYK B, 1988, CRC CR REV BIOCH MOL, V23, P77, DOI 10.3109/10409238809088317; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	35	105	106	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1990	5	1					39	46						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM620	2108402				2022-12-17	WOS:A1990CM62000006
J	SUAREZ, HG; DUVILLARD, JA; CAILLOU, B; SCHLUMBERGER, M; TUBIANA, M; PARMENTIER, C; MONIER, R				SUAREZ, HG; DUVILLARD, JA; CAILLOU, B; SCHLUMBERGER, M; TUBIANA, M; PARMENTIER, C; MONIER, R			DETECTION OF ACTIVATED RAS ONCOGENES IN HUMAN THYROID CARCINOMAS	ONCOGENE			English	Article									INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE	UNICANCER; Gustave Roussy	SUAREZ, HG (corresponding author), INST RECH SCI CANC,F-94802 VILLEJUIF,FRANCE.							AZZARONE B, 1985, EXP CELL RES, V159, P451, DOI 10.1016/S0014-4827(85)80018-5; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BYAR DP, 1979, EUR J CANCER, V15, P1033, DOI 10.1016/0014-2964(79)90291-3; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DER CJ, 1983, CELL, V32, P201, DOI 10.1016/0092-8674(83)90510-X; FEINBERG AP, 1983, SCIENCE, V220, P1175, DOI 10.1126/science.6304875; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HEIDINGER LE, 1974, INT HISTOLOGICAL CLA, V11; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUAREZ HG, 1985, RETROVIRUSES HUMAN P, P509; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TERRIER P, 1987, IN PRESS BRIT J CANC; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WISEMAN RW, 1986, P NATL ACAD SCI USA, V83, P5825, DOI 10.1073/pnas.83.16.5825; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0	26	105	107	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1988	2	4					403	406						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	3283656				2022-12-17	WOS:A1988M947200014
J	Qian, JY; Gao, J; Sun, X; Cao, MD; Shi, L; Xia, TS; Zhou, WB; Wang, S; Ding, Q; Wei, JF				Qian, Jia-Yi; Gao, Jian; Sun, Xi; Cao, Meng-Da; Shi, Liang; Xia, Tian-Song; Zhou, Wen-Bin; Wang, Shui; Ding, Qiang; Wei, Ji-Fu			KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner	ONCOGENE			English	Article							METHYLTRANSFERASE METTL3 PROMOTES; STEM-LIKE CELLS; RNA-METHYLATION; M(6)A; EXPRESSION; N-6-METHYLADENOSINE; TRANSLATION; IDENTIFICATION; PROGRESSION; KEGG	Most N6-methyladenosine (m(6)A) associated regulatory proteins (i.e., m(6)A writer, eraser, and reader proteins) are involved in the pathogenesis of various cancers, mostly in m(6)A-dependent manners. As a component in the m(6)A 'writers', KIAA1429 is reported to be an RNA-binding protein and involved in the m(6)A modification, mRNA splicing and processing. Till now, the functions of KIAA1429 in tumorigenesis and related mechanism have not been reported. In the present study, we found KIAA1429 was highly expressed in breast cancer tissues, but frequently down-regulated in non-cancerous breast tissues. The overall survival of breast cancer patients with high-expression KIAA1429 was significantly shorter than those with low-expression KIAA1429. Then, we demonstrated that KIAA1429 was associated with breast cancer proliferation and metastasis in vivo and in vitro. The potential targeting genes of KIAA1429 in breast cancer were identified by RNA immunoprecipitation sequencing. One of these genes is cyclin-dependent kinase 1 (CDK1), which plays an oncogenic role in cancers. Furthermore, we confirmed that KIAA1429 played its oncogenic role in breast cancer by regulating CDK1 by an m(6)A-independent manner. 5'-fluorouracil was found to be very effective in reducing the expression of KIAA1429 and CDK1 in breast cancer. These findings indicated that KIAA1429 could promote breast cancer progression and was correlated with pathogenesis. It may represent a promising therapeutic strategy on breast cancer, especially in combination with CDK1 treatment.	[Qian, Jia-Yi; Sun, Xi; Shi, Liang; Xia, Tian-Song; Zhou, Wen-Bin; Wang, Shui; Ding, Qiang] Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Breast Dis Ctr, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China; [Gao, Jian] Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210093, Jiangsu, Peoples R China; [Cao, Meng-Da; Wei, Ji-Fu] Nanjing Med Univ, Affiliated Hosp 1, Res Div Clin Pharmacol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing University; Nanjing Medical University	Wang, S; Ding, Q (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Breast Dis Ctr, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.; Wei, JF (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Res Div Clin Pharmacol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	ws0801@hotmail.com; dingqiang@njmu.edu.cn; weijifu@hotmail.com	Gao, Jian/AAU-8293-2021	Gao, Jian/0000-0002-2722-7067	National Natural Science Foundation of China [81572595, 81572607, 81602336]; Project of the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Project of the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This work was supported by the National Natural Science Foundation of China [grant numbers 81572595, 81572607, 81602336], and the Project of the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Barbieri I, 2017, NATURE, V552, P126, DOI 10.1038/nature24678; Cai XL, 2018, CANCER LETT, V415, P11, DOI 10.1016/j.canlet.2017.11.018; Chen MN, 2018, HEPATOLOGY, V67, P2254, DOI 10.1002/hep.29683; Chen X, 2015, MED ORAL PATOL ORAL, V20, pE7, DOI 10.4317/medoral.19841; Cui Q, 2017, CELL REP, V18, P2622, DOI 10.1016/j.celrep.2017.02.059; Dai DJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0129-x; Dassi E, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00067; Dominissini D, 2013, NAT PROTOC, V8, P176, DOI 10.1038/nprot.2012.148; Fry Nate J, 2018, Oncotarget, V9, P31231, DOI 10.18632/oncotarget.25782; Fu Y, 2014, NAT REV GENET, V15, P293, DOI 10.1038/nrg3724; Fustin JM, 2013, CELL, V155, P793, DOI 10.1016/j.cell.2013.10.026; Gao SY, 2014, ASIAN PAC J CANCER P, V15, P6437, DOI 10.7314/APJCP.2014.15.15.6437; Garcia-Maurino SM, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00071; Guo J, 2018, P NATL ACAD SCI USA, V115, P3674, DOI 10.1073/pnas.1720945115; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haussmann IU, 2016, NATURE, V540, P301, DOI 10.1038/nature20577; Hong S, 2017, J CANCER PREV, V22, P203, DOI 10.15430/JCP.2017.22.4.203; Jiang GL, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2911-z; Jiang HS, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-182; Jiao XL, 2012, BIOINFORMATICS, V28, P1805, DOI 10.1093/bioinformatics/bts251; Kanehisa M, 2008, NUCLEIC ACIDS RES, V36, pD480, DOI 10.1093/nar/gkm882; Kim SJ, 2008, ANN ONCOL, V19, P68, DOI 10.1093/annonc/mdm358; Knuckles P, 2018, GENE DEV, V32, P415, DOI 10.1101/gad.309146.117; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li ZJ, 2017, CANCER CELL, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Lin SB, 2016, MOL CELL, V62, P335, DOI 10.1016/j.molcel.2016.03.021; Ma JZ, 2017, HEPATOLOGY, V65, P529, DOI 10.1002/hep.28885; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Malumbres M, 2014, GENOME BIOL, V15, DOI 10.1186/gb4184; Mao XZ, 2005, BIOINFORMATICS, V21, P3787, DOI 10.1093/bioinformatics/bti430; Niessen M, 2001, GENETICS, V157, P679; Pan YT, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0590-8; Panneerdoss S, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar8263; Patil DP, 2016, NATURE, V537, P369, DOI 10.1038/nature19342; Payton M, 2006, CANCER RES, V66, P4299, DOI 10.1158/0008-5472.CAN-05-2507; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Roundtree IA, 2017, CELL, V169, P1187, DOI 10.1016/j.cell.2017.05.045; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; Schwartz S, 2014, CELL REP, V8, P284, DOI 10.1016/j.celrep.2014.05.048; Su R, 2018, CELL, V172, P90, DOI 10.1016/j.cell.2017.11.031; Tang C, 2018, P NATL ACAD SCI USA, V115, pE325, DOI 10.1073/pnas.1717794115; Tang JY, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0706-6; Tsai WC, 2008, DIS MARKERS, V24, P89, DOI 10.1155/2008/945197; Visvanathan A, 2018, ONCOGENE, V37, P522, DOI 10.1038/onc.2017.351; Wang SW, 2017, CANCER LETT, V408, P112, DOI 10.1016/j.canlet.2017.08.030; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Wen J, 2018, MOL CELL, V69, P1028, DOI 10.1016/j.molcel.2018.02.015; Xiao W, 2016, MOL CELL, V61, P507, DOI 10.1016/j.molcel.2016.01.012; Yue YA, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0019-0; Yue YN, 2015, GENE DEV, V29, P1343, DOI 10.1101/gad.262766.115; Zhang CZ, 2016, ONCOTARGET, V7, P64527, DOI 10.18632/oncotarget.11743; Zhang CZ, 2016, P NATL ACAD SCI USA, V113, pE2047, DOI 10.1073/pnas.1602883113; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhao BXS, 2017, NAT REV MOL CELL BIO, V18, P31, DOI 10.1038/nrm.2016.132	56	104	105	4	43	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2019	38	33					6123	6141		10.1038/s41388-019-0861-z	http://dx.doi.org/10.1038/s41388-019-0861-z			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IR6TP	31285549				2022-12-17	WOS:000481572400004
J	Avivar-Valderas, A; Bobrovnikova-Marjon, E; Diehl, JA; Bardeesy, N; Debnath, J; Aguirre-Ghiso, JA				Avivar-Valderas, A.; Bobrovnikova-Marjon, E.; Diehl, J. Alan; Bardeesy, N.; Debnath, J.; Aguirre-Ghiso, J. A.			Regulation of autophagy during ECM detachment is linked to a selective inhibition of mTORC1 by PERK	ONCOGENE			English	Article						anoikis; breast cancer; unfolded protein response	ACTIVATED PROTEIN-KINASE; EXTRACELLULAR-MATRIX DETACHMENT; ENDOPLASMIC-RETICULUM KINASE; ANOIKIS RESISTANCE; UPSTREAM KINASE; CELL-GROWTH; STRESS; PHOSPHORYLATION; SUPPRESSION; SURVIVAL	Adhesion to the extracellular matrix (ECM) is critical for epithelial tissue homeostasis and function. ECM detachment induces metabolic stress and programmed cell death via anoikis. ECM-detached mammary epithelial cells are able to rapidly activate autophagy allowing for survival and an opportunity for re-attachment. However, the mechanisms controlling detachment-induced autophagy remain unclear. Here we uncover that the kinase PERK rapidly promotes autophagy in ECM-detached cells by activating AMP-activated protein kinase (AMPK), resulting in downstream inhibition of mTORC1-p70(S6K) signaling. LKB1 and TSC2, but not TSC1, are required for PERK-mediated inhibition of mammalian target of rapamycinin MCF10A cells and mouse embryo fibroblast cells. Importantly, this pathway shows fast kinetics, is transcription-independent and is exclusively activated during ECM detachment, but not by canonical endoplasmic reticulum stressors. Moreover, enforced PERK or AMPK activation upregulates autophagy and causes luminal filling during acinar morphogenesis by perpetuating a population of surviving autophagic luminal cells that resist anoikis. Hence, we identify a novel pathway in which suspension-activated PERK promotes the activation of LKB1, AMPK and TSC2, leading to the rapid induction of detachment-induced autophagy. We propose that increased autophagy, secondary to persistent PERK and LKB1-AMPK signaling, can robustly protect cells from anoikis and promote luminal filling during early carcinoma progression.	[Avivar-Valderas, A.; Aguirre-Ghiso, J. A.] Mt Sinai Sch Med, Tisch Canc Inst, Black Family Stem Cell Inst, Dept Med, New York, NY 10029 USA; [Avivar-Valderas, A.; Aguirre-Ghiso, J. A.] Mt Sinai Sch Med, Tisch Canc Inst, Black Family Stem Cell Inst, Dept Otolaryngol, New York, NY 10029 USA; [Bobrovnikova-Marjon, E.; Diehl, J. Alan] Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA; [Bobrovnikova-Marjon, E.; Diehl, J. Alan] Univ Penn, Sch Med, Abramson Canc Res Inst, Philadelphia, PA 19104 USA; [Bardeesy, N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA; [Debnath, J.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Debnath, J.] Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Aguirre-Ghiso, JA (corresponding author), Mt Sinai Sch Med, Tisch Canc Inst, Black Family Stem Cell Inst, Dept Med, 1 Gustave L Levy Pl, New York, NY 10029 USA.	julio.aguirre-ghiso@mssm.edu		Aguirre-Ghiso, Julio/0000-0002-6694-6507; Debnath, Jayanta/0000-0002-8745-4069	NIH-NCI shared resources [5R24CA095823-04]; NSF Major Research Instrumentation grant [DBI-9724504]; NIH [1 S10RR0 9145-01, RO1 CA126792, CA126792-S1, P01 CA104838]; Samuel Waxman Cancer Research Foundation Tumor Dormancy Program; NIH/National Cancer Institute [CA109182, CA163131]; NIEHS [ES017146]; NYSTEM; Leukemia and Lymphoma Scholar; NATIONAL CANCER INSTITUTE [P01CA104838, R01CA109182, R01CA126792, R24CA095823, U54CA163131] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR009145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES017146] Funding Source: NIH RePORTER	NIH-NCI shared resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NSF Major Research Instrumentation grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Samuel Waxman Cancer Research Foundation Tumor Dormancy Program; NIH/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NYSTEM; Leukemia and Lymphoma Scholar; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Confocal laser scanning microscopy was performed at the MSSM-Microscopy Shared Resources Facility, supported with funding from NIH-NCI shared resources grant (5R24CA095823-04), NSF Major Research Instrumentation grant (DBI-9724504) and NIH shared instrumentation grant (1 S10RR0 9145-01). This work is supported by grants from the Samuel Waxman Cancer Research Foundation Tumor Dormancy Program, NIH/National Cancer Institute (CA109182, CA163131), NIEHS (ES017146) and NYSTEM to J. A. A-G, NIH RO1 CA126792, CA126792-S1 (ARRA) to JD, and P01 CA104838 and a Leukemia and Lymphoma Scholar award to JAD.	Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Avivar-Valderas A, 2011, MOL CELL BIOL, V31, P3616, DOI 10.1128/MCB.05164-11; Bobrovnikova-Marjon E, 2008, P NATL ACAD SCI USA, V105, P16314, DOI 10.1073/pnas.0808517105; Chen CH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001731; Collins NL, 2005, MOL CELL BIOL, V25, P5282, DOI 10.1128/MCB.25.12.5282-5291.2005; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Espina V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010240; Fuertes G, 2003, BIOCHEM J, V375, P75, DOI 10.1042/BJ20030282; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Kerlikowske K, 2010, JNCI-J NATL CANCER I, V102, P627, DOI 10.1093/jnci/djq101; Kim J, NAT CELL BIOL, V13, P132; Klionsky DJ, 2004, NATURE, V431, P31, DOI 10.1038/431031a; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; Leung CT, 2012, NATURE, V482, P410, DOI 10.1038/nature10826; Liu LP, 2006, MOL CELL, V21, P521, DOI 10.1016/j.molcel.2006.01.010; Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Nelson CM, 2006, ANNU REV CELL DEV BI, V22, P287, DOI 10.1146/annurev.cellbio.22.010305.104315; Ng TL, 2012, CELL DEATH DIFFER, V19, P501, DOI 10.1038/cdd.2011.119; Ozean U, 2008, MOL CELL, V29, P541, DOI [10.1016/j.moicel.2007.12.023, 10.1016/j.molcel.2007.12.023]; Partanen JI, 2007, P NATL ACAD SCI USA, V104, P14694, DOI 10.1073/pnas.0704677104; Partanen JI, 2012, P NATL ACAD SCI USA, V109, pE388, DOI 10.1073/pnas.1120421109; Peyton KJ, 2012, J PHARMACOL EXP THER, V342, P827, DOI 10.1124/jpet.112.194712; Qin L, 2010, AUTOPHAGY, V6, P239, DOI 10.4161/auto.6.2.11062; Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008-5472.CAN-05-3092; Ranganathan AC, 2008, CANCER RES, V68, P3260, DOI 10.1158/0008-5472.CAN-07-6215; Raven JF, 2008, CELL CYCLE, V7, P1146, DOI 10.4161/cc.7.9.5811; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Sequeira SJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000615; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	39	104	106	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4932	4940		10.1038/onc.2012.512	http://dx.doi.org/10.1038/onc.2012.512			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23160380	Green Accepted			2022-12-17	WOS:000325717800009
J	Kent, OA; Fox-Talbot, K; Halusha, MK				Kent, O. A.; Fox-Talbot, K.; Halusha, M. K.			RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets	ONCOGENE			English	Article						miRNA; miR-143; miR-145; KRAS; RREB1; colorectal	ZINC-FINGER PROTEIN; HUMAN COLON-CANCER; COLORECTAL-CANCER; TRANSCRIPTION FACTOR; PROSTATE-CANCER; RAS; MICRORNAS; EXPRESSION; MICE; TUMORIGENESIS	A lack of expression of miR-143 and miR-145 has been demonstrated to be a frequent feature of colorectal tumors. Activating KRAS mutations have been reported in 30-60% of colorectal cancers and an inverse correlation between Kras and miR-143/145 expression has been observed. Previously, we have demonstrated that oncogenic Kras leads to repression of the miR-143/145 cluster in pancreatic cancer and is dependent on the Ras responsive element (RRE) binding protein (RREB1), which negatively regulates miR-143/145 expression. In the present study, we have found that RREB1 is overexpressed in colorectal adenocarcinoma tumors and cell lines, and the expression of the miR-143/145 primary transcript is inversely related to RREB1 expression. In colorectal cancer cell lines, the miR-143/145 cluster is repressed by RREB1 downstream of constitutively active KRAS. RREB1 is activated by the MAPK pathway and negatively represses the miR-143/145 promoter through interaction with two RREs. In addition, overexpression of miR-143 or miR-145 in HCT116 cells abrogates signaling through the MAPK, PI3K and JNK pathways by downregulation of both KRAS and RREB1 in addition to downregulation of a cohort of genes in the MAPK signaling cascade. These results establish a complex network of regulation through which the miR-143/145 cluster is able to modulate KRAS signaling in colorectal cancer.	[Kent, O. A.; Fox-Talbot, K.; Halusha, M. K.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA	Johns Hopkins University	Kent, OA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, 720 Rutland Ave,Ross Res Bldg 632, Baltimore, MD 21205 USA.	kent@lunenfeld.ca		Halushka, Marc/0000-0002-7112-7389; Kent, Oliver/0000-0001-6494-4383	NIH [R01CA120185]; Doris Duke Foundation [2009040]; NATIONAL CANCER INSTITUTE [R01CA120185] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Doris Duke Foundation(Doris Duke Charitable Foundation (DDCF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Dr Joshua Mendell and Dr Anirban Maitra for helpful discussions and feedback during preparation of the manuscript. We thank Dr James Eshleman for kindly providing cell lines and Norman Barker for photography assistance. We would like to thank Dr Dan Durocher and members of the Durocher laboratory at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital Toronto for kindly providing laboratory space and reagents and helpful discussions during the review process of the manuscript. This work was supported in part through the NIH (R01CA120185) and by a Clinician Scientist Award to MKH from the Doris Duke Foundation Grant #: 2009040. OAK is a Life Sciences Research Foundation Fellow.	Adler V, 2005, BIOCHEMISTRY-US, V44, P10784, DOI 10.1021/bi050619j; Akao Y, 2006, ONCOL REP, V16, P845; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bandres E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bissonnette M, 2000, CANCER RES, V60, P4602; Borralho PM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023787; Borralho PM, 2009, FEBS J, V276, P6689, DOI 10.1111/j.1742-4658.2009.07383.x; Brink M, 2003, CARCINOGENESIS, V24, P703, DOI 10.1093/carcin/bgg009; Buzzi N, 2009, MOL CELL BIOCHEM, V328, P201, DOI 10.1007/s11010-009-0090-9; Calcagno SR, 2008, INT J CANCER, V122, P2462, DOI 10.1002/ijc.23383; Campbell PM, 2007, CANCER RES, V67, P2098, DOI 10.1158/0008-5472.CAN-06-3752; Cellurale C, 2011, MOL CELL BIOL, V31, P1565, DOI 10.1128/MCB.01122-10; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chen X, 2009, ONCOGENE, V28, P1385, DOI 10.1038/onc.2008.474; Clape C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007542; Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195; Date S, 2004, INT J MOL MED, V13, P637; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Esau C, 2004, J BIOL CHEM, V279, P52361, DOI 10.1074/jbc.C400438200; Feldmann G, 2008, GUT, V57, P1420, DOI 10.1136/gut.2007.148189; Gaspar C, 2008, AM J PATHOL, V172, P1363, DOI 10.2353/ajpath.2008.070851; Han SX, 2010, WORLD J GASTROENTERO, V16, P4541, DOI 10.3748/wjg.v16.i36.4541; Hao JM, 2010, J PATHOL, V220, P475, DOI 10.1002/path.2668; Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hingorani SR, 2003, CURR OPIN GENET DEV, V13, P6, DOI 10.1016/S0959-437X(02)00017-5; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kaiser S, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r131; Keller JW, 2007, ONCOGENE, V26, P3051, DOI 10.1038/sj.onc.1210103; Kent OA, 2010, GENE DEV, V24, P2754, DOI 10.1101/gad.1950610; Kent OA, 2009, CANCER BIOL THER, V8, P2013, DOI 10.4161/cbt.8.21.9685; Kressner U, 1998, BRIT J CANCER, V77, P1848, DOI 10.1038/bjc.1998.307; Liu AW, 2011, CLIN CANCER RES, V17, P710, DOI 10.1158/1078-0432.CCR-10-0331; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Michael MZ, 2003, MOL CANCER RES, V1, P882; Mosakhani N, 2012, GENE CHROMOSOME CANC, V51, P1, DOI 10.1002/gcc.20925; Mukhopadhyay NK, 2007, MOL ENDOCRINOL, V21, P2056, DOI 10.1210/me.2006-0503; Ng EKO, 2009, BRIT J CANCER, V101, P699, DOI 10.1038/sj.bjc.6605195; Nitz MD, 2011, AM J PATHOL, V179, P477, DOI 10.1016/j.ajpath.2011.03.038; Papadopoulos GL, 2009, BIOINFORMATICS, V25, P1991, DOI 10.1093/bioinformatics/btp299; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Sabates-Beliver J, 2007, MOL CANCER RES, V5, P1263, DOI 10.1158/1541-7786.MCR-07-0267; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Sancho R, 2009, EMBO J, V28, P1843, DOI 10.1038/emboj.2009.153; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Slaby O, 2007, ONCOLOGY-BASEL, V72, P397, DOI 10.1159/000113489; Starr TK, 2009, SCIENCE, V323, P1747, DOI 10.1126/science.1163040; Thiagalingam A, 1996, MOL CELL BIOL, V16, P5335; Thiagalingam A, 1997, GENOMICS, V45, P630, DOI 10.1006/geno.1997.5001; Uren AG, 2008, CELL, V133, P727, DOI 10.1016/j.cell.2008.03.021; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Zhang L, 1999, NUCLEIC ACIDS RES, V27, P2947, DOI 10.1093/nar/27.14.2947; Zhang SL, 2003, ONCOGENE, V22, P2285, DOI 10.1038/sj.onc.1206257; Zhu HY, 2011, MOL CANCER RES, V9, P960, DOI 10.1158/1541-7786.MCR-10-0531	57	104	110	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2013	32	20					2576	2585		10.1038/onc.2012.266	http://dx.doi.org/10.1038/onc.2012.266			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	148UY	22751122	Green Accepted			2022-12-17	WOS:000319274300009
J	Anderton, JA; Bose, S; Vockerodt, M; Vrzalikova, K; Wei, W; Kuo, M; Helin, K; Christensen, J; Rowe, M; Murray, PG; Woodman, CB				Anderton, J. A.; Bose, S.; Vockerodt, M.; Vrzalikova, K.; Wei, W.; Kuo, M.; Helin, K.; Christensen, J.; Rowe, M.; Murray, P. G.; Woodman, C. B.			The H3K27me3 demethylase, KDM6B, is induced by Epstein-Barr virus and over-expressed in Hodgkin's Lymphoma	ONCOGENE			English	Article						KDM6B; histone demethylase; Epstein-Barr virus; latent membrane protein-1; Hodgkins lymphoma	REED-STERNBERG CELLS; JMJD3 CONTRIBUTES; GENE-EXPRESSION; HISTONE; DIFFERENTIATION; INHIBITION; ACTIVATION; ROLES; UTX	There is now evidence for both increased and decreased activity of the enzymes controlling the methylation of lysine 27 on histone 3 (H3K27) in cancer. One of these enzymes, KDM6B formally known as JMJD3, a histone demethylase, which removes the trimethyl mark from H3K27, is required for the lineage commitment and terminal differentiation of neural stem cells and of keratinocytes. Our results suggest that KDM6B may also have a role in antigen-driven B-cell differentiation. KDM6B expression increases in B-cell subsets with increasing stage of differentiation, and gene expression profiling shows that KDM6B transcriptional targets in germinal centre B (GC B) cells are significantly enriched for those differentially expressed during memory and plasma cell differentiation. Our results also suggest that aberrant expression of KDM6B may contribute to the pathogenesis of Hodgkin's Lymphoma (HL), an Epstein-Barr virus (EBV) associated malignancy. KDM6B is over-expressed in primary HL and induced by the EBV oncogene, latent membrane protein (LMP1) in GC B cells, the presumptive progenitors of HL. Consistent with these observations, we found that KDM6B transcriptional targets in GC B cells are enriched for genes differentially expressed in HL, and that KDM6B depletion can restore the tri-methylation of H3K27 on these genes. Oncogene (2011) 30, 2037-2043; doi:10.1038/onc.2010.579; published online 17 January 2011	[Anderton, J. A.; Bose, S.; Vockerodt, M.; Vrzalikova, K.; Wei, W.; Rowe, M.; Murray, P. G.; Woodman, C. B.] Univ Birmingham, Coll Med & Dent Sci, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England; [Kuo, M.] Birmingham Childrens Hosp, Dept Paediat Otolaryngol, Birmingham, W Midlands, England; [Helin, K.; Christensen, J.] Univ Copenhagen, BRIC, Copenhagen, Denmark; [Helin, K.; Christensen, J.] Univ Copenhagen, Ctr Epigenet, Copenhagen, Denmark	University of Birmingham; University of Birmingham; University of Copenhagen; University of Copenhagen	Woodman, CB (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England.	c.b.woodman@bham.ac.uk	Helin, Kristian/HDM-8306-2022; Rowe, Martin/B-2880-2009; Helin, Kristian/K-2526-2019; Vockerodt, Martina/L-4465-2014	Helin, Kristian/0000-0003-1975-6097; Rowe, Martin/0000-0003-4139-7326; Vockerodt, Martina/0000-0001-7761-5829; Wei, Wenbin/0000-0003-1288-6999	Leukaemia and Lymphoma Research Fund; Medical Research Council [G9818340B] Funding Source: researchfish	Leukaemia and Lymphoma Research Fund; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Leukaemia and Lymphoma Research Fund.	Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145; Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809; Agherbi H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005622; Aldinucci D, 2010, J PATHOL, V221, P248, DOI 10.1002/path.2711; Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109; Brune V, 2008, J EXP MED, V205, P2251, DOI 10.1084/jem.20080809; Burgold T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003034; Dai JP, 2010, J CELL BIOCHEM, V110, P1457, DOI 10.1002/jcb.22703; De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019; De Santa F, 2009, EMBO J, V28, P3341, DOI 10.1038/emboj.2009.271; Delecluse HJ, 1998, P NATL ACAD SCI USA, V95, P8245, DOI 10.1073/pnas.95.14.8245; Dirmeier U, 2005, ONCOGENE, V24, P1711, DOI 10.1038/sj.onc.1208367; Fei T, 2010, GENOME RES, V20, P36, DOI 10.1101/gr.092114.109; Gunther T, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000935; HAAFTEN GV, 2010, FUNDERS GROUP HUMAN, V41, P521; Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514; Holland D, 2008, CANCER RES, V68, P9964, DOI 10.1158/0008-5472.CAN-08-1134; Hong SH, 2007, P NATL ACAD SCI USA, V104, P18439, DOI 10.1073/pnas.0707292104; Ishii M, 2009, BLOOD, V114, P3244, DOI 10.1182/blood-2009-04-217620; Jepsen K, 2007, NATURE, V450, P415, DOI 10.1038/nature06270; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Mainou-Fowler T, 2004, LEUKEMIA RES, V28, P159, DOI 10.1016/S0145-2126(03)00216-9; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Neuhierl B, 2002, P NATL ACAD SCI USA, V99, P15036, DOI 10.1073/pnas.232381299; Raaphorst FM, 2000, AM J PATHOL, V157, P709, DOI 10.1016/S0002-9440(10)64583-X; SANDVEJ KB, 1993, LEUKEMIA LYMPHOMA, V9, P95, DOI 10.3109/10428199309148510; Sen GL, 2008, GENE DEV, V22, P1865, DOI 10.1101/gad.1673508; Shannon-Lowe C, 2005, J GEN VIROL, V86, P3009, DOI 10.1099/vir.0.81153-0; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Skinnider BF, 2002, BLOOD, V99, P618, DOI 10.1182/blood.V99.2.618; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vockerodt M, 2008, J PATHOL, V216, P83, DOI 10.1002/path.2384	32	104	110	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	17					2037	2043		10.1038/onc.2010.579	http://dx.doi.org/10.1038/onc.2010.579			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21242977				2022-12-17	WOS:000289977400007
J	Yu, X; Wang, Y; DeGraff, DJ; Wills, ML; Matusik, RJ				Yu, X.; Wang, Y.; DeGraff, D. J.; Wills, M. L.; Matusik, R. J.			Wnt/beta-Catenin activation promotes prostate tumor progression in a mouse model	ONCOGENE			English	Article						prostate; Wnt/beta-catenin; AR; Foxa2; T-antigen	SMALL-CELL CARCINOMA; BETA-CATENIN; NEUROENDOCRINE DIFFERENTIATION; TRANSCRIPTION FACTORS; COLORECTAL-CANCER; WNT PATHWAY; ANDROGEN; GROWTH; EXPRESSION; MICROENVIRONMENT	Our previous studies have found that activation of Wnt/beta-catenin signaling resulted in mouse prostatic intraepithelial neoplasia (mPIN). In the large probasin promoter directed SV40-large T-antigen ( LPB- Tag) expressing mouse prostate, mPIN forms with rare areas of adenocarcinoma. Combining expression of both Wnt-signaling and Tag expression in the mouse prostate, we have studied the role of Wnt/beta-catenin signaling in the progression from mPIN to adenocarcinoma. Our results show that the prostates of mice expressing Tag alone or nuclear beta-catenin alone developed mPIN, whereas the activation of both Tag and the Wnt/beta-catenin pathway resulted in invasive prostate adenocarcinoma. Furthermore, Foxa2, a forkhead transcription factor, was induced by active Wnt/beta-catenin signaling, and the expression of Foxa2 was associated with the invasive phenotype in the primary prostate cancer. In the LPB-Tag/dominant active (DA) b-catenin prostates, MMP7, a Wnt/beta-catenin target gene, was upregulated. Furthermore, we also assessed AR and AR signaling pathway in these LPB-Tag/DA beta-catenin mice. Although beta-catenin is a well-known AR co-activator in vitro, our study provides strong in vivo evidences indicating that both AR protein and the AR pathway were downregulated in the prostate of LPB-Tag/DA beta-catenin mice. Histological analysis shows that prostate sections derived from the LPB-Tag/DA beta-catenin mice display neuroendocrine differentiation (NED), but NE cancer does not develop. Together, our findings indicate that Wnt/beta-catenin signaling has an important role in the progression of mPIN to prostate adenocarcinoma. Oncogene (2011) 30, 1868-1879; doi: 10.1038/onc.2010.560; published online 13 December 2010	[Matusik, R. J.] Vanderbilt Univ, Sch Med, Dept Urol Surg, Med Ctr, Nashville, TN 37232 USA; [Wang, Y.] Washington Biotechnol Inc, Columbia, MD USA; [Wills, M. L.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Matusik, RJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Urol Surg, Med Ctr, A-1302 Med Ctr N, Nashville, TN 37232 USA.	robert.matusik@vanderbilt.edu		Yu, Xiuping/0000-0003-2844-7026; Matusik, Robert/0000-0003-2057-9892	NIH [2R01 CA76142-11, 2R01-DK055748-10]; DOD [PC074022]; American Cancer Society Great Lakes Division; NATIONAL CANCER INSTITUTE [R01CA076142, T32CA119925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055748] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); American Cancer Society Great Lakes Division(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Angela Barth, the Stanford University, for kindly providing the mutant beta-catenin expressing vector, Tom Case and Manik Paul for technical support, Dr Barbara Fingleton and Dr Lynn Matrisian for advice and discussion. Grant support was provided by NIH to RJM (Grant Numbers: 2R01 CA76142-11; 2R01-DK055748-10), DOD to RJM (Grant Number: PC074022), and the Joe C. Davis Foundation. David DeGraff, PhD was supported by the American Cancer Society Great Lakes Division-Michigan Cancer Research Fund Postdoctoral Fellowship.	Barth AIM, 1999, P NATL ACAD SCI USA, V96, P4947, DOI 10.1073/pnas.96.9.4947; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; Bonfil RD, 2007, UROL ONCOL-SEMIN ORI, V25, P407, DOI 10.1016/j.urolonc.2007.05.008; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brabletz T, 2005, CELLS TISSUES ORGANS, V179, P56, DOI 10.1159/000084509; Bruxvoort KJ, 2007, CANCER RES, V67, P2490, DOI 10.1158/0008-5472.CAN-06-3028; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; de la Taille A, 2003, CLIN CANCER RES, V9, P1801; Deeb KK, 2007, CANCER RES, V67, P8065, DOI 10.1158/0008-5472.CAN-07-1515; Fingleton B, 2006, FRONT BIOSCI-LANDMRK, V11, P479, DOI 10.2741/1811; Gupta A, 2008, PROSTATE, V68, P50, DOI 10.1002/pros.20650; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Huang D, 2008, WORLD J GASTROENTERO, V14, P1823, DOI 10.3748/wjg.14.1823; Huss WJ, 2007, NEOPLASIA, V9, P938, DOI 10.1593/neo.07562; Kasper S, 2005, J CELL BIOCHEM, V94, P279, DOI 10.1002/jcb.20339; Kasper S, 1998, LAB INVEST, V78, P319; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P2884, DOI 10.1073/pnas.042688999; Klezovitch O, 2004, CANCER CELL, V6, P185, DOI 10.1016/j.ccr.2004.07.008; Lamberti C, 2001, J BIOL CHEM, V276, P42276, DOI 10.1074/jbc.M104227200; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; Masumori N, 2001, CANCER RES, V61, P2239; Millar JBA, 2002, GENOME BIOL, V3; Mirosevich J, 2005, PROSTATE, V62, P339, DOI 10.1002/pros.20131; Mirosevich J, 2006, PROSTATE, V66, P1013, DOI 10.1002/pros.20299; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Polakis P, 2000, GENE DEV, V14, P1837; Qi JF, 2010, CANCER CELL, V18, P23, DOI 10.1016/j.ccr.2010.05.024; Sciarra A, 2003, BJU INT, V91, P438, DOI 10.1046/j.1464-410X.2003.03066.x; Song ZG, 2002, CANCER RES, V62, P5096; Terry S, 2006, J CELL BIOCHEM, V99, P402, DOI 10.1002/jcb.20983; Wang W, 2008, AM J SURG PATHOL, V32, P65, DOI 10.1097/PAS.0b013e318058a96b; Wang YQ, 2006, LAB INVEST, V86, P1074, DOI 10.1038/labinvest.3700463; Wilson CL, 1996, INT J BIOCHEM CELL B, V28, P123, DOI 10.1016/1357-2725(95)00121-2; Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Yang XZ, 2005, CANCER RES, V65, P5263, DOI 10.1158/0008-5472.CAN-05-0162; Yao JL, 2006, AM J SURG PATHOL, V30, P705, DOI 10.1097/00000478-200606000-00005; Yardy GW, 2005, PROSTATE CANCER P D, V8, P119, DOI 10.1038/sj.pcan.4500794; Yu XP, 2009, PROSTATE, V69, P249, DOI 10.1002/pros.20877; Yu XP, 2005, ANN NY ACAD SCI, V1061, P77, DOI 10.1196/annals.1336.009; Zhang XJ, 1997, PROSTATE, V32, P16, DOI 10.1002/(SICI)1097-0045(19970615)32:1<16::AID-PROS3>3.0.CO;2-A	44	104	106	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	16					1868	1879		10.1038/onc.2010.560	http://dx.doi.org/10.1038/onc.2010.560			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21151173	Green Accepted			2022-12-17	WOS:000289777700003
J	Eramo, A; Haas, TL; De Maria, R				Eramo, A.; Haas, T. L.; De Maria, R.			Lung cancer stem cells: tools and targets to fight lung cancer	ONCOGENE			English	Review						lung cancer; cancer stem cells; therapy; stem cells	TUMOR-INITIATING CELLS; ACUTE MYELOID-LEUKEMIA; ALDEHYDE DEHYDROGENASE 1; BREAST-CANCER; PROGENITOR CELLS; SARS CORONAVIRUS; MARKER CD133; SOLID TUMORS; BASAL-CELLS; IDENTIFICATION	Cancer stem cell (CSC) theory states that tumors are organized in a similar hierarchical manner as normal tissues, with a sub-population of tumorigenic stem-like cells that generate the more differentiated nontumorigenic tumor cells. CSCs are chemoresistant and seem to be responsible for tumor recurrence and formation of metastases. Therefore, the study of these cells may lead to crucial advances in the understanding of tumor biology as well as to innovative and more effective therapies. Lung cancer represents the leading cause of cancer-related mortality worldwide. Despite improvements in medical and surgical management, patient survival rates remain stable at similar to 15%, calling for innovative strategies that may contribute to improve patient outcome. The discovery of lung CSCs and the possibility to characterize their biological properties may provide powerful translational tools to improve the clinical outcome of patients with lung cancer. In this report, we review what is known about lung CSCs and discuss the diagnostic, prognostic and therapeutic prospective of these findings. Oncogene (2010) 29, 4625-4635; doi:10.1038/onc.2010.207; published online 7 June 2010	[Eramo, A.; Haas, T. L.; De Maria, R.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; [Haas, T. L.; De Maria, R.] Mediterranean Inst Oncol, Catania, Italy	Istituto Superiore di Sanita (ISS); Mediterranean Institute of Oncology	De Maria, R (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.	demaria@iss.it	Eramo, Adriana/K-6694-2016; De Maria, Ruggero/S-6385-2019	Eramo, Adriana/0000-0002-0814-6683; De Maria, Ruggero/0000-0003-2255-0583; Haas, Tobias/0000-0003-2336-0263	Italian Association for Cancer Research (AIRC); Marie Curie network [MRTN-CT-2006-035624]	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Marie Curie network(European Commission)	We thank Giuseppe Loreto for technical assistance with figures and tables. We thank the Italian Association for Cancer Research (AIRC) and the Marie Curie network project 'ApopTrain' (MRTN-CT-2006-035624) for supporting the lung cancer stem cell research.	Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barker N, 2008, GENE DEV, V22, P1856, DOI 10.1101/gad.1674008; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bianchi F, 2008, CELL CYCLE, V7, P729, DOI 10.4161/cc.7.6.5591; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; BLENKINSOPP WK, 1967, EXP CELL RES, V46, P144, DOI 10.1016/0014-4827(67)90416-8; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Borczuk Alain C, 2009, Proc Am Thorac Soc, V6, P152, DOI 10.1513/pats.200807-076LC; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Chen YX, 2007, J EXP MED, V204, P2529, DOI 10.1084/jem.20070462; Chen YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002637; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Collins LG, 2007, AM FAM PHYSICIAN, V75, P56; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Dubey S, 2008, AM J RESP CRIT CARE, V177, P941, DOI 10.1164/rccm.200801-107UP; Dubey S, 2009, AM J RESP CRIT CARE, V179, P860, DOI 10.1164/rccm.200902-0289UP; Dylla SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002428; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Fuchs E, 2009, CELL, V137, P811, DOI 10.1016/j.cell.2009.05.002; Giangreco A, 2002, AM J PATHOL, V161, P173, DOI 10.1016/S0002-9440(10)64169-7; Giangreco A, 2007, AM J RESP CRIT CARE, V175, P547, DOI 10.1164/rccm.200607-984PP; Giangreco A, 2009, P NATL ACAD SCI USA, V106, P9286, DOI 10.1073/pnas.0900668106; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Guan YH, 2003, BLOOD, V101, P3142, DOI 10.1182/blood-2002-10-3062; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hill RP, 2006, CANCER RES, V66, P1891, DOI 10.1158/0008-5472.CAN-05-3450; Ho MM, 2007, CANCER RES, V67, P4827, DOI 10.1158/0008-5472.CAN-06-3557; Holyoake T, 1999, BLOOD, V94, P2056, DOI 10.1182/blood.V94.6.2056; Hong KU, 2004, AM J PHYSIOL-LUNG C, V286, pL643, DOI 10.1152/ajplung.00155.2003; Hong KU, 2004, AM J PATHOL, V164, P577, DOI 10.1016/S0002-9440(10)63147-1; Hu TS, 2008, CANCER RES, V68, P6533, DOI 10.1158/0008-5472.CAN-07-6642; Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418; Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350; Iwasaki H, 2007, IMMUNITY, V26, P726, DOI 10.1016/j.immuni.2007.06.004; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Janne PA, 2005, J CLIN ONCOL, V23, P3227, DOI 10.1200/JCO.2005.09.985; Jemal A, 2008, JNCI-J NATL CANCER I, V100, P1672, DOI 10.1093/jnci/djn389; Jiang F, 2009, MOL CANCER RES, V7, P330, DOI 10.1158/1541-7786.MCR-08-0393; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Jin LQ, 2009, CELL STEM CELL, V5, P31, DOI 10.1016/j.stem.2009.04.018; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Lantuejoul S, 2009, HISTOPATHOLOGY, V54, P43, DOI 10.1111/j.1365-2559.2008.03182.x; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lee A, 2005, NAT NEUROSCI, V8, P723, DOI 10.1038/nn1473; Levina V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003077; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Ling TY, 2006, P NATL ACAD SCI USA, V103, P9530, DOI 10.1073/pnas.0510232103; Maeda S, 2008, BRIT J CANCER, V98, P1389, DOI 10.1038/sj.bjc.6604307; MAHVI D, 1977, AM J PATHOL, V86, P559; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Orkin SH, 2002, NAT IMMUNOL, V3, P323, DOI 10.1038/ni0402-323; Pallini R, 2008, CLIN CANCER RES, V14, P8205, DOI 10.1158/1078-0432.CCR-08-0644; Pantel K, 2009, NAT REV CLIN ONCOL, V6, P339, DOI 10.1038/nrclinonc.2009.44; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Pollard SM, 2009, CELL STEM CELL, V4, P568, DOI 10.1016/j.stem.2009.03.014; Rawlins Emma L, 2008, Proc Am Thorac Soc, V5, P675, DOI 10.1513/pats.200801-006AW; Rawlins EL, 2009, CELL STEM CELL, V4, P525, DOI 10.1016/j.stem.2009.04.002; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Reynolds SD, 2000, AM J PATHOL, V156, P269, DOI 10.1016/S0002-9440(10)64727-X; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Riely Gregory J, 2009, Proc Am Thorac Soc, V6, P201, DOI 10.1513/pats.200809-107LC; Ross JS, 2009, AM J CLIN PATHOL, V132, P237, DOI 10.1309/AJCPJI7DEOLKCS6F; Scagliotti G, 2009, ONCOLOGIST, V14, P253, DOI 10.1634/theoncologist.2008-0232; Schatton T, 2009, BIOESSAYS, V31, P1038, DOI 10.1002/bies.200900058; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Sholl LM, 2010, APPL IMMUNOHISTO M M, V18, P55, DOI 10.1097/PAI.0b013e3181b16b88; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Song W, 2008, INT J CLIN PRACT, V62, P1212, DOI 10.1111/j.1742-1241.2008.01777.x; Storms RW, 1999, P NATL ACAD SCI USA, V96, P9118, DOI 10.1073/pnas.96.16.9118; Stripp Barry R, 2008, Proc Am Thorac Soc, V5, P328, DOI 10.1513/pats.200711-167DR; Stripp BR, 1995, AM J PHYSIOL-LUNG C, V269, pL791, DOI 10.1152/ajplung.1995.269.6.L791; Theodoropoulos PA, 2010, CANCER LETT, V288, P99, DOI 10.1016/j.canlet.2009.06.027; Tiseo M, 2009, EXPERT REV ANTICANC, V9, P425, DOI 10.1586/ERA.09.3; Todaro M, 2008, CELL CYCLE, V7, P309, DOI 10.4161/cc.7.3.5389; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; vanWinkle LS, 1995, AM J PHYSIOL-LUNG C, V269, pL800, DOI 10.1152/ajplung.1995.269.6.L800; Ventura JJ, 2007, NAT GENET, V39, P750, DOI 10.1038/ng2037; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wang JCY, 2005, TRENDS CELL BIOL, V15, P494, DOI 10.1016/j.tcb.2005.07.004; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Yanagi S, 2007, J CLIN INVEST, V117, P2929, DOI 10.1172/JCI31854; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zeng ZH, 2009, BLOOD, V113, P6215, DOI 10.1182/blood-2008-05-158311; Zeppernick F, 2008, CLIN CANCER RES, V14, P123, DOI 10.1158/1078-0432.CCR-07-0932; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137; Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589	103	104	112	4	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	33					4625	4635		10.1038/onc.2010.207	http://dx.doi.org/10.1038/onc.2010.207			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20531299				2022-12-17	WOS:000281127400002
J	Merkhofer, EC; Cogswell, P; Baldwin, AS				Merkhofer, E. C.; Cogswell, P.; Baldwin, A. S.			Her2 activates NF-kappa B and induces invasion through the canonical pathway involving IKK alpha	ONCOGENE			English	Article						Her2; IKKalpha; NF-KappaB	HUMAN-BREAST-CANCER; UP-REGULATION; PLASMINOGEN-ACTIVATOR; MONOCLONAL-ANTIBODY; SIGNALING NETWORK; GENE-EXPRESSION; KINASE-ACTIVITY; PHASE-II; CELLS; INHIBITOR	The membrane bound receptor tyrosine kinase Her2 is overexpressed in approximately 30% of human breast cancers, which correlates with poor prognosis. Her2-induced signaling pathways include MAPK and PI3K/Akt, of which the latter has been shown to be critical for Her2(+) breast cancer cell growth and survival. In addition, the NF-kappa B pathway has been shown to be activated downstream of Her2 overexpression; however, the mechanisms leading to this activation are not currently clear. Using Her2(+)/ER- breast cancer cells, we show that Her2 activates NF-kappa B through the canonical pathway which, surprisingly, involves IKK alpha. Knockdown of IKK alpha led to a significant decrease in transcription levels of multiple NF-kappa B-regulated cytokine and chemokine genes. siRNA-mediated knockdown of IKK alpha resulted in a decrease in cancer cell invasion, but had no effect on cell proliferation. Inhibition of the PI3K/Akt pathway had no effect on NF-kappa B activation, but significantly inhibited cell proliferation. Our study suggests different roles for the NF-kappa B and PI3K pathways downstream of Her2, leading to changes in invasion and proliferation of breast cancer cells. In addition this work indicates the importance of IKK alpha as a mediator of Her2-induced tumor progression. Oncogene ( 2010) 29, 1238-1248; doi: 10.1038/onc.2009.410; published online 30 November 2009	[Merkhofer, E. C.; Cogswell, P.; Baldwin, A. S.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Merkhofer, E. C.; Baldwin, A. S.] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; [Baldwin, A. S.] Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Baldwin, AS (corresponding author), Univ N Carolina, Lineberger Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.	albert_baldwin@med.unc.edu			NIH [RO1CA73756, RO1CA75080]; Department of Defense [BC074027]; Samuel Waxman Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R01CA073756, R01CA138937, R01CA075080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Samuel Waxman Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank William Comb for his assistance in the preparation of this paper, as well as Dr H Shelton Earp and Dr Carolyn Sartor for generously providing reagents. This work is funded by NIH RO1CA73756 and RO1CA75080, and Department of Defense Grant BC074027. Support is also provided by the Samuel Waxman Cancer Research Foundation.	Arihiro K, 2000, Breast Cancer, V7, P221, DOI 10.1007/BF02967464; Arora P, 2008, ONCOGENE, V27, P4434, DOI 10.1038/onc.2008.84; Baselga J, 1999, SEMIN ONCOL, V26, P78; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Belguise K, 2007, J CLIN INVEST, V117, P4009, DOI 10.1172/JCI32424; Bhaumik D, 2008, ONCOGENE, V27, P5643, DOI 10.1038/onc.2008.171; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Cao YX, 2007, P NATL ACAD SCI USA, V104, P15852, DOI 10.1073/pnas.0706728104; Chavey C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1648; Chen DY, 2003, ONCOGENE, V22, P4348, DOI 10.1038/sj.onc.1206532; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Dan HC, 2008, GENE DEV, V22, P1490, DOI 10.1101/gad.1662308; Dillon RL, 2007, ONCOGENE, V26, P1338, DOI 10.1038/sj.onc.1210202; ETHIER SP, 1993, CANCER RES, V53, P627; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; GUM R, 1995, ANTICANCER RES, V15, P1167; Habib AA, 2001, J BIOL CHEM, V276, P8865, DOI 10.1074/jbc.M008458200; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hegde PS, 2007, MOL CANCER THER, V6, P1629, DOI 10.1158/1535-7163.MCT-05-0399; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Klapper LN, 2000, ADV CANCER RES, V77, P25; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Lam LT, 2008, P NATL ACAD SCI USA, V105, P20798, DOI 10.1073/pnas.0806491106; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Makino K, 2004, ONCOGENE, V23, P3883, DOI 10.1038/sj.onc.1207485; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Papa S, 2006, CELL DEATH DIFFER, V13, P712, DOI 10.1038/sj.cdd.4401865; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; She QB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003065; Singh S, 2007, MOL CANCER THER, V6, P1973, DOI 10.1158/1535-7163.MCT-07-0063; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Solt LA, 2008, IMMUNOL RES, V42, P3, DOI 10.1007/s12026-008-8025-1; Steinbrecher KA, 2005, MOL CELL BIOL, V25, P8444, DOI 10.1128/MCB.25.19.8444-8455.2005; Vazquez-Martin A, 2008, ADV EXP MED BIOL, V617, P311, DOI 10.1007/978-0-387-69080-3_29; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; Weih F, 2003, IMMUNOL REV, V195, P91, DOI 10.1034/j.1600-065X.2003.00064.x; Wilson W, 2008, CANCER RES, V68, P8156, DOI 10.1158/0008-5472.CAN-08-1061; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Zhou H, 2004, INT J RADIAT ONCOL, V58, P344, DOI 10.1016/j.ijrobp.2003.09.046	48	104	107	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1238	1248		10.1038/onc.2009.410	http://dx.doi.org/10.1038/onc.2009.410			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19946332	Green Accepted, Green Submitted			2022-12-17	WOS:000274912100014
J	Singh, B; Berry, JA; Shoher, A; Ayers, GD; Wei, C; Lucci, A				Singh, B.; Berry, J. A.; Shoher, A.; Ayers, G. D.; Wei, C.; Lucci, A.			COX-2 involvement in breast cancer metastasis to bone	ONCOGENE			English	Article						breast cancer; COX-2; mouse model; MF-tricyclic; bone metastasis; cancer prevention	CYCLOOXYGENASE-2 INHIBITOR; OSTEOCLAST FORMATION; PROSTAGLANDIN E-2; IL-11 PRODUCTION; KNOCKOUT MICE; MURINE MODEL; CELL-LINES; EXPRESSION; CELECOXIB; GROWTH	Cyclooxygenase-2 (COX- 2) is expressed in 40% of human invasive breast cancers. Bone is the predominant site of metastasis in case of breast cancer. We investigated the role of COX- 2 in a suitable mouse model of breast cancer metastasis to bone using the whole-body luciferase imaging of cancer cells. We provide several lines of evidence that COX- 2 produced in breast cancer cells is important for bone metastasis in this model including (1) COX- 2 transfection enhanced the bone metastasis of MDA-435S cells and (2) breast cancer cells isolated and cultured from the bone metastases produced significantly more prostaglandin E-2 (an important mediator of COX- 2) than the parental injected cell populations of breast cancer cells. Next, we found that a COX- 2 inhibitor, MF-tricyclic, inhibited bone metastasis caused by a bone-seeking clone both in prevention regimen (in which case mice started receiving MF-tricyclic 1 week before the injection of cancer cells) and in treatment regimen (in which case mice received MF-tricyclic after the development of bone metastasis). These studies indicate that COX- 2 produced in breast cancer cells may be vital to the development of osteolytic bone metastases in patients with breast cancer, and that COX- 2 inhibitors may be useful in halting this process.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 444, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Adv Res Ctr Microscop Dis, Houston, TX 77030 USA; Baylor Coll Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Lucci, A (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 444, 1515 Holcombe Blvd, Houston, TX 77030 USA.	alucci@mdanderson.org		Berry, Jacob/0000-0002-5241-1720; Lucci, Anthony/0000-0003-4039-174X	NIDDK NIH HHS [R21 DK067682] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK067682] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGUELLO F, 1988, CANCER RES, V48, P6876; Basu GD, 2004, MOL CANCER RES, V2, P632; Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756-3282(03)00086-3; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Connolly EM, 2002, BRIT J CANCER, V87, P231, DOI 10.1038/sj.bjc.6600462; Crawford YG, 2004, CANCER CELL, V5, P263, DOI 10.1016/S1535-6108(04)00023-6; D Basu G, 2006, J IMMUNOL, V177, P2391, DOI 10.4049/jimmunol.177.4.2391; Fujita D, 2003, PROSTAG LEUKOTR ESS, V68, P351, DOI 10.1016/S0952-3278(03)00027-9; Gilhooly EM, 1999, INT J ONCOL, V15, P267; GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; Harms JF, 2003, CLIN EXP METASTAS, V20, P327, DOI 10.1023/A:1024062911144; Harris RE, 2000, CANCER RES, V60, P2101; Hiraga T, 2006, CANCER RES, V66, P2067, DOI 10.1158/0008-5472.CAN-05-2012; Howe LR, 2005, CANCER RES, V65, P10113, DOI 10.1158/0008-5472.CAN-05-1524; Howe LR, 2002, CANCER RES, V62, P5405; Howe LR, 2003, J MAMMARY GLAND BIOL, V8, P31, DOI 10.1023/A:1025731204719; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Khuder SA, 2001, BRIT J CANCER, V84, P1188, DOI 10.1054/bjoc.2000.1709; Kundu N, 2005, CANCER IMMUNOL IMMUN, V54, P981, DOI 10.1007/s00262-005-0669-2; Kundu N, 2001, INT J CANCER, V93, P681, DOI 10.1002/ijc.1397; Lal G, 2001, CANCER RES, V61, P6131; Li X, 2002, BONE, V30, P567, DOI 10.1016/S8756-3282(02)00683-X; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Morgan H, 2004, INT J CANCER, V109, P653, DOI 10.1002/ijc.20056; Ono K, 2002, J BONE MINER RES, V17, P774, DOI 10.1359/jbmr.2002.17.5.774; Ristimaki A, 2002, CANCER RES, V62, P632; Roche-Nagle G, 2004, BRIT J CANCER, V91, P359, DOI 10.1038/sj.bjc.6601967; Shaheen NJ, 2002, CANCER-AM CANCER SOC, V94, P950, DOI 10.1002/cncr.10333; Singh B, 2006, J SURG RES, V131, P267, DOI 10.1016/j.jss.2005.11.582; Singh B, 2005, INT J ONCOL, V26, P1393; Singh B, 2002, J SURG RES, V108, P173, DOI 10.1006/jsre.2002.6532; Singh B, 2006, J SURG RES, V134, P44, DOI 10.1016/j.jss.2006.03.018; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Wang HS, 2004, ASSAY DRUG DEV TECHN, V2, P31, DOI 10.1089/154065804322966298; Zhang S, 2004, BREAST CANCER RES TR, V87, P111, DOI 10.1023/B:BREA.0000041593.69178.57	37	104	107	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3789	3796		10.1038/sj.onc.1210154	http://dx.doi.org/10.1038/sj.onc.1210154			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17213821				2022-12-17	WOS:000247026400003
J	Zhong, S; Fields, CR; Su, N; Pan, YX; Robertson, KD				Zhong, S.; Fields, C. R.; Su, N.; Pan, Y-X; Robertson, K. D.			Pharmacologic inhibition of epigenetic modi. cations, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer	ONCOGENE			English	Article						lung cancer; DNA methylation; 5-aza-2 '-deoxycytidine; trichostatin A; histone acetylation; microarray	PROMOTER HYPERMETHYLATION; EARLY EVENT; TUMOR; MARKER; ADENOCARCINOMA; EPIGENOME; OXYTOCIN; BINDING; OCCURS; CELLS	Lung cancer is the leading cause of cancer-related deaths in the United States due, in large part, to the lack of early detection methods. Lung cancer arises from a complex series of genetic and epigenetic changes leading to uncontrolled cell growth and metastasis. Unlike genetic changes, epigenetic changes, such as DNA methylation and histone acetylation, are reversible with currently available pharmaceuticals and are early events in lung tumorigenesis detectable by non-invasive methods. In order to better understand how epigenetic changes contribute to lung cancer, and to identify new disease biomarkers, we combined pharmacologic inhibition of DNA methylation and histone deacetylation in non-small cell lung cancer (NSCLC) cell lines, with genome-wide expression proling. Of the more than 200 genes upregulated by these treatments, three of these, neuronatin, metallothionein 3 and cystatin E/M, were frequently hypermethylated and transcriptionally down-regulated in NSCLC cell lines and tumors. Interestingly, four other genes, cylindromatosis, CD9, activating transcription factor 3 and oxytocin receptor, were dominantly regulated by histone deacetylation and were also frequently down-regulated in lung tumors. The majority of these genes also suppressed NSCLC growth in culture when ectopically expressed. This study therefore reveals new putative NSCLC growth regulatory genes and epigenetic disease biomarkers that may enhance early detection strategies and serve as therapeutic targets.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, UF Shands Canc Ctr Program Canc Genet Epigenet &, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Genet Inst, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Robertson, KD (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, UF Shands Canc Ctr Program Canc Genet Epigenet &, Gainesville, FL 32610 USA.	keithr@ufl.edu	Pan, Yuan-Xiang/C-6576-2019	Pan, Yuan-Xiang/0000-0003-3219-4367; Robertson, Keith/0000-0002-7508-3328	NCI NIH HHS [K22CA084535, R01CA114229] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K22CA084535, R01CA114229] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrahamson M, 2003, BIOCHEM SOC SYMP, V70, P179, DOI 10.1042/bss0700179; Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576; Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432; Belinsky SA, 2003, CANCER RES, V63, P7089; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bottone FG, 2003, J BIOL CHEM, V278, P25790, DOI 10.1074/jbc.M301002200; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cassoni P, 2004, J NEUROENDOCRINOL, V16, P362, DOI 10.1111/j.0953-8194.2004.01165.x; Chen H, 2004, J BIOL CHEM, V279, P50829, DOI 10.1074/jbc.M409173200; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Digel W, 2005, CRIT REV ONCOL HEMAT, V55, P1, DOI 10.1016/j.critrevonc.2005.02.002; Dutta R, 2002, PROSTATE, V52, P89, DOI 10.1002/pros.10097; Eickhoff B, 2000, BIOL CHEM, V381, P107, DOI 10.1515/BC.2000.015; Espada J, 2004, J BIOL CHEM, V279, P37175, DOI 10.1074/jbc.M404842200; Esteller M, 1999, CANCER RES, V59, P67; Evans HK, 2001, GENOMICS, V77, P99, DOI 10.1006/geno.2001.6612; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fiegl H, 2005, CANCER RES, V65, P1141, DOI 10.1158/0008-5472.CAN-04-2438; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029; Hai T, 1999, GENE EXPRESSION, V7, P321; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Kim MS, 2003, CANCER RES, V63, P7291; Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552; Kuerbitz SJ, 2002, CARCINOGENESIS, V23, P559, DOI 10.1093/carcin/23.4.559; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Maruyama R, 2004, CANCER-AM CANCER SOC, V100, P1472, DOI 10.1002/cncr.20144; Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Pequeux C, 2005, LUNG CANCER, V50, P177, DOI 10.1016/j.lungcan.2005.05.027; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327; Schrump DS, 2005, SEMIN ONCOL, V32, P488, DOI 10.1053/j.seminoncol.2005.07.007; Somech R, 2004, CANCER TREAT REV, V30, P461, DOI 10.1016/j.ctrv.2004.04.006; Suh YH, 2005, BIOCHEM BIOPH RES CO, V337, P481, DOI 10.1016/j.bbrc.2005.09.078; Topaloglu O, 2004, CLIN CANCER RES, V10, P2284, DOI 10.1158/1078-0432.CCR-1111-3; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Wang L, 2005, MOL CELL BIOL, V25, P7953, DOI 10.1128/MCB.25.18.7953-7965.2005; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712	51	104	108	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2621	2634		10.1038/sj.onc.1210041	http://dx.doi.org/10.1038/sj.onc.1210041			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17043644				2022-12-17	WOS:000245831200009
J	Seng, TJ; Low, JSW; Li, H; Cui, Y; Goh, HK; Wong, MLY; Srivastava, G; Sidransky, D; Califano, J; Steenbergen, RDM; Rha, SY; Tan, J; Hsieh, WS; Ambinder, RF; Lin, X; Chan, ATC; Tao, Q				Seng, T. J.; Low, J. S. W.; Li, H.; Cui, Y.; Goh, H. K.; Wong, M. L. Y.; Srivastava, G.; Sidransky, D.; Califano, J.; Steenbergen, R. D. M.; Rha, S. Y.; Tan, J.; Hsieh, W-S; Ambinder, R. F.; Lin, X.; Chan, A. T. C.; Tao, Q.			The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation	ONCOGENE			English	Article						DLC1; 8p22; tumor suppressor gene; methylation; nasopharyngeal carcinoma; esophageal carcinoma; cervical carcinoma	EPSTEIN-BARR-VIRUS; COMPARATIVE GENOMIC HYBRIDIZATION; STRESS-RESPONSIVE GENE; HUMAN BREAST-CANCER; PROMOTER HYPERMETHYLATION; P53 GENE; EPIGENETIC INACTIVATION; SUSCEPTIBILITY LOCUS; TSLC1 GENE; MULTIPLE	Identification of tumor suppressor genes (TSG) silenced by methylation uncovers mechanisms of tumorigenesis and identifies new epigenetic tumor markers for early cancer detection. Both nasopharyngeal carcinoma (NPC) and esophageal carcinoma are major tumors in Southern China and Southeast Asia. Through expression subtraction of NPC, we identified Deleted in Liver Cancer 1 (DLC1)/ARHGAP7 (NM_006094) - an 8p22 TSG as a major downregulated gene. Although expressed in all normal tissues, DLC1 was silenced or downregulated in 11/12 (91%) NPC, 6/15 (40%) esophageal, 5/8 (63%) cervical and 3/9 (33%) breast carcinoma cell lines. No genetic deletion of DLC1 was detected in NPC although a hemizygous deletion at 8p22-11 was found by 1-Mb array-CGH in some cell lines. We then located the functional DLC1 promoter by 5'-RACE and promoter activity assays. This promoter was frequently methylated in all downregulated cell lines and in a large collection of primary tumors including 89% (64/72) NPC (endemic and sporadic types), 51% (48/94) esophageal, 87% (7/8) cervical and 36% (5/14) breast carcinomas, but seldom in paired surgical marginal tissues and not in any normal epithelial tissue. The transcriptional silencing of DLC1 could be reversed by 5-aza-20-deoxycytidine or genetic double knock-out of DNMT1 and DNMT3B. Furthermore, ectopic expression of DLC1 in NPC and esophageal carcinoma cells strongly inhibited their colony formation. We thus found frequent epigenetic silencing of DLC1 in NPC, esophageal and cervical carcinomas, and a high correlation of methylation with its downregulation, suggesting a predominant role of epigenetic inactivation. DLC1 appears to be a major TSG implicated in the pathogenesis of these tumors, and should be further tested as a molecular biomarker in patients with these cancers.	Chinese Univ Hong Kong, Ctr Canc, Canc Epigenet Lab, Dept Clin Oncol,PWH, Hong Kong, Hong Kong, Peoples R China; Johns Hopkins Singapore, Biopolis, Singapore, Singapore; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Johns Hopkins Med Inst, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA; Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1081 HV Amsterdam, Netherlands; Yonsei Univ, Coll Med, Ctr Canc, Seoul 120749, South Korea; Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA	Chinese University of Hong Kong; Prince of Wales Hospital; Johns Hopkins University; Johns Hopkins Medicine; University of Hong Kong; Johns Hopkins University; Johns Hopkins Medicine; Vrije Universiteit Amsterdam; Yonsei University; Yonsei University Health System; Johns Hopkins University; Johns Hopkins Medicine	Tao, Q (corresponding author), Chinese Univ Hong Kong, Ctr Canc, Canc Epigenet Lab, Dept Clin Oncol,PWH, Hong Kong, Hong Kong, Peoples R China.	qtao@clo.cuhk.edu.hk	Tao, Qian/T-4743-2018; Chan, Anthony Tak Cheung/R-3940-2018	Tao, Qian/0000-0001-5383-4808; Chan, Anthony Tak Cheung/0000-0002-6912-8091; Rha, Sun Young/0000-0002-2512-4531; Steenbergen, Renske/0000-0002-2327-9839	NATIONAL CANCER INSTITUTE [P01CA015396] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA15396] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; Chen YJ, 1999, GENE CHROMOSOME CANC, V25, P169, DOI 10.1002/(SICI)1098-2264(199906)25:2<169::AID-GCC13>3.3.CO;2-9; Cheng Y, 2002, GENE CHROMOSOME CANC, V34, P97, DOI 10.1002/gcc.10048; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Deng W, 2004, ONCOGENE, V23, P9090, DOI 10.1038/sj.onc.1208119; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feng BJ, 2002, NAT GENET, V31, P395, DOI 10.1038/ng932; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; Gulley ML, 1998, AM J PATHOL, V152, P865; HILDESHEIM A, 1993, EPIDEMIOL REV, V15, P466, DOI 10.1093/oxfordjournals.epirev.a036130; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Hui ABY, 2003, MOL CARCINOGEN, V38, P170, DOI 10.1002/mc.10156; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Kim TM, 2005, CLIN CANCER RES, V11, P79; Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573; Lo KW, 2000, CANCER RES, V60, P3348; LO KW, 1995, CANCER RES, V55, P2039; LU SJ, 1990, NATURE, V346, P470, DOI 10.1038/346470a0; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Murray PG, 2004, ONCOGENE, V23, P1326, DOI 10.1038/sj.onc.1207313; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; Plaumann M, 2003, J CANCER RES CLIN, V129, P349, DOI 10.1007/s00432-003-0440-z; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Raab-Traub N, 2002, SEMIN CANCER BIOL, V12, P431, DOI 10.1016/S1044579X0200086X; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; SPRUCK CH, 1992, CANCER RES, V52, P4787; Srivastava G, 2000, BLOOD, V95, P2443, DOI 10.1182/blood.V95.7.2443.007k18_2443_2445; Steenbergen RDM, 2004, JNCI-J NATL CANCER I, V96, P294, DOI 10.1093/jnci/djh031; Steenbergen RDM, 1996, ONCOGENE, V13, P1249; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; Tang JCO, 2001, CANCER GENET CYTOGEN, V124, P36, DOI 10.1016/S0165-4608(00)00317-4; Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7; Tao Q, 1998, J VIROL, V72, P7075, DOI 10.1128/JVI.72.9.7075-7083.1998; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Tao Q, 2006, FRONT BIOSCI-LANDMRK, V11, P2672, DOI 10.2741/2000; Teramoto A, 2004, ONCOL REP, V12, P141; Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2; Wang DZM, 1997, CANCER RES, V57, P2478; Wilson PJ, 2000, HUM MUTAT, V15, P156, DOI 10.1002/(SICI)1098-1004(200002)15:2<156::AID-HUMU4>3.0.CO;2-4; Wong CM, 2003, CANCER RES, V63, P7646; Wong ML, 2006, INT J ONCOL, V28, P767; Xiong W, 2004, CANCER RES, V64, P1972, DOI 10.1158/0008-5472.CAN-03-3253; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Yu MC, 2002, SEMIN CANCER BIOL, V12, P421, DOI 10.1016/S1044579X02000858; Yuan BZ, 1998, CANCER RES, V58, P2196; Yuan BZ, 2003, CANCER GENET CYTOGEN, V140, P113, DOI 10.1016/S0165-4608(02)00674-X; Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291; Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064; Zhou L, 2005, NEOPLASIA, V7, P809, DOI 10.1593/neo.05217	53	104	118	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2007	26	6					934	944		10.1038/sj.onc.1209839	http://dx.doi.org/10.1038/sj.onc.1209839			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16862168				2022-12-17	WOS:000244063800013
J	Zhang, L; Wang, C				Zhang, L; Wang, C			F-box protein Skp2: a novel transcriptional target of E2F	ONCOGENE			English	Article						transcription; SCFskp2; E2F; cell cycle	SCFSKP2 UBIQUITIN LIGASE; CELL-CYCLE; IN-VITRO; CHROMATIN IMMUNOPRECIPITATION; S-PHASE; C-MYC; DEGRADATION; EXPRESSION; COMPLEX; PROTEOLYSIS	The F-box-containing protein Skp2 plays a critical role in coordinating the G1/S transition and progression through the S phase of the mammalian cell cycle. Skp2 is overexpressed in a broad spectrum of human cancers and the expression level correlates with tumor malignancy. However, the Skp2 gene is neither amplified nor rearranged in most human cancers and the underlying mechanism of Skp2 overexpression remains poorly understood. We show here that the Skp2 gene contains a functional E2F response element ( hSRE2). Ectopic expression of E2F1 induces expression of the endogenous Skp2 gene in human fibroblast cells, whereas antisense-mediated knockdown of E2F1 in human tumor cell lines reduces expression of endogenous Skp2 gene. The hSRE2 element not only participates in activation of Skp2 promoter function during normal cell cycle progression into S phase, it is also required for the high-level Skp2 gene expression in many human tumor cell lines. These results reveal Skp2 as a novel target for E2F regulation that is disrupted in several human tumor cell lines.	Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Wang, C (corresponding author), Univ Illinois, Ctr Mol Biol Oral Dis, 801 S Paulina St,Room 530E,M-C 860, Chicago, IL 60612 USA.	chiayeng@uic.edu			NATIONAL CANCER INSTITUTE [R29CA074907, R01CA074907] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA074907, R29 CA074907, CA074907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amati B, 2004, P NATL ACAD SCI USA, V101, P8843, DOI 10.1073/pnas.0403046101; Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bashir T, 2004, CELL CYCLE, V3, P850; Bhattacharya S, 2003, ONCOGENE, V22, P2443, DOI 10.1038/sj.onc.1206339; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Cao Y, 2000, J BIOL CHEM, V275, P9854, DOI 10.1074/jbc.275.13.9854; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Ciechanover A, 2004, BBA-MOL CELL RES, V1695, P3, DOI 10.1016/j.bbamcr.2004.09.018; Coe BR, 2005, GENE CHROMOSOME CANC, V42, P308, DOI 10.1002/gcc.20137; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; Dowen SE, 2003, ONCOGENE, V22, P2531, DOI 10.1038/sj.onc.1206296; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Imaki H, 2003, CANCER RES, V63, P4607; Jin JP, 2003, CANCER CELL, V3, P517, DOI 10.1016/S1535-6108(03)00145-4; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Koga H, 2003, HEPATOLOGY, V37, P1086, DOI 10.1053/jhep.2003.50186; Koziczak M, 2000, MOL CELL BIOL, V20, P2014, DOI 10.1128/MCB.20.6.2014-2022.2000; Kurland JF, 2004, CANCER CELL, V5, P305, DOI 10.1016/S1535-6108(04)00091-1; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; MERCOLA M, 1985, SCIENCE, V227, P266, DOI 10.1126/science.3917575; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Ohta T, 2001, CANCER RES, V61, P1347; Oliveira AM, 2003, J CLIN ONCOL, V21, P722, DOI 10.1200/JCO.2003.05.112; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ross JF, 2001, GENE DEV, V15, P392, DOI 10.1101/gad.858501; Simile MM, 2004, CARCINOGENESIS, V25, P333, DOI 10.1093/carcin/bgh014; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vernell R, 2003, J BIOL CHEM, V278, P46124, DOI 10.1074/jbc.M304930200; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Yeh KH, 2001, BIOCHEM BIOPH RES CO, V281, P884, DOI 10.1006/bbrc.2001.4442; Yokoi S, 2004, AM J PATHOL, V165, P175, DOI 10.1016/S0002-9440(10)63286-5; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	65	104	107	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2615	2627		10.1038/sj.onc.1209286	http://dx.doi.org/10.1038/sj.onc.1209286			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16331253	Green Accepted			2022-12-17	WOS:000237099400005
J	Tsuji, Y				Tsuji, Y			JunD activates transcription of the human ferritin H gene through an antioxidant response element during oxidative stress	ONCOGENE			English	Article						ferritin; oxidative stress; JunD; AP1; ARE; iron	TUMOR-NECROSIS-FACTOR; YA-SUBUNIT GENE; CONTROLLING INDUCIBLE EXPRESSION; NF-KAPPA-B; HEAVY-CHAIN; FACTOR-ALPHA; C-JUN; PHENOLIC ANTIOXIDANTS; TISSUE ISOFERRITINS; MEDIATED EXPRESSION	Ferritin is the major intracellular iron storage protein that sequesters excess free iron to minimize generation of iron-catalysed reactive oxygen species. We previously demonstrated that expression of ferritin heavy chain (ferritin H) was induced by pro-oxidants, which is a part of cellular antioxidant response to protect cells from oxidative damage. In this study, we have identified that the antioxidant/electrophile response element (ARE) located 4.5 kb upstream to the human ferritin H transcription initiation site is responsible for the oxidant response. The human ferritin H ARE comprises two copies of bidirectional AP1 motifs. Mutations in each AP1 motif significantly impaired protein binding and the function of the ARE, indicating that both of the AP1 motifs are required for pro-oxidant-mediated activation of the ferritin H gene. We identified that JunD, an AP1 family basic-leucine zipper (bZip) trans cription factor, is one of the ferritin H ARE binding proteins and activates ferritin H transcription in HepG2 hepatocarcinoma cells. Gel retardation assay demonstrated that H2O2 (hydrogen peroxide) or t-BHQ (tert-butylhydroquinone) treatment increased total protein binding as well as JunD binding to the ferritin H ARE. Chromatin immunoprecipitation assay showed that H2O2 treatment induced JunD binding to the ferritin H ARE. Both H2O2 and t-BHQ induced phosphorylation of JunD at Ser-100, an activated form of JunD. Furthermore, overexpression of JunD induced endogenous ferritin H protein synthesis. Since JunD has recently been demonstrated to protect cells from several stress stimuli including oxidative stress, these results suggest that, in addition to NFE2-related factor 2 (Nrf2) as a major ARE regulatory protein, JunD is another ARE regulatory protein for transcriptional activation of the human ferritin H gene and probably other antioxidant genes containing the conserved ARE sequences by which JunD may confer cytoprotection during oxidative stress.	N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Tsuji, Y (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Campus Box 7633, Raleigh, NC 27695 USA.	yoshiaki_tsuji@ncsu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060007] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-60007, R01 DK060007, R01 DK060007-01A1, R01 DK060007-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ainbinder E, 1997, EUR J BIOCHEM, V243, P49, DOI 10.1111/j.1432-1033.1997.0049a.x; Arosio P, 2002, FREE RADICAL BIO MED, V33, P457, DOI 10.1016/S0891-5849(02)00842-0; BEAUMONT C, 1994, J BIOL CHEM, V269, P20281; BEAUMONT C, 1987, J BIOL CHEM, V262, P10619; Bevilacqua MA, 1998, BIOCHEM J, V335, P521, DOI 10.1042/bj3350521; Bevilacqua MA, 1997, J BIOL CHEM, V272, P20736, DOI 10.1074/jbc.272.33.20736; BOMFORD A, 1981, J BIOL CHEM, V256, P948; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; CHOI HS, 1993, MOL ENDOCRINOL, V7, P1596, DOI 10.1210/me.7.12.1596; CHOU CC, 1986, MOL CELL BIOL, V6, P566, DOI 10.1128/MCB.6.2.566; Cozzi A, 2000, J BIOL CHEM, V275, P25122, DOI 10.1074/jbc.M003797200; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Epsztejn S, 1999, BLOOD, V94, P3593, DOI 10.1182/blood.V94.10.3593.422k26_3593_3603; Faniello MC, 1999, J BIOL CHEM, V274, P7623, DOI 10.1074/jbc.274.12.7623; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Gallo A, 2002, ONCOGENE, V21, P6434, DOI 10.1038/sj.onc.1205822; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hayes JD, 2001, CANCER LETT, V174, P103, DOI 10.1016/S0304-3835(01)00695-4; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Inamdar NM, 1996, BIOCHEM BIOPH RES CO, V221, P570, DOI 10.1006/bbrc.1996.0637; Jaiswal AK, 2004, METHOD ENZYMOL, V378, P221; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; Jindra M, 2004, EMBO J, V23, P3538, DOI 10.1038/sj.emboj.7600356; KWAK EL, 1995, J BIOL CHEM, V270, P15285, DOI 10.1074/jbc.270.25.15285; Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325; LEVI S, 1988, J BIOL CHEM, V263, P18086; LEVI S, 1992, BIOCHEM J, V288, P591, DOI 10.1042/bj2880591; LI Y, 1992, J BIOL CHEM, V267, P15097; Liu SX, 1996, BIOCHEMISTRY-US, V35, P11517, DOI 10.1021/bi960572p; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Meneghini R, 1997, FREE RADICAL BIO MED, V23, P783, DOI 10.1016/S0891-5849(97)00016-6; MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Nioi P, 2003, BIOCHEM J, V374, P337, DOI 10.1042/BJ20030754; Orino K, 2001, BIOCHEM J, V357, P241, DOI 10.1042/0264-6021:3570241; Orino K, 1999, FEBS LETT, V461, P334, DOI 10.1016/S0014-5793(99)01443-X; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Pietsch EC, 2003, J BIOL CHEM, V278, P2361, DOI 10.1074/jbc.M210664200; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; SANTAMBROGIO P, 1992, J BIOL CHEM, V267, P14077; Theil EC, 2003, J NUTR, V133, p1549S, DOI 10.1093/jn/133.5.1549S; Theil EC, 2000, BIOCHEM PHARMACOL, V59, P87, DOI 10.1016/S0006-2952(99)00300-7; Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505; TORTI SV, 1988, J BIOL CHEM, V263, P12638; TSUJI Y, 1991, J BIOL CHEM, V266, P7257; Tsuji Y, 2000, MOL CELL BIOL, V20, P5818, DOI 10.1128/MCB.20.16.5818-5827.2000; TSUJI Y, 1993, J IMMUNOL, V150, P1897; TSUJI Y, 1995, MOL CELL BIOL, V15, P5152; Tsuji Y, 1999, J BIOL CHEM, V274, P7501, DOI 10.1074/jbc.274.11.7501; Vasiliou V, 1995, BIOCHEM PHARMACOL, V50, P2057, DOI 10.1016/0006-2952(95)02108-6; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Vinciguerra M, 2004, J BIOL CHEM, V279, P9634, DOI 10.1074/jbc.M308721200; WAGSTAFF M, 1978, BIOCHEM J, V173, P969, DOI 10.1042/bj1730969; Wasserman WW, 1997, ARCH BIOCHEM BIOPHYS, V344, P387, DOI 10.1006/abbi.1997.0215; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Xanthoudakis S, 1996, ADV EXP MED BIOL, V387, P69; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yazgan O, 2002, J BIOL CHEM, V277, P29710, DOI 10.1074/jbc.M204552200	71	104	111	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 17	2005	24	51					7567	7578		10.1038/sj.onc.1208901	http://dx.doi.org/10.1038/sj.onc.1208901			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16007120	Green Accepted			2022-12-17	WOS:000233333800006
J	Rosty, C; Sheffer, M; Tsafrir, D; Stransky, N; Tsafrir, I; Peter, M; de Cremoux, P; de La Rochefordiere, A; Salmon, R; Dorval, T; Thiery, JP; Couturier, J; Radvanyi, F; Domany, E; Sastre-Garau, X				Rosty, C; Sheffer, M; Tsafrir, D; Stransky, N; Tsafrir, I; Peter, M; de Cremoux, P; de La Rochefordiere, A; Salmon, R; Dorval, T; Thiery, JP; Couturier, J; Radvanyi, F; Domany, E; Sastre-Garau, X			Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma	ONCOGENE			English	Article						cervical cancer; gene expression; HPV; prognosis; bioinformatics	HUMAN-PAPILLOMAVIRUS TYPE-16; UTERINE CERVIX; MYC GENES; CANCER; INTEGRATION; AMPLIFICATION; RADIOTHERAPY; MICROARRAYS; PROGNOSIS; WORLDWIDE	Specific HPV DNA sequences are associated with more than 90% of invasive carcinomas of the uterine cervix. Viral E6 and E7 oncogenes are key mediators in cell transformation by disrupting TP53 and RB pathways. To investigate molecular mechanisms involved in the progression of invasive cervical carcinoma, we performed a gene expression study on cases selected according to viral and clinical parameters. Using Coupled Two-Way Clustering and Sorting Points Into Neighbourhoods methods, we identified a 'cervical cancer proliferation cluster' composed of 163 highly correlated transcripts. Most of these transcripts corresponded to E2F pathway genes controlling cell division or proliferation, whereas none was known as TP53 primary target. The average expression level of the genes of this cluster was higher in tumours with an early relapse than in tumours with a favourable course (P = 0.026). Moreover, we found that E6/E7 mRNA expression level was positively correlated with the expression level of the cluster genes and with viral DNA load. These findings suggest that HPV E6/E7 expression level plays a key role in the progression of invasive carcinoma of the uterine cervix via the deregulation of cellular genes controlling tumour cell proliferation. HPV expression level may thus provide a biological marker useful for prognosis assessment and specific therapy of the disease.	Inst Curie, Dept Biol Tumeurs, F-75248 Paris, France; Inst Curie, CNRS, Oncol Mol UMR 144, F-75248 Paris, France; Inst Curie, Dept Radiotherapy, F-75248 Paris, France; Inst Curie, Dept Chirurg, F-75248 Paris, France; Inst Curie, Dept Med Oncol, F-75248 Paris, France; Inst Curie, Dept Tranfert, F-75248 Paris, France; Weizmann Inst Sci, Dept Phys Complex Syst, Rehovot, Israel	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Weizmann Institute of Science	Sastre-Garau, X (corresponding author), Inst Curie, Med Sect, Dept Pathol, 26 Rue Ulm, F-75248 Paris, France.	xavier.sastre@curie.net	Thiery, Jean Paul/M-9387-2019; Rosty, Christophe/F-1796-2010; DOMANY, EYTAN/K-1560-2012; Thiery, Jean Paul/H-1550-2011	Radvanyi, Francois/0000-0002-5696-6424; Rosty, Christophe/0000-0001-7671-2651; Sastre-Garau, Xavier/0000-0001-5992-2083; Thiery, Jean Paul/0000-0003-0478-5020; Sheffer, Michal/0000-0001-5934-9950				BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BERUMEN J, 1994, INT J CANCER, V56, P640, DOI 10.1002/ijc.2910560506; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Burger RA, 1996, JNCI-J NATL CANCER I, V88, P1361, DOI 10.1093/jnci/88.19.1361; Chen Y, 2003, CANCER RES, V63, P1927; Clifford GM, 2003, BRIT J CANCER, V88, P63, DOI 10.1038/sj.bjc.6600688; COUTURIER J, 1991, J VIROL, V65, P4534, DOI 10.1128/JVI.65.8.4534-4538.1991; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; Dalstein W, 2003, INT J CANCER, V106, P396, DOI 10.1002/ijc.11222; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; FERLAY F, 2001, GLOBOCAN 2000 CANC I; Fisher RA, 1935, J R STAT SOC, V98, P39, DOI 10.2307/2342435; GERBAULET AL, 1992, RADIOTHER ONCOL, V23, P66, DOI 10.1016/0167-8140(92)90337-T; Getz G, 2000, P NATL ACAD SCI USA, V97, P12079, DOI 10.1073/pnas.210134797; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; IKENBERG H, 1994, INT J CANCER, V59, P322, DOI 10.1002/ijc.2910590306; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Klaes R, 1999, CANCER RES, V59, P6132; Lai HC, 1999, INT J CANCER, V84, P553, DOI 10.1002/(SICI)1097-0215(19991222)84:6&lt;553::AID-IJC2&gt;3.0.CO;2-4; Liu GY, 2003, NUCLEIC ACIDS RES, V31, P82, DOI 10.1093/nar/gkg121; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lombard I, 1998, J CLIN ONCOL, V16, P2613, DOI 10.1200/JCO.1998.16.8.2613; Markey MP, 2002, CANCER RES, V62, P6587; MATSUKURA T, 1989, VIROLOGY, V172, P63, DOI 10.1016/0042-6822(89)90107-4; MILYAVSKY M, IN PRESS CANC RES; Morris M, 1999, NEW ENGL J MED, V340, P1137, DOI 10.1056/NEJM199904153401501; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004; Omura GA, 1997, J CLIN ONCOL, V15, P165, DOI 10.1200/JCO.1997.15.1.165; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; ROMANCZUK H, 1992, P NATL ACAD SCI USA, V89, P3159, DOI 10.1073/pnas.89.7.3159; Rosty C, 2004, INT J GYNECOL PATHOL, V23, P13, DOI 10.1097/01.pgp.0000092137.88121.8d; Sastre-Garau X, 2000, J GEN VIROL, V81, P1983, DOI 10.1099/0022-1317-81-8-1983; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; Sopov I, 2004, INT J CANCER, V112, P33, DOI 10.1002/ijc.20351; TABACH Y, UNPUB; Thierry F, 2004, CANCER RES, V64, P895, DOI 10.1158/0008-5472.CAN-03-2349; Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520; Tsafrir D, 2005, BIOINFORMATICS, V21, P2301, DOI 10.1093/bioinformatics/bti329; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang HLL, 2004, AM J SURG PATHOL, V28, P901, DOI 10.1097/00000478-200407000-00009; Wells SI, 2003, P NATL ACAD SCI USA, V100, P7093, DOI 10.1073/pnas.1232309100; Wong YF, 2003, CLIN CANCER RES, V9, P5486; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	44	104	108	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7094	7104		10.1038/sj.onc.1208854	http://dx.doi.org/10.1038/sj.onc.1208854			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007141	Green Submitted			2022-12-17	WOS:000232833200011
J	Uddin, S; Hussain, AR; Manogaran, PS; Al-Hussein, K; Platanias, LC; Gutierrez, MI; Bhatia, KG				Uddin, S; Hussain, AR; Manogaran, PS; Al-Hussein, K; Platanias, LC; Gutierrez, MI; Bhatia, KG			Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma	ONCOGENE			English	Article						PEL; curcumin; cell death; NHL therapy	FACTOR-KAPPA-B; CYTOCHROME-C RELEASE; TRANSCRIPTION FACTOR; CELL-PROLIFERATION; SIGNAL TRANSDUCER; DIETARY CURCUMIN; IN-VITRO; ACTIVATION; INHIBITION; KINASE	The mechanisms that regulate induction of the antiapoptotic state and mitogenic signals in primary effusion lymphoma (PEL) are not well known. In efforts to identify novel approaches to block the proliferation of PEL cells, we found that curcumin (diferuloylmethane), a natural compound isolated from the plant Curcuma Ionga, inhibits cell proliferation and induces apoptosis in a dose dependent manner in several PEL cell lines. Such effects of curcumin appear to result from suppression of the constitutively active STAT3 through inhibition of Janus kinase 1 (JAK1). Our data also demonstrate that curcumin induces loss of mitochondrial membrane potential with subsequent release of cytochrome c and activation of caspase-3, followed by polyadenosin-5'-diphosphate-ribose polymerase (PARP) cleavage. Altogether, our findings suggest a novel function for curcumin, acting as a suppressor of JAK-1 and STAT3 activation in PEL cells, leading to inhibition of proliferation and induction of caspase-dependent apoptosis. Therefore, curcumin may have a future therapeutic role in PEL and possibly other malignancies with constitutive activation of STAT3.	King Fahad Natl Ctr Childrens Canc & Res, Riyadh 11211, Saudi Arabia; King Faisal Specialist Hosp & Res Ctr, BMR, Riyadh 11211, Saudi Arabia; Northwestern Univ, Sch Med, Div Hematol Oncol, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA; NCI, Canc Diagnosis Program, Rockville, MD USA	King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Uddin, S (corresponding author), King Fahad Natl Ctr Childrens Canc & Res, MBC98-16,POB 3354, Riyadh 11211, Saudi Arabia.	Shahab@kfshrc.edu.sa; Bhatiak@mail.nih.gov		Uddin, Shahab/0000-0003-1886-6710				Anto RJ, 2002, CARCINOGENESIS, V23, P143, DOI 10.1093/carcin/23.1.143; Aoki Y, 2000, BLOOD, V96, P1599, DOI 10.1182/blood.V96.4.1599.h8001599_1599_1601; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Barton BE, 2004, MOL CANCER THER, V3, P1183; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; Bharti AC, 2004, BLOOD, V103, P3175, DOI 10.1182/blood-2003-06-2151; Bharti AC, 2003, J IMMUNOL, V171, P3863, DOI 10.4049/jimmunol.171.7.3863; Bharti AC, 2003, BLOOD, V101, P1053, DOI 10.1182/blood-2002-05-1320; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Bush JA, 2001, EXP CELL RES, V271, P305, DOI 10.1006/excr.2001.5381; Cannon ML, 2004, ONCOGENE, V23, P514, DOI 10.1038/sj.onc.1207021; Chen H, 1999, ANTICANCER RES, V19, P3675; Cheong JW, 2003, LEUKEMIA RES, V27, P1159, DOI 10.1016/S0145-2126(03)00102-4; Chuang SE, 2000, CARCINOGENESIS, V21, P331, DOI 10.1093/carcin/21.2.331; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Drexler HG, 1998, LEUKEMIA, V12, P1507, DOI 10.1038/sj.leu.2401160; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Huang MT, 1998, CARCINOGENESIS, V19, P1697, DOI 10.1093/carcin/19.9.1697; Jones KD, 1999, BLOOD, V94, P2871; Kalechman Y, 2004, J BIOL CHEM, V279, P24724, DOI 10.1074/jbc.M312006200; Kawamori T, 1999, CANCER RES, V59, P597; Keller SA, 2000, BLOOD, V96, P2537; Kim HY, 2003, J IMMUNOL, V171, P6072, DOI 10.4049/jimmunol.171.11.6072; Klepfish A, 2001, LEUKEMIA LYMPHOMA, V41, P439, DOI 10.3109/10428190109058002; Li L, 2004, CANCER-AM CANCER SOC, V101, P2351, DOI 10.1002/cncr.20605; Limtrakul P, 1997, CANCER LETT, V116, P197, DOI 10.1016/S0304-3835(97)00187-0; Lodha R., 2000, Annals Academy of Medicine Singapore, V29, P37; MASOOD R, 1995, BLOOD, V85, P3423, DOI 10.1182/blood.V85.12.3423.bloodjournal85123423; Mukhopadhyay A, 2001, ONCOGENE, V20, P7597, DOI 10.1038/sj.onc.1204997; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Pene F, 2002, ONCOGENE, V21, P6587, DOI 10.1038/sj.onc.1205923; Prakash O, 2002, JNCI-J NATL CANCER I, V94, P926; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Sredni B, 2004, CANCER RES, V64, P1843, DOI 10.1158/0008-5472.CAN-03-3179; Syng-ai C, 2004, MOL CANCER THER, V3, P1101; Tomlinson CC, 2004, J VIROL, V78, P1918, DOI 10.1128/JVI.78.4.1918-1927.2004; Uddin S, 2005, CLIN CANCER RES, V11, P3102, DOI 10.1158/1078-0432.CCR-04-1857; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 2004, BIOCHEM BIOPH RES CO, V320, P932, DOI 10.1016/j.bbrc.2004.06.038; Uddin S, 2004, P NATL ACAD SCI USA, V101, P147, DOI 10.1073/pnas.0307075101; Zhang CL, 2002, CLIN CANCER RES, V8, P1234	44	104	108	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7022	7030		10.1038/sj.onc.1208864	http://dx.doi.org/10.1038/sj.onc.1208864			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16044161				2022-12-17	WOS:000232833200004
J	McKie, AB; Douglas, DA; Olijslagers, S; Graham, J; Omar, MM; Heer, R; Gnanapragasam, VJ; Robson, CN; Leung, HY				McKie, AB; Douglas, DA; Olijslagers, S; Graham, J; Omar, MM; Heer, R; Gnanapragasam, VJ; Robson, CN; Leung, HY			Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer	ONCOGENE			English	Article						hypermethylation; CpG; island; sprouty ( modulator); prostate cancer; tumour suppressor	GROWTH-FACTORS; CPG-ISLANDS; EXPRESSION; METHYLATION; ANTAGONIST; INHIBITOR; RECEPTORS	Abnormal signalling events mediated by receptor tyrosine kinases (RTKs) contribute to human carcinogenesis. Sprouty2 (Spry2) is a key antagonistic regulator of RTK signalling and suppression of its expression or function may facilitate proliferation and angiogenesis. Using prostate cancer (CaP) as a model, we investigated the significance of Spry2 in human malignancy. We observed downregulated Spry2 expression in invasive CaP cell lines and high-grade clinical CaP ( compared to benign prostatic hyperplasia (BPH) and well-differentiated tumours, P = 0.041). A large CpG island is associated with hSPRY2, and extensive hypermethylation of this CpG island was observed in 76 - 82% of high-grade CaP, while control BPH tissues were predominantly unmethylated (P = 0.0005). Furthermore, suppressed Spry2 expression correlated with methylation of the CpG region in clinical samples (P = 0.004) and treatment with 5-aza-2'-deoxycytidine reactivated Spry2 expression in LNCaP and PC-3M cells. hSPRY2 maps to the long arm of chromosome 13 (13q31.1), where loss of heterozygosity (LOH) has been reported. We found no evidence of mutation; however, we demonstrated 27 - 40% LOH using flanking markers to hSPRY2. Hence, while biallelic epigenetic inactivation of hSPRY2 represents the main genetic event in prostate carcinogenesis, the observed 27 - 40% LOH presents evidence of hemizygous deletion with the remaining allele hypermethylated. We therefore propose hSPRY2 as a potential tumour suppressor locus in CaP.	Univ Newcastle, Sch Med, No Inst Canc Res, Urol Res Grp, Newcastle Upon Tyne NE2 4AD, Tyne & Wear, England	Newcastle University - UK	Leung, HY (corresponding author), Univ Newcastle, Sch Med, No Inst Canc Res, Urol Res Grp, Paul O Gorman Bldg,N Terrace, Newcastle Upon Tyne NE2 4AD, Tyne & Wear, England.	h.y.leung@ncl.ac.uk		Leung, Hing Y./0000-0002-3933-3975	MRC [G0100100] Funding Source: UKRI; Medical Research Council [G0100100] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Christofori G, 2003, NAT CELL BIOL, V5, P377, DOI 10.1038/ncb0503-377; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Ding W, 2003, GENE, V322, P175, DOI 10.1016/j.gene.2003.09.004; Djakiew D, 2000, PROSTATE, V42, P150, DOI 10.1002/(SICI)1097-0045(20000201)42:2<150::AID-PROS10>3.0.CO;2-H; Dong JT, 2001, PROSTATE, V49, P166, DOI 10.1002/pros.1131; Dorkin TJ, 1999, ONCOGENE, V18, P2755, DOI 10.1038/sj.onc.1202624; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Lim J, 2002, MOL CELL BIOL, V22, P7953, DOI 10.1128/MCB.22.22.7953-7966.2002; Maegawa S, 2001, MOL CARCINOGEN, V31, P1, DOI 10.1002/mc.1034; McKie AB, 2001, HUM MOL GENET, V10, P1555, DOI 10.1093/hmg/10.15.1555; Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Reich A, 1999, DEVELOPMENT, V126, P4139; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200	24	104	107	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2166	2174		10.1038/sj.onc.1208371	http://dx.doi.org/10.1038/sj.onc.1208371			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735753				2022-12-17	WOS:000227857900004
J	Matsumoto, J; Ohshima, T; Isono, O; Shimotohno, K				Matsumoto, J; Ohshima, T; Isono, O; Shimotohno, K			HTLV-1 HBZ suppresses AP-1 activity by impairing both the DNA-binding ability and the stability of c-Jun protein	ONCOGENE			English	Article						HTLV-1; ATL; HBZ; AP-1; c-jun; transcription	VIRUS TYPE-I; HUMAN-PAPILLOMAVIRUS TYPE-16; CELL LEUKEMIA-CELLS; FACTOR-KAPPA-B; TAX PROTEIN; T-CELLS; TRANSCRIPTIONAL ACTIVITY; CONSTITUTIVE EXPRESSION; INTERLEUKIN-8 GENE; E6 ONCOPROTEIN	Disruption of transcriptional control of cellular genes by human T-cell leukemia virus type-1 (HTLV-1) is thought to be associated, at least in part, with the development of adult T-cell leukemia. It has been reported that activating protein-1 (AP-1) is dysregulated by HTLV-1 infection. HTLV-1-encoded Tax elevates AP-1 activity through the induction of AP-1 family member gene expression, including c-Jun, JunD, c-Fos, and Fra-1. However, the precise mechanism by which HTLV-1 regulates AP-1 activity remains to be addressed. Recently, a novel viral protein named HTLV-1 basic leucine-zipper factor, HBZ, has been shown to interact with c-Jun and repress c-Jun-mediated transcription by abrogating its DNA-binding activity. In the course of investigating HBZ function, we found that HBZ reduced the steady-state levels of c-Jun, and the levels were restored by treatment with a proteasome inhibitor. Together, this indicates that HBZ promotes c-Jun degradation through a proteasome-dependent pathway. Furthermore, HBZ deletion mutants revealed that both the N-terminal and leucine-zipper region of HBZ were required for the elimination of c-Jun. These results suggest dual effects of HBZ on the suppression of AP-1 activity by inhibiting c-Jun function, which may contribute to the dysregulation of cell proliferation.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Lab Human Tumor Viruses,Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Lab Human Tumor Viruses,Sakyo Ku, Kyoto 6068507, Japan.	tohshima@virus.kyoto-u.ac.jp; kshimoto@virus.kyoto-u.ac.jp		OHSHIMA, Takayuki/0000-0002-1501-6430				AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; Albrecht B, 2002, MICROBIOL MOL BIOL R, V66, P396, DOI 10.1128/MMBR.66.3.396-406.2002; Basbous J, 2003, J BIOL CHEM, V278, P43620, DOI 10.1074/jbc.M307275200; Curtiss VE, 1996, MOL CELL BIOL, V16, P3567; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Fu W, 1997, J NEUROVIROL, V3, P16, DOI 10.3109/13550289709015789; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; HOOPER WC, 1991, BIOCHEM BIOPH RES CO, V181, P976, DOI 10.1016/0006-291X(91)92032-F; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Iwai K, 2001, VIROLOGY, V279, P38, DOI 10.1006/viro.2000.0669; LAROCCA D, 1989, BIOCHEM BIOPH RES CO, V163, P1006, DOI 10.1016/0006-291X(89)92322-X; Mori N, 1998, CANCER RES, V58, P3993; Mori N, 2000, BLOOD, V95, P3915; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Thebault S, 2004, FEBS LETT, V562, P165, DOI 10.1016/S0014-5793(04)00225-X; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; UCHIJIMA M, 1994, J BIOL CHEM, V269, P14946; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Yamagata T, 1997, MOL CELL BIOL, V17, P4272, DOI 10.1128/MCB.17.8.4272; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	30	104	110	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1001	1010		10.1038/sj.onc.1208297	http://dx.doi.org/10.1038/sj.onc.1208297			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592508				2022-12-17	WOS:000226749200006
J	Squatrito, M; Mancino, M; Donzelli, M; Areces, LB; Draetta, GF				Squatrito, M; Mancino, M; Donzelli, M; Areces, LB; Draetta, GF			EBP1 is a nucleolar growth-regulating protein that is part of pre-ribosomal ribonucleoprotein complexes	ONCOGENE			English	Article						rRNA; nucleolus; growth control; localization signal; proteohics; ribosome assembly	ERBB-3 BINDING-PROTEIN; CELL-CYCLE; PROTEOMIC ANALYSIS; BIOGENESIS; INTERACTS; DOMAIN; PROLIFERATION; TRANSCRIPTION; REPRESSION; EXPRESSION	EBP1 was identified as a protein that interacts with the ErbB-3 receptor and possibly contributes to transducing growth regulatory signals. The existence of EBP1 homologs across species from simple eukaryotes to humans and its wide tissue expression pattern suggest that EBP1 acts as a general signaling molecule. We provide evidence that EBP1 is localized to the cytoplasm and to the nucleolus, and that its nucleolar localization requires amino-acid sequences present at both the amino- and carboxy-terminus of the molecule. We also show that EBP1 overexpression inhibits proliferation of human fibroblasts, and that this effect is linked to its nucleolar localization. Using mass spectrometry we demonstrate that EBP1 is part of ribonucleoprotein complexes and associates with different rRNA species. It is becoming clear that cell growth and proliferation are actively coordinated with rRNA processing and ribosome assembly. Our findings indicate that EBP1 is a nucleolar growth-regulating protein, and we propose that it could represent a new link between ribosome biosynthesis and cell proliferation.	European Inst Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Draetta, GF (corresponding author), European Inst Oncol, 435 Via Ripamonti, I-20141 Milan, Italy.	giulio.draetta@ieo-research.it	Squatrito, Massimo/F-4149-2016; Donzelli, Maddalena/ABD-3774-2020	Squatrito, Massimo/0000-0002-4593-3790; DONZELLI, MADDALENA/0000-0002-4045-0802	Telethon [E.0865] Funding Source: Medline	Telethon(Fondazione Telethon)		Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOURBON HM, 1983, MOL BIOL REP, V9, P39, DOI 10.1007/BF00777472; Bouvet P, 1998, J BIOL CHEM, V273, P19025, DOI 10.1074/jbc.273.30.19025; Catez F, 2002, MOL CELL BIOL, V22, P1126, DOI 10.1128/MCB.22.4.1126-1139.2002; Dragon F, 2002, NATURE, V417, P967, DOI 10.1038/nature00769; Eisenhaber F, 2001, TRENDS BIOCHEM SCI, V26, P345, DOI 10.1016/S0968-0004(01)01851-5; Fatica A, 2002, CURR OPIN CELL BIOL, V14, P313, DOI 10.1016/S0955-0674(02)00336-8; Filipowicz W, 2002, CURR OPIN CELL BIOL, V14, P319, DOI 10.1016/S0955-0674(02)00334-4; Granneman S, 2003, NUCLEIC ACIDS RES, V31, P1877, DOI 10.1093/nar/gkg300; Guarente L, 1997, GENE DEV, V11, P2449, DOI 10.1101/gad.11.19.2449; Hayano T, 2003, J BIOL CHEM, V278, P34309, DOI 10.1074/jbc.M304304200; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Hernandez-Verdun D, 2002, J CELL SCI, V115, P2265; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Lamartine J, 1997, CYTOGENET CELL GENET, V78, P31, DOI 10.1159/000134621; Lessor TJ, 2000, J CELL PHYSIOL, V183, P321, DOI 10.1002/(SICI)1097-4652(200006)183:3<321::AID-JCP4>3.0.CO;2-O; Lixin R, 2001, BIOCHEM BIOPH RES CO, V284, P185, DOI 10.1006/bbrc.2001.4953; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Mann M, 1996, CURR OPIN BIOTECH, V7, P11, DOI 10.1016/S0958-1669(96)80089-9; Mitchell SA, 2003, MOL CELL, V11, P757, DOI 10.1016/S1097-2765(03)00093-5; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nissan TA, 2002, EMBO J, V21, P5539, DOI 10.1093/emboj/cdf547; Pederson T, 1998, J CELL BIOL, V143, P279, DOI 10.1083/jcb.143.2.279; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Pilipenko EV, 2000, GENE DEV, V14, P2028; Pinol-Roma S, 1999, MOL BIOL CELL, V10, P77, DOI 10.1091/mbc.10.1.77; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Schafer T, 2003, EMBO J, V22, P1370, DOI 10.1093/emboj/cdg121; Scheer U, 1999, CURR OPIN CELL BIOL, V11, P385, DOI 10.1016/S0955-0674(99)80054-4; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; SCHNEITER R, 1995, MOL BIOL CELL, V6, P357, DOI 10.1091/mbc.6.4.357; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Strezoska Z, 2002, J BIOL CHEM, V277, P29617, DOI 10.1074/jbc.M204381200; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Warner JR, 2001, CELL, V107, P133, DOI 10.1016/S0092-8674(01)00531-1; Wehner KA, 2002, MOL CELL, V9, P329, DOI 10.1016/S1097-2765(02)00438-0; Xia XM, 2001, BIOCHEM BIOPH RES CO, V289, P240, DOI 10.1006/bbrc.2001.5942; Xia XM, 2001, J CELL PHYSIOL, V187, P209, DOI 10.1002/jcp.1075; Yanagida M, 2001, PROTEOMICS, V1, P1390, DOI 10.1002/1615-9861(200111)1:11<1390::AID-PROT1390>3.0.CO;2-Z; Yoo JY, 2000, BRIT J CANCER, V82, P683; Zhang YX, 2003, NUCLEIC ACIDS RES, V31, P2168, DOI 10.1093/nar/gkg318; Zhang YX, 2002, ONCOGENE, V21, P5609, DOI 10.1038/sj.onc.1205638	46	104	115	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4454	4465		10.1038/sj.onc.1207579	http://dx.doi.org/10.1038/sj.onc.1207579			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064750				2022-12-17	WOS:000221661300011
J	Han, SU; Kim, HT; Seong, DH; Kim, YS; Park, YS; Bang, YJ; Yang, HK; Kim, SJ				Han, SU; Kim, HT; Seong, DH; Kim, YS; Park, YS; Bang, YJ; Yang, HK; Kim, SJ			Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer	ONCOGENE			English	Article						TGF-b; Smad3; gastric cancer; tumorigenicity; gene expression	GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR GENE; II RECEPTOR GENE; TGF-BETA; E-CADHERIN; CARCINOMA-CELLS; MICROSATELLITE INSTABILITY; SIGNAL-TRANSDUCTION; TARGETED DISRUPTION; COLON	Loss of the tumor suppressive effect of transforming growth factor-beta (TGF-beta) has been commonly found at later stages in carcinogenic progression. Although the genes encoding TGF-beta receptors and Smads have been found genetically altered in certain human cancers, no mutation in Smad3 has been observed. Therefore, suppression of Smad3 expression may mediate key oncogenic properties of TGF-beta. First, we observed that 37.5% of human gastric cancer tissues showed low to undetectable levels of Smad3 and that in nine human gastric cancer cell lines examined, two showed deficient Smad3 expression. Introduction of Smad3 into human gastric cancer cells that did not express Smad3, restored TGF-beta responsiveness: induction of p21 and p15 gene expression, and growth inhibition in response to TGF-beta. Furthermore, these Smad3-expressing cells showed markedly decreased and delayed tumorigenicity in vivo. These findings suggest that Smad3 expression may have a critical role in tumor suppression in the early stages of gastric carcinogenesis.	NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; Hanyang Univ, Coll Med, Dept Biochem, Seoul 133791, South Korea; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Dept Gen Surg, Seoul 110744, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Hanyang University; Seoul National University (SNU); Seoul National University (SNU)	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bldg 41,Room B1106, Bethesda, MD 20892 USA.	kims@mail.nih.gov	Yang, Han-Kwang/J-2767-2012; Bang, Yung Jue/J-2759-2012	Bang, Yung Jue/0000-0001-6000-4597	NATIONAL CANCER INSTITUTE [Z01BC005617] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Chang J, 1997, CANCER RES, V57, P2856; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Datto MB, 1999, MOL CELL BIOL, V19, P2495; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Einstein M, 2001, MOL CELL BIOL, V21, P5122, DOI 10.1128/MCB.21.15.5122-5131.2001; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fink SP, 2001, CANCER RES, V61, P256; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Harada H, 1999, CANCER RES, V59, P3783; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Jong HS, 2002, BIOCHEM BIOPH RES CO, V292, P383, DOI 10.1006/bbrc.2002.6666; Kang SH, 1999, BRIT J CANCER, V80, P1144, DOI 10.1038/sj.bjc.6690478; Keller G., 2002, Pathologica (Genoa), V94, P229, DOI 10.1007/s102420200037; KIESER A, 1994, ONCOGENE, V9, P963; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Muller N, 2002, ONCOGENE, V21, P6049, DOI 10.1038/sj.onc.1205766; MYEROFF LL, 1995, CANCER RES, V55, P5545; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Powell SM, 1997, CANCER RES, V57, P4221; Riggins GJ, 1997, CANCER RES, V57, P2578; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Schutte M, 1999, ANN ONCOL, V10, P56, DOI 10.1023/A:1008336703450; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Shattuck TM, 2002, J CLIN ENDOCR METAB, V87, P3911, DOI 10.1210/jc.87.8.3911; Shitara Y, 1999, JPN J CLIN ONCOL, V29, P3, DOI 10.1093/jjco/29.1.3; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; Takagi Y, 1998, BRIT J CANCER, V78, P1152, DOI 10.1038/bjc.1998.645; Takenoshita S, 1998, CARCINOGENESIS, V19, P803, DOI 10.1093/carcin/19.5.803; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; WALL NA, 1994, CURR OPIN GENET DEV, V4, P517, DOI 10.1016/0959-437X(94)90066-C; Xiangming C, 2001, CLIN CANCER RES, V7, P277; Yanagisawa K, 2000, ONCOGENE, V19, P2305, DOI 10.1038/sj.onc.1203591; Yang HK, 1999, ONCOGENE, V18, P2213, DOI 10.1038/sj.onc.1202535; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	64	104	111	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1333	1341		10.1038/sj.onc.1207259	http://dx.doi.org/10.1038/sj.onc.1207259			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14647420				2022-12-17	WOS:000189035800001
J	Sumrejkanchanakij, P; Tamamori-Adachi, M; Matsunaga, Y; Eto, K; Ikeda, MA				Sumrejkanchanakij, P; Tamamori-Adachi, M; Matsunaga, Y; Eto, K; Ikeda, MA			Role of cyclin D1 cytoplasmic sequestration in the survival of postmitotic neurons	ONCOGENE			English	Article						cyclin D1; cyclin-dependent kinase; neuron; apoptosis; nuclear localization; terminal differentiation	DEPENDENT KINASE-ACTIVITY; PROGRAMMED CELL-DEATH; CDK INHIBITORS; NUCLEAR EXPORT; IN-VIVO; PHOSPHORYLATION; EXPRESSION; PROTEIN; DIFFERENTIATION; LOCALIZATION	Cyclin D-dependent kinases phosphorylate the retinoblastoma (Rb) protein and play a critical role in neuronal cell cycle control and apoptosis. Here we show that cyclin D1 became predominantly cytoplasmic as primary cortical progenitor cells underwent cell cycle withdrawal and terminal differentiation. Furthermore, ectopically expressed cyclin D1 sequestered in the cytoplasm of postmitotic neurons, whereas it efficiently entered the nucleus of proliferating progenitor cells. Cytoplasmic cyclin D1 were complexed with cyclin-dependent kinase 4 (CDK4), and also with CDK inhibitors, p27(KipI) or p21(CipI), which positively regulate assembly and nuclear accumulation of the cyclin D1-CDK4 complex. Although overexpression of p21CipI promoted cyclin D1 nuclear localization, inhibition of either glycogen synthase kinase 3beta- or CRM1-mediated cyclin D1 nuclear export did not, suggesting that the inhibition of its nuclear import, rather than the acceleration of nuclear export, contributes to cytoplasmic sequestration of cyclin D1 in postmitotic neurons. In differentiated progenitor cells, nuclear localization of ectopic cyclin D1 induced apoptosis, and the DNA-damaging compound camptothecin caused nuclear accumulation of endogenous cyclin D1, accompanied by Rb phosphorylation. These results indicate that nuclear accumulation of cyclin D1 is inhibited in postmitotic neurons and suggest a role of its subcellular localization in neuronal death and survival.	Tokyo Med & Dent Univ, Grad Sch, Sect Mol Embryol, Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Dept Internal Med 2, Bunkyo Ku, Tokyo 1138549, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Ikeda, MA (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Sect Mol Embryol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.							Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Alt JR, 2002, J BIOL CHEM, V277, P8517, DOI 10.1074/jbc.M108867200; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Copani A, 2001, TRENDS NEUROSCI, V24, P25, DOI 10.1016/S0166-2236(00)01663-5; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ferguson KL, 2000, J BIOL CHEM, V275, P33593, DOI 10.1074/jbc.M004879200; Ferguson KL, 2001, NEUROREPORT, V12, pA55, DOI 10.1097/00001756-200107030-00001; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Gill RM, 1998, EXP CELL RES, V244, P157, DOI 10.1006/excr.1998.4197; Giovanni A, 1999, J BIOL CHEM, V274, P19011, DOI 10.1074/jbc.274.27.19011; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Ino H, 2001, J NEUROSCI, V21, P6086, DOI 10.1523/JNEUROSCI.21-16-06086.2001; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Latella L, 2001, MOL CELL BIOL, V21, P5631, DOI 10.1128/MCB.21.16.5631-5643.2001; Liu DX, 2001, CELL TISSUE RES, V305, P217, DOI 10.1007/s004410100396; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Padmanabhan J, 1999, J NEUROSCI, V19, P8747, DOI 10.1523/JNEUROSCI.19-20-08747.1999; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 1997, J NEUROSCI, V17, P8975; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Takiguchi-Hayashi K, 1998, BRAIN RES, V801, P9, DOI 10.1016/S0006-8993(98)00496-X; TAMALE-SALI E G, 1992, Journal of Obstetrics and Gynaecology (Abingdon), V12, P19, DOI 10.3109/01443619209029911; Tamamori M, 1998, AM J PHYSIOL-HEART C, V275, pH2036, DOI 10.1152/ajpheart.1998.275.6.H2036; TAMARU T, 1994, NEUROSCI LETT, V168, P229, DOI 10.1016/0304-3940(94)90457-X; Timsit S, 1999, EUR J NEUROSCI, V11, P263, DOI 10.1046/j.1460-9568.1999.00434.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xie HQ, 1998, BRAIN RES, V798, P173, DOI 10.1016/S0006-8993(98)00407-7; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	36	104	106	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8723	8730		10.1038/sj.onc.1206870	http://dx.doi.org/10.1038/sj.onc.1206870			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647467				2022-12-17	WOS:000186844900010
J	Amin, HM; Medeiros, LJ; Ma, Y; Feretzaki, M; Das, P; Leventaki, V; Rassidakis, GZ; O'Connor, SL; McDonnell, TJ; Lai, R				Amin, HM; Medeiros, LJ; Ma, Y; Feretzaki, M; Das, P; Leventaki, V; Rassidakis, GZ; O'Connor, SL; McDonnell, TJ; Lai, R			Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma	ONCOGENE			English	Article						anaplastic large cell lymphoma; AG490; STAT; JAK; NPM-ALK	NON-HODGKINS LYMPHOMA; STAT3 ACTIVATION; TYROSINE KINASE; CONSTITUTIVE ACTIVATION; SURVIVIN EXPRESSION; SIGNAL TRANSDUCER; HUMAN OVARIAN; PROTEIN; GROWTH; AG490	Signal transducer and activator of transcription 3 (STAT3), normally activated by Janus kinase (JAK) in response to cytokine stimulation, has been shown to have oncogenic potential. In addition to JAK, recent data suggest that STAT3 can also be activated by other proteins such as the aberrant fusion protein, NPM-ALK, which is expressed in a subset of systemic anaplastic large cell lymphoma (ALCL). In this study, we investigated the possible role of JAK in activating STAT3 in ALCL using two ALK-positive ALCL cell lines, Karpas 299 and SU-DHL-1. At the steady state, JAK3 showed detectable tyrosine phosphorylation by immunoprecipitation. Treatment with AG490, a JAK inhibitor, decreased but did not completely abrogate tyrosine phosphorylation of JAK3 and STAT3 in a concentration-dependent manner. Similar results were obtained using two other inhibitors of JAK3, WHI-P131 and WHI-P154. These biochemical changes were associated with apoptosis in both cell lines that was coupled with activation of caspase 3 and decreased bcl-xL and bcl-2. Cell cycle analysis revealed a decrease in the S phase, which may be attributed to cyclin D3 downregulation and P21(waf1) upregulation. Importantly, the tyrosine kinase activity of NPM-ALK, as assessed by an in vitro assay, decreased with increasing concentrations of AG490. Our findings highlight the importance of JAK3 in activating STAT3 in ALCL, and that NPM-ALK-mediated activation of STAT3 is influenced by the functional status of JAK3.	Univ Texas, MD Anderson Canc Ctr, Dept Histopathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lai, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Histopathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	raymondmail_65@yahoo.com	Rassidakis, George/V-9553-2019; Leventaki, Vasiliki/N-8175-2018					Alas S, 2001, CANCER RES, V61, P5137; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; Delsol G, 2001, WHO CLASSIFICATION T, P230; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Epling-Burnette PK, 2001, J IMMUNOL, V166, P7486, DOI 10.4049/jimmunol.166.12.7486; EPSTEIN AL, 1974, CANCER-AM CANCER SOC, V34, P1851, DOI 10.1002/1097-0142(197412)34:6<1851::AID-CNCR2820340602>3.0.CO;2-4; Eriksen KW, 2001, LEUKEMIA, V15, P787, DOI 10.1038/sj.leu.2402093; Falini B, 1999, BLOOD, V93, P2697; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Gascoyne RD, 1999, BLOOD, V93, P3913, DOI 10.1182/blood.V93.11.3913.411k22_3913_3921; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Kijima T, 2002, CELL GROWTH DIFFER, V13, P355; Kirken RA, 2001, TRANSPLANT P, V33, P95, DOI 10.1016/S0041-1345(00)02791-3; Kube D, 2001, BLOOD, V98, P762, DOI 10.1182/blood.V98.3.762; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Liu JB, 2002, AM J RESP CELL MOL, V27, P306, DOI 10.1165/rcmb.4850; Ma ZG, 2000, BLOOD, V95, P2144, DOI 10.1182/blood.V95.6.2144; Mahboubi K, 2001, LAB INVEST, V81, P327, DOI 10.1038/labinvest.3780241; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MORGAN R, 1989, BLOOD, V73, P2155; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Narla RK, 1998, CLIN CANCER RES, V4, P2463; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; Ning ZQ, 2001, ONCOGENE, V20, P4528, DOI 10.1038/sj.onc.1204590; Pulford K, 2001, CURR OPIN HEMATOL, V8, P231, DOI 10.1097/00062752-200107000-00009; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; SHIOTA M, 1995, BLOOD, V86, P1954, DOI 10.1182/blood.V86.5.1954.bloodjournal8651954; Slupianek A, 2001, CANCER RES, V61, P2194; STEIN H, 1985, BLOOD, V66, P848; Sudbeck EA, 1999, CLIN CANCER RES, V5, P1569; Sun XM, 2001, BLOOD, V97, P2008, DOI 10.1182/blood.V97.7.2008; Turturro F, 2001, ONCOGENE, V20, P4466, DOI 10.1038/sj.onc.1204582; Uckun FM, 1999, CLIN CANCER RES, V5, P2954; Wang LH, 1999, J IMMUNOL, V162, P3897; Wei LH, 2001, ONCOGENE, V20, P5799, DOI 10.1038/sj.onc.1204733; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	51	104	112	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5399	5407		10.1038/sj.onc.1206849	http://dx.doi.org/10.1038/sj.onc.1206849			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934099				2022-12-17	WOS:000184735000004
J	Chen, LH; Chen, JD				Chen, LH; Chen, JD			MDM2-ARF complex regulates p53 sumoylation	ONCOGENE			English	Article						p53; mdm2; ARF; sumoylation	NUCLEOLAR-LOCALIZATION; NUCLEAR EXPORT; SUMO-1; MDM-2; UBIQUITINATION; ACTIVATION; P14(ARF); PIAS	The p53 tumor suppressor is regulated by MDM2-mediated ubiquitination and degradation. Ubiquitination of p53 is regulated by ARF, which binds to MDM2 and inhibits its E3 ligase function. P53 is also subjected to modification by conjugation of SUMO-1. We found that a p53 mutant deficient for MDM2 binding (p53(14Q19S)) is poorly sumoylated in vivo compared to wild-type p53. Overexpression of MDM2 increases the level of p53 sumoylation, which is further stimulated by expression of ARE Stimulation of p53 sumoylation requires a highly conserved region (102-116) encoded by exon 2 of ARF and correlates with the ability of ARF to target p53 to the nucleolus. An MDM2 deletion mutant (MDM2(Delta222-437)) with activated cryptic nucleolar localization signal also targets p53 to the nucleolus and efficiently promotes p53 sumoylation in the absence of ARE Direct targeting of p53 to the nucleolus enhances its sumoylation in an MDM2- and ARF-dependent fashion. These results show that p53 sumoylation is regulated by MDM2- and ARF-mediated nucleolar targeting.	H Lee Moffit Comprehens Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA		Chen, JD (corresponding author), H Lee Moffit Comprehens Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	jchen@moffitt.usf.edu						CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Melchior F, 2002, CELL CYCLE, V1, P243, DOI 10.4161/cc.1.4.131; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Miyauchi Y, 2002, J BIOL CHEM, V277, P50131, DOI 10.1074/jbc.M208319200; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Prives C, 1999, J PATHOL, V187, P112; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Xirodimas DP, 2002, FEBS LETT, V528, P207, DOI 10.1016/S0014-5793(02)03310-0; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; ZIRODIMAS D, 2002, ONCOGENE, V20, P4972	31	104	109	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5348	5357		10.1038/sj.onc.1206851	http://dx.doi.org/10.1038/sj.onc.1206851			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917636				2022-12-17	WOS:000184734900014
J	Tellez, C; Bar-Eli, M				Tellez, C; Bar-Eli, M			Role and regulation of the thrombin receptor (PAR-1) in human melanoma	ONCOGENE			English	Review						AP-2; angiogenesis; malignant melanoma; metastasis; thrombin receptor	TRANSCRIPTION FACTOR AP-2; PROTEASE-ACTIVATED RECEPTOR-1; ENDOTHELIAL GROWTH-FACTOR; TUMOR-GROWTH; DNA-BINDING; MALIGNANT-MELANOMA; EPITHELIAL-CELLS; BREAST-CANCER; TISSUE FACTOR; E-CADHERIN	To determine treatment strategies and predict the clinical outcome of patients with melanoma it is important to understand the etiology of this disease. Recently, there has been some insight into molecular basis of melanoma including identification of a few of the regulatory factors and genes involved in this disease. For instance, the transcription factor AP-2 plays a tumor suppressor-like role in melanoma progression by regulating genes involved in tumor growth and metastasis. Previously, we have shown that the progression of human melanoma to the metastatic phenotype is associated with loss of AP-2 expression and deregulation of target genes such as MUC18/MCAM, c-KIT, and MMP-2. Increasing evidence demonstrates that the thrombin receptor (protease-activated receptor-1, PAR-1) plays a major role in tumor invasion and contributes to the metastatic phenotype of human melanoma. This review focuses on the role of the thrombin receptor in melanoma and its regulation by AP-2. We show that loss of AP-2 expression in metastatic melanoma cells correlates with overexpression of the thrombin receptor. Our analysis of AP-2/Sp1 complexes within the regulatory region of the thrombin receptor demonstrates that AP-2 binds the proximal 3' region of the promoter and diminishes PAR-1 expression. Levels of AP-2 and Sp1 proteins in a panel of melanoma cell lines demonstrated a marked decrease in the ratio of AP-2/ Sp1, a decrease that correlated with overexpression of PAR-1 in metastatic melanoma cells. We propose that loss of AP-2 results in increased expression of the thrombin receptor, which subsequently contributes to the metastatic phenotype of melanoma by upregulating the expression of adhesion molecules, proteases, and angiogenic molecules.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Bar-Eli, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd,173, Houston, TX 77030 USA.	mbareli@mdanderson.org			NCI NIH HHS [CA76098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldi A, 2001, J CELL BIOCHEM, V83, P364, DOI 10.1002/jcb.1235; Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Brach MA, 1996, CYTOKINES MOL THER, V2, P81; BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen TT, 1997, MOL CELL BIOL, V17, P3056, DOI 10.1128/MCB.17.6.3056; Cucina A, 1999, J SURG RES, V82, P61, DOI 10.1006/jsre.1998.5514; De Simone G, 1999, BIOPOLYMERS, V51, P19, DOI 10.1002/(SICI)1097-0282(1999)51:1<19::AID-BIP4>3.0.CO;2-G; Degen SJF, 1998, CRIT REV EUKAR GENE, V8, P203, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.60; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; ESUMI N, 1991, CANCER RES, V51, P4549; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Even-Ram SC, 2001, J BIOL CHEM, V276, P10952, DOI 10.1074/jbc.M007027200; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; FISCHER EG, 1995, CANCER RES, V55, P1629; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GAYNOR RB, 1991, GENOMICS, V10, P1100, DOI 10.1016/0888-7543(91)90209-W; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; Gershenwald JE, 2001, ONCOGENE, V20, P3363, DOI 10.1038/sj.onc.1204450; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; Gille J, 2000, J INVEST DERMATOL, V115, P30, DOI 10.1046/j.1523-1747.2000.00020.x; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Goding CR, 2000, GENE DEV, V14, P1712; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; HASLINGER A, 1985, P NATL ACAD SCI USA, V82, P8572, DOI 10.1073/pnas.82.24.8572; Henrikson KP, 1999, BRIT J CANCER, V79, P401, DOI 10.1038/sj.bjc.6690063; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang S, 2000, CLIN CANCER RES, V6, P2573; Huang Y, 1998, BIOCHEM BIOPH RES CO, V249, P307, DOI 10.1006/bbrc.1998.9139; Huang YQ, 2001, THROMB HAEMOSTASIS, V86, P1094; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Jean D, 2000, ONCOGENE, V19, P2721, DOI 10.1038/sj.onc.1203569; Jiang JG, 2000, BIOCHEM BIOPH RES CO, V272, P882, DOI 10.1006/bbrc.2000.2848; Jiang MS, 2000, P NATL ACAD SCI USA, V97, P12519, DOI 10.1073/pnas.220426097; KANNO M, 1989, EMBO J, V8, P4205, DOI 10.1002/j.1460-2075.1989.tb08606.x; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Kaufmann R, 1997, CANCER, V80, P2068, DOI 10.1002/(SICI)1097-0142(19971201)80:11<2068::AID-CNCR5>3.0.CO;2-T; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; King R, 1999, AM J PATHOL, V155, P731, DOI 10.1016/S0002-9440(10)65172-3; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEBEAU B, 1994, CANCER, V74, P38, DOI 10.1002/1097-0142(19940701)74:1<38::AID-CNCR2820740108>3.0.CO;2-E; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; Li FZ, 1996, J BIOL CHEM, V271, P26320, DOI 10.1074/jbc.271.42.26320; LIU CY, 1979, J BIOL CHEM, V254, P421; Liu YN, 2001, CANCER LETT, V169, P173, DOI 10.1016/S0304-3835(01)00504-3; Luca MR, 1998, HISTOL HISTOPATHOL, V13, P1225, DOI 10.14670/HH-13.1225; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Meier F., 1998, FRONT BIOSCI J VIS L, V3, P1005, DOI [10.2741/a341, DOI 10.2741/A341]; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; Nierodzik ML, 1998, BLOOD, V92, P3694, DOI 10.1182/blood.V92.10.3694.422k40_3694_3700; Nottoli T, 1998, P NATL ACAD SCI USA, V95, P13714, DOI 10.1073/pnas.95.23.13714; NYBORG JK, 1990, J BIOL CHEM, V265, P8230; Ornstein DL, 2001, INT J HEMATOL, V73, P157, DOI 10.1007/BF02981932; Ornstein DL, 1999, HAEMOSTASIS, V29, P48; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Richard DE, 2001, ONCOGENE, V20, P1556, DOI 10.1038/sj.onc.1204193; Ropponen KM, 1999, BRIT J CANCER, V81, P133, DOI 10.1038/sj.bjc.6690662; Rudroff C, 1998, PANCREAS, V16, P189, DOI 10.1097/00006676-199803000-00013; Ruiz M, 2001, CLIN CANCER RES, V7, P4086; RUTBERG SE, 1994, MOL CARCINOGEN, V10, P82, DOI 10.1002/mc.2940100205; Schmidt VA, 1996, J BIOL CHEM, V271, P9307, DOI 10.1074/jbc.271.16.9307; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; Senger DR, 1996, AM J PATHOL, V149, P293; Shimizu S, 2000, AM J PHYSIOL-LUNG C, V279, pL503, DOI 10.1152/ajplung.2000.279.3.L503; TAPPARELLI C, 1993, TRENDS PHARMACOL SCI, V14, P366, DOI 10.1016/0165-6147(93)90095-2; THORNES RD, 1994, J CANCER RES CLIN, V120, pS32, DOI 10.1007/BF01377122; Turner BC, 1998, CANCER RES, V58, P5466; Ueno A, 1996, IMMUNOLOGY, V88, P76, DOI 10.1046/j.1365-2567.1996.d01-635.x; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wang DY, 1997, J BIOL CHEM, V272, P14244, DOI 10.1074/jbc.272.22.14244; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WOJTUKIEWICZ MZ, 1993, INT J CANCER, V54, P793, DOI 10.1002/ijc.2910540514; WOJTUKIEWICZ MZ, 1992, THROMB RES, V68, P233, DOI 10.1016/0049-3848(92)90081-K; WOJTUKIEWICZ MZ, 1990, AM J CLIN PATHOL, V93, P516, DOI 10.1093/ajcp/93.4.516; WOJTUKIEWICZ MZ, 1995, CANCER RES, V55, P698; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358; Yeh CC, 1998, DNA CELL BIOL, V17, P921, DOI 10.1089/dna.1998.17.921; YOSHIDA E, 1994, CANCER RES, V54, P3300; ZACHARSKI LR, 1995, THROMB HAEMOSTASIS, V73, P793; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhu CH, 2001, J BIOL CHEM, V276, P14407, DOI 10.1074/jbc.M009708200; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730	101	104	110	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3130	3137		10.1038/sj.onc.1206453	http://dx.doi.org/10.1038/sj.onc.1206453			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789289				2022-12-17	WOS:000183096600015
J	Ingram, WJ; Wicking, CA; Grimmond, SM; Forrest, AR; Wainwright, BJ				Ingram, WJ; Wicking, CA; Grimmond, SM; Forrest, AR; Wainwright, BJ			Novel genes regulated by Sonic Hedgehog in pluripotent mesenchymal cells	ONCOGENE			English	Article						Sonic Hedgehog; downstream target genes; C3H/10T1/2; microarray	ANIMAL DEVELOPMENT; CDNA MICROARRAY; CANDIDATE GENE; HUMAN HOMOLOG; GLI PROTEINS; MOUSE EMBRYO; FLOOR PLATE; DROSOPHILA; DIFFERENTIATION; THROMBOMODULIN	Sonic Hedgehog is a secreted morphogen involved in patterning a wide range of structures in the developing embryo. Disruption of the Hedgehog signalling cascade leads to a number of developmental disorders and plays a key role in the formation of a range of human cancers. The identification of genes regulated by Hedgehog is crucial to understanding how disruption of this pathway leads to neoplastic transformation. We have used a Sonic Hedgehog (Shh) responsive mouse cell line, C3H/10T1/2, to provide a model system for hedgehog target gene discovery. Following activation of cell cultures with Shh, RNA was used to interrogate microarrays to investigate downstream transcriptional consequences of hedgehog stimulation. As a result 11 target genes have been identified, seven of which are induced (Thrombomodulin, GILZ, BF-2, Nr4a1, IGF2, PMP22, LASP1) and four of which are repressed (SFRP-1, SFRP-2, Mip1-gamma, Amh) by Shh. These targets have a diverse range of putative functions and include transcriptional regulators and molecules known to be involved in regulating cell growth or apoptosis. The corroboration of genes previously implicated in hedgehog signalling, along with the finding of novel targets, demonstrates both the validity and power of the C3H/10T1/2 system for Shh target gene discovery.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Biochem & Mol Biol, Brisbane, Qld 4072, Australia; Cooperat Res Ctr Discovery Genes Common Human Dis, Richmond, Vic 3121, Australia	University of Queensland; University of Queensland	Wainwright, BJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.		Ingram, Wendy J/F-7317-2010; Grimmond, Sean/K-3246-2019; Forrest, Alistair/A-6597-2008; Grimmond, Sean M/J-5304-2016; Wicking, Carol/J-1814-2014	Ingram, Wendy J/0000-0002-7063-1081; Grimmond, Sean/0000-0002-8102-7998; Forrest, Alistair/0000-0003-4543-1675; Grimmond, Sean M/0000-0002-8102-7998; Wicking, Carol/0000-0002-7225-3803; Wainwright, Brandon/0000-0003-0406-2092				Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Barnes EA, 2001, EMBO J, V20, P2214, DOI 10.1093/emboj/20.9.2214; Bieche I, 1996, CANCER RES, V56, P3886; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2; Dobens LL, 2000, DEVELOPMENT, V127, P745; Dobens LL, 1997, MECH DEVELOP, V65, P197, DOI 10.1016/S0925-4773(97)00080-4; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Fiorenza MT, 2001, GENE, V278, P125, DOI 10.1016/S0378-1119(01)00715-6; Freedman JE, 2001, CIRC RES, V88, P651, DOI 10.1161/hh0701.089956; Garg V, 2001, DEV BIOL, V235, P62, DOI 10.1006/dbio.2001.0283; Gibson-Brown JJ, 1998, DEVELOPMENT, V125, P2499; Gustafsson MK, 2002, GENE DEV, V16, P114, DOI 10.1101/gad.940702; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Halgren RG, 2001, NUCLEIC ACIDS RES, V29, P582, DOI 10.1093/nar/29.2.582; Hargrave M, 2000, DEV BIOL, V219, P142, DOI 10.1006/dbio.1999.9581; HEALY AM, 1995, P NATL ACAD SCI USA, V92, P850, DOI 10.1073/pnas.92.3.850; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jetten AM, 2000, PROG NUCLEIC ACID RE, V64, P97, DOI 10.1016/S0079-6603(00)64003-5; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kato M, 2001, BIOCHEM BIOPH RES CO, V289, P472, DOI 10.1006/bbrc.2001.5976; Kinto N, 1997, FEBS LETT, V404, P319, DOI 10.1016/S0014-5793(97)00014-8; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; Krishnan V, 1997, SCIENCE, V278, P1947, DOI 10.1126/science.278.5345.1947; Lee CS, 2000, DEVELOPMENT, V127, P109; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; Nakamura T, 1997, BIOCHEM BIOPH RES CO, V237, P465, DOI 10.1006/bbrc.1997.7156; Pathi S, 2001, MECH DEVELOP, V106, P107, DOI 10.1016/S0925-4773(01)00427-0; Pepinsky RB, 2000, J BIOL CHEM, V275, P10995, DOI 10.1074/jbc.275.15.10995; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Pola R, 2001, NAT MED, V7, P706, DOI 10.1038/89083; Polakis P, 2000, GENE DEV, V14, P1837; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Saeki K, 2000, BBA-PROTEIN STRUCT M, V1476, P219, DOI 10.1016/S0167-4838(99)00254-X; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Spinella-Jaegle S, 2001, J CELL SCI, V114, P2085; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; TREISMAN JE, 1995, DEVELOPMENT, V121, P2835; Vasiliauskas D, 1999, MECH DEVELOP, V82, P79, DOI 10.1016/S0925-4773(99)00014-3; Villavicencio EH, 2000, AM J HUM GENET, V67, P1047, DOI 10.1016/S0002-9297(07)62934-6; WeilerGuettler H, 1996, DEVELOPMENT, V122, P2271; Wicking C, 1999, ONCOGENE, V18, P7844, DOI 10.1038/sj.onc.1203282; Wilhelm S, 1998, INT J ONCOL, V13, P645; Williams KP, 1999, J CELL SCI, V112, P4405; Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200	55	104	108	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2002	21	53					8196	8205		10.1038/sj.onc.1205975	http://dx.doi.org/10.1038/sj.onc.1205975			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444557				2022-12-17	WOS:000179231400015
J	Gebhardt, C; Breitenbach, U; Tuckermann, JP; Dittrich, BT; Richter, KH; Angel, P				Gebhardt, C; Breitenbach, U; Tuckermann, JP; Dittrich, BT; Richter, KH; Angel, P			Calgranulins S100A8 and S100A9 are negatively regulated by glucocorticoids in a c-Fos-dependent manner and overexpressed throughout skin carcinogenesis	ONCOGENE			English	Article						AP-1; epidermis; inflammation; papilloma; tumor promoter	CALCIUM-BINDING PROTEINS; MALIGNANT PROGRESSION; MOUSE KERATINOCYTES; EXPRESSION; RECEPTOR; GENE; TRANSCRIPTION; DIFFERENTIATION; MRP14; AP-1	The two calgranulins S100A8 and S100A9 were found to be differentially expressed at sites of acute and chronic inflammation. Here we have employed the phorbol ester-induced multistage skin carcinogenesis protocol in mice to determine the expression of both genes in inflamed skin and in skin tumors. We show that expression is coordinately induced by the phorbol ester TPA in epithelial cells as well as infiltrating leukocytes. By comparing S100A8 and S100A9 mRNA levels in wild type and c-Fos deficient mice (c-fos(-/-)) we found that expression is negatively regulated by c-Fos/AP-1. Glucocorticoids, which exhibit potent anti-inflammatory and anti-tumor promoting activities repressed TPA-mediated S100A8 and S100A9 induction in wild type, cfos(-/-) mice, thus identifying both genes as but not in the first examples of AP-1 target genes whose repression of TPA-induced transcription by glucocorticoids depends on c-Fos. Finally, we show that enhanced expression is not restricted to the initial TPA-induced inflammatory response but is observed at all stages of skin carcinogenesis. These data identify S100A8 and S100A9 as novel, tumor-associated genes and may point to an as yet unrecognized function of both genes in the development of epithelial skin tumors.	Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Angel, P (corresponding author), Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	p.angel@dkfz-heidelberg.de	Gebhardt, Christoffer/F-8170-2015; Gebhardt, Christoffer/B-5713-2009	Gebhardt, Christoffer/0000-0001-7090-9584; 				Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; BASSETSEGUIN N, 1991, J INVEST DERMATOL, V97, P672, DOI 10.1111/1523-1747.ep12483807; BELMAN S, 1972, CANCER RES, V32, P450; BOWDEN GT, 1994, CANCER RES, V54, pS1882; BRANDTZAEG P, 1987, AM J CLIN PATHOL, V87, P700, DOI 10.1093/ajcp/87.6.700; Breitenbach U, 2001, J INVEST DERMATOL, V117, P634, DOI 10.1046/j.0022-202x.2001.01437.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; DiSepio D, 1997, J BIOL CHEM, V272, P25555, DOI 10.1074/jbc.272.41.25555; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; EDGEWORTH J, 1991, J BIOL CHEM, V266, P7706; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; FISHER C, 1991, DEVELOPMENT, V111, P253; FURSTENBERGER G, 1995, CARCINOGENESIS, V16, P61, DOI 10.1093/carcin/16.1.61; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; Goova MT, 2001, AM J PATHOL, V159, P513, DOI 10.1016/S0002-9440(10)61723-3; Herrlich P, 2001, ONCOGENE, V20, P2465, DOI 10.1038/sj.onc.1204388; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Kerkhoff C, 1999, J BIOL CHEM, V274, P32672, DOI 10.1074/jbc.274.46.32672; Kerkhoff C, 1998, BBA-MOL CELL RES, V1448, P200, DOI 10.1016/S0167-4889(98)00144-X; Klempt M, 1999, J CELL BIOCHEM, V73, P49, DOI 10.1002/(SICI)1097-4644(19990401)73:1<49::AID-JCB6>3.0.CO;2-2; LAGASSE E, 1992, BLOOD, V79, P1907; LUGERING N, 1995, EUR J CLIN INVEST, V25, P659, DOI 10.1111/j.1365-2362.1995.tb01982.x; MARKS F, 1990, CARCINOGENESIS, V11, P2085, DOI 10.1093/carcin/11.12.2085; Melkonyan H, 1998, J BIOL CHEM, V273, P27026, DOI 10.1074/jbc.273.41.27026; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; Nacken W, 1996, BBA-MOL BASIS DIS, V1315, P1, DOI 10.1016/0925-4439(95)00108-5; Nacken W, 2001, J CELL BIOCHEM, V80, P606, DOI 10.1002/1097-4644(20010315)80:4<606::AID-JCB1015>3.3.CO;2-B; Newton RA, 1998, J IMMUNOL, V160, P1427; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; Passey RJ, 1999, J LEUKOCYTE BIOL, V66, P549, DOI 10.1002/jlb.66.4.549; Passey RJ, 1999, J IMMUNOL, V163, P2209; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Rammes A, 1997, J BIOL CHEM, V272, P9496; Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168; Rennecke J, 2000, BBA-MOL CELL RES, V1497, P289, DOI 10.1016/S0167-4889(00)00067-7; Rennecke J, 1999, INT J CANCER, V80, P98, DOI 10.1002/(SICI)1097-0215(19990105)80:1<98::AID-IJC19>3.0.CO;2-D; Rutberg SE, 1996, ONCOGENE, V13, P167; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7; Schmidt AM, 2000, BBA-MOL CELL RES, V1498, P99, DOI 10.1016/S0167-4889(00)00087-2; SCHNARR B, 2000, INT J CANCER, V88, P345; SCHONTHAL A, 1989, ONCOGENE, V4, P629; STEINBAKK M, 1990, LANCET, V336, P763, DOI 10.1016/0140-6736(90)93237-J; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Thorey IS, 2001, J BIOL CHEM, V276, P35818, DOI 10.1074/jbc.M104871200; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Tuckermann JP, 1999, J CELL BIOL, V147, P1365, DOI 10.1083/jcb.147.7.1365; Wang HQ, 1999, J CELL SCI, V112, P3497; Wang HQ, 2001, MOL PHARMACOL, V59, P860, DOI 10.1124/mol.59.4.860; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WILKINSON MM, 1988, J CELL SCI, V91, P221; WINTER H, 1983, ARCH DERMATOL RES, V275, P27, DOI 10.1007/BF00516551; Yuspa SH, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P147; ZWADLO G, 1988, CLIN EXP IMMUNOL, V72, P510	57	104	114	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4266	4276		10.1038/sj.onc.1205521	http://dx.doi.org/10.1038/sj.onc.1205521			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082614	Bronze			2022-12-17	WOS:000176174200009
J	Shea-Herbert, B; Pongracz, K; Shay, JW; Gryaznov, SM				Shea-Herbert, B; Pongracz, K; Shay, JW; Gryaznov, SM			Oligonucleotide N3 '-> P5 ' phosphoramidates as efficient telomerase inhibitors	ONCOGENE			English	Article						telomerase inhibitors; oligonucleotide; phosphoramidates	RNA COMPONENT; CANCER-CELLS; PROLIFERATION; THERAPY; GLIOMA; TARGET	Human telomerase is a unique reverse transcriptase that is expressed in multiple cancers, but not in the vast majority of normal cells. The enzyme is responsible for telomere protection and maintenance, and supports the proliferative immortality of cancer cells. Thus, it has been proposed that the specific inhibition of telomerase activity in tumors might have significant and beneficial therapeutic effects. To this goal we have designed, synthesized, and evaluated several oligonucleotide N3'-->P5' phosphoramidates as telomerase inhibitors. These oligonucleotides are complementary to the template region of the RNA domain of telomerase (hTR). The prepared compounds were evaluated in HME50-5E breast epithelial cells, where their effects on telomerase activity were determined using a cell-based telomerase (TRAP) assay at 24 as well as 72 h after exposure to compounds. The oligo-N3' -->P5' phosphoramidate inhibited telomerase activity in cells in the presence of the cellular up-take enhancer (FuGENE6(TM)) in a dose- and sequence-dependent manner, with IC50 values of approximately 1 nM. Inhibition of telomerase activity by this compound without the lipid carrier was not efficient. However, the isosequential oligonucleotide N3 '--> P5' thio-phosphoramidate was able to inhibit telomerase activity with or without lipid carriers at nM, or low-muM concentrations, respectively. This inhibition of telomerase activity in HME50-5E cells by the oligonucleotide thio-phosphoramidates was also sequence specific. Long-term treatment of the cells with 0.5 muM of FuGENE6 formulated 13-mer thio-phosphoramidates, fully complementary to hTR, resulted in gradual telomere shortening, followed by cellular senescence and apoptosis, as would be predicted for a telomerase inhibitor. The mismatched control compound had no effect on cell proliferation. The results suggest that the oligonucleotide N3'-->P5' phosphoramidates, and particularly thio-phosphoramidates, might be further developed as selective anti-telomerase reagents.	Geron Corp, Menlo Pk, CA 94025 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	Geron Corporation; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gryaznov, SM (corresponding author), Geron Corp, 230 Constitut Dr, Menlo Pk, CA 94025 USA.		Shay, Jerry W/F-7878-2011					Bare LA, 1998, DRUG DEVELOP RES, V43, P109, DOI 10.1002/(SICI)1098-2299(199802)43:2<109::AID-DDR4>3.0.CO;2-O; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; Elayadi AN, 2001, NUCLEIC ACIDS RES, V29, P1683, DOI 10.1093/nar/29.8.1683; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Glukhov AI, 1998, BIOCHEM BIOPH RES CO, V248, P368, DOI 10.1006/bbrc.1998.8801; Gryaznov S, 2001, NUCLEOS NUCLEOT NUCL, V20, P401, DOI 10.1081/NCN-100002314; Gryaznov SM, 1999, BBA-GENE STRUCT EXPR, V1489, P131, DOI 10.1016/S0167-4781(99)00151-7; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hisatake J, 1999, CANCER RES, V59, P4023; Hurley LH, 2000, PHARMACOL THERAPEUT, V85, P141, DOI 10.1016/S0163-7258(99)00068-6; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Matthes E, 1999, NUCLEIC ACIDS RES, V27, P1152, DOI 10.1093/nar/27.4.1152; Naasani I, 1999, CANCER RES, V59, P4004; Naasani I, 1998, BIOCHEM BIOPH RES CO, V249, P391, DOI 10.1006/bbrc.1998.9075; Neidle S, 2000, PHARMACOL THERAPEUT, V85, P133, DOI 10.1016/S0163-7258(99)00065-0; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; Pitts AE, 1998, P NATL ACAD SCI USA, V95, P11549, DOI 10.1073/pnas.95.20.11549; Pongracz K, 1999, TETRAHEDRON LETT, V40, P7661, DOI 10.1016/S0040-4039(99)01584-1; Sharma HW, 1996, ANTISENSE NUCLEIC A, V6, P3, DOI 10.1089/oli.1.1996.6.3; SHEAHERBERT B, 1999, P NATL ACAD SCI USA, V96, P14276; Wan MSK, 1998, ANTISENSE NUCLEIC A, V8, P309, DOI 10.1089/oli.1.1998.8.309; Yamaguchi F, 1999, ONCOL REP, V6, P773	23	104	123	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					638	642		10.1038/sj.onc.1205064	http://dx.doi.org/10.1038/sj.onc.1205064			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850790				2022-12-17	WOS:000173390500017
J	Pearson, M; Pelicci, PG				Pearson, M; Pelicci, PG			PML interaction with p53 and its role in apoptosis and replicative senescence	ONCOGENE			English	Article						PML; p53; apoptosis; senescence	PROMYELOCYTIC LEUKEMIA PROTEIN; TELOMERASE CATALYTIC SUBUNIT; CREB-BINDING-PROTEIN; NUCLEAR-BODIES; ONCOGENIC RAS; DNA-DAMAGE; PREMATURE SENESCENCE; CELLULAR SENESCENCE; TUMOR SUPPRESSION; HUMAN FIBROBLASTS	A network of control pathways has been characterized that arrest growth or induce apoptosis in response to potentially tumorogenic events such as genotoxic stress or oncogene expression. Ablation, or functional disruption, of these pathways is frequently observed during multistep carcinogenesis. Analysis of those genes most commonly compromized in tumours has led to the identification of the transcription factor p53 and the E2F binding protein Retinoblastoma (Rb), as key regulators of these processes. This review discusses recent data, demonstrating that the Promyelocytic Leukemia (PML) protein can physically and functionally interact with both p53 and Rb, suggesting that PML may be a novel regulator of these pathways.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Pearson, M (corresponding author), European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy.		Pelicci, Pier Giuseppe/AAL-6572-2020					ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Ahn JH, 2000, VIROLOGY, V274, P39, DOI 10.1006/viro.2000.0448; Ahn JH, 1997, J VIROL, V71, P4599, DOI 10.1128/JVI.71.6.4599-4613.1997; Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Appella E, 2000, PATHOL BIOL, V48, P227; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Bernstam L, 2000, J TOXICOL ENV HEAL B, V3, P293, DOI 10.1080/109374000436355; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; Everett RD, 1999, J CELL SCI, V112, P4581; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; Ferbeyre G, 2000, GENE DEV, V14, P2015; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; Grobelny JV, 2000, J CELL SCI, V113, P4577; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; HARVEY M, 1993, ONCOGENE, V8, P2457; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; Inoue K, 2000, GENE DEV, V14, P1797; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jiang WQ, 1997, CELL GROWTH DIFFER, V8, P513; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Lansdorp P M, 1997, Ciba Found Symp, V211, P209; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Le S, 1999, GENETICS, V152, P143; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lombard DB, 2000, CANCER RES, V60, P2331; LONGO L, 1993, LEUKEMIA LYMPHOMA, V11, P405, DOI 10.3109/10428199309067933; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Martin-Rivera L, 1998, P NATL ACAD SCI USA, V95, P10471, DOI 10.1073/pnas.95.18.10471; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Maul GG, 1996, VIROLOGY, V217, P67, DOI 10.1006/viro.1996.0094; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pelletier G, 2000, MOL CELL, V6, P1059, DOI 10.1016/S1097-2765(00)00104-0; Pluta AF, 1998, J CELL SCI, V111, P2029; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Regad T, 2001, EMBO J, V20, P3495, DOI 10.1093/emboj/20.13.3495; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Vallian S, 1998, ONCOGENE, V16, P2843, DOI 10.1038/sj.onc.1201837; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; von Mikecz A, 2000, J CELL BIOL, V150, P265, DOI 10.1083/jcb.150.1.265; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeager TR, 1999, CANCER RES, V59, P4175; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zheng P, 1998, NATURE, V396, P373, DOI 10.1038/24628; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	96	104	107	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	2001	20	49					7250	7256		10.1038/sj.onc.1204856	http://dx.doi.org/10.1038/sj.onc.1204856			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704853				2022-12-17	WOS:000171891900013
J	Hutchinson, JN; Muller, WJ				Hutchinson, JN; Muller, WJ			Transgenic mouse models of human breast cancer	ONCOGENE			English	Article						transgenic mice; knockout mice; mammary gland; cancer; oncogenes; tumor suppressors	MAMMARY-TUMOR VIRUS; GROWTH-FACTOR-ALPHA; C-MYC GENE; V-HA-RAS; NEU ONCOGENE; PROVIRAL INSERTION; PROGNOSTIC FACTORS; GLAND DEVELOPMENT; SYNERGISTIC INTERACTION; C-ERBB-2 PROTOONCOGENE	The pathogenesis of human breast cancer is thought to involve multiple genetic events, the majority of which fall into two categories, gain of function mutations in protooncogenes such as c-myc, cyclin D1, ErbB-2 and various growth factors which are involved in supporting cell growth, division and survival, and loss of function mutations in so called 'tumor suppressor' genes, such as p53, which are involved in preventing unrestrained cellular growth. A number of mouse systems exist to address the significance of these mutations in the pathogenesis of breast cancer including transgenic mice expressing high levels of a specific gene in target tissues and knockout mice in which specific genes have been ablated via homologous recombination. More recently, the:combination of these techniques to create bigenics as well as the use of 'knockin' and conditional tissue specific gene targeting strategies have allowed the models more reflective of the human disease to be devised. Studies with these models have not only implicated particular genetic events in the progression of the disease but have emphasized the complex, multi-step nature of breast cancer progression. These models also provide the opportunity to study various aspects of the pathogenesis of this disease, from hormonal effects to responses to chemotherapeutic drugs. It is hoped that through the combined use of these models, and the further development of more relevant models, that a deeper understanding of this disease and the generation of new therapeutic agents will result.	McMaster Univ, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8S 4K1, Canada	McMaster University; McMaster University; McMaster University; McMaster University	Muller, WJ (corresponding author), McMaster Univ, Inst Mol Biol & Biotechnol, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.		Hutchinson, John/AAA-1976-2020	Hutchinson, John/0000-0002-7804-7576				Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; ALLRED DC, 1992, HUM PATHOL, V23, P974, DOI 10.1016/0046-8177(92)90257-4; AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERNS EMJJ, 1992, J STEROID BIOCHEM, V43, P13, DOI 10.1016/0960-0760(92)90182-I; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Brisken C, 1999, DEV BIOL, V210, P96, DOI 10.1006/dbio.1999.9271; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; CALLAHAN R, 1992, CANCER, V69, P1582, DOI 10.1002/1097-0142(19920315)69:6+<1582::AID-CNCR2820691313>3.0.CO;2-Y; CARDIFF RD, 1993, CANCER SURV, V16, P97; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; Cool M, 1999, CANCER RES, V59, P2438; Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; Daphna-Iken D, 1998, ONCOGENE, V17, P2711, DOI 10.1038/sj.onc.1202212; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; ELLEDGE RM, 1994, BREAST CANCER RES TR, V32, P39, DOI 10.1007/BF00666204; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Fantl V, 1999, DEV BIOL, V212, P1, DOI 10.1006/dbio.1999.9329; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Garcia JM, 1999, BREAST CANCER RES TR, V57, P237, DOI 10.1023/A:1006273516976; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; Hadsell DL, 2000, ONCOGENE, V19, P889, DOI 10.1038/sj.onc.1203386; HALTER SA, 1992, AM J PATHOL, V140, P1131; Humphreys RC, 2000, ONCOGENE, V19, P1085, DOI 10.1038/sj.onc.1203278; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Kapoun AM, 1997, ONCOGENE, V14, P2985, DOI 10.1038/sj.onc.1201146; Kenney NJ, 1996, MOL CARCINOGEN, V15, P44; Kitsberg DI, 1996, ONCOGENE, V13, P2507; Krane IM, 1996, ONCOGENE, V12, P1781; Kwong KY, 1998, MOL CARCINOGEN, V23, P62, DOI 10.1002/(SICI)1098-2744(199810)23:2<62::AID-MC2>3.0.CO;2-O; Lamszus K, 1997, LAB INVEST, V76, P339; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LEMOINE NR, 1990, ONCOGENE, V5, P237; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; Liang TJ, 1996, J CLIN INVEST, V97, P2872, DOI 10.1172/JCI118744; LIDEREAU R, 1988, BIOCHIMIE, V70, P951, DOI 10.1016/0300-9084(88)90237-4; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Lydon JP, 1999, CANCER RES, V59, P4276; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MANSOUR EG, 1994, CANCER, V74, P381, DOI 10.1002/cncr.2820741326; MATSUI Y, 1990, CELL, V61, P1141; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Paterson JWE, 1998, DIS MARKERS, V13, P261, DOI 10.1155/1998/298530; PATTENGALE PK, 1989, AM J PATHOL, V135, P39; Pegram MD, 1998, BREAST CANCER RES TR, V52, P65, DOI 10.1023/A:1006111117877; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; Radany EH, 1997, P NATL ACAD SCI USA, V94, P8664, DOI 10.1073/pnas.94.16.8664; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; RAVDIN PM, 1995, GENE, V159, P19, DOI 10.1016/0378-1119(94)00866-Q; Ritland SR, 1997, CANCER RES, V57, P3520; Said TK, 1997, ENDOCRINOLOGY, V138, P3933, DOI 10.1210/en.138.9.3933; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STOCKLIN E, 1993, J CELL BIOL, V122, P199, DOI 10.1083/jcb.122.1.199; Tuck AB, 1996, AM J PATHOL, V148, P225; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Weaver ZA, 1999, GENE CHROMOSOME CANC, V25, P251, DOI 10.1002/(SICI)1098-2264(199907)25:3<251::AID-GCC7>3.0.CO;2-3; Wennbo H, 2000, ONCOGENE, V19, P1072, DOI 10.1038/sj.onc.1203349; XIE YM, 1995, ONCOGENE, V10, P2409; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; YAMASHITA J, 1994, CANCER RES, V54, P1630; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; ZOLL B, 1992, J CANCER RES CLIN, V118, P468, DOI 10.1007/BF01629432	94	104	113	0	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2000	19	53					6130	6137		10.1038/sj.onc.1203970	http://dx.doi.org/10.1038/sj.onc.1203970			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	387KH	11156526				2022-12-17	WOS:000166121400006
J	Chen, Y; Li, XF; Eswarakumar, VP; Seger, R; Lonai, P				Chen, Y; Li, XF; Eswarakumar, VP; Seger, R; Lonai, P			Fibroblast growth factor (FGF) signaling through PI 3-kinase and Akt/PKB is required for embryoid body differentiation	ONCOGENE			English	Article						embryoid bodies; FGF signaling; epithelial differentiation; Akt/PKB; PLC gamma-1	PHOSPHOLIPASE C-GAMMA; PHOSPHOINOSITIDE 3-KINASE; STEM-CELLS; PROTEIN-KINASE; MOUSE EMBRYOS; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; TARGETED DISRUPTION; MESODERM INDUCTION; VISCERAL ENDODERM; CELLULAR-SURVIVAL	The role of FGF signaling in early epithelial differentiation was investigated in ES (embryonic) stem) cell derived embryoid bodies. A dominant negative fibroblast growth factor receptor (FGFR) mutation was created by stably introducing into ES cells an Fgfr2 cDNA, truncated in its enzymatic domains. These cells failed to differentiate into cystic embryoid bodies. No epithelial differentiation and cavitation morphogenesis could be observed, in the mutant, although its rate of cell proliferation remained unchanged. This phenotype was associated with a significant decrease in the activation of Akt/PKB and PLC gamma-1, as compared to the wild type, while the activation of MAPK/Erk was less affected, Requirement for PL 3-kinase signaling in embryoid body differentiation was demonstrated by specific inhibitors, Akt/PKB activation was abrogated by wortmannin in short-term experiments. In long-term cultures Ly294002 inhibited the differentiation of ES cells into embryoid bodies. Our data demonstrate that for early epithelial differentiation FGF signaling is required through the PI 3-kinase-Akt/ PKB pathway.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Lonai, P (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.			Eswarakumar, Jacob/0000-0003-0784-0507; Eswarakumar, V.P./0000-0001-7941-8714				Arman E, 1999, P NATL ACAD SCI USA, V96, P11895, DOI 10.1073/pnas.96.21.11895; Arman E, 1998, P NATL ACAD SCI USA, V95, P5082, DOI 10.1073/pnas.95.9.5082; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Bagutti C, 1996, DEV BIOL, V179, P184, DOI 10.1006/dbio.1996.0250; Barbacci E, 1999, DEVELOPMENT, V126, P4795; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chai N, 1998, DEV BIOL, V198, P105, DOI 10.1016/S0012-1606(98)80031-6; CONLON RA, 1992, METHOD ENZYMOL, V225, P361; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; Cross MJ, 2000, J CELL SCI, V113, P643; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Duncan SA, 1997, DEVELOPMENT, V124, P279; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FRIEDMAN HM, 1982, CANCER RES, V42, P4683; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; HOGAN B, 1994, MANIPULATING MOUSE E; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; MARTIN GR, 1977, DEV BIOL, V61, P230, DOI 10.1016/0012-1606(77)90294-9; MCDONALD FJ, 1994, DEV GENET, V15, P148, DOI 10.1002/dvg.1020150205; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; NORTHROP J, 1995, DEV BIOL, V172, P242, DOI 10.1006/dbio.1995.0019; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; OSTROWSKI J, 1994, J BIOL CHEM, V269, P17626; Partanen J, 1998, GENE DEV, V12, P2332, DOI 10.1101/gad.12.15.2332; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rappolee DA, 1998, MOL REPROD DEV, V51, P254, DOI 10.1002/(SICI)1098-2795(199811)51:3&lt;254::AID-MRD4&gt;3.0.CO;2-O; RAZ V, 1991, ONCOGENE, V6, P753; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SPYROPOULOS DD, 1994, GENE DEV, V8, P1949, DOI 10.1101/gad.8.16.1949; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; Weinstein M, 1998, DEVELOPMENT, V125, P3615; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7	49	104	113	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3750	3756		10.1038/sj.onc.1203726	http://dx.doi.org/10.1038/sj.onc.1203726			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949929				2022-12-17	WOS:000088568400007
J	Perez-Losada, J; Pintado, B; Gutierrez-Adan, A; Flores, T; Banares-Gonzalez, B; del Campo, JC; Martin-Martin, JF; Battaner, E; Sanchez-Garcia, I				Perez-Losada, J; Pintado, B; Gutierrez-Adan, A; Flores, T; Banares-Gonzalez, B; del Campo, JC; Martin-Martin, JF; Battaner, E; Sanchez-Garcia, I			The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice	ONCOGENE			English	Article						chromosomal abnormality; malignant solid tumors; adipose tissue; cancer development	ENHANCER-BINDING-PROTEIN; HUMAN MYELOID-LEUKEMIA; ADIPOCYTE DIFFERENTIATION; CHROMOSOMAL TRANSLOCATION; MYXOID LIPOSARCOMA; TRANSCRIPTIONAL ACTIVATION; ONCOGENIC TRANSFORMATION; RETINOIC ACID; C/EBP-ALPHA; GENE	The characteristic t(12;16)(q13;p11) chromosomal translocation, which leads to gene fusion that encodes the FUS-CHOP chimeric protein, is associated with human Liposarcomas. The altered expression of FUS-CHOP has been implicated in a characteristic subgroup of human liposarcomas. We have introduced the FUS-CHOP transgene into the mouse genome in which the expression of the transgene is successfully driven by the elongation factor 1 alpha (EF1 alpha) promoter to all tissues, The consequent overexpression of FUS-CHOP results in most of the symptoms of human liposarcomas, including the presence of lipoblasts with round nuclei, accumulation of intracellular lipid, induction of adipocyte-specific genes and a concordant block in the differentiation program, We have demonstrated that liposarcomas in the FUS-CHOP transgenic mice express high Levels of the adipocyte regulatory protein PPAR gamma, whereas it is not expressed in embryonic fibroblasts from these animals following induction to differentiation toward the adipocyte lineage, indicating that the in vitro system does not really reflect the in vivo situation and the developmental defect is downstream of PPAR gamma expression. No tumors of other tissues were found in these transgenic mice despite widespread activity of the EF1 alpha promoter. This establishes FUS-CHOP overexpression as a key determinant of human liposarcomas and provide the first in vivo evidence for a link between a fusion gene created by a chromosomal translocation and a solid tumor.	Univ Salamanca, CSIC, Inst Microbiol Bioquim, Dept Proliferac & Diferenciac Celular, Salamanca 37007, Spain; Ctr Invest & Tecnol, Area Reprod Anim, Madrid 28040, Spain; Univ Salamanca, Serv Anat Patol, E-37008 Salamanca, Spain; Univ Salamanca, Serv Radiodiagnost, E-37008 Salamanca, Spain; Univ Salamanca, Dept Bioquim & Biol Mol, E-37008 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca; University of Salamanca; University of Salamanca; University of Salamanca	Sanchez-Garcia, I (corresponding author), Univ Salamanca, CSIC, Inst Microbiol Bioquim, Dept Proliferac & Diferenciac Celular, Edificio Dept,Avda Campo Charro S-N, Salamanca 37007, Spain.		SANCHEZ-GARCIA, ISIDRO/A-5631-2019; Pérez-Losada, Jesús/A-5883-2019; Pintado, Belen/N-3233-2014; Gutierrez-Adan, Alfonso/A-1485-2014	Pérez-Losada, Jesús/0000-0003-2400-624X; Pintado, Belen/0000-0002-8485-2520; Gutierrez-Adan, Alfonso/0000-0001-9893-9179; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905	NCI NIH HHS [1R01CA79955-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Adelmant G, 1998, J BIOL CHEM, V273, P15574, DOI 10.1074/jbc.273.25.15574; AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; Altabef M, 1996, EMBO J, V15, P2707, DOI 10.1002/j.1460-2075.1996.tb00631.x; Aman P, 1996, GENOMICS, V37, P1, DOI 10.1006/geno.1996.0513; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; BENNETT JH, 1995, J CLIN PATHOL, V48, P950, DOI 10.1136/jcp.48.10.950; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Castellanos A, 1997, BLOOD, V90, P2168, DOI 10.1182/blood.V90.6.2168.2168_2168_2174; CHANG HR, 1989, CANCER, V64, P1514, DOI 10.1002/1097-0142(19891001)64:7<1514::AID-CNCR2820640726>3.0.CO;2-2; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KNIGHT JC, 1995, CANCER RES, V55, P24; Kuroda M, 1997, AM J PATHOL, V151, P735; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MACK TM, 1995, CANCER-AM CANCER SOC, V75, P211, DOI 10.1002/1097-0142(19950101)75:1+<211::AID-CNCR2820751309>3.0.CO;2-X; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; PRASAD DDK, 1994, ONCOGENE, V9, P3717; PRICE BD, 1992, CANCER RES, V52, P3814; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; Sanchez-Garcia I, 1997, ANNU REV GENET, V31, P429, DOI 10.1146/annurev.genet.31.1.429; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Takada T, 1997, NAT BIOTECHNOL, V15, P458, DOI 10.1038/nbt0597-458; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	44	104	108	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2000	19	20					2413	2422		10.1038/sj.onc.1203572	http://dx.doi.org/10.1038/sj.onc.1203572			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828883				2022-12-17	WOS:000087018400006
J	Askham, JM; Moncur, P; Markham, AF; Morrison, EE				Askham, JM; Moncur, P; Markham, AF; Morrison, EE			Regulation and function of the interaction between the APC tumour suppressor protein and EB1	ONCOGENE			English	Article						APC; EB1; cell cycle; mitosis; phosphorylation; microtubules	BINDING PROTEIN; CELL-MIGRATION; FISSION YEAST; PHOSPHORYLATION; MICROTUBULES; P34(CDC2); DYNAMICS; PROMOTES; GENE; TAU	The interaction between the adenomatous polyposis coli (A PC) tumour suppressor and the microtubule-associated protein EB1 was examined, Immunoprecipitation suggested that APC and EB1 were not associated in cultures of HCT116 cells arrested in mitosis, The C-terminal 170 amino acids of APC, purified as a bacterial fusion protein, precipitated EB1 from cell extracts, significantly refining the location of the EB1 interaction domain in APC, In vitro phosphorylation of this fusion protein by either protein kinase A or p34(cdc2) reduced its ability to bind to EB1, Expression of GFP fusions to C-terminal APC sequences Lacking or including the APC basic domain but encompassing the EB1 binding region in SW480 cells revealed a microtubule tip association which co-localized with that of EB1, Expression of the basic domain alone revealed a non-specific microtubule localization. In vitro interaction studies confirmed that the APC basic domain did not contribute to EB1 binding. These findings strongly suggest that the interaction between APC and EB1 targets APC to microtubule tips, and that the interaction between the two proteins is down-regulated during mitosis by the previously described mitotic phosphorylation of APC.	Univ Leeds, St James Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Morrison, EE (corresponding author), Univ Leeds, St James Hosp, Mol Med Unit, Clin Sci Bldg, Leeds LS9 7TF, W Yorkshire, England.							ALFA CE, 1990, NATURE, V347, P680, DOI 10.1038/347680a0; ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; Berrueta L, 1999, CURR BIOL, V9, P425, DOI 10.1016/S0960-9822(99)80190-0; Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596; Cassimeris L, 1999, CURR OPIN CELL BIOL, V11, P134, DOI 10.1016/S0955-0674(99)80017-9; Deka J, 1998, EUR J BIOCHEM, V253, P591, DOI 10.1046/j.1432-1327.1998.2530591.x; Illenberger S, 1998, MOL BIOL CELL, V9, P1495, DOI 10.1091/mbc.9.6.1495; Juwana JP, 1999, INT J CANCER, V81, P275, DOI 10.1002/(SICI)1097-0215(19990412)81:2<275::AID-IJC18>3.0.CO;2-Z; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morrison EE, 1997, NEUROSCIENCE, V81, P553, DOI 10.1016/S0306-4522(97)00099-7; Morrison EE, 1998, J VIROL, V72, P7108, DOI 10.1128/JVI.72.9.7108-7114.1998; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Pollack AL, 1997, J CELL BIOL, V137, P1651, DOI 10.1083/jcb.137.7.1651; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; SMITH KJ, 1994, CANCER RES, V54, P3672; SU LK, 1995, CANCER RES, V55, P2972; Trzepacz C, 1997, J BIOL CHEM, V272, P21681, DOI 10.1074/jbc.272.35.21681; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588	24	104	107	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2000	19	15					1950	1958		10.1038/sj.onc.1203498	http://dx.doi.org/10.1038/sj.onc.1203498			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773885				2022-12-17	WOS:000086424300011
J	Wang, Y; Prywes, R				Wang, Y; Prywes, R			Activation of the c-fos enhancer by the Erk MAP kinase pathway through two sequence elements: the c-fos AP-1 and p62(TCF) sites	ONCOGENE			English	Article						c-fos; FAP1; Erk; MAPK	SERUM RESPONSE ELEMENT; EPIDERMAL GROWTH-FACTOR; DEPENDENT PROTEIN-KINASE; TERNARY COMPLEX FACTORS; COFFIN-LOWRY SYNDROME; TRANSCRIPTIONAL ACTIVATION; CYCLIC-AMP; BINDING PROTEIN; REGULATE CREB; TFII-I	The c-fos enhancer can be activated by many signaling pathways through distinct elements of the enhancer. The enhancer contains at its core the serum response element (SRE) that binds serum response factor (SRF), On the 5' side of the SRE is a site for p62(TCF) which binds only when SRF is bound as well. p62(TCF) is encoded by three ets-related genes, Elk-l, SAP1 and SAP2, Each of these factors contain a transcriptional activation domain that is activated by phosphorylation by MAP kinases, On the 3' side of the SRE is the 'c-fos API site) (FAP1) whose role has been less clear, We find here that the FAP1 site contributes strongly to phorbol ester (TPA) and Erk MAP kinase activation of the c-fos enhancer and that both the p62(TCF) and FAP1 sites are required for effective activation of the enhancer. We further find that the FAP1 site binds ATF1 and CREB from HeLa nuclear extracts and that the phosphorylation of these factors is induced by TPA. ATF1 and CREB can be phosphorylated by Rsk2 which is a protein kinase directly activated by Erk MAP kinases, These results suggest a signaling pathway in which Erk MAP kinase activates the c-fos enhancer by direct phosphorylation of p62(TCF) and by activation of Rsk related kinases that phosphorylate ATF1 and CREB.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prywes, R (corresponding author), Columbia Univ, Dept Biol Sci, Fairchild 813B,MC 2420, New York, NY 10027 USA.				NCI NIH HHS [CA50329] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050329] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTAR RM, 1992, MOL CELL BIOL, V12, P2432, DOI 10.1128/MCB.12.5.2432; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Chen X, 1999, MOL CELL BIOL, V19, P4695; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; De Cesare D, 1999, TRENDS BIOCHEM SCI, V24, P281, DOI 10.1016/S0968-0004(99)01414-0; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; LIU F, 1993, J BIOL CHEM, V268, P6714; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; METZ R, 1991, ONCOGENE, V6, P2165; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sambrook J, 1989, MOL CLONING LAB MANU; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang Y, 1998, CELL GROWTH DIFFER, V9, P513; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YOUNG ID, 1988, J MED GENET, V25, P344, DOI 10.1136/jmg.25.5.344; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	53	104	106	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 9	2000	19	11					1379	1385		10.1038/sj.onc.1203443	http://dx.doi.org/10.1038/sj.onc.1203443			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723128				2022-12-17	WOS:000085942700002
J	Paramio, JM; Navarro, M; Segrelles, C; Gomez-Casero, E; Jorcano, JL				Paramio, JM; Navarro, M; Segrelles, C; Gomez-Casero, E; Jorcano, JL			PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein	ONCOGENE			English	Article						PTEN/MMAC1/TEP1; cell cycle; retinoblastoma protein; signal transduction	PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; GROWTH SUPPRESSION; GLIOMA-CELLS; KINASE; PHOSPHATASE; INHIBITION; EXPRESSION; G(1); GENE	The tumour suppressor PTEN, also named MMAC1 or TEP1, is associated with a number of malignancies in human populations. This protein has a dual protein phosphatase activity, being also capable to dephosphorylate phosphatidylinositol 3,4,5 triphosphate. We have studied the mechanism of growth suppression attributable to PTEN, We observed that PTEN overexpression inhibits cell growth in a variety of normal and transformed, human and murine cells. Bromodeoxyuridine (BrdU) incorporation and TUNEL labelling experiments in transiently transfected cells demonstrate that this inhibition is due to a cell cycle arrest rather than induction of apoptosis, Given that PTEN is unable to cause cell growth arrest in retinoblastoma (Rb)deficient cell lines, we have explored the possible requirement for pRb in the PTEN-induced inhibition of cell proliferation. We found that the co-expression of SV40 antigen, but not a mutant form (which binds exclusively to p53), and cyclin D1/cdk4 are able to overcome the PTEN-mediated growth suppression. In addition, the reintroduction of a functional pRb, but not its relatives p107 or p130, in Rb-deficient cells restores the sensitivity to PTEN-induced arrest. Finally, the hyperphosphorylation of transfected pRb is inhibited by PTEN co-expression and restored by PI-3K co-expression, Accordingly, PTEN gene is mostly expressed, in parallel to Akt, in mid-late G(1) phase during cell cycle progression prior to pRb hyperphosphorylation. Finally, we have studied the signal transduction pathways modulated by PTEN expression. We found that PTEN-induced growth arrest can be rescued by the co-expression of active PI-3K and downstream effecters such as Akt or PDK1, and also certain small GTPases such as Rad and Cdc42, but not by active Ha-ras, paf or RhoA, Collectively, our data link the tumour suppressor activities of PTEN to the machinery controlling cell cycle through the modulation of signalling molecules whose final target is the functional inactivation of the retinoblastoma gene product.	CIEMAT, Dept Mol & Cell Biol, E-28040 Madrid, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas	Paramio, JM (corresponding author), CIEMAT, Dept Mol & Cell Biol, Ave Complutense 22, E-28040 Madrid, Spain.		Paramio, Jesus M/M-8482-2014; Navarro, Manuel/S-1496-2019; Gómez-Casero, Elena/A-7389-2016; Segrelles, Carmen/E-3655-2016; Esteban, Elena Gómez-Casero/AAK-3216-2020	Paramio, Jesus M/0000-0001-7520-3177; Navarro, Manuel/0000-0003-1118-8531; Gómez-Casero, Elena/0000-0002-7040-8832; Segrelles, Carmen/0000-0001-9340-2102; Esteban, Elena Gómez-Casero/0000-0002-7040-8832				Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; Pearson R B, 1995, Prog Cell Cycle Res, V1, P21; PICKSLEY SM, 1994, CURR OPIN CELL BIOL, V6, P853, DOI 10.1016/0955-0674(94)90056-6; PRENNAN P, 1997, IMMUNITY, V7, P679; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	44	104	106	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7462	7468		10.1038/sj.onc.1203151	http://dx.doi.org/10.1038/sj.onc.1203151			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602505				2022-12-17	WOS:000084119600007
J	Ricol, D; Cappellen, D; El Marjou, A; Gil-Diez-de-Medina, S; Girault, JM; Yoshida, T; Ferry, G; Tucker, G; Poupon, MF; Chopin, D; Thiery, JP; Radvanyi, F				Ricol, D; Cappellen, D; El Marjou, A; Gil-Diez-de-Medina, S; Girault, JM; Yoshida, T; Ferry, G; Tucker, G; Poupon, MF; Chopin, D; Thiery, JP; Radvanyi, F			Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer	ONCOGENE			English	Article						bladder; fibroblast growth factor receptor; human; urothelial cell carcinoma; tumour suppressor gene	LIGAND-BINDING SPECIFICITY; PROSTATE EPITHELIAL-CELLS; HUMAN PANCREATIC-CANCER; K-SAM; DIFFERENTIAL EXPRESSION; TRANSGENIC MICE; GASTRIC-CANCER; GENE; ACTIVATION; BFGF	FGFRs (fibroblast growth factor receptors) are encoded by four genes (FGFR1-4). Alternative splicing results in various receptor isoforms, The FGFR2-IIIb variant is present in a wide variety of epithelia, including the bladder epithelium. Recently, we have shown that FGFR2-IIIb is downregulated in a subset of transitional cell carcinomas of the bladder, and that this downregulation is associated with a poor prognosis. We investigated possible tumour suppressive properties of FGFR2-IIIb by transfecting two human bladder tumour cell lines, J82 and T24, which have no endogenous FGFR2-IIIb expression, with FGFR2-IIIb cDNA, No stable clones expressing FGFR2-IIIb were isolated with the J82 cell line, For the T24 cell line, stable transfectants expressing FGFR2-IIIb had reduced growth in vitro and formed fewer tumours in nude mice which, in addition, grew more slowly. The potential mechanisms leading to decreased FGFR2-IIIb mRNA levels mere also investigated, The 5' region of the human FGFR2 gene was isolated and found to contain a CpG island which was partially methylated in more than half the cell lines and tumours which do not express FGFR2-IIIb, No homozygous deletion was identified in any of the tumours or cell lines with reduced levels of FGFR2-IIIb, Mutational analysis of the entire coding region of FGFR2-IIIb at the transcript level was performed in 33 bladder tumours, In addition to normal FGFR2-IIIb mRNA, abnormal transcripts were detected in two tumour samples, These abnormal mRNAs resulted from exon skipping which affected the region encoding the kinase domain. Altogether, these results show that FGFR2-IIIb has tumour growth suppressive properties in bladder carcinomas and suggest possible mechanisms of FGFR2 gene inactivation.	Inst Curie, CNRS, UMR 144, Sect Rech, Paris 05, France; CHU Henri Mondor, Grp Etude Tumeurs Urol, F-94010 Creteil, France; CHU Henri Mondor, Serv Urol, F-94010 Creteil, France; Natl Canc Ctr, Res Inst, Div Genet, Tokyo 1040045, Japan; Inst Rech Servier, Div Cancerol Expt, F-92150 Suresnes, France; Inst Curie, CNRS, UMR 147, Sect Rech, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; National Cancer Center - Japan; Servier; Institut de Recherches Internationales Servier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite	Radvanyi, F (corresponding author), Inst Curie, CNRS, UMR 144, Sect Rech, 26 Rue Ulm, Paris 05, France.		Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020; Radvanyi, Francois/0000-0002-5696-6424	NATIONAL CANCER INSTITUTE [R01CA049417] Funding Source: NIH RePORTER; NCI NIH HHS [2RO1 CA 49417-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AHOMADEGBE JC, 1995, ONCOGENE, V10, P1217; AVIVI A, 1992, ONCOGENE, V7, P1957; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; Carstens RP, 1997, ONCOGENE, V15, P3059, DOI 10.1038/sj.onc.1201498; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DELL KR, 1992, J BIOL CHEM, V267, P21225; deMedina SGD, 1997, ONCOGENE, V14, P323, DOI 10.1038/sj.onc.1200830; DEMEDINA SGD, 1999, IN PRESS ONCOGENE; DeMoerlooze L, 1997, CURR OPIN GENET DEV, V7, P378, DOI 10.1016/S0959-437X(97)80152-9; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Feng SJ, 1997, CANCER RES, V57, P5369; Fenig E, 1997, CLIN CANCER RES, V3, P135; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GIROLDI LA, 1994, INVAS METAST, V14, P71; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HALABAN R, 1988, ONCOGENE RES, V3, P177; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; Ishiwata T, 1998, AM J PATHOL, V153, P213, DOI 10.1016/S0002-9440(10)65562-9; ITOH H, 1994, CANCER RES, V54, P3237; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KISHI T, 1994, BIOCHEM BIOPH RES CO, V202, P1387, DOI 10.1006/bbrc.1994.2084; Kornmann M, 1997, ONCOGENE, V15, P1417, DOI 10.1038/sj.onc.1201307; Lamm DL, 1996, CA-CANCER J CLIN, V46, P93, DOI 10.3322/canjclin.46.2.93; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; Mao L, 1998, J NATL CANCER I, V90, P412, DOI 10.1093/jnci/90.6.412; Matsubara A, 1998, CANCER RES, V58, P1509; MATTEI MG, 1991, HUM GENET, V87, P84, DOI 10.1007/BF01213098; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; REED JA, 1994, AM J PATHOL, V144, P329; Rubin J. S., 1995, V74, P191; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SCHWEIGERER L, 1987, J CLIN INVEST, V80, P1516, DOI 10.1172/JCI113236; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; SINGERSAM J, 1990, MOL CELL BIOL, V10, P4987, DOI 10.1128/MCB.10.9.4987; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159	56	104	115	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7234	7243		10.1038/sj.onc.1203186	http://dx.doi.org/10.1038/sj.onc.1203186			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602477				2022-12-17	WOS:000084119400007
J	Mancini, DN; Singh, SM; Archer, TK; Rodenhiser, DI				Mancini, DN; Singh, SM; Archer, TK; Rodenhiser, DI			Site-specific DNA methylation in the neurofibromatosis (NF1) promoter interferes with binding of CREB and SP1 transcription factors	ONCOGENE			English	Article						DNA methylation; neurofibromatosis; promoter; CpG island; SPI; CREB	TUMOR-SUPPRESSOR GENE; RECEPTOR CPG ISLAND; CYTOSINE METHYLATION; EXPRESSION; RETINOBLASTOMA; MOUSE; REGION; IDENTIFICATION; DINUCLEOTIDES; MUTATIONS	Tumour suppressor genes and growth regulatory genes are frequent targets for methylation defects that can result in aberrant expression and mutagenesis, We have established a methylation map of the promoter region of the neurofibromatosis (NF1) gene and demonstrated functional sensitivity for methylation at specific sites for the SP1 and CRE binding (CREB) proteins in the NF1 regulatory region. We evaluated the methylation status of CpG dinucleotides within five promoter subregions in the human and mouse homologues of the neurofibromatosis (NF1) genes, Three 5' subregions vc ere found to be consistently methylated in all the tissues analysed. In contrast, DNA methylation was absent in the vicinity of the transcription start site bounded by SP1 recognition sequences. Gelshift assays showed that methylation specifically inhibits the CREB transcription factor from binding to its recognition site at the NF1 transcription start site. Furthermore, SP1 elements within the NF1 promoter are methylation sensitive, particularly when methylation is present on the antisense strand. We propose that for NF1 as with several other tumour suppressor genes, CpG methylation occurs in a complex, site-specific manner with the maintenance of a methylation-free promoter region bounded by SP1 binding sites that allow an accessible promoter to be retained. When these SP1 boundaries are breached, methylation can sweep in, rendering the promoter inaccessible for specific methylation-sensitive transcription factors and leading to a loss of functional integrity of the methylation-free CpG island.	London Hlth Sci Ctr, Child Hlth Res Inst, Mol Med Genet Program, London, ON N6C 2V5, Canada; Univ Western Ontario, London Reg Canc Ctr, London, ON, Canada; Univ Western Ontario, Dept Biochem, London, ON, Canada; Univ Western Ontario, Dept Obstet & Gynecol, London, ON, Canada; Univ Western Ontario, Dept Oncol, London, ON, Canada; Univ Western Ontario, Dept Paediat, London, ON, Canada; Univ Western Ontario, Dept Zool, London, ON, Canada	London Health Sciences Centre; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Rodenhiser, DI (corresponding author), London Hlth Sci Ctr, Child Hlth Res Inst, Mol Med Genet Program, A4WT,800 Commiss Rd E, London, ON N6C 2V5, Canada.			Archer, Trevor K/0000-0001-7651-3644	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071006, Z01ES071007, ZIAES071006] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andrews JD, 1996, HUM MOL GENET, V5, P503, DOI 10.1093/hmg/5.4.503; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; ARCHER TK, 1990, P NATL ACAD SCI USA, V87, P7560, DOI 10.1073/pnas.87.19.7560; BARLOW DP, 1993, SCIENCE, V260, P309, DOI 10.1126/science.8469984; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; COOPER DN, 1989, HUM GENET, V83, P181, DOI 10.1007/BF00286715; DASTON MM, 1992, DEV DYNAM, V195, P216, DOI 10.1002/aja.1001950307; GAESSMAN M, 1993, DNA METHYLATION MOL, P404; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709; GUTMANN DH, 1993, J NEUROSCI RES, V36, P216, DOI 10.1002/jnr.490360212; HAJRA A, 1994, GENOMICS, V21, P649, DOI 10.1006/geno.1994.1328; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; HUYNH DP, 1994, DEV BIOL, V161, P538, DOI 10.1006/dbio.1994.1052; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; Issa JPJ, 1996, CANCER RES, V56, P973; Issa JPJ, 1996, CANCER RES, V56, P3655; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Mancini D, 1997, AM J HUM GENET, V61, P80, DOI 10.1086/513898; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Nan XS, 1996, MOL CELL BIOL, V16, P414; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; PURANDARE SM, 1996, AM J HUM GENET, V59; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Riccardi V M, 1992, Curr Probl Pediatr, V22, P66, DOI 10.1016/0045-9380(92)90053-2; RICCARDI VM, 1994, AM J PATHOL, V145, P994; Rodenhiser DI, 1997, MUTAT RES-FUND MOL M, V373, P185, DOI 10.1016/S0027-5107(96)00171-6; SAKAI T, 1991, AM J HUM GENET, V48, P880; Sambrook J, 1989, MOL CLONING LAB MANU; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; Wang F, 1997, BIOCHEMISTRY-US, V36, P7793, DOI 10.1021/bi963100j; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; Worrad DM, 1997, MOL REPROD DEV, V46, P268, DOI 10.1002/(SICI)1098-2795(199703)46:3&lt;268::AID-MRD5&gt;3.0.CO;2-N	41	104	106	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4108	4119		10.1038/sj.onc.1202764	http://dx.doi.org/10.1038/sj.onc.1202764			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435592				2022-12-17	WOS:000081431000008
J	Kawai, T; Nomura, F; Hoshino, K; Copeland, NG; Gilbert, DJ; Jenkins, NA; Akira, S				Kawai, T; Nomura, F; Hoshino, K; Copeland, NG; Gilbert, DJ; Jenkins, NA; Akira, S			Death-associated protein kinase 2 is a new calcium/calmodulin-dependent protein kinase that signals apoptosis through its catalytic activity	ONCOGENE			English	Article						DAP kinase family; calcium/calmodulin-dependent kinase; apoptosis	SERINE THREONINE KINASE; JUN ACTIVATION DOMAIN; INDUCED CELL-DEATH; C-JUN; DAP-KINASE; IDENTIFICATION; INDUCTION; CASPASES; PHOSPHORYLATES; REQUIREMENT	We have identified and characterized a new calcium/calmodulin (Ca2+/CaM) dependent protein kinase termed death-associated protein kinase 2 (DAPK2) that contains an N-terminal protein kinase domain followed by a conserved CaM-binding domain with significant homologies to those of DAP kinase, a protein kinase involved in apoptosis, DAPK2 mRNA is expressed abundantly in heart, lung and skeletal muscle. The mapping results indicated that DAPK2 is located in the central region of mouse chromosome 9, bl vitro kinase assay revealed that DAPK2 is autophosphorylated and phosphorylates myosin light chain (MLC) as an exogenous substrate. DAPK2 binds directly to CaM and is activated in a Ca2+/CaM-dependent manner. A constitutively active DAPK2 mutant is generated by removal of the CaM-binding domain (Delta CaM). Treatment of agonists that elevate intracellular Ca2+-concentration led to the activation of DAPK2 and transfection studies revealed that DAPK2 is localized in the cytoplasm. Overexpression of DAPK2, but not the kinase negative mutant, significantly induced the morphological changes characteristic of apoptosis, These results indicate that DAPK2 is an additional member of DAP kinase family involved in apoptotic signaling.	Hyogo Coll Med, Dept Biochem, Nishinomiya, Hyogo 6638501, Japan; NCI, Mammalian Genet Lab, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Japan Sci & Technol Corp, CREST, Tokyo, Japan	Hyogo College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Japan Science & Technology Agency (JST)	Akira, S (corresponding author), Hyogo Coll Med, Dept Biochem, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.		Hoshino, Katsuaki/AAE-2830-2022; Hoshino, Katsuaki/L-9162-2014; Akira, Shizuo/C-3134-2009	Hoshino, Katsuaki/0000-0003-0493-4815; Hoshino, Katsuaki/0000-0003-0493-4815; Kawai, Taro/0000-0001-7510-4662				ANDESON P, MICROBIOL MOL BIOL R, V61, P33; ASKEW DS, 1991, ONCOGENE, V6, P1915; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; GIGUERE V, 1995, GENOMICS, V28, P596, DOI 10.1006/geno.1995.1197; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; KISSIL JL, 1997, ONCOGENE, V15, P405; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LASSIGNALJOHNSO.N, 1996, J BIOL CHEM, V271, P3229; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pecker I, 1996, GENOMICS, V35, P39, DOI 10.1006/geno.1996.0320; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Roulston D, 1998, BLOOD, V92, P2879, DOI 10.1182/blood.V92.8.2879.420k22_2879_2885; Sanjo H, 1998, J BIOL CHEM, V273, P29066, DOI 10.1074/jbc.273.44.29066; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P2673; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TIAN QS, 1995, J EXP MED, V182, P865, DOI 10.1084/jem.182.3.865; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Wright SC, 1997, FASEB J, V11, P843, DOI 10.1096/fasebj.11.11.9285482; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	45	104	112	0	23	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 10	1999	18	23					3471	3480		10.1038/sj.onc.1202701	http://dx.doi.org/10.1038/sj.onc.1202701			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376525				2022-12-17	WOS:000080850600005
J	Klint, P; Kanda, S; Kloog, Y; Claesson-Welsh, L				Klint, P; Kanda, S; Kloog, Y; Claesson-Welsh, L			Contribution of Src and Ras pathways in FGF-2 induced endothelial cell differentiation	ONCOGENE			English	Article						FGF receptor; endothelial cell; differentiation; Src; Ras; Raf	FIBROBLAST GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; FOCAL ADHESION KINASE; MEDIATED SIGNAL-TRANSDUCTION; FARNESYLTRANSFERASE INHIBITORS; RECEPTOR ACTIVATION; TYROSINE KINASES; REGULATED KINASE; POINT MUTATION; SH2 DOMAIN	We have examined fibroblast growth factor (FGF) receptor-1 mediated signal transduction in differentiation of endothelial cells (EC). The activated FGFR-1 couples to Ras through two adaptor proteins, FRS2 and Shc. In FGF-2 treated proliferating EC, FRS2 as well as She are tyrosine phosphorylated and interact with Grb2, In contrast, in FGF-2 treated differentiating cells, Shc, but not FRS2, is engaged in Grb2-interactions, Sustained MAP kinase activity has previously been implicated in differentiation. In FGF stimulated proliferating and differentiating endothelial cells, the MAP kinase Erk2 is activated in a sustained manner. Inhibition of MEK and MAP kinase activity by PD98059 treatment of cells, still allows EC tube formation, The FGFR-1 mediates activation of protein kinase C (PKC) through direct binding and activation of phospholipase C-gamma (PLC-gamma), and has also been shown to activate the cytoplasmic tyrosine kinase Src. Treatment of the cells with the PKC inhibitor bisindolylmaleimide does not prevent tube formation. In contrast, Src kinase activity is prerequisite for EC differentiation, since treatment of the cells with PP1, a Src family specific inhibitor, abrogates tube formation. In differentiating EC, FGF-2 induces complex formation between Src and focal adhesion kinase (FAK). These data indicate that the Ras pathway is initiated via She or FRS2. dependent on the cellular program. Blocking the function of Src family kinases, attenuates differentiation.	BMC, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; Nagasaki Univ, Sch Med, Dept Urol, Nagasaki 852, Japan; Tel Aviv Univ, Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel	Nagasaki University; Tel Aviv University	Claesson-Welsh, L (corresponding author), BMC, Dept Med Biochem & Microbiol, Box 575, SE-75123 Uppsala, Sweden.			Claesson-Welsh, Lena/0000-0003-4275-2000				BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1986, CANCER RES, V46, P467; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARA M, 1993, P NATL ACAD SCI USA, V90, P2281, DOI 10.1073/pnas.90.6.2281; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; KANDA S, 1999, IN PRESS EXP CELL RE; Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; Kuo WL, 1997, MOL CELL BIOL, V17, P4633, DOI 10.1128/MCB.17.8.4633; LANDGREN E, 1995, ONCOGENE, V10, P2027; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTHEWS JA, 1985, ANAL BIOCHEM, V151, P205, DOI 10.1016/0003-2697(85)90073-9; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Nagase T, 1996, INT J CANCER, V65, P620, DOI 10.1002/(SICI)1097-0215(19960301)65:5<620::AID-IJC11>3.0.CO;2-B; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SCHLAEPFER DD, 1994, NATURE, V372, P786; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107	46	104	108	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	1999	18	22					3354	3364		10.1038/sj.onc.1202680	http://dx.doi.org/10.1038/sj.onc.1202680			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362356				2022-12-17	WOS:000080589300006
J	Czerniak, B; Chaturvedi, V; Li, L; Hodges, S; Johnston, D; Ro, JY; Luthra, R; Logothetis, C; Von Eschenbach, AC; Grossman, HB; Benedict, WF; Batsakis, JG				Czerniak, B; Chaturvedi, V; Li, L; Hodges, S; Johnston, D; Ro, JY; Luthra, R; Logothetis, C; Von Eschenbach, AC; Grossman, HB; Benedict, WF; Batsakis, JG			Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer	ONCOGENE			English	Article						bladder cancer; chromosome 9; MTS; microsatellites; multistep carcinogenesis; superimposed histologic and genetic mapping	TRANSITIONAL-CELL-CARCINOMA; TUMOR-SUPPRESSOR GENE; CRITICAL REGION; HIGH-FREQUENCY; LUNG CANCERS; DELETION; P16; MUTATIONS; LOCI; DEFINES	The evolution of alterations on chromosome 9, including the putative tumor suppressor genes mapped to the 9p21-22 region (the MTS genes), was studied in relation to the progression of human urinary bladder neoplasia by using whole organ superimposed histologic and genetic mapping in cystectomy specimens and was verified in urinary bladder tumors of various pathogenetic subsets with longterm follow-up, The applicability of chromosome 9 allelic losses as non-invasive markers of urothelial neoplasia was tested on voided urine and/or bladder washings of patients with urinary bladder cancer, Although sequential multiple hits in the MTS locus were documented in the development of intraurothelial precursor lesions, the MTS genes do not seem to represent a major target for p21-23 deletions in bladder cancer, Two additional tumor suppressor genes involved in bladder neoplasia located distally and proximally to the MTS locus within p22-23 and p11-13 regions respectively were identified. Several distinct putative tumor suppressor gene loci within the q12-13, q21-22, and q34 regions were identified on the q arm. In particular, the pericentromeric q12-13 area may contain the critical tumor suppressor gene or genes for the development of early urothelial neoplasia, Allelic losses of chromosome 9 were associated with expansion of the abnormal urothelial clone which frequently involved large areas of urinary bladder mucosa, These losses could be found in a high proportion of urothelial tumors and in voided urine or bladder washing samples of nearly all patients with urinary bladder carcinoma.	Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Biomath, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Urol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Czerniak, B (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA.				NCI NIH HHS [CA66723-04, CA54672] Funding Source: Medline; NEI NIH HHS [EYO6195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA066723, R01CA054672, R01CA066723] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1997, AJCC CANC STAGING MA; ATKIN NB, 1985, CANCER GENET CYTOGEN, V15, P253, DOI 10.1016/0165-4608(85)90169-4; BABU VR, 1987, CANCER RES, V47, P6800; Benedict WF, 1999, ONCOGENE, V18, P1197, DOI 10.1038/sj.onc.1202452; BERGER CS, 1986, CANCER GENET CYTOGEN, V23, P1, DOI 10.1016/0165-4608(86)90145-7; Brownlee K.A., 1965, STAT THEORY METHODOL; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1993, ONCOGENE, V8, P1083; CAIRNS P, 1993, CANCER RES, V53, P1230; Chaturvedi V, 1997, ONCOGENE, V14, P2059, DOI 10.1038/sj.onc.1201044; COLEMAN A, 1994, CANCER RES, V54, P344; DEVLIN J, 1994, ONCOGENE, V9, P2757; GIBAS Z, 1984, CANCER RES, V44, P1257; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HABUCHI T, 1995, ONCOGENE, V11, P1671; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; Hartigan J.A., 1975, CLUSTERING ALGORITHM; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KISHIMOTO Y, 1995, JNCI-J NATL CANCER I, V87, P1224, DOI 10.1093/jnci/87.16.1224; KOSS LG, 1995, DIAGNOSTIC CYTOLOGY; Larsen C J, 1997, Prog Cell Cycle Res, V3, P109; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; LIU Q, 1995, ONCOGENE, V10, P1061; Maniatis T., 1989, MOL CLONING LAB MANU; MERLO A, 1995, NATURE, V1, P7; MIYAO N, 1993, CANCER RES, V53, P4066; OLOPADE OI, 1993, CANCER RES, V53, P2410; OLUMI AF, 1990, CANCER RES, V50, P7081; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; Ott J., 1991, ANAL HUMAN GENETIC L; PACKENHAM JP, 1995, MOL CARCINOGEN, V14, P147, DOI 10.1002/mc.2940140303; Reed AL, 1996, CANCER RES, V56, P3630; Simoneau AR, 1996, CANCER RES, V56, P5039; SIMONEAU AR, 1994, WORLD J UROL, V12, P89; SMEETS W, 1987, CANCER GENET CYTOGEN, V29, P29, DOI 10.1016/0165-4608(87)90028-8; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SPRUCK CH, 1994, CANCER RES, V54, P784; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TSAI YC, 1990, CANCER RES, V50, P44; VANNI R, 1988, CANCER GENET CYTOGEN, V30, P35, DOI 10.1016/0165-4608(88)90090-8; WILLIAMSON MP, 1995, HUM MOL GENET, V4, P1569, DOI 10.1093/hmg/4.9.1569; Wong DJ, 1997, CANCER RES, V57, P2619	42	104	108	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1185	1196		10.1038/sj.onc.1202385	http://dx.doi.org/10.1038/sj.onc.1202385			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022124				2022-12-17	WOS:000078510700007
J	Lloyd, BH; Platt-Higgins, A; Rudland, PS; Barraclough, R				Lloyd, BH; Platt-Higgins, A; Rudland, PS; Barraclough, R			Human S100A4(p9Ka) induces the metastatic phenotype upon benign tumour cells	ONCOGENE			English	Article						breast cancer; calcium-binding protein; metastasis; p9Ka; S100A4	CALCIUM-BINDING PROTEIN; HUMAN BREAST-CANCER; RAT MAMMARY-GLAND; MESSENGER-RNA; MYOEPITHELIAL CELLS; MOLECULAR-CLONING; NONMUSCLE MYOSIN; GENE; P9KA; TRANSFECTION	The rodent S100-related calcium-binding protein, S100A4 induces metastasis in non-metastatic rat and mouse benign mammary cells and co-operates with benign-tumour-inducing changes in two transgenic mouse models, to yield metastatic mammary tumours, Cotransfection of the human gene for S100A4 with pSV2neo into the benign rat mammary cell line, Rama 37, yielded cells which expressed a low level of the endogenous S100A4 mRNA, and either high or undetectable levels of human S100A4 mRNA. The cells which expressed a high level of human S100A4 mRNA induced metastasis in the benign rat mammary cell line Rama 37 in an in vivo assay, whereas the cells which expressed an undetectable level of human S100A4 did not induce any detectable metastases. The primary tumours arising from the S100A4-expressing cells contained high levels of immunocytochemically-detected S100A4 and this high level of S100A4 and the metastatic potential were maintained when cells from a metastasis were re-injected into syngeneic rats, The results show that the human S100A4 possesses metastasis-inducing capabilities.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7BZ, Merseyside, England	University of Liverpool	Barraclough, R (corresponding author), Univ Liverpool, Sch Biol Sci, POB 147, Liverpool L69 7BZ, Merseyside, England.		Barraclough, Roger/AAH-6516-2020	Barraclough, Roger/0000-0002-7203-1194				Ambartsumian NS, 1996, ONCOGENE, V13, P1621; BARRACLOUGH R, 1987, J CELL PHYSIOL, V131, P393, DOI 10.1002/jcp.1041310311; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BARRACLOUGH R, 1984, BIOCHEM BIOPH RES CO, V120, P351, DOI 10.1016/0006-291X(84)91261-0; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V21, P8097; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIES BR, 1993, ONCOGENE, V8, P999; DAVIES BR, 1994, CANCER RES, V54, P2785; Davies MPA, 1996, ONCOGENE, V13, P1631; DAVIES MPA, 1993, THESIS U LIVERPOOL; DEVILEE P, 1991, CANCER RES, V51, P1020; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; DUNNINGTON DJ, 1984, J NATL CANCER I, V72, P455; DUNNINGTON DJ, 1984, THESIS U LONDON; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; ENGELKAMP D, 1992, BIOCHEMISTRY-US, V31, P10258, DOI 10.1021/bi00157a012; ENGELKAMP D, 1993, P NATL ACAD SCI USA, V90, P6547, DOI 10.1073/pnas.90.14.6547; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Flynn AM, 1996, BIOCHEM SOC T, V24, pS341, DOI 10.1042/bst024341s; FORD HL, 1995, ONCOGENE, V10, P1597; GENDLER SJ, 1990, INT J CANCER, V45, P431, DOI 10.1002/ijc.2910450309; GIBBS FEM, 1995, J HISTOCHEM CYTOCHEM, V43, P169, DOI 10.1177/43.2.7822773; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grigorian M, 1996, INT J CANCER, V67, P831, DOI 10.1002/(SICI)1097-0215(19960917)67:6<831::AID-IJC13>3.0.CO;2-4; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; JAMIESON S, 1990, INT J CANCER, V46, P1071, DOI 10.1002/ijc.2910460621; JAMIESON S, 1990, PATHOBIOLOGY, V58, P329, DOI 10.1159/000163605; JAMIESON S, 1987, THESIS U LONDON; KAMBY C, 1990, CANCER TREAT REV, V17, P37, DOI 10.1016/0305-7372(90)90075-Q; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MERLO GR, 1989, CANCER RES, V49, P6966; MICALE MA, 1994, HUM PATHOL, V25, P29, DOI 10.1016/0046-8177(94)90167-8; NEWMAN RA, 1979, J NATL CANCER I, V63, P1339; PANDIS N, 1992, GENE CHROMOSOME CANC, V5, P235, DOI 10.1002/gcc.2870050310; RAMAEKERS FCS, 1983, P NATL ACAD SCI-BIOL, V80, P2618, DOI 10.1073/pnas.80.9.2618; RUDLAND PS, 1993, HISTOL HISTOPATHOL, V8, P385; Sambrook J, 1989, MOL CLONING LAB MANU; SLOANE J, 1981, CANCER, V41, P1786; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1984, TRANSCRIPTION TRANSL, P1; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; WARBURTON MJ, 1982, J HISTOCHEM CYTOCHEM, V30, P667, DOI 10.1177/30.7.6179984; WARBURTON MJ, 1989, HISTOCHEM J, V21, P679, DOI 10.1007/BF01002489; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	51	104	109	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					465	473		10.1038/sj.onc.1201948	http://dx.doi.org/10.1038/sj.onc.1201948			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696040				2022-12-17	WOS:000075043000009
J	Vooijs, M; van der Valk, M; te Riele, H; Berns, A				Vooijs, M; van der Valk, M; te Riele, H; Berns, A			Flp-mediated tissue-specific inactivation of the retinoblastoma tumor suppressor gene in the mouse	ONCOGENE			English	Article						Rb inactivation; tissue-specific; Flp site-specific DNA recombination; pituitary gland tumor; tumor progression; mouse model for sporadic cancer	SITE-SPECIFIC RECOMBINATION; EMBRYONIC STEM-CELLS; LOCUS-CONTROL REGION; TRANSGENIC MICE; DNA RECOMBINATION; SWITCH RECOMBINATION; MAMMALIAN-CELLS; CRE RECOMBINASE; CHIMERIC MICE; IN-VIVO	The yeast-derived Flp-frt site-specific DNA recombination system was used to achieve pituitary-specific inactivation of the retinoblastoma (Rb) tumor suppressor gene. Whereas mice carrying only frt sites in both alleles of Iib remain tumor free, tumorigenesis ensues when the Flp recombinase is expressed. The rate of tumorigenesis in these mice depends both on the expression level of the Flp recombinase and on the presence of frt sites in one or both Rb alleles. This permitted a more accurate definition of the consecutive steps in pituitary tumorigenesis. Our study illustrates the potential of this approach for studying sporadic cancer in a defined mouse model.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Vooijs, Marc/K-3522-2019					Akagi K, 1997, NUCLEIC ACIDS RES, V25, P1766, DOI 10.1093/nar/25.9.1766; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; Betz UAK, 1996, CURR BIOL, V6, P1307, DOI 10.1016/S0960-9822(02)70717-3; Brown MA, 1997, TRENDS GENET, V13, P202, DOI 10.1016/S0168-9525(97)01132-3; Buchholz F, 1996, NUCLEIC ACIDS RES, V24, P4256, DOI 10.1093/nar/24.21.4256; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; Festenstein R, 1996, SCIENCE, V271, P1123, DOI 10.1126/science.271.5252.1123; FIERING S, 1993, P NATL ACAD SCI USA, V90, P8469, DOI 10.1073/pnas.90.18.8469; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HAMMER GD, 1990, MOL ENDOCRINOL, V4, P1689, DOI 10.1210/mend-4-11-1689; HARRISON DJ, 1995, ONCOGENE, V10, P1615; HARVEY M, 1995, CANCER RES, V55, P1146; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU NP, 1994, ONCOGENE, V9, P1021; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jacks T, 1996, ANNU REV GENET, V30, P603, DOI 10.1146/annurev.genet.30.1.603; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KNUDSON AG, 1993, NAT GENET, V5, P103, DOI 10.1038/ng1093-103; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LOW MJ, 1993, J BIOL CHEM, V268, P24967; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; ROBERTSON G, 1995, P NATL ACAD SCI USA, V92, P5371, DOI 10.1073/pnas.92.12.5371; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; Shoemaker AR, 1997, BBA-REV CANCER, V1332, pF25, DOI 10.1016/S0304-419X(96)00041-8; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; VALANCIUS V, 1991, MOL CELL BIOL, V11, P1402, DOI 10.1128/MCB.11.3.1402; VANDERLUGT N, 1991, GENE, V105, P263, DOI 10.1016/0378-1119(91)90161-4; Wang Y, 1996, P NATL ACAD SCI USA, V93, P3932, DOI 10.1073/pnas.93.9.3932; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	56	104	108	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	1998	17	1					1	12		10.1038/sj.onc.1202169	http://dx.doi.org/10.1038/sj.onc.1202169			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671308				2022-12-17	WOS:000074677800001
J	Chiariello, M; Visconti, R; Carlomagno, F; Melillo, RM; Bucci, C; de Franciscis, V; Fox, GM; Jing, SQ; Coso, OA; Gutkind, JS; Fusco, A; Santoro, M				Chiariello, M; Visconti, R; Carlomagno, F; Melillo, RM; Bucci, C; de Franciscis, V; Fox, GM; Jing, SQ; Coso, OA; Gutkind, JS; Fusco, A; Santoro, M			Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret	ONCOGENE			English	Article						tyrosine kinase; transformation; jun; MEN2; thyroid	GTP-BINDING PROTEINS; THYROID PAPILLARY CARCINOMAS; SIGNALING PATHWAY; GROWTH-FACTOR; HIRSCHSPRUNGS-DISEASE; ACTIVATION DOMAIN; RET/PTC1 ONCOGENE; ADAPTER PROTEINS; RESPONSE GENES; AP-1 ACTIVITY	The RET proto-oncogene encodes a functional receptor tyrosine kinase (Ret) for the Glial cell line Derived Neurotrophic Factor (GDNF). RET is involved in several neoplastic and non-neoplastic human diseases. Oncogenic activation of RET is detected in human papillary thyroid tumours and in multiple endocrine neoplasia type 2 syndromes. Inactivating mutations of RET have been associated to the congenital megacolon, i.e. Hirschprung's disease. In order to identify pathways that are relevant for Ret signalling to the nucleus, we have investigated its ability to induce the c-Jun NH2-terminal protein kinases (JNK). Here we show that triggering the endogenous Pet, expressed in PC12 cells, induces JNK activity; moreover, Ret is able to activate JNK either when transiently transfected in COS-1 cells or when stably expressed in NIH3T3 fibroblasts or in PC Cl 3 epithelial thyroid cells. JNK activation is dependent on the Pet kinase function, as a kinase-deficient RET mutant, associated with Hirschsprung's disease, fails to activate JNK. The pathway leading to the activation of JNK by RET is clearly divergent from that leading to the activation of ERK: substitution of the tyrosine 1062 of Pet, the Shc binding site, for phenylalanine abrogates ERK but not JNK activation. Experiments conducted with dominant negative mutants or with negative regulators demonstrate that JNK activation by Pet is mediated by Rho/Rac related small GTPases and, particularly, by Cdc42.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, CNR,Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Amgen Inc, Thousand Oaks, CA 91320 USA; NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Univ Reggio Calabria, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Amgen; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria	Santoro, M (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, CNR,Ctr Endocrinol & Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.		Gutkind, J. Silvio/J-1201-2016; Chiariello, Mario/O-3642-2014; Gutkind, J. Silvio/A-1053-2009; Bucci, Cecilia/F-6699-2012; melillo, rosa marina/O-5255-2015; Visconti, Roberta/C-5299-2009	Gutkind, J. Silvio/0000-0002-5150-4482; Chiariello, Mario/0000-0001-8434-5177; Bucci, Cecilia/0000-0002-6232-6183; Fusco, Alfredo/0000-0003-3332-5197; MELILLO, Rosa Marina/0000-0002-9233-5275; Visconti, Roberta/0000-0001-7613-3801				Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CALIFANO D, 1995, ONCOGENE, V11, P107; Califano D, 1996, P NATL ACAD SCI USA, V93, P7933, DOI 10.1073/pnas.93.15.7933; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GRIECO D, 1995, ONCOGENE, V11, P113; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; JANSSENTIMMEN U, 1989, GENE, V80, P325, DOI 10.1016/0378-1119(89)90296-5; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Santoro M, 1996, ONCOGENE, V12, P1821; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	71	104	108	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	1998	16	19					2435	2445		10.1038/sj.onc.1201778	http://dx.doi.org/10.1038/sj.onc.1201778			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627110	Green Accepted			2022-12-17	WOS:000073672300002
J	Altomare, DA; Lyons, GE; Mitsuuchi, Y; Cheng, JQ; Testa, JR				Altomare, DA; Lyons, GE; Mitsuuchi, Y; Cheng, JQ; Testa, JR			Akt2 mRNA is highly expressed in embryonic brown fat and the AKT2 kinase is activated by insulin	ONCOGENE			English	Article						Akt; serine-threonine kinase; oncogene; expression; insulin; phosphatidylinositol 3-kinase	RAC-PROTEIN KINASE; HUMAN PANCREATIC-CANCER; MOLECULAR-CLONING; PHOSPHATIDYLINOSITOL 3-KINASE; HEAT-SHOCK; C-AKT; ONCOGENE; CELLS; AMPLIFICATION; LOCALIZATION	Akt2 encodes a protein-serine/threonine kinase containing a pleckstrin homology domain characteristic of many signaling molecules. Although there has been extensive interest in the mechanism by which the closely-related Akt kinase participates in phosphatidylinositol S-kinase-mediated signaling, comparatively little is known regarding the expression and function of Akt2. This manuscript is the first to describe Akt2 mRNA expression in the developing mouse and the activation of AKT2 by insulin. These studies demonstrate that Akt2 is especially abundant in brown fat and, to a lesser extent, skeletal muscle and liver, tissues which are highly insulin-responsive and play a role in glucose metabolism. Endogenous Akt2 expression also is upregulated in fully-differentiated C2Cl2 myotubes and 3T3-L1 adipocytes, suggesting that these murine cell lines represent useful in vitro models for studies of Akt2 function. We show that HA-tagged AKTZ is activated in response to insulin stimulation in vitro and that activation of AKT2 is not induced in cells pretreated with wortmannin, an inhibitor of phosphatidylinositol 3-kinase. These data suggest that Akr2 expression is fundamental to the differentiated state of fat and muscle cells and that activation of AKT2 kinase by insulin is mediated through the phosphatidylinositol 3-kinase signaling pathway.	Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA; Univ Wisconsin, Sch Med, Dept Anat, Madison, WI 53706 USA	Fox Chase Cancer Center; University of Wisconsin System; University of Wisconsin Madison	Testa, JR (corresponding author), Fox Chase Canc Ctr, Dept Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NCI NIH HHS [CA-09035, R01 CA077429, P30 CA006927, CA-06927] Funding Source: Medline; NICHD NIH HHS [HD29471] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029471] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA077429, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALTOMARE DA, 1995, ONCOGENE, V11, P1055; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1993, ONCOGENE, V8, P745; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GUO K, 1995, MOL CELL BIOL, V15, P3823; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Klaus S, 1997, BIOESSAYS, V19, P215, DOI 10.1002/bies.950190307; Kobayashi M, 1996, NEUROSCI LETT, V213, P103, DOI 10.1016/0304-3940(96)12845-7; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P817, DOI 10.1006/bbrc.1994.2738; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; Matsuzaki H, 1996, FEBS LETT, V396, P305, DOI 10.1016/0014-5793(96)01120-9; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034	30	104	106	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2407	2411		10.1038/sj.onc.1201750	http://dx.doi.org/10.1038/sj.onc.1201750			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620559				2022-12-17	WOS:000073428000014
J	Takahashi, A; Hirata, H; Yonehara, S; Imai, Y; Lee, KK; Moyer, RW; Turner, PC; Mesner, PW; Okazaki, T; Sawai, H; Kishi, S; Yamamoto, K; Okuma, M; Sasada, M				Takahashi, A; Hirata, H; Yonehara, S; Imai, Y; Lee, KK; Moyer, RW; Turner, PC; Mesner, PW; Okazaki, T; Sawai, H; Kishi, S; Yamamoto, K; Okuma, M; Sasada, M			Affinity labeling displays the stepwise activation of ICE-related proteases by Fas, staurosporine, and CrmA-sensitive caspase-8	ONCOGENE			English	Article						apoptosis; apoptotic cell death; YV(bio)KD-aomk; serpin; Jurkat T cells	INTERLEUKIN-1-BETA CONVERTING-ENZYME; TUMOR NECROSIS FACTOR; POLY(ADP-RIBOSE) POLYMERASE; CELL-DEATH; MEDIATED APOPTOSIS; CYSTEINE PROTEASES; ICE/CED-3 PROTEASE; MOLECULAR-CLONING; INHIBITION; CLEAVAGE	The activation of multiple interleukin-1 beta converting enzyme-related proteases (caspases) in apoptotic mammalian cells raises questions as to whether the multiple active caspases have distinct roles in apoptotic execution as well as how these proteases are organized in apoptotic signaling pathways. Here we used an affinity-labeling agent, YV(bio)KD-aomk, to investigate the caspases activated during apoptotic cell death, YV(bio))KD-aomk identified sis distinct polypeptides corresponding to active caspases in Fas-stimulated Jurkat T cells, On staurosporine treatment, four polypeptides were detected, Competition experiments showed that the labelled caspases have distinct substrate preferences, Stepwise appearance of the labelled caspases in each cell death event was consistent with the view that the activated caspases are organized into protease cascades, Moreover, me found that stepwise activation of caspases similar to that induced by Fas ligation is triggered by exposing non-apoptotic Jurkat cell extracts to caspase-8 (MACH/FLICE/Mch5). Conversely, CrmA protein, a viral suppressor of Fas-induced apoptosis, inhibited the protease activity of caspase-8, Overall, these findings provide evidence that caspase-8, a CrmA-sensitive protease, is responsible for initiating the stepwise activation of multiple caspases in Fas-stimulated cells.	KYOTO UNIV,DEPT HEMATOL & ONCOL,GRAD SCH MED,KYOTO 606,JAPAN; KYOTO UNIV,DEPT VIRAL ONCOL,INST VIRUS RES,KYOTO 606,JAPAN; UNIV FLORIDA,COLL MED,DEPT MOL GENET & MICROBIOL,GAINESVILLE,FL 32610; MAYO CLIN & MAYO FDN,DIV ONCOL RES,ROCHESTER,MN 55905; JAPAN TOBACCO INC,PHARMACEUT BASIC RES LABS,YOKOHAMA,KANAGAWA 236,JAPAN; KYOTO UNIV,COLL MED TECHNOL,KYOTO 606,JAPAN	Kyoto University; Kyoto University; State University System of Florida; University of Florida; Mayo Clinic; Japan Tobacco Inc.; Kyoto University			Imai, Yuzuru/AAA-6472-2019	Imai, Yuzuru/0000-0003-2924-5231; Turner, Peter/0000-0002-7706-4593; Takahashi, Atsushi/0000-0003-3340-432X				Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Boise LH, 1996, SCIENCE, V274, P67, DOI 10.1126/science.274.5284.67; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; Henderson Peter J.F., 1993, P277; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KIKUCHI H, 1995, J BIOCHEM-TOKYO, V117, P936, DOI 10.1093/oxfordjournals.jbchem.a124823; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; Liu XS, 1996, J BIOL CHEM, V271, P13371, DOI 10.1074/jbc.271.23.13371; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1996, NAT MED, V2, P1306, DOI 10.1038/nm1296-1306; NETT MA, 1992, J IMMUNOL, V149, P3254; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Pai JT, 1996, P NATL ACAD SCI USA, V93, P5437, DOI 10.1073/pnas.93.11.5437; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Shi LF, 1996, P NATL ACAD SCI USA, V93, P11002, DOI 10.1073/pnas.93.20.11002; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; Takahashi A, 1996, J BIOL CHEM, V271, P32487, DOI 10.1074/jbc.271.51.32487; Takahashi A, 1997, EXP CELL RES, V231, P123, DOI 10.1006/excr.1996.3459; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TAKAHASHI A, 1997, CELL CYCLE REGULATIO; TAKAHASHI A, 1997, APOPTOSIS PHARM THER; Tatsuta T, 1996, J IMMUNOL, V157, P3949; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; THORNBERRY NA, 1997, IN PRESS APOPTOSIS P; Turner PC, 1995, VIROCEPTORS VIROKINE, P67; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	76	104	106	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2741	2752		10.1038/sj.onc.1201131	http://dx.doi.org/10.1038/sj.onc.1201131			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190889	Bronze			2022-12-17	WOS:A1997XD64300001
J	Arighi, E; Alberti, L; Torriti, F; Ghizzoni, S; Rizzetti, MG; Pelicci, G; Pasini, B; Bongarzone, I; Piutti, C; Pierotti, MA; Borrello, MG				Arighi, E; Alberti, L; Torriti, F; Ghizzoni, S; Rizzetti, MG; Pelicci, G; Pasini, B; Bongarzone, I; Piutti, C; Pierotti, MA; Borrello, MG			Identification of Shc docking site on Ret tyrosine kinase	ONCOGENE			English	Article						Ret; Shc; receptor tyrosine kinase; oncogene	PAPILLARY THYROID CARCINOMAS; SIGNAL-TRANSDUCTION; PROTO-ONCOGENE; INSULIN-RECEPTOR; DOMAIN; PROTEINS; PHOSPHOTYROSINE; PHOSPHORYLATION; PROTOONCOGENE; BINDING	The RET proto-oncogene encodes two isoforms of a receptor type tyrosine kinase which plays a role in neural crest and kidney development, Distinct germ-line mutations of RET have been associated inherited cancer syndromes MEN2A, MEN2B FMTC as well as with the congenital disorder Hirschsprung disease (HSCR), whereas somatic rearrangements (RET/PTCs) have been frequently detected in the papillary thyroid carcinoma, Despite these findings, suggesting a relevant role for RET product in development and neoplastic processes, little is known about the signalling triggered by this receptor, In this study, we have demonstrated that the transducing adaptor molecule She is recruited and activated by both Ret isoforms and by the rearranged cytoplasmatic Ret/ptc2 oncoproteins as well as by the membrane bound receptor activated by MEN2A or by MEN2B associated mutations, Moreover, our analysis has identified the Ret tyrosine residue and the She domains involved in the interaction, In fact, here we show that both the phosphotyrosine binding domains of She, PTB and SH2, interact with Ret/ptc2 in vitro, However, PTB domain binds 20 folds higher amount of Ret/ptc2 than SH2, The putative binding site for either SH2 and PTB domains has been identified as Tyr586 of Ret/ptc2 (Tyr1062 on proto-Ret). In keeping with this finding, by using RET/PTC2-Y586F mutant, we have demonstrated that this tyrosine residue, the last amino acid but one before the divergence of the two Ret isoforms, is the docking site for She.	IST NAZL TUMORI,DIV EXPT ONCOL A,I-20133 MILAN,ITALY; EUROPEAN INST ONCOL,I-20141 MILAN,ITALY; IST NAZL TUMORI,SCI DIRECT,I-20133 MILAN,ITALY; PHARMACIA & UPJOHN RES,ONCOL & IMMUNOL PRECLIN RES,I-20014 NERVIANO,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS European Institute of Oncology (IEO); Fondazione IRCCS Istituto Nazionale Tumori Milan			Bongarzone, Italia/B-9544-2017; Pasini, Barbara/AHI-2004-2022; Pierotti, Marco Alessandro/AAC-4728-2022; Pelicci, Giuliana/AAA-8921-2022; Borrello, Maria Grazia/C-3161-2017	Bongarzone, Italia/0000-0003-2530-9170; Pasini, Barbara/0000-0002-4373-1212; Pierotti, Marco Alessandro/0000-0002-7431-8332; Pelicci, Giuliana/0000-0003-0986-8255; Borrello, Maria Grazia/0000-0002-6854-2848				BALDARI CT, 1995, ONCOGENE, V10, P1141; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; Borrello MG, 1995, ONCOGENE, V11, P2419; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; DAMEN JE, 1993, BLOOD, V82, P2296; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DILWORTH S, 1993, NATURE, V367, P87; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LANZI C, 1992, ONCOGENE, V7, P2189; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pandit SD, 1996, J BIOL CHEM, V271, P5850, DOI 10.1074/jbc.271.10.5850; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; PONDER PAJ, 1995, CANCER SURV, V25, P195; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SEGATTO O, 1993, ONCOGENE, V8, P2105; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TRUB T, 1995, J BIOL CHEM, V270, P18205; TRUPP E, 1996, NATURE, V381, P785; TURCK CW, 1994, PEPTIDE RES, V7, P140; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHOU MM, 1996, J BIOL CHEM, V271, P31119	46	104	105	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					773	782		10.1038/sj.onc.1200896	http://dx.doi.org/10.1038/sj.onc.1200896			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047384				2022-12-17	WOS:A1997WJ11200003
J	SoferLevi, Y; Resnitzky, D				SoferLevi, Y; Resnitzky, D			Apoptosis induced by ectopic expression of cyclin D1 but not cyclin E	ONCOGENE			English	Article						cyclin D1; apoptosis; cell cycle	S-PHASE ENTRY; CELL-CYCLE; PROTEIN; GENE; RB; TRANSITION; LEADS; G(1); RETINOBLASTOMA; FIBROBLASTS	Deregulation of the pRb/E2F pathway leads to disruption of the normal control of the G(1)/S transition, and is associated with transformation. However, recent accumulated evidence suggest that under certain circumstances deregulation of the pRb/E2F pathway can also lead to apoptotic cell death. Apoptosis was shown to be induced by expression of DNA tumor virus oncoproteins, knockout of the rb gene, and expression of E2F from heterologous promoter. Since phosphorylation of pRb by G(1) cyclin-dependent kinases (Cdks) causes its inactivation, we examined whether deregulation of G(1) Cdks, also drives apoptosis. We have used rat fibroblast cell lines capable of expressing cyclin E, cyclin D1, or both, in an inducible manner, through a tetracycline responsive promoter. We show here that ectopic expression of cyclins D1 and E in rat fibroblasts under serum starvation, leads to deregulated entry into S phase, and subsequently to apoptotic cell death. Furthermore, expression of cyclin D1 alone is sufficient to provoke apoptosis, whereas expression of cyclin E alone during serum starvation does not. Moreover, expression of either cyclins D1 and E, and cyclin D1 alone, under serum starvation led to a significant increase in the fraction of hyper-phosphorylated pRb whereas cyclin E expression alone did not. These results demonstrate that expression of cyclin D1 from heterologous promoter leads to apoptosis in serum starved cells, which may be mediated by phosphorylation of pRb.	WEIZMANN INST SCI,DEPT MOL & CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; ASKEW DS, 1991, ONCOGENE, V6, P1915; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HINDS PW, 1995, CURR OPIN GENET DEV, V5, P79, DOI 10.1016/S0959-437X(95)90057-8; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Preston GA, 1996, MOL CELL BIOL, V16, P211; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RENZING J, 1995, ONCOGENE, V10, P1865; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8	43	104	105	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2431	2437						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957085				2022-12-17	WOS:A1996VX10800016
J	Spillman, MA; Bowcock, AM				Spillman, MA; Bowcock, AM			BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to estrogen	ONCOGENE			English	Article						estrogen; BRCA1; BRCA2; breast cancer; cycloheximide; cell line	SUSCEPTIBILITY GENE; OVARIAN-CANCER; EXPRESSION; RECEPTOR; PROLIFERATION; GROWTH; DIFFERENTIATION; CARCINOMAS; SEQUENCES; TISSUES	The steady state levels of BRCA1 and BRCA2 mRNAs were shown to be coordinately elevated by the steroid hormone estrogen but not progesterone in the human breast cancer cell lines BT-483 and MCF-7. Two different antiestrogens, trans 4'-hydroxytamoxifen and ICI 182,780, blocked the elevation of BRCA1 and BRCA2 mRNA levels, confirming that the effect was mediated through the estrogen receptor. In BT-483 cells, BRCA1 and BRCA2: mRNA levels were both elevated 18 to 24 h after estrogen stimulation, suggesting that the effect of estrogen was indirect. Cycloheximide blocked the estrogen effect implying that estrogen induces synthesis of an unidentified estrogen-responsive protein(s) that then result in the elevation of BRCA1 and BRCA2 mRNAs.	UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,MCDERMOTT CTR HUMAN GROWTH & DEV,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Bowcock, Anne/0000-0001-8691-9090	NCI NIH HHS [CA60650] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060650] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; DRIFE JO, 1986, ANN NY ACAD SCI, V464, P58, DOI 10.1111/j.1749-6632.1986.tb15993.x; DUBIK D, 1987, CANCER RES, V47, P6517; EASTON DF, 1993, AM J HUM GENET, V52, P678; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREEN S, 1990, J STEROID BIOCHEM, V37, P747, DOI 10.1016/0960-0760(90)90415-H; GUDAS JM, 1995, CANCER RES, V55, P4561; GUDAS JM, 1996, CELL GROWTH DIFFER, V7, P171; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; HECHT JR, 1994, AM J CLIN PATHOL, V102, pS25; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HORWITZ KB, 1978, J BIOL CHEM, V253, P2223; KASID A, 1987, J STEROID BIOCHEM, V27, P465, DOI 10.1016/0022-4731(87)90341-4; KING RJB, 1993, BREAST CANCER RES TR, V27, P3, DOI 10.1007/BF00683189; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; LASFARGUES EY, 1978, J NATL CANCER I, V61, P967; LONGACRE TA, 1986, AM J SURG PATHOL, V10, P382, DOI 10.1097/00000478-198606000-00003; MACLEAN HE, 1995, MOL CELL ENDOCRINOL, V112, P133, DOI 10.1016/0303-7207(95)03608-A; MARCUS JN, 1994, MONOGR NATL CANC I, V16, P23; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MAY FEB, 1986, CANCER RES, V46, P6034; MCGUIRE WL, 1992, J STEROID BIOCHEM, V43, P243, DOI 10.1016/0960-0760(92)90214-4; Merajver SD, 1995, CLIN CANCER RES, V1, P539; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1995, AM J HUM GENET, V56, P254; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; REW DA, 1992, BRIT J SURG, V79, P335, DOI 10.1002/bjs.1800790418; Sambrook J, 1989, MOL CLONING LAB MANU; SHI YE, 1994, HUM REPROD, V9, P162, DOI 10.1093/humrep/9.suppl_1.162; Spillman M. A., 1995, American Journal of Human Genetics, V57, pA5; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; WAKELING AE, 1991, CANCER RES, V51, P3867; WAKELING AE, 1989, J MOL ENDOCRINOL, V2, P255; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	40	104	107	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1639	1645						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895509				2022-12-17	WOS:A1996VM88700008
J	Hongo, A; DAmbrosio, C; Miura, M; Morrione, A; Baserga, R				Hongo, A; DAmbrosio, C; Miura, M; Morrione, A; Baserga, R			Mutational analysis of the mitogenic and transforming activities of the insulin-like growth factor I receptor	ONCOGENE			English	Article						IGF-1 receptor; transformation; growth; mutation	SIGNAL-TRANSDUCTION; TYROSINE KINASE; HEMATOPOIETIC-CELLS; RAS; TRANSPHOSPHORYLATION; PHOSPHORYLATION; OVEREXPRESSION; EXPRESSION; MECHANISM; IGF-1	The type 1 insulin-like growth factor receptor (IGF-IR) plays an important role in mitogenesis and transformation. It has been previously shown that mitogenic signaling and transforming activity of the IGF-IR can be dissociated: a receptor truncated at residue 1229 (C-terminus) is fully mitogenic, in terms of its response to IGF-I, but cannot transform 3T3-like cells that are devoid of endogenous IGF-IRs (R(-) cells). We have extended our mutational analysis of the C-terminus of the human IGF-IR, by stably transfecting several mutant receptors into R(-) cells, and testing the resulting cell lines for IGF-I-mediated mitogenic response and formation of colonies in soft agar. The results indicate that the transforming domain of the IGF-IR can be localized between residues 1245 and 1310, these sequences being not required for mitogenic signaling. Within these residues, there are at least two areas that contribute to the transforming activity of the receptor.	THOMAS JEFFERSON UNIV,JEFFERSON CANC CTR,PHILADELPHIA,PA 19107	Jefferson University					NIGMS NIH HHS [GM 33684] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BASERGA R, 1995, CANCER RES, V55, P249; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BURGAUD JL, 1995, BIOCHEM BIOPH RES CO, V214, P475, DOI 10.1006/bbrc.1995.2311; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; DEANGELIS T, 1995, J CELL PHYSIOL, V164, P214, DOI 10.1002/jcp.1041640126; DELALUNA S, 1988, GENE, V62, P121; FALCO JP, 1988, ONCOGENE, V2, P573; FARIA TN, 1994, J BIOL CHEM, V269, P13922; FRATTALI AL, 1993, J BIOL CHEM, V268, P7393; GRONBORG M, 1993, J BIOL CHEM, V268, P23435; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KALEBIC T, 1994, CANCER RES, V54, P5531; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KATO H, 1993, J BIOL CHEM, V268, P2655; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LANGLOIS WJ, 1995, ENDOCRINOLOGY, V136, P1978, DOI 10.1210/en.136.5.1978; LI SW, 1994, J BIOL CHEM, V269, P32558; LIU DL, 1993, J VIROL, V67, P6835, DOI 10.1128/JVI.67.11.6835-6840.1993; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; LONG L, 1995, CANCER RES, V55, P1006; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MIURA M, 1995, CANCER RES, V55, P663; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; MIURA M, 1994, CANCER RES, V54, P2472; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; TAOUIS M, 1994, J BIOL CHEM, V269, P27762; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427	63	104	105	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1231	1238						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649825				2022-12-17	WOS:A1996UC06700008
J	KENT, J; CORIAT, AM; SHARPE, PT; HASTIE, ND; VANHEYNINGEN, V				KENT, J; CORIAT, AM; SHARPE, PT; HASTIE, ND; VANHEYNINGEN, V			THE EVOLUTION OF WT1 SEQUENCE AND EXPRESSION PATTERN IN THE VERTEBRATES	ONCOGENE			English	Article						WILMS TUMOR; SEQUENCE COMPARISON; UROGENITAL DEVELOPMENT	WILMS-TUMOR GENE; DENYS-DRASH SYNDROME; KIDNEY DEVELOPMENT; UROGENITAL SYSTEM; DNA; MUTATIONS; PROTEIN; BINDING; NEPHROBLASTOMAS; SUBSTITUTION	WT1 is a Wilms' tumour predisposition gene, encoding a protein with four C-terminal Kruppel-type zinc fingers, which is also a major regulator of kidney and gonadal development, To pinpoint key regulatory domains involved in development and evolution of the vertebrate genitourinary system, we have isolated WT1 orthologues from all gnathostome classes. Partial nucleotide sequence from chick, alligator, Xenopus laevis and zebrafish reveals extensive conservation, Both the zinc fingers and the transregulatory domain exhibit a high level of similarity in all the species examined. However, of the two alternatively spliced regions only one, the three amino acid KTS insertion between zinc fingers 3 and 4, is found in species other than mammals, The 17 amino acid insertion at the C-terminal end of the transregulatory domain is present only in mammals, Residues with reported human pathological mutations are also unaltered across species, underlining their structural significance, Studies in chick and alligator reveal that the mammalian intermediate mesoderm expression pattern is conserved in birds and reptiles. A wider role in mesodermal differentiation is suggested by expression in some paraxial and lateral mesoderm derivatives.	WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; GUYS & ST THOMAS MED & DENT SCH,DEPT CRANIOFACIAL DEV,LONDON SE1 9RT,ENGLAND; MRC,LONDON W1N 4AL,ENGLAND	University of Edinburgh; University of London; King's College London			van Heyningen, Veronica/B-8039-2008; VAN HEYNINGEN, Veronica/GYE-0531-2022	van Heyningen, Veronica/0000-0003-0359-0141; Sharpe, Paul/0000-0003-2116-9561; Kent, Jill/0000-0001-7766-2473	Medical Research Council [MC_U127527199] Funding Source: Medline; MRC [MC_U127527199] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ARMSTRONG JF, 1992, MECH DEVELOP, V40, P85; BACKUS JW, 1991, NUCLEIC ACIDS RES, V19, P6781, DOI 10.1093/nar/19.24.6781; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BARDEESY N, 1994, GENOMICS, V21, P663, DOI 10.1006/geno.1994.1333; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BOYD AC, 1993, NUCLEIC ACIDS RES, V21, P817, DOI 10.1093/nar/21.4.817; Bruening Wendy, 1994, Seminars in Developmental Biology, V5, P333, DOI 10.1006/sedb.1994.1042; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DEHEINE V, 1962, J NATL CANCER I, V29, P41; DENYS P, 1967, ARCH FR PEDIATR, V24, P729; DRASH A, 1970, J PEDIATR-US, V76, P585, DOI 10.1016/S0022-3476(70)80409-7; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; ELKAN E, 1963, CANCER RES, V23, P1641; Ferguson M.W.J., 1987, P427; FERGUSON MWJ, 1982, NATURE, V296, P850, DOI 10.1038/296850a0; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HASTIE ND, 1994, ANNU REV GENET, V28, P523; JASMIN G, 1970, CANCER RES, V30, P321; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; JONES DSC, 1990, NUCLEIC ACIDS RES, V18, P7463; KENT GC, 1987, COMP ANATOMY VERTEBR; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LI WH, 1985, MOL BIOL EVOL, V2, P150; LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308; LITTLE MH, 1993, HUM MOL GENET, V2, P259, DOI 10.1093/hmg/2.3.259; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MADDEN SL, 1993, ONCOGENE, V8, P1713; MASAHITO P, 1992, CANCER RES, V52, P2575; MIERAU GW, 1987, ULTRASTRUCT PATHOL, V11, P313, DOI 10.3109/01913128709048329; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NEIUWKOOP PD, 1967, NORMAL TABLE XENOPUS; PARK S, 1993, CANCER RES, V53, P4757; PARK S, 1993, NAT GENET, V5, P363, DOI 10.1038/ng1293-363; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1991, ONCOGENE, V6, P2211; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Romanoff A., 1960, THE AVIAN EMBRYO, V1, P429; Saxen L., 1987, ORGANOGENESIS KIDNEY; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; SHARMA PM, 1992, CANCER RES, V52, P6407; SOUSSI T, 1990, ONCOGENE, V5, P945; UWANOGHO D, 1995, MECH DEVELOP, V49, P23, DOI 10.1016/0925-4773(94)00299-3; VANHEYNINGEN V, 1990, P NATL ACAD SCI USA, V87, P5383, DOI 10.1073/pnas.87.14.5383; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WASHABAUGH CH, 1993, J MORPHOL, V218, P107, DOI 10.1002/jmor.1052180109; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266; YOUNG JL, 1975, J PEDIATR-US, V86, P254, DOI 10.1016/S0022-3476(75)80484-7; 1991, PROGRAM MANUAL GCG P, V575	60	104	111	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1781	1792						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478606				2022-12-17	WOS:A1995TD09400013
J	MARTELLI, F; CENCIARELLI, C; SANTARELLI, G; POLIKAR, B; FELSANI, A; CARUSO, M				MARTELLI, F; CENCIARELLI, C; SANTARELLI, G; POLIKAR, B; FELSANI, A; CARUSO, M			MYOD INDUCES RETINOBLASTOMA GENE-EXPRESSION DURING MYOGENIC DIFFERENTIATION	ONCOGENE			English	Article							E2F TRANSCRIPTION FACTOR; LOOP-HELIX PROTEINS; DNA-BINDING; CELL-CYCLE; SUSCEPTIBILITY GENE; MOUSE MUSCLE; RB1 GENE; PRODUCT; DOMAIN; PHOSPHORYLATION	In skeletal muscle cells permanent withdrawal from the cell cycle is a prerequisite for terminal differentiation. The muscle-specific transcription factor MyoD can activate downstream muscle structural genes and myogenic conversion in many different cell types. It has been demonstrated that the product of the retinoblastoma susceptibility gene, with its growth-suppressive activity, is involved in the myogenic function of MyoD (Caruso et al., 1993; Gu et al., 1993). The present study characterises the modulation of retinoblastoma (Rb1) mRNA levels during myogenic differentiation of the murine C2 cell line and provides evidence that the muscle-specific regulatory factor MyoD enhances Rb1 gene transcription. We demonstrate that MyoD mediates the transactivation of a CAT construct whose expression is driven by the human Rbl gene promoter, and that this is not a consequence of direct binding of MyoD to an E-box DNA sequence motif present in the Rb1 promoter sequences. In addition we have tested the capability of several MyoD mutant proteins of inducing the Rb1 promoter CAT construct. Our results indicate that the MyoD function required for induction of Rb1 promoter activity is distinct from its myogenic function.	CNR,IST TECNOL BIOMED,I-00161 ROME,ITALY; IST REGINA ELENA STUDIO & CURA TUMORI,I-00158 ROME,ITALY; CNR,IST BIOL CELLULARE,I-00137 ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR)			Felsani, Armando/D-1784-2010; Martelli, Fabio/AAL-3788-2020; Caruso, Maurizia/G-8895-2013	Felsani, Armando/0000-0001-8851-6295; Martelli, Fabio/0000-0002-8624-7738; Caruso, Maurizia/0000-0001-5445-6343; Cenciarelli, Carlo/0000-0001-7480-4608	Telethon [298] Funding Source: Medline	Telethon(Fondazione Telethon)		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN TJ, 1990, J CELL BIOL, V110, P929, DOI 10.1083/jcb.110.4.929; CARUSO M, 1993, ONCOGENE, V8, P267; CARUSO M, 1990, EMBO J, V9, P947, DOI 10.1002/j.1460-2075.1990.tb08193.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COPPOLA JA, 1990, ONCOGENE, V5, P1731; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAUBAS P, 1985, NUCLEIC ACIDS RES, V13, P4623, DOI 10.1093/nar/13.13.4623; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HEINTZ N, 1991, BIOCHIM BIOPHYS ACTA, V1088, P327, DOI 10.1016/0167-4781(91)90122-3; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LARSON DE, 1989, BIOCHIM BIOPHYS ACTA, V1009, P177, DOI 10.1016/0167-4781(89)90098-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; MAIONE R, 1994, CELL GROWTH DIFFER, V5, P231; MILLER JB, 1990, J CELL BIOL, V111, P1149, DOI 10.1083/jcb.111.3.1149; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PAGANO M, 1992, ONCOGENE, V7, P1681; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PLUMB M, 1983, NUCLEIC ACIDS RES, V11, P2391, DOI 10.1093/nar/11.8.2391; RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SCHUBERT D, 1974, J CELL BIOL, V61, P398, DOI 10.1083/jcb.61.2.398; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SLACK RS, 1993, ONCOGENE, V8, P1585; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; STAPPERT J, 1992, NUCLEIC ACIDS RES, V20, P624, DOI 10.1093/nar/20.3.624; STEIN G S, 1992, Current Opinion in Cell Biology, V4, P166, DOI 10.1016/0955-0674(92)90028-B; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; TANG A, 1989, ONCOGENE, V4, P401; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TAUBMAN MB, 1989, J CELL BIOL, V108, P1799, DOI 10.1083/jcb.108.5.1799; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TROUCHE D, 1993, NATURE, V363, P79, DOI 10.1038/363079a0; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEYDERT A, 1985, P NATL ACAD SCI USA, V82, P7183, DOI 10.1073/pnas.82.21.7183; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZACKSENHAUS E, 1993, ONCOGENE, V8, P2343	69	104	104	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3579	3590						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970718				2022-12-17	WOS:A1994PT39200021
J	SCHLUTER, V; MEYER, M; HOFSCHNEIDER, PH; KOSHY, R; CASELMANN, WH				SCHLUTER, V; MEYER, M; HOFSCHNEIDER, PH; KOSHY, R; CASELMANN, WH			INTEGRATED HEPATITIS-B VIRUS-X AND 3' TRUNCATED PRES/S-SEQUENCES DERIVED FROM HUMAN HEPATOMAS ENCODE FUNCTIONALLY ACTIVE TRANSACTIVATORS	ONCOGENE			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; CELLULAR FLANKING SEQUENCES; LONG TERMINAL REPEAT; NF-KAPPA-B; TRANS-ACTIVATION; GENE-EXPRESSION; MAMMALIAN-CELLS; DNA INTEGRATION; VIRAL ENHANCERS; LIVER-CANCER	The hepatitis B virus (HBV) frequently integrates into hepatocellular genomic DNA during viral infection. Transcriptional transactivators encoded by integrated HBV X and 3' truncated preS/S sequences are known to stimulate gene expression from homologous and heterologous promoters. Here we demonstrate that 21 of 26 (81%) hepatocellular carcinoma tissues/cell lines contain coding sequences for at least one of the two known transactivators. Pour integrated X and three preS/S transactivator sequences contained in five isolates from three hepatoma primary tissues or cell lines were used as examples to prove functionality of the encoded transactivators, In one case, where both X and preS/S sequences were present, dissection of X and preS/S transactivator sequences showed independent functionality. The investigation of X- and preS/S-specific RNA and protein expression revealed the existence of. carboxyterminally truncated viral-cellular fusion proteins that were able to stimulate gene expression from the c-fos proto-oncogene promoter five- to ten-fold. These results demonstrate that structurally intact HBV transactivator sequences are integrated in the majority of HBV-associated HCCs/hepatoma cell lines. In all tested examples integrated DNAs had retained functionality as transactivators. This data thereby support indirectly the hypothesis of a possible involvement of HBV transactivators in liver cell proliferation and hepatocarcinogenesis.	MAX PLANCK INST BIOCHEM,DEPT VIRUS RES,D-82152 MARTINSRIED,GERMANY; UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT MED 2,D-81366 MUNICH,GERMANY	Max Planck Society; University of Munich								ARII M, 1992, ONCOGENE, V7, P397; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BUDKOWSKA A, 1986, J MED VIROL, V20, P111, DOI 10.1002/jmv.1890200204; CASELMANN WH, 1990, P NATL ACAD SCI USA, V87, P2970, DOI 10.1073/pnas.87.8.2970; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHOO KB, 1986, VIROLOGY, V154, P405, DOI 10.1016/0042-6822(86)90467-8; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DESCHAMPS J, 1985, SCIENCE, V230, P1174, DOI 10.1126/science.3865371; DIAMANTIS ID, 1992, J HEPATOL, V15, P400, DOI 10.1016/0168-8278(92)90077-3; FAUSTO N, 1989, LAB INVEST, V60, P4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEITELSON MA, 1989, GASTROENTEROLOGY, V98, P1071; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FUJIYAMA A, 1983, NUCLEIC ACIDS RES, V11, P4601, DOI 10.1093/nar/11.13.4601; GARCIA M, 1993, P NATL ACAD SCI USA, V90, P89, DOI 10.1073/pnas.90.1.89; GERBES AL, 1993, J HEPATOL, V19, P312, DOI 10.1016/S0168-8278(05)80587-2; GEY GO, 1952, CANCER RES, V12, P264; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAEF E, 1994, ONCOGENE, V9, P81; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HILGER C, 1991, J VIROL, V65, P4284, DOI 10.1128/JVI.65.8.4284-4291.1991; HINO O, 1991, P NATL ACAD SCI USA, V88, P9248, DOI 10.1073/pnas.88.20.9248; HINO O, 1989, J VIROL, V63, P2638, DOI 10.1128/JVI.63.6.2638-2643.1989; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; KAM W, 1982, VIRAL HEPATITIS, P809; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOCH S, 1984, NUCLEIC ACIDS RES, V17, P6871; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUER U, 1992, J VIROL, V66, P5284, DOI 10.1128/JVI.66.9.5284-5289.1992; LAUER U, 1994, HEPATOLOGY, V19, P23, DOI 10.1002/hep.1840190106; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MATSUMOTO H, 1988, INT J CANCER, V42, P1, DOI 10.1002/ijc.2910420102; MEYER M, 1992, EMBO J, V11, P2991, DOI 10.1002/j.1460-2075.1992.tb05369.x; MEYER M, 1992, HEPATOLOGY, V15, P665, DOI 10.1002/hep.1840150419; MIZUSAWA H, 1985, P NATL ACAD SCI USA, V82, P208, DOI 10.1073/pnas.82.1.208; NAGAYA T, 1987, GENE DEV, V1, P773, DOI 10.1101/gad.1.8.773; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; NATOLI G, 1992, VIROLOGY, V187, P663, DOI 10.1016/0042-6822(92)90469-6; OGATA N, 1990, HEPATOLOGY, V11, P1017, DOI 10.1002/hep.1840110617; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QUADE K, 1992, J GEN VIROL, V73, P179, DOI 10.1099/0022-1317-73-1-179; RITTER SE, 1991, VIROLOGY, V182, P841, DOI 10.1016/0042-6822(91)90626-M; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHAUL Y, 1984, J VIROL, V51, P776, DOI 10.1128/JVI.51.3.776-787.1984; SHIH CH, 1987, J VIROL, V61, P3491, DOI 10.1128/JVI.61.11.3491-3498.1987; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SLAGLE BL, 1991, CANCER RES, V51, P49; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; Szmuness W, 1978, Prog Med Virol, V24, P40; TAKADA S, 1990, J VIROL, V64, P822, DOI 10.1128/JVI.64.2.822-828.1990; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; TOKINO T, 1991, J VIROL, V65, P6761, DOI 10.1128/JVI.65.12.6761-6764.1991; TWU JS, 1989, P NATL ACAD SCI USA, V86, P2046, DOI 10.1073/pnas.86.6.2046; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG WL, 1991, CANCER RES, V51, P4971; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; YAGINUMA K, 1985, P NATL ACAD SCI USA, V82, P4458, DOI 10.1073/pnas.82.13.4458; YAGINUMA K, 1987, J VIROL, V61, P1808, DOI 10.1128/JVI.61.6.1808-1813.1987; YAMAMOTO S, 1993, BIOCHEM BIOPH RES CO, V192, P111, DOI 10.1006/bbrc.1993.1388; YAMAMOTO S, 1993, BIOCHEM BIOPH RES CO, V197, P1209, DOI 10.1006/bbrc.1993.2605; ZAHM P, 1988, ONCOGENE, V3, P169; ZHOU DX, 1990, J VIROL, V64, P4025, DOI 10.1128/JVI.64.8.4025-4028.1990; ZHOU YZ, 1988, J VIROL, V62, P4224, DOI 10.1128/JVI.62.11.4224-4231.1988	74	104	110	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3335	3344						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936659				2022-12-17	WOS:A1994PM65800028
J	JIANG, D; SRINIVASAN, A; LOZANO, G; ROBBINS, PD				JIANG, D; SRINIVASAN, A; LOZANO, G; ROBBINS, PD			SV40 T-ANTIGEN ABROGATES P53-MEDIATED TRANSCRIPTIONAL ACTIVITY	ONCOGENE			English	Article							LARGE TUMOR-ANTIGEN; WILD-TYPE P53; RETINOBLASTOMA SUSCEPTIBILITY GENE; HUMAN PAPILLOMAVIRUS TYPE-16; TRANSFORMED-CELLS; SV40-TRANSFORMED CELLS; CELLULAR PROTEIN; SUPPRESSOR GENE; BINDING-SITE; MUTANT P53	Recent evidence suggests that the tumor-suppressor protein p53 functions as a transcriptional regulator to control cell proliferation. An interaction with p53 is required for SV40 T antigen to transform primary cells; however, the effect of T antigen binding on p53 function is not known. In order to determine if an interaction with T antigen results in loss of p53-mediated transcriptional activity, we have used vectors expressing either a p53-GAL4 fusion protein or a wild-type p53 protein in transient co-transfection assays with T-antigen expression vectors. We have demonstrated that coexpression of T antigen significantly reduces both p53-GAL4-mediated transcription from a GAL4-dependent CAT reporter and p53-mediated transcription from a consensus p53 binding site in vivo. Moreover, T antigen was able to reduce binding of p53-GAL4 to its GAL4 binding sequence in gel shift experiments in vitro. These observed activities of T antigen were all dependent upon a functional p53-binding domain. In addition, coexpression of human papillomavirus type 18 E6 protein, able to bind to p53, was able to significantly reduce p53-mediated transcription. These results suggest that an interaction of certain viral oncoproteins with p53 results in loss of transcriptional activity of p53, a function that is important for maintaining normal cell growth.	UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261; UNIV TEXAS,MD ANDERSEN CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030; UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [R01CA055227] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55227] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARTEK J, 1990, ONCOGENE, V5, P893; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARK R, 1983, MOL CELL BIOL, V3, P220, DOI 10.1128/MCB.3.2.220; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LANFORD RE, 1988, VIROLOGY, V167, P72, DOI 10.1016/0042-6822(88)90055-4; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OROURKE RW, 1990, ONCOGENE, V5, P1829; OSIFCHIN N, 1993, UNPUB J BIOL CHEM; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PRIVES C, 1991, COLD SH Q B, V56, P227; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J., 1989, MOL CLONING LAB MANU; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; STEPHENS T, 1991, J NIH RES, V3, P34; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	63	104	107	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2805	2812						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378089				2022-12-17	WOS:A1993LX34300022
J	CUPP, C; TAYLOR, JP; KHALILI, K; AMINI, S				CUPP, C; TAYLOR, JP; KHALILI, K; AMINI, S			EVIDENCE FOR STIMULATION OF THE TRANSFORMING GROWTH-FACTOR-BETA-1 PROMOTER BY HIV-1 TAT IN CELLS DERIVED FROM CNS	ONCOGENE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNE-DEFICIENCY-SYNDROME; NECROSIS-FACTOR-ALPHA; LONG-TERMINAL REPEAT; MONONUCLEAR PHAGOCYTES; AIDS PATIENTS; INDEPENDENT ACTIVATION; KAPOSIS-SARCOMA; BRAIN CULTURES; GLIAL-CELLS	Infection by human immunodeficiency virus type 1 (HIV-1), the etiologic agent of the acquired immunodeficiency syndrome (AIDS), is often complicated with a high incidence of neurologic disorders. It is believed that HIV-1, in addition to infecting both macroglial and microglial cells, may influence the expression of several strategic genes of uninfected neighboring or latently infected brain cells. It is suspected that the viral-encoded transregulatory protein, Tat, facilitates cross-communications between these cells. In support of this concept, earlier studies demonstrated that Tat is released from the infected cells, and has the capacity to be taken up by the uninfected cells and exert its biological activity on the responsive gene. Recent studies in several laboratories suggest the involvement of Tat in altering the expression of a limited number of cellular regulatory factors which, in turn, may mediate the altered physiology of the cells. In this communication, we demonstrate the ability of the HIV-1 Tat protein to increase expression of transforming growth factor beta1 (TGF-beta1), a cytokine with potent immunosuppressive activity, in human astrocytic glial cells. Implications of the Tat-mediated induction of TGF-beta1 expression and cytokine involvement in the regulation of immune response and central nervous system (CNS) pathology are discussed.	THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOLEC BIOL,JEFFERSON INST MOLEC MED,MOLEC NEUROVIROL SECT,PHILADELPHIA,PA 19107	Jefferson University			Taylor, J. Paul/N-2482-2018	Taylor, J. Paul/0000-0002-5794-0349				BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BREEN EC, 1990, J IMMUNOL, V144, P480; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; CHOWDHURY M, 1993, ONCOGENE, V8, P887; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; HELLAND DE, 1991, J VIROL, V65, P4547, DOI 10.1128/JVI.65.8.4547-4549.1991; JEYAPAUL J, 1991, ONCOGENE, V6, P1507; KAMINE J, 1991, P NATL ACAD SCI USA, V88, P8510, DOI 10.1073/pnas.88.19.8510; KEKOW J, 1990, P NATL ACAD SCI USA, V87, P8321, DOI 10.1073/pnas.87.21.8321; KHALILI K, 1986, J VIROL, V60, P935, DOI 10.1128/JVI.60.3.935-942.1986; KIM SJ, 1989, J BIOL CHEM, V264, P402; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; LAZDINS JK, 1991, J IMMUNOL, V147, P1201; LAZDINS JK, 1991, RES VIROLOGY, V142, P239, DOI 10.1016/0923-2516(91)90063-9; LEPEZUNIGA JL, 1987, J CLIN MICROBIOL, V25, P1695, DOI 10.1128/JCM.25.9.1695-1700.1987; LOTZ M, 1990, FASEB J, V4, P1861; MARCUZZI A, 1992, J VIROL, V66, P4228, DOI 10.1128/JVI.66.7.4228-4232.1992; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MERRILL JE, 1992, J VIROL, V66, P2217, DOI 10.1128/JVI.66.4.2217-2225.1992; MERRILL JE, 1989, J VIROL, V63, P4404, DOI 10.1128/JVI.63.10.4404-4408.1989; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; OKAMOTO T, 1990, VIROLOGY, V177, P606, DOI 10.1016/0042-6822(90)90526-W; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SASTRY KJ, 1990, J BIOL CHEM, V265, P20091; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; TAYLOR JP, 1992, P NATL ACAD SCI USA, V89, P9617, DOI 10.1073/pnas.89.20.9617; TORNATORE C, 1991, J VIROL, V65, P6094, DOI 10.1128/JVI.65.11.6094-6100.1991; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WAHL SM, 1991, J EXP MED, V173, P981, DOI 10.1084/jem.173.4.981; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WRIGHT SC, 1988, J IMMUNOL, V141, P99	44	104	104	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2231	2236						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336945				2022-12-17	WOS:A1993LP17100024
J	DEPPERT, W; BUSCHHAUSENDENKER, G; PATSCHINSKY, T; STEINMEYER, K				DEPPERT, W; BUSCHHAUSENDENKER, G; PATSCHINSKY, T; STEINMEYER, K			CELL-CYCLE CONTROL OF P53 IN NORMAL (3T3) AND CHEMICALLY TRANSFORMED (METH-A) MOUSE CELLS .2. REQUIREMENT FOR CELL-CYCLE PROGRESSION	ONCOGENE			English	Article									UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,W-2000 HAMBURG 13,GERMANY; UNIV HAMBURG,INST MOLEK BIOL,W-2000 HAMBURG 13,GERMANY	Heinrich Pette Institute; University of Hamburg; University of Hamburg								ARAI N, 1986, MOL CELL BIOL, V6, P323; BENCHIMOL S, 1989, NATO ASI SERIES H, V34, P409; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DEPPERT W, 1989, NATO ASI SERIES H, V34, P399; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; JENKINS JR, 1988, ONCOGENE HDB, P403; KACZMAREK L, 1986, EXP CELL RES, V132, P105; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; PATSCHINSKY T, 1990, ONCOGENE, V5, P1071; PINHASI O, 1984, MOL CELL BIOL, V4, P2180, DOI 10.1128/MCB.4.10.2180; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; SHOHAT O, 1987, ONCOGENE, V1, P277; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STEINMEYER K, 1988, ONCOGENE, V3, P501	25	104	105	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1990	5	11					1701	1706						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EL401	2267136				2022-12-17	WOS:A1990EL40100013
J	SHIRSAT, NV; PIGNOLO, RJ; KREIDER, BL; ROVERA, G				SHIRSAT, NV; PIGNOLO, RJ; KREIDER, BL; ROVERA, G			A MEMBER OF THE RAS GENE SUPERFAMILY IS EXPRESSED SPECIFICALLY IN T-CELLS, B-CELLS AND MYELOID HEMATOPOIETIC-CELLS	ONCOGENE			English	Note									WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANDERSON PS, 1987, MOL CELL BIOL, V7, P3620, DOI 10.1128/MCB.7.10.3620; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KRAUS M, 1981, J CANCER RES CLIN, V100, P149, DOI 10.1007/BF00403364; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MEYER WH, 1983, BLOOD, V62, P308; OLOFSSON B, 1988, ONCOGENE, V3, P231; PIZON V, 1988, ONCOGENE, V3, P201; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WOODS D, 1984, FOCUS, V6, P1; YARAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394; ZAHRAOUI A, 1988, NUCLEIC ACIDS RES, V16, P1204, DOI 10.1093/nar/16.3.1204	27	104	110	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1990	5	5					769	772						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	2189110				2022-12-17	WOS:A1990DG37400019
J	NIMER, SD; GASSON, JC; HU, K; SMALBERG, I; WILLIAMS, JL; CHEN, ISY; ROSENBLATT, JD				NIMER, SD; GASSON, JC; HU, K; SMALBERG, I; WILLIAMS, JL; CHEN, ISY; ROSENBLATT, JD			ACTIVATION OF THE GM-CSF PROMOTER BY HTLV-I AND HTLV-II TAX PROTEINS	ONCOGENE			English	Article									JONSSON COMPREHENS CANC CTR,LOS ANGEES,CA 90024	UCLA Jonsson Comprehensive Cancer Center	NIMER, SD (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV HEMATOL ONCOL,42-121 CHS,LOS ANGELES,CA 90024, USA.				NATIONAL CANCER INSTITUTE [R01CA040163, P01CA032737] Funding Source: NIH RePORTER; NCI NIH HHS [CA 018011, CA 40163, CA 32737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAYNEY DW, 1983, ANN INTERN MED, V98, P144, DOI 10.7326/0003-4819-98-2-144; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CANN AJ, 1988, ONCOGENE, V3, P123; CHAN JY, 1986, P NATL ACAD SCI USA, V83, P8669, DOI 10.1073/pnas.83.22.8669; CHEN ISY, 1985, SCIENCE, V230, P570, DOI 10.1126/science.2996140; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DEPPER JM, 1984, J IMMUNOL, V133, P1691; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; GALLO RC, 1983, CANCER RES, V43, P3892; GOLDE DW, 1988, INFLAMMATION BASIC P, P253; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAY PW, 1982, NATURE, V298, P859, DOI 10.1038/298859a0; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3653, DOI 10.1073/pnas.84.11.3653; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KITADO H, 1987, SCIENCE, V235, P901, DOI 10.1126/science.3027896; KRONKE M, 1985, SCIENCE, V228, P1215, DOI 10.1126/science.2988127; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; MIYATAKE S, 1985, EMBO J, V4, P2561, DOI 10.1002/j.1460-2075.1985.tb03971.x; MUNKER R, 1986, NATURE, V323, P79, DOI 10.1038/323079a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAGASHIMA K, 1986, J VIROL, V60, P394, DOI 10.1128/JVI.60.2.394-399.1986; NIMER SD, 1988, MOL CELL BIOL, V8, P1979, DOI 10.1128/MCB.8.5.1979; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; ROSEN CA, 1985, P NATL ACAD SCI USA, V82, P6502, DOI 10.1073/pnas.82.19.6502; ROSENBLATT JD, 1988, SCIENCE, V240, P916, DOI 10.1126/science.2834826; ROSENBLATT JD, 1986, NEW ENGL J MED, V315, P372, DOI 10.1056/NEJM198608073150606; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHANNON MF, 1988, P NATL ACAD SCI USA, V85, P674, DOI 10.1073/pnas.85.3.674; SHIMA H, 1986, FEBS LETT, V209, P289, DOI 10.1016/0014-5793(86)81129-2; SHIMOTOHNO K, 1984, P NATL ACAD SCI-BIOL, V81, P1079, DOI 10.1073/pnas.81.4.1079; SHIMOTOHNO K, 1985, P NATL ACAD SCI USA, V82, P3101, DOI 10.1073/pnas.82.10.3101; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SLAMON DJ, 1984, SCIENCE, V226, P61, DOI 10.1126/science.6089351; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; STANLEY E, 1985, EMBO J, V4, P2569, DOI 10.1002/j.1460-2075.1985.tb03972.x; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; UCHIYAMA T, 1985, J CLIN INVEST, V76, P446, DOI 10.1172/JCI111992; WACHSMAN W, 1986, SEMIN HEMATOL, V23, P246; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; ZUCALI JR, 1986, J CLIN INVEST, V77, P1857, DOI 10.1172/JCI112512	53	104	104	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1989	4	6					671	676						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2660069				2022-12-17	WOS:A1989AA66000001
J	Hu, YB; Yan, C; Mu, L; Mil, YL; Zhao, H; Hu, H; Li, XL; Tao, DD; Wu, YQ; Gong, JP; Qin, JC				Hu, Y-B; Yan, C.; Mu, L.; Mil, Y-L; Zhao, H.; Hu, H.; Li, X-L; Tao, D-D; Wu, Y-Q; Gong, J-P; Qin, J-C			Exosomal Wnt-induced dedifferentiation of colorectal cancer cells contributes to chemotherapy resistance	ONCOGENE			English	Article							STEM-CELLS; SELF-RENEWAL; BETA-CATENIN; EXPRESSION; PROGRESSION; HETEROGENEITY; EQUILIBRIUM; ENVIRONMENT; FIBROBLASTS; POPULATION	Cancer stem cells (CSCs) are inherently resistant to chemotherapy, and CSCs in chemotherapy-failed recurrent tumors are enriched; however, the cellular origin of chemotherapy-induced CSC enrichment remains unclear. Communication with stromal fibroblasts may induce cancer cell dedifferentiation into CSCs through secreted factors. We recently demonstrated that fibroblast-derived exosomes promote chemoresistance in colorectal cancer (CRC). Here, we report that fibroblasts confer CRC chemoresistance via exosome-induced reprogramming (dedifferentiation) of bulk CRC cells to phenotypic and functional CSCs. At the molecular level, we provided evidence that the major reprogramming regulators in fibroblast-exosomes are Wnts. Exosomal Wnts were found to increase Wnt activity and drug resistance in differentiated CRC cells, and inhibiting Wnt release diminished this effect in vitro and in vivo. Together, our results indicate that exosomal Wnts derived from fibroblasts could induce the dedifferentiation of cancer cells to promote chemoresistance in CRC, and suggest that interfering with exosomal Wnt signaling may help to improve chemosensitivity and the therapeutic window.	[Hu, Y-B; Yan, C.; Mu, L.; Mil, Y-L; Zhao, H.; Hu, H.; Wu, Y-Q; Gong, J-P; Qin, J-C] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Surg, Wuhan 430030, Hubei, Peoples R China; [Hu, Y-B; Yan, C.; Mu, L.; Mil, Y-L; Zhao, H.; Hu, H.; Li, X-L; Tao, D-D; Gong, J-P; Qin, J-C] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Mol Med Ctr, Wuhan 430030, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology	Gong, JP; Qin, JC (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Surg, Wuhan 430030, Hubei, Peoples R China.; Gong, JP; Qin, JC (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Mol Med Ctr, Wuhan 430030, Hubei, Peoples R China.	jpgong@tjh.tjmu.edu.cn; jcqin@tjh.tjmu.edu.cn		Qin, Jichao/0000-0002-2961-7624	National Nature Science Foundation of China [81272660, 81572894, 81702948]; China Postdoctoral Science Foundation [2016M602313]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	The authors thank animal facility of Tongji Medical College for animal experiments. We apologize to the colleagues whose work was not cited owing to space constraint. This work was supported by National Nature Science Foundation of China (81272660, 81572894, 81702948), China Postdoctoral Science Foundation funded project (2016M602313).	Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Azmi AS, 2013, CANCER METAST REV, V32, P623, DOI 10.1007/s10555-013-9441-9; Bissell MJ, 2005, CANCER CELL, V7, P17, DOI 10.1016/j.ccr.2004.12.013; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chalamalasetty RB, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1381; Chen Y, 2017, ONCOGENE, V36, P4692, DOI 10.1038/onc.2017.100; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gregorieff A, 2005, GASTROENTEROLOGY, V129, P626, DOI 10.1053/j.gastro.2005.06.007; Gross JC, 2012, NAT CELL BIOL, V14, P1036, DOI 10.1038/ncb2574; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Hawinkels LJAC, 2014, ONCOGENE, V33, P97, DOI 10.1038/onc.2012.536; HONIG MG, 1986, J CELL BIOL, V103, P171, DOI 10.1083/jcb.103.1.171; Hu YB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125625; Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418; Janda CY, 2017, NATURE, V545, P234, DOI 10.1038/nature22306; Jeter CR, 2009, STEM CELLS, V27, P993, DOI 10.1002/stem.29; Koch R, 2014, BLOOD, V123, P2189, DOI 10.1182/blood-2013-08-523886; Kowal J, 2014, CURR OPIN CELL BIOL, V29, P116, DOI 10.1016/j.ceb.2014.05.004; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Lin L, 2011, CANCER RES, V71, P7226, DOI 10.1158/0008-5472.CAN-10-4660; Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110; Lotti F, 2013, J EXP MED, V210, P2851, DOI 10.1084/jem.20131195; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Marjanovic ND, 2013, CLIN CHEM, V59, P168, DOI 10.1373/clinchem.2012.184655; McAllister SS, 2014, NAT CELL BIOL, V16, P717, DOI 10.1038/ncb3015; Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714; Mincheva-Nilsson L, 2016, CURR PROTOC IMMUNOL, V115; Mittelbrunn M, 2012, NAT REV MOL CELL BIO, V13, P328, DOI 10.1038/nrm3335; Mu L, 2017, ONCOTARGET, V8, DOI DOI 10.18632/ONCOTARGET.22.392; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Qin JC, 2012, CELL STEM CELL, V10, P556, DOI 10.1016/j.stem.2012.03.009; Ratajczak J, 2006, LEUKEMIA, V20, P847, DOI 10.1038/sj.leu.2404132; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Saha S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13096; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007; Tammela T, 2017, NATURE, V545, P355, DOI 10.1038/nature22334; Tang DG, 2012, CELL RES, V22, P457, DOI 10.1038/cr.2012.13; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; TRAINER DL, 1988, INT J CANCER, V41, P287, DOI 10.1002/ijc.2910410221; Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Webber J, 2010, CANCER RES, V70, P9621, DOI 10.1158/0008-5472.CAN-10-1722; Wicha MS, 2014, NAT MED, V20, P14, DOI 10.1038/nm.3434; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wilson BJ, 2011, CANCER RES, V71, P5307, DOI 10.1158/0008-5472.CAN-11-0221; Yan C, 2016, ONCOTARGET, V7, P80700, DOI 10.18632/oncotarget.13029	53	103	110	1	40	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1951	1965		10.1038/s41388-018-0557-9	http://dx.doi.org/10.1038/s41388-018-0557-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30390075	Green Published, hybrid			2022-12-17	WOS:000461164400012
J	O'Brien, KP; Khan, S; Gilligan, KE; Zafar, H; Lalor, P; Glynn, C; O'Flatharta, C; Ingoldsby, H; Dockery, P; De Bhulbh, A; Schweber, JR; St John, K; Leahy, M; Murphy, JM; Gallagher, WM; O'Brien, T; Kerin, MJ; Dwyer, RM				O'Brien, K. P.; Khan, S.; Gilligan, K. E.; Zafar, H.; Lalor, P.; Glynn, C.; O'Flatharta, C.; Ingoldsby, H.; Dockery, P.; De Bhulbh, A.; Schweber, J. R.; St John, K.; Leahy, M.; Murphy, J. M.; Gallagher, W. M.; O'Brien, T.; Kerin, M. J.; Dwyer, R. M.			Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379	ONCOGENE			English	Article							BREAST-CANCER; CYCLOOXYGENASE-2 EXPRESSION; STROMAL CELLS; EXOSOMES; METASTASIS; MECHANISM; APOPTOSIS; THERAPY; MIR-379; BRAIN	Adult Mesenchymal Stem Cells (MSCs) have a well-established tumor-homing capacity, highlighting potential as tumor-targeted delivery vehicles. MSCs secrete extracellular vesicle (EV)-encapsulated microRNAs, which play a role in intercellular communication. The aim of this study was to characterize a potential tumor suppressor microRNA, miR-379, and engineer MSCs to secrete EVs enriched with miR-379 for in vivo therapy of breast cancer. miR-379 expression was significantly reduced in lymph node metastases compared to primary tumor tissue from the same patients. A significant reduction in the rate of tumor formation and growth in vivo was observed in T47D breast cancer cells stably expressing miR-379. In more aggressive HER2-amplified HCC-1954 cells, HCC-379 and HCC-NTC tumor growth rate in vivo was similar, but increased tumor necrosis was observed in HCC-379 tumors. In response to elevated miR-379, COX-2 mRNA and protein was also significantly reduced in vitro and in vivo. MSCs were successfully engineered to secrete EVs enriched with miR-379, with the majority found to be of the appropriate size and morphology of exosomal EVs. Administration of MSC-379 or MSC-NTC cells, or EVs derived from either cell population, resulted in no adverse effects in vivo. While MSC-379 cells did not impact tumor growth, systemic administration of cell-free EVs enriched with miR-379 was demonstrated to have a therapeutic effect. The data presented support miR-379 as a potent tumor suppressor in breast cancer, mediated in part through regulation of COX-2. Exploiting the tumor-homing capacity of MSCs while engineering the cells to secrete EVs enriched with miR-379 holds exciting potential as an innovative therapy for metastatic breast cancer.	[O'Brien, K. P.; Khan, S.; Gilligan, K. E.; Glynn, C.; De Bhulbh, A.; Schweber, J. R.; St John, K.; Kerin, M. J.; Dwyer, R. M.] Natl Univ Ireland Galway, Lambe Inst Translat Res, Sch Med, Discipline Surg, Galway, Ireland; [Zafar, H.] Natl Univ Ireland Galway, Sch Med, Cardiovasc Res Ctr Galway, Galway, Ireland; [Lalor, P.; Dockery, P.] Natl Univ Ireland Galway, Sch Med, Discipline Anat, Galway, Ireland; [O'Flatharta, C.; Murphy, J. M.; O'Brien, T.] Natl Univ Ireland Galway, CURAM, Regenerat Med Inst REMEDI, Galway, Ireland; [Ingoldsby, H.] Univ Hosp Galway, Div Anat Pathol, Galway, Ireland; [Leahy, M.] Natl Univ Ireland Galway, Sch Phys, Tissue Opt & Microcirculat Imaging Grp, Galway, Ireland; [Gallagher, W. M.] Univ Coll Dublin, UCD Conway Inst, UCD Sch Biomol & Biomed Sci, Canc Biol & Therapeut Lab, Dublin, Ireland	Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway; University College Dublin	Dwyer, RM (corresponding author), Natl Univ Ireland Galway, Lambe Inst Translat Res, Sch Med, Discipline Surg, Galway, Ireland.	roisin.dwyer@nuigalway.ie	Dwyer, Roisin M/C-6654-2013; leahy, martin j/C-8383-2009	Dwyer, Roisin M/0000-0002-5854-0339; leahy, martin j/0000-0003-1558-4574; Gilligan, Katie/0000-0001-5669-293X; Gallagher, William/0000-0002-4307-5999; Kerin, Michael/0000-0003-4164-5561; O'Brien, Killian/0000-0002-4340-6858; Dockery, Peter/0000-0001-5103-6589	Irish Cancer Society BREAST-PREDICT collaborative cancer research center [CCRGAL13]; Irish Research Council (IRC) Postgraduate Scholarship [GOIPG/2016/978]; IRC Enterprise Partnership Scheme Postdoctoral Research Fellowship [EPSPD/2016/20]; Wellcome Trust biomedical vacation scholarship; Health Research Board summer scholarship [SS-2015-1365]; Science Foundation Ireland from the European Union's 7th Framework Programme [09/SRC/B1794, 12/RI/2338, HEALTH-2007-B-223298]; charity Breast Cancer Research	Irish Cancer Society BREAST-PREDICT collaborative cancer research center; Irish Research Council (IRC) Postgraduate Scholarship(Irish Research Council for Science, Engineering and Technology); IRC Enterprise Partnership Scheme Postdoctoral Research Fellowship; Wellcome Trust biomedical vacation scholarship(Wellcome Trust); Health Research Board summer scholarship; Science Foundation Ireland from the European Union's 7th Framework Programme(Science Foundation Ireland); charity Breast Cancer Research	KPO'B and SK: Irish Cancer Society BREAST-PREDICT collaborative cancer research center CCRGAL13; KEG: Irish Research Council (IRC) Postgraduate Scholarship GOIPG/2016/978; HZ: IRC Enterprise Partnership Scheme Postdoctoral Research Fellowship EPSPD/2016/20. JRS and KSJ: Wellcome Trust biomedical vacation scholarship; ADB: Health Research Board summer scholarship SS-2015-1365. This research was also supported by Science Foundation Ireland grants 09/SRC/B1794 and 12/RI/2338, funding from the European Union's 7th Framework Programme under grant agreement no. HEALTH-2007-B-223298 (PurStem), and the charity Breast Cancer Research.	Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Calin GA, 2008, P NATL ACAD SCI USA, V105, P5166, DOI 10.1073/pnas.0800121105; Chen J S, 2016, Zhonghua Yi Xue Za Zhi, V96, P1450, DOI 10.3760/cma.j.issn.0376-2491.2016.18.013; Chen JS, 2016, CANCER LETT, V375, P73, DOI 10.1016/j.canlet.2016.02.043; Chen KH, 2016, ONCOTARGET, V7, P74537, DOI 10.18632/oncotarget.12902; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Clancy C, 2016, CANCER BIOMARK, V17, P427, DOI 10.3233/CBM-160659; Costa C, 2002, J CLIN PATHOL, V55, P429, DOI 10.1136/jcp.55.6.429; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Davoren PA, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-76; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Dwyer RM, 2007, CLIN CANCER RES, V13, P5020, DOI 10.1158/1078-0432.CCR-07-0731; Dwyer RM, 2011, STEM CELLS, V29, P1149, DOI 10.1002/stem.665; Gilligan KE, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061122; Gururajan M, 2014, CLIN CANCER RES, V20, P6559, DOI 10.1158/1078-0432.CCR-14-1784; Heijblom M, 2015, SCI REP-UK, V5, DOI 10.1038/srep11778; Hole P, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-2101-8; Holmes MD, 2011, BREAST CANCER RES TR, V130, P657, DOI 10.1007/s10549-011-1651-7; Hwang DW, 2015, SCI REP-UK, V5, DOI 10.1038/srep15636; Kamerkar S, 2017, NATURE, V546, P498, DOI 10.1038/nature22341; Katakowski M, 2013, CANCER LETT, V335, P201, DOI 10.1016/j.canlet.2013.02.019; Khan S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068753; Laddha SV, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-10; Lai CP, 2014, ACS NANO, V8, P483, DOI 10.1021/nn404945r; Li K, 2017, YONSEI MED J, V58, P234, DOI 10.3349/ymj.2017.58.1.234; Li Z, 2017, J CELL MOL MED, V21, P315, DOI 10.1111/jcmm.12966; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maguire Mark T, 2010, Rehab Manag, V23, P20; Martin FT, 2010, BREAST CANCER RES TR, V124, P317, DOI 10.1007/s10549-010-0734-1; McNeill RE, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-107; Mellin-Olsen J, 2010, EUR J ANAESTH, V27, P592, DOI 10.1097/EJA.0b013e32833b1adf; Momin Eric N., 2010, Current Immunology Reviews, V6, P137; Munoz JL, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.60; Ohno S, 2013, MOL THER, V21, P185, DOI 10.1038/mt.2012.180; Pollari S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037361; Ramasamy R, 2007, LEUKEMIA, V21, P304, DOI 10.1038/sj.leu.2404489; Ristimaki A, 2002, CANCER RES, V62, P632; Roggan A, 1999, J BIOMED OPT, V4, P36, DOI 10.1117/1.429919; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Singh-Ranger G, 2002, EUR J SURG ONCOL, V28, P729, DOI 10.1053/ejso.2002.1329; Spaeth E, 2008, GENE THER, V15, P730, DOI 10.1038/gt.2008.39; Squillaro T, 2016, CELL TRANSPLANT, V25, P829, DOI 10.3727/096368915X689622; Tian YH, 2014, BIOMATERIALS, V35, P2383, DOI 10.1016/j.biomaterials.2013.11.083; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Van Deun J, 2017, NAT METHODS, V14, P228, DOI 10.1038/nmeth.4185; Xu Z, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3443793; Yamamoto K, 2014, ONCOL REP, V32, P2365, DOI 10.3892/or.2014.3481; Yang TZ, 2015, PHARM RES-DORDR, V32, P2003, DOI 10.1007/s11095-014-1593-y; Yeo RWY, 2013, ADV DRUG DELIVER REV, V65, P336, DOI 10.1016/j.addr.2012.07.001	51	103	105	2	27	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	16					2137	2149		10.1038/s41388-017-0116-9	http://dx.doi.org/10.1038/s41388-017-0116-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GD5ZV	29367765	Green Submitted			2022-12-17	WOS:000430589000005
J	Lin, C; Wang, Y; Wang, Y; Zhang, S; Yu, L; Guo, C; Xu, H				Lin, C.; Wang, Y.; Wang, Y.; Zhang, S.; Yu, L.; Guo, C.; Xu, H.			Transcriptional and posttranscriptional regulation of HOXA13 by lncRNA HOTTIP facilitates tumorigenesis and metastasis in esophageal squamous carcinoma cells	ONCOGENE			English	Article							LONG NONCODING RNA; EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCELLULAR-CARCINOMA; LUNG-CANCER; PANCREATIC-CANCER; GENE-EXPRESSION; DOWN-REGULATION; POOR-PROGNOSIS; PROLIFERATION; PROGRESSION	The long non-coding RNA, HOTTIP, has an important role in tumorigenesis. It is known that HOTTIP regulates HOX gene family; however, its regulatory mechanism in esophageal squamous cell carcinoma (ESCC) remains elusive. In this study, we investigated the role of HOTTIP in ESCC and observed that HOTTIP/HOXA13 was upregulated in ESCC and promoted cell proliferation and metastasis in vivo and in vitro. Interestingly, harboring a miR-30b-binding site, HOTTIP as a molecular sponge mainly regulated miR-30b level in the nucleus and modulated the repression of HOXA13 mediated by miR-30b in the cytoplasm, resulting in the positive HOTTIP/HOXA13 correlation. In addition, HOTTIP upregulated snail1 by competitively binding miR-30b, subsequently promoting epithelial-mesenchymal transition (EMT) and invasion. HOTTIP directly bound the adaptor protein WDR5 and drove histone H3 lysine 4 trimethylation and HOXA13 gene transcription in ESCC cells. In conclusion, our findings indicated that HOTTIP modulated HOXA13 at both the transcriptional and posttranscriptional levels in ESCC cells and HOTTIP-miR-30b-HOXA13 axis may serve as potential diagnostic markers or drug targets for ESCC therapies.	[Lin, C.; Wang, Y.; Wang, Y.; Zhang, S.; Yu, L.; Guo, C.; Xu, H.] China Pharmaceut Univ, Ctr Peptide Drug Discovery & Dev, Dept Engn Res, Nanjing, Jiangsu, Peoples R China; [Lin, C.; Wang, Y.; Wang, Y.; Zhang, S.; Yu, L.; Guo, C.; Xu, H.] China Pharmaceut Univ, Dept State Key Lab Nat Med, Nanjing, Jiangsu, Peoples R China	China Pharmaceutical University; China Pharmaceutical University	Guo, C; Xu, H (corresponding author), China Pharmaceut Univ, Ctr Peptide Drug Discovery & Dev, Dept Engn Res, Nanjing, Jiangsu, Peoples R China.; Guo, C; Xu, H (corresponding author), China Pharmaceut Univ, Dept State Key Lab Nat Med, Nanjing, Jiangsu, Peoples R China.	guocha@cpu.edu.cn; 13913925346@126.com			State Key Laboratory of Natural Medicines in China [SKLNMBZ201403]; National Science and Technology Major Projects of New Drugs in China [2012ZX09103301-004, 2014ZX09508007]; National Natural Science Foundation of China [30873073]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Central University Basic Scientific Research Business Expenses [2016ZPY009]	State Key Laboratory of Natural Medicines in China; National Science and Technology Major Projects of New Drugs in China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Central University Basic Scientific Research Business Expenses	We are very grateful to Nanjing General Hospital for providing ESCC tissues and Professor Yifeng Zhou who provided ESCC cell lines. This work was supported by Project Program of State Key Laboratory of Natural Medicines in China (no. SKLNMBZ201403); National Science and Technology Major Projects of New Drugs in China (2012ZX09103301-004 and 2014ZX09508007); National Natural Science Foundation of China (30873073); the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); the Central University Basic Scientific Research Business Expenses (2016ZPY009). We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of the manuscript.	Chen FJ, 2013, MOL CARCINOGEN, V52, P908, DOI 10.1002/mc.21944; Cheng CW, 2012, BREAST CANCER RES TR, V134, P1081, DOI 10.1007/s10549-012-2034-4; Cheng YT, 2015, ONCOTARGET, V6, P10840, DOI 10.18632/oncotarget.3450; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Deng HP, 2015, CELL MOL BIOL, V61, P34; Engreitz JM, 2016, NATURE, V539, P452, DOI 10.1038/nature20149; Feng TB, 2016, ONCOTARGET, V7, P16205, DOI 10.18632/oncotarget.7578; Gagnon KT, 2014, CELL REP, V6, P211, DOI 10.1016/j.celrep.2013.12.013; Garcia-Fernandez J, 2005, NAT REV GENET, V6, P881, DOI 10.1038/nrg1723; Gaziel-Sovran A, 2011, CANCER CELL, V20, P104, DOI 10.1016/j.ccr.2011.05.027; Ge YX, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005726; George J, 2015, SEMIN LIVER DIS, V35, P63, DOI 10.1055/s-0034-1397350; Gu ZD, 2009, CANCER RES, V69, P4969, DOI 10.1158/0008-5472.CAN-08-4546; Guo B, 2011, CUAJ-CAN UROL ASSOC, V5, pE129, DOI DOI 10.5489/CUAJ.09118; Hajjari M, 2015, CANCER BIOL MED, V12, P1, DOI 10.7497/j.issn.2095-3941.2015.0006; Huang JW, 2013, CANCER SCI, V104, P1609, DOI 10.1111/cas.12291; Jin KZ, 2015, DRUG DES DEV THER, V9, P1247, DOI 10.2147/DDDT.S77597; Kao CJ, 2014, ONCOGENE, V33, P2495, DOI 10.1038/onc.2013.200; Kwak SY, 2015, FEBS J, V282, P1512, DOI 10.1111/febs.13238; Li W, 2014, GASTROENTEROLOGY, V146, P1714, DOI 10.1053/j.gastro.2014.03.002; Li WY, 2014, CANCER CELL, V25, P557, DOI 10.1016/j.ccr.2014.04.014; Li ZH, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0442-z; Liu ZH, 2016, ONCOTARGET, V7, P25350, DOI 10.18632/oncotarget.8129; Lu ZF, 2015, BLOOD, V126, P1730, DOI 10.1182/blood-2015-07-657999; Mohamadkhani A, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.18794; Pan F, 2014, INT J CLIN EXP PATHO, V7, P2838; Quagliata L, 2014, HEPATOLOGY, V59, P911, DOI 10.1002/hep.26740; Sugihara H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081839; Sun XL, 2017, J CELL PHYSIOL, V232, P625, DOI 10.1002/jcp.25466; Tsang FHC, 2015, LIVER INT, V35, P1597, DOI 10.1111/liv.12746; Wang Guang-Yu, 2014, Bull Cancer, V101, pE27, DOI 10.1684/bdc.2014.2023; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Wei Y, 2014, J BIOL CHEM, V289, P10270, DOI 10.1074/jbc.C113.541417; Wu YT, 2015, CURR PHARM DESIGN, V21, P5017, DOI 10.2174/1381612821666150724115625; Xie H, 2015, BIOCHEM BIOPH RES CO, V463, P569, DOI 10.1016/j.bbrc.2015.05.096; Xu YP, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-173; Yao J, 2010, HEPATOLOGY, V51, P846, DOI 10.1002/hep.23443; Ye ZX, 2015, INT J GYNECOL CANCER, V25, P1574, DOI 10.1097/IGC.0000000000000546; Yu HS, 2014, ONCOL LETT, V7, P799, DOI 10.3892/ol.2013.1754; Zhang H, 2015, TUMOR BIOL, V36, P8805, DOI 10.1007/s13277-015-3645-2; Zhong K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-703; Zhong ZP, 2014, MOL MED REP, V10, P2575, DOI 10.3892/mmr.2014.2494; Zhou XY, 2015, CELL PHYSIOL BIOCHEM, V36, P1440, DOI 10.1159/000430309	43	103	107	2	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2017	36	38					5392	5406		10.1038/onc.2017.133	http://dx.doi.org/10.1038/onc.2017.133			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FH7PJ	28534516				2022-12-17	WOS:000411382100006
J	Huang, B; Song, JH; Cheng, Y; Abraham, JM; Ibrahim, S; Sun, Z; Ke, X; Meltzer, SJ				Huang, B.; Song, J. H.; Cheng, Y.; Abraham, J. M.; Ibrahim, S.; Sun, Z.; Ke, X.; Meltzer, S. J.			Long non-coding antisense RNA KRT7-AS is activated in gastric cancers and supports cancer cell progression by increasing KRT7 expression	ONCOGENE			English	Article							NATURAL ANTISENSE; ESOPHAGEAL ADENOCARCINOMA; COLORECTAL-CANCER; GENE-EXPRESSION; MESSENGER-RNA; TRANSCRIPT; H19; OVEREXPRESSION; PROLIFERATION; EVOLUTION	Alterations in long non-coding RNAs (lncRNAs) are associated with human carcinogenesis. One group of lncRNAs, which are antisense in orientation to coding mRNAs (ASs), have been recently described in cancers but are poorly understood. We sought to identify ASs involved in human gastric cancer (GC) and to elucidate their mechanisms of action in carcinogenesis. We performed massively parallel RNA sequencing in GCs and matched normal tissues, as well as in GC-derived and normal gastric epithelial cell lines. One AS, designated Homo sapiens keratin 7 (KRT7-AS), was selected due to its marked upregulation and concordant expression with its cognate sense counterpart, KRT7, in GC tissues and cell lines. KRT7-AS formed an RNA-RNA hybrid with KRT7 and controlled KRT7 expression at both the mRNA and the post-transcriptional levels. Moreover, forced overexpression of the KRT7-overlapping region (OL) of KRT7-AS (but not its non-KRT7-OL portions) increased keratin 7 protein levels in cells. Finally, forced overexpression of full-length KRT7-AS or OL KRT7-AS (but not its non-KRT7-OL regions) promoted GC cell proliferation and migration. We conclude that lncRNA KRT7-AS promotes GC, at least in part, by increasing KRT7 expression.	[Huang, B.] Tongji Univ, Sch Med, Tongji Hosp, Dept Gastroenterol, Shanghai, Peoples R China; [Huang, B.; Song, J. H.; Cheng, Y.; Abraham, J. M.; Ibrahim, S.; Sun, Z.; Ke, X.; Meltzer, S. J.] Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, 1503 E Jefferson St,Room 112, Baltimore, MD 21287 USA; [Huang, B.; Song, J. H.; Cheng, Y.; Abraham, J. M.; Ibrahim, S.; Sun, Z.; Ke, X.; Meltzer, S. J.] Johns Hopkins Univ, Sch Med, Dept Oncol, Div Gastroenterol, 1503 E Jefferson St,Room 112, Baltimore, MD 21287 USA; [Huang, B.; Song, J. H.; Cheng, Y.; Abraham, J. M.; Ibrahim, S.; Sun, Z.; Ke, X.; Meltzer, S. J.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, 1503 E Jefferson St,Room 112, Baltimore, MD 21287 USA	Tongji University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Meltzer, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, 1503 E Jefferson St,Room 112, Baltimore, MD 21287 USA.; Meltzer, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Div Gastroenterol, 1503 E Jefferson St,Room 112, Baltimore, MD 21287 USA.; Meltzer, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, 1503 E Jefferson St,Room 112, Baltimore, MD 21287 USA.	smeltzer@jhmi.edu			NIH [CA190040, CA85069, DK087454, CA133012, CA173390]; China Scholarship Council (CSC); Joint Johns Hopkins University-Tongji University of China student scholarship; NATIONAL CANCER INSTITUTE [R01CA190040, R21CA173390, R01CA146799, U01CA085069, R01CA133012] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK087454] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); China Scholarship Council (CSC)(China Scholarship Council); Joint Johns Hopkins University-Tongji University of China student scholarship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	SJM, the Harry and Betty Myerberg/Thomas R Hendrix Professor of Gastroenterology, is also an American Cancer Society Clinical Research Professor and was supported by NIH grants CA190040, CA85069, DK087454, CA133012, CA173390, and Sidney Kimmel Comprehensive Cancer Center Core facilities. BH was supported by an Exchange Scholarship from the China Scholarship Council (CSC). BH is a recipient of a Joint Johns Hopkins University-Tongji University of China student scholarship. BH was supported by an Exchange Scholarship from the China Scholarship Council (CSC).	Alam T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109443; Balbin OA, 2015, GENOME RES, V25, P1068, DOI 10.1101/gr.180596.114; Byun HM, 2007, CANCER RES, V67, P10753, DOI 10.1158/0008-5472.CAN-07-0329; Carrieri C, 2012, NATURE, V491, P454, DOI 10.1038/nature11508; Cayre A, 2003, BREAST CANCER RES, V5, pR223, DOI 10.1186/bcr652; Cunnington MS, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000899; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Faghihi MA, 2008, NAT MED, V14, P723, DOI 10.1038/nm1784; Faghihi MA, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-5-r56; Faghihi MA, 2009, NAT REV MOL CELL BIO, V10, P637, DOI 10.1038/nrm2738; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Harbaum L, 2011, HISTOPATHOLOGY, V59, P225, DOI 10.1111/j.1365-2559.2011.03694.x; Houghton J, 2005, GASTROENTEROLOGY, V128, P1567, DOI 10.1053/j.gastro.2005.03.037; Iacobucci I, 2011, LEUKEMIA RES, V35, P1052, DOI 10.1016/j.leukres.2011.02.020; Kanduc D, 2002, J VIROL, V76, P7040, DOI 10.1128/JVI.76.14.7040-7048.2002; Karantza V, 2011, ONCOGENE, V30, P127, DOI 10.1038/onc.2010.456; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; Kimura T, 2013, CELL MOL LIFE SCI, V70, P1451, DOI 10.1007/s00018-012-1216-x; Lambaudie E, 2014, ANTICANCER RES, V34, P177; Liang WC, 2015, ONCOTARGET, V6, P22513, DOI 10.18632/oncotarget.4154; Medrzycki M, 2014, CANCER RES, V74, P6463, DOI 10.1158/0008-5472.CAN-13-2922; Michael DR, 2011, J BIOL CHEM, V286, P19523, DOI 10.1074/jbc.M111.233916; Munroe SH, 2006, CELL MOL LIFE SCI, V63, P2102, DOI 10.1007/s00018-006-6070-2; Nishizawa M, 2015, FRONT BIOSCI-LANDMRK, V20, P1, DOI 10.2741/4297; Oue N, 2012, ANN SURG ONCOL, V19, P1902, DOI 10.1245/s10434-011-2175-4; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Pujal J, 2009, FASEB J, V23, P1366, DOI 10.1096/fj.08-115576; Salameh A, 2015, P NATL ACAD SCI USA, V112, P8403, DOI 10.1073/pnas.1507882112; Sandilands A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064404; Saxonov S, 2006, P NATL ACAD SCI USA, V103, P1412, DOI 10.1073/pnas.0510310103; Schmid M, 2015, CELL REP, V12, P128, DOI 10.1016/j.celrep.2015.06.008; Span PN, 2011, ENDOCR-RELAT CANCER, V18, P323, DOI 10.1530/ERC-10-0184; Su WY, 2012, CELL RES, V22, P1374, DOI 10.1038/cr.2012.57; Tan JY, 2015, GENOME RES, V25, P655, DOI 10.1101/gr.181974.114; Thrash-Bingham CA, 1999, JNCI-J NATL CANCER I, V91, P143, DOI 10.1093/jnci/91.2.143; Villegas VE, 2015, INT J MOL SCI, V16, P3251, DOI 10.3390/ijms16023251; Wahlestedt C, 2006, DRUG DISCOV TODAY, V11, P503, DOI 10.1016/j.drudis.2006.04.013; Wight M, 2013, ESSAYS BIOCHEM, V54, P91, DOI [10.1042/bse0540091, 10.1042/BSE0540091]; Wu WJ, 2013, GASTROENTEROLOGY, V144, P956, DOI 10.1053/j.gastro.2013.01.019; Xi QL, 2014, INT J BIOCHEM CELL B, V55, P242, DOI 10.1016/j.biocel.2014.09.012; Yamaguchi N, 2001, LANCET ONCOL, V2, P88, DOI 10.1016/S1470-2045(00)00225-4; Yang F, 2012, FEBS J, V279, P3159, DOI 10.1111/j.1742-4658.2012.08694.x; Yang X, 2014, GUT, V63, P881, DOI 10.1136/gutjnl-2013-305266; Yap KL, 2010, MOL CELL, V38, P662, DOI 10.1016/j.molcel.2010.03.021; Zhou XY, 2015, SCI REP-UK, V5, DOI 10.1038/srep11516	45	103	106	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4927	4936		10.1038/onc.2016.25	http://dx.doi.org/10.1038/onc.2016.25			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26876208	Green Accepted			2022-12-17	WOS:000383330700010
J	Halaoui, R; McCaffrey, L				Halaoui, R.; McCaffrey, L.			Rewiring cell polarity signaling in cancer	ONCOGENE			English	Review							PROTEIN-KINASE-C; PEUTZ-JEGHERS-SYNDROME; LKB1 TUMOR-SUPPRESSOR; EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN-PAPILLOMAVIRUS E6; LYMPH-NODE METASTASIS; APICAL-BASAL POLARITY; BREAST-CANCER; SOMATIC MUTATIONS; DISCS LARGE	Disrupted cell polarity is a feature of epithelial cancers. The Crumbs, Par and Scribble polarity complexes function to specify and maintain apical and basolateral membrane domains, which are essential to organize intracellular signaling pathways that maintain epithelial homeostasis. Disruption of apical-basal polarity proteins facilitates rewiring of oncogene and tumor suppressor signaling pathways to deregulate proliferation, apoptosis, invasion and metastasis. Moreover, apical-basal polarity integrates intracellular signaling with the microenvironment by regulating metabolic signaling, extracellular matrix remodeling and tissue level organization. In this review, we discuss recent advances in our understanding of how polarity proteins regulate diverse signaling pathways throughout cancer progression from initiation to metastasis.	[Halaoui, R.; McCaffrey, L.] McGill Univ, Dept Oncol, Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ, Canada; [Halaoui, R.; McCaffrey, L.] McGill Univ, Div Expt Med, Montreal, PQ, Canada	McGill University; McGill University	McCaffrey, L (corresponding author), McGill Univ, Dept Oncol, Rosalind & Morris Goodman Canc Res Ctr, 1160 Pine Ave, Montreal, PQ, Canada.	luke.mccaffrey@mcgill.ca			Terry Fox Research Institute [1009]; Canadian Institutes of Health Research [MOP-119482]; McGill Integrated Cancer Research Training Program; Canderel Studentship award	Terry Fox Research Institute; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); McGill Integrated Cancer Research Training Program; Canderel Studentship award	Research by LM is supported by grants from the Terry Fox Research Institute (1009) and Canadian Institutes of Health Research (MOP-119482). LM is an FRQS Research Scholar. RH is supported by the McGill Integrated Cancer Research Training Program and a Canderel Studentship award.	Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Akhtar N, 2013, NAT CELL BIOL, V15, P17, DOI 10.1038/ncb2646; Al-Saad S, 2008, BRIT J CANCER, V99, P1476, DOI 10.1038/sj.bjc.6604713; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Anastas JN, 2012, ONCOGENE, V31, P3696, DOI 10.1038/onc.2011.528; Andrade-Vieira R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056567; Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042; Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Atwood SX, 2013, NATURE, V494, P484, DOI 10.1038/nature11889; Avizienyte E, 1998, CANCER RES, V58, P2087; Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Bambang IF, 2013, ONCOGENE, V32, P1240, DOI 10.1038/onc.2012.149; Bao YJ, 2011, J BIOCHEM, V149, P361, DOI 10.1093/jb/mvr021; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Beggs AD, 2010, GUT, V59, P975, DOI 10.1136/gut.2009.198499; Benton R, 2003, CELL, V115, P691, DOI 10.1016/S0092-8674(03)00938-3; Bergstralh DT, 2013, CURR BIOL, V23, P1707, DOI 10.1016/j.cub.2013.07.017; Bergstralh DT, 2012, ESSAYS BIOCHEM, V53, P129, DOI [10.1042/BSE0530129, 10.1042/bse0530129]; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x; Boggiano JC, 2012, DEV CELL, V22, P695, DOI 10.1016/j.devcel.2012.03.013; Bostwick DG, 2012, HISTOPATHOLOGY, V60, P4, DOI 10.1111/j.1365-2559.2011.04007.x; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598; Callahan CA, 2004, GENE DEV, V18, P2724, DOI 10.1101/gad.1221804; Carthew RW, 2005, CURR OPIN GENET DEV, V15, P358, DOI 10.1016/j.gde.2005.06.002; Cavatorta AL, 2004, INT J CANCER, V111, P373, DOI 10.1002/ijc.20275; Chatterjee S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034343; Cohen EEW, 2006, CANCER RES, V66, P6296, DOI 10.1158/0008-5472.CAN-05-3139; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Cunliffe HE, 2012, AM J CANCER RES, V2, P478; Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112; Dong SM, 1998, CANCER RES, V58, P3787; Dow LE, 2008, ONCOGENE, V27, P5988, DOI 10.1038/onc.2008.219; Du GS, 2009, ANN SURG ONCOL, V16, P1578, DOI 10.1245/s10434-009-0423-7; Du QS, 2004, CELL, V119, P503, DOI 10.1016/j.cell.2004.10.028; Du QS, 2001, NAT CELL BIOL, V3, P1069, DOI 10.1038/ncb1201-1069; Dugay F, 2013, INT J CANCER, V134, P251; Duivenvoorden WC, 2013, BRIT J CANCER, V108, P327, DOI 10.1038/bjc.2012.574; Durgan J, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.174235; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Ekizoglu S, 2013, TRANSL RES, V162, P122, DOI 10.1016/j.trsl.2013.06.001; Elsum I, 2012, ESSAYS BIOCHEM, V53, P141, DOI [10.1042/BSE0530141, 10.1042/bse0530141]; Elsum IA, 2013, J CELL SCI, V126, P3990, DOI 10.1242/jcs.129387; Elsum IA, 2013, CELLS TISSUES ORGANS, V198, P1, DOI 10.1159/000348423; Evans JD, 2003, AM J CLIN PATHOL, V119, P392, DOI 10.1309/BKPC9DX98R781B87; Ewald AJ, 2008, DEV CELL, V14, P570, DOI 10.1016/j.devcel.2008.03.003; Ewald AJ, 2012, J CELL SCI, V125, P2638, DOI 10.1242/jcs.096875; Fan Y, 2008, TRENDS CELL BIOL, V18, P467, DOI 10.1016/j.tcb.2008.08.001; Feng X, 2012, CANCER BIOMARK, V11, P99, DOI 10.3233/CBM-2012-0264; Forster LF, 2000, J CLIN PATHOL, V53, P791, DOI 10.1136/jcp.53.10.791; Frederick LA, 2008, ONCOGENE, V27, P4841, DOI 10.1038/onc.2008.119; Friedl P, 2010, J CELL BIOL, V188, P11, DOI 10.1083/jcb.200909003; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; Galvez AS, 2009, MOL CELL BIOL, V29, P104, DOI 10.1128/MCB.01294-08; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Geisbrecht ER, 2013, DEV DYNAM, V242, P414, DOI 10.1002/dvdy.23926; Goldstein B, 2007, DEV CELL, V13, P609, DOI 10.1016/j.devcel.2007.10.007; Gonzalez-Sanchez E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066933; Grifoni D, 2007, ONCOGENE, V26, P5960, DOI 10.1038/sj.onc.1210389; Grifoni D, 2004, ONCOGENE, V23, P8688, DOI 10.1038/sj.onc.1208023; Guldberg P, 1999, ONCOGENE, V18, P1777, DOI 10.1038/sj.onc.1202486; Gunaratne A, 2013, CELL ADHES MIGR, V7, P357, DOI 10.4161/cam.25651; Gustafson WC, 2004, J BIOL CHEM, V279, P9400, DOI 10.1074/jbc.M312840200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao Y, 2010, CURR BIOL, V20, P1809, DOI 10.1016/j.cub.2010.09.032; Hashizume A, 2006, BIOCHEM BIOPH RES CO, V339, P996, DOI 10.1016/j.bbrc.2005.11.106; Hayase J, 2013, J CELL BIOL, V200, P635, DOI 10.1083/jcb.201208150; Herrmann JL, 2011, CANCER LETT, V306, P1, DOI 10.1016/j.canlet.2011.01.014; Hidalgo-Carcedo C, 2011, NAT CELL BIOL, V13, P49, DOI 10.1038/ncb2133; Huang YH, 2013, ASIAN PAC J CANCER P, V14, P1985, DOI 10.7314/APJCP.2013.14.3.1985; Humbert PO, 2006, TRENDS CELL BIOL, V16, P622, DOI 10.1016/j.tcb.2006.10.005; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Hurov J, 2007, CELL CYCLE, V6, P1966, DOI 10.4161/cc.6.16.4576; Iden S, 2012, CANCER CELL, V22, P389, DOI 10.1016/j.ccr.2012.08.004; Jaffe AB, 2008, J CELL BIOL, V183, P625, DOI 10.1083/jcb.200807121; Jansen M, 2009, PHYSIOL REV, V89, P777, DOI 10.1152/physrev.00026.2008; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Justilien V, 2009, ONCOGENE, V28, P3597, DOI 10.1038/onc.2009.217; Justilien V, 2011, J BIOL CHEM, V286, P8149, DOI 10.1074/jbc.M110.196113; Karp CM, 2008, CANCER RES, V68, P4105, DOI 10.1158/0008-5472.CAN-07-6814; Kashyap A, 2013, ONCOGENE, V32, P1396, DOI 10.1038/onc.2012.162; Kato S, 2013, PANCREATOLOGY, V13, P360, DOI 10.1016/j.pan.2013.05.006; Kim JY, 2013, P NATL ACAD SCI USA, V110, P6418, DOI 10.1073/pnas.1221799110; Nguyen-Ngoc KV, 2012, P NATL ACAD SCI USA, V109, pE2595, DOI 10.1073/pnas.1212834109; Klezovitch O, 2004, GENE DEV, V18, P559, DOI 10.1101/gad.1178004; Knoblich JA, 2010, NAT REV MOL CELL BIO, V11, P849, DOI 10.1038/nrm3010; Kohjima M, 2002, BIOCHEM BIOPH RES CO, V299, P641, DOI 10.1016/S0006-291X(02)02698-0; Koivunen JP, 2008, BRIT J CANCER, V99, P245, DOI 10.1038/sj.bjc.6604469; Korsse SE, 2013, CARCINOGENESIS, V34, P1611, DOI 10.1093/carcin/bgt068; Korsse SE, 2013, J MED GENET, V50, P59, DOI 10.1136/jmedgenet-2012-101277; Kosinski C, 2010, GASTROENTEROLOGY, V139, P893, DOI 10.1053/j.gastro.2010.06.014; Krahn MP, 2010, CURR BIOL, V20, P636, DOI 10.1016/j.cub.2010.01.065; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Kuphal S, 2006, ONCOGENE, V25, P103, DOI 10.1038/sj.onc.1209008; Langzam L, 2001, AM J CLIN PATHOL, V116, P377, DOI 10.1309/1VKK-HWH7-YVJN-7UF7; Laprise P, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/868217; Laprise P, 2011, TRENDS CELL BIOL, V21, P401, DOI 10.1016/j.tcb.2011.03.005; Lazaro-Dieguez F, 2013, J CELL BIOL, V203, P251, DOI 10.1083/jcb.201303013; Lee JH, 2007, NATURE, V447, P1017, DOI 10.1038/nature05828; Levayer R, 2013, J CELL BIOL, V200, P689, DOI 10.1083/jcb.201301051; Lin HT, 2004, GYNECOL ONCOL, V93, P422, DOI 10.1016/j.ygyno.2004.01.025; Lin JI, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003813; Linch M, 2014, CARCINOGENESIS, V35, P396, DOI 10.1093/carcin/bgt313; Lisovsky M, 2010, VIRCHOWS ARCH, V457, P635, DOI 10.1007/s00428-010-0990-9; Lisovsky M, 2009, MODERN PATHOL, V22, P977, DOI 10.1038/modpathol.2009.68; Liu K, 2014, TUMOR BIOL, V35, P995, DOI 10.1007/s13277-013-1133-0; Liu Q, 1998, J IMMUNOL, V160, P1393; Lo B, 2012, J CELL BIOL, V199, P1117, DOI 10.1083/jcb.201208080; Lu XF, 2009, CLIN CANCER RES, V15, P3287, DOI 10.1158/1078-0432.CCR-08-2078; Ma L, 2013, CELL, V152, P599, DOI 10.1016/j.cell.2012.12.028; Mack HID, 2013, VIROLOGY, V446, P9, DOI 10.1016/j.virol.2013.07.009; Martin-Belmonte F, 2008, CURR OPIN CELL BIOL, V20, P227, DOI 10.1016/j.ceb.2008.01.001; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; McCaffrey LM, 2012, CANCER CELL, V22, P601, DOI 10.1016/j.ccr.2012.10.003; McCaffrey LM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a009654; McCaffrey LM, 2011, TRENDS CELL BIOL, V21, P727, DOI 10.1016/j.tcb.2011.06.005; McCaffrey LM, 2009, GENE DEV, V23, P1450, DOI 10.1101/gad.1795909; McCarthy A, 2009, J PATHOL, V219, P306, DOI 10.1002/path.2599; Moleirinho S, 2013, ONCOGENE, V32, P1821, DOI 10.1038/onc.2012.196; Morais-de-Sa E, 2010, CELL, V141, P509, DOI 10.1016/j.cell.2010.02.040; Murray NR, 2011, J CELL PHYSIOL, V226, P879, DOI 10.1002/jcp.22463; Murray NR, 2004, J CELL BIOL, V164, P797, DOI 10.1083/jcb.200311011; Nagaoka K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065127; Nagasaka K, 2010, ONCOGENE, V29, P5311, DOI 10.1038/onc.2010.265; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Nakajima Y, 2013, NATURE, V500, P359, DOI 10.1038/nature12335; Namdarian B, 2013, UROL ONCOL-SEMIN ORI, V31, P649, DOI 10.1016/j.urolonc.2011.03.012; Nance J, 2011, DEVELOPMENT, V138, P799, DOI 10.1242/dev.053538; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Nelson WJ, 2013, PROG MOL BIOL TRANSL, V116, P3, DOI 10.1016/B978-0-12-394311-8.00001-7; Nolan ME, 2008, CANCER RES, V68, P8201, DOI 10.1158/0008-5472.CAN-07-6567; O'Brien LE, 2001, NAT CELL BIOL, V3, P831, DOI 10.1038/ncb0901-831; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Park TJ, 2008, NAT GENET, V40, P871, DOI 10.1038/ng.104; Park WS, 1998, INT J ONCOL, V13, P601; Partanen JI, 2012, P NATL ACAD SCI USA, V109, pE388, DOI 10.1073/pnas.1120421109; Pearson HB, 2011, J CLIN INVEST, V121, P4257, DOI 10.1172/JCI58509; Petit MM, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-1; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Pocha SM, 2013, CURR BIOL, V23, pR289, DOI 10.1016/j.cub.2013.03.001; Powell CT, 1996, CANCER RES, V56, P4137; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Qin Y, 2010, J CELL BIOL, V189, P661, DOI 10.1083/jcb.201002097; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Richier L, 2010, J NEUROSCI, V30, P4796, DOI 10.1523/JNEUROSCI.3726-09.2010; Rothenberg SM, 2010, CANCER RES, V70, P2158, DOI 10.1158/0008-5472.CAN-09-3458; Rowan A, 1999, J INVEST DERMATOL, V112, P509, DOI 10.1046/j.1523-1747.1999.00551.x; Russ A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047734; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sato N, 2001, AM J PATHOL, V159, P2017, DOI 10.1016/S0002-9440(10)63053-2; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; Schlegelmilch K, 2011, CELL, V144, P782, DOI 10.1016/j.cell.2011.02.031; Schmoranzer J, 2009, CURR BIOL, V19, P1065, DOI 10.1016/j.cub.2009.05.065; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Siziopikou KP, 2013, ARCH PATHOL LAB MED, V137, P462, DOI 10.5858/arpa.2012-0078-RA; Smith CA, 2007, EMBO J, V26, P468, DOI 10.1038/sj.emboj.7601495; Sobottka SB, 2000, J NEURO-ONCOL, V49, P187, DOI 10.1023/A:1006442024874; Sohn J, 2013, ANN ONCOL, V24, P2522, DOI 10.1093/annonc/mdt248; Solinet S, 2011, HISTOCHEM CELL BIOL, V136, P245, DOI 10.1007/s00418-011-0840-0; Soltanian S, 2011, TUMOR BIOL, V32, P425, DOI 10.1007/s13277-011-0155-8; St Johnston D, 2010, CELL, V141, P757, DOI 10.1016/j.cell.2010.05.011; Stefanatos RKA, 2011, J GENET GENOMICS, V38, P431, DOI 10.1016/j.jgg.2011.09.004; Storrs CH, 2007, J VIROL, V81, P4080, DOI 10.1128/JVI.02545-06; Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5; Suzuki A, 2004, CURR BIOL, V14, P1425, DOI 10.1016/j.cub.2004.08.021; Tamehiro N, 2009, J BIOL CHEM, V284, P24881, DOI 10.1074/jbc.M109.014365; Tanwar PS, 2014, CARCINOGENESIS, V35, P546, DOI 10.1093/carcin/bgt357; Tepass U, 2012, ANNU REV CELL DEV BI, V28, P655, DOI 10.1146/annurev-cellbio-092910-154033; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Tsai JH, 2000, CANCER LETT, V161, P171, DOI 10.1016/S0304-3835(00)00597-8; Tsuruga T, 2007, ONCOL RES, V16, P431, DOI 10.3727/000000007783980855; Varelas X, 2010, DEV CELL, V19, P831, DOI 10.1016/j.devcel.2010.11.012; Vidal M, 2006, CURR OPIN GENET DEV, V16, P10, DOI 10.1016/j.gde.2005.12.004; Viloria-Petit AM, 2010, CELL CYCLE, V9, P623, DOI 10.4161/cc.9.4.10779; Viloria-Petit AM, 2009, P NATL ACAD SCI USA, V106, P14028, DOI 10.1073/pnas.0906796106; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wang Y, 2013, MOL CANCER RES, V11, P1624, DOI 10.1158/1541-7786.MCR-13-0371-T; Wang ZJ, 1999, BRIT J CANCER, V80, P70, DOI 10.1038/sj.bjc.6690323; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; WEAVER VM, 1995, SEMIN CANCER BIOL, V6, P175, DOI 10.1006/scbi.1995.0021; Xiao L, 2011, J BIOL CHEM, V286, P7788, DOI 10.1074/jbc.M110.173468; Xue B, 2013, NAT CELL BIOL, V15, P189, DOI 10.1038/ncb2663; Yang YL, 2008, GENE CHROMOSOME CANC, V47, P127, DOI 10.1002/gcc.20514; Yang ZQ, 2012, MOL CELL, V47, P469, DOI 10.1016/j.molcel.2012.06.037; Yao S, 2012, BRIT J CANCER, V107, P388, DOI 10.1038/bjc.2012.162; Yao Sheng, 2010, Genes Cancer, V1, P444, DOI 10.1177/1947601910376079; Yin F, 2013, CELL, V154, P1342, DOI 10.1016/j.cell.2013.08.025; Yoshihama Y, 2011, CURR BIOL, V21, P705, DOI 10.1016/j.cub.2011.03.029; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Yu W, 2005, MOL BIOL CELL, V16, P433, DOI 10.1091/mbc.e04-05-0435; Zen K, 2009, ONCOGENE, V28, P2910, DOI 10.1038/onc.2009.148; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045; Zhang L, 2006, P NATL ACAD SCI USA, V103, P17272, DOI 10.1073/pnas.0608531103; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111; Zhuang ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067431; Zhuo OY, 2010, ONCOL RES, V18, P593, DOI 10.3727/096504010X12767359114045; Zubakov D, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-106	209	103	104	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					939	950		10.1038/onc.2014.59	http://dx.doi.org/10.1038/onc.2014.59			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632617				2022-12-17	WOS:000350121300001
J	Chevet, E; Fessart, D; Delom, F; Mulot, A; Vojtesek, B; Hrstka, R; Murray, E; Gray, T; Hupp, T				Chevet, E.; Fessart, D.; Delom, F.; Mulot, A.; Vojtesek, B.; Hrstka, R.; Murray, E.; Gray, T.; Hupp, T.			Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development	ONCOGENE			English	Review						AGR2; PDI; endoplasmic reticulum; secretome; p53; tumour	ENDOPLASMIC-RETICULUM PROTEIN; XENOPUS CEMENT GLAND; ESTROGEN-RECEPTOR; PANCREATIC-CANCER; OVARIAN-CANCER; HIPPO PATHWAY; HUMAN HOMOLOG; PDI FAMILY; CYCLIN D1; AGR2	Clinical studies have defined the core 'genetic blueprint' of a cancer cell, but this information does not necessarily predict the cancer phenotype. Signalling hubs that mediate such phenotype have been identified largely using OMICS platforms that measure dynamic molecular changes within the cancer cell landscape. The pro-oncogenic protein anterior gradient 2 (AGR2) is a case in point; AGR2 has been shown using a range of expression platforms to be involved in asthma, inflammatory bowel disease, cell transformation, cancer drug resistance and metastatic growth. AGR2 protein is also highly overexpressed in a diverse range of human cancers and can be secreted and detected in extracellular fluids, thus representing a compelling pro-oncogenic signalling intermediate in human cancer. AGR2 belongs to the protein disulphide isomerase family with all the key features of an endoplasmic reticulum-resident protein-this gives clues into how it might function as an oncoprotein through the regulation of protein folding, maturation and secretion that can drive metastatic cell growth. In this review, we will describe the known aspects of AGR2 molecular biology, including gene structure and regulation, emerging protein interaction networks and how its subcellular localization mediates its biological functions. We will finally review the cases of AGR2 expression in human cancers, the pathophysiological consequences of AGR2 overexpression, its potential role as a tumour biomarker that predicts the response to therapy and how the AGR2 pathway might form the basis for drug discovery programmes aimed at targeting protein folding/maturation pathways that mediate secretion and metastasis.	[Chevet, E.; Mulot, A.] INSERM, U1053, Bordeaux, France; [Chevet, E.; Mulot, A.] Univ Bordeaux Segalen, Bordeaux, France; [Fessart, D.; Delom, F.] Univ Bordeaux Segalen, Ctr Rech Cardiothorac Bordeaux, Bordeaux, France; [Fessart, D.; Delom, F.] INSERM, Ctr Rech Cardiothorac Bordeaux, Bordeaux, France; [Vojtesek, B.; Hrstka, R.; Murray, E.] Masaryk Mem Canc Inst, Reg Ctr Appl Mol Oncol, Brno, Czech Republic; [Murray, E.; Gray, T.; Hupp, T.] Univ Edinburgh, Canc Res Ctr, Inst Genet & Mol Med, Signal Transduct Labs P53, Edinburgh, Midlothian, Scotland	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); Masaryk Memorial Cancer Institute; University of Edinburgh	Chevet, E (corresponding author), INSERM, U1053, Bordeaux, France.	eric.chevet@inserm.fr; vojtesek@mou.cz; ted.hupp@ed.ac.uk	Hrstka, Roman/AAM-4430-2020; Delom, Frederic/J-2782-2014; chevet, eric/E-4992-2016; FESSART, Delphine/J-2784-2014	Hrstka, Roman/0000-0002-6139-2664; Delom, Frederic/0000-0002-4600-7633; chevet, eric/0000-0001-5855-4522; FESSART, Delphine/0000-0001-7566-5670	INSERM; INCa; Ligue contre le Cancer; Association pour la Recherche sur le Cancer; Chaire mixte Inserm-Univ. Bordeaux; GACR [P301/10/1615]; IGA MZ CR [NT/13794-4/2012]; European Regional Development Fund [RECAMO CZ.1.05/2.1.00/03.0101]; Cancer Research UK; MRC; BBSRC	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); INCa(Institut National du Cancer (INCA) France); Ligue contre le Cancer(Ligue nationale contre le cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Chaire mixte Inserm-Univ. Bordeaux; GACR(Grant Agency of the Czech Republic); IGA MZ CR; European Regional Development Fund(European Commission); Cancer Research UK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	We apologize to authors whose work has not been cited here owing to space limitations. This work was supported by grants from INSERM, INCa, Ligue contre le Cancer, Association pour la Recherche sur le Cancer (EC), Ligue contre le Cancer and a Chaire mixte Inserm-Univ. Bordeaux (FD), GACR number P301/10/1615 (RH), IGA MZ CR number NT/13794-4/2012 (BV) and by the European Regional Development Fund (RECAMO CZ.1.05/2.1.00/03.0101) (BV, RH, EM), and Cancer Research UK, MRC and BBSRC (TH).	Aberger F, 1998, MECH DEVELOP, V72, P115, DOI 10.1016/S0925-4773(98)00021-5; Adam GC, 2002, MOL CELL PROTEOMICS, V1, P828, DOI 10.1074/mcp.T200007-MCP200; Adam GC, 2002, NAT BIOTECHNOL, V20, P805, DOI 10.1038/nbt714; Adam PJ, 2003, J BIOL CHEM, V278, P6482, DOI 10.1074/jbc.M210184200; Alanen HI, 2003, J BIOL CHEM, V278, P28912, DOI 10.1074/jbc.M304598200; Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Bambang IF, 2013, ONCOGENE, V32, P1240, DOI 10.1038/onc.2012.149; Benham AM, 2012, ANTIOXID REDOX SIGN, V16, P781, DOI 10.1089/ars.2011.4439; Bradley L, 1996, DEVELOPMENT, V122, P2739; Bu HJ, 2011, PROSTATE, V71, P575, DOI 10.1002/pros.21273; Chevet E, 2001, CURR OPIN STRUC BIOL, V11, P120, DOI 10.1016/S0959-440X(00)00168-8; Clarke DJ, 2011, J AM SOC MASS SPECTR, V22, P1432, DOI 10.1007/s13361-011-0155-3; Dong AW, 2011, J BIOL CHEM, V286, P18301, DOI 10.1074/jbc.M110.215707; Dumartin L, 2011, CANCER RES, V71, P7091, DOI 10.1158/0008-5472.CAN-11-1367; Fischer PM, 2000, J PEPT RES, V55, P163, DOI 10.1034/j.1399-3011.2000.00163.x; Fletcher GC, 2003, BRIT J CANCER, V88, P579, DOI 10.1038/sj.bjc.6600740; Fourtouna A, 2009, CURR CHEM BIOL, V3, P124; Fraser JA, 2010, J BIOL CHEM, V285, P37762, DOI 10.1074/jbc.M110.143099; Gray TA, 2012, J IMMUNOL METHODS, V378, P20, DOI 10.1016/j.jim.2012.01.013; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Gupta A, 2012, J BIOL CHEM, V287, P4773, DOI 10.1074/jbc.M111.301531; Hengel SM, 2011, J PROTEOME RES, V10, P4567, DOI 10.1021/pr2004117; Higa A, 2011, J BIOL CHEM, V286, P44855, DOI 10.1074/jbc.M111.275529; Hrstka R, 2010, ONCOGENE, V29, P4838, DOI 10.1038/onc.2010.228; Jessop CE, 2009, J CELL SCI, V122, P4287, DOI 10.1242/jcs.059154; Knoblach B, 2003, MOL CELL PROTEOMICS, V2, P1104, DOI 10.1074/mcp.M300053-MCP200; Komiya T, 1999, BBA-GENE STRUCT EXPR, V1444, P434, DOI 10.1016/S0167-4781(99)00010-X; Komuta M, 2012, HEPATOLOGY, V55, P1876, DOI 10.1002/hep.25595; Kozlov G, 2010, FEBS J, V277, P3924, DOI 10.1111/j.1742-4658.2010.07793.x; Krig SR, 2007, J BIOL CHEM, V282, P9703, DOI 10.1074/jbc.M611752200; Kumar A, 2007, SCIENCE, V318, P772, DOI 10.1126/science.1147710; Lepreux S, 2011, LIVER INT, V31, P322, DOI 10.1111/j.1478-3231.2010.02438.x; Li SR, 2012, DEVELOPMENT, V139, P2500, DOI 10.1242/dev.079699; Liu D, 2005, CANCER RES, V65, P3796, DOI 10.1158/0008-5472.CAN-04-3823; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Maslon MM, 2010, J MOL BIOL, V404, P418, DOI 10.1016/j.jmb.2010.09.035; Mejlvang J, 2007, MOL BIOL CELL, V18, P4615, DOI 10.1091/mbc.E07-05-0406; Moenner M, 2007, CANCER RES, V67, P10631, DOI 10.1158/0008-5472.CAN-07-1705; Ni M, 2007, FEBS LETT, V581, P3641, DOI 10.1016/j.febslet.2007.04.045; Norgaard P, 2001, BIOCHEM J, V358, P269, DOI 10.1042/0264-6021:3580269; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Panaretakis T, 2008, CELL DEATH DIFFER, V15, P1499, DOI 10.1038/cdd.2008.67; Park K, 2011, EXP MOL MED, V43, P91, DOI 10.3858/emm.2011.43.2.011; Park SW, 2009, P NATL ACAD SCI USA, V106, P6950, DOI 10.1073/pnas.0808722106; Persson S, 2005, MOL PHYLOGENET EVOL, V36, P734, DOI 10.1016/j.ympev.2005.04.002; Petek E, 2000, CYTOGENET CELL GENET, V89, P141, DOI 10.1159/000015594; Pohler E, 2004, MOL CELL PROTEOMICS, V3, P534, DOI 10.1074/mcp.M300089-MCP200; Ramachandran V, 2008, CANCER RES, V68, P7811, DOI 10.1158/0008-5472.CAN-08-1320; Raykhel I, 2007, J CELL BIOL, V179, P1193, DOI 10.1083/jcb.200705180; Schroeder BW, 2012, AM J RESP CELL MOL, V47, P178, DOI 10.1165/rcmb.2011-0421OC; Sive H, 1996, DEV DYNAM, V205, P265, DOI 10.1002/(SICI)1097-0177(199603)205:3<265::AID-AJA7>3.0.CO;2-G; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Sweeny L, 2012, EXP CELL RES, V318, P1788, DOI 10.1016/j.yexcr.2012.04.022; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thompson DA, 1997, J STEROID BIOCHEM, V62, P143, DOI 10.1016/S0960-0760(97)00029-0; Thompson DA, 1998, BIOCHEM BIOPH RES CO, V251, P111, DOI 10.1006/bbrc.1998.9440; Tian CH, 2008, CELL RES, V18, P458, DOI 10.1038/cr.2007.112; Vanderlaag KE, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2586; Varghese S, 2012, GASTROENTEROLOGY, V142, P435, DOI 10.1053/j.gastro.2012.01.013; Vendrell JA, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2158; Vivekanandan P, 2009, HUM PATHOL, V40, P293, DOI 10.1016/j.humpath.2008.08.003; Wang X, 2011, CELL, V145, P1023, DOI 10.1016/j.cell.2011.05.026; Wang Z, 2008, CANCER RES, V68, P492, DOI 10.1158/0008-5472.CAN-07-2930; Wilson CL, 2006, ENDOCR-RELAT CANCER, V13, P617, DOI 10.1677/erc.1.01165; Worrall Erin G, 2009, J Chem Biol, V2, P113, DOI 10.1007/s12154-009-0019-5; Worralll EG, 2010, J MOL BIOL, V398, P414, DOI 10.1016/j.jmb.2010.03.023; WUNDERLICH M, 1995, J MOL BIOL, V247, P28, DOI 10.1006/jmbi.1995.0119; Xu X, 2012, CELL, V148, P886, DOI 10.1016/j.cell.2012.02.025; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhang JS, 2005, GENE CHROMOSOME CANC, V43, P249, DOI 10.1002/gcc.20188; Zhang YX, 2010, CANCER RES, V70, P240, DOI 10.1158/0008-5472.CAN-09-2904; Zhao F, 2010, DEV BIOL, V338, P268, DOI 10.1016/j.ydbio.2009.12.008; Zheng W, 2006, GENES IMMUN, V7, P11, DOI 10.1038/sj.gene.6364263; Zweitzig DR, 2007, MOL CELL BIOCHEM, V306, P255, DOI 10.1007/s11010-007-9562-y	78	103	105	1	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2013	32	20					2499	2509		10.1038/onc.2012.346	http://dx.doi.org/10.1038/onc.2012.346			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	148UY	22945652				2022-12-17	WOS:000319274300001
J	Zhai, H; Song, B; Xu, X; Zhu, W; Ju, J				Zhai, H.; Song, B.; Xu, X.; Zhu, W.; Ju, J.			Inhibition of autophagy and tumor growth in colon cancer by miR-502	ONCOGENE			English	Article						miR-502; autophagy; p53; colon cancer	CELL-CYCLE; GENE-EXPRESSION; SMALL RNAS; TRANSCRIPTIONAL ACTIVATION; P53; MICRORNAS; MIR-34A; PROLIFERATION; CHEMORESISTANCE; 5-FLUOROURACIL	Autophagy is a catabolic process that allows cellular macromolecules to be broken down and recycled as metabolic precursors. The influence of non-coding microRNAs in autophagy has not been explored in colon cancer. In this study, we discover a novel mechanism of autophagy regulated by hsa-miR-502-5p (miR-502) by suppression of Rab1B, a critical mediator of autophagy. A number of other miR-502 suppressed mRNA targets (for example, dihydroorotate dehydrogenase) are also identified by microarray analysis. Ectopic expression of miR-502 inhibited autophagy, colon cancer cell growth and cell-cycle progression of colon cancer cells in vitro. miR-502 also inhibited in-vivo colon cancer growth in a mouse tumor xenografts model. In addition, the expression of miR-502 was regulated by p53 via a negative feedback regulatory mechanism. The expression of miR-502 was downregulated in colon cancer patient specimens compared with the paired normal control samples. These results suggest that miR-502 may function as a potential tumor suppressor and therefore be a novel candidate for developing miR-502-based therapeutic strategies. Oncogene (2013) 32, 1570-1579; doi:10.1038/onc.2012.167; published online 14 May 2012	[Zhai, H.; Ju, J.] SUNY Stony Brook, Dept Pathol, Translat Res Lab, Stony Brook, NY 11794 USA; [Song, B.] Dalian Med Univ, Dept Pathol, Dalian, Peoples R China; [Xu, X.; Zhu, W.] SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Dalian Medical University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Ju, J (corresponding author), SUNY Stony Brook, Dept Pathol, Translat Res Lab, BST L9,Room 185, Stony Brook, NY 11794 USA.	jingfang.ju@stonybrookmedicine.edu	zhai, haiyan/K-4659-2014	Ju, Jingfang/0000-0002-4821-7458	Stony Brook University Translational Research Laboratory [R01CA155019, R33CA147966]; NATIONAL CANCER INSTITUTE [R33CA147966, R01CA155019] Funding Source: NIH RePORTER	Stony Brook University Translational Research Laboratory; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We appreciate the critical review by Ms Sonya R Lorrain. We thank Dr Stella E Tsirka for technical support in animal experiments. This study was supported in part by Stony Brook University Translational Research Laboratory Start-up Fund (J Ju), R01CA155019 (J Ju) and R33CA147966 (J Ju).	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Akao Y, 2010, CANCER GENE THER, V17, P398, DOI 10.1038/cgt.2009.88; Akao Y, 2007, DNA CELL BIOL, V26, P311, DOI 10.1089/dna.2006.0550; Akao Y, 2009, LEUKEMIA RES, V33, P1530, DOI 10.1016/j.leukres.2009.04.019; Alwan A, 2007, DISASTER MED PUBLIC, V1, P7, DOI 10.1097/DMP.0b013e3180676d32; Baumann P, 2009, MOL CANCER THER, V8, P366, DOI 10.1158/1535-7163.MCT-08-0664; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Braun CJ, 2008, CANCER RES, V68, P10094, DOI 10.1158/0008-5472.CAN-08-1569; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Crawford L V, 1984, Mol Biol Med, V2, P261; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; DRESSLER LG, 1988, CANCER, V61, P420, DOI 10.1002/1097-0142(19880201)61:3<420::AID-CNCR2820610303>3.0.CO;2-0; Eisenberg-Lerner A, 2009, APOPTOSIS, V14, P376, DOI 10.1007/s10495-008-0307-5; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Georges SA, 2008, CANCER RES, V68, P10105, DOI 10.1158/0008-5472.CAN-08-1846; Ghodgaonkar MM, 2009, CELL DEATH DIFFER, V16, P858, DOI 10.1038/cdd.2009.15; Gunaratne PH, 2010, METHODS MOL BIOL, V667, P297, DOI 10.1007/978-1-60761-811-9_20; He H, 2002, GENE EXPRESSION, V10, P231, DOI 10.3727/000000002783992406; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hegde Sanjay R, 2008, Expert Rev Gastroenterol Hepatol, V2, P135, DOI 10.1586/17474124.2.1.135; Hirst J, 1999, MOL BIOL CELL, V10, P2787, DOI 10.1091/mbc.10.8.2787; Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023; Ibrahim AF, 2011, CANCER RES, V71, P5214, DOI 10.1158/0008-5472.CAN-10-4645; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Jung YS, 2010, CELL SIGNAL, V22, P1003, DOI 10.1016/j.cellsig.2010.01.013; Karaayvaz M, 2011, CLIN COLORECTAL CANC, V10, P340, DOI 10.1016/j.clcc.2011.06.002; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Zoppino FCM, 2010, TRAFFIC, V11, P1246, DOI 10.1111/j.1600-0854.2010.01086.x; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Michael MZ, 2003, MOL CANCER RES, V1, P882; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; Navarro F, 2010, J IMMUNOL, V184, P5939, DOI 10.4049/jimmunol.0902567; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Scherz-Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107; SCOTT N, 1991, BRIT J CANCER, V63, P317, DOI 10.1038/bjc.1991.74; Shi B, 2007, J BIOL CHEM, V282, P32582, DOI 10.1074/jbc.M702806200; Shin S, 2009, INT J ONCOL, V35, P1343, DOI 10.3892/ijo_00000452; Shin S, 2009, INT J ONCOL, V34, P1645, DOI 10.3892/ijo_00000295; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Slaby O, 2007, ONCOLOGY-BASEL, V72, P397, DOI 10.1159/000113489; Song B, 2009, ONCOGENE, V28, P4065, DOI 10.1038/onc.2009.274; Song B, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-96; Song B, 2008, CLIN CANCER RES, V14, P8080, DOI 10.1158/1078-0432.CCR-08-1422; Stenmark H, 2009, NAT REV MOL CELL BIO, V10, P513, DOI 10.1038/nrm2728; Tang FC, 2010, DIFFERENTIATION, V79, P141, DOI 10.1016/j.diff.2009.11.002; Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706; Tasdemir E, 2008, CELL CYCLE, V7, P3006, DOI 10.4161/cc.7.19.6702; Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wang XD, 2010, FEBS LETT, V584, P3392, DOI 10.1016/j.febslet.2010.06.033; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; White RM, 2011, NATURE, V471, P518, DOI 10.1038/nature09882; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Xi YG, 2006, BIOMARK INSIGHTS, V1, P113; Xi YG, 2006, CLIN CANCER RES, V12, P2014, DOI 10.1158/1078-0432.CCR-05-1853; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Zhao RB, 2000, GENE DEV, V14, P981; Zhou JF, 2010, ONCOL REP, V23, P121, DOI 10.3892/or_00000613	72	103	113	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2013	32	12					1570	1579		10.1038/onc.2012.167	http://dx.doi.org/10.1038/onc.2012.167			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22580605	Green Accepted			2022-12-17	WOS:000316456000010
J	Yue, P; Zhang, X; Paladino, D; Sengupta, B; Ahmad, S; Holloway, RW; Ingersoll, SB; Turkson, J				Yue, P.; Zhang, X.; Paladino, D.; Sengupta, B.; Ahmad, S.; Holloway, R. W.; Ingersoll, S. B.; Turkson, J.			Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells	ONCOGENE			English	Article						cisplatin-resistance; ovarian cancer; EGF receptor; Stat3; Jaks; cancer aggressiveness	GROWTH-FACTOR RECEPTOR; MESENCHYMAL TRANSITION; CONSTITUTIVE ACTIVATION; CONFERS RESISTANCE; PLATINUM COMPLEXES; MATRIX DEGRADATION; TUMOR PROGRESSION; INDUCED APOPTOSIS; DRUG-RESISTANCE; CARCINOMA CELLS	We present evidence that the cisplatin-resistant human ovarian cancer lines, A2780S/CP1 (S/CP1), A2780S/CP3 (S/CP3) and A2780S/CP5 (S/CP5), derived by subjecting the sensitive A2780S ovarian cancer line to multiple rounds of cisplatin treatments followed by recovery and are resistant to 1, 3 and 5 mu M cisplatin, respectively, have increased colony-forming ability and altered morphology that is consistent with enhanced motility, migration and invasiveness in vitro. The malignant phenotype progresses with increasing resistance and is associated with hyperactive epidermal growth factor receptor (EGFR)/extracellular signal-regulated kinase (Erk)1/2 and janus kinases (Jaks), aberrant signal transducer and activator of transcription (Stat) 3 activation promoted by EGFR and Jaks, and epithelial-mesenchymal transition (EMT) in vitro. Survivin and FLIP anti-apoptotic factors, vascular endothelial growth factor (VEGF) and matrix metalloproteinase activities are also elevated in the resistant cells. Accordingly, the ectopic expression of constitutively-active Stat3C in the sensitive A2780S cells diminished cisplatin sensitivity. The inhibition of EGFR or Stat3 activity repressed Survivin, VEGF and Vimentin expression and the colony-forming potential, viability, motility and migration of the resistant cells, and sensitized them to cisplatin. Analysis of human ovarian cancer patients' tumor tissues shows aberrantly-active EGFR and Stat3 that in certain cases correlate with Vimentin over-expression. Intra-peritoneal mouse xenograft studies revealed, compared with the sensitive A2780S line that had low tumor incidence restricted to the ovary, a high tumor incidence for the resistant S/CP3 and S/CP5 lines that formed tumor nodules at several locations on the small intestine and colon, and which responded poorly to cisplatin, but were sensitive to concurrent treatment with cisplatin and EGFR or Stat3 inhibitor. Hyperactive EGFR signaling through Stat3 and the Jak-Stat3 activity together promote ovarian cancer progression to cisplatin resistance and therefore represent targets for preventing the development of cisplatin resistance and the recurrent disease during cisplatin therapy in ovarian cancer. Oncogene (2012) 31, 2309-2322; doi:10.1038/onc.2011.409; published online 12 September 2011	[Yue, P.; Zhang, X.; Paladino, D.; Sengupta, B.; Turkson, J.] Univ Cent Florida, Coll Med, Barnett Sch Biomed Sci, Orlando, FL 32816 USA; [Ahmad, S.; Holloway, R. W.; Ingersoll, S. B.] Florida Hosp Canc Inst, Florida Hosp Gynecol Oncol, Orlando, FL USA	State University System of Florida; University of Central Florida; Adventist Health Services; AdventHealth	Turkson, J (corresponding author), Univ Hawaii Manoa, Univ Hawaii Canc Ctr, Canc Biol Program, Biomed Sci Bldg,Suite 222J,651 ILALO St, Honolulu, HI 96813 USA.	jturkson@cc.hawaii.edu	zhang, xiaolei/D-7698-2012; Yue, Peibin/J-9836-2015	Zhang, Xiaolei/0000-0003-2395-2453	National Cancer Institute [CA106439, CA128865]; Florida Hospital-UCF; State of Florida Bankhead-Coley Cancer Research Program; NATIONAL CANCER INSTITUTE [R01CA106439, R01CA128865, P30CA071789] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Florida Hospital-UCF; State of Florida Bankhead-Coley Cancer Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank all colleagues and members of our laboratory for the stimulating discussions and the University of Central Florida Confocal Microscopy and the Transgenic Animal facilities for their assistance. This work was supported by the National Cancer Institute Grants CA106439 and CA128865 (to JT) and the Florida Hospital-UCF-Gala Endowed Program for Oncologic Research Award (JT and RWH) and the State of Florida Bankhead-Coley Cancer Research Program (SBI, RWH and SA).	Ahmed N, 2007, J CELL PHYSIOL, V213, P581, DOI 10.1002/jcp.21240; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Arany I, 2004, AM J PHYSIOL-RENAL, V287, pF543, DOI 10.1152/ajprenal.00112.2004; Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Avizienyte E, 2005, CURR OPIN CELL BIOL, V17, P542, DOI 10.1016/j.ceb.2005.08.007; Bhattacharya S, 2005, BIOCHEM J, V392, P335, DOI 10.1042/BJ20050465; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brabec V, 2005, DRUG RESIST UPDATE, V8, P131, DOI 10.1016/j.drup.2005.04.006; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chan JK, 2005, CANCER RES, V65, P3243, DOI 10.1158/0008-5472.CAN-03-3013; Cui W, 2000, MOL CARCINOGEN, V29, P219, DOI 10.1002/1098-2744(200012)29:4<219::AID-MC1004>3.3.CO;2-4; Dancey JE, 2003, LANCET, V362, P62, DOI 10.1016/S0140-6736(03)13810-X; Darnell JE, 2005, NAT MED, V11, P595, DOI 10.1038/nm0605-595; Desai B, 2008, J BIOL CHEM, V283, P13856, DOI 10.1074/jbc.M709401200; Duan Z, 2006, CANCER RES, V12, P5056; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Fajac A, 1996, INT J CANCER, V68, P67, DOI 10.1002/(SICI)1097-0215(19960927)68:1<67::AID-IJC13>3.0.CO;2-3; Gallagher WM, 1997, ONCOGENE, V14, P185; Gan Y, 2010, ONCOGENE, V29, P4947, DOI 10.1038/onc.2010.240; Gonzalez VM, 2001, MOL PHARMACOL, V59, P657, DOI 10.1124/mol.59.4.657; Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Ikuta K, 2005, ONCOL REP, V13, P1229; Kassouf W, 2005, CANCER RES, V65, P10524, DOI 10.1158/0008-5472.CAN-05-1536; Kelland LR, 1999, J INORG BIOCHEM, V77, P111, DOI 10.1016/S0162-0134(99)00141-5; Kim YK, 2005, J APPL TOXICOL, V25, P374, DOI 10.1002/jat.1081; Lee MY, 2008, CLIN CANCER RES, V14, P4743, DOI 10.1158/1078-0432.CCR-08-0234; Matsuo M, 2007, CANCER LETT, V251, P288, DOI 10.1016/j.canlet.2006.11.027; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Richardson A, 2005, DRUG RESIST UPDATE, V8, P311, DOI 10.1016/j.drup.2005.09.001; Selvendiran K, 2008, CELL CYCLE, V7, P81, DOI 10.4161/cc.7.1.5103; Selvendiran K, 2009, INT J CANCER, V125, P2198, DOI 10.1002/ijc.24601; Shao H, 2003, CANCER RES, V63, P3923; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Siddiquee KAZ, 2007, ACS CHEM BIOL, V2, P787, DOI 10.1021/cb7001973; Song H, 2004, INT J ONCOL, V24, P1017; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Turkson J, 2004, EXPERT OPIN THER TAR, V8, P409, DOI 10.1517/14728222.8.5.409; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Villedieu M, 2006, GYNECOL ONCOL, V101, P507, DOI 10.1016/j.ygyno.2005.11.017; Wang GD, 2004, ONCOL REP, V12, P955; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhang XL, 2010, BIOCHEM PHARMACOL, V79, P1398, DOI 10.1016/j.bcp.2010.01.001; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200	49	103	108	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	18					2309	2322		10.1038/onc.2011.409	http://dx.doi.org/10.1038/onc.2011.409			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	936SR	21909139	Green Accepted			2022-12-17	WOS:000303610800006
J	Li, C; Ao, J; Fu, J; Lee, DF; Xu, J; Lonard, D; O'Malley, BW				Li, C.; Ao, J.; Fu, J.; Lee, D-F; Xu, J.; Lonard, D.; O'Malley, B. W.			Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1	ONCOGENE			English	Article						SRC-3/AIB1; tumor suppressor; SPOP; ubiquitin ligase; steroid receptor co-activator; breast cancer	STEROID-RECEPTOR COACTIVATOR-1; CANCER CELL-PROLIFERATION; REG-GAMMA-PROTEASOME; KINASE-I-EPSILON; F-BOX PROTEINS; BREAST-CANCER; NUCLEAR RECEPTORS; TRANSCRIPTIONAL COACTIVATOR; BETA-CATENIN; E3 LIGASE	Steroid receptor co-activator-3 (SRC-3/AIB1) is an oncogene that is amplified and overexpressed in many human cancers. However, the molecular mechanisms that regulate 'activated SRC-3 oncoprotein' turnover during tumorigenesis remain to be elucidated. Here, we report that speckle-type POZ protein (SPOP), a cullin 3 (CUL3)-based ubiquitin ligase, is responsible for SRC-3 ubiquitination and proteolysis. SPOP interacts directly with an SRC-3 phospho-degron in a phosphorylation-dependent manner. Casein kinase I epsilon phosphorylates the S102 in this degron and promotes SPOP-dependent turnover of SRC-3. Short hairpin RNA knockdown and overexpression experiments substantiated that the SPOP/CUL3/Rbx1 ubiquitin ligase complex promotes SRC-3 turnover. A systematic analysis of the SPOP genomic locus revealed that a high percentage of genomic loss or loss of heterozygosity occurs at this locus in breast cancers. Furthermore, we demonstrate that restoration of SPOP expression inhibited SRC-3-mediated oncogenic signaling and tumorigenesis, thus positioning SPOP as a tumor suppressor. Oncogene (2011) 30, 4350-4364; doi: 10.1038/onc.2011.151; published online 16 May 2011	[Li, C.; Ao, J.] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai 200032, Peoples R China; [Li, C.; Fu, J.; Xu, J.; Lonard, D.; O'Malley, B. W.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Lee, D-F] Mt Sinai Sch Med, Black Family Stem Cell Res Inst, Dept Gene & Cell Med, New York, NY USA	Shanghai Jiao Tong University; Baylor College of Medicine; Icahn School of Medicine at Mount Sinai	Li, C (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai 200032, Peoples R China.	01chao@gmail.com; berto@bcm.edu		Lee, Dung-Fang/0000-0003-2387-597X	State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute; National Natural Science Foundation of China [81072163]; NIH [HD-08188, HD-07857]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD008188, R01HD007857] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD007857, F32HD008188] Funding Source: NIH RePORTER	State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	We thank Ming-Jer Tsai and Sophia Y Tsai for their suggestions and Dr Kevin White (University of Chicago) for the monoclonal antibodies against SPOP. This work was supported by funding from State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute and grants (81072163) from National Natural Science Foundation of China (CL), and NIH HD-08188 and HD-07857 grants (BWO).	Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; Bennett EJ, 2010, CELL, V143, P951, DOI 10.1016/j.cell.2010.11.017; Bunce MW, 2008, J BIOL CHEM, V283, P8678, DOI 10.1074/jbc.M710222200; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen MH, 2009, GENE DEV, V23, P1910, DOI 10.1101/gad.1794109; Claiborn KC, 2010, J CLIN INVEST, V120, P3713, DOI 10.1172/JCI40440; DeMarchis L, 2004, BRIT J CANCER, V90, P2384, DOI 10.1038/sj.bjc.6601848; Durocher F, 1996, J MED GENET, V33, P814, DOI 10.1136/jmg.33.10.814; Eide EJ, 2005, MOL CELL BIOL, V25, P2795, DOI 10.1128/MCB.25.7.2795-2807.2005; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Glass CK, 2000, GENE DEV, V14, P121; Goel A, 2004, J BIOL CHEM, V279, P14909, DOI 10.1074/jbc.M400036200; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hernadez-Munoz I, 2005, P NATL ACAD SCI USA, V102, P7635, DOI 10.1073/pnas.0408918102; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Jin JP, 2005, METHOD ENZYMOL, V399, P287, DOI 10.1016/S0076-6879(05)99020-4; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; Kajiro M, 2009, NAT CELL BIOL, V11, P312, DOI 10.1038/ncb1839; Kuang SQ, 2004, CANCER RES, V64, P1875, DOI 10.1158/0008-5472.CAN-03-3745; KUMAR RPD, 2008, NR COREGULATORS HUMA, V11; Kwon JE, 2006, J BIOL CHEM, V281, P12664, DOI 10.1074/jbc.M600204200; Lee DF, 2009, MOL CELL, V36, P131, DOI 10.1016/j.molcel.2009.07.025; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Lerebours F, 2002, INT J CANCER, V102, P618, DOI 10.1002/ijc.10729; Li C, 2008, MOL CELL, V31, P835, DOI 10.1016/j.molcel.2008.07.019; Li C, 2007, MOL CELL BIOL, V27, P1296, DOI 10.1128/MCB.00336-06; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Li B, 2008, CANCER LETT, V261, P64, DOI 10.1016/j.canlet.2007.11.013; Li XT, 2007, MOL CELL, V26, P831, DOI 10.1016/j.molcel.2007.05.028; Li XT, 2006, CELL, V124, P381, DOI 10.1016/j.cell.2005.11.037; Liu J, 2009, SCIENCE, V323, P1218, DOI 10.1126/science.1157669; Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004; Luo W, 2007, EMBO J, V26, P1511, DOI 10.1038/sj.emboj.7601607; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; O'Malley BW, 2009, CANCER RES, V69, P8217, DOI 10.1158/0008-5472.CAN-09-2223; ONATE SA, 1995, SCIENCE, V270, P1354; Orsetti B, 1999, ONCOGENE, V18, P6262, DOI 10.1038/sj.onc.1203006; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Planas-Silva MD, 2001, CANCER RES, V61, P3858; Qin L, 2008, MOL CELL BIOL, V28, P5937, DOI 10.1128/MCB.00579-08; RADFORD DM, 1995, CANCER RES, V55, P3399; Rivers A, 1998, J BIOL CHEM, V273, P15980, DOI 10.1074/jbc.273.26.15980; Sakanaka C, 2002, J BIOCHEM, V132, P697, DOI 10.1093/oxfordjournals.jbchem.a003276; Shirogane T, 2005, J BIOL CHEM, V280, P26863, DOI 10.1074/jbc.M502862200; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Tang J, 2006, NAT CELL BIOL, V8, P855, DOI 10.1038/ncb1442; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Werbajh S, 2000, FEBS LETT, V485, P195, DOI 10.1016/S0014-5793(00)02223-7; Wu RC, 2007, CELL, V129, P1125, DOI 10.1016/j.cell.2007.04.039; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Yan J, 2008, CANCER RES, V68, P5460, DOI 10.1158/0008-5472.CAN-08-0955; Yan J, 2006, CANCER RES, V66, P11039, DOI 10.1158/0008-5472.CAN-06-2442; Yi P, 2008, MOL CELL, V29, P465, DOI 10.1016/j.molcel.2007.12.030; Yu CD, 2007, MOL CELL, V25, P765, DOI 10.1016/j.molcel.2007.01.025; Zhou G, 2003, MOL CELL BIOL, V23, P7742, DOI 10.1128/MCB.23.21.7742-7755.2003; Zhou HJ, 2005, CANCER RES, V65, P7976, DOI 10.1158/0008-5472.CAN-04-4076; Zhuang M, 2009, MOL CELL, V36, P39, DOI 10.1016/j.molcel.2009.09.022	70	103	114	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	42					4350	4364		10.1038/onc.2011.151	http://dx.doi.org/10.1038/onc.2011.151			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HP	21577200	Green Accepted			2022-12-17	WOS:000296356400006
J	Al-Ejeh, F; Kumar, R; Wiegmans, A; Lakhani, SR; Brown, MP; Khanna, KK				Al-Ejeh, F.; Kumar, R.; Wiegmans, A.; Lakhani, S. R.; Brown, M. P.; Khanna, K. K.			Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes	ONCOGENE			English	Review						DNA-damage response; DNA repair; cell cycle checkpoints; cell death; mitotic catastrophe; cellular senescence	DEPENDENT PROTEIN-KINASE; DOUBLE-STRAND BREAKS; POLY(ADP-RIBOSE) POLYMERASE-1 INHIBITOR; INDUCED MITOTIC CATASTROPHE; ADP-RIBOSE POLYMERASE; CELL-DEATH PATHWAYS; S-PHASE; HOMOLOGOUS RECOMBINATION; CHECKPOINT KINASE-1; TUMOR-CELLS	The DNA-damage response (DDR) pathways consist of interconnected components that respond to DNA damage to allow repair and promote cell survival. The DNA repair pathways and downstream cellular responses have diverged in cancer cells compared with normal cells because of genetic alterations that underlie drug resistance, disabled repair and resistance to apoptosis. Consequently, abrogating DDR pathways represents an important mechanism for enhancing the therapeutic index of DNA-damaging anticancer agents. In this review, we discuss the DDR pathways that determine antitumor effects of DNA-damaging agents with a specific focus on treatment outcomes in tumors carrying a defective p53 pathway. Finely tuned survival and death pathways govern the cellular responses downstream of the cytotoxic insults inherent in anticancer treatment. The significance and relative contributions of cellular responses including apoptosis, mitotic catastrophe and senescence are discussed in relation to the web of molecular interactions that affect such outcomes. We propose that promising combinations of DNA-damaging anticancer treatments with DDR-pathway inhibition would be further enhanced by activating downstream apoptotic pathways. The proposed rationale ensures that actual cell death is the preferred outcome of cancer treatment instead of other responses, including reversible cell cycle arrest, autophagy or senescence. Finally, to better measure the contribution of different cellular responses to anticancer treatments, multiplex in vivo assessments of therapy-induced response pathways such as cell death, senescence and mitotic catastrophe is desirable rather than the current reliance on the measurement of a single response pathway such as apoptosis. Oncogene (2010) 29, 6085-6098; doi:10.1038/onc.2010.407; published online 6 September 2010	[Al-Ejeh, F.; Wiegmans, A.; Khanna, K. K.] Queensland Inst Med Res, Signal Transduct Lab, Brisbane, Qld 4006, Australia; [Kumar, R.] Univ Adelaide, Breast Canc Genet Grp, Discipline Med, Adelaide, SA, Australia; [Kumar, R.] SA Pathol, Hanson Inst, Adelaide, SA, Australia; [Lakhani, S. R.] UQCCR, Royal Brisbane & Womens Hosp, Sch Med & Pathol Queensland, Brisbane, Qld, Australia; [Brown, M. P.] Royal Adelaide Hosp Canc Ctr, Canc Clin Trials Unit, Adelaide, SA, Australia; [Brown, M. P.] Univ Adelaide, Sch Med, Adelaide, SA, Australia	QIMR Berghofer Medical Research Institute; University of Adelaide; Hanson Institute; SA Pathology; Royal Brisbane & Women's Hospital; University of Queensland; Royal Adelaide Hospital; University of Adelaide	Al-Ejeh, F (corresponding author), Queensland Inst Med Res, Signal Transduct Lab, 300 Herston Rd, Brisbane, Qld 4006, Australia.	Fares.Al-Ejeh@qimr.edu.au	Al-Ejeh, Fares/M-7032-2016; Kumar, Raman/AHE-0538-2022; Lakhani, Sunil R/I-1970-2018; Wiegmans, Adrian/K-1609-2015; Khanna, Kum Kum/I-1747-2013	Al-Ejeh, Fares/0000-0002-1553-0077; Kumar, Raman/0000-0001-7976-8386; Lakhani, Sunil R/0000-0003-4067-2760; Wiegmans, Adrian/0000-0003-4059-5988; 	Cancer Council NSW [IG 09-04]; Cure Cancer Foundation Australia [ID 631924]; Cancer Council SA [ID 631923]; National Health & Medical Research Council [ID 442903]; Australian Research Council [ID DP0880372]	Cancer Council NSW(Cancer Council New South Wales); Cure Cancer Foundation Australia; Cancer Council SA(Cancer Council South Australia); National Health & Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council)	This work was supported by the Cancer Council NSW (IG 09-04 to FA); The Cure Cancer Foundation Australia (ID 631924 to FA); the Cancer Council SA (ID 631923 to FA); National Health & Medical Research Council Program Grant (ID 442903 to SRL and KKK); and Australian Research Council Grant (ID DP0880372 to KKK)	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adamo A, 2010, MOL CELL, V39, P25, DOI 10.1016/j.molcel.2010.06.026; Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Al-Ejeh F, 2007, CLIN CANCER RES, V13, p5509S, DOI 10.1158/1078-0432.CCR-07-0922; ALEJEH F, 2009, PLOS ONE, V4, pNIL12; Aliouat-Denis CM, 2005, MOL CANCER RES, V3, P627, DOI 10.1158/1541-7786.MCR-05-0121; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ashwell S, 2008, CLIN CANCER RES, V14, P4032, DOI 10.1158/1078-0432.CCR-07-5138; Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; Audebert M, 2008, BIOCHEM BIOPH RES CO, V369, P982, DOI 10.1016/j.bbrc.2007.11.132; Bahassi EM, 2006, MUTAT RES-FUND MOL M, V596, P166, DOI 10.1016/j.mrfmmm.2005.12.002; Barlow C, 1998, DEVELOPMENT, V125, P4007; Bentle MS, 2006, J MOL HISTOL, V37, P203, DOI 10.1007/s10735-006-9043-8; Bhattathiri NV, 1998, RADIOTHER ONCOL, V49, P61, DOI 10.1016/S0167-8140(98)00077-2; Blasina A, 2008, MOL CANCER THER, V7, P2394, DOI 10.1158/1535-7163.MCT-07-2391; Boulton SJ, 2010, NATURE, V465, P301, DOI 10.1038/465301a; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Branzei D, 2008, NAT REV MOL CELL BIO, V9, P297, DOI 10.1038/nrm2351; BREDESEN DE, 2008, APOPTOSIS CELLULAR O, P73; Brown EJ, 2000, GENE DEV, V14, P397; Brown JM, 1999, CANCER RES, V59, P1391; Brown JM, 2001, DRUG RESIST UPDATE, V4, P135, DOI 10.1054/drup.2001.0193; Brown M, 2003, CANCER BIOL THER, V2, P477, DOI 10.4161/cbt.2.5.450; Bryant HE, 2006, NUCLEIC ACIDS RES, V34, P1685, DOI 10.1093/nar/gkl108; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Bucher N, 2008, BRIT J CANCER, V98, P523, DOI 10.1038/sj.bjc.6604208; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Calabrese CR, 2004, J NATL CANCER I, V96, P56, DOI 10.1093/jnci/djh005; Calabrese CR, 2003, CLIN CANCER RES, V9, P2711; CAMPISI J, 2008, APOPTOSIS CELLULAR O, P175; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chen ZH, 2006, INT J CANCER, V119, P2784, DOI 10.1002/ijc.22198; Cho SH, 2005, CELL CYCLE, V4, P131, DOI 10.4161/cc.4.1.1299; Cohen A, 2007, TECHNOL CANCER RES T, V6, P221, DOI 10.1177/153303460700600310; Cohen-Jonathan E, 1999, CURR OPIN CHEM BIOL, V3, P77, DOI 10.1016/S1367-5931(99)80014-3; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Cowell IG, 2005, BIOCHEM PHARMACOL, V71, P13, DOI 10.1016/j.bcp.2005.09.029; Cragg MS, 2009, NAT REV CANCER, V9, P321, DOI 10.1038/nrc2615; Curtin NJ, 2004, CLIN CANCER RES, V10, P881, DOI 10.1158/1078-0432.CCR-1144-3; de Bruin EC, 2008, CANCER TREAT REV, V34, P737, DOI 10.1016/j.ctrv.2008.07.001; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Denchi EL, 2005, MOL CELL BIOL, V25, P2660, DOI 10.1128/MCB.25.7.2660-2672.2005; DIGIUSEPPE JA, 1995, AM J PATHOL, V147, P884; Duffy MJ, 2007, CANCER LETT, V249, P49, DOI 10.1016/j.canlet.2006.12.020; Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33; Evers B, 2008, CLIN CANCER RES, V14, P3916, DOI 10.1158/1078-0432.CCR-07-4953; Ewald B, 2007, MOL CANCER THER, V6, P1239, DOI 10.1158/1535-7163.MCT-06-0633; FALKVOLL KH, 1990, STRAHLENTHER ONKOL, V166, P487; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Gallmeier E, 2005, CANCER BIOL THER, V4, P703, DOI 10.4161/cbt.4.7.1909; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Goldsmith KC, 2006, ONCOGENE, V25, P4525, DOI 10.1038/sj.onc.1209489; Griffin RJ, 2005, J MED CHEM, V48, P569, DOI 10.1021/jm049526a; Gudiksen M, 2008, NAT REV DRUG DISCOV, V7, P563, DOI 10.1038/nrd2594; Haince JF, 2005, TRENDS MOL MED, V11, P456, DOI 10.1016/j.molmed.2005.08.003; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hardcastle IR, 2005, J MED CHEM, V48, P7829, DOI 10.1021/jm050444b; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Helt CE, 2005, CELL CYCLE, V4, P529, DOI 10.4161/cc.4.4.1598; Hong YL, 2004, P NATL ACAD SCI USA, V101, P14443, DOI 10.1073/pnas.0401346101; Hunter AM, 2007, APOPTOSIS, V12, P1543, DOI 10.1007/s10495-007-0087-3; Hurley LH, 2002, NAT REV CANCER, V2, P188, DOI 10.1038/nrc749; Iliakis G, 2009, RADIOTHER ONCOL, V92, P310, DOI 10.1016/j.radonc.2009.06.024; Ismail IH, 2004, ONCOGENE, V23, P873, DOI 10.1038/sj.onc.1207303; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Kartachova M, 2007, J CLIN ONCOL, V25, P2534, DOI 10.1200/JCO.2006.10.1337; Kashishian A, 2003, MOL CANCER THER, V2, P1257; Kass EM, 2010, CANCER CELL, V17, P423, DOI 10.1016/j.ccr.2010.04.021; Kelley MR, 2008, ANTI-CANCER AGENT ME, V8, P417, DOI 10.2174/187152008784220294; Kennedy RD, 2006, J CLIN ONCOL, V24, P3799, DOI 10.1200/JCO.2005.05.4171; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kilic M., 2008, APOPTOSIS CELLULAR O, P273, DOI [10.3109/9781420020502-17, DOI 10.3109/9781420020502-17]; Kim R, 2005, CANCER-AM CANCER SOC, V103, P1551, DOI 10.1002/cncr.20947; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; LaCasse EC, 2008, ONCOGENE, V27, P6252, DOI 10.1038/onc.2008.302; Lafarga V, 2009, MOL CELL BIOL, V29, P4341, DOI 10.1128/MCB.00210-09; Leahy JJJ, 2004, BIOORG MED CHEM LETT, V14, P6083, DOI 10.1016/j.bmcl.2004.09.060; Lieberman HB, 2008, CURR MED CHEM, V15, P360, DOI 10.2174/092986708783497328; Liu L, 2007, FASEB J, V21, pA1301; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Lock RB, 1996, CANCER RES, V56, P4006; LOCKSHIN RA, 2008, APOPTOSIS CELLULAR O, P55; Lord CJ, 2008, CURR OPIN PHARMACOL, V8, P363, DOI 10.1016/j.coph.2008.06.016; Lord CJ, 2006, CLIN CANCER RES, V12, P4463, DOI 10.1158/1078-0432.CCR-06-1269; Maddika S, 2007, DRUG RESIST UPDATE, V10, P13, DOI 10.1016/j.drup.2007.01.003; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; Marone R, 2008, BBA-PROTEINS PROTEOM, V1784, P159, DOI 10.1016/j.bbapap.2007.10.003; Martin RW, 2007, CANCER RES, V67, P9658, DOI 10.1158/0008-5472.CAN-07-0290; Matsuura K, 2008, J BIOL CHEM, V283, P25485, DOI 10.1074/jbc.M803111200; Matthews DJ, 2007, CELL CYCLE, V6, P104, DOI 10.4161/cc.6.1.3699; McCabe N, 2005, CANCER BIOL THER, V4, P934, DOI 10.4161/cbt.4.9.2141; McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140; Meulmeester E, 2008, CURR CANCER DRUG TAR, V8, P87, DOI 10.2174/156800908783769337; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Miknyoczki SJ, 2003, MOL CANCER THER, V2, P371; Mitchell J, 2009, INT J RADIAT ONCOL, V75, P1520, DOI 10.1016/j.ijrobp.2009.07.1722; Morgan MA, 2005, CANCER RES, V65, P6835, DOI 10.1158/0008-5472.CAN-04-2246; Myer DL, 2005, ONCOGENE, V24, P299, DOI 10.1038/sj.onc.1208278; Myers K, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000324; Noel G, 2006, MOL CANCER THER, V5, P564, DOI 10.1158/1535-7163.MCT-05-0418; O'Connor MJ, 2007, ONCOGENE, V26, P7816, DOI 10.1038/sj.onc.1210879; O'Shaughnessy J, 2009, J CLIN ONCOL, V27; Okita N, 2007, BIOL PHARM BULL, V30, P359, DOI 10.1248/bpb.30.359; Pace P, 2010, SCIENCE, V329, P219, DOI 10.1126/science.1192277; Parsels LA, 2009, MOL CANCER THER, V8, P45, DOI 10.1158/1535-7163.MCT-08-0662; Plummer ER, 2007, CLIN CANCER RES, V13, P6252, DOI 10.1158/1078-0432.CCR-07-0617; Plummer ER, 2006, CURR OPIN PHARMACOL, V6, P364, DOI 10.1016/j.coph.2006.02.004; Portugal J, 2010, CURR PHARM DESIGN, V16, P69, DOI 10.2174/138161210789941801; Portugal J, 2009, TUMORI J, V95, P409; Powell SN, 2009, DNA REPAIR, V8, P1153, DOI 10.1016/j.dnarep.2009.04.011; Rajaraman R, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-25; Ratnam K, 2007, CLIN CANCER RES, V13, P1383, DOI 10.1158/1078-0432.CCR-06-2260; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; Reed JC, 2006, NAT CLIN PRACT ONCOL, V3, P388, DOI 10.1038/ncponc0538; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Richard DJ, 2009, DNA DAMAGE RESPONSE: IMPLICATIONS ON CANCER FORMATION AND TREATMENT, P349, DOI 10.1007/978-90-481-2561-6_16; Roberson RS, 2005, CANCER RES, V65, P2795, DOI 10.1158/0008-5472.CAN-04-1270; Robert I, 2009, J EXP MED, V206, P1047, DOI 10.1084/jem.20082468; Rodriguez R, 2008, CELL DEATH DIFFER, V15, P889, DOI 10.1038/cdd.2008.4; Rodriguez R, 2006, MOL BIOL CELL, V17, P402, DOI 10.1091/mbc.E05-07-0594; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Roninson IB, 2002, DRUG RESIST UPDATE, V5, P204, DOI 10.1016/S1368764602001103; RONINSON IB, 2008, APOPTOSIS CELLULAR O, P223; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sato N, 2000, EXP CELL RES, V255, P321, DOI 10.1006/excr.1999.4797; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Shang ZF, 2010, CANCER RES, V70, P3657, DOI 10.1158/0008-5472.CAN-09-3362; Shinohara ET, 2005, CANCER RES, V65, P4987, DOI 10.1158/0008-5472.CAN-04-4250; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; Singh R, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-4; Stiff T, 2006, EMBO J, V25, P5775, DOI 10.1038/sj.emboj.7601446; STREFFER C, 1986, RADIOTHER ONCOL, V5, P303, DOI 10.1016/S0167-8140(86)80179-7; Sturgeon CM, 2006, MOL CANCER THER, V5, P885, DOI 10.1158/1535-7163.MCT-05-0358; Tao Zhi-Fu, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P377, DOI 10.2174/187152006777698132; Taylor BF, 2006, J PHARMACOL EXP THER, V318, P142, DOI 10.1124/jpet.106.103077; te Poele RH, 2002, CANCER RES, V62, P1876; Terzoudi GI, 2008, INT J ONCOL, V33, P871, DOI 10.3892/ijo_00000075; Thierry B, 2009, ADV MATER, V21, P541, DOI 10.1002/adma.200800998; Thornton TM, 2009, INT J BIOL SCI, V5, P44, DOI 10.7150/ijbs.5.44; Torres K, 1998, CANCER RES, V58, P3620; TOUNEKTI O, 1993, CANCER RES, V53, P5462; Tse AN, 2007, CLIN CANCER RES, V13, P591, DOI 10.1158/1078-0432.CCR-06-1424; Tung CH, 2004, CANCER RES, V64, P1579, DOI 10.1158/0008-5472.CAN-03-3226; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P555, DOI 10.1038/sj.cdd.4402286; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; Veuger SJ, 2004, ONCOGENE, V23, P7322, DOI 10.1038/sj.onc.1207984; WADDELL N, 2009, BREAST CANC RES TREA; Walensky LD, 2006, CELL DEATH DIFFER, V13, P1339, DOI 10.1038/sj.cdd.4401992; Wang HC, 2005, CANCER RES, V65, P4020, DOI 10.1158/0008-5472.CAN-04-3055; Wang ML, 2006, NUCLEIC ACIDS RES, V34, P6170, DOI 10.1093/nar/gkl840; Wang YM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-8; Widel M, 1999, BRIT J CANCER, V80, P1599, DOI 10.1038/sj.bjc.6690569; Willmore E, 2004, BLOOD, V103, P4659, DOI 10.1182/blood-2003-07-2527; Willmore E, 2008, CLIN CANCER RES, V14, P3984, DOI 10.1158/1078-0432.CCR-07-5158; Wu W, 2008, DNA REPAIR, V7, P329, DOI 10.1016/j.dnarep.2007.11.008; Yashige H, 1999, ACTA HAEMATOL-BASEL, V101, P32, DOI 10.1159/000040918; Zhang C, 2009, CLIN CANCER RES, V15, P4630, DOI 10.1158/1078-0432.CCR-08-3272; Zhang L, 2007, DRUG RESIST UPDATE, V10, P207, DOI 10.1016/j.drup.2007.08.002; Zhao Y, 2006, CANCER RES, V66, P5354, DOI 10.1158/0008-5472.CAN-05-4275; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zinkel S, 2006, CELL DEATH DIFFER, V13, P1351, DOI 10.1038/sj.cdd.4401987; ZOLZER F, 1995, RADIOTHER ONCOL, V36, P128, DOI 10.1016/0167-8140(95)01601-C	172	103	110	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	46					6085	6098		10.1038/onc.2010.407	http://dx.doi.org/10.1038/onc.2010.407			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681XD	20818418				2022-12-17	WOS:000284356500001
J	Plaza-Menacho, I; Morandi, A; Robertson, D; Pancholi, S; Drury, S; Dowsett, M; Martin, LA; Isacke, CM				Plaza-Menacho, I.; Morandi, A.; Robertson, D.; Pancholi, S.; Drury, S.; Dowsett, M.; Martin, L-A; Isacke, C. M.			Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance	ONCOGENE			English	Article						RET; breast cancer; endocrine therapy; tamoxifen; estrogen receptor; endocrine resistance	GROWTH-FACTOR RECEPTOR; ACTIVATED PROTEIN-KINASE; ESTROGEN-RECEPTOR; MCF-7 CELLS; MEDIATED TRANSCRIPTION; THERAPY RESISTANCE; GENE-EXPRESSION; CROSS-TALK; SERINE 118; S6 KINASE	Endocrine therapy is the main therapeutic option for patients with estrogen receptor (ER alpha)-positive breast cancer. Resistance to this treatment is often associated with estrogen-independent activation of ER alpha. In this study, we show that in ER alpha-positive breast cancer cells, activation of the receptor tyrosine kinase RET (REarranged during Transfection) by its ligand GDNF results in increased ER alpha phosphorylation on Ser118 and Ser167 and estrogen-independent activation of ER alpha transcriptional activity. Further, we identify mTOR as a key component in this downstream signaling pathway. In tamoxifen response experiments, RET downregulation resulted in 6.2-fold increase in sensitivity of MCF7 cells to antiproliferative effects of tamoxifen, whereas GDNF stimulation had a protective effect against the drug. In tamoxifen-resistant (TAM(R)-1) MCF7 cells, targeting RET restored tamoxifen sensitivity. Finally, examination of two independent tissue microarrays of primary human breast cancers revealed that expression of RET protein was significantly associated with ER alpha-positive tumors and that in primary tumors from patients who subsequently developed invasive recurrence after adjuvant tamoxifen treatment, there was a twofold increase in the number of wRET-positive tumors. Together these findings identify RET as a potentially important therapeutic target in ER alpha-positive breast cancers and in particular in tamoxifen-resistant tumors. Oncogene (2010) 29, 4648-4657; doi:10.1038/onc.2010.209; published online 7 June 2010	[Plaza-Menacho, I.; Morandi, A.; Robertson, D.; Pancholi, S.; Drury, S.; Dowsett, M.; Martin, L-A; Isacke, C. M.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Drury, S.; Dowsett, M.] Royal Marsden Hosp Trust, Acad Dept Biochem, London, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	Isacke, CM (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	clare.isacke@icr.ac.uk	Martin, Lesley-Ann/AAA-1841-2020; Piris, Alejandro/D-3830-2014; Plaza-Menacho, Ivan/K-8517-2017	Isacke, Clare/0000-0002-9222-3345; Pancholi, Sunil/0000-0002-0880-1588; Morandi, Andrea/0000-0002-9222-5332; Plaza-Menacho, Ivan/0000-0003-4666-9431	Breakthrough Breast Cancer; Association of International Cancer Research [09-0533]; Mary-Jean Mitchell Green Foundation; Ministerio de Educacion y Ciencia (MEC) of Spain [EX2006-1341]; NHS; Worldwide Cancer Research [09-0533] Funding Source: researchfish	Breakthrough Breast Cancer; Association of International Cancer Research; Mary-Jean Mitchell Green Foundation; Ministerio de Educacion y Ciencia (MEC) of Spain(Spanish Government); NHS; Worldwide Cancer Research	This work was supported by Breakthrough Breast Cancer (CMI, L-AM and MD), the Association of International Cancer Research (grant 09-0533; CMI, AM and IP-M), the Mary-Jean Mitchell Green Foundation (L-AM and MD) and the Ministerio de Educacion y Ciencia (MEC) of Spain (grant EX2006-1341; IP-M). We acknowledge NHS funding to the NIHR Biomedical Research Centre. We thank Anne E Lykkesfeldt for the TAM<SUP>R</SUP>-1 cells, Jorge Reis-Filho, Suzanne Parry, Kay Savage, Margaret Hills and Janine Salter for their help with the TMA staining and analysis, and to Ana Maria Pereira for her advice on the tamoxifen response experiments.	Abe Y, 2009, J BIOL CHEM, V284, P14939, DOI 10.1074/jbc.M900097200; Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Arpino G, 2008, ENDOCR REV, V29, P217, DOI 10.1210/er.2006-0045; Arpino G, 2007, JNCI-J NATL CANCER I, V99, P694, DOI 10.1093/jnci/djk151; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; Berry NB, 2008, MOL ENDOCRINOL, V22, P1535, DOI 10.1210/me.2007-0449; Boulay A, 2008, CANCER RES, V68, P3743, DOI 10.1158/0008-5472.CAN-07-5100; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Chang SB, 2007, J SURG RES, V138, P37, DOI 10.1016/j.jss.2006.07.003; Creighton CJ, 2006, CANCER RES, V66, P3903, DOI 10.1158/0008-5472.CAN-05-4363; DeGraffenried LA, 2004, CLIN CANCER RES, V10, P8059, DOI 10.1158/1078-0432.CCR-04-0035; Dowsett M, 2006, ANN ONCOL, V17, P818, DOI 10.1093/annonc/mdl016; Esseghir S, 2007, CANCER RES, V67, P11732, DOI 10.1158/0008-5472.CAN-07-2343; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Gee JMW, 2001, INT J CANCER, V95, P247, DOI 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S; Ghayad SE, 2008, CANCER SCI, V99, P1992, DOI 10.1111/j.1349-7006.2008.00955.x; Green KA, 2007, NAT REV CANCER, V7, P713, DOI 10.1038/nrc2211; Gutierrez MC, 2005, J CLIN ONCOL, V23, P2469, DOI 10.1200/JCO.2005.01.172; Howell A, 2004, BREAST CANCER RES, V6, P269, DOI 10.1186/bcr945; Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; Johnston SRD, 2009, CLIN BREAST CANCER, V9, pS28, DOI 10.3816/CBC.2009.s.003; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kok M, 2009, JNCI-J NATL CANCER I, V101, P1725, DOI 10.1093/jnci/djp412; Kurokawa H, 2000, CANCER RES, V60, P5887; Leary AF, 2010, CLIN CANCER RES, V16, P1486, DOI 10.1158/1078-0432.CCR-09-1764; Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087; LYKKESFELDT AE, 1994, CANCER RES, V54, P1587; Macedo LF, 2008, CANCER RES, V68, P3516, DOI 10.1158/0008-5472.CAN-07-6807; Martin LA, 2003, J BIOL CHEM, V278, P30458, DOI 10.1074/jbc.M305226200; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; Massarweh S, 2006, ENDOCR-RELAT CANCER, V13, pS15, DOI 10.1677/erc.1.01273; Menacho IP, 2005, CANCER RES, V65, P1729, DOI 10.1158/0008-5472.CAN-04-2363; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nicholson RI, 1999, ENDOCR-RELAT CANCER, V6, P373, DOI 10.1677/erc.0.0060373; Nicholson RI, 2001, ENDOCR-RELAT CANCER, V8, P175, DOI 10.1677/erc.0.0080175; Oh AS, 2001, MOL ENDOCRINOL, V15, P1344, DOI 10.1210/me.15.8.1344; Osborne CK, 2005, CLIN CANCER RES, V11, p865S; Pancholi S, 2008, ENDOCR-RELAT CANCER, V15, P985, DOI 10.1677/ERC-07-0240; Perez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj.bjc.6600126; Plaza-Menacho I, 2007, J BIOL CHEM, V282, P29230, DOI 10.1074/jbc.M703461200; Plaza-Menacho I, 2007, J BIOL CHEM, V282, P6415, DOI 10.1074/jbc.M608952200; Reis JS, 2006, MODERN PATHOL, V19, P307, DOI 10.1038/modpathol.3800542; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200; Savage K, 2007, CLIN CANCER RES, V13, P90, DOI 10.1158/1078-0432.CCR-06-1371; Shahbazian D, 2006, EMBO J, V25, P2781, DOI 10.1038/sj.emboj.7601166; Shim WS, 2000, ENDOCRINOLOGY, V141, P396, DOI 10.1210/en.141.1.396; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Yamashita H, 2008, ENDOCR-RELAT CANCER, V15, P755, DOI 10.1677/ERC-08-0078; Yamnik RL, 2009, J BIOL CHEM, V284, P6361, DOI 10.1074/jbc.M807532200; Yue W, 2002, ENDOCRINOLOGY, V143, P3221, DOI 10.1210/en.2002-220186	54	103	111	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	33					4648	4657		10.1038/onc.2010.209	http://dx.doi.org/10.1038/onc.2010.209			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20531297				2022-12-17	WOS:000281127400004
J	Niu, Y; Chang, TM; Yeh, S; Ma, WL; Wang, YZ; Chang, C				Niu, Y.; Chang, T-M; Yeh, S.; Ma, W-L; Wang, Y. Z.; Chang, C.			Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails	ONCOGENE			English	Review						prostate metastasis; anti-androgen therapy; androgen replacement therapy	TESTOSTERONE REPLACEMENT THERAPY; GROWTH-IN-VIVO; TUMOR-SUPPRESSOR; MOLECULAR CHARACTERIZATION; STROMAL MICROENVIRONMENT; EPITHELIAL INTERACTIONS; XENOGRAFT MODELS; CASTRATION; INHIBITION; PROGRESSION	Prostate cancer is one of the major causes of cancer-related death in the western world. Androgen-deprivation therapy (ADT) for the suppression of androgens binding to the androgen receptor (AR) has been the norm of prostate cancer treatment. Despite early success to suppress prostate tumor growth, ADT eventually fails leading to recurrent tumor growth in a hormone-refractory manner, even though AR remains to function in hormone-refractory prostate cancer. Interestingly, some prostate cancer survivors who received androgen replacement therapy had improved quality of life without adverse effect on their cancer progression. These contrasting clinical data suggest that differential androgen/AR signals in individual cells of prostate tumors can exist in the same or different patients, and may be used to explain why ADT of prostate cancer fails. Such a hypothesis is supported by the results obtained from transgenic mice with selective knockout of AR in prostatic stromal vs epithelial cells and orthotopic transplants of various human prostate cancer cell lines with AR overexpression or knockout. These studies concluded that AR functions as a stimulator for prostate cancer proliferation and metastasis in stromal cells, as a survival factor of prostatic cancer epithelial luminal cells, and as a suppressor for prostate cancer basal intermediate cell growth and metastasis. These dual yet opposite functions of the stromal and epithelial AR may challenge the current ADT to battle prostate cancer and should be taken into consideration when developing new AR-targeting therapies in selective prostate cancer cells. Oncogene (2010) 29, 3593-3604; doi: 10.1038/onc.2010.121; published online 3 May 2010	[Niu, Y.; Chang, T-M; Yeh, S.; Ma, W-L; Chang, C.] Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA; [Niu, Y.; Chang, T-M; Yeh, S.; Ma, W-L; Chang, C.] Univ Rochester, Med Ctr, Dept Urol, Rochester, NY 14642 USA; [Niu, Y.; Chang, T-M; Yeh, S.; Ma, W-L; Chang, C.] Univ Rochester, Med Ctr, Dept Radiat Oncol, Rochester, NY 14642 USA; [Niu, Y.; Chang, T-M; Yeh, S.; Ma, W-L; Chang, C.] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Wilmot Canc Ctr, Rochester, NY 14642 USA; [Niu, Y.] Tianjin Med Univ, Tianjin Inst Urol, Sex Hormone Res Ctr, Tianjin, Peoples R China; [Ma, W-L] China Med Univ Hosp, Sex Hormone Res Ctr, Taichung, Taiwan; [Wang, Y. Z.] Univ British Columbia, Dept Urol Sci, Vancouver, BC V5Z 1M9, Canada	University of Rochester; University of Rochester; University of Rochester; University of Rochester; Tianjin Medical University; China Medical University Taiwan; China Medical University Hospital - Taiwan; University of British Columbia	Chang, C (corresponding author), Univ Rochester Med, Dept Pathol, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.	chang@urmc.rochester.edu	Ma, Wen-Lung/O-2745-2015	Ma, Wen-Lung/0000-0002-5571-3302; Wang, Yuzhuo/0000-0002-9749-8591	George Whipple Professorship; NIH [CA122840]; NSFC [30872587]; NATIONAL CANCER INSTITUTE [R01CA122840] Funding Source: NIH RePORTER	George Whipple Professorship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSFC(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the George Whipple Professorship and NIH grant CA122840 and NSFC grant project 30872587.	Agarwal PK, 2005, J UROLOGY, V173, P533, DOI 10.1097/01.ju.0000143942.55896.64; AKAKURA K, 1993, CANCER, V71, P2782, DOI 10.1002/1097-0142(19930501)71:9<2782::AID-CNCR2820710916>3.0.CO;2-Z; Altuwaijri S, 2007, ASIAN J ANDROL, V9, P181, DOI 10.1111/j.1745-7262.2007.00258.x; ANDERSON KM, 1968, NATURE, V219, P277, DOI 10.1038/219277a0; Banach-Petrosky W, 2007, CANCER RES, V67, P9089, DOI 10.1158/0008-5472.CAN-07-2887; Baritaki S, 2009, ONCOGENE, V28, P3573, DOI 10.1038/onc.2009.214; Basaria S, 2008, J ANDROL, V29, P534, DOI 10.2164/jandrol.108.005454; Bhatia B, 2005, ONCOGENE, V24, P3583, DOI 10.1038/sj.onc.1208406; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Bouzin C, 2007, DRUG RESIST UPDATE, V10, P109, DOI 10.1016/j.drup.2007.03.001; BRUCHOVSKY N, 1968, J BIOL CHEM, V243, P2012; BRUCHOVSKY N, 1990, CANCER RES, V50, P2275; BRUCHOVSKY N, 1993, CANC MED, P884; Buchanan G, 2001, CANCER METAST REV, V20, P207, DOI 10.1023/A:1015531326689; CHODAK GW, 1992, J UROLOGY, V147, P798, DOI 10.1016/S0022-5347(17)37389-5; Chuu CP, 2006, CANCER RES, V66, P6482, DOI 10.1158/0008-5472.CAN-06-0632; Condon MS, 2005, SEMIN CANCER BIOL, V15, P132, DOI 10.1016/j.semcancer.2004.08.002; Crook JM, 1999, UROLOGY, V53, P530, DOI 10.1016/S0090-4295(98)00547-0; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; Cunha GR, 2003, INT J CANCER, V107, P1, DOI 10.1002/ijc.11335; Denis LJ, 2000, SEMIN SURG ONCOL, V18, P52, DOI 10.1002/(SICI)1098-2388(200001/02)18:1<52::AID-SSU8>3.0.CO;2-6; Eder IE, 2002, CANCER GENE THER, V9, P117, DOI 10.1038/sj.cgt.7700416; Eder IE, 2000, CANCER GENE THER, V7, P997, DOI 10.1038/sj.cgt.7700202; Eisenberger MA, 1998, NEW ENGL J MED, V339, P1036, DOI 10.1056/NEJM199810083391504; Ferreira U, 2006, PROSTATE CANCER P D, V9, P39, DOI 10.1038/sj.pcan.4500833; FOWLER JE, 1981, J UROLOGY, V126, P372, DOI 10.1016/S0022-5347(17)54531-0; GARCIAARENAS R, 1995, MOL CELL ENDOCRINOL, V111, P29, DOI 10.1016/0303-7207(95)03544-H; George DJ, 1999, CANCER RES, V59, P2395; GINGRICH JR, 1991, CANCER RES, V57, P4687; GLEAVE M, 1991, CANCER RES, V51, P3753; Haag P, 2005, J STEROID BIOCHEM, V96, P251, DOI 10.1016/j.jsbmb.2005.04.029; Halin S, 2007, PROSTATE, V67, P370, DOI 10.1002/pros.20473; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Heisler LE, 1997, MOL CELL ENDOCRINOL, V126, P59, DOI 10.1016/S0303-7207(96)03970-6; Hobisch A, 1996, PROSTATE, V28, P129; Hofmeister V, 2008, CANCER IMMUNOL IMMUN, V57, P1, DOI 10.1007/s00262-007-0365-5; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Huggins C, 1941, CANCER RES, V1, P293; Hurtado-Coll A, 2002, UROLOGY, V60, P52, DOI 10.1016/S0090-4295(02)01572-8; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; Inui S, 2002, FASEB J, V16, P1967, DOI 10.1096/fj.02-0043fje; Jemal A, 2005, JAMA-J AM MED ASSOC, V294, P1255, DOI 10.1001/jama.294.10.1255; Johansson A, 2007, PROSTATE, V67, P1664, DOI 10.1002/pros.20657; Johnson MA, 2005, PROSTATE, V62, P322, DOI 10.1002/pros.20148; Joly-Pharaboz MO, 2000, J STEROID BIOCHEM, V73, P237, DOI 10.1016/S0960-0760(00)00076-5; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kaufman JM, 2004, J UROLOGY, V172, P920, DOI 10.1097/01.ju.0000136269.10161.32; Khera M, 2009, J SEX MED, V6, P1165, DOI 10.1111/j.1743-6109.2009.01161.x; Kleeberger W, 2007, CANCER RES, V67, P9199, DOI 10.1158/0008-5472.CAN-07-0806; KOKONTIS J, 1994, CANCER RES, V54, P1566; Kokontis JM, 1998, MOL ENDOCRINOL, V12, P941, DOI 10.1210/me.12.7.941; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Liao XB, 2005, MOL CANCER THER, V4, P505, DOI 10.1158/1535-7163.MCT-04-0313; Litvinov IV, 2004, PROSTATE, V61, P299, DOI 10.1002/pros.20187; Litvinov IV, 2003, J CLIN ENDOCR METAB, V88, P2972, DOI 10.1210/jc.2002-022038; Litvinov IV, 2006, PROSTATE, V66, P1329, DOI 10.1002/pros.20483; Liu AY, 2004, AM J PATHOL, V165, P1543, DOI 10.1016/S0002-9440(10)63412-8; Marques RB, 2005, INT J CANCER, V117, P221, DOI 10.1002/ijc.21201; Mathew P, 2008, ANN ONCOL, V19, P395, DOI 10.1093/annonc/mdm568; Mercader M, 2001, P NATL ACAD SCI USA, V98, P14565, DOI 10.1073/pnas.251140998; Mirosevich J, 1999, J ENDOCRINOL, V162, P341, DOI 10.1677/joe.0.1620341; Miyamoto H, 2005, MOL CARCINOGEN, V44, P1, DOI 10.1002/mc.20121; Mohler JL, 1996, CLIN CANCER RES, V2, P889; Morris MJ, 2009, EUR UROL, V56, P237, DOI 10.1016/j.eururo.2009.03.073; Mostaghel EA, 2007, CANCER RES, V67, P5033, DOI 10.1158/0008-5472.CAN-06-3332; Nagabhushan M, 1996, CANCER RES, V56, P3042; Nelius T, 2007, INT J CANCER, V121, P999, DOI 10.1002/ijc.22802; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12188, DOI 10.1073/pnas.0804701105; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; OLEA N, 1990, ENDOCRINOLOGY, V126, P1457, DOI 10.1210/endo-126-3-1457; Olumi AF, 1999, CANCER RES, V59, P5002; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Pinkas J, 2006, BIOCHEM PHARMACOL, V72, P523, DOI 10.1016/j.bcp.2006.03.004; Rahman M, 2004, CLIN CANCER RES, V10, P2208, DOI 10.1158/1078-0432.CCR-0746-3; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricke WA, 2006, INT J CANCER, V118, P2123, DOI 10.1002/ijc.21614; Roy AK, 1999, VITAM HORM, V55, P309; SADI MV, 1991, CANCER, V67, P3057, DOI 10.1002/1097-0142(19910615)67:12<3057::AID-CNCR2820671221>3.0.CO;2-S; Schmitt B, 2001, UROLOGY, V57, P727, DOI 10.1016/S0090-4295(00)01086-4; SHIMAZAKI JUN, 1965, GUNMA J MED SCI, V14, P313; Soto AM, 1995, ONCOL RES, V7, P545; Szmulewitz R, 2009, EUR UROL, V56, P97, DOI 10.1016/j.eururo.2009.02.022; Taylor LG, 2009, CANCER-AM CANCER SOC, V115, P2388, DOI 10.1002/cncr.24283; Thalmann GN, 2000, PROSTATE, V44, P91; THOMPSON TC, 1993, MOL CARCINOGEN, V7, P165, DOI 10.1002/mc.2940070307; Titus MA, 2005, CLIN CANCER RES, V11, P4653, DOI 10.1158/1078-0432.CCR-05-0525; Tokar EJ, 2005, DIFFERENTIATION, V73, P463, DOI 10.1111/j.1432-0436.2005.00047.x; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; van Leenders GJLH, 2003, CRIT REV ONCOL HEMAT, V46, pS3, DOI 10.1016/S1040-8428(03)00059-3; van Leenders GJLH, 2001, J PATHOL, V195, P563, DOI 10.1002/path.993; van Weerden WM, 2000, PROSTATE, V43, P263; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; vanWeerden WM, 1996, AM J PATHOL, V149, P1055; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; Wang L, 2005, PROSTATE, V63, P117, DOI 10.1002/pros.20170; Wang XD, 2006, DEV BIOL, V290, P66, DOI 10.1016/j.ydbio.2005.11.009; Wang YZ, 2001, CANCER RES, V61, P6064; Webber MM, 1999, CARCINOGENESIS, V20, P1185, DOI 10.1093/carcin/20.7.1185; Wu CT, 2007, P NATL ACAD SCI USA, V104, P12679, DOI 10.1073/pnas.0704940104; Yang ZM, 2007, NAT MED, V13, P348, DOI 10.1038/nm1547; Zhou JR, 2004, INT J CANCER, V110, P800, DOI 10.1002/ijc.20206	104	103	107	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2010	29	25					3593	3604		10.1038/onc.2010.121	http://dx.doi.org/10.1038/onc.2010.121			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20440270				2022-12-17	WOS:000279108600001
J	Kitzing, TM; Wang, Y; Pertz, O; Copeland, JW; Grosse, R				Kitzing, T. M.; Wang, Y.; Pertz, O.; Copeland, J. W.; Grosse, R.			Formin-like 2 drives amoeboid invasive cell motility downstream of RhoC	ONCOGENE			English	Article						cancer cell invasion; Diaphanous formins; RhoC; FMNL2; actin	GENOMIC ANALYSIS; ACTIVATION; GTPASES; G-ALPHA(12/13); METASTASIS; TRANSITION; MECHANISM; MIGRATION; INHIBIT; LARG	Invasive cell migration is a key step for cancer metastasis and involves Rho GTPase-controlled reorganization of the actin cytoskeleton. Altered Rho GTPase expression is found in various malignancies. Particularly, the closely related GTPases RhoA and RhoC are upregulated in many aggressive tumours, but specific effectors that distinguish between these two GTPases to explain mechanistic differences have not been identified. The formins are by far the largest family of Rho GTPase effectors and are characterized by the actin-nucleating formin homology 2 domain. Using siRNA-based screening against all 15 human formins, we systematically analysed their functions in 3D cell motility using three different cancer cell lines. These results reveal distinct requirements for specific formins in amoeboid versus mesenchymal invasive cell migration. Importantly, by knocking down all Rho proteins, we identified formin-like 2 ( FMNL2) as a specific RhoC effector, showing selective interaction of FMNL2 with active RhoC, but not RhoA or RhoB. Functional analysis shows that RhoC regulates auto-inhibition of FMNL2, whereas suppression of FMNL2 inhibits RhoC-, but not RhoA-dependent, rounded invasive cell migration. Thus, our data uncover a novel regulatory and functional interaction between RhoC and FMNL2 for modulating cell shape and invasiveness and provide mechanistic insight into RhoC-specific signalling events. Oncogene (2010) 29, 2441-2448; doi:10.1038/onc.2009.515; published online 25 January 2010	[Grosse, R.] Univ Marburg, Inst Pharmacol, D-35032 Marburg, Hessen, Germany; [Kitzing, T. M.; Wang, Y.] Heidelberg Univ, Inst Pharmacol, D-6900 Heidelberg, Germany; [Wang, Y.] Heidelberg Univ, HBIGS, Heidelberg, Germany; [Pertz, O.] Univ Basel, Ctr Biomed, Basel, Switzerland; [Copeland, J. W.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada	Philipps University Marburg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Basel; University of Ottawa	Grosse, R (corresponding author), Univ Marburg, Inst Pharmacol, Karl von Frisch Str 1, D-35032 Marburg, Hessen, Germany.	robert.grosse@staff.uni-marburg.de		Wang, Ying/0000-0001-8699-5974; Grosse, Robert/0000-0002-3380-5273; pertz, olivier/0000-0001-8579-4919	Deutsche Krebshilfe e. V. [108293]; C.H.S.-Foundation; Heart and Stroke Foundation of Ontario [T6317]; Krebsliga beider Basel	Deutsche Krebshilfe e. V.(Deutsche Krebshilfe); C.H.S.-Foundation; Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario); Krebsliga beider Basel	We thank Erik Sahai for supplying siRNAs against human Rho proteins. We thank Barbara Di Ventura for comments on the paper, Philippe Chavrier for discussions and Anke Niemann for excellent technical assistance. This work was funded by the Deutsche Krebshilfe e. V. (108293) and a group leader fellowship from the C.H.S.-Foundation to RG. JWC is supported by the Heart and Stroke Foundation of Ontario (T6317) and OP by grants from the Krebsliga beider Basel.	Brandt DT, 2009, NAT CELL BIOL, V11, P557, DOI 10.1038/ncb1862; Chesarone M, 2009, DEV CELL, V16, P292, DOI 10.1016/j.devcel.2008.12.001; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; Fackler OT, 2008, J CELL BIOL, V181, P879, DOI 10.1083/jcb.200802081; Faix J, 2006, DEV CELL, V10, P693, DOI 10.1016/j.devcel.2006.05.001; Fleming YM, 2009, ONCOGENE, V28, P983, DOI 10.1038/onc.2008.449; Goode BL, 2007, ANNU REV BIOCHEM, V76, P593, DOI 10.1146/annurev.biochem.75.103004.142647; Goulimari P, 2005, J BIOL CHEM, V280, P42242, DOI 10.1074/jbc.M508690200; Goulimari P, 2008, MOL BIOL CELL, V19, P30, DOI 10.1091/mbc.E06-11-1045; Grosse R, 2003, EMBO J, V22, P3050, DOI 10.1093/emboj/cdg287; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Ji P, 2008, NAT CELL BIOL, V10, P314, DOI 10.1038/ncb1693; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Kitzing TM, 2007, GENE DEV, V21, P1478, DOI 10.1101/gad.424807; Lizarraga F, 2009, CANCER RES, V69, P2792, DOI 10.1158/0008-5472.CAN-08-3709; Mellor H, 1998, J BIOL CHEM, V273, P4811, DOI 10.1074/jbc.273.9.4811; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pille JY, 2005, MOL THER, V11, P267, DOI 10.1016/j.ymthe.2004.08.029; Pinner S, 2008, NAT CELL BIOL, V10, P127, DOI 10.1038/ncb1675; Rose R, 2005, NATURE, V435, P513, DOI 10.1038/nature03604; Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Simpson KJ, 2004, CANCER RES, V64, P8694, DOI 10.1158/0008-5472.CAN-04-2247; Vaillant DC, 2008, J BIOL CHEM, V283, P33750, DOI 10.1074/jbc.M803156200; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Wolf K, 2007, NAT CELL BIOL, V9, P893, DOI 10.1038/ncb1616; Zhu XL, 2008, INT J COLORECTAL DIS, V23, P1041, DOI 10.1007/s00384-008-0520-2	33	103	108	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	16					2441	2448		10.1038/onc.2009.515	http://dx.doi.org/10.1038/onc.2009.515			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20101212				2022-12-17	WOS:000276951500012
J	Lemjabbar-Alaoui, H; van Zante, A; Singer, MS; Xue, Q; Wang, YQ; Tsay, D; He, B; Jablons, DM; Rosen, SD				Lemjabbar-Alaoui, H.; van Zante, A.; Singer, M. S.; Xue, Q.; Wang, Y-Q; Tsay, D.; He, B.; Jablons, D. M.; Rosen, S. D.			Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis	ONCOGENE			English	Article						lung cancer; Sulf-2; sulfatase; heparan sulfate proteoglycans	WNT SIGNALING PATHWAY; CANCER-CELLS; HUMAN BREAST; HEPATOCELLULAR-CARCINOMA; PANCREATIC-CANCER; WNT/BETA-CATENIN; IN-VIVO; GROWTH; ACTIVATION; BINDING	Heparan sulfate (HS) proteoglycans (HSPGs) bind to multiple growth factors/morphogens and regulate their signaling. 6-O-sulfation (6S) of glucosamine within HS chains is critical for many of these ligand interactions. Sulf-1 and Sulf-2, which are extracellular neutral-pH sulfatases, provide a novel post-synthetic mechanism for regulation of HSPG function by removing 6S from intact HS chains. The Sulfs can thereby modulate several signaling pathways, including the promotion of Wnt signaling. We found induction of SULF2 transcripts and Sulf-2 protein in human lung adenocarcinoma and squamous cell carcinoma, the two major classes of nonsmall-cell lung carcinomas (NSCLCs). We confirmed widespread Sulf-2 protein expression in tumor cells of 10/10 surgical specimens of human lung squamous carcinomas. We studied five Sulf-2(+) NSCLC cell lines, including two, which were derived by cigarette-smoke transformation of bronchial epithelial cells. shRNA-mediated Sulf-2 knockdown in these lines caused an increase in 6S on their cell surface and in parallel reversed their transformed phenotype in vitro, eliminated autocrine Wnt signaling and strongly blunted xenograft tumor formation in nude mice. Conversely, forced Sulf-2 expression in non-malignant bronchial epithelial cells produced a partially transformed phenotype. Our findings support an essential role for Sulf-2 in lung cancer, the leading cancer killer. Oncogene (2010) 29, 635-646; doi: 10.1038/onc.2009.365; published online 26 October 2009	[Lemjabbar-Alaoui, H.; Singer, M. S.; Xue, Q.; Wang, Y-Q; Tsay, D.; Rosen, S. D.] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; [van Zante, A.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; [He, B.; Jablons, D. M.] Univ Calif San Francisco, Ctr Comprehens Canc, Dept Surg, Thorac Oncol Lab, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Rosen, SD (corresponding author), Univ Calif San Francisco, Dept Anat, 513 Parnassus Ave,Box 0452, San Francisco, CA 94143 USA.	steven.rosen@ucsf.edu		Rosen, Steven/0000-0002-6245-701X	University of California [17RT-0216, NIH P01 AI053194, NIH R21 CA122025]; Susan Komen Breast Cancer Foundation [PDF0402844, NIH RO1 HL075602]; NIH [RO1 HL075602, R01CA125030]; The Larry Hall and Zygielbaum Memorial Trust; The Kazan, McClain, Edises, Abrams, Fernandez, Lyons & Farrise Foundation; NATIONAL CANCER INSTITUTE [R21CA122025, R01CA125030] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI053194] Funding Source: NIH RePORTER	University of California(University of California System); Susan Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); The Larry Hall and Zygielbaum Memorial Trust; The Kazan, McClain, Edises, Abrams, Fernandez, Lyons & Farrise Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	RB4CD12 was a kind gift from Drs Guido Jenniskens and Toin van Kuppevelt of Nijmegen Medical Center. We thank Dr Roman Nawroth for preliminary work with lung cancer cell lines. We thank Drs Zena Werb, Joanna Phillips and Inna Maltseva for comments on the paper. This work was performed with support from the Tobacco-Related Disease Research Program of the University of California Grant 17RT-0216, NIH P01 AI053194 and NIH R21 CA122025; Susan Komen Breast Cancer Foundation PDF0402844 to SDR; NIH RO1 HL075602 to Dr Zena Werb; The Larry Hall and Zygielbaum Memorial Trust, and The Kazan, McClain, Edises, Abrams, Fernandez, Lyons & Farrise Foundation to DMJ and NIH R01CA125030 to BH.	Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Ai XB, 2007, DEVELOPMENT, V134, P3327, DOI 10.1242/dev.007674; Aikawa T, 2008, J CLIN INVEST, V118, P89, DOI 10.1172/JCI32412; Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bishop JR, 2007, NATURE, V446, P1030, DOI 10.1038/nature05817; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; Capurro MI, 2005, CANCER RES, V65, P6245, DOI 10.1158/0008-5472.CAN-04-4244; Castro NP, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2157; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dai YM, 2005, J BIOL CHEM, V280, P40066, DOI 10.1074/jbc.M508136200; Danesin C, 2006, J NEUROSCI, V26, P5037, DOI 10.1523/JNEUROSCI.0715-06.2006; DeAlmeida VI, 2007, CANCER RES, V67, P5371, DOI 10.1158/0008-5472.CAN-07-0266; Dennissen MABA, 2002, J BIOL CHEM, V277, P10982, DOI 10.1074/jbc.M104852200; Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Freeman SD, 2008, DEV BIOL, V320, P436, DOI 10.1016/j.ydbio.2008.05.554; Furuuchi K, 2000, AM J PATHOL, V156, P1997, DOI 10.1016/S0002-9440(10)65072-9; Fuster MM, 2005, NAT REV CANCER, V5, P526, DOI 10.1038/nrc1649; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Grigoriadis A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1604; Groen RWJ, 2008, CANCER RES, V68, P6969, DOI 10.1158/0008-5472.CAN-08-1322; Habuchi H, 2004, GLYCOCONJUGATE J, V21, P47, DOI 10.1023/B:GLYC.0000043747.87325.5e; Habuchi H, 2007, J BIOL CHEM, V282, P15578, DOI 10.1074/jbc.M607434200; Hoang BH, 2004, INT J CANCER, V109, P106, DOI 10.1002/ijc.11677; Holst CR, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000575; HOSSAIN MM, 2009, GLYCOBIOLOGY; Huang CL, 2008, EUR J CANCER, V44, P2680, DOI 10.1016/j.ejca.2008.08.004; HUGUET EL, 1994, CANCER RES, V54, P2615; Janssens N, 2004, TUMOR BIOL, V25, P161, DOI 10.1159/000081098; Johansson FK, 2004, P NATL ACAD SCI USA, V101, P11334, DOI 10.1073/pnas.0402716101; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kim J, 2007, J THORAC CARDIOV SUR, V133, P733, DOI 10.1016/j.jtcvs.2006.09.053; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Kudo Y, 2006, CANCER RES, V66, P6928, DOI 10.1158/0008-5472.CAN-05-4540; Lai JP, 2008, HEPATOLOGY, V47, P1211, DOI 10.1002/hep.22202; Lai JP, 2004, GASTROENTEROLOGY, V126, P231, DOI 10.1053/j.gastro.2003.09.043; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; Lamanna WC, 2008, J BIOL CHEM, V283, P27724, DOI 10.1074/jbc.M802130200; Langsdorf A, 2007, DEV BIOL, V311, P464, DOI 10.1016/j.ydbio.2007.08.053; Lemjabbar-Alaoui H, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000093; Li JS, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-14; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lum DH, 2007, MOL CELL BIOL, V27, P678, DOI 10.1128/MCB.01279-06; Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389; Mikami I, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-53; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morimoto-Tomita M, 2005, NEOPLASIA, V7, P1001, DOI 10.1593/neo.05496; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Nakashima T, 2008, ONCOL REP, V19, P203; Nawroth R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000392; Ohgaki H, 2004, CANCER LETT, V207, P197, DOI 10.1016/j.canlet.2003.10.020; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; Parish CR, 2001, BBA-REV CANCER, V1471, pM99, DOI 10.1016/S0304-419X(01)00017-8; Ratzka A, 2008, DEV DYNAM, V237, P339, DOI 10.1002/dvdy.21423; Sato M, 2007, J THORAC ONCOL, V2, P327, DOI 10.1097/01.JTO.0000263718.69320.4c; Schlange T, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1769; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Sunaga N, 2001, GENE CHROMOSOME CANC, V30, P316, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1097>3.0.CO;2-9; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tang RH, 2009, J BIOL CHEM, V284, P21505, DOI 10.1074/jbc.M109.028472; Uchimura Kenji, 2006, BMC Biochem, V7, P2, DOI 10.1186/1471-2091-7-2; Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817; Viviano BL, 2004, J BIOL CHEM, V279, P5604, DOI 10.1074/jbc.M310691200; Vlodavsky I, 2007, CURR PHARM DESIGN, V13, P2057; Wang SW, 2004, P NATL ACAD SCI USA, V101, P4833, DOI 10.1073/pnas.0401028101; Winn RA, 2006, J BIOL CHEM, V281, P26943, DOI 10.1074/jbc.M604145200; You L, 2004, ONCOGENE, V23, P6170, DOI 10.1038/sj.onc.1207844	70	103	107	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					635	646		10.1038/onc.2009.365	http://dx.doi.org/10.1038/onc.2009.365			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19855436	Green Submitted, Green Accepted			2022-12-17	WOS:000274223700002
J	Gruhne, B; Sompallae, R; Masucci, MG				Gruhne, B.; Sompallae, R.; Masucci, M. G.			Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints	ONCOGENE			English	Article						Epstein-Barr virus; genomic instability; DNA repair; mitotic spindle checkpoint	NUCLEAR ANTIGEN 3C; BURKITTS-LYMPHOMA CELLS; HUMAN EPITHELIAL-CELLS; NASOPHARYNGEAL CARCINOMA; MEMBRANE ANTIGEN; GENE-EXPRESSION; DOWN-REGULATION; TRANSCRIPTION; PATHWAY; LINES	Epstein-Barr virus (EBV) has been implicated in the pathogenesis of human malignancies, but its contribution to tumorigenesis is not well understood. EBV carriage is associated with increased genomic instability in Burkitt's lymphoma, suggesting that viral products may induce this tumor phenotype. Using a panel of transfected sublines of the B-lymphoma line BJAB expressing the viral genes associated with latent infection, we show that the EBV nuclear antigens, EBNA-1 and EBNA-3C, and the latent membrane protein 1, LMP-1, independently promote genomic instability, as detected by nonclonal chromosomal aberrations, DNA breaks and phosphorylation of histone H2AX. EBNA-1 promotes the generation of DNA damage by inducing reactive oxygen species (ROS), whereas DNA repair is inhibited in LMP-1-expressing cells through downregulation of the DNA damage-sensing kinase, ataxia telangiectasia mutated (ATM), reduction of phosphorylation of its downstream targets Chk2 and inactivation of the G(2) checkpoint. EBNA-3C enhances the propagation of damaged DNA through inactivation of the mitotic spindle checkpoint and transcriptional downregulation of BubR1. Thus, multiple cellular functions involved in the maintenance of genome integrity seem to be independently targeted by EBV, pointing to the induction of genomic instability as a critical event in viral oncogenesis. Oncogene (2009) 28, 3997-4008; doi:10.1038/onc.2009.258; published online 31 August 2009	[Gruhne, B.; Sompallae, R.; Masucci, M. G.] Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Masucci, MG (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Berzelius Vag 35, S-17177 Stockholm, Sweden.	maria.masucci@ki.se	Masucci, Maria/AAC-6666-2019	Masucci, Maria/0000-0002-5541-2809	Swedish Cancer Society; Swedish Medical Research Council; Karolinska Institutet, Stockholm, Sweden; INCA [LSHC-CT-2005-018704]	Swedish Cancer Society(Swedish Cancer Society); Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Karolinska Institutet, Stockholm, Sweden; INCA(Institut National du Cancer (INCA) France)	We thank L Rymo, M Rowe and J Middledorp for the kind gift of transfected cell lines and antibodies and also many colleagues for helpful discussions. This study was supported by grants awarded by the Swedish Cancer Society, the Swedish Medical Research Council and Karolinska Institutet, Stockholm, Sweden and by the European Community Integrated Project on Infection and Cancer, INCA, Project No. LSHC-CT-2005-018704.	AMAN P, 1990, INT J CANCER, V45, P77, DOI 10.1002/ijc.2910450115; Bolt J, 2005, ORAL ONCOL, V41, P1013, DOI 10.1016/j.oraloncology.2005.06.003; Bose S, 2007, J PATHOL, V213, P329, DOI 10.1002/path.2232; Bose S, 2009, J PATHOL, V217, P345, DOI 10.1002/path.2487; Chandel NS, 2001, J BIOL CHEM, V276, P42728, DOI 10.1074/jbc.M103074200; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chen YR, 2008, J VIROL, V82, P8124, DOI 10.1128/JVI.00430-08; Choudhuri T, 2007, J VIROL, V81, P6718, DOI 10.1128/JVI.00053-07; CUOMO L, 1990, EUR J IMMUNOL, V20, P2293, DOI 10.1002/eji.1830201019; Eclache V, 2004, CANCER GENET CYTOGEN, V152, P72, DOI 10.1016/j.cancergencyto.2003.10.010; Erickson KD, 2000, J VIROL, V74, P1057, DOI 10.1128/JVI.74.2.1057-1060.2000; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Greene LM, 2008, MOL PHARMACOL, V73, P419, DOI 10.1124/mol.107.039024; Gruhne B, 2009, P NATL ACAD SCI USA, V106, P2313, DOI 10.1073/pnas.0810619106; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; Huggett J, 2005, GENES IMMUN, V6, P279, DOI 10.1038/sj.gene.6364190; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Kamranvar SA, 2007, ONCOGENE, V26, P5115, DOI 10.1038/sj.onc.1210324; Kang MS, 2001, P NATL ACAD SCI USA, V98, P15233, DOI 10.1073/pnas.211556598; Kelly G, 2002, NAT MED, V8, P1098, DOI 10.1038/nm758; Kelly GL, 2006, P NATL ACAD SCI USA, V103, P14935, DOI 10.1073/pnas.0509988103; KLEIN G, 1986, AIDS RES HUM RETROV, V2, pS167; Knight JS, 2005, P NATL ACAD SCI USA, V102, P18562, DOI 10.1073/pnas.0503886102; Knight JS, 2004, J VIROL, V78, P1981, DOI 10.1128/JVI.78.4.1981-1991.2004; Kulukian A, 2009, DEV CELL, V16, P105, DOI 10.1016/j.devcel.2008.11.005; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; Leao M, 2007, J VIROL, V81, P248, DOI 10.1128/JVI.01096-06; Liu MT, 2005, ONCOGENE, V24, P2635, DOI 10.1038/sj.onc.1208319; Liu MT, 2004, ONCOGENE, V23, P2531, DOI 10.1038/sj.onc.1207375; MARSHALL D, 1995, J VIROL, V69, P3624, DOI 10.1128/JVI.69.6.3624-3630.1995; MCINTOSH JR, 1991, COLD SPRING HARB SYM, V56, P613; MENEZES J, 1975, BIOMEDICINE, V22, P276; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Pan SH, 2009, CARCINOGENESIS, V30, P366, DOI 10.1093/carcin/bgn291; Parish Christopher R, 2009, Curr Protoc Immunol, VChapter 4, DOI 10.1002/0471142735.im0409s84; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; Ranjan D, 1998, AM SURGEON, V64, P47; Rao CV, 2005, P NATL ACAD SCI USA, V102, P4365, DOI 10.1073/pnas.0407822102; Raptis S, 2006, EXP SUPPL, V96, P303; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; ROWE DT, 1986, EMBO J, V5, P2599, DOI 10.1002/j.1460-2075.1986.tb04540.x; Saha A, 2009, J VIROL, V83, P4652, DOI 10.1128/JVI.02408-08; SCHAEFER BC, 1995, P NATL ACAD SCI USA, V92, P10565, DOI 10.1073/pnas.92.23.10565; Shea LM, 1996, J IMMUNOL, V157, P3902; Sivachandran N, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000170; STOLLMANN B, 1985, BRIT J HAEMATOL, V60, P183, DOI 10.1111/j.1365-2141.1985.tb07399.x; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; Winberg G, 2000, MOL CELL BIOL, V20, P8526, DOI 10.1128/MCB.20.22.8526-8535.2000; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051	54	103	109	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2009	28	45					3997	4008		10.1038/onc.2009.258	http://dx.doi.org/10.1038/onc.2009.258			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AC	19718051				2022-12-17	WOS:000272560300005
J	Qin, J; Xie, Y; Wang, B; Hoshino, M; Wolff, DW; Zhao, J; Scofield, MA; Dowd, FJ; Lin, MF; Tu, Y				Qin, J.; Xie, Y.; Wang, B.; Hoshino, M.; Wolff, D. W.; Zhao, J.; Scofield, M. A.; Dowd, F. J.; Lin, M-F; Tu, Y.			Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis	ONCOGENE			English	Article						prostate cancer metastasis; P-Rex1; Rac-selective guanine nucleotide exchange factor; G-protein-coupled receptors; receptor tyrosine kinases	PROTEIN-COUPLED RECEPTORS; BETA-GAMMA-SUBUNITS; PHOSPHOINOSITIDE 3-KINASE; CELL-MIGRATION; GROWTH-FACTOR; RHO GTPASES; ACTIVATION; PROGRESSION; EXPRESSION; INVASION	Excessive activation of G-protein-coupled receptor (GPCR) and receptor tyrosine kinase (RTK) pathways has been linked to prostate cancer metastasis. Rac activation by guanine nucleotide exchange factors (GEFs) plays an important role in directional cell migration, a critical step of tumor metastasis cascades. We found that the upregulation of P-Rex1, a Rac-selective GEF synergistically activated by Gb gamma freed during GPCR signaling, and PIP3, generated during either RTK or GPCR signaling, strongly correlates with metastatic phenotypes in both prostate cancer cell lines and human prostate cancer specimens. Silencing endogenous P-Rex1 in metastatic prostate cancer PC-3 cells selectively inhibited Rac activity and reduced cell migration and invasion in response to ligands of both epidermal growth factor receptor and G-protein-coupled CXC chemokine receptor 4. Conversely, expression of recombinant P-Rex1, but not its 'GEF-dead' mutant, in non-metastatic prostate cancer cells, such as CWR22Rv1, increased cell migration and invasion through Rac-dependent lamellipodia formation. More importantly, using a mouse xenograft model, we showed that the expression of P-Rex1, but not its mutant, induced lymph node metastasis of CWR22Rv1 cells without an effect on primary tumor growth. Thus, by functioning as a coincidence detector of chemotactic signals from both GPCRs and RTKs, P-Rex1-dependent activation of Rac promotes prostate cancer metastasis.	[Qin, J.; Xie, Y.; Wolff, D. W.; Zhao, J.; Scofield, M. A.; Dowd, F. J.; Tu, Y.] Creighton Univ, Sch Med, Dept Pharmacol, Omaha, NE 68178 USA; [Wang, B.] Creighton Univ, Sch Med, Dept Pathol, Omaha, NE 68178 USA; [Hoshino, M.] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Biochem & Cellular Biol, Kyoto, Japan; [Zhao, J.; Tu, Y.] Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100080, Peoples R China; [Lin, M-F] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE USA	Creighton University; Creighton University; National Center for Neurology & Psychiatry - Japan; Chinese Academy of Sciences; Institute of Biophysics, CAS; University of Nebraska System; University of Nebraska Medical Center	Tu, Y (corresponding author), Creighton Univ, Sch Med, Dept Pharmacol, 2500 Calif Plaza,Crsis 3, Omaha, NE 68178 USA.	yapingtu@creighton.edu			Nebraska State Grant [LB595]; NIH [1R011CA125661]; Department of Defense Prostate Cancer Research Program [W81XWH-07-1-0189]; National Center for Research Resources [G20RR024001]; NATIONAL CANCER INSTITUTE [R01CA125661] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [G20RR024001] Funding Source: NIH RePORTER	Nebraska State Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Prostate Cancer Research Program(United States Department of Defense); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This study was supported in part by Nebraska State Grant LB595, NIH 1R011CA125661 and by the Department of Defense Prostate Cancer Research Program W81XWH-07-1-0189 (YT). We thank Dr Laura Hansen for helpful comments and discussions; Dr Haihong Jiang, Lyudmila Batalkina, Dr Greg Perry and Lisa Linder-Stephenson for their technical assistance. The project described was also supported by Grant G20RR024001 from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health.	Albini A, 2007, NAT PROTOC, V2, P504, DOI 10.1038/nprot.2006.466; Arya Manit, 2004, J Exp Ther Oncol, V4, P291; Barber MA, 2007, J BIOL CHEM, V282, P29967, DOI 10.1074/jbc.M701877200; Bex A, 1999, PROSTATE CANCER P D, V2, P36, DOI 10.1038/sj.pcan.4500286; Bonacci TM, 2006, SCIENCE, V312, P443, DOI 10.1126/science.1120378; Bookout AL, 2003, J BIOL CHEM, V278, P37569, DOI 10.1074/jbc.M306276200; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cao X, 2006, ONCOGENE, V25, P3719, DOI 10.1038/sj.onc.1209408; CHING KZ, 1993, MOL CELL BIOCHEM, V126, P151, DOI 10.1007/BF00925693; DAAKA Y, 2004, SCI STKE, pRE2; Dada S, 2008, BIOCHEM BIOPH RES CO, V372, P875, DOI 10.1016/j.bbrc.2008.05.154; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Engers R, 2006, BRIT J CANCER, V95, P1081, DOI 10.1038/sj.bjc.6603385; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gao XH, 2005, ENDOCRINOLOGY, V146, P1707, DOI 10.1210/en.2004-1198; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Hernandez-Negrete I, 2007, J BIOL CHEM, V282, P23708, DOI 10.1074/jbc.M703771200; Hill K, 2005, J BIOL CHEM, V280, P4166, DOI 10.1074/jbc.M411262200; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jimenez-Sainz MC, 2003, MOL PHARMACOL, V64, P773, DOI 10.1124/mol.64.3.773; Kedrin D, 2007, J MAMMARY GLAND BIOL, V12, P143, DOI 10.1007/s10911-007-9046-4; Kelly P, 2006, J BIOL CHEM, V281, P26483, DOI 10.1074/jbc.M604376200; Knight-Krajewski S, 2004, ONCOGENE, V23, P5513, DOI 10.1038/sj.onc.1207708; Kovar JL, 2006, AM J PATHOL, V169, P1415, DOI 10.2353/ajpath.2006.060324; Lehmann DM, 2008, MOL PHARMACOL, V73, P410, DOI 10.1124/mol.107.041780; Lu Y, 2007, J CELL BIOCHEM, V101, P676, DOI 10.1002/jcb.21220; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; MENSING H, 1983, EUR J CELL BIOL, V29, P268; Mimeault M, 2006, CARCINOGENESIS, V27, P1, DOI 10.1093/carcin/bgi229; Minard ME, 2004, BREAST CANCER RES TR, V84, P21, DOI 10.1023/B:BREA.0000018421.31632.e6; Moepps B, 1997, EUR J IMMUNOL, V27, P2102, DOI 10.1002/eji.1830270839; Neptune ER, 1999, J BIOL CHEM, V274, P2824, DOI 10.1074/jbc.274.5.2824; Rosenfeldt H, 2004, FEBS LETT, V572, P167, DOI 10.1016/j.febslet.2004.06.097; Schiller MR, 2006, CELL SIGNAL, V18, P1834, DOI 10.1016/j.cellsig.2006.01.022; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Steeg PS, 2008, NAT CLIN PRACT ONCOL, V5, P206, DOI 10.1038/ncponc1066; Sun D, 2006, DRUG RESIST UPDATE, V9, P274, DOI 10.1016/j.drup.2006.12.001; Wang ZL, 2008, PROSTAG OTH LIPID M, V87, P9, DOI 10.1016/j.prostaglandins.2008.04.001; Welch HCE, 2005, CURR BIOL, V15, P1867, DOI 10.1016/j.cub.2005.09.050; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x; Yoshizawa M, 2005, J NEUROSCI, V25, P4406, DOI 10.1523/JNEUROSCI.4955-04.2005	44	103	105	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2009	28	16					1853	1863		10.1038/onc.2009.30	http://dx.doi.org/10.1038/onc.2009.30			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PW	19305425	Green Accepted, Green Submitted			2022-12-17	WOS:000265640500004
J	Lopez, JI; Mouw, JK; Weaver, VM				Lopez, J. I.; Mouw, J. K.; Weaver, V. M.			Biomechanical regulation of cell orientation and fate	ONCOGENE			English	Review						tension; integrins; migration; extracellular matrix; epithelial cell; force	SMOOTH-MUSCLE-CELLS; MAMMARY-GLAND DEVELOPMENT; VITRO MECHANICAL COMPRESSION; TRACTION FORCE MICROSCOPY; BREAST EPITHELIAL-CELLS; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; LYSYL OXIDASE; IN-VITRO; BRANCHING MORPHOGENESIS	Biomechanical regulation of tumor phenotypes have been noted for several decades, yet the function of mechanics in the co-evolution of the tumor epithelium and altered cancer extracellular matrix has not been appreciated until fairly recently. In this review, we examine the dynamic interaction between the developing epithelia and the extracellular matrix, and discuss how similar interactions are exploited by the genetically modified epithelium during tumor progression. We emphasize the process of mechanoreciprocity, which is a phenomenon observed during epithelial transformation, in which tension generated within the extracellular microenvironment induce and cooperate with opposing reactive forces within transformed epithelium to drive tumor progression and metastasis. We highlight the importance of matrix remodeling, and present a new, emerging paradigm that underscores the importance of tissue morphology as a key regulator of epithelial cell invasion and metastasis.	[Lopez, J. I.; Mouw, J. K.; Weaver, V. M.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; [Lopez, J. I.; Mouw, J. K.; Weaver, V. M.] Univ Calif San Francisco, Ctr Bioengn & Tissue Regenerat, San Francisco, CA 94143 USA; [Weaver, V. M.] Univ Calif San Francisco, Inst Regenerat Med, San Francisco, CA 94143 USA; [Weaver, V. M.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Weaver, V. M.] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; [Weaver, V. M.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Pennsylvania	Weaver, VM (corresponding author), Univ Calif San Francisco, Dept Surg, 513 Parnassus Ave,Med Sci S1364, San Francisco, CA 94143 USA.	Valerie.Weaver@ucsfmedctr.org		Mouw, Janna K/0000-0002-9846-8466; Weaver, Valerie marie/0000-0003-4786-6752	NIH [7R01CA078731-07]; DOD Breast Cancer Research Era of Hope [W81XWH-05-1-330 (BC044791), BC06262]; CIRM [RS1-00449]; DOE [A107165]; NIH NCI Training [5T32CA108462-04]; NATIONAL CANCER INSTITUTE [T32CA108462, R01CA078731] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD Breast Cancer Research Era of Hope(United States Department of Defense); CIRM(California Institute for Regenerative Medicine); DOE(United States Department of Energy (DOE)); NIH NCI Training(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We apologize to the authors whose work is not cited because of space limitations. This work was supported by NIH Grant 7R01CA078731-07, DOD Breast Cancer Research Era of Hope Grant W81XWH-05-1-330 (BC044791), CIRM Grant RS1-00449 and DOE Grant A107165 to VMW, NIH NCI Training Grant 5T32CA108462-04 to JL and DOD Breast Cancer Research Era of Hope Grant BC06262 to JM.	Adam RM, 2003, J UROLOGY, V169, P2388, DOI 10.1097/01.ju.0000063980.99368.35; Akiri G, 2003, CANCER RES, V63, P1657; Alowami S, 2003, BREAST CANCER RES, V5, pR129, DOI 10.1186/bcr622; AUNINS JG, 1990, BIOTECHNOL PROGR, V6, P54, DOI 10.1021/bp00001a009; Avvisato CL, 2007, J CELL SCI, V120, P2672, DOI 10.1242/jcs.03476; BARCELLOSHOFF MH, 1989, DEVELOPMENT, V105, P223; Beningo KA, 2002, TRENDS CELL BIOL, V12, P79, DOI 10.1016/S0962-8924(01)02205-X; Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x; Bissell MJ, 1999, CANCER RES, V59, p1757S; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; Brancaccio M, 2006, CARDIOVASC RES, V70, P422, DOI 10.1016/j.cardiores.2005.12.015; BUTCHER DT, 2008, NAT REV CAN IN PRESS; Cardoso WV, 2006, DEVELOPMENT, V133, P1611, DOI 10.1242/dev.02310; CHAMBARD M, 1984, BIOL CELL, V51, P315, DOI 10.1111/j.1768-322X.1984.tb00310.x; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Chiquet M, 2007, APPL PHYSIOL NUTR ME, V32, P967, DOI 10.1139/H07-053; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; Chrenek MA, 2001, BREAST CANCER RES, V3, P224, DOI 10.1186/bcr300; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Decitre M, 1998, LAB INVEST, V78, P143; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Demou ZN, 2005, CANCER RES, V65, P5674, DOI 10.1158/0008-5472.CAN-04-1682; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; EMERMAN JT, 1977, IN VITRO CELL DEV B, V13, P316, DOI 10.1007/BF02616178; Erler JT, 2006, CANCER RES, V66, P10238, DOI 10.1158/0008-5472.CAN-06-3197; Eshchenko TY, 2007, BIOCHEMISTRY-MOSCOW+, V72, P1016, DOI 10.1134/S0006297907090143; Farge E, 2003, CURR BIOL, V13, P1365, DOI 10.1016/S0960-9822(03)00576-1; Friedrichs J, 2007, J MOL BIOL, V372, P594, DOI 10.1016/j.jmb.2007.06.078; Fukuda S, 2003, P NATL ACAD SCI USA, V100, P13152, DOI 10.1073/pnas.2336130100; Gan Y, 2007, REV SCI INSTRUM, V78, DOI 10.1063/1.2754076; Garcia R, 2007, NAT MATER, V6, P405, DOI 10.1038/nmat1925; Ghosh K, 2007, BIOMATERIALS, V28, P671, DOI 10.1016/j.biomaterials.2006.09.038; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Grodzinsky AJ, 2000, ANNU REV BIOMED ENG, V2, P691, DOI 10.1146/annurev.bioeng.2.1.691; Gudjonsson T, 2002, J CELL SCI, V115, P39; Gupta V, 2006, CARDIOVASC RES, V72, P375, DOI 10.1016/j.cardiores.2006.08.017; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Hebner C, 2008, ANNU REV PATHOL-MECH, V3, P313, DOI 10.1146/annurev.pathmechdis.3.121806.151526; Heinemeier KM, 2007, J PHYSIOL-LONDON, V582, P1303, DOI 10.1113/jphysiol.2007.127639; Helmlinger G, 1997, NAT BIOTECHNOL, V15, P778, DOI 10.1038/nbt0897-778; Hochmuth RM, 2000, J BIOMECH, V33, P15, DOI 10.1016/S0021-9290(99)00175-X; Huang HD, 2004, AM J PHYSIOL-CELL PH, V287, pC1, DOI 10.1152/ajpcell.00559.2003; Ichimiya H, 2007, ORAL SURG ORAL MED O, V103, P334, DOI 10.1016/j.tripleo.2006.05.026; INGBER DE, 1986, ENDOCRINOLOGY, V119, P1768, DOI 10.1210/endo-119-4-1768; Ingman WV, 2006, DEV DYNAM, V235, P3222, DOI 10.1002/dvdy.20972; Kass L, 2007, INT J BIOCHEM CELL B, V39, P1987, DOI 10.1016/j.biocel.2007.06.025; Katsumi A, 2005, J BIOL CHEM, V280, P16546, DOI 10.1074/jbc.C400455200; Katsumi A, 2004, J BIOL CHEM, V279, P12001, DOI 10.1074/jbc.R300038200; Keller R, 2003, DIFFERENTIATION, V71, P171, DOI 10.1046/j.1432-0436.2003.710301.x; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Kirschmann DA, 2002, CANCER RES, V62, P4478; Kleinman HK, 2003, CURR OPIN BIOTECH, V14, P526, DOI 10.1016/j.copbio.2003.08.002; Larsen M, 2006, CURR OPIN CELL BIOL, V18, P463, DOI 10.1016/j.ceb.2006.08.009; LEIVO I, 1983, MED BIOL, V61, P1; Leivonen SK, 2007, INT J CANCER, V121, P2119, DOI 10.1002/ijc.23113; Lelievre S, 1996, RECENT PROG HORM RES, V51, P417; Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006-3495(00)76279-5; LOKESHWAR VB, 2008, J BIOL CHEM; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Mogilner A, 2003, BIOPHYS J, V84, P1591, DOI 10.1016/S0006-3495(03)74969-8; Moore KA, 2005, DEV DYNAM, V232, P268, DOI 10.1002/dvdy.20237; Munevar S, 2001, BIOPHYS J, V80, P1744, DOI 10.1016/S0006-3495(01)76145-0; Muroi Y, 2007, J DENT RES, V86, P786, DOI 10.1177/154405910708600819; Muschler J, 2002, CANCER RES, V62, P7102; Nelson CM, 2006, ANNU REV CELL DEV BI, V22, P287, DOI 10.1146/annurev.cellbio.22.010305.104315; Nguyen HT, 2000, AM J PHYSIOL-CELL PH, V279, pC1155, DOI 10.1152/ajpcell.2000.279.4.C1155; Numaguchi Yasushi, 2003, Angiogenesis, V6, P55, DOI 10.1023/A:1025821517679; O'Brien LE, 2001, NAT CELL BIOL, V3, P831, DOI 10.1038/ncb0901-831; Padera TP, 2004, NATURE, V427, P695, DOI 10.1038/427695a; Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125; PANJABI MM, 1979, ACTA ORTHOP SCAND, V50, P653, DOI 10.3109/17453677908991288; Paszek MJ, 2004, J MAMMARY GLAND BIOL, V9, P325, DOI 10.1007/s10911-004-1404-x; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Payne SL, 2007, J CELL BIOCHEM, V101, P1338, DOI 10.1002/jcb.21371; Pedersen JA, 2005, ANN BIOMED ENG, V33, P1469, DOI 10.1007/s10439-005-8159-4; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; PETERSEN OW, 1993, P NATL ACAD SCI USA, V90, P2556; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Polte TR, 2004, AM J PHYSIOL-CELL PH, V286, pC518, DOI 10.1152/ajpcell.00280.2003; Pommerenke H, 1996, EUR J CELL BIOL, V70, P157; Quinn TP, 2002, AM J PHYSIOL-LUNG C, V282, pL897, DOI 10.1152/ajplung.00044.2001; Reichelt J, 2007, EUR J CELL BIOL, V86, P807, DOI 10.1016/j.ejcb.2007.06.004; Reno F, 2005, WOUND REPAIR REGEN, V13, P255, DOI 10.1111/j.1067-1927.2005.130307.x; Reno F, 2002, ARCH DERMATOL, V138, P475, DOI 10.1001/archderm.138.4.475; Robinson GW, 2007, NAT REV GENET, V8, P963, DOI 10.1038/nrg2227; RODRIGUEZBOULAN E, 1983, J CELL BIOL, V96, P866, DOI 10.1083/jcb.96.3.866; Rutkowski JM, 2007, TRENDS CELL BIOL, V17, P44, DOI 10.1016/j.tcb.2006.11.007; Sabass B, 2008, BIOPHYS J, V94, P207, DOI 10.1529/biophysj.107.113670; Samani A, 2007, PHYS MED BIOL, V52, P1565, DOI 10.1088/0031-9155/52/6/002; Schmedlen KH, 2002, BIOMATERIALS, V23, P4325, DOI 10.1016/S0142-9612(02)00177-1; SCHWARTZ MA, 2008, CURR OPIN CELL BIOL; Silver Frederick H, 2003, Crit Rev Biomed Eng, V31, P255, DOI 10.1615/CritRevBiomedEng.v31.i4.10; Simian M, 2001, DEVELOPMENT, V128, P3117; Stern R, 2008, SEMIN CANCER BIOL, V18, P275, DOI 10.1016/j.semcancer.2008.03.017; Sternlicht MD, 2006, DIFFERENTIATION, V74, P365, DOI 10.1111/j.1432-0436.2006.00105.x; Strongin AY, 2006, CANCER METAST REV, V25, P87, DOI 10.1007/s10555-006-7892-y; Tamada M, 2004, DEV CELL, V7, P709, DOI 10.1016/j.devcel.2004.08.021; Triplett Jason W., 2007, Molecular & Cellular Biomechanics, V4, P13; Unger Meredith, 2003, Methods Mol Biol, V223, P315; Vanderploeg EJ, 2004, J BIOMECH, V37, P1941, DOI 10.1016/j.jbiomech.2004.02.048; Vincent TL, 2007, OSTEOARTHR CARTILAGE, V15, P752, DOI 10.1016/j.joca.2007.01.021; Volokh KY, 2006, ACTA BIOMATER, V2, P493, DOI 10.1016/j.actbio.2006.04.002; Wall ME, 2007, J BIOMECH, V40, P173, DOI 10.1016/j.jbiomech.2005.10.032; WANG AZ, 1990, J CELL SCI, V95, P137; WANG AZ, 1990, J CELL SCI, V95, P153; Wang HB, 2001, P NATL ACAD SCI USA, V98, P11295, DOI 10.1073/pnas.201201198; Wang JHC, 2006, BIOMECH MODEL MECHAN, V5, P1, DOI 10.1007/s10237-005-0012-z; Watson CJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1401; WEAVER VM, 1995, SEMIN CANCER BIOL, V6, P175, DOI 10.1006/scbi.1995.0021; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Wells RG, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.110pe13; Willis BC, 2007, AM J PHYSIOL-LUNG C, V293, pL525, DOI 10.1152/ajplung.00163.2007; Wipff PJ, 2007, J CELL BIOL, V179, P1311, DOI 10.1083/jcb.200704042; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Wong JY, 2003, LANGMUIR, V19, P1908, DOI 10.1021/la026403p; Wyckoff JB, 2006, CURR BIOL, V16, P1515, DOI 10.1016/j.cub.2006.05.065; Yeung T, 2005, CELL MOTIL CYTOSKEL, V60, P24, DOI 10.1002/cm.20041	122	103	104	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2008	27	55					6981	6993		10.1038/onc.2008.348	http://dx.doi.org/10.1038/onc.2008.348			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029939	Green Accepted			2022-12-17	WOS:000261108200010
J	Song, LL; Peng, Y; Yun, J; Rizzo, P; Chaturvedi, V; Weijzen, S; Kast, WM; Stone, PJB; Santos, L; Loredo, A; Lendahl, U; Sonenshein, G; Osborne, B; Qin, JZ; Pannuti, A; Nickoloff, BJ; Miele, L				Song, L. L.; Peng, Y.; Yun, J.; Rizzo, P.; Chaturvedi, V.; Weijzen, S.; Kast, W. M.; Stone, P. J. B.; Santos, L.; Loredo, A.; Lendahl, U.; Sonenshein, G.; Osborne, B.; Qin, J. -Z; Pannuti, A.; Nickoloff, B. J.; Miele, L.			Notch-1 associates with IKK alpha and regulates IKK activity in cervical cancer cells	ONCOGENE			English	Article						Notch; NF-kappa B; apoptosis; IKK alpha	NF-KAPPA-B; KINASE-ALPHA; SIGNALING PATHWAY; EXPRESSION; ACTIVATION; APOPTOSIS; TRANSFORMATION; TRANSCRIPTION; DEREPRESSION; PROTEINS	Notch-1 inhibits apoptosis in some transformed cells through incompletely understood mechanisms. Notch-1 can increase nuclear factor-kappa B (NF-kappa B) activity through a variety of mechanisms. Overexpression of cleaved Notch-1 in T-cell acute lymphoblastic leukemia cells activates NF-kappa B via interaction with the I kappa B kinase (IKK) signalosome. Concomitant activation of the Notch and NF-kappa B pathways has been described in a large series of cervical cancer specimens. Here, we show that wild-type, spontaneously expressed Notch-1 stimulates NF-kappa B activity in CaSki cervical cancer cells by associating with the IKK signalosome through IKK alpha. A significant fraction of tumor necrosis factor (TNF)-alpha-stimulated I kappa B kinase activity in CaSki cells is Notch-1-dependent. In addition, Notch-1 is found in the nucleus in association with IKK alpha at IKK alpha-stimulated promoters and is required for association of IKK alpha with these promoters under basal and TNF-alpha-stimulated conditions. Notch-1-IKK alpha complexes are found in normal human keratinocytes as well, suggesting that IKK regulation is a physiological function of Notch-1. Both Notch-1 and IKK alpha knockdown sensitize CaSki cells to cisplatin-induced apoptosis to equivalent extents. Our data indicate that Notch-1 regulates NF-kappa B in cervical cancer cells at least in part via cytoplasmic and nuclear IKK-mediated pathways.	[Song, L. L.; Peng, Y.; Yun, J.; Rizzo, P.; Pannuti, A.; Miele, L.] Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Breast Canc Program, Maywood, IL USA; [Chaturvedi, V.; Qin, J. -Z; Nickoloff, B. J.] Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Dept Pathol, Maywood, IL USA; [Chaturvedi, V.; Qin, J. -Z; Nickoloff, B. J.] Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Skin Can Program, Maywood, IL USA; [Weijzen, S.] Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Canc Immunol Program, Maywood, IL USA; [Kast, W. M.; Stone, P. J. B.] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; [Santos, L.] Inst Sci & Technol Res San Luis Potosi, Dept Mol Biol, San Luis Potosi, Mexico; [Santos, L.] Mexican Inst Social Secur, Dept Pathol, Mexico City, DF, Mexico; [Lendahl, U.] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden; [Sonenshein, G.] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; [Osborne, B.] Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; University of Southern California; Instituto Potosino Investigacion Cientifica y Tecnologica; Instituto Mexicano del Seguro Social; Karolinska Institutet; Boston University; University of Massachusetts System; University of Massachusetts Amherst	Miele, L (corresponding author), Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, 2160 S 1st Ave,Bldg 112,Room 236, Maywood, IL 60153 USA.	lmiele@lumc.edu		Kast, W Martin/0000-0003-2321-3159; Miele, Lucio/0000-0002-5853-7287; rizzo, paola/0000-0001-7174-9674; Lendahl, Urban/0000-0001-9543-8141	NIH [RO1 CA084065, 1 PO1 AG025531]; V + Whittier Foundation; NATIONAL CANCER INSTITUTE [R01CA084065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG025531] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); V + Whittier Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by NIH grants RO1 CA084065 and 1 PO1 AG025531, and the V + Whittier Foundation (WMK). WMK holds the Walter A Richter Cancer Research Chair. We are grateful to Anna Bigas for critical reading of this manuscript and to Raphael Kopan for helpful discussion of our data and for the gift of the Notch-1/Renilla construct used for quantitative immunoprecipitation.	Aguilera C, 2004, P NATL ACAD SCI USA, V101, P16537, DOI 10.1073/pnas.0404429101; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Bash J, 1999, EMBO J, V18, P2803, DOI 10.1093/emboj/18.10.2803; Daniel B, 1997, J GEN VIROL, V78, P1095, DOI 10.1099/0022-1317-78-5-1095; Fernandez-Majada V, 2007, P NATL ACAD SCI USA, V104, P276, DOI 10.1073/pnas.0606476104; Gray GE, 1999, AM J PATHOL, V154, P785, DOI 10.1016/S0002-9440(10)65325-4; Guan E, 1996, J EXP MED, V183, P2025, DOI 10.1084/jem.183.5.2025; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kim SH, 2004, J CANCER RES CLIN, V130, P551, DOI 10.1007/s00432-004-0567-6; Lathion S, 2003, CANCER RES, V63, P8687; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Manna SK, 2000, J IMMUNOL, V165, P4927, DOI 10.4049/jimmunol.165.9.4927; Miele L, 2006, CLIN CANCER RES, V12, P1074, DOI 10.1158/1078-0432.CCR-05-2570; Miele L, 2006, CURR MOL MED, V6, P905, DOI 10.2174/156652406779010830; Nair A, 2003, ONCOGENE, V22, P50, DOI 10.1038/sj.onc.1206043; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; Osipo C, 2008, LAB INVEST, V88, P11, DOI 10.1038/labinvest.3700700; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; PROCHASKA HJ, 1988, ANAL BIOCHEM, V169, P328, DOI 10.1016/0003-2697(88)90292-8; Prusty BK, 2005, FRONT BIOSCI-LANDMRK, V10, P1510, DOI 10.2741/1635; Ramdass B, 2007, GYNECOL ONCOL, V104, P352, DOI 10.1016/j.ygyno.2006.08.054; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Shin HM, 2006, EMBO J, V25, P129, DOI 10.1038/sj.emboj.7600902; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Vacca A, 2006, EMBO J, V25, P1000, DOI 10.1038/sj.emboj.7600996; Venkatraman M, 2005, MOL CARCINOGEN, V44, P51, DOI 10.1002/mc.20116; Vilimas T, 2007, NAT MED, V13, P70, DOI 10.1038/nm1524; Vooijs M, 2004, J BIOL CHEM, V279, P50864, DOI 10.1074/jbc.M409430200; Wang JH, 2001, J IMMUNOL, V167, P289, DOI 10.4049/jimmunol.167.1.289; Wei LH, 2005, ONCOGENE, V24, P390, DOI 10.1038/sj.onc.1208192; Weijzen S, 2003, J CELL PHYSIOL, V194, P356, DOI 10.1002/jcp.10217; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Woo SH, 2004, INT J CANCER, V112, P596, DOI 10.1002/ijc.20433; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	40	103	114	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2008	27	44					5833	5844		10.1038/onc.2008.190	http://dx.doi.org/10.1038/onc.2008.190			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QC	18560356				2022-12-17	WOS:000259722400007
J	De Boer, L; Oakes, V; Beamish, H; Giles, N; Stevens, F; Somodevilla-Torres, M; DeSouza, C; Gabrielli, B				De Boer, L.; Oakes, V.; Beamish, H.; Giles, N.; Stevens, F.; Somodevilla-Torres, M.; DeSouza, C.; Gabrielli, B.			Cyclin A/cdk2 coordinates centrosomal and nuclear mitotic events	ONCOGENE			English	Article						cyclin A/cdk2; G(2)/M; centrosome	XENOPUS EGG EXTRACTS; HUMAN-CELLS; CYTOPLASMIC ACCUMULATION; G2-M TRANSITION; PROTEIN-KINASE; CDK2; ACTIVATION; PHOSPHORYLATION; MITOSIS; CDC25B	Cyclin A/cdk2 has a role in progression through Sphase, and a large pool is also activated in G(2) phase. Here we report that this G(2) phase pool regulates the timing of progression into mitosis. Knock down of cyclin A by siRNA or addition of a specific cdk2 small molecule inhibitor delayed entry into mitosis by delaying cells in G(2) phase. The G(2) phase-delayed cells contained elevated levels of inactive cyclin B/cdk1. However, increased microtubule nucleation at the centrosomes was observed, and the centrosomes stained for markers of cyclin B/cdk1 activity. Both microtubule nucleation at the centrosomes and the phosphoprotein markers were lost with short-term treatment of the cdk1/2 inhibitor roscovitine but not the Mek1/2 inhibitor U0126. Cyclin A/cdk2 localized at the centrosomes in late G(2) phase after separation of the centrosomes but before the start of prophase. Thus G(2) phase cyclin A/cdk2 controls the timing of entry into mitosis by controlling the subsequent activation of cyclin B/cdk1, but also has an unexpected role in coordinating the activation of cyclin B/cdk1 at the centrosome and in the nucleus.	[De Boer, L.; Oakes, V.; Beamish, H.; Giles, N.; Stevens, F.; Somodevilla-Torres, M.; Gabrielli, B.] Univ Queensland, Princess Alexandra Hosp, Diamantina Inst Canc Immunol & Metab Med, Canc Biol Program, Brisbane, Qld 4102, Australia; [DeSouza, C.] Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	University of Queensland; University System of Ohio; Ohio State University	Gabrielli, B (corresponding author), Univ Queensland, Princess Alexandra Hosp, Diamantina Inst Canc Immunol & Metab Med, Canc Biol Program, Brisbane, Qld 4102, Australia.	brianG@uq.edu.au	Gabrielli, Brian G/B-3655-2011	Gabrielli, Brian G/0000-0003-3933-1651; Stevens, Frankie/0000-0002-2556-473X				Andrews PD, 2003, CURR OPIN CELL BIOL, V15, P672, DOI 10.1016/j.ceb.2003.10.013; BAILLY E, 1992, J CELL SCI, V101, P529; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; BUENDIA B, 1992, J CELL BIOL, V116, P1431, DOI 10.1083/jcb.116.6.1431; CLARKE PR, 1992, EMBO J, V11, P1751, DOI 10.1002/j.1460-2075.1992.tb05227.x; De Souza CPC, 2000, EXP CELL RES, V257, P11, DOI 10.1006/excr.2000.4872; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; Fung TK, 2007, MOL BIOL CELL, V18, P1861, DOI 10.1091/mbc.E06-12-1092; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Goldstone S, 2001, ONCOGENE, V20, P921, DOI 10.1038/sj.onc.1204177; Gong DQ, 2007, CURR BIOL, V17, P85, DOI 10.1016/j.cub.2006.11.066; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hu B, 2001, MOL CELL BIOL, V21, P2755, DOI 10.1128/MCB.21.8.2755-2766.2001; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Krauer KG, 2004, ONCOGENE, V23, P1342, DOI 10.1038/sj.onc.1207253; Lindqvist A, 2005, J CELL BIOL, V171, P35, DOI 10.1083/jcb.200503066; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Mitra J, 2004, ONCOGENE, V23, P3361, DOI 10.1038/sj.onc.1207446; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Qiu L, 2000, MOL BIOL CELL, V11, P2069, DOI 10.1091/mbc.11.6.2069; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Sherr CJ, 2000, CANCER RES, V60, P3689; Stead E, 2002, ONCOGENE, V21, P8320, DOI 10.1038/sj.onc.1206015; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9	31	103	106	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4261	4268		10.1038/onc.2008.74	http://dx.doi.org/10.1038/onc.2008.74			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18372919				2022-12-17	WOS:000257691100001
J	Corso, S; Migliore, C; Ghiso, E; De Rosa, G; Comoglio, PM; Giordano, S				Corso, S.; Migliore, C.; Ghiso, E.; De Rosa, G.; Comoglio, P. M.; Giordano, S.			Silencing the MET oncogene leads to regression of experimental tumors and metastases	ONCOGENE			English	Article						growth factor receptor; tumor progression; invasion; metastasis	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; FACTOR-RECEPTOR; INVASIVE GROWTH; C-MET; TYROSINE KINASE; LENTIVIRAL VECTORS; CANCER METASTASIS; DOWN-REGULATION; GENE-TRANSFER	In spite of the established knowledge of the genetic alterations responsible for cancer onset, the genes promoting and maintaining the invasive/metastatic phenotype are still elusive. The MET proto-oncogene, encoding the tyrosine kinase receptor for hepatocyte growth factor (HGF), senses unfavorable micro-environmental conditions and drives cell invasion and metastasis. MET overexpression, often induced by tumor hypoxia, leads to constitutive activation of the receptor and correlates with poor prognosis. To establish the role of MET in different phases of tumor progression, we developed an inducible lentiviral delivery system of RNA interference. Silencing the endogenous MET gene, overexpressed in tumor cells, resulted in (i) impairment of the execution of the full invasive growth program in vitro, (ii) lack of tumor growth and (iii) decreased generation of experimental metastases in vivo. Notably, silencing MET in already established metastases led to their almost complete regression. This indicates that persistent expression of the MET oncogene is mandatory until the advanced phases of cancer progression.	[Corso, S.; Migliore, C.; Ghiso, E.; Comoglio, P. M.; Giordano, S.] Univ Turin, Sch Med, Inst Canc Res & Treatment IRCC, Div Mol Oncol, I-10060 Turin, Italy; [De Rosa, G.] Univ Turin, Sch Med, Inst Canc Res & Treatment IRCC, Unit Pathol, I-10060 Turin, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Giordano, S (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment IRCC, Div Mol Oncol, Str Prov 142, I-10060 Turin, Italy.	silvia.giordano@ircc.it	Giordano, Silvia/J-9858-2018	Giordano, Silvia/0000-0003-1854-1086; Comoglio, Paolo/0000-0002-7056-5328; CORSO, Simona/0000-0002-5069-1503; Migliore, Cristina/0000-0003-3722-2814	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boccaccio C, 2005, NATURE, V434, P396, DOI 10.1038/nature03357; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Christensen JG, 2003, CANCER RES, V63, P7345; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Corbel SY, 2002, CURR OPIN BIOTECH, V13, P448, DOI 10.1016/S0958-1669(02)00361-0; Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; FIXMAN ED, 1995, ONCOGENE, V10, P237; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Galimi F, 2001, J IMMUNOL, V166, P1241, DOI 10.4049/jimmunol.166.2.1241; Gambarotta G, 1996, ONCOGENE, V13, P1911; Gao CF, 2005, CELL RES, V15, P49, DOI 10.1038/sj.cr.7290264; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Grotegut S, 2006, EMBO J, V25, P3534, DOI 10.1038/sj.emboj.7601213; Gunther EJ, 2003, GENE DEV, V17, P488, DOI 10.1101/gad.1051603; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Ivan M, 1997, ONCOGENE, V14, P2417, DOI 10.1038/sj.onc.1201083; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Kong-Beltran M, 2004, CANCER CELL, V6, P75, DOI 10.1016/j.ccr.2004.06.013; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Patane S, 2006, CANCER RES, V66, P4750, DOI 10.1158/0008-5472.CAN-05-4422; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Petrelli A, 2006, P NATL ACAD SCI USA, V103, P5090, DOI 10.1073/pnas.0508156103; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; REGECAMBRIN G, 1992, CANCER GENET CYTOGEN, V64, P170, DOI 10.1016/0165-4608(92)90350-H; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Rosario M, 2004, DEV CELL, V7, P3, DOI 10.1016/j.devcel.2004.06.015; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Shinomiya N, 2004, CANCER RES, V64, P7962, DOI 10.1158/0008-5472.CAN-04-1043; Skibinski G, 2001, IMMUNOLOGY, V102, P506, DOI 10.1046/j.1365-2567.2001.01186.x; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Taulli R, 2005, CANCER GENE THER, V12, P456, DOI 10.1038/sj.cgt.7700815; Taulli R, 2006, CANCER RES, V66, P4742, DOI 10.1158/0008-5472.CAN-05-4292; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Valabrega G, 2005, ONCOGENE, V24, P3002, DOI 10.1038/sj.onc.1208478; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; VANDEWOUDE GF, 1997, CIBA F SYMP, V212, P130; Vigna E, 2000, J GENE MED, V2, P308; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358	64	103	109	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2008	27	5					684	693		10.1038/sj.onc.1210697	http://dx.doi.org/10.1038/sj.onc.1210697			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17684486				2022-12-17	WOS:000252674900012
J	Shtiegman, K; Kochupurakkal, BS; Zwang, Y; Pines, G; Starr, A; Vexler, A; Citri, A; Katz, M; Lavi, S; Ben-Basat, Y; Benjamin, S; Corso, S; Gan, J; Yosef, RB; Giordano, S; Yarden, Y				Shtiegman, K.; Kochupurakkal, B. S.; Zwang, Y.; Pines, G.; Starr, A.; Vexler, A.; Citri, A.; Katz, M.; Lavi, S.; Ben-Basat, Y.; Benjamin, S.; Corso, S.; Gan, J.; Yosef, R. B.; Giordano, S.; Yarden, Y.			Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling	ONCOGENE			English	Article						endocytosis; Gefitinib; growth factor; NSCLC; tyrosine kinase	GROWTH-FACTOR RECEPTOR; DOWN-REGULATION; TYROSINE KINASES; ERBB RECEPTORS; BREAST-CANCER; GEFITINIB; ENDOCYTOSIS; MUTATIONS; PROTEINS; PHOSPHORYLATION	Several distinct mutations within the kinase domain of the epidermal growth factor receptor (EGFR) are associated with non-small cell lung cancer, but mechanisms underlying their oncogenic potential are incompletely understood. Although normally ligand-induced kinase activation targets EGFR to Cbl-mediated receptor ubiquitinylation and subsequent degradation in lysosomes, we report that certain EGFR mutants escape this regulation. Defective endocytosis characterizes a deletion mutant of EGFR, as well as a point mutant (L858R-EGFR), whose association with c-Cbl and ubiquitinylation are impaired. Our data raise the possibility that refractoriness of L858R-EGFR to downregulation is due to enhanced heterodimerization with the oncogene product HER2, which leads to persistent stimulation.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Tel Aviv Sourasky Med Ctr, Div Oncol, Ramat Aviv, Israel; Tel Aviv Univ, Sch Med, Ramat Aviv, Israel; Tel Aviv Univ, Dept Cell Res & Immunol, Ramat Aviv, Israel; Univ Turin, Sch Med, Inst Cancer Res & Treatment, Dept Oncol Sci,Div Mol Oncol, Turin, Italy	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Tel Aviv University; University of Turin	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, Room 32 Candiotty Bldg,1 Hertzl St, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	Pines, Gur/X-7501-2019; YARDEN, YOSEF/K-1467-2012; Giordano, Silvia/J-9858-2018; Citri, Ami/R-8973-2019	Pines, Gur/0000-0002-1757-6722; Giordano, Silvia/0000-0003-1854-1086; Citri, Ami/0000-0002-9914-0278; CORSO, Simona/0000-0002-5069-1503; Starr, Alexander/0000-0002-9329-3740	NATIONAL CANCER INSTITUTE [R01CA072981, R37CA072981] Funding Source: NIH RePORTER; NCI NIH HHS [CA72981] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amann J, 2005, CANCER RES, V65, P226; Baulida J, 1996, J BIOL CHEM, V271, P5251; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Friedman LM, 2005, P NATL ACAD SCI USA, V102, P1915, DOI 10.1073/pnas.0409610102; Hynes NE, 2001, ENDOCR-RELAT CANCER, V8, P151, DOI 10.1677/erc.0.0080151; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Ouyang XM, 2001, MOL CELL BIOCHEM, V218, P47, DOI 10.1023/A:1007249004222; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; PORTA DG, 1997, EMBO J, V16, P1647; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Tracy S, 2004, CANCER RES, V64, P7241, DOI 10.1158/0008-5472.CAN-04-1905; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Yang SC, 2006, CANCER RES, V66, P6990, DOI 10.1158/0008-5472.CAN-06-1042; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	31	103	106	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	49					6968	6978		10.1038/sj.onc.1210503	http://dx.doi.org/10.1038/sj.onc.1210503			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17486068				2022-12-17	WOS:000250412200002
J	Diry, M; Tomkiewicz, C; Koehle, C; Coumoul, X; Bock, KW; Barouki, R; Transy, C				Diry, M.; Tomkiewicz, C.; Koehle, C.; Coumoul, X.; Bock, K. Walter; Barouki, R.; Transy, C.			Activation of the dioxin/aryl hydrocarbon receptor (AhR) modulates cell plasticity through a JNK-dependent mechanism	ONCOGENE			English	Article						dioxin; Ah receptor; JNK; epithelial plasticity; cell motility; cell scattering	SIGNALING CASCADE; PROTEIN-KINASES; EXPRESSION; MOTILITY; CHEMICALS; ADHESION; ELEGANS; PATHWAY; LACKING; SEVESO	Environmental chemicals such as dioxin adversely affect immune, neurological and reproductive functions and have been implicated in cancer development. However, the mechanisms responsible for dioxin toxicity are still poorly understood. Here, we show that dioxin and related pollutants trigger a marked morphological change in epithelial cells that remodel their cytoskeleton to increase interaction with extra cellular matrix while loosening cell cell contacts. Furthermore, dioxin-treated cells show increased motility. These dioxin-mediated effects are mimicked by constitutive expression and activation of the intracellular dioxin receptor (aryl hydrocarbon receptor (AhR)). They correlate with activation of the Jun NH2-terminal kinase (JNK) and are reverted by treatment with a JNK inhibitor. Dioxin-induced effects occur 48 h post-treatment initiation, a time scale, which argues for a genomic effect of the AhR, linked to induction of target genes. This novel Ahr action on cell plasticity points to a role in cancer progression.	INSERM, U567, CNRS, Dept Malad Infect,Inst Cochin,UMR8104,UFR Biomed, F-75014 Paris, France; Univ Tubingen, Inst Toxicol, D-72074 Tubingen, Germany	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Eberhard Karls University of Tubingen	Transy, C (corresponding author), INSERM, U567, CNRS, Dept Malad Infect,Inst Cochin,UMR8104,UFR Biomed, 27 Rue Faubourg St Jacques,UMR-S 490, F-75014 Paris, France.	transy@cochin.inserm.fr	COUMOUL, Xavier/AAR-3649-2020	COUMOUL, Xavier/0000-0003-2928-9648				Baccarelli A, 2002, ENVIRON HEALTH PERSP, V110, P1169, DOI 10.1289/ehp.021101169; Coumoul X, 2001, CANCER RES, V61, P3942; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Fashena SJ, 2002, J CELL SCI, V115, P99; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Foekens JA, 2000, CANCER RES, V60, P636; Frueh FW, 2001, TOXICOL LETT, V122, P189, DOI 10.1016/S0378-4274(01)00364-2; Gotzmann J, 2004, MUTAT RES-REV MUTAT, V566, P9, DOI 10.1016/S1383-5742(03)00033-4; Huang X, 2004, DEVELOPMENT, V131, P819, DOI 10.1242/dev.00959; Kohle C, 2002, ARCH BIOCHEM BIOPHYS, V402, P172, DOI 10.1016/S0003-9861(02)00076-0; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Marchand A, 2005, MOL PHARMACOL, V67, P444, DOI 10.1124/mol.104.004010; Mulero-Navarro S, 2005, J BIOL CHEM, V280, P28731, DOI 10.1074/jbc.M504538200; Nesaretnam K, 1998, EUR J CANCER, V34, P389, DOI 10.1016/S0959-8049(97)10026-0; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Pastor-Pareja JC, 2004, DEV CELL, V7, P387, DOI 10.1016/j.devcel.2004.07.022; Pelclova D, 2001, ARCH ENVIRON HEALTH, V56, P493, DOI 10.1080/00039890109602897; Pesatori AC, 2003, IND HEALTH, V41, P127, DOI 10.2486/indhealth.41.127; Poellinger L, 2000, FOOD ADDIT CONTAM A, V17, P261, DOI 10.1080/026520300283333; Puga A, 2000, BIOCHEM PHARMACOL, V60, P1129, DOI 10.1016/S0006-2952(00)00403-2; Qin HT, 2004, DEV BIOL, V270, P64, DOI 10.1016/j.ydbio.2004.02.004; Safe S, 2003, CHEM RES TOXICOL, V16, P807, DOI 10.1021/tx034036r; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sisci D, 2004, ONCOGENE, V23, P8920, DOI 10.1038/sj.onc.1208098; Tan ZQ, 2002, BIOCHEM PHARMACOL, V64, P771, DOI 10.1016/S0006-2952(02)01138-3; Weiss C, 2005, ONCOGENE, V24, P4975, DOI 10.1038/sj.onc.1208679; Xia Y, 2004, TRENDS CELL BIOL, V14, P94, DOI 10.1016/j.tcb.2003.12.005; Yamamoto O, 2003, J DERMATOL SCI, V32, P85, DOI 10.1016/S0923-1811(03)00097-5; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927	31	103	114	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2006	25	40					5570	5574		10.1038/sj.onc.1209553	http://dx.doi.org/10.1038/sj.onc.1209553			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16619036	Green Submitted			2022-12-17	WOS:000240370400010
J	Ferraro, D; Corso, S; Fasano, E; Panieri, E; Santangelo, R; Borrello, S; Giordano, S; Pani, G; Galeotti, T				Ferraro, D.; Corso, S.; Fasano, E.; Panieri, E.; Santangelo, R.; Borrello, S.; Giordano, S.; Pani, G.; Galeotti, T.			Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS)	ONCOGENE			English	Article						signal transduction; c-Met; reactive oxygen species; metastasis; Rac-1	PROTEIN-TYROSINE-PHOSPHATASE; GROWTH-FACTOR RECEPTOR; REDOX REGULATION; CELL-ADHESION; SUPEROXIDE-DISMUTASE; SCATTER-FACTOR; KINASE; RHO; ACTIVATION; INACTIVATION	Overexpression of the c-Met/hepatocyte growth factor receptor( HGF-R) proto-oncogene and abnormal generation of intracellular oxygen species ( reactive oxygen species ( ROS)) have been linked, by independent lines of evidence, to cell transformation and to malignant growth. By comparing two subpopulations of the B16 mouse melanoma ( B16-F0 and B16-F10) endowed with different lung metastasis capacities ( low and high, respectively) we found that both the expression/phosphorylation of c-Met and the steady-state levels of ROS positively correlated with metastatic growth. shRNA-mediated downregulation of c-Met in F10 cells led to a parallel decrease in the generation of oxygen species and in metastatic capacity, suggesting that oxidants may mediate the pro-metastatic activity of the HGF receptor. c-Met activation by a ligand elicits the formation of oxidant species through the oxidase-coupled small GTPase Rac-1, a relevant downstream target of the HGF-R. Moreover, cell treatment with the catalytic ROS scavengers EUK-134 and EUK-189 attenuates Met signaling to ERKs and inhibits the anchorage-independent growth of F10 cells, consistent with a critical role for oxygen species in HGF signaling and in aggressive cell behavior. Finally, genetic manipulation of the Rac-ROS cascade at different levels demonstrated its crucial role in the pro-metastatic activity of c- Met in vivo. Thus, we have outlined a novel cascade triggered by c- Met and mediated by ROS, linked to metastasis and potentially targetable by new antimetastatic, redox-based therapies.	Catholic Univ, Sch Med, Inst Gen Pathol, I-00168 Rome, Italy; Univ Turin, Sch Med, Inst Canc Res & Treatment, Div Mol Oncol,IRCC, Turin, Italy; Catholic Univ, Sch Med, Inst Microbiol, Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Pani, G (corresponding author), Catholic Univ, Sch Med, Inst Gen Pathol, Largo F Vito 1 Largo A Gemelli 1, I-00168 Rome, Italy.	gpani@rm.unicatt.it	Santangelo, Rosaria/AAL-1213-2020; Giordano, Silvia/J-9858-2018; Panieri, Emiliano/AAB-9028-2021; Pani, Giovambattista/AAB-1446-2019	Giordano, Silvia/0000-0003-1854-1086; Panieri, Emiliano/0000-0001-7989-7145; Pani, Giovambattista/0000-0001-7133-8728; Santangelo, Rosaria/0000-0002-8056-218X; CORSO, Simona/0000-0002-5069-1503				Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bedogni B, 2003, J BIOL CHEM, V278, P16510, DOI 10.1074/jbc.M301089200; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bouzahzah B, 2001, MOL MED, V7, P816, DOI 10.1007/BF03401974; Caplan JF, 2004, J BIOL CHEM, V279, P7740, DOI 10.1074/jbc.M313049200; Chiarugi P, 2003, J CELL BIOL, V161, P933, DOI 10.1083/jcb.200211118; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; Comoglio PM, 2001, SEMIN CANCER BIOL, V11, P153, DOI 10.1006/scbi.2000.0366; Comoglio PM, 2003, CURR OPIN CELL BIOL, V15, P565, DOI 10.1016/S0955-0674(03)00096-6; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; FIDLER IJ, 1975, CANCER RES, V35, P218; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; FIDLER IJ, 1976, JNCI-J NATL CANCER I, V57, P1199, DOI 10.1093/jnci/57.5.1199; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Fischer OM, 2004, J BIOL CHEM, V279, P28970, DOI 10.1074/jbc.M402508200; Fu XW, 2000, P NATL ACAD SCI USA, V97, P4374, DOI 10.1073/pnas.97.8.4374; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Liu RG, 2001, ONCOGENE, V20, P1486, DOI 10.1038/sj.onc.1204214; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Pani G, 2000, J BIOL CHEM, V275, P38891, DOI 10.1074/jbc.M007319200; PONZETTO C, 1991, ONCOGENE, V6, P553; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rhee S G, 2000, Sci STKE, V2000, ppe1; Ridley A, 2000, NATURE, V406, P466, DOI 10.1038/35020170; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Rong YQ, 1999, P NATL ACAD SCI USA, V96, P9897, DOI 10.1073/pnas.96.17.9897; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; RUSCIANO D, 1995, ONCOGENE, V11, P1979; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Shinomiya N, 2004, CANCER RES, V64, P7962, DOI 10.1158/0008-5472.CAN-04-1043; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Terman JR, 2002, CELL, V109, P887, DOI 10.1016/S0092-8674(02)00794-8; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Ventura A., 2002, SCI STKE, V2002, pPE44; Villa-Moruzzi E, 1998, BIOCHEM J, V336, P235, DOI 10.1042/bj3360235; Wells A, 2000, ADV CANCER RES, V78, P31; Werner E, 2002, J CELL BIOL, V158, P357, DOI 10.1083/jcb.200111028; Xu D, 2002, DEV CELL, V2, P251, DOI 10.1016/S1534-5807(02)00132-6; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200; ZHU DZ, 1991, P NATL ACAD SCI USA, V88, P9568, DOI 10.1073/pnas.88.21.9568	53	103	107	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3689	3698		10.1038/sj.onc.1209409	http://dx.doi.org/10.1038/sj.onc.1209409			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16462764				2022-12-17	WOS:000238448300008
J	Korkmaz, CG; Korkmaz, KS; Kurys, P; Elbi, C; Wang, L; Klokk, TI; Hammarstrom, C; Troen, G; Svindland, A; Hager, GL; Saatcioglu, F				Korkmaz, CG; Korkmaz, KS; Kurys, P; Elbi, C; Wang, L; Klokk, TI; Hammarstrom, C; Troen, G; Svindland, A; Hager, GL; Saatcioglu, F			Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer	ONCOGENE			English	Article						androgens; prostate cancer; six transmembrane; Golgi; transcription	GREEN FLUORESCENT PROTEIN; KALLIKREIN GENE FAMILY; NEOPLASTIC PROSTATE; RESPONSIVE GENES; SERINE-PROTEASE; GOLGI-COMPLEX; HOMEOBOX GENE; IN-VIVO; ANTIGEN; LOCALIZATION	We have identified a novel gene, six transmembrane protein of prostate 2 (STAMP2), named for its high sequence similarity to the recently identified STAMP1 gene. STAMP2 displays a tissue-restricted expression with highest expression levels in placenta, lung, heart, and prostate and is predicted to code for a 459-amino acid six transmembrane protein. Using a form of STAMP2 labeled with green flourescent protein (GFP) in quantitative time-lapse and immuno fluorescence confocal microscopy, we show that STAMP2 is primarily localized to the Golgi complex, trans-Golgi network, and the plasma membrane. STAMP 2 also localizes to vesicular-tubular structures in the cytosol and colocalizes with the Early Endosome Antigen1 (EEA1) suggesting that it may be involved in the secretory/endocytic pathways. STAMP2 expression is exquisitely androgen regulated in the androgen-sensitive, androgen receptor-positive prostate cancer cell line LNCaP, but not in androgen receptor-negative prostate cancer cell lines PC-3 and DU145. Analysis of STAMP2 expression in matched normal and tumor samples microdissected from prostate cancer specimens indicates that STAMP2 is overexpressed in prostate cancer cells compared with normal prostate epithelial cells. Further more, ectopic expression of STAMP2 in prostate cancer cells significantly increases cell growth and colony formation suggesting that STAMP2 may have a role in cell proliferation. Taken together, these data suggest that STAMP2 may contribute to the normal biology of the prostate cell, as well as prostate cancer progression.	Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway; NCI, Lab Receptor Biol & Gene Express, Bethesda, MD 20892 USA; Aker Univ Hosp, Dept Pathol, Oslo, Norway; Norwegian Radium Hosp, Dept Pathol, Oslo, Norway	University of Oslo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Oslo; University of Oslo	Saatcioglu, F (corresponding author), Univ Oslo, Dept Mol Biosci, Postboks 1050, N-0316 Oslo, Norway.	fahris@imbv.uio.no	Korkmaz, Kemal Sami/ABI-5112-2020	Korkmaz, Kemal Sami/0000-0003-4040-2568	NATIONAL CANCER INSTITUTE [Z01BC005450, ZIABC005450] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSEBEL FM, 1997, CURR PROTOCLS MOL BI; Bieberich CJ, 1996, J BIOL CHEM, V271, P31779, DOI 10.1074/jbc.271.50.31779; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; COFFEY DS, 1993, CANCER, V71, P880, DOI 10.1002/1097-0142(19930201)71:3+<880::AID-CNCR2820711403>3.0.CO;2-6; Crawford ED, 1999, UROLOGY, V54, P1, DOI 10.1016/S0090-4295(99)00447-1; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; Deppenmeier U, 2002, CELL MOL LIFE SCI, V59, P1513, DOI 10.1007/s00018-002-8526-3; Donaldson JG, 2000, CELL, V101, P693, DOI 10.1016/S0092-8674(00)80881-8; Haass C, 1996, CURR OPIN NEUROL, V9, P254, DOI 10.1097/00019052-199608000-00002; HAIGH NG, 2002, PROTEIN TARGETING TR, P74; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Hubert RS, 1999, P NATL ACAD SCI USA, V96, P14523, DOI 10.1073/pnas.96.25.14523; Huggins C, 1941, ARCH SURG-CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004; Jenster G, 1999, SEMIN ONCOL, V26, P407; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; Kokontis JM, 1999, VITAM HORM, V55, P219; Korkmaz KS, 2000, DNA CELL BIOL, V19, P499, DOI 10.1089/10445490050128421; Korkmaz KS, 2002, J BIOL CHEM, V277, P36689, DOI 10.1074/jbc.M202414200; Korkmaz KS, 2001, DNA CELL BIOL, V20, P435, DOI 10.1089/104454901750361497; Lemmon SK, 2000, CURR OPIN CELL BIOL, V12, P457, DOI 10.1016/S0955-0674(00)00117-4; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Lippincott-Schwartz J, 1998, TRENDS CELL BIOL, V8, P16, DOI 10.1016/S0962-8924(97)01199-9; Mellman I, 2000, J CELL BIOL, V149, P529, DOI 10.1083/jcb.149.3.529; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Moldes M, 2001, J BIOL CHEM, V276, P33938, DOI 10.1074/jbc.M105726200; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Nelson PS, 1999, P NATL ACAD SCI USA, V96, P3114, DOI 10.1073/pnas.96.6.3114; Ordovas JM, 2000, NUTR REV, V58, P76; Passer BJ, 2003, P NATL ACAD SCI USA, V100, P2284, DOI 10.1073/pnas.0530298100; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PHANG JM, 1985, CURR TOP CELL REGUL, V25, P91; Ponnambalam S, 1996, CURR BIOL, V6, P1076, DOI 10.1016/S0960-9822(02)70669-6; Rittenhouse HG, 1998, CRIT REV CL LAB SCI, V35, P275, DOI 10.1080/10408369891234219; Roy AK, 1999, VITAM HORM, V55, P309; Srikantan V, 2000, P NATL ACAD SCI USA, V97, P12216, DOI 10.1073/pnas.97.22.12216; Steiner MS, 2000, CANCER RES, V60, P4419; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Stephan C, 2002, UROLOGY, V59, P2, DOI 10.1016/S0090-4295(01)01449-2; Stephenson SA, 1999, J BIOL CHEM, V274, P23210, DOI 10.1074/jbc.274.33.23210; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Warkentin E, 2001, EMBO J, V20, P6561, DOI 10.1093/emboj/20.23.6561; Xu LL, 2001, INT J CANCER, V92, P322, DOI 10.1002/ijc.1196; Yousef GM, 1999, CANCER RES, V59, P4252	45	103	111	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4934	4945		10.1038/sj.onc.1208677	http://dx.doi.org/10.1038/sj.onc.1208677			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897894	Bronze			2022-12-17	WOS:000230646500006
J	Schwarzer, R; Tondera, D; Arnold, W; Giese, K; Klippel, A; Kaufmann, J				Schwarzer, R; Tondera, D; Arnold, W; Giese, K; Klippel, A; Kaufmann, J			REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase	ONCOGENE			English	Article						apoptosis; hypoxia; phosphoinositide; 3-kinase; prostate cancer; gene silencing; RNA interference	INDUCIBLE FACTOR-I; CELL-GROWTH DOWNSTREAM; PHOSPHOINOSITIDE 3-KINASE; INDUCED APOPTOSIS; PERICELLULAR HYPOXIA; TUMOR SUPPRESSION; CANCER-THERAPY; EXPRESSION; HIF-1-ALPHA; TARGET	Cancer cells frequently evade apoptosis during tumorigenesis by acquiring mutations in apoptotic regulators. Chronic activation of the PI 3-kinase-Akt pathway through loss of the tumor suppressor PTEN is one mechanism by which these cells can gain increased protection against apoptosis. W e report here that REDD1 ( RTP801) can act as a transcriptional downstream target of PI 3-kinase signaling in human prostate cancer cells (PC-3). REDD1 expression is markedly reduced in PC-3 cells treated with LY294002 (LY) or Rapamycin and strongly induced under hypoxic conditions in a hypoxia-inducible factor-1 (HIF-1)-dependent manner. Loss of function studies employing antisense molecules or RNA interference indicate that REDD1 is essential for invasive growth of prostate cancer cells in vitro and in vivo. Reduced REDD1 levels can sensitize cells towards apoptosis, whereas elevated levels of REDD1 induced by hypoxia or overexpression desensitize cells to apoptotic stimuli. Taken together our data designate REDD1 as a novel target for therapeutic intervention in prostate cancer.	Atugen AG, D-13125 Berlin, Germany		Kaufmann, J (corresponding author), Atugen AG, Otto Warburg Haus Nr 80,Robert Roessle Str 10, D-13125 Berlin, Germany.	kaufmann@atugen.com		Schwarzer, Rolf/0000-0002-8934-8788				Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Akakura N, 2001, CANCER RES, V61, P6548; Alvarez-Tejado M, 2002, J BIOL CHEM, V277, P13508, DOI 10.1074/jbc.M200017200; Anastasiadis AG, 2003, CURR DRUG TARGETS, V4, P191, DOI 10.2174/1389450033491136; Arsham AM, 2004, CANCER RES, V64, P3500, DOI 10.1158/0008-5472.CAN-03-2239; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; Baek JH, 2000, ONCOGENE, V19, P4621, DOI 10.1038/sj.onc.1203814; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Blouw B, 2003, CANCER CELL, V4, P133, DOI 10.1016/S1535-6108(03)00194-6; Bottaro DP, 2003, NATURE, V423, P593, DOI 10.1038/423593a; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chrastina A, 2003, NEOPLASMA, V50, P251; Chun YS, 2000, EUR J BIOCHEM, V267, P4198, DOI 10.1046/j.1432-1327.2000.01453.x; Coffer PJ, 1998, BIOCHEM J, V335, P1; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng127; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, P670, DOI 10.1093/nar/gkg141; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Ghafar MA, 2003, PROSTATE, V54, P58, DOI 10.1002/pros.10162; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hockel M, 2001, SEMIN ONCOL, V28, P36, DOI 10.1016/S0093-7754(01)90211-8; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Kaufmann J, 2004, BIOCHEM SOC T, V32, P355, DOI 10.1042/BST0320355; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kretschmer A, 2003, ONCOGENE, V22, P6748, DOI 10.1038/sj.onc.1206791; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Leenders F, 2004, EMBO J, V23, P3303, DOI 10.1038/sj.emboj.7600345; Mudgil AV, 2003, J INVEST DERMATOL, V121, P191, DOI 10.1046/j.1523-1747.2003.12320.x; Paul SAM, 2004, J CELL PHYSIOL, V200, P20, DOI 10.1002/jcp.10479; Piret JP, 2004, EXP CELL RES, V295, P340, DOI 10.1016/j.yexcr.2004.01.024; Piret JP, 2002, ANN NY ACAD SCI, V973, P443, DOI 10.1111/j.1749-6632.2002.tb04680.x; Piret JP, 2002, BIOCHEM PHARMACOL, V64, P889, DOI 10.1016/S0006-2952(02)01155-3; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Salnikow K, 2000, CANCER RES, V60, P3375; Schmeichel KL, 2003, J CELL SCI, V116, P2377, DOI 10.1242/jcs.00503; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; STEPHENSON RA, 1992, J NATL CANCER I, V84, P951, DOI 10.1093/jnci/84.12.951; Sternberger M, 2002, ANTISENSE NUCLEIC A, V12, P131, DOI 10.1089/108729002760220734; Tondera D, 2004, J BIOL CHEM, V279, P31544, DOI 10.1074/jbc.M404704200; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vazquez F, 2000, BBA-REV CANCER, V1470, pM21, DOI 10.1016/S0304-419X(99)00032-3; Yim S, 2003, J BIOL CHEM, V278, P38260, DOI 10.1074/jbc.M306016200; Zaman K, 1999, J NEUROSCI, V19, P9821; Zhang SXL, 2003, FASEB J, V17, P1709, DOI 10.1096/fj.02-1111fje; Zhong H, 1999, CANCER RES, V59, P5830; Zhou J, 2004, J BIOL CHEM, V279, P13506, DOI 10.1074/jbc.M310164200	58	103	123	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1138	1149		10.1038/sj.onc.1208236	http://dx.doi.org/10.1038/sj.onc.1208236			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592522				2022-12-17	WOS:000226898700002
J	Abedini, MR; Qiu, Q; Yan, XJ; Tsang, BK				Abedini, MR; Qiu, Q; Yan, XJ; Tsang, BK			Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro	ONCOGENE			English	Article						FLIP; caspases; chemoresistance; cisplatin; ovarian cancer	X-LINKED INHIBITOR; APOPTOSIS-INDUCING LIGAND; FAS-MEDIATED APOPTOSIS; DOWN-REGULATION; CELLULAR FLIP; UP-REGULATION; C-FLIP; CISPLATIN; EXPRESSION; RESISTANCE	Chemoresistance is a major therapeutic problem and the current knowledge on cellular mechanisms involved is incomplete. In the present study, we have investigated the possible involvement of Fas-associated death domain-like interleukin-1beta-converting enzyme (FLICE)-like inhibitory protein ( FLIP) in ovarian cancer resistance by comparing chemosensitive (OV2008) and chemoresistant (C13*) ovarian cancer cells treated with cisplatin in vitro, and/ or transfected with FLIP sense cDNA or FLIP small interfering RNA ( siRNA) and determining FLIP protein content, cleavage of caspase-8 and caspase-3 and apoptosis. Cisplatin significantly decreased FLIP protein level, induced cleavage of caspase-8 and caspase-3 and apoptosis in a concentration-dependent manner in cisplatin-sensitive but not - resistant cells. While overexpression of FLIP-attenuated cisplatin-induced cleavage of caspase-8 and caspase-3 and apoptosis in chemosensitive cells, downregulation of FLIP in chemoresistant cells by siRNA increased apoptosis induced by cisplatin. These results suggest that FLIP plays a significant role in the regulation of apoptosis in human ovarian cancer cells and their sensitivity to cisplatin. This cell survival factor may be an important determinant in chemoresistance in ovarian cancer and may serve as a molecular target for the development of novel therapy for chemoresistant ovarian cancer.	Univ Ottawa, Dept Obstet, Reprod Biol Unit, Ottawa, ON, Canada; Univ Ottawa, Dept Gynaecol, Div Gynecol Oncol, Ottawa, ON, Canada; Univ Ottawa, Dept Cellular Med, Ottawa, ON, Canada; Univ Ottawa, Dept Mol Med, Ottawa, ON, Canada; Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada	University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Tsang, BK (corresponding author), 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.	btsang@ohri.ca		Tsang, Benjamin K./0000-0003-1213-3946				Arts HJG, 2000, INT J GYNECOL CANCER, V10, P47, DOI 10.1046/j.1525-1438.2000.99511.x; Asselin E, 2001, CANCER RES, V61, P1862; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; Bin LH, 2002, FEBS LETT, V510, P37, DOI 10.1016/S0014-5793(01)03222-7; Cheng JQ, 2002, DRUG RESIST UPDATE, V5, P131, DOI 10.1016/S1368-7646(02)00003-1; Delmastro DA, 1997, CANCER CHEMOTH PHARM, V39, P245; EASTMAN A, 1986, BIOCHEMISTRY-US, V25, P3912, DOI 10.1021/bi00361a026; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; Fraser M, 2003, CANCER RES, V63, P7081; Fukazawa T, 2001, ONCOGENE, V20, P5225, DOI 10.1038/sj.onc.1204673; Hennino A, 2000, J IMMUNOL, V165, P3023, DOI 10.4049/jimmunol.165.6.3023; Hu LM, 2002, CANCER RES, V62, P1087; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kamarajan P, 2003, BIOCHEM J, V376, P253, DOI 10.1042/BJ20030659; Kamsteeg M, 2003, ONCOGENE, V22, P2611, DOI 10.1038/sj.onc.1206422; Kim JH, 2003, CLIN CANCER RES, V9, P3134; Kinoshita H, 2000, INT J CANCER, V88, P986, DOI 10.1002/1097-0215(20001215)88:6<986::AID-IJC23>3.0.CO;2-B; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; Ryu BK, 2001, J PATHOL, V194, P15, DOI 10.1002/path.835; Sasaki H, 2000, CANCER RES, V60, P5659; Schneiderman D, 1999, APOPTOSIS, V4, P271, DOI 10.1023/A:1008186323178; Song JH, 2003, CLIN CANCER RES, V9, P4255; Vignati S, 2002, EUR J CANCER, V38, P177, DOI 10.1016/S0959-8049(01)00345-8; Wajant Harald, 2003, Mol Interv, V3, P124, DOI 10.1124/mi.3.3.124; Wang J, 2000, EUR J IMMUNOL, V30, P155, DOI 10.1002/1521-4141(200001)30:1<155::AID-IMMU155>3.3.CO;2-O; Xiao CW, 2003, ENDOCRINOLOGY, V144, P623, DOI 10.1210/en.2001-211024; Yang BF, 2003, J BIOL CHEM, V278, P7043, DOI 10.1074/jbc.M211278200; Yoshikawa H, 2000, J IMMUNOL, V165, P6262, DOI 10.4049/jimmunol.165.11.6262; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200	31	103	105	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					6997	7004		10.1038/sj.onc.1207925	http://dx.doi.org/10.1038/sj.onc.1207925			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15258564				2022-12-17	WOS:000223885100001
J	Pike, MC; Pearce, CL; Wu, AH				Pike, MC; Pearce, CL; Wu, AH			Prevention of cancers of the breast, endometrium and ovary	ONCOGENE			English	Review						prevention; breast cancer; endometrial cancer; ovarian cancer	HORMONE REPLACEMENT THERAPY; BODY-MASS INDEX; RISK-FACTORS; POSTMENOPAUSAL WOMEN; REPRODUCTIVE FACTORS; MAMMOGRAPHIC DENSITIES; CHORIONIC-GONADOTROPIN; EPITHELIAL TUMORS; ESTROGEN-LEVELS; UNITED-STATES	A central epidemiological feature of cancers of the breast, endometrium and ovary is the sharp slowing down in their rate of increase with age around the time of menopause. The incidence of these tumors by the age of 70 years would be between fourfold and eightfold increased if the rapid increase with age seen in young women continued into old age. These phenomena can be explained by the different effects of ovarian hormones on cell division rates in the relevant tissues. Models of these effects provide a plausible explanation of most of the known epidemiology of each of the cancers, including the increase in breast cancer risk from menopausal estrogen-progestin therapy. Some recent epidemiological findings in endometrial and ovarian cancer suggest new avenues for possible chemoprevention of these cancers.	USC, Norris Canc Ctr, Los Angeles, CA 90089 USA	University of Southern California	Pike, MC (corresponding author), USC, Norris Canc Ctr, Los Angeles, CA 90089 USA.	mcpike@usc.edu						ALBREKTSEN G, 1995, INT J CANCER, V61, P485, DOI 10.1002/ijc.2910610410; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; ANDERSON TJ, 1982, BRIT J CANCER, V46, P376, DOI 10.1038/bjc.1982.213; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BERNSTEIN L, 1990, CANCER CAUSE CONTROL, V1, P51, DOI 10.1007/BF00053183; BERNSTEIN L, 1995, CANCER EPIDEM BIOMAR, V4, P437; Blankenstein MA, 1999, J STEROID BIOCHEM, V69, P293, DOI 10.1016/S0960-0760(99)00048-5; Boyd NF, 2002, NEW ENGL J MED, V347, P886, DOI 10.1056/NEJMoa013390; BOYD NF, 1995, J NATL CANCER I, V87, P670, DOI 10.1093/jnci/87.9.670; BRINTON LA, 1992, AM J OBSTET GYNECOL, V167, P1317, DOI 10.1016/S0002-9378(11)91709-8; Cairns J, 2002, P NATL ACAD SCI USA, V99, P10567, DOI 10.1073/pnas.162369899; Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development, 1987, N Engl J Med, V316, P650; CASAGRANDE JT, 1979, LANCET, V2, P170; Cauley JA, 2001, BREAST CANCER RES TR, V65, P125, DOI 10.1023/A:1006478317173; Cerin A, 1996, NEW ENGL J MED, V334, P668, DOI 10.1056/NEJM199603073341018; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Colditz GA, 2000, AM J EPIDEMIOL, V152, P950, DOI 10.1093/aje/152.10.950; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P711; CUTLER SJ, 1975, NATL CANC I MONOGR, V41; DOLL R, 1971, J R STAT SOC SER A-G, V134, P133, DOI 10.2307/2343871; Dubeau L, 1999, GYNECOL ONCOL, V72, P437, DOI 10.1006/gyno.1998.5275; El-Bastawissi AY, 2001, ANN EPIDEMIOL, V11, P257, DOI 10.1016/S1047-2797(00)00225-8; Engeland A, 2003, JNCI-J NATL CANCER I, V95, P1244, DOI 10.1093/jnci/djg010; ETTINGER B, 1994, OBSTET GYNECOL, V83, P693; Fairfield KM, 2002, OBSTET GYNECOL, V100, P288, DOI 10.1016/S0029-7844(02)02053-7; FARROW DC, 1989, AM J EPIDEMIOL, V129, P1300, DOI 10.1093/oxfordjournals.aje.a115249; Fathalla M F, 1972, Obstet Gynecol Surv, V27, P751, DOI 10.1097/00006254-197211000-00001; FLOWERS CE, 1983, OBSTET GYNECOL, V61, P135; FUJIMOTO I, 1979, NATL CANCER I MONOGR, V53, P5; Gapstur SM, 2003, CANCER EPIDEM BIOMAR, V12, P1074; GOLDIN BR, 1986, AM J CLIN NUTR, V44, P945, DOI 10.1093/ajcn/44.6.945; Gram IT, 2001, CANCER EPIDEM BIOMAR, V10, P1117; Greendale GA, 2003, J NATL CANCER I, V95, P30, DOI 10.1093/jnci/95.1.30; HENDERSON BE, 1982, CANCER RES, V42, P3232; HENDERSON BE, 1983, BRIT J CANCER, V47, P749, DOI 10.1038/bjc.1983.127; HENDERSON BE, 1981, LANCET, V2, P363; HENDERSON BE, 1981, HORMONES BREAST CANC, P115; HOEL DG, 1983, AM J EPIDEMIOL, V118, P78, DOI 10.1093/oxfordjournals.aje.a113619; Jakes RW, 2002, CANCER EPIDEM BIOMAR, V11, P608; JANERICH DT, 1979, LANCET, V1, P1240; Kelsey JL, 1996, ANNU REV PUBL HEALTH, V17, P47, DOI 10.1146/annurev.pu.17.050196.000403; KEY TJA, 1988, BRIT J CANCER, V57, P205, DOI 10.1038/bjc.1988.44; KEY TJA, 1990, BRIT J CANCER, V62, P631, DOI 10.1038/bjc.1990.344; KING RJB, 1984, MED MANAGEMENT ENDOM, P67; Kuper H, 2002, CANCER CAUSE CONTROL, V13, P455, DOI 10.1023/A:1015751105039; KVALE G, 1988, CANCER RES, V48, P6217; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; Lambe M, 1999, CANCER CAUSE CONTROL, V10, P43, DOI 10.1023/A:1008860615584; LANE G, 1986, FERTIL STERIL, V45, P345; LEE NC, 1987, JAMA-J AM MED ASSOC, V257, P796; LEE NC, 1986, AGING REPROD CLIMACT; Lippman SM, 1999, JNCI-J NATL CANCER I, V91, P1809, DOI 10.1093/jnci/91.21.1809; Lubin F, 2003, AM J EPIDEMIOL, V157, P113, DOI 10.1093/aje/kwf184; Lukanova A, 2002, INT J CANCER, V99, P603, DOI 10.1002/ijc.10374; Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.3.CO;2-Y; McPherson CP, 1996, AM J EPIDEMIOL, V143, P1195, DOI 10.1093/oxfordjournals.aje.a008707; Ness RB, 2000, AM J EPIDEMIOL, V152, P233, DOI 10.1093/aje/152.3.233; Ness RB, 2002, AM J EPIDEMIOL, V155, P217, DOI 10.1093/aje/155.3.217; NEWHOUSE ML, 1977, BRIT J PREV SOC MED, V31, P148; *OFF POP CENS SURV, 1978, DEC SUPPL OCC MORT 1, V1; PATERSON MEL, 1980, BRIT MED J, V280, P822, DOI 10.1136/bmj.280.6217.822; PEARCE CL, 2004, UNPUB; Peto R, 1977, ORIGINS HUMAN CANC C, P1403; PETTERSSON B, 1986, ACTA OBSTET GYN SCAN, V65, P247, DOI 10.3109/00016348609155179; Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000; PIKE MC, 1987, J CHRON DIS, V40, pS59, DOI 10.1016/S0021-9681(87)80009-7; Pike MC, 1997, J NATL CANCER I, V89, P1110, DOI 10.1093/jnci/89.15.1110; Pike MC, 2004, FERTIL STERIL, V82, P186, DOI 10.1016/j.fertnstert.2004.03.013; Pike MC, 2002, CANCER EPIDEM BIOMAR, V11, P795; PIKE MC, 1983, NATURE, V303, P767, DOI 10.1038/303767a0; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; PIKE MC, 1989, BRIT J CANCER, V60, P142, DOI 10.1038/bjc.1989.237; Purdie DM, 1999, BRIT J CANCER, V81, P559, DOI 10.1038/sj.bjc.6690731; Purdie DM, 2001, CANCER CAUSE CONTROL, V12, P855, DOI 10.1023/A:1012267619561; Riman T, 2002, AM J EPIDEMIOL, V156, P363, DOI 10.1093/aje/kwf048; Riman T, 2002, JNCI-J NATL CANCER I, V94, P497, DOI 10.1093/jnci/94.7.497; Risch HA, 1996, GYNECOL ONCOL, V63, P254, DOI 10.1006/gyno.1996.0315; RISCH HA, 1994, AM J EPIDEMIOL, V140, P585, DOI 10.1093/oxfordjournals.aje.a117296; Rodriguez C, 2002, CANCER EPIDEM BIOMAR, V11, P822; Rodriguez C, 2001, JAMA-J AM MED ASSOC, V285, P1460, DOI 10.1001/jama.285.11.1460; Rodriguez GC, 1998, J SOC GYNECOL INVEST, V5, P271, DOI 10.1016/S1071-5576(98)00017-3; Rodriguez GC, 2002, JNCI-J NATL CANCER I, V94, P50; ROSNER B, 1994, AM J EPIDEMIOL, V139, P819, DOI 10.1093/oxfordjournals.aje.a117079; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Royar J, 2001, INT J CANCER, V95, P370, DOI 10.1002/1097-0215(20011120)95:6<370::AID-IJC1065>3.0.CO;2-T; RUSSO IH, 1991, BRIT J CANCER, V64, P481, DOI 10.1038/bjc.1991.335; RUSSO J, 1994, CANCER EPIDEM BIOMAR, V3, P353; Schairer C, 2000, JAMA-J AM MED ASSOC, V284, P693; Schildkraut JM, 2001, OBSTET GYNECOL, V98, P85, DOI 10.1016/S0029-7844(01)01388-6; Schildkraut JM, 2002, JNCI-J NATL CANCER I, V94, P32; Schouten LJ, 2003, AM J EPIDEMIOL, V157, P424, DOI 10.1093/aje/kwf224; SHIMIZU H, 1990, BRIT J CANCER, V62, P451, DOI 10.1038/bjc.1990.316; SIITERI PK, 1981, HORMONES BREAST CANC, P87; Siiteri PK, 1973, HDB PHYSIOLOGY ENDOC, P615; SIMEONS ATW, 1954, LANCET, V2, P946; Sit ASY, 2002, GYNECOL ONCOL, V86, P118, DOI 10.1006/gyno.2002.6746; SPICER DV, 1994, J NATL CANCER I, V86, P431, DOI 10.1093/jnci/86.6.431; SPICER DV, 1993, CONTRACEPTION, V47, P427, DOI 10.1016/0010-7824(93)90095-O; SPICER DV, 1991, CONTRACEPTION, V44, P289, DOI 10.1016/0010-7824(91)90019-C; Titus-Ernstoff L, 2001, BRIT J CANCER, V84, P714, DOI 10.1054/bjoc.2000.1596; TORNBERG SA, 1994, BRIT J CANCER, V69, P358, DOI 10.1038/bjc.1994.65; Tung KH, 2003, AM J EPIDEMIOL, V158, P629, DOI 10.1093/aje/kwg177; Ursin G, 1998, CANCER EPIDEM BIOMAR, V7, P43; WATERHOUSE J, 1976, IARC SCI PUBLICATION, V1; WEISS NS, 1982, J NATL CANCER I, V68, P95; WELSCH CW, 1981, HORMONES BREAST CANC, P299; Whiteman DC, 2003, CANCER EPIDEM BIOMAR, V12, P42; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; WILLIAMS DB, 1994, OBSTET GYNECOL, V84, P787; Zhou H, 2002, CANCER BIOL THER, V1, P300, DOI 10.4161/cbt.86; [No title captured]	111	103	106	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6379	6391		10.1038/sj.onc.1207899	http://dx.doi.org/10.1038/sj.onc.1207899			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322512	Bronze			2022-12-17	WOS:000223468800006
J	Oh, J; Takahashi, R; Adachi, E; Kondo, S; Kuratomi, S; Noma, A; Alexander, DB; Motoda, H; Okada, A; Seiki, M; Itoh, T; Itohara, S; Takahashi, C; Noda, M				Oh, J; Takahashi, R; Adachi, E; Kondo, S; Kuratomi, S; Noma, A; Alexander, DB; Motoda, H; Okada, A; Seiki, M; Itoh, T; Itohara, S; Takahashi, C; Noda, M			Mutations in two matrix metalloproteinase genes, MMP-2 and MT1-MMP, are synthetic lethal in mice	ONCOGENE			English	Article						MMP-2; MT1-MMP; angiogenesis; myogenesis	CENTRAL CORE DISEASE; ARTERIAL ENLARGEMENT; EXTRACELLULAR-MATRIX; CONGENITAL MYOPATHIES; IV COLLAGENASE; KEY REGULATOR; GELATINASE-A; ANGIOGENESIS; EXPRESSION; ACTIVATION	The matrix metalloproteinase (MMP) family (similar to25 members in mammals) has been implicated in extracellular matrix remodeling associated with embryonic development, cancer formation and progression, and various other physiological and pathological events. Inactivating mutations in individual matrix metalloproteinase genes in mice described so far, however, are nonlethal at least up to the first few weeks after birth, suggesting functional redundancy among MMP family members. Here, we report that mice lacking two MMPs, MMP-2 (nonmembrane type) and MT1-MMP ( membrane type), die immediately after birth with respiratory failure, abnormal blood vessels, and immature muscle fibers reminiscent of central core disease. In the absence of MMP-2 and MT1-MMP, myoblast fusion in vitro is also significantly retarded. These findings suggest functional overlap in mice between the two MMPs with distinct molecular natures.	Kyoto Univ, Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Sakyo Ku, Kyoto 6068501, Japan; Kitasato Univ, Grad Sch Med Sci, Dept Physiol & Biophys, Kanagawa 2288555, Japan; Kyoto Univ, Grad Sch Med, Dept Phys & Biophys, Sakyo Ku, Kyoto 6068501, Japan; Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Tokyo 1088639, Japan; Shionogi & Co Ltd, Discovery Res Labs, Fukushima Ku, Osaka 5530002, Japan; RIKEN, Brain Sci Inst, Lab Behav Genet, Wako, Saitama 3510198, Japan	Kyoto University; Kyoto University; Kitasato University; Kyoto University; University of Tokyo; Shionogi & Company Limited; RIKEN	Noda, M (corresponding author), Kyoto Univ, Sch Med, Dept Mol Oncol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	mnoda@virus.kyoto-u.ac.jp	Itohara, Shigeyoshi/I-8769-2012; Seiki, Motoharu/K-9443-2015	Itohara, Shigeyoshi/0000-0002-2410-9989; Oh, Junseo/0000-0002-0754-4946				Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; COUCH CB, 1983, CELL, V32, P257, DOI 10.1016/0092-8674(83)90516-0; de Kleijn DPV, 2001, FEBS LETT, V501, P37, DOI 10.1016/S0014-5793(01)02622-9; Deryugina EI, 2002, CANCER RES, V62, P580; Durbeej M, 1998, CURR OPIN CELL BIOL, V10, P594, DOI 10.1016/S0955-0674(98)80034-3; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; FAHIME EE, 2000, EXP CELL RES, V258, P279; FANANAPAZIR L, 1993, P NATL ACAD SCI USA, V90, P3993, DOI 10.1073/pnas.90.9.3993; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; FELIPE MI, 1983, HISTOCHEM PATHOL, P319; FURST DO, 1989, J CELL BIOL, V109, P517, DOI 10.1083/jcb.109.2.517; Haas TL, 2000, AM J PHYSIOL-HEART C, V279, pH1540, DOI 10.1152/ajpheart.2000.279.4.H1540; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Itoh T, 1998, CANCER RES, V58, P1048; Karwowski JK, 1999, J SURG RES, V87, P122, DOI 10.1006/jsre.1999.5707; Lattanzi G, 2000, BIOCHEM BIOPH RES CO, V277, P639, DOI 10.1006/bbrc.2000.3735; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; Morrison CJ, 2001, J BIOL CHEM, V276, P47402, DOI 10.1074/jbc.M108643200; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; PODLESKI TR, 1979, EXP CELL RES, V122, P317, DOI 10.1016/0014-4827(79)90308-2; REPONEN P, 1992, J BIOL CHEM, V267, P7856; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; Sho E, 2002, EXP MOL PATHOL, V73, P142, DOI 10.1006/exmp.2002.2457; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Tronc F, 2000, ARTERIOSCL THROM VAS, V20, pE120, DOI 10.1161/01.ATV.20.12.e120; Tubridy N, 2001, CURR OPIN NEUROL, V14, P575, DOI 10.1097/00019052-200110000-00005; VANDERVEN PFM, 1995, J NEUROL SCI, V129, P199, DOI 10.1016/0022-510X(94)00282-S; VITA G, 1994, J NEUROL SCI, V124, P71, DOI 10.1016/0022-510X(94)90013-2; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	36	103	105	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5041	5048		10.1038/sj.onc.1207688	http://dx.doi.org/10.1038/sj.onc.1207688			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15064723				2022-12-17	WOS:000222237300010
J	Seales, EC; Jurado, GA; Singhal, A; Bellis, SL				Seales, EC; Jurado, GA; Singhal, A; Bellis, SL			Ras oncogene directs expression of a differentially sialylated, functionally altered beta 1 integrin	ONCOGENE			English	Article						integrin; ras; collagen; glycosylation; sialic acid	CELL-ADHESION RECEPTORS; INTEGRIN ACTIVATION; FIBRONECTIN RECEPTORS; HA-RAS; BETA(1) INTEGRINS; EPITHELIAL-CELLS; N-GLYCOSYLATION; CANCER CELLS; R-RAS; SIALYLTRANSFERASE	Intense investigation has centered on understanding the regulation of integrin cell adhesion receptors. In the present study, we propose that variant N-glycosylation represents an important mechanism for regulation of beta1, but not beta3 or beta5 integrins. We find that expression of oncogenic ras in HD3 colonocytes causes increased alpha2-6 sialylation of b1 integrins, whereas expression of dominant-negative ras induces decreased alpha2-6 sialylation, relative to cells with wild-type ras. In contrast, neither beta3 nor beta5 integrins are alpha2-6 sialylated, regardless of the state of ras activation. Results from RT-PCR analyses suggest that differential integrin sialylation is due to a ras-dependent alteration in the expression of ST6Gal I, the enzyme that adds alpha2-6-linked sialic acids. Cells that express differentially sialylated beta1 integrins exhibit altered adhesion to collagen I (a beta ligand), but not to vitronectin (a beta3 or beta5 ligand). Similarly, the enzymatic removal of cell surface sialic acids from control cells alters binding to collagen, but not to vitronectin. Finally, using a cell-free receptor/ligand-binding assay, we show that purified, desialylated alpha1beta1 integrins have diminished collagen-binding capability, providing strong evidence that sialic acids play a causal role in regulating b1 integrin function.	Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Bellis, SL (corresponding author), Univ Alabama, Dept Physiol & Biophys, Room 982A MCLM,1918 Univ Blvd, Birmingham, AL 35294 USA.				NCI NIH HHS [R01CA84248] Funding Source: Medline; NIAMS NIH HHS [5 P60 AR20614-23] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020614] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; Aplin AE, 1998, PHARMACOL REV, V50, P197; Asada M, 1997, CANCER RES, V57, P1073; Bellis SL, 1999, J CELL PHYSIOL, V181, P33, DOI 10.1002/(SICI)1097-4652(199910)181:1<33::AID-JCP4>3.0.CO;2-#; Braut-Boucher F, 1998, LEUKEMIA RES, V22, P947, DOI 10.1016/S0145-2126(98)00094-0; DALLOLIO F, 1989, INT J CANCER, V44, P434; EASTON EW, 1991, J BIOL CHEM, V266, P21674; Gangopadhyay A, 1998, HYBRIDOMA, V17, P117, DOI 10.1089/hyb.1998.17.117; GESSNER P, 1993, CANCER LETT, V75, P143, DOI 10.1016/0304-3835(93)90056-F; Guo HB, 2002, CANCER RES, V62, P6837; HEINO J, 1989, J BIOL CHEM, V264, P380; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Jasiulionis MG, 1996, CANCER RES, V56, P1682; KIM LT, 1992, J CELL SCI, V103, P743; Kinashi T, 2000, J BIOL CHEM, V275, P22590, DOI 10.1074/jbc.M000633200; LEMARER N, 1995, GLYCOBIOLOGY, V5, P219, DOI 10.1093/glycob/5.2.219; LEMARER N, 1992, GLYCOBIOLOGY, V2, P49, DOI 10.1093/glycob/2.1.49; LENTER M, 1994, J BIOL CHEM, V269, P12263; LEPPA S, 1995, CELL GROWTH DIFFER, V6, P853; LI M, 1995, CLIN SCI, V89, P397, DOI 10.1042/cs0890397; Lise M, 2000, HYBRIDOMA, V19, P281, DOI 10.1089/027245700429828; Ma JY, 1999, J BIOL CHEM, V274, P8046, DOI 10.1074/jbc.274.12.8046; MOSS L, 1994, GLYCOBIOLOGY, V4, P567, DOI 10.1093/glycob/4.5.567; OZ OK, 1989, INT J CANCER, V44, P343, DOI 10.1002/ijc.2910440226; Praetorius J, 2002, EXP CELL RES, V276, P52, DOI 10.1006/excr.2002.5516; Pretzlaff RK, 2000, CELL ADHES COMMUN, V7, P491, DOI 10.3109/15419060009040306; Recchi MA, 1998, CANCER RES, V58, P4066; SATA T, 1991, AM J PATHOL, V139, P1435; Semel AC, 2002, J BIOL CHEM, V277, P32830, DOI 10.1074/jbc.M202493200; SYMINGTON BE, 1989, J BIOL CHEM, V264, P13258; VANDAMME V, 1992, BIOCHIMIE, V74, P89, DOI 10.1016/0300-9084(92)90188-K; VANDEWATER L, 1988, CANCER RES, V48, P5730; VEIGA SS, 1995, INT J CANCER, V61, P420, DOI 10.1002/ijc.2910610324; VONLAMPE B, 1993, GUT, V34, P829, DOI 10.1136/gut.34.6.829; WADSWORTH S, 1993, J IMMUNOL, V150, P847; Woodside DG, 2001, THROMB HAEMOSTASIS, V86, P316, DOI 10.1055/s-0037-1616229; Yan ZF, 1997, J BIOL CHEM, V272, P30928, DOI 10.1074/jbc.272.49.30928; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325; Zhu YT, 2001, BBA-MOL BASIS DIS, V1536, P148, DOI 10.1016/S0925-4439(01)00044-8	40	103	109	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7137	7145		10.1038/sj.onc.1206834	http://dx.doi.org/10.1038/sj.onc.1206834			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562042				2022-12-17	WOS:000185955000005
J	Martin, J; Hunt, SL; Dubus, P; Sotillo, R; Nehme-Pelluard, F; Magnuson, MA; Parlow, AF; Malumbres, M; Ortega, S; Barbacid, M				Martin, J; Hunt, SL; Dubus, P; Sotillo, R; Nehme-Pelluard, F; Magnuson, MA; Parlow, AF; Malumbres, M; Ortega, S; Barbacid, M			Genetic rescue of Cdk4 null mice restores pancreatic beta-cell proliferation but not homeostatic cell number	ONCOGENE			English	Article						adenohypophysis; cell cycle regulation; cell proliferation; gene-targeted mice; pancreatic beta cells	RETINOBLASTOMA PROTEIN; CYCLIN D1; INHIBITORS; DEFICIENT; GROWTH; EXPRESSION; ROLES; LIFE; MASS; E2F	Lack of Cdk4 expression in mice leads to insulin-deficient diabetes and female infertility owing to a reduced number of pancreatic beta cells and prolactin-producing pituitary lactotrophs, respectively. Cdk4 null mice display also reduced body and organ size. Here, we show that Cdk4 is essential for the postnatal proliferation of pancreatic beta cells but not for embryonic neogenesis from ductal epithelial cells. Re-expression of endogenous Cdk4 in beta cells and in the pituitary gland of Cdk4 null mice restores cell proliferation and results in fertile and normoglycemic animals, thus, demonstrating that the proliferation defects in these cellular populations are cell autonomous because of the lack of Cdk4 expression. However, these mice remain small in size, indicating that this phenotype is not because of pancreatic- or pituitary-mediated endocrine defects. This phenotype is a consequence of reduced cell numbers rather than reduced cell size. Thus, mammalian Cdk4 is not only involved in controlling proliferation of specific cell types but may play a wider role in establishing homeostatic cell numbers.	Ctr Nacl Invest Oncol, Mol Oncol Program, Madrid 28029, Spain; CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain; Univ Bordeaux 2, F-33076 Bordeaux, France; Vanderbilt Univ, Med Ctr N CCC 3322, Nashville, TN 37232 USA; Harbor UCLA Med Ctr, Res & Educ Inst, Natl Hormone & Peptide Program, Torrance, CA 90509 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); UDICE-French Research Universities; Universite de Bordeaux; Vanderbilt University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Ortega, S (corresponding author), Ctr Nacl Invest Oncol, Mol Oncol Program, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	s.ortega@cnio.es	Magnuson, Mark/AAY-7172-2021; Malumbres, Marcos/E-8834-2011; Holt, Janet E/B-2415-2013; Magnuson, Mark A/B-1335-2009	Magnuson, Mark/0000-0002-8824-6499; Malumbres, Marcos/0000-0002-0829-6315; Magnuson, Mark A/0000-0002-8824-6499; Sotillo, Rocio/0000-0002-0855-7917; Dubus, Pierre/0000-0003-1803-4711				Bonner-Weir S, 2000, TRENDS ENDOCRIN MET, V11, P375, DOI 10.1016/S1043-2760(00)00305-2; Bonner-Weir S, 2000, J MOL ENDOCRINOL, V24, P297, DOI 10.1677/jme.0.0240297; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FINEGOOD DT, 1995, DIABETES, V44, P249, DOI 10.2337/diabetes.44.3.249; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Gannon M, 2000, GENESIS, V26, P139, DOI 10.1002/(SICI)1526-968X(200002)26:2<139::AID-GENE12>3.0.CO;2-7; HERRERA PL, 1991, DEVELOPMENT, V113, P1257; Kim SK, 2001, GENE DEV, V15, P111, DOI 10.1101/gad.859401; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Meyer CA, 2000, EMBO J, V19, P4533, DOI 10.1093/emboj/19.17.4533; Montanya E, 2000, DIABETES, V49, P1341, DOI 10.2337/diabetes.49.8.1341; Moons DS, 2002, ENDOCRINOLOGY, V143, P3001, DOI 10.1210/en.143.8.3001; Moons DS, 2002, ENDOCRINOLOGY, V143, P647, DOI 10.1210/en.143.2.647; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Reed SI, 1997, CANCER SURV, V29, P7; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	34	103	109	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5261	5269		10.1038/sj.onc.1206506	http://dx.doi.org/10.1038/sj.onc.1206506			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917627				2022-12-17	WOS:000184734900005
J	Derry, JJ; Prins, GS; Ray, V; Tyner, AL				Derry, JJ; Prins, GS; Ray, V; Tyner, AL			Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells	ONCOGENE			English	Article						prostate cancer; BRK; Sik; tyrosine kinase; Sam68; PTK6	GASTROINTESTINAL-TRACT; GROWTH-FACTORS; SAM68; CANCER; EXPRESSION; RNA; BRK; PHOSPHORYLATION; INHIBITION; SUBSTRATE	Breast tumor kinase (BRK) is an intracellular tyrosine kinase expressed in differentiating epithelial cells of the gastrointestinal tract and skin, and in several epithelial cancers including carcinomas of the breast and colon. We examined expression of BRK and its mouse ortholog Src-related intestinal kinase (Sik) in prostate tissues and detected it in the nuclei of normal luminal prostate epithelial cells. BRK localization was then examined in 58 human prostate biopsy samples representing various grades of prostate cancer. While nuclear localization of BRK was present in well-differentiated tumors, it was absent in poorly differentiated tumors. However localization of Sam68, a nuclear substrate of BRK/Sik, was unaltered in all prostate tumors examined. Consistent with these results, nuclear BRK was detected in the more differentiated androgen-responsive LNCaP human prostate cancer cell line that is poorly tumorigenic in host animals, but it was primarily cytoplasmic in the undifferentiated androgen-unresponsive PC3 prostate cancer cell line that forms aggressive tumors. While PC3 cells expressed higher levels of endogenous BRK than LNCaP cells, BRK was less active in these cells. Our data suggest that BRK plays a role in differentiation of prostate epithelial cells. Altered BRK localization and/or activity may provide a prognostic indicator for prostate tumor progression and be a potential target for therapeutic intervention.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Dept Urol, Chicago, IL 60607 USA; Provident Hosp Cook Cty, Dept Pathol, Chicago, IL 60615 USA; Univ Illinois, Dept Med, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Tyner, AL (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.	atyner@uic.edu		Tyner, Angela/0000-0001-7448-8625	NIDDK NIH HHS [R01 DK040890, DK44525, R01 DK044525-09, R01 DK044525] Funding Source: Medline; PHS HHS [40890] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK044525, R01DK040890, R01DK044525] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Coyle JH, 2003, MOL CELL BIOL, V23, P92, DOI 10.1128/MCB.23.1.92-103.2003; Denegri M, 2001, MOL BIOL CELL, V12, P3502, DOI 10.1091/mbc.12.11.3502; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Djakiew D, 2000, PROSTATE, V42, P150, DOI 10.1002/(SICI)1097-0045(20000201)42:2<150::AID-PROS10>3.0.CO;2-H; Easty DJ, 1997, INT J CANCER, V71, P1061, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1061::AID-IJC24>3.0.CO;2-F; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; Hellawell GO, 2002, BJU INT, V89, P230, DOI 10.1046/j.1464-4096.2001.001067.x; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; KAIGHN ME, 1979, INVEST UROL, V17, P16; LEE ST, 1993, ONCOGENE, V8, P3403; LIM DJ, 1993, PROSTATE, V22, P109, DOI 10.1002/pros.2990220203; Llor X, 1999, CLIN CANCER RES, V5, P1767; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; SIYANOVA EY, 1994, ONCOGENE, V9, P2053; Soros VB, 2001, J VIROL, V75, P8203, DOI 10.1128/JVI.75.17.8203-8215.2001; Vasioukhin V, 1997, P NATL ACAD SCI USA, V94, P14477, DOI 10.1073/pnas.94.26.14477; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9	29	103	109	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4212	4220		10.1038/sj.onc.1206465	http://dx.doi.org/10.1038/sj.onc.1206465			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833144				2022-12-17	WOS:000183979800008
J	Kim, YC; Yamaguchi, Y; Kondo, N; Masutani, H; Yodoi, J				Kim, YC; Yamaguchi, Y; Kondo, N; Masutani, H; Yodoi, J			Thioredoxin-dependent redox regulation of the antioxidant responsive element (ARE) in electrophile response	ONCOGENE			English	Article						thioredoxin; Nrf2; antioxidant responsive element (ARE); tert-butylhydroquinone (tBHQ); redox regulation; electrophile	SITE-DIRECTED MUTAGENESIS; MEDIATED EXPRESSION; ACTIVATION; TRANSCRIPTION; NRF2; BINDING; GENE; PROTEINS; DIFFERENTIATION; ASSOCIATION	Thioredoxin is a redox-regulating protein, the expression of which is induced by various forms of oxidative stress. Thioredoxin controls the interactions of various transcription factors through redox regulation. In K562 cells, we have previously reported that hemin induces activation of the thioredoxin gene by regulating NF-E2-related factor (Nrf2) through the antioxidant responsive element (ARE). We showed here that tert-butylhydroquinone (tBHQ), an electrophile stressor, activates the thioredoxin gene through the ARE. In an electrophoretic mobility shift assay, a specific Nrf2/small Maf binding complex was induced by tBHQ and bound to the ARE. Overexpression of Nrf2 increased the tBHQ-induced thioredoxin gene activation through the ARE, whereas that of Jun and Fos suppressed the activation. The tBHQ-induced ARE binding activity was completely abrogated by an oxidizing agent, diamide, whereas 2-mereaptoethanol (2-ME) reversibly recovered the inhibitory effects of diamide, suggesting that ARE binding activity is redox-dependent. Moreover, overexpression of thioredoxin enhanced the ARE-mediated thioredoxin gene activation by tBHQ. Therefore, ARE-mediated induction of thioredoxin expression is a mechanism of enhancing signal transduction through the ARE in electrophile-induced stress responses.	Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, Kyoto 6068507, Japan; Natl Inst Adv Ind Sci & Technol, Human Stress Signal Res Ctr, Biomed Special Res Unit, AIST, Osaka 5638577, Japan	Kyoto University; National Institute of Advanced Industrial Science & Technology (AIST)	Masutani, H (corresponding author), Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, 53 Shogoin,Kawahara Cho, Kyoto 6068507, Japan.	hmasutan@virus.kyoto-u.ac.jp	Masutani, Hiroshi/B-5114-2014	Masutani, Hiroshi/0000-0001-7633-2827				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; Bloom D, 2002, ONCOGENE, V21, P2191, DOI 10.1038/sj.onc.1205288; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Kim YC, 2001, J BIOL CHEM, V276, P18399, DOI 10.1074/jbc.M100103200; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MILLER EC, 1981, CANCER-AM CANCER SOC, V47, P2327, DOI 10.1002/1097-0142(19810515)47:10<2327::AID-CNCR2820471003>3.0.CO;2-Z; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; OBLONG JE, 1994, J BIOL CHEM, V269, P11714; PACKER L, 1999, REDOX REGULATION CEL, P251; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; TSUJI Y, 1995, MOL CELL BIOL, V15, P5152; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; VERHAGEN H, 1989, CARCINOGENESIS, V10, P1947, DOI 10.1093/carcin/10.10.1947	23	103	111	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1860	1865		10.1038/sj.onc.1206369	http://dx.doi.org/10.1038/sj.onc.1206369			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660821				2022-12-17	WOS:000181678200012
J	Shigeno, M; Nako, K; Ichikawa, T; Suzuki, K; Kawakami, A; Abiru, S; Miyazoe, S; Nakagawa, Y; Ishikawa, H; Hamasaki, K; Nakata, K; Ishii, N; Eguchi, K				Shigeno, M; Nako, K; Ichikawa, T; Suzuki, K; Kawakami, A; Abiru, S; Miyazoe, S; Nakagawa, Y; Ishikawa, H; Hamasaki, K; Nakata, K; Ishii, N; Eguchi, K			Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation	ONCOGENE			English	Article						TRAIL; interferon-alpha; hepatoma; DR5 survivin; NF-kappa B	HUMAN HEPATOCELLULAR-CARCINOMA; CYTOTOXIC LIGAND TRAIL; LUNG-CANCER CELLS; IN-VIVO; CHEMOTHERAPEUTIC-AGENTS; TRANSCRIPTION FACTORS; CASPASE-8 ACTIVATION; IONIZING-RADIATION; MEDIATED APOPTOSIS; DEATH RECEPTOR-4	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily, induces apoptosis in a variety of cancer cells with little or no effect on normal cells. Human hepatoma cells, however, are resistant to TRAIL-induced apoptosis. Since interferon-alpha (IFN-alpha) is capable of enhancing TNF-alpha-induced apoptosis in certain cancer cells, we evaluated the effect of IFN-alpha on TRAIL-induced apoptosis of human hepatoma cells. IFN-alpha pretreatment enhanced TRAIL-induced apoptosis of HuH-7 and Hep3B cells, in which IFN-alpha upregulated the expression of DR5, a death receptor of TRAIL, and downregulated the expression of survivin, which has an antiapoptotic function. In contrast, IFN-alpha did not enhance TRAIL-induced apoptosis of HepG2 cells, in which expression of DR5 and survivin was not affected by IFN-alpha. On the other hand, TRAIL activated NF-kappaB composed of RelA-p50 heterodimer, a key transcription factor regulating cell survival, in HuH-7 and HepG2 cells. However, IFN-alpha pretreatment repressed the TRAIL-mediated activation of NF-kappaB and decreased its transcriptional activity in HuH-7 but not in HepG2 cells. Moreover, IFN-alpha pretreatment clearly augmented TRAIL-mediated caspase-8 activation in HuH-7 cells. Our results suggest that IFN-alpha could sensitize certain human hepatoma cells to TRAIL-induced apoptosis by stimulating its death signaling and by repressing the survival function in these cells.	Nagasaki Univ, Sch Med, Dept Internal Med 1, Nagasaki 8528501, Japan; Nagasaki Univ, Hlth Res Ctr, Nagasaki 8528501, Japan; Nagasaki Univ, Dept Clin Pharmacol, Nagasaki 8528501, Japan	Nagasaki University; Nagasaki University; Nagasaki University	Eguchi, K (corresponding author), Nagasaki Univ, Sch Med, Dept Internal Med 1, 1-7-1 Sakamoto, Nagasaki 8528501, Japan.							Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Chawla-Sarkar M, 2001, CLIN CANCER RES, V7, P1821; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Di Pietro R, 2001, BLOOD, V97, P2596, DOI 10.1182/blood.V97.9.2596; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Griffith TS, 2002, CANCER RES, V62, P3093; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Ichikawa T, 2001, BIOCHEM BIOPH RES CO, V280, P933, DOI 10.1006/bbrc.2000.4228; Inan MS, 2000, GASTROENTEROLOGY, V118, P724, DOI 10.1016/S0016-5085(00)70142-9; Ito T, 2000, HEPATOLOGY, V31, P1080, DOI 10.1053/he.2000.6496; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Lacour S, 2001, CANCER RES, V61, P1645; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Manna SK, 2000, J IMMUNOL, V165, P4927, DOI 10.4049/jimmunol.165.9.4927; Nagane M, 2000, CANCER RES, V60, P847; NAKABAYASHI H, 1984, JPN J CANCER RES, V75, P151; Nakao K, 1999, J BIOL CHEM, V274, P28075, DOI 10.1074/jbc.274.40.28075; Nimmanapalli R, 2001, CANCER RES, V61, P759; Olie RA, 2000, CANCER RES, V60, P2805; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Suk K, 2001, FEBS LETT, V495, P66, DOI 10.1016/S0014-5793(01)02335-3; Sun SY, 2000, CANCER RES, V60, P7149; Tamm I, 1998, CANCER RES, V58, P5315; Toomey NL, 2001, ONCOGENE, V20, P7029, DOI 10.1038/sj.onc.1204895; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wen Y, 2000, CANCER RES, V60, P42; Yamanaka T, 2000, HEPATOLOGY, V32, P482, DOI 10.1053/jhep.2000.16266; Zhou Q, 2000, CANCER RES, V60, P2611	45	103	118	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1653	1662		10.1038/sj.onc.1206139	http://dx.doi.org/10.1038/sj.onc.1206139			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642868				2022-12-17	WOS:000181580500007
J	Sugiyama, T; Shimizu, S; Matsuoka, Y; Yoneda, Y; Tsujimoto, Y				Sugiyama, T; Shimizu, S; Matsuoka, Y; Yoneda, Y; Tsujimoto, Y			Activation of mitochondrial voltage-dependent anion channel by a pro-apoptotic BH3-only protein Bim	ONCOGENE			English	Article						VDAC; Bcl-2; Bim; apoptosis; mitochondria	CYTOCHROME-C RELEASE; BCL-2 FAMILY MEMBERS; PERMEABILITY TRANSITION PORE; CELL-DEATH; YEAST MITOCHONDRIA; INDUCE APOPTOSIS; MAMMALIAN-CELLS; BAX; MEMBRANE; VDAC	Bcl-2 family of proteins regulates apoptosis by controlling mitochondrial membrane permeability. We have previously shown that the voltage-dependent anion channel (VDAC) plays a crucial role in apoptotic changes of the mitochondria and its activity is directly regulated by some Bcl-2 family members, including Bcl-2/Bcl-X-L and Bax/Bak but not Bid. Here, we showed that in isolated mitochondria, Bim induced loss of membrane potential and cytochrome c release like Bax/Bak, with these changes being inhibited by an anti-VDAC antibody. In addition, microinjection of the anti-VDAC antibody significantly reduced Bim-induced apoptosis. Study using purified proteins indicated that Bim directly interacts with the VDAC. Immunoprecipitation analysis revealed that Bim interacts with the VDAC and the interaction is remarkably enhanced during apoptosis. An experiment using liposomes indicated that Bim enhanced VDAC activity, as did Bax/Bak. Furthermore, Bim (but not tBid) was able to induce apoptotic changes of yeast mitochondria in a VDAC-dependent manner, and also induced the lysis of red blood cells, with this effect being inhibited by the anti-VDAC antibody. These results indicate that Bim has an ability to activate directly the VDAC, which plays an important role in apoptosis of mammalian cells.	Osaka Univ, Grad Sch Med, Mol Genet Lab, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Cell Biol & Neurosci, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Tsujimoto, Y (corresponding author), Osaka Univ, Grad Sch Med, Mol Genet Lab, Room B8,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.			Sugiyama, Tomoyasu/0000-0001-5704-6606				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V905, P499, DOI 10.1016/0005-2736(87)90480-9; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Harris CA, 2001, J BIOL CHEM, V276, P37754; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hieda M, 1999, J CELL BIOL, V144, P645, DOI 10.1083/jcb.144.4.645; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; MATSUOKA Y, 1994, J CELL SCI, V107, P693; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Pavlov EV, 2001, J CELL BIOL, V155, P725, DOI 10.1083/jcb.200107057; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, ONCOGENE, V19, P4309, DOI 10.1038/sj.onc.1203788; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	43	103	126	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4944	4956		10.1038/sj.onc.1205621	http://dx.doi.org/10.1038/sj.onc.1205621			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118373				2022-12-17	WOS:000176874800009
J	Bentires-Alj, M; Dejardin, E; Viatour, P; Van Lint, C; Froesch, B; Reed, JC; Merville, MP; Bours, V				Bentires-Alj, M; Dejardin, E; Viatour, P; Van Lint, C; Froesch, B; Reed, JC; Merville, MP; Bours, V			Inhibition of the NF-kappa B transcription factor increases Bax expression in cancer cell lines	ONCOGENE			English	Article						Bax; apoptosis; cancer; transcription factors.; NF-kappa B	NECROSIS-FACTOR-ALPHA; CREB-BINDING PROTEIN; TUMOR-SUPPRESSOR PROTEIN; BCL-X EXPRESSION; VIRUS TYPE-1 TAX; INDUCED APOPTOSIS; BREAST-CANCER; IN-VIVO; P53; GENE	The NF-kappaB transcription factor has been shown to inhibit apoptosis in several experimental systems. We therefore investigated whether the expression of the Bax proapoptotic protein could be influenced by NF-kappaB activity. Increased Bax protein expression was detected in HCT116, OVCAR-3 and MCF7 cells stably expressing a mutated unresponsive I kappaB-alpha inhibitory protein that blocks NF-kappaB activity. Northern blots showed that bax mRNA expression was increased as a consequence of mutated I kappaB-alpha expression in HCT116 cells. A careful examination of the human bax gene promoter sequence showed three putative binding sites for NF-kappaB, and the kappa B2 site at position -687 could indeed bind NF-kappaB complexes in vitro. Transient transfection of a bax promoter luciferase construct in HCT116 cells showed that NF-kappaB proteins could partially inhibit the transactivation of the bax promoter by p53, Mutations or deletions of the kappaB sites, including kappa B2, indicated that this NF-kappaB-dependent inhibitory effect did not require NF-kappaB DNA-binding, and was thus an indirect effect. However, cotransfection of expression vectors for several known cofactors failed to identify a competition between p53 and NF-kappaB for a transcription coactivator. Our findings thus demonstrate for the first time that NF-kappaB regulates, through an indirect pathway, the bax gene expression.	Univ Liege, CHU B35, Lab Med Chem & Med Oncol, B-4000 Liege, Belgium; Free Univ Brussels, Dept Mol Biol, Biol Chem Lab, Brussels, Belgium; Burnham Inst, La Jolla, CA 92037 USA	University of Liege; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Sanford Burnham Prebys Medical Discovery Institute	Bours, V (corresponding author), Univ Liege, CHU B35, Lab Med Chem & Med Oncol, B-4000 Liege, Belgium.		Dejardin, Emmanuel/AAE-9076-2021; Mohamed, Bentires-Alj/F-4484-2015	Mohamed, Bentires-Alj/0000-0001-6344-1127				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chariot A, 1999, J BIOL CHEM, V274, P5318, DOI 10.1074/jbc.274.9.5318; Chen F, 1999, J BIOL CHEM, V274, P35591, DOI 10.1074/jbc.274.50.35591; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Dejardin E, 1999, ONCOGENE, V18, P2567, DOI 10.1038/sj.onc.1202599; DEJARDIN E, 1995, ONCOGENE, V11, P1835; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Ferreira V, 1998, J BIOL CHEM, V273, P592, DOI 10.1074/jbc.273.1.592; Friess H, 1998, GUT, V43, P414, DOI 10.1136/gut.43.3.414; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Perera PY, 1996, INFECT IMMUN, V64, P878, DOI 10.1128/IAI.64.3.878-884.1996; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Ravi R, 1998, CANCER RES, V58, P4531; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Schmidt T, 1999, CELL DEATH DIFFER, V6, P873, DOI 10.1038/sj.cdd.4400562; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; Scolnick DM, 1997, CANCER RES, V57, P3693; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Tai YT, 1998, J CLIN ONCOL, V16, P2583, DOI 10.1200/JCO.1998.16.8.2583; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; VAN AD, 1996, SCIENCE, V274, P787; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	64	103	106	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2805	2813		10.1038/sj.onc.1204343	http://dx.doi.org/10.1038/sj.onc.1204343			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420692				2022-12-17	WOS:000168712000008
J	Behrend, L; Milne, DM; Stoter, M; Deppert, W; Campbell, LE; Meek, DW; Knippschild, U				Behrend, L; Milne, DM; Stoter, M; Deppert, W; Campbell, LE; Meek, DW; Knippschild, U			IC261, a specific inhibitor of the protein kinases casein kinase 1-delta and -epsilon, triggers the mitotic checkpoint and induces p53-dependent postmitotic effects	ONCOGENE			English	Article						casein kinase 1; mitotic checkpoint; chromosome segregation; centrosome amplification; micronucleation	CELL-CYCLE PROGRESSION; SPINDLE CHECKPOINT; MOLECULAR-CLONING; P53 PROTEIN; DNA-DAMAGE; I ISOFORM; PHOSPHORYLATION; EXPRESSION; MOUSE; FIBROBLASTS	The p53-targeted kinases casein kinase 1 delta (CK1 delta) and casein kinase 1 epsilon (CK1 epsilon) have been proposed to be involved in regulating DNA repair and chromosomal segregation. Recently, we showed that CK1 delta localizes to the spindle apparatus and the centrosomes in cells with mitotic failure caused by DNA-damage prior to mitotic entry. We provide here evidence that 3-[(2,4,6-trimethoxyphenyl)methylidenyl]-indolin-2-one (IC261), a novel inhibitor of CK1 delta and CK1 epsilon, triggers the mitotic checkpoint control. At low micromolar concentrations IC261 inhibits cytokinesis causing a transient mitotic arrest. Cells containing active p53 arrest in the postmitotic G1 phase by blockage of entry into the S phase. Cells with non-functional p53 undergo postmitotic replication developing an 8N DNA content. The increase of DNA content is accompanied by a high amount of micronucleated and apoptotic cells. Immunfluorescence images show that at low concentrations IC261 leads to centrosome amplification causing multipolar mitosis. Our data are consistent with a role for CK1 delta and CK1 epsilon isoforms in regulating key aspects of cell division, possibly through the regulation of centrosome or spindle function during mitosis.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland	Heinrich Pette Institute; University of Hamburg; University of Dundee	Knippschild, U (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Behrend L, 2000, EUR J CELL BIOL, V79, P240, DOI 10.1078/S0171-9335(04)70027-8; Boleti H, 1996, CELL, V84, P49, DOI 10.1016/S0092-8674(00)80992-7; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; Busson S, 1998, CURR BIOL, V8, P541, DOI 10.1016/S0960-9822(98)70208-8; Cassimeris L, 1999, CURR OPIN CELL BIOL, V11, P134, DOI 10.1016/S0955-0674(99)80017-9; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Christenson E, 1997, Recent Results Cancer Res, V143, P263; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DAHMUS ME, 1981, J BIOL CHEM, V256, P1239; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; Di Leonardo A, 1997, CANCER RES, V57, P1013; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; ENDOW SA, 1994, J CELL SCI, V107, P859; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FujikawaYamamoto K, 1997, CELL STRUCT FUNCT, V22, P399, DOI 10.1247/csf.22.399; Gaglio T, 1996, J CELL BIOL, V135, P399, DOI 10.1083/jcb.135.2.399; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Gross SD, 1997, J CELL SCI, V110, P3083; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; KASTAN MB, 1991, CANCER RES, V51, P6304; Khan SH, 1998, CANCER RES, V58, P396; KNIPPSCHILD U, 1995, ONCOGENE, V11, P683; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Kuret J, 1997, J NEUROCHEM, V69, P2506; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; Longenecker KL, 1998, ACTA CRYSTALLOGR D, V54, P473, DOI 10.1107/S0907444997011724; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; MILNE DM, 1992, ONCOGENE, V7, P1361; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Mountain V, 2000, ANAT REC, V261, P14, DOI 10.1002/(SICI)1097-0185(20000215)261:1<14::AID-AR5>3.0.CO;2-E; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; OTTO A, 1993, ONCOGENE, V8, P2591; Palazzo RE, 1999, J CELL SCI, V112, P1291; ROBERTS JR, 1990, CANCER RES, V50, P710; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; Sablina AA, 1998, J CELL SCI, V111, P977; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Santos JA, 1996, J CELL SCI, V109, P1847; Sato N, 2000, EXP CELL RES, V255, P321, DOI 10.1006/excr.1999.4797; Sharp DJ, 1999, NAT CELL BIOL, V1, P51, DOI 10.1038/9025; SIMKOWSKI KW, 1980, J BIOL CHEM, V255, P6456; SINGH TJ, 1983, ARCH BIOCHEM BIOPHYS, V220, P615, DOI 10.1016/0003-9861(83)90454-X; SINGH TJ, 1995, J NEUROCHEM, V64, P1420; THOMAS NSB, 1991, ONCOGENE, V6, P317; VAIDYA AB, 1978, VIROLOGY, V90, P12, DOI 10.1016/0042-6822(78)90328-8; VANDRE DD, 1989, J CELL SCI, V94, P245; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588; Yang PF, 2000, J BIOL CHEM, V275, P18905, DOI 10.1074/jbc.M002134200; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717	66	103	108	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2000	19	47					5303	5313		10.1038/sj.onc.1203939	http://dx.doi.org/10.1038/sj.onc.1203939			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103931				2022-12-17	WOS:000165302300001
J	Gabet, AS; Mortreux, F; Talarmin, A; Plumelle, Y; Leclercq, I; Leroy, A; Gessain, A; Clity, E; Joubert, M; Wattel, E				Gabet, AS; Mortreux, F; Talarmin, A; Plumelle, Y; Leclercq, I; Leroy, A; Gessain, A; Clity, E; Joubert, M; Wattel, E			High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis	ONCOGENE			English	Article						HTLV; leukemogenesis; adult T cell leukemia; genetic instability	VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; FRENCH-WEST-INDIES; EPSTEIN-BARR-VIRUS; LEUKEMIA-LYMPHOMA; TAX PROTEIN; SEMIQUANTITATIVE ANALYSIS; POLYCLONAL INTEGRATION; STERCORALIS INFECTION; PERIPHERAL-BLOOD	Adult T cell leukemia (ATLL) develops in 3-5% of HTLV-1 carriers after a long period of latency during which a persistent polyclonal expansion of HTLV-1 infected lymphocytes is observed in all individuals. This incubation period is significantly shortened in HTLV-1 carrier with Strongyloides stercoralis (Ss) infection, suggesting that Ss could be a cofactor of ATLL, As an increased T cell proliferation at the asymptomatic stage of HTLV-1 infection could increase the risk of malignant transformation, the effect of Ss infection on infected T lymphocytes was assessed in vivo in HTLV-1 asymptomatic carriers. After real-time quantitative PCR, the mean circulating HTLV-1 proviral load was more than five times higher in HTLV-1 carriers with stongyloidiasis than in HTLV-1+ individuals without Ss infection (P < 0,009), This increased proviral load was found to result from the extensive proliferation of a restricted number of infected clones, i,e, from oligoclonal expansion, as evidenced by the semiquantitative amplification of HTLV-1 flanking sequences. The positive effect of Ss on clonal expansion was reversible under effective treatment of strongyloidiasis in one patient with parasitological cure whereas no significant modification of the HTLV-1 replication pattern was observed in an additional case with strongyloidiasis treatment failure. Therefore, Ss stimulates the oligoclonal proliferation of HTLV-1 infected cells in HTLV-1 asymptomatic carriers in vivo, This is thought to account for the shortened period of latency observed in ATLL patients with strongyloidiasis.	Univ Lyon 1, CNRS, UMR5537, Unit Oncogenese Virale,Ctr Leon Berard, F-69373 Lyon 08, France; Inst Rech Canc Lille, INSERM, Unite 524, Lille, France; Inst Pasteur Guyane, Cayenne, France; CHU Ft France, Serv Hematol Biol, Martinique, France; Ctr Oscar Lambret, Unite Oncogenese Virale, F-59020 Lille, France; Inst Pasteur, Unite Epidemiol Virus Oncogenes, Paris, France; Univ Mons, Serv Biol Mol, B-7000 Mons, Belgium	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Martinique; UNICANCER; Centre Oscar Lambret; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Mons	Wattel, E (corresponding author), Univ Lyon 1, CNRS, UMR5537, Unit Oncogenese Virale,Ctr Leon Berard, 28 Rue Laennec, F-69373 Lyon 08, France.		mortreux, franck/T-4564-2019; mortreux, franck/M-5944-2014	mortreux, franck/0000-0002-4840-021X; mortreux, franck/0000-0002-4840-021X				Agape P, 1999, J ACQ IMMUN DEF SYND, V20, P394, DOI 10.1097/00042560-199904010-00011; ALBERTINI RJ, 1990, ANNU REV GENET, V24, P305; ARAKAKI T, 1992, J TROP MED HYG, V95, P210; ARAKAKI T, 1992, TROP MED PARASITOL, V43, P199; Cavrois M, 1996, ONCOGENE, V12, P2419; CAVROIS M, 1995, RES VIROLOGY, V146, P179, DOI 10.1016/0923-2516(96)80578-4; Cavrois M, 1998, ONCOGENE, V17, P77, DOI 10.1038/sj.onc.1201906; Cavrois M, 1996, BLOOD, V88, P4646, DOI 10.1182/blood.V88.12.4646.bloodjournal88124646; CESARMAN E, 1992, BLOOD, V80, P3205; CHEN YX, 1995, INT J CANCER, V60, P798; CLEGHORN FR, 1995, JNCI-J NATL CANCER I, V87, P1009, DOI 10.1093/jnci/87.13.1009; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; de-The G, 1985, IARC Sci Publ, P165; DEOLIVEIRA MSP, 1995, INT J CANCER, V60, P823, DOI 10.1002/ijc.2910600617; deThe G, 1997, ANN MED INTERNE, V148, P357; DEVAULT GA, 1990, REV INFECT DIS, V12, P653; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; EGUCHI K, 1992, ANN RHEUM DIS, V51, P769, DOI 10.1136/ard.51.6.769; FACER CA, 1989, ADV CANCER RES, V53, P33; FUJII M, 1991, ONCOGENE, V6, P1023; GELBER M, 1996, HAREFUAH, V130, P13; Gelber Moshe, 1996, Harefuah, V130, P90; GESSAIN A, 1990, BLOOD, V75, P428; GESSAIN A, 1985, LANCET, V2, P407; GORDON SM, 1994, J AM ACAD DERMATOL, V31, P255, DOI 10.1016/S0190-9622(94)70158-X; Goyal SB, 1998, SOUTHERN MED J, V91, P768, DOI 10.1097/00007611-199808000-00016; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; Hayashi J, 1997, AM J TROP MED HYG, V56, P71, DOI 10.4269/ajtmh.1997.56.71; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; LAGRENADE L, 1990, LANCET, V336, P1345; Leclercq I, 1998, BRIT J HAEMATOL, V101, P500, DOI 10.1046/j.1365-2141.1998.00743.x; Leclercq I, 1999, BRIT J HAEMATOL, V105, P743, DOI 10.1046/j.1365-2141.1999.01389.x; MASSEY AC, 1990, VA MED Q, V117, P31; MATSUMOTO T, 1990, CLIN EXP IMMUNOL, V81, P207, DOI 10.1111/j.1365-2249.1990.tb03319.x; Mattos K, 1993, Arq Neuropsiquiatr, V51, P134; MINGHETTI PP, 1986, J BIOL CHEM, V261, P6747; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; MOCHIZUKI M, 1994, BRIT J OPHTHALMOL, V78, P149, DOI 10.1136/bjo.78.2.149; MOLBAK K, 1994, J INFECT DIS, V169, P581, DOI 10.1093/infdis/169.3.581; NAKANE S, 1988, J PHARM PHARMACOL, V40, P1, DOI 10.1111/j.2042-7158.1988.tb05139.x; NEWTON RC, 1992, AM J MED, V92, P202, DOI 10.1016/0002-9343(92)90113-P; Nonaka D, 1998, AM J TROP MED HYG, V59, P535, DOI 10.4269/ajtmh.1998.59.535; OHSHIMA K, 1991, CANCER RES, V51, P4639; OSAME M, 1986, LANCET, V1, P1031; Pagliuca A, 1999, BRIT J HAEMATOL, V105, P1, DOI 10.1111/j.1365-2141.1999.01401.x; PAGLIUCA A, 1988, BRIT MED J, V297, P1456, DOI 10.1136/bmj.297.6661.1456; PATEY O, 1992, AIDS, V6, P575, DOI 10.1097/00002030-199206000-00009; PHELPS KR, 1991, AM J MED SCI, V302, P224, DOI 10.1097/00000441-199110000-00006; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Plumelle Y, 1997, AM J CLIN PATHOL, V107, P81; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SATO K, 1991, ARTHRITIS RHEUM, V34, P714, DOI 10.1002/art.1780340612; SHERMAN MP, 1995, ARTHRITIS RHEUM, V38, P690, DOI 10.1002/art.1780380518; SHIMAMOTO Y, 1994, BLOOD, V84, P853; SHINZATO O, 1991, BLOOD, V78, P2082; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Tamiya S, 1996, BLOOD, V88, P3065, DOI 10.1182/blood.V88.8.3065.bloodjournal8883065; Tsukasaki K, 1997, BLOOD, V89, P948, DOI 10.1182/blood.V89.3.948; WATTEL E, 1992, J ACQ IMMUN DEF SYND, V5, P943; WATTEL E, 1995, J VIROL, V69, P2863, DOI 10.1128/JVI.69.5.2863-2868.1995; YAMAGUCHI K, 1987, LANCET, V2, P94, DOI 10.1016/S0140-6736(87)92752-8; YAMAGUCHI K, 1988, BRIT J HAEMATOL, V68, P169, DOI 10.1111/j.1365-2141.1988.tb06185.x; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	67	103	107	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2000	19	43					4954	4960		10.1038/sj.onc.1203870	http://dx.doi.org/10.1038/sj.onc.1203870			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF	11042682				2022-12-17	WOS:000089834300002
J	Branch, P; Masson, M; Aquilina, G; Bignami, M; Karran, P				Branch, P; Masson, M; Aquilina, G; Bignami, M; Karran, P			Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells	ONCOGENE			English	Article						A2780 ovarian carcinoma; hMLHI silencing; methylation tolerance	OVARIAN-CANCER; DNA-DAMAGE; COLORECTAL-CARCINOMA; ACQUIRED-RESISTANCE; METHYLATING AGENTS; MUTATOR PHENOTYPE; HMLH1 PROMOTER; SENSITIVITY; APOPTOSIS; LINES	The contributions of defective mismatch repair and mutated p53 to cisplatin resistance of human tumor cells were analysed. Mismatch repair defects were not associated with a predictable degree of resistance among several tumor cell Lines. Repair defective variants of the A2780 ovarian carcinoma cell Line which were isolated 62 selection for a methylation tolerant phenotype and did not express the hMLH1 mismatch repair protein, were highly resistant to cisplatin, Their cisplatin resistance was not a simple consequence of the mismatch repair defect. They were members of a drug-naive subpopulation of A2780 in which a silent hMLH1 gene accompanies a mutated p53. Two complementary approaches indicated that each defect contributes to cisplatin resistance independently and to a different extent, Firstly separate introduction of a p53 defect into A2780 cells significantly increased their cisplatin resistance; defective hMLH1 provided less extensive protection. Secondly, azadeoxycytidine reactivation of the silent hMLH1 gene or expression of a transfected hMLH1 cDNA sensitized the doubly hMLH1/p53 deficient cells only slightly to cisplatin, Both approaches indicate that defective p53 status is a major determinant of cisplatin resistance and defective mismatch repair is a minor, and independent, contributor. The data have implications for the development of intrinsic cisplatin resistance.	Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; Ist Super Sanita, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Karran, P (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.		Aquilina, Gabriele/AAI-7978-2021	Aquilina, Gabriele/0000-0002-3280-7883				Aebi S, 1996, CANCER RES, V56, P3087; Anthoney DA, 1996, CANCER RES, V56, P1374; AQUILINA G, 1995, CANCER RES, V55, P2569; Aquilina G, 1998, CANCER RES, V58, P135; Aquilina G, 2000, CLIN CANCER RES, V6, P671; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRANCH P, 1995, CANCER RES, V55, P2304; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; Buermeyer AB, 1999, CANCER RES, V59, P538; D'Atri S, 1998, MOL PHARMACOL, V54, P334, DOI 10.1124/mol.54.2.334; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Durant ST, 1999, CURR BIOL, V9, P51, DOI 10.1016/S0960-9822(99)80047-5; Einhorn LH, 1997, CLIN CANCER RES, V3, P2630; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; FAN SJ, 1995, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; Fink D, 1996, CANCER RES, V56, P4881; Fink D, 1998, CLIN CANCER RES, V4, P1; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; Hampson R, 1997, J BIOL CHEM, V272, P28596, DOI 10.1074/jbc.272.45.28596; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Humbert O, 1999, CARCINOGENESIS, V20, P205, DOI 10.1093/carcin/20.2.205; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; JOHNSON SW, 1994, CANCER RES, V54, P5911; KARRAN P, 1993, J BIOL CHEM, V268, P15878; Koberle B, 1999, CURR BIOL, V9, P273, DOI 10.1016/S0960-9822(99)80118-3; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MCLAUGHLIN K, 1991, CANCER RES, V51, P2242; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; O'Driscoll M., 1998, NUCL ACID M, V12, P173; Siddik ZH, 1998, CANCER RES, V58, P698; Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540; Vasey PA, 1996, MOL PHARMACOL, V50, P1536; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491; [No title captured]	39	103	106	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3138	3145		10.1038/sj.onc.1203668	http://dx.doi.org/10.1038/sj.onc.1203668			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918568				2022-12-17	WOS:000088019200002
J	Tomita, A; Towatari, M; Tsuzuki, S; Hayakawa, F; Kosugi, H; Tamai, K; Miyazaki, T; Kinoshita, T; Saito, H				Tomita, A; Towatari, M; Tsuzuki, S; Hayakawa, F; Kosugi, H; Tamai, K; Miyazaki, T; Kinoshita, T; Saito, H			c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300	ONCOGENE			English	Article						c-Myb; p300; GCN5; acetylation; bromodomain	NEGATIVE REGULATORY DOMAIN; GENE V-MYB; HISTONE ACETYLTRANSFERASES; DNA-BINDING; PHOSPHORYLATION SITE; B-MYB; CBP; PROTOONCOGENE; EXPRESSION; TRANSACTIVATION	Transcription factor c-Myb plays important roles in cell survival and differentiation in immature hematopoietic cells, Here we demonstrate that c-Myb is acetylated at the carboxyl-terminal conserved domain by histone acetyltransferase p300 both in vitro and in vivo. The acetylation sites in Pho have been located at the lysine residues of the conserved domain (K471, K480, K485) by the use of the mutant Myb (Myb-KAmut), in which all three lysine residues are substituted into alanine. Electrophoretic mobility shift assay reveals that Myb-KAmut shows higher DNA binding activity than wild type c-Myb and that acetylation of c-Myb in vitro by p300 causes dramatic increase in DNA binding activity, Accordingly, transactivation activity of both mim-1 and CD34 promoters by Myb-KAmut is higher than that driven by wild type c-Myb. Furthermore, the bromodomain of p300, in addition to the histone acetyltransferase (HAT) domain, is required for effective acetylation of Myb, and hGCN5 is revealed to be a factor acetyltransferase for c-Myb in vitro. We present a new manner of post-translational modification of the c-Myb protein and the potential significance of the acetylation in c-Myb.	Nagoya Univ, Sch Med, Dept Internal Med 1, Showa Ku, Nagoya, Aichi 4668550, Japan; Med & Biol Labs Co Ltd, Nagano, Japan; CycLex Inc, Nagano, Japan	Nagoya University	Towatari, M (corresponding author), Nagoya Univ, Sch Med, Dept Internal Med 1, Showa Ku, Tsurumai Cho 65, Nagoya, Aichi 4668550, Japan.		Tamai, Katsuyuki/F-4743-2013; Hayakawa, Fumihiko/I-7288-2014	Tamai, Katsuyuki/0000-0003-4094-3911; Tsuzuki, Shinobu/0000-0002-3209-3550				AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BURN TC, 1992, BLOOD, V80, P3051; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; Gonda TJ, 1998, INT J BIOCHEM CELL B, V30, P547, DOI 10.1016/S1357-2725(98)00003-X; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HU YL, 1991, ONCOGENE, V6, P1549; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; Liu L, 1999, MOL CELL BIOL, V19, P1202; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Nakahara Y, 1999, INT J HEMATOL, V69, P237; Ness SA, 1999, ONCOGENE, V18, P3039, DOI 10.1038/sj.onc.1202726; NESS SA, 1989, CELL, V59, P115; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tanaka Y, 1997, FEBS LETT, V413, P162, DOI 10.1016/S0014-5793(97)00900-9; TASHIRO S, 1995, ONCOGENE, V10, P1699; Tomita A, 1998, LEUKEMIA, V12, P1422, DOI 10.1038/sj.leu.2401113; VORBRUEGGEN G, 1994, NUCLEIC ACIDS RES, V22, P2466, DOI 10.1093/nar/22.13.2466; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Weston K, 1999, ONCOGENE, V18, P3034, DOI 10.1038/sj.onc.1202728; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	44	103	103	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					444	451		10.1038/sj.onc.1203329	http://dx.doi.org/10.1038/sj.onc.1203329			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656693				2022-12-17	WOS:000084873700016
J	Georgiades, IB; Curtis, LJ; Morris, RM; Bird, CC; Wyllie, AH				Georgiades, IB; Curtis, LJ; Morris, RM; Bird, CC; Wyllie, AH			Heterogeneity studies identify a subset of sporadic colorectal cancers without evidence for chromosomal or microsatellite instability	ONCOGENE			English	Article						colorectal cancer; chromosomal instability; genomic instability; microsatellite instability; RER	ANEUPLOID CLONAL DIVERGENCE; NONPOLYPOSIS COLON-CANCER; DNA-REPLICATION ERRORS; MISMATCH REPAIR GENES; GENOMIC INSTABILITY; SOMATIC MUTATIONS; MUTATOR PHENOTYPE; TUMORS; P53; CARCINOGENESIS	Two apparently independent mechanisms of instability are recognized in colorectal cancer, microsatellite instability and chromosomal instability. Evidence from colorectal cancer cell lines indicates the presence of either, or both, types of instability in the vast majority, Here, we sought to determine the prevalence of such instability in primary sporadic colorectal cancers. Microsatellite instability was established by demonstration of ovel clonal, nongerm-line alleles in at least two of four tested loci. Chromosomal abnormalities were identified by comparative genomic hybridization (CGH) and flow cytometric analysis of nuclear DNA content. Tumours harbouring chromosomal instability were distinguished from those with stable but aneuploid karyotypes by comparing chromosomal defects at multiple sites throughout each cancer. This analysis allowed assessment of both the number of chromosomal abnormalities and their heterogeneity throughout the tumour. The results confirm that microsatellite instability is consistently associated with multiple, repeated changes in microsatellites throughout the growth of the affected colorectal carcinomas, There were also several carcinomas in which major structural or numerical abnormalities in chromosomes had clearly continued to arise during tumour growth, However, a substantial subset of tumours shelved neither microsatellite instability nor multiple, major chromosomal abnormalities. We suggest that the development of a proportion of colorectal cancers proceeds via a different pathway of carcinogenesis not associated with either of the currently recognized forms of genomic instability.	Univ Edinburgh, Western Gen Hosp, Mol Med Ctr, Sir Alastair Currie CRC Labs, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Curtis, LJ (corresponding author), Gen Infirm Leeds, Dept Histopathol, Great George St, Leeds LS1 3CX, W Yorkshire, England.							AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Akiyama Y, 1997, CANCER RES, V57, P3920; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Bubb VJ, 1996, ONCOGENE, V12, P2641; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CARDER P, 1993, ONCOGENE, V8, P1397; CARDER PJ, 1995, BRIT J CANCER, V71, P215, DOI 10.1038/bjc.1995.46; Eshleman JR, 1996, ONCOGENE, V12, P1425; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hoang JM, 1997, CANCER RES, V57, P300; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KIM HG, 1994, AM J PATHOL, V145, P148; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LOEB LA, 1991, CANCER RES, V51, P3075; LOTHE RA, 1993, CANCER RES, V53, P5849; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MCQUEEN HA, 1991, BRIT J CANCER, V63, P94, DOI 10.1038/bjc.1991.19; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NYSTROMLAHTI M, 1994, AM J HUM GENET, V55, P659; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PELTOMAKI P, 1993, CANCER RES, V53, P5853; PURDIE CA, 1991, AM J PATHOL, V138, P807; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Senba S, 1998, CANCER, V82, P279, DOI 10.1002/(SICI)1097-0142(19980115)82:2<279::AID-CNCR6>3.3.CO;2-D; Thibodeau SN, 1998, CANCER RES, V58, P1713; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Togo G, 1996, CANCER RES, V56, P5620; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WIJNEN J, 1995, AM J HUM GENET, V56, P1060; WU C, 1994, ONCOGENE, V9, P991; Yao J, 1999, INT J CANCER, V80, P667, DOI 10.1002/(SICI)1097-0215(19990301)80:5<667::AID-IJC6>3.0.CO;2-0	43	103	106	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					7933	7940		10.1038/sj.onc.1203368	http://dx.doi.org/10.1038/sj.onc.1203368			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637503				2022-12-17	WOS:000084634600001
J	Kang, SH; Bang, YJ; Im, YH; Yang, HK; Lee, DA; Lee, HY; Lee, HS; Kim, NK; Kim, SJ				Kang, SH; Bang, YJ; Im, YH; Yang, HK; Lee, DA; Lee, HY; Lee, HS; Kim, NK; Kim, SJ			Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-beta resistance in human gastric cancer	ONCOGENE			English	Article						transforming growth factor-beta; CpG methylation; cancer; receptor	TUMOR-SUPPRESSOR GENE; COLON-CARCINOMA CELLS; MICROSATELLITE INSTABILITY; CPG ISLAND; COLORECTAL-CANCER; MISMATCH REPAIR; EXPRESSION; ACTIVATION; MALIGNANCY; PROMOTER	The transforming growth factor-beta (TGF-beta) signaling pathway subserves an essential tumor suppressor function in various cell types. A heteromeric complex composed of TGF-beta type I (RI) and type II (RII) receptors is required for TGF-beta signaling. We have identified a subset of human gastric cancer cell lines which are insensitive to TGF-beta and which express a low level of TGF-beta type I receptor mRNA relative to a gastric cancer cell line which is highly responsive to TGF-beta. Using these cells, we show that hypermethylation of a CpG island in the 5' region of the TGF-beta RI gene provides another potentially important mechanism of escape from negative growth control by TGF-beta, This hypermethylation was found in four of five human gastric cancer cell lines and five out of 40 (12.5%) primary tumors examined, In human gastric cancer cell lines, treatment with the demethylating agent, 5-aza-2'-deoxycytidine, resulted in increased expression of the TGF-beta RI gene, but not the RII gene, Transient transfection of an RI expression vector into the TGF-beta resistant SNU-601 cell line restores TGF-beta responsiveness. These findings suggest that one of the mechanisms of escape from autocrine or paracrine growth control by TGF-beta during carcinogenesis could involve aberrant methylation of CpG islands in the 5' region of the TGF-beta RI gene.	Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul, South Korea; NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA	Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kim, SJ (corresponding author), Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul, South Korea.		Bang, Yung Jue/J-2759-2012; Yang, Han-Kwang/J-2767-2012	Bang, Yung Jue/0000-0001-6000-4597; 				BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bloom BB, 1996, BBA-MOL CELL RES, V1312, P243, DOI 10.1016/0167-4889(96)00043-2; Chang J, 1997, CANCER RES, V57, P2856; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3892; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GREENBERG ME, 1987, CURRENT PROTOCOLS MO; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Jones PA, 1996, CANCER RES, V56, P2463; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; Kim David H., 1996, Journal of Biomedical Science, V3, P143, DOI 10.1007/BF02253095; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MYEROFF LL, 1995, CANCER RES, V55, P5545; PARK K, 1994, P NATL ACAD SCI USA, V81, P8772; PARSONS R, 1995, CANCER RES, V55, P5548; Reiss M, 1997, ONCOL RES, V9, P447; RIDEOUT WM, 1994, MOL CELL BIOL, V14, P6143, DOI 10.1128/MCB.14.9.6143; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SAKAI T, 1991, AM J HUM GENET, V48, P880; SUARDET L, 1992, CANCER RES, V52, P3705; SUN LZ, 1994, J BIOL CHEM, V269, P26449; WAKEFIELD LM, 1991, TUMOR SUPPRESSOR GEN, P217; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	41	103	114	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7280	7286		10.1038/sj.onc.1203146	http://dx.doi.org/10.1038/sj.onc.1203146			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602482				2022-12-17	WOS:000084119400012
J	Stronach, BE; Perrimon, N				Stronach, BE; Perrimon, N			Stress signaling in Drosophila	ONCOGENE			English	Review						dorsal closure; morphogenesis; tissue polarity; immunity; JNK; p38	ACTIVATED PROTEIN-KINASE; AMINO-TERMINAL KINASE; CELL SHEET MOVEMENT; ETS-DOMAIN PROTEIN; DORSAL CLOSURE; MYOBLAST CITY; THICK VEINS; CYTOSKELETAL ORGANIZATION; TRANSDUCTION PATHWAY; MECHANICAL STRETCH	Cells commonly use multiprotein kinase cascades to signal information from the cell membrane to the nucleus. Several conserved signaling pathways related to the mitogen activated protein kinase (MAPK) pathway allow cells to respond to normal developmental signals as well as signals produced under stressful conditions. Genetic and molecular studies in Drosophila melanogaster over the last several years have related that components of stress signaling pathways, namely the Jun kinase (JNK) and p38 kinase signaling modules, are functionally conserved and participate in numerous processes during normal development. Specifically, the JNK pathway is required for morphogenetic movements in embryogenesis and generation of tissue polarity in the adult. The role of the p38 pathway in generation of axial polarity during oogenesis has been inferred from phenotypic analysis of mutations in the Drosophila homolog of DMKK3. In addition to their requirement for normal development, cell culture and genetic investigations point to a role for both the (JNK) and p38 pathways in regulation of the immune response in the fly. This review details the known components of stress signaling pathways in Drosophila and recent insights into how these pathways are used and regulated during development and homeostasis.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Stronach, BE (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.			Stronach, Beth/0000-0002-1699-8683; Perrimon, Norbert/0000-0001-7542-472X				Adachi-Yamada T, 1999, MOL CELL BIOL, V19, P2322; AFFOLTER M, 1994, DEVELOPMENT, V120, P3105; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Blake KJ, 1998, DEV BIOL, V203, P177, DOI 10.1006/dbio.1998.9036; Borchiellini C, 1996, ROUX ARCH DEV BIOL, V205, P468, DOI 10.1007/BF00377228; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BROWN NH, 1994, DEVELOPMENT, V120, P1221; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; Chou TB, 1996, GENETICS, V144, P1673; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Das P, 1998, DEVELOPMENT, V125, P1519; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; FEHON RG, 1994, DEVELOPMENT, V120, P545; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; HAFEN E, 1993, PHILOS T R SOC B, V340, P273, DOI 10.1098/rstb.1993.0068; Hamada K, 1998, J BIOL CHEM, V273, P6334, DOI 10.1074/jbc.273.11.6334; Han SJ, 1998, J BIOL CHEM, V273, P369, DOI 10.1074/jbc.273.1.369; Han ZQS, 1998, MOL CELL BIOL, V18, P3527, DOI 10.1128/MCB.18.6.3527; Harden N, 1996, MOL CELL BIOL, V16, P1896; HARDEN N, 1995, DEVELOPMENT, V121, P903; Harden N, 1999, J CELL SCI, V112, P273; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Hou XS, 1997, GENE DEV, V11, P1728, DOI 10.1101/gad.11.13.1728; Hudson JB, 1998, DEVELOPMENT, V125, P1407; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JURGENS G, 1984, ROUXS ARCH, V193; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; Kockel L, 1997, GENE DEV, V11, P1748, DOI 10.1101/gad.11.13.1748; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Kyriakis JM, 1999, BIOCHEM SOC SYMP, P29; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; Liu HZ, 1999, CURR BIOL, V9, P101, DOI 10.1016/S0960-9822(99)80023-2; Lu Y, 1999, GENE DEV, V13, P1168, DOI 10.1101/gad.13.9.1168; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MacKenna DA, 1998, J CLIN INVEST, V101, P301, DOI 10.1172/JCI1026; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIYAMOTO H, 1995, GENE DEV, V9, P612, DOI 10.1101/gad.9.5.612; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; PERRIMON N, 1988, DEV BIOL, V127, P392, DOI 10.1016/0012-1606(88)90326-0; PERRIMON N, 1989, GENETICS, V121, P333; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P265, DOI 10.1016/S0968-0004(00)89040-4; Ricos MG, 1999, J CELL SCI, V112, P1225; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; RiesgoEscovar JR, 1997, GENE DEV, V11, P1717, DOI 10.1101/gad.11.13.1717; RING JM, 1993, DEVELOPMENT, P251; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; RUSHTON E, 1995, DEVELOPMENT, V121, P1979; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; STAEHLINGHAMPTON K, 1995, DEVELOPMENT, V121, P3393; Stark KA, 1997, DEVELOPMENT, V124, P4583; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Su YC, 1998, GENE DEV, V12, P2371, DOI 10.1101/gad.12.15.2371; Suzanne M, 1999, GENE DEV, V13, P1464, DOI 10.1101/gad.13.11.1464; Takeyama Y, 1998, J SURG RES, V78, P97, DOI 10.1006/jsre.1998.5360; TOONE WM, 1998, GENES CELLS, P8; Treisman JE, 1997, GENE, V186, P119, DOI 10.1016/S0378-1119(96)00694-4; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wisotzkey RG, 1998, DEVELOPMENT, V125, P1433; Wu LP, 1998, NATURE, V392, P93, DOI 10.1038/32195; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29; Zecchini V, 1999, CURR BIOL, V9, P460, DOI 10.1016/S0960-9822(99)80211-5; Zeitlinger J, 1997, EMBO J, V16, P7393, DOI 10.1093/emboj/16.24.7393	86	103	104	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	1999	18	45			SI		6172	6182		10.1038/sj.onc.1203125	http://dx.doi.org/10.1038/sj.onc.1203125			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251LL	10557109	Green Published			2022-12-17	WOS:000083447100012
J	Watts, RG; Huang, CS; Young, MR; Li, JJ; Dong, ZG; Pennie, WD; Colburn, NH				Watts, RG; Huang, CS; Young, MR; Li, JJ; Dong, ZG; Pennie, WD; Colburn, NH			Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation	ONCOGENE			English	Article						MAP kinases; transcription factors; tumor promotion; neoplastic transformation	ACTIVATED PROTEIN-KINASE; SERUM RESPONSE ELEMENT; PROMOTER-INDUCED TRANSFORMATION; SIGNAL-REGULATED KINASES; GROWTH-FACTOR RECEPTOR; C-FOS EXPRESSION; TERNARY COMPLEX; MAP KINASE; JB6 CELLS; S6 KINASE	The mitogen activated protein (MAP) kinases or extracellular signal-regulated kinases (Erks) are activated in response to Ras expression or exposure to tumor promoters or to growth factors, and have been implicated in AP-I transactivation in some models. We have shown that tumor promoter induced activation of the transcription factor AP-1 is required for induced neoplastic transformation in the Balb/C JB6 cell model. Jun and Fos family protein levels have been found not to be limiting for AP-l response. The present study asks whether activation of Erks1 and 2 is required for AP-1 transactivation and transformation of JB6 cells and whether Erks might be targeted for cancer prevention. Expression of either of two different dominant negative kinase inactive Erk2 mutants in transformation sensitive (P+) JB6 cells substantially inhibited the tumor promoter induced activation of Erks1 and 2 and of AP-I measured by a collagenase-luciferase reporter. Multiple mutant Erk2 expressing clonal lines were also rendered non-responsive to induced neoplastic transformation. These observations, together with our recent finding attributing AP-1 non-responsiveness to Erk deficiency in a clonal line of transformation resistant (P-) cells, argue for a requirement for Erks1 and/or 2 activation in AP-1 transactivation in the mouse JB6 neoplastic progression model, and suggest the utility of Erks as a prevention target.	NCI, Frederick Canc Res & Dev Ctr, Lab Biochem Pathol, Frederick, MD 21702 USA; Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Minnesota System	Colburn, NH (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Lab Biochem Pathol, Bldg 560, Frederick, MD 21702 USA.			Li, Jian Jian/0000-0003-3694-9675; Huang, Chuanshu/0000-0003-4133-5096				AHN NG, 1990, J BIOL CHEM, V265, P11495; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, CELL, V5, P62; BENARI ET, 1992, MOL CARCINOGEN, V5, P62, DOI 10.1002/mc.2940050111; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BERNSTEIN LR, 1991, ENVIRON HEALTH PERSP, V93, P111, DOI 10.2307/3431178; Buttice G, 1996, ONCOGENE, V13, P2297; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; GRUDA MC, 1994, ONCOGENE, V9, P2537; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; LEE RM, 1992, J BIOL CHEM, V267, P1088; Li JJ, 1996, CANCER RES, V56, P483; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Strahl T, 1996, P NATL ACAD SCI USA, V93, P11563, DOI 10.1073/pnas.93.21.11563; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKASHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TRIESMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WATTS RG, 1995, MOL CARCINOGEN, V13, P27, DOI 10.1002/mc.2940130106; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	45	103	105	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3493	3498		10.1038/sj.onc.1202259	http://dx.doi.org/10.1038/sj.onc.1202259			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030673				2022-12-17	WOS:000078086200010
J	Izzo, JG; Papadimitrakopoulou, VA; Li, XQ; Ibarguen, H; Lee, JS; Ro, JY; El-Naggar, A; Hong, WK; Hittelman, WN				Izzo, JG; Papadimitrakopoulou, VA; Li, XQ; Ibarguen, H; Lee, JS; Ro, JY; El-Naggar, A; Hong, WK; Hittelman, WN			Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification	ONCOGENE			English	Article						cyclin D1; tumorigenesis; dysregulated expression; amplification; FISH; immunohistochemistry	SQUAMOUS-CELL CARCINOMAS; CHROMOSOME 11Q13 REGION; G1 PHASE PROGRESSION; PREMALIGNANT LESIONS; INSITU HYBRIDIZATION; TUMOR PROGRESSION; AMPLIFIED REGION; CANCER; OVEREXPRESSION; PROTEIN	Cyclin D1 proto-oncogene is a key regulator of the mammalian cell-cycle acting at the restriction point in late G1, Amplification of the cyclin D1 locus, located on chromosome 11q13, as well as cyclin D1 protein overexpression have been reported in several human malignancies. The purpose of this study was to evaluate cyclin D1 gene copy status and protein expression during the multistep process of head and neck tumorigenesis, using a combination of fluorescence in situ hybridization and immunohistochemistry techniques. From 29 selected patients presenting with head and neck squamous carcinoma and whose tumor cytospins had been previously screened for presence (16 cases) or absence (13 cases) of amplification at the 11q13 band, we analysed 46 paraffin-embedded tissue specimens that demonstrated, besides the primary tumor, the presence of contiguous adjacent normal tissue and/or premalignant lesions. Of the 16 amplified cases, nine demonstrated a continuous progression from premalignant to invasive carcinoma and seven (77.7%) of these cases showed cyclin D1 gene amplification in premalignant lesions prior to development of invasive carcinoma. Increased cyclin D1 protein expression was observed in all 16 amplified tumors' and five of the 13 (38.4%) nonamplified tumors. Interestingly, dysregulated cyclin D1 expression was also found in the premalignant lesions adjacent to all 16 amplified tumors, and it appeared to precede cyclin D1 gene amplification. In contrast no dysregulated expression was detected in the premalignant lesions of the non-amplified tumors. In conclusion, these findings provide strong evidence for early dysregulation of cyclin D1 expression during the tumorigenesis process and suggest that dysregulated increased expression precedes and possibly enables gene amplification.	Univ Texas, MD Anderson Canc Ctr, Dept Clin Invest, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Hittelman, WN (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Clin Invest, 1515 holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA-16672, CA-52051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052051, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ALMASAN A, 1995, CANCER METAST REV, V14, P59, DOI 10.1007/BF00690212; Arber N, 1996, CANCER EPIDEM BIOMAR, V5, P457; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; BARTKOVA J, 1995, CANCER RES, V55, P949; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BERENSON JR, 1989, ONCOGENE, V4, P1111; BOHR VA, 1988, J CELL SCI, V91, P175; BOYLE JO, 1993, CANCER RES, V53, P4477; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; BROOKES S, 1993, GENE CHROMOSOME CANC, V6, P222, DOI 10.1002/gcc.2870060406; Califano J, 1996, CANCER RES, V56, P2488; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; COWAN JM, 1992, J NATL CANCER I, V84, P793, DOI 10.1093/jnci/84.10.793; ELNAGGAR AK, 1995, CYTOMETRY, V21, P47, DOI 10.1002/cyto.990210110; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; Farber E, 1996, ADV CANCER RES, V70, P21, DOI 10.1016/S0065-230X(08)60870-2; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; HINDS PW, 1994, P NATL ACAD SCI USA, V87, P6281; Izzo J., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P361; JARES P, 1994, CANCER RES, V54, P4813; JIAN W, 1993, ONCOGENE, V8, P2159; JUNIEN C, 1992, GENOMICS, V12, P620, DOI 10.1016/0888-7543(92)90461-Z; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; KUO MT, 1994, MOL CELL BIOL, V14, P5202, DOI 10.1128/MCB.14.8.5202; LAMMIE GA, 1991, ONCOGENE, V6, P439; LESE CM, 1995, GENE CHROMOSOME CANC, V12, P288, DOI 10.1002/gcc.2870120409; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1995, ONCOGENE, V10, P2125; LUTZ S, 1992, J PATHOL, V167, P279, DOI 10.1002/path.1711670304; Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682; MICHALIDES R, 1995, CANCER RES, V55, P975; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; NAWROZ H, 1994, CANCER RES, V54, P1152; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Roh H. J., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P117; SAUTER G, 1995, INT J CANCER, V64, P99, DOI 10.1002/ijc.2910640205; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SCHUURING E, 1992, ONCOGENE, V7, P355; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIN DM, 1994, CANCER RES, V54, P3153; SHIN DM, 1993, J NATL CANCER I, V85, P971, DOI 10.1093/jnci/85.12.971; SHIN DM, 1994, CANCER RES, V54, P321; SODER AI, 1995, CANCER RES, V55, P5030; SOMERS KD, 1990, ONCOGENE, V5, P915; TAINSKY MA, 1995, CANCER METAST REV, V14, P43, DOI 10.1007/BF00690210; TAM SW, 1994, ONCOGENE, V9, P2663; TANIGAMI A, 1992, GENOMICS, V13, P21, DOI 10.1016/0888-7543(92)90196-Y; TLSTY TD, 1993, COLD SPRING HARB SYM, V58, P645, DOI 10.1101/SQB.1993.058.01.072; Uchimaru K, 1996, JPN J CANCER RES, V87, P459, DOI 10.1111/j.1349-7006.1996.tb00246.x; Uhlman DL, 1996, CANCER RES, V56, P2199; VORAVUD N, 1993, CANCER RES, V53, P2874; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Zhou P, 1996, CANCER RES, V56, P36	55	103	109	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2313	2322		10.1038/sj.onc.1202153	http://dx.doi.org/10.1038/sj.onc.1202153			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811462				2022-12-17	WOS:000076723300005
J	Pelton, PD; Sherman, LS; Rizvi, TA; Marchionni, MA; Wood, P; Friedman, RA; Ratner, N				Pelton, PD; Sherman, LS; Rizvi, TA; Marchionni, MA; Wood, P; Friedman, RA; Ratner, N			Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells	ONCOGENE			English	Article						merlin; schwannomin; actin; Rho; Rac; C3 transferase; adenovirus	NEUROFIBROMATOSIS-2 TUMOR-SUPPRESSOR; NERVE SHEATH TUMORS; ERM FAMILY MEMBERS; FIBRILLARY ACIDIC-PROTEIN; ACTIN-BASED CYTOSKELETONS; GERM-LINE MUTATIONS; PERIPHERAL-NERVE; GENE-PRODUCT; FOCAL ADHESIONS; TYPE-2 GENE	Schwannomas are peripheral nerve tumors that typically have mutations in the NF2 tumor suppressor gene. We compared cultured schwannoma cells with Schwann cells from normal human peripheral nerves (NHSC). Both cell types expressed specific antigenic markers, interacted with neurons, and proliferated in response to glial growth factor, confirming their identity as Schwann cells. Schwannoma cells frequently had elevated basal proliferation compared to NHSC. Schwannoma cells also showed spread areas 5-7-fold greater than NHSC, aberrant membrane ruffling and numerous, frequently disorganized stress fibers. Dominant negative Rac inhibited schwannoma cell ruffling but had no apparent effect on NHSC. Schwannoma cell stress fibers were inhibited by C3 transferase, tyrphostin A25, or dominant negative RhoA. These data suggest that the Rho and Rac pathways are abnormally activated in schwannoma cells. Levels of ezrin and moesin, proteins related to the NF2 gene product, merlin, were unchanged in schwannoma cells compared to NHSC. Our findings demonstrate for the first time that cell proliferation and actin organization are aberrant in schwannoma cells. Because NF2 is mutant in most or all human schwannomas, we postulate that loss of NF2 contributes to the cell growth and cytoskeletal dysfunction reported here.	Univ Cincinnati, Coll Med, Dept Otolaryngol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Univ Miami, Miami Project, Miami, FL 33136 USA; Cambridge Neurosci, Cambridge, MA 02139 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Miami	Ratner, N (corresponding author), Univ Cincinnati, Coll Med, Dept Otolaryngol, Cincinnati, OH 45267 USA.			RATNER, NANCY/0000-0001-5030-9354	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028840] Funding Source: NIH RePORTER; NINDS NIH HHS [NS10133, NS10297, NS28840] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; BARON P, 1991, ACTA NEUROPATHOL, V81, P491, DOI 10.1007/BF00310128; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BROCKES JP, 1986, ANN NEUROL, V20, P317, DOI 10.1002/ana.410200308; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; CRAVIOTO H, 1969, ACTA NEUROPATHOL, V12, P141, DOI 10.1007/BF00692502; CRAVIOTO H, 1969, ACTA NEUROPATHOL, V12, P116, DOI 10.1007/BF00692501; DARDENNE AJ, 1984, J CLIN PATHOL, V37, P895, DOI 10.1136/jcp.37.8.895; DENBAKKER MA, 1995, ONCOGENE, V10, P757; DENBAKKER MA, 1995, AM J PATHOL, V147, P1339; EINHEBER S, 1993, J CELL BIOL, V123, P1223, DOI 10.1083/jcb.123.5.1223; ERLANDSON RA, 1982, CANCER, V49, P273, DOI 10.1002/1097-0142(19820115)49:2<273::AID-CNCR2820490213>3.0.CO;2-R; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FELTRI ML, 1994, DEVELOPMENT, V120, P1287; FernandezValle C, 1997, J NEUROSCI, V17, P241, DOI 10.1523/JNEUROSCI.17-01-00241.1997; FERNANDEZVALLE C, 1994, J NEUROBIOL, V25, P1207, DOI 10.1002/neu.480251004; FRANCK Z, 1993, J CELL SCI, V105, P219; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hitotsumatsu T, 1997, ACTA NEUROPATHOL, V93, P225, DOI 10.1007/s004010050608; Huynh DP, 1996, ONCOGENE, V13, P73; Huynh DP, 1997, J NEUROPATH EXP NEUR, V56, P382, DOI 10.1097/00005072-199704000-00007; JAAKKOLA S, 1993, J NEUROCYTOL, V22, P215, DOI 10.1007/BF01246360; JAASKELAINEN J, 1994, J NEUROSURG, V80, P541, DOI 10.3171/jns.1994.80.3.0541; Jacoby LB, 1996, GENE CHROMOSOME CANC, V17, P45, DOI 10.1002/(SICI)1098-2264(199609)17:1<45::AID-GCC7>3.0.CO;2-2; JACOBY LB, 1994, HUM MOL GENET, V3, P413, DOI 10.1093/hmg/3.3.413; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JOHNSON MD, 1988, ARCH PATHOL LAB MED, V112, P155; KAWAHARA E, 1988, AM J SURG PATHOL, V12, P115, DOI 10.1097/00000478-198802000-00004; KLEITMAN N, 1991, CULTURING NERVE CELL, P251; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LEVI ADO, 1995, J NEUROSCI, V15, P1329; LUTCHMAN M, 1995, CANCER RES, V55, P2270; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARKWELL MA, 1978, ANAL BIOCHEM, V82, P206; McCartney BM, 1996, J CELL BIOL, V133, P843, DOI 10.1083/jcb.133.4.843; MCCOMB RD, 1985, J NEUROPATH EXP NEUR, V44, P242, DOI 10.1097/00005072-198505000-00003; MCGARVEY ML, 1984, DEV BIOL, V105, P18, DOI 10.1016/0012-1606(84)90257-4; MEREL P, 1995, GENE CHROMOSOME CANC, V12, P117, DOI 10.1002/gcc.2870120206; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; MORRISSEY TK, 1991, J NEUROSCI, V11, P2433; NANCE WE, 1993, ARCH NEUROL-CHICAGO, V45, P575; NOBES CD, 1995, J CELL SCI, V108, P225; Parry DM, 1996, AM J HUM GENET, V59, P529; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Raabe TD, 1996, J NEUROSCI RES, V46, P263; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rosenbaum C, 1997, EXP NEUROL, V148, P604, DOI 10.1006/exnr.1997.6696; Rosenbaum T, 1997, NEUROSCIENTIST, V3, P412, DOI 10.1177/107385849700300614; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUTKOWSKI JL, 1992, ANN NEUROL, V31, P580, DOI 10.1002/ana.410310603; SAINZ J, 1994, HUM MOL GENET, V3, P885, DOI 10.1093/hmg/3.6.885; SALZER JL, 1980, J CELL BIOL, V84, P767, DOI 10.1083/jcb.84.3.767; Scherer SS, 1996, J NEUROSCI RES, V46, P595, DOI 10.1002/(SICI)1097-4547(19961201)46:5<595::AID-JNR8>3.0.CO;2-E; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; SOBEL RA, 1993, J NEUROPATH EXP NEUR, V52, P106, DOI 10.1097/00005072-199303000-00002; StemmerRachamimov AO, 1997, AM J PATHOL, V151, P1649; TAKAISHI K, 1995, ONCOGENE, V11, P39; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TIKOO A, 1994, J BIOL CHEM, V269, P1; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; WECHSLER W., 1965, BEITR PATHOL ANAT ALLG PATHOL, V132, P319; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; YONEMURA S, 1993, J CELL BIOL, V120, P437, DOI 10.1083/jcb.120.2.437	82	103	120	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2195	2209		10.1038/sj.onc.1202141	http://dx.doi.org/10.1038/sj.onc.1202141			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811451				2022-12-17	WOS:000076698200006
J	Kinoshita, T; Shirouzu, M; Kamiya, A; Hashimoto, K; Yokoyama, S; Miyajima, A				Kinoshita, T; Shirouzu, M; Kamiya, A; Hashimoto, K; Yokoyama, S; Miyajima, A			Raf/MAPK and rapamycin-sensitive pathways mediate the anti-apoptotic function of p21Ras in IL3-dependent hematopoietic cells	ONCOGENE			English	Article						cell survival; anti-apoptosis; ras; rapamycin	COLONY-STIMULATING FACTOR; ACTIVATED PROTEIN-KINASE; NUCLEOTIDE DISSOCIATION STIMULATOR; COMMON BETA-SUBUNIT; P70 S6 KINASE; SIGNAL-TRANSDUCTION; RAS TRANSFORMATION; ONCOGENIC RAS; NEURITE OUTGROWTH; GROWTH-FACTOR	The Ras signal transduction pathway is activated by a number of hematopoietic cytokines and is implicated in the prevention of apoptotic death in hematopoietic cells, Recent studies have provided evidence that the downstream of Ras is highly divergent and several independent pathways appear to mediate distinct biological functions of Ras, In the present study, we investigated the downstream pathway(s) of Ras responsible for the maintenance of hematopoietic cell survival by using various mutants of signaling molecules, Activation of the Raf/MAPK pathway in interleukin (IL) 3-dependent cells by expression of an oncogenic Raf or a Ras mutant (G12V/T35S) prevented apoptosis following IL-3 deprivation, In contrast, another Ras mutant (G12V/V45E), which is apparently incapable of activating MAPK, efficiently blocked apoptosis as well, It is therefore likely that the activation of the Raf/MAPK pathway is not an absolute requirement for the prevention of apoptosis, and there appears to be a Raf/MAPK-independent pathway that contributes to hematopoietic cell survival, Since Ras(G12V/V45E) was able to cause the phosphorylation of p70/S6 kinase, we inhibited the S6 kinase pathway by rapamycin and by wortmannin, and found that the anti-apoptotic function of Ras(G12V/V45E), but not of Ras(G12V), was critically influenced by both inhibitors, These results indicate that the Raf/MAPK and a rapamycin/wortmannin-sensitive pathways mediate Ras function to prevent apoptotic death in hematopoietic cells.	UNIV TOKYO,INST MOL & CELLULAR BIOSCI,DEPT CELLULAR BIOSYNTH,BUNKYO KU,TOKYO 113,JAPAN; RIKEN,INST PHYS & CHEM RES,CELLULAR SIGNALING LAB,WAKO,SAITAMA 35101,JAPAN; UNIV TOKYO,FAC SCI,DEPT BIOCHEM & BIOPHYS,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo; RIKEN; University of Tokyo			Shirouzu, Mikako/A-6521-2016; Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338				Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; ANDERSON MW, 1992, ENVIRON HEALTH PERSP, V98, P13, DOI 10.2307/3431243; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN CY, 1995, ONCOGENE, V11, P1487; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DOWNWARD J, 1992, NATURE, V359, P273, DOI 10.1038/359273a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; Hara T, 1996, STEM CELLS, V14, P605, DOI 10.1002/stem.140605; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIYAJIMA A, 1987, GENE, V58, P273, DOI 10.1016/0378-1119(87)90382-9; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUTHUKKUMAR S, 1995, TRANSPLANTATION, V60, P264, DOI 10.1097/00007890-199508000-00010; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; SCHWAB M, 1990, Critical Reviews in Oncogenesis, V2, P35; SHI YF, 1995, CANCER RES, V55, P1982; SHIROUZU M, 1994, ONCOGENE, V9, P2153; SHIROUZU M, 1992, ONCOGENE, V7, P475; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; Troppmair J, 1992, Curr Top Microbiol Immunol, V182, P453; VANAELST L, 1994, COLD SPRING HARB SYM, V59, P181, DOI 10.1101/SQB.1994.059.01.022; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WHETTON AD, 1983, NATURE, V303, P629, DOI 10.1038/303629a0; WHETTON AD, 1984, EMBO J, V3, P409, DOI 10.1002/j.1460-2075.1984.tb01821.x; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	73	103	104	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					619	627		10.1038/sj.onc.1201234	http://dx.doi.org/10.1038/sj.onc.1201234			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264402				2022-12-17	WOS:A1997XP68300001
J	Grandis, JR; Chakraborty, A; Melhem, MF; Zeng, Q; Tweardy, DJ				Grandis, JR; Chakraborty, A; Melhem, MF; Zeng, Q; Tweardy, DJ			Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells	ONCOGENE			English	Article						epidermal growth factor receptor; head and neck cancer	FACTOR-ALPHA; EGF-RECEPTOR; BREAST-CANCER; TGF-ALPHA; MONOCLONAL-ANTIBODIES; PSEUDOMONAS EXOTOXIN; TYROSINE KINASE; FUSION PROTEIN; MESSENGER-RNA; TUMOR-GROWTH	Previous reports have shown that fresh tissues and cell lines from patients with squamous cell carcinoma of the head and neck (SCCHN) overexpress transforming growth factor alpha (TGF-alpha) and its receptor, the epidermal growth factor receptor (EGFR) at both the mRNA and protein levels. Protein localization studies confirm that TGF-alpha and EGFR are produced by the same epithelial cells in tissues from head and neck cancer patients further supporting an autocrine growth pathway. Using three strategies, we examined the hypothesis that downmodulation of EGFR would reduce the proliferation of SCCHN cells. We targeted EGFR mRNA using antisense oligonucleotides and the mature EGFR protein at two sites, the ligand-binding domain and the kinase domain, and determined the effects of this targeting on SCCHN proliferation. Treatment of several SCCHN cell lines with a pair of antisense oligodeoxynucleotides directed against the translation start site and first intron-exon splice junction of the human EGFR gene resulted in decreased EGFR protein production and inhibited growth by 86% compared to a 13% reduction in cells treated with sense oligonucleotides (P=0.03). Growth inhibition was specific for carcinoma cells since the same EGFR antisense oligonucleotides had no effect on the proliferation of normal mucosa cells harvested from non-cancer patients. Two monoclonal antibodies which block ligand binding to EGFR (MAbs 425 and 528) inhibited the growth of several SCCHN cell lines by up to 97% which suggests that EGFR is participating in an autocrine pathway in SCCHN that is, at least in part, external. An EGFR-specific tyrosine kinase inhibitor (PD 153035) was found to inhibit EGFR phosphorylation in SCCHN cell lines and to reduce growth by 68% although it had no effect on the growth rate of normal mucosal epithelial cells. These experiments indicate that EGFR gene expression and function is critical for SCCHN cell growth but not for growth of normal mucosa cells and therefore may serve as a tumor-specific target for preventive and therapeutic strategies in head and neck cancer.	UNIV PITTSBURGH,DEPT PATHOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,DEPT OTOLARYNGOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,DEPT MED & MOL GENET & BIOCHEM,PITTSBURGH,PA 15213; UNIV PITTSBURGH,INST CANC,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Tweardy, David/L-3929-2019		NCI NIH HHS [1 K11 CA01760-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA001760] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATLAS I, 1992, CANCER RES, V2, P3353; BASELGA J, 1994, PHARMACOL THERAPEUT, V64, P127, DOI 10.1016/0163-7258(94)90036-1; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; BASELGA J, 1994, BREAST CANCER RES TR, V29, P127, DOI 10.1007/BF00666188; CHRISTENSEN ME, 1992, EUR ARCH OTO-RHINO-L, V249, P243, DOI 10.1007/BF00714485; DERUI L, 1992, AM J CLIN ONCOL-CANC, V15, P288, DOI 10.1097/00000421-199208000-00003; DIFORE PP, 1992, CANC TREAT RES, V61, P139; DIMARCO E, 1989, ONCOGENE, V4, P831; DIVGI CR, 1991, J NATL CANCER I, V83, P97, DOI 10.1093/jnci/83.2.97; EISBRUCH A, 1987, CANCER RES, V47, P3603; FAN Z, 1993, CANCER RES, V53, P4322; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Grandis JR, 1996, CANCER-AM CANCER SOC, V78, P1284, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1284::AID-CNCR17>3.0.CO;2-X; GRANDIS JR, 1993, CANCER RES, V53, P3579; Grandis JR, 1996, NAT MED, V2, P237, DOI 10.1038/nm0296-237; HALEY J, 1987, ONCOGENE RES, V1, P375; HARRIS AL, 1989, CANCER CEL, V7, P353; HEO DS, 1989, CANCER RES, V49, P5167; ISHITOYA J, 1989, BRIT J CANCER, V59, P559, DOI 10.1038/bjc.1989.113; KAMEYAMA S, 1994, J CANCER RES CLIN, V120, P507, DOI 10.1007/BF01221026; KAWAMOTO T, 1991, JPN J CANCER RES, V82, P403, DOI 10.1111/j.1349-7006.1991.tb01863.x; Kelloff GJ, 1996, CANCER EPIDEM BIOMAR, V5, P657; KENNEY NJ, 1993, J CELL PHYSIOL, V156, P497, DOI 10.1002/jcp.1041560309; KIHARA A, 1994, BIOCONJUGATE CHEM, P532; LAIRD AD, 1994, CANCER RES, V54, P4224; LEMAISTRE CF, 1992, BLOOD, V82, pA444; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MAXWELL SA, 1989, CANCER RES, V49, P1130; MORISHIGE KI, 1991, CANCER RES, V51, P5322; MORONI MC, 1992, J BIOL CHEM, V267, P2714; MURTHY U, 1990, BIOCHEM BIOPH RES CO, V172, P471, DOI 10.1016/0006-291X(90)90696-K; NICHOLSON S, 1988, BRIT J CANCER, V58, P810, DOI 10.1038/bjc.1988.315; OZANNE B, 1986, J PATHOL, V149, P9, DOI 10.1002/path.1711490104; PHILLIPS PC, 1994, CANCER RES, V54, P1008; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; RIKIMARU K, 1992, HEAD NECK-J SCI SPEC, V14, P8, DOI 10.1002/hed.2880140103; RODECK U, 1987, CANCER RES, V47, P3692; SACCHI M, 1990, CANCER RES, V50, P3113; SAINSBURY JRC, 1987, LANCET, V1, P1398; SHIN DM, 1994, CANCER RES, V54, P3153; THEUER CP, 1993, J UROLOGY, V149, P1626, DOI 10.1016/S0022-5347(17)36464-9; TODD R, 1989, CARCINOGENESIS, V10, P1553, DOI 10.1093/carcin/10.8.1553; TOI M, 1991, EUR J CANCER, V27, P977, DOI 10.1016/0277-5379(91)90262-C; VEALE D, 1987, BRIT J CANCER, V55, P513, DOI 10.1038/bjc.1987.104; WEICHSELBAUM RR, 1989, HEAD NECK-J SCI SPEC, V11, P437, DOI 10.1002/hed.2880110510; YAMAMOTO T, 1986, CANCER RES, V46, P414	46	103	111	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					409	416		10.1038/sj.onc.1201188	http://dx.doi.org/10.1038/sj.onc.1201188			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242377				2022-12-17	WOS:A1997XM23800005
J	Fujimura, Y; Ohno, T; Siddique, H; Lee, L; Rao, VN; Reddy, ESP				Fujimura, Y; Ohno, T; Siddique, H; Lee, L; Rao, VN; Reddy, ESP			The EWS-ATF-1 gene involved in malignant melanoma of soft parts with t(12;22) chromosome translocation, encodes a constitutive transcriptional activator	ONCOGENE			English	Article						malignant melanoma; EWS; transactivation; ATF-1; chromosome translocation	ETS-RELATED GENE; TISSUE-SPECIFIC EXTINGUISHER; PROTEIN-KINASE-A; EWINGS-SARCOMA; DNA-BINDING; REGULATORY SUBUNIT; TSE1 ENCODES; FACTOR CREB; CYCLIC-AMP; FLI-1 GENE	Molecular characterization of malignant melanoma of soft parts or soft tissue clear cell sarcoma which shares t(12;22) chromosome translocation revealed fusion of EWS with a transcriptional factor gene ATF-1. The EWS gene, which encodes an RNA binding protein, was also shown to be involved in Ewing sarcoma, related primitive neuroectodermal tumors and desmoplastic small round cell tumors. In order to understand the functional role of EWS-ATF-1 chimeric protein in human solid tumors, we have cloned the aberrant human ATF-1 (EWS-ATF-1) cDNA and studied its DNA binding, transcriptional activation properties and compared with normal ATF-1 protein. Our results demonstrate that EWS-ATF-1 binds weakly to DNA in vitro but functions as an efficient constitutive transcriptional activator unlike the normal ATF-1 which needs to be induced with cAMP. Deletion analysis revealed that EWS-fusion domain functions as a regulatory domain for the transcriptional activation properties of EWS-ATF-1 chimeric protein. Deletion of leucine zipper domain results in a loss of transcriptional activation of EWS-ATF-1 chimeric protein suggesting that protein-protein interaction play a role in the transcriptional activation properties of EWS-ATF-1. We demonstrate that EWS-fusion domain negatively regulates the DNA binding activity of EWS-ATF-1 chimeric protein. Therefore replacement of part of the amino-terminal kinase regulatory domain of ATF-1 protein with EWS regulatory domain results in an altered DNA binding, protein-protein interactions and transcriptional activation properties of EWS-ATF-1 causing deregulated gene expression which may be responsible for the genesis of t(12;22) chromosome translocation-bearing human solid tumors. Targeting the transcriptional cofactors (CBP, etc) by EWS-fusion proteins could be one of the mechanisms of activation of EWS-fusion proteins in human neoplasia.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; SAIC,FREDERICK,MD 21702	Jefferson University; Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [CA 51083, CA 58642, CA 57157] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083, R01CA057157, R01CA058642] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; AURIAS A, 1983, NEW ENGL J MED, V309, P496; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; BROWN AD, 1995, ONCOGENE, V10, P1749; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUNN T, 1994, CANCER GENET CYTOGEN, V76, P19, DOI 10.1016/0165-4608(94)90063-9; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; HELM S, 1994, GENES CHROM CANC, V11, P256; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; ICHIKAWA H, 1994, CANCER RES, V54, P2865; JEON IS, 1995, ONCOGENE, V10, P1229; JONES KW, 1991, CELL, V66, P861, DOI 10.1016/0092-8674(91)90433-Y; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LADANYI M, 1994, CANCER RES, V54, P2837; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LIU F, 1993, J BIOL CHEM, V268, P6714; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MITELMAN F, 1991, CATALOG CHROMOSOME A; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; PRASAD DDK, 1994, ONCOGENE, V9, P669; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; VAIRO G, 1990, J BIOL CHEM, V265, P2692; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	55	103	104	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					159	167						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552387				2022-12-17	WOS:A1996TQ01400020
J	BUDAY, L; WARNE, PH; DOWNWARD, J				BUDAY, L; WARNE, PH; DOWNWARD, J			DOWN-REGULATION OF THE RAS ACTIVATION PATHWAY BY MAP KINASE PHOSPHORYLATION OF SOS	ONCOGENE			English	Article						SOS; PAS; MAP KINASE; T CELL	NUCLEOTIDE EXCHANGE FACTOR; SIGNAL TRANSDUCTION; LYMPHOCYTES-T; RECEPTOR; PROTEIN; GRB2; P21RAS; STIMULATION; COMPLEX; BINDS	Formation of a complex of the nucleotide exchange factor Sos, the SH2 and SH3 containing adaptor protein Grb2/Sem-5 and tyrosine phosphorylated EGF receptor and She has been implicated in the activation of Ras by epidermal growth factor (EGF) in fibroblasts: related mechanisms for activation of Ras operate in other cell types. An increase in the apparent molecular weight of Sos has been reported to occur after several minutes of receptor stimulation due to phosphorylation by mitogen-activated protein (MAP) kinases. We report here that treatment of human peripheral blood T lymphoblasts with phorbol esters causes a similar shift in mobility of Sos. This modification of Sos does not alter its ability to bind Grb2, but correlates with strong inhibition of the binding of the Sos/Grb2 complex to tyrosine phosphorylated sequences, either a tyrosine phosphopeptide in cell lysates or p36 in intact cells. This effect, along with the mobility shift of Sos, can be mimicked in vitro by phosphorylation of Sos by the mitogen-activated protein kinase, ERK1. A novel negative feedback mechanism therefore exists whereby activation of MAP kinases through Ras results in the uncoupling of the Sos/Grb2 complex from tyrosine kinase substrates without blocking the interaction of Sos with Grb2.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; SEMMELWEIS UNIV MED,SCH MED,INST BIOCHEM 1,H-1088 BUDAPEST,HUNGARY	Cancer Research UK; Semmelweis University				Downward, Julian/0000-0002-2331-4729				BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; HALLBERG B, 1994, J BIOL CHEM, V270, P3913; HARLOW E, 1988, ANTIBODIES LABORATOR; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; NEL AE, 1990, J IMMUNOL, V144, P2683; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; WATERS SB, 1995, MOL CELL BIOL, V15, P2791	21	103	104	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1327	1331						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478553				2022-12-17	WOS:A1995RY96700013
J	DEBOER, CJ; VANKRIEKEN, JHJM; KLUINNELEMANS, HC; KLUIN, PM; SCHUURING, E				DEBOER, CJ; VANKRIEKEN, JHJM; KLUINNELEMANS, HC; KLUIN, PM; SCHUURING, E			CYCLIN D1 MESSENGER-RNA OVEREXPRESSION AS A MARKER FOR MANTLE CELL LYMPHOMA	ONCOGENE			English	Article						MANTLE CELL LYMPHOMA; 11Q13; BCL-1; PRAD1; CCND1; NHL	GENOMIC ORGANIZATION; CENTROCYTIC LYMPHOMA; GENE REARRANGEMENT; CHROMOSOME 11Q13; EXPRESSION; TRANSLOCATION; BREAKPOINTS; LEUKEMIA; CLONING; LINES	In mantle cell lymphoma (MCL) a recurrent chromosomal rearrangement, t(11;14)(q13;q32), has been described. Most breakpoints have been detected within the 120 kb BCL-1 region, upstream of the cyclin D1 gene. To evaluate the association between BCL-1 rearrangement and expression of cyclin D1 in lymphoproliferative disorders, we analysed a series of 24 MCL, 56 other B-cell non-Hodgkin's lymphomas (NHL), 28 chronic B-cell leukemias, 18 hematopoietic cell lines and 10 normal lymphoid tissues at the RNA level. Hematopoietic cell lines with a known 11q13 translocation showed high expression of the 4.5 kb cyclin D1 transcript. Three B-cell lines without known 11q13 breakpoint showed low expression. We detected high expression in all (11/11) MCL with and in 11 out of 13 cases of MCL without detectable t(11;14) rearrangement. In three cases with a rearrangement at the 3' end of cyclin D1, two showed overexpression of the 1.5 kb transcript and one expression of an aberrant (3.0 kb) transcript. In other lymphoproliferative disorders, only 5/15 hairy cell leukemias, all without detectable t(11;14), and 5/8 B-cell leukemias suspected to be MCL in leukemic phase showed expression levels comparable to MCL, whereas no or only low expression were observed in 56 cases of other NHL, seven chronic B-cell leukemias and all (10/10) normal lymphoid tissues. Cell sorting experiments on fresh tonsils showed that this low expression was present in normal B-cells and not in T-cells. In contrast to other studies, our data indicate that cyclin D1 is expressed in many lymphoproliferative disorders and normal tissues, albeit at low levels. High levels of expression of cyclin D1 however is restricted to MCL and some hairy cell leukemias. We therefore propose that overexpression of cyclin D1 is a reliable marker for the classification of MCL.	LEIDEN UNIV,ACAD HOSP LEIDEN,DEPT PATHOL,2300 RC LEIDEN,NETHERLANDS; LEIDEN UNIV,ACAD HOSP LEIDEN,DEPT HEMATOL,2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC			Kluin-Nelemans, Johanna C/F-8658-2018; van Krieken, Joannes H J M/D-4138-2009	Kluin-Nelemans, Johanna C/0000-0003-2617-9427; van Krieken, Joannes H J M/0000-0001-6544-1040				AKIYAMA N, 1994, CANCER RES, V54, P377; BANKS PM, 1992, AM J SURG PATHOL, V16, P637, DOI 10.1097/00000478-199207000-00001; BATES S, 1994, ONCOGENE, V9, P1633; BONTROP RE, 1986, TISSUE ANTIGENS, V27, P22; BOSCH F, 1994, BLOOD, V84, P2726; BOSCH ML, 1987, HUM IMMUNOL, V19, P91, DOI 10.1016/0198-8859(87)90097-8; DEBOER CJ, 1993, CANCER RES, V53, P4148; DEKROON JFE, 1992, BLOOD S1, V80, pA436; FALKENBURG JHF, 1986, EXP HEMATOL, V14, P101; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JADAYEL D, 1994, BLOOD, V83, P3664; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; KLUINNELEMANS HC, 1991, LEUKEMIA, V5, P221; KLUINNELEMANS JC, 1994, LEUKEMIA, V8, P2095; KLUINNELEMANS JC, 1994, BLOOD, V84, P3134; KOEFFLER HP, 1980, BLOOD, V56, P344; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LANGE B, 1987, BLOOD, V70, P192; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MELO JV, 1986, INT J CANCER, V38, P531, DOI 10.1002/ijc.2910380413; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; NACHEVA E, 1990, BRIT J HAEMATOL, V74, P70, DOI 10.1111/j.1365-2141.1990.tb02540.x; OKA K, 1994, BRIT J HAEMATOL, V86, P786, DOI 10.1111/j.1365-2141.1994.tb04830.x; RAFFELD M, 1992, LEUKEMIA LYMPHOMA, V8, P161, DOI 10.3109/10428199209054902; RAYNAUD SD, 1993, GENE CHROMOSOME CANC, V8, P80, DOI 10.1002/gcc.2870080204; RIMOKH R, 1994, BLOOD, V83, P3689; RIMOKH R, 1993, BLOOD, V81, P3063; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHUURING E, 1992, ONCOGENE, V7, P355; SCHUURING E, 1995, IN PRESS GENE; SETO M, 1992, ONCOGENE, V7, P1401; TAM SW, 1994, ONCOGENE, V9, P2663; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; WILLIAMS ME, 1994, ANN ONCOL, V5, pS71, DOI 10.1093/annonc/5.suppl_1.S71; WILLIAMS ME, 1993, LEUKEMIA, V7, P241; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; ZUCCA E, 1994, ANN ONCOL, V5, P507, DOI 10.1093/oxfordjournals.annonc.a058904; ZUCCA E, 1994, LEUKEMIA LYMPHOMA, V13, P105, DOI 10.3109/10428199409051659	43	103	104	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1833	1840						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753558				2022-12-17	WOS:A1995QX46900016
J	PENG, M; LUNDGREN, E				PENG, M; LUNDGREN, E			TRANSIENT EXPRESSION OF THE EPSTEIN-BARR-VIRUS LMP1 GENE IN HUMAN PRIMARY B-CELLS INDUCES CELLULAR ACTIVATION AND DNA-SYNTHESIS	ONCOGENE			English	Article							MEMBRANE-PROTEIN LMP1; HUMAN LYMPHOCYTES-B; NUCLEAR ANTIGEN-2; SURFACE-ANTIGEN; GROWTH-FACTOR; RODENT CELLS; 3T3 CELLS; TRANSFORMATION; INFECTION; IMMORTALIZATION	The Epstein- Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) and Epstein-Barr virus nuclear antigen 2 (EBNA2) are expressed in EBV-immortalized human B cells. It has previously been shown that transfection of the LMP1 and EBNA2 genes into Burkitt's lymphoma cell lines results in the up-regulation of CD23, CD21, ICAM-1 and LFA-1 cell-surface proteins. In the present study, the effects of transient expression of the LMP1 and EBNA2 genes were studied in normal primary human B cells pretreated with UV-inactivated EBV particles. To identify and purify cells which express the transfected DNA we used a gene encoding a surface molecule, CD2, as a co-transfection marker. We show that transient expression of the LMP1 gene, from heterologous promoters, is sufficient to induce cellular enlargement and up-regulation of surface expression of the activation markers CD23, CD21, ICAM-1 and LFA-1 in primary B cells. Most importantly, we show that transient expression of the LMP1 gene is sufficient to induce DNA synthesis in human primary B cells. Transient EBNA2 expression enhanced the effect of transient LMP1 expression on CD21 and CD23 cell-surface expression but, under our experimental conditions, inhibited the induction of DNA synthesis by LMP1. We conclude that activation of primary B cells with inactivated EBV particles, followed by transient expression of only two viral genes, EBNA2 and LMP1, is sufficient to reconstitute some of the early events of B-cell immortalization by EBV.			PENG, M (corresponding author), UMEA UNIV,UNIT APPL CELL & MOLEC BIOL,S-90187 UMEA,SWEDEN.		Pilon, Marc/AAY-4082-2020; Pilon, Marc/B-9955-2008	Pilon, Marc/0000-0003-3919-2882; Pilon, Marc/0000-0003-3919-2882				ABBOTT SD, 1900, J VIROL, V64, P2126; ALESMARTINEZ JE, 1991, IMMUNOL TODAY, V12, P201, DOI 10.1016/0167-5699(91)90054-W; ALFIERI C, 1991, VIROLOGY, V181, P595, DOI 10.1016/0042-6822(91)90893-G; ALLDAY MJ, 1989, J GEN VIROL, V70, P1755, DOI 10.1099/0022-1317-70-7-1755; AMAN P, 1990, EMBO J, V9, P147, DOI 10.1002/j.1460-2075.1990.tb08090.x; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BOOS H, 1990, J GEN VIROL, V71, P1811, DOI 10.1099/0022-1317-71-8-1811; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; CORDIER M, 1990, J VIROL, V64, P1002, DOI 10.1128/JVI.64.3.1002-1013.1990; CUOMO L, 1990, EUR J IMMUNOL, V20, P2293, DOI 10.1002/eji.1830201019; DAMBAUGH T, 1986, J VIROL, V59, P453, DOI 10.1128/JVI.59.2.453-462.1986; DOSCH HM, 1990, INT IMMUNOL, V2, P833, DOI 10.1093/intimm/2.9.833; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1990, P NATL ACAD SCI USA, V87, P7390, DOI 10.1073/pnas.87.19.7390; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; GORDON J, 1986, IMMUNOLOGY, V58, P591; GORDON J, 1984, J EXP MED, V159, P1554, DOI 10.1084/jem.159.5.1554; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HAUER CA, 1989, NUCLEIC ACIDS RES, V17, P1989, DOI 10.1093/nar/17.5.1989; HE Q, 1988, CELL, V54, P979, DOI 10.1016/0092-8674(88)90112-2; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HUTTFLETCHER LM, 1987, J VIROL, V61, P774, DOI 10.1128/JVI.61.3.774-781.1987; KIEFF E, 1990, VIROLOGY, P1889; KISHIMOTO T, 1989, FUNDAMENTAL IMMUNOLO, P385; KLAUS GGB, 1986, EUR J IMMUNOL, V16, P92, DOI 10.1002/eji.1830160118; KLEIN G, 1989, CELL, V58, P5, DOI 10.1016/0092-8674(89)90394-2; KNUTSON JC, 1990, J VIROL, V64, P2530, DOI 10.1128/JVI.64.6.2530-2536.1990; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; LIEBOWITZ D, 1987, MOL CELL BIOL, V7, P2299, DOI 10.1128/MCB.7.7.2299; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; MASUCCI MG, 1987, EUR J IMMUNOL, V17, P815, DOI 10.1002/eji.1830170613; MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190; MONROE JG, 1985, J IMMUNOL, V135, P1674; OHNO H, 1991, J IMMUNOL, V147, P2100; PILON M, 1991, J IMMUNOL, V146, P1047; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; RYMO L, 1985, P NATL ACAD SCI USA, V82, P3435, DOI 10.1073/pnas.82.10.3435; SUGDEN B, 1989, CELL, V57, P5, DOI 10.1016/0092-8674(89)90165-7; SWAMINATHAN S, 1991, P NATL ACAD SCI USA, V88, P1546, DOI 10.1073/pnas.88.4.1546; SWENDEMAN S, 1987, EMBO J, V6, P1637, DOI 10.1002/j.1460-2075.1987.tb02412.x; TOSATO G, 1990, J VIROL, V64, P3033, DOI 10.1128/JVI.64.6.3033-3041.1990; TRIVEDI P, 1991, INT J CANCER, V48, P794, DOI 10.1002/ijc.2910480527; WALLS EV, 1987, LYMPHOCYTES PRACTICA, P149; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P3407, DOI 10.1128/JVI.64.7.3407-3416.1990; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WANG F, 1987, P NATL ACAD SCI USA, V84, P3452, DOI 10.1073/pnas.84.10.3452; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	53	103	107	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1775	1782						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1354347				2022-12-17	WOS:A1992JJ37600014
J	NISHIMURA, T; VOGT, PK				NISHIMURA, T; VOGT, PK			THE AVIAN CELLULAR HOMOLOG OF THE ONCOGENE JUN	ONCOGENE			English	Article									UNIV SO CALIF,SCH MED,DEPT MICROBIOL,2011 ZONAL AVE,LOS ANGELES,CA 90033	University of Southern California			Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NCI NIH HHS [CA42564] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKHURST RJ, 1987, J MOL BIOL, V194, P193, DOI 10.1016/0022-2836(87)90368-8; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BALL AR, 1988, IN PRESS COLD SPRING, V53; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CHANG SC, 1987, P NATL ACAD SCI USA, V84, P680, DOI 10.1073/pnas.84.3.680; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; HOUGHTON M, 1981, NUCLEIC ACIDS RES, V9, P247, DOI 10.1093/nar/9.2.247; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MAXSON R, 1983, ANNU REV GENET, V17, P239, DOI 10.1146/annurev.ge.17.120183.001323; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; OHNO S, 1981, P NATL ACAD SCI-BIOL, V78, P5305, DOI 10.1073/pnas.78.9.5305; RAUSCHER RJ, 1988, SCIENCE, V240, P1010; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1988, SCIENCE, V85, P1487; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; SUCOV HM, 1987, DEV BIOL, V120, P507, DOI 10.1016/0012-1606(87)90254-5; TAVERNIER J, 1981, NUCLEIC ACIDS RES, V9, P461, DOI 10.1093/nar/9.3.461; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TUY PD, 1988, EUR J BIOCHEM, V173, P507; VANBEVEREN C, 1981, NATURE, V289, P258, DOI 10.1038/289258a0; VOGT PK, 1988, ONCOGENE, V3, P3; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; WANG LH, 1987, ONCOGENE RES, V1, P43	35	103	104	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1988	3	6					659	663						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R6460	2577867				2022-12-17	WOS:A1988R646000006
J	Castagnoli, L; Cancila, V; Cordoba-Romero, SL; Faraci, S; Talarico, G; Belmonte, B; Iorio, MV; Milani, M; Volpari, T; Chiodoni, C; Hidalgo-Miranda, A; Tagliabue, E; Tripodo, C; Sangaletti, S; Di Nicola, M; Pupa, SM				Castagnoli, Lorenzo; Cancila, Valeria; Cordoba-Romero, Sandra L.; Faraci, Simona; Talarico, Giovanna; Belmonte, Beatrice; Iorio, Marilena V.; Milani, Matteo; Volpari, Tatiana; Chiodoni, Claudia; Hidalgo-Miranda, Alfredo; Tagliabue, Elda; Tripodo, Claudio; Sangaletti, Sabina; Di Nicola, Massimo; Pupa, Serenella M.			WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer	ONCOGENE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; PROGNOSTIC VALUE; PATHWAY; STABILIZATION; ONTOLOGY	Triple-negative breast cancers (TNBCs) are characterized by a poor prognosis and lack of targeted treatments, and thus, new therapeutic strategies are urgently needed. Inhibitors against programmed death-1 (PD-1)/PD-1 ligand (PD-L1) have shown significant efficacy in various solid cancers, but their activity against TNBCs remains limited. Here, we report that human TNBCs molecularly stratified for high levels of PD-L1 (PD-L1(High)) showed significantly enriched expression of immune and cancer stemness pathways compared with those with low PD-L1 expression (PD-L1(Low)). In addition, the PD-L1(High) cases were significantly associated with a high stemness score (SSHigh) signature. TNBC cell lines gated for aldehyde dehydrogenase (ALDH) and CD44 stemness markers exhibited increased levels of PD-L1 versus their ALDH-negative and CD44(Low) counterparts, and PD-L1(High) cells generated significantly more mammospheres than PD-L1(Low) cells. Murine mammary SCA-1-positive tumor cells with PD-L1(High) expression generated tumors in vivo with higher efficacy than PD-L1(Low) cells. Furthermore, treatment of TNBC cells with selective WNT inhibitors or activators downregulated or upregulated PD-L1 expression, respectively, implying a functional cross-talk between WNT activity and PD-L1 expression. Remarkably, human TNBC samples contained tumor elements co-expressing PD-L1 with ALDH1A1 and/or CD44v6. Additionally, both PD-L1-/SCA1-positive and ALDH1A1-positive tumor elements were found in close contact with CD3-, and PD-1-positive T cells in murine and human tumor samples. Overall, our study suggests that PD-L1-positive tumor elements with a stemness phenotype may participate in the complex dynamics of TNBC-related immune evasion, which might be targeted through WNT signaling inhibition.	[Castagnoli, Lorenzo; Cordoba-Romero, Sandra L.; Faraci, Simona; Iorio, Marilena V.; Tagliabue, Elda; Pupa, Serenella M.] Fdn IRCCS Ist Nazl Tumori Milano, Dept Res, Mol Targeting Unit, Milan, Italy; [Cancila, Valeria; Belmonte, Beatrice; Tripodo, Claudio] Univ Palermo, Sch Med, Dept Hlth Sci, Tumor Immunol Unit,Human Pathol Sect, Palermo, Italy; [Talarico, Giovanna; Milani, Matteo; Chiodoni, Claudia; Sangaletti, Sabina] Fdn IRCCS Ist Nazl Tumori Milano, Dept Res, Mol Immunol Unit, Milan, Italy; [Volpari, Tatiana; Di Nicola, Massimo] Fdn IRCCS Ist Nazl Tumori Milano, Dept Med Oncol & Hematol, Unit Immunotherapy & Anticanc Innovat Therapeut, Milan, Italy; [Hidalgo-Miranda, Alfredo] Natl Inst Genom Med, Canc Genom Lab, Mexico City, DF, Mexico	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Palermo; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Instituto Nacional de Medicina Genomica	Pupa, SM (corresponding author), Fdn IRCCS Ist Nazl Tumori Milano, Dept Res, Mol Targeting Unit, Milan, Italy.; Di Nicola, M (corresponding author), Fdn IRCCS Ist Nazl Tumori Milano, Dept Med Oncol & Hematol, Unit Immunotherapy & Anticanc Innovat Therapeut, Milan, Italy.	massimo.dinicola@istitutotumori.mi.it; serenella.pupa@istitutotumori.mi.it	Sangaletti, Sabina/AAB-5873-2019; Tagliabue, Elda/B-9377-2017; Pupa, Serenella/K-6388-2016; Iorio, Marilena V/K-5446-2016; Hidalgo-Miranda, Alfredo/B-2123-2010; Romero, Sandra/A-2246-2014; Tripodo, Claudio/AAB-6004-2022; Cancila, Valeria/AIE-4354-2022; Talarico, Giovanna/AAB-2251-2019; Cancila, Valeria/AAJ-3041-2021; Castagnoli, Lorenzo/J-1893-2014; Milani, Matteo/AAC-1988-2020; Chiodoni, Claudia/C-2172-2017	Sangaletti, Sabina/0000-0001-7047-287X; Tagliabue, Elda/0000-0001-9877-2903; Pupa, Serenella/0000-0002-4592-6830; Iorio, Marilena V/0000-0002-6058-1527; Hidalgo-Miranda, Alfredo/0000-0003-2315-3977; Romero, Sandra/0000-0002-5591-696X; Tripodo, Claudio/0000-0002-0821-6231; Cancila, Valeria/0000-0002-9502-1191; Talarico, Giovanna/0000-0001-5051-6468; Castagnoli, Lorenzo/0000-0002-0220-6497; Milani, Matteo/0000-0002-9127-9523; Belmonte, Beatrice/0000-0001-9668-0925; Chiodoni, Claudia/0000-0002-7644-9969	Associazione Italiana Ricerca Cancro (AIRC) [16918]; Mexican National Council of Science and Technology [CVU 363453]	Associazione Italiana Ricerca Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Mexican National Council of Science and Technology(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	This work was funded by grants from Ricerca Strategica Istituzionale call 2016 to M. Di Nicola and the Associazione Italiana Ricerca Cancro (AIRC) 16918 to S.M. Pupa. S.L. Cordoba-Romero received the Postdoctoral fellowship "Estancias Posdoctorales en el Extranjero Vinculadas a la Consolidacion de Grupos de Investigatiocion y Fortalecimiento del Posgrado Nacional" from the Mexican National Council of Science and Technology (CVU 363453).	Abramson VG, 2015, CANCER-AM CANCER SOC, V121, P8, DOI 10.1002/cncr.28914; Adams S, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.SABCS15-P2-11-06; Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; Almozyan S, 2017, INT J CANCER, V141, P1402, DOI 10.1002/ijc.30834; Alsuliman A, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0421-2; Annett S, 2018, PHARMACOL THERAPEUT, V187, P13, DOI 10.1016/j.pharmthera.2018.02.001; Ascierto PA, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1309-2; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bruttel VS, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00360; Carbon S, 2009, BIOINFORMATICS, V25, P288, DOI 10.1093/bioinformatics/btn615; Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019; Dey N, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-537; Emens LA, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-2859; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Guastella D, 2016, J VIS COMMUN IMAGE R, V36, P149, DOI 10.1016/j.jvcir.2016.01.012; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hsu JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04313-6; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Jang GB, 2015, SCI REP-UK, V5, DOI 10.1038/srep12465; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Juneja VR, 2017, J EXP MED, V214, P895, DOI 10.1084/jem.20160801; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lee Y, 2016, CLIN CANCER RES, V22, P3571, DOI 10.1158/1078-0432.CCR-15-2665; Li CL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12574; Li CW, 2018, CANCER CELL, V33, P187, DOI 10.1016/j.ccell.2018.01.009; Lim SO, 2016, CANCER CELL, V30, P925, DOI 10.1016/j.ccell.2016.10.010; Liu SZ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3148; Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902; McCloskey CW, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00053; Mittendorf EA, 2014, CANCER IMMUNOL RES, V2, P361, DOI 10.1158/2326-6066.CIR-13-0127; Mohammed MK, 2016, GENES DIS, V3, P11, DOI 10.1016/j.gendis.2015.12.004; Muenst S, 2015, EXPERT OPIN THER TAR, V19, P201, DOI 10.1517/14728222.2014.980235; Nanda R, 2016, J CLIN ONCOL, V34, P2460, DOI 10.1200/JCO.2015.64.8931; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pohl SG, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.14; Polonia A, 2017, J CLIN PATHOL, V70, P860, DOI 10.1136/jclinpath-2016-203990; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Sangaletti S, 2016, CELL REP, V17, P233, DOI 10.1016/j.celrep.2016.08.075; Sciortino G, 2016, IMAGE ANAL STEREOL, V35, P105, DOI 10.5566/ias.1352; Shats I, 2011, CANCER RES, V71, P1772, DOI 10.1158/0008-5472.CAN-10-1735; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tai D, 2015, ONCOLOGIST, V20, P1189, DOI 10.1634/theoncologist.2015-0057; Vareki SM, 2017, CRIT REV ONCOL HEMAT, V116, P116, DOI 10.1016/j.critrevonc.2017.06.001; Xu JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117097; Yam C, 2017, ONCOLOGIST, V22, P1086, DOI 10.1634/theoncologist.2017-0095; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118	49	102	105	5	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4047	4060		10.1038/s41388-019-0700-2	http://dx.doi.org/10.1038/s41388-019-0700-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30705400	Green Published, hybrid			2022-12-17	WOS:000468740200006
J	Mishra, S; Deng, JJ; Gowda, PS; Rao, MK; Lin, CL; Chen, CL; Huang, T; Sun, LZ				Mishra, S.; Deng, J. J.; Gowda, P. S.; Rao, M. K.; Lin, C-L; Chen, C. L.; Huang, T.; Sun, L-Z			Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer	ONCOGENE			English	Article						microRNA; androgen receptor; tumor suppressor; prostate cancer	CROSS-TALK; MIR-21; PTEN; CELLS; METHYLATION; ACTIVATION; APOPTOSIS; PROTEIN	Prostate cancer cells escape growth inhibition from transforming growth factor beta (TGF beta) by downregulating TGF beta receptors. However, the mechanism by which cancer cells downregulate TGF beta receptors in prostate is not clear. Here, we showed that coordinated action of miR-21 and androgen receptor (AR) signaling had a critical role in inhibiting TGF beta receptor II (TGFBR2) expression in prostate cancer cells. Our results revealed that miR-21 suppresses TGFBR2 levels by binding to its 3'-UTR and AR signaling further potentiates this effect in both untransformed and transformed human prostate epithelial cells as well as in human prostate cancers. Analysis of primary prostate cancers showed that increased miR-21/AR expression parallel a significantly reduced expression of TGFBR2. Manipulation of androgen signaling or the expression levels of AR or miR-21 negatively altered TGFBR2 expression in untransformed and transformed human prostate epithelial cells, human prostate cancer xenografts and mouse prostate glands. Importantly, we demonstrated that miR-21 and AR regulated each other's expression resulting in a positive feedback loop. Our results indicated that miR-21/AR mediate its tumor-promoting function by attenuating TGF beta-mediated Smad2/3 activation, cell growth inhibition, cell migration and apoptosis. Together, these results suggest that the AR and miR-21 axis exerts its oncogenic effects in prostate tumors by downregulating TGFBR2, hence inhibiting the tumor-suppressive activity of TGF beta pathway. Targeting miR-21 alone or in combination with AR may restore the tumor inhibitory activity of TGF beta in prostate cancer.	[Mishra, S.; Deng, J. J.; Gowda, P. S.; Rao, M. K.; Sun, L-Z] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Lin, C-L; Chen, C. L.; Huang, T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA; [Huang, T.; Sun, L-Z] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio	Sun, LZ (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr,Mail Code 7762, San Antonio, TX 78229 USA.	SUNL@UTHSCSA.EDU	, LuZhe/AAW-4095-2021	Chen, Chun-Liang/0000-0002-6774-9003	NIH [R01CA75253, R01CA79683]; William and Ella Owens Foundation; Thrive Well foundation [U54 CA113001]; Cancer Therapy and Research Center at University of Texas Health Science Center at San Antonio through the NCI Cancer Center [2P30CA054174-17]; NATIONAL CANCER INSTITUTE [P30CA054174, R01CA075253, R01CA079683, U54CA113001] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); William and Ella Owens Foundation; Thrive Well foundation; Cancer Therapy and Research Center at University of Texas Health Science Center at San Antonio through the NCI Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by funding from NIH Grants R01CA75253 and R01CA79683 to LuZhe Sun, William and Ella Owens Foundation and Thrive Well foundation to Manjeet Rao, U54 CA113001 (Integrative Cancer Biology Program) to Tim Huang and the Cancer Therapy and Research Center at University of Texas Health Science Center at San Antonio through the NCI Cancer Center Support Grant 2P30CA054174-17 to the optical imaging core facility. We thank Dr Clifford G Tepper and Dr Paramita Ghosh at UC Davis Cancer Center for the CWR22 xenograft tissue and PSA-luciferase plasmid, respectively, and Dr Scott Lucia at University of Colorado Health Science Center for providing us with BPH-1 cells.	Agaoglu FY, 2011, TUMOR BIOL, V32, P583, DOI 10.1007/s13277-011-0154-9; Balk Steven P, 2008, Nucl Recept Signal, V6, pe001, DOI 10.1621/nrs.06001; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brattain Michael G., 1996, Current Opinion in Oncology, V8, P49, DOI 10.1097/00001622-199601000-00009; Brodin G, 1999, CANCER RES, V59, P2731; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; Chowdhury Sanjib, 2009, Mol Cell Pharmacol, V1, P57; Danielpour D, 2005, EUR J CANCER, V41, P846, DOI 10.1016/j.ejca.2004.12.027; Folini M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-12; Guo YP, 1997, INT J CANCER, V71, P573, DOI 10.1002/(SICI)1097-0215(19970516)71:4<573::AID-IJC11>3.3.CO;2-1; Hayes SA, 2001, CANCER RES, V61, P2112; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Huang WQ, 2005, J BIOL CHEM, V280, P10047, DOI 10.1074/jbc.M408680200; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Kim IY, 1996, MOL ENDOCRINOL, V10, P107, DOI 10.1210/me.10.1.107; Kim YJ, 2009, STEM CELLS, V27, P3093, DOI 10.1002/stem.235; Leite KR, 2011, UROL ONCOL, V31, P796; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li T, 2012, J UROLOGY, V187, P1466, DOI 10.1016/j.juro.2011.11.082; Lin HK, 2004, MOL ENDOCRINOL, V18, P2409, DOI 10.1210/me.2004-0117; Lou YH, 2010, INT J MOL MED, V26, P819, DOI 10.3892/ijmm_00000530; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lucia MS, 1998, J CELL PHYSIOL, V175, P184, DOI 10.1002/(SICI)1097-4652(199805)175:2<184::AID-JCP8>3.0.CO;2-K; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Mishra S, 2011, PROSTATE, V71, P1441, DOI 10.1002/pros.21361; Mulholland DJ, 2006, ONCOGENE, V25, P329, DOI 10.1038/sj.onc.1209020; Nagabhushan M, 1996, CANCER RES, V56, P3042; Osada H, 2001, CANCER RES, V61, P8331; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Ribas J, 2010, CELL CYCLE, V9, P923, DOI 10.4161/cc.9.5.10930; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Shen J, 2012, PROSTATE, V72, P1469, DOI 10.1002/pros.22499; Song K, 2008, CANCER RES, V68, P8173, DOI 10.1158/0008-5472.CAN-08-2290; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang T, 2012, INT J BIOCHEM CELL B, V44, P366, DOI 10.1016/j.biocel.2011.11.012; Williams RH, 1996, CLIN CANCER RES, V2, P635; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yamashita S, 2008, CANCER RES, V68, P2112, DOI 10.1158/0008-5472.CAN-07-5282; Zeng L, 2004, HUM PATHOL, V35, P290, DOI 10.1016/j.humpath.2003.11.001; Zhang HL, 2011, PROSTATE, V71, P326, DOI 10.1002/pros.21246; Zhang Q, 2005, MOL ENDOCRINOL, V19, P2390, DOI 10.1210/me.2005-0096; Zhu ML, 2008, PROSTATE, V68, P287, DOI 10.1002/pros.20698; Zhu ML, 2008, ENDOCR-RELAT CANCER, V15, P841, DOI 10.1677/ERC-08-0084	45	102	106	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2014	33	31					4097	4106		10.1038/onc.2013.374	http://dx.doi.org/10.1038/onc.2013.374			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YG	24037531	Green Accepted			2022-12-17	WOS:000340595300009
J	Wu, Q; Wang, H; Zhao, X; Shi, Y; Jin, M; Wan, B; Xu, H; Cheng, Y; Ge, H; Zhang, Y				Wu, Q.; Wang, H.; Zhao, X.; Shi, Y.; Jin, M.; Wan, B.; Xu, H.; Cheng, Y.; Ge, H.; Zhang, Y.			Identification of G-protein-coupled receptor 120 as a tumor-promoting receptor that induces angiogenesis and migration in human colorectal carcinoma	ONCOGENE			English	Article						GPR120; colorectal carcinoma; angiogenesis; migration	FREE FATTY-ACIDS; EPITHELIAL-MESENCHYMAL TRANSITION; NF-KAPPA-B; INSULIN-SECRETION; BREAST-CANCER; GPR120; CELLS; INFLAMMATION; BEVACIZUMAB; EXPRESSION	G-protein-coupled receptor 120 (GPR120) functions as a receptor for unsaturated long-chain free fatty acids and has an important role in regulating lipid and glucose metabolism. However, a role for GPR120 in the development of tumors has not yet been clarified. Here, we show that GPR120 signaling promotes angiogenic switching and motility of human colorectal carcinoma (CRC) cells. We show that the expression of GPR120 is significantly induced in CRC tissues and cell lines, which is associated with tumor progression. Activation of GPR120 signaling in human CRC promotes angiogenesis in vitro and in vivo, largely by inducing the expression and secretion of proangiogenic mediators such as vascular endothelial growth factor (VEGF), interleukin-8 and cyclooxygenase-2-derived prostaglandin E-2. The PI3K/Akt-NF-kappa B pathway is activated by GPR120 signaling and is required for GPR120 signaling-induced angiogenic switching in CRC cells. And, GPR120 activation enhances the motility of CRC cells and induces epithelial-mesenchymal transition. Furthermore, in vivo study shows that activation of GPR120 promotes angiogenesis and tumor growth. Finally, we find that GPR120 expression is positively correlated with VEGF expression and inversely correlated with the epithelial marker E-cadherin in CRC tissues. Collectively, our results demonstrate that GPR120 functions as a tumor-promoting receptor in CRC and, therefore, shows promise as a new potential target for cancer therapeutics.	[Wu, Q.; Wang, H.; Zhao, X.; Shi, Y.; Jin, M.; Wan, B.; Xu, H.; Cheng, Y.; Ge, H.; Zhang, Y.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai 200025, Peoples R China; [Wu, Q.; Wang, H.; Zhao, X.; Shi, Y.; Jin, M.; Wan, B.; Xu, H.; Cheng, Y.; Ge, H.; Zhang, Y.] Shanghai Jiao Tong Univ, Sch Med SJTUSM, Shanghai 200030, Peoples R China; [Wu, Q.; Wang, H.; Zhao, X.; Shi, Y.; Jin, M.; Wan, B.; Xu, H.; Cheng, Y.; Ge, H.; Zhang, Y.] SJTUSM, Shanghai Inst Immunol, Inst Med Sci, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Jiao Tong University	Zhang, Y (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai 200025, Peoples R China.	gehl@shsmu.edu.cn; yyzhang@sibs.ac.cn	Shi, Yufang/AAE-4431-2020	Shi, Yufang/0000-0001-8964-319X	Ministry of Science and Technology of China [2011CB966200, 2010CB945600]; Strategic Priority Research Program of the Chinese Academy of Sciences [XDA01040000]; Program of Chinese Academy of Sciences [KSCX1-YW-22]; National Natural Science Foundation of China [81071748, 30873045, 81130057]; China Postdoctoral Science Foundation [2012M510906]; Leading Academic Discipline Project of Shanghai Municipal Education Commission [J50207]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); Program of Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Leading Academic Discipline Project of Shanghai Municipal Education Commission(Shanghai Leading Academic Discipline Project)	We thank Dr G Brewer (University of Medicine and Dentistry of New Jersey) for his critical review of the manuscript. This work was supported by the Ministry of Science and Technology of China (2011CB966200, 2010CB945600), the Strategic Priority Research Program of the Chinese Academy of Sciences (XDA01040000), the Program of Chinese Academy of Sciences (KSCX1-YW-22), the National Natural Science Foundation of China (81071748, 30873045, 81130057), the China Postdoctoral Science Foundation (2012M510906) and the Leading Academic Discipline Project of Shanghai Municipal Education Commission (J50207).	Briscoe CP, 2006, BRIT J PHARMACOL, V148, P619, DOI 10.1038/sj.bjp.0706770; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Cheng JCH, 2006, ONCOGENE, V25, P7009, DOI 10.1038/sj.onc.1209706; Fukata M, 2007, GASTROENTEROLOGY, V133, P1869, DOI 10.1053/j.gastro.2007.09.008; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Habbel P, 2009, WORLD J GASTROENTERO, V15, P1079, DOI 10.3748/wjg.15.1079; Hara T, 2011, J PHARM SCI-US, V100, P3594, DOI 10.1002/jps.22639; Hatanaka H, 2010, CANCER SCI, V101, P54, DOI 10.1111/j.1349-7006.2009.01348.x; Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168; Hossain Z, 2009, NUTR CANCER, V61, P123, DOI 10.1080/01635580802395725; Ichimura A, 2012, NATURE, V483, P350, DOI 10.1038/nature10798; Im DS, 2012, PROG LIPID RES, V51, P232, DOI 10.1016/j.plipres.2012.02.003; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kotarsky K, 2003, BIOCHEM BIOPH RES CO, V301, P406, DOI 10.1016/S0006-291X(02)03064-4; Koukourakis GV, 2011, CLIN TRANSL ONCOL, V13, P710, DOI 10.1007/s12094-011-0720-z; Oh DY, 2012, CELL METAB, V15, P564, DOI 10.1016/j.cmet.2012.04.009; Oh DY, 2011, CURR OPIN CLIN NUTR, V14, P322, DOI 10.1097/MCO.0b013e3283479230; Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041; Polozova A, 2007, J MOL NEUROSCI, V33, P56, DOI 10.1007/s12031-007-0039-y; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Roodhart JML, 2011, CANCER CELL, V20, P370, DOI 10.1016/j.ccr.2011.08.010; Sakurai T, 2011, ONCOLOGY-BASEL, V81, P24, DOI 10.1159/000333256; Song LB, 2011, CLIN CANCER RES, V17, P1839, DOI 10.1158/1078-0432.CCR-10-0720; Strickler JH, 2012, ONCOLOGIST, V17, P513, DOI 10.1634/theoncologist.2012-0003; Strieter RM, 2005, NAT MED, V11, P925, DOI 10.1038/nm0905-925; Taborga M, 2007, MINI-REV MED CHEM, V7, P245, DOI 10.2174/138955707780059826; Tanaka T, 2008, N-S ARCH PHARMACOL, V377, P523, DOI 10.1007/s00210-007-0200-8; Turk HF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039682; Wang DZ, 2005, GASTROENTEROLOGY, V128, P1445, DOI 10.1053/j.gastro.2004.09.080; Wang SL, 2009, CELL MOL IMMUNOL, V6, P327, DOI 10.1038/cmi.2009.43; Wang YG, 2012, CANCER RES, V72, P5396, DOI 10.1158/0008-5472.CAN-12-0474; Wendt MK, 2013, ONCOGENE, V32, P2005, DOI 10.1038/onc.2012.230; Williams K, 2012, CANCER RES, V72, P5407, DOI 10.1158/0008-5472.CAN-12-1158; Wu YY, 2011, ONCOGENE, V30, P3682, DOI 10.1038/onc.2011.85; Xu HB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027399; Yeung Y, 2012, EXPERT REV ANTICANC, V12, P1263, DOI [10.1586/ERA.12.104, 10.1586/era.12.104]; Zhao F, 2011, BLOOD, V117, P1723, DOI 10.1182/blood-2010-04-281659; Zheng HX, 2013, ONCOGENE, V32, P1183, DOI 10.1038/onc.2012.126	41	102	105	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2013	32	49					5541	5550		10.1038/onc.2013.264	http://dx.doi.org/10.1038/onc.2013.264			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	269XF	23851494				2022-12-17	WOS:000328276400005
J	Chell, V; Balmanno, K; Little, AS; Wilson, M; Andrews, S; Blockley, L; Hampson, M; Gavine, PR; Cook, SJ				Chell, V.; Balmanno, K.; Little, A. S.; Wilson, M.; Andrews, S.; Blockley, L.; Hampson, M.; Gavine, P. R.; Cook, S. J.			Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance	ONCOGENE			English	Article						acquired resistance; ERK1/2; FGFR; PKB; tyrosine kinase inhibitors	MULTIPLE-MYELOMA; BLADDER-CANCER; STOMACH-CANCER; GASTRIC-CANCER; PROTEIN-KINASE; C/EBP-ALPHA; LINES; GENE; PHOSPHORYLATION; AMPLIFICATION	Fibroblast growth factor receptors (FGFRs) can act as driving oncoproteins in certain cancers, making them attractive drug targets. Here we have characterized tumour cell responses to two new inhibitors of FGFR1-3, AZ12908010 and the clinical candidate AZD4547, making comparisons with the well-characterized FGFR inhibitor PD173074. In a panel of 16 human tumour cell lines, the anti-proliferative activity of AZ12908010 or AZD4547 was strongly linked to the presence of deregulated FGFR signalling, indicating that addiction to deregulated FGFRs provides a therapeutic opportunity for selective intervention. Acquired resistance to targeted tyrosine kinase inhibitors is a growing problem in the clinic but has not yet been explored for FGFR inhibitors. To assess how FGFR-dependent tumour cells adapt to long-term FGFR inhibition, we generated a derivative of the KMS-11 myeloma cell line (FGFR(Y373C)) with acquired resistance to AZ12908010 (KMS-11R cells). Basal phosphorylated FGFR and FGFR-dependent downstream signalling were constitutively elevated and refractory to drug in KMS-11R cells. Sequencing of FGFR3 in KMS-11R cells revealed the presence of a heterozygous mutation at the gatekeeper residue, encoding FGFR3(V555M); consistent with this, KMS-11R cells were cross-resistant to AZD4547 and PD173074. These results define the selectivity and efficacy of two new FGFR inhibitors and identify a secondary gatekeeper mutation as a mechanism of acquired resistance to FGFR inhibitors that should be anticipated as clinical evaluation proceeds.	[Chell, V.; Balmanno, K.; Little, A. S.; Wilson, M.; Cook, S. J.] Babraham Inst, Signalling Lab, Cambridge CB22 3AT, England; [Andrews, S.] Babraham Inst, Bioinformat Grp, Cambridge CB22 3AT, England; [Blockley, L.; Hampson, M.] AstraZeneca, R&D Genet, Macclesfield, Cheshire, England; [Gavine, P. R.] AstraZeneca R&D, Innovat Ctr China, Shanghai, Peoples R China	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; AstraZeneca; AstraZeneca	Cook, SJ (corresponding author), Babraham Inst, Signalling Lab, Babraham Res Campus, Cambridge CB22 3AT, England.	simon.cook@babraham.ac.uk		Cook, Simon/0000-0001-9087-1616; Balmanno, Kathryn/0000-0002-6417-3889	CASE PhD studentship (nee Victoria Knights); Biotechnology and Biological Sciences Research Council (BBSRC); AstraZeneca; Babraham Institute; BBSRC [BBS/E/B/000C0419, BBS/E/B/0000C235, BBS/E/B/000C0417] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BBS/E/B/000C0417, BBS/E/B/000C0419, BBS/E/B/0000C235, BBS/E/B/0000C199] Funding Source: researchfish; Worldwide Cancer Research [12-1259] Funding Source: researchfish	CASE PhD studentship (nee Victoria Knights); Biotechnology and Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); AstraZeneca(AstraZeneca); Babraham Institute(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Worldwide Cancer Research	We would like to thank Anne Segonds-Pichon (Babraham Bioinformatics Group) for statistical analysis of qRT-PCR data and Jonathan Keats, Janet Nutt, Margaret Knowles, Matthias Ebert and Andrew Garner for provision of some of the cell lines used in this study. We would especially like to thank Andrew Garner for initiating this project, and for discussions and encouragement in its early stages. We are grateful to Teresa Klinowska, Nigel Brooks, Elaine Kilgour and Paul Smith for many useful discussions and suggestions throughout. This work was supported by a CASE PhD studentship (VC, nee Victoria Knights) funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and AstraZeneca, and a sponsored research agreement between AstraZeneca and the Babraham Institute.	Al-Ahmadie HA, 2011, J PATHOL, V224, P270, DOI 10.1002/path.2892; Azam M, 2008, NAT STRUCT MOL BIOL, V15, P1109, DOI 10.1038/nsmb.1486; Azam M, 2006, MOL DIAGN THER, V10, P67, DOI 10.1007/BF03256446; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; Binato R, 2009, MOL MED REP, V2, P657, DOI 10.3892/mmr_00000153; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Daub H, 2004, NAT REV DRUG DISCOV, V3, P1001, DOI 10.1038/nrd1579; Davies BR, 2007, MOL CANCER THER, V6, P2209, DOI 10.1158/1535-7163.MCT-07-0231; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Ewings KE, 2007, EMBO J, V26, P2856, DOI 10.1038/sj.emboj.7601723; Gavine PR, 2012, CANCER RES, V72, P2045, DOI 10.1158/0008-5472.CAN-11-3034; Hammerman PS, 2009, CLIN CANCER RES, V15, P7502, DOI 10.1158/1078-0432.CCR-09-0189; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; Hilberg F, 2008, CANCER RES, V68, P4774, DOI 10.1158/0008-5472.CAN-07-6307; Huynh H, 2008, CLIN CANCER RES, V14, P6146, DOI 10.1158/1078-0432.CCR-08-0509; Jang JH, 2001, CANCER RES, V61, P3541; Jebar AH, 2005, ONCOGENE, V24, P5218, DOI 10.1038/sj.onc.1208705; Jeffers Michael, 2002, Expert Opin Ther Targets, V6, P469, DOI 10.1517/14728222.6.4.469; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Keats JJ, 2006, LEUKEMIA LYMPHOMA, V47, P2289, DOI 10.1080/10428190600822128; Kimura T, 2001, CANCER-AM CANCER SOC, V92, P2555, DOI 10.1002/1097-0142(20011115)92:10<2555::AID-CNCR1607>3.0.CO;2-M; Klinowska T, 2008, GORD RES C 2 7 MARCH; Klint Peter, 1999, Frontiers in Bioscience, V4, pD165, DOI 10.2741/Klint; Knights V, 2010, PHARMACOL THERAPEUT, V125, P105, DOI 10.1016/j.pharmthera.2009.10.001; Kunii K, 2008, CANCER RES, V68, P2340, DOI 10.1158/0008-5472.CAN-07-5229; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; Lamont FR, 2011, BRIT J CANCER, V104, P75, DOI 10.1038/sj.bjc.6606016; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Lombardi L, 2007, GENE CHROMOSOME CANC, V46, P226, DOI 10.1002/gcc.20404; Milojkovic D, 2009, CLIN CANCER RES, V15, P7519, DOI 10.1158/1078-0432.CCR-09-1068; Moffa AB, 2004, MOL CANCER RES, V2, P643; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; MOR O, 1993, CANCER GENET CYTOGEN, V65, P111, DOI 10.1016/0165-4608(93)90217-A; Normanno N, 2009, NAT REV CLIN ONCOL, V6, P519, DOI 10.1038/nrclinonc.2009.111; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Qing J, 2009, J CLIN INVEST, V119, P1216, DOI 10.1172/JCI38017; Radomska HS, 2006, J EXP MED, V203, P371, DOI 10.1084/jem.20052242; Ray ME, 2004, CANCER RES, V64, P40, DOI 10.1158/0008-5472.CAN-03-1022; Reiter A, 1998, BLOOD, V92, P1735, DOI 10.1182/blood.V92.5.1735.417k11_1735_1742; Ronchetti D, 2001, ONCOGENE, V20, P3553, DOI 10.1038/sj.onc.1204465; Squires M, 2011, MOL CANCER THER, V10, P1542, DOI 10.1158/1535-7163.MCT-11-0426; Sun SS, 2012, J SURG ONCOL, V105, P773, DOI 10.1002/jso.22120; Tannheimer SL, 2000, BREAST CANCER RES, V2, P311, DOI 10.1186/bcr73; Todd DE, 2004, ONCOGENE, V23, P3284, DOI 10.1038/sj.onc.1207467; Tomlinson D, 2007, ONCOGENE, V26, P5889, DOI 10.1038/sj.onc.1210399; Tomlinson DC, 2007, J PATHOL, V213, P91, DOI 10.1002/path.2207; Trudel S, 2005, BLOOD, V105, P2941, DOI 10.1182/blood-2004-10-3913; Trudel S, 2004, BLOOD, V103, P3521, DOI 10.1182/blood-2003-10-3650; Tsujimoto H, 1997, VIRCHOWS ARCH, V431, P383, DOI 10.1007/s004280050115; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97; Zhou WJ, 2010, CHEM BIOL, V17, P285, DOI 10.1016/j.chembiol.2010.02.007	60	102	108	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2013	32	25					3059	3070		10.1038/onc.2012.319	http://dx.doi.org/10.1038/onc.2012.319			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	168KX	22869148				2022-12-17	WOS:000320705700006
J	Sullivan, RJ; Flaherty, K				Sullivan, R. J.; Flaherty, K.			MAP kinase signaling and inhibition in melanoma	ONCOGENE			English	Review						melanoma; targeted therapy; BRAF	RANDOMIZED DISCONTINUATION TRIAL; CHRONIC MYELOID-LEUKEMIA; B-RAF INHIBITOR; NF-KAPPA-B; BRAF INHIBITION; WILD-TYPE; MULTIKINASE INHIBITOR; ACQUIRED-RESISTANCE; AZD6244 ARRY-142886; IMPROVED SURVIVAL	The mitogen-activated protein kinase (MAPK) pathway is critical to oncogenic signaling in the majority of patients with malignant melanoma. Driver mutations in both NRAS and BRAF have important implications for prognosis and treatment. The development of inhibitors to mediators of the MAPK pathway, including those to CRAF, BRAF, and MEK, has led to major advances in the treatment of patients with melanoma. In particular, the selective BRAF inhibitor vemurafenib has been shown to improve overall survival in patients with tumors harboring BRAF mutations. However, the duration of benefit is limited in many patients and highlights the need for understanding the limitations of therapy in order to devise more effective strategies. MEK inhibitors have proven to particularly active in BRAF mutant melanomas also. Emerging knowledge about mechanisms of resistance as well as a more complete understanding of the biology of MAPK pathway signaling provides insight into rational combination regimens and sequences of molecularly targeted therapies.	[Sullivan, R. J.; Flaherty, K.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Flaherty, K (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St, Boston, MA 02114 USA.	kflaherty@partners.org	Sullivan, Ryan J/O-2965-2013					Adjei AA, 2008, J CLIN ONCOL, V26, P2139, DOI 10.1200/JCO.2007.14.4956; Amaravadi RK, 2009, CLIN CANCER RES, V15, P7711, DOI 10.1158/1078-0432.CCR-09-2074; Banerji U, 2010, CLIN CANCER RES, V16, P1613, DOI 10.1158/1078-0432.CCR-09-2483; Bardeesy N, 2005, MOL CELL BIOL, V25, P4176, DOI 10.1128/MCB.25.10.4176-4188.2005; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; Beeram M, 2005, J CLIN ONCOL, V23, P6771, DOI 10.1200/JCO.2005.08.036; Boisvert-Adamo K, 2008, ONCOGENE, V27, P3301, DOI 10.1038/sj.onc.1211003; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Boni A, 2010, CANCER RES, V70, P5213, DOI 10.1158/0008-5472.CAN-10-0118; Cartlidge RA, 2008, PIGM CELL MELANOMA R, V21, P534, DOI 10.1111/j.1755-148X.2008.00491.x; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Chen S, 2007, CANCER RES, V67, P782, DOI 10.1158/0008-5472.CAN-06-3964; Chiarion-Sileni V, 2013, J CLIN ONCOL, V31; Chong HR, 2003, J BIOL CHEM, V278, P36269, DOI 10.1074/jbc.M212803200; Comin-Anduix B, 2010, CLIN CANCER RES, V16, P6040, DOI 10.1158/1078-0432.CCR-10-1911; COROMINAS M, 1989, P NATL ACAD SCI USA, V86, P6372, DOI 10.1073/pnas.86.16.6372; Cragg MS, 2008, J CLIN INVEST, V118, P3651, DOI 10.1172/JCI35437; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delord J, 2010, J CLIN ONCOL, V28, P2504; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Dong JL, 2003, CANCER RES, V63, P3883; DR Trefzer UM, P SOC MEL RES C 2011; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Eisen T, 2006, BRIT J CANCER, V95, P581, DOI 10.1038/sj.bjc.6603291; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5; Fischer A, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M607458200; Flaherty KT, 2008, CLIN CANCER RES, V14, P4836, DOI 10.1158/1078-0432.CCR-07-4123; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Furge KA, 2001, P NATL ACAD SCI USA, V98, P10722, DOI 10.1073/pnas.191067898; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Halaban R, 2010, PIGM CELL MELANOMA R, V23, P190, DOI 10.1111/j.1755-148X.2010.00685.x; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Hauschild A, 2009, J CLIN ONCOL, V27, P2823, DOI 10.1200/JCO.2007.15.7636; Hauschild Axel JJG, 2012, J CLIN ONCOL S, V30; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Infante JR, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.2503; Jakob JA, 2011, CANCER, DOI [10.1002/cncr.26724, DOI 10.1002/CNCR.26724)]; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Kaplan FM, 2011, ONCOGENE, V30, P366, DOI 10.1038/onc.2010.408; KIRKWOOD JM, 2012, J CLIN ONCOL S, V30; Levey R, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.e15053; Lin J, 2011, BRIT J CANCER, V104, P464, DOI 10.1038/sj.bjc.6606072; Liu J, 2007, ONCOGENE, V26, P1954, DOI 10.1038/sj.onc.1209994; Long GV, 2011, J CLIN ONCOL, V29, P1239, DOI 10.1200/JCO.2010.32.4327; LoRusso PM, 2010, CLIN CANCER RES, V16, P1924, DOI 10.1158/1078-0432.CCR-09-1883; Mahoney S, 2010, J CLIN ONCOL S, V28, p15s; Margolin KA, 2012, CLIN CANCER RES, V18, P1129, DOI 10.1158/1078-0432.CCR-11-2488; Marquette A, 2011, NAT STRUCT MOL BIOL, V18, P584, DOI 10.1038/nsmb.2022; Monsel G, 2010, ONCOGENE, V29, P227, DOI 10.1038/onc.2009.320; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Moreno C, 2012, J CLIN ONCOL, V30; Nathanson KL, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.8501; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Omholt K, 2003, CLIN CANCER RES, V9, P6483; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Ratain MJ, 2006, J CLIN ONCOL, V24, P2505, DOI 10.1200/JCO.2005.03.6723; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Roche-Lestienne C, 2002, BLOOD, V100, P1014, DOI 10.1182/blood.V100.3.1014; Roumiantsev S, 2002, P NATL ACAD SCI USA, V99, P10700, DOI 10.1073/pnas.162140299; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Shi HB, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1727; Smalley KSM, 2008, MOL CANCER THER, V7, P2876, DOI 10.1158/1535-7163.MCT-08-0431; Solit DB, 2011, NEW ENGL J MED, V364, P772, DOI 10.1056/NEJMcibr1013704; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Sosman JA, 2012, J CLIN ONCOL, V30; Strausman RT, NATURE, DOI [10.1038/nature11183, DOI 10.1038/NATURE11183)]; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Tap WD, 2010, NEOPLASIA, V12, P637, DOI 10.1593/neo.10414; Terai K, 2006, EMBO J, V25, P3556, DOI 10.1038/sj.emboj.7601241; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tran NH, 2005, J BIOL CHEM, V280, P16244, DOI 10.1074/jbc.M501185200; Vakiani E, 2011, J PATHOL, V223, P219, DOI 10.1002/path.2796; VanBrocklin MW, 2009, CANCER RES, V69, P1985, DOI 10.1158/0008-5472.CAN-08-3934; Vergani E, 2011, NEOPLASIA, V13, P1132, DOI 10.1593/neo.111102; Verhaegen M, 2006, CANCER RES, V66, P11348, DOI 10.1158/0008-5472.CAN-06-1748; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Wardelmann E, 2006, CLIN CANCER RES, V12, P1743, DOI 10.1158/1078-0432.CCR-05-1211; Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130; Wilmott JS, 2012, CLIN CANCER RES, V18, P1386, DOI 10.1158/1078-0432.CCR-11-2479; Winkler DG, 1998, J BIOL CHEM, V273, P21578, DOI 10.1074/jbc.273.34.21578; Xing F, 2012, ONCOGENE, V31, P446, DOI 10.1038/onc.2011.250; Zhao YH, 2008, BIOCHEM BIOPH RES CO, V370, P509, DOI 10.1016/j.bbrc.2008.03.148; Zheng B, 2009, MOL CELL, V33, P237, DOI 10.1016/j.molcel.2008.12.026	96	102	106	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2013	32	19					2373	2379		10.1038/onc.2012.345	http://dx.doi.org/10.1038/onc.2012.345			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22945644	Bronze			2022-12-17	WOS:000318694900001
J	Bernardo, GM; Bebek, G; Ginther, CL; Sizemore, ST; Lozada, KL; Miedler, JD; Anderson, LA; Godwin, AK; Abdul-Karim, FW; Slamon, DJ; Keri, RA				Bernardo, G. M.; Bebek, G.; Ginther, C. L.; Sizemore, S. T.; Lozada, K. L.; Miedler, J. D.; Anderson, L. A.; Godwin, A. K.; Abdul-Karim, F. W.; Slamon, D. J.; Keri, R. A.			FOXA1 represses the molecular phenotype of basal breast cancer cells	ONCOGENE			English	Article						FOXA1; luminal; basal; breast cancer	ESTROGEN-RECEPTOR-ALPHA; ANDROGEN RECEPTOR; TRANSCRIPTION FACTOR; GENE-EXPRESSION; LUMINAL SUBTYPE; GATA-3; MORPHOGENESIS; BINDING; BRCA1; DIFFERENTIATION	Breast cancer is a heterogeneous disease that comprises multiple subtypes. Luminal subtype tumors confer a more favorable patient prognosis, which is, in part, attributed to estrogen receptor (ER)-alpha positivity and antihormone responsiveness. Expression of the forkhead box transcription factor, FOXA1, similarly correlates with the luminal subtype and patient survival, but is also present in a subset of ER-negative tumors. FOXA1 is also consistently expressed in luminal breast cancer cell lines even in the absence of ER. In contrast, breast cancer cell lines representing the basal subtype do not express FOXA1. To delineate an ER-independent role for FOXA1 in maintaining the luminal phenotype, and hence a more favorable prognosis, we performed expression microarray analyses on FOXA1-positive and ER-positive (MCF7, T47D), or FOXA1-positive and ER-negative (MDA-MB-453, SKBR3) luminal cell lines in the presence or absence of transient FOXA1 silencing. This resulted in three FOXA1 transcriptomes: (1) a lumina! signature (consistent across cell lines), (2) an ER-positive signature (restricted to MCF7 and T47D) and (3) an ER-negative signature (restricted to MDA-MB-453 and SKBR3). Gene set enrichment analyses revealed FOXA1 silencing causes a partial transcriptome shift from luminal to basal gene expression signatures. FOXA1 binds to a subset of both luminal and basal genes within luminal breast cancer cells, and loss of FOXA1 increases enhancer RNA transcription for a representative basal gene (CD58). These data suggest FOXA1 directly represses a subset of basal signature genes. Functionally, FOXA1 silencing increases migration and invasion of luminal cancer cells, both of which are characteristics of basal subtype cells. We conclude FOXA1 controls plasticity between basal and luminal breast cancer cells, not only by inducing luminal genes but also by repressing the basal phenotype, and thus aggressiveness. Although it has been proposed that FOXA1-targeting agents may be useful for treating luminal tumors, these data suggest that this approach may promote transitions toward more aggressive cancers. Oncogene (2013) 32, 554-563; doi:10.1038/onc.2012.62; published online 5 March 2012	[Bernardo, G. M.; Sizemore, S. T.; Lozada, K. L.; Keri, R. A.] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; [Bebek, G.] Case Western Reserve Univ, Sch Med, Case Ctr Prote & Bioinformat, Cleveland, OH 44106 USA; [Bebek, G.] Cleveland Clin, Genom Med Inst, Cleveland, OH 44106 USA; [Ginther, C. L.; Anderson, L. A.; Slamon, D. J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA; [Miedler, J. D.; Abdul-Karim, F. W.] Univ Hosp Case Med Ctr, Dept Pathol, Cleveland, OH USA; [Godwin, A. K.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA; [Abdul-Karim, F. W.] Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA; [Keri, R. A.] Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; [Keri, R. A.] Case Western Reserve Univ, Sch Med, Div Gen Med Sci Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Cleveland Clinic Foundation; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Case Western Reserve University; Case Western Reserve University Hospital; University of Kansas; University of Kansas Medical Center; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Keri, RA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	keri@case.edu	Sizemore, Gina/ABI-7542-2020; Keri, Ruth/ABF-2209-2021	Keri, Ruth/0000-0002-1640-3088	Department of Defense [W81XWH-06-1-0712, W81XWH-09-1-0696, W81XWH-08-1-0347]; National Institutes of Health [T32-HD-07104-33, UL1-RR024989, R01 CA090398]; Case Western Reserve University Comprehensive Cancer Center [P30 CA043703]; University Hospitals of Cleveland Pathology Research Associates Grant; Fox Chase Cancer Center [P30 CA006927]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007104] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA090398, P30CA043703, P30CA006927] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024989] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Case Western Reserve University Comprehensive Cancer Center; University Hospitals of Cleveland Pathology Research Associates Grant; Fox Chase Cancer Center; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work is supported by the Department of Defense (W81XWH-06-1-0712, GMB; W81XWH-09-1-0696, STS; W81XWH-08-1-0347, RAK), the National Institutes of Health (T32-HD-07104-33, GMB; UL1-RR024989, GB; R01 CA090398, RAK), the Case Western Reserve University Comprehensive Cancer Center (P30 CA043703, GB and RAK), a University Hospitals of Cleveland Pathology Research Associates Grant (FWA and RAK) and a Fox Chase Cancer Center Support Grant (P30 CA006927, AKG).	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Albergaria A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2327; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Badve S, 2007, CLIN CANCER RES, V13, P4415, DOI 10.1158/1078-0432.CCR-07-0122; Bernardo GM, 2012, BIOSCIENCE REP, V32, P113, DOI 10.1042/BSR20110046; Bernardo GM, 2010, DEVELOPMENT, V137, P2045, DOI 10.1242/dev.043299; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Cirillo LA, 1999, MOL CELL, V4, P961, DOI 10.1016/S1097-2765(00)80225-7; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; de Graauw M, 2010, P NATL ACAD SCI USA, V107, P6340, DOI 10.1073/pnas.0913360107; Doane AS, 2006, ONCOGENE, V25, P3994, DOI 10.1038/sj.onc.1209415; Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006; Feng Y, 2007, P NATL ACAD SCI USA, V104, P14718, DOI 10.1073/pnas.0706933104; Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Fu XY, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2849; Gorski JJ, 2010, BREAST CANCER RES TR, V122, P721, DOI 10.1007/s10549-009-0565-0; Habashy HO, 2008, EUR J CANCER, V44, P1541, DOI 10.1016/j.ejca.2008.04.020; Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Krum SA, 2008, MOL ENDOCRINOL, V22, P2393, DOI 10.1210/me.2008-0100; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Malik S, 2010, MOL CELL BIOL, V30, P399, DOI 10.1128/MCB.00907-09; Mallepell S, 2006, P NATL ACAD SCI USA, V103, P2196, DOI 10.1073/pnas.0510974103; Mehta RJ, 2012, BREAST CANCER RES TR, V131, P881, DOI 10.1007/s10549-011-1482-6; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Mueller SO, 2002, ENDOCRINOLOGY, V143, P2357, DOI 10.1210/en.143.6.2357; Naderi A, 2008, NEOPLASIA, V10, P542, DOI 10.1593/neo.08274; Nakanishi T, 2010, BRIT J CANCER, V102, P815, DOI 10.1038/sj.bjc.6605553; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Ni M, 2011, CANCER CELL, V20, P119, DOI 10.1016/j.ccr.2011.05.026; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748; Robinson JLL, 2011, EMBO J, V30, P3019, DOI 10.1038/emboj.2011.216; Sahu B, 2011, EMBO J, V30, P3962, DOI 10.1038/emboj.2011.328; Schug J, 2008, CURR PROTOC BIOINFOR, V21, P261, DOI DOI 10.1002/; Serandour AA, 2011, GENOME RES, V21, P555, DOI 10.1101/gr.111534.110; Smyth GK, 2005, P 55 SESS INT STAT I; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thorat MA, 2008, J CLIN PATHOL, V61, P327, DOI 10.1136/jcp.2007.052431; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Williamson EA, 2006, ONCOGENE, V25, P1391, DOI 10.1038/sj.onc.1209170; Wolf I, 2007, INT J CANCER, V120, P1013, DOI 10.1002/ijc.22389; Yamaguchi N, 2008, BIOCHEM BIOPH RES CO, V365, P711, DOI 10.1016/j.bbrc.2007.11.064	53	102	104	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2013	32	5					554	563		10.1038/onc.2012.62	http://dx.doi.org/10.1038/onc.2012.62			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22391567	Green Accepted			2022-12-17	WOS:000316164700003
J	Zheng, B; Liang, L; Huang, S; Zha, R; Liu, L; Jia, D; Tian, Q; Wang, Q; Wang, C; Long, Z; Zhou, Y; Cao, X; Du, C; Shi, Y; He, X				Zheng, B.; Liang, L.; Huang, S.; Zha, R.; Liu, L.; Jia, D.; Tian, Q.; Wang, Q.; Wang, C.; Long, Z.; Zhou, Y.; Cao, X.; Du, C.; Shi, Y.; He, X.			MicroRNA-409 suppresses tumour cell invasion and metastasis by directly targeting radixin in gastric cancers	ONCOGENE			English	Article						gastric cancer; metastasis; microRNA-409; radixin	PANCREATIC-CANCER; IDENTIFICATION; SPECIFICITY; EXPRESSION; CARCINOMA; MIGRATION; PROTEINS; MIR-31; GENES	Emerging evidence has shown that aberrantly expressed microRNAs (miRNAs) are highly associated with tumour development and progression. However, little is known about the potential role of miRNAs in gastric cancer (GC) metastasis. In this study, miR-409-3p was found to be downregulated frequently in human GCs, and its expression was significantly associated with tumor-node-metastasis (TNM) stage and lymph node metastasis. Enforced expression of miR-409 in GC cells significantly reduced their migration and invasion in vitro and their capacity to develop distal pulmonary metastases and peritoneal dissemination in vivo. Moreover, we found that miR-409 exerted its function predominantly through the mature miR-409-3p, but not miR-409-5p. Microarray and bioinformatics analysis identified the pro-metastatic gene radixin (RDX) as a potential miR-409-3p target. Further studies confirmed that miR-409-3p suppressed the expression of RDX by directly binding to its 3'-untranslated region. Silencing of RDX by small interfering RNAs phenocopied the effects of miR-409 overexpression, whereas restoration of RDX in miR-409-overexpressed GC cells reversed the suppressive effects of miR-409. Taken together, these results demonstrate that miR-409 suppresses GC cell invasion and metastasis by directly targeting RDX and that patients with downregulated miR-409-3p are prone to lymph node metastasis.	[Zheng, B.; Wang, Q.; Wang, C.; Long, Z.; Zhou, Y.; Cao, X.; Du, C.; Shi, Y.; He, X.] Fudan Univ, Shanghai Canc Ctr, Dept Gastr Canc & Soft Tissue Sarcomas, Shanghai 200032, Peoples R China; [Zheng, B.; Wang, Q.; Wang, C.; Long, Z.; Zhou, Y.; Cao, X.; Du, C.; Shi, Y.; He, X.] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Liang, L.; Huang, S.; Zha, R.; Liu, L.; Jia, D.; Tian, Q.; He, X.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai 200030, Peoples R China	Fudan University; Fudan University; Shanghai Jiao Tong University	Shi, Y (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Gastr Canc & Soft Tissue Sarcomas, Shanghai 200032, Peoples R China.	yingqiangshi@126.com; xhhe@shsci.org	Huang, Shenglin/N-9472-2018; Jia, Deshui/U-9732-2019; He, Xianghuo/I-1497-2014; liang, linhui/AAW-4176-2021	Huang, Shenglin/0000-0003-1279-0794; He, Xianghuo/0000-0001-8872-668X; Guo, Weijie/0000-0001-7167-9899				Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Arpin M, 2011, CELL ADHES MIGR, V5, P199, DOI 10.4161/cam.5.2.15081; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cappetta A, 2012, CRIT REV ONCOL HEMAT, V81, P38, DOI 10.1016/j.critrevonc.2010.12.006; Chen ZL, 2011, J BIOL CHEM, V286, P10725, DOI 10.1074/jbc.M110.165654; Cui YZ, 2009, INT J CANCER, V124, P1614, DOI 10.1002/ijc.24163; Deng JY, 2010, J SURG RES, V161, P47, DOI 10.1016/j.jss.2008.12.019; Ding J, 2010, NAT CELL BIOL, V12, P390, DOI 10.1038/ncb2039; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Hoeflich KP, 2004, INT J BIOCHEM CELL B, V36, P2131, DOI 10.1016/j.biocel.2003.11.018; Hohenberger P, 2003, LANCET, V362, P305, DOI 10.1016/S0140-6736(03)13975-X; Hou J, 2011, CANCER CELL, V19, P232, DOI 10.1016/j.ccr.2011.01.001; Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308; Kanaan Z, 2010, GENET TEST MOL BIOMA, V14, P347, DOI 10.1089/gtmb.2009.0197; Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li XH, 2011, J CELL MOL MED, V15, P1887, DOI 10.1111/j.1582-4934.2010.01194.x; Li YW, 2010, CANCER RES, V70, P1486, DOI 10.1158/0008-5472.CAN-09-2792; Liang SL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018409; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu GQ, 2005, J BIOL CHEM, V280, P39042, DOI 10.1074/jbc.M504341200; Ming OY, 2011, BIOCHIMIE, V93, P954, DOI 10.1016/j.biochi.2011.01.017; Oue N, 2004, CANCER RES, V64, P2397, DOI 10.1158/0008-5472.CAN-03-3514; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Song YX, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-1; Stacker SA, 2002, NAT REV CANCER, V2, P573, DOI 10.1038/nrc863; Stock M, 2005, GENE, V360, P1, DOI 10.1016/j.gene.2005.06.026; Takei Y, 2011, CANCER RES, V71, P1442, DOI 10.1158/0008-5472.CAN-10-2530; Tie J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000879; Tsai KW, 2011, INT J CANCER, V129, P2600, DOI 10.1002/ijc.25919; Tsukamoto Y, 2010, CANCER RES, V70, P2339, DOI 10.1158/0008-5472.CAN-09-2777; Ueda T, 2010, LANCET ONCOL, V11, P136, DOI 10.1016/S1470-2045(09)70343-2; Valastyan S, 2010, CANCER RES, V70, P5147, DOI 10.1158/0008-5472.CAN-10-0410; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Wang JB, 2010, CANCER LETT, V297, P137, DOI 10.1016/j.canlet.2010.07.018; Wu WKK, 2010, ONCOGENE, V29, P5761, DOI 10.1038/onc.2010.352; Yu HF, 2011, FRONT BIOSCI-LANDMRK, V16, P1536, DOI 10.2741/3803	40	102	110	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	42					4509	4516		10.1038/onc.2011.581	http://dx.doi.org/10.1038/onc.2011.581			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	022SH	22179828				2022-12-17	WOS:000309982100002
J	Dunn, EF; Iida, M; Myers, RA; Campbell, DA; Hintz, KA; Armstrong, EA; Li, C; Wheeler, DL				Dunn, E. F.; Iida, M.; Myers, R. A.; Campbell, D. A.; Hintz, K. A.; Armstrong, E. A.; Li, C.; Wheeler, D. L.			Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab	ONCOGENE			English	Article						colorectal cancer; KRAS mutation; cetuximab resistance; Src family kinases; dasatinib	GROWTH-FACTOR RECEPTOR; SRC-FAMILY KINASES; COLON-CANCER CELLS; CARCINOMA-ASSOCIATED ANTIGEN; PP60C-SRC PROTEIN-KINASE; FOCAL-ADHESION KINASE; C-SRC; ACQUIRED-RESISTANCE; TYROSINE KINASES; SIGNAL-TRANSDUCTION	KRAS mutation is a predictive biomarker for resistance to cetuximab (Erbitux) in metastatic colorectal cancer (mCRC). This study sought to determine if KRAS mutant CRC lines could be sensitized to cetuximab using dasatinib (BMS-354825, Sprycel), a potent, orally bioavailable inhibitor of several tyrosine kinases, including the Src family kinases (SFKs). We analyzed 16 CRC lines for: (1) KRAS mutation status, (2) dependence on mutant KRAS signaling and (3) expression level of epidermal growth factor receptor (EGFR) and SFKs. From these analyses, we selected three KRAS mutant (LS180, LoVo and HCT116) cell lines and two KRAS wild-type cell lines (SW48 and CaCo2). In vitro, using poly-D-lysine/laminin plates, KRAS mutant cell lines were resistant to cetuximab, whereas KRAS wild-type lines showed sensitivity to cetuximab. Treatment with cetuximab and dasatinib showed a greater antiproliferative effect on KRAS mutant lines when compared with either agent alone in vitro and in vivo. To investigate potential mechanisms for this antiproliferative response in the combinatorial therapy, we performed Human Phospho-Kinase Antibody Array analysis, measuring the relative phosphorylation levels of 39 intracellular proteins in untreated, cetuximab, dasatinib or the combinatorial treatment in the KRAS mutant lines LS180, LoVo and HCT116 cells. The results of this experiment showed a decrease in a broad spectrum of kinases centered on the beta-catenin pathway, the mitogen-activated protein kinase (MAPK) pathway, AKT/mammalian target of rapamycin (mTOR) pathway and the family of signal transducers and activators of transcription (STATs) when compared with the untreated control or monotherapy treatments. Next, we analyzed tumor growth with cetuximab, dasatinib or their combination in vivo. KRAS mutant xenografts showed resistance to cetuximab therapy, whereas KRAS wild type demonstrated an antitumor response when treated with cetuximab. KRAS mutant tumors exhibited minimal response to dasatinib monotherapy. However, as in vitro, KRAS mutant lines exhibited a response to the combination of cetuximab and dasatinib. Combinatorial treatment of KRAS mutant xenografts resulted in decreased cell proliferation, as measured by Ki67, and higher rates of apoptosis, as measured by TUNEL terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling). The data presented in this study indicate that dasatinib can sensitize KRAS mutant CRC tumors to cetuximab and may do so by altering the activity of several key signaling pathways. Furthermore, these results suggest that signaling via EGFR and SFKs may be necessary for cell proliferation and survival of KRAS mutant CRC tumors. These data strengthen the rationale for clinical trials combining cetuximab and dasatinib in the KRAS mutant CRC genetic setting. Oncogene (2011) 30, 561-574; doi: 10.1038/onc.2010.430; published online 18 October 2010	[Wheeler, D. L.] Univ Wisconsin, Dept Human Oncol, Ctr Comprehens Canc, Sch Med & Publ Hlth, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	Wheeler, DL (corresponding author), Univ Wisconsin, Dept Human Oncol, Ctr Comprehens Canc, Sch Med & Publ Hlth, 1111 Highland Ave,WIMR 3159, Madison, WI 53705 USA.	dlwheeler@wisc.edu	Li, Chunrong/F-6955-2011; Wheeler, Deric/B-7175-2013	Wheeler, Deric/0000-0001-5915-3675	Bristol-Myers Squibb; National Cancer Institute [P30CA014520]; National Center for Research Resources, National Institutes of Health [1UL1RR025011]; American Cancer Society [RSG-10-193-01TBG]; National Institutes of Health [CA009614-17]; NATIONAL CANCER INSTITUTE [P30CA014520, T32CA009614] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011] Funding Source: NIH RePORTER	Bristol-Myers Squibb(Bristol-Myers Squibb); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Research Resources, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); American Cancer Society(American Cancer Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	DLW has held a sponsored research agreement with Bristol-Myers Squibb.; This project was supported, in part, by grant P30CA014520 from the National Cancer Institute, grant 1UL1RR025011 from the Clinical and Translational Science Award program of the National Center for Research Resources, National Institutes of Health (to DLW), by grant RSG-10-193-01TBG from the American Cancer Society (to DLW) and T32 grant CA009614-17 Physician Scientist Training in Cancer Medicine from the National Institutes of Health (to EFD).	Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Allegra CJ, 2009, J CLIN ONCOL, V27, P2091, DOI 10.1200/JCO.2009.21.9170; Allgayer H, 2002, CANCER, V94, P344, DOI 10.1002/cncr.10221; Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116; Belsches A P, 1997, Front Biosci, V2, pd501; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Benvenuti S, 2007, CANCER RES, V67, P2643, DOI 10.1158/0008-5472.CAN-06-4158; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cappuzzo F, 2008, ANN ONCOL, V19, P717, DOI 10.1093/annonc/mdm492; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; De Roock W, 2008, ANN ONCOL, V19, P508, DOI 10.1093/annonc/mdm496; DeMali KA, 1999, EXP CELL RES, V253, P271, DOI 10.1006/excr.1999.4669; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Di Fiore F, 2007, BRIT J CANCER, V96, P1166, DOI 10.1038/sj.bjc.6603685; Emaduddin M, 2008, P NATL ACAD SCI USA, V105, P2358, DOI 10.1073/pnas.0712176105; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fu YN, 2008, ONCOGENE, V27, P957, DOI 10.1038/sj.onc.1210684; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Hantschel O, 2008, LEUKEMIA LYMPHOMA, V49, P615, DOI 10.1080/10428190801896103; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Irby R, 1997, CELL GROWTH DIFFER, V8, P1287; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jhawer M, 2008, CANCER RES, V68, P1953, DOI 10.1158/0008-5472.CAN-07-5659; Joseloff E, 2002, J BIOL CHEM, V277, P12318, DOI 10.1074/jbc.M111618200; Kantarjian H, 2006, NAT REV DRUG DISCOV, V5, P717, DOI 10.1038/nrd2135; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437; Kijima T, 2002, CELL GROWTH DIFFER, V13, P355; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Koppikar P, 2008, CLIN CANCER RES, V14, P4284, DOI 10.1158/1078-0432.CCR-07-5226; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; Li C, 2009, ONCOGENE, V28, P3801, DOI 10.1038/onc.2009.234; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, BIOCHEM BIOPH RES CO, V281, P440, DOI 10.1006/bbrc.2001.4383; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Marmor MD, 2004, INT J RADIAT ONCOL, V58, P903, DOI 10.1016/j.ijrobp.2003.06.002; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Normanno N, 2003, ENDOCR-RELAT CANCER, V10, P1, DOI 10.1677/erc.0.0100001; Normanno N, 2009, NAT REV CLIN ONCOL, V6, P519, DOI 10.1038/nrclinonc.2009.111; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Rini BI, 2008, CLIN CANCER RES, V14, P1286, DOI 10.1158/1078-0432.CCR-07-4719; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Viloria-Petit A, 2001, CANCER RES, V61, P5090; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; Wheeler DL, 2008, ONCOGENE, V27, P3944, DOI 10.1038/onc.2008.19; Wheeler DL, 2009, CANCER BIOL THER, V8, P696, DOI 10.4161/cbt.8.8.7903; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang J, 2007, AM J PATHOL, V170, P366, DOI 10.2353/ajpath.2007.060706	78	102	107	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	5					561	574		10.1038/onc.2010.430	http://dx.doi.org/10.1038/onc.2010.430			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	715WG	20956938	Green Accepted			2022-12-17	WOS:000286922300005
J	Ye, Y; Pringle, LM; Lau, AW; Riquelme, DN; Wang, H; Jiang, T; Lev, D; Welman, A; Blobel, GA; Oliveira, AM; Chou, MM				Ye, Y.; Pringle, L. M.; Lau, A. W.; Riquelme, D. N.; Wang, H.; Jiang, T.; Lev, D.; Welman, A.; Blobel, G. A.; Oliveira, A. M.; Chou, M. M.			TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase production via activation of NF-kappa B	ONCOGENE			English	Article						TRE17/USP6; aneurysmal bone cyst; MMP-9; Arf6; NF-kappa B; RhoA	ENDOTHELIAL GROWTH-FACTOR; IN-SITU HYBRIDIZATION; DEUBIQUITINATING ENZYME; MATRIX-METALLOPROTEINASE-9 EXPRESSION; STROMELYSIN-2 MMP-10; UBIQUITIN LIGASE; CARCINOMA CELLS; CDC42 GTPASES; RHO-GTPASES; PATHWAY	Aneurysmal bone cyst (ABC) is an aggressive, pediatric bone tumor characterized by extensive destruction of the surrounding bone. Although first described over 60 years ago, its molecular etiology remains poorly understood. Recent work revealed that ABCs harbor translocation of TRE17/USP6, leading to its transcriptional upregulation. TRE17 encodes a ubiquitin-specific protease (USP), and a TBC domain that mediates binding to the Arf6 GTPase. However, the mechanisms by which TRE17 overexpression contributes to tumor pathogenesis, and the role of its USP and TBC domains, are unknown. ABCs are characterized by osteolysis, inflammatory recruitment and extensive vascularization, the processes in which matrix proteases have a prominent role. This led us to explore whether TRE17 regulates the production of matrix metalloproteinases ( MMPs). In this study we show that TRE17 is sufficient to induce expression of MMP-9 and MMP-10, in a manner requiring its USP activity, but not its ability to bind Arf6. TRE17 induces transcription of MMP-9 through activation of nuclear factor-kappa B (NF-kappa B), mediated in part by the GTPase RhoA and its effector kinase, ROCK. Furthermore, xenograft studies show that TRE17 induces formation of tumors that reproduce multiple features of ABC, including a high degree of vascularization, with an essential role for the USP domain. In sum, these studies reveal that TRE17 is sufficient to initiate tumorigenesis, identify MMPs as novel TRE17 effectors that likely contribute to ABC pathogenesis and define the underlying signaling mechanism of their induction. Oncogene ( 2010) 29, 3619-3629; doi: 10.1038/onc.2010.116; published online 26 April 2010	[Ye, Y.; Pringle, L. M.; Lau, A. W.; Riquelme, D. N.; Chou, M. M.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Wang, H.; Blobel, G. A.] Univ Penn, Childrens Hosp Philadelphia, Div Pediat, Sch Med, Philadelphia, PA 19104 USA; [Jiang, T.] Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Lev, D.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Welman, A.] Univ Edinburgh, Edinburgh Canc Res Ctr, Edinburgh, Midlothian, Scotland; [Oliveira, A. M.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Edinburgh; Mayo Clinic	Chou, MM (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Sch Med, 3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	mmc@mail.med.upenn.edu			NIH [CA081415, DK58044, P30 AR050950]; Mayo Foundation; Pennsylvania Muscle Institute; Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE [R01CA081415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR050950] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK058044, R01DK058044] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mayo Foundation; Pennsylvania Muscle Institute; Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the NIH Grants CA081415 (MMC), DK58044 (GAB) and P30 AR050950 (Penn Center for Musculoskeletal Disorders). Additional support was from the Mayo Foundation CR20 Program (AMO), the Pennsylvania Muscle Institute Pilot Project Grant (MMC) and the Pennsylvania Department of Health (MMC), which specifically disclaims responsibility for any analysis, interpretations or conclusions. We thank Yvette Liu for invaluable assistance with bioluminescence imaging.	Althof PA, 2004, MODERN PATHOL, V17, P518, DOI 10.1038/modpathol.3800090; Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Anwar KN, 2004, J IMMUNOL, V173, P6965, DOI 10.4049/jimmunol.173.11.6965; Barksby HE, 2006, ARTHRITIS RHEUM-US, V54, P3244, DOI 10.1002/art.22167; Benitah SA, 2003, MOL BIOL CELL, V14, P3041, DOI 10.1091/mbc.E03-01-0016; Bernards A, 2003, BBA-REV CANCER, V1603, P47, DOI 10.1016/S0304-419X(02)00082-3; Bizimungu C, 2005, BIOCHEM BIOPH RES CO, V335, P883, DOI 10.1016/j.bbrc.2005.07.159; Bizimungu C, 2007, BIOTECHNOL LETT, V29, P1927, DOI 10.1007/s10529-007-9475-6; Bord S, 1998, BONE, V23, P7, DOI 10.1016/S8756-3282(98)00064-7; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Bryan B, 2005, FEBS LETT, V579, P1015, DOI 10.1016/j.febslet.2004.12.074; Cho A, 2000, ARTERIOSCL THROM VAS, V20, P2527, DOI 10.1161/01.ATV.20.12.2527; Cottalorda J, 2007, ARCH ORTHOP TRAUM SU, V127, P105, DOI 10.1007/s00402-006-0223-5; Cui RW, 2006, CIRC RES, V99, P723, DOI 10.1161/01.RES.0000244015.10655.3f; Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879; Genersch E, 2000, J CELL SCI, V113, P4319; Ghajar CM, 2008, CRIT REV EUKAR GENE, V18, P251, DOI 10.1615/CritRevEukarGeneExpr.v18.i3.30; Giambernardi TA, 1998, MATRIX BIOL, V16, P483, DOI 10.1016/S0945-053X(98)90019-1; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; Haeusler G, 2005, CALCIFIED TISSUE INT, V76, P326, DOI 10.1007/s00223-004-0161-6; Han SW, 2006, J BIOL CHEM, V281, P29614, DOI 10.1074/jbc.M604013200; John Anitha, 2001, Pathology and Oncology Research, V7, P14; Kanangat S, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2086; Kim KC, 2005, ARCH PHARM RES, V28, P1257, DOI 10.1007/BF02978209; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Krampert M, 2004, MOL BIOL CELL, V15, P5242, DOI 10.1091/mbc.E04-02-0109; Kumta SM, 2003, LIFE SCI, V73, P1427, DOI 10.1016/S0024-3205(03)00434-X; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Liu J, 2006, MOL CANCER RES, V4, P803, DOI 10.1158/1541-7786.MCR-06-0201; Martinu L, 2004, MOL CELL BIOL, V24, P9752, DOI 10.1128/MCB.24.22.9752-9762.2004; Masuda-Robens JM, 2003, MOL CELL BIOL, V23, P2151, DOI 10.1128/MCB.23.6.2151-2161.2003; Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010; Nakakuki T, 2005, ARTERIOSCL THROM VAS, V25, P2088, DOI 10.1161/01.ATV.0000183607.50230.9f; NAKAMURA T, 1992, ONCOGENE, V7, P733; Nielsen GP, 2002, AM J SURG PATHOL, V26, P64, DOI 10.1097/00000478-200201000-00007; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; Oliveira AM, 2005, ONCOGENE, V24, P3419, DOI 10.1038/sj.onc.1208506; Oliveira AM, 2004, CANCER RES, V64, P1920, DOI 10.1158/0008-5472.CAN-03-2827; Oliveira AM, 2004, AM J PATHOL, V165, P1773, DOI 10.1016/S0002-9440(10)63432-3; Onodera S, 2002, J BIOL CHEM, V277, P7865, DOI 10.1074/jbc.M106020200; Panoutsakopoulos G, 1999, GENE CHROMOSOME CANC, V26, P265, DOI 10.1002/(SICI)1098-2264(199911)26:3<265::AID-GCC12>3.0.CO;2-#; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Paulding CA, 2003, P NATL ACAD SCI USA, V100, P2507, DOI 10.1073/pnas.0437015100; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Rundhaug JE, 2005, J CELL MOL MED, V9, P267, DOI 10.1111/j.1582-4934.2005.tb00355.x; Saccomanni B, 2008, ARCH ORTHOP TRAUM SU, V128, P1145, DOI 10.1007/s00402-007-0477-6; Sebban H, 2006, TRENDS CELL BIOL, V16, P569, DOI 10.1016/j.tcb.2006.09.004; Shen CL, 2005, J BIOL CHEM, V280, P35967, DOI 10.1074/jbc.M505220200; Shinde A, 2006, PEDIATR DEVEL PATHOL, V9, P38, DOI 10.2350/06-05-0070.1; Singhal S, 2008, BMC BIOCHEM, V9, DOI 10.1186/1471-2091-9-S1-S3; Solt LA, 2007, J BIOL CHEM, V282, P8724, DOI 10.1074/jbc.M609613200; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Subramaniam M, 2002, J CELL BIOCHEM, V87, P9, DOI 10.1002/jcb.10259; Sukov WR, 2008, SKELETAL RADIOL, V37, P321, DOI 10.1007/s00256-007-0442-z; Tolboom TCA, 2002, ANN RHEUM DIS, V61, P975, DOI 10.1136/ard.61.11.975; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; Wang HR, 2006, METHOD ENZYMOL, V406, P437, DOI 10.1016/S0076-6879(06)06032-0; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Welman A, 2006, NEOPLASIA, V8, P905, DOI 10.1593/neo.06475; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Yamaguchi T, 2007, J BIOL CHEM, V282, P33943, DOI 10.1074/jbc.M706282200; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	67	102	107	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	2010	29	25					3619	3629		10.1038/onc.2010.116	http://dx.doi.org/10.1038/onc.2010.116			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20418905	Green Accepted			2022-12-17	WOS:000279108600003
J	Wang, J; Kim, J; Roh, M; Franco, OE; Hayward, SW; Wills, ML; Abdulkadir, SA				Wang, J.; Kim, J.; Roh, M.; Franco, O. E.; Hayward, S. W.; Wills, M. L.; Abdulkadir, S. A.			Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma	ONCOGENE			English	Article						Pim1; c-MYC; prostate cancer; mouse model; neuroendocrine	INDUCED NEUROENDOCRINE DIFFERENTIATION; UROGENITAL SINUS MESENCHYME; TRANSGENIC MOUSE MODEL; CANCER CELLS; INTRAEPITHELIAL NEOPLASIA; ONCOGENIC TRANSFORMATION; SIGNALING PATHWAY; MURINE PROSTATE; TUMOR-CELLS; PROTEIN	The oncogenic PIM1 kinase has been implicated as a cofactor for c-MYC in prostate carcinogenesis. In this study, we show that in human prostate tumors, coexpression of c-MYC and PIM1 is associated with higher Gleason grades. Using a tissue recombination model coupled with lentiviral-mediated gene transfer we find that Pim1 is weakly oncogenic in naive adult mouse prostatic epithelium. However, it cooperates dramatically with c-MYC to induce prostate cancer within 6-weeks. Importantly, c-MYC/Pim1 synergy is critically dependent on Pim1 kinase activity. c-MYC/Pim1 tumors showed increased levels of the active serine-62 (S62) phosphorylated form of c-MYC. Grafts expressing a phosphomimetic c-MYCS62D mutant had higher rates of proliferation than grafts expressing wild type c-MYC but did not form tumors like c-MYC/Pim1 grafts, indicating that Pim1 cooperativity with c-MYC in vivo involves additional mechanisms other than enhancement of c-MYC activity by S62 phosphorylation. c-MYC/Pim1-induced prostate carcinomas show evidence of neuroendocrine (NE) differentiation. Additional studies, including the identification of tumor cells coexpressing androgen receptor and NE cell markers synaptophysin and Ascl1 suggested that NE tumors arose from adenocarcinoma cells through transdifferentiation. These results directly show functional cooperativity between c-MYC and PIM1 in prostate tumorigenesis in vivo and support efforts for targeting PIM1 in prostate cancer. Oncogene (2010) 29, 2477-2487; doi:10.1038/onc.2010.10; published online 8 February 2010	[Kim, J.; Roh, M.; Wills, M. L.; Abdulkadir, S. A.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; [Wang, J.; Hayward, S. W.; Abdulkadir, S. A.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; [Franco, O. E.; Hayward, S. W.] Vanderbilt Univ, Med Ctr, Dept Urol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Abdulkadir, SA (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pathol, B33321A MCN,1161 21st Ave S, Nashville, TN 37232 USA.	sarki.abdulkadir@vanderbilt.edu	Hayward, Simon/A-1688-2011	Kim, Jongchan/0000-0002-9733-9881; Hayward, Simon/0000-0002-6059-6550	NIH [CA123484]; NATIONAL CANCER INSTITUTE [R01CA123484] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Robert Matusik, Vito Quaranta, Fritz Parl and Susan Kasper for helpful discussions. This work was supported by NIH Grant CA123484 (SAA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the paper.	Abdulkadir SA, 2002, MOL CELL BIOL, V22, P1495, DOI 10.1128/MCB.22.5.1495-1503.2002; Abdulkadir SA, 2001, HUM PATHOL, V32, P935, DOI 10.1053/hupa.2001.27102; Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Bachmann M, 2006, INT J BIOCHEM CELL B, V38, P430, DOI 10.1016/j.biocel.2005.10.010; Bachmann M, 2005, INT J BIOCHEM CELL B, V37, P726, DOI 10.1016/j.biocel.2004.11.005; Bachmann M, 2004, J BIOL CHEM, V279, P48319, DOI 10.1074/jbc.M404440200; Bhattacharya N, 2002, CHROMOSOMA, V111, P80, DOI 10.1007/s00412-002-0192-6; Chen WW, 2005, MOL CANCER RES, V3, P443, DOI 10.1158/1541-7786.MCR-05-0007; Cindolo L, 2007, UROL INT, V79, P287, DOI 10.1159/000109711; CUNHA GR, 1978, J EXP ZOOL, V205, P181, DOI 10.1002/jez.1402050203; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; DISANTAGNESE PA, 1987, HUM PATHOL, V18, P849; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Garabedian EM, 1998, P NATL ACAD SCI USA, V95, P15382, DOI 10.1073/pnas.95.26.15382; Hansel DE, 2009, PROSTATE, V69, P603, DOI 10.1002/pros.20910; Hayward SW, 1998, DIFFERENTIATION, V63, P131, DOI 10.1046/j.1432-0436.1998.6330131.x; Hu Y, 2004, P NATL ACAD SCI USA, V101, P5559, DOI 10.1073/pnas.0306988101; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Kim J, 2002, CANCER RES, V62, P1549; Kim J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000542; Mirosevich J, 2006, PROSTATE, V66, P1013, DOI 10.1002/pros.20299; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Morishita D, 2008, CANCER RES, V68, P5076, DOI 10.1158/0008-5472.CAN-08-0634; Pinski J, 2006, PROSTATE, V66, P1136, DOI 10.1002/pros.20440; Roh M, 2005, J BIOL CHEM, V280, P40568, DOI 10.1074/jbc.M509369200; Roh M, 2003, CANCER RES, V63, P8079; Roh M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002572; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Sauer CG, 2006, PROSTATE, V66, P227, DOI 10.1002/pros.20338; Schmidt T, 1998, EMBO J, V17, P5349, DOI 10.1093/emboj/17.18.5349; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Valdman A, 2004, PROSTATE, V60, P367, DOI 10.1002/pros.20064; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Vias M, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-17; Wafa LA, 2007, HUM PATHOL, V38, P161, DOI 10.1016/j.humpath.2006.07.003; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Xin L, 2003, P NATL ACAD SCI USA, V100, P11896, DOI 10.1073/pnas.1734139100; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yuan TC, 2007, ENDOCR-RELAT CANCER, V14, P531, DOI 10.1677/ERC-07-0061; Zhang XQ, 2003, ONCOGENE, V22, P6704, DOI 10.1038/sj.onc.1206764; Zhang Y, 2008, ONCOGENE, V27, P4809, DOI 10.1038/onc.2008.123; Zhou ZX, 2006, CANCER RES, V66, P7889, DOI 10.1158/0008-5472.CAN-06-0486; Zippo A, 2007, NAT CELL BIOL, V9, P932, DOI 10.1038/ncb1618	45	102	111	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	17					2477	2487		10.1038/onc.2010.10	http://dx.doi.org/10.1038/onc.2010.10			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20140016	Green Accepted			2022-12-17	WOS:000277169400003
J	Jang, GY; Jeon, JH; Cho, SY; Shin, DM; Kim, CW; Jeong, EM; Bae, HC; Kim, TW; Lee, SH; Choi, Y; Lee, DS; Park, SC; Kim, IG				Jang, G-Y; Jeon, J-H; Cho, S-Y; Shin, D-M; Kim, C-W; Jeong, E. M.; Bae, H. C.; Kim, T. W.; Lee, S-H; Choi, Y.; Lee, D-S; Park, S-C; Kim, I-G			Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappa B activity in hypoxic tumor cells	ONCOGENE			English	Article						apoptosis; caspase 3; hypoxia-inducible factor-1; NF-kappa B; transglutaminase 2	TISSUE TRANSGLUTAMINASE; OXIDATIVE STRESS; CANCER-THERAPY; BREAST-CANCER; GENE-EXPRESSION; DRUG-RESISTANT; IDENTIFICATION; ACTIVATION; PROTEIN; ALPHA	The expression of hypoxia-inducible factor-1 (HIF-1) correlates with poor clinical outcomes and confers resistance to the apoptosis of the tumor cells that are exposed to hypoxia. Presently, the mechanism underlying this phenomenon is poorly understood. In this study we provide evidence that transglutaminase 2 (TG2), an enzyme that catalyses protein crosslinking reactions, is a transcriptional target of HIF-1 to enhance the survival of hypoxic cells. We found that hypoxia induces TG2 expression through an HIF-1 dependent pathway and concurrently activates intracellular TG2. The hypoxic cells overexpressing TG2 showed resistance to apoptosis. Conversely, the hypoxic cells treated with either TG2 inhibitor or small interfering RNA (siRNA) became sensitive to apoptosis. Activation of TG2 in response to hypoxic stress inhibited caspase-3 activity by forming crosslinked multimer, resulting in insoluble aggregates. TG2 also activates nuclear factor (NF)-kappa B pathway after hypoxic stress, and thereby induces the expression of cellular inhibitor of apoptosis 2. The anti-apoptotic role of TG2 was further confirmed in vivo using xenografts in athymic mice. Our results indicate that TG2 is an antiapoptotic mediator of HIF-1 through modulating both apoptosis and survival pathways and may confer a selective growth advantage to tumor cells. These findings suggest that the inhibition of TG2 may offer a novel strategy for anticancer therapy. Oncogene (2010) 29, 356-367; doi:10.1038/onc.2009.342; published online 19 October 2009	[Jang, G-Y; Cho, S-Y; Shin, D-M; Kim, C-W; Jeong, E. M.; Lee, S-H; Choi, Y.; Park, S-C; Kim, I-G] Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, AARC, Seoul 110799, South Korea; [Jeon, J-H] Seoul Natl Univ, Coll Med, Dept Physiol, Seoul 110799, South Korea; [Bae, H. C.; Kim, T. W.] Korea Univ, Grad Sch Med, Lab Infect & Immunol, Seoul, South Korea; [Lee, D-S] Seoul Natl Univ, Coll Med, Inst Canc Res, Seoul 110799, South Korea	Seoul National University (SNU); Seoul National University (SNU); Korea University; Korea University Medicine (KU Medicine); Seoul National University (SNU)	Kim, IG (corresponding author), Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, AARC, 28 Yongon Dong, Seoul 110799, South Korea.	igkim@plaza.snu.ac.kr	Jeon, Ju-Hong/D-5740-2012; Lee, Dong-Sup/J-2777-2012	Kim, Chai-Wan/0000-0001-5105-2829; Jeong, Eui Man/0000-0003-0692-2033; /0000-0001-8564-2392; Jeon, Ju-Hong/0000-0002-5603-2955	Korea Science and Engineering Foundation [R11-2002-097-09005-0, R01-2005000-10364-0]; Research Program for New Drug Target Discovery [M10748000296-07N4800-29610]; Korea Ministry of Education, Science and Technology	Korea Science and Engineering Foundation(Korea Science and Engineering Foundation); Research Program for New Drug Target Discovery(Ministry of Education, Science & Technology (MEST), Republic of Korea); Korea Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	We thank Dr YD Kim for critical comments on this paper. We also thank Dr Shigetaka Kitajima (Tokyo Medical and Dental University, Japan) for providing cIAP2 reporter construct. This work was supported by the grants from Korea Science and Engineering Foundation (R11-2002-097-09005-0 and R01-2005000-10364-0) and also by the Research Program for New Drug Target Discovery (M10748000296-07N4800-29610). GYJ, SYC, EMJ, SHL and YC were supported by the graduate program of BK21, Korea Ministry of Education, Science and Technology.	Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Antonyak MA, 2004, J BIOL CHEM, V279, P41461, DOI 10.1074/jbc.M404976200; Antonyak MA, 2006, P NATL ACAD SCI USA, V103, P18609, DOI 10.1073/pnas.0604844103; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Baylin SB, 1997, SCIENCE, V277, P1948, DOI 10.1126/science.277.5334.1948; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Brunelle JK, 2002, APOPTOSIS, V7, P475, DOI 10.1023/A:1020668923852; Bubici C, 2006, ONCOGENE, V25, P6731, DOI 10.1038/sj.onc.1209936; Choi K, 2005, CHEM BIOL, V12, P469, DOI 10.1016/j.chembiol.2005.02.007; Dachs GU, 1997, NAT MED, V3, P515, DOI 10.1038/nm0597-515; De Laurenzi V, 2001, MOL CELL BIOL, V21, P148, DOI 10.1128/MCB.21.1.148-155.2001; Dirmeier R, 2004, METHOD ENZYMOL, V381, P589; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Filiano AJ, 2008, FASEB J, V22, P2662, DOI 10.1096/fj.07-097709; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Hasegawa G, 2003, BIOCHEM J, V373, P793, DOI 10.1042/BJ20021084; Herman JF, 2006, ONCOGENE, V25, P3049, DOI 10.1038/sj.onc.1209324; Hui AS, 2006, FASEB J, V20, P466, DOI 10.1096/fj.05-5086com; Jeon JH, 2004, EXP MOL MED, V36, P576, DOI 10.1038/emm.2004.74; Jeon JH, 2003, EMBO J, V22, P5273, DOI 10.1093/emboj/cdg495; Jeon JH, 2003, FEBS LETT, V534, P180, DOI 10.1016/S0014-5793(02)03836-X; Kaidi A, 2006, CANCER RES, V66, P6683, DOI 10.1158/0008-5472.CAN-06-0425; Kuhlicke J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001364; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Maxwell PH, 2005, SEMIN CELL DEV BIOL, V16, P523, DOI 10.1016/j.semcdb.2005.03.001; Mehta K, 2004, CLIN CANCER RES, V10, P8068, DOI 10.1158/1078-0432.CCR-04-1107; Mishra S, 2004, J BIOL CHEM, V279, P23863, DOI 10.1074/jbc.M311919200; Park SS, 2006, J BIOL CHEM, V281, P34965, DOI 10.1074/jbc.M604150200; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Piret JP, 2002, BIOCHEM PHARMACOL, V64, P889, DOI 10.1016/S0006-2952(02)01155-3; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Reed JC, 2006, NAT CLIN PRACT ONCOL, V3, P388, DOI 10.1038/ncponc0538; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shin DM, 2004, J BIOL CHEM, V279, P15032, DOI 10.1074/jbc.M308734200; Shin DM, 2008, FASEB J, V22, P2498, DOI 10.1096/fj.07-095455; Sohn J, 2003, J CLIN INVEST, V111, P121, DOI 10.1172/JCI200315937; Verma A, 2007, DRUG RESIST UPDATE, V10, P144, DOI 10.1016/j.drup.2007.06.002; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Yamaguchi H, 2006, MOL CELL BIOL, V26, P569, DOI 10.1128/MCB.26.2.569-579.2006; Yuan L, 2005, MOL CANCER THER, V4, P1293, DOI 10.1158/1535-7163.MCT-04-0328; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W; Zhang RL, 2003, GLIA, V42, P194, DOI 10.1002/glia.10222; Zhang ZB, 2003, CIRC RES, V92, P1153, DOI 10.1161/01.RES.0000071749.22027.45	45	102	104	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					356	367		10.1038/onc.2009.342	http://dx.doi.org/10.1038/onc.2009.342			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19838207				2022-12-17	WOS:000273793200005
J	Dydensborg, AB; Rose, AAN; Wilson, BJ; Grote, D; Paquet, M; Giguere, V; Siegel, PM; Bouchard, M				Dydensborg, A. B.; Rose, A. A. N.; Wilson, B. J.; Grote, D.; Paquet, M.; Giguere, V.; Siegel, P. M.; Bouchard, M.			GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis	ONCOGENE			English	Article						GATA3; breast cancer; lung metastasis	GENE-EXPRESSION PROFILES; LUMINAL CELL FATE; CARCINOMA IN-SITU; LYMPH-NODE; ESTROGEN-RECEPTOR; LUNG METASTASIS; MAMMARY-GLAND; DIFFERENTIATION; GLYCODELIN; MORPHOGENESIS	The loss of expression of the transcription factor GATA3 in breast tumors has been linked to aggressive tumor development and poor patient survival. In the present work, we address potential roles for GATA3 in breast tumor lung metastasis and progression. Using an aggressive breast cancer cell line, which metastasizes specifically to the lung, we show that GATA3 expression results in reduced tumor outgrowth in the mammary fat pad and lower lung metastatic burden in nude mice. Specifically, GATA3 expression inhibits breast cancer cell expansion inside the lung parenchyma. This phenotype correlates with the ability of GATA3 to negatively regulate the expression of several genes that promote breast cancer lung metastasis (ID1/-3, KRTHB1, LY6E and RARRES3). Conversely, the expression of genes encoding known inhibitors of lung metastasis (DLC1 (deleted in liver cancer 1) and PAEP (progestagen-associated endometrial protein)) is upregulated by GATA3. These data correlate with microarray data from human breast cancer patients, showing a strong correlation between high GATA3 expression and absence of metastases specifically to the lungs. We conclude that GATA3 inhibits primary breast tumor outgrowth and reduces lung metastatic burden by regulating key genes involved in metastatic breast tumor progression. Oncogene (2009) 28, 2634-2642; doi: 10.1038/onc.2009.126; published online 1 June 2009	[Dydensborg, A. B.; Rose, A. A. N.; Wilson, B. J.; Grote, D.; Giguere, V.; Siegel, P. M.; Bouchard, M.] McGill Univ, Dept Biochem, Goodman Canc Ctr, Montreal, PQ H3G 1Y6, Canada; [Paquet, M.] McGill Univ, Comparat Pathol Facil, Dept Med, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Bouchard, M (corresponding author), McGill Univ, Dept Biochem, Goodman Canc Ctr, 1160 Ave Des Pins Ouest, Montreal, PQ H3G 1Y6, Canada.	maxime.bouchard@mcgill.ca	Rose, April/AAR-8222-2020; Paquet, Marilene/L-3414-2019	Rose, April/0000-0002-9845-4603; Paquet, Marilene/0000-0002-3562-4636; Giguere, Vincent/0000-0001-9567-3694; Bouchard, Maxime/0000-0002-7619-9680	Canadian Institutes for Health Research [MOP-84470]; Canderel New Initiative Award; Carlsberg Foundation fellowship [2006_01_0102]; Canadian Institutes for Health Research Cancer Consortium Training Grant Fellowship Award; National Cancer Institute of Canada; Fonds de la Recherche en Sante ' du Que ' bec studentship	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Canderel New Initiative Award; Carlsberg Foundation fellowship; Canadian Institutes for Health Research Cancer Consortium Training Grant Fellowship Award(Canadian Institutes of Health Research (CIHR)); National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Fonds de la Recherche en Sante ' du Que ' bec studentship	The authors are grateful to Dr Perou (Division of Cancer Epidemiology and Genetics, the National Cancer Institute, MD 20852-7234, USA) for sharing cDNA constructs. The work was supported by the Canadian Institutes for Health Research grant MOP-84470 and a Canderel New Initiative Award to MB. ABD was supported by a fellowship from the Carlsberg Foundation (2006_01_0102) and a Canadian Institutes for Health Research Cancer Consortium Training Grant Fellowship Award. AANR is supported by a studentship from the Fonds de la Recherche en Sante ' du Que ' bec. PS is a research scientist of the National Cancer Institute of Canada. MB holds a Canada Research Chair in Developmental Genetics of the Urogenital System.	Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Buess M, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r191; de Kok JB, 2005, LAB INVEST, V85, P154, DOI 10.1038/labinvest.3700208; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Goodison S, 2005, CANCER RES, V65, P6042, DOI 10.1158/0008-5472.CAN-04-3043; Grote D, 2006, DEVELOPMENT, V133, P53, DOI 10.1242/dev.02184; Gupta GP, 2007, P NATL ACAD SCI USA, V104, P19506, DOI 10.1073/pnas.0709185104; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hautala LC, 2008, INT J CANCER, V123, P2279, DOI 10.1002/ijc.23773; Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jeschke U, 2005, ONCOL REP, V13, P413; JOHNSTON SRD, 2006, HDB METASTATIC BREAS, P232; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kouros-Mehr H, 2008, CURR OPIN CELL BIOL, V20, P164, DOI 10.1016/j.ceb.2008.02.003; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Lim KC, 2000, NAT GENET, V25, P209, DOI 10.1038/76080; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Murphy KM, 2005, IMMUNOL RES, V32, P193, DOI 10.1385/IR:32:1-3:193; Ni HH, 2005, ONCOGENE, V24, P6820, DOI 10.1038/sj.onc.1208848; Oh DS, 2006, J CLIN ONCOL, V24, P1656, DOI 10.1200/JCO.2005.03.2755; Parikh P, 2005, J AM COLL SURGEONS, V200, P705, DOI 10.1016/j.jamcollsurg.2004.12.025; Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2; Shabani N, 2005, ANTICANCER RES, V25, P1761; Solomayer EF, 2000, BREAST CANCER RES TR, V59, P271, DOI 10.1023/A:1006308619659; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Voduc D, 2008, CANCER EPIDEM BIOMAR, V17, P365, DOI 10.1158/1055-9965.EPI-06-1090; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1	36	102	105	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2009	28	29					2634	2642		10.1038/onc.2009.126	http://dx.doi.org/10.1038/onc.2009.126			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473MO	19483726				2022-12-17	WOS:000268211200002
J	Bellovin, DI; Simpson, KJ; Danilov, T; Maynard, E; Rimm, DL; Oettgen, P; Mercurio, AM				Bellovin, D. I.; Simpson, K. J.; Danilov, T.; Maynard, E.; Rimm, D. L.; Oettgen, P.; Mercurio, A. M.			Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma	ONCOGENE			English	Article						RhoC; epithelial mesenchymal transition; colorectal carcinoma	EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTIONAL REPRESSOR SNAIL; INFLAMMATORY BREAST-CANCER; ETS-1 PROTOONCOGENE; GENOMIC ANALYSIS; METASTASIS; EXPRESSION; PHENOTYPE; ORGANOIDS; SURVIVAL	Understanding how RhoC expression and activation are regulated is essential for deciphering its contribution to tumorigenesis. Here, we report that RhoC expression and activation are induced by the epithelial to mesenchymal transition (EMT) of colon carcinoma. Using LIM 1863 colon cancer cells, RhoC protein expression and subsequent activation were detected coincident with the loss of E-cadherin and acquisition of mesenchymal characteristics. Several Ets-1 binding sites were identified in the RhoC promoter, and evidence was obtained using chromatin immunoprecipitation that Ets-1 can regulate RhoC expression during the EMT. Interestingly, a marked decrease in RhoA activation associated with the EMT was observed that corresponds to the increase in RhoC expression. Use of shRNA established that RhoA inhibits and RhoC promotes post-EMT cell migration, demonstrating functional significance for their coordinate regulation. To assess the importance of RhoC expression in colon cancer, immunohistochemistry was performed on 566 colorectal tumors with known clinical outcome. The level of RhoC ranged from no expression to high expression, and statistical analysis revealed that elevated RhoC expression correlates with poor outcome as well as aberrant expression and localization of E-cadherin. These data provide one mechanism for how RhoC expression is regulated in colon carcinoma and substantiate its utility as a prognostic marker.	Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA; Beth Israel Deaconess Med Ctr, Div Prevent Cardiol, Boston, MA 02215 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Yale University	Mercurio, AM (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, LRB-408,364 Plantat St, Worcester, MA 01605 USA.	arthur.mercurio@umassmed.edu	Oettgen, Peter/AAF-5026-2021	Rimm, David/0000-0001-5820-4397; Simpson, Kaylene/0000-0001-9136-1781	NCI NIH HHS [CA107548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alipov G, 2005, HISTOPATHOLOGY, V46, P202, DOI 10.1111/j.1365-2559.2005.02059.x; Bates RC, 2005, J CLIN INVEST, V115, P339, DOI 10.1172/JCI200523183; Bates RC, 2003, CURR BIOL, V13, P1721, DOI 10.1016/j.cub.2003.09.002; Bates RC, 2003, MOL BIOL CELL, V14, P1790, DOI 10.1091/mbc.E02-09-0583; Bellovin DI, 2005, CANCER RES, V65, P10938, DOI 10.1158/0008-5472.CAN-05-1947; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; Hu M, 2005, CANCER RES, V65, P8715, DOI 10.1158/0008-5472.CAN-05-0700; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Roy HK, 2005, DIGEST DIS SCI, V50, P42, DOI 10.1007/s10620-005-1275-z; Sato Y, 1998, Hum Cell, V11, P207; Schwiebert LM, 1997, AM J RESP CELL MOL, V17, P106, DOI 10.1165/ajrcmb.17.1.2775; Shikada Y, 2003, CLIN CANCER RES, V9, P5282; Simpson KJ, 2004, CANCER RES, V64, P8694, DOI 10.1158/0008-5472.CAN-04-2247; Span PN, 2002, ONCOGENE, V21, P8506, DOI 10.1038/sj.onc.1206040; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Tootle TL, 2005, BIOESSAYS, V27, P285, DOI 10.1002/bies.20198; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van Golen KL, 2000, CANCER RES, V60, P5832; Wang H, 2004, CLIN CANCER RES, V10, P1633, DOI 10.1158/1078-0432.CCR-0829-3; Wang W, 2004, BRIT J CANCER, V90, P2349, DOI 10.1038/sj.bjc.6601749; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	28	102	114	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	52					6959	6967		10.1038/sj.onc.1209682	http://dx.doi.org/10.1038/sj.onc.1209682			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16715134				2022-12-17	WOS:000241732300006
J	Ehrlich, M; Woods, CB; Yu, MC; Dubeau, L; Yang, F; Campan, M; Weisenberger, DJ; Long, TI; Youn, B; Fiala, ES; Laird, PW				Ehrlich, M; Woods, CB; Yu, MC; Dubeau, L; Yang, F; Campan, M; Weisenberger, DJ; Long, TI; Youn, B; Fiala, ES; Laird, PW			Quantitative analysis of associations between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors	ONCOGENE			English	Article						DNA hypomethylation; DNA hypermethylation; DNA methyltransferases; ovarian tumors	DE-NOVO METHYLATION; CPG ISLAND METHYLATION; SATELLITE DNA; WILMS-TUMORS; ICF SYNDROME; FREQUENT HYPOMETHYLATION; METHYLTRANSFERASE GENE; PROMOTER METHYLATION; PERICENTROMERIC DNA; CELL-PROLIFERATION	How hypermethylation and hypomethylation of different parts of the genome in cancer are related to each other and to DNA methyltransferase ( DNMT) gene expression is ill defined. We used ovarian epithelial tumors of different malignant potential to look for associations between 5'-gene region or promoter hypermethylation, satellite, or global DNA hypomethylation, and RNA levels for ten DNMT isoforms. In the quantitative MethyLight assay, six of the 55 examined gene loci ( LTB4R, MTHFR, CDH13, PGR, CDH1, and IGSF4) were significantly hypermethylated relative to the degree of malignancy ( after adjustment for multiple comparisons; P < 0.001). Importantly, hypermethylation of these genes was associated with degree of malignancy independently of the association of satellite or global DNA hypomethylation with degree of malignancy. Cancer-related increases in methylation of only two studied genes, LTB4R and MTHFR, which were appreciably methylated even in control tissues, were associated with DNMT1 RNA levels. Cancer-linked satellite DNA hypomethylation was independent of RNA levels for all DNMT3B isoforms, despite the ICF syndrome-linked DNMT3B deficiency causing juxtacentromeric satellite DNA hypomethylation. Our results suggest that there is not a simple association of gene hypermethylation in cancer with altered DNMT RNA levels, and that this hypermethylation is neither the result nor the cause of satellite and global DNA hypomethylation.	Tulane Med Sch, Human Genet Program SL31, New Orleans, LA 70112 USA; Tulane Med Sch, Tulane Canc Ctr, Dept Biochem, New Orleans, LA 70112 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN USA; Univ So Calif, Dept Pathol, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Dept Surg & Mol Biol, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90089 USA; Amer Hlth Fdn, Dept Biochem Pharmacol, Valhalla, NY 10595 USA; NYU, Sch Med, Tuxedo Pk, NY USA	Tulane University; Tulane University; University of Minnesota System; University of Minnesota Twin Cities; University of Southern California; University of Southern California; University of Southern California; American Health Foundation; New York University	Ehrlich, M (corresponding author), Tulane Med Sch, Human Genet Program SL31, 1430 Tulane Ave, New Orleans, LA 70112 USA.	ehrlich@tulane.edu	Laird, Peter W/G-8683-2012; Weisenberger, Daniel/AAA-8314-2020	Laird, Peter W/0000-0001-9117-3641; Weisenberger, Daniel/0000-0001-8303-2603	NATIONAL CANCER INSTITUTE [P01CA070972, R01CA081506, P01CA046589, R01CA096958] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA096958, CA96958, P01 CA070972, P01CA46589, R01 CA081506, CA81506, P01 CA70972] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agoston AT, 2005, J BIOL CHEM, V280, P18302, DOI 10.1074/jbc.M501675200; Ahluwalia A, 2001, GYNECOL ONCOL, V82, P261, DOI 10.1006/gyno.2001.6291; Bariol C, 2003, AM J PATHOL, V162, P1361, DOI 10.1016/S0002-9440(10)63932-6; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Broday L, 1999, MOL CELL BIOL, V19, P3198; Chedin F, 2002, P NATL ACAD SCI USA, V99, P16916, DOI 10.1073/pnas.262443999; Chen TP, 2002, J BIOL CHEM, V277, P38746, DOI 10.1074/jbc.M205312200; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Draper N. R., 2014, APPL REGRESSION ANAL; Dubeau L, 1999, GYNECOL ONCOL, V72, P437, DOI 10.1006/gyno.1998.5275; Eads CA, 2001, CANCER RES, V61, P3410; Eads CA, 1999, CANCER RES, V59, P2302; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; EHRLICH M, 1982, NUCLEIC ACIDS RES, V10, P2709, DOI 10.1093/nar/10.8.2709; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Ehrlich M, 2003, CLIN IMMUNOL, V109, P17, DOI 10.1016/S1521-6616(03)00201-8; Ehrlich M, 2003, CANCER GENET CYTOGEN, V141, P97, DOI 10.1016/S0165-4608(02)00668-4; Ehrlich M, 2002, ONCOGENE, V21, P6694, DOI 10.1038/sj.onc.1205890; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Feinberg AP, 2002, SEMIN CANCER BIOL, V12, P389, DOI 10.1016/S1044-579X(02)00059-7; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; Gowher H, 2002, J BIOL CHEM, V277, P20409, DOI 10.1074/jbc.M202148200; Graff JR, 1998, CANCER RES, V58, P2063; Grunau C, 2005, GENE CHROMOSOME CANC, V43, P11, DOI 10.1002/gcc.20155; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Hermann A, 2003, J BIOL CHEM, V278, P31717, DOI 10.1074/jbc.M305448200; Hernandez R, 1997, CYTOGENET CELL GENET, V76, P196, DOI 10.1159/000134548; Hibi K, 2004, BRIT J CANCER, V90, P1030, DOI 10.1038/sj.bjc.6601647; Hollander M., 1999, NONPARAMETRIC STAT M; ISAACS WB, 1995, CANCER SURV, V23, P19; Issa Jean-Pierre, 2000, P311; Jackson K, 2004, CANCER BIOL THER, V3, P1225, DOI 10.4161/cbt.3.12.1222; Jacobsen SE, 1997, SCIENCE, V277, P1100, DOI 10.1126/science.277.5329.1100; Jansen M, 2002, CANCER BIOL THER, V1, P293, DOI 10.4161/cbt.84; JEANPIERRE M, 1993, HUM MOL GENET, V2, P731, DOI 10.1093/hmg/2.6.731; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaneda A, 2004, CANCER SCI, V95, P58, DOI 10.1111/j.1349-7006.2004.tb03171.x; Kawakami M, 1999, INT J ONCOL, V15, P715; Kimura F, 2003, INT J CANCER, V104, P568, DOI 10.1002/ijc.10988; KOKALJVOKAC N, 1993, CYTOGENET CELL GENET, V63, P11, DOI 10.1159/000133492; Kondo T, 2000, HUM MOL GENET, V9, P597, DOI 10.1093/hmg/9.4.597; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; Li JD, 2005, GYNECOL ONCOL, V96, P150, DOI 10.1016/j.ygyno.2004.08.050; McCluskey Lisa L., 1997, Current Opinion in Oncology, V9, P465, DOI 10.1097/00001622-199709050-00011; Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V; Nishiyama R, 2005, CANCER BIOL THER, V4, P440; Nishiyama R, 2005, MOL CANCER RES, V3, P617, DOI 10.1158/1541-7786.MCR-05-0146; Okada H, 2005, INT J ONCOL, V26, P369; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pogribny IP, 1997, CANCER LETT, V115, P31, DOI 10.1016/S0304-3835(97)04708-3; Qu GZ, 1999, CANCER GENET CYTOGEN, V109, P34, DOI 10.1016/S0165-4608(98)00143-5; Qu GZ, 1999, NUCLEIC ACIDS RES, V27, P2332, DOI 10.1093/nar/27.11.2332; Qu GZ, 1999, MUTAT RES-FUND MOL M, V423, P91, DOI 10.1016/S0027-5107(98)00229-2; Rathi A, 2002, CLIN CANCER RES, V8, P3324; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Saito Y, 2002, P NATL ACAD SCI USA, V99, P10060, DOI 10.1073/pnas.152121799; Santourlidis S, 1999, PROSTATE, V39, P166; Sasaki M, 2003, MOL CELL ENDOCRINOL, V202, P201, DOI 10.1016/S0303-7207(03)00084-4; Strathdee G, 2004, CARCINOGENESIS, V25, P693, DOI 10.1093/carcin/bgh066; Tang LY, 2003, J BIOL CHEM, V278, P33613, DOI 10.1074/jbc.C300255200; Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852; Viel A, 1997, BRIT J CANCER, V75, P1105, DOI 10.1038/bjc.1997.191; Wei SH, 2002, CLIN CANCER RES, V8, P2246; Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987; Weisenberger DJ, 2004, MOL CANCER RES, V2, P62; Widschwendter M, 2004, CANCER RES, V64, P4472, DOI 10.1158/0008-5472.CAN-04-0238; ZHENG JP, 1995, J NATL CANCER I, V87, P1146, DOI 10.1093/jnci/87.15.1146; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	72	102	113	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2636	2645		10.1038/sj.onc.1209145	http://dx.doi.org/10.1038/sj.onc.1209145			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16532039	Green Accepted			2022-12-17	WOS:000237099400007
J	Gladden, AB; Woolery, R; Aggarwal, P; Wasik, MA; Diehl, JA				Gladden, AB; Woolery, R; Aggarwal, P; Wasik, MA; Diehl, JA			Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma	ONCOGENE			English	Article						CDK4; cyclin D1; mantle cell lymphoma; apoptosis	TUMOR-SUPPRESSOR PATHWAY; EARLY PRE-B; C-MYC; DEPENDENT KINASE; TRANSGENIC MICE; CDK INHIBITORS; P53 MUTATIONS; T-CELLS; TRANSFORMATION; APOPTOSIS	Mantle cell lymphoma (MCL) is a B- cell lymphoma characterized by overexpression of cyclin D1 due to the t(11;14) chromosomal translocation. While expression of cyclin D1 correlates with MCL development, expression of wild- type (WT) cyclin D1 transgene in murine lymphocytes is unable to drive B- cell lymphoma. As cyclin D1 mutants that are refractory to nuclear export display heighten oncogenicity in vitro compared with WT D1, we generated mice expressing FLAG-D1/T286A, a constitutively nuclear mutant, under the control of the immunoglobulin enhancer, E mu. D1/T286A transgenic mice universally develop a mature B- cell lymphoma. Expression of D1/T286A in B lymphocytes results in S phase entry in resting lymphocytes and increased apoptosis in spleens of young premalignant mice. Lymphoma onset correlates with perturbations in p53/MDM2/p19(Arf) expression and with BcL-2 overexpression suggesting that alterations in one or both of these pathways may contribute to lymphoma development. Our results describe a cyclin D1-driven model of B-cell lymphomagenesis and provide evidence that nuclear-retention of cyclin D1 is oncogenic in vivo.	Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Diehl, JA (corresponding author), Univ Penn, Abramson Family Canc Res Inst, Ctr Canc, 454 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu			NCI NIH HHS [R01 CA093237, R01 CA093237-05, R01 CA089194, CA93237, CA89194] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089194, R01CA093237] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AKIYAMA N, 1994, CANCER RES, V54, P377; ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Argatoff LH, 1997, BLOOD, V89, P2067, DOI 10.1182/blood.V89.6.2067; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BORZILLO GV, 1989, MOL CELL BIOL, V9, P3973, DOI 10.1128/MCB.9.9.3973; Bosch F, 1998, CANCER, V82, P567, DOI 10.1002/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z; Chen WG, 1996, LAB INVEST, V75, P519; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gladden AB, 2003, J BIOL CHEM, V278, P9754, DOI 10.1074/jbc.M212088200; Gronbaek K, 2002, BLOOD, V100, P1430, DOI 10.1182/blood-2002-02-0382; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hernandez L, 1999, LEUKEMIA, V13, P2087, DOI 10.1038/sj.leu.2401599; Hosokawa Y, 1999, INT J CANCER, V81, P616, DOI 10.1002/(SICI)1097-0215(19990517)81:4<616::AID-IJC18>3.3.CO;2-J; Howe D, 2001, HAEMATOLOGICA, V86, P563; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lai R, 2002, LEUKEMIA RES, V26, P849, DOI 10.1016/S0145-2126(02)00013-9; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; Lu FM, 2003, CANCER RES, V63, P7056; Martinez N, 2003, CANCER RES, V63, P8226; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; Nagy B, 2003, BRIT J HAEMATOL, V120, P434, DOI 10.1046/j.1365-2141.2003.04121.x; NOELLE RJ, 1990, IMMUNOL TODAY, V11, P361, DOI 10.1016/0167-5699(90)90142-V; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Rosenwald A, 2003, CANCER CELL, V3, P185, DOI 10.1016/S1535-6108(03)00028-X; SETO M, 1992, ONCOGENE, V7, P1401; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; STRASSER A, 1993, ONCOGENE, V8, P1; Uchimaru K, 1996, JPN J CANCER RES, V87, P459, DOI 10.1111/j.1349-7006.1996.tb00246.x; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	46	102	102	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					998	1007		10.1038/sj.onc.1209147	http://dx.doi.org/10.1038/sj.onc.1209147			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247460	Green Accepted			2022-12-17	WOS:000235361000005
J	Amundson, SA; Do, KT; Vinikoor, L; Koch-Paiz, CA; Bittner, ML; Trent, JM; Meltzer, P; Fornace, AJ				Amundson, SA; Do, KT; Vinikoor, L; Koch-Paiz, CA; Bittner, ML; Trent, JM; Meltzer, P; Fornace, AJ			Stress-specific signatures: expression profiling of p53 wild-type and -null human cells	ONCOGENE			English	Article						cDNA microarray; DNA damage; heavy metals; p53	THYMIDINE KINASE LOCUS; GENE-EXPRESSION; CDNA MICROARRAY; PROTEIN-KINASE; UV-RADIATION; TK6 CELLS; RESPONSES; APOPTOSIS; IDENTIFICATION; KERATINOCYTES	Gene expression responses of human cell lines exposed to a diverse set of stress agents were compared by cDNA microarray hybridization. The B-lymphoblastoid cell line TK6 (p53 wild- type) and its p53-null derivative, NH32, were treated in parallel to facilitate investigation of p53-dependent responses. RNA was extracted 4 h after the beginning of treatment when no notable decrease in cell viability was evident in the cultures. Gene expression signatures were defined that discriminated between four broad general mechanisms of stress agents: Non-DNA-damaging stresses ( heat shock, osmotic shock, and 12-O-tetradecanoylphorbol 13-acetate), agents causing mainly oxidative stress ( arsenite and hydrogen peroxide), ionizing radiations ( neutron and gamma-ray exposures), and other DNA-damaging agents ( ultraviolet radiation, methyl methanesulfonate, adriamycin, camptothecin, and cis-Platinum( II) diammine dichloride ( cisplatin)). Within this data set, non-DNA-damaging stresses could be discriminated from all DNA-damaging stresses, and profiles for individual agents were also defined. While DNA-damaging stresses showed a strong p53-dependent element in their responses, no discernible p53-dependent responses were triggered by the non-DNA-damaging stresses. A set of 16 genes did exhibit a robust p53-dependent pattern of induction in response to all nine DNA-damaging agents, however.	NCI, Gene Response Sect, Canc Res Ctr, Bethesda, MD 20892 USA; NHGRI, Canc Genet Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Fornace, AJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.	afornace@hsph.harvard.edu	Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	NCI NIH HHS [CA-37967] Funding Source: Medline; NIBIB NIH HHS [EB-002033] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB002033] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Amundson SA, 2000, RADIAT RES, V154, P342, DOI 10.1667/0033-7587(2000)154[0342:IOPMBI]2.0.CO;2; Amundson SA, 2003, MOL CANCER RES, V1, P445; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Beyersmann D, 2002, TOXICOL LETT, V127, P63, DOI 10.1016/S0378-4274(01)00484-2; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Burczynski ME, 2000, TOXICOL SCI, V58, P399, DOI 10.1093/toxsci/58.2.399; Burg MB, 1996, FASEB J, V10, P1598, DOI 10.1096/fasebj.10.14.9002551; Chen Y, 1997, J Biomed Opt, V2, P364, DOI 10.1117/12.281504; Chen YD, 2002, BIOINFORMATICS, V18, P1207, DOI 10.1093/bioinformatics/18.9.1207; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Chuang YYE, 1999, CANCER RES, V59, P3073; DELUCA JG, 1983, MUTAT RES, V107, P347, DOI 10.1016/0027-5107(83)90176-8; DeRisi J, 1996, NAT GENET, V14, P457; GOODHEAD DT, 1989, INT J RADIAT BIOL, V56, P623, DOI 10.1080/09553008914551841; Hamadeh HK, 2002, TOXICOL SCI, V67, P219, DOI 10.1093/toxsci/67.2.219; Hamadeh HK, 2002, TOXICOL SCI, V69, P306, DOI 10.1093/toxsci/69.2.306; Hildesheim J, 2002, CANCER RES, V62, P7305; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; KELSEY KT, 1994, ENVIRON RES, V64, P18, DOI 10.1006/enrs.1994.1003; Koch-Paiz CA, 2000, BIOTECHNIQUES, V29, P706, DOI 10.2144/00294bm07; Koch-Paiz CA, 2004, MUTAT RES-FUND MOL M, V549, P65, DOI 10.1016/j.mrfmmm.2004.01.010; Koizumi S, 2003, J OCCUP HEALTH, V45, P331, DOI 10.1539/joh.45.331; KOPEMAIER P, 1992, CHEM-BIOL INTERACT, V82, P295; Kultz D, 1998, J BIOL CHEM, V273, P13645, DOI 10.1074/jbc.273.22.13645; McClellan M, 1999, EXP CELL RES, V246, P471, DOI 10.1006/excr.1998.4328; Park WY, 2002, ONCOGENE, V21, P8521, DOI 10.1038/sj.onc.1205977; Rea MA, 2003, CARCINOGENESIS, V24, P747, DOI 10.1093/carcin/bgg010; SHIMIZU N, 1991, J BIOL CHEM, V266, P12157; SKOPEK TR, 1978, BIOCHEM BIOPH RES CO, V84, P411, DOI 10.1016/0006-291X(78)90185-7; Steen AM, 1997, MUTAGENESIS, V12, P359, DOI 10.1093/mutage/12.5.359; Zhan L, 2004, MUTAT RES-GEN TOX EN, V557, P1, DOI 10.1016/j.mrgentox.2003.09.006; Zhan QM, 1996, ONCOGENE, V13, P2287; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805	35	102	105	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4572	4579		10.1038/sj.onc.1208653	http://dx.doi.org/10.1038/sj.onc.1208653			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15824734				2022-12-17	WOS:000230157100010
J	Oka, M; Meacham, AM; Hamazaki, T; Rodic, N; Chang, LJ; Terada, N				Oka, M; Meacham, AM; Hamazaki, T; Rodic, N; Chang, LJ; Terada, N			De novo DNA methyltransferases Dnmt3a and Dnmt3b primarily mediate the cytotoxic effect of 5-aza-2 '-deoxycytidine	ONCOGENE			English	Article						DNA methyltransferase; azacytidine; embryonic stem cell; differentiation; apoptosis	EMBRYONIC STEM-CELLS; COLON-CANCER; LENTIVIRAL VECTORS; SATELLITE REGIONS; MAMMALIAN-CELLS; MISMATCH REPAIR; MESSENGER-RNA; CPG ISLANDS; METHYLATION; EXPRESSION	The deoxycytidine analog 5-aza-2'-deoxycitidine (5-aza-dC) is a potent chemotherapeutic agent effective against selective types of cancer. The molecular mechanism by which 5-aza-dC induces cancer cell death, however, is not fully understood. It has been accepted that the mechanism of toxicity is due to the covalent binding between the DNA methyltransferase (Dnmt) and 5-aza-dC-substituted DNA. In order to de. ne which member of the Dnmt family plays a dominant role in the cytotoxicity, we examined the effect of 5-aza-dC on cell growth and apoptosis in various Dnmt null mutant embryonic stem (ES) cells. Of interest, Dnmt3a - Dnmt3b double null ES cells were highly resistant to 5-aza-dC when compared to wild type, Dnmt3a null, Dnmt3b null, or Dnmt1 null ES cells. The cellular sensitivity to 5-aza-dC correlated well with the expression status of Dnmt3 in both undifferentiated and differentiated ES cells. When exogenous Dnmt3a or Dnmt3b was expressed in double null ES cells, the sensitivity to 5-aza-dC was partially restored. These results suggest that the cytotoxic effect of 5-aza-dC may be mediated primarily through Dnmt3a and Dnmt3b de novo DNA methyltransferases. Further, the ability to form Dnmt-DNA adducts was similar in Dnmt1 and Dnmt3, and the expression level of Dnmt3 was not higher than that of Dnmt1 in ES cells. Therefore, Dnmt3-DNA adducts may be more effective for inducing apoptosis than Dnmt1-DNA adducts. These results imply a therapeutic potential of 5-aza-dC to cancers expressing Dnmt3.	Univ Florida, Coll Med, Dept Pathol, Gainesville, FL 32610 USA; Univ Florida, Dept Mol Genet & Microbiol, Powell Gene Therapy Ctr, Gainesville, FL 32610 USA; Univ Florida, McKnight Brain Inst, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Terada, N (corresponding author), Univ Florida, Coll Med, Dept Pathol, POBA 100275, Gainesville, FL 32610 USA.	terada@pathology.ufl.edu						Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Baylin SB, 1998, ADV CANCER RES, V72, P141; Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Chen TP, 2002, J BIOL CHEM, V277, P38746, DOI 10.1074/jbc.M205312200; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260; GABBARA S, 1995, BIOCHEM J, V307, P87, DOI 10.1042/bj3070087; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Girault I, 2003, CLIN CANCER RES, V9, P4415; Goffin J, 2002, ANN ONCOL, V13, P1699, DOI 10.1093/annonc/mdf314; GORCZYCA W, 1993, CANCER RES, V53, P3186; Hamaguchi I, 2000, J VIROL, V74, P10778, DOI 10.1128/JVI.74.22.10778-10784.2000; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Iwakuma T, 1999, VIROLOGY, V261, P120, DOI 10.1006/viro.1999.9850; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kanai Y, 2001, INT J CANCER, V91, P205, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1040>3.0.CO;2-2; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; KIZAKI H, 1993, IMMUNOPHARMACOLOGY, V25, P19, DOI 10.1016/0162-3109(93)90027-N; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Liu K, 2003, MOL CELL BIOL, V23, P2709, DOI 10.1128/MCB.23.8.2709-2719.2003; Melki JR, 1998, LEUKEMIA, V12, P311, DOI 10.1038/sj.leu.2400932; MICHALOWSKY LA, 1987, MOL CELL BIOL, V7, P3076, DOI 10.1128/MCB.7.9.3076; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; MURAKAMI T, 1995, CANCER RES, V55, P3093; Nieto M, 2004, ONCOGENE, V23, P735, DOI 10.1038/sj.onc.1207175; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pfeifer A, 2002, P NATL ACAD SCI USA, V99, P2140, DOI 10.1073/pnas.251682798; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Schneider-Stock R, 2005, J PHARMACOL EXP THER, V312, P525, DOI 10.1124/jpet.104.074195; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; Soejima K, 2003, ONCOGENE, V22, P4723, DOI 10.1038/sj.onc.1206510; Suetake I, 2001, CELL STRUCT FUNCT, V26, P79, DOI 10.1247/csf.26.79; TAKAGI H, 1995, EUR J BIOCHEM, V231, P282, DOI 10.1111/j.1432-1033.1995.tb20698.x; Trinh BN, 2002, MOL CELL BIOL, V22, P2906, DOI 10.1128/MCB.22.9.2906-2917.2002; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Weisenberger DJ, 2004, MOL CANCER RES, V2, P62; Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8; Zaiss AK, 2002, J VIROL, V76, P7209, DOI 10.1128/JVI.76.14.7209-7219.2002; Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200	56	102	104	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3091	3099		10.1038/sj.onc.1208540	http://dx.doi.org/10.1038/sj.onc.1208540			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735669				2022-12-17	WOS:000228728100003
J	Hideshima, T; Podar, K; Chauhan, D; Ishitsuka, K; Mitsiades, C; Tai, YT; Hamasaki, M; Raje, N; Hideshima, H; Schreiner, G; Nguyen, AN; Navas, T; Munshi, NC; Richardson, PG; Higgins, LS; Anderson, KC				Hideshima, T; Podar, K; Chauhan, D; Ishitsuka, K; Mitsiades, C; Tai, YT; Hamasaki, M; Raje, N; Hideshima, H; Schreiner, G; Nguyen, AN; Navas, T; Munshi, NC; Richardson, PG; Higgins, LS; Anderson, KC			p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells	ONCOGENE			English	Article						multiple myeloma; p38 MAPK inhibitor; SCIO-469; PS-341; Hsp27	MARROW STROMAL CELLS; PROTEASOME INHIBITOR; DRUG-RESISTANCE; MITOCHONDRIAL PROTEIN; MOLECULAR-MECHANISMS; BIOLOGIC SEQUELAE; SIGNALING PATHWAY; KINASE PATHWAY; APOPTOSIS; GROWTH	Although PS-341 (bortezomib) is a promising agent to improve multiple myeloma ( MM) patient outcome, 65% of patients with relapsed and refractory disease do not respond. We have previously shown that heat shock protein (Hsp)27 is upregulated after PS-341 treatment, that overexpression of Hsp27 confers PS-341 resistance, and that inhibition of Hsp27 overcomes PS-341 resistance. Since Hsp27 is a downstream target of p38 mitogen-activated protein kinase (MAPK)/MAPK-mitogen-activated protein kinase-2 (MAPKAPK2), we hypothesized that inhibition of p38 MAPK activity could augment PS-341 cytotoxicity by downregulating Hsp27. Although p38 MAPK inhibitor SCIO-469 (Scios Inc, CA, USA) alone did not induce significant growth inhibition, it blocked baseline and PS-341-triggered phosphorylation of p38 MAPK as well as upregulation of Hsp27, associated with enhanced cytotoxicity in MM.1S cells. Importantly, SCIO-469 enhanced phosphorylation of c-Jun NH2-terminal kinase (JNK) and augmented cleavage of caspase-8 and poly(ADP)-ribose polymerase. Moreover, SCIO-469 downregulated PS-341-induced increases in G2/M-phase cells, associated with downregulation of p21(Cip1) expression. Importantly, SCIO-469 treatment augmented cytotoxicity of PS-341 even against PS-341-resistant cell lines and patient MM cells. These studies therefore provide the framework for clinical trials of SCIO-469 to enhance sensitivity and overcome resistance to PS-341, thereby improving patient outcome in MM.	Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Scios Inc, Fremont, CA 94555 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Scios	Anderson, KC (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Mayer 557,44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu	Ishitsuka, Kenji/O-9296-2019; Podar, Klaus/ABD-1112-2020; Hamasaki, Makoto/AAO-2229-2020; Munshi, Nikhil/ABE-2338-2021	Ishitsuka, Kenji/0000-0002-7030-497X; Podar, Klaus/0000-0002-7414-3632; 	NATIONAL CANCER INSTITUTE [R01CA050947] Funding Source: NIH RePORTER; NCI NIH HHS [R0-1 CA 50947, IP50 CA10070-01] Funding Source: Medline; PHS HHS [P0-1 78378] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chauhan D, 2004, BLOOD, V103, P3158, DOI 10.1182/blood-2003-08-2873; Chauhan D, 2003, BLOOD, V102, P3379, DOI 10.1182/blood-2003-05-1417; Chauhan D, 2003, CANCER RES, V63, P6174; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Christians U, 2002, CLIN PHARMACOKINET, V41, P813, DOI 10.2165/00003088-200241110-00003; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; Creagh EM, 2000, LEUKEMIA, V14, P1161, DOI 10.1038/sj.leu.2401841; Dalton WS, 1999, SEMIN ONCOL, V26, P23; Guay J, 1997, J CELL SCI, V110, P357; Herrmann JL, 1998, ONCOGENE, V17, P2889, DOI 10.1038/sj.onc.1202221; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Hideshima T, 2003, ONCOGENE, V22, P8797, DOI 10.1038/sj.onc.1206919; Hideshima T, 2003, CANCER RES, V63, P8428; Hideshima T, 2003, ONCOGENE, V22, P8386, DOI 10.1038/sj.onc.1207170; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2003, BLOOD, V101, P703, DOI 10.1182/blood-2002-06-1874; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423; Kisselv AF, 2001, CHEM BIOL, V21, P1; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; LeBlanc R, 2002, CANCER RES, V62, P4996; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood-2002-06-1768; Neumann C, 1996, EUR J IMMUNOL, V26, P379, DOI 10.1002/eji.1830260217; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Ogata A, 1997, J IMMUNOL, V159, P2212; Orlowski RZ, 2003, BLOOD, V102, p449A; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Schwarzenbach H, 2002, MED ONCOL, V19, P87, DOI 10.1385/MO:19:2:87; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sun JZ, 2001, CANCER RES, V61, P1280; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tu YP, 2000, CANCER RES, V60, P6763; UCHIYAMA H, 1993, BLOOD, V82, P3712; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643; Yang F, 2003, CYTOGENET GENOME RES, V102, P235, DOI 10.1159/000075755; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885	48	102	119	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8766	8776		10.1038/sj.onc.1208118	http://dx.doi.org/10.1038/sj.onc.1208118			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480425	Bronze			2022-12-17	WOS:000225165100006
J	Donninger, H; Bonome, T; Radonovich, M; Pise-Masison, CA; Brady, J; Shih, JH; Barrett, JC; Birrer, MJ				Donninger, H; Bonome, T; Radonovich, M; Pise-Masison, CA; Brady, J; Shih, JH; Barrett, JC; Birrer, MJ			Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways	ONCOGENE			English	Article						ovarian cancer; microarray; signaling pathways	FOCAL ADHESION KINASE; TUMOR-SUPPRESSOR GENE; TYPE-1 MATRIX-METALLOPROTEINASE; PROTEIN-TYROSINE KINASE; INTEGRIN-ASSOCIATED PROTEIN; SURFACE EPITHELIAL-CELLS; CARCINOMA-CELLS; CYCLIN D1; BREAST-CARCINOMA; CDNA MICROARRAY	Ovarian cancer is the most lethal type of gynecologic cancer in the Western world. The high case fatality rate is due in part because most ovarian cancer patients present with advanced stage disease which is essentially incurable. In order to obtain a whole genome assessment of aberrant gene expression in advanced ovarian cancer, we used oligonucleotide microarrays comprising over 40000 features to profile 37 advanced stage papillary serous primary carcinomas. We identified 1191 genes that were significantly (P<0.001) differentially regulated between the ovarian cancer specimens and normal ovarian surface epithelium. The microarray data were validated using real time RT-PCR on 14 randomly selected differentially regulated genes. The list of differentially expressed genes includes ones that are involved in cell growth, differentiation, adhesion, apoptosis and migration. In addition, numerous genes whose function remains to be elucidated were also identified. The microarray data were imported into PathwayAssist software to identify signaling pathways involved in ovarian cancer tumorigenesis. Based on our expression results, a signaling pathway associated with tumor cell migration, spread and invasion was identified as being activated in advanced ovarian cancer. The data generated in this study represent a comprehensive list of genes aberrantly expressed in serous papillary ovarian adenocarcinoma and may be useful for the identification of potentially new and novel markers and therapeutic targets for ovarian cancer.	NCI, Dept Cell & Canc Biol, Rockville, MD 20850 USA; NCI, Cellular Oncol Lab, Virus Tumor Biol Sect, Rockville, MD 20850 USA; NCI, Biometr Res Branch, Rockville, MD 20852 USA; NCI, Lab Biosyst & Canc, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Birrer, MJ (corresponding author), NCI, Dept Cell & Canc Biol, Rockville, MD 20850 USA.	birrerm@bprb.nci.nih.gov	Donninger, Howard/I-9874-2019	Donninger, Howard/0000-0002-8589-1660				Adib TR, 2004, BRIT J CANCER, V90, P686, DOI 10.1038/sj.bjc.6601603; Astier A, 1997, LEUKEMIA LYMPHOMA, V28, P65, DOI 10.3109/10428199709058332; Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249; Baciu PC, 2003, EXP CELL RES, V291, P167, DOI 10.1016/S0014-4827(03)00387-2; Bagnato A, 1999, CANCER RES, V59, P720; Bagnato A, 1997, CANCER RES, V57, P1306; Bao JJ, 2002, CANCER RES, V62, P7264; Barbieri F, 1999, CLIN CANCER RES, V5, P1837; Bayani J, 2002, CANCER RES, V62, P3466; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Booden MA, 2004, MOL CELL BIOL, V24, P1990, DOI 10.1128/MCB.24.5.1990-1999.2004; CAMPBELL IG, 1992, CANCER RES, V52, P5416; Capo-Chichi CD, 2003, CANCER RES, V63, P4967; Cary LA, 1996, J CELL SCI, V109, P1787; Darmoul D, 2003, AM J PATHOL, V162, P1503, DOI 10.1016/S0002-9440(10)64283-6; Davidson B, 1999, CLIN EXP METASTAS, V17, P799, DOI 10.1023/A:1006723011835; Davidson B, 2001, AM J CLIN PATHOL, V115, P517; Dhar KK, 1999, BRIT J CANCER, V81, P1174, DOI 10.1038/sj.bjc.6690826; Ellerbroek SM, 1999, CANCER RES, V59, P1635; Etienne W, 2004, BIOTECHNIQUES, V36, P618, DOI 10.2144/04364ST02; Even-Ram SC, 2001, J BIOL CHEM, V276, P10952, DOI 10.1074/jbc.M007027200; Fashena SJ, 2002, J CELL SCI, V115, P99; Fishman DA, 1996, INVAS METAST, V16, P150; Friedlander ML, 1998, SEMIN ONCOL, V25, P305; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; Gibson MA, 1998, J HISTOCHEM CYTOCHEM, V46, P871, DOI 10.1177/002215549804600802; Gibson MA, 1999, J BIOL CHEM, V274, P13060, DOI 10.1074/jbc.274.19.13060; GODWIN AK, 1992, J NATL CANCER I, V84, P592, DOI 10.1093/jnci/84.8.592; Hauptmann S, 2002, HUM PATHOL, V33, P632, DOI 10.1053/hupa.2002.124913; Hocevar BA, 2003, EMBO J, V22, P3084, DOI 10.1093/emboj/cdg286; Hough CD, 2000, CANCER RES, V60, P6281; Hu J, 2003, GYNECOL ONCOL, V89, P369, DOI 10.1016/S0090-8258(03)00056-8; Imai K, 1996, CANCER RES, V56, P2707; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Ismail RS, 2000, CANCER RES, V60, P6744; Israeli O, 2003, GYNECOL ONCOL, V90, P629, DOI 10.1016/S0090-8258(03)00375-5; IWABUCHI H, 1995, CANCER RES, V55, P6172; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Judson PL, 1999, CANCER, V86, P1551, DOI 10.1002/(SICI)1097-0142(19991015)86:6<1551::AID-CNCR23>3.0.CO;2-P; Kreuzer KA, 1999, CLIN CHEM, V45, P297; Kurochkin IV, 2001, BIOCHEM BIOPH RES CO, V280, P340, DOI 10.1006/bbrc.2000.4125; Law SF, 1996, MOL CELL BIOL, V16, P3327; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lozano E, 2003, BIOESSAYS, V25, P452, DOI 10.1002/bies.10262; Luo RZ, 2003, ONCOGENE, V22, P2897, DOI 10.1038/sj.onc.1206380; MAWBY WJ, 1994, BIOCHEM J, V304, P525, DOI 10.1042/bj3040525; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Molino M, 1997, J BIOL CHEM, V272, P11133; Nap M, 1996, TUMOR BIOL, V17, P325; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; O'Brien PJ, 2001, ONCOGENE, V20, P1570, DOI 10.1038/sj.onc.1204194; Oberst M, 2001, AM J PATHOL, V158, P1301, DOI 10.1016/S0002-9440(10)64081-3; Oberst MD, 2002, CLIN CANCER RES, V8, P1101; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Ono K, 2000, CANCER RES, V60, P5007; Peng HQ, 2000, INT J CANCER, V86, P690, DOI 10.1002/(SICI)1097-0215(20000601)86:5<690::AID-IJC14>3.0.CO;2-K; Rhee JS, 2002, TRENDS CELL BIOL, V12, P209, DOI 10.1016/S0962-8924(02)02280-8; Rosano L, 2003, AM J PATHOL, V163, P753, DOI 10.1016/S0002-9440(10)63702-9; Rosano L, 2001, CANCER RES, V61, P8340; Sachdev P, 2002, J BIOL CHEM, V277, P17638, DOI 10.1074/jbc.M111575200; Sambrano GR, 1999, J BIOL CHEM, V274, P20178, DOI 10.1074/jbc.274.29.20178; Sasaki H, 2000, CANCER RES, V60, P5659; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, J BIOCHEM-TOKYO, V119, P209; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; Schaner ME, 2003, MOL BIOL CELL, V14, P4376, DOI 10.1091/mbc.E03-05-0279; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schummer M, 1999, GENE, V238, P375, DOI 10.1016/S0378-1119(99)00342-X; Schwartz DR, 2002, CANCER RES, V62, P4722; Scully RE, 1998, TUMORS OVARY MALDEVE, V23; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com; Span PN, 2003, CANCER, V97, P2710, DOI 10.1002/cncr.11395; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tapper J, 2001, CANCER GENET CYTOGEN, V128, P1, DOI 10.1016/S0165-4608(01)00386-7; TESTA JR, 1994, CANCER RES, V54, P2778; Tiruppathi C, 2000, P NATL ACAD SCI USA, V97, P7440, DOI 10.1073/pnas.97.13.7440; Tonin PN, 2001, ONCOGENE, V20, P6617, DOI 10.1038/sj.onc.1204804; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9; Wang L, 2003, CLIN CANCER RES, V9, P3660; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wiener JR, 2003, GYNECOL ONCOL, V88, P73, DOI 10.1006/gyno.2002.6851; Wong KK, 2001, BIOTECHNIQUES, V30, P670, DOI 10.2144/01303dd05; Yin YJ, 2003, FASEB J, V17, P163, DOI 10.1096/fj.02-0316com; Yu YH, 2003, ANN NY ACAD SCI, V983, P268, DOI 10.1111/j.1749-6632.2003.tb05981.x; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066; Zhao JH, 2003, MOL CELL, V11, P1503, DOI 10.1016/S1097-2765(03)00179-5	92	102	109	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8065	8077		10.1038/sj.onc.1207959	http://dx.doi.org/10.1038/sj.onc.1207959			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361855				2022-12-17	WOS:000224692500004
J	Wu, JH; Lingrel, JB				Wu, JH; Lingrel, JB			KLF2 inhibits Jurkat T leukemia cell growth via upregulation of cyclin-dependent kinase inhibitor p21(WAF1/CIP1)	ONCOGENE			English	Article						Kruppel-like factor; KLF2; Jurkat leukemia cells; cell proliferation; p21(WAF1/CIP1)	KRUPPEL-LIKE FACTOR; ZINC-FINGER PROTEIN; TRANSCRIPTION FACTOR; GENE PROMOTER; SP1 SITES; IN-VIVO; CANCER; LKLF; P53; SUPPRESSION	Kruppel-like factor 2 (KLF2) is a member of the KLF family of zinc-finger transcription factors and is involved in maintaining T-cell quiescence, regulating preadipocyte differentiation, endothelial cell function and lung development. We used a tetracycline-inducible system in Jurkat T leukemia cells to study the biological role of KLF2 in cellular growth and differentiation. Our results show that expression of KLF2 inhibits cell growth in autonomously proliferating Jurkat cells. Further, 3H-thymidine uptake assays indicate that KLF2 inhibits DNA synthesis in these cells. Moreover, both activation and inhibitory domains are required for KLF2 to suppress Jurkat cell proliferation. In addition, KLF2 upregulates p21(WAF1/CIP1) expression. Additionally, we found that KLF2 upregulates p21(WAF1/CIP1) promoter activity in Jurkat, HepG2 and SW480 cells. Our analysis shows that the potential KLF2 responsive elements are located between -124 and -60 of the p21(WAF1/CIP1) promoter. The sole CACCC site, a sequence recognized by KLF2, in this region is not the element responsive to KLF2. Finally, we determined that the Sp1-3-binding site is the functional responsive element of KLF2 in the p21(WAF1/CIP1) promoter, and we conclude that KLF2 directly regulates p21(WAF1/CIP1) expression.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Lingrel, JB (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	jerry.lingrel@uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057281] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 57281] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Banerjee SS, 2003, J BIOL CHEM, V278, P2581, DOI 10.1074/jbc.M210859200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Buckley AF, 2001, NAT IMMUNOL, V2, P698, DOI 10.1038/90633; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Conkright MD, 2001, J BIOL CHEM, V276, P29299, DOI 10.1074/jbc.M103670200; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Denkinger DJ, 2001, GENE, V281, P133, DOI 10.1016/S0378-1119(01)00792-2; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Koritschoner NP, 1997, J BIOL CHEM, V272, P9573; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Kuo CT, 1997, SCIENCE, V278, P788; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Lagger G, 2003, MOL CELL BIOL, V23, P2669, DOI 10.1128/MCB.23.8.2669-2679.2003; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Omotehara F, 2002, BRIT J CANCER, V87, P1042, DOI 10.1038/sj.bjc.6600592; Ratziu V, 1998, P NATL ACAD SCI USA, V95, P9500, DOI 10.1073/pnas.95.16.9500; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; Wani MA, 1998, TRANSGENIC RES, V7, P229, DOI 10.1023/A:1008809809843; Wani MA, 1999, J BIOL CHEM, V274, P21180, DOI 10.1074/jbc.274.30.21180; Wani MA, 1999, GENOMICS, V60, P78, DOI 10.1006/geno.1999.5888; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200	39	102	104	3	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8088	8096		10.1038/sj.onc.1207996	http://dx.doi.org/10.1038/sj.onc.1207996			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361832				2022-12-17	WOS:000224692500006
J	Yamada, S; Ohira, M; Horie, H; Ando, K; Takayasu, H; Suzuki, Y; Sugano, S; Hirata, T; Goto, T; Matsunaga, T; Hiyama, E; Hayashi, Y; Ando, H; Suita, S; Kaneko, M; Sasaki, F; Hashizume, K; Ohnuma, N; Nakagawara, A				Yamada, S; Ohira, M; Horie, H; Ando, K; Takayasu, H; Suzuki, Y; Sugano, S; Hirata, T; Goto, T; Matsunaga, T; Hiyama, E; Hayashi, Y; Ando, H; Suita, S; Kaneko, M; Sasaki, F; Hashizume, K; Ohnuma, N; Nakagawara, A			Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: Identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas	ONCOGENE			English	Article						hepatoblastoma; expression profile; oligocapping cDNA library; PLK1; prognostic factor	POLO-LIKE-KINASE; ALPHA-FETOPROTEIN LEVELS; BETA-CATENIN GENE; HEPATOCELLULAR-CARCINOMA; APC GENE; METASTATIC HEPATOBLASTOMA; CHILDHOOD HEPATOBLASTOMA; CANCER; MUTATIONS; TUMOR	Hepatoblastoma is one of the most common malignant liver tumors in young children. Recent evidences have suggested that the abnormalities in Wnt signaling pathway, as seen in frequent mutation of the beta-catenin gene, may play a role in the genesis of hepatoblastoma. However, the precise mechanism to cause the tumor has been elusive. To identify novel hepatoblastoma-related genes for unveiling the molecular mechanism of the tumorigenesis, a large-scale cloning of cDNAs and differential screening of their expression between hepatoblastomas and the corresponding normal livers were performed. We constructed four full-length-enriched cDNA libraries using an oligo-capping method from the primary tissues which included two hepatoblastomas with high levels of alpha-fetoprotein (AFP), a hepatoblastoma without production of AFP, and a normal liver tissue corresponded to the tumor. Among the 10431 cDNAs randomly picked up and successfully sequenced, 847 (8.1%) were the genes with unknown function. Of interest, the expression profile among the two subsets of hepatoblastoma and a normal liver was extremely different. A semiquantitative RT-PCR analysis showed that 86 out of 1188 genes tested were differentially expressed between hepatoblastomas and the corresponding normal livers, but that only 11 of those were expressed at high levels in the tumors. Notably, PLK1 oncogene was expressed at very high levels in hepatoblastomas as compared to the normal infant's livers. Quantitative real-time RT-PCR analysis for the PLK1 mRNA levels in 74 primary hepatoblastomas and 29 corresponding nontumorous livers indicated that the patients with hepatoblastoma with high expression of PLK1 represented significantly poorer outcome than those with its low expression (5-year survival rate: 55.9 vs 87.0%, respectively, p = 0.042), suggesting that the level of PLK1 expression is a novel marker to predict the prognosis of hepatoblastoma. Thus, the differentially expressed genes we have identified may become a useful tool to develop new diagnostic as well as therapeutic strategies of hepatoblastoma.	Chiba Cancer Ctr Res Inst, Div Biochem, Chiba 2608717, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo 1088639, Japan; Hisamitsu Pharmaceut Co Inc, Tokyo 1006221, Japan	Chiba Cancer Center; University of Tokyo; Hisamitsu Pharmaceutical Co Ltd	Nakagawara, A (corresponding author), Chiba Cancer Ctr Res Inst, Div Biochem, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-ccri.chuo.chiba.jp	Hiyama, Eiso/A-2013-2019	Hiyama, Eiso/0000-0001-9179-5037				ALBRECHT S, 1994, CANCER RES, V54, P5041; BRADY RO, 1989, NEUROL CLIN, V7, P75, DOI 10.1016/S0733-8619(18)30829-6; Buendia MA, 2002, MED PEDIATR ONCOL, V39, P530, DOI 10.1002/mpo.10180; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; Dietzmann K, 2001, J NEURO-ONCOL, V53, P1, DOI 10.1023/A:1011808200978; EXELBY PR, 1975, J PEDIATR SURG, V10, P329; Fukuzawa R, 1999, INT J CANCER, V82, P490, DOI 10.1002/(SICI)1097-0215(19990812)82:4<490::AID-IJC4>3.0.CO;2-I; Giardiello FM, 1996, GUT, V39, P867, DOI 10.1136/gut.39.6.867; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Gray SG, 2000, BRIT J CANCER, V82, P1561, DOI 10.1054/bjoc.1999.1179; HAAS JE, 1989, CANCER-AM CANCER SOC, V64, P1082, DOI 10.1002/1097-0142(19890901)64:5<1082::AID-CNCR2820640520>3.0.CO;2-G; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; HATA Y, 1990, JPN J SURG, V20, P498, DOI 10.1007/BF02471004; HATA Y, 1991, CANCER, V68, P2566, DOI 10.1002/1097-0142(19911215)68:12<2566::AID-CNCR2820681206>3.0.CO;2-Z; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Idilman R, 1998, J VIRAL HEPATITIS, V5, P285, DOI 10.1046/j.1365-2893.1998.00116.x; Kinoshita M, 2002, HEPATOLOGY, V36, P433, DOI 10.1053/jhep.2002.34851; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Knecht R, 1999, CANCER RES, V59, P2794; Koch A, 1999, CANCER RES, V59, P269; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LI FP, 1987, JAMA-J AM MED ASSOC, V257, P2475, DOI 10.1001/jama.257.18.2475; LI XR, 1995, ONCOGENE, V11, P221; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; MANN JR, 1978, ARCH DIS CHILD, V53, P366, DOI 10.1136/adc.53.5.366; Miao JY, 2003, HEPATOL RES, V25, P174, DOI 10.1016/S1386-6346(02)00264-4; MONTAGNA M, 1994, J CANCER RES CLIN, V120, P732, DOI 10.1007/BF01194272; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nagata T, 2003, CANCER GENET CYTOGEN, V145, P152, DOI 10.1016/S0165-4608(03)00065-7; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; ODA H, 1995, INT J CANCER, V60, P786, DOI 10.1002/ijc.2910600610; Oda H, 1996, CANCER RES, V56, P3320; Okabe H, 2001, CANCER RES, V61, P2129; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; ORTEGA JA, 1991, J CLIN ONCOL, V9, P2167, DOI 10.1200/JCO.1991.9.12.2167; Park WS, 2001, J PATHOL, V193, P483; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; RAINIER S, 1995, CANCER RES, V55, P1836; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Ryazanov AG, 1999, CURR BIOL, V9, pR43, DOI 10.1016/S0960-9822(99)80006-2; Sasaki F, 2002, J PEDIATR SURG, V37, P851, DOI 10.1053/jpsu.2002.32886; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; Suzuki Y, 1997, GENE, V200, P149, DOI 10.1016/S0378-1119(97)00411-3; Takai N, 2001, CANCER LETT, V164, P41, DOI 10.1016/S0304-3835(00)00703-5; Takayasu H, 2001, CLIN CANCER RES, V7, P901; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Thomas D, 2003, EUR J CANCER, V39, P2200, DOI 10.1016/S0959-8049(03)00618-X; Tokumitsu Y, 1999, INT J ONCOL, V15, P687; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Uotani H, 1998, J PEDIATR SURG, V33, P639, DOI 10.1016/S0022-3468(98)90333-5; VanTornout J, 1997, J CLIN ONCOL, V15, P1190, DOI 10.1200/JCO.1997.15.3.1190; Velculescu VE, 2000, TRENDS GENET, V16, P423, DOI 10.1016/S0168-9525(00)02114-4; von Horn H, 2001, CANCER LETT, V162, P253, DOI 10.1016/S0304-3835(00)00668-6; VONSCHWEINITZ D, 1995, J PEDIATR SURG, V30, P845, DOI 10.1016/0022-3468(95)90762-9; VONSCHWEINITZ D, 1994, EUR J CANCER, V30, P152; Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503; Weber RG, 2000, AM J PATHOL, V157, P571, DOI 10.1016/S0002-9440(10)64567-1; Wei Y, 2000, ONCOGENE, V19, P498, DOI 10.1038/sj.onc.1203356; WEINBERG AG, 1983, HUM PATHOL, V14, P512, DOI 10.1016/S0046-8177(83)80005-7; Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398; Yun K, 1998, J PATHOL, V185, P91, DOI 10.1002/(SICI)1096-9896(199805)185:1<91::AID-PATH44>3.0.CO;2-K	72	102	136	4	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5901	5911		10.1038/sj.onc.1207782	http://dx.doi.org/10.1038/sj.onc.1207782			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15221005				2022-12-17	WOS:000222941100004
J	Shah, K; Tang, Y; Breakefield, X; Weissleder, R				Shah, K; Tang, Y; Breakefield, X; Weissleder, R			Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo	ONCOGENE			English	Article						TRAIL; bioluminescence; apoptosis	ANTITUMOR-ACTIVITY; GENE-TRANSFER; LIGAND TRAIL; APO-2 LIGAND; CANCER; DEATH; VECTORS; THERAPY; APO2L/TRAIL; RECEPTORS	Tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL) has been shown to induce apoptosis in neoplastic cells. While many previous studies have been performed in cell culture, the delivery and efficiency of TRAIL variants in vivo is less well established. Using dual substrate/reporter bioluminescence imaging (Fluc: firefly luciferase - luciferin and Rluc: Renilla luciferase - coelenterazine), we tested the efficacy of TRAIL using replication deficient herpes simplex virus (HSV) type 1 amplicon vectors in gliomas. The cDNA for complete TRAIL and the extracellular domain of TRAIL (aa 114 - 281) were cloned into HSV amplicons and packaged into helper virus-free vectors. Both forms of TRAIL induced similar degrees of apoptosis in human glioma cells (Gli36) in culture within 24 h of infection with TRAIL amplicon vectors. Growth of tumors stably transfected with Fluc (Gli36fluc(+)) was readily monitored in vivo by bioluminescence imaging following luciferin administration. HSV amplicon vectors bearing the genes for TRAIL and Rluc injected directly into Gli36fluc(+)-expressing subcutaneous gliomas revealed peak Rluc activity 36 h after intratumoral injection as determined by coelenterazine injection followed by imaging. TRAIL-treated gliomas regressed in size over a period of 4 weeks as compared to the mock-injected gliomas. These results show the efficacy of vector delivered TRAIL in treating tumors in vivo and offer a unique way to monitor both gene delivery and efficacy of TRAIL-induced apoptosis in tumors in vivo in real time by dual enzyme substrate (Rluc/Fluc) imaging.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Mol Imaging Res, Boston, MA USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol,Mol Neurogenet Unit, Boston, MA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Shah, K (corresponding author), Massachusetts Gen Hosp, Ctr Mol Imaging Res, Bldg 149,13th St,Room 5421, Charlestown, MA 02129 USA.	kshah@helix.mgh.har-vard.edu		/0000-0003-0828-4143	NCI NIH HHS [CA6924, R24-CA92782, P50 CA86335] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA092782, R01CA086335] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bhaumik S, 2002, P NATL ACAD SCI USA, V99, P377, DOI 10.1073/pnas.012611099; BOVIATSIS EJ, 1994, GENE THER, V1, P323; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Contag CH, 2000, NEOPLASIA, V2, P41, DOI 10.1038/sj.neo.7900079; Contag CH, 2002, ANNU REV BIOMED ENG, V4, P235, DOI 10.1146/annurev.bioeng.4.111901.093336; Contag PR, 1998, NAT MED, V4, P245, DOI 10.1038/nm0298-245; Di X, 1997, J EXP CLIN CANC RES, V16, P389; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; Fraefel C, 2000, ADV VIRUS RES, V55, P425, DOI 10.1016/S0065-3527(00)55011-8; Fulci G, 2003, FRONT BIOSCI-LANDMRK, V8, pE346, DOI 10.2741/976; Gambhir SS, 2002, NAT REV CANCER, V2, P683, DOI 10.1038/nrc882; Gliniak B, 1999, CANCER RES, V59, P6153; Griffith TS, 2001, MOL THER, V4, P257, DOI 10.1006/mthe.2001.0439; Griffith TS, 2000, J IMMUNOL, V165, P2886, DOI 10.4049/jimmunol.165.5.2886; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kagawa S, 2001, CANCER RES, V61, P3330; KASHIMA T, 1995, J NEUROPATH EXP NEUR, V54, P23, DOI 10.1097/00005072-199501000-00003; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Luker GD, 2002, J VIROL, V76, P12149, DOI 10.1128/JVI.76.23.12149-12161.2002; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Pulkkanen KJ, 2001, CANCER GENE THER, V8, P529, DOI 10.1038/sj.cgt.7700342; Rehemtulla A, 2000, NEOPLASIA, V2, P491, DOI 10.1038/sj.neo.7900121; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Saeki Y, 2001, MOL THER, V3, P591, DOI 10.1006/mthe.2001.0294; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; Tjuvajev JG, 2002, J NUCL MED, V43, P1072; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; Voelkel-Johnson C, 2002, CANCER GENE THER, V9, P164, DOI 10.1038/sj.cgt.7700420; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Weissleder R, 2002, NAT REV CANCER, V2, P11, DOI 10.1038/nrc701	40	102	116	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2003	22	44					6865	6872		10.1038/sj.onc.1206748	http://dx.doi.org/10.1038/sj.onc.1206748			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534533				2022-12-17	WOS:000185843400007
J	Eymin, B; Leduc, C; Coll, JL; Brambilla, E; Gazzeri, S				Eymin, B; Leduc, C; Coll, JL; Brambilla, E; Gazzeri, S			P14(ARF) induces G(2) arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice	ONCOGENE			English	Article						apoptosis; G(2) arrest; tumour regression; ARF; p53	DNA-DAMAGE CHECKPOINT; CELL-CYCLE ARREST; INHIBITORY PHOSPHORYLATION; P53-DEPENDENT APOPTOSIS; PROTEIN-KINASE; CDC25 PROTEIN; FEEDBACK LOOP; LUNG-CANCER; SUPPRESSOR; P19(ARF)	Until recently, the ability of ARF (human p14(ARF), murine p19(ARF)) tumour-suppressor protein, encoded by the INK4A/ARF locus, to inhibit cell growth in response to various stimuli was related to its ability to stabilize p53 through the so-called ARF/MDM2/p53 pathway. However, recent data have demonstrated that ARF is not implicated in this unique p53-dependent pathway. By use of transient and stable expression, we show here that human p14(ARF) inhibits the growth of human tumoral cells lacking functional p53 by inducing a transient G(2) arrest and subsequently apoptosis. This p14(ARF)-induced G2 arrest was correlated with inhibition of CDC2 activity, inactivation of CDC25C phosphatase and induction of the CDK inhibitor p21(WAF1). Apoptosis was demonstrated using Hoechst 33352 staining, proteolytic activation of caspase-3 and PARP cleavage. Similar results were obtained in experiments with cells synchronized by hydroxyurea block. Importantly, we were able to reproduce these effects 'in vivo' by showing that p14(ARF) inhibits the growth of p53 nullizygous human tumours in nude mice and induces the regression of p53 -/- established tumours. In these experiments, tumoral regression was associated with inhibition of cell proliferation as well as induction of apoptosis confirming the data obtained in cell lines.	Inst Albert Bonniot, INSERM, Equipe 9924, Grp Rech Canc Poumon,EA 2021, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Gazzeri, S (corresponding author), Inst Albert Bonniot, INSERM, Equipe 9924, Grp Rech Canc Poumon,EA 2021, F-38706 La Tronche, France.	Sylvie.Gazzeri@ujf-grenoble.fr	Brambilla, Elisabeth MP/L-8796-2013; Coll, Jean-Luc/G-2520-2013; eymin, beatrice/U-4670-2019; gazzeri, sylvie/U-4669-2019; Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/M-1961-2013	Coll, Jean-Luc/0000-0002-2453-3552; eymin, beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Athar M, 2000, BIOCHEM BIOPH RES CO, V277, P107, DOI 10.1006/bbrc.2000.3436; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Draetta G.F., 1997, CURR BIOL, V7, P50; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Esteller M, 2000, CANCER RES, V60, P129; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; FAN SJ, 1995, CANCER RES, V55, P1649; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gazzeri S, 1998, CANCER RES, V58, P3926; Goldstone S, 2001, ONCOGENE, V20, P921, DOI 10.1038/sj.onc.1204177; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; Labat-Moleur F, 1998, J HISTOCHEM CYTOCHEM, V46, P327, DOI 10.1177/002215549804600306; LI CY, 1995, ONCOGENE, V11, P1885; LI Y, 1994, ONCOGENE, V9, P2261; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Poon RYC, 1997, CANCER RES, V57, P5168; POWELL SN, 1995, CANCER RES, V55, P1643; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Raj K, 2001, NATURE, V412, P914, DOI 10.1038/35091082; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Walworth NC, 2000, CURR OPIN CELL BIOL, V12, P697, DOI 10.1016/S0955-0674(00)00154-X; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Weber HO, 2002, ONCOGENE, V21, P3207, DOI 10.1038/sj.onc.1205429; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; Winters ZE, 1998, ONCOGENE, V17, P673, DOI 10.1038/sj.onc.1201991; Yarbrough WG, 2002, CANCER RES, V62, P1171; Ye XS, 1996, EMBO J, V15, P3599, DOI 10.1002/j.1460-2075.1996.tb00729.x; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	69	102	111	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1822	1835		10.1038/sj.onc.1206303	http://dx.doi.org/10.1038/sj.onc.1206303			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660818	Green Submitted			2022-12-17	WOS:000181678200009
J	Chan, AOO; Kim, SG; Bedeir, A; Issa, JP; Hamilton, SR; Rashid, A				Chan, AOO; Kim, SG; Bedeir, A; Issa, JP; Hamilton, SR; Rashid, A			CpG island methylation in carcinoid and pancreatic endocrine tumors	ONCOGENE			English	Article						methylation; carcinoid tumors; pancreatic; endocrine tumors	ACID RECEPTOR-BETA; DNA METHYLATION; ABERRANT METHYLATION; NEUROENDOCRINE TUMORS; GENE-EXPRESSION; SUPPRESSOR GENE; UP-REGULATION; CYCLOOXYGENASE-2; INACTIVATION; HYPERMETHYLATION	Carcinoid tumors and pancreatic endocrine tumors (PETs) are uncommon neuroendocrine neoplasms and their genetic alterations are not well characterized. CpG island methylation is a mechanism of gene silencing, and concordant methylation of multiple CpG islands as CpG island methylator phenotype (CIMP) has been described in tumors. The aim of this study was to evaluate CIMP in carcinoid tumors and PETs. We studied 16 carcinoid tumors, 11 PETs, and 22 associated normal mucosa or pancreas. Methylation status of the p14, p16, cyclooxygenase 2 (COX2), O-6-methyl-guanine methyltransferase (MGMT), estrogen receptor (ER), thrombospondin 1 (THBS1), retinoic acid receptor beta 2 (RARbeta), T-type calcium channel (CACNA1G), and multiple endocrine neoplasia type-1 (MEN1) genes, and of MINT1, MINT2, MINT25, MINT27 and MINT31 loci was evaluated by methylation-specific-PCR (MSP) or combined bisultite restriction analysis (COBRA). Carcinoid tumors were frequently methylated at RARbeta, MGMT, p16, COX2, p14, THBS1, and ER ranging from 25 to 63% of tumors. Other CpG islands were infrequently methylated or unmethylated. The adjoining normal mucosa was also methylated for ER, COX2, and RARbeta, but methylation at p14, p16, THBS1, and MGMT was tumor-specific. By contrast, PETs and normal pancreas were frequently methylated only at ER. Methylation was more frequent in carcinoid tumors than PETs at MGMT (25 versus 0%, P = 0.03), THBS1 (44 versus 9%, P = 0.04), p14 (44 versus 9%, P = 0.04) and RARP (25 versus 0%, P = 0.03). Loss of p16 protein expression correlated with methylation of p16 gene in carcinoid tumors (P = 0.006). Our study indicates that methylation profile of carcinoid tumors differs from PETs, reflecting different molecular pathogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Rashid, A (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, 1515 Holcombe Blvd,Box 85, Houston, TX 77030 USA.			Issa, Jean-Pierre/0000-0003-2258-5030				Ahuja N, 1998, CANCER RES, V58, P5489; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Calender A, 1999, RECENT ADV PATHOPHYS, P155; CAPELLA C, 2000, WHO CLASSIFICATION T, P53; Eads CA, 2001, CANCER RES, V61, P3410; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Esteller M, 2000, CANCER RES, V60, P129; Esteller M, 1999, CANCER RES, V59, P793; Fujimori M, 2001, CANCER RES, V61, P6656; GODWIN JD, 1975, CANCER, V36, P560, DOI 10.1002/1097-0142(197508)36:2<560::AID-CNCR2820360235>3.0.CO;2-4; Gortz B, 1999, AM J PATHOL, V154, P429, DOI 10.1016/S0002-9440(10)65289-3; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jensen R.T., 1999, RECENT ADV PATHOPHYS, P192; Konishi N, 2002, AM J PATHOL, V160, P1207, DOI 10.1016/S0002-9440(10)62547-3; Li Q, 1999, ONCOGENE, V18, P3284, DOI 10.1038/sj.onc.1202663; Lim HY, 2000, CLIN CANCER RES, V6, P519; Lubomierski N, 2001, CANCER RES, V61, P5905; Marx SJ, 1999, RECENT PROG HORM RES, V54, P397; Mignon M, 2000, DIGESTION, V62, P51, DOI 10.1159/000051856; Muscarella P, 1998, CANCER RES, V58, P237; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Rashid A, 2001, CANCER RES, V61, P3406; Rindi G, 1999, ITAL J GASTROENTEROL, V31, pS135; Rindi G, 1999, RECENT ADV PATHOPHYS, P177; Ristimaki A, 1997, CANCER RES, V57, P1276; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; ROMAN SD, 1992, CANCER RES, V52, P2236; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Serrano J, 2000, J CLIN ENDOCR METAB, V85, P4146, DOI 10.1210/jc.85.11.4146; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SOLCIA E, 1997, ATLAS TUMOR PATHOL, P145; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; Toyooka S, 2001, MOL CANCER THER, V1, P61; Toyota M, 2001, BLOOD, V97, P2823, DOI 10.1182/blood.V97.9.2823; Toyota M, 2000, CANCER RES, V60, P4044; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P5438; Toyota M, 1999, CANCER RES, V59, P4535; Uefuji K, 2000, CLIN CANCER RES, V6, P135; Ueki T, 2000, CANCER RES, V60, P1835; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; WEBER HC, 1996, ADV PANCREATIC DIS M, P55; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532	47	102	108	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					924	934		10.1038/sj.onc.1206123	http://dx.doi.org/10.1038/sj.onc.1206123			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584572				2022-12-17	WOS:000180864300015
J	Fukuhara, A; Irie, K; Nakanishi, H; Takekuni, K; Kawakatsu, T; Ikeda, W; Yamada, A; Katata, T; Honda, T; Sato, T; Shimizu, K; Ozaki, H; Horiuchi, H; Kita, T; Takai, Y				Fukuhara, A; Irie, K; Nakanishi, H; Takekuni, K; Kawakatsu, T; Ikeda, W; Yamada, A; Katata, T; Honda, T; Sato, T; Shimizu, K; Ozaki, H; Horiuchi, H; Kita, T; Takai, Y			Involvement of nectin in the localization of junctional adhesion molecule at tight junctions	ONCOGENE			English	Article						nectin; JAM; cadherin; adherens junctions; tight junctions	CELL-CELL-ADHESION; KIDNEY EPITHELIAL-CELLS; SIMPLEX VIRUS TYPE-1; POLIOVIRUS RECEPTOR GENE; IMMUNOGLOBULIN SUPERFAMILY; CYTOPLASMIC DOMAIN; ADHERENS JUNCTIONS; ALPHA-CATENIN; DESMOPLAKIN ORGANIZATION; SPATIAL REGULATION	Junctional adhesion molecule (JAM) is a Ca2+-independent immunoglobulin-like cell-cell adhesion molecule which localizes at tight junctions (TJs). Claudin is a key cell-cell adhesion molecule that forms TJ strands at TJs. JAM is associated with claudin through their cytoplasmic tail-binding protein, ZO-1. JAM is furthermore associated with Par-3, a cell polarity protein which forms a ternary complex with Par-6 and atypical protein kinase C. Nectin is another Ca2+-independent immunoglobulin-like cell-cell adhesion molecule which localizes at adherens junctions (AJs). Nectin is associated with E-cadherin through their respective cytoplasmic tail-binding proteins, afadin and catenins, and involved in the formation of AJs cooperatively with E-cadherin. We show here that nectin is furthermore involved in the localization of JAM at TJs. During the formation of the junctional complex consisting of AJs and Us in Madin-Darby canine kidney (MDCK) cells, JAM was recruited to the nectin-based cell-cell adhesion sites. This recruitment of JAM was inhibited by nectin inhibitors, which inhibited the trans-interaction of nectin. Microbeads coated with the extracellular fragment of nectin, that interacted with cellular nectin, also recruited JAM to the bead-MDCK cell contact sites. Furthermore, when cadherin-deficient L fibroblasts stably expressing both exogenous JAM and nectin (nectin-JAM-L cells) were co-cultured with L fibroblasts expressing only nectin (nectin-L cells), JAM was concentrated at the cell-cell adhesion sites between nectin-JAM-L and nectin-L cells without the trans-interaction of JAM. Analyses of the localization and immunoprecipitation of JAM revealed that it was associated with nectin through afadin and ZO-1. These results suggest that nectin has a role in the localization of JAM at Us in the process of the formation of the junctional complex in epithelial cells.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; Kyoto Univ, Fac Med, Dept Geriatr Med, Kyoto 6068501, Japan	Osaka University; Kyoto University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Ikeda, Wataru/V-8531-2019; Fukuhara, Atsunori/A-9601-2018	Ikeda, Wataru/0000-0002-6907-9058; Fukuhara, Atsunori/0000-0002-6289-3778; Nakanishi, Hiroyuki/0000-0002-9765-0266				Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Ando-Akatsuka Y, 1999, J CELL PHYSIOL, V179, P115, DOI 10.1002/(SICI)1097-4652(199905)179:2<115::AID-JCP1>3.0.CO;2-T; AOKI J, 1994, J BIOL CHEM, V269, P8431; Arrate MP, 2001, J BIOL CHEM, V276, P45826, DOI 10.1074/jbc.M105972200; Asakura T, 1999, GENES CELLS, V4, P573, DOI 10.1046/j.1365-2443.1999.00283.x; Aurrand-Lions M, 2001, J BIOL CHEM, V276, P2733, DOI 10.1074/jbc.M005458200; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8; Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campadelli-Fiume G, 2000, REV MED VIROL, V10, P305, DOI 10.1002/1099-1654(200009/10)10:5<305::AID-RMV286>3.0.CO;2-T; Cocchi F, 1998, P NATL ACAD SCI USA, V95, P15700, DOI 10.1073/pnas.95.26.15700; Cocchi F, 2000, J VIROL, V74, P3909, DOI 10.1128/JVI.74.8.3909-3917.2000; Cunningham SA, 2000, J BIOL CHEM, V275, P34750, DOI 10.1074/jbc.M002718200; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu Y, 2000, J CELL SCI, V113, P2363; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; Lopez M, 2000, J VIROL, V74, P1267, DOI 10.1128/JVI.74.3.1267-1274.2000; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; Mizoguchi A, 2002, J CELL BIOL, V156, P555, DOI 10.1083/jcb.200103113; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Nishioka H, 2000, J COMP NEUROL, V424, P297, DOI 10.1002/1096-9861(20000821)424:2<297::AID-CNE8>3.0.CO;2-J; Ostermann G, 2002, NAT IMMUNOL, V3, P151, DOI 10.1038/ni755; Ozaki H, 1999, J IMMUNOL, V163, P553; Ozaki-Kuroda K, 2002, CURR BIOL, V12, P1145, DOI 10.1016/S0960-9822(02)00922-3; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; PASDAR M, 1988, J CELL BIOL, V106, P677, DOI 10.1083/jcb.106.3.677; PASDAR M, 1988, J CELL BIOL, V106, P687, DOI 10.1083/jcb.106.3.687; PRASAD R, 1993, CANCER RES, V53, P5624; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Sakisaka T, 2001, J VIROL, V75, P4734, DOI 10.1128/JVI.75.10.4734-4743.2001; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; SILICIANO JD, 1988, J CELL BIOL, V107, P2389, DOI 10.1083/jcb.107.6.2389; Spear PG, 2000, VIROLOGY, V275, P1, DOI 10.1006/viro.2000.0529; Suzuki K, 2000, NAT GENET, V25, P427, DOI 10.1038/78119; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Tsukita S, 1999, CURR OPIN CELL BIOL, V11, P628, DOI 10.1016/S0955-0674(99)00016-2; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Wittchen ES, 2000, J CELL BIOL, V151, P825, DOI 10.1083/jcb.151.4.825; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Yokoyama S, 2001, MOL BIOL CELL, V12, P1595, DOI 10.1091/mbc.12.6.1595; YONEMURA S, 1995, J CELL SCI, V108, P127	78	102	105	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7642	7655		10.1038/sj.onc.1205875	http://dx.doi.org/10.1038/sj.onc.1205875			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400007				2022-12-17	WOS:000178756200004
J	Koo, TH; Lee, JJ; Kim, EM; Kim, KW; Do Kim, H; Lee, JH				Koo, TH; Lee, JJ; Kim, EM; Kim, KW; Do Kim, H; Lee, JH			Syntenin is overexpressed and promotes cell migration in metastatic human breast and gastric cancer cell lines	ONCOGENE			English	Article						syntenin; migration; invasion; breast cancer; gastric cancer	SUBTRACTIVE HYBRIDIZATION; EPHRIN LIGANDS; PDZ DOMAINS; NUDE-MICE; EXPRESSION; PROTEIN; CARCINOMA; RECEPTOR; BINDING; ESTABLISHMENT	Two human breast cancer cell lines of differing invasive and metastatic potential, MDA-MB-435 and MCF7, were examined using subtractive suppression hybridization in a search for any genes associated with metastasis. Of the 17 cDNAs identified as being differentially expressed genes, it was determined that syntenin was overexpressed in metastatic MDA-MB-435 cells. Expression analysis showed that the expression level of syntenin was well correlated with invasive and metastatic potential in various human breast and gastric cancer cell lines. Moreover, gastric tumor tissues exhibited a much higher syntenin mRNA expression than their normal counterparts. Syntenin-transfected MCF7 cells migrated more actively, and showed an increased invasion rate relative to vector-transfectants or parental MCF7 in vitro, without evidencing any effect on the adhesion to fibronectin, type I collagen and laminin. Similarly, the forced expression of syntenin to human gastric cancer cell line Az521 increased its migratory and invasive potential in vitro. Syntenin-expressing MCF7 cells were associated with the appearance of numerous cell surface extensions and with pseudopodia formation on collagen 1, suggesting that syntenin may be involved in the signaling cascade to actin-reorganization. Mutation study suggested that PDZ2 domain of syntenin could be an essential role in its stimulatory effect on the cell migration. This is the first demonstration that syntenin, a PDZ motif-containing protein, can be overexpressed during the metastatic progression of human breast and gastric cancer cells and that it can function as a meta stasis-inducing gene.	Korea Res Inst Biosci & Biotechnol, Anticanc Res Lab, Taejon 305600, South Korea; Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea; Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Seoul National University (SNU); Pusan National University	Lee, JH (corresponding author), Korea Res Inst Biosci & Biotechnol, Anticanc Res Lab, POB 115,Yuseong, Taejon 305600, South Korea.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Byers RJ, 2000, INT J EXP PATHOL, V81, P391, DOI 10.1046/j.1365-2613.2000.00174.x; Cos S, 1998, CANCER RES, V58, P4383; Cowan CA, 2000, NEURON, V26, P417, DOI 10.1016/S0896-6273(00)81174-5; Davies EL, 1999, EUR J CANCER, V35, P902, DOI 10.1016/S0959-8049(99)00031-3; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Fialka I, 1999, J BIOL CHEM, V274, P26233, DOI 10.1074/jbc.274.37.26233; Grootjans JJ, 2000, J BIOL CHEM, V275, P19933, DOI 10.1074/jbc.M002459200; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Inki P, 1996, ANN MED, V28, P63, DOI 10.3109/07853899608999076; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; Klein R, 2001, CURR OPIN CELL BIOL, V13, P196, DOI 10.1016/S0955-0674(00)00197-6; Koroll M, 2001, J BIOL CHEM, V276, P10646, DOI 10.1074/jbc.M010647200; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Park JG, 1997, INT J CANCER, V70, P443, DOI 10.1002/(SICI)1097-0215(19970207)70:4<443::AID-IJC12>3.0.CO;2-G; PARK JG, 1990, CANCER RES, V50, P2773; PRICE JE, 1990, CANCER RES, V50, P717; Schaller G, 1996, CLIN CANCER RES, V2, P1879; SHEIKH MS, 1994, INVAS METAST, V14, P329; SIMU G, 1978, CELL MOL BIOL, V23, P145; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; STOVER DM, 1994, CANCER RES, V54, P3092; Takai N, 2001, ONCOL REP, V8, P567; Talts JF, 1999, J CELL SCI, V112, P1855; Tang XX, 1999, CLIN CANCER RES, V5, P455; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Tuck AB, 1999, ONCOGENE, V18, P4237, DOI 10.1038/sj.onc.1202799; WHELAN SL, 1990, PATTERNS CANC 5 CONT; Wiksten JP, 2001, INT J CANCER, V95, P1, DOI 10.1002/1097-0215(20010120)95:1<1::AID-IJC1000>3.0.CO;2-5; Yasoshima T, 1996, JPN J CANCER RES, V87, P153, DOI 10.1111/j.1349-7006.1996.tb03153.x; Yokota J, 2000, CARCINOGENESIS, V21, P497, DOI 10.1093/carcin/21.3.497; Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D; Zimmermann P, 2001, MOL BIOL CELL, V12, P339, DOI 10.1091/mbc.12.2.339	38	102	107	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4080	4088		10.1038/sj.onc.1205514	http://dx.doi.org/10.1038/sj.onc.1205514			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037664				2022-12-17	WOS:000176186000002
J	Tomicic, MT; Thust, R; Kaina, B				Tomicic, MT; Thust, R; Kaina, B			Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and caspase-9 activation	ONCOGENE			English	Article						apoptosis; Bcl-2 cleavage; caspase-9; ganciclovir; DNA breakage; suicide gene therapy	CYTOCHROME-C; GENE-THERAPY; CANCER-CELLS; VIRUS; DEATH; P53; PROTEASE; SIGNALS; RELEASE; DAMAGE	Although ganciclovir (GCV) is most often used in suicide anticancer gene therapy, the mechanism of GCV-induced cell killing and apoptosis is not fully understood. We analysed the mechanism of apoptosis triggered by GCV using a model system of CHO cells stably transfected with HSV-1 thymidine kinase (HSVtk). GCV-induced apoptosis is due to incorporation of the drug into DNA resulting in replication-dependent formation of DNA double-strand breaks and, at later stages, S and G2/M arrest. GCV-provoked DNA instability was likely to be responsible for the observed initial decline in Bcl-2 level and caspase-9/-3 activation. Further decline in the Bcl-2 level was due to cleavage of the protein by caspase-9 as demonstrated by use of caspase inhibitors and transfection with trans-dominant negative caspase expression vectors. Bcl-2 cleavage resulted in the appearance of a pro-apoptotic 23 kDa Bcl-2 fragment and in excessive cytochrome c release, dephosphorylation of BAD, cleavage of PARP and finally DNA degradation. Since Fas/CD95 and caspase-8 were only slightly activated we conclude GCV-induced apoptosis to occur in this cell system mainly by activating the mitochondrial damage pathway. This process is independent of p53 for which the cells are mutated. Caspase-9 mediated cleavage of Bel-2 accelerates the apoptotic process and may explain the high potential of GCV to induce apoptosis. Data are also discussed as to implications for HSVtk gene therapy utilizing GCV.	Johannes Gutenberg Univ Mainz, Fac Med, Inst Toxicol, Div Appl Toxicol, D-55131 Mainz, Germany; Univ Jena, Fac Med, Inst Antiviral Chemotherapy, D-07745 Jena, Germany	Johannes Gutenberg University of Mainz; Friedrich Schiller University of Jena	Kaina, B (corresponding author), Johannes Gutenberg Univ Mainz, Fac Med, Inst Toxicol, Div Appl Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.	kaina@mail.uni-mainz.de	Tomicic, Maja/S-1377-2019	Tomicic, Maja/0000-0001-9289-4168				Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; Beltinger C, 2000, CANCER RES, V60, P3212; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Craperi D, 1999, HUM GENE THER, V10, P679, DOI 10.1089/10430349950018751; Crumpacker CS, 1996, NEW ENGL J MED, V335, P721, DOI 10.1056/NEJM199609053351007; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Dunkern TR, 2001, ONCOGENE, V20, P6026, DOI 10.1038/sj.onc.1204754; Feinmesser M, 1999, HUM PATHOL, V30, P1367, DOI 10.1016/S0046-8177(99)90070-9; Ferreira CG, 2000, CLIN CANCER RES, V6, P203; Fujita N, 1998, BIOCHEM BIOPH RES CO, V246, P484, DOI 10.1006/bbrc.1998.8587; Gallo O, 1999, INT J CANCER, V84, P573, DOI 10.1002/(SICI)1097-0215(19991222)84:6<573::AID-IJC6>3.0.CO;2-R; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Halloran PJ, 1998, CANCER RES, V58, P3855; Hamel W, 1996, CANCER RES, V56, P2697; Hu T, 1999, MUTAT RES-FUND MOL M, V426, P51, DOI 10.1016/S0027-5107(99)00077-9; Ioannou YA, 1996, NUCLEIC ACIDS RES, V24, P992; Izquierdo M, 1996, GENE THER, V3, P491; Kaina B, 1997, MUTAT RES-FUND MOL M, V381, P227, DOI 10.1016/S0027-5107(97)00187-5; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Klatzmann D, 1996, HUM GENE THER, V7, P109, DOI 10.1089/hum.1996.7.1-109; Klaude M, 1996, MUTAT RES-DNA REPAIR, V363, P89, DOI 10.1016/0921-8777(95)00063-1; Lee HY, 1997, GENE, V184, P177, DOI 10.1016/S0378-1119(96)00592-6; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lips J, 2001, CARCINOGENESIS, V22, P579, DOI 10.1093/carcin/22.4.579; Mesnil M, 1996, P NATL ACAD SCI USA, V93, P1831, DOI 10.1073/pnas.93.5.1831; MOOLTEN FL, 1986, CANCER RES, V46, P5276; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OBE G, 1985, MUTAT RES, V150, P359; Ochs K, 2000, CANCER RES, V60, P5815; OLDFIELD EH, 1993, HUM GENE THER, V4, P39, DOI 10.1089/hum.1993.4.1-39; OLIVE PL, 1991, CANCER RES, V51, P4671; ORREN DK, 1995, MOL CELL BIOL, V15, P3722; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P229, DOI 10.1080/09553009414550261; Rubsam LZ, 1998, CANCER RES, V58, P3873; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1999, CANCER RES, V59, P999; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Thust R, 2000, CANCER GENE THER, V7, P107, DOI 10.1038/sj.cgt.7700106; Thust R, 2000, MUTAGENESIS, V15, P177, DOI 10.1093/mutage/15.2.177; Tomicic M, 1997, MUTAT RES-DNA REPAIR, V383, P155, DOI 10.1016/S0921-8777(96)00055-9; Tomicic MT, 2001, BIOCHEM BIOPH RES CO, V281, P404, DOI 10.1006/bbrc.2001.4367; Tomicic MT, 2000, BIOCHEM BIOPH RES CO, V275, P899, DOI 10.1006/bbrc.2000.3386; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wang XN, 1997, EXP CELL RES, V235, P210, DOI 10.1006/excr.1997.3667; Wei SJ, 1999, GENE THER, V6, P420, DOI 10.1038/sj.gt.3300817; Wei SJ, 1998, EXP CELL RES, V241, P66, DOI 10.1006/excr.1998.4005; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053	53	102	109	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2141	2153		10.1038/sj.onc.1205280	http://dx.doi.org/10.1038/sj.onc.1205280			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948397				2022-12-17	WOS:000174555300003
J	Horiguchi, N; Takayama, H; Toyoda, M; Otsuka, T; Fukusato, T; Merlino, G; Takagi, H; Mori, M				Horiguchi, N; Takayama, H; Toyoda, M; Otsuka, T; Fukusato, T; Merlino, G; Takagi, H; Mori, M			Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine	ONCOGENE			English	Article						HGF transgenic; hepatocellular carcinoma; c-Met; diethylnitrosamine; VEGF	FACTOR SCATTER FACTOR; FULMINANT HEPATIC-FAILURE; FACTOR-ALPHA; HEPATOCELLULAR CARCINOMAS; ABNORMAL-DEVELOPMENT; LIVER-REGENERATION; MOLECULAR-CLONING; SOMATIC MUTATIONS; EPITHELIAL-CELLS; GENE-EXPRESSION	Hepatocyte growth factor (HGF) is a mitogen for hepatocytes, but it is not clear whether HGF stimulates or inhibits hepatocarcinogenesis. We previously reported that HGF transgenic mice under the metallothionein gene promoter developed benign and malignant liver tumors spontaneously after 17 months of age. To elucidate the role of HGF in hepatocarcinogenesis, diethylnitrosamine (DEN) was administered to HGF transgenic mice. HGF overexpression accelerated DEN-induced hepatocarcinogenesis, often accompanied by abnormal blood vessel formation. In this study, 59% of transgenic mates (versus 20% of wild-type males) and 39% of transgenic females (versus 2% of wild-type females) developed either benign or malignant liver tumors by 48 weeks (P<0.005, P<0.001, respectively). Moreover, 33% of males and 23% of female transgenic mice developed hepatocellular carcinoma (HCC), while none of the wild-type mice developed HCC (P<0.001, P<0.005, respectively). Enhanced kinase activity of the HGF receptor, Met, was detected in most of these tumors. Expression of vascular endothelial growth factor (VEGF) was up-regulated in parallel with HGF transgene expression. Taken together, our results suggest that HGF promotes hepatocarcinogenesis through the autocrine activation of the HGF-Met signaling pathway in association with stimulation of angiogenesis by HGF itself and/or indirectly through VEGF.	Gunma Univ, Sch Med, Dept Internal Med 1, Gunma 3718511, Japan; Gunma Univ, Sch Med, Div Diagnost Pathol, Gunma 3718511, Japan; NCI, Mol Biol Lab, Bethesda, MD 20892 USA	Gunma University; Gunma University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Takagi, H (corresponding author), Gunma Univ, Sch Med, Dept Internal Med 1, Showa Machi 3-39-15, Gunma 3718511, Japan.							Bell A, 1999, ONCOGENE, V18, P887, DOI 10.1038/sj.onc.1202379; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; CRAIG JR, 1989, ATLAS TUMOR PATHOLOG; DErrico A, 1996, HEPATOLOGY, V24, P60, DOI 10.1002/hep.510240112; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; FARBER E, 1987, LAB INVEST, V56, P4; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FUJIWARA K, 1993, HEPATOLOGY, V18, P1443, DOI 10.1016/0270-9139(93)90237-H; Gille J, 1998, J INVEST DERMATOL, V111, P1160, DOI 10.1046/j.1523-1747.1998.00418.x; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HSIA CC, 1992, CANCER, V70, P1049, DOI 10.1002/1097-0142(19920901)70:5&lt;1049::AID-CNCR2820700507&gt;3.0.CO;2-C; ISHIKI Y, 1992, HEPATOLOGY, V16, P1227, DOI 10.1016/0270-9139(92)90019-6; Jeffers M, 1996, ONCOGENE, V13, P853; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Kosai K, 1998, BIOCHEM BIOPH RES CO, V244, P683, DOI 10.1006/bbrc.1998.8293; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; LIU ML, 1995, CARCINOGENESIS, V16, P841, DOI 10.1093/carcin/16.4.841; LIU YH, 1993, BIOCHIM BIOPHYS ACTA, V1216, P299, DOI 10.1016/0167-4781(93)90159-B; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; Mise M, 1996, HEPATOLOGY, V23, P455; MIYAZAKI M, 1992, CELL BIOL INT REP, V16, P145, DOI 10.1016/S0309-1651(06)80108-6; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Morishita R, 2000, ANN NY ACAD SCI, V902, P369; Moriyama T, 1998, BIOCHEM BIOPH RES CO, V249, P73, DOI 10.1006/bbrc.1998.9078; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Ogasawara H, 1998, GASTROENTEROLOGY, V114, P775, DOI 10.1016/S0016-5085(98)70591-8; Otsuka T, 1998, CANCER RES, V58, P5157; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Park WS, 1999, CANCER RES, V59, P307; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; PRESUMANN R, 1988, BIOCH CHEM CARCINOGE, P25; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Rosen EM, 1997, CIBA F SYMP, V212, P215; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513; SantoniRugiu E, 1996, P NATL ACAD SCI USA, V93, P9577, DOI 10.1073/pnas.93.18.9577; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SHIOTA G, 1994, HEPATOLOGY, V19, P962, DOI 10.1016/0270-9139(94)90297-6; SHIOTA G, 1992, P NATL ACAD SCI USA, V89, P373, DOI 10.1073/pnas.89.1.373; SHIOTA G, 1995, RES COMMUN MOL PATH, V90, P17; Suzuki K, 1996, CANCER RES, V56, P3004; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; TAKAGI H, 1992, CANCER RES, V52, P5171; TAKAGI H, 1993, CANCER RES, V53, P4329; Takayama H, 1997, LAB INVEST, V77, P131; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Takayama H, 2001, LAB INVEST, V81, P297, DOI 10.1038/labinvest.3780238; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Tuck AB, 1996, AM J PATHOL, V148, P225; Ueki T, 1999, NAT MED, V5, P226, DOI 10.1038/5593; Van Belle E, 1998, CIRCULATION, V97, P381; WU JC, 1994, CANCER RES, V54, P5964; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; YAONO M, 1995, JPN J CANCER RES, V86, P718, DOI 10.1111/j.1349-7006.1995.tb02459.x; YEH YC, 1987, CANCER RES, V47, P896; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	65	102	120	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2002	21	12					1791	1799		10.1038/sj.onc.1205248	http://dx.doi.org/10.1038/sj.onc.1205248			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896611				2022-12-17	WOS:000174284500001
J	Joseph, B; Marchetti, P; Formstecher, P; Kroemer, G; Lewensohn, R; Zhivotovsky, B				Joseph, B; Marchetti, P; Formstecher, P; Kroemer, G; Lewensohn, R; Zhivotovsky, B			Mitochondrial dysfunction is an essential step for killing of non-small cell lung carcinomas resistant to conventional treatment	ONCOGENE			English	Article						lung cancer; apoptosis; staurosporine; caspases; AIF	PROTEIN-KINASE-C; CYTOCHROME-C; APOPTOSIS; STAUROSPORINE; CASPASES; INHIBITION; TRANSLOCATION; RELEASE; LINES	Apoptosis, a tightly controlled multi-step mechanism of cell death, is important for anti-cancer therapy-based elimination of tumor cells. However, this process is not always efficient. Small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) cells display different susceptibility to undergo apoptosis induced by anticancer treatment. In contrast to SCLC, NSCLC cells are cross-resistant to a broad spectrum of apoptotic stimuli, including receptor stimulation, cytotoxic drugs and gamma -radiation. Since resistance of tumor cells to treatment often accounts for the failure of traditional forms of cancer therapy, in the present study attempts to find a potent broad-range apoptosis inductor, which can kill therapy-resistant NSCLC cells were undertaken and the mechanism of apoptosis induction by this drug was investigated in detail. We found that staurosporine (STS) had cell killing effect on both types of lung carcinomas. Release of cytochrome c, activation of apical and effector caspases followed by cleavage of their nuclear substrates and morphological changes specific for apoptosis were observed in STS-treated cells. In contrast to treatment with radiation or chemotherapy drugs, STS induces mitochondrial dysfunction followed by translocation of AIF into the nuclei. These events preceded the activation of nuclear apoptosis. Thus, in lung carcinomas two cell death pathways, caspase-dependent and caspase-independent, coexist. In NSCLC cells, where the caspase-dependent pathway is less efficient, the triggering of an AIF-mediated caspase-independent mechanism circumvents the resistance of these cells to treatment.	Karolinska Inst, Inst Environm Med, Dept Toxicol, S-17177 Stockholm, Sweden; Fac Med Lille, INSERM, U459, F-59045 Lille, France; Inst Gustave Roussy, CNRS, ULR1599, F-94805 Villejuif, France; Karolinska Inst, Unit Med Radiobiol, Canc Ctr Karolinska, S-17176 Stockholm, Sweden	Karolinska Institutet; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Karolinska Institutet	Zhivotovsky, B (corresponding author), Karolinska Inst, Inst Environm Med, Dept Toxicol, Box 210, S-17177 Stockholm, Sweden.	Boris.Zhivotovsky@imm.ki.se	Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013; Zhivotovsky, Boris/A-4346-2014	KROEMER, Guido/0000-0002-9334-4405; Zhivotovsky, Boris/0000-0002-2238-3482; Joseph, Bertrand/0000-0001-5655-9979; MARCHETTI, Philippe/0000-0002-4663-6800				Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; BERGH J, 1985, ACTA PATH MICRO IM A, V93, P133; BERGH J, 1982, ACTA PATH MICRO IM A, V90, P149; Caponigro F, 1997, ANTI-CANCER DRUG, V8, P26, DOI 10.1097/00001813-199701000-00003; Comis RL, 1998, ONCOLOGY-NY, V12, P44; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Deas O, 1998, J IMMUNOL, V161, P3375; Ekert PG, 1999, EMBO J, V18, P330, DOI 10.1093/emboj/18.2.330; GALLI G, 1993, EXP CELL RES, V204, P54, DOI 10.1006/excr.1993.1008; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Gescher A, 2000, CRIT REV ONCOL HEMAT, V34, P127, DOI 10.1016/S1040-8428(00)00058-5; Han Z, 2000, CELL DEATH DIFFER, V7, P521, DOI 10.1038/sj.cdd.4400681; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jarvis WD, 1999, INVEST NEW DRUG, V17, P227, DOI 10.1023/A:1006328303451; Johnson VL, 2000, J CELL SCI, V113, P2941; Joseph B, 2000, ANN NY ACAD SCI, V926, P204; Joseph B, 2001, ONCOGENE, V20, P2877, DOI 10.1038/sj.onc.1204402; Joseph B, 1999, BIOCHEM BIOPH RES CO, V262, P381, DOI 10.1006/bbrc.1999.1191; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OWENS AH, 1985, MED ONCOL, P715; SCHOTTENFELD D, 1996, LUNG CANC PRINCIPLES, P305; Sirzen F, 1998, LUNG CANCER-J IASLC, V22, P1, DOI 10.1016/S0169-5002(98)00066-X; Stennicke HR, 2000, BBA-PROTEIN STRUCT M, V1477, P299, DOI 10.1016/S0167-4838(99)00281-2; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tafani M, 2001, CANCER RES, V61, P2459; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TRAVIS WD, 1996, LUNG CANC PRINCIPLES, P361; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhivotovsky B, 1999, EXP CELL RES, V248, P10, DOI 10.1006/excr.1999.4452; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	37	102	109	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2002	21	1					65	77		10.1038/sj/onc/1205018	http://dx.doi.org/10.1038/sj/onc/1205018			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791177				2022-12-17	WOS:000172887800007
J	Varga-Weisz, P				Varga-Weisz, P			ATP-dependent chromatin remodeling factors: Nucleosome shufflers with many missions	ONCOGENE			English	Review						DNA superhelical torsion; chromatin domain; Bromodomain; histone code; DNA repair	YEAST SWI/SNF COMPLEX; SWI-SNF COMPLEX; HISTONE ACETYLATION; IN-VITRO; TRANSCRIPTIONAL REPRESSION; SACCHAROMYCES-CEREVISIAE; ACTIVATOR BINDING; OCTAMER TRANSFER; GENE-EXPRESSION; ERYTHROID-CELLS	This review addresses recent developments in the field of ATP-dependent chromatin remodeling factors. These factors use the energy of ATP hydrolysis to introduce superhelical torsion into DNA, which suggests a common mechanistic basis of action. Chromatin remodeling factors function both in transcriptional activation and repression, but they may hale roles outside of transcriptional regulation such as DNA repair. A study of the nucleosome dependent ATPase ISWI in yeast illustrates the involvement of ATP-dependent chromatin remodeling in transcriptional repression by setting up inaccessible chromatin structures at promoters. However, factors such as ISWI are also involved in the restructuring of large chromatin domains and even whole chromosomes. Transcriptional regulation by ATP-dependent chromatin remodeling factors occurs in concert with histone modifying enzymes such as histone acetyltransferases and histone deacetylases: In yeast, SWI/SNF targeting is a requirement for histone acetyltransferases activity at promoters that are active at late stages of mitosis, when the chromatin is still condensed, This demonstrates that ATP-dependent remodeling factors facilitate covalent histone modifications. However, they are also regulated by histone modifications and in some circumstances they function in parallel with histone modifications towards the same goal.	Marie Curie Res Inst, Surrey RH8 0TL, England		Varga-Weisz, P (corresponding author), Marie Curie Res Inst, Surrey RH8 0TL, England.			Varga-Weisz, Patrick/0000-0001-7409-8686				Amedeo P, 2000, NATURE, V405, P203, DOI 10.1038/35012108; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bazett-Jones DP, 1999, MOL CELL BIOL, V19, P1470; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bochar DA, 2000, P NATL ACAD SCI USA, V97, P1038, DOI 10.1073/pnas.97.3.1038; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Brown SA, 1997, GENE DEV, V11, P3116, DOI 10.1101/gad.11.23.3116; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; Clapier CR, 2001, MOL CELL BIOL, V21, P875, DOI 10.1128/MCB.21.3.875-883.2001; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Dimova D, 1999, MOL CELL, V4, P75, DOI 10.1016/S1097-2765(00)80189-6; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Gavin IM, 1997, EMBO J, V16, P6263, DOI 10.1093/emboj/16.20.6263; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; Goldmark JP, 2000, CELL, V103, P423, DOI 10.1016/S0092-8674(00)00134-3; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Gregory PD, 1999, EMBO J, V18, P6407, DOI 10.1093/emboj/18.22.6407; Guschin D, 2000, J BIOL CHEM, V275, P35248, DOI 10.1074/jbc.M006041200; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; Hennig W, 1999, CHROMOSOMA, V108, P1, DOI 10.1007/s004120050346; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Howe L, 1999, CRIT REV EUKAR GENE, V9, P231, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.80; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; Imhof A, 1998, CURR BIOL, V8, pR422, DOI 10.1016/S0960-9822(98)70268-4; Ito T, 2000, GENE DEV, V14, P1899; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Janscak P, 2000, J MOL BIOL, V295, P1089, DOI 10.1006/jmbi.1999.3414; Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kal AJ, 2000, GENE DEV, V14, P1058; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kikyo N, 2000, SCIENCE, V289, P2360, DOI 10.1126/science.289.5488.2360; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; Lee CH, 1999, P NATL ACAD SCI USA, V96, P12311, DOI 10.1073/pnas.96.22.12311; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LeRoy G, 2000, J BIOL CHEM, V275, P14787, DOI 10.1074/jbc.C000093200; Logie C, 1999, BIOCHEMISTRY-US, V38, P2514, DOI 10.1021/bi982109d; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Natarajan K, 1999, MOL CELL, V4, P657, DOI 10.1016/S1097-2765(00)80217-8; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; O'Neill DW, 2000, MOL CELL BIOL, V20, P7572, DOI 10.1128/MCB.20.20.7572-7582.2000; Ornaghi P, 1999, J MOL BIOL, V287, P1, DOI 10.1006/jmbi.1999.2577; Perez-Martin J, 1998, MOL CELL BIOL, V18, P4157, DOI 10.1128/MCB.18.7.4157; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Phelan ML, 2000, MOL CELL BIOL, V20, P6380, DOI 10.1128/MCB.20.17.6380-6389.2000; Picketts DJ, 1996, HUM MOL GENET, V5, P1899, DOI 10.1093/hmg/5.12.1899; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Tran HG, 2000, EMBO J, V19, P2323, DOI 10.1093/emboj/19.10.2323; TRAVERS AA, 1992, CELL, V69, P573, DOI 10.1016/0092-8674(92)90218-2; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; Varga-Weisz PD, 1998, CURR OPIN CELL BIOL, V10, P346, DOI 10.1016/S0955-0674(98)80010-0; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wallrath L, 1998, CURR OPIN GENET DEV, V8, P147, DOI 10.1016/S0959-437X(98)80135-4; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wu DY, 2000, J VIROL, V74, P8893, DOI 10.1128/JVI.74.19.8893-8903.2000; Yudkovsky N, 1999, GENE DEV, V13, P2369, DOI 10.1101/gad.13.18.2369; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	94	102	105	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3076	3085		10.1038/sj.onc.1204332	http://dx.doi.org/10.1038/sj.onc.1204332			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420723				2022-12-17	WOS:000169308500011
J	Kockel, L; Homsy, JG; Bohmann, D				Kockel, L; Homsy, JG; Bohmann, D			Drosophila AP-1: lessons from an invertebrate	ONCOGENE			English	Review						Drosophila; AP-1; Fos; Jun; transcription factor; JNK	SIGNAL-TRANSDUCTION PATHWAY; N-TERMINAL KINASE; EMBRYONIC DORSAL CLOSURE; CELL SHEET MOVEMENT; PLANAR POLARITY; MAP KINASE; ENDODERM INDUCTION; C-JUN; PATTERN-FORMATION; GENE-EXPRESSION	In recent years, studies in the model organism Drosophila melanogaster have contributed significant insights into the molecular and developmental biology of the AP-1 transcription factors Jun and Fos, Powerful genetic and biochemical approaches uncovered a baffling complexity and variability of the signaling connections to and from AP-1, The range of biological processes that Jun and Fos regulate in this organism is equally multifaceted, Regulatory interactions between AP-1 and JNK, ERK, TGF beta, Notch or other signaling systems have been implicated in the control of a multitude of embryonic and adult events, including tissue closure processes, patterning of eye, gut and wing, as well as apoptosis, Here we review the information that has been gathered on Drosophila AP-1 in signal transduction and on the developmental and cellular functions controlled by AP-1-mediated signals in the fly. Lessons learned from the studies on AP-1 in Drosophila may contribute to our general understanding, beyond species boundaries, of this fundamental class of transcriptional regulators.	Univ Rochester, Med Ctr, Ctr Canc Biol, Rochester, NY 14642 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	University of Rochester; European Molecular Biology Laboratory (EMBL); Harvard University; Harvard Medical School	Bohmann, D (corresponding author), Univ Rochester, Med Ctr, Ctr Canc Biol, 601 Elmwood Ave,Box 633, Rochester, NY 14642 USA.							Adachi-Yamada T, 1999, NATURE, V400, P166, DOI 10.1038/22112; Agnes F, 1999, DEVELOPMENT, V126, P5453; Andrew DJ, 1997, DEVELOPMENT, V124, P181; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; BASDRA EK, 1994, BBA-MOL CELL RES, V1222, P315, DOI 10.1016/0167-4889(94)90185-6; Belvin MP, 1999, NEURON, V22, P777, DOI 10.1016/S0896-6273(00)80736-9; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhat KM, 1998, CELL, V95, P1027, DOI 10.1016/S0092-8674(00)81726-2; Bienz M, 1997, CURR OPIN GENET DEV, V7, P683, DOI 10.1016/S0959-437X(97)80017-2; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; Blair SS, 1999, CURR BIOL, V9, pR356, DOI 10.1016/S0960-9822(99)80226-7; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BOHMANN D, 1994, CELL, V78, P973, DOI 10.1016/0092-8674(94)90273-9; Boutros M, 1999, MECH DEVELOP, V83, P27, DOI 10.1016/S0925-4773(99)00046-5; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; Bray S, 2000, CURR BIOL, V10, pR155, DOI 10.1016/S0960-9822(00)00330-4; Brook WJ, 1996, ANNU REV CELL DEV BI, V12, P161, DOI 10.1146/annurev.cellbio.12.1.161; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Byars CL, 1999, DEVELOPMENT, V126, P4913; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Chen YJ, 1998, DEVELOPMENT, V125, P1759; Cho KO, 1998, NATURE, V396, P272, DOI 10.1038/24394; Cooper MTD, 1999, NATURE, V397, P526, DOI 10.1038/17395; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dominguez M, 1998, NATURE, V396, P276, DOI 10.1038/24402; Eresh S, 1997, EMBO J, V16, P2014, DOI 10.1093/emboj/16.8.2014; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fanto M, 1999, NATURE, V397, P523, DOI 10.1038/17389; Fanto M, 2000, CURR BIOL, V10, P979, DOI 10.1016/S0960-9822(00)00645-X; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; Fernandez R, 2000, GENE DEV, V14, P604; Freeman M, 2000, NATURE, V408, P313, DOI 10.1038/35042500; Geneva JL, 2000, DEV BIOL, V221, P181, DOI 10.1006/dbio.2000.9671; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; GUBB D, 1993, DEVELOPMENT, P269; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; Harden N, 1996, MOL CELL BIOL, V16, P1896; HARDEN N, 1995, DEVELOPMENT, V121, P903; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hewes RS, 2000, GENETICS, V155, P1711; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Hou XS, 1997, GENE DEV, V11, P1728, DOI 10.1101/gad.11.13.1728; Hudson JB, 1998, DEVELOPMENT, V125, P1407; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jacinto A, 2000, CURR BIOL, V10, P1420, DOI 10.1016/S0960-9822(00)00796-X; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; Kiehart DP, 2000, J CELL BIOL, V149, P471, DOI 10.1083/jcb.149.2.471; Knust E, 1996, CURR BIOL, V6, P379, DOI 10.1016/S0960-9822(02)00500-6; Kockel L, 1997, GENE DEV, V11, P1748, DOI 10.1101/gad.11.13.1748; Lawrence Peter A, 1993, MAKING FLY GENETICS, V6; Li YS, 1996, MOL CELL BIOL, V16, P5947; Lisi S, 2000, GENETICS, V154, P669; Lu Y, 1999, GENE DEV, V13, P1168, DOI 10.1101/gad.13.9.1168; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; Martin-Blanco E, 2000, P NATL ACAD SCI USA, V97, P7888, DOI 10.1073/pnas.97.14.7888; McEwen DG, 2000, DEVELOPMENT, V127, P3607; MIHALY J, 2001, IN PRESS MECH DEV; Mlodzik M, 1999, EMBO J, V18, P6873, DOI 10.1093/emboj/18.24.6873; Morimura S, 1996, DEV BIOL, V177, P136, DOI 10.1006/dbio.1996.0151; Muller HAJ, 1999, DEVELOPMENT, V126, P577; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; Papayannopoulos V, 1998, SCIENCE, V281, P2031, DOI 10.1126/science.281.5385.2031; Paricio N, 1999, EMBO J, V18, P4669, DOI 10.1093/emboj/18.17.4669; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PERKINS KK, 1990, GENE DEV, V4, P822, DOI 10.1101/gad.4.5.822; PERKINS KK, 1988, EMBO J, V7, P4265, DOI 10.1002/j.1460-2075.1988.tb03324.x; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; Peverali FA, 1996, EMBO J, V15, P3943, DOI 10.1002/j.1460-2075.1996.tb00768.x; Raabe T, 2000, BBA-MOL CELL RES, V1496, P151, DOI 10.1016/S0167-4889(00)00020-3; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Ricos MG, 1999, J CELL SCI, V112, P1225; Riese J, 1997, DEVELOPMENT, V124, P3353; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; RiesgoEscovar JR, 1997, GENE DEV, V11, P1717, DOI 10.1101/gad.11.13.1717; RiesgoEscovar JR, 1997, SCIENCE, V278, P669, DOI 10.1126/science.278.5338.669; RING JM, 1993, DEVELOPMENT, P251; Roulier EM, 1998, MOL CELL, V1, P819, DOI 10.1016/S1097-2765(00)80081-7; Sawamoto K, 1999, J CELL BIOL, V146, P361, DOI 10.1083/jcb.146.2.361; Shulman JM, 1998, TRENDS GENET, V14, P452, DOI 10.1016/S0168-9525(98)01584-4; Simin K, 1998, GENETICS, V148, P801; Sluss HK, 1997, J CELL BIOCHEM, V67, P1; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Strutt H, 1999, CURR OPIN GENET DEV, V9, P442, DOI 10.1016/S0959-437X(99)80067-7; Su YC, 1998, GENE DEV, V12, P2371, DOI 10.1101/gad.12.15.2371; Szuts D, 2000, MECH DEVELOP, V98, P71, DOI 10.1016/S0925-4773(00)00455-X; Szuts D, 2000, P NATL ACAD SCI USA, V97, P5351, DOI 10.1073/pnas.97.10.5351; Szuts D, 1998, GENE DEV, V12, P2022, DOI 10.1101/gad.12.13.2022; Takatsu Y, 2000, MOL CELL BIOL, V20, P3015, DOI 10.1128/MCB.20.9.3015-3026.2000; Tateno M, 2000, SCIENCE, V287, P324, DOI 10.1126/science.287.5451.324; THEISEN H, 1994, DEVELOPMENT, V120, P347; Tomlinson A, 1999, DEVELOPMENT, V126, P5725; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; TREMML G, 1992, DEVELOPMENT, V116, P447; Usui K, 2000, DEV BIOL, V225, P13, DOI 10.1006/dbio.2000.9766; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Watson L, 2000, EUR J CLIN INVEST, V30, P11; Weber U, 2000, DEVELOPMENT, V127, P3619; Wehrli M, 1998, DEVELOPMENT, V125, P1421; WOLFF T, 1993, BIOL DROSOPHILA MELA; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29; Zeidler MP, 2000, ONCOGENE, V19, P2598, DOI 10.1038/sj.onc.1203482; Zeidler MP, 1999, GENE DEV, V13, P1342, DOI 10.1101/gad.13.10.1342; Zeidler MP, 2000, DEV BIOL, V228, P181, DOI 10.1006/dbio.2000.9940; Zeitlinger J, 1999, DEVELOPMENT, V126, P3947; Zeitlinger J, 1997, EMBO J, V16, P7393, DOI 10.1093/emboj/16.24.7393; ZHANG K, 1990, P NATL ACAD SCI USA, V87, P6281, DOI 10.1073/pnas.87.16.6281; ZHENG L, 1995, DEVELOPMENT, V121, P3045	124	102	106	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2001	20	19					2347	2364		10.1038/sj.onc.1204300	http://dx.doi.org/10.1038/sj.onc.1204300			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402332				2022-12-17	WOS:000168568700003
J	Martin, CB; Mahon, GM; Klinger, MB; Kay, RJ; Symons, M; Der, CJ; Whitehead, IP				Martin, CB; Mahon, GM; Klinger, MB; Kay, RJ; Symons, M; Der, CJ; Whitehead, IP			The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways	ONCOGENE			English	Article						PAR-1; thrombin; transformation; RhoA	PROTEIN-COUPLED RECEPTOR; NUCLEOTIDE EXCHANGE FACTORS; ACTIN STRESS FIBERS; NIH 3T3 CELLS; RAS TRANSFORMATION; EXPRESSION CLONING; MALIGNANT TRANSFORMATION; STRUCTURAL SIMILARITIES; INDEPENDENT PATHWAYS; FAMILY PROTEINS	We utilized a cDNA expression library derived from the B6SutA(1) mouse myeloid progenitor cell line to search for novel oncogenes that promote growth transformation of NIH3T3 cells. A 2.2 kb transforming cDNA was recovered that encodes the wild type thrombin-stimulated G protein-coupled receptor PAR-I, In addition to its potent focus forming activity, constitutive overexpression of PAR-1 in NIH3T3 cells promoted the loss of anchorage- and serum-dependent growth. Although inhibitors of thrombin failed to block PAR-I transforming activity, a PAR-1 mutant that cannot be cleaved by thrombin was nontransforming. Since the foci of transformed cells induced by PAR-1 bear a striking resemblance to those induced by activated RhoA, we determined if PAR-1 transformation was due to the aberrant activation of a specific Rho family member. Like RhoA, PAR-I cooperated with activated Raf-l and caused synergistic enhancement of transforming activity, induced stress fibers when microinjected into porcine aortic endothelial cells, stimulated the activity of the serum response factor and NF-kappaB transcription factors, and PAR-1 transformation was blocked by co-expression of dominant negative RhoA, Finally, PAR-I transforming activity was blocked by pertussis toxin and by coexpression of the RGS domain of Lsc, implicating G alpha (i) and G alpha (12)/G alpha (13) subunits, respectively, as mediators of PAR-I transformation. Taken together, these observations suggest that PAR-1 growth transformation is mediated, in part, by activation of RhoA.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA; Univ N Carolina, Sch Med, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Picower Inst Med Res, Mol Oncol Lab, Manhasset, NY 11030 USA; British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 4E6, Canada	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Northwell Health; British Columbia Cancer Agency	Whitehead, IP (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, 185 S Orange Ave, Newark, NJ 07103 USA.			Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA42978, CA55008, CA63071, CA77493] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA077493, R01CA055008, R01CA063071, R01CA042978] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Betuing S, 1998, J BIOL CHEM, V273, P15804, DOI 10.1074/jbc.273.25.15804; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V70, P184; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Fareed J, 1999, CLIN APPL THROMB-HEM, V5, pS45, DOI 10.1177/10760296990050S109; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Genda T, 1999, HEPATOLOGY, V30, P1027, DOI 10.1002/hep.510300420; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Henrikson KP, 1999, BRIT J CANCER, V79, P401, DOI 10.1038/sj.bjc.6690063; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Macey MG, 1996, LEUKEMIA, V10, P687; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; TORDAI A, 1993, J IMMUNOL, V150, P4876; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANOBBERGHENSCH.E, 1998, THROMBIN ITS RECEPTO; VANOBBERGHENSCHILLING E, 1993, THROMB HAEMOSTASIS, V70, P163; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1998, MOL CELL BIOL, V18, P4689, DOI 10.1128/MCB.18.8.4689; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P5339, DOI 10.1073/pnas.85.14.5339; Zohn IE, 2000, ONCOGENE, V19, P3866, DOI 10.1038/sj.onc.1203731; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	61	102	106	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					1953	1963		10.1038/sj.onc.1204281	http://dx.doi.org/10.1038/sj.onc.1204281			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360179				2022-12-17	WOS:000168043800003
J	Kirn, D				Kirn, D			Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer	ONCOGENE			English	Article						gene therapy; adenovirus; oncolytic; replication-selective	TUMOR-NECROSIS-FACTOR; HERPES-SIMPLEX VIRUS; COMPETENT ADENOVIRUS; NECK-CANCER; P53 STATUS; IN-VIVO; ATTENUATED ADENOVIRUS; ANTITUMORAL EFFICACY; RECURRENT HEAD; DEATH PROTEIN		Hammersmith Hosp, Imperial Coll, Sch Med, Imperial Canc Res Fund,Program Viral & Genet Ther, London W12 0NN, England	Cancer Research UK; Imperial College London	Kirn, D (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, Imperial Canc Res Fund,Program Viral & Genet Ther, DuCane Rd, London W12 0NN, England.							Agha-Mohammadi S, 2000, J CLIN INVEST, V105, P1173, DOI 10.1172/JCI10026; ASADA T, 1974, CANCER, V34, P1907, DOI 10.1002/1097-0142(197412)34:6<1907::AID-CNCR2820340609>3.0.CO;2-4; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; CHINNADURAI G, 1983, CELL, V33, P759, DOI 10.1016/0092-8674(83)90018-1; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Dimitrov T, 1997, J VIROL, V71, P2830, DOI 10.1128/JVI.71.4.2830-2837.1997; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Doronin K, 2000, J VIROL, V74, P6147, DOI 10.1128/JVI.74.13.6147-6155.2000; Douglas JT, 1996, NAT BIOTECHNOL, V14, P1574, DOI 10.1038/nbt1196-1574; Freytag SO, 1998, HUM GENE THER, V9, P1323, DOI 10.1089/hum.1998.9.9-1323; Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251; Ganly I, 2000, CLIN CANCER RES, V6, P798; GOODING LR, 1994, INFECT AGENT DIS, V3, P106; Goodrum FD, 1997, J VIROL, V71, P548, DOI 10.1128/JVI.71.1.548-561.1997; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; Hallenbeck PL, 1999, HUM GENE THER, V10, P1721, DOI 10.1089/10430349950017725; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Hawkins L., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P476; HECHT R, 2000, P AN M AM SOC CLIN, V19, P1039; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Heise C, 2000, J CLIN INVEST, V105, P847, DOI 10.1172/JCI9762; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; HEISE C, 2000, IN PRESS CLIN CANC R; HEISE C, 1999, CANC GENE THERAPY, V6; Heise CC, 1999, CANCER RES, V59, P2623; Hermiston T, 2000, J CLIN INVEST, V105, P1169, DOI 10.1172/JCI9973; HERMISTON TW, 1993, J VIROL, V67, P5289, DOI 10.1128/JVI.67.9.5289-5298.1993; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kim DH, 2000, GENE THER, V7, P815, DOI 10.1038/sj.gt.3301213; Kirn D, 1998, NAT MED, V4, P1341, DOI 10.1038/3902; KIRN D, 1998, CANC GENE THERAPY; Kirn DH, 2000, J CLIN INVEST, V105, P837, DOI 10.1172/JCI9761; Kurihara T, 2000, J CLIN INVEST, V106, P763, DOI 10.1172/JCI9180; Lattime EC, 1996, SEMIN ONCOL, V23, P88; Low KB, 1999, NAT BIOTECHNOL, V17, P37, DOI 10.1038/5205; Martuza RL, 2000, J CLIN INVEST, V105, P841, DOI 10.1172/JCI9744; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; Mastrangelo MJ, 2000, J CLIN INVEST, V105, P1031, DOI 10.1172/JCI9819; Medina DJ, 1999, BLOOD, V94, P3499; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Nemunaitis J, 2000, CANCER RES, V60, P6359; NEMUNAITIS J, 1999, P CANC GENE THER M, V18, P714; NEMUNAITIS J, 2000, P AN M AM SOC CLIN, V19, P724; NIELSCH U, 1991, ONCOGENE, V6, P1031; Norman KL, 2000, J CLIN INVEST, V105, P1035, DOI 10.1172/JCI9871; OLSON DC, 1994, CELL GROWTH DIFFER, V5, P61; Reid T, 2000, P AN M AM SOC CLIN, V19, P953; RIED A, 1999, EORTC NCI AACR M MOL; Ries SJ, 2000, NAT MED, V6, P1128, DOI 10.1038/80466; Rodriguez R, 1997, CANCER RES, V57, P2559; Roelvink PW, 1999, SCIENCE, V286, P1568, DOI 10.1126/science.286.5444.1568; Rogulski KR, 2000, CANCER RES, V60, P1193; Rothmann T, 1998, J VIROL, V72, P9470, DOI 10.1128/JVI.72.12.9470-9478.1998; Sauthoff H, 2000, HUM GENE THER, V11, P379, DOI 10.1089/10430340050015851; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHENK T, 1996, FIELDS VIROLOGY, P2135; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; SMITH RR, 1956, CANCER, V9, P1211, DOI 10.1002/1097-0142(195611/12)9:6<1211::AID-CNCR2820090624>3.0.CO;2-7; SOUTHAM CM, 1952, CANCER, V5, P1025, DOI 10.1002/1097-0142(195209)5:5<1025::AID-CNCR2820050518>3.0.CO;2-Q; Sparer TE, 1996, J VIROL, V70, P2431, DOI 10.1128/JVI.70.4.2431-2439.1996; Sznol M, 2000, J CLIN INVEST, V105, P1027, DOI 10.1172/JCI9818; Toda M, 1999, HUM GENE THER, V10, P385, DOI 10.1089/10430349950018832; Tollefson AE, 1996, VIROLOGY, V220, P152, DOI 10.1006/viro.1996.0295; VASEY P, 2000, P AN M AM SOC CLIN, V19, P1512; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; Wickham TJ, 1996, J VIROL, V70, P6831, DOI 10.1128/JVI.70.10.6831-6838.1996; Wildner O, 1999, CANCER RES, V59, P410; Wold W S, 1995, Curr Top Microbiol Immunol, V199 ( Pt 1), P237; Wold William S. M., 1994, Trends in Microbiology, V2, P437, DOI 10.1016/0966-842X(94)90801-X; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Yu DC, 1999, CANCER RES, V59, P1498; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	77	102	120	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6660	6669		10.1038/sj.onc.1204094	http://dx.doi.org/10.1038/sj.onc.1204094			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426652				2022-12-17	WOS:000167704000013
J	Ise, K; Nakamura, K; Nakao, K; Shimizu, S; Harada, H; Ichise, T; Miyoshi, J; Gondo, Y; Ishikawa, T; Aiba, A; Katsuki, M				Ise, K; Nakamura, K; Nakao, K; Shimizu, S; Harada, H; Ichise, T; Miyoshi, J; Gondo, Y; Ishikawa, T; Aiba, A; Katsuki, M			Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis	ONCOGENE			English	Article						H-ras mutant; skin papilloma; chemical carcinogenesis	CHEMICAL CARCINOGENESIS; MALIGNANT PROGRESSION; ANIMAL-MODEL; KI-RAS; ACTIVATION; INITIATION; ONCOGENES; MICE; MUTAGENESIS; MUTATIONS	To clarify the role of the H-Ras in vivo, we generated H-ras null mutant mice by gene targeting. In spite of the importance of the Ras in cell proliferation and differentiation, H-ras null mutant mice grew normally and were fertile. The oldest H-ras mutant mice grew to be more than 30 months old. We used the H-ras deficient mice to study the importance of the H-ras and other ras genes in the development of skin tumors induced by initiation with 7,12-dimethylbenz(a)anthracene (DMBA) followed by promotion with 12-O-tetradecanoylphorbol-13-acetate (TPA), We showed that H-ras null mutant mice develop approximately six times less papillomas compared with wild-type littermates after 20 weeks of TPA treatment. While all papillomas examined (17 out of 17) in wild-type mice have mutations of H-ras at codon 61, 13 (62%) out of 21 papillomas in H-ras null mutant mice have mutations of K-vas gene at codon 12, 13, or 61 and another eight (38%) papillomas have no mutations in these codons of K-ras or N-ras genes. This suggests that the activation of H-ras gene is critical in the wild-type mice, but the activation of K-ras gene can replace the H-ras activation in the initiation step of skin tumor development in the H-ras deficient mice.	Univ Tokyo, Inst Med Sci, Div DNA Biol & Embryo Engn, Ctr Med Expt,Minato Ku, Tokyo 1088638, Japan; Univ Tokyo, Inst Med Sci, Ctr Med Expt, Core Res Evolut Sci & Technol, Tokyo 1088639, Japan; Univ Tokyo, Dept Pathol, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Cell Biol, Fukuoka 8128582, Japan; Med Ctr Canc & Cardiovasc Dis, Osaka 5378511, Japan; RIKEN, Genom Sci Ctr, Kanagawa 2440804, Japan	University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo; University of Tokyo; University of Tokyo; Kyushu University; RIKEN	Katsuki, M (corresponding author), Univ Tokyo, Inst Med Sci, Div DNA Biol & Embryo Engn, Ctr Med Expt,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088638, Japan.		Gondo, Yoichi/A-5375-2016	Gondo, Yoichi/0000-0003-2184-6489; Ichise, Taeko/0000-0002-1441-1463; Aiba, Atsu/0000-0002-8192-0778; zhong wei, he gui/0000-0002-3066-3564				BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BROOKES P, 1988, MOL CARCINOGEN, V1, P82, DOI 10.1002/mc.2940010203; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; HARVEY JJ, 1964, NATURE, V204, P1104, DOI 10.1038/2041104b0; HECKER E, 1982, CARCINOGENESIS COMPR; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KIRSTEN WH, 1967, J NATL CANCER I, V39, P311; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MANAM S, 1992, CANCER RES, V52, P3347; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SEKIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P4771, DOI 10.1073/pnas.81.15.4771; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; YUSPA SH, 1994, CANCER RES, V54, P1178; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	26	102	103	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 15	2000	19	26					2951	2956		10.1038/sj.onc.1203600	http://dx.doi.org/10.1038/sj.onc.1203600			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323TQ	10871846				2022-12-17	WOS:000087581400001
J	Wai, DH; Knezevich, SR; Lucas, T; Jansen, B; Kay, RJ; Sorensen, PHB				Wai, DH; Knezevich, SR; Lucas, T; Jansen, B; Kay, RJ; Sorensen, PHB			The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells	ONCOGENE			English	Article						ETV6-NTRK3; TEL-TRKC; receptor tyrosine kinase; translocation; chimeric oncoprotein	NERVE GROWTH-FACTOR; ACUTE LYMPHOBLASTIC-LEUKEMIA; CONGENITAL-INFANTILE FIBROSARCOMA; CHRONIC MYELOMONOCYTIC LEUKEMIA; ETS-VARIANT GENE-6; NEUROTROPHIN RECEPTORS; SIGNAL-TRANSDUCTION; TRK FAMILY; TEL GENE; MYELOPROLIFERATIVE DISORDERS	The congenital fibrosarcoma t(12;15)(p13;q25) rearrangement splices the ETV6 (TEL) gene on chromosome 12p13 in frame with the NTRK3 (TRKC) neurotrophin-3 receptor gene on chromosome 15q25, Resultant ETV6-NTRK3 fusion transcripts encode the helix-loop-helix (HLH) dimerization domain of ETV6 fused to the protein tyrosine kinase (PTK) domain of NTRK3, We show here that ETV6-NTRK3 homodimerizes and is capable of forming heterodimers with wild-type ETV6, Moreover, ETV6-NTRK3 has PTK activity and is autophosphorylated on tyrosine residues. To determine if the fusion protein has transforming activity, NIH3T3 cells were infected with recombinant retroviral vectors carrying the full-length ETV6-NTRK3 cDNA, These cells exhibited a transformed phenotype, grew macroscopic colonies in soft agar, and formed tumors in severe combined immunodeficient (SCID) mice, We hypothesize that chimeric proteins mediate transformation by dysregulating NTRK3 signal transduction pathways via ligand-independent dimerization and PTK activation. To test this hypothesis, we expressed a series of ETY6-NTRK3 mutants in NIH3T3 cells and assessed their transformation activities, Deletion of the ETV6 HLH domain abolished dimer formation with either ETV6 or ETV6-NTRK3, and cells expressing this mutant protein were morphologically non-transformed and failed to grow in soft agar, An ATP-binding mutant failed to autophosphorylate and completely lacked transformation activity. Mutants of the three NTRK3 PTK activation-loop tyrosines had variable PTK activity but had limited to absent transformation activity. Of a series of signaling molecules well known to bind to wild-type NTRK3, only phospholipase-C gamma (PLC gamma) associated with ETV6-TRK3, However, a PTK active mutant unable to bind PLC gamma did not show defects in transformation activity, Our studies confirm that ETV6-NTRK3 is a transforming protein that requires both an intact dimerization domain and a functional PTK domain for transformation activity.	British Columbia Childrens Hosp, Dept Pathol, Vancouver, BC V6H 3V4, Canada; Univ Vienna, Dept Clin Pharmacol, Sect Expt Oncol Mol Pharmacol, A-1090 Vienna, Austria; Univ Vienna, Dept Dermatol, Div Gen Dermatol, A-1090 Vienna, Austria; British Columbia Canc Agcy, Dept Med Genet, Terry Fox Lab, Vancouver, BC V5Z 4E6, Canada	BC Childrens Hospital; University of British Columbia; University of Vienna; University of Vienna; British Columbia Cancer Agency	Sorensen, PHB (corresponding author), British Columbia Childrens Hosp, Dept Pathol, 4480 Oak St, Vancouver, BC V6H 3V4, Canada.			Lucas, Trevor/0000-0002-5114-8035				ADAM LR, 1990, CANCER GENET CYTOGEN, V48, P193; ARGYLE JC, 1992, ARCH PATHOL LAB MED, V116, P972; Baens M, 1996, GENOME RES, V6, P404, DOI 10.1101/gr.6.5.404; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Barbacid M, 1995, ANN NY ACAD SCI, V766, P442, DOI 10.1111/j.1749-6632.1995.tb26693.x; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/0968-0004(96)10033-5; BUIJS A, 1995, ONCOGENE, V10, P1511; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Cave H, 1997, LEUKEMIA, V11, P1459, DOI 10.1038/sj.leu.2400798; Chase A, 1999, BLOOD, V93, P1025, DOI 10.1182/blood.V93.3.1025.403a20_1025_1031; COCKCROFT S, 1992, BIOCHEM J, V288, P1; COFFIN CM, 1994, PEDIATR PATHOL, V14, P133, DOI 10.3109/15513819409022033; Conover JC, 1997, REV NEUROSCIENCE, V8, P13; Cools J, 1999, BLOOD, V94, P1820, DOI 10.1182/blood.V94.5.1820.417k09_1820_1824; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; Downward J, 1996, CANCER SURV, V27, P87; Ebadi M, 1997, NEUROCHEM INT, V30, P347, DOI 10.1016/S0197-0186(96)00071-X; Edel MJ, 1998, ANTICANCER RES, V18, P4505; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GUITON M, 1995, J BIOL CHEM, V270, P20384, DOI 10.1074/jbc.270.35.20384; GunnMoore FJ, 1997, BIOCHEM J, V322, P193, DOI 10.1042/bj3220193; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; HAWLEY RG, 1994, GENE THER, V1, P136; Ho JMY, 1999, BLOOD, V93, P4354, DOI 10.1182/blood.V93.12.4354.412k30_4354_4364; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Ichaso N, 1998, ONCOGENE, V17, P1871, DOI 10.1038/sj.onc.1202100; JANSSEN JWG, 1995, BRIT J HAEMATOL, V90, P222, DOI 10.1111/j.1365-2141.1995.tb03407.x; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Knezevich SR, 1998, CANCER RES, V58, P5046; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; MANDAHL N, 1989, CANCER GENET CYTOGEN, V40, P137, DOI 10.1016/0165-4608(89)90156-8; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MCGREGOR LM, 1994, GENOMICS, V22, P267, DOI 10.1006/geno.1994.1383; MITRA G, 1991, ONCOGENE, V6, P2237; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; O'Connor HE, 1998, LEUKEMIA, V12, P1099, DOI 10.1038/sj.leu.2401070; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Peeters P, 1997, CANCER RES, V57, P564; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Poirel H, 1998, ONCOGENE, V16, P2895, DOI 10.1038/sj.onc.1201817; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Rubin BP, 1998, AM J PATHOL, V153, P1451, DOI 10.1016/S0002-9440(10)65732-X; SANKARY S, 1993, CANCER GENET CYTOGEN, V65, P152, DOI 10.1016/0165-4608(93)90225-B; SPELEMAN F, 1989, CANCER GENET CYTOGEN, V39, P21, DOI 10.1016/0165-4608(89)90224-0; Suto Y, 1997, GENE CHROMOSOME CANC, V18, P254, DOI 10.1002/(SICI)1098-2264(199704)18:4<254::AID-GCC3>3.0.CO;2-#; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; Tsoulfas P, 1996, J BIOL CHEM, V271, P5691, DOI 10.1074/jbc.271.10.5691; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Yagasaki F, 1999, GENE CHROMOSOME CANC, V26, P192, DOI 10.1002/(SICI)1098-2264(199911)26:3<192::AID-GCC2>3.0.CO;2-E	73	102	105	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2000	19	7					906	915		10.1038/sj.onc.1203396	http://dx.doi.org/10.1038/sj.onc.1203396			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702799				2022-12-17	WOS:000085567700008
J	Ide, N; Hata, Y; Nishioka, H; Hirao, K; Yao, I; Deguchi, M; Mizoguchi, A; Nishimori, H; Tokino, T; Nakamura, Y; Takai, Y				Ide, N; Hata, Y; Nishioka, H; Hirao, K; Yao, I; Deguchi, M; Mizoguchi, A; Nishimori, H; Tokino, T; Nakamura, Y; Takai, Y			Localization of membrane-associated guanylate kinase (MAGI)-1/BAI-associated protein (BAP) 1 at tight junctions of epithelial cells	ONCOGENE			English	Article						MAGI-1/BAP1; SAP97/hDLG; E-cadherin; ZO-1; tight junction	TUMOR-SUPPRESSOR PROTEIN; POSTSYNAPTIC DENSITY; SIGNALING PATHWAYS; HUMAN HOMOLOG; DOMAIN; FAMILY; APC; INTERACTS; BINDING; PSD-95	Membrane-associated guanylate kinase (MAGI)-1/BAI-associated protein (BAP) 1 and Synapse-associated protein (SAP) 97/human Discs-large tumor suppressor gene (hDLG) are ubiquitous isoforms of synaptic scaffolding molecule (S-SCAM) and Postsynaptic density(PSD)-95/SAP90, both of which are implicated in the structures of synapses, respectively. SAP97/hDLG is localized at epithelial junctions and may function as a scaffolding protein, but the subcellular localization or the function of MAGI-1/BAP1 has not been clarified. In intestinal epithelial cells, MAGI-1/BAP1 was localized at tight junctions, whereas SAP97/hDLG was localized diffusely at cell-cell junctions. In Madine Darby canine kidney (MDCK) cells, MAGI-1/BAP1 was colocalized with ZO-1, whereas SAP97/hDLG was colocalized with E-cadherin. In MDCK cells, dominant active and negative mutants of Rad small G protein changed the amounts of SAP97/hDLG at cell-cell junctions, but not that of MAGI-1/BAP1. When MDCK cells were switched to a low Ca2+ medium, E-cadherin disappeared from the plasma membrane, and cells were dissociated. The phorbol 12-myristate 13-acetate-treatment after the low Ca2+ switch induced a tight junction-like structure. MAGI-1/BAP1 was recruited with ZO-1 to this structure, but SAP97/hDLG or E-cadherin was not. These findings suggest that MAGI-1/BAP1 is a component of tight junctions of epithelial cells, and that its role is different from that of SAP97/hDLG.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, ERATO, Takai Biotimer Project, JCR Pharmaceut Co Ltd, Kobe, Hyogo 6512241, Japan; Kyoto Univ, Grad Sch, Dept Anat & Neurobiol, Kyoto 6068315, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan	Osaka University; Japan Science & Technology Agency (JST); Kyoto University; University of Tokyo	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Tokino, Takashi/AAI-9887-2021					Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Hata Y, 1998, NEUROSCI RES, V32, P1, DOI 10.1016/S0168-0102(98)00069-8; Hata Y, 1996, J NEUROSCI, V16, P2488; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Ide N, 1999, BIOCHEM BIOPH RES CO, V256, P456, DOI 10.1006/bbrc.1999.0364; Irie M, 1999, ONCOGENE, V18, P2811, DOI 10.1038/sj.onc.1202652; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Reuver SM, 1998, J CELL SCI, V111, P1071; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Shiratsuchi T, 1998, BIOCHEM BIOPH RES CO, V247, P597, DOI 10.1006/bbrc.1998.8603; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Yao I, 1999, J BIOL CHEM, V274, P11889, DOI 10.1074/jbc.274.17.11889	31	102	102	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	1999	18	54					7810	7815		10.1038/sj.onc.1203153	http://dx.doi.org/10.1038/sj.onc.1203153			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618722				2022-12-17	WOS:000084256900011
J	Tuveson, DA; Jacks, T				Tuveson, DA; Jacks, T			Modeling human lung cancer in mice: similarities and shortcomings	ONCOGENE			English	Review						lung cancer; mouse models; genetic modifiers; K-ras; p53; Rb	INDUCED PULMONARY ADENOMAS; STRAIN-A MICE; RETINOBLASTOMA SUSCEPTIBILITY GENE; TUMOR-SUPPRESSOR GENE; SMALL-CELL CARCINOMA; K-RAS GENE; MOUSE LUNG; TRANSGENIC MICE; NONSMALL CELL; P53 GENE	Lung cancer kills more Americans yearly than any other neoplastic process. Mortality rates have changed little over the past several decades, despite improvements in surgical techniques, radiation therapy and chemotherapy. The identification of mutations in oncogenes and tumor suppressor genes in human lung tumor specimens, including K-ras, p53, p16(INK4a) and Rb, offers molecular explanations for tumor development and resistance to therapy. Mouse models of human lung cancer may advance our understanding of this disease. The examination of mice which develop lung cancer either spontaneously or due to carcinogen exposure, and the creation of mouse strains harboring the specific genetic mutations found in human lung cancer are among strategies being pursued.	MIT, Ctr Canc Res, Cambridge, MA 02139 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Jacks, T (corresponding author), MIT, Ctr Canc Res, E17-518,40 Ames St, Cambridge, MA 02139 USA.				NATIONAL CANCER INSTITUTE [T32CA071345] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA71345] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUAYO SM, 1992, NEW ENGL J MED, V327, P1285, DOI 10.1056/NEJM199210293271806; Andervont HB, 1940, J NATL CANCER I, V1, P225; [Anonymous], 1982, AM J CLIN PATHOL, V77, P123; AUERBACH O, 1961, NEW ENGL J MED, V265, P253, DOI 10.1056/NEJM196108102650601; Balsara BR, 1997, CANCER RES, V57, P2116; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; CHEN B, 1994, CARCINOGENESIS, V15, P2031, DOI 10.1093/carcin/15.9.2031; CHEN B, 1994, P NATL ACAD SCI USA, V91, P1589, DOI 10.1073/pnas.91.4.1589; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DAGATI VD, 1985, CANCER, V55, P2472, DOI 10.1002/1097-0142(19850515)55:10<2472::AID-CNCR2820551027>3.0.CO;2-Y; DAMICO D, 1992, ONCOGENE, V7, P339; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; DIXON D, 1991, EXP LUNG RES, V17, P131, DOI 10.3109/01902149109064407; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; Fijneman RJA, 1996, NAT GENET, V14, P465, DOI 10.1038/ng1296-465; FOLEY JF, 1991, EXP LUNG RES, V17, P157, DOI 10.3109/01902149109064408; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; Glover TW, 1998, CANCER RES, V58, P3409; Harvey RG, 1991, POLYCYCLIC AROMATIC; HECHT SS, 1989, CARCINOGENESIS, V10, P1901, DOI 10.1093/carcin/10.10.1901; HENSEL CH, 1991, ONCOGENE, V6, P1067; HENSEL CH, 1990, CANCER RES, V50, P3067; Herzog CR, 1996, ONCOGENE, V13, P1885; HERZOG CR, 1994, CANCER RES, V54, P4007; Horio Y, 1996, MOL CARCINOGEN, V17, P217, DOI 10.1002/(SICI)1098-2744(199612)17:4<217::AID-MC5>3.0.CO;2-A; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KERN JA, 1990, CANCER RES, V50, P5184; Kim SH, 1996, ANTICANCER RES, V16, P465; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KONDO K, 1992, BIOCHEM BIOPH RES CO, V183, P1139, DOI 10.1016/S0006-291X(05)80309-2; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lin L, 1998, EXP LUNG RES, V24, P481, DOI 10.3109/01902149809087382; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; Lopez AD, 1999, B WORLD HEALTH ORGAN, V77, P82; Lynch CJ, 1926, J EXP MED, V43, P339, DOI 10.1084/jem.43.3.339; MABRY M, 1988, P NATL ACAD SCI USA, V85, P6523, DOI 10.1073/pnas.85.17.6523; MALKINSON AM, 1985, J NATL CANCER I, V75, P971, DOI 10.1093/jnci/75.5.971; Manenti G, 1996, NAT GENET, V12, P455, DOI 10.1038/ng0496-455; Manenti G, 1997, CANCER RES, V57, P4164; MAO L, 1994, CANCER RES, V54, P1634; Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857; MARONPOT RR, 1991, EXP LUNG RES, V17, P305, DOI 10.3109/01902149109064420; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mertens F, 1997, CANCER RES, V57, P2765; MILLS NE, 1995, CANCER RES, V55, P1444; MITSUDOMI T, 1992, ONCOGENE, V7, P171; *MMWR, 1996, MMWR-MORBID MORTAL W, V45, P971; NAKANISHI K, 1990, ARCH PATHOL LAB MED, V114, P363; NESBITT JC, 1997, CANC MED, P1723; NOGUCHI M, 1990, CANCER, V66, P2053, DOI 10.1002/1097-0142(19901115)66:10<2053::AID-CNCR2820661002>3.0.CO;2-K; Obata M, 1996, ONCOGENE, V13, P1599; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Pataer A, 1997, CANCER RES, V57, P2904; Pekarsky Y, 1998, CANCER RES, V58, P3401; Petersen I, 1997, CANCER RES, V57, P2331; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; REISSMANN PT, 1993, ONCOGENE, V8, P1913; RIES LAG, 1994, SEMIN SURG ONCOL, V10, P21, DOI 10.1002/ssu.2980100106; RODENHUIS S, 1990, AM REV RESPIR DIS, V142, pS27, DOI 10.1164/ajrccm/142.6_Pt_2.S27; ROGGLI VL, 1985, HUM PATHOL, V16, P569, DOI 10.1016/S0046-8177(85)80106-4; RONAI ZA, 1993, CARCINOGENESIS, V14, P2419, DOI 10.1093/carcin/14.11.2419; RYBERG D, 1995, CANCER RES, V55, P3996; SAITOH A, 1990, ONCOGENE, V5, P1195; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SANDMOLLER A, 1995, CELL GROWTH DIFFER, V6, P97; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SCHAUER IE, 1994, P NATL ACAD SCI USA, V91, P7827, DOI 10.1073/pnas.91.16.7827; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHAPIRO GI, 1995, CANCER RES, V55, P505; Shimkin M B, 1975, Adv Cancer Res, V21, P1, DOI 10.1016/S0065-230X(08)60970-7; Shimkin MB, 1940, J NATL CANCER I, V1, P241; SHIMKIN MB, 1955, ADV CANCER RES, V3, P223, DOI 10.1016/S0065-230X(08)60921-5; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; SHOPLAND DR, 1991, JNCI-J NATL CANCER I, V83, P1142, DOI 10.1093/jnci/83.16.1142; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; SOZZI G, 1995, CANCER RES, V55, P135; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Stewart HL, 1979, PATHOLOGY TUMORS LAB, VII, P251; STONER GD, 1993, J CELL BIOCHEM, P95; STONER GD, 1991, EXP LUNG RES, V17, P405, DOI 10.3109/01902149109064428; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; Suzuki K, 1998, BRIT J CANCER, V77, P1003, DOI 10.1038/bjc.1998.165; TAKAHASHI T, 1989, CANCER RES, V49, P2683; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; THAETE LG, 1991, EXP LUNG RES, V17, P219, DOI 10.3109/01902149109064413; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; WATTENBERG LW, 1970, CANCER RES, V30, P1922; WEINER DB, 1990, CANCER RES, V50, P421; Weiss KM, 1998, GENOME RES, V8, P691, DOI 10.1101/gr.8.7.691; WIKENHEISER KA, 1992, CANCER RES, V52, P5342; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WISEMAN RW, 1994, P NATL ACAD SCI USA, V91, P3759, DOI 10.1073/pnas.91.9.3759; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366; Witschi H, 1997, CARCINOGENESIS, V18, P2035, DOI 10.1093/carcin/18.11.2035; XIAO S, 1995, CANCER RES, V55, P2968; XU HJ, 1991, CANCER RES, V51, P2735; YOKOTA J, 1988, ONCOGENE, V3, P471; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804	108	102	106	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	1999	18	38					5318	5324		10.1038/sj.onc.1203107	http://dx.doi.org/10.1038/sj.onc.1203107			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498884				2022-12-17	WOS:000082808400010
J	Fischer, J; Palmedo, G; von Knobloch, R; Bugert, P; Prayer-Galetti, T; Pagano, F; Kovacs, G				Fischer, J; Palmedo, G; von Knobloch, R; Bugert, P; Prayer-Galetti, T; Pagano, F; Kovacs, G			Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours	ONCOGENE			English	Article						MET tyrosine kinase; germline mutation; allelic duplication; papillary renal cell tumours	HEPATOCYTE GROWTH-FACTOR; NORMAL KIDNEY TISSUE; SCATTER FACTOR; EPITHELIAL-CELLS; RECEPTOR; CARCINOMA; TUMORS; CYTOGENETICS; ABERRATIONS	Previous karyotyping showed a combined trisomy of chromosome 7 and 17 in sporadic and hereditary papillary renal cell rumours (RCT). A recent molecular analysis revealed a mutation in the MET tyrosine kinase (chromosome 7q31) in the germline of four out of seven families with hereditary papillary RCT (HPRCT), We have analysed germline cells as well as multiple tumours obtained from HPRCT families and sporadic cases for alteration of the MET tyrosine kinase and for allelic duplication at chromosome 7 and 17. We have detected a germ line mutation in the MET tyrosine kinase in one of the two families with HPRCTs and also found the same mutation in the germ line of one patient with clinically recognized multiple, bilateral papillary RCTs but without family history. The mutant MET allele is consequently duplicated and overexpressed in tumour cells indicating that duplication of the mutant MET allele is necessary before cells enter the tumorigenic pathway. The lack of germline mutation in two members of another HPRT family and duplication of the same parental allele of chromosome 7 in multiple tumours suggests that a germ Line event other than mutation of MET tyrosine kinase is involved in the development of these tumours, Duplication of different alleles of chromosome 7 in sporadic and of chromosome 17 in both types of tumours excludes a germline mutation at these chromosomal sites.	Ruprecht Karls Univ, Dept Urol, Mol Oncol Lab, D-69120 Heidelberg, Germany; Univ Padua, Dept Urol, I-35128 Padua, Italy	Ruprecht Karls University Heidelberg; University of Padua	Kovacs, G (corresponding author), Ruprecht Karls Univ, Dept Urol, Mol Oncol Lab, Neuenheimer Feld 365, D-69120 Heidelberg, Germany.		von Knobloch, Prof. Dr. Rolf/GRF-5837-2022	von Knobloch, Prof. Dr. Rolf/0000-0002-0358-203X				BENTZ M, 1996, CYTOGENET CELL GENET, V75, P177; Bernues M, 1995, CANCER GENET CYTOGEN, V84, P123, DOI 10.1016/0165-4608(95)00044-5; Besser D, 1997, ONCOGENE, V14, P705, DOI 10.1038/sj.onc.1200879; Bugert P, 1996, AM J PATHOL, V149, P2081; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; Duh FM, 1997, ONCOGENE, V15, P1583, DOI 10.1038/sj.onc.1201338; EMANUEL A, 1992, GENE CHROMOSOME CANC, V4, P75, DOI 10.1002/gcc.2870040110; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Kovacs A, 1993, J UROL PATHOL, V1, P301; Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G; KOVACS G, 1989, AM J PATHOL, V134, P27; KOVACS G, 1991, GENE CHROMOSOME CANC, V3, P249, DOI 10.1002/gcc.2870030403; KOVACS G, 1993, ADV CANCER RES, V62, P89, DOI 10.1016/S0065-230X(08)60316-4; KOVACS G, 1989, CANCER GENET CYTOGEN, V37, P289, DOI 10.1016/0165-4608(89)90063-0; MOGHUL A, 1994, ONCOGENE, V9, P2045; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PLMEDO G, 1997, LAB INVEST, V77, P633; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; SACCONE S, 1992, GENOMICS, V13, P912, DOI 10.1016/0888-7543(92)90191-T; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; ZBAR B, 1995, J UROLOGY, V153, P907, DOI 10.1016/S0022-5347(01)67601-8	26	102	108	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 13	1998	17	6					733	739		10.1038/sj.onc.1201983	http://dx.doi.org/10.1038/sj.onc.1201983			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715275	Bronze			2022-12-17	WOS:000075337200008
J	Ankoma-Sey, V; Matli, M; Chang, KB; Lalazar, A; Donner, DB; Wong, L; Warren, RS; Friedman, SL				Ankoma-Sey, V; Matli, M; Chang, KB; Lalazar, A; Donner, DB; Wong, L; Warren, RS; Friedman, SL			Coordinated induction of VEGF receptors in mesenchymal cell types during rat hepatic wound healing	ONCOGENE			English	Article						hepatic stellate cells; sinusoidal endothelium; hepatic fibrosis; receptor tyrosine kinases	ENDOTHELIAL GROWTH-FACTOR; HUMAN HEPATOCELLULAR-CARCINOMA; FACTOR-BETA-RECEPTOR; HUMAN COLON-CANCER; FAT-STORING CELLS; TYROSINE KINASE; GENE-EXPRESSION; IN-VIVO; LIVER; LIPOCYTES	Homology PCR has been used to identify receptor tyrosine kinases (RTKs) expressed during activation of rat hepatic stellate cells, the key fibrogenic mesenchymal element in the liver. Partial cDNAs encoding several RTKs were cloned from stellate cells activated in vivo, including those of Flt-1, Flk-1, c-met, PDGFR, and Tyro10/DDR2, RNAse protection from cells activated in vivo demonstrated biphasic induction of flt-1 and flk-1 mRNAs, receptors for vascular endothelial growth factor (VEGF), Culture-activation of stellate cells was associated with increased [I-125]VEGF binding and Flt-1 and Flk-1 receptor protein. Induction of VEGF binding sites correlated with an 2.5-fold increase in DNA synthesis in response to VEGF, but only if cells were activated by growth on collagen I, whereas cells maintained in a quiescent state on a basement membrane-like substratum (EHS matrix) were nonproliferative, In both stellate and endothelial cells VEGF-induced mitogenesis was augmented by co-incubation with basic fibroblast growth factor (bFGF), a cytokine with known synergy with VEGF, These findings suggest that the cellular targets of VEGF in liver may not be confined to sinusoidal endothelial cells, and that VEGF responses reflect combined effects on both hepatic stellate cells and sinusoidal endothelium.	Univ Calif San Francisco, Ctr Liver, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Indiana Univ, Sch Med, Dept Physiol & Biophys, Indianapolis, IN 46202 USA; Indiana Univ, Walther Oncol Ctr, Indianapolis, IN 46202 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Friedman, SL (corresponding author), CUNY Mt Sinai Sch Med, Div Liver Dis, Box 1123,1425 Madison Ave,Room 11-70F, New York, NY 10029 USA.				NIDDK NIH HHS [DK37340, DK26743, DK 07007] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037340, P30DK026743, T32DK007007] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Batard P, 1996, BLOOD, V87, P2212, DOI 10.1182/blood.V87.6.2212.bloodjournal8762212; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DAVIS BH, 1988, J CELL PHYSIOL, V136, P547, DOI 10.1002/jcp.1041360323; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUMONT DJ, 1993, ONCOGENE, V8, P1293; ENZAN H, 1994, HEPATOLOGY, V19, P895, DOI 10.1016/0270-9139(94)90289-5; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Friedman S L, 1996, Prog Liver Dis, V14, P101; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FRIEDMAN SL, 1989, J BIOL CHEM, V264, P10756; FRIEDMAN SL, 1994, J BIOL CHEM, V269, P10551; FRIEDMAN SL, 1985, P NATL ACAD SCI USA, V82, P8681, DOI 10.1073/pnas.82.24.8681; FRIEDMAN SL, 1993, METHODS TOXICOL, V1, P292; GEERTS A, 1991, HEPATOLOGY, V13, P1193, DOI 10.1002/hep.1840130628; GRESSNER AM, 1995, J HEPATOL, V22, P28; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hioki O, 1996, J HEPATOL, V24, P217, DOI 10.1016/S0168-8278(96)80032-8; Ikeda H., 1996, Hepatology, V24, p460A; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KAWADA N, 1992, BIOCHEM J, V285, P367, DOI 10.1042/bj2850367; LAI C, 1994, ONCOGENE, V9, P877; Lalazar A, 1997, GENE, V195, P235, DOI 10.1016/S0378-1119(97)00159-5; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; MAHER JJ, 1990, J CLIN INVEST, V86, P1641, DOI 10.1172/JCI114886; Mise M, 1996, HEPATOLOGY, V23, P455; Mochida S, 1996, BIOCHEM BIOPH RES CO, V226, P176, DOI 10.1006/bbrc.1996.1329; MORI S, 1991, J BIOL CHEM, V266, P21158; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; MYOKEN Y, 1991, P NATL ACAD SCI USA, V88, P5819, DOI 10.1073/pnas.88.13.5819; NOMURA M, 1995, J BIOL CHEM, V270, P28316; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P9082; PROCTOR E, 1982, GASTROENTEROLOGY, V83, P1183; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RAZ V, 1991, ONCOGENE, V6, P753; ROCKEY DC, 1993, J CLIN INVEST, V92, P1795, DOI 10.1172/JCI116769; Rodewald HR, 1996, ONCOGENE, V12, P397; ROSENBAUM J, 1995, GASTROENTEROLOGY, V109, P1986, DOI 10.1016/0016-5085(95)90767-X; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schlessinger J, 1993, Harvey Lect, V89, P105; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; STAVRI GT, 1995, CIRCULATION, V92, P11, DOI 10.1161/01.CIR.92.1.11; Suzuki K, 1996, CANCER RES, V56, P3004; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; UNEMORI EN, 1992, J CELL PHYSIOL, V153, P557, DOI 10.1002/jcp.1041530317; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; WONG L, 1994, J CLIN INVEST, V94, P1563, DOI 10.1172/JCI117497; Xu JH, 1996, J CELL BIOL, V132, P239, DOI 10.1083/jcb.132.1.239; YAMANE A, 1994, ONCOGENE, V9, P2683	54	102	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					115	121		10.1038/sj.onc.1201912	http://dx.doi.org/10.1038/sj.onc.1201912			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671320	Bronze			2022-12-17	WOS:000074677800013
J	Takahashi, K; Sasaki, T; Mammoto, A; Hotta, I; Takaishi, K; Imamura, H; Nakano, K; Kodama, A; Takai, Y				Takahashi, K; Sasaki, T; Mammoto, A; Hotta, I; Takaishi, K; Imamura, H; Nakano, K; Kodama, A; Takai, Y			Interaction of radixin with Rho small G protein GDP/GTP exchange protein Dbl	ONCOGENE			English	Article						Rho; ERM; Dbl; Rho GEP; Rho GDI	GUANINE-NUCLEOTIDE EXCHANGE; GTP-BINDING PROTEIN; GDP-DISSOCIATION INHIBITOR; SIGNAL-TRANSDUCTION; ONCOGENE PRODUCT; STRUCTURAL SIMILARITIES; HEMATOPOIETIC-CELLS; EXPRESSION CLONING; MEMBRANE; FAMILY	The Rho small G protein family, consisting of the Rho, Rac, and Cdc42 subfamilies, regulates various actin cytoskeleton-dependent cell functions. The Rho subfamily members regulate ERM (ezrin, radixin and moesin)dependent association of the actin cytoskeleton,vith the plasma membrane. Moreover, the N-terminal regions of ERM interact with Rho GDI, an inhibitory regulator of all the Rho family members, and reduce its inhibitory action, finally initiating the activation of the Rho family members. We show here that the N-terminal region of radixin furthermore interacts with DM, a stimulatory GDP/GTP exchange protein of the Rho family members. This interaction does not affect the Dbl activity to stimulate the GDP/GTP exchange reaction of RhoA, a member of the Rho subfamily. DM does not interact with radixin which is precomplexed with Rho GDI, and Rho GDI displaces Dbl from radixin. Thus, radixin plays an important role in activation of the Rho family members by recruiting their positive and negative regulators.	Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 565, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 565, Japan.							Adra CN, 1997, P NATL ACAD SCI USA, V94, P4279, DOI 10.1073/pnas.94.9.4279; ANDREOLI C, 1994, J CELL SCI, V107, P2509; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; GRAZIANI G, 1989, ONCOGENE, V4, P823; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MAGENDANTZ M, 1995, J BIOL CHEM, V270, P25324, DOI 10.1074/jbc.270.43.25324; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; PASTERIS NG, 1994, CELL, V79, P669; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; SHIMIZU K, 1991, BIOCHEM BIOPH RES CO, V175, P199, DOI 10.1016/S0006-291X(05)81220-3; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TOKSOZ D, 1994, ONCOGENE, V9, P621; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; UEDA T, 1990, J BIOL CHEM, V265, P9373; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; Zalcman G, 1996, J BIOL CHEM, V271, P30366, DOI 10.1074/jbc.271.48.30366; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	48	102	102	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3279	3284		10.1038/sj.onc.1201874	http://dx.doi.org/10.1038/sj.onc.1201874			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681826				2022-12-17	WOS:000074343600008
J	Gaudino, G; Avantaggiato, V; Follenzi, A; Acampora, D; Simeone, A; Comoglio, PM				Gaudino, G; Avantaggiato, V; Follenzi, A; Acampora, D; Simeone, A; Comoglio, PM			The proto-oncogene RON is involved in development of epithelial, bone and neuro-endocrine tissues	ONCOGENE			English	Article						bone; development; MSP; neuroendocrine tissues; RON	HEPATOCYTE GROWTH-FACTOR; MACROPHAGE STIMULATING PROTEIN; TYROSINE KINASE; SCATTER FACTOR; C-MET; FACTOR-RECEPTOR; PROTOONCOGENE; CELLS; IDENTIFICATION; EXPRESSION	We previously showed that the proto-oncogene RON encodes the tyrosine kinase receptor for Macrophage Stimulating Protein (MSP), originally isolated as a chemotactic factor for peritoneal macrophages. To elucidate the biological role of MSP we studied the expression of the Ron receptor in vivo, and the response to the factor in vitro, RON specific transcripts were detectable in mouse liver from early embryonal life (day 12.5 p.c.) through adult life, Adrenal gland, spinal ganglia, skin, lung and - unexpectedly - ossification centers of developing mandible, clavicle and ribs were also positive at later stages (day 13.5-16.5 p.c.). From day 17.5 RON was expressed in the gut epithelium and in a specific area of the central nervous system, corresponding to the nucleus of the hypoglossus, In adult mouse tissues RON transcripts were observed in brain, adrenal glands, gastro-intestinal tract, testis and kidney, Epithelial, osteoclast-like and neuroendocrine cells express the Ron receptor and respond to MSP in vitro. In the neuroendocrine PC12 cell line, while NGF induced growth arrest and morphological differentiation, MSP behaved as a strong mitogen. These findings show that the Ron receptor and its ligand are involved in the development of epithelial tissues, bones, and neuroendocrine derivatives driving cells towards the proliferation program.	UNIV TURIN,CANC RES INST,SCH MED,I-10126 TURIN,ITALY; INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY	University of Turin; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)			Simeone, Antonio/ABG-5269-2020; Acampora, Dario/C-2156-2013	Simeone, Antonio/0000-0003-2693-9836; Comoglio, Paolo/0000-0002-7056-5328; Follenzi, Antonia/0000-0001-9780-300X				BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAN AML, 1988, ONCOGENE, V2, P593; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; FRIEZNERDEGEN SJ, 1991, BIOCHEMISTRY-US, V30, P9781; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GRANO M, 1994, J BONE MINER RES, V9, P1013; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; Kuhlenbeck H., 1973, CENTRAL NERVOUS SYST; Larsen WJ, 1993, HUMAN EMBRYOLOGY; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PFEILSCHIFTER J, 1990, J BONE MINER RES, V5, P825; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RONSIN C, 1993, ONCOGENE, V8, P1195; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SACCONE S, 1992, GENOMICS, V13, P912, DOI 10.1016/0888-7543(92)90191-T; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS OFP, 1993, DEV BIOL, V160, P293, DOI 10.1006/dbio.1993.1308; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; THEILER K, 1989, HOUSE MOUSE; THOROGOOD P, 1988, DEVELOPMENT, V103, P141; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	43	102	107	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2627	2637						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545120				2022-12-17	WOS:A1995TP18800019
J	WEINBERG, WC; AZZOLI, CG; CHAPMAN, K; LEVINE, AJ; YUSPA, SH				WEINBERG, WC; AZZOLI, CG; CHAPMAN, K; LEVINE, AJ; YUSPA, SH			P53-MEDIATED TRANSCRIPTIONAL ACTIVITY INCREASES IN DIFFERENTIATING EPIDERMAL-KERATINOCYTES IN ASSOCIATION WITH DECREASED P53 PROTEIN	ONCOGENE			English	Article						P53; EPIDERMIS; DIFFERENTIATION; TRANSCRIPTIONAL ACTIVATION; WAF1; MDM-2	WILD-TYPE P53; TUMOR-SUPPRESSOR GENE; LARGE T-ANTIGEN; DNA-BINDING; MONOCLONAL-ANTIBODIES; MALIGNANT PROGRESSION; ACTIVATING MUTATIONS; CELL-DIFFERENTIATION; EPITHELIAL-CELLS; GROWTH-FACTOR	The regulation of p53 protein synthesis and p53-mediated gene transactivation mere evaluated in cultured mouse keratinocytes maintained as basal cells or induced to differentiate by Ca2+>0.1 mM. p53 protein half-life, p53 protein synthesis and the level of p53 mRNA decreased during terminal differentiation, as detected by immunoprecipitation ,vith a panel of p53-specific antibodies and Northern blotting. Thus differentiating keratinocytes have lower levels of p53 protein. This decline is not observed following growth arrest alone, or in papilloma cell lines which do not terminally differentiate in response to Ca2+. In contrast, the ability of endogenous p53 to transactivate transcription from the PGI, CAT plasmid increased during differentiation in vitro. This change in activity cannot be explained by changes in p53 conformation or nuclear localization. Consistent with these findings, mRNA for the p53-mediated genes WAF1 and mdm-2 increased with Ca2+-induced differentiation in a time dependent manner, suggesting activation of p53 contributes to the differentiated phenotype. However, p53-null mice exhibit histologically normal skin and epidermal keratinocytes from these mice express the appropriate markers of differentiation and suppression of DNA synthesis in vitro when the [Ca2+] is >0.1 mM. The observation that proliferating cells have higher levels of p53 protein which is less active for its function than differentiated cell types could have a consequence for the selection of p53 gene mutations during carcinogenesis, depending upon the stage of differentiation of the tumor cell type.	PRINCETON UNIV,DEPT MOLEC BIOL,LEWIS THOMAS LAB,PRINCETON,NJ 08544	Princeton University	WEINBERG, WC (corresponding author), NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BLDG 37,BETHESDA,MD 20892, USA.		Weinberg, Wendy/A-8920-2009					ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOND JA, 1994, ONCOGENE, V9, P1885; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; BURNS PA, 1991, ONCOGENE, V6, P2363; COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOTTO GP, 1988, MOL CARCINOGEN, V1, P171, DOI 10.1002/mc.2940010305; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GINSBERG D, P NATL ACAD SCI US; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HAINAUT P, 1993, CANCER RES, V53, P4469; HALEVY O, 1993, BIOCHEM BIOPH RES CO, V192, P714, DOI 10.1006/bbrc.1993.1473; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARTLEY JA, 1985, CANCER RES, V45, P4864; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HUFF CA, 1993, J BIOL CHEM, V268, P377; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1991, CANCER RES, V51, P4279; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KINJILAL S, 1993, CANCER RES, V53, P2961; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NAGANO T, 1993, ARCH DERMATOL, V129, P1157, DOI 10.1001/archderm.129.9.1157; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REISS M, 1993, CANCER RES, V53, P899; RUGGERI B, 1991, CANCER RES, V51, P6615; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SPANDAU DF, 1994, ONCOGENE, V9, P1861; SRINIVASAN R, 1993, CANCER RES, V53, P5361; STRICKLAND JE, 1988, CANCER RES, V48, P165; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAGUCHI M, 1994, J INVEST DERMATOL, V103, P500, DOI 10.1111/1523-1747.ep12395643; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WEINBERG WC, 1994, CANCER RES, V54, P5584; WEINBERG WC, 1990, DIFFERENTIATION, V45, P168, DOI 10.1111/j.1432-0436.1990.tb00470.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; YUSPA SH, 1985, METHODS SKIN RES, P213; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHANG W, 1994, CANCER RES, V54, P4448	90	102	103	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2271	2279						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784075				2022-12-17	WOS:A1995RE54300001
J	GOODYER, P; DEHBI, M; TORBAN, E; BRUENING, W; PELLETIER, J				GOODYER, P; DEHBI, M; TORBAN, E; BRUENING, W; PELLETIER, J			REPRESSION OF THE RETINOIC ACID RECEPTOR-ALPHA GENE BY THE WILMS-TUMOR SUPPRESSOR GENE-PRODUCT, WT1	ONCOGENE			English	Article						WILMS TUMOR; RETINOIC ACID RECEPTOR; WT1; CANCER GENETICS	ACUTE PROMYELOCYTIC LEUKEMIA; FACTOR-A-CHAIN; PROMOTER ACTIVITY; GROWTH; LOCUS; TRANSCRIPTION; EXPRESSION; BINDING; INDUCTION; DELETION	The Wilms' tumor (WT) suppressor gene, WT1, encodes a zinc finger DNA binding protein (wt1) which functions as a transcriptional regulator. Germline WT1 mutations predispose to WTs and in many cases are associated with urogenital anomalies. Identification of wt1 downstream targets is essential to understanding regulatory processes involved in development of this system. In this study, we demonstrate that wt1 can repress transcription of the retinoic acid receptor-alpha 1 (RAR-alpha 1) promoter. Transient transfection, deletion mutagenesis, and mobility shift assays suggest that wt1 mediates repression of the human RAR-alpha 1 promoter through a GC-rich DNA binding motif (5'-GCGGGGGCG-3'), at positions -111 to -120 bp (relative to the transcription initiation site). In contrast, the murine RAR-alpha 1 promoter contains a cryptic binding motif and is not responsive to wt1. These results indicate that some wt1-regulatory pathways are not conserved across species, suggesting a molecular basis for differences in phenotypes between humans and mice harboring WT1 lesions.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA; MONTREAL CHILDRENS HOSP,DEPT EXPTL MED,MONTREAL,PQ H3H 1P3,CANADA	McGill University; McGill University; McGill University								BORROW J, 1990, SCIENCE, V249, P1557; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HONG WK, 1994, RETINOIDS BIOL CHEM; KRIEDBERG JA, 1993, CELL, V74, P679; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; MILLER RW, 1964, NEW ENGL J MED, V270, P922, DOI 10.1056/NEJM196404302701802; MORIYA N, 1993, DEV GROWTH DIFFER, V35, P123; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SHENEFELT RE, 1972, TERATOLOGY, V5, P5103; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WANGWUU S, 1990, CANCER RES, V50, P2786; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828	34	102	110	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1125	1129						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700638				2022-12-17	WOS:A1995QN35300013
J	HICKMAN, ES; PICKSLEY, SM; VOUSDEN, KH				HICKMAN, ES; PICKSLEY, SM; VOUSDEN, KH			CELLS EXPRESSING HPV16 E7 CONTINUE CELL-CYCLE PROGRESSION FOLLOWING DNA-DAMAGE INDUCED P53 ACTIVATION	ONCOGENE			English	Article							WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; SUSCEPTIBILITY GENE; DEPENDENT KINASES; ADENOVIRUS E1A; TUMOR-ANTIGEN; GROWTH ARREST; BINDING-SITE; PROTEIN	Stabilisation and activation of p53 contributes to the G1 arrest exhibited by many cells in response to DNA damage. One function of p53 is the transcriptional activation of an inhibitor of cyclin dependent kinases; enzymes which phosphorylate and inactivate the growth inhibitory function of the pRB tumour suppressor protein. In this study we show that expression of either of the human papillomavirus encoded E6 and E7 oncoproteins allows cell cycle progression following DNA damage. This suggests that both viral proteins can function in the same pathway; E6 by directly targeting p53 for degradation and E7 through the interaction with pRB, one of the potential downstream effecters of p53.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND; UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,CRC,CELL TRANSFORMAT GRP,DUNDEE DD1 4HN,SCOTLAND	Imperial College London; Ludwig Institute for Cancer Research; University of Dundee								BANKS L, 1990, ONCOGENE, V5, P1383; BARTEK J, 1992, ONCOGENE, V7, P101; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CASEY G, 1991, ONCOGENE, V6, P1791; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hollingsworth RE, 1993, CURR OPIN CELL BIOL, V5, P194, DOI 10.1016/0955-0674(93)90102-V; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARSTON N, 1994, IN PRESS ONCOGENE; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORRIS JDH, 1993, ONCOGENE, V8, P892; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PICKSLEY SM, 1994, IN PRESS ONCOGENE; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; TOMMASINO M, 1993, ONCOGENE, V8, P195; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILKINSON D, 1988, J EXP MED, V167, P1442, DOI 10.1084/jem.167.4.1442; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	58	102	105	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2177	2181						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036003				2022-12-17	WOS:A1994NX62900008
J	MYMRYK, JS; SHIRE, K; BAYLEY, ST				MYMRYK, JS; SHIRE, K; BAYLEY, ST			INDUCTION OF APOPTOSIS BY ADENOVIRUS TYPE-5 E1A IN RAT-CELLS REQUIRES A PROLIFERATION BLOCK	ONCOGENE			English	Article							WILD-TYPE P53; CELLULAR PROTEIN; HOST-CELL; DNA; DEGRADATION; SUPPRESSOR; BINDING; ANTIGEN; 19-KDA; GENE	Infection with Ad5dl520EIB-, an adenovirus producing only the 243 residue EIA protein and lacking the EIB region, caused apoptosis in normal rat kidney (NRK) cells as judged by the production of nucleosomal DNA fragments. Apoptosis occurred only when the celts were growth-inhibited by cell-cell contacts in confluent cultures or by serum starvation and not when they were actively growing. In uninfected cultures, apoptosis also occurred at confluency, but more slowly than after infection. Studies with EIA deletion mutants of dl520E1B- showed that the regions of the EIA protein essential for induction of apoptosis were those in exon 1 required for binding to the cellular proteins p300 and pRb. Mutants defective at inducing apoptosis were previously found to be defective at inducing baby rat kidney cells to synthesize cellular DNA. In our experiments, cells underwent apoptosis when stimulated by E1A to proliferate under conditions where proliferation was blocked. It is possible that it was the proliferation block opposing the induction of proliferation that led directly to apoptosis. Circumstances leading to induction of apoptosis by c-myc (Evan et al., 1992) are similar and can be interpreted in a similar way.	MCMASTER UNIV,DEPT BIOL,HAMILTON L8S 4K1,ONTARIO,CANADA; MCMASTER UNIV,DEPT BIOCHEM,HAMILTON L8S 4K1,ONTARIO,CANADA	McMaster University; McMaster University								BARBEAU D, 1992, BIOCHEM CELL BIOL, V70, P1123, DOI 10.1139/o92-158; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; DHALLUIN JC, 1979, J VIROL, V32, P61, DOI 10.1128/JVI.32.1.61-71.1979; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EZOE H, 1981, J VIROL, V40, P20, DOI 10.1128/JVI.40.1.20-27.1981; FATT RBL, 1982, J VIROL, V42, P969, DOI 10.1128/JVI.42.3.969-977.1982; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOWE JA, 1992, VIROLOGY, V186, P15, DOI 10.1016/0042-6822(92)90057-V; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MYMRYK JS, 1993, J GEN VIROL, V74, P2131, DOI 10.1099/0022-1317-74-10-2131; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; SUBRAMANIAN T, 1984, J BIOL CHEM, V259, P1777; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; WILLIAMS G T, 1992, Trends in Cell Biology, V2, P263, DOI 10.1016/0962-8924(92)90198-V; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	33	102	105	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1187	1193						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134121				2022-12-17	WOS:A1994NC04800022
J	LYMAN, SD; JAMES, L; ZAPPONE, J; SLEATH, PR; BECKMANN, MP; BIRD, T				LYMAN, SD; JAMES, L; ZAPPONE, J; SLEATH, PR; BECKMANN, MP; BIRD, T			CHARACTERIZATION OF THE PROTEIN ENCODED BY THE FLT3 (FLK2) RECEPTOR-LIKE TYROSINE KINASE GENE	ONCOGENE			English	Article							SITE-SPECIFIC MUTAGENESIS; CELL-SURFACE EXPRESSION; GROWTH-FACTOR; PHENOTYPIC SELECTION; ONCOGENE PRODUCT; PDGF RECEPTOR; W-LOCUS; FMS; IDENTIFICATION; LOCALIZATION	We have developed rabbit polyclonal antibodies to the C-terminus of the flt3-encoded protein, which is a member of the receptor tyrosine kinase family. Immunoprecipitation using this antiserum brings down two protein bands, a major band of 143 kDa and a less abundant, more diffuse, band of 158 kDa. Pulse-chase analysis of flt3 protein from transfected COS-7 cells shows that the larger band is derived from the smaller one and presumably represents maturation of the protein from a glycosylated high-mannose form to a complex carbohydrate form. N-glycosidase F digestion confirmed the presence of N-linked carbohydrates, and cell-surface labeling of flt3-transfected cells indicated that the 158-kDa glycoprotein is the species found on the cell surface. A mutated form of the flt3 protein that was defective in its glycosylational processing was identified. Western blotting of the immunoprecipitated flt3 protein showed that it is heavily phosphorylated on tyrosine, and that this phosphorylation probably occurs in the absence of ligand. In this regard, the flt3 protein resembles the c-erbB2 protein, which is also highly phosphorylated in the absence of ligand. These data suggest that the flt3 receptor regulates the growth and differentiation of cells via an as yet unknown ligand.	IMMUNEX RES & DEV CORP,DEPT HYBRIDOMA,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT PROTEIN CHEM,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT BIOCHEM,SEATTLE,WA 98101		LYMAN, SD (corresponding author), IMMUNEX RES & DEV CORP,DEPT MOLEC BIOL,51 UNIV ST,SEATTLE,WA 98101, USA.							CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COSMAN D, 1986, MOL IMMUNOL, V23, P935, DOI 10.1016/0161-5890(86)90123-9; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LONARDO F, 1990, New Biologist, V2, P992; LYMAN SD, 1989, ONCOGENE RES, V4, P149; LYMAN SD, 1992, J AM SOC PED HEM ONC, V14, P1; MAJUMDER S, 1988, MOL CELL BIOL, V8, P4896, DOI 10.1128/MCB.8.11.4896; MANGER R, 1984, CELL, V39, P327, DOI 10.1016/0092-8674(84)90011-4; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NICHOLS EJ, 1985, MOL CELL BIOL, V5, P3467, DOI 10.1128/MCB.5.12.3467; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; RETTENMIER CW, 1986, J CLIN INVEST, V77, P1740, DOI 10.1172/JCI112496; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; SATOH H, 1987, JPN J CANCER RES, V78, P772; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WILLIAMS DE, 1992, PROG GROWTH FACTOR R, V3, P235; WOOLFORD J, 1985, MOL CELL BIOL, V5, P3458, DOI 10.1128/MCB.5.12.3458; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	31	102	109	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					815	822						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	7681159				2022-12-17	WOS:A1993KT22000001
J	GIEBEL, LB; STRUNK, KM; HOLMES, SA; SPRITZ, RA				GIEBEL, LB; STRUNK, KM; HOLMES, SA; SPRITZ, RA			ORGANIZATION AND NUCLEOTIDE-SEQUENCE OF THE HUMAN KIT (MAST STEM-CELL GROWTH-FACTOR RECEPTOR) PROTOONCOGENE	ONCOGENE			English	Article							W-MUTANT MICE; C-KIT; TYROSINE KINASE; PDGF RECEPTOR; SIGNAL-TRANSDUCTION; POINT MUTATIONS; TRANSCRIPTION FACTOR; MOUSE EMBRYOGENESIS; HEMATOPOIETIC STEM; CDNA CLONING	We have cloned and sequenced the human KIT protooncogene, which contains 21 exons and spans more than 34 kb of DNA on chromosome segment 4q12. We also establish physical linkage between the KIT gene and the related PDGFRA gene. The organization of the KIT gene is virtually identical to that of the homologous FMS gene, located on chromosome 5. Together, these data suggest that the KIT and PDGFRA genes on chromosome 4 and the FMS and PDGFRB genes on chromosome 5 arose by duplication of a common ancestral gene, followed by duplication of a chromosome.	UNIV WISCONSIN, DEPT MED GENET, 317 LAB GENET, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT PEDIAT, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIAMS NIH HHS [AR39892] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039892] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANDRE C, 1989, ONCOGENE, V4, P1047; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLARK L, 1988, GENE DEV, V2, P991, DOI 10.1101/gad.2.8.991; COOKE JV, 1952, J PEDIATR-US, V41, P1, DOI 10.1016/S0022-3476(52)80022-8; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DAURIOL L, 1988, HUM GENET, V78, P374, DOI 10.1007/BF00291740; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DISTECHE CM, 1989, CYTOGENET CELL GENET, V51, P990; FLEISCHMAN RA, 1991, P NATL ACAD SCI USA, V88, P10885, DOI 10.1073/pnas.88.23.10885; FROGGAT P, 1951, IRISH J MED SCI, V398, P86; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; HAMPE A, 1989, ONCOGENE RES, V4, P9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3799, DOI 10.1093/nar/19.14.3799; Keeler CE, 1934, J AMER MED ASSOC, V103, P0179, DOI 10.1001/jama.1934.72750290001009; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRUG MS, 1987, METHOD ENZYMOL, V152, P316; LASSAM N, 1992, ONCOGENE, V7, P51; Locker J, 1990, DNA Seq, V1, P3, DOI 10.3109/10425179009041342; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MERCOLA M, 1990, DEV BIOL, V138, P114, DOI 10.1016/0012-1606(90)90181-H; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; OCHOA A, 1989, NUCLEIC ACIDS RES, V17, P119, DOI 10.1093/nar/17.1.119; REGENSTREIF LJ, 1989, DEV BIOL, V133, P284, DOI 10.1016/0012-1606(89)90319-9; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROBERTS WM, 1992, BLOOD, V79, P586; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH H, 1987, JPN J CANCER RES, V78, P772; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIBAHARA S, 1991, J BIOL CHEM, V266, P15895; SHIBUYA M, 1990, ONCOGENE, V5, P519; SMITH DR, 1990, P NATL ACAD SCI USA, V87, P8242, DOI 10.1073/pnas.87.21.8242; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPRITZ RA, 1992, AM J HUM GENET, V50, P261; SPRITZ RA, 1992, IN PRESS AM J MED GE; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TERMAN BI, 1991, ONCOGENE, V6, P1677; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	69	102	112	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2207	2217						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1279499				2022-12-17	WOS:A1992JW66500013
J	LITTLEWOOD, TD; AMATI, B; LAND, H; EVAN, GI				LITTLEWOOD, TD; AMATI, B; LAND, H; EVAN, GI			MAX AND C-MYC MAX DNA-BINDING ACTIVITIES IN CELL-EXTRACTS	ONCOGENE			English	Article							LEUCINE ZIPPER; MONOCLONAL-ANTIBODIES; PROTEIN; DIMERIZATION; OLIGOMERIZATION; TRANSFORMATION; TRANSCRIPTION; LOCALIZATION; REGIONS; DOMAINS	We have examined the interactions and DNA-binding activities of the c-Myc oncoprotein and its partner Max. In cell extracts virtually all c-Mvc molecules are associated with Max in heterodimeric complexes. Moreover, DNA-binding studies with in vitro-translated protein and cell extracts show that both Max alone and c-Myc/Max bind the same DNA sequence. Conversely, c-Myc is unable to bind this sequence in the absence of Max. These findings suggest that c-Myc may function via obligate complex formation with Max.	IMPERIAL CANC RES FUND,GROWTH CONTROL & DEV LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	LITTLEWOOD, TD (corresponding author), IMPERIAL CANC RES FUND,BIOCHEM CELL NUCLEUS LAB,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.		Amati, Bruno/AAM-3418-2020	Amati, Bruno/0000-0002-2958-1799				ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BADER JP, 1985, J VIROL, V53, P509, DOI 10.1128/JVI.53.2.509-514.1985; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EVAN GI, 1984, J IMMUNOL METHODS, V73, P427, DOI 10.1016/0022-1759(84)90417-4; EVAN GI, 1986, CURR TOP MICROBIOL, V132, P362; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KERKHOFF E, 1991, ONCOGENE, V6, P93; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MOORE JP, 1987, ONCOGENE RES, V2, P65; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; WATERS C, 1991, ONCOGENE, V6, P101; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	27	102	102	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1783	1792						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501888				2022-12-17	WOS:A1992JJ37600015
J	JORCYK, CL; WATSON, DK; MAVROTHALASSITIS, GJ; PAPAS, TS				JORCYK, CL; WATSON, DK; MAVROTHALASSITIS, GJ; PAPAS, TS			THE HUMAN ETS1 GENE - GENOMIC STRUCTURE, PROMOTER CHARACTERIZATION AND ALTERNATIVE SPLICING	ONCOGENE			English	Article							LONG TERMINAL REPEAT; ONCOGENE C-ETS; PROTO-ONCOGENE; TRANSCRIPTION FACTOR; FUNCTIONAL-CHARACTERIZATION; TRANSFORMING GENE; NUCLEAR PROTEINS; LEUKEMIA VIRUSES; E26 RETROVIRUS; SARCOMA-VIRUS	Genomic clones encompassing the human ETS1 gene were isolated and utilized to define its molecular organization. This gene consists of eight exons spanning over 60 kb. The 5' end of the human ETS1 gene was subcloned and characterized. S1 nuclease, primer extension and RNAase protection analyses of human mRNAs showed multiple transcription initiation sites. DNA sequence analysis indicated a high G + C content in the promoter region and the absence of either a 'TATA' box or a 'CAAT' box. Six consensus recognition sequences for the transcription factor SP1, two AP1 consensus sequences and one consensus AP2 recognition sequence were identified, as well as two GC elements with dyad symmetry. A palindromic region similar to the serum response element of the c-fos gene and two octamer consensus recognition sequences were located upstream of the promoter region. A series of promoter deletion constructs positioned upstream from the bacterial chloramphenicol acetyl transferase gene were transfected into HeLa cells and their functional promoter activity assayed. The deletion constructs identified the 5' boundary for maximum promoter activity at 486 bp upstream of the first initiation site and suggest possible positive and negative regulatory regions. Polymerase chain reaction analysis of ETS1 cDNA identified several amplified products, indicating alternative splicing. In addition to the presence of mRNA products lacking exon VII, products lacking exon IV, as well as ones lacking both exons IV and VII, were found.			JORCYK, CL (corresponding author), NCI, MOLEC ONCOL LAB, FREDERICK, MD 21702 USA.							ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; BERG PE, 1989, NUCLEIC ACIDS RES, V17, P8833, DOI 10.1093/nar/17.21.8833; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CHEN JH, 1988, ONCOGENE RES, V2, P371; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DESIMONE V, 1989, NUCLEIC ACIDS RES, V17, P9407, DOI 10.1093/nar/17.22.9407; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; EVANS T, 1988, J MOL BIOL, V199, P61, DOI 10.1016/0022-2836(88)90379-8; FIELD LJ, 1985, P NATL ACAD SCI USA, V82, P6196, DOI 10.1073/pnas.82.18.6196; GEGONNE A, 1987, MOL CELL BIOL, V7, P806, DOI 10.1128/MCB.7.2.806; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAF T, 1979, VIROLOGY, V99, P431, DOI 10.1016/0042-6822(79)90024-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAMPE A, 1989, ONCOGENE RES, V4, P9; HANVEY JC, 1988, P NATL ACAD SCI USA, V85, P6292, DOI 10.1073/pnas.85.17.6292; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JOHNSON DG, 1990, MOL CELL BIOL, V10, P982, DOI 10.1128/MCB.10.3.982; JOHNSTON BH, 1988, SCIENCE, V241, P1800, DOI 10.1126/science.2845572; KEOHAVONG P, 1982, NUCLEIC ACIDS RES, V10, P1215, DOI 10.1093/nar/10.4.1215; KIM SJ, 1989, J BIOL CHEM, V264, P402; KOIZUMI S, 1990, ONCOGENE, V5, P675; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; Maniatis T., 1982, MOL CLONING; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; Maxam A M, 1980, Methods Enzymol, V65, P499; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; ROVIGATTI U, 1986, SCIENCE, V232, P398, DOI 10.1126/science.3457468; SACCHI N, 1988, LEUKEMIA, V2, P12; SACCHI N, 1986, SCIENCE, V231, P379, DOI 10.1126/science.3941901; SALIER JP, 1989, BIOTECHNIQUES, V7, P30; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; SETH A, 1991, IN PRESS ONCOGENE; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1988, VIROLOGY, V164, P99, DOI 10.1016/0042-6822(88)90624-1; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WIDEN SG, 1988, J BIOL CHEM, V263, P16992; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220	64	102	102	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1991	6	4					523	532						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	2030910				2022-12-17	WOS:A1991FR93900005
J	TAKAHASHI, M; BUMA, Y; TANIGUCHI, M				TAKAHASHI, M; BUMA, Y; TANIGUCHI, M			IDENTIFICATION OF THE RET PROTOONCOGENE PRODUCTS IN NEUROBLASTOMA AND LEUKEMIA-CELLS	ONCOGENE			English	Article							EXPRESSION; PROTOONCOGENE; RNA	Monoclonal and/or polyclonal antibodies were generated against the products synthesized from two portions of the ret proto-oncogene (c-ret) cDNA expressed in Escherichia coli. These antibodies were reactive in immunoblotting with 150 kd and 170 kd proteins in cell lysates from three human neuroblastoma cell lines expressing the ret proto-oncogene. When the neuroblastoma cells were treated with tunicamycin, a protein with an apparent molecular weight of 120 kd, which is consistent with that of the c-ret protein predicted from the cDNA sequence, appeared on immunoblots. These results indicated that the 150 kd and 170 kd proteins in neuroblastoma cells are produced from a single polypeptide of 120 kd by post-translational glycosylation. Furthermore, the antibodies detected a unique 190 kd protein as well as 150 kd protein in a cell lysate from THP-1 human monocytic leukemia cell line, suggesting that glycosylated forms of the c-ret protein are different between neuroblastoma and leukemia cells.	AICHI CANC CTR,RES INST,EXPTL PATHOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Aichi Cancer Center	TAKAHASHI, M (corresponding author), NAGOYA UNIV,SCH MED,DEPT PATHOL 2,65 TSURUMAI CHO,NAGOYA,AICHI 466,JAPAN.		TAKAHASHI, Masahide/I-7244-2014; Takahashi, Masahide/AAN-4770-2020	Takahashi, Masahide/0000-0002-2803-2683				IKEDA I, 1990, ONCOGENE, V5, P1291; KIKUCHI T, 1990, HYBRIDOMA, V9, P189, DOI 10.1089/hyb.1990.9.189; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; NAGAO M, 1990, JPN J CANCER RES, V81, P309, DOI 10.1111/j.1349-7006.1990.tb02566.x; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571	12	102	105	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					297	301						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	2000222				2022-12-17	WOS:A1991FZ13400016
J	MILLER, WH; MOY, D; LI, A; GRIPPO, JF; DMITROVSKY, E				MILLER, WH; MOY, D; LI, A; GRIPPO, JF; DMITROVSKY, E			RETINOIC ACID INDUCES DOWN-REGULATION OF SEVERAL GROWTH-FACTORS AND PROTOONCOGENES IN A HUMAN EMBRYONAL CANCER CELL-LINE	ONCOGENE			English	Article									CORNELL UNIV,MED CTR,COLL MED,MEM SLOAN KETTERING CANC CTR,DEPT MED,DIV SOLID TUMOR ONCOL,NEW YORK,NY 10021; HOFFMANN LA ROCHE INC,DEPT TOXICOL & PATHOL,NUTLEY,NJ 07110	Cornell University; Memorial Sloan Kettering Cancer Center; Roche Holding								ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ADAMSON ED, 1979, CELL, V17, P469, DOI 10.1016/0092-8674(79)90254-X; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1986, DIFFERENTIATION, V31, P119, DOI 10.1111/j.1432-0436.1986.tb00392.x; ANDREWS PW, 1984, LAB INVEST, V50, P147; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BROOKES S, 1989, ONCOGENE, V4, P429; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CUYPERS HT, 1984, CELL, V37, P141; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DESCHAMPS J, 1987, P NATL ACAD SCI USA, V84, P1304, DOI 10.1073/pnas.84.5.1304; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DMITROVSKY E, 1990, IN PRESS ONCOGENE RE; DONY C, 1988, DIFFERENTIATION, V37, P115, DOI 10.1111/j.1432-0436.1988.tb00803.x; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; EDWARDS SA, 1986, EXP CELL RES, V165, P473, DOI 10.1016/0014-4827(86)90600-2; EDWARDS SA, 1988, DEV BIOL, V129, P91, DOI 10.1016/0012-1606(88)90164-9; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; FIDDES JC, 1980, NATURE, V286, P684, DOI 10.1038/286684a0; FINKLESTEIN R, 1988, ONCOGENE RES, V3, P287; Fogh J, 1978, Natl Cancer Inst Monogr, P5; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRIEP AE, 1986, P NATL ACAD SCI USA, V83, P5539, DOI 10.1073/pnas.83.15.5539; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALABAN R, 1988, ONCOGENE RES, V3, P177; HAUSER CA, 1985, CELL, V43, P19, DOI 10.1016/0092-8674(85)90008-X; HELMAN LJ, 1988, J BIOL CHEM, V263, P11559; INGVARSSON S, 1988, ONCOGENE, V3, P679; JAKOBOVITS A, 1985, NATURE, V318, P188, DOI 10.1038/318188a0; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; LEE VMY, 1986, J NEUROSCI, V6, P514; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MAVILIO F, 1988, DIFFERENTIATION, V37, P73, DOI 10.1111/j.1432-0436.1988.tb00798.x; MULLER R, 1986, TRENDS BIOCHEM SCI, V11, P129, DOI 10.1016/0968-0004(86)90066-6; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; PIERCE GB, 1974, CURRENT TOPICS MOL B, P223; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; REES AR, 1979, NATURE, V281, P309, DOI 10.1038/281309a0; RIZZINO A, 1988, DEV BIOL, V129, P61, DOI 10.1016/0012-1606(88)90161-3; RIZZINO A, 1987, CANCER RES, V47, P4386; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SAMBUCETTI LC, 1986, GENE, V43, P69, DOI 10.1016/0378-1119(86)90009-0; SCOTT RW, 1984, NATURE, V310, P562, DOI 10.1038/310562a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STERNFELD MD, 1988, J CELL PHYSIOL, V136, P297, DOI 10.1002/jcp.1041360212; STRICKLAND S, 1980, DEV BIOL, V78, P76, DOI 10.1016/0012-1606(80)90319-X; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1981, CELL, V24, P277, DOI 10.1016/0092-8674(81)90313-5; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TSUTSUI Y, 1987, CELL DIFFER DEV, V21, P137, DOI 10.1016/0045-6039(87)90421-0; VERMA IM, 1987, ADV CANCER RES, V49, P29, DOI 10.1016/S0065-230X(08)60793-9; WANG N, 1980, CANCER RES, V40, P796; WANG SY, 1983, P NATL ACAD SCI-BIOL, V80, P5880, DOI 10.1073/pnas.80.19.5880; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V157, P618, DOI 10.1016/S0006-291X(88)80295-X; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; ZEUTHEN J, 1980, INT J CANCER, V25, P19, DOI 10.1002/ijc.2910250104	72	102	102	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					511	517						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	2158037				2022-12-17	WOS:A1990DB85300009
J	RABBITTS, PH; DOUGLAS, J; FISCHER, P; NACHEVA, E; KARPAS, A; CATOVSKY, D; MELO, JV; BAER, R; STINSON, MA; RABBITTS, TH				RABBITTS, PH; DOUGLAS, J; FISCHER, P; NACHEVA, E; KARPAS, A; CATOVSKY, D; MELO, JV; BAER, R; STINSON, MA; RABBITTS, TH			CHROMOSOME-ABNORMALITIES AT 11Q13 IN B-CELL TUMORS	ONCOGENE			English	Article									MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND; MRC,LUDWIG INST CANC RES,CAMBRIDGE CB2 2QH,ENGLAND; UNIV CAMBRIDGE,CTR MRC,DEPT HAEMATOL MED,CAMBRIDGE CB2 2QH,ENGLAND; ROYAL POSTGRAD MED SCH,MRC,LEUKAEMIA UNIT,LONDON W12 0HS,ENGLAND	MRC Laboratory Molecular Biology; Ludwig Institute for Cancer Research; University of Cambridge; University of Cambridge; Imperial College London								BANKIER AT, 1983, NUCLEIC ACID BIOCH B, V408, P1; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BOEHM T, 1988, IN PRESS EMBO J, V7; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHER P, 1988, UNPUB; FLANAGAN JG, 1982, EMBO J, V1, P655, DOI 10.1002/j.1460-2075.1982.tb01223.x; GOODFELLOW PN, 1982, EUR J IMMUNOL, V12, P659, DOI 10.1002/eji.1830120807; GRAHAM M, 1986, EMBO J, V5, P2845, DOI 10.1002/j.1460-2075.1986.tb04578.x; HALUSKA FG, 1986, NATURE, V324, P158, DOI 10.1038/324158a0; KARN J, 1984, GENE, V32, P219; KELLY A, 1985, NUCLEIC ACIDS RES, V13, P1607, DOI 10.1093/nar/13.5.1607; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; MELO JV, 1986, INT J CANCER, V38, P531, DOI 10.1002/ijc.2910380413; MENGLEGAW L, 1987, EMBO J, V6, P1959, DOI 10.1002/j.1460-2075.1987.tb02458.x; RABBITTS TH, 1985, TRENDS GENET, V1, P327, DOI 10.1016/0168-9525(85)90127-1; ROGAN PK, 1985, MOL BIOL EVOL; SMITH SD, 1984, CANCER RES, V44, P5657; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STADEN R, 1986, NUCLEIC ACIDS RES, V14, P217, DOI 10.1093/nar/14.1.217; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; VANDENBERGHE H, 1984, CANCER GENET CYTOGEN, V11, P381, DOI 10.1016/0165-4608(84)90017-7; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310	26	102	104	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1988	3	1					99	103						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	P0354					2022-12-17	WOS:A1988P035400014
J	Yang, F; Jin, H; Que, B; Chao, YH; Zhang, HQ; Ying, XL; Zhou, ZY; Yuan, ZS; Su, JL; Wu, B; Zhang, WJ; Qi, DF; Chen, DM; Min, W; Lin, SB; Ji, WD				Yang, Fan; Jin, Huan; Que, Biao; Chao, Yinghui; Zhang, Haiqing; Ying, Xiaoling; Zhou, Zhongyang; Yuan, Zusen; Su, Jialin; Wu, Bin; Zhang, Wenjuan; Qi, Defeng; Chen, Demeng; Min, Wang; Lin, Shuibin; Ji, Weidong			Dynamic m(6)A mRNA methylation reveals the role of METTL3-m(6)A-CDCP1 signaling axis in chemical carcinogenesis	ONCOGENE			English	Article							INDUCED MALIGNANT-TRANSFORMATION; STEM-LIKE CELLS; EPITHELIAL-CELLS; NUCLEAR-RNA; N-6-METHYLADENOSINE; CDCP1; GENE; N6-METHYLADENOSINE; TRANSLATION; DEMETHYLASE	N6-methyladenosine (m(6)A) is the most abundant internal modification in mammalian mRNAs. Despite its functional importance in various physiological events, the role of m(6)A in chemical carcinogenesis remains largely unknown. Here we profiled the dynamic m(6)A mRNA modification during cellular transformation induced by chemical carcinogens and identified a subset of cell transformation-related, concordantly modulated m(6)A sites. Notably, the increased m(6)A in 3'-UTR mRNA of oncogene CDCP1 was found in malignant transformed cells. Mechanistically, the m(6)A methyltransferase METTL3 and demethylases ALKBH5 mediate the m(6)A modification in 3'-UTR of CDCP1 mRNA. METTL3 and m(6)A reader YTHDF1 preferentially recognize m(6)A residues on CPCP1 3'-UTR and promote CDCP1 translation. We further showed that METTL3 and CDCP1 are upregulated in the bladder cancer patient samples and the expression of METTL3 and CDCP1 is correlated with the progression status of the bladder cancers. Inhibition of the METTL3-m(6)A-CDCP1 axis resulted in decreased growth and progression of chemical-transformed cells and bladder cancer cells. Most importantly, METTL3-m(6)A-CDCP1 axis has synergistic effect with chemical carcinogens in promoting malignant transformation of uroepithelial cells and bladder cancer tumorigenesis in vitro and in vivo. Taken together, our results identify dynamic m(6)A modification in chemical-induced malignant transformation and provide insight into critical roles of the METTL3-m(6)A-CDCP1 axis in chemical carcinogenesis.	[Yang, Fan; Jin, Huan; Que, Biao; Chao, Yinghui; Zhang, Haiqing; Ying, Xiaoling; Zhou, Zhongyang; Su, Jialin; Chen, Demeng; Min, Wang; Lin, Shuibin; Ji, Weidong] Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Translat Med, Guangzhou 510080, Guangdong, Peoples R China; [Jin, Huan] Zunyi Med Coll, Dept Physiol, Zunyi 563000, Guizhou, Peoples R China; [Que, Biao; Yuan, Zusen; Qi, Defeng] Guangzhou Med Univ, Affiliated Hosp 1, Minimally Invas Surg Ctr, Guangdong Key Lab Urol,Dept Urol, Guangzhou 510230, Guangdong, Peoples R China; [Wu, Bin] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangzhou 510080, Guangdong, Peoples R China; [Zhang, Wenjuan] Jinan Univ, Sch Med, Dept Prevent Med, Guangzhou 510632, Guangdong, Peoples R China; [Min, Wang] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06519 USA; [Min, Wang] Yale Univ, Sch Med, Vasc Biol & Therapeut Program, New Haven, CT 06519 USA	Sun Yat Sen University; Zunyi Medical University; Guangzhou Medical University; Guangzhou University of Chinese Medicine; Jinan University; Yale University; Yale University	Min, W; Lin, SB; Ji, WD (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Translat Med, Guangzhou 510080, Guangdong, Peoples R China.; Min, W (corresponding author), Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06519 USA.; Min, W (corresponding author), Yale Univ, Sch Med, Vasc Biol & Therapeut Program, New Haven, CT 06519 USA.	wang.min@yale.edu; linshb6@mail.sysu.edu.cn; jiweidong@mail.sysu.edu.cn	ji, weidong/AAX-7397-2020	Lin, Shuibin/0000-0002-7065-614X	National Natural Science Foundation of China [81472999, 81772699, 81772999, 81473014, 81272350]; Key Natural Science Foundation of Guangdong [8151012003000011]; Guangzhou People's Livelihood Science and Technology Project [201803010052]; Key projects of Guangzhou Scientific Research [201804020023]; National Key Research and Development Program of China [2016YFC1300600]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Natural Science Foundation of Guangdong; Guangzhou People's Livelihood Science and Technology Project; Key projects of Guangzhou Scientific Research; National Key Research and Development Program of China	This work was supported by grants from National Natural Science Foundation of China (Number 81472999, Number 81772699, Number 81772999, Number 81473014, and Number 81272350), Key Natural Science Foundation of Guangdong (Number 8151012003000011), Guangzhou People's Livelihood Science and Technology Project (201803010052), Key projects of Guangzhou Scientific Research (201804020023), National Key Research and Development Program of China (2016YFC1300600).	Achanzar WE, 2001, CANCER RES, V61, P455; Batista PJ, 2014, CELL STEM CELL, V15, P707, DOI 10.1016/j.stem.2014.09.019; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Clark SJ, 2017, CANCER CELL, V32, P278, DOI 10.1016/j.ccell.2017.08.016; Cui Q, 2017, CELL REP, V18, P2622, DOI 10.1016/j.celrep.2017.02.059; Dominissini D, 2013, NAT PROTOC, V8, P176, DOI 10.1038/nprot.2012.148; Dominissini D, 2012, NATURE, V485, P201, DOI 10.1038/nature11112; Dunn SJ, 2014, SCIENCE, V344, P1156, DOI 10.1126/science.1248882; Feinberg AP, 2016, NAT REV GENET, V17, P284, DOI 10.1038/nrg.2016.13; Fu Y, 2014, NAT REV GENET, V15, P293, DOI 10.1038/nrg3724; Haussmann IU, 2016, NATURE, V540, P301, DOI 10.1038/nature20577; He Y, 2016, ONCOGENE, V35, P468, DOI 10.1038/onc.2015.101; HEIDELBERGER C, 1975, ANNU REV BIOCHEM, V44, P79, DOI 10.1146/annurev.bi.44.070175.000455; Ji WD, 2006, BIOMED ENVIRON SCI, V19, P277; Ji WD, 2008, CARCINOGENESIS, V29, P1267, DOI 10.1093/carcin/bgn012; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Lence T, 2016, NATURE, V540, P242, DOI 10.1038/nature20568; Li ZJ, 2017, CANCER CELL, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Lin SB, 2018, MOL CELL, V71, P244, DOI 10.1016/j.molcel.2018.06.001; Lin SB, 2016, MOL CELL, V62, P335, DOI 10.1016/j.molcel.2016.03.021; Liu JZ, 2014, NAT CHEM BIOL, V10, P93, DOI 10.1038/nchembio.1432; Luch A, 2005, NAT REV CANCER, V5, P113, DOI 10.1038/nrc1546; Ma JZ, 2017, HEPATOLOGY, V65, P529, DOI 10.1002/hep.28885; Meng J, 2014, METHODS, V69, P274, DOI 10.1016/j.ymeth.2014.06.008; Meyer KD, 2017, ANNU REV CELL DEV BI, V33, P319, DOI 10.1146/annurev-cellbio-100616-060758; Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003; Ping XL, 2014, CELL RES, V24, P177, DOI 10.1038/cr.2014.3; Ravegnini G, 2015, TOXICOL SCI, V148, P2, DOI 10.1093/toxsci/kfv165; REZNIKOFF CA, 1988, CARCINOGENESIS, V9, P1427, DOI 10.1093/carcin/9.8.1427; Roundtree IA, 2017, ELIFE, V6, DOI 10.7554/eLife.31311; Roundtree IA, 2016, CURR OPIN CHEM BIOL, V30, P46, DOI 10.1016/j.cbpa.2015.10.024; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566; Sens DA, 2004, TOXICOL SCI, V79, P56, DOI 10.1093/toxsci/kfh086; Tuck MT, 1996, CANCER LETT, V103, P107, DOI 10.1016/0304-3835(96)04203-6; Uekita T, 2014, MOL CANCER RES, V12, P1449, DOI 10.1158/1541-7786.MCR-13-0587; Vaz M, 2017, CANCER CELL, V32, P360, DOI 10.1016/j.ccell.2017.08.006; Visvanathan A, 2018, ONCOGENE, V37, P522, DOI 10.1038/onc.2017.351; Vu LP, 2017, NAT MED, V23, P1369, DOI 10.1038/nm.4416; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Wang Y, 2014, NAT CELL BIOL, V16, P191, DOI 10.1038/ncb2902; Wortmann A, 2009, IUBMB LIFE, V61, P723, DOI 10.1002/iub.198; Wright HJ, 2016, ONCOGENE, V35, P4762, DOI 10.1038/onc.2016.7; Xiao W, 2016, MOL CELL, V61, P507, DOI 10.1016/j.molcel.2016.01.012; Yoon KJ, 2017, CELL, V171, P877, DOI 10.1016/j.cell.2017.09.003; Zhang CZ, 2016, P NATL ACAD SCI USA, V113, pE2047, DOI 10.1073/pnas.1602883113; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zheng GQ, 2013, MOL CELL, V49, P18, DOI 10.1016/j.molcel.2012.10.015	49	101	103	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4755	4772		10.1038/s41388-019-0755-0	http://dx.doi.org/10.1038/s41388-019-0755-0			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30796352	Green Published, hybrid			2022-12-17	WOS:000471160500008
J	Tang, JM; Li, YX; Sang, YZ; Yu, B; Lv, DG; Zhang, WW; Feng, HZ				Tang, Jianming; Li, Yanxin; Sang, Youzhou; Yu, Bo; Lv, Deguan; Zhang, Weiwei; Feng, Haizhong			LncRNA PVT1 regulates triple-negative breast cancer through KLF5/beta-catenin signaling	ONCOGENE			English	Article							CELL-PROLIFERATION; POOR-PROGNOSIS; GASTRIC-CANCER; MYC; AMPLIFICATION; METASTASIS; EXPRESSION; INVASION; CATENIN; GENE	Recent molecularly targeted approach gains advance in breast cancer treatment. However, the estimated 5-year survival rate has not met the desired expectation for improvement, especially for patients with triple-negative breast cancer (TNBC). Here we report that the lncRNA PVT1 promotes KLF5/beta-catenin signaling to drive TNBC tumorigenesis. PVT1 is upregulated in clinical TNBC tumors. Using genetic approaches targeting PVT1 in TNBC cells, we found that PVT1 depletion inhibited cell proliferation, colony formation, and orthotopic xenograft tumor growth. Mechanistically, PVT1 binds with KLF5 and increases its stability via BAP1, which upregulates beta-catenin signaling, resulting in enhanced TNBC tumorigenesis. PVT1, KLF5, and beta-catenin were also revealed to be co-expressed in clinical TNBC samples. Our findings uncover a new singaling pathway to mediate TNBC, and provide PVT1 as a new target for improving treatment of TNBC.	[Tang, Jianming; Sang, Youzhou; Yu, Bo; Lv, Deguan; Zhang, Weiwei; Feng, Haizhong] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Renji Med Clin Stem Cell Res Ctr 10,State Key Lab, Shanghai 200127, Peoples R China; [Li, Yanxin] Shanghai Jiao Tong Univ, Pediat Translat Med Inst, Key Lab Pediat Hematol & Oncol, Shanghai Childrens Med Ctr,Minist Hlth,Sch Med, Shanghai 200127, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Feng, HZ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Renji Med Clin Stem Cell Res Ctr 10,State Key Lab, Shanghai 200127, Peoples R China.; Li, YX (corresponding author), Shanghai Jiao Tong Univ, Pediat Translat Med Inst, Key Lab Pediat Hematol & Oncol, Shanghai Childrens Med Ctr,Minist Hlth,Sch Med, Shanghai 200127, Peoples R China.	liyanxin@scmc.com.cn; Fenghaizhong@sjtu.edu.cn	Feng, Haizhong/E-5795-2017	Feng, Haizhong/0000-0003-3552-6865; Tang, Jianming/0000-0003-3738-9761; Lv, Deguan/0000-0003-3142-9814	National Natural Science Foundation of China [81372704, 81572467, 81470315, 81772663]; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning [2014024]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20161310]; New Hundred Talent Program (Outstanding Academic Leader) at Shanghai Municipal Health Bureau [2017BR021]; State Key Laboratory of Oncogenes and Related Genes in China [91-17-25]; Technology Transfer Project of Science and Technology Department at Shanghai Jiao Tong University School of Medicine [ZT201701]; Shanghai Jiao Tong University School of Medicine Hospital Fund [14XJ10069]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support; New Hundred Talent Program (Outstanding Academic Leader) at Shanghai Municipal Health Bureau; State Key Laboratory of Oncogenes and Related Genes in China; Technology Transfer Project of Science and Technology Department at Shanghai Jiao Tong University School of Medicine; Shanghai Jiao Tong University School of Medicine Hospital Fund	This work was supported in part by the National Natural Science Foundation of China (No. 81372704, 81572467 to H.F.; No. 81470315, 81772663 to Y.L.); the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (No. 2014024), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (No. 20161310), New Hundred Talent Program (Outstanding Academic Leader) at Shanghai Municipal Health Bureau (2017BR021), the State Key Laboratory of Oncogenes and Related Genes in China (No. 91-17-25), and Technology Transfer Project of Science and Technology Department at Shanghai Jiao Tong University School of Medicine (ZT201701) to H.F.; and Shanghai Jiao Tong University School of Medicine Hospital Fund (No. 14XJ10069) to Y.L.	Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; CORY S, 1985, EMBO J, V4, P675, DOI 10.1002/j.1460-2075.1985.tb03682.x; Grampp S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13183; Guan YH, 2007, CLIN CANCER RES, V13, P5745, DOI 10.1158/1078-0432.CCR-06-2882; Guo LL, 2015, CELL SIGNAL, V27, P961, DOI 10.1016/j.cellsig.2015.02.005; Iden M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156274; Ishikawa ET, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2645; Jones RA, 2016, J CLIN INVEST, V126, P3739, DOI 10.1172/JCI81568; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Kong R, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0355-8; Li PD, 2017, ONCOTARGET, V8, P34164, DOI 10.18632/oncotarget.15878; Li WJ, 2017, J CLIN INVEST, V127, P3427, DOI 10.1172/JCI94233; Li Z, 2016, CELL DEATH DIFFER, V23, P583, DOI 10.1038/cdd.2015.125; Lin AF, 2017, NAT CELL BIOL, V19, P238, DOI 10.1038/ncb3473; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Mathelier A, 2014, NUCLEIC ACIDS RES, V42, pD142, DOI 10.1093/nar/gkt997; Nakaya T, 2014, CANCER RES, V74, P2882, DOI 10.1158/0008-5472.CAN-13-2574; Qin JY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9471; Shi PG, 2017, CELL DISCOV, V3, DOI 10.1038/celldisc.2017.10; SHTIVELMAN E, 1989, MOL CELL BIOL, V9, P1148, DOI 10.1128/MCB.9.3.1148; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Takahashi Y, 2014, Br J Cancer, V110, P164, DOI 10.1038/bjc.2013.698; Tong D, 2006, CLIN CANCER RES, V12, P2442, DOI 10.1158/1078-0432.CCR-05-0964; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Wan L, 2016, MOL CANCER THER, V15, P1082, DOI 10.1158/1535-7163.MCT-15-0707; Wang F, 2014, HEPATOLOGY, V60, P1278, DOI 10.1002/hep.27239; WEBB E, 1984, NATURE, V312, P777, DOI 10.1038/312777a0; Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909; Xu MD, 2017, CLIN CANCER RES, V23, P2071, DOI 10.1158/1078-0432.CCR-16-0742; Zhang L, 2016, ONCOGENE, V35, P5641, DOI 10.1038/onc.2016.100; Zhou Q, 2016, ONCOTARGET, V7, P82620, DOI 10.18632/oncotarget.13012; Zhou W, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aak9557	33	101	108	5	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2018	37	34					4723	4734		10.1038/s41388-018-0310-4	http://dx.doi.org/10.1038/s41388-018-0310-4			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GR3SE	29760406				2022-12-17	WOS:000442514400007
J	Ren, T; Zhang, H; Wang, J; Zhu, J; Jin, M; Wu, Y; Guo, X; Ji, L; Huang, Q; Zhang, H; Yang, H; Xing, J				Ren, T.; Zhang, H.; Wang, J.; Zhu, J.; Jin, M.; Wu, Y.; Guo, X.; Ji, L.; Huang, Q.; Zhang, H.; Yang, H.; Xing, J.			MCU-dependent mitochondrial Ca2+ inhibits NAD(+)/SIRT3/SOD2 pathway to promote ROS production and metastasis of HCC cells	ONCOGENE			English	Article							OPERATED CALCIUM-ENTRY; HEPATOCELLULAR-CARCINOMA; PYRUVATE-DEHYDROGENASE; TUMOR PROGRESSION; CANCER CELLS; UNIPORTER; MIGRATION; PROTEIN; DEATH; JNK	Mitochondrial Ca2+ signaling, which is strongly dependent on the mitochondrial Ca2+ uniporter (MCU) complex, has a series of key roles in physiopathological processes, including energy metabolism, reactive oxygen species (ROS) production and cell apoptosis. However, a mechanistic understanding of how the mitochondrial Ca2+ signaling is remodeled and its functional roles remains greatly limited in cancers, especially in hepatocellular carcinoma. Here we demonstrated that the MCU complex was dysregulated in hepatocellular carcinoma (HCC) cells and significantly correlated with metastasis and poor prognosis of HCC patients. Upregulation of MCU clearly enhanced the Ca2+ uptake into mitochondria, which significantly promoted ROS production by downregulating nicotinamide adenine dinucleotide(+) (NAD(+))/reduced form of nicotinamide adenine dinucleotid (NADH) ratio and the NAD+-dependent deacetylase activity of sirtuin 3 to inhibit superoxide dismutase 2 (SOD2) activity. Moreover, our data indicated that the MCU-dependent mitochondrial Ca2+ uptake promotes matrix metalloproteinase-2 activity and cell motility by ROS-activated c-Jun N-terminal kinase pathway, and thus contributed to the increased ability of invasion and migration in vitro and intrahepatic and distal lung metastasis in vivo of HCC cells. In addition, treatment with the mitochondrial Ca2+-buffering protein parvalbumin significantly suppressed ROS production and the ability of HCC metastasis. Our study uncovers a mechanism that links the remodeling of mitochondrial Ca2+ homeostasis to ROS production, and provides evidence supporting a metastasis-promoting role for the MCU-dependent mitochondrial Ca2+ uptake in HCC. Our findings suggest that the mitochondrial Ca2+ uptake machinery may potentially be a novel therapeutic target for HCC metastasis.	[Ren, T.; Wang, J.; Zhu, J.; Jin, M.; Wu, Y.; Guo, X.; Ji, L.; Huang, Q.; Xing, J.] Fourth Mil Med Univ, State Key Lab Canc Biol, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China; [Ren, T.; Wang, J.; Zhu, J.; Jin, M.; Wu, Y.; Guo, X.; Ji, L.; Huang, Q.; Xing, J.] Fourth Mil Med Univ, Expt Teaching Ctr Basic Med, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China; [Zhang, H.; Zhang, H.] Fourth Mil Med Univ, Tangdu Hosp, Dept Pain Treatment, Xian, Shaanxi, Peoples R China; [Yang, H.] Thomas Jefferson Univ, Dept Med Oncol, Kimmel Canc Ctr, Div Populat Sci, Philadelphia, PA 19107 USA	Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University; Jefferson University	Xing, J (corresponding author), Fourth Mil Med Univ, State Key Lab Canc Biol, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.; Xing, J (corresponding author), Fourth Mil Med Univ, Expt Teaching Ctr Basic Med, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.	xingjl@fmmu.edu.cn			National Natural Science Foundation of China [81572727, 81320108021]; National Basic Research Program [2015CB553703]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program(National Basic Research Program of China)	This work was supported by the National Natural Science Foundation of China (grants 81572727 and 81320108021) and National Basic Research Program (grant 2015CB553703).	Adam-Vizi V, 2010, J ALZHEIMERS DIS, V20, pS413, DOI 10.3233/JAD-2010-100465; Arvizo RR, 2013, J BIOL CHEM, V288, P17610, DOI 10.1074/jbc.M112.435206; Asimakis GK, 2002, CIRCULATION, V105, P981, DOI 10.1161/hc0802.104502; Baughman JM, 2011, NATURE, V476, P341, DOI 10.1038/nature10234; Campanella M, 2004, BIOL RES, V37, P653; Chaudhari S, 2014, FASEB J, V28; Chen YH, 2011, EMBO REP, V12, P534, DOI 10.1038/embor.2011.65; Chiba T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084807; Curry MC, 2013, BIOCHEM BIOPH RES CO, V434, P695, DOI 10.1016/j.bbrc.2013.04.015; De Stefani D, 2011, NATURE, V476, P336, DOI 10.1038/nature10230; Hakanpaa L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6962; Hall DD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096866; HANSFORD RG, 1994, J BIOENERG BIOMEMBR, V26, P495, DOI 10.1007/BF00762734; HINMAN LM, 1981, J BIOL CHEM, V256, P6583; Hsu CC, 2013, BBA-GEN SUBJECTS, V1830, P4743, DOI 10.1016/j.bbagen.2013.06.004; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Huang QC, 2016, AUTOPHAGY, V12, P999, DOI 10.1080/15548627.2016.1166318; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P15835, DOI 10.1021/bi981512h; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Ke ZJ, 2006, INT J CANCER, V119, P8, DOI 10.1002/ijc.21769; Kermorgant S, 2004, EMBO J, V23, P3721, DOI 10.1038/sj.emboj.7600396; Klaunig JE, 1998, ENVIRON HEALTH PERSP, V106, P289, DOI 10.2307/3433929; Koch-Nolte F, 2011, FEBS LETT, V585, P1651, DOI 10.1016/j.febslet.2011.03.045; Marchi S, 2013, CURR BIOL, V23, P58, DOI 10.1016/j.cub.2012.11.026; MCCORMACK JG, 1985, BIOCHEM J, V231, P581, DOI 10.1042/bj2310581; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MCCORMACK JG, 1979, BIOCHEM J, V180, P533, DOI 10.1042/bj1800533; Min LH, 2011, SEMIN CANCER BIOL, V21, P10, DOI 10.1016/j.semcancer.2010.10.011; Nath A, 2015, SCI REP-UK, V5, DOI 10.1038/srep14752; Perocchi F, 2010, NATURE, V467, P291, DOI 10.1038/nature09358; Plovanich M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055785; Qiu J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3034; Raffaello A, 2013, EMBO J, V32, P2362, DOI 10.1038/emboj.2013.157; Rizzuto R, 2012, NAT REV MOL CELL BIO, V13, P566, DOI 10.1038/nrm3412; Sancak Y, 2013, SCIENCE, V342, P1379, DOI 10.1126/science.1242993; Son G, 2006, J HEPATOL, V45, P688, DOI 10.1016/j.jhep.2006.04.011; Storz P, 2005, FRONT BIOSCI-LANDMRK, V10, P1881, DOI 10.2741/1667; Sun YY, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0210-7; Tang SH, 2015, BIOCHEM BIOPH RES CO, V458, P186, DOI 10.1016/j.bbrc.2015.01.092; Tosatto A, 2016, EMBO MOL MED, V8, P569, DOI 10.15252/emmm.201606255; Trerotola M, 2013, CANCER RES, V73, P3155, DOI 10.1158/0008-5472.CAN-12-3266; Wagenblast E, 2015, NATURE, V520, P358, DOI 10.1038/nature14403; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; Wu WS, 2006, CANCER METAST REV, V25, P695, DOI 10.1007/s10555-006-9037-8; Xu P, 2010, MECH AGEING DEV, V131, P287, DOI 10.1016/j.mad.2010.03.006; Ying WH, 2008, FRONT BIOSCI-LANDMRK, V13, P1141, DOI 10.2741/2751; Yu TZ, 2008, CARDIOVASC RES, V79, P341, DOI 10.1093/cvr/cvn104; Zeng X, 2011, HEPATOLOGY, V54, P2036, DOI 10.1002/hep.24647; Zhang Z, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.182	51	101	109	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5897	5909		10.1038/onc.2017.167	http://dx.doi.org/10.1038/onc.2017.167			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28650465	Bronze			2022-12-17	WOS:000413292900011
J	Chen, H; Lorton, B; Gupta, V; Shechter, D				Chen, H.; Lorton, B.; Gupta, V.; Shechter, D.			A TGF beta-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression	ONCOGENE			English	Article							SYMMETRIC DIMETHYLATION; LUNG ADENOCARCINOMA; DNA METHYLATION; PRMT5; METHYLTRANSFERASE; PROTEIN; EXPRESSION; EMT; PROGRESSION; VALIDATION	Protein arginine methyltransferase 5 (PRMT5) complexed with MEP50/WDR77 catalyzes arginine methylation on histones and other proteins. PRMT5-MEP50 activity is elevated in cancer cells and its expression is highly correlated with poor prognosis in many human tumors. We demonstrate that PRMT5-MEP50 is essential for transcriptional regulation promoting cancer cell invasive phenotypes in lung adenocarcinoma, lung squamous cell carcinoma and breast carcinoma cancer cells. RNA-Seq transcriptome analysis demonstrated that PRMT5 and MEP50 are required to maintain expression of metastasis and Epithelial-to-mesenchymal transition (EMT) markers and to potentiate an epigenetic mechanism of the TGF beta response. We show that PRMT5-MEP50 activity both positively and negatively regulates expression of a wide range of genes. Exogenous TGF beta promotes EMT in a unique pathway of PRMT5-MEP50 catalyzed histone mono-and dimethylation of chromatin at key metastasis suppressor and EMT genes, defining a new mechanism regulating cancer invasivity. PRMT5 methylation of histone H3R2me1 induced transcriptional activation by recruitment of WDR5 and concomitant H3K4 methylation at targeted genes. In parallel, PRMT5 methylation of histone H4R3me2s suppressed transcription at distinct genomic loci. Our decoding of histone methylarginine at key genes supports a critical role for complementary PRMT5-MEP50 transcriptional activation and repression in cancer invasion pathways and in response to TGF beta stimulation and therefore orients future chemotherapeutic opportunities.	[Chen, H.; Lorton, B.; Shechter, D.] Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA; [Gupta, V.] Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Chen, H; Shechter, D (corresponding author), Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	hongshan.chen@einstein.yu.edu; david.shechter@einstein.yu.edu	Shechter, David/B-4660-2008	Shechter, David/0000-0001-9388-6004	Albert Einstein College of Medicine; Alexandrine and Alexander Sinsheimer Fund; American Cancer Society - Robbie Sue Mudd Kidney Cancer Research Scholar Grant [124891-RSG-13-396-01-DMC]; NIH [R01GM108646-01A1]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM108646] Funding Source: NIH RePORTER	Albert Einstein College of Medicine; Alexandrine and Alexander Sinsheimer Fund; American Cancer Society - Robbie Sue Mudd Kidney Cancer Research Scholar Grant(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to C. Arrowsmith, GlaxoSmithKline and the Structural Genomics Consortium for the gift of GSK591, C. Wilczek, R. Mazur and P. Bailey for preliminary knockdown experiments, E. Burgos for recombinant PRMT5-MEP50, S. Maqbool, R. Dubin, and B. Ye at the Einstein Center for Epigenomics for assistance with RNASeq and initial analysis, and members of the Shechter lab for comments. This work was supported by startup funds from the Albert Einstein College of Medicine, The Alexandrine and Alexander Sinsheimer Fund, The American Cancer Society - Robbie Sue Mudd Kidney Cancer Research Scholar Grant (124891-RSG-13-396-01-DMC) and NIH R01GM108646-01A1 (all to D.S.).	Alinari L, 2015, BLOOD, V125, P2530, DOI 10.1182/blood-2014-12-619783; Bao XX, 2013, J HISTOCHEM CYTOCHEM, V61, P206, DOI 10.1369/0022155413475452; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; Burgos ES, 2015, J BIOL CHEM, V290, P9674, DOI 10.1074/jbc.M115.636894; Chan-Penebre E, 2015, NAT CHEM BIOL, V11, P432, DOI [10.1038/NCHEMBIO.1810, 10.1038/nchembio.1810]; Chen HS, 2015, MOL CELL, V59, P719, DOI 10.1016/j.molcel.2015.07.011; Chen HS, 2014, NAT STRUCT MOL BIOL, V21, P981, DOI 10.1038/nsmb.2903; Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876; Chung J, J BIOL CHEM, V288, P35534; Cline MS, 2013, SCI REP-UK, V3, DOI 10.1038/srep02652; Dacwag CS, 2009, MOL CELL BIOL, V29, P1909, DOI 10.1128/MCB.00742-08; Dhar SS, 2012, GENE DEV, V26, P2749, DOI 10.1101/gad.203356.112; Dhar S, 2013, SCI REP-UK, V3, DOI 10.1038/srep01311; Di Lorenzo A, 2011, FEBS LETT, V585, P2024, DOI 10.1016/j.febslet.2010.11.010; Diez-Villanueva A, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/s13072-015-0014-8; Duncan KW, 2015, ACS MED CHEM LETT; Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48; Girardot M, 2014, NUCLEIC ACIDS RES, V42, P235, DOI 10.1093/nar/gkt884; Grebien F, 2015, NAT CHEM BIOL, V11, P571, DOI [10.1038/NCHEMBIO.1859, 10.1038/nchembio.1859]; Greenblatt SM, 2016, EXP HEMATOL, V44, P435, DOI 10.1016/j.exphem.2016.03.009; Guccione E, 2007, NATURE, V449, P933, DOI 10.1038/nature06166; Ho MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057008; Ibrahim R, 2014, HUM PATHOL, V45, P1397, DOI 10.1016/j.humpath.2014.02.013; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Kakuguchi W, 2010, MOL CANCER RES, V8, P520, DOI 10.1158/1541-7786.MCR-09-0367; Kallio MA, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-507; Kamburov A, 2013, NUCLEIC ACIDS RES, V41, pD793, DOI 10.1093/nar/gks1055; Kasai H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-56; Koh C.M., 2015, CURR MOL BIOL REP, V1, P19, DOI [10.1007/s40610-015-0003-5, DOI 10.1007/S40610-015-0003-5]; Kryukov GV, 2016, SCIENCE, V351, P1214, DOI 10.1126/science.aad5214; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Li Y, 2015, CANCER DISCOV, V5, P288, DOI 10.1158/2159-8290.CD-14-0625; Liu J, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.37; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lu G, 2013, SCI WORLD J, DOI 10.1155/2013/424617; Mavrakis KJ, 2016, SCIENCE, V351, P1208, DOI 10.1126/science.aad5944; May CD, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2789; Migliori V, 2012, NAT STRUCT MOL BIOL, V19, P136, DOI 10.1038/nsmb.2209; Nicklay JJ, 2009, J BIOL CHEM, V284, P1075, DOI 10.1074/jbc.M807274200; Otani J, 2009, EMBO REP, V10, P1235, DOI 10.1038/embor.2009.218; Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sarkar S, 2013, INT J MOL SCI, V14, P21087, DOI 10.3390/ijms141021087; Scoumanne A, 2009, NUCLEIC ACIDS RES, V37, P4965, DOI 10.1093/nar/gkp516; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Smil D, 2015, ACS MED CHEM LETT, V6, P408, DOI 10.1021/ml500467h; Stafford LJ, 2008, INT J BIOCHEM CELL B, V40, P874, DOI 10.1016/j.biocel.2007.12.016; Stopa N, 2015, CELL MOL LIFE SCI, V72, P2041, DOI 10.1007/s00018-015-1847-9; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tarighat SS, 2016, LEUKEMIA, V30, P789, DOI 10.1038/leu.2015.308; Wang M, 2014, BIOCHEMISTRY-US, V53, P7884, DOI 10.1021/bi501279g; Wang M, 2013, BIOCHEMISTRY-US, V52, P5430, DOI 10.1021/bi4005123; Wilczek C, 2011, J BIOL CHEM, V286, P42221, DOI 10.1074/jbc.M111.303677; Wu YC, 2016, ONCOGENE, V35, P2123, DOI 10.1038/onc.2015.274; Yan FT, 2014, CANCER RES, V74, P1752, DOI 10.1158/0008-5472.CAN-13-0884; Yan JC, 2013, HISTOL HISTOPATHOL, V28, P285, DOI 10.14670/HH-28.285; Yang HP, 2015, ONCOL REP, V34, P87, DOI 10.3892/or.2015.3961; Yang YZ, 2013, NAT REV CANCER, V13, P37, DOI 10.1038/nrc3409; Yuan CC, 2012, CELL REPORTS, V1, P83, DOI 10.1016/j.celrep.2011.12.008; Zhao Q, 2009, NAT STRUCT MOL BIOL, V16, P304, DOI 10.1038/nsmb.1568	61	101	108	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					373	386		10.1038/onc.2016.205	http://dx.doi.org/10.1038/onc.2016.205			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27270440	Green Accepted			2022-12-17	WOS:000394166000007
J	Than, BLN; Linnekamp, JF; Starr, TK; Largaespada, DA; Rod, A; Zhang, Y; Bruner, V; Abrahante, J; Schumann, A; Luczak, T; Niemczyk, A; O'Sullivan, MG; Medema, JP; Fijneman, RJA; Meijer, GA; Van den Broek, E; Hodges, CA; Scott, PM; Vermeulen, L; Cormier, RT				Than, B. L. N.; Linnekamp, J. F.; Starr, T. K.; Largaespada, D. A.; Rod, A.; Zhang, Y.; Bruner, V.; Abrahante, J.; Schumann, A.; Luczak, T.; Niemczyk, A.; O'Sullivan, M. G.; Medema, J. P.; Fijneman, R. J. A.; Meijer, G. A.; Van den Broek, E.; Hodges, C. A.; Scott, P. M.; Vermeulen, L.; Cormier, R. T.			CFTR is a tumor suppressor gene in murine and human intestinal cancer	ONCOGENE			English	Article							CYSTIC-FIBROSIS; COLORECTAL-CANCER; IDENTIFIES GENES; MOUSE MODELS; HUMAN COLON; STEM-CELLS; RISK; EXPRESSION; REGULATOR; MICE	CFTR, the cystic fibrosis (CF) gene, encodes for the CFTR protein that plays an essential role in anion regulation and tissue homeostasis of various epithelia. In the gastrointestinal (GI) tract CFTR promotes chloride and bicarbonate secretion, playing an essential role in ion and acid-base homeostasis. Cftr has been identified as a candidate driver gene for colorectal cancer (CRC) in several Sleeping Beauty DNA transposon-based forward genetic screens in mice. Further, recent epidemiological and clinical studies indicate that CF patients are at high risk for developing tumors in the colon. To investigate the effects of CFTR dysregulation on GI cancer, we generated Apc(Min) mice that carried an intestinal-specific knockout of Cftr. Our results indicate that Cftr is a tumor suppressor gene in the intestinal tract as Cftr mutant mice developed significantly more tumors in the colon and the entire small intestine. In Apc(+/+) mice aged to similar to 1 year, Cftr deficiency alone caused the development of intestinal tumors in >60% of mice. Colon organoid formation was significantly increased in organoids created from Cftr mutant mice compared with wild-type controls, suggesting a potential role of Cftr in regulating the intestinal stem cell compartment. Microarray data from the Cftr-deficient colon and the small intestine identified dysregulated genes that belong to groups of immune response, ion channel, intestinal stem cell and other growth signaling regulators. These associated clusters of genes were confirmed by pathway analysis using Ingenuity Pathway Analysis and gene set enrichment analysis (GSEA). We also conducted RNA Seq analysis of tumors from Apc(+/+) Cftr knockout mice and identified sets of genes dysregulated in tumors including altered Wnt beta-catenin target genes. Finally we analyzed expression of CFTR in early stage human CRC patients stratified by risk of recurrence and found that loss of expression of CFTR was significantly associated with poor disease-free survival.	[Than, B. L. N.; Rod, A.; Bruner, V.; Schumann, A.; Luczak, T.; Niemczyk, A.; Scott, P. M.; Cormier, R. T.] Univ Minnesota, Sch Med, Dept Biomed Sci, 1035 Univ Dr,247 Med, Duluth, MN 55812 USA; [Linnekamp, J. F.; Medema, J. P.; Vermeulen, L.] Acad Med Ctr, Ctr Expt Mol Med, Lab Expt Oncol & Radiobiol, Amsterdam, Netherlands; [Starr, T. K.; Abrahante, J.] Univ Minnesota, Sch Med, Masonic Canc Ctr, Dept Genet Cell Biol & Dev,Ctr Genome Engn, Minneapolis, MN 55455 USA; [Starr, T. K.] Univ Minnesota, Sch Med, Masonic Canc Ctr, Dept Obstet Gynecol & Womens Hlth, Minneapolis, MN 55455 USA; [Largaespada, D. A.] Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA; [Zhang, Y.] Univ Minnesota, Inst Supercomp, Minneapolis, MN 55455 USA; [O'Sullivan, M. G.] Univ Minnesota, Coll Vet Med, St Paul, MN 55108 USA; [Fijneman, R. J. A.; Meijer, G. A.; Van den Broek, E.] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands; [Fijneman, R. J. A.; Meijer, G. A.] Netherlands Canc Inst, Amsterdam, Netherlands; [Hodges, C. A.] Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; [Than, B. L. N.] Weill Cornell Med Coll, Div Gastroenterol & Hepatol, New York, NY USA	University of Minnesota System; University of Minnesota Duluth; University of Amsterdam; Academic Medical Center Amsterdam; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Vrije Universiteit Amsterdam; Netherlands Cancer Institute; Case Western Reserve University; Cornell University	Scott, PM; Cormier, RT (corresponding author), Univ Minnesota, Sch Med, Dept Biomed Sci, 1035 Univ Dr,247 Med, Duluth, MN 55812 USA.; Vermeulen, L (corresponding author), Acad Med Ctr, Ctr Expt Mol Med, Lab Expt Oncol & Radiobiol, Amsterdam, Netherlands.	pscott@d.umn.edu; l.vermeulen@amc.nl; rcormier@d.umn.edu	Fijneman, Remond/X-4199-2019; Starr, Tim/AAX-9342-2021; Vermeulen, Louis/B-7488-2008	Fijneman, Remond/0000-0003-2076-5521; Vermeulen, Louis/0000-0002-6066-789X; Starr, Timothy/0000-0002-6308-3451; Abrahante, Juan/0000-0002-9074-4307; Medema, Jan Paul/0000-0003-3045-2924; Meijer, Gerrit/0000-0003-0330-3130	National Cancer Institute (NCI) [NCI R01 CA134759-01A1, NCI P30-CA775598, NCI 5R00CA151672-04, P30-CA77598]; Mezin-Koats Colon Cancer Research fund; Whiteside Institute for Clinical Research; University of Minnesota Foundation; Essentia Health Systems; AICR [14-1164]; Dutch Cancer Society [UVA2011-4969, UVA2014-7245]; NWO gravitation grant; NATIONAL CANCER INSTITUTE [P30CA008748, R01CA113636, P30CA077598, R01CA134759, R00CA151672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651] Funding Source: NIH RePORTER	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Mezin-Koats Colon Cancer Research fund; Whiteside Institute for Clinical Research; University of Minnesota Foundation(University of Minnesota System); Essentia Health Systems; AICR; Dutch Cancer Society(KWF Kankerbestrijding); NWO gravitation grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the grant from the National Cancer Institute (NCI) to RC and DL (NCI R01 CA134759-01A1); grant from the Mezin-Koats Colon Cancer Research fund to TS; grant from NCI to support the University of Minnesota Masonic Cancer Center (NCI P30-CA775598); grant from the Whiteside Institute for Clinical Research to RC and PS; grant from the University of Minnesota Foundation to RC, TS and DL; grant from Essentia Health Systems to RC; grant from the AICR (14-1164) to LV; grants from the Dutch Cancer Society (UVA2011-4969, UVA2014-7245) to LV; NWO gravitation grant to JL; grants from the National Cancer Institute to TS (NCI 5R00CA151672-04 and P30-CA77598). We also wish to thank Drs Mitchell Drumm and Craig Hodges of CWRU for providing the Cftr mutant mice.	Billings JL, 2014, J CLIN GASTROENTEROL, V48, pE85, DOI 10.1097/MCG.0000000000000034; Boivin GP, 2003, GASTROENTEROLOGY, V124, P762, DOI 10.1053/gast.2003.50094; Burger-van Paassen N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038798; Chen J, 2012, J CELL PHYSIOL, V227, P2759, DOI 10.1002/jcp.23020; Clarke LL, 1996, LAB ANIM SCI, V46, P612; Clarke LL, 2004, AM J PHYSIOL-GASTR L, V286, pG1050, DOI 10.1152/ajpgi.00393.2003; Collawn JF, 2014, AM J PHYSIOL-LUNG C, V307, pL431, DOI 10.1152/ajplung.00177.2014; Dalerba P, 2011, NAT BIOTECHNOL, V29, P1120, DOI 10.1038/nbt.2038; De Lisle RC, 2014, CELL TISSUE RES, V355, P131, DOI 10.1007/s00441-013-1734-3; De Lisle RC, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a009753; De Lisle RC, 2011, J PEDIATR GASTR NUTR, V53, P371, DOI 10.1097/MPG.0b013e318219c397; De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174; de Sousa e Melo F, 2011, CELL STEM CELL, V9, P476, DOI 10.1016/j.stem.2011.10.008; DENAMUR E, 1995, DNA CELL BIOL, V14, P811, DOI 10.1089/dna.1995.14.811; Fijneman RJA, 2012, CANCER SCI, V103, P593, DOI 10.1111/j.1349-7006.2011.02189.x; Garcia MAS, 2009, J CLIN INVEST, V119, P2613, DOI 10.1172/JCI38662; Gelfond D, 2013, CLIN GASTROENTEROL H, V11, P333, DOI 10.1016/j.cgh.2012.11.006; Hodges CA, 2008, GENESIS, V46, P546, DOI 10.1002/dvg.20433; Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224; Juric M, 2013, INFLAMM BOWEL DIS, V19, P904, DOI 10.1097/MIB.0b013e3182813322; Maisonneuve P, 2003, JNCI-J NATL CANCER I, V95, P381, DOI 10.1093/jnci/95.5.381; Maisonneuve P, 2013, JNCI-J NATL CANCER I, V105, P122, DOI 10.1093/jnci/djs481; March HN, 2011, NAT GENET, V43, P1202, DOI 10.1038/ng.990; McWilliams R, 2005, GUT, V54, P1661, DOI 10.1136/gut.2005.074534; Medema JP, 2011, NATURE, V474, P318, DOI 10.1038/nature10212; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Munck A, 2014, INT J BIOCHEM CELL B, V52, P180, DOI 10.1016/j.biocel.2014.02.005; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; NEGLIA JP, 1995, NEW ENGL J MED, V332, P494, DOI 10.1056/NEJM199502233320803; Norkina O, 2004, AM J PHYSIOL-GASTR L, V286, pG1032, DOI 10.1152/ajpgi.00473.2003; Oh SC, 2012, GUT, V61, P1291, DOI 10.1136/gutjnl-2011-300812; Pedersen SF, 2013, CANCER RES, V73, P1658, DOI 10.1158/0008-5472.CAN-12-4188; RIORDAN JR, 1989, SCIENCE, V245, P1066; Roth EK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024445; Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Schutte A, 2014, P NATL ACAD SCI USA, V111, P12396, DOI 10.1073/pnas.1407597111; Shan MM, 2013, SCIENCE, V342, P447, DOI 10.1126/science.1237910; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; Son JW, 2011, RESPIROLOGY, V16, P1203, DOI 10.1111/j.1440-1843.2011.01994.x; Starr TK, 2009, SCIENCE, V323, P1747, DOI 10.1126/science.1163040; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun TT, 2014, BBA-MOL CELL RES, V1843, P618, DOI 10.1016/j.bbamcr.2013.12.013; Takeda H, 2015, NAT GENET, V47, P142, DOI 10.1038/ng.3175; Than BLN, 2014, ONCOGENE, V33, P3861, DOI 10.1038/onc.2013.350; Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; Vij N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004664; Wilke M, 2011, J CYST FIBROS, V10, pS152, DOI 10.1016/S1569-1993(11)60020-9; Xie C, 2013, ONCOGENE, V32, P2282, DOI 10.1038/onc.2012.251; Xu ZD, 1998, GENE, V211, P117, DOI 10.1016/S0378-1119(98)00090-0; Yang K, 2008, CANCER RES, V68, P7313, DOI 10.1158/0008-5472.CAN-08-0598; Zhang JT, 2013, BBA-MOL CELL RES, V1833, P2961, DOI 10.1016/j.bbamcr.2013.07.021	53	101	104	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4191	4199		10.1038/onc.2015.483	http://dx.doi.org/10.1038/onc.2015.483			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26751771	Green Accepted			2022-12-17	WOS:000382149800004
J	Miao, H; Gale, NW; Guo, H; Qian, J; Petty, A; Kaspar, J; Murphy, AJ; Valenzuela, DM; Yancopoulos, G; Hambardzumyan, D; Lathia, JD; Rich, JN; Lee, J; Wang, B				Miao, H.; Gale, N. W.; Guo, H.; Qian, J.; Petty, A.; Kaspar, J.; Murphy, A. J.; Valenzuela, D. M.; Yancopoulos, G.; Hambardzumyan, D.; Lathia, J. D.; Rich, J. N.; Lee, J.; Wang, B.			EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties	ONCOGENE			English	Article						EphA2; Akt; stem cells; glioma; invasion; ephrin-A	INTEGRATED GENOMIC ANALYSIS; HUMAN BRAIN; GLIOBLASTOMA; RECEPTOR; ACTIVATION; EXPRESSION; EPHRINA1; TUMORS; LIGAND; ROLES	Diffuse infiltrative invasion is a major cause for the dismal prognosis of glioblastoma multiforme (GBM), but the underlying mechanisms remain incompletely understood. Using human glioma stem cells (GSCs) that recapitulate the invasive propensity of primary GBM, we find that EphA2 critically regulates GBM invasion in vivo. EphA2 was expressed in all seven GSC lines examined, and overexpression of EphA2 enhanced intracranial invasion. The effects required Akt-mediated phosphorylation of EphA2 on serine 897. In vitro the Akt-EphA2 signaling axis is maintained in the absence of ephrin-A ligands and is disrupted upon ligand stimulation. To test whether ephrin-As in tumor microenvironment can regulate GSC invasion, the newly established Efna1;Efna3;Efna4 triple knockout mice (TKO) were used in an ex vivo brain slice invasion assay. We observed significantly increased GSC invasion through the brain slices of TKO mice relative to wild-type (WT) littermates. Mechanistically EphA2 knockdown suppressed stem cell properties of GSCs, causing diminished self-renewal, reduced stem marker expression and decreased tumorigenicity. In a subset of GSCs, the reduced stem cell properties were associated with lower Sox2 expression. Overexpression of EphA2 promoted stem cell properties in a kinase-independent manner and increased Sox2 expression. Disruption of Akt-EphA2 cross-talk attenuated stem cell marker expression and neurosphere formation while having minimal effects on tumorigenesis. Taken together, the results show that EphA2 endows invasiveness of GSCs in vivo in cooperation with Akt and regulates glioma stem cell properties.	[Miao, H.; Guo, H.; Qian, J.; Petty, A.; Kaspar, J.; Wang, B.] Case Western Reserve Univ, Sch Med, MetroHlth Med Ctr, Rammelkamp Ctr Res, Cleveland, OH 44109 USA; [Miao, H.; Guo, H.; Qian, J.; Petty, A.; Kaspar, J.; Wang, B.] Case Western Reserve Univ, Sch Med, Dept Pharmacol & Oncol, Cleveland, OH 44109 USA; [Gale, N. W.; Murphy, A. J.; Valenzuela, D. M.; Yancopoulos, G.] Regeneron Pharmaceut Inc, VelociGene Div, Tarrytown, NY 10591 USA; [Hambardzumyan, D.; Lathia, J. D.; Rich, J. N.; Lee, J.] Cleveland Clin, Dept Stem Cell Biol & Regenerat Med, Lerner Res Inst, Cleveland, OH 44106 USA; [Hambardzumyan, D.; Lathia, J. D.; Rich, J. N.; Lee, J.; Wang, B.] Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH 44109 USA	Case Western Reserve University; MetroHealth System; Case Western Reserve University; Regeneron; Cleveland Clinic Foundation; Case Western Reserve University	Wang, B (corresponding author), Case Western Reserve Univ, Sch Med, MetroHlth Med Ctr, Rammelkamp Ctr Res, R421,2500 MetroHlth Dr, Cleveland, OH 44109 USA.	bxw14@case.edu	Rich, Jeremy/AAM-1445-2021; Lathia, Justin/AHB-8296-2022	Murphy, Andrew/0000-0003-4152-4081	National Institute of Health [CA152371, CA155676]; FAMRI Foundation [072216_CIA]; Maria Foundation; Case Comprehensive Cancer Center [P30 CA43703]; NATIONAL CANCER INSTITUTE [T32CA059366, P30CA043703, R01CA152371, R01CA155676] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FAMRI Foundation; Maria Foundation; Case Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from National Institute of Health CA152371 (HM and BW), CA155676 (BW) and by awards to BW from FAMRI Foundation (072216_CIA) and Prayers From Maria Foundation. This research was also supported by the Case Comprehensive Cancer Center (P30 CA43703).	Annovazzi L, 2011, CANCER GENOM PROTEOM, V8, P139; [Anonymous], 1997, Cell, V90, P403; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Beauchamp A, 2012, MOL CELL BIOL, V32, P3253, DOI 10.1128/MCB.06791-11; Binda E, 2012, CANCER CELL, V22, P765, DOI 10.1016/j.ccr.2012.11.005; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chakravarti Arnab, 2008, P173; Cheng L, 2011, BIOCHEM BIOPH RES CO, V406, P643, DOI 10.1016/j.bbrc.2011.02.123; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Day BW, 2013, CANCER CELL, V23, P238, DOI 10.1016/j.ccr.2013.01.007; Dunn GP, 2012, GENE DEV, V26, P756, DOI 10.1101/gad.187922.112; Frattini V, 2013, NAT GENET, V45, P1141, DOI 10.1038/ng.2734; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493; Garcia JL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-454; Gu CY, 2013, STEM CELLS, V31, P870, DOI 10.1002/stem.1322; Guo H, 2006, CANCER RES, V66, P7050, DOI 10.1158/0008-5472.CAN-06-0004; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Holmberg J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018454; Ignatova TN, 2002, GLIA, V39, P193, DOI 10.1002/glia.10094; Johnson RA, 2010, NATURE, V466, P632, DOI 10.1038/nature09173; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lee J, 2008, CANCER CELL, V13, P69, DOI 10.1016/j.ccr.2007.12.005; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Miao H, 2012, SEMIN CELL DEV BIOL, V23, P16, DOI 10.1016/j.semcdb.2011.10.013; Miao H, 2009, CANCER CELL, V16, P9, DOI 10.1016/j.ccr.2009.04.009; Miao H, 2009, INT J BIOCHEM CELL B, V41, P762, DOI 10.1016/j.biocel.2008.07.019; Molina JR, 2010, NEOPLASIA, V12, P453, DOI 10.1593/neo.10126; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Petty A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042120; Pevny LH, 2010, INT J BIOCHEM CELL B, V42, P421, DOI 10.1016/j.biocel.2009.08.018; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Pollard SM, 2009, CELL STEM CELL, V4, P568, DOI 10.1016/j.stem.2009.03.014; Singh D, 2012, SCIENCE, V337, P1231, DOI 10.1126/science.1220834; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Valenzuela DM, 2003, NAT BIOTECHNOL, V21, P652, DOI 10.1038/nbt822; Venere M, 2011, GLIA, V59, P1148, DOI 10.1002/glia.21185; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wegner M, 2011, GENE DEV, V25, P2423, DOI 10.1101/gad.181487.111; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515; Wykosky J, 2005, MOL CANCER RES, V3, P541, DOI 10.1158/1541-7786.MCR-05-0056; Wykosky J, 2008, ONCOGENE, V27, P7260, DOI 10.1038/onc.2008.328; Wykosky J, 2007, MOL CANCER THER, V6, P3208, DOI 10.1158/1535-7163.MCT-07-0200; Wykosky J, 2008, MOL CANCER RES, V6, P1795, DOI 10.1158/1541-7786.MCR-08-0244	55	101	106	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					558	567		10.1038/onc.2013.590	http://dx.doi.org/10.1038/onc.2013.590			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24488013	Green Accepted			2022-12-17	WOS:000348853500003
J	Butt, AQ; Mills, KHG				Butt, A. Q.; Mills, K. H. G.			Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines	ONCOGENE			English	Review						immunotherapy; vaccine; antitumor immunity; immune checkpoint; regulatory T cell; Toll-like receptor agonist	REGULATORY T-CELLS; TUMOR-ASSOCIATED MACROPHAGES; MYELOID SUPPRESSOR-CELLS; SURFACE SIGNALING MOLECULES; TYROSINE KINASE INHIBITOR; TOLL-LIKE; DENDRITIC CELLS; ALTERNATIVE ACTIVATION; MONOCLONAL-ANTIBODY; RECEPTOR AGONIST	Vaccines that promote protective adaptive immune responses have been successfully developed against a range of infectious diseases, and these are normally administered prior to exposure with the relevant virus or bacteria. Adaptive immunity also plays a critical role in the control of tumors. Immunotherapeutics and vaccines that promote effector T cell responses have the potential to eliminate tumors when used in a therapeutic setting. However, the induction of protective antitumor immunity is compromised by innate immunosuppressive mechanisms and regulatory cells that often dominate the tumor microenvironment. Recent studies have shown that blocking these suppressor cells and immune checkpoints to allow induction of antitumor immunity is a successful immunotherapeutic modality for the treatment of cancer. Furthermore, stimulation of innate and consequently adaptive immune responses with concomitant inhibition of immune suppression, especially that mediated by regulatory T (Treg) cells, is emerging as a promising approach to enhance the efficacy of therapeutic vaccines against cancer. This review describes the immunosuppressive mechanisms controlling antitumor immunity and the novel strategies being employed to design effective immunotherapeutics against tumors based on inhibition of suppressor cells or blockade of immune checkpoints to allow induction of more potent effector T cell responses. This review also discusses the potential of using a combination of adjuvants with inhibition of immune checkpoint or suppressor cells for therapeutic vaccines and the translation of pre-clinical studies to the next-generation vaccines against cancer in humans.	[Butt, A. Q.; Mills, K. H. G.] Univ Dublin Trinity Coll, Trinity Biomed Sci Inst, Sch Biochem & Immunol, Immune Regulat Res Grp, Dublin 2, Ireland	Trinity College Dublin	Mills, KHG (corresponding author), Univ Dublin Trinity Coll, Trinity Biomed Sci Inst, Sch Biochem & Immunol, Immune Regulat Res Grp, Dublin 2, Ireland.	kingston.mills@tcd.ie	Mills, Kingston H/F-5684-2013	Mills, Kingston H/0000-0003-3646-8222	Science Foundation Ireland	Science Foundation Ireland(Science Foundation IrelandEuropean Commission)	Kingston Mills's research group is supported by grants from Science Foundation Ireland.	Ahn GO, 2010, P NATL ACAD SCI USA, V107, P8363, DOI 10.1073/pnas.0911378107; Akdis CA, 2003, EUR J IMMUNOL, V33, P2717, DOI 10.1002/eji.200323329; Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Amendola M, 2009, MOL THER, V17, P1039, DOI 10.1038/mt.2009.48; Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592; Baxevanis CN, 2009, CANCER IMMUNOL IMMUN, V58, P317, DOI 10.1007/s00262-008-0576-4; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Bronte V, 1998, J IMMUNOL, V161, P5313; Bunt SK, 2009, J LEUKOCYTE BIOL, V85, P996, DOI 10.1189/jlb.0708446; Byrne WL, 2011, CANCER RES, V71, P6915, DOI 10.1158/0008-5472.CAN-11-1156; Casares N, 2010, J IMMUNOL, V185, P5150, DOI 10.4049/jimmunol.1001114; Chen W, 2012, CANCER RES, V72, P1363, DOI 10.1158/0008-5472.CAN-11-2684; Chung KY, 2010, J CLIN ONCOL, V28, P3485, DOI 10.1200/JCO.2010.28.3994; Cluff CW, 2009, ADV EXP MED BIOL, V667, P111, DOI 10.1007/978-1-4419-1603-7_10; Coe D, 2010, CANCER IMMUNOL IMMUN, V59, P1367, DOI 10.1007/s00262-010-0866-5; Conroy H, 2008, ONCOGENE, V27, P168, DOI 10.1038/sj.onc.1210910; Conroy H, 2012, CANCER IMMUNOL IMMUN, V61, P425, DOI 10.1007/s00262-011-1188-y; Corsello SM, 2013, J CLIN ENDOCR METAB, V98, P1361, DOI 10.1210/jc.2012-4075; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Curiel TJ, 2003, NAT MED, V9, P562, DOI 10.1038/nm863; Dangaj D, 2013, CANCER RES, V73, P4820, DOI 10.1158/0008-5472.CAN-12-3457; De Santo C, 2005, P NATL ACAD SCI USA, V102, P4185, DOI 10.1073/pnas.0409783102; Delano MJ, 2007, J EXP MED, V204, P1463, DOI 10.1084/jem.20062602; Di Giacomo AM, 2010, SEMIN ONCOL, V37, P499, DOI 10.1053/j.seminoncol.2010.09.007; Doedens AL, 2010, CANCER RES, V70, P7465, DOI 10.1158/0008-5472.CAN-10-1439; Edwards JP, 2010, INT IMMUNOPHARMACOL, V10, P1220, DOI 10.1016/j.intimp.2010.07.002; Fischer C, 2007, CELL, V131, P463, DOI 10.1016/j.cell.2007.08.038; Fong L, 2008, J CLIN ONCOL, V26, P5275, DOI 10.1200/JCO.2008.17.8954; Fourcade J, 2010, J EXP MED, V207, P2175, DOI 10.1084/jem.20100637; Fujita M, 2011, CANCER RES, V71, P2664, DOI 10.1158/0008-5472.CAN-10-3055; Fujiwara Y, 2011, ONCOL REP, V26, P1533, DOI 10.3892/or.2011.1454; Fujiwara Y, 2011, CANCER SCI, V102, P206, DOI 10.1111/j.1349-7006.2010.01772.x; Gabrilovich DI, 2001, J IMMUNOL, V166, P5398, DOI 10.4049/jimmunol.166.9.5398; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Garbi N, 2004, J IMMUNOL, V172, P5861, DOI 10.4049/jimmunol.172.10.5861; Goding SR, 2013, J IMMUNOL, V190, P4899, DOI 10.4049/jimmunol.1300271; Goldberg MV, 2011, CURR TOP MICROBIOL, V344, P269, DOI 10.1007/82_2010_114; Golgher D, 2002, EUR J IMMUNOL, V32, P3267, DOI 10.1002/1521-4141(200211)32:11<3267::AID-IMMU3267>3.0.CO;2-1; Hiraoka K, 2008, CANCER SCI, V99, P1595, DOI 10.1111/j.1349-7006.2008.00880.x; Hoechst B, 2011, BLOOD, V117, P6532, DOI 10.1182/blood-2010-11-317321; HOON DSB, 1990, CANCER RES, V50, P5358; Huang B, 2006, CANCER RES, V66, P1123, DOI 10.1158/0008-5472.CAN-05-1299; Hussain SF, 2007, CANCER RES, V67, P9630, DOI 10.1158/0008-5472.CAN-07-1243; Jarnicki AG, 2008, J IMMUNOL, V180, P3797, DOI 10.4049/jimmunol.180.6.3797; Jarnicki AG, 2006, J IMMUNOL, V177, P896, DOI 10.4049/jimmunol.177.2.896; Jiang JT, 2010, CANCER IMMUNOL IMMUN, V59, P1707, DOI 10.1007/s00262-010-0900-7; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kanzler H, 2007, NAT MED, V13, P552, DOI 10.1038/nm1589; Karanikas V, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-19; KIKKAWA F, 1993, EUR J CANCER, V29A, P1542, DOI 10.1016/0959-8049(93)90291-M; Ko HJ, 2007, CANCER RES, V67, P7477, DOI 10.1158/0008-5472.CAN-06-4639; Ko JS, 2010, CANCER RES, V70, P3526, DOI 10.1158/0008-5472.CAN-09-3278; Ko JS, 2009, CLIN CANCER RES, V15, P2148, DOI 10.1158/1078-0432.CCR-08-1332; Ko K, 2005, J EXP MED, V202, P885, DOI 10.1084/jem.20050940; Kodumudi KN, 2010, CLIN CANCER RES, V16, P4583, DOI 10.1158/1078-0432.CCR-10-0733; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059; Kryczek I, 2006, J EXP MED, V203, P871, DOI 10.1084/jem.20050930; Kubota Y, 2009, J EXP MED, V206, P1089, DOI 10.1084/jem.20081605; Kusmartsev S, 2003, CANCER RES, V63, P4441; Lanier LL, 2008, NAT IMMUNOL, V9, P495, DOI 10.1038/ni1581; Lathers DMR, 2004, CANCER IMMUNOL IMMUN, V53, P422, DOI 10.1007/s00262-003-0459-7; Liao XD, 2011, J CLIN INVEST, V121, P2736, DOI 10.1172/JCI45444; Love WE, 2009, ARCH DERMATOL, V145, P1431, DOI 10.1001/archdermatol.2009.291; Manthey CL, 2009, MOL CANCER THER, V8, P3151, DOI 10.1158/1535-7163.MCT-09-0255; Marshall NA, 2012, CANCER RES, V72, P581, DOI 10.1158/0008-5472.CAN-11-0307; Melief CJM, 2008, IMMUNITY, V29, P372, DOI 10.1016/j.immuni.2008.08.004; Mills KHG, 2004, NAT REV IMMUNOL, V4, P841, DOI 10.1038/nri1485; Mirza N, 2006, CANCER RES, V66, P9299, DOI 10.1158/0008-5472.CAN-06-1690; Miselis NR, 2008, MOL CANCER THER, V7, P788, DOI 10.1158/1535-7163.MCT-07-0579; Mizutani K, 2009, NEOPLASIA, V11, P1235, DOI 10.1593/neo.09988; Morita R, 2012, IMMUNOTHERAPY-UK, V4, P1103, DOI [10.2217/IMT.12.116, 10.2217/imt.12.116]; Mougiakakos D, 2010, ADV CANCER RES, V107, P57, DOI 10.1016/S0065-230X(10)07003-X; Mullard A, 2013, NAT REV DRUG DISCOV, V12, P489, DOI 10.1038/nrd4066; Nagai T, 2009, CANCER IMMUNOL IMMUN, V58, P1577, DOI 10.1007/s00262-009-0667-x; Nagaraj S, 2010, CLIN CANCER RES, V16, P1812, DOI 10.1158/1078-0432.CCR-09-3272; Nava-Parada P, 2007, CANCER RES, V67, P1326, DOI 10.1158/0008-5472.CAN-06-3290; Nefedova Y, 2007, CANCER RES, V67, P11021, DOI 10.1158/0008-5472.CAN-07-2593; Obermajer N, 2011, BLOOD, V118, P5498, DOI 10.1182/blood-2011-07-365825; Ostrand-Rosenberg S, 2010, CANCER IMMUNOL IMMUN, V59, P1593, DOI 10.1007/s00262-010-0855-8; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Ozao-Choy J, 2009, CANCER RES, V69, P2514, DOI 10.1158/0008-5472.CAN-08-4709; Palucka K, 2010, CURR OPIN IMMUNOL, V22, P258, DOI 10.1016/j.coi.2010.02.010; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Paulus P, 2006, CANCER RES, V66, P4349, DOI 10.1158/0008-5472.CAN-05-3523; Pello OM, 2012, BLOOD, V119, P411, DOI 10.1182/blood-2011-02-339911; Peng GY, 2005, SCIENCE, V309, P1380, DOI 10.1126/science.1113401; Peranzoni E, 2010, CURR OPIN IMMUNOL, V22, P238, DOI 10.1016/j.coi.2010.01.021; Puig-Kroger A, 2009, CANCER RES, V69, P9395, DOI 10.1158/0008-5472.CAN-09-2050; Pyonteck SM, 2012, ONCOGENE, V31, P1459, DOI 10.1038/onc.2011.337; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Ralph C, 2010, CLIN CANCER RES, V16, P1662, DOI 10.1158/1078-0432.CCR-09-2870; Rasku MA, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-12; Rech AJ, 2009, ANN NY ACAD SCI, V1174, P99, DOI 10.1111/j.1749-6632.2009.04939.x; Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643; Schmidt C, 2007, NAT BIOTECHNOL, V25, P825, DOI 10.1038/nbt0807-825; Serafini P, 2008, CANCER RES, V68, P5439, DOI 10.1158/0008-5472.CAN-07-6621; Seya T, 2012, ONCOIMMUNOLOGY, V1, P1000, DOI 10.4161/onci.19894; Sharma S, 2013, EXPERT OPIN THER TAR, V17, P481, DOI 10.1517/14728222.2013.781585; Shime H, 2012, P NATL ACAD SCI USA, V109, P2066, DOI 10.1073/pnas.1113099109; Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Sinha P, 2005, CANCER IMMUNOL IMMUN, V54, P1137, DOI 10.1007/s00262-005-0703-4; Sinha P, 2005, CANCER RES, V65, P11743, DOI 10.1158/0008-5472.CAN-05-0045; Sinha P, 2005, J IMMUNOL, V174, P636, DOI 10.4049/jimmunol.174.2.636; Sinha P, 2007, J IMMUNOL, V179, P977, DOI 10.4049/jimmunol.179.2.977; Sinha P, 2007, CANCER RES, V67, P4507, DOI 10.1158/0008-5472.CAN-06-4174; Smyth MJ, 2006, ADV IMMUNOL, V90, P1, DOI 10.1016/S0065-2776(06)90001-7; Solinas G, 2009, J LEUKOCYTE BIOL, V86, P1065, DOI 10.1189/jlb.0609385; Speiser DE, 2005, J CLIN INVEST, V115, P739, DOI 10.1172/JCI200523373; Steitz J, 2001, CANCER RES, V61, P8643; Stewart TJ, 2011, CANCER METAST REV, V30, P125, DOI 10.1007/s10555-011-9280-5; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; Suzuki E, 2005, CLIN CANCER RES, V11, P6713, DOI 10.1158/1078-0432.CCR-05-0883; Suzuki T, 2007, PLOS PATHOG, V3, P1082, DOI 10.1371/journal.ppat.0030111; Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tormo D, 2006, CANCER RES, V66, P5427, DOI 10.1158/0008-5472.CAN-06-0399; Ugel S, 2009, CURR OPIN PHARMACOL, V9, P470, DOI 10.1016/j.coph.2009.06.014; Vincent J, 2010, CANCER RES, V70, P3052, DOI 10.1158/0008-5472.CAN-09-3690; Waickman AT, 2012, CANCER IMMUNOL IMMUN, V61, P917, DOI 10.1007/s00262-011-1155-7; Walter S, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22246; Wang RF, 2006, SEMIN IMMUNOL, V18, P136, DOI 10.1016/j.smim.2006.01.008; WATANABE Y, 1987, J BIOL RESP MODIF, V6, P169; Weisser SB, 2011, EUR J IMMUNOL, V41, P1742, DOI 10.1002/eji.201041105; Wilson HL, 2006, INT REV IMMUNOL, V25, P183, DOI 10.1080/08830180600785868; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Woo EY, 2001, CANCER RES, V61, P4766; Woo SR, 2012, CANCER RES, V72, P917, DOI 10.1158/0008-5472.CAN-11-1620; Xin H, 2009, CANCER RES, V69, P2506, DOI 10.1158/0008-5472.CAN-08-4323; Yang YP, 2004, NAT IMMUNOL, V5, P508, DOI 10.1038/ni1059; Yao S, 2013, NAT REV DRUG DISCOV, V12, P130, DOI 10.1038/nrd3877; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; Zabuawala T, 2010, CANCER RES, V70, P1323, DOI 10.1158/0008-5472.CAN-09-1474; Zeisberger SM, 2006, BRIT J CANCER, V95, P272, DOI 10.1038/sj.bjc.6603240; Zhang W, 2010, CLIN CANCER RES, V16, P3420, DOI 10.1158/1078-0432.CCR-09-2904; Zhao ED, 2012, ONCOIMMUNOLOGY, V1, P152, DOI 10.4161/onci.1.2.18480; Zhu XM, 2011, J NEURO-ONCOL, V104, P83, DOI 10.1007/s11060-010-0473-5; Zhu YW, 2011, IMMUNITY, V34, P466, DOI 10.1016/j.immuni.2011.04.008; Zou LH, 2004, CANCER RES, V64, P8451, DOI 10.1158/0008-5472.CAN-04-1987	142	101	109	1	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2014	33	38					4623	4631		10.1038/onc.2013.432	http://dx.doi.org/10.1038/onc.2013.432			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3VX	24141774	Green Submitted			2022-12-17	WOS:000342007200001
J	Cittelly, DM; Finlay-Schultz, J; Howe, EN; Spoelstra, NS; Axlund, SD; Hendricks, P; Jacobsen, BM; Sartorius, CA; Richer, JK				Cittelly, D. M.; Finlay-Schultz, J.; Howe, E. N.; Spoelstra, N. S.; Axlund, S. D.; Hendricks, P.; Jacobsen, B. M.; Sartorius, C. A.; Richer, J. K.			Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4	ONCOGENE			English	Article						breast cancer; microRNA; progesterone; KLF4; cancer stem cells	STEM-CELLS; TRANSCRIPTION FACTOR; REPLACEMENT THERAPY; STEROID-RECEPTOR; DOWN-REGULATION; LUNG-CANCER; C-MYC; EXPRESSION; ESTROGEN; MAINTENANCE	The female hormone progesterone (P4) promotes the expansion of stem-like cancer cells in estrogen receptor (ER)- and progesterone receptor (PR)-positive breast tumors. The expanded tumor cells lose expression of ER and PR, express the tumor-initiating marker CD44, the progenitor marker cytokeratin 5 (CK5) and are more resistant to standard endocrine and chemotherapies. The mechanisms underlying this hormone-stimulated reprogramming have remained largely unknown. In the present study, we investigated the role of microRNAs in progestin-mediated expansion of this dedifferentiated tumor cell population. We demonstrate that P4 rapidly downregulates miR-29 family members, particularly in the CD44(+) cell population. Downregulation of miR-29 members potentiates the expansion of CK5(+) and CD44(+) cells in response to progestins, and results in increased stem-like properties in vitro and in vivo. We demonstrate that miR-29 directly targets Kruppel-like factor 4 (KLF4), a transcription factor required for the reprogramming of differentiated cells to pluripotent stem cells, and for the maintenance of breast cancer stem cells. These results reveal a novel mechanism, whereby progestins increase the stem cell-like population in hormone-responsive breast cancers, by decreasing miR-29 to augment PR-mediated upregulation of KLF4. Elucidating the mechanisms whereby hormones mediate the expansion of stem-like cells furthers our understanding of the progression of hormone-responsive breast cancers.	[Cittelly, D. M.; Finlay-Schultz, J.; Howe, E. N.; Spoelstra, N. S.; Axlund, S. D.; Hendricks, P.; Sartorius, C. A.; Richer, J. K.] Univ Colorado Denver, Dept Pathol, Aurora, CO 80045 USA; [Jacobsen, B. M.] Univ Colorado Denver, Dept Med, Div Endocrinol, Aurora, CO 80045 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Richer, JK (corresponding author), Univ Colorado Denver, Dept Pathol, Anschutz Med Campus, Aurora, CO 80045 USA.	Jennifer.Richer@ucdenver.edu		Howe, Erin/0000-0003-0314-6999; Jacobsen, Britta/0000-0001-8234-1690; Cittelly, Diana/0000-0002-8392-0800; Finlay-Schultz, Jessica/0000-0002-7855-9870	University of Colorado Cancer Center Cytometry and Cell Sorting Shared Resource Facility [P30CA046934]; NIH [F31CA165668-01, RO1CA140985]; DOD BCRP Postdoctoral Fellowship [W81XWH-11-1-0101]; DOD Idea Award [BCRP W81XWH-11-1-0210]; NATIONAL CANCER INSTITUTE [F31CA165668, R01CA140985, P30CA046934] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER	University of Colorado Cancer Center Cytometry and Cell Sorting Shared Resource Facility; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD BCRP Postdoctoral Fellowship; DOD Idea Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank the University of Colorado Cancer Center Cytometry and Cell Sorting Shared Resource Facility supported by P30CA046934. The human CK5 promoter (KRT5) was a gift from Elaine Fuchs (The Rockefeller University). NIH F31CA165668-01 supported ENH. NIH RO1CA140985 supported CAS. DOD BCRP Postdoctoral Fellowship W81XWH-11-1-0101 (DMC) and DOD Idea Award BCRP W81XWH-11-1-0210 (CAS, JKR) supported this work.	Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214; Bocker W, 2002, LAB INVEST, V82, P737, DOI 10.1097/01.LAB.0000017371.72714.C5; Bu W, 2011, ONCOGENE, V30, P4399, DOI 10.1038/onc.2011.147; Cittelly DM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-317; Cittelly DM, 2010, CARCINOGENESIS, V31, P2049, DOI 10.1093/carcin/bgq192; Cochrane DR, 2012, MOL CELL ENDOCRINOL, V355, P15, DOI 10.1016/j.mce.2011.12.020; Cochrane DR, 2011, STEROIDS, V76, P1, DOI 10.1016/j.steroids.2010.11.003; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Graham JD, 2009, ENDOCRINOLOGY, V150, P3318, DOI 10.1210/en.2008-1630; Haughian JM, 2012, P NATL ACAD SCI USA, V109, P2742, DOI 10.1073/pnas.1106509108; Horwitzt KB, 2008, P NATL ACAD SCI USA, V105, P5774, DOI 10.1073/pnas.0706216105; Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867; Hwang HW, 2007, SCIENCE, V315, P97, DOI 10.1126/science.1136235; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Ismail PM, 2003, STEROIDS, V68, P779, DOI 10.1016/S0039-128X(03)00133-8; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Kabos P, 2011, BREAST CANCER RES TR, V128, P45, DOI 10.1007/s10549-010-1078-6; Lange CA, 2008, STEROIDS, V73, P914, DOI 10.1016/j.steroids.2007.12.023; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Lin SL, 2008, RNA, V14, P2115, DOI 10.1261/rna.1162708; Lin SL, 2011, NUCLEIC ACIDS RES, V39, P1054, DOI 10.1093/nar/gkq850; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu HP, 2010, P NATL ACAD SCI USA, V107, P18115, DOI 10.1073/pnas.1006732107; Liu R, 2011, MOL ENDOCRINOL, V25, P1137, DOI 10.1210/me.2010-0497; Lydon JP, 1999, CANCER RES, V59, P4276; Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.3.CO;2-Y; Moore MR, 1997, J STEROID BIOCHEM, V62, P243, DOI 10.1016/S0960-0760(97)00036-8; Mott JL, 2010, J CELL BIOCHEM, V110, P1155, DOI 10.1002/jcb.22630; Mulac-Jericevic B, 2003, P NATL ACAD SCI USA, V100, P9744, DOI 10.1073/pnas.1732707100; Nguyen T, 2011, EPIGENETICS-US, V6, P388, DOI 10.4161/epi.6.3.14056; Park SY, 2009, NAT STRUCT MOL BIOL, V16, P23, DOI 10.1038/nsmb.1533; Pekarsky Y, 2006, CANCER RES, V66, P11590, DOI 10.1158/0008-5472.CAN-06-3613; Radisky DC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2885; Rao X, 2011, ONCOGENE, V30, P1082, DOI 10.1038/onc.2010.487; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Sartorius CA, 2005, CANCER RES, V65, P9779, DOI 10.1158/0008-5472.CAN-05-0505; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387; Sengupta S, 2008, P NATL ACAD SCI USA, V105, P5874, DOI 10.1073/pnas.0801130105; Shcherbata HR, 2006, CELL CYCLE, V5, P172, DOI 10.4161/cc.5.2.2343; Sridharan R, 2009, CELL, V136, P364, DOI 10.1016/j.cell.2009.01.001; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tessel MA, 2010, CURR OPIN ONCOL, V22, P592, DOI 10.1097/CCO.0b013e32833ea80c; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wong CW, 2010, STEM CELLS, V28, P1510, DOI 10.1002/stem.477; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yang CS, 2011, RNA, V17, P1451, DOI 10.1261/rna.2664111; Yu F, 2011, ONCOGENE, V30, P2161, DOI 10.1038/onc.2010.591; Yu F, 2010, ONCOGENE, V29, P4194, DOI 10.1038/onc.2010.167; Zhang J, 2012, INT J ONCOL, V40, P747, DOI 10.3892/ijo.2011.1242; Zhang PL, 2010, J BIOL CHEM, V285, P9180, DOI 10.1074/jbc.M109.077958; Zhang Z, 2011, NUCLEIC ACIDS RES, V39, P4387, DOI 10.1093/nar/gkr020; Zhu M, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r77	55	101	103	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2013	32	20					2555	2564		10.1038/onc.2012.275	http://dx.doi.org/10.1038/onc.2012.275			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	148UY	22751119	Green Accepted			2022-12-17	WOS:000319274300007
J	Goidts, V; Bageritz, J; Puccio, L; Nakata, S; Zapatka, M; Barbus, S; Toedt, G; Campos, B; Korshunov, A; Momma, S; Van Schaftingen, E; Reifenberger, G; Herold-Mende, C; Lichter, P; Radlwimmer, B				Goidts, V.; Bageritz, J.; Puccio, L.; Nakata, S.; Zapatka, M.; Barbus, S.; Toedt, G.; Campos, B.; Korshunov, A.; Momma, S.; Van Schaftingen, E.; Reifenberger, G.; Herold-Mende, C.; Lichter, P.; Radlwimmer, B.			RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival	ONCOGENE			English	Article						loss-of-function screen; apoptosis; glioblastoma; cancer stem-like cells; glycolysis	HYPOXIA-INDUCIBLE FACTOR-1; TUMOR-GROWTH; HUMAN BRAIN; EXPRESSION; GLIOBLASTOMA; GENE; 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE; METABOLISM; ACTIVATION; DIFFERENTIATION	The concept of cancer stem-like cells (CSCs) has gained considerable attention in various solid tumors including glioblastoma, the most common primary brain tumor. This sub-population of tumor cells has been intensively investigated and their role in therapy resistance as well as tumor recurrence has been demonstrated. In that respect, development of therapeutic strategies that target CSCs (and possibly also the tumor bulk) appears a promising approach in patients suffering from primary brain tumors. In the present study, we utilized RNA interference (RNAi) to screen the complete human kinome and phosphatome (682 and 180 targets, respectively) in order to identify genes and pathways relevant for the survival of brain CSCs and thereby potential therapeutical targets for glioblastoma. We report of 46 putative candidates including known survival-related kinases and phosphatases. Interestingly, a number of genes identified are involved in metabolism, especially glycolysis, such as PDK1 and PKM2 and, most prominently PFKFB4. In vitro studies confirmed an essential role of PFKFB4 in the maintenance of brain CSCs. Furthermore, high PFKFB4 expression was associated with shorter survival of primary glioblastoma patients. Our findings support the importance of the glycolytic pathway in the maintenance of malignant glioma cells and brain CSCs and imply tumor metabolism as a promising therapeutic target in glioblastoma. Oncogene (2012) 31, 3235-3243; doi:10.1038/onc.2011.490; published online 7 November 2011	[Goidts, V.; Bageritz, J.; Puccio, L.; Nakata, S.; Zapatka, M.; Barbus, S.; Toedt, G.; Lichter, P.; Radlwimmer, B.] German Canc Res Ctr, Div Mol Genet, D-69120 Heidelberg, Germany; [Goidts, V.] Univ Heidelberg, Childrens Hosp, Dept Pediat Oncol Hematol & Immunol, D-6900 Heidelberg, Germany; [Campos, B.; Herold-Mende, C.] Univ Heidelberg, Dept Neurosurg, Div Neurosurg Res, Heidelberg, Germany; [Korshunov, A.] Univ Heidelberg, Dept Neuropathol, Heidelberg, Germany; [Korshunov, A.] German Canc Res Ctr, Clin Cooperat Unit Neuropathol, D-69120 Heidelberg, Germany; [Momma, S.] Goethe Univ Frankfurt, Sch Med, Edinger Inst, Frankfurt, Germany; [Van Schaftingen, E.] Catholic Univ Louvain, de Duve Inst, Lab Physiol Chem, B-1200 Brussels, Belgium; [Reifenberger, G.] Univ Dusseldorf, Dept Neuropathol, D-40225 Dusseldorf, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Goethe University Frankfurt; Universite Catholique Louvain; Heinrich Heine University Dusseldorf	Goidts, V (corresponding author), German Canc Res Ctr, Div Mol Genet, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	v.goidts@dkfz.de	Van+Schaftingen, Emile/AAF-5532-2020; Radlwimmer, Bernhard F/I-3229-2013; Reifenberger, Guido/AAE-3599-2019; Zapatka, Marc/G-9896-2013	Radlwimmer, Bernhard F/0000-0002-4553-7800; Zapatka, Marc/0000-0001-8287-5967; Bageritz, Josephine/0000-0002-9531-0452; Korshunov, Andrey/0000-0002-5257-3623; Van Schaftingen, Emile/0000-0002-6199-7647	German Federal Ministry of Education and Research (BMBF) within the National Genome Research Network (NGFNplus) [01GS0883, 01GS0884]; Alexander von Humboldt foundation; Medical Faculty of Heidelberg; Grants-in-Aid for Scientific Research [23791491] Funding Source: KAKEN	German Federal Ministry of Education and Research (BMBF) within the National Genome Research Network (NGFNplus)(Federal Ministry of Education & Research (BMBF)); Alexander von Humboldt foundation(Alexander von Humboldt Foundation); Medical Faculty of Heidelberg; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr S Pfister and D Haag for their helpful comments. We thank Mrs V Lang and G Iren for their technical help. We thank Dr J Chesney for kindly providing 3PO. This work was supported by the German Federal Ministry of Education and Research (BMBF) within the National Genome Research Network (NGFNplus; 01GS0883, 01GS0884), a stipend from the Alexander von Humboldt foundation (to SN) and by the grant 'Young Investigator Fellowship' of the Medical Faculty of Heidelberg (to VG).	Al-Hajj M, 2007, CURR OPIN ONCOL, V19, P61; Atsumi T, 2002, CANCER RES, V62, P5881; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Campos B, 2010, CLIN CANCER RES, V16, P2715, DOI 10.1158/1078-0432.CCR-09-1800; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Clem B, 2008, MOL CANCER THER, V7, P110, DOI 10.1158/1535-7163.MCT-07-0482; Eramo A, 2006, CELL DEATH DIFFER, V13, P1238, DOI 10.1038/sj.cdd.4401872; Ernst A, 2009, CLIN CANCER RES, V15, P6541, DOI 10.1158/1078-0432.CCR-09-0695; Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524; Floridi A, 1989, J Neurosurg Sci, V33, P55; Giroux V, 2006, FASEB J, V20, P1982, DOI 10.1096/fj.06-6239com; Gomez M, 2005, FEBS LETT, V579, P357, DOI 10.1016/j.febslet.2004.11.096; Gomez-Brouchet A, 2007, MOL PHARMACOL, V72, P341, DOI 10.1124/mol.106.033738; Heddleston JM, 2009, CELL CYCLE, V8, P3274, DOI 10.4161/cc.8.20.9701; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Kessler R, 2001, MOL BRAIN RES, V87, P190, DOI 10.1016/S0169-328X(01)00014-6; Kress S, 1998, J CANCER RES CLIN, V124, P315, DOI 10.1007/s004320050175; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Lu HS, 2002, J BIOL CHEM, V277, P23111, DOI 10.1074/jbc.M202487200; MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258; Manzano A, 1998, CYTOGENET CELL GENET, V83, P214, DOI 10.1159/000015181; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Minchenko O, 2004, FEBS LETT, V576, P14, DOI 10.1016/j.febslet.2004.08.053; Okuyama H, 2006, J BIOL CHEM, V281, P15554, DOI 10.1074/jbc.M602003200; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Park CY, 2009, MOL THER, V17, P219, DOI 10.1038/mt.2008.254; Pradelli LA, 2010, ONCOGENE, V29, P1641, DOI 10.1038/onc.2009.448; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; SAKATA J, 1991, J BIOL CHEM, V266, P15764; Singh SK, 2003, CANCER RES, V63, P5821; Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252; Stupp R, 2007, J CLIN ONCOL, V25, P4127, DOI 10.1200/JCO.2007.11.8554; Toedt G, 2011, INT J CANCER, V128, P1095, DOI 10.1002/ijc.25448; Vescovi AL, 2006, NAT REV CANCER, V6, P425, DOI 10.1038/nrc1889; Wigfield SM, 2008, BRIT J CANCER, V98, P1975, DOI 10.1038/sj.bjc.6604356; Wurdak H, 2010, CELL STEM CELL, V6, P37, DOI 10.1016/j.stem.2009.11.002; Yalcin A, 2009, EXP MOL PATHOL, V86, P174, DOI 10.1016/j.yexmp.2009.01.003; ZIMMERMAN DW, 1993, CAN J EXP PSYCHOL, V47, P523, DOI 10.1037/h0078850	42	101	108	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	27					3235	3243		10.1038/onc.2011.490	http://dx.doi.org/10.1038/onc.2011.490			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	970FL	22056879				2022-12-17	WOS:000306113400003
J	Spiegel, S; Milstien, S; Grant, S				Spiegel, S.; Milstien, S.; Grant, S.			Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy	ONCOGENE			English	Review						histone deacetylase; histone deacetylase inhibitor; apoptosis; sphingosine-1-phosphate; cancer	NF-KAPPA-B; HUMAN LEUKEMIA-CELLS; SUBEROYLANILIDE HYDROXAMIC ACID; SYNERGISTICALLY INDUCES APOPTOSIS; DNA-DAMAGE; MULTIPLE-MYELOMA; HDAC INHIBITORS; MEDIATED PHOSPHORYLATION; DIFFERENTIAL EXPRESSION; REVERSIBLE ACETYLATION	The class-I histone deacetylases (HDACs) HDAC1 and HDAC2 belong to a family of 11 zinc-dependent human HDACs and are overexpressed in many cancers. Inhibitors of these HDACs now in clinical trials show activity against several types of cancers. This review is focused on recent advances in both clinical and preclinical efforts to understand the basis for the actions of HDACis, with emphasis on implications for rational combinations with conventional or other targeted agents. We will address new perspectives on the molecular mechanisms by which HDACs act and how these actions relate to cancer. We will also review new evidence showing that HDACs are direct intracellular targets of the potent sphingolipid mediator S1P, the first identified endogenous nuclear regulator of these enzymes, linking sphingolipid metabolism in the nucleus to remodeling of chromatin and epigenetic regulation of gene expression. Understanding how endogenous molecules regulate HDAC activity in vivo may facilitate the search for safer and more effective anticancer drugs capable of interfering with HDAC functions in a highly specific manner. Oncogene (2012) 31, 537-551; doi:10.1038/onc.2011.267; published online 4 July 2011	[Spiegel, S.; Milstien, S.] Virginia Commonwealth Univ, Sch Med Richmond, Dept Biochem & Mol Biol, Richmond, VA 23298 USA; [Grant, S.] Virginia Commonwealth Univ, Sch Med Richmond, Dept Med, Richmond, VA 23298 USA; [Spiegel, S.; Grant, S.] Virginia Commonwealth Univ, Sch Med Richmond, Massey Canc Ctr, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, 1101 E Marshall St,2011 Sanger Hall, Richmond, VA 23298 USA.	sspiegel@vcu.edu			Leukemia and Lymphoma Society of America [6181-10]; V Foundation; Multiple Myeloma Research Foundation;  [R01CA61774];  [R37GM043880];  [R01AI50094];  [1U19AI077435];  [RO1CA93738-05];  [CA100866];  [1P50CA142509];  [RC2CA148431];  [1P50CA130805];  [1R21CA137823]; NATIONAL CANCER INSTITUTE [P50CA142509, R21CA137823, P50CA130805, R01CA100866, R01CA093738, R01CA061774, RC2CA148431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050094, U19AI077435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880, R01GM043880] Funding Source: NIH RePORTER	Leukemia and Lymphoma Society of America(Leukemia and Lymphoma Society); V Foundation; Multiple Myeloma Research Foundation; ; ; ; ; ; ; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We apologize to authors whose work has not been cited here owing to space limitations. This work was supported by R01CA61774 (SS) R37GM043880 (SS), R01AI50094 (SS), 1U19AI077435 (SS),), R01AI50094 (SS), 1U19AI077435 (SS), RO1CA93738-05 (SG), CA100866 (SG), 1P50CA142509 (SG), RC2CA148431 (SG), 1P50CA130805 (SG), 1R21CA137823, the Leukemia and Lymphoma Society of America 6181-10 (SG), the V Foundation and the Multiple Myeloma Research Foundation (SG).	Albi E, 2008, BIOCHEM J, V410, P381, DOI 10.1042/BJ20070758; Almenara J, 2002, LEUKEMIA, V16, P1331, DOI 10.1038/sj.leu.2402535; Badros A, 2009, CLIN CANCER RES, V15, P5250, DOI 10.1158/1078-0432.CCR-08-2850; Bali P, 2004, CLIN CANCER RES, V10, P4991, DOI 10.1158/1078-0432.CCR-04-0210; Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200; Bantscheff M, 2011, NAT BIOTECHNOL, V29, P255, DOI 10.1038/nbt.1759; Bhaskara S, 2008, MOL CELL, V30, P61, DOI 10.1016/j.molcel.2008.02.030; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Boyault C, 2007, ONCOGENE, V26, P5468, DOI 10.1038/sj.onc.1210614; Buchwald M, 2009, CANCER LETT, V280, P160, DOI 10.1016/j.canlet.2009.02.028; Calao M, 2008, TRENDS BIOCHEM SCI, V33, P339, DOI 10.1016/j.tibs.2008.04.015; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7; Cerchietti LC, 2011, J CLIN INVE IN PRESS; Chang HH, 2009, ORAL ONCOL, V45, P610, DOI 10.1016/j.oraloncology.2008.08.011; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966-7975.2005; Chen S, 2007, CANCER RES, V67, P782, DOI 10.1158/0008-5472.CAN-06-3964; Chen S, 2009, MOL CELL BIOL, V29, P6149, DOI 10.1128/MCB.01481-08; Choi JH, 2001, JPN J CANCER RES, V92, P1300, DOI 10.1111/j.1349-7006.2001.tb02153.x; Clayton AL, 2006, MOL CELL, V23, P289, DOI 10.1016/j.molcel.2006.06.017; COCCO L, 1980, BIOCHEM BIOPH RES CO, V96, P890, DOI 10.1016/0006-291X(80)91439-4; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Dai CL, 2008, CANCER RES, V68, P7905, DOI 10.1158/0008-5472.CAN-08-0499; Dai Y, 2005, MOL CELL BIOL, V25, P5429, DOI 10.1128/MCB.25.13.5429-5444.2005; Dai Y, 2008, CLIN CANCER RES, V14, P549, DOI 10.1158/1078-0432.CCR-07-1934; Dai Y, 2010, BRIT J HAEMATOL, V151, P70, DOI 10.1111/j.1365-2141.2010.08319.x; Ding G, 2007, J BIOL CHEM, V282, P27493, DOI 10.1074/jbc.M701641200; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fiskus W, 2006, CLIN CANCER RES, V12, P5869, DOI 10.1158/1078-0432.CCR-06-0980; Fotheringham S, 2009, CANCER CELL, V15, P57, DOI 10.1016/j.ccr.2008.12.001; Fritzsche FR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-381; Gaymes TJ, 2006, MOL CANCER RES, V4, P563, DOI 10.1158/1541-7786.MCR-06-0111; Gillespie S, 2006, APOPTOSIS, V11, P2251, DOI 10.1007/s10495-006-0283-6; Gloghini A, 2009, BRIT J HAEMATOL, V147, P515, DOI 10.1111/j.1365-2141.2009.07887.x; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Grant S, 2007, NAT REV DRUG DISCOV, V6, P21, DOI 10.1038/nrd2227; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Hait NC, 2007, J BIOL CHEM, V282, P12058, DOI 10.1074/jbc.M609559200; Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709; Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102; Hinz M, 2010, MOL CELL, V40, P63, DOI 10.1016/j.molcel.2010.09.008; Hodawadekar SC, 2007, ONCOGENE, V26, P5528, DOI 10.1038/sj.onc.1210619; Hu YM, 2010, BLOOD, V116, P2732, DOI 10.1182/blood-2009-11-256354; Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Kachhap SK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011208; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kawada J, 2009, J BIOL CHEM, V284, P17102, DOI 10.1074/jbc.M809090200; Khan O, 2010, P NATL ACAD SCI USA, V107, P6532, DOI 10.1073/pnas.0913912107; Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Lagger S, 2010, EMBO J, V29, P3992, DOI 10.1038/emboj.2010.264; Lahm A, 2007, P NATL ACAD SCI USA, V104, P17335, DOI 10.1073/pnas.0706487104; Lee JH, 2010, P NATL ACAD SCI USA, V107, P14639, DOI 10.1073/pnas.1008522107; Lee JS, 2010, CELL, V142, P682, DOI 10.1016/j.cell.2010.08.011; Luszczek W, 2010, MOL CANCER THER, V9, P2309, DOI 10.1158/1535-7163.MCT-10-0309; Mandawat A, 2010, BLOOD, V116, P5306, DOI 10.1182/blood-2010-05-284414; Marchion DC, 2004, J CELL BIOCHEM, V92, P223, DOI 10.1002/jcb.20045; Marks PA, 2010, EXPERT OPIN INV DRUG, V19, P1049, DOI 10.1517/13543784.2010.510514; Miller KM, 2010, NAT STRUCT MOL BIOL, V17, P1144, DOI 10.1038/nsmb.1899; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100; Miyake K, 2008, PANCREAS, V36, pE1, DOI 10.1097/MPA.0b013e31815f2c2a; Moreno DA, 2010, BRIT J HAEMATOL, V150, P665, DOI 10.1111/j.1365-2141.2010.08301.x; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Neckers Len, 2003, Current Opinion in Oncology, V15, P419, DOI 10.1097/00001622-200311000-00003; Nusinzon I, 2003, P NATL ACAD SCI USA, V100, P14742, DOI 10.1073/pnas.2433987100; Ocker M, 2007, INT J BIOCHEM CELL B, V39, P1367, DOI 10.1016/j.biocel.2007.03.001; Oehme I, 2009, EXPERT OPIN INV DRUG, V18, P1605, DOI 10.1517/14728220903241658; Osada H, 2004, INT J CANCER, V112, P26, DOI 10.1002/ijc.20395; Ozdag H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-90; Park MA, 2008, CANCER BIOL THER, V7, P1648, DOI 10.4161/cbt.7.10.6623; Park MA, 2010, CANCER RES, V70, P6313, DOI 10.1158/0008-5472.CAN-10-0999; Qian DZ, 2004, CANCER RES, V64, P6626, DOI 10.1158/0008-5472.CAN-04-0540; Rahmani M, 2003, CANCER RES, V63, P8420; Rahmani M, 2005, CANCER RES, V65, P2422, DOI 10.1158/0008-5472.CAN-04-2440; Ray S, 2008, NUCLEIC ACIDS RES, V36, P4510, DOI 10.1093/nar/gkn419; Rikimaru T, 2007, ONCOLOGY-BASEL, V72, P69, DOI 10.1159/000111106; Ropero S, 2006, NAT GENET, V38, P566, DOI 10.1038/ng1773; Rosato RR, 2008, MOL CANCER THER, V7, P3285, DOI 10.1158/1535-7163.MCT-08-0385; Rosato RR, 2010, J BIOL CHEM, V285, P10064, DOI 10.1074/jbc.M109.095208; Rosato RR, 2003, MOL CANCER THER, V2, P1273; Rosato RR, 2003, CANCER RES, V63, P3637; Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598; Sakuma T, 2006, INT J ONCOL, V29, P117; Sankala HM, 2007, CANCER RES, V67, P10466, DOI 10.1158/0008-5472.CAN-07-2090; Schuler S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-80; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shida D, 2008, CURR DRUG TARGETS, V9, P662, DOI 10.2174/138945008785132402; Simboeck E, 2010, J BIOL CHEM, V285, P41062, DOI 10.1074/jbc.M110.184481; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 2007, J BIOL CHEM, V282, P2125, DOI 10.1074/jbc.R600028200; Subramanian C, 2005, P NATL ACAD SCI USA, V102, P4842, DOI 10.1073/pnas.0408351102; Takabe K, 2008, PHARMACOL REV, V60, P181, DOI 10.1124/pr.107.07113; Takabe K, 2010, J BIOL CHEM, V285, P10477, DOI 10.1074/jbc.M109.064162; Thangaraju M, 2006, CANCER RES, V66, P11560, DOI 10.1158/0008-5472.CAN-06-1950; Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102; Valenzuela-Fernandez A, 2008, TRENDS CELL BIOL, V18, P291, DOI 10.1016/j.tcb.2008.04.003; Walker T, 2009, MOL PHARMACOL, V76, P342, DOI 10.1124/mol.109.056523; Walkinshaw DR, 2008, J CELL BIOCHEM, V104, P1541, DOI 10.1002/jcb.21746; Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warrener R, 2003, FASEB J, V17, P1550, DOI 10.1096/fj.02-1003fje; Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988; Wooten-Blanks LG, 2007, FASEB J, V21, P3386, DOI 10.1096/fj.07-8621com; Workman P, 2007, ANN NY ACAD SCI, V1113, P202, DOI 10.1196/annals.1391.012; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Wu ZH, 2010, MOL CELL, V40, P75, DOI 10.1016/j.molcel.2010.09.010; Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346; Yu CR, 2003, CANCER RES, V63, P2118; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang ZH, 2005, BREAST CANCER RES TR, V94, P11, DOI 10.1007/s10549-005-6001-1; Zhao Y, 2005, P NATL ACAD SCI USA, V102, P16090, DOI 10.1073/pnas.0505585102; Zupkovitz G, 2010, MOL CELL BIOL, V30, P1171, DOI 10.1128/MCB.01500-09	123	101	108	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	5					537	551		10.1038/onc.2011.267	http://dx.doi.org/10.1038/onc.2011.267			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21725353	Green Accepted			2022-12-17	WOS:000300221800001
J	Welti, JC; Gourlaouen, M; Powles, T; Kudahetti, SC; Wilson, P; Berney, DM; Reynolds, AR				Welti, J. C.; Gourlaouen, M.; Powles, T.; Kudahetti, S. C.; Wilson, P.; Berney, D. M.; Reynolds, A. R.			Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib	ONCOGENE			English	Article						angiogenesis; growth factors; sunitinib; renal cancer; resistance	TYROSINE KINASE INHIBITOR; IN-VITRO; ANTITUMOR-ACTIVITY; TARGETED THERAPY; INTERFERON-ALPHA; TUMOR-GROWTH; ANGIOGENESIS; VEGF; RESISTANCE; EXPRESSION	The vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor sunitinib has been approved for first-line treatment of patients with metastatic renal cancer and is currently being trialled in other cancers. However, the effectiveness of this anti-angiogenic agent is limited by the presence of innate and acquired drug resistance. By screening a panel of candidate growth factors we identified fibroblast growth factor 2 (FGF2) as a potent regulator of endothelial cell sensitivity to sunitinib. We show that FGF2 supports endothelial proliferation and de novo tubule formation in the presence of sunitinib and that FGF2 can suppress sunitinib-induced retraction of tubules. Importantly, these effects of FGF2 were ablated by PD173074, a small molecule inhibitor of FGF receptor signalling. We also show that FGF2 can stimulate pro-angiogenic signalling pathways in endothelial cells despite the presence of sunitinib. Finally, analysis of clinical renal-cancer samples demonstrates that a large proportion of renal cancers strongly express FGF2. We suggest that therapeutic strategies designed to simultaneously target both VEGF and FGF2 signalling may prove more efficacious than sunitinib in renal cancer patients whose tumours express FGF2. Oncogene (2011) 30, 1183-1193; doi:10.1038/onc.2010.503; published online 8 November 2010	[Welti, J. C.; Gourlaouen, M.; Reynolds, A. R.] Inst Canc Res, Tumour Angiogenesis Grp, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Powles, T.; Kudahetti, S. C.; Berney, D. M.] Queen Mary Univ London, Ctr Mol Oncol, Barts & London Sch Med & Dent, John Vane Sci Ctr,Inst Canc, London, England; [Wilson, P.] Dept Med Oncol, London, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; Queen Mary University London	Reynolds, AR (corresponding author), Inst Canc Res, Tumour Angiogenesis Grp, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	andrew.reynolds@icr.ac.uk		Welti, Jonathan/0000-0002-9433-8138; Berney, Daniel/0000-0001-5474-8696	Breakthrough Breast Cancer; Pfizer Global Pharmaceuticals	Breakthrough Breast Cancer; Pfizer Global Pharmaceuticals(Pfizer)	Thomas Powles is the recipient of an educational research grant from Pfizer Global Pharmaceuticals. The other authors declare no potential conflict of interest.; We would like to thank Alan Ashworth, Clare Isacke and Nicholas Turner for critical comments on the paper and Breakthrough Breast Cancer for research funding.	Abrams TJ, 2003, MOL CANCER THER, V2, P1011; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Britten CD, 2008, CANCER CHEMOTH PHARM, V61, P515, DOI 10.1007/s00280-007-0498-4; Bryant DM, 2005, TRAFFIC, V6, P947, DOI 10.1111/j.1600-0854.2005.00332.x; Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005; Crawford Y, 2009, CANCER CELL, V15, P21, DOI 10.1016/j.ccr.2008.12.004; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; Ebos JML, 2009, CLIN CANCER RES, V15, P5020, DOI 10.1158/1078-0432.CCR-09-0095; EGUCHI J, 1992, BIOCHEM BIOPH RES CO, V183, P937, DOI 10.1016/S0006-291X(05)80280-3; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403; Faivre S, 2006, J CLIN ONCOL, V24, P25, DOI 10.1200/JCO.2005.02.2194; Faivre S, 2007, NAT REV DRUG DISCOV, V6, P734, DOI 10.1038/nrd2380; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Fischer C, 2007, CELL, V131, P463, DOI 10.1016/j.cell.2007.08.038; Fukata S, 2005, CANCER-AM CANCER SOC, V103, P931, DOI 10.1002/cncr.20887; Giavazzi R, 2003, AM J PATHOL, V162, P1913, DOI 10.1016/S0002-9440(10)64325-8; Gualandris A, 1996, CELL GROWTH DIFFER, V7, P147; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Huang D, 2010, CANCER RES, V70, P1053, DOI 10.1158/0008-5472.CAN-09-3722; Huang D, 2010, CANCER RES, V70, P1063, DOI 10.1158/0008-5472.CAN-09-3965; Joy A, 1997, ONCOGENE, V14, P171, DOI 10.1038/sj.onc.1200823; Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612; Mavria G, 2006, CANCER CELL, V9, P33, DOI 10.1016/j.ccr.2005.12.021; Mendel DB, 2003, CLIN CANCER RES, V9, P327; Meyer RD, 2003, J BIOL CHEM, V278, P16347, DOI 10.1074/jbc.M300259200; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293; Nakatsu MN, 2008, METHOD ENZYMOL, V443, P65, DOI 10.1016/S0076-6879(08)02004-1; NANUS DM, 1993, J NATL CANCER I, V85, P1597, DOI 10.1093/jnci/85.19.1597; O'Farrell AM, 2003, BLOOD, V101, P3597, DOI 10.1182/blood-2002-07-2307; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Pardo OE, 2009, CANCER RES, V69, P8645, DOI 10.1158/0008-5472.CAN-09-1576; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; Pintucci G, 2002, FASEB J, V16, P598, DOI 10.1096/fj.01-0815fje; PRESTA M, 1991, CELL REGUL, V2, P719, DOI 10.1091/mbc.2.9.719; Presta M, 2005, CYTOKINE GROWTH F R, V16, P159, DOI 10.1016/j.cytogfr.2005.01.004; Ravaud A, 2008, J CLIN ONCOL, V26, P2285, DOI 10.1200/JCO.2007.14.5029; Relf M, 1997, CANCER RES, V57, P963; Rini BI, 2009, LANCET ONCOL, V10, P992, DOI 10.1016/S1470-2045(09)70240-2; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; Slaton JW, 2001, AM J PATHOL, V158, P735, DOI 10.1016/S0002-9440(10)64016-3; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780	51	101	103	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	10					1183	1193		10.1038/onc.2010.503	http://dx.doi.org/10.1038/onc.2010.503			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732QD	21057538				2022-12-17	WOS:000288202400005
J	Qiu, W; Leibowitz, B; Zhang, L; Yu, J				Qiu, W.; Leibowitz, B.; Zhang, L.; Yu, J.			Growth factors protect intestinal stem cells from radiation-induced apoptosis by suppressing PUMA through the PI3K/AKT/p53 axis	ONCOGENE			English	Article						PUMA; growth factors; p53; apoptosis; intestinal stem cells; PI3K	GASTROINTESTINAL-TRACT; IONIZING-RADIATION; BH3-ONLY PROTEINS; IN-VIVO; P53; SURVIVAL; GENE; INDUCTION; IDENTIFICATION; EXPRESSION	Gastrointestinal toxicity is the primary limiting factor in abdominal and pelvic radiotherapy, but has no effective treatment currently. We recently showed a critical role of the BH3-only protein p53 upregulated modulator of apoptosis (PUMA) in acute radiation-induced GI damage and GI syndrome in mice. Growth factors such as insulin-like growth factor 1 (IGF-1) and basic fibroblast growth factor (bFGF) have been shown to protect against radiation-induced intestinal injury, although the underlying mechanisms remain to be identified. We report here the suppression of PUMA through the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/p53 axis in the intestinal stem cells as a novel molecular mechanism of growth factor-mediated intestinal radioprotection. IGF-1 or bFGF impaired radiation-induced apoptosis and the expression of PUMA and p53 in the crypt cells and intestinal stem cells. Using colonic epithelial cells that undergo PUMA-dependent and radiation-induced apoptosis, we found that a PI3K inhibitor, dominant-negative PI3K or Mdm2 antagonist restored the induction of PUMA, p53 and apoptosis in the presence of growth factors. In contrast, overexpression of AKT suppressed the induction of PUMA and p53 by radiation. Furthermore, inhibiting PI3K or activating p53 abrogated growth factor-mediated suppression of apoptosis and PUMA expression in the intestinal crypts and stem cells after radiation. Oncogene (2010) 29, 1622-1632; doi:10.1038/onc.2009.451; published online 7 December 2009	[Yu, J.] Univ Pittsburgh, Hillman Canc Ctr Res Pavil, Dept Pathol, Sch Med, Pittsburgh, PA 15213 USA; [Qiu, W.; Leibowitz, B.; Zhang, L.; Yu, J.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; [Zhang, L.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Yu, J (corresponding author), Univ Pittsburgh, Hillman Canc Ctr Res Pavil, Dept Pathol, Sch Med, Suite 2-26H,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	yuj2@upmc.edu	Yu, Jian/A-8301-2009; Zhang, Lin/A-7389-2009	Yu, Jian/0000-0002-4021-1000; Zhang, Lin/0000-0003-0018-3903	NIH [CA106348, CA121105, CA129829, UO1-DK085570, U19-A1068021]; American Cancer Society [RSG-07-156-01-CNE]; ACGT; FAMRI; NATIONAL CANCER INSTITUTE [R01CA129829, R01CA121105, R01CA106348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK085570] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); ACGT; FAMRI; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank other members of our labs for helpful discussion and advice and Ms Hong Tao Liu for breeding mice. This work is supported in part by NIH grants CA106348, CA121105, and American Cancer Society grant RSG-07-156-01-CNE (L Zhang), and NIH grants CA129829, UO1-DK085570, U19-A1068021 (pilot project), and those from ACGT and FAMRI (J Yu).	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Booth D, 2001, J Natl Cancer Inst Monogr, P16; Bouleau S, 2007, APOPTOSIS, V12, P1377, DOI 10.1007/s10495-007-0072-x; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Butt AJ, 1999, IMMUNOL CELL BIOL, V77, P256, DOI 10.1046/j.1440-1711.1999.00822.x; Ch'ang HJ, 2005, NAT MED, V11, P484, DOI 10.1038/nm1237; Clarke AR, 2007, ONCOGENE, V26, P6349, DOI 10.1038/sj.onc.1210457; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; George RJ, 2009, AM J PHYSIOL-GASTR L, V296, pG245, DOI 10.1152/ajpgi.00021.2008; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Gu QY, 2004, RADIAT RES, V161, P692, DOI 10.1667/RR3158; Gulati AS, 2008, AM J PHYSIOL-GASTR L, V294, pG286, DOI 10.1152/ajpgi.00416.2007; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Houchen CW, 1999, AM J PHYSIOL-GASTR L, V276, pG249, DOI 10.1152/ajpgi.1999.276.1.G249; Ishizuka S, 2003, NUCLEIC ACIDS RES, V31, P6198, DOI 10.1093/nar/gkg840; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Katoh M, 2006, INT J ONCOL, V29, P163; Kohli M, 2004, P NATL ACAD SCI USA, V101, P16897, DOI 10.1073/pnas.0403405101; Komarova EA, 2004, ONCOGENE, V23, P3265, DOI 10.1038/sj.onc.1207494; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; Levine AJ, 2006, GENE DEV, V20, P267, DOI 10.1101/gad.1363206; MERRITT AJ, 1994, CANCER RES, V54, P614; Ming LH, 2008, CARCINOGENESIS, V29, P1878, DOI 10.1093/carcin/bgn150; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Potten CS, 2004, RADIAT RES, V161, P123, DOI 10.1667/RR3104; Qiu W, 2008, CELL STEM CELL, V2, P576, DOI 10.1016/j.stem.2008.03.009; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165; Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Sun Q, 2009, ONCOGENE, V28, P2348, DOI 10.1038/onc.2009.108; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang P, 2007, P NATL ACAD SCI USA, V104, P4054, DOI 10.1073/pnas.0700020104; Wilkins HR, 2002, AM J PHYSIOL-GASTR L, V283, pG457, DOI 10.1152/ajpgi.00019.2002; Wu B, 2007, GUT, V56, P645, DOI 10.1136/gut.2006.101683; Yang JY, 2006, INT J ONCOL, V29, P643; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; Yu J, 2007, ONCOGENE, V26, P4189, DOI 10.1038/sj.onc.1210196; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yu J, 2004, CURR OPIN ONCOL, V16, P19, DOI 10.1097/00001622-200401000-00005; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589	51	101	116	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2010	29	11					1622	1632		10.1038/onc.2009.451	http://dx.doi.org/10.1038/onc.2009.451			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	19966853	Green Accepted			2022-12-17	WOS:000275694700007
J	Harada, T; Chelala, C; Bhakta, V; Chaplin, T; Caulee, K; Baril, P; Young, BD; Lemoine, NR				Harada, T.; Chelala, C.; Bhakta, V.; Chaplin, T.; Caulee, K.; Baril, P.; Young, B. D.; Lemoine, N. R.			Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays	ONCOGENE			English	Article						pancreatic cancer; tissue microdissection; SNP array; genetic alterations; SKAP2/SCAP2	UNIPARENTAL DISOMY; TISSUE MICRODISSECTION; HOMOZYGOUS DELETIONS; GENETIC ALTERATIONS; HETEROZYGOSITY; ADENOCARCINOMA; HYBRIDIZATION; ABERRATIONS	To identify genomic abnormalities characteristic of pancreatic ductal adenocarcinoma (PDAC) in vivo, a panel of 27 microdissected PDAC specimens were analysed using high-density microarrays representing similar to 116000 single nucleotide polymorphism (SNP) loci. We detected frequent gains of 1q, 2, 3, 5, 7p, 8q, 11, 14q and 17q (>= 78% of cases), and losses of 1p, 3p, 6, 9p, 13q, 14q, 17p and 18q (>= 44%). Although the results were comparable with those from array CGH, regions of those genetic changes were defined more accurately by SNP arrays. Integrating the Ensembl public data, we have generated 'gene' copy number indices that facilitate the search for novel candidates involved in pancreatic carcinogenesis. Copy numbers in a subset of the genes were validated using quantitative real-time PCR. The SKAP2/SCAP2 gene (7p15.2), which belongs to the src family kinases, was most frequently (63%) amplified in our sample set and its recurrent overexpression (67%) was confirmed by reverse transcription-PCR. Furthermore, fluorescence in situ hybridization and in situ RNA hybridization analyses for this gene have demonstrated a significant correlation between DNA copy number and mRNA expression level in an independent sample set (P < 0.001). These findings indicate that the dysregulation of SKAP2/SCAP2, which is mostly caused by its increased gene copy number, is likely to be associated with the development of PDA C.	[Harada, T.; Chelala, C.; Bhakta, V.; Caulee, K.; Baril, P.; Lemoine, N. R.] Univ London, Ctr Mol Oncol, Inst Canc, Barts & London Sch Med & Dent,Canc Res UK, London EC1M 6BQ, England; [Chaplin, T.; Young, B. D.] Univ London, Ctr Med Oncol, Inst Canc, Barts & London Sch Med & Dent,Canc Res UK, London EC1M 6BQ, England	Cancer Research UK; University of London; Queen Mary University London; Cancer Research UK; University of London; Queen Mary University London	Lemoine, NR (corresponding author), Univ London, Ctr Mol Oncol, Inst Canc, Barts & London Sch Med & Dent,Canc Res UK, Charterhouse Sq, London EC1M 6BQ, England.	nick.lemoine@cancer.org.uk		chelala, claude/0000-0002-2488-0669; BARIL, Patrick/0000-0001-8290-9899	Cancer Research UK [A6789, A6253, A6438] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Andersen CL, 2007, CARCINOGENESIS, V28, P38, DOI 10.1093/carcin/bgl086; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Bignell GR, 2004, GENOME RES, V14, P287, DOI 10.1101/gr.2012304; Buchholz M, 2005, ONCOGENE, V24, P6626, DOI 10.1038/sj.onc.1208804; Calhoun ES, 2006, CANCER RES, V66, P7920, DOI 10.1158/0008-5472.CAN-06-0721; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Fitzgibbon J, 2005, CANCER RES, V65, P9152, DOI 10.1158/0008-5472.CAN-05-2017; Fujita M, 2007, J BIOL CHEM, V282, P5736, DOI 10.1074/jbc.M606175200; GRIFFIN CA, 1995, CANCER RES, V55, P2394; Harada T, 2007, BRIT J CANCER, V96, P373, DOI 10.1038/sj.bjc.6603563; Harada T, 2002, CANCER RES, V62, P835; Harada T, 2002, ONCOLOGY-BASEL, V62, P251, DOI 10.1159/000059573; Huang Jing, 2004, Human Genomics, V1, P287; Iacobuzio-Donahue CA, 2004, CANCER RES, V64, P871, DOI 10.1158/0008-5472.CAN-03-2756; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Janne PA, 2004, ONCOGENE, V23, P2716, DOI 10.1038/sj.onc.1207329; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Karhu R, 2006, GENE CHROMOSOME CANC, V45, P721, DOI 10.1002/gcc.20337; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; Lips EH, 2007, J PATHOL, V212, P269, DOI 10.1002/path.2180; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Midorikawa Y, 2006, ONCOGENE, V25, P5581, DOI 10.1038/sj.onc.1209537; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; Raghavan M, 2005, CANCER RES, V65, P375; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; Ried T, 1999, GENE CHROMOSOME CANC, V25, P195, DOI 10.1002/(SICI)1098-2264(199907)25:3<195::AID-GCC1>3.0.CO;2-8; Saramaki OR, 2006, INT J CANCER, V119, P1322, DOI 10.1002/ijc.21976; TAKAHASHI T, 2003, J BIOL, P42225; Yamamoto G, 2007, AM J HUM GENET, V81, P114, DOI 10.1086/518809; Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308; Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603	32	101	106	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1951	1960		10.1038/sj.onc.1210832	http://dx.doi.org/10.1038/sj.onc.1210832			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17952125	Green Accepted			2022-12-17	WOS:000254150600015
J	Claperon, A; Therrien, M				Claperon, A.; Therrien, M.			KSR and CNK: two scaffolds regulating RAS-mediated RAF activation	ONCOGENE			English	Review						RAF; RAS; KSR; CNK; scaffold; signal transduction	CYSTEINE-RICH DOMAIN; PROTEIN-KINASE; MAP KINASE; B-RAF; SIGNAL-TRANSDUCTION; PHOSPHATASE 2A; GROWTH-FACTOR; RAS/RAF/MEK/ERK PATHWAY; CAENORHABDITIS-ELEGANS; FUNCTIONAL-ANALYSIS	The RAS-RAF-MEK-extracellular-regulated kinase (RAS/ERK) pathway is a major intracellular route used by metazoan cells to channel to downstream targets a diverse array of signals, including those controlling cell proliferation and survival. Recent findings suggest that the pathway is assembled by specific scaffolding proteins that in turn regulate the efficiency, the location and/or the duration of signal transmission. Here, through the angle of studies conducted in Drosophila and C. elegans, we present two such proteins, the kinase suppressor of RAS (KSR) and connector enhancer of KSR (CNK) scaffolds, and highlight their implication in a novel mechanism regulating RAS-mediated RAF activation. Based on recent findings, we discuss the possibility that KSR, a RAF-like protein, does not solely act as a scaffold, but directly induces RAF catalytic function by a kinase-independent mechanism apparently shared by RAF-like proteins.	Univ Montreal, Inst Res Immunol & Canc, Lab Intracellular Signaling, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Pathol & Biol Cellulaire, Montreal, PQ H2X 3J4, Canada	Universite de Montreal; Universite de Montreal	Therrien, M (corresponding author), Univ Montreal, Inst Res Immunol & Canc, Lab Intracellular Signaling, CP 6128 Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	marc.therrien@umontreal.ca						Anselmo AN, 2002, J BIOL CHEM, V277, P5940, DOI 10.1074/jbc.M110498200; Baonza A, 2000, P NATL ACAD SCI USA, V97, P7331, DOI 10.1073/pnas.97.13.7331; Bell B, 1999, J BIOL CHEM, V274, P7982, DOI 10.1074/jbc.274.12.7982; Boudeau J, 2006, TRENDS CELL BIOL, V16, P443, DOI 10.1016/j.tcb.2006.07.003; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Bumeister R, 2004, CURR BIOL, V14, P439, DOI 10.1016/j.cub.2004.02.037; Cabernard C, 2005, DEV CELL, V9, P831, DOI 10.1016/j.devcel.2005.10.008; Cacabelos R, 1999, INT J GERIATR PSYCH, V14, P3, DOI 10.1002/(SICI)1099-1166(199901)14:1<3::AID-GPS897>3.0.CO;2-7; Chadee DN, 2006, P NATL ACAD SCI USA, V103, P4463, DOI 10.1073/pnas.0510651103; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; Channavajhala PL, 2005, BIOCHEM BIOPH RES CO, V334, P1214, DOI 10.1016/j.bbrc.2005.07.009; Channavajhala PL, 2003, J BIOL CHEM, V278, P47089, DOI 10.1074/jbc.M306002200; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Colon-Gonzalez F, 2006, BBA-MOL CELL BIOL L, V1761, P827, DOI 10.1016/j.bbalip.2006.05.001; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Dard N, 2006, BIOESSAYS, V28, P146, DOI 10.1002/bies.20351; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Douziech M, 2006, GENE DEV, V20, P807, DOI 10.1101/gad.1390406; Douziech M, 2003, EMBO J, V22, P5068, DOI 10.1093/emboj/cdg506; Dumaz N, 2003, J BIOL CHEM, V278, P29819, DOI 10.1074/jbc.C300182200; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Friedman A, 2006, NATURE, V444, P230, DOI 10.1038/nature05280; Fritz RD, 2005, BIOCHEM BIOPH RES CO, V338, P1906, DOI 10.1016/j.bbrc.2005.10.168; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; Gollob JA, 2006, SEMIN ONCOL, V33, P392, DOI 10.1053/j.seminoncol.2006.04.002; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Jaffe AB, 2005, CURR BIOL, V15, P405, DOI 10.1016/j.cub.2004.12.082; Jaffe AB, 2004, MOL CELL BIOL, V24, P1736, DOI 10.1128/MCB.24.4.1736-1746.2004; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; Kao GT, 2004, DEVELOPMENT, V131, P755, DOI 10.1242/dev.00987; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; Laberge G, 2005, EMBO J, V24, P487, DOI 10.1038/sj.emboj.7600558; Lanigan TM, 2003, FASEB J, V17, P2048, DOI 10.1096/fj.02-1096com; Lemmon MA, 2004, BIOCHEM SOC T, V32, P707, DOI 10.1042/BST0320707; Li W, 1997, DEVELOPMENT, V124, P4163; Lopez-Ilasaca MA, 2005, FEBS LETT, V579, P648, DOI 10.1016/j.febslet.2004.12.039; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Manning G, 2002, TRENDS BIOCHEM SCI, V27, P514, DOI 10.1016/S0968-0004(02)02179-5; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Matheny SA, 2004, NATURE, V427, P256, DOI 10.1038/nature02237; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Muller J, 2000, MOL CELL BIOL, V20, P5529, DOI 10.1128/MCB.20.15.5529-5539.2000; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nguyen A, 2002, MOL CELL BIOL, V22, P3035, DOI 10.1128/MCB.22.9.3035-3045.2002; NOURRY C, 2003, SCI STKE; Ohmachi M, 2002, CURR BIOL, V12, P427, DOI 10.1016/S0960-9822(02)00690-5; Ohtakara K, 2002, GENES CELLS, V7, P1149, DOI 10.1046/j.1365-2443.2002.00589.x; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; QIAO F, 2005, SCI STKE; Rabizadeh S, 2004, J BIOL CHEM, V279, P29247, DOI 10.1074/jbc.M401699200; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; Rocheleau CE, 2005, P NATL ACAD SCI USA, V102, P11757, DOI 10.1073/pnas.0500937102; Roignant JY, 2006, GENE DEV, V20, P795, DOI 10.1101/gad.1390506; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; Rommel C, 1996, ONCOGENE, V12, P609; Roy F, 2002, GENE DEV, V16, P427, DOI 10.1101/gad.962902; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Rushworth LK, 2006, MOL CELL BIOL, V26, P2262, DOI 10.1128/MCB.26.6.2262-2272.2006; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sieburth DS, 1998, CELL, V94, P119, DOI 10.1016/S0092-8674(00)81227-1; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; Terai K, 2006, EMBO J, V25, P3556, DOI 10.1038/sj.emboj.7601241; Therrien M, 1999, P NATL ACAD SCI USA, V96, P13259, DOI 10.1073/pnas.96.23.13259; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Torii S, 2004, J BIOCHEM, V136, P557, DOI 10.1093/jb/mvh159; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Venkateswarlu K, 2003, J BIOL CHEM, V278, P43460, DOI 10.1074/jbc.M304078200; von Kriegsheim A, 2006, NAT CELL BIOL, V8, P1011, DOI 10.1038/ncb1465; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wassarman DA, 1996, GENE DEV, V10, P272, DOI 10.1101/gad.10.3.272; Weber CK, 2001, CANCER RES, V61, P3595; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Werry TD, 2006, CURR PHARM DESIGN, V12, P1683, DOI 10.2174/138161206776873725; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Williams JG, 2000, J BIOL CHEM, V275, P22172, DOI 10.1074/jbc.M000397200; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; Yan F, 2001, CANCER RES, V61, P963; Yao I, 1999, J BIOL CHEM, V274, P11889, DOI 10.1074/jbc.274.17.11889; Yao I, 2000, BIOCHEM BIOPH RES CO, V270, P538, DOI 10.1006/bbrc.2000.2475; Yoder JH, 2004, EMBO J, V23, P111, DOI 10.1038/sj.emboj.7600025; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zhou M, 2002, J MOL BIOL, V315, P435, DOI 10.1006/jmbi.2001.5263; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Ziogas A, 2005, J BIOL CHEM, V280, P24205, DOI 10.1074/jbc.M413327200	117	101	103	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3143	3158		10.1038/sj.onc.1210408	http://dx.doi.org/10.1038/sj.onc.1210408			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496912				2022-12-17	WOS:000246603600005
J	Bloch, M; Ousingsawat, J; Simon, R; Schraml, P; Gasser, TC; Mihatsch, MJ; Kunzelmann, K; Bubendorf, L				Bloch, M.; Ousingsawat, J.; Simon, R.; Schraml, P.; Gasser, T. C.; Mihatsch, M. J.; Kunzelmann, K.; Bubendorf, L.			KCNMA1 gene amplification promotes tumor cell proliferation in human prostate cancer	ONCOGENE			English	Article						prostate cancer; progression; amplification; BK channel; KCNMA1	COMPARATIVE GENOMIC HYBRIDIZATION; ACTIVATED POTASSIUM CHANNELS; MAXI-K CHANNELS; LARGE-CONDUCTANCE; EPITHELIAL-CELLS; UROKINASE GENE; BREAST-CANCER; BK CHANNELS; RECEPTOR; KINASE	Molecular mechanisms of prostate cancer progression are poorly understood. Here, we studied gene amplification of the large conductance calcium-activated potassium channel alpha subunit (KCNMA1), which is located at the chromosomal region 10q22. Fluorescence in situ hybridization ( FISH) revealed KCNMA1 amplification in 16% of 119 late-stage human prostate cancers and in the hormone-insensitive prostate cancer cell line PC-3. In contrast, KCNMA1 amplification was absent in 33 benign controls, 32 precursor lesions and in 105 clinically organ-confined prostate cancers. Amplification was associated with mRNA and protein overexpression as well as increased density of BK channel protein and beta-estradiol-insensitive BK currents in PC-3 cells as compared to non-amplified control cell lines. Specific blockade of BK channels by iberiotoxin or RNA(i) significantly inhibited K+ currents and growth of PC-3 cells. The data demonstrate that 10q22 amplification drives KCNMA1 expression and cell proliferation. Thus, KCNMA1 qualifies as a promising diagnostic and therapeutic target in patients with prostate cancer.	Univ Basel Hosp, Inst Pathol, CH-4003 Basel, Switzerland; Univ Regensburg, Dept Physiol, D-8400 Regensburg, Germany; Univ Basel, Dept Urol, Liestal, Switzerland	University of Basel; University of Regensburg; University of Basel	Bubendorf, L (corresponding author), Univ Basel Hosp, Inst Pathol, Schonbeinstr 40, CH-4003 Basel, Switzerland.	lbubendorf@uhbs.ch	Bubendorfl, Lukas/H-5880-2011; Bubendorf, Lukas/G-5299-2015	Bubendorf, Lukas/0000-0001-5970-1803; Kunzelmann, Karl/0000-0002-4583-7037				Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Amberg GC, 2003, J CLIN INVEST, V112, P717, DOI 10.1172/JC1200318684; Amberg GC, 2003, CIRC RES, V93, P965, DOI 10.1161/01.RES.0000100068.43006.36; Basrai D, 2002, NEUROREPORT, V13, P403, DOI 10.1097/00001756-200203250-00008; Bernardino J, 1997, CANCER GENET CYTOGEN, V96, P123, DOI 10.1016/S0165-4608(96)00258-0; Calderone V, 2002, CURR MED CHEM, V9, P1385, DOI 10.2174/0929867023369871; Christow SP, 1999, EUR J BIOCHEM, V265, P264, DOI 10.1046/j.1432-1327.1999.00729.x; Coiret G, 2005, FEBS LETT, V579, P2995, DOI 10.1016/j.febslet.2005.02.085; Conti DJ, 2004, AM J TRANSPLANT, V4, P166; Davies AG, 2003, CELL, V115, P655, DOI 10.1016/S0092-8674(03)00979-6; El Gedaily A, 2001, PROSTATE, V46, P184; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; HAYWARD SW, 1995, IN VITRO CELL DEV-AN, V31, P14; Helenius MA, 2006, BJU INT, V97, P404, DOI 10.1111/j.1464-410X.2005.05912.x; Helenius MA, 2001, CANCER RES, V61, P5340; Henke G, 2004, J CELL PHYSIOL, V199, P194, DOI 10.1002/jcp.10430; Ho SM, 2004, J CELL BIOCHEM, V91, P491, DOI 10.1002/jcb.10759; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Hsing AW, 2000, INT J CANCER, V85, P60, DOI 10.1002/(SICI)1097-0215(20000101)85:1&lt;60::AID-IJC11&gt;3.0.CO;2-B; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kauraniemi P, 2001, CANCER RES, V61, P8235; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Koochekpour S, 2005, GENE CHROMOSOME CANC, V44, P351, DOI 10.1002/gcc.20249; Kunzelmann K, 2002, PHYSIOL REV, V82, P245, DOI 10.1152/physrev.00026.2001; Lau KM, 2000, CANCER RES, V60, P3175; MCCOBB DP, 1995, AM J PHYSIOL, V269, P767; O'Grady SM, 2005, INT J BIOCHEM CELL B, V37, P1578, DOI 10.1016/j.biocel.2005.04.002; O'Malley D, 2004, MOL PHARMACOL, V65, P1352, DOI 10.1124/mol.65.6.1352; Olsen ML, 2005, J NEUROSCI RES, V81, P179, DOI 10.1002/jnr.20543; Orio P, 2002, NEWS PHYSIOL SCI, V17, P156, DOI 10.1152/nips.01387.2002; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; Pardo LA, 2004, PHYSIOLOGY, V19, P285, DOI 10.1152/physiol.00011.2004; Parihar AS, 2003, EUR J PHARMACOL, V471, P157, DOI 10.1016/S0014-2999(03)01825-9; Pei L, 2003, P NATL ACAD SCI USA, V100, P7803, DOI 10.1073/pnas.1232448100; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Quirk JC, 2001, NEURON, V32, P13, DOI 10.1016/S0896-6273(01)00444-5; Rebhan M, 1997, TRENDS GENET, V13, P163, DOI 10.1016/S0168-9525(97)01103-7; Reiter RE, 2000, GENE CHROMOSOME CANC, V27, P95, DOI 10.1002/(SICI)1098-2264(200001)27:1<95::AID-GCC12>3.0.CO;2-3; ROBITAILLE R, 1992, J NEUROSCI, V12, P297; Sausbier M, 2006, J AM SOC NEPHROL, V17, P1275, DOI 10.1681/ASN.2005101111; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Van Coppenolle F, 2004, BIOCHEM J, V377, P569, DOI 10.1042/BJ20030859; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; Wang ZG, 2004, PFLUG ARCH EUR J PHY, V448, P274, DOI 10.1007/s00424-004-1258-5; Weaver AK, 2004, J NEUROSCI RES, V78, P224, DOI 10.1002/jnr.20240; Zhou XB, 2000, AM J PHYSIOL-CELL PH, V279, pC1751, DOI 10.1152/ajpcell.2000.279.6.C1751	48	101	108	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2007	26	17					2525	2534		10.1038/sj.onc.1210036	http://dx.doi.org/10.1038/sj.onc.1210036			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17146446				2022-12-17	WOS:000245831000014
J	Jones, RA; Campbell, CI; Gunther, EJ; Chodosh, LA; Petrik, JJ; Khokha, R; Moorehead, RA				Jones, R. A.; Campbell, C. I.; Gunther, E. J.; Chodosh, L. A.; Petrik, J. J.; Khokha, R.; Moorehead, R. A.			Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation	ONCOGENE			English	Article						IGF-IR; transgenic mice; mammary tumorigenesis; mammary development	GROWTH-FACTOR-I; BREAST-CANCER; GENE-EXPRESSION; FACTOR RECEPTOR; INSULIN; ACTIVATION; STAT3; MICE; RISK; PROLIFERATION	Overexpression and hyperactivation of the type I insulin-like growth factor receptor (IGF-IR) has been observed in human breast tumor biopsies. In addition, in vitro studies indicate that overexpression of IGF-IR is sufficient to transform cells such as mouse embryo fibroblasts and this receptor promotes proliferation and survival in breast cancer cell lines. To fully understand the function of the IGF-IR in tumor initiation and progression, transgenic mice containing human IGF-IR under a doxycycline-inducible MMTV promoter system were generated. Administration of 2 mg/ml doxycycline in the animals' water supply beginning at 21 days of age resulted in elevated levels of IGF-IR in mammary epithelial cells as detected by Western blotting and immunohistochemistry. Whole mount analysis of 55-day-old mouse mammary glands revealed that IGF-IR overexpression significantly impaired ductal elongation. Moreover, histological analyses revealed multiple hyperplasic lesions in the mammary glands of these 55-day-old mice. The formation of palpable mammary tumors was evident at approximately 2 months of age and was associated with increased levels of IGF-IR signaling molecules including phosphorylated Akt, Erk1/Erk2 and STAT3. Therefore, these transgenic mice provide evidence that IGF-IR overexpression is sufficient to induce mammary epithelial hyperplasia and tumor formation in vivo and provide a model to further understand the function of IGF-IR in mammary epithelial transformation.	Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada; Penn State Hershey Med Sch, Hershey, PA USA; Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Toronto, Princess Margaret Hosp, Hlth Network, Toronto, ON, Canada	University of Guelph; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Pennsylvania; Pennsylvania Medicine; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Moorehead, RA (corresponding author), Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Room 3605, Guelph, ON N1G 2W1, Canada.	rmoorehe@uoguelph.ca		Jones, Robert/0000-0001-7665-9301; , Roger/0000-0001-9539-6295				Adams TE, 2004, GROWTH FACTORS, V22, P89, DOI 10.1080/08977190410001700998; Althuis MD, 2004, CANCER EPIDEM BIOMAR, V13, P1558; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; Berclaz G, 2001, INT J ONCOL, V19, P1155; Bonnette SG, 2001, ENDOCRINOLOGY, V142, P4937, DOI 10.1210/en.142.11.4937; Butler AA, 1998, CANCER RES, V58, P3021; Carboni JM, 2005, CANCER RES, V65, P3781, DOI 10.1158/0008-5472.CAN-04-4602; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Clarke M, 1998, LANCET, V351, P1451; Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014; Diaz N, 2006, CLIN CANCER RES, V12, P20, DOI 10.1158/1078-0432.CCR-04-1749; El-Rehim DMA, 2004, J PATHOL, V203, P661, DOI 10.1002/path.1559; ELLIS MJC, 1994, BREAST CANCER RES TR, V31, P249, DOI 10.1007/BF00666158; Giani C, 1996, BREAST CANCER RES TR, V41, P43, DOI 10.1007/BF01807035; Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752; Gunther EJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0551com; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hadsell DL, 2000, ONCOGENE, V19, P889, DOI 10.1038/sj.onc.1203386; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Helle SI, 1996, ACTA ONCOL, V35, P19, DOI 10.3109/02841869609083963; Kumar R, 2005, CANCER RES, V65, P2511, DOI 10.1158/0008-5472.CAN-05-0189; Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001; Li L, 2002, J BIOL CHEM, V277, P17397, DOI 10.1074/jbc.M109962200; Linnerth NM, 2005, INT J CANCER, V114, P977, DOI 10.1002/ijc.20814; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Moorehead RA, 2001, CELL DEATH DIFFER, V8, P16, DOI 10.1038/sj.cdd.4400762; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PAPA V, 1993, CANCER RES, V53, P3736; Pravtcheva DD, 1998, J EXP ZOOL, V281, P43, DOI 10.1002/(SICI)1097-010X(19980501)281:1<43::AID-JEZ7>3.3.CO;2-3; Resnik JL, 1998, CANCER RES, V58, P1159; Richards RG, 1998, J BIOL CHEM, V273, P11962, DOI 10.1074/jbc.273.19.11962; Richards RG, 2004, ENDOCRINOLOGY, V145, P3106, DOI 10.1210/en.2003-1112; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Ruan WF, 1999, ENDOCRINOLOGY, V140, P5075, DOI 10.1210/en.140.11.5075; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Surmacz E, 1998, BREAST CANCER RES TR, V47, P255, DOI 10.1023/A:1005907101686; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; Takahashi T, 1999, CIRC RES, V85, P884; Turner BC, 1997, CANCER RES, V57, P3079; Werner H, 2000, CELL MOL LIFE SCI, V57, P932, DOI 10.1007/PL00000735; Wetterau LA, 1999, MOL GENET METAB, V68, P161, DOI 10.1006/mgme.1999.2920; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhang WZ, 2006, MOL CELL BIOL, V26, P413, DOI 10.1128/MCB.26.2.413-424.2006; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	47	101	109	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1636	1644		10.1038/sj.onc.1209955	http://dx.doi.org/10.1038/sj.onc.1209955			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16953219				2022-12-17	WOS:000244782500013
J	Ramjaun, AR; Tomlinson, S; Eddaoudi, A; Downward, J				Ramjaun, A. R.; Tomlinson, S.; Eddaoudi, A.; Downward, J.			Upregulation of two BH3-only proteins, Bmf and Bim, during TGF beta-induced apoptosis	ONCOGENE			English	Article						Smad4; TGF beta; apoptosis; p38; Bmf; Bim	GROWTH-FACTOR-BETA; SMAD-DEPENDENT EXPRESSION; CYTOCHROME-C RELEASE; FAO HEPATOMA-CELLS; FAMILY-MEMBER BIM; P38 MAP KINASE; EPITHELIAL-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; (TGF-BETA)-INDUCED APOPTOSIS; CASPASE ACTIVATION	Transforming growth factor-beta (TGF beta)-activated signalling pathways can lead to apoptosis, growth arrest or promotion of malignant behaviour, dependent on cellular context. The molecular mechanisms involved in TGF beta-induced apoptosis remain controversial; although changes in gene expression are thought to be pivotal to the process, several different candidate apoptotic initiators and mediators have been proposed. Smad4, a critical component of the TGF beta-induced transcriptional machinery, is shown here to be essential for induction of apoptosis. Gene expression analysis identified the proapoptotic Bcl-2 family members, Bmf and Bim, as induced by TGFb, dependent on both Smad4 and p38 function and the generation of reactive oxygen species. TGF beta-induced Bmf and Bim localize to cellular membranes implicated in apoptosis. Inhibition of the TGF beta-induced expression of both these proteins together provides significant protection of cells from apoptosis. The TGF beta-triggered cell death programme thus involves induction of multiple BH3-only proteins during the induction of apoptosis.	Canc Res UK, London Res Inst, Signal Transduct Lab, London WC2A 3PX, England; Canc Res UK, London Res Inst, Fluorescence Activated Cell Storing Labs, London WC2A 3PX, England	Cancer Research UK; Cancer Research UK	Downward, J (corresponding author), Canc Res UK, London Res Inst, Signal Transduct Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	downward@cancer.org.uk	Downward, Julian/A-3251-2012	Eddaoudi, Ayad/0000-0001-5272-6426; Downward, Julian/0000-0002-2331-4729				Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Bakin AV, 2005, FREE RADICAL BIO MED, V38, P375, DOI 10.1016/j.freeradbiomed.2004.10.033; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Coyle B, 2003, J BIOL CHEM, V278, P5920, DOI 10.1074/jbc.M211300200; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; Franz Wolfgang, 2000, PERSPEKTIVEN WIRTSCH, V1, P53, DOI DOI 10.1111/1468-2516.00005; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; Herrera B, 2001, HEPATOLOGY, V34, P548, DOI 10.1053/jhep.2001.27447; Hishikawa K, 1999, J BIOL CHEM, V274, P37461, DOI 10.1074/jbc.274.52.37461; InayatHussain SH, 1997, HEPATOLOGY, V25, P1516, DOI 10.1002/hep.510250634; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Kanamaru C, 2002, HEPATOL RES, V23, P211, DOI 10.1016/S1386-6346(01)00175-9; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; Kim BC, 2002, MOL CELL BIOL, V22, P1369, DOI 10.1128/MCB.22.5.1369-1378.2002; Kim SG, 2004, MOL BIOL CELL, V15, P420, DOI 10.1091/mbc.E03-04-0201; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Liao JH, 2001, CELL RES, V11, P89, DOI 10.1038/sj.cr.7290072; Liu JW, 2005, ONCOGENE, V24, P2020, DOI 10.1038/sj.onc.1208385; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nass SJ, 1996, BIOCHEM BIOPH RES CO, V227, P248, DOI 10.1006/bbrc.1996.1497; Ohgushi M, 2005, MOL CELL BIOL, V25, P10017, DOI 10.1128/MCB.25.22.10017-10028.2005; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Saltzman A, 1998, EXP CELL RES, V242, P244, DOI 10.1006/excr.1998.4096; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Schiffer M, 2004, J BIOL CHEM, V279, P37004, DOI 10.1074/jbc.M403534200; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Valderrama-Carvajal H, 2002, NAT CELL BIOL, V4, P963, DOI 10.1038/ncb885; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wildey GM, 2003, J BIOL CHEM, V278, P18069, DOI 10.1074/jbc.M211958200; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366	47	101	108	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					970	981		10.1038/sj.onc.1209852	http://dx.doi.org/10.1038/sj.onc.1209852			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909112	Bronze			2022-12-17	WOS:000244245400003
J	Mueller, W; Nutt, CL; Ehrich, M; Riemenschneider, MJ; von Deimling, A; van den Boom, D; Louis, DN				Mueller, W.; Nutt, C. L.; Ehrich, M.; Riemenschneider, M. J.; von Deimling, A.; van den Boom, D.; Louis, D. N.			Downregulation of RUNX3 and TES by hypermethylation in glioblastoma	ONCOGENE			English	Article						glioblastoma; glioma; methylation; 5-aza-dC; mass spectrometry	CPG ISLAND HYPERMETHYLATION; TUMOR-SUPPRESSOR GENE; DNA METHYLATION; PROMOTER HYPERMETHYLATION; EPIGENETIC INACTIVATION; ASTROCYTIC GLIOMAS; MULTIPLE GENES; 14-3-3 SIGMA; CANCER; EXPRESSION	Glioblastoma, the most aggressive and least treatable form of malignant glioma, is the most common human brain tumor. Although many regions of allelic loss occur in glioblastomas, relatively few tumor suppressor genes have been found mutated at such loci. To address the possibility that epigenetic alterations are an alternative means of glioblastoma gene inactivation, we coupled pharmacological manipulation of methylation with gene profiling to identify potential methylation-regulated, tumor-related genes. Duplicates of three short-term cultured glioblastomas were exposed to 5 mu m 5-aza-dC for 96h followed by cRNA hybridization to an oligonucleotide microarray (Affymetrix U133A). We based candidate gene selection on bioinformatics, reverse transcription-polymerase chain reaction (RT-PCR), bisulfite sequencing, methylation-specific PCR and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Two genes identified in this manner, RUNX3 and Testin (TES), were subsequently shown to harbor frequent tumor-specific epigenetic alterations in primary glioblastomas. This overall approach therefore provides a powerful means to identify candidate tumor-suppressor genes for subsequent evaluation and may lead to the identification of genes whose epigenetic dysregulation is integral to glioblastoma tumorigenesis.	Massachusetts Gen Hosp, Pathol Serv, Dept Pathol, Ctr Canc, Boston, MA 02114 USA; Massachusetts Gen Hosp, Neurosurg Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Johns Hopkins Ct, Sequenom Inc, San Diego, CA USA; Univ Hosp Charite, Dept Neuropathol, Berlin, Germany	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Johns Hopkins University; Sequenom; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Louis, DN (corresponding author), Massachusetts Gen Hosp, Pathol Serv, Dept Pathol, Ctr Canc, WRN2, Boston, MA 02114 USA.	louis@helix.mgh.harvard.edu	Nutt, Catherine/K-8794-2012; Reifenberger, Guido/AAE-3599-2019; von Deimling, Andreas/F-7774-2013	von Deimling, Andreas/0000-0002-5863-540X	NCI NIH HHS [CA57683] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057683] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ballestar E, 2005, PROG MOLEC, V38, P169; Bhatia K, 2003, CANCER EPIDEM BIOMAR, V12, P165; Blanc JL, 2004, J NEURO-ONCOL, V68, P275, DOI 10.1023/B:NEON.0000033385.37098.85; Ching TT, 2005, NAT GENET, V37, P645, DOI 10.1038/ng1563; CHUNG R, 1991, GENE CHROMOSOME CANC, V3, P323, DOI 10.1002/gcc.2870030502; Collins V P, 2004, J Neurol Neurosurg Psychiatry, V75 Suppl 2, pii2, DOI 10.1136/jnnp.2004.040337; Costello J F, 2000, Brain Tumor Pathol, V17, P49, DOI 10.1007/BF02482735; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Costello JF, 2002, METHODS, V27, P144, DOI 10.1016/S1046-2023(02)00067-1; Costello JF, 1996, CANCER RES, V56, P2405; Costello Joseph F, 2002, Methods Mol Biol, V200, P53; Curtis CD, 2005, METH MOLEC MED, V103, P123; Dallol A, 2003, ONCOGENE, V22, P4611, DOI 10.1038/sj.onc.1206687; Dickinson RE, 2004, BRIT J CANCER, V91, P2071, DOI 10.1038/sj.bjc.6602222; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2003, ADV EXP MED BIOL, V532, P39; Fan X, 2002, INT J ONCOL, V21, P667; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Gasco M, 2002, CANCER RES, V62, P2072; Gonzalez-Gomez P, 2003, INT J MOL MED, V11, P655; Gonzalez-Gomez P, 2003, INT J ONCOL, V22, P601; Hegi ME, 2004, CLIN CANCER RES, V10, P1871, DOI 10.1158/1078-0432.CCR-03-0384; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; HENSON JW, 1994, ANN NEUROL, V36, P714, DOI 10.1002/ana.410360505; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hill C, 2003, ADV ANAT PATHOL, V10, P212, DOI 10.1097/00125480-200307000-00004; Hong CB, 2003, CANCER RES, V63, P7600; Ichimura K, 2000, CANCER RES, V60, P417; Ichimura K, 1996, ONCOGENE, V13, P1065; Imamura Y, 2005, ANTICANCER RES, V25, P2627; Ino Y, 2000, J NEUROSURG, V92, P983, DOI 10.3171/jns.2000.92.6.0983; Jain PK, 2003, ANN NY ACAD SCI, V983, P71, DOI 10.1111/j.1749-6632.2003.tb05963.x; Jeanteur P, 2000, Bull Cancer, V87, P525; Kamiryo T, 2004, NEUROSURGERY, V54, P349, DOI 10.1227/01.NEU.0000103422.51382.99; Kang GH, 2004, J PATHOL, V202, P233, DOI 10.1002/path.1503; Kato N, 2003, AM J PATHOL, V163, P387, DOI 10.1016/S0002-9440(10)63668-1; KIM DH, 1995, INT J CANCER, V60, P812, DOI 10.1002/ijc.2910600615; Kim TY, 2004, LAB INVEST, V84, P479, DOI 10.1038/labinvest.3700060; Kleihues P, 2000, PATHOLOGY GENETICS T; Kohno T, 1998, HUM GENET, V102, P258, DOI 10.1007/s004390050689; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li Q, 1998, ONCOGENE, V16, P3197, DOI 10.1038/sj.onc.1201831; Li Q, 1999, ONCOGENE, V18, P3284, DOI 10.1038/sj.onc.1202663; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li QL, 2004, BIOCHEM BIOPH RES CO, V314, P223, DOI 10.1016/j.bbrc.2003.12.079; Liang G, 1998, GENOMICS, V53, P260, DOI 10.1006/geno.1998.5502; Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407; Louis DN, 2006, ANNU REV PATHOL-MECH, V1, P97, DOI 10.1146/annurev.pathol.1.110304.100043; MATSUMURA T, 1989, EXP GERONTOL, V24, P477, DOI 10.1016/0531-5565(89)90054-5; Mohapatra G, 1998, GENE CHROMOSOME CANC, V21, P195, DOI 10.1002/(SICI)1098-2264(199803)21:3<195::AID-GCC3>3.3.CO;2-A; Mori T, 2005, LIVER INT, V25, P380, DOI 10.1111/j.1478-3231.2005.1059.x; Morris MR, 2005, CANCER RES, V65, P4598, DOI 10.1158/0008-5472.CAN-04-3371; Nishizaki T, 1998, GENE CHROMOSOME CANC, V21, P340, DOI 10.1002/(SICI)1098-2264(199804)21:4<340::AID-GCC8>3.0.CO;2-Z; Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303; Sarti M, 2005, CLIN CANCER RES, V11, P806; Sato N, 2004, ONCOGENE, V23, P1531, DOI 10.1038/sj.onc.1207269; Schmidt MC, 2002, J NEUROPATH EXP NEUR, V61, P321, DOI 10.1093/jnen/61.4.321; Schulmann K, 2005, ONCOGENE, V24, P4138, DOI 10.1038/sj.onc.1208598; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840; Stanssens P, 2004, GENOME RES, V14, P126; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stone AR, 2004, AM J PATHOL, V165, P1151, DOI 10.1016/S0002-9440(10)63376-7; Suzuki H, 2000, CANCER RES, V60, P4353; Tatarelli C, 2000, GENOMICS, V68, P1, DOI 10.1006/geno.2000.6272; Tobias ES, 2001, ONCOGENE, V20, P2844, DOI 10.1038/sj.onc.1204433; Tozawa T, 2004, CANCER SCI, V95, P736, DOI 10.1111/j.1349-7006.2004.tb03254.x; Ueki K, 1996, CANCER RES, V56, P150; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; von Deimling A, 2000, J NEUROPATH EXP NEUR, V59, P544, DOI 10.1093/jnen/59.6.544; von Deimling A, 1994, Recent Results Cancer Res, V135, P33; Wang SI, 1997, CANCER RES, V57, P4183; Watanabe T, 2002, ACTA NEUROPATHOL, V104, P357, DOI 10.1007/s00401-002-0549-1; Wei DY, 2005, CANCER RES, V65, P4809, DOI 10.1158/0008-5472.CAN-04-3741; Wooten E C, 1999, Neuro Oncol, V1, P169, DOI 10.1093/neuonc/1.3.169; Xiao WH, 2004, WORLD J GASTROENTERO, V10, P376; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5; Zardo G, 2002, NAT GENET, V32, P453, DOI 10.1038/ng1007	80	101	107	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					583	593		10.1038/sj.onc.1209805	http://dx.doi.org/10.1038/sj.onc.1209805			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16909125				2022-12-17	WOS:000243731600010
J	Yang, G; Xu, Y; Chen, X; Hu, G				Yang, G.; Xu, Y.; Chen, X.; Hu, G.			IFITM1 plays an essential role in the antiproliferative action of interferon-gamma	ONCOGENE			English	Article						control of cell cycle progression; IFITM1; interferon-gamma; p53; extracellular signal-regulated kinase	SIGNAL-TRANSDUCTION PATHWAYS; BREAST-CANCER PROGRESSION; CYCLIN-DEPENDENT KINASE; MYC MESSENGER-RNA; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; DOWN-REGULATION; CELL-GROWTH; C-MYC; DIFFERENTIAL RESPONSE	Interferon-gamma (IFN-gamma) is a pleiotropic cytokine involved in antiproliferative and anti-virus responses, immune surveillance and tumor suppression. These biological responses to IFN-gamma are mainly mediated by the regulation of gene expression. It has been reported that growth-inhibitory role of IFN-gamma is dependent on activation of signal transducers and activators of transcription 1 (STAT1); however, the molecular basis downstream of STAT1 remains unclear. Here, we report that an IFN-gamma-induced gene, interferon-induced transmembrane protein 1 (IFITM1), plays a key role in the antiproliferative action of IFN-gamma. Overexpression of IFITM1 negatively regulated cell growth, whereas suppression of IFITM1 blocked the antiproliferative effect of IFN-gamma, accelerated the cell growth rate and conferred tumorigenicity to a nonmalignant hepatocyte in nude mice. Further, IFITM1 could inhibit the activity of extracellular signal-regulated kinase, enhance the transcriptional activity of p53 and stabilize the p53 protein by inhibiting p53 phosphorylation on Thr55. Suppression of p53 reduced the growth-inhibitory capacity of both IFITM1 and IFN-gamma. Therefore, these findings indicated that the antiproliferative action of IFN-gamma requires the induction of IFITM1, and provided a crosstalk between two well-known signaling mediators, STAT1 and p53, both of which play critical roles in tumor suppression.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Hu, G (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China.	hgxgene@sunm.shcnc.ac.cn						Abba MC, 2004, BREAST CANCER RES, V6, pR499, DOI 10.1186/bcr899; ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P591, DOI 10.1093/nar/19.3.591; Akyerli CB, 2005, LEUKEMIA RES, V29, P283, DOI 10.1016/j.leukres.2004.07.007; Alber D, 1996, J INTERF CYTOK RES, V16, P375, DOI 10.1089/jir.1996.16.375; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Buard A, 1998, CANCER RES, V58, P840; Catchpoole D, 1997, J MED GENET, V34, P353, DOI 10.1136/jmg.34.5.353; CHEN YX, 1984, J IMMUNOL, V133, P2496; Cheng M, 1999, J BIOL CHEM, V274, P6553, DOI 10.1074/jbc.274.10.6553; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEBLANDRE GA, 1995, J BIOL CHEM, V270, P23860, DOI 10.1074/jbc.270.40.23860; DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVANS SS, 1990, BLOOD, V76, P2583; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Halaschek-Wiener J, 2004, CELL SIGNAL, V16, P1319, DOI 10.1016/j.cellsig.2004.04.003; Huang HT, 2000, CANCER RES, V60, P6868; Huang RM, 2002, FASEB J, V16, DOI 10.1096/fj.01-0687com; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Karnik P, 1998, HUM MOL GENET, V7, P895, DOI 10.1093/hmg/7.5.895; KELLY JM, 1985, EUR J BIOCHEM, V153, P367, DOI 10.1111/j.1432-1033.1985.tb09312.x; Kominsky SL, 2000, CANCER RES, V60, P3904; Li HH, 2004, MOL CELL, V13, P867, DOI 10.1016/S1097-2765(04)00123-6; LIU MK, 1994, INFECT IMMUN, V62, P2722, DOI 10.1128/IAI.62.7.2722-2731.1994; Lu KH, 1997, CANCER RES, V57, P387; MAIER JAM, 1995, BIOCHEM BIOPH RES CO, V214, P582, DOI 10.1006/bbrc.1995.2325; Mandal M, 1998, ONCOGENE, V16, P217, DOI 10.1038/sj.onc.1201529; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; MATSUMOTO AK, 1993, J EXP MED, V178, P1407, DOI 10.1084/jem.178.4.1407; Matsushita K, 2006, CANCER SCI, V97, P57, DOI 10.1111/j.1349-7006.2006.00137.x; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NEGRINI M, 1995, CANCER RES, V55, P3003; Nguyen DT, 2004, MOL BIOL CELL, V15, P4248, DOI 10.1091/mbc.E03-11-0851; Notari M, 2006, BLOOD, V107, P2507, DOI 10.1182/blood-2005-09-3732; OBriant KC, 1997, GENE CHROMOSOME CANC, V18, P111, DOI 10.1002/(SICI)1098-2264(199702)18:2<111::AID-GCC5>3.0.CO;2-5; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Rodig S, 1998, EUR CYTOKINE NETW, V9, P49; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Sakatsume M, 1998, J BIOL CHEM, V273, P3021, DOI 10.1074/jbc.273.5.3021; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schlegel A, 2001, J BIOL CHEM, V276, P4398, DOI 10.1074/jbc.M005448200; SELIGER B, 1991, J VIROL, V65, P6307, DOI 10.1128/JVI.65.11.6307-6311.1991; Stancato LF, 1998, J BIOL CHEM, V273, P18701, DOI 10.1074/jbc.273.30.18701; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; Tran YK, 1996, CANCER RES, V56, P2916; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yeh PY, 2004, ONCOGENE, V23, P3580, DOI 10.1038/sj.onc.1207426; Yeh PY, 2001, BIOCHEM BIOPH RES CO, V284, P880, DOI 10.1006/bbrc.2001.5043; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	60	101	107	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					594	603		10.1038/sj.onc.1209807	http://dx.doi.org/10.1038/sj.onc.1209807			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16847454				2022-12-17	WOS:000243731600011
J	Zhang, YW; Staal, B; Su, Y; Swiatek, P; Zhao, P; Cao, B; Resau, J; Sigler, R; Bronson, R; Vande Woude, GF				Zhang, Y-W; Staal, B.; Su, Y.; Swiatek, P.; Zhao, P.; Cao, B.; Resau, J.; Sigler, R.; Bronson, R.; Vande Woude, G. F.			Evidence that MIG-6 is a tumor-suppressor gene	ONCOGENE			English	Article						MIG-6; mutation; lung carcinogenesis; signal transduction; EGF; HGF/SF	CELL LUNG-CANCER; EGF RECEPTOR; ENDOGENOUS INHIBITOR; ALLELIC LOSS; C-MET; EXPRESSION; MUTATIONS; GROWTH; ACTIVATION; P73	Mitogen-inducible gene 6 (MIG-6) is located in human chromosome 1p36, a locus frequently associated with human lung cancer. MIG-6 is a negative regulator of epidermal growth factor (EGF) signaling, and we show that Mig-6 - like EGF - is induced by hepatocyte growth factor/scatter factor (HGF/SF) in human lung cancer cell lines. Frequently, the receptors for both factors, EGFR and Met, are expressed in same lung cancer cell line, and MIG-6 is induced by both factors in a mitogen-activated protein kinase-dependent fashion. However, not all tumor lines express MIG-6 in response to either EGF or HGF/SF. In these cases, we. nd missense and nonsense mutations in the MIG-6 coding region, as well as evidence for MIG-6 transcriptional silencing. Moreover, germline disruption of Mig-6 in mice leads to the development of animals with epithelial hyperplasia, adenoma, and adenocarcinoma in organs like the lung, gallbladder, and bile duct. These data suggests that MIG-6 is a tumor-suppressor gene and is therefore a candidate gene for the frequent 1p36 genetic alterations found in lung cancer.	Andel Res Inst, Mol Oncol Lab, Grand Rapids, MI 49503 USA; Andel Res Inst, Lab Germline Modificat, Grand Rapids, MI 49503 USA; Andel Res Inst, Lab Antibody Technol, Grand Rapids, MI 49503 USA; Andel Res Inst, Lab Analyt Cellular & Mol Microscopy, Grand Rapids, MI 49503 USA; Div Pfizer, Esper Therapeut, Ann Arbor, MI USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Pfizer; Harvard University; Harvard Medical School	Zhang, YW (corresponding author), Andel Res Inst, Mol Oncol Lab, 333 Bostwick NE, Grand Rapids, MI 49503 USA.	yu-wen.zhang@vai.org; george.vandewoude@vai.org						Amatschek S, 2004, CANCER RES, V64, P844, DOI 10.1158/0008-5472.CAN-03-2361; Anastasi S, 2005, ONCOGENE, V24, P4540, DOI 10.1038/sj.onc.1208658; Anastasi S, 2003, ONCOGENE, V22, P4221, DOI 10.1038/sj.onc.1206516; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Ferby I, 2006, NAT MED, V12, P568, DOI 10.1038/nm1401; Fiorentino L, 2000, MOL CELL BIOL, V20, P7735, DOI 10.1128/MCB.20.20.7735-7750.2000; Fujii T, 2002, CANCER RES, V62, P3340; Girard L, 2000, CANCER RES, V60, P4894; Herzog CR, 2002, CANCER RES, V62, P6424; HERZOG CR, 1995, ONCOGENE, V11, P1811; Keeton AB, 2005, J CELL BIOCHEM, V94, P1190, DOI 10.1002/jcb.20370; Keeton AB, 2004, BBA-GENE STRUCT EXPR, V1679, P248, DOI 10.1016/j.bbaexp.2004.07.002; Kohno T, 1999, CARCINOGENESIS, V20, P1403, DOI 10.1093/carcin/20.8.1403; Koo HM, 1999, CANCER RES, V59, P6057; Ma PC, 2005, CANCER RES, V65, P1479, DOI 10.1158/0008-5472.CAN-04-2650; Ma PC, 2003, CANCER RES, V63, P6272; Mai M, 1998, CANCER RES, V58, P2347; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Miettinen PJ, 1997, DEV BIOL, V186, P224, DOI 10.1006/dbio.1997.8593; Nomoto S, 1998, CANCER RES, V58, P1380; Nomoto S, 2000, GENE CHROMOSOME CANC, V28, P342, DOI 10.1002/1098-2264(200007)28:3<342::AID-GCC13>3.0.CO;2-A; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pante G, 2005, J CELL BIOL, V171, P337, DOI 10.1083/jcb.200502013; Ragnarsson G, 1999, BRIT J CANCER, V79, P1468, DOI 10.1038/sj.bjc.6690234; Sargent LM, 2002, CANCER RES, V62, P1152; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Thiagalingam S, 2002, CURR OPIN ONCOL, V14, P65, DOI 10.1097/00001622-200201000-00012; Tokuchi Y, 1999, BRIT J CANCER, V80, P1623, DOI 10.1038/sj.bjc.6690572; Tsunoda T, 2002, CANCER RES, V62, P5668; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; WICK M, 1995, EXP CELL RES, V219, P527, DOI 10.1006/excr.1995.1261; Xu DZ, 2005, J BIOL CHEM, V280, P2924, DOI 10.1074/jbc.M408907200; Xu J, 2005, BREAST CANCER RES TR, V91, P207, DOI 10.1007/s10549-005-1040-1; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Zhang YW, 2005, P NATL ACAD SCI USA, V102, P11740, DOI 10.1073/pnas.0505171102; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100; Zochbauer-Muller S, 2002, ANNU REV PHYSIOL, V64, P681, DOI 10.1146/annurev.physiol.64.081501.155828	40	101	108	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	2					269	276		10.1038/sj.onc.1209790	http://dx.doi.org/10.1038/sj.onc.1209790			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819504				2022-12-17	WOS:000243398300010
J	Yang, DQ; Halaby, MJ; Zhang, Y				Yang, D. -Q; Halaby, M. -J; Zhang, Y.			The identification of an internal ribosomal entry site in the 5 '-untranslated region of p53 mRNA provides a novel mechanism for the regulation of its translation following DNA damage	ONCOGENE			English	Article						p53; translation; 5 '-UTR; IRES; DNA damage	UNTRANSLATED REGION; INDUCED APOPTOSIS; BINDING PROTEIN; PARTICIPATION; REPRESSION; PHOSPHORYLATION; IRRADIATION; INITIATION; SEGMENT; KINASE	The tumor suppressor p53 plays a crucial role in maintaining the genetic integrity of the cell and in suppressing cell transformation. Its cellular levels are usually low and rise substantially in response to DNA damage. Although research on p53 induction following DNA damage has mainly focused on the post-translational modification of p53 by Mdm2, it is known that protein translation also contributes to p53 induction. However, the mechanisms underlying translational regulation of the p53 protein in response to DNA damage are still poorly understood. We show that p53 synthesis increases dramatically in MCF-7 cells treated with etoposide. Interestingly, this increase is accompanied by an increase in the association of the translation initiation factor eIF-4E with its binding protein 4E-BP1, an inhibitor of cap-dependent protein translation. We further identified an internal ribosomal entry site (IRES) located in the 5'-untranslated region of the p53 transcript, that is capable of driving the cap-independent translation of a downstream cistron encoding Firefly luciferase in a dicistronic expression vector. Moreover, we found that the activity of the IRES element increases in response to etoposide-induced DNA damage in MCF-7 cells. These findings provide a novel mechanism for the regulation of p53 translation in response to DNA damage.	Univ S Dakota, Div Basic Biomed Sci, Sanford Sch Med, Vermillion, SD 57069 USA	University of South Dakota	Yang, DQ (corresponding author), Univ S Dakota, Div Basic Biomed Sci, Sanford Sch Med, 414 E Clark St,Lee Med Bldg, Vermillion, SD 57069 USA.	dyang@usd.edu						Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Fu LN, 1999, ONCOGENE, V18, P6419, DOI 10.1038/sj.onc.1203064; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Holcik M, 2004, CURR CANCER DRUG TAR, V4, P299, DOI 10.2174/1568009043333005; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; KASTAN MB, 1991, CANCER RES, V51, P6304; KOMAR AA, 2005, J BIOL CHEM, V4, P4; Kumar V, 2000, J BIOL CHEM, V275, P10779, DOI 10.1074/jbc.275.15.10779; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; Mazan-Mamczarz K, 2003, P NATL ACAD SCI USA, V100, P8354, DOI 10.1073/pnas.1432104100; Miskimins WK, 2001, MOL CELL BIOL, V21, P4960, DOI 10.1128/MCB.21.15.4960-4967.2001; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Quinn JE, 2003, CANCER RES, V63, P6221; Schumacher B, 2005, CELL, V120, P357, DOI 10.1016/j.cell.2004.12.009; Sherrill KW, 2004, J BIOL CHEM, V279, P29066, DOI 10.1074/jbc.M402727200; Spriggs KA, 2005, CELL DEATH DIFFER, V12, P585, DOI 10.1038/sj.cdd.4401642; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; SULLIVAN NF, 1989, ONCOGENE, V4, P1497; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542	27	101	107	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4613	4619		10.1038/sj.onc.1209483	http://dx.doi.org/10.1038/sj.onc.1209483			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16607284				2022-12-17	WOS:000239457500011
J	Durkin, SG; Arlt, MF; Howlett, NG; Glover, TW				Durkin, S. G.; Arlt, M. F.; Howlett, N. G.; Glover, T. W.			Depletion of CHK1, but not CHK2, induces chromosomal instability and breaks at common fragile sites	ONCOGENE			English	Article						fragile sites; checkpoints; CHK1; CHK2	S-PHASE CHECKPOINT; DNA-DAMAGE; ATR; REPLICATION; BRCA1; PHOSPHATIDYLSERINE; PHOSPHORYLATION; RECOGNITION; INVOLVEMENT; INHIBITION	Common fragile sites are specific regions of the genome that form gaps and breaks on metaphase chromosomes when DNA synthesis is partially inhibited. Fragile sites and their associated genes show frequent deletions and other rearrangements in cancer cells, and may be indicators of DNA replication stress early in tumorigenesis. We have previously shown that the DNA damage response proteins ATR, BRCA1 and FANCD2 play critical roles in maintaining the stability of fragile site regions. To further elucidate the pathways regulating fragile site stability, we have investigated the effects of depletion of the cell cycle checkpoint kinases, CHK1 and CHK2 on common fragile site stability in human cells. We demonstrate that both CHK1 and CHK2 are activated following treatment of cells with low doses of aphidicolin that induce fragile site breakage. Furthermore, we show that depletion of CHK1, but not CHK2, using short-interfering RNA (siRNA) leads to highly destabilized chromosomes and specific common fragile site breakage. In many cells, CHK1 depletion resulted in extensive chromosome fragmentation, which was distinct from endonucleolytic cleavage commonly associated with apoptosis. These findings demonstrate a critical role for the CHK1 kinase in regulating chromosome stability, and in particular, common fragile site stability.	Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Glover, TW (corresponding author), Univ Michigan, Dept Human Genet, 4909 Buhl,Box 0618,1241 E Catherine St, Ann Arbor, MI 48109 USA.	glover@umich.edu			NCI NIH HHS [CA 43222] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07544] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007544] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Alderton GK, 2004, HUM MOL GENET, V13, P3127, DOI 10.1093/hmg/ddh335; Arlt MF, 2004, MOL CELL BIOL, V24, P6701, DOI 10.1128/mcb.24.15.6701-6709.2004; Arlt MF, 2002, GENE CHROMOSOME CANC, V33, P82, DOI 10.1002/gcc.10000; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; BARTKOVA J, 2005, AM J HUM GENET, V75, P654; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; CASPER AM, 2004, AM J HUM GENET, V4, P456; FADOK VA, 1992, J IMMUNOL, V148, P2207; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Glover TW, 2005, HUM MOL GENET, V14, pR197, DOI 10.1093/hmg/ddi265; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Howlett NG, 2005, HUM MOL GENET, V14, P693, DOI 10.1093/hmg/ddi065; Huang HJ, 1999, GENE CHROMOSOME CANC, V24, P48, DOI 10.1002/(SICI)1098-2264(199901)24:1<48::AID-GCC7>3.3.CO;2-M; Le Beau MM, 1998, HUM MOL GENET, V7, P755, DOI 10.1093/hmg/7.4.755; Lee SB, 2001, CANCER RES, V61, P8062; Liu QH, 2000, GENE DEV, V14, P1448; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Mangelsdorf M, 2000, CANCER RES, V60, P1683; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Musio A, 2005, HUM MOL GENET, V14, P525, DOI 10.1093/hmg/ddi049; Niida H, 2005, J BIOL CHEM, V280, P39246, DOI 10.1074/jbc.M505009200; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; RODRIGUEZ R, 2005, MOLL CELL BIOL; Schwartz M, 2005, GENE DEV, V19, P2715, DOI 10.1101/gad.340905; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; TAIT JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P187, DOI 10.1016/0003-9861(92)90111-9; Takai H, 2000, GENE DEV, V14, P1439; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Zachos G, 2005, MOL CELL BIOL, V25, P563, DOI 10.1128/MCB.25.2.563-574.2005; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhang YW, 2005, MOL CELL, V19, P607, DOI 10.1016/j.molcel.2005.07.019; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	41	101	102	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	32					4381	4388		10.1038/sj.onc.1209466	http://dx.doi.org/10.1038/sj.onc.1209466			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16732333				2022-12-17	WOS:000239326000001
J	Zhu, Y; McAvoy, S; Kuhn, R; Smith, DI				Zhu, Y.; McAvoy, S.; Kuhn, R.; Smith, D. I.			RORA, a large common fragile site gene, is involved in cellular stress response	ONCOGENE			English	Article						RORA; breast cancer; common fragile site; stress response	ORPHAN RECEPTOR-ALPHA; N-MYC GENE; CANCER-CELLS; DNA-DAMAGE; FHIT GENE; NUCLEAR RECEPTORS; HUMAN-CHROMOSOMES; STAGGERER MICE; EXPRESSION; FRA16D	Common fragile sites ( CFSs) are large genomic regions present in all individuals that are highly unstable and prone to breakage and rearrangement, especially in cancer cells with genomic instability. Eight of the 90 known CFSs have been precisely defined and five of these span genes that extend from 700 kb to over 1.5Mb of genomic sequence. Although these genes reside within some of the most unstable chromosomal regions in the human genome, they are highly conserved evolutionarily. These genes are targets for large chromosomal deletions and rearrangements in cancer and are frequently inactivated in multiple tumor types. There is also an association between these genes and cellular responses to stress. Based upon the association between large genes and CFSs, we began to systematically test other large genes derived from chromosomal regions that were known to contain a CFS. In this study, we demonstrate that the 730 kb retinoic acid receptor- related orphan receptor alpha ( RORA) gene is derived from the middle of the FRA15A ( 15q22.2) CFS. Although this gene is expressed in normal breast, prostate and ovarian epithelium, it is frequently inactivated in cancers that arise from these organs. RORA was previously shown to be involved in the cellular response to hypoxia and here we demonstrate changes in the amount of RORA message produced in cells exposed to a variety of different cellular stresses. Our results demonstrate that RORA is another very large CFS gene that is inactivated in multiple tumors. In addition, RORA appears to play a critical role in responses to cellular stress, lending further support to the idea that the large CFS genes function as part of a highly conserved stress response network that is uniquely susceptible to genomic instability in cancer cells.	Mayo Clin & Mayo Fdn, Coll Med, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA; Univ Calif Santa Cruz, Dept Biomol Sci & Engn, Santa Cruz, CA 95064 USA	Mayo Clinic; University of California System; University of California Santa Cruz	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Dept Lab Med & Pathol, Div Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.	smith.david@mayo.edu						Arlt MF, 2003, CYTOGENET GENOME RES, V100, P92, DOI 10.1159/000072843; Becker NA, 2002, ONCOGENE, V21, P8713, DOI 10.1038/sj.onc.1205950; BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; Bednarek AK, 2001, CANCER RES, V61, P8068; Broussard DR, 2004, J VIROL, V78, P4943, DOI 10.1128/JVI.78.9.4943-4946.2004; Buttel I, 2004, ANN NY ACAD SCI, V1028, P14, DOI 10.1196/annals.1322.002; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Chang NS, 2003, BIOCHEM PHARMACOL, V66, P1347, DOI 10.1016/S0006-2952(03)00484-2; Chauvet C, 2004, BIOCHEM J, V384, P79, DOI 10.1042/BJ20040709; Chauvet C, 2002, BIOCHEM J, V364, P449, DOI 10.1042/BJ20011558; Druck T, 1997, CANCER RES, V57, P504; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Dussault I, 1997, MOL CELL BIOL, V17, P1860, DOI 10.1128/MCB.17.4.1860; Finnis M, 2005, HUM MOL GENET, V14, P1341, DOI 10.1093/hmg/ddi144; Gemma A, 1997, CANCER RES, V57, P1435; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; Gopalakrishnan VK, 2003, PANCREATOLOGY, V3, P293, DOI 10.1159/000071767; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; He YW, 1998, IMMUNITY, V9, P797, DOI 10.1016/S1074-7613(00)80645-7; HIROSE T, 1994, BIOCHEM BIOPH RES CO, V205, P1976, DOI 10.1006/bbrc.1994.2902; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; HUEBNER K, 1997, BIOCHIM BIOPHYS ACTA, V1332, P65; Ishii H, 2005, MOL CANCER RES, V3, P130, DOI 10.1158/1541-7786.MCR-04-0209; Jetten AM, 2002, CELL DEATH DIFFER, V9, P1167, DOI 10.1038/sj.cdd.4401085; Jetten Anton M., 2004, Current Drug Targets - Inflammation and Allergy, V3, P395, DOI 10.2174/1568010042634497; Jiang HB, 2004, HUM MOL GENET, V13, P1745, DOI 10.1093/hmg/ddh180; Krummel KA, 2002, GENE CHROMOSOME CANC, V34, P154, DOI 10.1002/gcc.10047; Laiho M, 2003, ANN MED, V35, P391, DOI 10.1080/07853890310014605; Lau P, 1999, NUCLEIC ACIDS RES, V27, P411, DOI 10.1093/nar/27.2.411; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; Littman DR, 1999, COLD SPRING HARB SYM, V64, P373, DOI 10.1101/sqb.1999.64.373; Ludes-Meyers JH, 2003, CYTOGENET GENOME RES, V100, P101, DOI 10.1159/000072844; Matsuyama A, 2003, P NATL ACAD SCI USA, V100, P14988, DOI 10.1073/pnas.2336256100; MatysiakScholze U, 1997, GENOMICS, V43, P78, DOI 10.1006/geno.1997.4757; Migita H, 2004, FEBS LETT, V557, P269, DOI 10.1016/S0014-5793(03)01502-3; Missbach M, 1996, J BIOL CHEM, V271, P13515, DOI 10.1074/jbc.271.23.13515; Moretti RM, 2001, PROSTATE, V46, P327, DOI 10.1002/1097-0045(20010301)46:4<327::AID-PROS1040>3.0.CO;2-6; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Pawlikowski M, 1999, ADV EXP MED BIOL, V460, P369; Schrader M, 1996, J BIOL CHEM, V271, P19732, DOI 10.1074/jbc.271.33.19732; Smith DI, 1998, INT J ONCOL, V12, P187; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; SUTHERLAND GR, 1995, CURR OPIN GENET DEV, V5, P323, DOI 10.1016/0959-437X(95)80046-8; Wang F, 2004, GENE CHROMOSOME CANC, V40, P85, DOI 10.1002/gcc.20020	48	101	104	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2901	2908		10.1038/sj.onc.1209314	http://dx.doi.org/10.1038/sj.onc.1209314			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16462772				2022-12-17	WOS:000237448200008
J	Yuan, J; Kramer, A; Matthess, Y; Yan, R; Spankuch, B; Gatje, R; Knecht, R; Kaufmann, M; Strebhardt, K				Yuan, J; Kramer, A; Matthess, Y; Yan, R; Spankuch, B; Gatje, R; Knecht, R; Kaufmann, M; Strebhardt, K			Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo	ONCOGENE			English	Article						RNA interference; cyclin B1; inhibition in vivo; apoptosis; taxol	CLINICAL-SIGNIFICANCE; NUCLEAR-LOCALIZATION; CANCER; OVEREXPRESSION; INHIBITION; EXPRESSION; PHOSPHORYLATION; ACTIVATION; KINASE; PROLIFERATION	Cyclin B1 is the regulatory subunit of cyclin-dependent kinase 1 (Cdk1) and is critical for the initiation of mitosis. Accumulating data indicate that the deregulation of cyclin B1 is tightly linked to neoplastic transformation. To study the phenotype and the potential preclinical relevance, we generated HeLa cell lines stably transfected with the plasmids encompassing short hairpin RNA (shRNA) targeting cyclin B1. We demonstrate that the reduction of cyclin B1 caused inhibit ion of proliferation by arresting cells in G2 phase and by inducing apoptosis. Cells, entering mitosis, were impaired in chromosome condensation and alignment. Importantly, HeLa cells with reduced cyclin B1 were more susceptible to the treatment of small interfering RNA targeting Polo-like kinase 1 (Plk1) and to the administration of the chemotherapeutic agent taxol. Finally, HeLa cells with reduced cyclin B1 showed inhibited tumor growth in nude mice compared to that of control cells. In summary, our data indicate that cyclin B1 is an essential molecule for tumor cell survival and aggressive proliferation, suggesting that the downregulation of cyclin B1, especially in combination with other molecular targets, might become an interesting strategy for antitumor intervention.	Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, D-60590 Frankfurt, Germany; So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL USA; So Illinois Univ, Sch Med, Inst Canc, Springfield, IL USA; Goethe Univ Frankfurt, Sch Med, Dept Otorhinolaryngol, D-6000 Frankfurt, Germany	Goethe University Frankfurt; Southern Illinois University System; Southern Illinois University; Southern Illinois University System; Southern Illinois University; Goethe University Frankfurt	Yuan, J (corresponding author), Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	yuan@em.uni-frankfurt.de; Strebhardt@em.uni-frankfurt.de	Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				Brandeis M, 1998, P NATL ACAD SCI USA, V95, P4344, DOI 10.1073/pnas.95.8.4344; Carnero A, 2002, BRIT J CANCER, V87, P129, DOI 10.1038/sj.bjc.6600458; Chang THT, 1996, J CELL BIOCHEM, V60, P161, DOI 10.1002/(SICI)1097-4644(19960201)60:2<161::AID-JCB1>3.0.CO;2-V; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Garrett MD, 1999, CURR OPIN GENET DEV, V9, P104, DOI 10.1016/S0959-437X(99)80015-X; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; Hassan KA, 2002, CANCER RES, V62, P6414; Hassan KA, 2001, CLIN CANCER RES, V7, P2458; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kao GD, 1997, CANCER RES, V57, P753; Kaufmann WK, 1997, CELL GROWTH DIFFER, V8, P1105; Korenaga D, 2002, SURGERY, V131, pS114, DOI 10.1067/msy.2002.119362; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Matthess Y, 2005, ONCOGENE, V24, P2973, DOI 10.1038/sj.onc.1208472; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Park M, 2000, CANCER RES, V60, P542; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Sarafan-Vasseur N, 2002, ONCOGENE, V21, P2051, DOI 10.1038/sj.onc.1205257; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Shen ML, 2004, CANCER RES, V64, P1607, DOI 10.1158/0008-5472.CAN-03-3321; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; Soria JC, 2000, CANCER RES, V60, P4000; Spankuch B, 2004, JNCI-J NATL CANCER I, V96, P862, DOI 10.1093/jnci/djh146; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Takeno S, 2002, CANCER, V94, P2874, DOI 10.1002/cncr.10542; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Viallard JF, 1999, EXP CELL RES, V247, P208, DOI 10.1006/excr.1998.4352; Walsh S, 2003, MOL CANCER RES, V1, P280; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yang J, 2001, J BIOL CHEM, V276, P3604, DOI 10.1074/jbc.M008151200; Yasuda M, 2002, J CANCER RES CLIN, V128, P412, DOI 10.1007/s00432-002-0359-9; Yin XY, 2001, CANCER RES, V61, P6487; Yoshida T, 2004, ANN ONCOL, V15, P252, DOI 10.1093/annonc/mdh073; Yuan J, 2005, LETT DRUG DES DISCOV, V2, P274, DOI 10.2174/1570180054038378; Yuan JP, 2002, CANCER RES, V62, P4186; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Yuan JP, 2004, ONCOGENE, V23, P5843, DOI 10.1038/sj.onc.1207757	45	101	113	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1753	1762		10.1038/sj.onc.1209202	http://dx.doi.org/10.1038/sj.onc.1209202			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16278675				2022-12-17	WOS:000236013700007
J	Zhang, Z; Wang, H; Li, M; Rayburn, ER; Agrawal, S; Zhang, RW				Zhang, Z; Wang, H; Li, M; Rayburn, ER; Agrawal, S; Zhang, RW			Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway	ONCOGENE			English	Article						MDM2; E2F1; ubiquitination; protein-protein interaction	IN-VIVO ACTIVITIES; ANTISENSE ANTI-MDM2 OLIGONUCLEOTIDES; MIXED-BACKBONE OLIGONUCLEOTIDE; TRANSCRIPTION FACTOR E2F-1; HUMAN CANCER; PROSTATE-CANCER; BREAST-CANCER; CELL-GROWTH; P53; EXPRESSION	Although previous studies suggested that the tumorigenicity of mouse double minute 2 (MDM2) was due to its negative regulation of p53, the p53-independent interactions may be equally as important. During recent studies utilizing MDM2 inhibitors, we noted that E2F transcription factor 1 (E2F1) was downregulated upon inhibition of MDM2, regardless of the p53 status of the cancer. The present study investigated the mechanisms responsible for the MDM2-mediated increase in E2F1 expression. MDM2 prolongs the half-life of the E2F1 protein by inhibiting its ubiquitination. MDM2 displaces SCFSKP2, the E2F1 E3 ligase. Direct binding between MDM2 and E2F1 is necessary for the negative effects of MDM2 on E2F1 ubiquitination, and deletion of the MDM2 nuclear localization signal does not result in loss of the ability to increase the E2F1 protein level. The downregulation of E2F1 upon MDM2 inhibition was not due to either pRB or p14(Arf). In addition, E2F1 was responsible for at least part of the inhibition of cell proliferation induced by MDM2 knockdown. In conclusion, the present study provides evidence that stabilization of the E2F1 protein is likely another p53-independent component of MDM2-mediated tumorigenesis. More knowledge about the MDM2-E2F1 interaction may be helpful in developing novel anticancer therapies.	Univ Alabama Birmingham, Ctr Comprehens Canc, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Div Clin Pharmacol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA; Hybridon Inc, Cambridge, MA 02139 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Zhang, RW (corresponding author), Univ Alabama Birmingham, Ctr Comprehens Canc, Dept Pharmacol & Toxicol, VH 113,1670 Univ Blvd, Birmingham, AL 35294 USA.	ruiwen.zhang@ccc.uab.edu		Agrawal, Sudhir/0000-0003-4275-2510	NCI NIH HHS [CA 112029, CA80698] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112029] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arakawa Y, 2004, BIOCHEM BIOPH RES CO, V322, P297, DOI 10.1016/j.bbrc.2004.04.208; Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004; Bartel F, 2004, MOL CANCER RES, V2, P29; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Bell LA, 2004, CELL DEATH DIFFER, V11, P137, DOI 10.1038/sj.cdd.4401324; Bond GL, 2005, CURR CANCER DRUG TAR, V5, P3, DOI 10.2174/1568009053332627; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CORDONCARDO C, 1994, CANCER RES, V54, P794; Datta A, 2002, MOL CELL BIOL, V22, P8398, DOI 10.1128/MCB.22.24.8398-8408.2002; Deb SP, 2003, MOL CANCER RES, V1, P1009; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Gorgoulis VG, 2002, J PATHOL, V198, P142, DOI 10.1002/path.1121; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Imai MA, 2004, J CANCER RES CLIN, V130, P320, DOI 10.1007/s00432-003-0538-3; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Jiang YY, 2004, J BIOL CHEM, V279, P40511, DOI 10.1074/jbc.M404496200; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kinyamu HK, 2003, MOL CELL BIOL, V23, P5867, DOI 10.1128/MCB.23.16.5867-5881.2003; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; La Thangue NB, 2003, NAT CELL BIOL, V5, P587, DOI 10.1038/ncb0703-587; Lee JS, 2004, NAT GENET, V36, P1306, DOI 10.1038/ng1481; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Liang HL, 2004, GENE, V338, P217, DOI 10.1016/j.gene.2004.05.015; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin WC, 2001, GENE DEV, V15, P1833; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Meek DW, 2003, MOL CANCER RES, V1, P1017; Minsky N, 2004, MOL CELL, V16, P631, DOI 10.1016/j.molcel.2004.10.016; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Mundle SD, 2003, FASEB J, V17, P569, DOI 10.1096/fj.02-0431rev; Onda M, 2004, J HUM GENET, V49, P312, DOI 10.1007/s10038-004-0146-3; Rayburn E, 2005, CURR CANCER DRUG TAR, V5, P27, DOI 10.2174/1568009053332636; Stanelle J, 2005, CELL DEATH DIFFER, V12, P347, DOI 10.1038/sj.cdd.4401532; Steinman HA, 2004, J BIOL CHEM, V279, P4877, DOI 10.1074/jbc.M305966200; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Vargas DA, 2003, ADV CANCER RES, V89, P1, DOI 10.1016/S0065-230X(03)01001-7; Wang H, 2003, ANN NY ACAD SCI, V1002, P217, DOI 10.1196/annals.1281.025; Wang H, 1999, INT J ONCOL, V15, P653; Wang H, 2003, PROSTATE, V54, P194, DOI 10.1002/pros.10187; Wang H, 2002, MOL MED, V8, P185, DOI 10.1007/BF03402011; Wang H, 2001, CLIN CANCER RES, V7, P3613; Wikonkal NM, 2003, NAT CELL BIOL, V5, P655, DOI 10.1038/ncb1001; Yamazaki K, 2003, PATHOL RES PRACT, V199, P23, DOI 10.1078/0344-0338-00348; Zhang RW, 2005, CURR CANCER DRUG TAR, V5, P43, DOI 10.2174/1568009053332663; Zhang RW, 2000, CURR PHARM DESIGN, V6, P393, DOI 10.2174/1381612003400911; Zhang Z, 2004, CLIN CANCER RES, V10, P1263, DOI 10.1158/1078-0432.CCR-0245-03; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zhang Z, 2003, P NATL ACAD SCI USA, V100, P11636, DOI 10.1073/pnas.1934692100; Zhang Z, 2005, CURR CANCER DRUG TAR, V5, P9, DOI 10.2174/1568009053332618	58	101	102	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7238	7247		10.1038/sj.onc.1208814	http://dx.doi.org/10.1038/sj.onc.1208814			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16170383				2022-12-17	WOS:000232990100012
J	Mainou, BA; Everly, DN; Raab-Traub, N				Mainou, BA; Everly, DN; Raab-Traub, N			Epstein-Barr virus latent membrane protein 1 CTAR1 mediates rodent and human fibroblast transformation through activation of PI3K	ONCOGENE			English	Article						EBV; LMP1; CTAR; Rat-1; PI3K; transformation	NF-KAPPA-B; MEMBRANE-PROTEIN 1; SYNTHASE KINASE 3-BETA; GROWTH-FACTOR RECEPTOR; TRAF-BINDING-SITE; LYMPHOCYTE TRANSFORMATION; SIGNALING PATHWAYS; EPITHELIAL-CELLS; BETA-CATENIN; LMP1	Epstein-Barr virus (EBV) is a ubiquitous herpesvirus associated with a variety of malignancies including nasopharyngeal carcinoma. The EBV-encoded latent membrane protein 1 (LMP1) is considered the EBV oncogene as it is necessary for EBV-induced B-lymphocyte transformation and has been shown to transform rodent fibroblasts. LMP1 contains two signaling domains, the carboxy-terminal activating region 1 and 2 (CTAR1 and CTAR2), by which NF-kappa B, phosphatidylinositol 3-kinase (PI3K), mitogen- activated protein kinase, and c-Jun N-terminal kinase are activated. In this study, the role of CTAR1 and CTAR2 in LMP1-mediated transformation of rodent fibroblasts was analysed. CTAR1 was found to be necessary for rodent. broblast transformation, whereas CTAR2 was dispensable. The activation of the PI3K pathway in Rat-1 cells by LMP1 and LMP1-CTAR1 in transformed cells resulted in phosphorylated Akt and phosphorylated glycogen synthase kinase 3 beta. The role of PI3K and NF-kappa B activation in LMP1-mediated transformation was further analysed using the chemical inhibitors LY294002 and BAY 11-7085. LY294002 inhibited CTAR1-induced focus formation and anchorage independent growth, whereas BAY 11-7085 did not inhibit focus formation or anchorage-independent growth. Similar studies in human fibroblasts confirmed that LMP1-CTAR1 also mediates aberrant growth, phosphorylation of Akt, and decreased levels of p27. These findings indicate that LMP1-mediated rodent. broblast transformation is dependent upon activation of PI3K and Akt and is independent of activation of NF-kappa B.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol Immunol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Raab-Traub, N (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	nrt@med.unc.edu	Mainou, Bernardo A./H-4164-2019	Mainou, Bernardo A./0000-0002-7721-183X	NATIONAL CANCER INSTITUTE [P01CA019014, R01CA032979] Funding Source: NIH RePORTER; NCI NIH HHS [CA 32979, CA 19014] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atkinson PGP, 2003, J BIOL CHEM, V278, P51134, DOI 10.1074/jbc.M304771200; BAICHWAL VR, 1988, ONCOGENE, V2, P461; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dawson CW, 2003, J BIOL CHEM, V278, P3694, DOI 10.1074/jbc.M209840200; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Everly DN, 2004, J VIROL, V78, P13470, DOI 10.1128/JVI.78.24.13470-13478.2004; Everly DN, 2004, J VIROL, V78, P11648, DOI 10.1128/JVI.78.21.11648-11655.2004; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; He ZM, 2000, CANCER RES, V60, P1845; Higuchi M, 2001, P NATL ACAD SCI USA, V98, P4675, DOI 10.1073/pnas.081075298; Izumi KM, 1999, MOL CELL BIOL, V19, P5759; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kieff E, 2001, FIELDS VIROLOGY, V2, P2511; LIEBOWITZ D, 1989, J VIROL, V63, P4051, DOI 10.1128/JVI.63.9.4051-4054.1989; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Mehl AM, 2001, J BIOL CHEM, V276, P984, DOI 10.1074/jbc.M003758200; Meng FY, 2002, J BIOL CHEM, V277, P29674, DOI 10.1074/jbc.M112464200; MILLER WE, 1995, J VIROL, V69, P4390, DOI 10.1128/JVI.69.7.4390-4398.1995; Miller WE, 1998, ONCOGENE, V16, P1869, DOI 10.1038/sj.onc.1201696; Miller WE, 1998, MOL CELL BIOL, V18, P2835, DOI 10.1128/MCB.18.5.2835; Miller WE, 1997, J VIROL, V71, P586, DOI 10.1128/JVI.71.1.586-594.1997; Morrison JA, 2004, CANCER RES, V64, P5251, DOI 10.1158/0008-5472.CAN-04-0538; Morrison JA, 2003, J VIROL, V77, P12276, DOI 10.1128/JVI.77.22.12276-12284.2003; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Puls A, 1999, J CELL SCI, V112, P2983; Raab-Traub N, 2002, SEMIN CANCER BIOL, V12, P431, DOI 10.1016/S1044579X0200086X; REYNOLDS VL, 1987, CANCER RES, V47, P6384; Roberts ML, 1998, VIROLOGY, V240, P93, DOI 10.1006/viro.1997.8901; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; Saito N, 2003, J BIOL CHEM, V278, P46565, DOI 10.1074/jbc.M302549200; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Thornburg NJ, 2003, CANCER RES, V63, P8293; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	44	101	105	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6917	6924		10.1038/sj.onc.1208846	http://dx.doi.org/10.1038/sj.onc.1208846			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007144				2022-12-17	WOS:000232701700006
J	Grifoni, D; Garoia, F; Schimanski, CC; Schmitz, G; Laurenti, E; Galle, PR; Pession, A; Cavicchi, S; Strand, D				Grifoni, D; Garoia, F; Schimanski, CC; Schmitz, G; Laurenti, E; Galle, PR; Pession, A; Cavicchi, S; Strand, D			The human protein Hugl-1 substitutes for Drosophila Lethal giant larvae tumour suppressor function in vivo	ONCOGENE			English	Article						Hugl-1; Lethal giant larvae; tumour suppressor; cell polarity; epithelial cancers; Drosophila	II HEAVY-CHAIN; CELL POLARITY; GENE-EXPRESSION; HUMAN HOMOLOG; DISCS LARGE; NE-DLG; GROWTH; LGL; COMPLEX; LOCALIZATION	Drosophila lethal giant larvae (lgl), discs large (dlg) and scribble (scrib) are tumour suppressor genes acting in a common pathway, whose loss of function leads to disruption of cell polarity and tissue architecture, uncontrolled proliferation and growth of neoplastic lesions. Mammalian homologues of these genes are highly conserved and evidence is emerging concerning their role in cell proliferation control and tumorigenesis in humans. Here we investigate the functional conservation between Drosophila lethal giant larvae and its human homologue Hugl-1(Llgl1). We first show that Hugl-1 is lost in human solid malignancies, supporting its role as a tumour suppressor in humans. Hugl-1 expression in homozygous Igl Drosophila mutants is able to rescue larval lethality; imaginal tissues do not show any neoplastic features, with Dig and Scrib exhibiting the correct localization; animals undergo a complete metamorphosis and hatch as viable adults. These data demonstrate that Hugl-1 can act as a tumour suppressor in Drosophila and thus is the functional homologue of lgl. Furthermore, our data suggest that the genetic pathway including the tumour suppressors lgl, dlg and scrib may be conserved in mammals, since human scrib and mammalian dlg can also rescue their respective Drosophila mutations. Our results highlight the usefulness of fruit fly as a model system for investigating in vivo the mechanisms linking loss of cell polarity and cell proliferation control in human cancers.	Dipartimento Biol Evoluz Sperimentale, Alma Mater Studiorum, I-40126 Bologna, Italy; Johannes Gutenberg Univ Mainz, Dept Internal Med 1, D-55131 Mainz, Germany; Osped Bellaria, Sez Patol, Dipartimento Oncol, Alma Mater Studiorum, I-40139 Bologna, Italy	Johannes Gutenberg University of Mainz	Grifoni, D (corresponding author), Dipartimento Biol Evoluz Sperimentale, Alma Mater Studiorum, Via Selmi 3, I-40126 Bologna, Italy.	dgrifoni@alma.unibo.it	Garoia, Flavio/AAW-1313-2020; Pession, Annalisa/B-9014-2012; Garoia, Flavio/AAL-4528-2020; Galle, Peter R/T-5292-2018; Grifoni, Daniela/A-3954-2012; Galle, Peter/ABE-2872-2021	Galle, Peter R/0000-0001-8294-0992; Galle, Peter/0000-0001-8294-0992; Pession, Annalisa/0000-0001-9035-9698; GRIFONI, DANIELA/0000-0001-7429-4062; Garoia, Flavio/0000-0001-7849-0036; Laurenti, Elisa/0000-0002-9917-9092				AGRAWAL N, 1995, DEV BIOL, V172, P218, DOI 10.1006/dbio.1995.0017; Albertson R, 2003, NAT CELL BIOL, V5, P166, DOI 10.1038/ncb922; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Boussioutas A, 2003, CANCER RES, V63, P2569; BRAND AH, 1993, DEVELOPMENT, V118, P401; Dow LE, 2003, ONCOGENE, V22, P9225, DOI 10.1038/sj.onc.1207154; GATEFF E, 1978, SCIENCE, V200, P1448, DOI 10.1126/science.96525; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; Hanada N, 2000, INT J CANCER, V86, P480, DOI 10.1002/(SICI)1097-0215(20000515)86:4<480::AID-IJC6>3.0.CO;2-6; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; JACOB L, 1987, CELL, V50, P215, DOI 10.1016/0092-8674(87)90217-0; Jakobs R, 1996, J MOL BIOL, V264, P484, DOI 10.1006/jmbi.1996.0656; Kalmes A, 1996, J CELL SCI, V109, P1359; Kim YS, 2003, INT J ONCOL, V23, P1515; Larsson K, 1998, J BIOL CHEM, V273, P33610, DOI 10.1074/jbc.273.50.33610; Liu LX, 2002, WORLD J GASTROENTERO, V8, P580, DOI 10.3748/wjg.v8.i4.580; Makino K, 1997, ONCOGENE, V14, P2425, DOI 10.1038/sj.onc.1201087; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Stowers RS, 1999, GENETICS, V152, P1631; STRAND D, 1994, J CELL BIOL, V127, P1361, DOI 10.1083/jcb.127.5.1361; STRAND D, 1994, J CELL BIOL, V127, P1345, DOI 10.1083/jcb.127.5.1345; STRAND D, 1995, ONCOGENE, V11, P291; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; TIMMONS L, 1993, DEV BIOL, V158, P364, DOI 10.1006/dbio.1993.1195; TOMOTSUNE D, 1993, NATURE, V365, P69, DOI 10.1038/365069a0; WATSON KL, 1994, J CELL SCI, P19; Wodarz A, 2000, CURR BIOL, V10, pR624, DOI 10.1016/S0960-9822(00)00658-8; WOODHOUSE E, 1994, CELL GROWTH DIFFER, V5, P151; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; Woods DF, 1997, DEV GENET, V20, P111, DOI 10.1002/(SICI)1520-6408(1997)20:2<111::AID-DVG4>3.3.CO;2-O; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6	37	101	107	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8688	8694		10.1038/sj.onc.1208023	http://dx.doi.org/10.1038/sj.onc.1208023			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467749				2022-12-17	WOS:000224988800015
J	Muller, S; Kunkel, P; Lamszus, K; Ulbricht, U; Lorente, GA; Nelson, AM; von Schack, D; Chin, DJ; Lohr, SC; Westphal, M; Melcher, T				Muller, S; Kunkel, P; Lamszus, K; Ulbricht, U; Lorente, GA; Nelson, AM; von Schack, D; Chin, DJ; Lohr, SC; Westphal, M; Melcher, T			A role for receptor tyrosine phosphatase zeta in glioma cell migration	ONCOGENE			English	Article						glioblastoma; custom cDNA array; RNA interference; migration; receptor tyrosine phosphatase zeta; pleiotrophin	ANTIBODY 81C6 TREATMENT; GENE-EXPRESSION; MAMMALIAN-CELLS; TENASCIN-C; BRAIN; ADHESION; ZETA/BETA; BETA; IDENTIFICATION; SUPPRESSION	Glioblastomas (GBM) are the most frequent and malignant human brain tumor type. Typically striking in adulthood, tumor progression is rapid, relentless, and ultimately leads to the patient's death within a year of diagnosis. The identification of transcriptionally regulated genes can lead to the discovery of targets for antibody or small-molecule-mediated therapy, as well as diagnostic markers. We prepared cDNA arrays that are specifically enriched for genes expressed in human brain tumors and pro. led gene expression patterns in 14 individual tumor samples. Out of 25 000 clones arrayed, greater than 200 genes were found transcriptionally induced in glioblastomas compared to normal human brain tissue including the receptor tyrosine phosphatasezeta (RPTPzeta) and one of its ligands, pleiotrophin (Ptn). We confirmed by Northern blot analysis and immunohistochemistry that RPTPzeta is enriched in tumor samples. Knockdown of RPTPzeta by RNA interference studies established a functional role of RPTPzeta in cell migration. Our results suggest a novel function for RPTPzeta in regulating glioblastoma cell motility and point to the therapeutic utility of RPTPzeta as a target for antibody-mediated therapy of brain tumors.	AGY Therapeut Inc, San Francisco, CA 94080 USA; Univ Hamburg, Hosp Eppendorf, Dept Neurosurg, D-20246 Hamburg, Germany	University of Hamburg	Muller, S (corresponding author), AGY Therapeut Inc, 290 Utah Ave, San Francisco, CA 94080 USA.	sabine@agyinc.com						Adamsky K, 2001, ONCOGENE, V20, P609, DOI 10.1038/sj.onc.1204119; Berens Michael E., 1999, Neoplasia (New York), V1, P208, DOI 10.1038/sj.neo.7900034; Besson A, 2001, ONCOGENE, V20, P7398, DOI 10.1038/sj.onc.1204899; Bigner DD, 1998, J CLIN ONCOL, V16, P2202, DOI 10.1200/JCO.1998.16.6.2202; Brown MT, 1996, CLIN CANCER RES, V2, P963; Butte A, 2002, NAT REV DRUG DISCOV, V1, P951, DOI 10.1038/nrd961; Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498; Davis FG, 2001, NEURO-ONCOLOGY, V3, P152, DOI 10.1093/neuonc/3.3.152; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Dirks PB, 1997, NEUROSURGERY, V40, P1000, DOI 10.1097/00006123-199705000-00025; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gary S C, 2000, Clin Neurosurg, V47, P72; GRUMET M, 1994, J BIOL CHEM, V269, P12142; Huang HT, 2000, CANCER RES, V60, P6868; Kawachi H, 1999, MOL BRAIN RES, V72, P47, DOI 10.1016/S0169-328X(99)00204-1; Kawachi H, 2001, P NATL ACAD SCI USA, V98, P6593, DOI 10.1073/pnas.041608698; Kim CH, 2000, SURG NEUROL, V54, P235, DOI 10.1016/S0090-3019(00)00307-4; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; LEVY JB, 1993, J BIOL CHEM, V268, P10573; MAEDA N, 1995, NEUROSCIENCE, V67, P23, DOI 10.1016/0306-4522(94)00069-H; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; Menon PM, 2000, INT J ONCOL, V17, P683; Oz Buge, 2000, Pathology and Oncolgy Research, V6, P118; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Revest JM, 1999, EUR J NEUROSCI, V11, P1134, DOI 10.1046/j.1460-9568.1999.00521.x; Rhee CH, 1999, ONCOGENE, V18, P2711, DOI 10.1038/sj.onc.1202623; Thomaidou D, 2001, J NEUROCHEM, V78, P767, DOI 10.1046/j.1471-4159.2001.00454.x; WESTPHAL M, 1994, ACTA NEUROCHIR, V126, P17, DOI 10.1007/BF01476489; Zhang H, 1998, J NEUROSCI, V18, P2370	30	101	109	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2003	22	43					6661	6668		10.1038/sj.onc.1206763	http://dx.doi.org/10.1038/sj.onc.1206763			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555979				2022-12-17	WOS:000185799300001
J	Okumura, T; Shimada, Y; Imamura, M; Yasumoto, S				Okumura, T; Shimada, Y; Imamura, M; Yasumoto, S			Neurotrophin receptor p75(NTR) characterizes human esophageal keratinocyte stem cells in vitro	ONCOGENE			English	Article						p75(NTR); stem cells; esophagus; keratinocytes; integrin beta 1; integrin beta 4	NERVE GROWTH-FACTOR; TRANSIT AMPLIFYING CELLS; HUMAN EPITHELIAL-CELLS; EPIDERMAL-CELLS; TELOMERASE ACTIVITY; SURFACE PHENOTYPE; HUMAN-SKIN; INTEGRIN; FOLLICLE; EXPRESSION	We report here that human esophageal keratinocyte stem cells are characterized by the expression of the low-affinity neurotrophin receptor p75(NTR) and differentially expressed cell adhesion molecules, the beta1 and beta4 integrins. The candidate stem cells could be fractionated from keratinocytes as a minor cell subset by means of immunocytochemical cell sorting based on the different levels of expression of these cell surface molecules. Flow cytometric analysis revealed that this minor cell subset retained a relatively slow-cycling phenotype in vitro. These cells expressed low levels of involucrin and cytokeratin 13, indicating that the p75(NTR)-positive cell subset is immature relative to the other predominant subpopulations coexpressing beta1 integrin at higher levels. The p75(NTR)-positive cell subset was crucial for achieving longevity and the greatest output of keratinocytes comprising all distinguishable subpopulations in vitro. This process was associated with self-renewal and self-amplification of the p75(NTR)-positive cell subset. These findings strongly implicate p75(NTR) as a stem cell marker, which will be valuable for prospectively investigating stem cell regulation in association with different biological processes including neoplastic transformation of regenerative epithelia.	Kanagawa Canc Ctr, Res Inst, Lab Mol Cell Biol & Oncol, Asahi Ku, Yokohama, Kanagawa 2410815, Japan; Kyoto Univ, Grad Sch Med, Dept Surg & Surg Basic Sci, Kyoto, Japan	Kanagawa Prefectural Cancer Center; Kyoto University	Yasumoto, S (corresponding author), Kanagawa Canc Ctr, Res Inst, Lab Mol Cell Biol & Oncol, Asahi Ku, 1-1-2 Nakao, Yokohama, Kanagawa 2410815, Japan.	yasumoto@gancen.asahi.yokohama.jp						ALBARWARI SE, 1976, INT J RADIAT BIOL, V30, P201, DOI 10.1080/09553007614550981; Asakura A, 2001, DIFFERENTIATION, V68, P245, DOI 10.1046/j.1432-0436.2001.680412.x; Botchkarev VA, 2000, FASEB J, V14, P1931, DOI 10.1096/fj.99-0930com; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; Dechant G, 1997, CURR OPIN NEUROBIOL, V7, P413, DOI 10.1016/S0959-4388(97)80071-2; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; HALL PA, 1989, DEVELOPMENT, V106, P619; Hodivala-Dilke KM, 1998, J CELL BIOL, V142, P1357, DOI 10.1083/jcb.142.5.1357; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Kaur P, 2000, J INVEST DERMATOL, V114, P413, DOI 10.1046/j.1523-1747.2000.00884.x; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Kunimura C, 1998, ONCOGENE, V17, P187, DOI 10.1038/sj.onc.1201916; Lako M, 2002, J CELL SCI, V115, P3967, DOI 10.1242/jcs.00060; Li A, 1998, P NATL ACAD SCI USA, V95, P3902, DOI 10.1073/pnas.95.7.3902; Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028; Micera A, 2001, P NATL ACAD SCI USA, V98, P6162, DOI 10.1073/pnas.101130898; Miller Stanley J., 1997, P331, DOI 10.1016/B978-012563455-7/50012-X; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Ohta Y, 1997, JPN J CANCER RES, V88, P644, DOI 10.1111/j.1349-7006.1997.tb00432.x; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; Pincelli C, 2000, J DERMATOL SCI, V22, P71, DOI 10.1016/S0923-1811(99)00065-1; Potten CS, 2002, J CELL SCI, V115, P2381; POTTEN CS, 1988, J CELL SCI, P45; Price J, 2001, CURR OPIN NEUROBIOL, V11, P564, DOI 10.1016/S0959-4388(00)00250-6; REYNOLDS AJ, 1992, DEVELOPMENT, V115, P587; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; Seery JP, 2002, J CELL SCI, V115, P1783; Seery JP, 2000, CURR BIOL, V10, P1447, DOI 10.1016/S0960-9822(00)00803-4; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Tani H, 2000, P NATL ACAD SCI USA, V97, P10960, DOI 10.1073/pnas.97.20.10960; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Watt FM, 1998, PHILOS T R SOC B, V353, P831, DOI 10.1098/rstb.1998.0247; Yasumoto S, 1996, ONCOGENE, V13, P433	34	101	115	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2003	22	26					4017	4026		10.1038/sj.onc.1206525	http://dx.doi.org/10.1038/sj.onc.1206525			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821936	Green Submitted			2022-12-17	WOS:000183707600005
J	An, JB; Sun, YP; Sun, R; Rettig, MB				An, JB; Sun, YP; Sun, R; Rettig, MB			Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappa B and JNK/AP1 pathways	ONCOGENE			English	Article						KSHV; vFLIP; interleukin-6; NF-kappa B; jun N-terminal kinase; AP1	MULTICENTRIC CASTLEMANS-DISEASE; INTERLEUKIN-6 GENE-EXPRESSION; C-JUN; DNA-SEQUENCES; TERMINAL KINASE; NUCLEAR ANTIGEN; GROWTH-FACTOR; UP-REGULATION; ACTIVATION; HUMAN-HERPESVIRUS-8	The Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a FADD-like interferon converting enzyme or caspase 8 (FLICE) inhibitory protein (vFLIP) that prevents death receptor-mediated apoptosis by inhibiting the recruitment and activation of FLICE. Since vFLIP physically interacts with tumor necrosis factor receptor associated factor 2 (TRAF2) and TRAF2 mediates activation of the jun NH2-terminal kinase (JNK)/activation protein 1 (AP1) pathway, we hypothesized that vFLIP might also activate this pathway. To evaluate this hypothesis, we transiently and stably transfected a vFLIP expression construct and performed several complementary assays to document that vFLIP activates the JNK/AP1 pathway and does so in a TRAF-dependent fashion. As vFLIP also activates the nuclear factor kappaB (NF-kappaB) signaling pathway and the NF-kappaB and JNK/AP1 pathways both modulate cellular interleukin-6 (cIL-6) expression, we postulated that vFLIP induces expression of this cytokine. We show that vFLIP induces cIL-6 expression and activates the cIL-6 promoter, and maximal activation of the cIL-6 promoter by vFLIP requires NF-kappaB and AP1 activation. In addition, vFLIP and latency-associated nuclear antigen (LANA), another KSHV-encoded latent protein, potentiate each other's ability to activate the cIL-6 promoter. Gene silencing experiments by RNA interference demonstrate that vFLIP in BCBL-1 endogenously infected primary effusion lymphoma (PEL) cells mediates JNK/AP1 activation and cIL-6 expression. Thus, we conclude that vFLIP, in addition to its known effects on NF-kappaB activation, also modulates the JNK/AP1 pathway and induces gene expression from the cIL-6 promoter in a JNK/AP1-dependent fashion.	VA Greater Los Angeles Healthcare Syst W LA, Dept Med, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Rettig, MB (corresponding author), VA Greater Los Angeles Healthcare Syst W LA, Dept Med, 11301 Wilshire Blvd,Bldg 304,Room E1-113, Los Angeles, CA 90073 USA.	matthew.rettig@med.va.gov			NCI NIH HHS [1R01CA80004-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080004] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An JB, 2002, BLOOD, V99, P649, DOI 10.1182/blood.V99.2.649; Asou H, 1998, BLOOD, V91, P2475, DOI 10.1182/blood.V91.7.2475.2475_2475_2481; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; BLACK EJ, 1991, ONCOGENE, V6, P1949; Butterfield L, 1997, J BIOL CHEM, V272, P10110; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Dadgostar H, 1998, J BIOL CHEM, V273, P24775, DOI 10.1074/jbc.273.38.24775; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; Diaz BV, 2000, J BIOL CHEM, V275, P642, DOI 10.1074/jbc.275.1.642; Dittmer D, 1998, J VIROL, V72, P8309, DOI 10.1128/JVI.72.10.8309-8315.1998; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; Foreman KE, 1997, NEW ENGL J MED, V336, P163, DOI 10.1056/NEJM199701163360302; Foussat A, 1999, EUR CYTOKINE NETW, V10, P501; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; Glykofrydes D, 2000, J VIROL, V74, P11919, DOI 10.1128/JVI.74.24.11919-11927.2000; Grandadam M, 1997, J INFECT DIS, V175, P1198, DOI 10.1086/593567; Grundhoff A, 2001, J VIROL, V75, P1857, DOI 10.1128/JVI.75.4.1857-1863.2001; Hu SM, 1997, J BIOL CHEM, V272, P9621; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Keller SA, 2000, BLOOD, V96, P2537; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LEGERRAVET MB, 1991, BLOOD, V78, P2923; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Liu B, 2001, J BIOL CHEM, V276, P36624, DOI 10.1074/jbc.M101085200; Low W, 2001, J VIROL, V75, P2938, DOI 10.1128/JVI.75.6.2938-2945.2001; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Panyutich EA, 1998, AIDS, V12, P467, DOI 10.1097/00002030-199805000-00007; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Sarid R, 1999, J VIROL, V73, P1438, DOI 10.1128/JVI.73.2.1438-1446.1999; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; Screpanti I, 1996, J EXP MED, V184, P1561, DOI 10.1084/jem.184.4.1561; Siegmund D, 2001, J BIOL CHEM, V276, P32585, DOI 10.1074/jbc.M100444200; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Talbot SJ, 1999, VIROLOGY, V257, P84, DOI 10.1006/viro.1999.9672; THORNE M, 1997, NATURE, V386, P517	46	101	105	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3371	3385		10.1038/sj.onc.1206407	http://dx.doi.org/10.1038/sj.onc.1206407			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776188	Bronze			2022-12-17	WOS:000183128500003
J	Pichierri, P; Rosselli, F; Franchitto, A				Pichierri, P; Rosselli, F; Franchitto, A			Werner's syndrome protein is phosphorylated in an ATR/ATM-dependent manner following replication arrest and DNA damage induced during the S phase of the cell cycle	ONCOGENE			English	Article						Werner's syndrome protein; RecQ helicases; ATR; replication arrest; DNA damage response	SYNDROME LYMPHOBLASTOID-CELLS; BLOOMS-SYNDROME PROTEIN; ATAXIA-TELANGIECTASIA; FUNCTIONAL INTERACTION; IONIZING-RADIATION; CHECKPOINT PATHWAY; FORK ARREST; ATM KINASE; RECOMBINATION; EXONUCLEASE	Werner's syndrome (WS) is an autosomal recessive disorder, characterized at the cellular level by genomic instability in the form of variegated translocation mosaicism and extensive deletions. Individuals with WS prematurely develop multiple age-related pathologies and exhibit increased incidence of cancer. WRN, the gene defective in WS, encodes a 160-kDa protein (WRN), which has 3'-5' exonuclease, DNA helicase and DNA-dependent ATPase activities. WRN-defective cells are hypersensitive to certain genotoxic agents that cause replication arrest and/or double-strand breaks at the replication fork, suggesting a pivotal role for WRN in the protection of the integrity of the genoma during the DNA replication process. Here, we show that WRN is phosphorylated through an ATR/ATM dependent pathway in response to replication blockage. However, we provide evidence that WRN phosphorylation is not essential for its subnuclear relocalization after replication arrest. Finally, we show that WRN and ATR colocalize after replication fork arrest, suggesting that WRN and the ATR kinase collaborate to prevent genome instability during the S phase.	Inst Gustave Roussy, CNRS, UPR2169, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Franchitto, A (corresponding author), Inst Gustave Roussy, CNRS, UPR2169, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Franchitto, Annapaola/K-7564-2016; Filippo, Rosselli/AAO-6393-2020; Pichierri, Pietro/AAA-5476-2021	Franchitto, Annapaola/0000-0003-4232-4727; Filippo, Rosselli/0000-0003-1080-5745; Pichierri, Pietro/0000-0002-2702-3523				Ababou M, 2002, ONCOGENE, V21, P2079, DOI 10.1038/sj.onc.1205246; Ababou M, 2000, ONCOGENE, V19, P5955, DOI 10.1038/sj.onc.1204003; Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; BIERNE H, 1994, MOL MICROBIOL, V13, P17, DOI 10.1111/j.1365-2958.1994.tb00398.x; Bohr VA, 2001, ENVIRON MOL MUTAGEN, V38, P227, DOI 10.1002/em.1076; Brosh RM, 2002, EXP GERONTOL, V37, P491, DOI 10.1016/S0531-5565(01)00227-3; CAO G, 1991, EXP CELL RES, V193, P405, DOI 10.1016/0014-4827(91)90113-9; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cooper MP, 2000, GENE DEV, V14, P907; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; Franchitto A, 2002, J CELL BIOL, V157, P19, DOI 10.1083/jcb.200110009; Frei C, 2000, J CELL SCI, V113, P2641; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Imamura O, 2002, ONCOGENE, V21, P954, DOI 10.1038/sj.onc.1205143; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; KARMAKAR P, 2002, J BIOL CHEM, V11, P11; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; KREPINSKY AB, 1979, HUM GENET, V50, P151, DOI 10.1007/BF00390236; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Michel B, 2000, TRENDS BIOCHEM SCI, V25, P173, DOI 10.1016/S0968-0004(00)01560-7; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mohaghegh P, 2001, HUM MOL GENET, V10, P741, DOI 10.1093/hmg/10.7.741; Orren DK, 2001, NUCLEIC ACIDS RES, V29, P1926, DOI 10.1093/nar/29.9.1926; Pichierri P, 2000, MUTAT RES-DNA REPAIR, V459, P123, DOI 10.1016/S0921-8777(99)00065-8; Pichierri P, 2001, MOL BIOL CELL, V12, P2412, DOI 10.1091/mbc.12.8.2412; Pichierri P, 2000, MUTAT RES-FUND MOL M, V456, P45, DOI 10.1016/S0027-5107(00)00109-3; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Poot M, 1999, HUM GENET, V104, P10, DOI 10.1007/s004390050903; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; Rothstein R, 2000, GENE DEV, V14, P1; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Salk D, 1985, Basic Life Sci, V35, P419; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCAPPATICCI S, 1982, HUM GENET, V62, P16, DOI 10.1007/BF00295599; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 2000, ONCOGENE, V19, P6176, DOI 10.1038/sj.onc.1203971; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Wang HY, 2001, CANCER RES, V61, P8554; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Yannone SM, 2001, J BIOL CHEM, V276, P38242; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	61	101	102	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2003	22	10					1491	1500		10.1038/sj.onc.1206169	http://dx.doi.org/10.1038/sj.onc.1206169			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629512				2022-12-17	WOS:000181411900006
J	Bundy, LM; Sealy, L				Bundy, LM; Sealy, L			CCAAT/enhancer binding protein beta (C/EBP beta)-2 transforms normal mammary epithelial cells and induces epithelial to mesenchymal transition in culture	ONCOGENE			English	Article						C/EBP transcription factor; anchorage independence; EMT; invasion; mammary gland; retroviral vector	HUMAN BREAST-CANCER; C/EBP-BETA; CYCLIN D1; TRANSCRIPTIONAL REGULATION; CYCLOOXYGENASE-2 GENE; INHIBITORY PROTEIN; GLAND DEVELOPMENT; TRANSGENIC MICE; MESSENGER-RNA; EXPRESSION	The transcription factor CCAAT/enhancer binding protein (C/EBP)p is critical for normal growth and differentiation of the mammary gland. The intronless C/EBPbeta gene encodes a single mRNA that produces three protein isoforms, C/EBPbeta-1, -2, and -3, which share a common basic-leucine zipper domain at their C-terminus, but are distinguished at their N-termini by the in-frame methionine codon used to initiate translation. Although C/EBPbeta-1 and -2 are both transactivators, they likely perform distinct functions in mammary epithelial cells. C/EBPbeta-1 is the only isoform detected in normal human mammary tissue. In breast cancer cell lines, C/EBPbeta-1 is absent, and the C/EBPbeta-2 transactivator is expressed. Moreover, our data suggest that C/EBPbeta-2 is upregulated in human primary breast tumors. To assess C/EBPbeta-2's ability to participate in the transformation process, we generated recombinant retrovirus selectively encoding epitope-tagged C/EBPbeta-2. Strikingly, 10 days after infecting a normal human mammary epithelial cell line (MCF10A) with C/EBPbeta-2 virus, transformed subcultures were readily generated. Specifically, C/EBPbeta-2-overexpressing MCF10A cells form foci, gain anchorage independence, express markers associated with having undergone an epithelial-to-mesenchymal transition, and acquire an invasive phenotype. These studies, and our previous observations, provide supportive evidence that deregulated expression of C/EBPbeta-2 contributes to malignant conversion of the human breast.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Sealy, L (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA68485, CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baer M, 2000, J BIOL CHEM, V275, P26582, DOI 10.1074/jbc.M004268200; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; Calkhoven CF, 2000, GENE DEV, V14, P1920; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Eaton EM, 2001, J CELL PHYSIOL, V189, P91, DOI 10.1002/jcp.1139; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fantl V, 1999, DEV BIOL, V212, P1, DOI 10.1006/dbio.1999.9329; GILLES C, 1996, BREAST J, V2, P83; Gorgoni B, 2001, J BIOL CHEM, V276, P40769, DOI 10.1074/jbc.M106865200; Grignani F, 1998, CANCER RES, V58, P14; Half E, 2002, CANCER RES, V62, P1676; Hanlon M, 2000, BMC Cell Biol, V1, P2, DOI 10.1186/1471-2121-1-2; Hay ED, 1995, ACTA ANAT, V154, P8; Hirai Y, 2001, J CELL BIOL, V153, P785, DOI 10.1083/jcb.153.4.785; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Lochter A, 1997, J BIOL CHEM, V272, P5007, DOI 10.1074/jbc.272.8.5007; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Montell DJ, 2001, MECH DEVELOP, V105, P19, DOI 10.1016/S0925-4773(01)00393-8; Raught B, 1996, CANCER RES, V56, P4382; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; SEARS RC, 1994, MOL CELL BIOL, V14, P4855, DOI 10.1128/MCB.14.7.4855; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SOMMERS CL, 1992, CANCER RES, V52, P5190; SOMMERS CL, 1989, CANCER RES, V49, P4258; SOULE HD, 1990, CANCER RES, V50, P6075; TAIT L, 1990, CANCER RES, V50, P6087; Thomas B, 2000, EUR J BIOCHEM, V267, P6798, DOI 10.1046/j.1432-1327.2000.01778.x; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wardlaw SA, 2002, MOL PHARMACOL, V62, P326, DOI 10.1124/mol.62.2.326; Xiong W, 2001, NUCLEIC ACIDS RES, V29, P3087, DOI 10.1093/nar/29.14.3087; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Yuan CJ, 2000, CANCER RES, V60, P1084; Zahnow CA, 1997, J NATL CANCER I, V89, P1887, DOI 10.1093/jnci/89.24.1887; Zahnow CA, 2001, CANCER RES, V61, P261; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299	49	101	103	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					869	883		10.1038/sj.onc.1206216	http://dx.doi.org/10.1038/sj.onc.1206216			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584567				2022-12-17	WOS:000180864300010
J	Karimpour, S; Lou, JY; Lin, LL; Rene, LM; Lagunas, L; Ma, XR; Karra, S; Bradbury, CM; Markovina, S; Goswami, P; Spitz, DR; Hirota, K; Kalvakolanu, DV; Yodoi, J; Gius, D				Karimpour, S; Lou, JY; Lin, LL; Rene, LM; Lagunas, L; Ma, XR; Karra, S; Bradbury, CM; Markovina, S; Goswami, P; Spitz, DR; Hirota, K; Kalvakolanu, DV; Yodoi, J; Gius, D			Thioredoxin reductase regulates AP-1 activity as well as thioredoxin nuclear localization via active cysteines in response to ionizing radiation	ONCOGENE			English	Article						thioredoxin reductase; thioredoxin; AP-1; redox; ionizing radiation	NF-KAPPA-B; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; REDOX REGULATION; GENE-EXPRESSION; RETINOID COMBINATION; OXIDATIVE STRESS; DRUG TARGET; CELL-LINES; ACTIVATION	A recently identified class of signaling factors uses critical cysteine motif(s) that act as redox-sensitive 'sulfhydryl switches' to reversibly modulate specific signal transduction cascades regulating downstream proteins with similar redox-sensitive sites. For example, signaling factors such as redox factor-1 (Ref-1) and transcription factors such as the AP-1 complex both contain redox-sensitive cysteine motifs that regulate activity in response to oxidative stress. The mammalian thioredoxin reductase-1 (TR) is an oxidoreductase selenocysteine-containing flavoprotein that also appears to regulate multiple downstream intracellular redox-sensitive proteins. Since ionizing radiation (IR) induces oxidative stress as well as increases AP-1 DNA-binding activity via the activation of Ref-1, the potential roles of TR and thioredoxin (TRX) in the regulation of AP-1 activity in response to IR were investigated. Permanently transfected cell lines that overexpress wild type TR demonstrated constitutive increases in AP-1 DNA-binding activity as well as AP-1-dependent reporter gene expression, relative to vector control cells. In contrast, permanently transfected cell lines expressing a TR gene with the active site cysteine motif deleted were unable to induce AP-1 activity or reporter gene expression in response to IR. Transient genetic overexpression of either the TR wild type or dominant-negative genes demonstrated similar results using a transient assay system. One mechanism through which TR regulates AP-1 activity appears to involve TRX sub-cellular localization, with no change in the total TRX content of the cell. These results identify a novel function of the TR enzyme as a signaling factor in the regulation of AP-1 activity via a cysteine motif located in the protein.	NCI, Radiat Oncol Branch, Radiat Oncol Sci Program, Canc Res Ctr,NIH, Bethesda, MD 20892 USA; Washington Univ, Sch Med, Sect Canc Biol, Mallinckrodt Inst Radiol, St Louis, MO USA; Univ Maryland, Sch Med, Greenbaum Canc Ctr, Dept Microbiol & Immunol,Mol & Cellular Biol Prog, Baltimore, MD 21201 USA; Univ Iowa, Free Rad & Radiat Biol Program, Dept Radiol, Iowa City, IA USA; Kyoto Univ Hosp, Dept Anesthesia, Kyoto 606, Japan; Kyoto Univ, Dept Biol Responses, Inst Virus Res, Kyoto, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Washington University (WUSTL); University System of Maryland; University of Maryland Baltimore; University of Iowa; Kyoto University; Kyoto University	Gius, D (corresponding author), NCI, Radiat Oncol Branch, Radiat Oncol Sci Program, Canc Res Ctr,NIH, 9000 Rockville Pike,Bldg 10,Room B3B69, Bethesda, MD 20892 USA.	giusd@mail.nih.gov	; Hirota, Kiichi/E-9181-2010	Spitz, Douglas/0000-0002-1254-8765; Goswami, Prabhat/0000-0002-5700-2096; Hirota, Kiichi/0000-0003-1110-0827	NATIONAL CANCER INSTITUTE [R01CA078282, K08CA072602, R01CA071401, R29CA069593] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051469] Funding Source: NIH RePORTER; NCI NIH HHS [CA 71401, R01 CA 78282, CA69593, 1 K08 CA72602-01] Funding Source: Medline; NHLBI NIH HHS [R01 HL51469] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1991, ONCOGENE, V6, P2179; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; Beetz A, 2000, INT J RADIAT BIOL, V76, P1443, DOI 10.1080/09553000050176207; Berggren M, 1996, ANTICANCER RES, V16, P3459; Curry HA, 1999, J BIOL CHEM, V274, P23061, DOI 10.1074/jbc.274.33.23061; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; Gallegos A, 1996, CANCER RES, V56, P5765; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; HALLAHAN DE, 1993, J BIOL CHEM, V268, P4903; HALLIWELL B, 1988, HUM TOXICOL, V7, P7, DOI 10.1177/096032718800700102; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 2000, BIOCHEM BIOPH RES CO, V275, P825, DOI 10.1006/bbrc.2000.3392; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Hu JD, 2001, ONCOGENE, V20, P4235, DOI 10.1038/sj.onc.1204585; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KERPPOLA T, 1995, NATURE, V373, P199, DOI 10.1038/373199a0; KERR L D, 1992, Current Opinion in Cell Biology, V4, P496, DOI 10.1016/0955-0674(92)90017-7; Kirkpatrick DL, 1997, ONCOL RES, V9, P351; Ma XR, 2001, ONCOGENE, V20, P3703, DOI 10.1038/sj.onc.1204477; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; Martin M, 1997, ONCOGENE, V15, P981, DOI 10.1038/sj.onc.1201433; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Oberley TD, 2001, FREE RADICAL BIO MED, V30, P412, DOI 10.1016/S0891-5849(00)00486-X; Poole LB, 2000, EUR J BIOCHEM, V267, P6126, DOI 10.1046/j.1432-1327.2000.01704.x; Powis G, 1998, CHEM-BIOL INTERACT, V112, P23, DOI 10.1016/S0009-2797(97)00148-8; Sasada Tetsuro, 1996, Journal of Toxicological Sciences, V21, P285; Spitz DR, 2000, ANN NY ACAD SCI, V899, P349, DOI 10.1111/j.1749-6632.2000.tb06199.x; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TUTTLE SW, 1992, INT J RADIAT ONCOL, V22, P671, DOI 10.1016/0360-3016(92)90500-H; Wei SJ, 2000, CANCER RES, V60, P6688; Williams CH, 2000, EUR J BIOCHEM, V267, P6110, DOI 10.1046/j.1432-1327.2000.01702.x; Xanthoudakis S, 1996, ADV EXP MED BIOL, V387, P69; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	39	101	107	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2002	21	41					6317	6327		10.1038/sj.onc.1205749	http://dx.doi.org/10.1038/sj.onc.1205749			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214272				2022-12-17	WOS:000177829000008
J	Duensing, S; Munger, K				Duensing, S; Munger, K			Human papillomaviruses and centrosome duplication errors: modeling the origins of genomic instability	ONCOGENE			English	Review						HPV; centrosomes; genomic instability; cervical cancer	E7 ONCOPROTEIN; TYPE-16 E7; GENETIC INSTABILITY; CELL-LINE; HUMAN KERATINOCYTES; E6 ONCOPROTEIN; DNA ANEUPLOIDY; EXPRESSION; PROTEIN; PROLIFERATION	The majority of human cancers are genomically unstable, often with gains or losses of whole chromosomes. In high-risk human papillomavirus (HPV)-associated cervical neoplasia, the two HPV-encoded oncoproteins E6 and E7 have been implicated in mitotic infidelity by their ability to induce centrosome-related mitotic disturbances. However, the mechanisms by which HPV E6 and E7 subvert centrosome homeostasis are strikingly different. Whereas the E7 oncoprotein rapidly drives centrosome duplication errors in cells that appear phenotypically normal, expression of the HPV E6 oncoprotein results in an accumulation of supernumerary centrosomes in multinucleated cells. The primary centrosome duplication defect in HPV E7 expressing cells may be linked to the ability of E7 to disrupt regulatory nodes that govern both the host cell division cycle machinery and the initiation of centrosome duplication. Most importantly, the E7 oncoprotein has been shown to dysregulate cdk2 activity, a major determinant for the initiation of centrosome duplication. HPV-induced centrosome abnormalities, multipolar mitoses, and aneuploidy often occur at early stages during cervical carcinogenesis and increase with malignant conversion. These findings suggest that HPV oncoprotein-induced chromosomal instability increases the risk for genetic changes that may ultimately facilitate carcinogenic progression.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Armenise Res Bldg,D2-537,200 Longwood Ave, Boston, MA 02115 USA.	karl_munger@hms.harvard.edu		Munger, Karl/0000-0003-3288-9935	NCI NIH HHS [R01 CA66980, R01 CA81135] Funding Source: Medline; NIDCR NIH HHS [P01 DE00275] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081135, R01CA066980] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Backsch C, 2001, GENE CHROMOSOME CANC, V31, P196, DOI 10.1002/gcc.1134; Bardelli A, 2001, P NATL ACAD SCI USA, V98, P5770, DOI 10.1073/pnas.081082898; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; BIBBO M, 1989, AM J CLIN PATHOL, V92, P261, DOI 10.1093/ajcp/92.3.261; Boveri T., 1914, FRAGE ENTSTEHUNG MAL; Boyer SN, 1996, CANCER RES, V56, P4620; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Bulten J, 1998, AM J PATHOL, V152, P495; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; CRUM CP, 1984, NEW ENGL J MED, V310, P880, DOI 10.1056/NEJM198404053101403; DOLLARD SC, 1992, GENE DEV, V6, P1131, DOI 10.1101/gad.6.7.1131; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2001, J VIROL, V75, P7712, DOI 10.1128/JVI.75.16.7712-7716.2001; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; Duensing S, 2001, CANCER RES, V61, P2356; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Flores ER, 1999, VIROLOGY, V262, P344, DOI 10.1006/viro.1999.9868; FU YS, 1981, GYNECOL ONCOL, V12, pS220, DOI 10.1016/0090-8258(81)90076-7; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gisselsson D., 2001, RING CHROMOSOMES VIC; HASHIDA T, 1991, J GEN VIROL, V72, P1569, DOI 10.1099/0022-1317-72-7-1569; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hittelman WN, 2001, ANN NY ACAD SCI, V952, P1; Howley P. M., 2001, FIELDS VIROLOGY, V2, P2197; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; JONES HW, 1967, OBSTET GYNECOL, V30, P790; Kashyap V, 1998, CANCER LETT, V123, P47, DOI 10.1016/S0304-3835(97)00396-0; Katich SC, 2001, ONCOGENE, V20, P543, DOI 10.1038/sj.onc.1204130; Kessis TD, 1996, ONCOGENE, V13, P427; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Larson AA, 1997, CANCER RES, V57, P4171; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Lowy DR, 2001, FIELDS VIROLOGY, P2231; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; MEYERS C, 1992, SCIENCE, V257, P971, DOI 10.1126/science.1323879; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Munger K, 2002, FRONT BIOSCI-LANDMRK, V7, pD641, DOI 10.2741/munger; MUNGER K, 1989, J VIROL, V63, P4417; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Pihan GA, 1998, CANCER RES, V58, P3974; Poignee M, 2001, CANCER RES, V61, P7118; REID R, 1984, CANCER-AM CANCER SOC, V53, P943, DOI 10.1002/1097-0142(19840215)53:4<943::AID-CNCR2820530421>3.0.CO;2-X; Rihet S, 1996, J CLIN PATHOL, V49, P892, DOI 10.1136/jcp.49.11.892; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schulze A, 1998, J VIROL, V72, P2323, DOI 10.1128/JVI.72.3.2323-2334.1998; Skyldberg B, 2001, MODERN PATHOL, V14, P279, DOI 10.1038/modpathol.3880303; SolinasToldo S, 1997, P NATL ACAD SCI USA, V94, P3854, DOI 10.1073/pnas.94.8.3854; Southern SA, 1997, CANCER RES, V57, P4210; Southern SA, 2001, CANCER RES, V61, P4858; Steinbeck RG, 1997, ACTA ONCOL, V36, P3, DOI 10.3109/02841869709100723; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; *WHO, 1995, IARC MONOGR EVAL CAR, V64, P35; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZerfassThome K, 1996, ONCOGENE, V13, P2323; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	74	101	107	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2002	21	40					6241	6248		10.1038/sj.onc.1205709	http://dx.doi.org/10.1038/sj.onc.1205709			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214255				2022-12-17	WOS:000177840500014
J	Kikuchi, T; Toyota, M; Itoh, F; Suzuki, H; Obata, T; Yamamoto, H; Kakiuchi, H; Kusano, M; Issa, JPJ; Tokino, T; Imai, K				Kikuchi, T; Toyota, M; Itoh, F; Suzuki, H; Obata, T; Yamamoto, H; Kakiuchi, H; Kusano, M; Issa, JPJ; Tokino, T; Imai, K			Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors	ONCOGENE			English	Article						cell cycle; gene expression; CIMP; chromatin; acetylation	DEPENDENT KINASE INHIBITOR; ISLAND METHYLATOR PHENOTYPE; BECKWITH-WIEDEMANN-SYNDROME; CPG-ISLAND; ABERRANT METHYLATION; GASTRIC-CANCER; CHROMOSOME 11P15; PROTEIN MBD1; P57(KIP2); GENE	To clarify the role of DNA methylation in the silencing of the expression of cyclin-dependent kinase inhibitor p57KIP2 seen in certain tumors, we investigated the methylation status of its 5' CpG island in various tumor cell lines and primary cancers. Dense methylation of the region around the transcription start site was detected in I out of 10 colorectal, 2 out of 8 gastric, and 6 out of 14 hematopoietic tumor cell lines and in 5 out of 35 (14%) gastric, 6 out of 20 (30%) hepatocellular, and 2 out of IS (11%) pancreatic cancers; 7 out of 25 (28%) acute myeloid leukemia cases also showed methylation of the p57KIP2 gene, which strongly correlated with the CpG island methylator phenotype (P < 0.001). Detailed mapping revealed that dense methylation of the region around the transcription start site (-300 to +400), but not of the edges of the CpG island, was closely associated with gene silencing. 5-aza-2'-deoxycytidine, a methyltransferase inhibitor, restored expression of p57KIP2, and chromatin immunoprecipitation using anti-histone H3 and H4 antibodies showed histone to be deacetylated in cell lines where p57KIP2 was methylated at the transcription start site. Regional methylation and histone deacetylation thus appear to be crucially involved in the silencing of p57KIP2 expression in human tumors.	Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan; Sapporo Med Univ, Canc Res Inst, Dept Mol Biol, Sapporo, Hokkaido 0608556, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA	Sapporo Medical University; Sapporo Medical University; University of Texas System; UTMD Anderson Cancer Center	Toyota, M (corresponding author), Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan.		Tokino, Takashi/AAI-9887-2021	Issa, Jean-Pierre/0000-0003-2258-5030				Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chung WY, 1996, HUM MOL GENET, V5, P1101, DOI 10.1093/hmg/5.8.1101; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Fujita N, 2000, MOL CELL BIOL, V20, P5107, DOI 10.1128/MCB.20.14.5107-5118.2000; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; Herman JG, 1996, CANCER RES, V56, P722; Issa JP, 2000, CURR TOP MICROBIOL, V249, P101; Jackson SM, 2000, WILDLIFE RES, V27, P39, DOI 10.1071/WR98045; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Krskova-Honzatkova L, 2001, LEUKEMIA RES, V25, P45, DOI 10.1016/S0145-2126(00)00086-2; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Matsumoto M, 2000, ANTICANCER RES, V20, P1947; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; Mummaneni P, 1998, NUCLEIC ACIDS RES, V26, P5163, DOI 10.1093/nar/26.22.5163; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Oya M, 2000, BRIT J CANCER, V83, P626, DOI 10.1054/bjoc.2000.1298; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Salem CE, 2000, INT J CANCER, V87, P179, DOI 10.1002/1097-0215(20000715)87:2<179::AID-IJC4>3.0.CO;2-X; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; Sherr CJ, 2000, CANCER RES, V60, P3689; Sheu JC, 1999, BRIT J CANCER, V80, P468, DOI 10.1038/sj.bjc.6690380; Shin JY, 2000, CANCER RES, V60, P262; Shin JY, 2000, EXP MOL MED, V32, P79, DOI 10.1038/emm.2000.14; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; Toyota M, 2001, BLOOD, V97, P2823, DOI 10.1182/blood.V97.9.2823; Toyota M, 2000, CANCER RES, V60, P4044; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P5438; Toyota M, 1999, CANCER RES, V59, P4535; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; Ueki T, 2000, CANCER RES, V60, P1835; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; WINQVIST R, 1993, CANCER RES, V53, P4486; Wong DJ, 1999, MOL CELL BIOL, V19, P5642; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	48	101	104	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 18	2002	21	17					2741	2749		10.1038/sj.onc.1205376	http://dx.doi.org/10.1038/sj.onc.1205376			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965547				2022-12-17	WOS:000174996500014
J	Oku, N; Asai, T; Watanabe, K; Kuromi, K; Nagatsuka, M; Kurohane, K; Kikkawa, H; Ogino, K; Tanaka, M; Ishikawa, D; Tsukada, H; Momose, M; Nakayama, J; Taki, T				Oku, N; Asai, T; Watanabe, K; Kuromi, K; Nagatsuka, M; Kurohane, K; Kikkawa, H; Ogino, K; Tanaka, M; Ishikawa, D; Tsukada, H; Momose, M; Nakayama, J; Taki, T			Anti-neovascular therapy using novel peptides homing to angiogenic vessels	ONCOGENE			English	Article						anti-neovascular therapy; phage-displayed peptide library; liposome; PRP	ALPHA-V INTEGRINS; DRUG-DELIVERY; BINDING; CANCER; CELLS; LIGANDS; TUMORS	Cancer chemotherapy targeted to angiogenic vessels is expected to cause indirect tumor regression through the damage of the neovasculature without the induction of drug resistance. To develop a tool for neovasculature-specific drug delivery, we isolated novel peptides homing to angiogenic vessels formed by a dorsal air sac method from a phage-displayed peptide library. Three distinct phage clones that markedly accumulated in murine tumor xenografts presented PRPGAPLAGSWPGTS-, DRWRPALPVVLFPLH- or ASSSYPLIHWRPWAR-peptide respectively. After the determination of the epitope sequences of these peptides, we modified liposomes with epitope penta-peptides. Liposome modified with APRPG-peptide showed high accumulation in murine tumor xenografts, and APRPG-modified liposome encapsulating adriamycin effectively suppressed experimental tumor growth. Finally, specific binding of APRPG-modified liposome to human umbilical endothelial cells, and that of PRP-containing peptide to angiogenic vessels in human tumors, i.e., islet cell tumor and glioblastoma, were demonstrated. The present study indicates the usefulness of APRPG-peptide as a tool for anti-neovascular therapy, a novel modality of cancer treatment.	Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem Med, Shizuoka 4228526, Japan; Otsuka Pharmaceut Co Ltd, Inst Mol Sci Med, Tokushima 7710192, Japan; Hamamatsu Photon KK, Shizuoka 4340041, Japan; Shinshu Univ Hosp, Dept Lab Med, Matsumoto, Nagano 3908621, Japan; Shinshu Univ Hosp, Cent Clin Labs, Matsumoto, Nagano 3908621, Japan	University of Shizuoka; National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); Otsuka Pharmaceutical; Hamamatsu Photonics; Shinshu University; Shinshu University	Oku, N (corresponding author), Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem Med, 52-1 Yada, Shizuoka 4228526, Japan.	oku@u-shizuoka-ken.ac.jp						Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Asai T, 1998, BIOL PHARM BULL, V21, P766; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Browder T, 2000, CANCER RES, V60, P1878; Brower V, 1999, NAT BIOTECHNOL, V17, P963, DOI 10.1038/13654; Brown JM, 1998, CANCER RES, V58, P1408; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Gho YS, 1997, CANCER RES, V57, P3733; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HEALY JM, 1995, BIOCHEMISTRY-US, V34, P3948, DOI 10.1021/bi00012a012; Huang XM, 1997, SCIENCE, V275, P547, DOI 10.1126/science.275.5299.547; Ishikawa D, 1998, FEBS LETT, V441, P20, DOI 10.1016/S0014-5793(98)01511-7; Ito H, 1999, CANCER RES, V59, P5875; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; Kurohane K, 2001, CANCER LETT, V167, P49, DOI 10.1016/S0304-3835(01)00475-X; Langer R, 1998, NATURE, V392, P5; MARTENS CL, 1995, J BIOL CHEM, V270, P21129, DOI 10.1074/jbc.270.36.21129; Nishi T, 1996, FEBS LETT, V399, P237, DOI 10.1016/S0014-5793(96)01329-4; Oku N, 1999, ADV DRUG DELIVER REV, V37, P53, DOI 10.1016/S0169-409X(98)00110-0; Oku N, 1999, ADV DRUG DELIVER REV, V40, P63, DOI 10.1016/S0169-409X(99)00040-X; OKU N, 1994, INT J CANCER, V58, P415, DOI 10.1002/ijc.2910580318; OKU N, 1992, BIOCHIM BIOPHYS ACTA, V1126, P255, DOI 10.1016/0005-2760(92)90238-Q; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; St Croix B, 2000, SCIENCE, V289, P1197; Takikawa M, 2000, FEBS LETT, V466, P381, DOI 10.1016/S0014-5793(00)01110-8; Viti F, 1999, CANCER RES, V59, P347; Zetter BR, 1997, NAT BIOTECHNOL, V15, P1243, DOI 10.1038/nbt1197-1243	34	101	115	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2662	2669		10.1038/sj.onc.1205347	http://dx.doi.org/10.1038/sj.onc.1205347			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965539				2022-12-17	WOS:000174996500006
J	Valenzuela, MT; Guerrero, R; Nunez, MI; de Almodovar, JMR; Sarker, M; de Murcia, G; Oliver, FJ				Valenzuela, MT; Guerrero, R; Nunez, MI; de Almodovar, JMR; Sarker, M; de Murcia, G; Oliver, FJ			PARP-1 modifies the effectiveness of p53-mediated DNA damage response	ONCOGENE			English	Article						PARP-1; p53-mediated DNA damage response; ionising radiation; alkylating agent	POLY(ADP-RIBOSE) POLYMERASE GENE; IONIZING-RADIATION; EXCISION-REPAIR; MICE RESISTANT; CELL-LINES; P53; PHOSPHORYLATION; ACTIVATION; APOPTOSIS; MDM2	The tumour supressor protein p53 plays a key role in the cell's decision to arrest the cell cycle or undergo apoptosis following a genotoxic insult. p53 is stabilized and activated after DNA damage, however the cascade of events signalling from DNA lesions to p53 stabilization and activation is still controversial. Poly (ADP-ribosylation) of different nuclear acceptors by PARP-1 is an early event when a single strand DNA lesion is produced. We present here evidences that interplay between PARP-1 and p53 is dependent on the type of damage induced to DNA. Primary mouse embryonic fibroblasts derived from parp-1-/- mice exhibited decreased p53 accumulation and activation following gamma-irradiation compared to parp-1 proficient cells. On the other hand. treatment with the single alklating agent 2'-methyl-2'-nitrose-urea (MNU), resulted in the rapid and sustained accumulation and activation of p53 in parp-1-deficient cells, while very little accumulation was observed in parp-1 +/+ cells. After IR, the turnover of the p53 inhibitory protein MDM-2 is perturbed and the level of phosphorylation of p53 at serine-15 is blunted in parp-1-/- cells. PARP-1 is determinant in the cytotoxic response to alkylating agents but only partially contributes to radiation-induced cell killing, as determined by colony forming assay. Altogether, these results suggest that PARP-1 participates in the p53 response following irradiation, resides upstream of p53 and indirectly modulates the level of phosphorylation of key substrates in this pathway while treatment with MNU results in an enhanced p53-mediated response in parp-1-null cells.	Hosp Univ San Cecilio, Unidad Mixta Invest Med, Granada 18012, Spain; Univ Granada, Fac Med, Dept Radiol, Granada 18012, Spain; CSIC, Inst Parasitol & Biomed, Granada 18001, Spain; Univ Louis Pasteur Strasbourg 1, Ecole Super Biotechnol, CNRS, UPR 9003, F-67400 Illkirch Graffenstaden, France	Hospital Universitario San Cecilio; University of Granada; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Oliver, FJ (corresponding author), Hosp Univ San Cecilio, Unidad Mixta Invest Med, Avda Dr Oloriz 16, Granada 18012, Spain.		Oliver, Javier/S-1725-2018; Núñez, María Isabel/L-9924-2014	Oliver, Javier/0000-0001-8468-1998; Núñez, María Isabel/0000-0001-8159-7969; Ruiz De Almodovar Rivera, Jose Mariano/0000-0002-7053-1072				Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Beneke R, 2000, MOL CELL BIOL, V20, P6695, DOI 10.1128/MCB.20.18.6695-6703.2000; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; CURTIS SB, 1986, RADIAT RES, V106, P252, DOI 10.2307/3576798; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; DEALMODOVAR JMR, 1994, BRIT J CANCER, V69, P457, DOI 10.1038/bjc.1994.83; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Fernet M, 2000, INT J RADIAT BIOL, V76, P1621, DOI 10.1080/09553000050201118; Freedman DA, 1999, CANCER RES, V59, P1; HALL EJ, 1994, RADIOBIOLOGY RADIOLO, P29; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Masutani M, 1999, P NATL ACAD SCI USA, V96, P2301, DOI 10.1073/pnas.96.5.2301; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Menissier De Murcia Josiane, 1997, Proceedings of the National Academy of Sciences of the United States of America, V94, P7303; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Oliver FJ, 1999, AM J HUM GENET, V64, P1282, DOI 10.1086/302389; OLSON DC, 1993, ONCOGENE, V8, P2353; Schlicker A, 1999, INT J RADIAT BIOL, V75, P91, DOI 10.1080/095530099140843; STEEL GG, 1997, BASIC CLIN RADIOBIOL, P52; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Wang YX, 1998, PANCREAS, V17, P289, DOI 10.1097/00006676-199810000-00011; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	37	101	104	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1108	1116		10.1038/sj.onc.1205169	http://dx.doi.org/10.1038/sj.onc.1205169			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850828				2022-12-17	WOS:000173580100014
J	Deneen, B; Denny, CT				Deneen, B; Denny, CT			Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation	ONCOGENE			English	Article						EWS/FLI1; P16(INK4a); p19(ARF); SV40 large T antigen; apoptosis	HUMAN-PAPILLOMAVIRUS TYPE-16; LARGE T-ANTIGEN; TUMOR-SUPPRESSOR; J DOMAIN; P53; FAMILY; GENES; DIFFERENTIATION; INACTIVATION; FIBROBLASTS	Ewings sarcoma and primitive neuroectodermal tumors (ES/PNET) are characterized by the fusion of the N-terminus of the EWS gene to the C-terminus of a member of the ETS family of transcription factors. While such fusion proteins are thought to play dominant oncogenic roles, it is unlikely that a single genetic alteration by itself will support cellular transformation. Given that EWS/FLI1 is only able to transform immortalized 3T3 fibroblasts and that 30% of ES/PNET tumors contain a homozygous deletion of the p16 focus, it is likely that other genetic events are required for EWS/FLI1 oncogenesis. Here we describe a complementary mechanism utilized in the establishment ES/PNET tumors. EWS/FLI1 has the capacity to induce apoptosis. and growth arrest in normal MEFs. Such effects prevent the establishment of stable expression of the protein in these cells. When expressed in p16, p19(ARF), or p53 deficient MEFs, the apoptotic and growth arrest effects are attenuated, creating a environment permissive for stable expression of the protein. While loss of a single tumor suppressor is sufficient to establish expression of EWS/FLI1, cellular transformation requires further genetic perturbation.	Univ Calif Los Angeles, Inst Mol Biol, Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Gwynne Hazen Cherry Mem Labs, Dept Pediat, Div Hematol Oncol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Denny, CT (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90095 USA.	cdenny@ucla.edu		Deneen, Benjmain/0000-0002-6335-1081	NCI NIH HHS [CA 87771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, CANCER RES, V50, P7717; Damania B, 1998, MOL CELL BIOL, V18, P1331, DOI 10.1128/MCB.18.3.1331; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Esteller M, 2000, CANCER RES, V60, P129; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fletcher JA, 1998, J CLIN ONCOL, V16, P1241, DOI 10.1200/JCO.1998.16.4.1241; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gjoerup O, 2000, J VIROL, V74, P864, DOI 10.1128/JVI.74.2.864-874.2000; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; JEN J, 1994, CANCER RES, V54, P5523; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kovar H, 1997, ONCOGENE, V15, P2225, DOI 10.1038/sj.onc.1201397; KOVAR H, 1998, CURR OPIN ONCOL, V4, P334; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOWRY DR, 1978, J VIROL, V26, P291; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MILLER DG, 1980, CANCER, V46, P1307, DOI 10.1002/1097-0142(19800915)46:6<1307::AID-CNCR2820460602>3.0.CO;2-6; Moens U, 1997, VIRUS GENES, V15, P135, DOI 10.1023/A:1007962908248; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Teitell MA, 1999, LAB INVEST, V79, P1535; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wei G, 2000, CANCER-AM CANCER SOC, V89, P793, DOI 10.1002/1097-0142(20000815)89:4<793::AID-CNCR11>3.0.CO;2-M; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245	38	101	107	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2001	20	46					6731	6741		10.1038/sj.onc.1204875	http://dx.doi.org/10.1038/sj.onc.1204875			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709708				2022-12-17	WOS:000171551600010
J	Rincon, M; Flavell, RA; Davis, RJ				Rincon, M; Flavell, RA; Davis, RJ			Signal transduction by MAP kinases in T lymphocytes	ONCOGENE			English	Review						c-Jun; p38; ERK; JNK	ACTIVATED PROTEIN-KINASE; INTERLEUKIN-2 MESSENGER-RNA; C-JUN; NEGATIVE SELECTION; ERK ACTIVATION; CELL-ACTIVATION; PKC-THETA; P38; JNK; APOPTOSIS		Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Mol Med, Dept Biochem & Mol Biol, Worcester, MA 01605 USA; Univ Vermont, Dept Med, Immunobiol Program, Burlington, VT 05405 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Vermont; Howard Hughes Medical Institute; Yale University; Yale University	Davis, RJ (corresponding author), Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA.							AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; Awad MM, 2000, J BIOL CHEM, V275, P38716, DOI 10.1074/jbc.M008040200; Behrens A, 2001, P NATL ACAD SCI USA, V98, P1769, DOI 10.1073/pnas.98.4.1769; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bommhardt U, 2000, J IMMUNOL, V164, P2326, DOI 10.4049/jimmunol.164.5.2326; Bommhardt U, 1999, J IMMUNOL, V163, P715; Carter LL, 1999, J EXP MED, V189, P1355, DOI 10.1084/jem.189.8.1355; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chen CY, 2000, GENE DEV, V14, P1236; CHEN JZ, 1994, IMMUNITY, V1, P65, DOI 10.1016/1074-7613(94)90010-8; Chow CW, 2000, MOL CELL BIOL, V20, P5227, DOI 10.1128/MCB.20.14.5227-5234.2000; Constant SL, 2000, J IMMUNOL, V165, P2671, DOI 10.4049/jimmunol.165.5.2671; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; Conze D, 2000, MOL IMMUNOL, V37, P503, DOI 10.1016/S0161-5890(00)00078-X; Crompton T, 1996, CELL, V86, P243, DOI 10.1016/S0092-8674(00)80096-3; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Delgado P, 2000, NATURE, V406, P426, DOI 10.1038/35019102; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Diehl NL, 2000, J EXP MED, V191, P321, DOI 10.1084/jem.191.2.321; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Fernandez E, 2000, BLOOD, V95, P1356, DOI 10.1182/blood.V95.4.1356.004k23_1356_1361; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Han J, 1999, NAT CELL BIOL, V1, pE39, DOI 10.1038/10032; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Iritani BM, 1999, IMMUNITY, V10, P713, DOI 10.1016/S1074-7613(00)80070-9; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Li BY, 2000, SCIENCE, V288, P2219, DOI 10.1126/science.288.5474.2219; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Lilic M, 1999, EUR J IMMUNOL, V29, P3971, DOI 10.1002/(SICI)1521-4141(199912)29:12<3971::AID-IMMU3971>3.0.CO;2-5; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Mariathasan S, 2000, EUR J IMMUNOL, V30, P1060, DOI 10.1002/(SICI)1521-4141(200004)30:4<1060::AID-IMMU1060>3.0.CO;2-2; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; Merritt C, 2000, MOL CELL BIOL, V20, P936, DOI 10.1128/MCB.20.3.936-946.2000; Michie AM, 1999, J EXP MED, V190, P1647, DOI 10.1084/jem.190.11.1647; Mori A, 1999, J IMMUNOL, V163, P4763; Nishina H, 1997, J EXP MED, V186, P941, DOI 10.1084/jem.186.6.941; OShea CC, 1996, EUR J IMMUNOL, V26, P2350, DOI 10.1002/eji.1830261012; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; Rincon M, 1998, J EXP MED, V188, P1817, DOI 10.1084/jem.188.10.1817; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Rincon Mercedes, 1997, Genes and Function, V1, P51; Rodewald HR, 1998, ADV IMMUNOL, V69, P1, DOI 10.1016/S0065-2776(08)60606-9; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Sabapathy K, 2001, J EXP MED, V193, P317, DOI 10.1084/jem.193.3.317; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schafer PH, 1999, J IMMUNOL, V162, P7110; Sen J, 1996, J IMMUNOL, V156, P4535; Sharp LL, 1999, J IMMUNOL, V163, P6598; Sharp LL, 1997, IMMUNITY, V7, P609, DOI 10.1016/S1074-7613(00)80382-9; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Sugawara T, 1998, IMMUNITY, V9, P565, DOI 10.1016/S1074-7613(00)80639-1; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; Swat W, 1998, IMMUNITY, V8, P625, DOI 10.1016/S1074-7613(00)80567-1; Swat W, 1996, P NATL ACAD SCI USA, V93, P4683, DOI 10.1073/pnas.93.10.4683; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Visconti R, 2000, BLOOD, V96, P1844, DOI 10.1182/blood.V96.5.1844.h8001844_1844_1852; Weiss L, 2000, J EXP MED, V191, P139, DOI 10.1084/jem.191.1.139; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Yamashita M, 1999, P NATL ACAD SCI USA, V96, P1024, DOI 10.1073/pnas.96.3.1024; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1; Zhang SM, 2000, J IMMUNOL, V165, P1374, DOI 10.4049/jimmunol.165.3.1374	73	101	102	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2001	20	19					2490	2497		10.1038/sj.onc.1204382	http://dx.doi.org/10.1038/sj.onc.1204382			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402343				2022-12-17	WOS:000168568700014
J	Balana, ME; Labriola, L; Salatino, M; Movsichoff, F; Peters, G; Charreau, EH; Elizalde, PV				Balana, ME; Labriola, L; Salatino, M; Movsichoff, F; Peters, G; Charreau, EH; Elizalde, PV			Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells	ONCOGENE			English	Article						ErbB receptors; mammary tumorigenesis; progestin; type I insulin-like growth factor receptor	HUMAN-BREAST-CANCER; MEDROXYPROGESTERONE-ACETATE; CARCINOMA-CELLS; SIGNAL-TRANSDUCTION; ESTROGEN-RECEPTOR; PROGESTIN REGULATION; BALB/C MICE; EXPRESSION; PROLIFERATION; PROTEIN	The present study focused on interactions between signaling pathways activated by progestins and by type I and II receptor tyrosine kinases (RTKs) in mammary tumors. An experimental model in which the synthetic progestin medroxyprogesterone acetate (MPA) induced mammary adenocarcinomas in Balb/c mice was used. MPA-stimulated proliferation, both in vivo and in vitro, of progestin-dependent tumors induced up-regulation of ErbB-2 protein levels and tyrosine phosphorylation of this receptor. Combinations of antisense oligodeoxynucleotides (ASODNs) directed to ErbB-2 mRNA with ASODNs directed to the insulin-like growth factor-I receptor (IGF-IR) were used to study the effect of the simultaneous block of these receptors on the MPA-induced proliferation of epithelial cells from the progestin-dependent C4HD line. Neither synergistic nor additive effects on the inhibition of MPA-induced proliferation of C4HD cells were observed as a result of the combination of these ASODNs, Suppression of IGF-IR expression by ASODNs resulted in complete abrogation of MPA-induced phosphorylation of ErbB-2 in C4HD cells, whereas blockage of ErbB-2 did not affect ICF-IR phosphorylation, These results show the existence of a hierarchical interaction between IGF-IR and ErbB-2, by means of which IGF-IR directs ErbB-2 phosphorylation, We demonstrated, for the first time, that this hierarchical interaction involves physical association of both receptors, resulting in the formation of a heteromeric complex, Furthermore, confocal laser microscopy experiments demonstrated that MPA was able to induce co-localization of ErbB-2 and IGF-IR, This hetero-oligomer was also found in MCF-7 human breast cancer cells in which association of IGF-IR and Erbs-2 was induced by heregulin and IGF-I.	Inst Biol & Med Expt, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Ciencias Exactas & Nat, RA-1053 Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; University of Buenos Aires	Elizalde, PV (corresponding author), Inst Biol & Med Expt, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.		Labriola, Leticia/ABF-9079-2020; Labriola, Leticia/E-9059-2012	Labriola, Leticia/0000-0003-3899-6088; Labriola, Leticia/0000-0003-3899-6088; Peters, Maria/0000-0002-9271-4590; Elizalde, Patricia V./0000-0002-5923-9898				BACKER JM, 1993, J BIOL CHEM, V268, P8204; Balana ME, 1999, ONCOGENE, V18, P6370, DOI 10.1038/sj.onc.1203028; BASERGA R, 1995, CANCER RES, V55, P249; BRAUNSBERG H, 1987, EUR J CANCER CLIN ON, V23, P563, DOI 10.1016/0277-5379(87)90321-X; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DATI C, 1990, ONCOGENE, V5, P1001; De Bortoli M, 1997, J MAMMARY GLAND BIOL, V2, P175, DOI 10.1023/A:1026308015763; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; DRAN G, 1995, BREAST CANCER RES TR, V35, P173, DOI 10.1007/BF00668207; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ELIZALDE PV, 1990, J EXP CLIN CANC RES, V9, P193; Elizalde PV, 1998, J STEROID BIOCHEM, V67, P305, DOI 10.1016/S0960-0760(98)00123-X; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Groshong SD, 1997, MOL ENDOCRINOL, V11, P1593, DOI 10.1210/me.11.11.1593; GRUNT TW, 1995, INT J CANCER, V63, P560, DOI 10.1002/ijc.2910630417; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KISS R, 1986, JNCI-J NATL CANCER I, V77, P173; KORDON EC, 1994, INT J CANCER, V59, P196, DOI 10.1002/ijc.2910590210; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LANARI C, 1989, INT J CANCER, V43, P845, DOI 10.1002/ijc.2910430518; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Lewis GD, 1996, CANCER RES, V56, P1457; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUPU R, 1993, BREAST CANCER RES TR, V27, P83, DOI 10.1007/BF00683195; MANNI A, 1987, CANCER RES, V47, P3066; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MODIANO JF, 1991, J CELL BIOCHEM, V45, P196, DOI 10.1002/jcb.240450211; MOLINOLO AA, 1987, J NATL CANCER I, V79, P1341; MURPHY LC, 1988, CANCER RES, V48, P4555; MURPHY LJ, 1986, CANCER RES, V46, P728; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pinkas-Kramarski R, 1997, J MAMMARY GLAND BIOL, V2, P97, DOI 10.1023/A:1026343528967; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; RAM TG, 1995, J CELL PHYSIOL, V163, P589, DOI 10.1002/jcp.1041630320; Ram TG, 1996, MOL CARCINOGEN, V15, P227, DOI 10.1002/(SICI)1098-2744(199603)15:3<227::AID-MC8>3.0.CO;2-E; READ LD, 1990, CANCER RES, V50, P3947; Richer JK, 1998, J BIOL CHEM, V273, P31317, DOI 10.1074/jbc.273.47.31317; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SARUP JC, 1988, CANCER RES, V48, P5071; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; Swantek JL, 1999, ENDOCRINOLOGY, V140, P3163, DOI 10.1210/en.140.7.3163; TAVERNA D, 1994, INT J CANCER, V56, P522, DOI 10.1002/ijc.2910560411; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Woods Ignatoski Kathleen M., 1999, Endocrinology, V140, P3615; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	59	101	105	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					34	47		10.1038/sj.onc.1204050	http://dx.doi.org/10.1038/sj.onc.1204050			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244498	Green Published			2022-12-17	WOS:000166361400005
